<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="0" size="14" family="Times" color="#000000"/>
	<fontspec id="1" size="12" family="Times" color="#000000"/>
	<fontspec id="2" size="21" family="Times" color="#000000"/>
	<fontspec id="3" size="16" family="Times" color="#000000"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1073" width="10" height="20" font="1">1 </text>
<text top="108" left="355" width="483" height="31" font="2"><b>2017 Hypertension Guideline Data Supplements </b></text>
<text top="156" left="386" width="420" height="23" font="3"><b>(Section numbers correspond to the full-text guideline.) </b></text>
<text top="197" left="594" width="4" height="23" font="3"><b> </b></text>
<text top="237" left="528" width="136" height="23" font="3"><b>Table of Contents </b></text>
<text top="276" left="108" width="3" height="20" font="1"> </text>
<text top="303" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#7">Data Supplement 1. Coexistence of Hypertension and Related Chronic Conditions (Section 2.4) ................................................................................................................................. 7</a></text>
<text top="303" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#7"> </a></text>
<text top="330" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#8">Data Supplement 2. Definition of High BP (Section 3.1) .................................................................................................................................................................................................. 8</a></text>
<text top="330" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#8"> </a></text>
<text top="358" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#18">Data Supplement 3. Out-of-Office and Self-Monitoring of BP (Section 4.2) .................................................................................................................................................................. 18</a></text>
<text top="358" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#18"> </a></text>
<text top="385" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#21">Data Supplement 4. White Coat Hypertension (Section 4.4) ......................................................................................................................................................................................... 21</a></text>
<text top="385" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#21"> </a></text>
<text top="412" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#23">Data Supplement 5. White Coat Hypertension (Prevalence) (Section 4.4) ................................................................................................................................................................... 23</a></text>
<text top="412" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#23"> </a></text>
<text top="440" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#25">Data Supplement 6. White Coat Hypertension (Correlation with Clinical Outcomes) (Section 4.4) .............................................................................................................................. 25</a></text>
<text top="439" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#25"> </a></text>
<text top="467" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#27">Data Supplement 7. Renal Artery Stenosis (Section 5.4.3) ........................................................................................................................................................................................... 27</a></text>
<text top="467" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#27"> </a></text>
<text top="494" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#29">Data Supplement 8. RCTs Comparing Obstructive Sleep Apnea (Section 5.4.4) ......................................................................................................................................................... 29</a></text>
<text top="494" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#29"> </a></text>
<text top="521" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#31">Data Supplement 9. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Fiber Intake) (Section 6.2) .................................................................................. 31</a></text>
<text top="521" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#31"> </a></text>
<text top="549" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#33">Data Supplement 10. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Fish Oil) (Section 6.2) ................................................................................................... 33</a></text>
<text top="549" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#33"> </a></text>
<text top="576" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#34">Data Supplement 11. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Potassium Supplementation to Placebo or Usual Diet) (Section 6.2) ........................... 34</a></text>
<text top="576" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#34"> </a></text>
<text top="603" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#36">Data Supplement 12. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Protein Intake on BP) (Section 6.2) ............................................................................... 36</a></text>
<text top="603" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#36"> </a></text>
<text top="631" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#38">Data Supplement 13. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Sodium Reduction to Placebo or Usual Diet) (Section 6.2) .......................................... 38</a></text>
<text top="630" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#38"> </a></text>
<text top="658" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#43">Data Supplement 14. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Stress Reduction) (Section 6.2) .................................................................................... 43</a></text>
<text top="658" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#43"> </a></text>
<text top="685" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#44">Data Supplement 15. RCTs and Meta-analyses Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Patterns) (Section 6.2) ...................................................... 44</a></text>
<text top="685" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#44"> </a></text>
<text top="713" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#51">Data Supplement 16. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Alcohol Reduction) (Section 6.2) .......................................... 51</a></text>
<text top="712" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#51"> </a></text>
<text top="740" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#55">Data Supplement 17. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Calcium Supplementation) (Section 6.2) .............................. 55</a></text>
<text top="739" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#55"> </a></text>
<text top="767" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#56">Data Supplement 18. RCTs and Meta-analyses RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Physical Activity) (Section 6.2) ............................................ 56</a></text>
<text top="767" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#56"> </a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1073" width="10" height="20" font="1">2 </text>
<text top="106" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#59">Data Supplement 19. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Magnesium Supplementation) (Section 6.2) ......................... 59</a></text>
<text top="106" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#59"> </a></text>
<text top="134" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#61">Data Supplement 20. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Weight Loss) (Section 6.2) ............................................................................................ 61</a></text>
<text top="133" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#61"> </a></text>
<text top="161" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#64">Data Supplement 21. RCTs and Systematic Reviews for RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Section 6.2) ........................................................... 64</a></text>
<text top="161" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#64"> </a></text>
<text top="188" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#66">Data Supplement 22. Observational Studies of CV Target Organ Damage Including LVH (Section 7.2) ..................................................................................................................... 66</a></text>
<text top="188" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#66"> </a></text>
<text top="216" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#67">Data Supplement 23. RCTs on Use of Risk Estimation to Guide Treatment of Hypertension (Section 8.1.2) .............................................................................................................. 67</a></text>
<text top="215" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#67"> </a></text>
<text top="243" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#81">Data Supplement 24. Follow-Up After Initial BP Evaluation (Section 8.1.3) .................................................................................................................................................................. 81</a></text>
<text top="243" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#81"> </a></text>
<text top="270" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#83">Data Supplement 25. RCTs for General Principles of Drug Therapy (Combination Therapies that Inhibit the RAAS) (Section 8.1.4) ......................................................................... 83</a></text>
<text top="270" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#83"> </a></text>
<text top="297" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#85">Data Supplement 26.  BP Goal for Patients with Hypertension (Section 8.1.5) ............................................................................................................................................................. 85</a></text>
<text top="297" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#85"> </a></text>
<text top="325" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#92">Data Supplement 27. Choice of Initial Medication (Section 8.1.6) ................................................................................................................................................................................. 92</a></text>
<text top="324" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#92"> </a></text>
<text top="352" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#95">Data Supplement 28. Follow-Up After Initiating Antihypertensive Drug Therapy (Section 8.3.1) .................................................................................................................................. 95</a></text>
<text top="352" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#95"> </a></text>
<text top="379" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#97">Data Supplement 29. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP (Section 8.3.2) ................................................................................ 97</a></text>
<text top="379" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#97"> </a></text>
<text top="407" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#100">Data Supplement 30. RCTs Comparing Stable Ischemic Heart Disease (Section 9.1) ............................................................................................................................................... 100</a></text>
<text top="406" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#100"> </a></text>
<text top="434" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#110">Data Supplement 31. Meta-analyses of ischemic heart disease (Section 9.1) ............................................................................................................................................................ 110</a></text>
<text top="434" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#110"> </a></text>
<text top="461" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#111">Data Supplement 32. Nonrandomized Trials, Observational Studies, and/or Registries of Ischemic Heart Disease (Section 9.1) ............................................................................ 111</a></text>
<text top="461" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#111"> </a></text>
<text top="488" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#112">Data Supplement 33. RCTs Comparing Heart Failure (Section 9.2) ........................................................................................................................................................................... 112</a></text>
<text top="488" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#112"> </a></text>
<text top="516" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#112">Data Supplement 34. RCTs Comparing HFrEF (Section 9.2.1) .................................................................................................................................................................................. 113</a></text>
<text top="515" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#112"> </a></text>
<text top="543" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#119">Data Supplement 35. RCTs Comparing HFpEF (Section 9.2.2) .................................................................................................................................................................................. 119</a></text>
<text top="543" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#119"> </a></text>
<text top="570" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#122">Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries of HFpEF (Section 9.2.2) .................................................................................................... 122</a></text>
<text top="570" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#122"> </a></text>
<text top="598" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#123">Data Supplement 37. RCTs Comparing CKD (Section 9.3) ........................................................................................................................................................................................ 123</a></text>
<text top="597" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#123"> </a></text>
<text top="625" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#133">Data Supplement 38. Nonrandomized Trials, Observational Studies, and/or Registries of CKD (Section 9.3) ........................................................................................................... 133</a></text>
<text top="625" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#133"> </a></text>
<text top="652" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#137">Data Supplement 39. RCTs Comparing Hypertension after Renal Transplantation (Section 9.3.1) ........................................................................................................................... 137</a></text>
<text top="652" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#137"> </a></text>
<text top="679" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#140">Data Supplement 40. Nonrandomized Trials, Observational Studies, and/or Registries for Hypertension after Renal Transplantation (Section 9.3.1) ............................................ 140</a></text>
<text top="679" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#140"> </a></text>
<text top="707" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#143">Data Supplement 41.  RCTs Comparing Acute Intracerebral Hemorrhage Outcomes (Section 9.4.1) ....................................................................................................................... 143</a></text>
<text top="707" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#143"> </a></text>
<text top="734" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#147">Data Supplement 42. RCTs Comparing Acute Ischemic Stroke Outcomes (Section 9.4.2) ........................................................................................................................................ 147</a></text>
<text top="734" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#147"> </a></text>
<text top="761" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#158">Data Supplement 43.  RCTs Comparing Secondary Stroke Prevention (Section 9.4.3) ............................................................................................................................................. 158</a></text>
<text top="761" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#158"> </a></text>
<text top="789" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#161">Data Supplement 44. Nonrandomized Trials, Observational Studies, and/or Registries of Secondary Stroke Prevention (Section 9.4.3) ................................................................ 161</a></text>
<text top="788" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#161"> </a></text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1073" width="10" height="20" font="1">3 </text>
<text top="106" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#168">Data Supplement 45. RCTs and Meta-analysis Comparing PAD (Section 9.5) .......................................................................................................................................................... 168</a></text>
<text top="106" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#168"> </a></text>
<text top="134" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#174">Data Supplement 46. RCTs and Meta-analyses Comparing BP Targets in DM (Section 9.6) .................................................................................................................................... 174</a></text>
<text top="133" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#174"> </a></text>
<text top="161" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#183">Data Supplement 47.  Nonrandomized Trials, Observational Studies, and/or Registries in DM (Section 9.6) ............................................................................................................ 183</a></text>
<text top="161" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#183"> </a></text>
<text top="188" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#190">Data Supplement 48. Atrial Fibrillation (Section 9.8) ................................................................................................................................................................................................... 190</a></text>
<text top="188" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#190"> </a></text>
<text top="216" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#191">Data Supplement 49. Valvular Heart Disease (Section 9.9) ........................................................................................................................................................................................ 191</a></text>
<text top="215" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#191"> </a></text>
<text top="243" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#194">Data Supplement 50. RCTs and Meta-analysis Comparing Valvular Heart Disease (Section 9.9) ............................................................................................................................. 194</a></text>
<text top="243" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#194"> </a></text>
<text top="270" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#197">Data Supplement 51. RCTs Comparing Race/Ethnicity (Section 10.1) ....................................................................................................................................................................... 197</a></text>
<text top="270" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#197"> </a></text>
<text top="297" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#201">Data Supplement 52. RCTs Comparing Women With Hypertension (Section 10.2.1) ................................................................................................................................................ 201</a></text>
<text top="297" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#201"> </a></text>
<text top="325" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#203">Data Supplement 53. RCTs Comparing Pregnancy (Section 10.2.2) .......................................................................................................................................................................... 203</a></text>
<text top="324" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#203"> </a></text>
<text top="352" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#204">Data Supplement 54. RCT for Older Persons (Section 10.3.1) ................................................................................................................................................................................... 204</a></text>
<text top="352" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#204"> </a></text>
<text top="379" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#204">Data Supplement 55.  RCTs Comparing Hypertensive Crises and Emergencies (Section 11.2) ................................................................................................................................ 204</a></text>
<text top="379" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#204"> </a></text>
<text top="407" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#207">Data Supplement 56. RCTs Assessing Impact of Hypertension Therapy on Dementia Incidence (Section 11.3) ...................................................................................................... 207</a></text>
<text top="406" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#207"> </a></text>
<text top="434" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#210">Data Supplement 57. RCTs for Patients Undergoing Surgical Procedures (Section 11.5) ......................................................................................................................................... 210</a></text>
<text top="434" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#210"> </a></text>
<text top="461" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#211">Data Supplement 58. Observational and Nonrandomized Studies for Patients Undergoing Surgical Procedures (Section 11.5) .............................................................................. 211</a></text>
<text top="461" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#211"> </a></text>
<text top="488" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#213">Data Supplement 59. RCTs of Adherence and Compliance with Fixed Dose Combinations Regimens (Section 12.1.1) .......................................................................................... 213</a></text>
<text top="488" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#213"> </a></text>
<text top="516" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#214">Data Supplement 60.  Nonrandomized Trials, Observational Studies, and/or Registries of Antihypertensive Medication Adherence Strategies (Section 12.1.1) ............................ 214</a></text>
<text top="515" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#214"> </a></text>
<text top="543" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#220">Data Supplement 61. RCTs and Meta-analysis on Strategies to Promote Lifestyle Modification (Section 12.1.2) ..................................................................................................... 220</a></text>
<text top="543" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#220"> </a></text>
<text top="570" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#221">Data Supplement 62. RCTs, Meta-analyses, and Systematic Reviews on the Effect of Structured, Team-based Care Interventions for Hypertension Control (Section 12.2) ........ 221</a></text>
<text top="570" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#221"> </a></text>
<text top="598" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#227">Data Supplement 63. Electronic Health Records and Patient Registries (Section 12.3.1) .......................................................................................................................................... 227</a></text>
<text top="597" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#227"> </a></text>
<text top="625" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#232">Data Supplement 64. RCTs, Meta-analyses, and Systematic Reviews on the Effect of Telehealth Interventions to Improve Hypertension Control (Section 12.3.2) ....................... 232</a></text>
<text top="625" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#232"> </a></text>
<text top="652" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#236">Data Supplement 65. RCTs and Observational Studies that Report on the Effect of Performance Measures and on Hypertension Control (Section 12.4.1) .................................. 236</a></text>
<text top="652" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#236"> </a></text>
<text top="679" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#238">Data Supplement 66.  RCTs, Meta-analyses, and Systematic Reviews on Quality Improvement Strategies on Hypertension Treatment Outcomes (Section 12.4.2) ..................... 238</a></text>
<text top="679" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#238"> </a></text>
<text top="707" left="108" width="972" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#244">Data Supplement 67.  Nonrandomized Trials, Observational Studies, and/or Registries of Effect of Quality Improvement Strategies on Hypertension Treatment Outcomes (Section </a></text>
<text top="727" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#244">12.4.2) .......................................................................................................................................................................................................................................................................... 244</a></text>
<text top="726" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#244"> </a></text>
<text top="754" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#245">Data Supplement 68.  RCTs Comparing Financial Incentives (Section 12.5) ............................................................................................................................................................. 245</a></text>
<text top="754" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#245"> </a></text>
<text top="781" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#252">Additional Data Supplement Tables and Figures ......................................................................................................................................................................................................... 252</a></text>
<text top="781" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#252"> </a></text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="4" size="12" family="Times" color="#000000"/>
	<fontspec id="5" size="12" family="Times" color="#000000"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1073" width="10" height="20" font="1">4 </text>
<text top="106" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#252">Data Supplement A. Treatment of HFrEF Stages C and D ..................................................................................................................................................................................... 252</a></text>
<text top="106" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#252"> </a></text>
<text top="134" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#253">Data Supplement B. Medication Adherence Assessment Scales ........................................................................................................................................................................... 253</a></text>
<text top="133" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#253"> </a></text>
<text top="161" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#253">Data Supplement C. Categories Defining Normal BP, Elevated BP, and Stages 1, 2, and 3 Hypertension ........................................................................................................... 253</a></text>
<text top="161" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#253"> </a></text>
<text top="188" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#255">Data Supplement D. Fixed-Dose Combination Antihypertensive Drugs ................................................................................................................................................................. 255</a></text>
<text top="188" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#255"> </a></text>
<text top="216" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#256">Data Supplement E. Examples of Hypertension Quality Improvement Strategies .................................................................................................................................................. 256</a></text>
<text top="215" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#256"> </a></text>
<text top="243" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#257">Data Supplement F. Barriers and Improvement Strategies in Antihypertensive Medication Adherence (350-354) ................................................................................................ 257</a></text>
<text top="243" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#257"> </a></text>
<text top="270" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#258">Data Supplement G. Examples of Strategies to Promote Lifestyle Modification Interventions in Patients With Hypertension (319,320,356-362) ................................................. 258</a></text>
<text top="270" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#258"> </a></text>
<text top="297" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#259">Data Supplement H. Responsibilities and Roles of the Hypertension Team ........................................................................................................................................................... 259</a></text>
<text top="297" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#259"> </a></text>
<text top="325" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#260">Data Supplement I. Examples of Telehealth Strategies and Technologies to Promote Effective Hypertension Management ............................................................................... 260</a></text>
<text top="324" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#260"> </a></text>
<text top="352" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#261">Data Supplement J. Publicly Available Performance Measures Used to Assess Hypertension Care Quality Services (364-368) ......................................................................... 261</a></text>
<text top="352" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#261"> </a></text>
<text top="379" left="123" width="956" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#263">Data Supplement K. Online Quality Improvement Resources for Treatment and Control of Hypertension ............................................................................................................ 263</a></text>
<text top="379" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#263"> </a></text>
<text top="407" left="108" width="971" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">References ................................................................................................................................................................................................................................................................... 264</a></text>
<text top="406" left="1079" width="4" height="21" font="0"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264"> </a></text>
<text top="435" left="108" width="3" height="19" font="4"><b> </b></text>
<text top="471" left="108" width="91" height="19" font="4"><b>Search Terms:</b> </text>
<text top="508" left="108" width="924" height="19" font="1">An extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE </text>
<text top="529" left="108" width="953" height="19" font="1">(through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, </text>
<text top="550" left="108" width="934" height="19" font="1">was conducted between February and August 2015. Key search words included but were not limited to the following: <i>adherence; aerobic; alcohol intake; </i></text>
<text top="570" left="108" width="965" height="19" font="5"><i>ambulatory care; antihypertensive: agents, drug, medication, therapy; beta adrenergic blockers; blood pressure: arterial, control, determination, devises, goal, </i></text>
<text top="591" left="108" width="894" height="19" font="5"><i>high, improve, measurement, monitoring, ambulatory; calcium channel blockers; diet; diuretic agent; drug therapy; heart failure: diastolic, systolic; </i></text>
<text top="612" left="108" width="937" height="19" font="5"><i>hypertension: white coat, masked, ambulatory, isolated ambulatory, isolated clinic, diagnosis, reverse white coat, prevention, therapy, treatment, control; </i></text>
<text top="633" left="108" width="958" height="19" font="5"><i>intervention; lifestyle: measures, modification; office visits; patient outcome; performance measures; physical activity; potassium intake; protein intake; renin </i></text>
<text top="654" left="108" width="970" height="19" font="5"><i>inhibitor; risk reduction: behavior, counseling; screening; sphygmomanometers; spironolactone; therapy; treatment: adherence, compliance, efficacy, outcome, </i></text>
<text top="675" left="108" width="962" height="20" font="5"><i>protocol, regimen; weight.</i> Additional relevant studies published through June 2016, during the guideline writing process, were also considered by the writing </text>
<text top="697" left="108" width="397" height="19" font="1">committee, and added to the evidence tables when appropriate. </text>
<text top="733" left="108" width="3" height="19" font="1"> </text>
<text top="769" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="6" size="7" family="Times" color="#000000"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1073" width="10" height="20" font="1">5 </text>
<text top="108" left="108" width="95" height="19" font="4"><b>Abbreviations: </b></text>
<text top="145" left="108" width="949" height="19" font="1">1°, primary; 2º, secondary; AASK, African American Study of Kidney Disease and Hypertension; ABI, ankle-brachial index; ABCD, Appropriate Blood Pressure </text>
<text top="166" left="108" width="970" height="19" font="1">Control in Diabetes; ABPM, ambulatory blood pressure monitoring; ACCESS, Acute Candesartan Cilexetil Evaluation in Stroke Survivors; ACCOMPLISH, Avoiding </text>
<text top="187" left="108" width="968" height="19" font="1">Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension; ACCORD, Action to Control Cardiovascular Risk in Diabetes; </text>
<text top="208" left="108" width="922" height="19" font="1">ACE, angiotensin-converting enzyme; ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ADVANCE, Action in Diabetes and </text>
<text top="229" left="108" width="948" height="19" font="1">Vascular Disease; AF, atrial fibrillation; AFL, atrial flutter; AHR, adjusted hazard ratio; AIPRD, Angiotensin-Converting Enzyme Inhibition in Progressive Renal </text>
<text top="250" left="108" width="927" height="19" font="1">Disease; ALLHAT, Antihypertensive Lipid Lowering Treatment to Prevent Heart Attack Trial; AMI, acute myocardial infarction; ARB, angiotensin-receptor </text>
<text top="271" left="108" width="944" height="19" font="1">blocker; ARIC, Atherosclerosis Risk in Communities; ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; BB, beta blocker; BMI, body mass index; BP, blood </text>
<text top="292" left="108" width="973" height="19" font="1">pressure; BPLTTC, Blood Pressure Lowering Treatment Trialists’ Collaboration<i>;</i> bpm, beats per minute; BUN, blood urea nitrogen; CABG, coronary artery bypass </text>
<text top="313" left="108" width="966" height="19" font="1">graft; CAD, coronary artery disease;<i> </i>CATIS, China Antihypertensive Trial in Acute Ischemic Stroke; CCB, calcium-channel blocker; CCU, coronary care unit; CHD, </text>
<text top="334" left="108" width="946" height="19" font="1">coronary heart disease; CHF, congestive heart failure; CHHIPS, Controlling Hypertension and Hypotension Immediately Post-Stroke; CI, confidence interval; </text>
<text top="356" left="108" width="941" height="19" font="1">CKD, chronic kidney disease; COMFORT, Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Mediation Compliance Trial; </text>
<text top="377" left="108" width="961" height="19" font="1">COSSACS, the Continue or Stop Post-Stroke Antihypertensives Collaborative Study; CPAP, continuous positive airway pressure; Cr, creatinine; CrCL, creatinine </text>
<text top="398" left="108" width="969" height="19" font="1">clearance; CRP, c-reactive protein; CR/XL, metoprolol controlled release/extended release; CT, computed tomography; CV, cardiovascular; CVD, cardiovascular </text>
<text top="419" left="108" width="973" height="19" font="1">disease; DASH, Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; DM, diabetes mellitus; DM-1, diabetes mellitus type-1; DM-2, diabetes </text>
<text top="440" left="108" width="963" height="19" font="1">mellitus type-2; ECG, electrocardiogram; ED, emergency department; EF, ejection fraction; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney </text>
<text top="461" left="108" width="975" height="19" font="1">disease; ESRD, end-stage renal disease; FC, functional class; FDC, fixed dose combination; FEVER, Felodipine EVent Reduction; GITS, gastrointestinal therapeutic </text>
<text top="482" left="108" width="964" height="19" font="1">system; GFR, glomerular filtration rate; HBPM, home blood pressure monitoring; HCTZ, hydrochlorthiazide; HDL, high-density lipoprotein; HDL-C, high-density </text>
<text top="503" left="108" width="969" height="19" font="1">lipoprotein cholesterol; HEDIS, Healthcare Effectiveness Data and Information Set; HF, heart failure; HF<i>r</i>EF, reduced ejection fraction; HF<i>p</i>EF, heart failure with </text>
<text top="524" left="108" width="919" height="19" font="1">preserved ejection fraction; HIV, human immunodeficiency virus; HR, hazard ratio; HTN, hypertension; ICD, implantable cardioverter-defibrillator; ICH, </text>
<text top="545" left="108" width="954" height="19" font="1">intracerebral hemorrhage; IDACO, International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome; IHD, ischemic heart disease; </text>
<text top="566" left="108" width="957" height="19" font="1">IMT, intimal media thickness; INDANA, Individual Data Analysis of Antihypertensive drug intervention trials; INTERACT2, the second Intensive Blood Pressure </text>
<text top="587" left="108" width="935" height="19" font="1">Reduction in Acute Cerebral Hemorrhage Trial; INVEST, International Verapamil-Trandolapril Study; INWEST, the Intravenous Nimodipine West European </text>
<text top="608" left="108" width="843" height="19" font="1">Stroke Trial; IQI, interquartile interval; IQR, interquartile range; IRR, incident rate ratio; ISDN, isosorbide dinitrate; IV, intravenous; JNC-7, 7</text>
<text top="608" left="951" width="8" height="12" font="6">th</text>
<text top="608" left="959" width="121" height="19" font="1"> Report of the Joint </text>
<text top="629" left="108" width="947" height="19" font="1">National Committee; KPNC, Kaiser Permanente Northern California; LDL, low-density lipoprotein; LGSAS, low-gradient severe aortic stenosis; LIFE, Losartan </text>
<text top="650" left="108" width="942" height="19" font="1">Intervention For Endpoint Reduction in Hypertension; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVMI; left ventricular mass </text>
<text top="671" left="108" width="957" height="19" font="1">index; MACCE, major adverse cardiac and cerebrovascular events; MACE, major adverse cardiac events; MAP, mean arterial pressure; MD, mean difference;  </text>
<text top="692" left="108" width="897" height="19" font="1">MDPIT, Multicenter Dilitiazem Postinfarction Research Group; MDRD, Modification of Diet in Renal Disease; MERIT, Metoprolol CR/XL Randomised </text>
<text top="713" left="108" width="946" height="19" font="1">Intervention Trial; MESA, Multi-Ethnic Study of Atherosclerosis; MH, masked hypertension; MI, myocardial infarction; MOSES, The Morbidity and Mortality </text>
<text top="734" left="108" width="956" height="19" font="1">After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention; MPR, medication possession ratio; MRFIT, Multiple Risk Factor Intervention </text>
<text top="755" left="108" width="917" height="19" font="1">Trial; MRI, magnetic resonance imaging; N/A, not available; NCQA, National Committee for Quality Assurance; NEMESIS, North East Melbourne Stroke </text>
<text top="777" left="108" width="975" height="19" font="1">Incidence Study; NHANES, National Health and Nutrition Examination Surveys; NIH, National Institute of Health; NNT, number needed to treat; NR, not relative; </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1073" width="10" height="20" font="1">6 </text>
<text top="108" left="108" width="971" height="19" font="1">NS, nonsignificant; NSAID, nonsteroidal anti-inflammatory drug; NUTRICODE, Nutrition and Chronic Diseases Expert Group; NYHA, New York Heart Association; </text>
<text top="129" left="108" width="945" height="19" font="1">ONTARGET, Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial; OR, odds ratio; OSA, obstructive sleep apnea; P4P, pay for </text>
<text top="150" left="108" width="963" height="19" font="1">performance; PA, pulmonary artery; PAD, peripheral artery disease; PAMELA, Pressione Arteriose Monitorate E Loro Associazioni; PCP, primary care provider; </text>
<text top="171" left="108" width="934" height="19" font="1">periop, perioperative; PREDIMED, Prevention with a Mediterranean Diet; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; </text>
<text top="192" left="108" width="965" height="19" font="1">PROBE, Prospective, randomized, open, blinded endpoint; PROGRESS, The perindopril protection against recurrent stroke study; PRONTO, Prospective Optical </text>
<text top="213" left="108" width="951" height="19" font="1">Coherence Tomography Imaging of Patients with endovascular Age-Related Macular Degeneration Treated with Intraocular Ranibizumab; pt, patient; PTCA, </text>
<text top="234" left="108" width="971" height="19" font="1">percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease; QI, quality improvement; RAAS, renin angiotensin aldosterone system; RCT, </text>
<text top="255" left="108" width="952" height="19" font="1">randomized controlled trial; REIN-2, Blood Pressure Control for Renoprotection in Patients with Non-diabetic Renal Disease; RH, relative hazard; ROADMAP, </text>
<text top="277" left="108" width="963" height="19" font="1">Randomized Olmesartan and Diabetes Microalbuminuria Prevention; RR, relative risk; Rx, medical prescription; SAE, severe adverse event; SBP, systolic blood </text>
<text top="298" left="108" width="946" height="19" font="1">pressure; SCOPE-AS, Symptomatic Cardiac Obstruction – Pilot Study of Enalapril in Aortic Stenosis; SD, standard deviation; SE, stress echocardiography; SH, </text>
<text top="319" left="108" width="928" height="19" font="1">sustained hypertension; SHEP, Summer Health Enrichment; SITS-ISTR, Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis </text>
<text top="340" left="108" width="950" height="19" font="1">Register; SKIPOGH, Swiss Kidney Project on Genes in Hypertension; SPC, single pill combination; SPRINT, Systolic Blood Pressure Intervention Trial; Syst-Eur, </text>
<text top="361" left="108" width="908" height="19" font="1">Systolic Hypertension in Europe; t-PA, tissue plasminogen activator; TIA, transient ischemic attack; TOHP, Trials of Hypertension Prevention; TOMHS, </text>
<text top="382" left="108" width="962" height="19" font="1">Treatment of Mild Hypertension Study; TONE, Trial of Nonpharmacologic Intervention in the Elderly; TOPCAT, Treatment of Preserved Cardiac Function Heart </text>
<text top="403" left="108" width="958" height="19" font="1">Failure With Aldosterone Antagonist; TR, target range; UA, unstable angina; U.K., United Kingdom; UKPDS, United Kingdom Prospective Diabetes Study; U.S., </text>
<text top="424" left="108" width="969" height="19" font="1">United States; VA, Veterans Affairs; VA Coop; Veterans Administration Cooperative Study Group on Antihypertensive Agents; VA NEPHRON-D, Veterans Affairs </text>
<text top="445" left="108" width="959" height="19" font="1">Nephropathy in Diabetes; VALIANT, Valsartan in Acute Myocardial Infarction Trial; VALUE, Valsartan Antihypertensive Long-term Use Evaluation; WCH, white </text>
<text top="466" left="108" width="398" height="19" font="1">coat hypertension; and WPW; Wolff-Parkinson-White syndrome. </text>
<text top="502" left="108" width="3" height="19" font="1"> </text>
<text top="538" left="108" width="3" height="19" font="1"> </text>
<text top="538" left="324" width="3" height="19" font="1"> </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="7" size="12" family="Times" color="#0000ff"/>
	<fontspec id="8" size="19" family="Times" color="#000000"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1073" width="10" height="20" font="1">7 </text>
<text top="106" left="81" width="669" height="24" font="3"><b>Data Supplement 1. Coexistence of Hypertension and Related Chronic Conditions (Section 2.4) </b></text>
<text top="146" left="109" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="163" left="134" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="180" left="112" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="249" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="163" left="265" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="419" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="594" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="163" left="579" width="208" height="20" font="4"><b>(include P value; OR RR; &amp; 95% CI) </b></text>
<text top="146" left="880" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="163" left="907" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="198" left="98" width="100" height="20" font="1">Wilson PW, et al., </text>
<text top="215" left="98" width="49" height="20" font="1">1999 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(1)</a> </text>
<text top="233" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10335688?dopt=Citation">10335688</a></text>
<text top="233" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10335688?dopt=Citation"> </a></text>
<text top="198" left="231" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="215" left="231" width="94" height="20" font="1">Nonrandomized  </text>
<text top="233" left="231" width="3" height="20" font="1"> </text>
<text top="250" left="231" width="131" height="20" font="4"><b>Size:</b> 2,406 men, 2,569 </text>
<text top="267" left="231" width="146" height="20" font="1">women (1,759 men, 1,818 </text>
<text top="284" left="231" width="125" height="20" font="1">women with follow-up) </text>
<text top="198" left="397" width="133" height="20" font="4"><b>Inclusion criteria:</b> Men </text>
<text top="215" left="397" width="138" height="20" font="1">and women 18–74 y and </text>
<text top="233" left="397" width="134" height="20" font="1">free of CHD at baseline, </text>
<text top="250" left="397" width="121" height="20" font="1">from the Framingham </text>
<text top="267" left="397" width="88" height="20" font="1">Offspring Study </text>
<text top="284" left="397" width="3" height="20" font="1"> </text>
<text top="301" left="397" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="199" left="565" width="228" height="20" font="4"><b>1</b>°<b> endpoint:</b> Total CHD (first occurrence </text>
<text top="217" left="565" width="219" height="20" font="1">of angina, UA, MI, and coronary death), </text>
<text top="234" left="565" width="218" height="20" font="1">Hard CHD (first MI and coronary death) </text>
<text top="251" left="565" width="3" height="20" font="1"> </text>
<text top="268" left="565" width="228" height="20" font="4"><b>Results:</b> Presence of ≥3 risk factors was </text>
<text top="285" left="565" width="237" height="20" font="1">associated with a 2.39 times greater risk of </text>
<text top="303" left="565" width="236" height="20" font="1">CHD in men (95% CI: 1.56–3.36; p&lt;0.001) </text>
<text top="320" left="565" width="198" height="20" font="1">and a 5.90 increased risk of CHD in </text>
<text top="337" left="565" width="215" height="20" font="1">women (95% CI: 2.54–13.73; p&lt;0.001) </text>
<text top="200" left="815" width="7" height="18" font="1">•</text>
<text top="199" left="822" width="209" height="20" font="1"> CVD risk factors infrequently occur in </text>
<text top="217" left="815" width="207" height="20" font="1">isolation (only 28%–30% of the time); </text>
<text top="234" left="815" width="242" height="20" font="1">presence of ≥3 risk factors occurred 17% of </text>
<text top="251" left="815" width="253" height="20" font="1">the time in both men and women; presence of </text>
<text top="268" left="815" width="232" height="20" font="1">≥3 risk factors associated with high risk of </text>
<text top="285" left="815" width="244" height="20" font="1">CHD and coronary death (attributable risk of </text>
<text top="303" left="815" width="181" height="20" font="1">20% in men and 48% in women) </text>
<text top="355" left="98" width="119" height="20" font="1">Berry JD, et al., 2012 </text>
<text top="372" left="98" width="22" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(2)</a>  </text>
<text top="389" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22276822?dopt=Citation">22276822</a></text>
<text top="389" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22276822?dopt=Citation"> </a></text>
<text top="355" left="231" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="372" left="231" width="90" height="20" font="1">Nonrandomized </text>
<text top="389" left="231" width="3" height="20" font="1"> </text>
<text top="407" left="231" width="136" height="20" font="4"><b>Size:</b> 257,384 black and </text>
<text top="424" left="231" width="130" height="20" font="1">white men and women, </text>
<text top="441" left="231" width="145" height="20" font="1">including 67,890 pts (from </text>
<text top="458" left="231" width="124" height="20" font="1">17 meta-analysis) and </text>
<text top="476" left="231" width="145" height="20" font="1">189,494 pts (from MRFIT) </text>
<text top="355" left="397" width="137" height="20" font="4"><b>Inclusion criteria:</b> Meta-</text>
<text top="372" left="397" width="116" height="20" font="1">analysis of 18 cohort </text>
<text top="389" left="397" width="46" height="20" font="1">studies  </text>
<text top="407" left="397" width="3" height="20" font="1"> </text>
<text top="424" left="397" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="356" left="565" width="234" height="20" font="4"><b>1</b>°<b> endpoint:</b> Fatal CHD, nonfatal MI, fatal </text>
<text top="373" left="565" width="98" height="20" font="1">or nonfatal stroke </text>
<text top="391" left="565" width="3" height="20" font="1"> </text>
<text top="408" left="565" width="208" height="20" font="4"><b>Results:</b> Participants with optimal RF </text>
<text top="425" left="565" width="203" height="20" font="1">profile (total cholesterol &lt;180 mg/dL, </text>
<text top="442" left="565" width="220" height="20" font="1">untreated BP &lt;120 mm Hg systolic, and </text>
<text top="460" left="565" width="188" height="20" font="1">&lt;80 mm Hg diastolic, nondiabetic, </text>
<text top="477" left="565" width="232" height="20" font="1">nonsmoker) compared to participants with </text>
<text top="494" left="565" width="204" height="20" font="1">≥2 risk factors had lower risk of CVD </text>
<text top="511" left="565" width="223" height="20" font="1">through the age of 80 y (4.7% vs. 29.6% </text>
<text top="528" left="565" width="206" height="20" font="1">for men, 6.4% vs. 20.5% for women), </text>
<text top="546" left="565" width="215" height="20" font="1">lower lifetime risk of fatal heart disease </text>
<text top="563" left="565" width="230" height="20" font="1">and nonfatal MI (3.6% vs. 37.5% for men, </text>
<text top="580" left="565" width="211" height="20" font="1">&lt;1% vs. 18.3% for women), and lower </text>
<text top="597" left="565" width="204" height="20" font="1">lifetime risk of fatal or nonfatal stroke </text>
<text top="614" left="565" width="224" height="20" font="1">(2.3% vs. 8.3% for men, 5.3% vs. 10.7% </text>
<text top="632" left="565" width="65" height="20" font="1">for women) </text>
<text top="357" left="815" width="7" height="18" font="1">•</text>
<text top="356" left="822" width="196" height="20" font="1"> Increased burden of 80 risk factors </text>
<text top="373" left="815" width="233" height="20" font="1">associated with higher lifetime risk of CVD </text>
<text top="651" left="108" width="3" height="19" font="1"> </text>
<text top="693" left="108" width="3" height="19" font="1"> </text>
<text top="687" left="324" width="5" height="27" font="8"><b> </b></text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1073" width="10" height="20" font="1">8 </text>
<text top="106" left="81" width="385" height="24" font="3"><b>Data Supplement 2. Definition of High BP (Section 3.1) </b></text>
<text top="146" left="94" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="163" left="120" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="180" left="97" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="226" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="163" left="242" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="435" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="671" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="163" left="626" width="269" height="20" font="4"><b>(include P value; OR or RR; and CI; &amp; 95% CI) </b></text>
<text top="146" left="932" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="163" left="960" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="198" left="89" width="108" height="20" font="1">Lewington S, et al., </text>
<text top="215" left="89" width="31" height="20" font="1">2002 </text>
<text top="233" left="89" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12493255">12493255</a></text>
<text top="233" left="144" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12493255"> </a></text>
<text top="198" left="211" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="215" left="211" width="110" height="20" font="1">Meta-analysis of 61 </text>
<text top="233" left="211" width="114" height="20" font="1">observational cohort </text>
<text top="250" left="211" width="42" height="20" font="1">studies<b> </b></text>
<text top="198" left="373" width="226" height="20" font="4"><b>Inclusion criteria:</b> Men and women with </text>
<text top="215" left="373" width="226" height="20" font="1">no history of previous CVD and record of </text>
<text top="233" left="373" width="111" height="20" font="1">key study variables. </text>
<text top="250" left="373" width="3" height="20" font="1"> </text>
<text top="267" left="373" width="169" height="20" font="4"><b>Exclusion criteria: </b>Prior CVD<b> </b></text>
<text top="199" left="622" width="210" height="20" font="4"><b>1</b>°<b> endpoint: </b>Cause-specific mortality </text>
<text top="217" left="622" width="3" height="20" font="1"> </text>
<text top="234" left="622" width="271" height="20" font="4"><b>Results</b>: 958,074 persons followed for a mean of </text>
<text top="251" left="622" width="235" height="20" font="1">12 y to death (12.7 million person-y at risk. </text>
<text top="268" left="622" width="173" height="20" font="1">Number of deaths attributed to: </text>
<text top="285" left="622" width="84" height="20" font="1">-Stroke: 11960 </text>
<text top="303" left="622" width="73" height="20" font="1">-IHD: 34,283 </text>
<text top="320" left="622" width="125" height="20" font="1">-Other vascular:10092 </text>
<text top="337" left="622" width="121" height="20" font="1">-Non-vascular: 60797 </text>
<text top="354" left="622" width="3" height="20" font="1"> </text>
<text top="371" left="622" width="276" height="20" font="1">Above a SBP ≥115 mm Hg and DBP ≥75 mm Hg, </text>
<text top="389" left="622" width="254" height="20" font="1">there was a progressive rise in vascular death </text>
<text top="406" left="622" width="267" height="20" font="1">with progressively high BP with no evidence of a </text>
<text top="423" left="622" width="277" height="20" font="1">J-curve (approximately doubling of stroke and IHD </text>
<text top="440" left="622" width="260" height="20" font="1">mortality for a 20 mm Hg higher level of SBP or </text>
<text top="458" left="622" width="273" height="20" font="1">10 mm Hg higher level of DBP, in those 40–69 y). </text>
<text top="475" left="622" width="251" height="20" font="1">With progressively higher age, the BP-related </text>
<text top="492" left="622" width="229" height="20" font="1">proportional risk of vascular mortality was </text>
<text top="509" left="622" width="230" height="20" font="1">somewhat reduced but the corresponding </text>
<text top="526" left="622" width="172" height="20" font="1">absolute risk was much higher.<b> </b></text>
<text top="200" left="913" width="7" height="18" font="1">•</text>
<text top="200" left="919" width="98" height="20" font="1"> In adults aged 40</text>
<text top="199" left="1017" width="8" height="21" font="0">–</text>
<text top="200" left="1025" width="30" height="20" font="1">89 y, </text>
<text top="218" left="913" width="166" height="20" font="1">usual BP is strongly related to </text>
<text top="236" left="913" width="121" height="20" font="1">vascular (and overall) </text>
<text top="253" left="913" width="162" height="20" font="1">mortality, without evidence of </text>
<text top="270" left="913" width="154" height="20" font="1">a threshold down to at least </text>
<text top="287" left="913" width="152" height="20" font="1">an SBP/DBP of 115/75 mm </text>
<text top="304" left="913" width="19" height="20" font="1">Hg.</text>
<text top="304" left="932" width="4" height="21" font="0"> </text>
<text top="544" left="89" width="103" height="20" font="1">Rapsomaniki E, et </text>
<text top="562" left="89" width="51" height="20" font="1">al., 2014 </text>
<text top="579" left="89" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24881994">24881994</a></text>
<text top="579" left="144" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24881994"> </a></text>
<text top="544" left="211" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="562" left="211" width="117" height="20" font="1">Observational cohort </text>
<text top="579" left="211" width="33" height="20" font="1">study </text>
<text top="596" left="211" width="3" height="20" font="1"> </text>
<text top="613" left="211" width="32" height="20" font="4"><b>Size:</b> </text>
<text top="630" left="211" width="128" height="20" font="1">1.25 million patients, in </text>
<text top="648" left="211" width="148" height="20" font="1">225 primary care practices </text>
<text top="665" left="211" width="134" height="20" font="1">in the UK, followed for a </text>
<text top="682" left="211" width="120" height="20" font="1">median of 5.2 y using </text>
<text top="699" left="211" width="102" height="20" font="1">electronic medical </text>
<text top="716" left="211" width="51" height="20" font="1">records. <b> </b></text>
<text top="544" left="373" width="226" height="20" font="4"><b>Inclusion criteria: </b>Men and women ≥30 </text>
<text top="562" left="373" width="233" height="20" font="1">y, with no previous diagnosis of CVD, who </text>
<text top="579" left="373" width="224" height="20" font="1">had been registered at their practices for </text>
<text top="596" left="373" width="49" height="20" font="1">≥1 year. </text>
<text top="613" left="373" width="3" height="20" font="1"> </text>
<text top="630" left="373" width="137" height="20" font="4"><b>Exclusion criteria</b>: N/A <b> </b></text>
<text top="546" left="622" width="222" height="20" font="4"><b>1</b>°<b> endpoint: </b>12 acute and chronic CVD </text>
<text top="563" left="622" width="57" height="20" font="1">outcomes </text>
<text top="580" left="622" width="3" height="20" font="1"> </text>
<text top="597" left="622" width="249" height="20" font="4"><b>Results: </b>83,098 initial CVD events recorded. </text>
<text top="614" left="622" width="267" height="20" font="1">Within each of 3 age groups (30–59, 60–79, and </text>
<text top="632" left="622" width="268" height="20" font="1">≥80 y), the lowest risk for CVD was in those with </text>
<text top="649" left="622" width="262" height="20" font="1">a SBP 90–114 mm Hg and DBP 60–74 mm Hg. </text>
<text top="666" left="622" width="263" height="20" font="1">There was a direct relationship between level of </text>
<text top="683" left="622" width="272" height="20" font="1">BP and most CVD outcomes, with no evidence of </text>
<text top="700" left="622" width="259" height="20" font="1">J-curve, with the strongest relationship for SBP </text>
<text top="718" left="622" width="276" height="20" font="1">and stroke and weakest for abdominal aneurysm. <b> </b></text>
<text top="546" left="913" width="7" height="18" font="1">•</text>
<text top="546" left="919" width="162" height="20" font="1"> Despite modern treatments,  </text>
<text top="563" left="913" width="139" height="20" font="1">the lifetime burden of BP-</text>
<text top="580" left="913" width="158" height="20" font="1">related CVD was substantial.</text>
<text top="580" left="1070" width="4" height="21" font="0"> </text>
<text top="736" left="89" width="100" height="20" font="1">Wilson PW, et al., </text>
<text top="753" left="89" width="53" height="20" font="1">1999 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(1)</a>  </text>
<text top="770" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10335688?dopt=Citation">10335688</a></text>
<text top="770" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10335688?dopt=Citation"> </a></text>
<text top="736" left="211" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="753" left="211" width="90" height="20" font="1">Nonrandomized </text>
<text top="770" left="211" width="3" height="20" font="1"> </text>
<text top="736" left="373" width="221" height="20" font="4"><b>Inclusion criteria:</b> Men and women 18–</text>
<text top="753" left="373" width="234" height="20" font="1">74 y and free of CHD at baseline, from the </text>
<text top="770" left="373" width="161" height="20" font="1">Framingham Offspring Study </text>
<text top="787" left="373" width="3" height="20" font="1"> </text>
<text top="737" left="622" width="242" height="20" font="4"><b>1</b>°<b> endpoint:</b> Total CHD (first occurrence of </text>
<text top="754" left="622" width="265" height="20" font="1">angina, UA, MI, and coronary death), Hard CHD </text>
<text top="771" left="622" width="158" height="20" font="1">(first MI and coronary death) </text>
<text top="788" left="622" width="3" height="20" font="1"> </text>
<text top="737" left="913" width="7" height="18" font="1">•</text>
<text top="737" left="919" width="96" height="20" font="1"> CVD risk factors </text>
<text top="754" left="913" width="162" height="20" font="1">infrequently occur in isolation </text>
<text top="771" left="913" width="155" height="20" font="1">(only 28%–30% of the time) </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1073" width="10" height="20" font="1">9 </text>
<text top="107" left="211" width="131" height="20" font="4"><b>Size:</b> 2,406 men, 2,569 </text>
<text top="124" left="211" width="146" height="20" font="1">women (1,759 men, 1,818 </text>
<text top="141" left="211" width="125" height="20" font="1">women with follow-up) </text>
<text top="107" left="373" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="107" left="622" width="228" height="20" font="4"><b>Results:</b> Presence of ≥3 risk factors was </text>
<text top="124" left="622" width="266" height="20" font="1">associated with a 2.39 times greater risk of CHD </text>
<text top="141" left="622" width="267" height="20" font="1">in men (95% CI: 1.56–3.36; p&lt;0.001) and a 5.90 </text>
<text top="159" left="622" width="261" height="20" font="1">increased risk of CHD in women (95% CI: 2.54–</text>
<text top="176" left="622" width="90" height="20" font="1">13.73; p&lt;0.001) </text>
<text top="109" left="913" width="7" height="18" font="1">•</text>
<text top="108" left="919" width="154" height="20" font="1"> Presence of ≥3 risk factors </text>
<text top="125" left="913" width="153" height="20" font="1">occurred 17% of the time in </text>
<text top="143" left="913" width="122" height="20" font="1">both men and women </text>
<text top="162" left="913" width="7" height="18" font="1">•</text>
<text top="161" left="919" width="154" height="20" font="1"> Presence of ≥3 risk factors </text>
<text top="178" left="913" width="150" height="20" font="1">associated with high risk of </text>
<text top="195" left="913" width="139" height="20" font="1">CHD and coronary death </text>
<text top="213" left="913" width="145" height="20" font="1">(attributable risk of 20% in </text>
<text top="230" left="913" width="139" height="20" font="1">men and 48% in women) </text>
<text top="248" left="89" width="106" height="20" font="1">Guo X, et al., 2013 </text>
<text top="265" left="89" width="19" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(3)</a> </text>
<text top="282" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23634212?dopt=Citation">23634212</a></text>
<text top="282" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23634212?dopt=Citation"> </a></text>
<text top="248" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="265" left="211" width="61" height="20" font="1">analysis of </text>
<text top="282" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="299" left="211" width="3" height="20" font="1"> </text>
<text top="317" left="211" width="100" height="20" font="4"><b>Size:</b> 870,678 pts </text>
<text top="248" left="373" width="202" height="20" font="4"><b>Inclusion criteria:</b> Studies reporting </text>
<text top="265" left="373" width="231" height="20" font="1">adjusted risk for CVD or mortality with pre-</text>
<text top="282" left="373" width="29" height="20" font="1">HTN </text>
<text top="299" left="373" width="3" height="20" font="1"> </text>
<text top="317" left="373" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="249" left="622" width="231" height="20" font="4"><b>1</b>°<b> endpoint:</b> CVD and all-cause mortality </text>
<text top="266" left="622" width="3" height="20" font="1"> </text>
<text top="283" left="622" width="241" height="20" font="4"><b>Results:</b> SBP/DBP 120–129/80–84 mm Hg </text>
<text top="301" left="622" width="166" height="20" font="1">compared to &lt;120/80 mm Hg: </text>
<text top="320" left="622" width="7" height="18" font="1">•</text>
<text top="319" left="629" width="244" height="20" font="1"> All-cause mortality: RR: 0.91; 95% CI: 0.81–</text>
<text top="336" left="622" width="31" height="20" font="1">1.02) </text>
<text top="355" left="622" width="7" height="18" font="1">•</text>
<text top="355" left="629" width="252" height="20" font="1"> CVD mortality: RR: 1.10 (95% CI: 0.92, 1.30) </text>
<text top="372" left="622" width="260" height="20" font="1">SBP/DBP 130–139/85–89 mm Hg compared to </text>
<text top="389" left="622" width="95" height="20" font="1">&lt;120/80 mm Hg: </text>
<text top="408" left="622" width="7" height="18" font="1">•</text>
<text top="407" left="629" width="247" height="20" font="1"> All-cause mortality: 1.00; 95% CI: 0.95–1.06 </text>
<text top="426" left="622" width="7" height="18" font="1">•</text>
<text top="426" left="629" width="247" height="20" font="1"> CVD mortality: RR: 1.26; 95% CI: 1.13–1.41 </text>
<text top="250" left="913" width="7" height="18" font="1">•</text>
<text top="249" left="919" width="146" height="20" font="1"> SBP/DBP of 120–129/80–</text>
<text top="266" left="913" width="147" height="20" font="1">84 mm Hg associated with </text>
<text top="283" left="913" width="164" height="20" font="1">increased risk for all-cause or </text>
<text top="301" left="913" width="83" height="20" font="1">CVD mortality. </text>
<text top="320" left="913" width="7" height="18" font="1">•</text>
<text top="319" left="919" width="146" height="20" font="1"> SBP/DBP of 130–139/85–</text>
<text top="336" left="913" width="165" height="20" font="1">89 mm Hg associated with an </text>
<text top="354" left="913" width="126" height="20" font="1">increased risk for CVD </text>
<text top="371" left="913" width="53" height="20" font="1">mortality. </text>
<text top="444" left="89" width="106" height="20" font="1">Guo X, et al., 2013 </text>
<text top="461" left="89" width="19" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(4)</a> </text>
<text top="478" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24234576?dopt=Citation">24234576</a></text>
<text top="478" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24234576?dopt=Citation"> </a></text>
<text top="444" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="461" left="211" width="61" height="20" font="1">analysis of </text>
<text top="478" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="495" left="211" width="3" height="20" font="1"> </text>
<text top="513" left="211" width="110" height="20" font="4"><b>Size:</b> 1,010,858 pts </text>
<text top="444" left="373" width="202" height="20" font="4"><b>Inclusion criteria:</b> Studies reporting </text>
<text top="461" left="373" width="228" height="20" font="1">adjusted risk for fatal and nonfatal stroke, </text>
<text top="478" left="373" width="217" height="20" font="1">CHD, MI and total CVD events with pre-</text>
<text top="495" left="373" width="206" height="20" font="1">HTN, 120–129/80–84 mm Hg or 130–</text>
<text top="513" left="373" width="105" height="20" font="1">139/85–89 mm Hg </text>
<text top="530" left="373" width="3" height="20" font="1"> </text>
<text top="547" left="373" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="445" left="622" width="268" height="20" font="4"><b>1</b>°<b> endpoint:</b> Fatal and nonfatal stroke, CHD, MI </text>
<text top="462" left="622" width="120" height="20" font="1">and total CVD events </text>
<text top="479" left="622" width="3" height="20" font="1"> </text>
<text top="497" left="622" width="235" height="20" font="4"><b>Results:</b> SBP/DBP 120-129/80-84 mm Hg </text>
<text top="514" left="622" width="166" height="20" font="1">compared to &lt;120/80 mm Hg: </text>
<text top="533" left="622" width="7" height="18" font="1">•</text>
<text top="532" left="629" width="194" height="20" font="1"> CVD RR: 1.24; 95% CI: 1.10–1.39 </text>
<text top="551" left="622" width="7" height="18" font="1">•</text>
<text top="550" left="629" width="181" height="20" font="1"> MI RR: 1.43; 95% CI: 1.10–1.86 </text>
<text top="569" left="622" width="7" height="18" font="1">•</text>
<text top="569" left="629" width="207" height="20" font="1"> Stroke: RR: 1.35; 95% CI: 1.10–1.66 </text>
<text top="586" left="622" width="3" height="20" font="1"> </text>
<text top="603" left="622" width="260" height="20" font="1">SBP/DBP 130–139/85–89 mm Hg compared to </text>
<text top="620" left="622" width="95" height="20" font="1">&lt;120/80 mm Hg: </text>
<text top="639" left="622" width="7" height="18" font="1">•</text>
<text top="639" left="629" width="194" height="20" font="1"> CVD RR: 1.56; 95% CI: 1.36–1.78 </text>
<text top="658" left="622" width="7" height="18" font="1">•</text>
<text top="657" left="629" width="181" height="20" font="1"> MI RR: 1.99; 95% CI: 1.59–2.50 </text>
<text top="676" left="622" width="7" height="18" font="1">•</text>
<text top="676" left="629" width="203" height="20" font="1"> Stroke RR: 1.95; 95% CI: 1.69–2.24 </text>
<text top="446" left="913" width="7" height="18" font="1">•</text>
<text top="445" left="919" width="123" height="20" font="1"> Compared to pts with </text>
<text top="462" left="913" width="168" height="20" font="1">SBP/DBP&lt;120/80 mm Hg, the </text>
<text top="479" left="913" width="150" height="20" font="1">RR for CVD, MI and stroke </text>
<text top="497" left="913" width="128" height="20" font="1">were larger for pts with </text>
<text top="514" left="913" width="159" height="20" font="1">SBP/DBP of 130–139/85–89 </text>
<text top="531" left="913" width="160" height="20" font="1">mm Hg vs. SBP/DBP of 120–</text>
<text top="548" left="913" width="108" height="20" font="1">129/80–84 mm Hg. </text>
<text top="694" left="89" width="88" height="20" font="1">Huang Y, et al., </text>
<text top="711" left="89" width="49" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(5)</a> </text>
<text top="728" left="89" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23915102?dopt=Citation">23915102 </a></text>
<text top="694" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="711" left="211" width="61" height="20" font="1">analysis of </text>
<text top="728" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="745" left="211" width="3" height="20" font="1"> </text>
<text top="762" left="211" width="145" height="20" font="4"><b>Size:</b> 468,561 pts from 18 </text>
<text top="780" left="211" width="146" height="20" font="1">prospective cohort studies </text>
<text top="694" left="373" width="225" height="20" font="4"><b>Inclusion criteria:</b> Studies reporting risk </text>
<text top="711" left="373" width="198" height="20" font="1">for CVD, CHD and stroke, with 120–</text>
<text top="728" left="373" width="221" height="20" font="1">139/80–89 mm Hg, 120–129/80–84 mm </text>
<text top="745" left="373" width="162" height="20" font="1">Hg or130–139/85–89 mm Hg </text>
<text top="762" left="373" width="73" height="20" font="1">Adults ≥18 y </text>
<text top="780" left="373" width="139" height="20" font="1">BP evaluated at baseline </text>
<text top="695" left="622" width="203" height="20" font="4"><b>1</b>°<b> endpoint:</b> CVD, CHD, and stroke </text>
<text top="712" left="622" width="3" height="20" font="4"><b> </b></text>
<text top="729" left="622" width="261" height="20" font="4"><b>Results:</b> Comparing SBP/DBP 120–129/80–84 </text>
<text top="746" left="622" width="151" height="20" font="1">mm Hg to &lt;120/80 mm Hg: </text>
<text top="765" left="622" width="7" height="18" font="1">•</text>
<text top="765" left="629" width="193" height="20" font="1"> CVD RR: 1.46; 95% CI: 1.32–1.62 </text>
<text top="695" left="913" width="7" height="18" font="1">•</text>
<text top="695" left="919" width="123" height="20" font="1"> Compared to pts with </text>
<text top="712" left="913" width="151" height="20" font="1">SBP/DBP &lt;120/80 mm Hg, </text>
<text top="729" left="913" width="167" height="20" font="1">the RR for CVD was larger for </text>
<text top="746" left="913" width="143" height="20" font="1">pts with SBP/DBP of 130–</text>
<text top="764" left="913" width="124" height="20" font="1">139/85–89 mm Hg vs. </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">10 </text>
<text top="107" left="373" width="155" height="20" font="1">≥2 y follow-up for outcomes </text>
<text top="124" left="373" width="183" height="20" font="1">Results reported with adjustment </text>
<text top="141" left="373" width="3" height="20" font="1"> </text>
<text top="159" left="373" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="107" left="622" width="277" height="20" font="1">Comparing SBP/DBP RR: 130–139/85–89 mm Hg </text>
<text top="124" left="622" width="108" height="20" font="1">to &lt;120/80 mm Hg: </text>
<text top="143" left="622" width="7" height="18" font="1">•</text>
<text top="143" left="629" width="197" height="20" font="1"> CVD RR: 1.63; 95% CI: 1.47–1.80; </text>
<text top="160" left="622" width="225" height="20" font="1">p value comparing these risk ratios=0.02 </text>
<text top="179" left="622" width="7" height="18" font="1">•</text>
<text top="178" left="629" width="266" height="20" font="1"> The RR comparing CHD and stroke by levels of </text>
<text top="195" left="622" width="273" height="20" font="1">SBP/DBP: 130–139/85–89 mm Hg and SBP/DBP </text>
<text top="213" left="622" width="256" height="20" font="1">of 120–129/80–84 mm Hg vs. &lt;120/80 mm Hg </text>
<text top="230" left="622" width="103" height="20" font="1">were not reported. </text>
<text top="107" left="913" width="159" height="20" font="1">SBP/DBP of 120–129/80–84 </text>
<text top="124" left="913" width="43" height="20" font="1">mm Hg </text>
<text top="248" left="89" width="88" height="20" font="1">Huang Y, et al., </text>
<text top="265" left="89" width="49" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(6)</a> </text>
<text top="282" left="89" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24074825?dopt=Citation">24074825 </a></text>
<text top="282" left="147" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24074825?dopt=Citation"> </a></text>
<text top="248" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="265" left="211" width="61" height="20" font="1">analysis of </text>
<text top="282" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="299" left="211" width="3" height="20" font="1"> </text>
<text top="317" left="211" width="140" height="20" font="4"><b>Size:</b> 1,003,793 pts were </text>
<text top="334" left="211" width="148" height="20" font="1">derived from 6 prospective </text>
<text top="351" left="211" width="80" height="20" font="1">cohort studies </text>
<text top="248" left="373" width="202" height="20" font="4"><b>Inclusion criteria:</b> Studies reporting </text>
<text top="265" left="373" width="225" height="20" font="1">adjusted risk for ESRD with 120–139/80–</text>
<text top="282" left="373" width="195" height="20" font="1">89 mm Hg, 120–129/80–84 mm Hg </text>
<text top="300" left="373" width="143" height="20" font="1">or130–139/85–89 mm Hg </text>
<text top="317" left="373" width="234" height="20" font="1">Adults ≥18 y BP evaluated at baseline ≥ 1 </text>
<text top="334" left="373" width="118" height="20" font="1">y follow-up for ESRD </text>
<text top="351" left="373" width="183" height="20" font="1">Results reported with adjustment </text>
<text top="368" left="373" width="3" height="20" font="1"> </text>
<text top="386" left="373" width="185" height="20" font="4"><b>Exclusion criteria:</b> 1) enrollment </text>
<text top="403" left="373" width="215" height="20" font="1">depended on having a condition or risk </text>
<text top="420" left="373" width="233" height="20" font="1">factor, 2) the study reported only age- and </text>
<text top="437" left="373" width="104" height="20" font="1">sex-adjusted RRs, </text>
<text top="454" left="373" width="222" height="20" font="1">and 3) data were derived from the same </text>
<text top="472" left="373" width="153" height="20" font="1">cohort or from a 2º analysis </text>
<text top="249" left="622" width="113" height="20" font="4"><b>1</b>°<b> endpoint:</b> ESRD </text>
<text top="266" left="622" width="3" height="20" font="4"><b> </b></text>
<text top="283" left="622" width="261" height="20" font="4"><b>Results:</b> Comparing SBP/DBP 120–129/80–84 </text>
<text top="301" left="622" width="151" height="20" font="1">mm Hg to &lt;120/80 mm Hg: </text>
<text top="320" left="622" width="7" height="18" font="1">•</text>
<text top="319" left="629" width="202" height="20" font="1"> ESRD RR: 1.44; 95% CI: 1.19–1.74 </text>
<text top="336" left="622" width="266" height="20" font="1">Comparing SBP/DBP 130–139/85–89 mm Hg to </text>
<text top="354" left="622" width="95" height="20" font="1">&lt;120/80 mm Hg: </text>
<text top="373" left="622" width="7" height="18" font="1">•</text>
<text top="372" left="629" width="205" height="20" font="1"> ESRD RR: 2.02; 95% CI: 1.70–2.40; </text>
<text top="391" left="622" width="7" height="18" font="1">•</text>
<text top="390" left="629" width="228" height="20" font="1"> p value comparing these risk ratios=0.01 </text>
<text top="250" left="913" width="7" height="18" font="1">•</text>
<text top="249" left="919" width="123" height="20" font="1"> Compared to pts with </text>
<text top="266" left="913" width="151" height="20" font="1">SBP/DBP &lt;120/80 mm Hg, </text>
<text top="283" left="913" width="157" height="20" font="1">the RR for ESRD was larger </text>
<text top="301" left="913" width="161" height="20" font="1">for pts with SBP/DBP of 130–</text>
<text top="318" left="913" width="124" height="20" font="1">139/85–89 mm Hg vs. </text>
<text top="335" left="913" width="159" height="20" font="1">SBP/DBP of 120–129/80–84 </text>
<text top="352" left="913" width="43" height="20" font="1">mm Hg </text>
<text top="490" left="89" width="88" height="20" font="1">Huang Y, et al., </text>
<text top="507" left="89" width="49" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(7)</a> </text>
<text top="524" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24623843?dopt=Citation">24623843</a></text>
<text top="524" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24623843?dopt=Citation"> </a></text>
<text top="490" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="507" left="211" width="61" height="20" font="1">analysis of </text>
<text top="524" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="541" left="211" width="3" height="20" font="1"> </text>
<text top="558" left="211" width="145" height="20" font="4"><b>Size:</b> 762,393 pts from 19 </text>
<text top="576" left="211" width="146" height="20" font="1">prospective cohort studies </text>
<text top="490" left="373" width="202" height="20" font="4"><b>Inclusion criteria:</b> Studies reporting </text>
<text top="507" left="373" width="224" height="20" font="1">adjusted risk for stroke with 120–139/80–</text>
<text top="524" left="373" width="231" height="20" font="1">89 mm Hg, 120–129/80-84 mm Hg or130–</text>
<text top="541" left="373" width="105" height="20" font="1">139/85–89 mm Hg </text>
<text top="560" left="373" width="7" height="18" font="1">•</text>
<text top="560" left="379" width="76" height="20" font="1"> Adults ≥18 y </text>
<text top="579" left="373" width="7" height="18" font="1">•</text>
<text top="578" left="379" width="143" height="20" font="1"> BP evaluated at baseline </text>
<text top="597" left="373" width="7" height="18" font="1">•</text>
<text top="596" left="379" width="139" height="20" font="1"> ≥1 y follow-up for stroke </text>
<text top="615" left="373" width="7" height="18" font="1">•</text>
<text top="615" left="379" width="186" height="20" font="1"> Results reported with adjustment </text>
<text top="632" left="373" width="3" height="20" font="1"> </text>
<text top="649" left="373" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="668" left="373" width="7" height="18" font="1">•</text>
<text top="667" left="379" width="191" height="20" font="1"> Enrollment depended on having a </text>
<text top="685" left="373" width="222" height="20" font="1">specific risk factor condition (e.g., DM or </text>
<text top="702" left="373" width="180" height="20" font="1">other baseline chronic diseases) </text>
<text top="721" left="373" width="7" height="18" font="1">•</text>
<text top="720" left="379" width="228" height="20" font="1"> The RR was unadjusted or only adjusted </text>
<text top="737" left="373" width="88" height="20" font="1">for age and sex </text>
<text top="756" left="373" width="7" height="18" font="1">•</text>
<text top="756" left="379" width="226" height="20" font="1"> Data were derived from the same cohort </text>
<text top="773" left="373" width="222" height="20" font="1">or meta-analysis of other cohort studies. </text>
<text top="491" left="622" width="115" height="20" font="4"><b>1</b>°<b> endpoint:</b> Stroke </text>
<text top="508" left="622" width="3" height="20" font="4"><b> </b></text>
<text top="525" left="622" width="261" height="20" font="4"><b>Results:</b> Comparing SBP/DBP 120–129/80–84 </text>
<text top="542" left="622" width="151" height="20" font="1">mm Hg to &lt;120/80 mm Hg: </text>
<text top="561" left="622" width="7" height="18" font="1">•</text>
<text top="561" left="629" width="207" height="20" font="1"> Stroke: RR: 1.44; 95% CI: 1.27–1.63 </text>
<text top="578" left="622" width="266" height="20" font="1">Comparing SBP/DBP 130–139/85–89 mm Hg to </text>
<text top="595" left="622" width="95" height="20" font="1">&lt;120/80 mm Hg: </text>
<text top="614" left="622" width="7" height="18" font="1">•</text>
<text top="613" left="629" width="207" height="20" font="1"> Stroke: RR: 1.95; 95% CI: 1.73–2.21 </text>
<text top="633" left="622" width="7" height="18" font="1">•</text>
<text top="632" left="629" width="239" height="20" font="1"> p value comparing these risk ratios ≤0.001 </text>
<text top="491" left="913" width="7" height="18" font="1">•</text>
<text top="491" left="919" width="123" height="20" font="1"> Compared to pts with </text>
<text top="508" left="913" width="151" height="20" font="1">SBP/DBP &lt;120/80 mm Hg, </text>
<text top="525" left="913" width="156" height="20" font="1">the RR for stroke was larger </text>
<text top="542" left="913" width="161" height="20" font="1">for pts with SBP/DBP of 130–</text>
<text top="560" left="913" width="124" height="20" font="1">139/85–89 mm Hg vs. </text>
<text top="577" left="913" width="159" height="20" font="1">SBP/DBP of 120–129/80–84 </text>
<text top="594" left="913" width="43" height="20" font="1">mm Hg </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">11 </text>
<text top="107" left="89" width="88" height="20" font="1">Huang Y, et al., </text>
<text top="124" left="89" width="49" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(8)</a> </text>
<text top="141" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24439976?dopt=Citation">24439976</a></text>
<text top="141" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24439976?dopt=Citation"> </a></text>
<text top="107" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="124" left="211" width="61" height="20" font="1">analysis of </text>
<text top="141" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="159" left="211" width="3" height="20" font="1"> </text>
<text top="176" left="211" width="138" height="20" font="4"><b>Size:</b> 1,129,098 pts from </text>
<text top="193" left="211" width="121" height="20" font="1">20 prospective cohort </text>
<text top="210" left="211" width="42" height="20" font="1">studies </text>
<text top="107" left="373" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="126" left="373" width="7" height="18" font="1">•</text>
<text top="125" left="379" width="207" height="20" font="1"> Studies reporting adjusted risk for all-</text>
<text top="143" left="373" width="230" height="20" font="1">cause/CVD mortality with 120–139/80–89 </text>
<text top="160" left="373" width="217" height="20" font="1">mm Hg, 120-129/80–84 mm Hg or 130–</text>
<text top="177" left="373" width="105" height="20" font="1">139/85–89 mm Hg </text>
<text top="196" left="373" width="7" height="18" font="1">•</text>
<text top="195" left="379" width="76" height="20" font="1"> Adults ≥18 y </text>
<text top="215" left="373" width="7" height="18" font="1">•</text>
<text top="214" left="379" width="143" height="20" font="1"> BP evaluated at baseline </text>
<text top="233" left="373" width="7" height="18" font="1">•</text>
<text top="232" left="379" width="152" height="20" font="1"> ≥2 y follow-up for mortality </text>
<text top="251" left="373" width="7" height="18" font="1">•</text>
<text top="251" left="379" width="186" height="20" font="1"> Results reported with adjustment </text>
<text top="268" left="373" width="3" height="20" font="1"> </text>
<text top="285" left="373" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="304" left="373" width="7" height="18" font="1">•</text>
<text top="303" left="379" width="191" height="20" font="1"> Enrollment depended on having a </text>
<text top="321" left="373" width="222" height="20" font="1">specific risk factor condition (e.g., DM or </text>
<text top="338" left="373" width="183" height="20" font="1">other baseline chronic diseases)  </text>
<text top="357" left="373" width="7" height="18" font="1">•</text>
<text top="356" left="379" width="228" height="20" font="1"> The RR was unadjusted or only adjusted </text>
<text top="373" left="373" width="88" height="20" font="1">for age and sex </text>
<text top="392" left="373" width="7" height="18" font="1">•</text>
<text top="392" left="379" width="226" height="20" font="1"> Data were derived from the same cohort </text>
<text top="409" left="373" width="222" height="20" font="1">or meta-analysis of other cohort studies. </text>
<text top="108" left="622" width="233" height="20" font="4"><b>1</b>°<b> endpoint:</b> All-cause and CVD mortality </text>
<text top="125" left="622" width="3" height="20" font="4"><b> </b></text>
<text top="143" left="622" width="258" height="20" font="4"><b>Results:</b> Comparing SBP/DBP 120–129/80-84 </text>
<text top="160" left="622" width="151" height="20" font="1">mm Hg to &lt;120/80 mm Hg: </text>
<text top="179" left="622" width="7" height="18" font="1">•</text>
<text top="178" left="629" width="268" height="20" font="1"> All-cause mortality RR: 0.96; 95% CI: 0.85–1.08 </text>
<text top="197" left="622" width="7" height="18" font="1">•</text>
<text top="197" left="629" width="244" height="20" font="1"> CVD mortality RR: 1.08; 95% CI: 0.98–1.18 </text>
<text top="214" left="622" width="3" height="20" font="1"> </text>
<text top="231" left="622" width="260" height="20" font="1">Comparing SBP/DBP 130-139/85-89 mm Hg to </text>
<text top="248" left="622" width="95" height="20" font="1">&lt;120/80 mm Hg: </text>
<text top="267" left="622" width="7" height="18" font="1">•</text>
<text top="267" left="629" width="268" height="20" font="1"> All-cause mortality RR: 1.03; 95% CI: 0.95–1.12 </text>
<text top="286" left="622" width="7" height="18" font="1">•</text>
<text top="285" left="629" width="244" height="20" font="1"> CVD mortality RR: 1.28; 95% CI: 1.16–1.41 </text>
<text top="304" left="622" width="7" height="18" font="1">•</text>
<text top="303" left="629" width="200" height="20" font="1"> p value comparing these risk ratios: </text>
<text top="322" left="622" width="7" height="18" font="1">•</text>
<text top="322" left="629" width="149" height="20" font="1"> All-cause mortality p=0.33 </text>
<text top="341" left="622" width="7" height="18" font="1">•</text>
<text top="340" left="629" width="124" height="20" font="1"> CVD mortality p=0.01 </text>
<text top="109" left="913" width="7" height="18" font="1">•</text>
<text top="108" left="919" width="123" height="20" font="1"> Compared to pts with </text>
<text top="125" left="913" width="151" height="20" font="1">SBP/DBP &lt;120/80 mm Hg, </text>
<text top="143" left="913" width="164" height="20" font="1">the RR for CVD mortality was </text>
<text top="160" left="913" width="168" height="20" font="1">larger for pts with SBP/DBP of </text>
<text top="177" left="913" width="148" height="20" font="1">130–139/85-89 mm Hg vs. </text>
<text top="194" left="913" width="156" height="20" font="1">SBP/DBP of 120–129/80-84 </text>
<text top="212" left="913" width="46" height="20" font="1">mm Hg. </text>
<text top="231" left="913" width="7" height="18" font="1">•</text>
<text top="230" left="919" width="140" height="20" font="1"> The RR for not all-cause </text>
<text top="247" left="913" width="165" height="20" font="1">mortality was similar for these </text>
<text top="264" left="913" width="68" height="20" font="1">2 BP levels. </text>
<text top="427" left="89" width="88" height="20" font="1">Huang Y, et al., </text>
<text top="444" left="89" width="49" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(9)</a> </text>
<text top="461" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25699996?dopt=Citation">25699996</a></text>
<text top="461" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25699996?dopt=Citation"> </a></text>
<text top="427" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="444" left="211" width="61" height="20" font="1">analysis of </text>
<text top="461" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="479" left="211" width="3" height="20" font="1"> </text>
<text top="496" left="211" width="145" height="20" font="4"><b>Size:</b> 591,664 pts from 17 </text>
<text top="513" left="211" width="146" height="20" font="1">prospective cohort studies </text>
<text top="427" left="373" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="446" left="373" width="7" height="18" font="1">•</text>
<text top="445" left="379" width="220" height="20" font="1"> Studies reporting adjusted risk for CHD </text>
<text top="463" left="373" width="233" height="20" font="1">with 120–139/80–89 mm Hg, 120–129/80–</text>
<text top="480" left="373" width="203" height="20" font="1">84 mm Hg or130–139/85–89 mm Hg </text>
<text top="499" left="373" width="7" height="18" font="1">•</text>
<text top="498" left="379" width="76" height="20" font="1"> Adults ≥18 y </text>
<text top="517" left="373" width="7" height="18" font="1">•</text>
<text top="516" left="379" width="143" height="20" font="1"> BP evaluated at baseline </text>
<text top="535" left="373" width="7" height="18" font="1">•</text>
<text top="535" left="379" width="186" height="20" font="1"> Results reported with adjustment </text>
<text top="552" left="373" width="3" height="20" font="1"> </text>
<text top="569" left="373" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="588" left="373" width="7" height="18" font="1">•</text>
<text top="588" left="379" width="191" height="20" font="1"> Enrollment depended on having a </text>
<text top="605" left="373" width="222" height="20" font="1">specific risk factor condition (e.g., DM or </text>
<text top="622" left="373" width="183" height="20" font="1">other baseline chronic diseases)  </text>
<text top="641" left="373" width="7" height="18" font="1">•</text>
<text top="640" left="379" width="228" height="20" font="1"> The RR was unadjusted or only adjusted </text>
<text top="658" left="373" width="88" height="20" font="1">for age and sex </text>
<text top="677" left="373" width="7" height="18" font="1">•</text>
<text top="676" left="379" width="226" height="20" font="1"> Data were derived from the same cohort </text>
<text top="693" left="373" width="222" height="20" font="1">or meta-analysis of other cohort studies. </text>
<text top="428" left="622" width="106" height="20" font="4"><b>1</b>°<b> endpoint:</b> CHD </text>
<text top="445" left="622" width="3" height="20" font="4"><b> </b></text>
<text top="463" left="622" width="261" height="20" font="4"><b>Results:</b> Comparing SBP/DBP 120–129/80–84 </text>
<text top="480" left="622" width="151" height="20" font="1">mm Hg to &lt;120/80 mm Hg: </text>
<text top="499" left="622" width="7" height="18" font="1">•</text>
<text top="498" left="629" width="194" height="20" font="1"> CHD RR: 1.27; 95% CI: 1.07–1.50 </text>
<text top="515" left="622" width="260" height="20" font="1">Comparing SBP/DBP 130-139/85-89 mm Hg to </text>
<text top="533" left="622" width="95" height="20" font="1">&lt;120/80 mm Hg: </text>
<text top="552" left="622" width="7" height="18" font="1">•</text>
<text top="551" left="629" width="194" height="20" font="1"> CHD RR: 1.58; 95% CI: 1.24–2.02 </text>
<text top="570" left="622" width="7" height="18" font="1">•</text>
<text top="569" left="629" width="193" height="20" font="1"> p value comparing these RR: 0.15 </text>
<text top="429" left="913" width="7" height="18" font="1">•</text>
<text top="428" left="919" width="123" height="20" font="1"> Compared to pts with </text>
<text top="445" left="913" width="168" height="20" font="1">SBP/DBP&lt;120/80 mm Hg, the </text>
<text top="463" left="913" width="167" height="20" font="1">RR for CHD was larger for pts </text>
<text top="480" left="913" width="123" height="20" font="1">with SBP/DBP of 130–</text>
<text top="497" left="913" width="124" height="20" font="1">139/85–89 mm Hg vs. </text>
<text top="514" left="913" width="156" height="20" font="1">SBP/DBP of 120-129/80–84 </text>
<text top="531" left="913" width="50" height="20" font="1">mm Hg.  </text>
<text top="550" left="913" width="7" height="18" font="1">•</text>
<text top="550" left="919" width="139" height="20" font="1"> However, this difference </text>
<text top="567" left="913" width="109" height="20" font="1">was not statistically </text>
<text top="584" left="913" width="62" height="20" font="1">significant. </text>
<text top="711" left="89" width="105" height="20" font="1">Lee M, et al., 2011 </text>
<text top="728" left="89" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(10)</a> </text>
<text top="746" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21956722?dopt=Citation">21956722</a></text>
<text top="746" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21956722?dopt=Citation"> </a></text>
<text top="711" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="728" left="211" width="61" height="20" font="1">analysis of </text>
<text top="746" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="763" left="211" width="3" height="20" font="1"> </text>
<text top="711" left="373" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="730" left="373" width="7" height="18" font="1">•</text>
<text top="730" left="379" width="227" height="20" font="1"> Studies reporting adjusted risk for stroke </text>
<text top="747" left="373" width="233" height="20" font="1">with 120–139/80–89 mm Hg, 120–129/80–</text>
<text top="764" left="373" width="203" height="20" font="1">84 mm Hg or130–139/85–89 mm Hg </text>
<text top="783" left="373" width="7" height="18" font="1">•</text>
<text top="782" left="379" width="76" height="20" font="1"> Adults ≥18 y </text>
<text top="712" left="622" width="159" height="20" font="4"><b>1</b>°<b> endpoint:</b> Incident stroke </text>
<text top="730" left="622" width="3" height="20" font="4"><b> </b></text>
<text top="747" left="622" width="261" height="20" font="4"><b>Results:</b> Comparing SBP/DBP 120–129/80–84 </text>
<text top="764" left="622" width="151" height="20" font="1">mm Hg to &lt;120/80 mm Hg: </text>
<text top="783" left="622" width="7" height="18" font="1">•</text>
<text top="782" left="629" width="203" height="20" font="1"> Stroke RR: 1.22; 95% CI: 0.95–1.57 </text>
<text top="713" left="913" width="7" height="18" font="1">•</text>
<text top="712" left="919" width="123" height="20" font="1"> Compared to pts with </text>
<text top="730" left="913" width="151" height="20" font="1">SBP/DBP &lt;120/80 mm Hg, </text>
<text top="747" left="913" width="156" height="20" font="1">the RR for stroke was larger </text>
<text top="764" left="913" width="161" height="20" font="1">for pts with SBP/DBP of 130–</text>
<text top="781" left="913" width="124" height="20" font="1">139/85–89 mm Hg vs. </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">12 </text>
<text top="107" left="211" width="145" height="20" font="4"><b>Size:</b> 518,520 pts from 18 </text>
<text top="124" left="211" width="146" height="20" font="1">prospective cohort studies </text>
<text top="109" left="373" width="7" height="18" font="1">•</text>
<text top="108" left="379" width="143" height="20" font="1"> BP evaluated at baseline </text>
<text top="127" left="373" width="7" height="18" font="1">•</text>
<text top="127" left="379" width="186" height="20" font="1"> Results reported with adjustment </text>
<text top="144" left="373" width="3" height="20" font="1"> </text>
<text top="161" left="373" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="180" left="373" width="7" height="18" font="1">•</text>
<text top="179" left="379" width="180" height="20" font="1"> Cross-sectional, case-control or </text>
<text top="197" left="373" width="115" height="20" font="1">retrospective cohort  </text>
<text top="216" left="373" width="7" height="18" font="1">•</text>
<text top="215" left="379" width="228" height="20" font="1"> The RR was unadjusted or only adjusted </text>
<text top="232" left="373" width="88" height="20" font="1">for age and sex </text>
<text top="251" left="373" width="7" height="18" font="1">•</text>
<text top="251" left="379" width="117" height="20" font="1"> 95% CI not reported </text>
<text top="270" left="373" width="7" height="18" font="1">•</text>
<text top="269" left="379" width="226" height="20" font="1"> Data were derived from the same cohort </text>
<text top="286" left="373" width="219" height="20" font="1">or meta-analysis of other cohort studies </text>
<text top="305" left="373" width="7" height="18" font="1">•</text>
<text top="305" left="379" width="206" height="20" font="1"> Results from trial of antihypertensive </text>
<text top="322" left="373" width="63" height="20" font="1">medication </text>
<text top="107" left="622" width="266" height="20" font="1">Comparing SBP/DBP 130–139/85–89 mm Hg to </text>
<text top="124" left="622" width="95" height="20" font="1">&lt;120/80 mm Hg: </text>
<text top="143" left="622" width="7" height="18" font="1">•</text>
<text top="143" left="629" width="203" height="20" font="1"> Stroke RR: 1.79; 95% CI: 1.49–2.16 </text>
<text top="107" left="913" width="159" height="20" font="1">SBP/DBP of 120–129/80–84 </text>
<text top="124" left="913" width="43" height="20" font="1">mm Hg </text>
<text top="340" left="89" width="79" height="20" font="1">Shen L, et al., </text>
<text top="357" left="89" width="56" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(11)</a> </text>
<text top="374" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23608614?dopt=Citation">23608614</a></text>
<text top="374" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23608614?dopt=Citation"> </a></text>
<text top="340" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="357" left="211" width="61" height="20" font="1">analysis of </text>
<text top="374" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="391" left="211" width="3" height="20" font="1"> </text>
<text top="409" left="211" width="145" height="20" font="4"><b>Size:</b> 934,106 pts from 18 </text>
<text top="426" left="211" width="146" height="20" font="1">prospective cohort studies </text>
<text top="340" left="373" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="359" left="373" width="7" height="18" font="1">•</text>
<text top="358" left="379" width="220" height="20" font="1"> Studies reporting adjusted risk for CHD </text>
<text top="375" left="373" width="233" height="20" font="1">with 120–139/80–89 mm Hg, 120–129/80–</text>
<text top="393" left="373" width="206" height="20" font="1">84 mm Hg or 130–139/85–89 mm Hg </text>
<text top="412" left="373" width="7" height="18" font="1">•</text>
<text top="411" left="379" width="143" height="20" font="1"> BP evaluated at baseline </text>
<text top="430" left="373" width="7" height="18" font="1">•</text>
<text top="429" left="379" width="122" height="20" font="1"> 95% CI was reported </text>
<text top="446" left="373" width="3" height="20" font="1"> </text>
<text top="464" left="373" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="341" left="622" width="106" height="20" font="4"><b>1</b>°<b> endpoint:</b> CHD </text>
<text top="358" left="622" width="3" height="20" font="4"><b> </b></text>
<text top="375" left="622" width="261" height="20" font="4"><b>Results:</b> Comparing SBP/DBP 120–129/80–84 </text>
<text top="393" left="622" width="151" height="20" font="1">mm Hg to &lt;120/80 mm Hg: </text>
<text top="412" left="622" width="7" height="18" font="1">•</text>
<text top="411" left="629" width="194" height="20" font="1"> CHD RR: 1.16; 95% CI: 0.96–1.42 </text>
<text top="428" left="622" width="266" height="20" font="1">Comparing SBP/DBP 130–139/85–89 mm Hg to </text>
<text top="445" left="622" width="95" height="20" font="1">&lt;120/80 mm Hg: </text>
<text top="464" left="622" width="7" height="18" font="1">•</text>
<text top="464" left="629" width="198" height="20" font="1"> CHD RR: 1.53; 95% CI: 1.19–1.97) </text>
<text top="342" left="913" width="7" height="18" font="1">•</text>
<text top="341" left="919" width="123" height="20" font="1"> Compared to pts with </text>
<text top="358" left="913" width="151" height="20" font="1">SBP/DBP &lt;120/80 mm Hg, </text>
<text top="375" left="913" width="167" height="20" font="1">the RR for CHD was larger for </text>
<text top="393" left="913" width="143" height="20" font="1">pts with SBP/DBP of 130–</text>
<text top="410" left="913" width="124" height="20" font="1">139/85–89 mm Hg vs. </text>
<text top="427" left="913" width="159" height="20" font="1">SBP/DBP of 120–129/80–84 </text>
<text top="444" left="913" width="43" height="20" font="1">mm Hg </text>
<text top="482" left="89" width="84" height="20" font="1">Wang S, et al., </text>
<text top="499" left="89" width="56" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(12)</a> </text>
<text top="516" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23932039?dopt=Citation">23932039</a></text>
<text top="516" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23932039?dopt=Citation"> </a></text>
<text top="482" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="499" left="211" width="61" height="20" font="1">analysis of </text>
<text top="516" left="211" width="134" height="20" font="1">nonrandomized studies  </text>
<text top="533" left="211" width="3" height="20" font="1"> </text>
<text top="550" left="211" width="145" height="20" font="4"><b>Size:</b> 396,200 pts from 13 </text>
<text top="568" left="211" width="146" height="20" font="1">prospective cohort studies </text>
<text top="482" left="373" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="501" left="373" width="7" height="18" font="1">•</text>
<text top="500" left="379" width="226" height="20" font="1"> Prospective cohort studies reporting risk </text>
<text top="517" left="373" width="235" height="20" font="1">for outcomes with 120–139/80–89 mm Hg  </text>
<text top="536" left="373" width="7" height="18" font="1">•</text>
<text top="536" left="379" width="162" height="20" font="1"> Pts free of CVD at baseline,  </text>
<text top="555" left="373" width="7" height="18" font="1">•</text>
<text top="554" left="379" width="88" height="20" font="1"> Follow-up ≥5 y </text>
<text top="573" left="373" width="7" height="18" font="1">•</text>
<text top="572" left="379" width="144" height="20" font="1"> Adjusted results reported </text>
<text top="591" left="373" width="7" height="18" font="1">•</text>
<text top="591" left="379" width="122" height="20" font="1"> 95% CI was reported </text>
<text top="608" left="373" width="3" height="20" font="1"> </text>
<text top="625" left="373" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="483" left="622" width="244" height="20" font="4"><b>1</b>°<b> endpoint:</b> CVD, CVD mortality, all-cause </text>
<text top="500" left="622" width="50" height="20" font="1">mortality </text>
<text top="517" left="622" width="3" height="20" font="4"><b> </b></text>
<text top="534" left="622" width="256" height="20" font="4"><b>Results:</b> Comparing SBP/DBP 120-129/80-84 </text>
<text top="552" left="622" width="151" height="20" font="1">mm Hg to &lt;120/80 mm Hg: </text>
<text top="571" left="622" width="7" height="18" font="1">•</text>
<text top="570" left="629" width="194" height="20" font="1"> CVD RR: 1.41; 95% CI: 1.25–1.59 </text>
<text top="589" left="622" width="7" height="18" font="1">•</text>
<text top="588" left="629" width="244" height="20" font="1"> CVD mortality RR: 1.18; 95% CI: 0.98–1.42 </text>
<text top="607" left="622" width="7" height="18" font="1">•</text>
<text top="607" left="629" width="268" height="20" font="1"> All-cause mortality RR: 0.99; 95% CI: 0.88–1.13 </text>
<text top="624" left="622" width="266" height="20" font="1">Comparing SBP/DBP 130–139/85–89 mm Hg to </text>
<text top="641" left="622" width="95" height="20" font="1">&lt;120/80 mm Hg: </text>
<text top="660" left="622" width="7" height="18" font="1">•</text>
<text top="660" left="629" width="193" height="20" font="1"> CVD RR: 1.74; 95% CI: 1.51–2.01 </text>
<text top="679" left="622" width="7" height="18" font="1">•</text>
<text top="678" left="629" width="244" height="20" font="1"> CVD mortality RR: 1.33; 95% CI: 1.13–1.58 </text>
<text top="697" left="622" width="7" height="18" font="1">•</text>
<text top="696" left="629" width="268" height="20" font="1"> All-cause mortality RR: 1.02; 95% CI: 0.97–1.08 </text>
<text top="483" left="913" width="7" height="18" font="1">•</text>
<text top="483" left="919" width="123" height="20" font="1"> Compared to pts with </text>
<text top="500" left="913" width="169" height="20" font="1">SBP/DBP&lt;120/80 mm Hg, RR </text>
<text top="517" left="913" width="150" height="20" font="1">for CVD and CVD mortality </text>
<text top="534" left="913" width="128" height="20" font="1">were larger for pts with </text>
<text top="552" left="913" width="159" height="20" font="1">SBP/DBP of 130–139/85–89 </text>
<text top="569" left="913" width="160" height="20" font="1">mm Hg vs. SBP/DBP of 120–</text>
<text top="586" left="913" width="111" height="20" font="1">129/80–84 mm Hg.  </text>
<text top="605" left="913" width="7" height="18" font="1">•</text>
<text top="604" left="919" width="146" height="20" font="1"> No difference in all-cause </text>
<text top="622" left="913" width="159" height="20" font="1">mortality was present across </text>
<text top="639" left="913" width="58" height="20" font="1">BP levels. </text>
<text top="714" left="89" width="97" height="20" font="1">Cushman WC, et </text>
<text top="731" left="89" width="79" height="20" font="1">al., 2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(13)</a>  </text>
<text top="749" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12461301?dopt=Citation">12461301</a></text>
<text top="749" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12461301?dopt=Citation"> </a></text>
<text top="714" left="211" width="147" height="20" font="4"><b>Study type:</b> 2º analysis of </text>
<text top="731" left="211" width="46" height="20" font="1">an RCT </text>
<text top="749" left="211" width="3" height="20" font="1"> </text>
<text top="766" left="211" width="126" height="20" font="4"><b>Size:</b> 33,357 pts in the </text>
<text top="783" left="211" width="50" height="20" font="1">ALLHAT </text>
<text top="714" left="373" width="235" height="20" font="4"><b>Inclusion criteria:</b> Men and women ≥55 y </text>
<text top="731" left="373" width="231" height="20" font="1">with HTN and 1 additional CHD risk factor </text>
<text top="749" left="373" width="3" height="20" font="1"> </text>
<text top="766" left="373" width="213" height="20" font="4"><b>Exclusion criteria:</b> Pts randomized to </text>
<text top="783" left="373" width="66" height="20" font="1">doxazosin.  </text>
<text top="715" left="622" width="258" height="20" font="4"><b>1</b>°<b> endpoint:</b> Achieving SBP/DBP&lt;140/90 mm </text>
<text top="733" left="622" width="150" height="20" font="1">Hg, use of ≥2 drug classes </text>
<text top="750" left="622" width="3" height="20" font="1"> </text>
<text top="716" left="913" width="7" height="18" font="1">•</text>
<text top="715" left="919" width="140" height="20" font="1"> BP control (&lt;140/90 mm </text>
<text top="733" left="913" width="159" height="20" font="1">Hg) can be achieved in most </text>
<text top="750" left="913" width="157" height="20" font="1">pts ≥2 or more drug classes </text>
<text top="767" left="913" width="104" height="20" font="1">are often required. </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">13 </text>
<text top="107" left="622" width="271" height="20" font="4"><b>Results:</b> SBP/DBP control was achieved by 66% </text>
<text top="124" left="622" width="251" height="20" font="1">at 5 y of follow-up and 63% of pts were on ≥2 </text>
<text top="141" left="622" width="76" height="20" font="1">drug classes. </text>
<text top="159" left="89" width="87" height="20" font="1">Dalhof B, et al., </text>
<text top="177" left="89" width="56" height="20" font="1">2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(14)</a> </text>
<text top="194" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11937178?dopt=Citation">11937178</a></text>
<text top="194" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11937178?dopt=Citation"> </a></text>
<text top="159" left="211" width="102" height="20" font="4"><b>Study type:</b> RCT  </text>
<text top="177" left="211" width="3" height="20" font="1"> </text>
<text top="194" left="211" width="146" height="20" font="4"><b>Size:</b> 9,193 pts 55–80 y in </text>
<text top="211" left="211" width="140" height="20" font="1">the Losartan Intervention </text>
<text top="228" left="211" width="141" height="20" font="1">For Endpoint reduction in </text>
<text top="246" left="211" width="29" height="20" font="1">HTN<b> </b></text>
<text top="159" left="373" width="226" height="20" font="4"><b>Inclusion criteria:</b> Men and women with </text>
<text top="177" left="373" width="213" height="20" font="1">ECG signs of LVH. Trough sitting SBP </text>
<text top="194" left="373" width="225" height="20" font="1">160–200 mm Hg or DBP 95–115 mm Hg </text>
<text top="211" left="373" width="138" height="20" font="1">after 1–2 wk of placebo.  </text>
<text top="228" left="373" width="3" height="20" font="1"> </text>
<text top="245" left="373" width="211" height="20" font="4"><b>Exclusion criteria:</b> 2º HTN, MI/stroke </text>
<text top="263" left="373" width="220" height="20" font="1">within 6 mo, angina, HF or LVEF &lt;40%.<b> </b></text>
<text top="161" left="622" width="251" height="20" font="4"><b>1</b>°<b> endpoint:</b> Following a titration schedule to </text>
<text top="178" left="622" width="224" height="20" font="1">reach a target SBP/DBP&lt;140/90 mm Hg </text>
<text top="195" left="622" width="3" height="20" font="1"> </text>
<text top="212" left="622" width="272" height="20" font="4"><b>Results:</b> Mean SBP/DBP at baseline was 174/98 </text>
<text top="229" left="622" width="233" height="20" font="1">mm Hg. Over 90% of pts required ≥2 drug </text>
<text top="247" left="622" width="138" height="20" font="1">classes during follow-up.<b> </b></text>
<text top="161" left="913" width="7" height="18" font="1">•</text>
<text top="161" left="919" width="151" height="20" font="1"> Pts with a mean SBP/DBP </text>
<text top="178" left="913" width="152" height="20" font="1">of 160–200/95–115 mm Hg </text>
<text top="195" left="913" width="128" height="20" font="1">will need ≥2 classes of </text>
<text top="212" left="913" width="156" height="20" font="1">antihypertensive medication </text>
<text top="229" left="913" width="164" height="20" font="1">to achieve SBP/DBP &lt;140/90 </text>
<text top="247" left="913" width="46" height="20" font="1">mm Hg. </text>
<text top="281" left="89" width="92" height="20" font="1">Wald DS, et. al., </text>
<text top="298" left="89" width="56" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(15)</a> </text>
<text top="315" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19272490?dopt=Citation">19272490</a></text>
<text top="315" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19272490?dopt=Citation"> </a></text>
<text top="281" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="298" left="211" width="90" height="20" font="1">analysis of RCT </text>
<text top="315" left="211" width="3" height="20" font="1"> </text>
<text top="332" left="211" width="123" height="20" font="4"><b>Size:</b> 10,968 pts in 42 </text>
<text top="350" left="211" width="135" height="20" font="1">trials of factorial designs </text>
<text top="367" left="211" width="140" height="20" font="1">comparing monotherapy, </text>
<text top="384" left="211" width="138" height="20" font="1">combination therapy and </text>
<text top="401" left="211" width="50" height="20" font="1">placebo.<b> </b></text>
<text top="281" left="373" width="225" height="20" font="4"><b>Inclusion criteria:</b> Randomized placebo-</text>
<text top="298" left="373" width="181" height="20" font="1">controlled trials comparing 2 of 4 </text>
<text top="315" left="373" width="220" height="20" font="1">(thiazides, BB s, ACEIs, and CCB) drug </text>
<text top="332" left="373" width="48" height="20" font="1">classes. </text>
<text top="350" left="373" width="3" height="20" font="1"> </text>
<text top="367" left="373" width="231" height="20" font="4"><b>Exclusion criteria:</b> Trials &lt;2 wk duration, </text>
<text top="384" left="373" width="236" height="20" font="1">no placebo group, nonrandomized order of </text>
<text top="401" left="373" width="59" height="20" font="1">treatment.<b> </b></text>
<text top="282" left="622" width="187" height="20" font="4"><b>1</b>°<b> endpoint:</b> Mean BP reduction. </text>
<text top="299" left="622" width="3" height="20" font="1"> </text>
<text top="316" left="622" width="263" height="20" font="4"><b>Results:</b> Combination therapy vs. monotherapy </text>
<text top="334" left="622" width="181" height="20" font="1">produced larger SBP reductions: </text>
<text top="353" left="622" width="7" height="18" font="1">•</text>
<text top="352" left="629" width="162" height="20" font="1"> Thiazide alone (7.3 mm Hg)  </text>
<text top="371" left="622" width="7" height="18" font="1">•</text>
<text top="370" left="629" width="238" height="20" font="1"> Thiazide+second drug class (14.6 mm Hg) </text>
<text top="389" left="622" width="7" height="18" font="1">•</text>
<text top="389" left="629" width="132" height="20" font="1"> BB alone (9.3 mm Hg)  </text>
<text top="408" left="622" width="7" height="18" font="1">•</text>
<text top="407" left="629" width="212" height="20" font="1"> BB +second drug class (18.9 mm Hg) </text>
<text top="426" left="622" width="7" height="18" font="1">•</text>
<text top="425" left="629" width="188" height="20" font="1"> ACE-inhibitor alone (6.8 mm Hg)  </text>
<text top="444" left="622" width="7" height="18" font="1">•</text>
<text top="444" left="629" width="264" height="20" font="1"> ACE-inhibitor+second drug class (13.9 mm Hg) </text>
<text top="463" left="622" width="7" height="18" font="1">•</text>
<text top="462" left="629" width="141" height="20" font="1"> CCB alone (8.4 mm Hg)  </text>
<text top="481" left="622" width="7" height="18" font="1">•</text>
<text top="480" left="629" width="225" height="20" font="1"> CCB +second drug class (14.3 mm Hg) <b> </b></text>
<text top="283" left="913" width="7" height="18" font="1">•</text>
<text top="282" left="919" width="160" height="20" font="1"> Combination therapy results </text>
<text top="299" left="913" width="147" height="20" font="1">in substantially larger SBP </text>
<text top="316" left="913" width="113" height="20" font="1">and DBP reductions </text>
<text top="334" left="913" width="162" height="20" font="1">compared with monotherapy, </text>
<text top="351" left="913" width="135" height="20" font="1">even after dose titration. </text>
<text top="498" left="89" width="108" height="20" font="1">Lewington S, et al., </text>
<text top="516" left="89" width="56" height="20" font="1">2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(16)</a> </text>
<text top="533" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12493255?dopt=Citation">12493255</a></text>
<text top="533" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12493255?dopt=Citation"> </a></text>
<text top="498" left="211" width="144" height="20" font="4"><b>Aim:</b> To describe the age-</text>
<text top="516" left="211" width="148" height="20" font="1">specific relevance of BP to </text>
<text top="533" left="211" width="131" height="20" font="1">cause-specific mortality </text>
<text top="550" left="211" width="3" height="20" font="1"> </text>
<text top="567" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="584" left="211" width="141" height="20" font="1">analysis of cohort studies </text>
<text top="602" left="211" width="3" height="20" font="1"> </text>
<text top="619" left="211" width="115" height="20" font="4"><b>Size:</b> 61 prospective </text>
<text top="636" left="211" width="133" height="20" font="1">studies with 12.7 million </text>
<text top="653" left="211" width="135" height="20" font="1">person-y of observation, </text>
<text top="670" left="211" width="143" height="20" font="1">56,000 vascular deaths in </text>
<text top="688" left="211" width="51" height="20" font="1">40–89 y. </text>
<text top="498" left="373" width="207" height="20" font="4"><b>Inclusion criteria: </b>Collaboration was </text>
<text top="516" left="373" width="191" height="20" font="1">sought from the investigators of all </text>
<text top="533" left="373" width="233" height="20" font="1">prospective observational studies in which </text>
<text top="550" left="373" width="236" height="20" font="1">data on BP, blood cholesterol, date of birth </text>
<text top="567" left="373" width="227" height="20" font="1">(or age), and sex had been recorded at a </text>
<text top="584" left="373" width="206" height="20" font="1">baseline screening visit, and in which </text>
<text top="602" left="373" width="230" height="20" font="1">cause and date of death (or age at death) </text>
<text top="619" left="373" width="225" height="20" font="1">had been routinely sought for all screens </text>
<text top="636" left="373" width="231" height="20" font="1">during more than 5,000 person-y of follow-</text>
<text top="653" left="373" width="211" height="20" font="1">up (see appendix A). Relevant studies </text>
<text top="671" left="373" width="236" height="20" font="1">were identified through computer searches </text>
<text top="688" left="373" width="184" height="20" font="1">of Medline and Embase, by hand-</text>
<text top="705" left="373" width="211" height="20" font="1">searches of meeting abstracts, and by </text>
<text top="722" left="373" width="227" height="20" font="1">extensive discussions with investigators.  </text>
<text top="739" left="373" width="3" height="20" font="1"> </text>
<text top="757" left="373" width="200" height="20" font="4"><b>Exclusion criteria:</b> To minimize the </text>
<text top="774" left="373" width="203" height="20" font="1">effects of reverse causality (whereby </text>
<text top="498" left="622" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="517" left="622" width="7" height="18" font="1">•</text>
<text top="517" left="629" width="239" height="20" font="1"> Not completely clear, but for our purposes, </text>
<text top="534" left="622" width="276" height="20" font="1">stroke and IHD death would be co-1°. Also looked </text>
<text top="551" left="622" width="138" height="20" font="1">at other vascular deaths. </text>
<text top="570" left="622" width="7" height="18" font="1">•</text>
<text top="570" left="629" width="256" height="20" font="1"> HRs for stroke mortality for a 20 mm Hg lower </text>
<text top="587" left="622" width="104" height="20" font="1">SBP by age-group </text>
<text top="604" left="622" width="182" height="20" font="1">40–49: 0.36 (95% CI: 0.32–0.40) </text>
<text top="621" left="622" width="182" height="20" font="1">50–59: 0.38 (95% CI: 0.35–0.40) </text>
<text top="638" left="622" width="182" height="20" font="1">60–69: 0.43 (95% CI: 0.41–0.45) </text>
<text top="656" left="622" width="182" height="20" font="1">70–79: 0.50 (95% CI: 0.48–0.52) </text>
<text top="673" left="622" width="182" height="20" font="1">80–89: 0.67 (95% CI: 0.63–0.71) </text>
<text top="692" left="622" width="7" height="18" font="1">•</text>
<text top="691" left="629" width="244" height="20" font="1"> HRs for IHD mortality for a 20 mm Hg lower </text>
<text top="709" left="622" width="104" height="20" font="1">SBP by age-group </text>
<text top="726" left="622" width="182" height="20" font="1">40–49: 0.49 (95% CI: 0.45–0.53) </text>
<text top="743" left="622" width="182" height="20" font="1">50–59: 0.50 (95% CI: 0.49–0.52) </text>
<text top="760" left="622" width="182" height="20" font="1">60–69: 0.54 (95% CI: 0.53–0.55) </text>
<text top="777" left="622" width="182" height="20" font="1">70–79: 0.60 (95% CI: 0.58–0.61) </text>
<text top="500" left="913" width="7" height="18" font="1">•</text>
<text top="500" left="919" width="153" height="20" font="1"> Throughout middle and old </text>
<text top="517" left="913" width="163" height="20" font="1">age, usual BP is strongly and </text>
<text top="534" left="913" width="146" height="20" font="1">directly related to vascular </text>
<text top="551" left="913" width="167" height="20" font="1">(and overall) mortality, without </text>
<text top="568" left="913" width="154" height="20" font="1">any evidence of a threshold </text>
<text top="586" left="913" width="154" height="20" font="1">down to at least 115/75 mm </text>
<text top="603" left="913" width="22" height="20" font="1">Hg. </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">14 </text>
<text top="107" left="373" width="209" height="20" font="1">established disease could change the </text>
<text top="124" left="373" width="222" height="20" font="1">usual BP), studies were excluded if they </text>
<text top="141" left="373" width="232" height="20" font="1">had selected pts on the basis of a positive </text>
<text top="159" left="373" width="209" height="20" font="1">history of stroke or heart disease, and </text>
<text top="176" left="373" width="228" height="20" font="1">individuals from contributing studies were </text>
<text top="193" left="373" width="234" height="20" font="1">excluded from the present analyses if they </text>
<text top="210" left="373" width="222" height="20" font="1">had such a history recorded at baseline. </text>
<text top="227" left="373" width="3" height="20" font="1"> </text>
<text top="107" left="622" width="182" height="20" font="1">80–89: 0.67 (95% CI: 0.64–0.70) </text>
<text top="126" left="622" width="7" height="18" font="1">•</text>
<text top="125" left="629" width="267" height="20" font="1"> HRs for other vascular mortality for a 20 mm Hg </text>
<text top="143" left="622" width="137" height="20" font="1">lower SBP by age-group </text>
<text top="160" left="622" width="182" height="20" font="1">40–49: 0.43 (95% CI: 0.38–0.48) </text>
<text top="177" left="622" width="182" height="20" font="1">50–59: 0.50 (95% CI: 0.47–0.54) </text>
<text top="194" left="622" width="182" height="20" font="1">60–69: 0.53 (95% CI: 0.51–0.56) </text>
<text top="212" left="622" width="182" height="20" font="1">70–79: 0.64 (95% CI: 0.61–0.67) </text>
<text top="229" left="622" width="182" height="20" font="1">80–89: 0.70 (95% CI: 0.65–0.75) </text>
<text top="248" left="622" width="7" height="18" font="1">•</text>
<text top="247" left="629" width="217" height="20" font="1"> Similar results for DBP also in figure 1. </text>
<text top="266" left="622" width="7" height="18" font="1">•</text>
<text top="265" left="629" width="257" height="20" font="1"> Similar results for men and women separately </text>
<text top="283" left="622" width="206" height="20" font="1">for stroke, figure 3, and IHD, figure 5. </text>
<text top="301" left="89" width="95" height="20" font="1">Ettehad D, et al., </text>
<text top="318" left="89" width="56" height="20" font="1">2016 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(17)</a> </text>
<text top="335" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178?dopt=Citation">26724178</a></text>
<text top="335" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178?dopt=Citation"> </a></text>
<text top="301" left="211" width="119" height="20" font="4"><b>Aim:</b> This systematic </text>
<text top="318" left="211" width="142" height="20" font="1">review and meta-analysis </text>
<text top="335" left="211" width="148" height="20" font="1">aims to combine data from </text>
<text top="352" left="211" width="135" height="20" font="1">all published large-scale </text>
<text top="370" left="211" width="113" height="20" font="1">BP-lowering trials to </text>
<text top="387" left="211" width="140" height="20" font="1">quantify the effects of BP </text>
<text top="404" left="211" width="148" height="20" font="1">reduction on CV outcomes </text>
<text top="421" left="211" width="141" height="20" font="1">and death across various </text>
<text top="438" left="211" width="141" height="20" font="1">baseline BP levels, major </text>
<text top="456" left="211" width="79" height="20" font="1">comorbidities, </text>
<text top="473" left="211" width="72" height="20" font="1">and different </text>
<text top="490" left="211" width="93" height="20" font="1">pharmacological </text>
<text top="507" left="211" width="77" height="20" font="1">interventions. </text>
<text top="524" left="211" width="3" height="20" font="1"> </text>
<text top="542" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="559" left="211" width="96" height="20" font="1">analysis of RCTs </text>
<text top="576" left="211" width="3" height="20" font="1"> </text>
<text top="593" left="211" width="124" height="20" font="4"><b>Size:</b> 123 studies with </text>
<text top="610" left="211" width="68" height="20" font="1">613,815 pts </text>
<text top="301" left="373" width="113" height="20" font="4"><b>Inclusion criteria:</b>   </text>
<text top="320" left="373" width="7" height="18" font="1">•</text>
<text top="319" left="379" width="201" height="20" font="1"> RCTs of BP-lowering treatment that </text>
<text top="336" left="373" width="198" height="20" font="1">included a minimum of 1,000 pt-y of </text>
<text top="354" left="373" width="235" height="20" font="1">follow-up in each study arm. No trials were </text>
<text top="371" left="373" width="233" height="20" font="1">excluded because of presence of baseline </text>
<text top="388" left="373" width="146" height="20" font="1">comorbidities, and trials of </text>
<text top="405" left="373" width="206" height="20" font="1">antihypertensive drugs for indications </text>
<text top="422" left="373" width="163" height="20" font="1">other than HTN were eligible. </text>
<text top="441" left="373" width="7" height="18" font="1">•</text>
<text top="441" left="379" width="228" height="20" font="1"> Eligible studies fell into 3 categories: 1st, </text>
<text top="458" left="373" width="228" height="20" font="1">random allocation of pts to a BP-lowering </text>
<text top="475" left="373" width="234" height="20" font="1">drug or placebo; 2nd, random allocation of </text>
<text top="492" left="373" width="213" height="20" font="1">pts to different BP-lowering drugs; and </text>
<text top="510" left="373" width="226" height="20" font="1">third, random allocation of pts to different </text>
<text top="527" left="373" width="114" height="20" font="1">BP-lowering targets. </text>
<text top="544" left="373" width="3" height="20" font="1"> </text>
<text top="561" left="373" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="578" left="373" width="229" height="20" font="1">&lt;1,000 pt y of follow-up in each treatment </text>
<text top="596" left="373" width="38" height="20" font="1">group. </text>
<text top="613" left="373" width="3" height="20" font="1"> </text>
<text top="630" left="373" width="184" height="20" font="4"><b>Intervention:</b> BP-lowering meds  </text>
<text top="647" left="373" width="7" height="20" font="1">  </text>
<text top="664" left="373" width="230" height="20" font="4"><b>Comparator:</b> Placebo, active comparator </text>
<text top="682" left="373" width="147" height="20" font="1">or less intensive treatment </text>
<text top="302" left="622" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="321" left="622" width="7" height="18" font="1">•</text>
<text top="320" left="629" width="36" height="20" font="1"> CVD. </text>
<text top="339" left="622" width="7" height="18" font="1">•</text>
<text top="339" left="629" width="238" height="20" font="1"> Major CVD events, CHD, stroke, HF, renal </text>
<text top="356" left="622" width="170" height="20" font="1">failure, and all-cause mortality. </text>
<text top="375" left="622" width="7" height="18" font="1">•</text>
<text top="374" left="629" width="249" height="20" font="1"> Standardized RR for 10 mm Hg difference in </text>
<text top="391" left="622" width="28" height="20" font="1">SBP </text>
<text top="410" left="622" width="7" height="18" font="1">•</text>
<text top="410" left="629" width="198" height="20" font="1"> CVD RR: 0.80 (95% CI: 0.77–0.83) </text>
<text top="427" left="622" width="3" height="20" font="1"> </text>
<text top="444" left="622" width="103" height="20" font="4"><b>Other endpoints: </b></text>
<text top="461" left="622" width="196" height="20" font="1">CHD RR: 0.83 (95% CI: 0.78–0.88) </text>
<text top="479" left="622" width="204" height="20" font="1">Stroke RR: 0.73 (95% CI: 0.68–0.77) </text>
<text top="496" left="622" width="185" height="20" font="1">HF RR: 0.72 (95% CI: 0.67–0.78) </text>
<text top="513" left="622" width="237" height="20" font="1">Total deaths RR: 0.87 (95% CI: 0.84–0.91) </text>
<text top="530" left="622" width="3" height="20" font="1"> </text>
<text top="547" left="622" width="84" height="20" font="4"><b>Other results: </b></text>
<text top="566" left="622" width="7" height="18" font="1">•</text>
<text top="566" left="629" width="225" height="20" font="1"> Benefit for CVD and other endpoints not </text>
<text top="583" left="622" width="271" height="20" font="1">different by baseline SBP, including &lt;130 mm Hg </text>
<text top="600" left="622" width="75" height="20" font="1">fig 4 in paper </text>
<text top="617" left="622" width="214" height="20" font="1">CVD: 0.63; 95% CI: 0.50–0.80; p=0.22 </text>
<text top="635" left="622" width="214" height="20" font="1">CHD: 0.55; 95% CI: 0.42–0.72; p=0.93 </text>
<text top="652" left="622" width="223" height="20" font="1">Stroke: 0.65; 95% CI: 0.27–1.57; p=0.38 </text>
<text top="669" left="622" width="204" height="20" font="1">HF: 0.83; 95% CI: 0.41–1.70; p=0.27 </text>
<text top="686" left="622" width="255" height="20" font="1">Total deaths: 0.53; 95% CI: 0.37–0.76; p=0.79 </text>
<text top="705" left="622" width="7" height="18" font="1">•</text>
<text top="705" left="629" width="259" height="20" font="1"> More precision around estimates of benefits in </text>
<text top="722" left="622" width="220" height="20" font="1">SBP 130–139 at baseline, fig 4 in paper </text>
<text top="741" left="622" width="7" height="18" font="1">•</text>
<text top="740" left="629" width="232" height="20" font="1"> Results similar in trials of people with and </text>
<text top="757" left="622" width="179" height="20" font="1">without CVD at baseline figure 5 </text>
<text top="775" left="622" width="177" height="20" font="1">CVD+ 0.77 (95% CI: 0.71–0.81) </text>
<text top="303" left="913" width="7" height="18" font="1">•</text>
<text top="302" left="919" width="140" height="20" font="1"> BP-lowering significantly </text>
<text top="319" left="913" width="158" height="20" font="1">reduces vascular risk across </text>
<text top="336" left="913" width="147" height="20" font="1">various baseline BP levels </text>
<text top="354" left="913" width="167" height="20" font="1">and comorbidities. Our results </text>
<text top="371" left="913" width="144" height="20" font="1">provide strong support for </text>
<text top="388" left="913" width="162" height="20" font="1">lowering BP to SBP&lt;130 mm </text>
<text top="405" left="913" width="166" height="20" font="1">Hg and providing BP-lowering </text>
<text top="422" left="913" width="165" height="20" font="1">treatment to individuals with a </text>
<text top="440" left="913" width="160" height="20" font="1">history of CVD, CHD, stroke, </text>
<text top="457" left="913" width="106" height="20" font="1">DM, HF, and CKD. </text>
<text top="476" left="913" width="7" height="18" font="1">•</text>
<text top="475" left="919" width="141" height="20" font="1"> In stratified analyses, we </text>
<text top="492" left="913" width="156" height="20" font="1">saw no strong evidence that </text>
<text top="510" left="913" width="138" height="20" font="1">proportional effects were </text>
<text top="527" left="913" width="128" height="20" font="1">diminished in trials that </text>
<text top="544" left="913" width="148" height="20" font="1">included people with lower </text>
<text top="561" left="913" width="163" height="20" font="1">baseline SBP (&lt;130 mm Hg), </text>
<text top="578" left="913" width="148" height="20" font="1">and major CV events were </text>
<text top="596" left="913" width="150" height="20" font="1">clearly reduced in high-risk </text>
<text top="613" left="913" width="137" height="20" font="1">pts with various baseline </text>
<text top="630" left="913" width="155" height="20" font="1">comorbidities. Both of these </text>
<text top="647" left="913" width="168" height="20" font="1">major findings—the efficacy of </text>
<text top="664" left="913" width="153" height="20" font="1">BP-lowering below 130 mm </text>
<text top="682" left="913" width="102" height="20" font="1">Hg and the similar </text>
<text top="699" left="913" width="148" height="20" font="1">proportional effects in high </text>
<text top="716" left="913" width="119" height="20" font="1">risk populations—are </text>
<text top="733" left="913" width="169" height="20" font="1">consistent with and extend the </text>
<text top="750" left="913" width="159" height="20" font="1">findings of the SPRINT trial.  </text>
<text top="768" left="913" width="3" height="20" font="1"> </text>
<text top="785" left="913" width="80" height="20" font="4"><b>Limitations:</b>   </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">15 </text>
<text top="107" left="622" width="174" height="20" font="1">CVD- 0.74 (95% CI: 0.67–0.83) </text>
<text top="124" left="622" width="71" height="20" font="1">Total deaths </text>
<text top="141" left="622" width="177" height="20" font="1">CVD+ 0.90 (95% CI: 0.83–0.98) </text>
<text top="159" left="622" width="178" height="20" font="1">CVD- 0.84 (95% CI: 0.75–0.93)  </text>
<text top="176" left="622" width="196" height="20" font="1">Other outcomes similarly in figure 5 </text>
<text top="195" left="622" width="7" height="18" font="1">•</text>
<text top="194" left="629" width="228" height="20" font="1"> In appendix, in general, benefits for CVD </text>
<text top="211" left="622" width="237" height="20" font="1">prevention seen in groups with and without </text>
<text top="229" left="622" width="257" height="20" font="1">baseline CHD, Stroke, DM, CKD and HF when </text>
<text top="246" left="622" width="237" height="20" font="1">examined separately, but no absolute risks </text>
<text top="263" left="622" width="275" height="20" font="1">provided to enable estimation of how far down the </text>
<text top="280" left="622" width="246" height="20" font="1">absolute risk curve these findings have been </text>
<text top="298" left="622" width="82" height="20" font="1">demonstrated. </text>
<text top="317" left="622" width="7" height="18" font="1">•</text>
<text top="316" left="629" width="251" height="20" font="1"> Some evidence of BB inferiority to other med </text>
<text top="333" left="622" width="105" height="20" font="1">classes in figure 6. </text>
<text top="352" left="622" width="7" height="18" font="1">•</text>
<text top="352" left="629" width="246" height="20" font="1"> Did not report absolute risks so do not know </text>
<text top="369" left="622" width="222" height="20" font="1">lower level of risk in treated populations. </text>
<text top="109" left="913" width="7" height="18" font="1">•</text>
<text top="108" left="919" width="146" height="20" font="1"> Lack of individual pt data, </text>
<text top="125" left="913" width="156" height="20" font="1">which would have allowed a </text>
<text top="143" left="913" width="157" height="20" font="1">more reliable assessment of </text>
<text top="160" left="913" width="156" height="20" font="1">treatment effects in different </text>
<text top="177" left="913" width="58" height="20" font="1">pt groups. </text>
<text top="196" left="913" width="7" height="18" font="1">•</text>
<text top="195" left="919" width="150" height="20" font="1"> Interpretation: Lowering of </text>
<text top="213" left="913" width="126" height="20" font="1">BP into what has been </text>
<text top="230" left="913" width="150" height="20" font="1">regarded the normotensive </text>
<text top="247" left="913" width="144" height="20" font="1">range should therefore be </text>
<text top="264" left="913" width="152" height="20" font="1">routinely considered for the </text>
<text top="282" left="913" width="145" height="20" font="1">prevention of CVD among </text>
<text top="299" left="913" width="126" height="20" font="1">those deemed to be of </text>
<text top="316" left="913" width="128" height="20" font="1">sufficient absolute risk. </text>
<text top="387" left="89" width="85" height="20" font="1">Law MR, et al., </text>
<text top="404" left="89" width="56" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(18)</a> </text>
<text top="421" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation">19454737</a></text>
<text top="421" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation"> </a></text>
<text top="387" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="404" left="211" width="119" height="20" font="1">analysis of use of BP-</text>
<text top="421" left="211" width="96" height="20" font="1">lowering drugs in </text>
<text top="438" left="211" width="132" height="20" font="1">prevention of CVD from </text>
<text top="456" left="211" width="121" height="20" font="1">147 randomized trials </text>
<text top="473" left="211" width="3" height="20" font="1"> </text>
<text top="490" left="211" width="140" height="20" font="4"><b>Size:</b> Of 147 randomized </text>
<text top="507" left="211" width="131" height="20" font="1">trials of 464,000 pts, 37 </text>
<text top="524" left="211" width="111" height="20" font="1">trials of BBs in CAD </text>
<text top="542" left="211" width="137" height="20" font="1">included 38,892 pts, and </text>
<text top="559" left="211" width="92" height="20" font="1">37 trials of other </text>
<text top="576" left="211" width="140" height="20" font="1">antihypertensive drugs in </text>
<text top="593" left="211" width="139" height="20" font="1">CAD included 85,395 pts </text>
<text top="387" left="373" width="225" height="20" font="4"><b>Inclusion criteria:</b> The database search </text>
<text top="404" left="373" width="202" height="20" font="1">used Medline (1966 to Dec. 2007) to </text>
<text top="421" left="373" width="223" height="20" font="1">identify randomized trials of BP-lowering </text>
<text top="438" left="373" width="208" height="20" font="1">drugs in which CAD events or strokes </text>
<text top="456" left="373" width="226" height="20" font="1">were recorded. The search also included </text>
<text top="473" left="373" width="219" height="20" font="1">the Cochrane Collaboration and Web of </text>
<text top="490" left="373" width="213" height="20" font="1">Science databases and the citations in </text>
<text top="507" left="373" width="211" height="20" font="1">trials and previous meta-analyses and </text>
<text top="524" left="373" width="88" height="20" font="1">review articles.  </text>
<text top="542" left="373" width="3" height="20" font="1"> </text>
<text top="559" left="373" width="236" height="20" font="4"><b>Exclusion criteria:</b> Trials were excluded if </text>
<text top="576" left="373" width="229" height="20" font="1">there were &lt;5 CAD events and strokes or </text>
<text top="593" left="373" width="179" height="20" font="1">if treatment duration was &lt;6 mo. </text>
<text top="388" left="622" width="185" height="20" font="4"><b>1</b>°<b> endpoint:</b> CAD events; stroke </text>
<text top="405" left="622" width="3" height="20" font="1"> </text>
<text top="422" left="622" width="267" height="20" font="4"><b>Results:</b> In 37 trials of pts with a history of CAD, </text>
<text top="440" left="622" width="247" height="20" font="1">BB reduced CAD events 29% (95% CI: 22%–</text>
<text top="457" left="622" width="258" height="20" font="1">34%). In 27 trials in which BBs were used after </text>
<text top="474" left="622" width="270" height="20" font="1">acute MI, BB reduced CAD events 31% (95% CI: </text>
<text top="491" left="622" width="248" height="20" font="1">24%–38%), and in 11 trials in which BB were </text>
<text top="508" left="622" width="242" height="20" font="1">used after long-term CAD, BB insignificantly </text>
<text top="526" left="622" width="273" height="20" font="1">reduced CAD events 13%. In 7 trials, BB reduced </text>
<text top="543" left="622" width="275" height="20" font="1">stroke 17% (95% CI: 1%–30%). CAD events were </text>
<text top="560" left="622" width="257" height="20" font="1">reduced 14% (95% CI: 2%–25%) in 11 trials of </text>
<text top="577" left="622" width="271" height="20" font="1">thiazide diuretics, 17% (95% CI: 11%–22%) in 21 </text>
<text top="594" left="622" width="255" height="20" font="1">trials of ACEIs, insignificantly 14% in 4 trials of </text>
<text top="612" left="622" width="271" height="20" font="1">angiotensin receptor blockers, and 15% (95% CI: </text>
<text top="629" left="622" width="275" height="20" font="1">8%–22%) in 22 trials of CCB. Stroke was reduced </text>
<text top="646" left="622" width="262" height="20" font="1">38% (95% CI: 28%–47%) in 10 trials of thiazide </text>
<text top="663" left="622" width="262" height="20" font="1">diuretics, 22% (95% CI: 8%–34%) in 13 trials of </text>
<text top="680" left="622" width="269" height="20" font="1">ACEI, and 34% (95% CI: 25%–42%) in 9 trials of </text>
<text top="698" left="622" width="33" height="20" font="1">CCB. </text>
<text top="389" left="913" width="7" height="18" font="1">•</text>
<text top="388" left="919" width="142" height="20" font="1"> With the exception of the </text>
<text top="405" left="913" width="154" height="20" font="1">extra protective effect of BB </text>
<text top="422" left="913" width="152" height="20" font="1">given shortly after a MI and </text>
<text top="440" left="913" width="158" height="20" font="1">the minor additional effect of </text>
<text top="457" left="913" width="165" height="20" font="1">CCBs in preventing stroke, all </text>
<text top="474" left="913" width="148" height="20" font="1">the classes of BP-lowering </text>
<text top="491" left="913" width="160" height="20" font="1">drugs have a similar effect in </text>
<text top="508" left="913" width="143" height="20" font="1">reducing CAD events and </text>
<text top="526" left="913" width="165" height="20" font="1">stroke for a given reduction in </text>
<text top="543" left="913" width="23" height="20" font="1">BP. </text>
<text top="716" left="89" width="89" height="20" font="1">Sundstrom J, et </text>
<text top="733" left="89" width="76" height="20" font="1">al., 2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(19)</a> </text>
<text top="750" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25531552?dopt=Citation">25531552</a></text>
<text top="750" left="144" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25531552?dopt=Citation"> </a> </text>
<text top="716" left="211" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="733" left="211" width="131" height="20" font="1">whether pharmacologic </text>
<text top="750" left="211" width="145" height="20" font="1">BP reduction prevents CV </text>
<text top="767" left="211" width="137" height="20" font="1">events and deaths in pts </text>
<text top="784" left="211" width="103" height="20" font="1">with grade 1 HTN. </text>
<text top="716" left="373" width="217" height="20" font="4"><b>Inclusion criteria:</b> RCTs of at least 1 y </text>
<text top="733" left="373" width="230" height="20" font="1">duration; pts ≥18 y, at least 80% of whom </text>
<text top="750" left="373" width="218" height="20" font="1">had grade 1 HTN and no previous CVD </text>
<text top="767" left="373" width="224" height="20" font="1">(MI, angina pectoris, CABG, PCI, stroke, </text>
<text top="784" left="373" width="213" height="20" font="1">TIA, carotid surgery, peripheral arterial </text>
<text top="717" left="622" width="267" height="20" font="4"><b>1</b>°<b> endpoint:</b> Total major CV events, comprising </text>
<text top="734" left="622" width="202" height="20" font="1">stroke (nonfatal stroke or death from </text>
<text top="751" left="622" width="235" height="20" font="1">cerebrovascular disease), coronary events </text>
<text top="768" left="622" width="274" height="20" font="1">(nonfatal MI or death from CHD, including sudden </text>
<text top="786" left="622" width="223" height="20" font="1">death), HF (causing death or resulting in </text>
<text top="717" left="913" width="7" height="18" font="1">•</text>
<text top="717" left="919" width="161" height="20" font="1"> BP-lowering therapy is likely </text>
<text top="734" left="913" width="166" height="20" font="1">to prevent stroke and death in </text>
<text top="751" left="913" width="163" height="20" font="1">pts with uncomplicated grade </text>
<text top="768" left="913" width="42" height="20" font="1">1 HTN. </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">16 </text>
<text top="107" left="211" width="3" height="20" font="1"> </text>
<text top="124" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="141" left="211" width="96" height="20" font="1">analysis of RCTs </text>
<text top="159" left="211" width="3" height="20" font="1"> </text>
<text top="176" left="211" width="109" height="20" font="4"><b>Size:</b> 10 RTCs with </text>
<text top="193" left="211" width="61" height="20" font="1">15,266 pts </text>
<text top="107" left="373" width="229" height="20" font="1">surgery, intermittent claudication, or renal </text>
<text top="124" left="373" width="237" height="20" font="1">failure); and compared an antihypertensive </text>
<text top="141" left="373" width="195" height="20" font="1">drug provided as monotherapy or a </text>
<text top="159" left="373" width="209" height="20" font="1">stepped-care algorithm vs. placebo or </text>
<text top="176" left="373" width="137" height="20" font="1">another control regimen. </text>
<text top="193" left="373" width="3" height="20" font="1"> </text>
<text top="210" left="373" width="234" height="20" font="4"><b>Exclusion criteria:</b> Excluded trials did not </text>
<text top="227" left="373" width="183" height="20" font="1">contribute an event for any of the </text>
<text top="245" left="373" width="118" height="20" font="1">outcomes of interest. </text>
<text top="107" left="622" width="265" height="20" font="1">hospitalization), or CV death; OR: 0.86 (95% CI: </text>
<text top="124" left="622" width="62" height="20" font="1">0.74–1.01) </text>
<text top="141" left="622" width="3" height="20" font="1"> </text>
<text top="159" left="622" width="103" height="20" font="4"><b>Other endpoints: </b></text>
<text top="176" left="622" width="267" height="20" font="1">Each of the above outcomes independently; and </text>
<text top="193" left="622" width="74" height="20" font="1">total deaths.  </text>
<text top="210" left="622" width="3" height="20" font="1"> </text>
<text top="228" left="622" width="171" height="20" font="1">CHD 0.91 (95% CI: 0.74–1.12) </text>
<text top="245" left="622" width="180" height="20" font="1">Stroke 0.72 (95% CI: 0.55–0.99) </text>
<text top="262" left="622" width="161" height="20" font="1">HF 0.80 (95% CI: 0.57–1.12) </text>
<text top="279" left="622" width="211" height="20" font="1">CVD deaths 0.75 (95% CI: 0.57–0.98) </text>
<text top="296" left="622" width="215" height="20" font="1">Total deaths 0.78 (95% CI: 0.67–0.92)  </text>
<text top="314" left="622" width="3" height="20" font="1"> </text>
<text top="331" left="622" width="241" height="20" font="1">Only the first event for a pt was used for the </text>
<text top="348" left="622" width="257" height="20" font="1">analysis of each outcome, but a pt who had &gt;1 </text>
<text top="365" left="622" width="250" height="20" font="1">outcome type could contribute to more than 1 </text>
<text top="382" left="622" width="269" height="20" font="1">analysis. They also tabulated overall withdrawals </text>
<text top="400" left="622" width="219" height="20" font="1">and withdrawals due to adverse events. </text>
<text top="109" left="913" width="7" height="18" font="1">•</text>
<text top="108" left="919" width="156" height="20" font="1"> 5 y risks in BPLTTC control </text>
<text top="125" left="913" width="145" height="20" font="1">groups CVD events 7.4%, </text>
<text top="143" left="913" width="101" height="20" font="1">CVD deaths 3.1%<b> </b></text>
<text top="418" left="89" width="107" height="20" font="1">Thomopoulos C, et </text>
<text top="435" left="89" width="76" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(20)</a> </text>
<text top="452" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25259547?dopt=Citation">25259547</a></text>
<text top="452" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25259547?dopt=Citation"> </a></text>
<text top="418" left="211" width="103" height="20" font="4"><b>Aim:</b> Investigating </text>
<text top="435" left="211" width="146" height="20" font="1">whether all grades of HTN </text>
<text top="452" left="211" width="138" height="20" font="1">benefit from BP-lowering </text>
<text top="469" left="211" width="135" height="20" font="1">treatment and which are </text>
<text top="487" left="211" width="124" height="20" font="1">the target BP levels to </text>
<text top="504" left="211" width="106" height="20" font="1">maximize outcome </text>
<text top="521" left="211" width="57" height="20" font="1">reduction. </text>
<text top="538" left="211" width="3" height="20" font="1"> </text>
<text top="555" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="573" left="211" width="96" height="20" font="1">analysis of RCTs </text>
<text top="590" left="211" width="3" height="20" font="1"> </text>
<text top="607" left="211" width="109" height="20" font="4"><b>Size:</b> 32 RCTs with </text>
<text top="624" left="211" width="71" height="20" font="1">104,359 pts  </text>
<text top="418" left="373" width="236" height="20" font="4"><b>Inclusion criteria:</b> Intentional BP-lowering </text>
<text top="435" left="373" width="205" height="20" font="1">comparing active drug treatment with </text>
<text top="452" left="373" width="180" height="20" font="1">placebo, or less active treatment </text>
<text top="469" left="373" width="185" height="20" font="1">(intentional BP-lowering trials), or </text>
<text top="487" left="373" width="233" height="20" font="1">comparison of an active drug with placebo </text>
<text top="504" left="373" width="228" height="20" font="1">over baseline antihypertensive treatment, </text>
<text top="521" left="373" width="217" height="20" font="1">resulting in a BP difference of at least 2 </text>
<text top="538" left="373" width="161" height="20" font="1">mm Hg in either SBP or DBP </text>
<text top="555" left="373" width="191" height="20" font="1">(nonintentional BP-lowering trials); </text>
<text top="573" left="373" width="224" height="20" font="1">enrolling of hypertensive individuals only </text>
<text top="590" left="373" width="203" height="20" font="1">or a high proportion (at least 40%) of </text>
<text top="607" left="373" width="34" height="20" font="1">them. </text>
<text top="624" left="373" width="3" height="20" font="1"> </text>
<text top="641" left="373" width="134" height="20" font="4"><b>Exclusion criteria: </b>N/A </text>
<text top="419" left="622" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="438" left="622" width="7" height="18" font="1">•</text>
<text top="437" left="629" width="268" height="20" font="1"> As some trials were done on low-risk pts, others </text>
<text top="454" left="622" width="264" height="20" font="1">on higher risk pts, no evaluation of absolute risk-</text>
<text top="472" left="622" width="270" height="20" font="1">reduction was made. However, a 2º analysis was </text>
<text top="489" left="622" width="270" height="20" font="1">done including trials or trial subgroups with mean </text>
<text top="506" left="622" width="272" height="20" font="1">baseline SBP/DBP values in grade 1 range and a </text>
<text top="523" left="622" width="261" height="20" font="1">low-to-moderate risk (&lt;5% CV deaths in 10 y in </text>
<text top="540" left="622" width="245" height="20" font="1">controls): FEVER stratum with baseline SBP </text>
<text top="558" left="622" width="270" height="20" font="1">below the median (&lt;153 mm Hg); HTN Detection </text>
<text top="575" left="622" width="250" height="20" font="1">and Follow-up Program stratum with baseline </text>
<text top="592" left="622" width="256" height="20" font="1">DBP 90–94 mm Hg and no CVD; OSLO (e17); </text>
<text top="609" left="622" width="274" height="20" font="1">TOMHS (e28) and USPHS. Risks of stroke, CHD, </text>
<text top="627" left="622" width="265" height="20" font="1">the composite of stroke and CHD, and all-cause </text>
<text top="644" left="622" width="265" height="20" font="1">death were significantly reduced by BP-lowering </text>
<text top="661" left="622" width="264" height="20" font="1">in these low-to-moderate risk pts (control group: </text>
<text top="678" left="622" width="226" height="20" font="1">average CV mortality 4.5% in10 y) with a </text>
<text top="695" left="622" width="236" height="20" font="1">moderate BP elevation (average SBP/DBP </text>
<text top="713" left="622" width="272" height="20" font="1">145.5/91 mm Hg) at randomization. Standardized </text>
<text top="730" left="622" width="263" height="20" font="1">RR associated with 10/5 reduction in BP: stroke </text>
<text top="747" left="622" width="144" height="20" font="1">0.33 (95% CI: 0.11–0.98)  </text>
<text top="764" left="622" width="171" height="20" font="1">CHD 0.68 (95% CI: 0.48–0.95) </text>
<text top="420" left="913" width="7" height="18" font="1">•</text>
<text top="419" left="919" width="138" height="20" font="1"> Meta-analyses favor BP-</text>
<text top="436" left="913" width="148" height="20" font="1">lowering treatment even in </text>
<text top="453" left="913" width="124" height="20" font="1">grade 1 HTN at low-to-</text>
<text top="470" left="913" width="154" height="20" font="1">moderate risk, and lowering </text>
<text top="488" left="913" width="168" height="20" font="1">SBP/DBP to &lt;140/90 mm Hg.  </text>
<text top="507" left="913" width="7" height="18" font="1">•</text>
<text top="506" left="919" width="151" height="20" font="1"> Achieving &lt;130/80 mm Hg </text>
<text top="523" left="913" width="154" height="20" font="1">appears safe, but only adds </text>
<text top="540" left="913" width="146" height="20" font="1">further reduction in stroke. </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">17 </text>
<text top="107" left="622" width="265" height="20" font="1">CVD death 0.57 (95% CI: 0.32–1.02) total death </text>
<text top="124" left="622" width="122" height="20" font="1">0.53 (95% 0.35–0.80) </text>
<text top="143" left="622" width="7" height="18" font="1">•</text>
<text top="143" left="629" width="265" height="20" font="1"> Compared outcomes of achieved on study SBP </text>
<text top="160" left="622" width="82" height="20" font="1">&lt;130 vs. ≥130 </text>
<text top="177" left="622" width="245" height="20" font="1">Standardized Risk ratio associated with 10/5 </text>
<text top="194" left="622" width="271" height="20" font="1">reduction in BP: stroke 0.68 (95% CI: 0.57, 0.83)  </text>
<text top="211" left="622" width="171" height="20" font="1">CHD 0.87 (95% CI: 0.76, 1.00) </text>
<text top="229" left="622" width="161" height="20" font="1">HF 0.92 (95% CI: 0.47, 1.77) </text>
<text top="246" left="622" width="170" height="20" font="1">CVD 0.81 (95% CI: 0.67, 1.00) </text>
<text top="263" left="622" width="265" height="20" font="1">CVD death 0.88 (95% CI: 0.77, 1.01) total death </text>
<text top="280" left="622" width="141" height="20" font="1">0.88 (95% CI: 0.77, 0.99) </text>
<text top="299" left="622" width="7" height="18" font="1">•</text>
<text top="299" left="629" width="256" height="20" font="1"> Outcomes of achieved on study SBP 130-139 </text>
<text top="316" left="622" width="51" height="20" font="1">vs. ≥140 </text>
<text top="333" left="622" width="266" height="20" font="1">Standardized RR associated with 10/5 reduction </text>
<text top="350" left="622" width="217" height="20" font="1">in BP: stroke 0.63 (95% CI: 0.52, 0.77)  </text>
<text top="368" left="622" width="171" height="20" font="1">CHD 0.77 (95% CI: 0.70, 0.86) </text>
<text top="385" left="622" width="161" height="20" font="1">HF 0.76 (95% CI: 0.47, 1.25) </text>
<text top="402" left="622" width="170" height="20" font="1">CVD 0.74 (95% CI: 0.62, 0.88) </text>
<text top="419" left="622" width="265" height="20" font="1">CVD death 0.81 (95% CI: 0.67, 0.97) total death </text>
<text top="437" left="622" width="141" height="20" font="1">0.87 (95% CI: 0.75, 1.00) </text>
<text top="456" left="622" width="7" height="18" font="1">•</text>
<text top="455" left="629" width="262" height="20" font="1"> Similar pattern of results for on treatment DBP.<b> </b></text>
<text top="473" left="89" width="73" height="20" font="1">Xie X, et al.,  </text>
<text top="490" left="89" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(21)</a> </text>
<text top="507" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation">26559744</a></text>
<text top="507" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation"> </a></text>
<text top="473" left="211" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="490" left="211" width="119" height="20" font="1">efficacy and safety of </text>
<text top="507" left="211" width="121" height="20" font="1">intensive BP-lowering </text>
<text top="524" left="211" width="60" height="20" font="1">strategies. </text>
<text top="542" left="211" width="3" height="20" font="1"> </text>
<text top="559" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="576" left="211" width="96" height="20" font="1">analysis of RCTs </text>
<text top="593" left="211" width="3" height="20" font="1"> </text>
<text top="610" left="211" width="109" height="20" font="4"><b>Size:</b> 19 RCTs with </text>
<text top="628" left="211" width="61" height="20" font="1">44,989 pts </text>
<text top="473" left="373" width="219" height="20" font="4"><b>Inclusion criteria:</b> RCTs with at least 6 </text>
<text top="490" left="373" width="224" height="20" font="1">mo follow-up that randomly assigned pts </text>
<text top="507" left="373" width="214" height="20" font="1">to more intensive vs. less intensive BP-</text>
<text top="524" left="373" width="201" height="20" font="1">lowering treatment, with different BP </text>
<text top="542" left="373" width="201" height="20" font="1">targets or different BP changes from </text>
<text top="559" left="373" width="218" height="20" font="1">baseline. Reference lists from identified </text>
<text top="576" left="373" width="217" height="20" font="1">trials and review articles were manually </text>
<text top="593" left="373" width="208" height="20" font="1">scanned to identify any other relevant </text>
<text top="610" left="373" width="49" height="20" font="1">studies.  </text>
<text top="628" left="373" width="3" height="20" font="1"> </text>
<text top="645" left="373" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="662" left="373" width="3" height="20" font="4"><b> </b></text>
<text top="679" left="373" width="184" height="20" font="4"><b>Intervention:</b> BP-lowering meds  </text>
<text top="697" left="373" width="7" height="20" font="1">  </text>
<text top="714" left="373" width="84" height="20" font="4"><b>Comparator:</b>   </text>
<text top="733" left="373" width="7" height="18" font="1">•</text>
<text top="732" left="379" width="140" height="20" font="1"> Less intensive treatment </text>
<text top="751" left="373" width="7" height="18" font="1">•</text>
<text top="750" left="379" width="122" height="20" font="1"> BP difference 6.8/3.5 </text>
<text top="769" left="373" width="7" height="18" font="1">•</text>
<text top="769" left="379" width="135" height="20" font="1"> The mean follow-up BP </text>
<text top="786" left="373" width="215" height="20" font="1">levels in the less intensive BP-lowering </text>
<text top="474" left="622" width="83" height="20" font="4"><b>1</b>°<b>  endpoint:</b>  </text>
<text top="493" left="622" width="7" height="18" font="1">•</text>
<text top="492" left="629" width="257" height="20" font="1"> CVD, other major CV events, defined as a MI, </text>
<text top="510" left="622" width="220" height="20" font="1">stroke, HF, or CV death, separately and </text>
<text top="527" left="622" width="260" height="20" font="1">combined; nonvascular and all-cause mortality; </text>
<text top="544" left="622" width="237" height="20" font="1">ESKD, and adverse events. Progression of </text>
<text top="561" left="622" width="239" height="20" font="1">albuminuria (defined as new onset of micro-</text>
<text top="578" left="622" width="269" height="20" font="1">albuminuria/macro-albuminuria or a change from </text>
<text top="596" left="622" width="224" height="20" font="1">micro-albuminuria to macro-albuminuria) </text>
<text top="613" left="622" width="263" height="20" font="1">and retinopathy (retinopathy progression of 2 or </text>
<text top="630" left="622" width="248" height="20" font="1">more steps) were also recorded for trials that </text>
<text top="647" left="622" width="141" height="20" font="1">were done in pts with DM </text>
<text top="666" left="622" width="7" height="18" font="1">•</text>
<text top="666" left="629" width="198" height="20" font="1"> CVD RR: 0.86 (95% CI: 0.78–0.96) </text>
<text top="683" left="622" width="3" height="20" font="1"> </text>
<text top="700" left="622" width="103" height="20" font="4"><b>Other endpoints: </b></text>
<text top="717" left="622" width="231" height="20" font="1">MI RR: 0.87 (95% CI: 0.76–1.00) p=0.042 </text>
<text top="734" left="622" width="204" height="20" font="1">Stroke RR: 0.78 (95% CI: 0.68–0.90) </text>
<text top="752" left="622" width="185" height="20" font="1">HF RR: 0.85 (95% CI: 0.66–1.11) </text>
<text top="769" left="622" width="229" height="20" font="1">CVD death RR: 0.91 (95% CI: 0.74–1.11) </text>
<text top="786" left="622" width="237" height="20" font="1">Total deaths RR: 0.91 (95% CI: 0.81–1.03) </text>
<text top="475" left="913" width="7" height="18" font="1">•</text>
<text top="474" left="919" width="129" height="20" font="1"> Intensive BP-lowering, </text>
<text top="491" left="913" width="143" height="20" font="1">including to &lt;130 mm Hg, </text>
<text top="508" left="913" width="142" height="20" font="1">provided greater vascular </text>
<text top="526" left="913" width="136" height="20" font="1">protection than standard </text>
<text top="543" left="913" width="57" height="20" font="1">regimens. </text>
<text top="562" left="913" width="7" height="18" font="1">•</text>
<text top="561" left="919" width="143" height="20" font="1"> In high-risk pts, there are </text>
<text top="578" left="913" width="162" height="20" font="1">additional benefits from more </text>
<text top="596" left="913" width="125" height="20" font="1">intensive BP-lowering, </text>
<text top="613" left="913" width="156" height="20" font="1">including for those with SPB </text>
<text top="630" left="913" width="144" height="20" font="1">&lt;140 mm Hg at baseline.  </text>
<text top="649" left="913" width="7" height="18" font="1">•</text>
<text top="648" left="919" width="159" height="20" font="1"> The net absolute benefits of </text>
<text top="666" left="913" width="162" height="20" font="1">intensive BP-lowering in high-</text>
<text top="683" left="913" width="139" height="20" font="1">risk individuals are large. </text>
<text top="700" left="913" width="3" height="20" font="1"> </text>
<text top="717" left="913" width="80" height="20" font="4"><b>Limitations:</b>   </text>
<text top="736" left="913" width="7" height="18" font="1">•</text>
<text top="736" left="919" width="146" height="20" font="1"> Lack of individual pt data, </text>
<text top="753" left="913" width="156" height="20" font="1">which would have allowed a </text>
<text top="770" left="913" width="157" height="20" font="1">more reliable assessment of </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">18 </text>
<text top="107" left="373" width="200" height="20" font="1">regimen group were 140/81 mm Hg, </text>
<text top="124" left="373" width="83" height="20" font="1">compared with </text>
<text top="141" left="373" width="201" height="20" font="1">133/76 mm Hg in the more intensive </text>
<text top="159" left="373" width="94" height="20" font="1">treatment group. </text>
<text top="107" left="622" width="3" height="20" font="1"> </text>
<text top="124" left="622" width="84" height="20" font="4"><b>Other results: </b></text>
<text top="143" left="622" width="7" height="18" font="1">•</text>
<text top="143" left="629" width="254" height="20" font="1"> Benefit for CVD not different by baseline SBP </text>
<text top="160" left="622" width="196" height="20" font="1">120–139: 0.89 (95% CI: 0.76–1.05) </text>
<text top="177" left="622" width="196" height="20" font="1">140–160: 0.83 (95% CI: 0.68–1.00) </text>
<text top="194" left="622" width="176" height="20" font="1">&gt;160: 0.89 (95% CI: 0.73–1.09) </text>
<text top="211" left="622" width="120" height="20" font="1">p-heterogeneity: 0.60 </text>
<text top="231" left="622" width="7" height="18" font="1">•</text>
<text top="230" left="629" width="262" height="20" font="1"> Benefit for CVD not different for more intensive </text>
<text top="247" left="622" width="242" height="20" font="1">and less intensive targets in intensive group </text>
<text top="264" left="622" width="264" height="20" font="1">&lt;140 or &lt;150 mm Hg: 0.76 (95% CI: 0.60–0.97) </text>
<text top="282" left="622" width="267" height="20" font="1">&lt;120– &lt;130 mm Hg: 0.91 (95% CI: 0.84–1.00; p-</text>
<text top="299" left="622" width="73" height="20" font="1">hetero: 0.06) </text>
<text top="318" left="622" width="7" height="18" font="1">•</text>
<text top="317" left="629" width="263" height="20" font="1"> Absolute benefits were proportional to absolute </text>
<text top="334" left="622" width="26" height="20" font="1">risk. </text>
<text top="353" left="622" width="7" height="18" font="1">•</text>
<text top="353" left="629" width="260" height="20" font="1"> For trials in which all pts had vascular disease, </text>
<text top="370" left="622" width="252" height="20" font="1">renal disease, or DM at baseline, the average </text>
<text top="387" left="622" width="262" height="20" font="1">control group rate of major vascular events was </text>
<text top="404" left="622" width="254" height="20" font="1">2·9% per y compared with 0·9% per y in other </text>
<text top="422" left="622" width="262" height="20" font="1">trials, and the numbers needed to treat were 94 </text>
<text top="439" left="622" width="270" height="20" font="1">(95% CI: 44–782) in these trials vs. 186 (95% CI: </text>
<text top="456" left="622" width="148" height="20" font="1">107–708) in all other trials. </text>
<text top="475" left="622" width="7" height="18" font="1">•</text>
<text top="474" left="629" width="265" height="20" font="1"> Increase in Severe hypotension: 0.3% vs. 0.1% </text>
<text top="492" left="622" width="238" height="20" font="1">per person y OR: 2.68 (95% CI: 1.21–5.89) </text>
<text top="107" left="913" width="170" height="20" font="1">treatment effects in different pt </text>
<text top="124" left="913" width="44" height="20" font="1">groups. </text>
<text top="143" left="913" width="7" height="18" font="1">•</text>
<text top="143" left="919" width="135" height="20" font="1"> Interpretation: Supports </text>
<text top="160" left="913" width="150" height="20" font="1">treating pt with and without </text>
<text top="177" left="913" width="148" height="20" font="1">CVD at threshold of 130 to </text>
<text top="194" left="913" width="145" height="20" font="1">&lt;130. Supports treating at </text>
<text top="211" left="913" width="156" height="20" font="1">threshold of about 130 even </text>
<text top="229" left="913" width="158" height="20" font="1">down to a CVD event rate of </text>
<text top="246" left="913" width="66" height="20" font="1">0.9% per y. </text>
<text top="511" left="108" width="3" height="19" font="1"> </text>
<text top="545" left="81" width="514" height="24" font="3"><b>Data Supplement 3. Out-of-Office and Self-Monitoring of BP (Section 4.2) </b></text>
<text top="585" left="96" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="602" left="121" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="620" left="99" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="585" left="232" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="602" left="248" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="585" left="429" width="132" height="20" font="4"><b>Patient Population (N) </b></text>
<text top="585" left="627" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="602" left="635" width="167" height="20" font="4"><b>(include P value; OR or RR;  </b></text>
<text top="620" left="687" width="60" height="20" font="4"><b>&amp; 95% CI) </b></text>
<text top="585" left="892" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="602" left="919" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="637" left="89" width="111" height="20" font="1">Pickering TG, et al., </text>
<text top="655" left="89" width="60" height="20" font="1">1988 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(22)</a>  </text>
<text top="672" left="89" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3336140?dopt=Citation">3336140</a></text>
<text top="672" left="137" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3336140?dopt=Citation"> </a> </text>
<text top="637" left="214" width="73" height="20" font="4"><b>Study type</b>:  </text>
<text top="655" left="214" width="132" height="20" font="1">● Observational Cohort </text>
<text top="672" left="214" width="127" height="20" font="1">● 24-h ABPM &lt;134/90 </text>
<text top="689" left="214" width="115" height="20" font="1">● Systematic review </text>
<text top="706" left="214" width="120" height="20" font="1">● Office vs. ABPM or </text>
<text top="724" left="214" width="39" height="20" font="1">HBPM </text>
<text top="741" left="214" width="3" height="20" font="1"> </text>
<text top="758" left="214" width="76" height="20" font="4"><b>Size: </b>292 pts<b> </b></text>
<text top="637" left="381" width="24" height="20" font="1">N/A </text>
<text top="639" left="622" width="140" height="20" font="4"><b>1</b>°<b> endpoint:</b> WCH=21% </text>
<text top="637" left="825" width="248" height="20" font="1">● Multiple methodologies used to define MH. </text>
<text top="655" left="825" width="254" height="20" font="1">Prevalence 8.5%–16.6% (general population), </text>
<text top="672" left="825" width="250" height="20" font="1">14.7%–30.4% (nonelevated clinic population) </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="9" size="12" family="Times" color="#231f20"/>
	<fontspec id="10" size="12" family="Times" color="#1a171c"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">19 </text>
<text top="107" left="89" width="111" height="20" font="1">Uhlig K, et al., 2012 </text>
<text top="124" left="89" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(23)</a> </text>
<text top="141" left="89" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22439158">22439158</a></text>
<text top="141" left="144" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22439158"> </a></text>
<text top="107" left="214" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="124" left="214" width="115" height="20" font="1">● Systematic review </text>
<text top="141" left="214" width="150" height="20" font="1">● Self-monitoring vs. usual </text>
<text top="159" left="214" width="70" height="20" font="1">care vs. self-</text>
<text top="176" left="214" width="109" height="20" font="1">monitoring+support<b> </b></text>
<text top="107" left="381" width="24" height="20" font="1">N/A </text>
<text top="108" left="622" width="166" height="20" font="4"><b>1</b>°<b> endpoint:</b> Change in clinic </text>
<text top="125" left="622" width="57" height="20" font="1">SBP/DBP<b> </b></text>
<text top="109" left="825" width="7" height="18" font="1">•</text>
<text top="108" left="832" width="229" height="20" font="1"> Self-monitoring vs. usual care resulted in </text>
<text top="125" left="825" width="238" height="20" font="1">lower SBP/DBP (-3.1/-2.0 mm Hg) at 6 mo  </text>
<text top="144" left="825" width="7" height="18" font="1">•</text>
<text top="144" left="832" width="224" height="20" font="1"> Self-monitoring + support vs. usual care </text>
<text top="161" left="825" width="242" height="20" font="1">resulted in lower SBP/DBP SBP/DBP -3.4– -</text>
<text top="178" left="825" width="192" height="20" font="1">8.9/-1.9– -4.4 mm Hg up to 12 mo. </text>
<text top="197" left="825" width="7" height="18" font="1">•</text>
<text top="197" left="832" width="254" height="20" font="1"> Self-monitoring may confer a small benefit for </text>
<text top="214" left="825" width="64" height="20" font="1">BP control. </text>
<text top="232" left="89" width="92" height="20" font="1">McManus RJ, et </text>
<text top="249" left="89" width="79" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(24)</a>  </text>
<text top="266" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25157723?dopt=Citation">25157723</a></text>
<text top="266" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25157723?dopt=Citation"> </a></text>
<text top="232" left="214" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="249" left="214" width="41" height="20" font="1">● RCT </text>
<text top="266" left="214" width="147" height="20" font="1">● Self-monitoring with self-</text>
<text top="283" left="214" width="127" height="20" font="1">titration vs. usual care. </text>
<text top="301" left="214" width="3" height="20" font="1"> </text>
<text top="318" left="214" width="75" height="20" font="4"><b>Size</b>: 552 pts </text>
<text top="232" left="381" width="211" height="20" font="4"><b>Inclusion criteria</b>: SBP/DBP ≥130/85 </text>
<text top="249" left="381" width="43" height="20" font="1">mm Hg </text>
<text top="233" left="622" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="233" left="698" width="59" height="20" font="9">Change in </text>
<text top="250" left="622" width="108" height="20" font="9">SBP/DBP at 12 mo </text>
<text top="250" left="730" width="3" height="20" font="4"><b> </b></text>
<text top="234" left="825" width="7" height="18" font="1">•</text>
<text top="233" left="832" width="207" height="20" font="1"> Self-monitoring with self-titration was </text>
<text top="250" left="825" width="87" height="20" font="1">associated with </text>
<text top="250" left="912" width="158" height="20" font="10">SBP and DBP differences of </text>
<text top="267" left="825" width="223" height="20" font="10">9.2 mm Hg and 3.4 mm Hg, respectively.</text>
<text top="267" left="1048" width="3" height="20" font="1"> </text>
<text top="336" left="89" width="105" height="20" font="1">Margolis KL, et al., </text>
<text top="353" left="89" width="56" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(25)</a> </text>
<text top="370" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23821088?dopt=Citation">23821088</a></text>
<text top="370" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23821088?dopt=Citation"> </a></text>
<text top="336" left="214" width="127" height="20" font="4"><b>Aim:</b> Assess impact of </text>
<text top="353" left="214" width="137" height="20" font="1">follow-up and monitoring </text>
<text top="370" left="214" width="148" height="20" font="1">system including home BP </text>
<text top="387" left="214" width="109" height="20" font="1">tele-monitoring and </text>
<text top="405" left="214" width="93" height="20" font="1">pharmacist case </text>
<text top="422" left="214" width="152" height="20" font="1">management on BP control </text>
<text top="439" left="214" width="121" height="20" font="1">in pts treated for HTN </text>
<text top="456" left="214" width="3" height="20" font="4"><b> </b></text>
<text top="474" left="214" width="141" height="20" font="4"><b>Study type:</b> Cluster RCT </text>
<text top="491" left="214" width="3" height="20" font="1"> </text>
<text top="508" left="214" width="75" height="20" font="4"><b>Size</b>: 450 pts </text>
<text top="525" left="214" width="3" height="20" font="1"> </text>
<text top="336" left="381" width="221" height="20" font="4"><b>Inclusion criteria</b>: Pts from 16 clinics in </text>
<text top="353" left="381" width="223" height="20" font="1">integrated health system in Minneapolis, </text>
<text top="370" left="381" width="22" height="20" font="1">MN </text>
<text top="336" left="622" width="168" height="20" font="1">222 pts randomized to 8 usual </text>
<text top="353" left="622" width="180" height="20" font="1">care clinics and 228 randomized </text>
<text top="370" left="622" width="128" height="20" font="1">to 8 intervention clinics </text>
<text top="387" left="622" width="3" height="20" font="1"> </text>
<text top="405" left="622" width="168" height="20" font="1">Intervention included 12 mo of </text>
<text top="422" left="622" width="163" height="20" font="1">home BP tele-monitoring and </text>
<text top="439" left="622" width="172" height="20" font="1">pharmacist case management, </text>
<text top="456" left="622" width="177" height="20" font="1">with 6 mo of follow-up afterward </text>
<text top="338" left="825" width="7" height="18" font="1">•</text>
<text top="337" left="832" width="254" height="20" font="1"> Intervention group achieved better BP control </text>
<text top="354" left="825" width="221" height="20" font="1">compared to usual care during 12 mo of </text>
<text top="371" left="825" width="229" height="20" font="1">intervention and persisting during 6 mo of </text>
<text top="389" left="825" width="53" height="20" font="1">follow-up </text>
<text top="408" left="825" width="7" height="18" font="1">•</text>
<text top="407" left="832" width="249" height="20" font="1"> SBP was &lt;140/90 in 57.2% (95% CI: 44.8%, </text>
<text top="424" left="825" width="248" height="20" font="1">68.7%) of intervention pts at 6 and 12 mo vs. </text>
<text top="441" left="825" width="237" height="20" font="1">30% (95% CI: 23.2%, 37.8%) in usual care </text>
<text top="459" left="825" width="60" height="20" font="1">(p=0.001)  </text>
<text top="478" left="825" width="7" height="18" font="1">•</text>
<text top="477" left="832" width="252" height="20" font="1"> Combination of home BP tele-monitoring and </text>
<text top="494" left="825" width="249" height="20" font="1">pharmacist case management helped control </text>
<text top="511" left="825" width="240" height="20" font="1">HTN better than usual care at 6, 12, and 18 </text>
<text top="529" left="825" width="38" height="20" font="1">mo.24 </text>
<text top="547" left="89" width="105" height="20" font="1">Margolis KL, et al., </text>
<text top="564" left="89" width="60" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(25)</a>  </text>
<text top="581" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23821088?dopt=Citation">23821088</a></text>
<text top="581" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23821088?dopt=Citation"> </a></text>
<text top="547" left="214" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="564" left="214" width="41" height="20" font="1">● RCT </text>
<text top="581" left="214" width="149" height="20" font="1">● Home BP telemonitoring </text>
<text top="598" left="214" width="118" height="20" font="1">with pharmacist case </text>
<text top="615" left="214" width="127" height="20" font="1">management vs. usual </text>
<text top="633" left="214" width="31" height="20" font="1">care. </text>
<text top="650" left="214" width="3" height="20" font="1"> </text>
<text top="667" left="214" width="75" height="20" font="4"><b>Size</b>: 450 pts </text>
<text top="547" left="381" width="198" height="20" font="4"><b>Inclusion criteria</b>: Uncontrolled BP </text>
<text top="548" left="622" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="548" left="698" width="105" height="20" font="9">SBP/DBP &lt;140/90 </text>
<text top="565" left="622" width="188" height="20" font="9">mm Hg (&lt;130/80 mm Hg in DM or </text>
<text top="582" left="622" width="126" height="20" font="9">CKD) at 6 and 12 mo.  </text>
<text top="599" left="622" width="3" height="20" font="9"> </text>
<text top="618" left="622" width="76" height="20" font="4"><b>2</b>°<b> endpoint:</b> </text>
<text top="618" left="698" width="96" height="20" font="9">Change in BP, pt </text>
<text top="635" left="622" width="183" height="20" font="9">satisfaction, and BP control at 18 </text>
<text top="652" left="622" width="150" height="20" font="9">mo (6 mo after intervention </text>
<text top="669" left="622" width="51" height="20" font="9">stopped).</text>
<text top="669" left="674" width="3" height="20" font="1"> </text>
<text top="547" left="825" width="252" height="20" font="1">● Telemonitoring resulted in better BP control </text>
<text top="564" left="825" width="255" height="20" font="1">(57% vs. 30%) at 6 and 12 mo and larger SBP </text>
<text top="581" left="825" width="161" height="20" font="1">declines at 6, 12, and 18 mo. </text>
<text top="598" left="825" width="218" height="20" font="1">● Some aspects of pt satisfaction (e.g., </text>
<text top="615" left="825" width="234" height="20" font="1">clinicians listening carefully) improved with </text>
<text top="633" left="825" width="84" height="20" font="1">telemonitoring. </text>
<text top="687" left="89" width="92" height="20" font="1">McManus RJ, et </text>
<text top="704" left="89" width="79" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(24)</a>  </text>
<text top="722" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25157723?dopt=Citation">25157723</a></text>
<text top="722" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25157723?dopt=Citation"> </a></text>
<text top="687" left="214" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="704" left="214" width="41" height="20" font="1">● RCT </text>
<text top="722" left="214" width="147" height="20" font="1">● Self-monitoring with self-</text>
<text top="739" left="214" width="127" height="20" font="1">titration vs. usual care. </text>
<text top="756" left="214" width="3" height="20" font="1"> </text>
<text top="773" left="214" width="75" height="20" font="4"><b>Size</b>: 552 pts </text>
<text top="687" left="381" width="211" height="20" font="4"><b>Inclusion criteria</b>: SBP/DBP ≥130/85 </text>
<text top="704" left="381" width="43" height="20" font="1">mm Hg </text>
<text top="688" left="622" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="688" left="698" width="59" height="20" font="9">Change in </text>
<text top="706" left="622" width="104" height="20" font="9">SBP/DBP at 12 mo</text>
<text top="706" left="727" width="3" height="20" font="1"> </text>
<text top="687" left="825" width="216" height="20" font="1">● Self-monitoring with self-titration was </text>
<text top="704" left="825" width="87" height="20" font="1">associated with </text>
<text top="704" left="912" width="158" height="20" font="10">SBP and DBP differences of </text>
<text top="722" left="825" width="223" height="20" font="10">9.2 mm Hg and 3.4 mm Hg, respectively.</text>
<text top="722" left="1048" width="3" height="20" font="1"> </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">20 </text>
<text top="107" left="89" width="107" height="20" font="1">Siu AL, et al., 2015 </text>
<text top="124" left="89" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26458123">26458123</a></text>
<text top="124" left="144" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26458123"> </a></text>
<text top="107" left="214" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="124" left="214" width="139" height="20" font="1">U.S. Preventive Services </text>
<text top="141" left="214" width="147" height="20" font="1">Task Force commissioned </text>
<text top="159" left="214" width="124" height="20" font="1">systematic review and </text>
<text top="176" left="214" width="150" height="20" font="1">meta-analysis of office and </text>
<text top="193" left="214" width="87" height="20" font="1">out of office BP </text>
<text top="210" left="214" width="149" height="20" font="1">relationships for diagnostic </text>
<text top="228" left="214" width="129" height="20" font="1">accuracy of diagnosing </text>
<text top="245" left="214" width="123" height="20" font="1">high BP after an initial </text>
<text top="262" left="214" width="143" height="20" font="1">office-based classification </text>
<text top="279" left="214" width="64" height="20" font="1">of high BP.<b> </b></text>
<text top="107" left="381" width="109" height="20" font="4"><b>Inclusion criteria</b>:  </text>
<text top="124" left="381" width="88" height="20" font="1">● Adults ≥18 y. </text>
<text top="141" left="381" width="221" height="20" font="1">● 24 studies based on “confirmation” by </text>
<text top="159" left="381" width="197" height="20" font="1">means of ABPM and 6 by means of </text>
<text top="176" left="381" width="42" height="20" font="1">HPBM. </text>
<text top="108" left="622" width="167" height="20" font="4"><b>1</b>°<b> endpoint: </b>ABPM or HBPM </text>
<text top="125" left="622" width="159" height="20" font="1">conformation of office-based </text>
<text top="143" left="622" width="122" height="20" font="1">diagnosis of high BP.  </text>
<text top="160" left="622" width="3" height="20" font="1"> </text>
<text top="177" left="622" width="155" height="20" font="1">● CVD risk-relationships for </text>
<text top="194" left="622" width="175" height="20" font="1">ABPM, HBPM and office-based </text>
<text top="211" left="622" width="111" height="20" font="1">BPs also reviewed.  </text>
<text top="229" left="622" width="174" height="20" font="1">● ABPM was recommended as </text>
<text top="246" left="622" width="166" height="20" font="1">the best method to confirm an </text>
<text top="263" left="622" width="189" height="20" font="1">office-based diagnosis of high BP, </text>
<text top="280" left="622" width="144" height="20" font="1">with HBPM an acceptable </text>
<text top="298" left="622" width="149" height="20" font="1">alternative, based on “over </text>
<text top="315" left="622" width="178" height="20" font="1">diagnosis” of high BP with office </text>
<text top="332" left="622" width="170" height="20" font="1">BP measurements (White coat </text>
<text top="349" left="622" width="150" height="20" font="1">hypertension) and stronger </text>
<text top="366" left="622" width="189" height="20" font="1">relationships between out of office </text>
<text top="384" left="622" width="166" height="20" font="1">BP measurements (especially </text>
<text top="401" left="622" width="163" height="20" font="1">ABPM) with vascular events. <b> </b></text>
<text top="107" left="825" width="227" height="20" font="1">● Screen for high BP in adults ≥18 y and </text>
<text top="124" left="825" width="260" height="20" font="1">confirm office-based high BP using out of office </text>
<text top="141" left="825" width="215" height="20" font="1">BP measurements 9preferably ABPM). </text>
<text top="419" left="89" width="111" height="20" font="1">Uhlig K, et al., 2012 </text>
<text top="436" left="89" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(23)</a> </text>
<text top="453" left="89" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22439158">22439158</a></text>
<text top="453" left="144" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22439158"> </a></text>
<text top="419" left="214" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="436" left="214" width="115" height="20" font="1">● Systematic review </text>
<text top="453" left="214" width="150" height="20" font="1">● Self-monitoring vs. usual </text>
<text top="470" left="214" width="70" height="20" font="1">care vs. self-</text>
<text top="488" left="214" width="109" height="20" font="1">monitoring+support </text>
<text top="419" left="381" width="24" height="20" font="1">N/A </text>
<text top="420" left="622" width="166" height="20" font="4"><b>1</b>°<b> endpoint:</b> Change in clinic </text>
<text top="437" left="622" width="57" height="20" font="1">SBP/DBP </text>
<text top="419" left="825" width="238" height="20" font="1">● Self-monitoring vs. usual care resulted in </text>
<text top="436" left="825" width="238" height="20" font="1">lower SBP/DBP (-3.1/-2.0 mm Hg) at 6 mo  </text>
<text top="453" left="825" width="233" height="20" font="1">● Self-monitoring + support vs. usual care </text>
<text top="470" left="825" width="242" height="20" font="1">resulted in lower SBP/DBP SBP/DBP -3.4– -</text>
<text top="488" left="825" width="192" height="20" font="1">8.9/-1.9– -4.4 mm Hg up to 12 mo. </text>
<text top="505" left="825" width="251" height="20" font="1">Self-monitoring may confer a small benefit for </text>
<text top="522" left="825" width="64" height="20" font="1">BP control. </text>
<text top="540" left="89" width="75" height="20" font="1">Yi SS, et al.,  </text>
<text top="557" left="89" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(26)</a> </text>
<text top="574" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25737487">25737487</a></text>
<text top="574" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25737487"> </a></text>
<text top="540" left="214" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="557" left="214" width="41" height="20" font="1">● RCT </text>
<text top="574" left="214" width="151" height="20" font="1">● Self-monitoring of BP vs. </text>
<text top="592" left="214" width="64" height="20" font="1">usual care. </text>
<text top="609" left="214" width="3" height="20" font="1"> </text>
<text top="626" left="214" width="75" height="20" font="4"><b>Size</b>: 900 pts<b> </b></text>
<text top="540" left="381" width="24" height="20" font="1">N/A </text>
<text top="541" left="622" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="558" left="622" width="183" height="20" font="1">● Change in clinic SBP/DBP and </text>
<text top="576" left="622" width="178" height="20" font="1">HTN control (SBP/DBP &lt;140/90 </text>
<text top="593" left="622" width="47" height="20" font="1">mm Hg) </text>
<text top="610" left="622" width="168" height="20" font="1">● Decline in SBP at 9 mo was </text>
<text top="627" left="622" width="178" height="20" font="1">14.7 mm Hg and 14.1 mm Hg in </text>
<text top="644" left="622" width="172" height="20" font="1">the intervention and usual care </text>
<text top="662" left="622" width="148" height="20" font="1">groups (p=0.70); HTN was </text>
<text top="679" left="622" width="183" height="20" font="1">controlled in 38.9% and 39.1% in </text>
<text top="696" left="622" width="152" height="20" font="1">the intervention and control </text>
<text top="713" left="622" width="91" height="20" font="1">groups (p=0.91)<b> </b></text>
<text top="540" left="825" width="228" height="20" font="1">● Self-monitoring of BP by itself does not </text>
<text top="557" left="825" width="171" height="20" font="1">improve BP above usual care.  </text>
<text top="731" left="89" width="100" height="20" font="1">Agarwal R, et. al., </text>
<text top="748" left="89" width="56" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(27)</a> </text>
<text top="766" left="89" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21115879">21115879</a></text>
<text top="766" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21115879"> </a></text>
<text top="731" left="214" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="748" left="214" width="115" height="20" font="1">● Systematic review </text>
<text top="731" left="381" width="24" height="20" font="1">N/A </text>
<text top="732" left="622" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="750" left="622" width="183" height="20" font="1">● Change in clinic SBP/DBP and </text>
<text top="767" left="622" width="30" height="20" font="1">MAP </text>
<text top="731" left="825" width="263" height="20" font="1">● Self-monitoring is associated with a reduction </text>
<text top="748" left="825" width="253" height="20" font="1">in BP. This effect is larger when accompanied </text>
<text top="766" left="825" width="100" height="20" font="1">by telemonitoring. </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">21 </text>
<text top="107" left="214" width="150" height="20" font="1">● Self-monitoring vs. usual </text>
<text top="124" left="214" width="70" height="20" font="1">care vs. self-</text>
<text top="141" left="214" width="145" height="20" font="1">monitoring+telemonitoring </text>
<text top="159" left="214" width="3" height="20" font="1"> </text>
<text top="176" left="214" width="85" height="20" font="4"><b>Size</b>: 9,446 pts </text>
<text top="107" left="622" width="174" height="20" font="1">● Mean reduction in SBP, DBP </text>
<text top="124" left="622" width="174" height="20" font="1">and MAP with home monitoring </text>
<text top="141" left="622" width="178" height="20" font="1">was 2.63 mm Hg (95% CI: 4.24–</text>
<text top="159" left="622" width="179" height="20" font="1">1.02), 1.68 (95% CI: 2.58–0.79), </text>
<text top="176" left="622" width="162" height="20" font="1">4.0 (95% CI: 1.79–6.22). The </text>
<text top="193" left="622" width="172" height="20" font="1">effect for SBP was larger when </text>
<text top="210" left="622" width="174" height="20" font="1">accompanied by telemonitoring </text>
<text top="228" left="622" width="159" height="20" font="1">(3.20; 95% CI: 4.66–1.73 vs. </text>
<text top="245" left="622" width="147" height="20" font="1">1.26; 95% CI: 2.20–0.31).  </text>
<text top="263" left="89" width="104" height="20" font="1">Fagard RH, et. al., </text>
<text top="280" left="89" width="56" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(28)</a> </text>
<text top="297" left="89" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17921809">17921809 </a></text>
<text top="263" left="214" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="280" left="214" width="115" height="20" font="1">● Systematic review </text>
<text top="297" left="214" width="111" height="20" font="1">● MH and WCH vs. </text>
<text top="314" left="214" width="134" height="20" font="1">sustained normotension </text>
<text top="332" left="214" width="3" height="20" font="1"> </text>
<text top="349" left="214" width="92" height="20" font="4"><b>Size</b>: 11,502 pts </text>
<text top="263" left="381" width="24" height="20" font="1">N/A </text>
<text top="264" left="622" width="148" height="20" font="4"><b>1</b>°<b> endpoint:</b> CVD events. </text>
<text top="281" left="622" width="182" height="20" font="1">The adjusted HR for CVD events </text>
<text top="298" left="622" width="184" height="20" font="1">was 1.12 (95% CI: 0.84–1.50) for </text>
<text top="316" left="622" width="186" height="20" font="1">WCH vs. sustained normotension </text>
<text top="333" left="622" width="183" height="20" font="1">(p=0.59) and 2.00 (95% CI: 1.58–</text>
<text top="350" left="622" width="147" height="20" font="1">2.52) for MH vs. sustained </text>
<text top="367" left="622" width="134" height="20" font="1">normotension (p&lt;0.001) </text>
<text top="263" left="825" width="244" height="20" font="1">● MH is associated with increased CVD risk </text>
<text top="280" left="825" width="256" height="20" font="1">but WCH is not associated with increased risk. </text>
<text top="387" left="108" width="3" height="19" font="1"> </text>
<text top="421" left="81" width="413" height="24" font="3"><b>Data Supplement 4. White Coat Hypertension (Section 4.4) </b></text>
<text top="461" left="100" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="478" left="125" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="495" left="103" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="461" left="232" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="478" left="258" width="67" height="20" font="4"><b>Definitions </b></text>
<text top="461" left="384" width="112" height="20" font="4"><b>Patient Population </b></text>
<text top="478" left="430" width="21" height="20" font="4"><b>(N) </b></text>
<text top="461" left="540" width="62" height="20" font="4"><b>HBPM (%) </b></text>
<text top="461" left="660" width="55" height="20" font="4"><b>Daytime  </b></text>
<text top="478" left="655" width="62" height="20" font="4"><b>ABPM (%) </b></text>
<text top="461" left="776" width="29" height="20" font="4"><b>24-h </b></text>
<text top="478" left="759" width="62" height="20" font="4"><b>ABPM (%) </b></text>
<text top="461" left="918" width="115" height="20" font="4"><b>Results/Comments </b></text>
<text top="520" left="98" width="87" height="20" font="1">Viera AJ, et al., </text>
<text top="537" left="98" width="56" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(29)</a> </text>
<text top="555" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20671718?dopt=Citation">20671718</a></text>
<text top="555" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20671718?dopt=Citation"> </a></text>
<text top="522" left="214" width="7" height="18" font="1">•</text>
<text top="521" left="221" width="76" height="20" font="1"> Office BP ×3 </text>
<text top="540" left="214" width="7" height="18" font="1">•</text>
<text top="540" left="221" width="133" height="20" font="1"> Duplicate measures of: </text>
<text top="557" left="214" width="114" height="20" font="1">24-h ABPM &gt;130/80 </text>
<text top="574" left="214" width="132" height="20" font="1">Daytime ABPM&gt;135/85 </text>
<text top="591" left="214" width="87" height="20" font="1">HBPM &gt;135/85 </text>
<text top="522" left="383" width="7" height="18" font="1">•</text>
<text top="521" left="389" width="40" height="20" font="1"> 50 pts </text>
<text top="540" left="383" width="7" height="18" font="1">•</text>
<text top="540" left="389" width="61" height="20" font="1"> Untreated </text>
<text top="559" left="383" width="7" height="18" font="1">•</text>
<text top="558" left="389" width="91" height="20" font="1"> Borderline HTN </text>
<text top="575" left="383" width="92" height="20" font="1">and BP &gt;110/70 </text>
<text top="592" left="383" width="79" height="20" font="1">and &lt;160/110 </text>
<text top="522" left="511" width="7" height="18" font="1">•</text>
<text top="521" left="518" width="64" height="20" font="1"> MH=43/35 </text>
<text top="522" left="644" width="7" height="18" font="1">•</text>
<text top="521" left="651" width="64" height="20" font="1"> MH=54/53 </text>
<text top="522" left="740" width="7" height="18" font="1">•</text>
<text top="521" left="747" width="64" height="20" font="1"> MH=51/45 </text>
<text top="522" left="854" width="7" height="18" font="1">•</text>
<text top="521" left="860" width="103" height="20" font="1"> For MH diagnosis </text>
<text top="540" left="854" width="7" height="18" font="1">•</text>
<text top="540" left="860" width="234" height="20" font="1"> 95% agreement daytime and 24-h ABPM  </text>
<text top="559" left="854" width="7" height="18" font="1">•</text>
<text top="558" left="860" width="204" height="20" font="1"> Only 47%–53% agreement between </text>
<text top="575" left="854" width="224" height="20" font="1">HBPM and either daytime or 24-h ABPM </text>
<text top="610" left="98" width="87" height="20" font="1">Viera AJ, et al., </text>
<text top="628" left="98" width="56" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(30)</a> </text>
<text top="645" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24842491?dopt=Citation">24842491</a></text>
<text top="645" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24842491?dopt=Citation"> </a></text>
<text top="612" left="214" width="7" height="18" font="1">•</text>
<text top="611" left="221" width="76" height="20" font="1"> Office BP ×3 </text>
<text top="630" left="214" width="7" height="18" font="1">•</text>
<text top="630" left="221" width="133" height="20" font="1"> Duplicate measures of: </text>
<text top="647" left="214" width="114" height="20" font="1">24-h ABPM &gt;130/80 </text>
<text top="664" left="214" width="135" height="20" font="1">Daytime ABPM &gt;135/85 </text>
<text top="681" left="214" width="87" height="20" font="1">HBPM &gt;135/85 </text>
<text top="612" left="383" width="7" height="18" font="1">•</text>
<text top="611" left="389" width="47" height="20" font="1"> 420 pts </text>
<text top="630" left="383" width="7" height="18" font="1">•</text>
<text top="630" left="389" width="61" height="20" font="1"> Untreated </text>
<text top="649" left="383" width="7" height="18" font="1">•</text>
<text top="648" left="389" width="91" height="20" font="1"> Borderline HTN </text>
<text top="665" left="383" width="92" height="20" font="1">and BP &gt;120/80 </text>
<text top="683" left="383" width="72" height="20" font="1">and &lt;149/95 </text>
<text top="612" left="511" width="7" height="18" font="1">•</text>
<text top="611" left="518" width="67" height="20" font="1"> MH=15–17 </text>
<text top="612" left="644" width="7" height="18" font="1">•</text>
<text top="611" left="651" width="67" height="20" font="1"> MH=43–44 </text>
<text top="612" left="740" width="7" height="18" font="1">•</text>
<text top="611" left="747" width="67" height="20" font="1"> MH=48–50 </text>
<text top="612" left="854" width="7" height="18" font="1">•</text>
<text top="611" left="860" width="105" height="20" font="1"> For MH Diagnosis </text>
<text top="630" left="854" width="7" height="18" font="1">•</text>
<text top="630" left="860" width="224" height="20" font="1"> 92%–94% agreement daytime and 24-h </text>
<text top="647" left="854" width="38" height="20" font="1">ABPM </text>
<text top="666" left="854" width="7" height="18" font="1">•</text>
<text top="665" left="860" width="207" height="20" font="1"> 70% agreement between HBPM and </text>
<text top="683" left="854" width="151" height="20" font="1">either daytime K=0.3–0.36  </text>
<text top="701" left="98" width="80" height="20" font="1">Bayo B, et al., </text>
<text top="718" left="98" width="56" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(31)</a> </text>
<text top="735" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16534404">16534404</a></text>
<text top="735" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16534404"> </a></text>
<text top="702" left="214" width="7" height="18" font="1">•</text>
<text top="702" left="221" width="76" height="20" font="1"> Office BP ×3 </text>
<text top="721" left="214" width="7" height="18" font="1">•</text>
<text top="720" left="221" width="70" height="20" font="1"> HBPM ×3 d </text>
<text top="702" left="383" width="7" height="18" font="1">•</text>
<text top="702" left="389" width="103" height="20" font="1"> 190 untreated pts </text>
<text top="721" left="383" width="7" height="18" font="1">•</text>
<text top="720" left="389" width="51" height="20" font="1"> Spanish </text>
<text top="739" left="383" width="7" height="18" font="1">•</text>
<text top="739" left="389" width="63" height="20" font="1"> Borderline </text>
<text top="702" left="511" width="7" height="18" font="1">•</text>
<text top="702" left="518" width="57" height="20" font="1"> WCH=35 </text>
<text top="719" left="511" width="93" height="20" font="1">(95% CI: 28–42) </text>
<text top="701" left="644" width="3" height="20" font="1"> </text>
<text top="702" left="740" width="7" height="18" font="1">•</text>
<text top="702" left="747" width="57" height="20" font="1"> WCH=42 </text>
<text top="719" left="740" width="96" height="20" font="1"> (95% CI: 34, 48) </text>
<text top="701" left="854" width="200" height="20" font="1">● Compared to ABPM, HBPM pulse </text>
<text top="718" left="854" width="239" height="20" font="1">pressure variation: 59% negative predictive </text>
<text top="735" left="854" width="64" height="20" font="1">value: 69% </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">22 </text>
<text top="107" left="98" width="103" height="20" font="1">Asayama K, et al., </text>
<text top="124" left="98" width="60" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(32)</a>  </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25135185">25135185</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25135185"> </a></text>
<text top="109" left="214" width="7" height="18" font="1">•</text>
<text top="108" left="221" width="30" height="20" font="1"> Obs </text>
<text top="125" left="214" width="105" height="20" font="1">(IDACO) database </text>
<text top="143" left="214" width="3" height="20" font="1"> </text>
<text top="162" left="214" width="7" height="18" font="1">•</text>
<text top="161" left="221" width="120" height="20" font="1"> CV outcomes risk by </text>
<text top="178" left="214" width="91" height="20" font="1">WCH, MH, NTN </text>
<text top="195" left="214" width="100" height="20" font="1">ABPM measured: </text>
<text top="213" left="214" width="73" height="20" font="1">Office BP ×2 </text>
<text top="230" left="214" width="89" height="20" font="1">&gt;140/90 (office) </text>
<text top="247" left="214" width="123" height="20" font="1">&gt;130/80 (24-h ABPM) </text>
<text top="264" left="214" width="141" height="20" font="1">&gt;135/85 (daytime ABPM) </text>
<text top="281" left="214" width="144" height="20" font="1">&gt;120/70 (nighttime ABPM </text>
<text top="109" left="383" width="7" height="18" font="1">•</text>
<text top="108" left="389" width="93" height="20" font="1"> 8,237 untreated </text>
<text top="125" left="383" width="20" height="20" font="1">pts </text>
<text top="107" left="511" width="24" height="20" font="1">N/A </text>
<text top="109" left="644" width="7" height="18" font="1">•</text>
<text top="108" left="651" width="60" height="20" font="1"> WCH=9.1 </text>
<text top="127" left="644" width="7" height="18" font="1">•</text>
<text top="127" left="651" width="57" height="20" font="1"> MH=13.4 </text>
<text top="109" left="740" width="7" height="18" font="1">•</text>
<text top="108" left="747" width="67" height="20" font="1"> WCH=10.7 </text>
<text top="127" left="740" width="7" height="18" font="1">•</text>
<text top="127" left="747" width="50" height="20" font="1"> MH=9.7 </text>
<text top="107" left="854" width="217" height="20" font="1">● Overlap from daytime to 24-h ABPM: </text>
<text top="124" left="854" width="68" height="20" font="1">WCH=86%  </text>
<text top="141" left="854" width="54" height="20" font="1">MH=61% </text>
<text top="299" left="98" width="89" height="20" font="1">Conen D, et al., </text>
<text top="317" left="98" width="60" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(33)</a>  </text>
<text top="334" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25185130">25185130</a></text>
<text top="334" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25185130"> </a></text>
<text top="301" left="214" width="7" height="18" font="1">•</text>
<text top="301" left="221" width="36" height="20" font="1"> Obs   </text>
<text top="318" left="214" width="106" height="20" font="1">13 IDACO Cohorts </text>
<text top="335" left="214" width="3" height="20" font="1"> </text>
<text top="354" left="214" width="7" height="18" font="1">•</text>
<text top="353" left="221" width="57" height="20" font="1"> Office ×2 </text>
<text top="373" left="214" width="7" height="18" font="1">•</text>
<text top="372" left="221" width="130" height="20" font="1"> Awake ABPM &gt;135/85 </text>
<text top="391" left="214" width="7" height="18" font="1">•</text>
<text top="390" left="221" width="108" height="20" font="1"> 24-h ABP &gt;130/80 </text>
<text top="409" left="214" width="7" height="18" font="1">•</text>
<text top="409" left="221" width="140" height="20" font="1"> Analyzed by decade in y </text>
<text top="301" left="383" width="7" height="18" font="1">•</text>
<text top="301" left="389" width="93" height="20" font="1"> 7,506 untreated </text>
<text top="318" left="383" width="20" height="20" font="1">pts </text>
<text top="301" left="511" width="7" height="18" font="1">•</text>
<text top="301" left="518" width="95" height="20" font="1"> WCH=2.2% age </text>
<text top="318" left="511" width="114" height="20" font="1">18–30, increasing to </text>
<text top="335" left="511" width="114" height="20" font="1">19.5% in both sexes </text>
<text top="352" left="511" width="58" height="20" font="1">age &gt;70 y </text>
<text top="371" left="511" width="7" height="18" font="1">•</text>
<text top="371" left="518" width="89" height="20" font="1"> MH=inverted U </text>
<text top="388" left="511" width="63" height="20" font="1">distribution </text>
<text top="405" left="511" width="97" height="20" font="1">(13% and 11% in </text>
<text top="422" left="511" width="99" height="20" font="1">18–30 y 18% and </text>
<text top="440" left="511" width="112" height="20" font="1">20% in those 30–50 </text>
<text top="457" left="511" width="10" height="20" font="1">y </text>
<text top="476" left="511" width="7" height="18" font="1">•</text>
<text top="475" left="517" width="61" height="20" font="1"> Increased </text>
<text top="492" left="511" width="104" height="20" font="1">prevalence in men </text>
<text top="299" left="644" width="3" height="20" font="1"> </text>
<text top="317" left="644" width="3" height="20" font="1"> </text>
<text top="301" left="740" width="7" height="18" font="1">•</text>
<text top="301" left="747" width="74" height="20" font="1"> WCH=3.0 in </text>
<text top="318" left="740" width="62" height="20" font="1">age 18–30 </text>
<text top="335" left="740" width="73" height="20" font="1">increasing to </text>
<text top="352" left="740" width="66" height="20" font="1">19.1% both </text>
<text top="370" left="740" width="93" height="20" font="1">sexes age &gt;70 y </text>
<text top="389" left="740" width="7" height="18" font="1">•</text>
<text top="388" left="747" width="89" height="20" font="1"> MH=inverted U </text>
<text top="405" left="740" width="63" height="20" font="1">distribution </text>
<text top="422" left="740" width="90" height="20" font="1">(12% and 9% in </text>
<text top="440" left="740" width="77" height="20" font="1">youngest and </text>
<text top="457" left="740" width="91" height="20" font="1">oldest, 19% and </text>
<text top="474" left="740" width="95" height="20" font="1">17% in those 30–</text>
<text top="491" left="740" width="27" height="20" font="1">50 y </text>
<text top="510" left="740" width="7" height="18" font="1">•</text>
<text top="510" left="747" width="54" height="20" font="1"> Increase </text>
<text top="527" left="740" width="76" height="20" font="1">prevalence in </text>
<text top="544" left="740" width="27" height="20" font="1">men </text>
<text top="299" left="854" width="227" height="20" font="1">● Similar prevalence using either 24-h or </text>
<text top="317" left="854" width="77" height="20" font="1">awake ABPM </text>
<text top="562" left="98" width="96" height="20" font="1">Nasothimiou EG, </text>
<text top="579" left="98" width="90" height="20" font="1">et al., 2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(34)</a> </text>
<text top="596" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22357523">22357523</a></text>
<text top="596" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22357523"> </a></text>
<text top="564" left="214" width="7" height="18" font="1">•</text>
<text top="563" left="221" width="135" height="20" font="1"> Office BP ×3 × &gt;140/90 </text>
<text top="582" left="214" width="7" height="18" font="1">•</text>
<text top="581" left="221" width="91" height="20" font="1"> HBPM &gt;135/85 </text>
<text top="600" left="214" width="7" height="18" font="1">•</text>
<text top="600" left="221" width="139" height="20" font="1"> Daytime ABPM &gt;135/85 </text>
<text top="564" left="383" width="7" height="18" font="1">•</text>
<text top="563" left="389" width="79" height="20" font="1"> 613 pts (66% </text>
<text top="580" left="383" width="87" height="20" font="1">untreated, 34% </text>
<text top="597" left="383" width="46" height="20" font="1">treated) </text>
<text top="564" left="511" width="7" height="18" font="1">•</text>
<text top="563" left="518" width="68" height="20" font="1"> WCH=15% </text>
<text top="582" left="511" width="7" height="18" font="1">•</text>
<text top="581" left="518" width="58" height="20" font="1"> MH=15% </text>
<text top="564" left="644" width="7" height="18" font="1">•</text>
<text top="563" left="651" width="68" height="20" font="1"> WCH=14% </text>
<text top="582" left="644" width="7" height="18" font="1">•</text>
<text top="581" left="651" width="58" height="20" font="1"> MH=16% </text>
<text top="562" left="740" width="24" height="20" font="1">N/A </text>
<text top="562" left="854" width="224" height="20" font="1">● WCH: 89% agreement daytime ABPM </text>
<text top="579" left="854" width="134" height="20" font="1">and HBPM, kappa=0.79 </text>
<text top="596" left="854" width="200" height="20" font="1">● MH: 88% agreement, kappa=0.56 </text>
<text top="620" left="98" width="99" height="20" font="1">Coll de TG, et al., </text>
<text top="637" left="98" width="56" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(35)</a> </text>
<text top="654" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21183853">21183853</a></text>
<text top="654" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21183853"> </a></text>
<text top="622" left="214" width="7" height="18" font="1">•</text>
<text top="621" left="221" width="105" height="20" font="1"> Office ×2 &gt;140/90 </text>
<text top="640" left="214" width="7" height="18" font="1">•</text>
<text top="640" left="221" width="139" height="20" font="1"> Daytime ABPM &gt;135/85 </text>
<text top="659" left="214" width="7" height="18" font="1">•</text>
<text top="658" left="221" width="91" height="20" font="1"> HBPM &gt;135/85 </text>
<text top="622" left="383" width="7" height="18" font="1">•</text>
<text top="621" left="389" width="196" height="20" font="1"> 403 untreated pts  • WCH=24% </text>
<text top="622" left="644" width="7" height="18" font="1">•</text>
<text top="621" left="651" width="113" height="20" font="1"> WCH=8.1%  N/A </text>
<text top="620" left="854" width="24" height="20" font="1">N/A </text>
<text top="678" left="98" width="87" height="20" font="1">Stergiou GS, et </text>
<text top="695" left="98" width="79" height="20" font="1">al., 2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(36)</a>  </text>
<text top="712" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15925734">15925734</a></text>
<text top="712" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15925734"> </a></text>
<text top="680" left="214" width="7" height="18" font="1">•</text>
<text top="679" left="221" width="122" height="20" font="1"> Office ×3 ×2 &gt;140/90 </text>
<text top="698" left="214" width="7" height="18" font="1">•</text>
<text top="697" left="221" width="141" height="20" font="1"> HBPM ≥135/85 awake • </text>
<text top="715" left="214" width="87" height="20" font="1">ABPM ≥135/85 </text>
<text top="680" left="383" width="7" height="18" font="1">•</text>
<text top="679" left="389" width="86" height="20" font="1"> 438 untreated/ </text>
<text top="696" left="383" width="62" height="20" font="1">treated pts </text>
<text top="680" left="511" width="7" height="18" font="1">•</text>
<text top="679" left="518" width="58" height="20" font="1"> MH=12% </text>
<text top="698" left="511" width="7" height="18" font="1">•</text>
<text top="697" left="518" width="68" height="20" font="1"> WCH=16% </text>
<text top="680" left="644" width="7" height="18" font="1">•</text>
<text top="679" left="651" width="58" height="20" font="1"> MH=14% </text>
<text top="698" left="644" width="7" height="18" font="1">•</text>
<text top="697" left="651" width="68" height="20" font="1"> WCH=15% </text>
<text top="678" left="740" width="24" height="20" font="1">N/A </text>
<text top="678" left="854" width="219" height="20" font="1">● No difference in proportions of pts Dx </text>
<text top="695" left="854" width="242" height="20" font="1">with MH or WCH by HBPM or awake ABPM </text>
<text top="712" left="854" width="205" height="20" font="1">● No difference between treated and </text>
<text top="730" left="854" width="230" height="20" font="1">untreated. However, only 44% overlap for </text>
<text top="747" left="854" width="213" height="20" font="1">MH, but 90%–95% if 5 mm Hg zone of </text>
<text top="764" left="854" width="105" height="20" font="1">uncertainty added. </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">23 </text>
<text top="107" left="98" width="81" height="20" font="1">Sega R, et al., </text>
<text top="124" left="98" width="60" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(37)</a>  </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11560854">11560854</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11560854"> </a></text>
<text top="109" left="214" width="7" height="18" font="1">•</text>
<text top="108" left="221" width="103" height="20" font="1"> Population-based </text>
<text top="125" left="214" width="88" height="20" font="1">PAMELA Study </text>
<text top="143" left="214" width="3" height="20" font="1"> </text>
<text top="162" left="214" width="7" height="18" font="1">•</text>
<text top="161" left="221" width="105" height="20" font="1"> Office ×3 &gt;140/90 </text>
<text top="180" left="214" width="7" height="18" font="1">•</text>
<text top="179" left="221" width="91" height="20" font="1"> HBPM &gt;132/83 </text>
<text top="198" left="214" width="7" height="18" font="1">•</text>
<text top="198" left="221" width="90" height="20" font="1"> ABPM &gt;125/79 </text>
<text top="217" left="214" width="7" height="18" font="1">•</text>
<text top="216" left="221" width="82" height="20" font="1"> LVMI by echo </text>
<text top="109" left="383" width="7" height="18" font="1">•</text>
<text top="108" left="389" width="58" height="20" font="1"> 2,051 pts </text>
<text top="109" left="511" width="7" height="18" font="1">•</text>
<text top="108" left="518" width="68" height="20" font="1"> WCH=12% </text>
<text top="127" left="511" width="7" height="18" font="1">•</text>
<text top="127" left="518" width="51" height="20" font="1"> MH=9% </text>
<text top="109" left="644" width="7" height="18" font="1">•</text>
<text top="108" left="651" width="68" height="20" font="1"> WCH=12% </text>
<text top="127" left="644" width="7" height="18" font="1">•</text>
<text top="127" left="651" width="51" height="20" font="1"> MH=9% </text>
<text top="107" left="740" width="24" height="20" font="1">N/A </text>
<text top="107" left="854" width="215" height="20" font="1">● 70% agreement between ABPM and </text>
<text top="124" left="854" width="182" height="20" font="1">HBPM for WCH and 57% for MH </text>
<text top="236" left="108" width="3" height="19" font="1"> </text>
<text top="270" left="81" width="505" height="24" font="3"><b>Data Supplement 5. White Coat Hypertension (Prevalence) (Section 4.4) </b></text>
<text top="310" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="327" left="129" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="344" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="310" left="289" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="327" left="316" width="66" height="20" font="4"><b>Study Size </b></text>
<text top="310" left="491" width="115" height="20" font="4"><b>Patient Population  </b></text>
<text top="310" left="643" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="327" left="620" width="224" height="20" font="4"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="310" left="907" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="327" left="934" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="362" left="98" width="95" height="20" font="1">Vinyoles E et al., </text>
<text top="379" left="98" width="56" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(38)</a> </text>
<text top="397" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18300853">18300853</a></text>
<text top="397" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18300853"> </a></text>
<text top="362" left="221" width="73" height="20" font="4"><b>Study type</b>:  </text>
<text top="379" left="221" width="238" height="20" font="1">● Cross-sectional, comparative multicenter </text>
<text top="397" left="221" width="95" height="20" font="1">descriptive study </text>
<text top="414" left="221" width="3" height="20" font="4"><b> </b></text>
<text top="431" left="221" width="86" height="20" font="4"><b>Size: </b>6,176 pts<b> </b></text>
<text top="362" left="489" width="24" height="20" font="1">N/A </text>
<text top="379" left="489" width="3" height="20" font="1"> </text>
<text top="363" left="617" width="144" height="20" font="4"><b>1</b>°<b> endpoint:</b> WCH=21%  </text>
<text top="362" left="860" width="222" height="20" font="1">● Multiple methodologies used to define </text>
<text top="379" left="860" width="29" height="20" font="1">MH.  </text>
<text top="397" left="860" width="199" height="20" font="1">● Prevalence 8.5%–16.6% (general </text>
<text top="414" left="860" width="222" height="20" font="1">population), 14.7%–30.4% (nonelevated </text>
<text top="431" left="860" width="95" height="20" font="1">clinic population) </text>
<text top="449" left="98" width="91" height="20" font="1">Pickering TG, et </text>
<text top="466" left="98" width="76" height="20" font="1">al., 1988 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(22)</a> </text>
<text top="483" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3336140?dopt=Citation">3336140</a></text>
<text top="483" left="145" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3336140?dopt=Citation">  </a></text>
<text top="449" left="221" width="73" height="20" font="4"><b>Study type</b>:  </text>
<text top="466" left="221" width="129" height="20" font="1">● Observational cohort </text>
<text top="483" left="221" width="127" height="20" font="1">● 24-h ABPM &lt;134/90 </text>
<text top="501" left="221" width="115" height="20" font="1">● Systematic review </text>
<text top="518" left="221" width="159" height="20" font="1">● Office vs. ABPM or HBPM </text>
<text top="535" left="221" width="3" height="20" font="1"> </text>
<text top="552" left="221" width="76" height="20" font="4"><b>Size: </b>292 pts<b> </b></text>
<text top="449" left="489" width="24" height="20" font="1">N/A </text>
<text top="466" left="489" width="7" height="20" font="4"><b> </b> </text>
<text top="450" left="617" width="140" height="20" font="4"><b>1</b>°<b> endpoint:</b> WCH=21% </text>
<text top="449" left="860" width="222" height="20" font="1">● Multiple methodologies used to define </text>
<text top="466" left="860" width="29" height="20" font="1">MH.  </text>
<text top="483" left="860" width="199" height="20" font="1">● Prevalence 8.5%–16.6% (general </text>
<text top="501" left="860" width="222" height="20" font="1">population), 14.7%–30.4% (nonelevated </text>
<text top="518" left="860" width="95" height="20" font="1">clinic population) </text>
<text top="570" left="98" width="91" height="20" font="1">Piper MA, et al., </text>
<text top="587" left="98" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(39)</a> </text>
<text top="605" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25531400?dopt=Citation">25531400</a></text>
<text top="605" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25531400?dopt=Citation"> </a></text>
<text top="570" left="221" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="587" left="221" width="115" height="20" font="1">● Systematic review </text>
<text top="605" left="221" width="159" height="20" font="1">● Office vs. ABPM or HBPM </text>
<text top="570" left="489" width="27" height="20" font="1">N/A<b> </b> </text>
<text top="571" left="617" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="588" left="617" width="134" height="20" font="1">●WCH=5–35% (ABPM) </text>
<text top="606" left="617" width="205" height="20" font="1">● WCH conversion to SH ~1%–5% y<b> </b></text>
<text top="570" left="860" width="212" height="20" font="1">● Prevalence of WCH sufficiently high </text>
<text top="587" left="860" width="211" height="20" font="1">to require ABPM confirmation of SH in </text>
<text top="605" left="860" width="159" height="20" font="1">those with elevated clinic BP </text>
<text top="624" left="98" width="103" height="20" font="1">Asayama K, et al., </text>
<text top="641" left="98" width="56" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(32)</a> </text>
<text top="658" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25135185?dopt=Citation">25135185</a></text>
<text top="658" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25135185?dopt=Citation"> </a></text>
<text top="624" left="221" width="77" height="20" font="4"><b>Study type:</b>   </text>
<text top="641" left="221" width="196" height="20" font="1">● Observational (IDACO) database </text>
<text top="658" left="221" width="112" height="20" font="1">● ABPM measured: </text>
<text top="675" left="221" width="85" height="20" font="1">● Office BP ×2 </text>
<text top="692" left="221" width="102" height="20" font="1">● &gt;140/90 (office) </text>
<text top="710" left="221" width="135" height="20" font="1">● &gt;130/80 (24-h ABPM) </text>
<text top="727" left="220" width="154" height="20" font="1">● &gt;135/85 (daytime ABPM) </text>
<text top="744" left="220" width="161" height="20" font="1">● &gt;120/70 (nighttime ABPM) </text>
<text top="761" left="220" width="3" height="20" font="1"> </text>
<text top="778" left="221" width="70" height="20" font="4"><b>Size: </b>8,237  </text>
<text top="624" left="489" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="641" left="489" width="95" height="20" font="1">Untreated, &gt;18 y </text>
<text top="658" left="489" width="3" height="20" font="1"> </text>
<text top="675" left="489" width="3" height="20" font="1"> </text>
<text top="692" left="489" width="3" height="20" font="1"> </text>
<text top="710" left="545" width="3" height="20" font="1"> </text>
<text top="625" left="617" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="642" left="617" width="122" height="20" font="1">● WCH=6.3%–12.5% </text>
<text top="659" left="617" width="112" height="20" font="1">● MH=9.7%–19.6% </text>
<text top="624" left="860" width="222" height="20" font="1">● Variable prevalence of both WCH and </text>
<text top="641" left="860" width="181" height="20" font="1">MH based on method of defining </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">24 </text>
<text top="107" left="98" width="92" height="20" font="1">Conen D, et al.,  </text>
<text top="124" left="98" width="56" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(33)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25185130?dopt=Citation">25185130</a></text>
<text top="141" left="152" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25185130?dopt=Citation">  </a></text>
<text top="107" left="221" width="81" height="20" font="4"><b>Study type:</b>    </text>
<text top="124" left="221" width="92" height="20" font="1">● Observational </text>
<text top="141" left="221" width="116" height="20" font="1">● 13 IDACO cohorts </text>
<text top="159" left="221" width="66" height="20" font="1">● Office ×2 </text>
<text top="176" left="221" width="139" height="20" font="1">● Awake ABPM &gt;135/85 </text>
<text top="193" left="221" width="117" height="20" font="1">● 24-h ABP &gt;130/80 </text>
<text top="210" left="221" width="149" height="20" font="1">● Analyzed by decade in y </text>
<text top="228" left="221" width="3" height="20" font="1"> </text>
<text top="245" left="221" width="86" height="20" font="4"><b>Size: </b>7,506 pts </text>
<text top="107" left="489" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="124" left="489" width="93" height="20" font="1">&gt;18 y, untreated </text>
<text top="108" left="617" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="125" left="617" width="228" height="20" font="1">● WCH=2.2% age 18–30 y, increasing to </text>
<text top="143" left="617" width="159" height="20" font="1">19.5% both sexes age &gt;70 y </text>
<text top="160" left="617" width="161" height="20" font="1">● MH=inverted U distribution </text>
<text top="177" left="617" width="214" height="20" font="1">(13% and 11% in youngest and oldest, </text>
<text top="194" left="617" width="178" height="20" font="1">18% and 20% in those 30–50 y) </text>
<text top="212" left="617" width="163" height="20" font="1">Increase prevalence in males </text>
<text top="107" left="860" width="198" height="20" font="1">● Increase in WCH prevalence with </text>
<text top="124" left="860" width="159" height="20" font="1">increasing age in both sexes </text>
<text top="141" left="860" width="201" height="20" font="1">● Peak MH prevalence age 30–50 y </text>
<text top="159" left="860" width="194" height="20" font="1">with drop at age extremes. Greater </text>
<text top="176" left="860" width="152" height="20" font="1">prevalence of MH in males. </text>
<text top="193" left="860" width="197" height="20" font="1">● Similar prevalence when 24-h vs. </text>
<text top="210" left="860" width="107" height="20" font="1">awake ABPM used </text>
<text top="263" left="98" width="90" height="20" font="1">Alwan H, et al.,  </text>
<text top="280" left="98" width="56" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(40)</a> </text>
<text top="297" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24663506?dopt=Citation">24663506</a></text>
<text top="297" left="152" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24663506?dopt=Citation">  </a></text>
<text top="263" left="221" width="81" height="20" font="4"><b>Study type:</b>    </text>
<text top="280" left="221" width="92" height="20" font="1">● Observational </text>
<text top="297" left="221" width="72" height="20" font="1">● SKIPOGH </text>
<text top="314" left="221" width="85" height="20" font="1">● Office BP ×4 </text>
<text top="332" left="221" width="99" height="20" font="1">● Daytime ABPM </text>
<text top="349" left="221" width="96" height="20" font="1">● Office &gt;140/90 </text>
<text top="366" left="220" width="109" height="20" font="1">● Daytime &gt;135/85 </text>
<text top="383" left="220" width="3" height="20" font="1"> </text>
<text top="400" left="221" width="60" height="20" font="4"><b>Size:</b> 652  </text>
<text top="263" left="489" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="280" left="489" width="93" height="20" font="1">&gt;18 y, untreated </text>
<text top="264" left="617" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="281" left="617" width="80" height="20" font="1">● WCH=2.6% </text>
<text top="298" left="617" width="80" height="20" font="1">● MH=15.8%  </text>
<text top="263" left="860" width="214" height="20" font="1">● Pts with pre-HTN had 7 times higher </text>
<text top="280" left="860" width="61" height="20" font="1">rate of MH </text>
<text top="418" left="98" width="107" height="20" font="1">Stergiou GS, et al., </text>
<text top="436" left="98" width="56" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(41)</a> </text>
<text top="453" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24420553?dopt=Citation">24420553</a></text>
<text top="453" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24420553?dopt=Citation"> </a></text>
<text top="418" left="221" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="436" left="221" width="92" height="20" font="1">● Observational </text>
<text top="453" left="221" width="147" height="20" font="1">● 5 IDACO cohort Studies </text>
<text top="470" left="220" width="114" height="20" font="1">● Office ×2 &gt;140/90 </text>
<text top="487" left="220" width="97" height="20" font="1">● Home &gt;135/85 </text>
<text top="504" left="220" width="140" height="20" font="1">● Median 8.3-y follow-up </text>
<text top="522" left="221" width="3" height="20" font="1"> </text>
<text top="539" left="221" width="90" height="20" font="4"><b>Size: </b>5,007 pts  </text>
<text top="418" left="489" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="436" left="489" width="93" height="20" font="1">&gt;18 y, untreated </text>
<text top="420" left="617" width="206" height="20" font="4"><b>1</b>°<b> endpoint:</b> Long-term follow-up for </text>
<text top="437" left="617" width="69" height="20" font="1">CVD events </text>
<text top="418" left="860" width="91" height="20" font="1">● WCH=13.8%  </text>
<text top="436" left="860" width="70" height="20" font="1">● MH=8.1% </text>
<text top="557" left="98" width="102" height="20" font="1">Pierdomenico SD, </text>
<text top="574" left="98" width="68" height="20" font="1">et al., 2011  </text>
<text top="591" left="98" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(42)</a> </text>
<text top="608" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20847724?dopt=Citation">20847724</a></text>
<text top="608" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20847724?dopt=Citation"> </a></text>
<text top="557" left="221" width="240" height="20" font="4"><b>Study type:</b> Meta-analysis of observational </text>
<text top="574" left="221" width="167" height="20" font="1">cohort studies (8 WCH, 5 MH) </text>
<text top="591" left="221" width="114" height="20" font="1">24-h ABPM &gt;130/80 </text>
<text top="608" left="221" width="97" height="20" font="1">Daytime &gt;135/85 </text>
<text top="626" left="221" width="3" height="20" font="1"> </text>
<text top="643" left="221" width="89" height="20" font="4"><b>Size</b>: 7,961 pts  </text>
<text top="557" left="489" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="574" left="489" width="93" height="20" font="1">&gt;18 y, untreated </text>
<text top="557" left="617" width="206" height="20" font="4"><b>1° endpoint: </b>Long-term follow-up for </text>
<text top="574" left="617" width="69" height="20" font="1">CVD events </text>
<text top="557" left="860" width="91" height="20" font="1">● WCH=16.1%  </text>
<text top="574" left="860" width="70" height="20" font="1">● MH=5.8% </text>
<text top="661" left="98" width="105" height="20" font="1">Hansen TW, et al., </text>
<text top="678" left="98" width="56" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(43)</a> </text>
<text top="695" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17620947?dopt=Citation">17620947</a></text>
<text top="695" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17620947?dopt=Citation"> </a></text>
<text top="661" left="221" width="74" height="20" font="4"><b>Study type: </b> </text>
<text top="678" left="221" width="142" height="20" font="1">● 4 observational studies </text>
<text top="695" left="221" width="96" height="20" font="1">● Office &lt;140/90 </text>
<text top="712" left="220" width="127" height="20" font="1">● 24-h ABPM &gt;135/85 </text>
<text top="730" left="220" width="3" height="20" font="1"> </text>
<text top="747" left="221" width="90" height="20" font="4"><b>Size: </b>7,030 pts  </text>
<text top="663" left="489" width="7" height="18" font="1">•</text>
<text top="662" left="496" width="87" height="20" font="1"> 78% untreated </text>
<text top="661" left="617" width="107" height="20" font="4"><b>Study endpoints: </b> </text>
<text top="678" left="617" width="73" height="20" font="1">● F/NF CVD </text>
<text top="695" left="617" width="146" height="20" font="1">● Median follow-up =9.5 y </text>
<text top="712" left="617" width="3" height="20" font="1"> </text>
<text top="730" left="617" width="68" height="20" font="4"><b>1° Results: </b></text>
<text top="747" left="617" width="103" height="20" font="1">● Adj HR vs. NTN </text>
<text top="764" left="617" width="207" height="20" font="1">● WCH=1.22 (CI: 0.96–1.53), p=0.09 </text>
<text top="781" left="617" width="203" height="20" font="1">● MH=1.62 (CI: 1.35–1.96), p&lt;0.001 </text>
<text top="661" left="860" width="24" height="20" font="1">N/A </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">25 </text>
<text top="107" left="617" width="201" height="20" font="1">● SH=1.80 (CI: 1.59–2.03), p&lt;0.001 </text>
<text top="127" left="108" width="3" height="19" font="1"> </text>
<text top="161" left="81" width="676" height="24" font="3"><b>Data Supplement 6. White Coat Hypertension (Correlation with Clinical Outcomes) (Section 4.4)  </b></text>
<text top="200" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="218" left="128" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="235" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="200" left="240" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="218" left="256" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="200" left="417" width="44" height="20" font="4"><b>Patient </b></text>
<text top="218" left="405" width="67" height="20" font="4"><b>Population </b></text>
<text top="200" left="501" width="126" height="20" font="4"><b>Study Endpoints and </b></text>
<text top="218" left="504" width="121" height="20" font="4"><b>Length of Follow-up </b></text>
<text top="200" left="707" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="218" left="690" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="235" left="672" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="200" left="911" width="140" height="20" font="4"><b>Summary/Conclusions/ </b></text>
<text top="218" left="951" width="64" height="20" font="4"><b>Comment  </b></text>
<text top="253" left="98" width="36" height="20" font="4"><b>NICE</b>  </text>
<text top="270" left="98" width="56" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(44)</a> </text>
<text top="287" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22855971">22855971</a></text>
<text top="287" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22855971"><b> </b></a></text>
<text top="253" left="219" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="272" left="219" width="7" height="18" font="1">•</text>
<text top="271" left="226" width="111" height="20" font="1"> Systematic Review </text>
<text top="290" left="219" width="7" height="18" font="1">•</text>
<text top="290" left="226" width="97" height="20" font="1"> 3 Meta-analyses </text>
<text top="309" left="219" width="7" height="18" font="1">•</text>
<text top="308" left="226" width="139" height="20" font="1"> 11 observational studies </text>
<text top="325" left="219" width="146" height="20" font="1">”best method” comparison </text>
<text top="343" left="219" width="157" height="20" font="1">of office vs. HBPM or ABPM </text>
<text top="360" left="219" width="132" height="20" font="1">that best predicted (i.e., </text>
<text top="377" left="219" width="121" height="20" font="1">statistically significant </text>
<text top="394" left="219" width="140" height="20" font="1">predictors and higher HR </text>
<text top="411" left="219" width="140" height="20" font="1">values) clinical outcomes </text>
<text top="429" left="219" width="114" height="20" font="1">(after adjustment for </text>
<text top="446" left="219" width="139" height="20" font="1">covariates in multivariate </text>
<text top="463" left="219" width="56" height="20" font="1">analyses) </text>
<text top="480" left="219" width="3" height="20" font="1"> </text>
<text top="253" left="392" width="63" height="20" font="1">• Home vs. </text>
<text top="270" left="392" width="89" height="20" font="1">office (n=7,685) </text>
<text top="287" left="392" width="65" height="20" font="1">• ABPM vs. </text>
<text top="305" left="392" width="36" height="20" font="1">office  </text>
<text top="322" left="392" width="63" height="20" font="1">(n=33,158) </text>
<text top="339" left="392" width="63" height="20" font="1">• Home vs. </text>
<text top="356" left="392" width="93" height="20" font="1">ABPM vs. Office </text>
<text top="374" left="392" width="56" height="20" font="1">(n=2,442) </text>
<text top="255" left="499" width="7" height="18" font="1">•</text>
<text top="254" left="505" width="124" height="20" font="1"> Outcomes of interest: </text>
<text top="271" left="499" width="114" height="20" font="1">mortality, stroke, MI, </text>
<text top="289" left="499" width="98" height="20" font="1">HF, DM, vascular </text>
<text top="306" left="499" width="68" height="20" font="1">procedures, </text>
<text top="323" left="499" width="99" height="20" font="1">hospitalization for </text>
<text top="340" left="499" width="99" height="20" font="1">angina, and other </text>
<text top="357" left="499" width="48" height="20" font="1">MACCE </text>
<text top="253" left="644" width="183" height="20" font="1">For predicting clinical outcomes:  </text>
<text top="270" left="644" width="158" height="20" font="1">ABPM vs. office (9 studies):  </text>
<text top="289" left="644" width="7" height="18" font="1">•</text>
<text top="289" left="651" width="200" height="20" font="1"> ABPM superior to office (8 studies)  </text>
<text top="308" left="644" width="7" height="18" font="1">•</text>
<text top="307" left="651" width="192" height="20" font="1"> No difference between ABPM and </text>
<text top="324" left="644" width="87" height="20" font="1">office (1 study)  </text>
<text top="341" left="644" width="3" height="20" font="1"> </text>
<text top="359" left="644" width="159" height="20" font="1">HBPM vs. office (3 studies):  </text>
<text top="378" left="644" width="7" height="18" font="1">•</text>
<text top="377" left="651" width="201" height="20" font="1"> HBPM superior to office (2 studies)  </text>
<text top="396" left="644" width="7" height="18" font="1">•</text>
<text top="395" left="651" width="193" height="20" font="1"> No difference between HBPM and </text>
<text top="413" left="644" width="87" height="20" font="1">office (1 study)  </text>
<text top="430" left="644" width="3" height="20" font="1"> </text>
<text top="447" left="644" width="216" height="20" font="1">HBPM vs. ABPM vs. office (2 studies):  </text>
<text top="466" left="644" width="7" height="18" font="1">•</text>
<text top="465" left="651" width="185" height="20" font="1"> HBPM similar to ABPM and both </text>
<text top="483" left="644" width="149" height="20" font="1">superior to office (1 study)  </text>
<text top="502" left="644" width="7" height="18" font="1">•</text>
<text top="501" left="651" width="211" height="20" font="1"> No difference between HBPM, ABPM </text>
<text top="518" left="644" width="111" height="20" font="1">and office (1 study)  </text>
<text top="255" left="887" width="7" height="18" font="1">•</text>
<text top="254" left="894" width="159" height="20" font="1"> Overall recommendation for </text>
<text top="271" left="887" width="180" height="20" font="1">ABPM to confirm HTN diagnosis </text>
<text top="289" left="887" width="173" height="20" font="1">(HBPM recommended if ABPM </text>
<text top="306" left="887" width="74" height="20" font="1">not practical) </text>
<text top="536" left="98" width="102" height="20" font="1">Pierdomenico SD, </text>
<text top="553" left="98" width="90" height="20" font="1">et al., 2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(42)</a> </text>
<text top="571" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20847724">20847724</a></text>
<text top="571" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20847724"> </a></text>
<text top="536" left="219" width="150" height="20" font="4"><b>Study type:</b> Meta-analysis </text>
<text top="553" left="219" width="61" height="20" font="1">(8 studies) </text>
<text top="572" left="219" width="7" height="18" font="1">•</text>
<text top="572" left="226" width="121" height="20" font="1"> NTN vs. WCH or MH </text>
<text top="589" left="219" width="139" height="20" font="1">based mostly on daytime </text>
<text top="606" left="219" width="87" height="20" font="1">ABPM &lt;135/85 </text>
<text top="623" left="219" width="3" height="20" font="1"> </text>
<text top="641" left="219" width="69" height="20" font="4"><b>Size</b>: 7,961  </text>
<text top="536" left="392" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="553" left="392" width="48" height="20" font="4"><b>criteria:</b> </text>
<text top="571" left="392" width="57" height="20" font="1">Untreated<b> </b></text>
<text top="588" left="392" width="3" height="20" font="4"><b> </b></text>
<text top="605" left="392" width="3" height="20" font="1"> </text>
<text top="538" left="499" width="7" height="18" font="1">•</text>
<text top="537" left="505" width="121" height="20" font="1"> Follow-up 3.2–12.8 y </text>
<text top="556" left="499" width="7" height="18" font="1">•</text>
<text top="556" left="505" width="95" height="20" font="1"> Composite CVD </text>
<text top="538" left="644" width="7" height="18" font="1">•</text>
<text top="537" left="651" width="191" height="20" font="1"> WCH vs. NTN: OR: 0.96; 95% CI: </text>
<text top="554" left="644" width="58" height="20" font="1">0.65–1.42 </text>
<text top="573" left="644" width="7" height="18" font="1">•</text>
<text top="573" left="651" width="211" height="20" font="1"> MH vs. NTN: OR: 2.09; 95% CI: 1.55–</text>
<text top="590" left="644" width="27" height="20" font="1">2.81 </text>
<text top="609" left="644" width="7" height="18" font="1">•</text>
<text top="608" left="651" width="209" height="20" font="1"> SH vs. NTN: OR: 2.59; 95% CI: 2.00–</text>
<text top="626" left="644" width="27" height="20" font="1">3.35 </text>
<text top="536" left="887" width="24" height="20" font="1">N/A </text>
<text top="658" left="98" width="103" height="20" font="1">Asayama K, et al., </text>
<text top="676" left="98" width="56" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(32)</a> </text>
<text top="693" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25135185">25135185</a></text>
<text top="693" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25135185"> </a></text>
<text top="658" left="219" width="150" height="20" font="4"><b>Study type:</b> Observational </text>
<text top="676" left="219" width="105" height="20" font="1">(IDACO) database </text>
<text top="695" left="219" width="7" height="18" font="1">•</text>
<text top="694" left="226" width="120" height="20" font="1"> CV outcomes risk by </text>
<text top="711" left="219" width="91" height="20" font="1">WCH, MH, NTN </text>
<text top="728" left="219" width="3" height="20" font="1"> </text>
<text top="747" left="219" width="7" height="18" font="1">•</text>
<text top="747" left="226" width="103" height="20" font="1"> ABPM measured: </text>
<text top="764" left="219" width="121" height="20" font="1">Office BP ×2 &gt;140/90 </text>
<text top="781" left="219" width="41" height="20" font="1">(office) </text>
<text top="658" left="392" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="676" left="392" width="86" height="20" font="4"><b>criteria: </b>&gt;18 y,<b> </b></text>
<text top="693" left="392" width="55" height="20" font="1">untreated </text>
<text top="660" left="499" width="7" height="18" font="1">•</text>
<text top="660" left="505" width="104" height="20" font="1"> F/NF CVD/stroke, </text>
<text top="677" left="499" width="87" height="20" font="1">729 CV events  </text>
<text top="696" left="499" width="7" height="18" font="1">•</text>
<text top="695" left="505" width="97" height="20" font="1"> Follow-up 10.6 y </text>
<text top="660" left="644" width="7" height="18" font="1">•</text>
<text top="660" left="651" width="213" height="20" font="1"> WCH adjusted HR: 1.2; 95% CI: 0.93–</text>
<text top="677" left="644" width="72" height="20" font="1">1.54; p=0.16 </text>
<text top="696" left="644" width="7" height="18" font="1">•</text>
<text top="695" left="651" width="209" height="20" font="1"> MH adjusted HR: 1.81; 95% CI: 1.41–</text>
<text top="712" left="644" width="86" height="20" font="1">2.32; p&lt;0.0001 </text>
<text top="731" left="644" width="7" height="18" font="1">•</text>
<text top="731" left="651" width="207" height="20" font="1"> SH adjusted HR: 2.31; 95% CI: 1.91–</text>
<text top="748" left="644" width="86" height="20" font="1">2.80; p&lt;0.0001 </text>
<text top="658" left="887" width="24" height="20" font="1">N/A </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">26 </text>
<text top="107" left="219" width="123" height="20" font="1">(24-h ABPM) &gt;130/80 </text>
<text top="124" left="219" width="145" height="20" font="1">(daytime ABPM) &gt;135/85  </text>
<text top="141" left="219" width="148" height="20" font="1">(nighttime ABPM) &gt;120/70 </text>
<text top="159" left="219" width="3" height="20" font="1"> </text>
<text top="176" left="219" width="69" height="20" font="4"><b>Size</b>: 8,237  </text>
<text top="194" left="98" width="94" height="20" font="1">Verdecchia P, et </text>
<text top="211" left="98" width="76" height="20" font="1">al., 2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(45)</a> </text>
<text top="228" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15596572">15596572</a></text>
<text top="228" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15596572"> </a></text>
<text top="194" left="219" width="133" height="20" font="4"><b>Study type:</b> Population-</text>
<text top="211" left="219" width="122" height="20" font="1">based (4 international </text>
<text top="228" left="219" width="48" height="20" font="1">cohorts) </text>
<text top="247" left="219" width="7" height="18" font="1">•</text>
<text top="247" left="226" width="105" height="20" font="1"> Office ×3 &gt;140/90 </text>
<text top="266" left="219" width="7" height="18" font="1">•</text>
<text top="265" left="226" width="130" height="20" font="1"> Awake ABPM &gt;130/80 </text>
<text top="282" left="219" width="3" height="20" font="1"> </text>
<text top="299" left="219" width="66" height="20" font="4"><b>Size</b>: 5,955 </text>
<text top="196" left="392" width="7" height="18" font="1">•</text>
<text top="195" left="399" width="60" height="20" font="1"> 26% NTN </text>
<text top="196" left="499" width="7" height="18" font="1">•</text>
<text top="195" left="505" width="42" height="20" font="1"> Stroke </text>
<text top="214" left="499" width="7" height="18" font="1">•</text>
<text top="213" left="505" width="90" height="20" font="1"> Follow-up 5.4 y </text>
<text top="196" left="644" width="7" height="18" font="1">•</text>
<text top="195" left="651" width="219" height="20" font="1"> WCH adjusted HR: 1.15; 95% CI: 0.61–</text>
<text top="212" left="644" width="72" height="20" font="1">2.16; p=0.66 </text>
<text top="231" left="644" width="7" height="18" font="1">•</text>
<text top="231" left="651" width="207" height="20" font="1"> SH adjusted HR: 2.01; 95% CI: 1.31–</text>
<text top="248" left="644" width="79" height="20" font="1">3.08; p&lt;0.001 </text>
<text top="196" left="887" width="7" height="18" font="1">•</text>
<text top="195" left="894" width="165" height="20" font="1"> Stroke not increased in WCH </text>
<text top="212" left="887" width="174" height="20" font="1">but tended to approach systolic </text>
<text top="229" left="887" width="148" height="20" font="1">HTN risk 6 y after baseline </text>
<text top="247" left="887" width="42" height="20" font="1">ABPM. </text>
<text top="317" left="98" width="105" height="20" font="1">Hansen TW, et al., </text>
<text top="335" left="98" width="60" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(43)</a>  </text>
<text top="352" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17620947?dopt=Citation">17620947 </a></text>
<text top="317" left="219" width="150" height="20" font="4"><b>Study type:</b> Observational </text>
<text top="335" left="219" width="53" height="20" font="1">4 studies </text>
<text top="354" left="219" width="7" height="18" font="1">•</text>
<text top="353" left="226" width="87" height="20" font="1"> Office &lt;140/90 </text>
<text top="372" left="219" width="7" height="18" font="1">•</text>
<text top="371" left="226" width="118" height="20" font="1"> 24-h ABPM &gt;135/85 </text>
<text top="389" left="219" width="3" height="20" font="1"> </text>
<text top="406" left="219" width="66" height="20" font="4"><b>Size</b>: 7,030 </text>
<text top="319" left="392" width="7" height="18" font="1">•</text>
<text top="319" left="399" width="170" height="20" font="1"> 78% untreated  • F/NF CVD </text>
<text top="338" left="499" width="7" height="18" font="1">•</text>
<text top="337" left="505" width="124" height="20" font="1"> Median follow-up=9.5 </text>
<text top="354" left="499" width="10" height="20" font="1">y </text>
<text top="319" left="644" width="7" height="18" font="1">•</text>
<text top="319" left="651" width="220" height="20" font="1"> WCH adjusted HR: 1.22 (95% CI: 0.96, </text>
<text top="336" left="644" width="76" height="20" font="1">1.53), p=0.09 </text>
<text top="355" left="644" width="7" height="18" font="1">•</text>
<text top="354" left="651" width="209" height="20" font="1"> MH adjusted HR: 1.62; 95% CI: 1.35–</text>
<text top="371" left="644" width="79" height="20" font="1">1.96; p&lt;0.001 </text>
<text top="390" left="644" width="7" height="18" font="1">•</text>
<text top="390" left="651" width="207" height="20" font="1"> SH adjusted HR: 1.80; 95% CI: 1.59–</text>
<text top="407" left="644" width="79" height="20" font="1">2.03; p&lt;0.001 </text>
<text top="317" left="887" width="24" height="20" font="1">N/A </text>
<text top="425" left="98" width="100" height="20" font="1">Fagard RH, et al., </text>
<text top="442" left="98" width="60" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(28)</a>  </text>
<text top="459" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17921809?dopt=Citation">17921809</a></text>
<text top="459" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17921809?dopt=Citation"> </a></text>
<text top="425" left="219" width="150" height="20" font="4"><b>Study type:</b> Meta-analysis </text>
<text top="442" left="219" width="53" height="20" font="1">7 studies </text>
<text top="461" left="219" width="7" height="18" font="1">•</text>
<text top="460" left="226" width="87" height="20" font="1"> Office &lt;140/90 </text>
<text top="480" left="219" width="7" height="18" font="1">•</text>
<text top="479" left="226" width="123" height="20" font="1"> 24-h ABPM or HBPM </text>
<text top="496" left="219" width="3" height="20" font="1"> </text>
<text top="513" left="219" width="73" height="20" font="4"><b>Size</b>: 11,502 </text>
<text top="427" left="392" width="7" height="18" font="1">•</text>
<text top="426" left="399" width="73" height="20" font="1"> Treated and </text>
<text top="443" left="392" width="55" height="20" font="1">untreated </text>
<text top="427" left="499" width="7" height="18" font="1">•</text>
<text top="426" left="505" width="89" height="20" font="1"> F or F/NF CVD </text>
<text top="445" left="499" width="7" height="18" font="1">•</text>
<text top="444" left="505" width="121" height="20" font="1"> Follow-up 3.2–12.3 y </text>
<text top="462" left="499" width="66" height="20" font="1">(mean=8 y) </text>
<text top="427" left="644" width="7" height="18" font="1">•</text>
<text top="426" left="651" width="220" height="20" font="1"> WCH adjusted HR: 1.12 (95% CI: 0.84–</text>
<text top="443" left="644" width="76" height="20" font="1">1.50), p=0.59 </text>
<text top="462" left="644" width="7" height="18" font="1">•</text>
<text top="462" left="651" width="202" height="20" font="1"> MH adjusted HR: 2.0; 95% CI: 1.58–</text>
<text top="479" left="644" width="79" height="20" font="1">2.52; p&lt;0.001 </text>
<text top="498" left="644" width="7" height="18" font="1">•</text>
<text top="497" left="651" width="211" height="20" font="1"> Systolic HTN adjusted HR: 2.28; 95% </text>
<text top="514" left="644" width="129" height="20" font="1">CI: 1.87–2.78; p&lt;0.001 </text>
<text top="425" left="887" width="24" height="20" font="1">N/A </text>
<text top="532" left="98" width="93" height="20" font="1">Mancia G, et al., </text>
<text top="550" left="98" width="60" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(46)</a>  </text>
<text top="567" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23716584?dopt=Citation">23716584</a></text>
<text top="567" left="152" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23716584?dopt=Citation">  </a></text>
<text top="532" left="219" width="150" height="20" font="4"><b>Study type:</b> Observational </text>
<text top="550" left="219" width="88" height="20" font="1">PAMELA Study </text>
<text top="569" left="219" width="7" height="18" font="1">•</text>
<text top="568" left="226" width="101" height="20" font="1"> Office ×3&lt;140/90 </text>
<text top="587" left="219" width="7" height="18" font="1">•</text>
<text top="586" left="226" width="150" height="20" font="1"> HBPM&gt;135/85 and-24-h • </text>
<text top="604" left="219" width="83" height="20" font="1">ABPM&gt;130/80 </text>
<text top="621" left="219" width="3" height="20" font="1"> </text>
<text top="638" left="219" width="66" height="20" font="4"><b>Size</b>: 2,051 </text>
<text top="534" left="392" width="7" height="18" font="1">•</text>
<text top="534" left="399" width="73" height="20" font="1"> 22% treated </text>
<text top="534" left="499" width="7" height="18" font="1">•</text>
<text top="534" left="505" width="68" height="20" font="1"> CV and all- </text>
<text top="551" left="499" width="86" height="20" font="1">cause mortality </text>
<text top="570" left="499" width="7" height="18" font="1">•</text>
<text top="569" left="505" width="87" height="20" font="1"> Follow-up 16 y </text>
<text top="534" left="644" width="7" height="18" font="1">•</text>
<text top="534" left="651" width="221" height="20" font="1"> CV mortality in WCH adjusted HR: 2.04 </text>
<text top="551" left="644" width="158" height="20" font="1">(95% CI: 0.87–4.78), p=0.10 </text>
<text top="570" left="644" width="7" height="18" font="1">•</text>
<text top="569" left="651" width="203" height="20" font="1"> All-cause mortality in WCH adjusted </text>
<text top="586" left="644" width="206" height="20" font="1">HR: 1.50; 95% CI: 1.03–2.18; p=0.03 </text>
<text top="534" left="887" width="7" height="18" font="1">•</text>
<text top="534" left="894" width="177" height="20" font="1"> Trend but insignificant increase </text>
<text top="551" left="887" width="165" height="20" font="1">in CV mortality and significant </text>
<text top="568" left="887" width="185" height="20" font="1">increase in total mortality in WCH </text>
<text top="587" left="887" width="7" height="18" font="1">•</text>
<text top="586" left="894" width="180" height="20" font="1"> Risk of developing systolic HTN </text>
<text top="604" left="887" width="147" height="20" font="1">greater in those with WCH </text>
<text top="656" left="98" width="92" height="20" font="1">Tomiyama M, et </text>
<text top="673" left="98" width="76" height="20" font="1">al., 2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(47)</a> </text>
<text top="690" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16942927">16942927</a></text>
<text top="690" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16942927"> </a></text>
<text top="656" left="219" width="159" height="20" font="4"><b>Study type:</b> Cross-sectional </text>
<text top="673" left="219" width="126" height="20" font="1">study assessing target </text>
<text top="690" left="219" width="159" height="20" font="1">organ damage by BP control </text>
<text top="708" left="219" width="121" height="20" font="1">status. Control: Office </text>
<text top="725" left="219" width="150" height="20" font="1">&lt;140/90, daytime &lt;135/85. </text>
<text top="742" left="219" width="3" height="20" font="1"> </text>
<text top="759" left="219" width="59" height="20" font="4"><b>Size</b>: 332  </text>
<text top="658" left="392" width="7" height="18" font="1">•</text>
<text top="657" left="399" width="69" height="20" font="1"> Treated pts </text>
<text top="658" left="499" width="7" height="18" font="1">•</text>
<text top="657" left="505" width="107" height="20" font="1"> LVMI, carotid IMT, </text>
<text top="674" left="499" width="29" height="20" font="1">UAE </text>
<text top="693" left="499" width="7" height="18" font="1">•</text>
<text top="693" left="505" width="92" height="20" font="1"> Cross-sectional </text>
<text top="658" left="644" width="7" height="18" font="1">•</text>
<text top="657" left="651" width="213" height="20" font="1"> LVMI, carotid IMT and UAE increased </text>
<text top="674" left="644" width="230" height="20" font="1">in masked uncontrolled HTN compared to </text>
<text top="692" left="644" width="230" height="20" font="1">controlled HTN. LVMI and UAE increased </text>
<text top="709" left="644" width="33" height="20" font="1">in SH </text>
<text top="658" left="887" width="7" height="18" font="1">•</text>
<text top="657" left="894" width="165" height="20" font="1"> SH and masked uncontrolled </text>
<text top="674" left="887" width="164" height="20" font="1">HTN but not WCE associated </text>
<text top="692" left="887" width="152" height="20" font="1">with increased target organ </text>
<text top="709" left="887" width="48" height="20" font="1">damage </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">27 </text>
<text top="107" left="98" width="94" height="20" font="1">Ohkubo T, et al., </text>
<text top="124" left="98" width="60" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(48)</a>  </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16053966?dopt=Citation">16053966</a></text>
<text top="141" left="152" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16053966?dopt=Citation">  </a></text>
<text top="107" left="219" width="150" height="20" font="4"><b>Study type:</b> Observational </text>
<text top="124" left="219" width="38" height="20" font="1">cohort </text>
<text top="143" left="219" width="7" height="18" font="1">•</text>
<text top="143" left="226" width="105" height="20" font="1"> Office ×2 &gt;140/90 </text>
<text top="162" left="219" width="7" height="18" font="1">•</text>
<text top="161" left="226" width="130" height="20" font="1"> Awake ABPM &gt;135/85 </text>
<text top="178" left="219" width="3" height="20" font="1"> </text>
<text top="195" left="219" width="66" height="20" font="4"><b>Size</b>: 1,332 </text>
<text top="109" left="392" width="7" height="18" font="1">•</text>
<text top="108" left="399" width="61" height="20" font="1"> Untreated </text>
<text top="125" left="392" width="36" height="20" font="1">(70%) </text>
<text top="144" left="392" width="7" height="18" font="1">•</text>
<text top="144" left="399" width="85" height="20" font="1"> Treated (30%) </text>
<text top="109" left="499" width="7" height="18" font="1">•</text>
<text top="108" left="505" width="120" height="20" font="1"> CVD mortality/stroke </text>
<text top="127" left="499" width="7" height="18" font="1">•</text>
<text top="127" left="505" width="87" height="20" font="1"> Follow-up 10 y </text>
<text top="109" left="644" width="7" height="18" font="1">•</text>
<text top="108" left="651" width="204" height="20" font="1"> WCH RH: 1.28; 95% CI: 0.76–2.14); </text>
<text top="125" left="644" width="35" height="20" font="1">p=0.4 </text>
<text top="144" left="644" width="7" height="18" font="1">•</text>
<text top="144" left="651" width="187" height="20" font="1"> MH RH: 2.13; 95% CI:1.38–3.29; </text>
<text top="161" left="644" width="48" height="20" font="1">p&lt;0.001 </text>
<text top="180" left="644" width="7" height="18" font="1">•</text>
<text top="179" left="651" width="185" height="20" font="1"> SH RH: 2.26; 95% CI:1.77–4.54; </text>
<text top="197" left="644" width="55" height="20" font="1">p&lt;0.0001 </text>
<text top="109" left="887" width="7" height="18" font="1">•</text>
<text top="108" left="894" width="150" height="20" font="1"> Similar results treated and </text>
<text top="125" left="887" width="172" height="20" font="1">untreated, males, and females  </text>
<text top="215" left="98" width="107" height="20" font="1">Tientcheu D, et al., </text>
<text top="232" left="98" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(49)</a> </text>
<text top="249" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26564592">26564592</a></text>
<text top="249" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26564592"> </a></text>
<text top="215" left="219" width="150" height="20" font="4"><b>Study type:</b> Observational </text>
<text top="232" left="219" width="38" height="20" font="1">cohort </text>
<text top="251" left="219" width="7" height="18" font="1">•</text>
<text top="250" left="226" width="125" height="20" font="1"> Home readings ×5 ×2 </text>
<text top="267" left="219" width="159" height="20" font="1">visits taken by research staff </text>
<text top="286" left="219" width="7" height="18" font="1">•</text>
<text top="286" left="226" width="107" height="20" font="1"> Office readings ×5 </text>
<text top="303" left="219" width="3" height="20" font="1"> </text>
<text top="320" left="219" width="66" height="20" font="4"><b>Size</b>: 3,027 </text>
<text top="216" left="392" width="7" height="18" font="1">•</text>
<text top="216" left="399" width="75" height="20" font="1"> Dallas Heart </text>
<text top="233" left="392" width="35" height="20" font="1">Study </text>
<text top="252" left="392" width="7" height="18" font="1">•</text>
<text top="251" left="399" width="73" height="20" font="1"> 54% African </text>
<text top="270" left="392" width="62" height="20" font="1">American• </text>
<text top="287" left="392" width="60" height="20" font="1">30%–39% </text>
<text top="304" left="392" width="42" height="20" font="1">treated </text>
<text top="216" left="499" width="7" height="18" font="1">•</text>
<text top="216" left="505" width="124" height="20" font="1"> Clinical CVD incl TIA, </text>
<text top="235" left="499" width="7" height="18" font="1">•</text>
<text top="234" left="505" width="24" height="20" font="1"> UA </text>
<text top="216" left="644" width="7" height="18" font="1">•</text>
<text top="216" left="651" width="220" height="20" font="1"> WCH adj HR: 2.09; 95% CI: 1.05–4.15; </text>
<text top="233" left="644" width="48" height="20" font="1">p=0.035 </text>
<text top="252" left="644" width="7" height="18" font="1">•</text>
<text top="251" left="651" width="210" height="20" font="1"> MH adj HR: 2.03; 95% CI: 1.36–3.03; </text>
<text top="269" left="644" width="48" height="20" font="1">p&lt;0.001 </text>
<text top="286" left="644" width="204" height="20" font="1">SH adj HR: 3.12; 95% CI: 2.13–4.56; </text>
<text top="303" left="644" width="48" height="20" font="1">p&lt;0.001 </text>
<text top="216" left="887" width="7" height="18" font="1">•</text>
<text top="216" left="894" width="168" height="20" font="1"> Higher CVD with SH, MH and </text>
<text top="233" left="887" width="174" height="20" font="1">WCH (African Americans only). </text>
<text top="250" left="887" width="180" height="20" font="1">CVD risk not increased in whites </text>
<text top="267" left="887" width="58" height="20" font="1">with WCH </text>
<text top="340" left="108" width="3" height="19" font="1"> </text>
<text top="374" left="81" width="407" height="24" font="3"><b>Data Supplement 7. Renal Artery Stenosis (Section 5.4.3)  </b></text>
<text top="414" left="98" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="431" left="104" width="86" height="20" font="4"><b>(if applicable)  </b></text>
<text top="448" left="123" width="44" height="20" font="4"><b>Author </b></text>
<text top="465" left="99" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="414" left="220" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="431" left="236" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="414" left="391" width="44" height="20" font="4"><b>Patient </b></text>
<text top="431" left="380" width="67" height="20" font="4"><b>Population </b></text>
<text top="414" left="582" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="431" left="560" width="224" height="20" font="4"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="414" left="922" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="431" left="949" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="483" left="98" width="78" height="20" font="1">Lawes CM, et </text>
<text top="501" left="98" width="76" height="20" font="1">al., 2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(50)</a> </text>
<text top="518" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12658016">12658016</a></text>
<text top="518" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12658016"> </a></text>
<text top="483" left="205" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="501" left="205" width="130" height="20" font="1">analysis of RCTs of BP </text>
<text top="518" left="205" width="119" height="20" font="1">drugs recording CHD </text>
<text top="535" left="205" width="107" height="20" font="1">events and strokes </text>
<text top="552" left="205" width="3" height="20" font="1"> </text>
<text top="569" left="205" width="99" height="20" font="4"><b>Size</b>: 464,000 pts </text>
<text top="483" left="366" width="24" height="20" font="1">N/A </text>
<text top="485" left="474" width="7" height="18" font="1">•</text>
<text top="484" left="481" width="168" height="20" font="1"> CHD RR or 46% Stroke 64%  </text>
<text top="485" left="883" width="7" height="18" font="1">•</text>
<text top="484" left="890" width="170" height="20" font="1"> All classes of BP meds confer </text>
<text top="502" left="883" width="172" height="20" font="1">benefit while BB confer greater </text>
<text top="519" left="883" width="141" height="20" font="1">benefit in those with CAD </text>
<text top="587" left="98" width="80" height="20" font="1">Riaz IB, et al., </text>
<text top="605" left="98" width="60" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(51)</a>  </text>
<text top="622" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25145333?dopt=Citation">25145333</a></text>
<text top="622" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25145333?dopt=Citation"> </a></text>
<text top="587" left="205" width="137" height="20" font="4"><b>Study type:</b> 540 studies </text>
<text top="605" left="205" width="69" height="20" font="1">and 7 RCTs </text>
<text top="622" left="205" width="3" height="20" font="1"> </text>
<text top="639" left="205" width="85" height="20" font="4"><b>Size</b>: 2,139 pts </text>
<text top="587" left="366" width="24" height="20" font="1">N/A </text>
<text top="589" left="474" width="7" height="18" font="1">•</text>
<text top="588" left="481" width="353" height="20" font="1"> Incidence of nonfatal MI 6.74% in both the stenting and medical </text>
<text top="606" left="474" width="368" height="20" font="1">therapy groups: OR: 0.99; 95% CI: 0.70–1.43; p=0.99, incidence of </text>
<text top="623" left="474" width="390" height="20" font="1">renal events in stenting population was found to be 19.58% vs. 20.53% </text>
<text top="640" left="474" width="313" height="20" font="1">in medical therapy OR: 0.95; 95% CI: 0.76–1.18; p=0.62. </text>
<text top="589" left="883" width="7" height="18" font="1">•</text>
<text top="588" left="890" width="150" height="20" font="1"> BP effect, CV accident not </text>
<text top="606" left="883" width="112" height="20" font="1">specifically reported </text>
<text top="658" left="98" width="79" height="20" font="1">Cooper CJ, et </text>
<text top="675" left="98" width="79" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(52)</a>  </text>
<text top="692" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24245566?dopt=Citation">24245566</a></text>
<text top="692" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24245566?dopt=Citation"> </a></text>
<text top="658" left="205" width="135" height="20" font="4"><b>Study type:</b> Residential </text>
<text top="675" left="205" width="139" height="20" font="1">treatment center medical </text>
<text top="692" left="205" width="126" height="20" font="1">therapy with or without </text>
<text top="710" left="205" width="61" height="20" font="1">renal stent </text>
<text top="727" left="205" width="3" height="20" font="1"> </text>
<text top="744" left="205" width="75" height="20" font="4"><b>Size</b>: 947 pts </text>
<text top="658" left="366" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="675" left="366" width="48" height="20" font="4"><b>criteria</b>: </text>
<text top="692" left="366" width="85" height="20" font="1">Atherosclerotic </text>
<text top="710" left="366" width="66" height="20" font="1">renal artery </text>
<text top="727" left="366" width="49" height="20" font="1">stenosis </text>
<text top="660" left="474" width="7" height="18" font="1">•</text>
<text top="659" left="481" width="365" height="20" font="1"> Composite endpoint of death from CV or renal causes, MI, stroke, </text>
<text top="676" left="474" width="391" height="20" font="1">hospitalization for congestive HF, progressive renal insufficiency, or the </text>
<text top="694" left="474" width="396" height="20" font="1">need for renal-replacement therapy. 35.1% and 35.8%, respectively; HR </text>
<text top="711" left="474" width="256" height="20" font="1">with stenting: 0.94; 95% CI: 0.76–1.17; p=0.58 </text>
<text top="728" left="474" width="391" height="20" font="1">Difference in SBP favoring the stent group: -2.3 mm Hg; 95% CI: -4.4– -</text>
<text top="745" left="474" width="69" height="20" font="1">0.2; p=0.03. </text>
<text top="658" left="883" width="24" height="20" font="1">N/A </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">28 </text>
<text top="107" left="98" width="70" height="20" font="1">Xie X, et al., </text>
<text top="124" left="98" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(21)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation">26559744</a></text>
<text top="141" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation"><b> </b></a></text>
<text top="107" left="205" width="135" height="20" font="4"><b>Study type:</b> MA of RTC </text>
<text top="124" left="205" width="131" height="20" font="1">that randomly assigned </text>
<text top="141" left="205" width="122" height="20" font="1">individuals to different </text>
<text top="159" left="205" width="90" height="20" font="1">target BP levels </text>
<text top="176" left="205" width="3" height="20" font="1"> </text>
<text top="193" left="205" width="92" height="20" font="4"><b>Size</b>: 44,989 pts </text>
<text top="109" left="366" width="7" height="18" font="1">•</text>
<text top="108" left="373" width="50" height="20" font="1"> 19 trials </text>
<text top="109" left="474" width="7" height="18" font="1">•</text>
<text top="108" left="481" width="339" height="20" font="1"> Achieved BP 133/76 mm Hg (intensive) 140/81 (less intense) </text>
<text top="127" left="474" width="7" height="18" font="1">•</text>
<text top="127" left="481" width="233" height="20" font="1"> Major CV events: 14%; 95% CI: 4%–22% </text>
<text top="146" left="474" width="7" height="18" font="1">•</text>
<text top="145" left="481" width="155" height="20" font="1"> MI: 13%; 95% CI: 0%–24% </text>
<text top="164" left="474" width="7" height="18" font="1">•</text>
<text top="163" left="481" width="184" height="20" font="1"> Stroke: 22%; 95% CI: 10%–32% </text>
<text top="182" left="474" width="7" height="18" font="1">•</text>
<text top="182" left="481" width="207" height="20" font="1"> Albuminuria: 10%; 95% CI: 3%–16% </text>
<text top="201" left="474" width="7" height="18" font="1">•</text>
<text top="200" left="481" width="282" height="20" font="1"> Retinopathy progression: 19%; 95% CI: 0%–34%.  </text>
<text top="219" left="474" width="7" height="18" font="1">•</text>
<text top="218" left="481" width="350" height="20" font="1"> More intensive had no effects on HF: 15%; 95% CI: -11%–34% </text>
<text top="238" left="474" width="7" height="18" font="1">•</text>
<text top="237" left="481" width="200" height="20" font="1"> CV death: 9%; 95% CI: –11%–26% </text>
<text top="256" left="474" width="7" height="18" font="1">•</text>
<text top="255" left="481" width="216" height="20" font="1"> Total mortality: 9%; 95% CI: -3%–19% </text>
<text top="274" left="474" width="7" height="18" font="1">•</text>
<text top="274" left="481" width="179" height="20" font="1"> ESKD: 10%; 95% CI: -6%–23%<b> </b></text>
<text top="109" left="883" width="7" height="18" font="1">•</text>
<text top="108" left="890" width="190" height="20" font="1"> More intensive approach reduced </text>
<text top="125" left="883" width="180" height="20" font="1">major CV events (stroke and MI) </text>
<text top="143" left="883" width="205" height="20" font="1">except heat failure, CVD, ESRD, and </text>
<text top="160" left="883" width="80" height="20" font="1">total mortality. </text>
<text top="314" left="98" width="91" height="20" font="1">Brunström M, et </text>
<text top="331" left="98" width="76" height="20" font="1">al., 2016 <a href="">(53)</a> </text>
<text top="348" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26920333">26920333</a></text>
<text top="348" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26920333"> </a></text>
<text top="314" left="205" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="331" left="205" width="130" height="20" font="1">analysis of levels of BP </text>
<text top="348" left="205" width="76" height="20" font="1">control in DM </text>
<text top="365" left="205" width="83" height="20" font="1">hypertensives. </text>
<text top="382" left="205" width="3" height="20" font="1"> </text>
<text top="400" left="205" width="92" height="20" font="4"><b>Size</b>: 73,738 pts </text>
<text top="315" left="366" width="7" height="18" font="1">•</text>
<text top="315" left="373" width="87" height="20" font="1"> 49 trials ( most </text>
<text top="332" left="366" width="83" height="20" font="1">pts with DM-2) </text>
<text top="314" left="474" width="113" height="20" font="1">Baseline SBP &gt;150  </text>
<text top="331" left="474" width="42" height="20" font="1">RR for  </text>
<text top="350" left="474" width="7" height="18" font="1">•</text>
<text top="349" left="481" width="191" height="20" font="1"> All death: 0.89; 95% CI:0.80–0.99 </text>
<text top="368" left="474" width="7" height="18" font="1">•</text>
<text top="368" left="481" width="172" height="20" font="1"> CVD: 0.75; 95% CI: 0.57–0.99 </text>
<text top="387" left="474" width="7" height="18" font="1">•</text>
<text top="386" left="481" width="160" height="20" font="1"> MI: 0.74; 95% CI: 0.63–0.87 </text>
<text top="405" left="474" width="7" height="18" font="1">•</text>
<text top="404" left="481" width="182" height="20" font="1"> Stroke: 0.77; 95% CI: 0.65–0.91 </text>
<text top="423" left="474" width="7" height="18" font="1">•</text>
<text top="423" left="481" width="181" height="20" font="1"> ESRD: 0.82; 95% CI: 0.71–0.94 </text>
<text top="440" left="474" width="3" height="20" font="1"> </text>
<text top="457" left="474" width="165" height="20" font="1">Baseline SBP140–150 RR of  </text>
<text top="476" left="474" width="7" height="18" font="1">•</text>
<text top="476" left="481" width="183" height="20" font="1"> Death: 0.87; 95% CI: 0.78–0.98) </text>
<text top="495" left="474" width="7" height="18" font="1">•</text>
<text top="494" left="481" width="157" height="20" font="1"> MI: 0.84; 95% CI: 0.76–0.9  </text>
<text top="513" left="474" width="7" height="18" font="1">•</text>
<text top="512" left="481" width="163" height="20" font="1"> HF: 0.80; 95% CI: 0.66–0.97 </text>
<text top="530" left="474" width="306" height="20" font="1">If baseline SBP,140 mm Hg, however, further treatment </text>
<text top="547" left="474" width="324" height="20" font="1">increased the risk of CV mortality (1.15; 95% CI: 1.00–1.32 </text>
<text top="315" left="883" width="7" height="18" font="1">•</text>
<text top="315" left="890" width="174" height="20" font="1"> BP lowering reduces major CV </text>
<text top="332" left="883" width="191" height="20" font="1">events in DM. Caution for initiating </text>
<text top="349" left="883" width="174" height="20" font="1">treatment in diabetics with SBP </text>
<text top="366" left="883" width="48" height="20" font="1">&lt;140/90 </text>
<text top="570" left="98" width="75" height="20" font="1">Ettehad D, et </text>
<text top="587" left="98" width="76" height="20" font="1">al., 2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(17)</a> </text>
<text top="605" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178">26724178</a></text>
<text top="605" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178"> </a></text>
<text top="570" left="205" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="587" left="205" width="141" height="20" font="1">analysis of large RTCs of </text>
<text top="605" left="205" width="93" height="20" font="1">antihypertensive </text>
<text top="622" left="205" width="55" height="20" font="1">treatment </text>
<text top="639" left="205" width="3" height="20" font="1"> </text>
<text top="656" left="205" width="99" height="20" font="4"><b>Size</b>: 613,815 pts </text>
<text top="572" left="366" width="7" height="18" font="1">•</text>
<text top="571" left="373" width="70" height="20" font="1"> 123 studies </text>
<text top="588" left="366" width="3" height="20" font="1"> </text>
<text top="570" left="474" width="215" height="20" font="1">Every 10 mm Hg reduction in SBP RR: </text>
<text top="589" left="474" width="7" height="18" font="1">•</text>
<text top="588" left="481" width="237" height="20" font="1"> Major CV events: 0.80; 95% CI: 0.77–0.83 </text>
<text top="607" left="474" width="7" height="18" font="1">•</text>
<text top="607" left="481" width="173" height="20" font="1"> CHD: 0.83; 95% CI: 0.78–0.88 </text>
<text top="626" left="474" width="7" height="18" font="1">•</text>
<text top="625" left="481" width="302" height="20" font="1"> Stroke: 0.73; 95% CI: 0.68–0.77), HF (0.72, 0.67–0.78 </text>
<text top="644" left="474" width="7" height="18" font="1">•</text>
<text top="644" left="481" width="278" height="20" font="1"> All-cause mortality: 0.87; 95% CI: 0.87; 0.84–0.91 </text>
<text top="663" left="474" width="7" height="18" font="1">•</text>
<text top="662" left="481" width="133" height="20" font="1"> ESRD: 0.95; 0.84–1.07 </text>
<text top="572" left="883" width="7" height="18" font="1">•</text>
<text top="571" left="890" width="163" height="20" font="1"> BP lowering reduces CV risk </text>
<text top="588" left="883" width="187" height="20" font="1">across various baseline BP levels </text>
<text top="606" left="883" width="201" height="20" font="1">and comorbidities. Suggest lowering </text>
<text top="623" left="883" width="196" height="20" font="1">SBP &lt;130 mm Hg and BP-lowering </text>
<text top="640" left="883" width="178" height="20" font="1">treatment to pts with a history of </text>
<text top="657" left="883" width="180" height="20" font="1">CVD, CHD, stroke, DM, HF, and </text>
<text top="674" left="883" width="33" height="20" font="1">CKD. </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">29 </text>
<text top="107" left="98" width="94" height="20" font="1">Thomopolous C, </text>
<text top="124" left="98" width="33" height="20" font="1">et al., </text>
<text top="141" left="98" width="56" height="20" font="1">2016 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(54)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26848994">26848994</a></text>
<text top="159" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26848994"> </a></text>
<text top="107" left="205" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="124" left="205" width="141" height="20" font="1">analysis of RTCs of more </text>
<text top="141" left="205" width="148" height="20" font="1">vs. less intense BP control </text>
<text top="109" left="366" width="7" height="18" font="1">•</text>
<text top="108" left="373" width="50" height="20" font="1"> 16 trials </text>
<text top="125" left="366" width="69" height="20" font="1">(52,235 pts) </text>
<text top="143" left="366" width="90" height="20" font="1">compared more </text>
<text top="160" left="366" width="87" height="20" font="1">vs. less intense </text>
<text top="177" left="366" width="55" height="20" font="1">treatment </text>
<text top="194" left="366" width="69" height="20" font="1">34 (138,127 </text>
<text top="212" left="366" width="79" height="20" font="1">pts) active vs. </text>
<text top="229" left="366" width="46" height="20" font="1">placebo </text>
<text top="107" left="474" width="98" height="20" font="1">More intense BP  </text>
<text top="126" left="474" width="7" height="18" font="1">•</text>
<text top="125" left="481" width="207" height="20" font="1"> Stroke RR: 0.71; 95% CI: 0.60–0.84) </text>
<text top="144" left="474" width="7" height="18" font="1">•</text>
<text top="144" left="481" width="198" height="20" font="1"> CHD RR: 0.80; 95% CI: 0.68–0.95) </text>
<text top="163" left="474" width="7" height="18" font="1">•</text>
<text top="162" left="481" width="258" height="20" font="1"> Major CV events RR: 0.75; 95% CI: 0.68–0.85 </text>
<text top="181" left="474" width="7" height="18" font="1">•</text>
<text top="181" left="481" width="235" height="20" font="1"> CV mortality RR: 0.79; 95% CI: 0.63–0.97 </text>
<text top="198" left="474" width="3" height="20" font="1"> </text>
<text top="215" left="474" width="380" height="20" font="1">Stratification of SBP cutoffs (150,140 and 130 mm Hg) showed that a </text>
<text top="232" left="474" width="372" height="20" font="1">SBP/DBP difference of 10/5 mm Hg across each cutoff reduced risk </text>
<text top="249" left="474" width="86" height="20" font="1">of all outcomes </text>
<text top="109" left="883" width="7" height="18" font="1">•</text>
<text top="108" left="890" width="183" height="20" font="1"> Intensive BP reduction improves </text>
<text top="125" left="883" width="174" height="20" font="1">CV outcomes compared to less </text>
<text top="143" left="883" width="43" height="20" font="1">intense </text>
<text top="160" left="883" width="166" height="20" font="1">Achieved BP &lt;130/80 may be </text>
<text top="177" left="883" width="152" height="20" font="1">associated with CV benefit. </text>
<text top="269" left="98" width="83" height="20" font="1">Julius S, et al., </text>
<text top="286" left="98" width="56" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(55)</a> </text>
<text top="303" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16537662">16537662</a></text>
<text top="303" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16537662"> </a></text>
<text top="269" left="205" width="134" height="20" font="4"><b>Study type:</b> RCT in pre-</text>
<text top="286" left="205" width="141" height="20" font="1">HTN; 16 mg candesartan </text>
<text top="303" left="205" width="66" height="20" font="1">vs. placebo </text>
<text top="321" left="205" width="3" height="20" font="1"> </text>
<text top="338" left="205" width="75" height="20" font="4"><b>Size</b>: 809 pts </text>
<text top="270" left="366" width="73" height="20" font="1"> •  58% men </text>
<text top="271" left="474" width="7" height="18" font="1">•</text>
<text top="270" left="481" width="382" height="20" font="1"> During the first 2 y, HTN developed in 154 (40.4%) pts in the placebo </text>
<text top="287" left="474" width="360" height="20" font="1">group compared with only 53 (13.6%) of those in the candesartan </text>
<text top="305" left="474" width="364" height="20" font="1">group, for RR: 66.3% (p&lt;0.0001). After 4 y, HTN developed in 240 </text>
<text top="322" left="474" width="382" height="20" font="1">(63.0%) in the placebo group vs. only 208 (53.2%) in the candesartan </text>
<text top="339" left="474" width="165" height="20" font="1">group RR: 15.6% (p&lt;0.0069). </text>
<text top="271" left="883" width="7" height="18" font="1">•</text>
<text top="270" left="890" width="193" height="20" font="1"> 2/3 of those with pre-HTN develop </text>
<text top="287" left="883" width="161" height="20" font="1">HTN within 4 y. Candesartan </text>
<text top="305" left="883" width="197" height="20" font="1">interrupts the onset and reduced by </text>
<text top="322" left="883" width="38" height="20" font="1">15.6% </text>
<text top="364" left="98" width="85" height="20" font="1">Ference BA, et </text>
<text top="381" left="98" width="76" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(56)</a> </text>
<text top="398" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24591335">24591335</a></text>
<text top="398" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24591335"> </a></text>
<text top="364" left="205" width="128" height="20" font="4"><b>Study type:</b> Evaluated </text>
<text top="381" left="205" width="85" height="20" font="1">the effect of 12 </text>
<text top="398" left="205" width="86" height="20" font="1">polymorphisms </text>
<text top="415" left="205" width="132" height="20" font="1">(associated with BP) on </text>
<text top="432" left="205" width="118" height="20" font="1">the odds of CHD and </text>
<text top="450" left="205" width="147" height="20" font="1">compared it with the effect </text>
<text top="467" left="205" width="141" height="20" font="1">of lower SBP observed in </text>
<text top="484" left="205" width="131" height="20" font="1">both prospective cohort </text>
<text top="501" left="205" width="136" height="20" font="1">studies and BP-lowering </text>
<text top="518" left="205" width="97" height="20" font="1">randomized trials </text>
<text top="536" left="205" width="3" height="20" font="1"> </text>
<text top="553" left="205" width="99" height="20" font="4"><b>Size</b>: 199,477 pts </text>
<text top="365" left="366" width="7" height="18" font="1">•</text>
<text top="365" left="373" width="63" height="20" font="1"> 63 studies </text>
<text top="365" left="474" width="7" height="18" font="1">•</text>
<text top="365" left="481" width="366" height="20" font="1"> 12 polymorphisms were associated with a 0.32 mm Hg lower SBP </text>
<text top="382" left="474" width="63" height="20" font="1">(p=1.79×10</text>
<text top="384" left="537" width="7" height="13" font="6">-7</text>
<text top="382" left="544" width="304" height="20" font="1">) and a 0.093-mm Hg/decade slower age-related rise in </text>
<text top="399" left="474" width="91" height="20" font="1">SBP (p=3.05×10</text>
<text top="401" left="565" width="7" height="13" font="6">-5</text>
<text top="399" left="572" width="284" height="20" font="1">). The effect of long-term exposure to lower SBP on </text>
<text top="416" left="474" width="374" height="20" font="1">CHD mediated by these polymorphisms was 2-fold greater than that </text>
<text top="434" left="474" width="370" height="20" font="1">observed in prospective cohort studies (p=0.006) and 3-fold greater </text>
<text top="451" left="474" width="346" height="20" font="1">than that observed in short-term BP treatment trials (p=0.001).  </text>
<text top="365" left="883" width="7" height="18" font="1">•</text>
<text top="365" left="890" width="185" height="20" font="1"> SBP may be causally associated </text>
<text top="382" left="883" width="198" height="20" font="1">with the rate of rise in SBP with age </text>
<text top="399" left="883" width="191" height="20" font="1">and has a cumulative effect on the </text>
<text top="416" left="883" width="70" height="20" font="1">risk of CHD. </text>
<text top="572" left="108" width="3" height="19" font="1"> </text>
<text top="607" left="81" width="549" height="24" font="3"><b>Data Supplement 8. RCTs Comparing Obstructive Sleep Apnea (Section 5.4.4) </b></text>
<text top="646" left="126" width="38" height="20" font="4"><b>Study </b></text>
<text top="664" left="114" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="681" left="121" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="698" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="646" left="226" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="664" left="231" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="681" left="225" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="646" left="373" width="44" height="20" font="4"><b>Patient </b></text>
<text top="664" left="361" width="67" height="20" font="4"><b>Population </b></text>
<text top="646" left="469" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="664" left="485" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="681" left="470" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="698" left="491" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="646" left="669" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="664" left="652" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="681" left="634" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="648" left="875" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="665" left="907" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="682" left="912" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="699" left="933" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="717" left="98" width="77" height="20" font="1">Barb F, et al., </text>
<text top="734" left="98" width="60" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(57)</a>  </text>
<text top="752" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20007932?dopt=Citation">20007932 </a></text>
<text top="717" left="204" width="94" height="20" font="4"><b>Aim: </b>Assess the </text>
<text top="734" left="204" width="118" height="20" font="1">effect on BP of 1 y of </text>
<text top="752" left="204" width="117" height="20" font="1">treatment with CPAP </text>
<text top="769" left="204" width="117" height="20" font="1">in nonsleepy pts with </text>
<text top="786" left="204" width="85" height="20" font="1">HTN and OSA. </text>
<text top="717" left="344" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="734" left="344" width="95" height="20" font="4"><b>criteria:</b> Pts with </text>
<text top="752" left="344" width="50" height="20" font="1">HTN (on </text>
<text top="769" left="344" width="83" height="20" font="1">medications or </text>
<text top="788" left="344" width="8" height="18" font="1">≥</text>
<text top="787" left="353" width="69" height="20" font="1">140/90) and </text>
<text top="717" left="458" width="118" height="20" font="4"><b>Intervention:</b> CPAP  </text>
<text top="734" left="458" width="3" height="20" font="1"> </text>
<text top="752" left="458" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="769" left="458" width="130" height="20" font="1">Conservative treatment </text>
<text top="718" left="605" width="165" height="20" font="4"><b>1</b>°<b> endpoint:</b> Decrease in BP </text>
<text top="735" left="605" width="3" height="20" font="1"> </text>
<text top="753" left="605" width="205" height="20" font="4"><b>Results</b>: At 12 mo, CPAP decreased </text>
<text top="770" left="605" width="224" height="20" font="1">SBP by 1.89 mm Hg (95% CI: 3.90–0.11 </text>
<text top="787" left="605" width="222" height="20" font="1">mm Hg; p=0.065) and DBP 2.19 mm Hg </text>
<text top="717" left="850" width="210" height="20" font="4"><b>Limitations</b>: Not blinded; both groups </text>
<text top="734" left="850" width="188" height="20" font="1">consisted of pts with severe sleep-</text>
<text top="752" left="850" width="41" height="20" font="1">apnea. </text>
<text top="769" left="850" width="3" height="20" font="1"> </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">30 </text>
<text top="107" left="204" width="3" height="20" font="1"> </text>
<text top="124" left="204" width="102" height="20" font="4"><b>Study type:</b> RCT  </text>
<text top="141" left="204" width="3" height="20" font="1"> </text>
<text top="159" left="204" width="117" height="20" font="4"><b>Size:</b> 359 pts; 12 mo </text>
<text top="176" left="204" width="66" height="20" font="1">of follow-up </text>
<text top="107" left="344" width="96" height="20" font="1">apnea-hypopnea </text>
<text top="124" left="344" width="60" height="20" font="1">index &gt;19. </text>
<text top="107" left="458" width="131" height="20" font="1">(dietary counseling and </text>
<text top="124" left="458" width="126" height="20" font="1">sleep hygiene advice). </text>
<text top="107" left="605" width="219" height="20" font="1">(95% CI: 3.46– -0.93 mm Hg; p=0.001). </text>
<text top="124" left="605" width="225" height="20" font="1">The most significant reduction in BP was </text>
<text top="141" left="605" width="223" height="20" font="1">in pts who used CPAP for more than 5.6 </text>
<text top="159" left="605" width="44" height="20" font="1">h/night. </text>
<text top="107" left="850" width="174" height="20" font="4"><b>Conclusions</b>: CPAP induced a </text>
<text top="124" left="850" width="217" height="20" font="1">significant reduction in BP, albeit small, </text>
<text top="141" left="850" width="164" height="20" font="1">in hypertensive pts with OSA.<b> </b></text>
<text top="194" left="98" width="91" height="20" font="1">Martinez-Garcia </text>
<text top="211" left="98" width="89" height="20" font="1">MA, et al., 2013 </text>
<text top="228" left="98" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(58)</a> </text>
<text top="245" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24327037?dopt=Citation">24327037 </a></text>
<text top="194" left="204" width="94" height="20" font="4"><b>Aim:</b> Assess the </text>
<text top="211" left="204" width="121" height="20" font="1">effect of CPAP on BP </text>
<text top="228" left="204" width="111" height="20" font="1">in pts with OSA and </text>
<text top="246" left="204" width="50" height="20" font="1">resistant </text>
<text top="263" left="204" width="77" height="20" font="1">hypertension. </text>
<text top="280" left="204" width="3" height="20" font="1"> </text>
<text top="297" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="314" left="204" width="3" height="20" font="1"> </text>
<text top="332" left="204" width="110" height="20" font="4"><b>Size:</b> 194 pts; 3 mo </text>
<text top="349" left="204" width="53" height="20" font="1">follow-up </text>
<text top="194" left="344" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="211" left="344" width="95" height="20" font="4"><b>criteria:</b> Pts with </text>
<text top="228" left="344" width="50" height="20" font="1">resistant </text>
<text top="245" left="344" width="98" height="20" font="1">hypertension and </text>
<text top="263" left="344" width="33" height="20" font="1">OSA. </text>
<text top="194" left="458" width="118" height="20" font="4"><b>Intervention:</b> CPAP  </text>
<text top="211" left="458" width="3" height="20" font="1"> </text>
<text top="228" left="458" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="245" left="458" width="44" height="20" font="1">therapy </text>
<text top="195" left="605" width="230" height="20" font="4"><b>1</b>°<b> endpoint:</b> Change in 24-h ABPM from </text>
<text top="212" left="605" width="102" height="20" font="1">baseline to 12 wk. </text>
<text top="229" left="605" width="3" height="20" font="1"> </text>
<text top="247" left="605" width="55" height="20" font="4"><b>Results</b>:  </text>
<text top="266" left="605" width="7" height="18" font="1">•</text>
<text top="265" left="612" width="172" height="20" font="1"> When the changes in BP were </text>
<text top="282" left="605" width="213" height="20" font="1">compared between groups by intent to </text>
<text top="300" left="605" width="229" height="20" font="1">treat, the CPAP group achieved a greater </text>
<text top="317" left="605" width="217" height="20" font="1">decrease in 24-h mean BP (3.1 mm Hg </text>
<text top="334" left="605" width="229" height="20" font="1">(95% CI: 0.6, 5.6); p=0.02) and 24-h DBP </text>
<text top="351" left="605" width="219" height="20" font="1">(3.2 mm Hg (95% CI: 1.0, 5.4; p=0.005) </text>
<text top="368" left="605" width="229" height="20" font="1">but not in 24-h SBP (3.1 mm Hg (95% CI: </text>
<text top="386" left="605" width="213" height="20" font="1">-0.6–6.7; p=0.10) compared to control. </text>
<text top="405" left="605" width="7" height="18" font="1">•</text>
<text top="404" left="612" width="217" height="20" font="1"> There was also a greater nocturnal BP </text>
<text top="421" left="605" width="224" height="20" font="1">dipping pattern in CPAP treated pts than </text>
<text top="438" left="605" width="219" height="20" font="1">control (35.9% vs. 21.6%; adjusted OR: </text>
<text top="456" left="605" width="140" height="20" font="1">2.4; CI: 1.2–5.1; p=0.02). </text>
<text top="475" left="605" width="7" height="18" font="1">•</text>
<text top="474" left="612" width="178" height="20" font="1"> There was a significant positive </text>
<text top="491" left="605" width="219" height="20" font="1">correlation between h of CPAP use and </text>
<text top="508" left="605" width="216" height="20" font="1">the decrease in mean 24-h BP (r=0.29; </text>
<text top="526" left="605" width="214" height="20" font="1">0.006), SBP (r=0.25; p=0.02) and DBP </text>
<text top="543" left="605" width="102" height="20" font="1">(r=0.30; p=0.005). </text>
<text top="194" left="850" width="225" height="20" font="4"><b>Limitations</b>: Did not use sham CPAP as </text>
<text top="211" left="850" width="201" height="20" font="1">placebo; open-label; short follow-up. </text>
<text top="228" left="850" width="3" height="20" font="1"> </text>
<text top="245" left="850" width="218" height="20" font="4"><b>Conclusions</b>: Among pts with resistant </text>
<text top="263" left="850" width="223" height="20" font="1">hypertension and OSA, CPAP treatment </text>
<text top="280" left="850" width="224" height="20" font="1">for 12 wk compared with control resulted </text>
<text top="297" left="850" width="205" height="20" font="1">in a decrease in 24-h mean and DBP </text>
<text top="314" left="850" width="217" height="20" font="1">and improvement in nocturnal pressure </text>
<text top="332" left="850" width="45" height="20" font="1">pattern. </text>
<text top="561" left="98" width="91" height="20" font="1">Lozano L, et al., </text>
<text top="578" left="98" width="60" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(59)</a>  </text>
<text top="595" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20577130?dopt=Citation">20577130 </a></text>
<text top="561" left="204" width="121" height="20" font="4"><b>Aim:</b> Assess effect of </text>
<text top="578" left="204" width="99" height="20" font="1">CPAP on pts with </text>
<text top="595" left="204" width="103" height="20" font="1">OSA and resistant </text>
<text top="612" left="204" width="77" height="20" font="1">hypertension. </text>
<text top="630" left="204" width="3" height="20" font="1"> </text>
<text top="647" left="204" width="102" height="20" font="4"><b>Study type</b>: RCT  </text>
<text top="664" left="204" width="3" height="20" font="1"> </text>
<text top="681" left="204" width="117" height="20" font="4"><b>Size:</b> 96 pts; 3 mo of </text>
<text top="698" left="204" width="53" height="20" font="1">follow-up </text>
<text top="561" left="344" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="578" left="344" width="95" height="20" font="4"><b>criteria:</b> Pts with </text>
<text top="595" left="344" width="50" height="20" font="1">resistant </text>
<text top="612" left="344" width="98" height="20" font="1">hypertension and </text>
<text top="630" left="344" width="33" height="20" font="1">OSA. </text>
<text top="561" left="458" width="125" height="20" font="4"><b>Intervention:</b> CPAP + </text>
<text top="578" left="458" width="100" height="20" font="1">conventional drug </text>
<text top="595" left="458" width="55" height="20" font="1">treatment </text>
<text top="612" left="458" width="3" height="20" font="1"> </text>
<text top="630" left="458" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="647" left="458" width="103" height="20" font="1">Conventional drug </text>
<text top="664" left="458" width="89" height="20" font="1">treatment alone </text>
<text top="562" left="605" width="211" height="20" font="4"><b>1</b>°<b> endpoint:</b> Decrease in 24-h ABPM </text>
<text top="579" left="605" width="130" height="20" font="1">from baseline to 12 wk. </text>
<text top="596" left="605" width="3" height="20" font="1"> </text>
<text top="614" left="605" width="193" height="20" font="4"><b>Results</b>: Pts with ABPM confirmed </text>
<text top="631" left="605" width="231" height="20" font="1">resistant hypertension treated with CPAP, </text>
<text top="648" left="605" width="209" height="20" font="1">unlike those treated with conventional </text>
<text top="665" left="605" width="228" height="20" font="1">therapy, showed a decrease in 24-h DBP </text>
<text top="682" left="605" width="221" height="20" font="1">(-4.9±6.4 vs. 0.1±7.3 mm Hg; p=0.027). </text>
<text top="700" left="605" width="208" height="20" font="1">Pts who used CPAP &gt;5.8 h showed a </text>
<text top="717" left="605" width="220" height="20" font="1">greater reduction in daytime DBP (-6.12 </text>
<text top="734" left="605" width="222" height="20" font="1">mm Hg; 95% CI: -1.45–10.82; p=0.004), </text>
<text top="751" left="605" width="228" height="20" font="1">24-h DBP (-6.98 mm Hg; 95% CI: -1.86– -</text>
<text top="768" left="605" width="223" height="20" font="1">12.1; p=0.009) and 24-h SBP (-9.71 mm </text>
<text top="786" left="605" width="199" height="20" font="1">Hg; 95% CI: -0.20– -19.22; p=0.46). </text>
<text top="561" left="850" width="200" height="20" font="4"><b>Limitations</b>: Small study; only 3 mo </text>
<text top="578" left="850" width="172" height="20" font="1">follow-up; lack of sham control. </text>
<text top="595" left="850" width="3" height="20" font="1"> </text>
<text top="612" left="850" width="215" height="20" font="4"><b>Conclusions</b>: CPAP as a complement </text>
<text top="630" left="850" width="218" height="20" font="1">to usual treatment improved mean 24-h </text>
<text top="647" left="850" width="179" height="20" font="1">DBP in pts with OSA and ABPM-</text>
<text top="664" left="850" width="185" height="20" font="1">confirmed resistant hypertension. </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">31 </text>
<text top="107" left="98" width="87" height="20" font="1">Muxfeldt ES, et </text>
<text top="124" left="98" width="76" height="20" font="1">al., 2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(60)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25601933?dopt=Citation">25601933</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25601933?dopt=Citation"> </a></text>
<text top="107" left="204" width="102" height="20" font="4"><b>Aim:</b> Evaluate the </text>
<text top="124" left="204" width="121" height="20" font="1">effect of CPAP on pts </text>
<text top="141" left="204" width="75" height="20" font="1">with resistant </text>
<text top="159" left="204" width="98" height="20" font="1">hypertension and </text>
<text top="176" left="204" width="33" height="20" font="1">OSA. </text>
<text top="193" left="204" width="3" height="20" font="1"> </text>
<text top="210" left="204" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="227" left="204" width="3" height="20" font="1"> </text>
<text top="245" left="204" width="124" height="20" font="4"><b>Size:</b> 434 pts; 6 mo of </text>
<text top="262" left="204" width="53" height="20" font="1">follow-up </text>
<text top="107" left="344" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="124" left="344" width="95" height="20" font="4"><b>criteria:</b> Pts with </text>
<text top="141" left="344" width="50" height="20" font="1">resistant </text>
<text top="159" left="344" width="98" height="20" font="1">hypertension and </text>
<text top="176" left="344" width="29" height="20" font="1">OSA </text>
<text top="107" left="458" width="125" height="20" font="4"><b>Intervention:</b> CPAP + </text>
<text top="124" left="458" width="72" height="20" font="1">conventional </text>
<text top="141" left="458" width="93" height="20" font="1">antihypertensive </text>
<text top="159" left="458" width="48" height="20" font="1">therapy  </text>
<text top="176" left="458" width="3" height="20" font="1"> </text>
<text top="193" left="458" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="210" left="458" width="94" height="20" font="1">Antihypertensive </text>
<text top="227" left="458" width="81" height="20" font="1">therapy alone. </text>
<text top="245" left="458" width="75" height="20" font="1">Conventional </text>
<text top="262" left="458" width="93" height="20" font="1">antihypertensive </text>
<text top="279" left="458" width="94" height="20" font="1">therapy included </text>
<text top="296" left="458" width="87" height="20" font="1">spironolactone. </text>
<text top="108" left="605" width="213" height="20" font="4"><b>1</b>°<b> endpoint:</b> BP reduction at 6 mo via </text>
<text top="125" left="605" width="42" height="20" font="1">ABPM  </text>
<text top="143" left="605" width="3" height="20" font="1"> </text>
<text top="160" left="605" width="55" height="20" font="4"><b>Results</b>:  </text>
<text top="179" left="605" width="7" height="18" font="1">•</text>
<text top="178" left="612" width="216" height="20" font="1"> On an intention-to-treat analysis, there </text>
<text top="195" left="605" width="214" height="20" font="1">was no significant difference in any BP </text>
<text top="213" left="605" width="198" height="20" font="1">change, neither in nocturnal BP fall, </text>
<text top="230" left="605" width="220" height="20" font="1">between CPAP and control groups. The </text>
<text top="247" left="605" width="211" height="20" font="1">best effect of CPAP was on night-time </text>
<text top="264" left="605" width="229" height="20" font="1">SBP in per-protocol analysis, with greater </text>
<text top="282" left="605" width="221" height="20" font="1">reduction of 4.7 mm Hg (95% CI: -1.6%–</text>
<text top="299" left="605" width="206" height="20" font="1">5.8%; p=0.25, in comparison with the </text>
<text top="316" left="605" width="79" height="20" font="1">control group. </text>
<text top="335" left="605" width="7" height="18" font="1">•</text>
<text top="334" left="612" width="181" height="20" font="1"> Median use of CPAP was 4.8 h. </text>
<text top="107" left="850" width="203" height="20" font="4"><b>Limitations</b>: Nonblinded design; per </text>
<text top="124" left="850" width="223" height="20" font="1">protocol analysis underpowered to show </text>
<text top="141" left="850" width="222" height="20" font="1">the prespecified outcome of 6–7 mm Hg </text>
<text top="159" left="850" width="202" height="20" font="1">SBP differences between CPAP and </text>
<text top="176" left="850" width="85" height="20" font="1">control groups. </text>
<text top="193" left="850" width="3" height="20" font="1"> </text>
<text top="210" left="850" width="217" height="20" font="4"><b>Conclusions</b>: CPAP had no significant </text>
<text top="227" left="850" width="213" height="20" font="1">effect on clinic or ambulatory BP in pts </text>
<text top="245" left="850" width="173" height="20" font="1">with resistant hypertension and </text>
<text top="262" left="850" width="191" height="20" font="1">moderately severe to severe OSA. </text>
<text top="279" left="850" width="222" height="20" font="1">However, in the specific subgroup of pts </text>
<text top="296" left="850" width="220" height="20" font="1">with uncontrolled ambulatory BP, CPAP </text>
<text top="314" left="850" width="206" height="20" font="1">may modestly reduce night-time SBP </text>
<text top="331" left="850" width="185" height="20" font="1">and improve the nocturnal BP fall </text>
<text top="348" left="850" width="187" height="20" font="1">pattern. The reason for lack of BP </text>
<text top="365" left="850" width="217" height="20" font="1">reduction in the overall study may have </text>
<text top="383" left="850" width="219" height="20" font="1">been due to excellent control of BP with </text>
<text top="400" left="850" width="178" height="20" font="1">median 5 medications, including </text>
<text top="417" left="850" width="204" height="20" font="1">spironolactone, in the majority of pts. </text>
<text top="435" left="98" width="87" height="20" font="1">Pedrosa RP, et </text>
<text top="452" left="98" width="76" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(61)</a> </text>
<text top="469" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23598607?dopt=Citation">23598607</a></text>
<text top="469" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23598607?dopt=Citation"> </a></text>
<text top="435" left="204" width="102" height="20" font="4"><b>Aim:</b> Evaluate the </text>
<text top="452" left="204" width="121" height="20" font="1">effect of CPAP on pts </text>
<text top="469" left="204" width="75" height="20" font="1">with resistant </text>
<text top="487" left="204" width="98" height="20" font="1">hypertension and </text>
<text top="504" left="204" width="33" height="20" font="1">OSA. </text>
<text top="521" left="204" width="3" height="20" font="1"> </text>
<text top="538" left="204" width="127" height="20" font="4"><b>Study type</b>: RCT with  </text>
<text top="555" left="204" width="3" height="20" font="1"> </text>
<text top="573" left="204" width="103" height="20" font="4"><b>Size:</b> 40 pts; 6 mo </text>
<text top="590" left="204" width="53" height="20" font="1">follow-up </text>
<text top="435" left="344" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="452" left="344" width="95" height="20" font="4"><b>criteria:</b> Pts with </text>
<text top="469" left="344" width="50" height="20" font="1">resistant </text>
<text top="487" left="344" width="98" height="20" font="1">hypertension and </text>
<text top="504" left="344" width="29" height="20" font="1">OSA </text>
<text top="435" left="458" width="125" height="20" font="4"><b>Intervention:</b> CPAP + </text>
<text top="452" left="458" width="72" height="20" font="1">conventional </text>
<text top="469" left="458" width="93" height="20" font="1">antihypertensive </text>
<text top="487" left="458" width="87" height="20" font="1">therapy (n=20)  </text>
<text top="504" left="458" width="3" height="20" font="1"> </text>
<text top="521" left="458" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="538" left="458" width="94" height="20" font="1">Antihypertensive </text>
<text top="555" left="458" width="121" height="20" font="1">therapy alone (n=20). </text>
<text top="436" left="605" width="210" height="20" font="4"><b>1</b>°<b> endpoint:</b> BP reduction at 6 mo by </text>
<text top="453" left="605" width="42" height="20" font="1">ABPM. </text>
<text top="470" left="605" width="3" height="20" font="1"> </text>
<text top="488" left="605" width="211" height="20" font="4"><b>Results</b>: BP was 162±4/97±2 mm Hg </text>
<text top="505" left="605" width="218" height="20" font="1">prior to randomization. CPAP was used </text>
<text top="522" left="605" width="219" height="20" font="1">for 6 h/night. Compared with the control </text>
<text top="539" left="605" width="195" height="20" font="1">group, awake SBP/DBP decreased </text>
<text top="557" left="605" width="180" height="20" font="1">significantly in the CPAP group (-</text>
<text top="574" left="605" width="214" height="20" font="1">6.5±3.3/-4.5±1.9 vs. +3.1±3.3/2.1±2/7 </text>
<text top="591" left="605" width="195" height="20" font="1">mm Hg; p&lt;0.05). BP changes were </text>
<text top="608" left="605" width="226" height="20" font="1">significant only when pts were awake but </text>
<text top="625" left="605" width="122" height="20" font="1">not at night by ABPM. </text>
<text top="435" left="850" width="204" height="20" font="4"><b>Limitations</b>: Small; but strength was </text>
<text top="452" left="850" width="192" height="20" font="1">rigorous exclusion of pts who were </text>
<text top="469" left="850" width="181" height="20" font="1">nonadherent; control arm did not </text>
<text top="487" left="850" width="221" height="20" font="1">undergo placebo treatment; nonblinded. </text>
<text top="504" left="850" width="3" height="20" font="1"> </text>
<text top="521" left="850" width="208" height="20" font="4"><b>Conclusions</b>: Treatment of OSA with </text>
<text top="538" left="850" width="217" height="20" font="1">CPAP significantly reduces daytime BP </text>
<text top="555" left="850" width="185" height="20" font="1">in pts with resistant hypertension.<b> </b></text>
<text top="645" left="108" width="3" height="19" font="4"><b> </b></text>
<text top="679" left="81" width="865" height="24" font="3"><b>Data Supplement 9. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Fiber Intake) (Section 6.2) </b></text>
<text top="719" left="101" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="736" left="127" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="753" left="104" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="719" left="245" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="736" left="250" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="753" left="244" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="719" left="375" width="255" height="20" font="4"><b>Patient Population  Study Intervention (# </b></text>
<text top="736" left="537" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="753" left="505" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="771" left="540" width="55" height="20" font="4"><b>patients) </b></text>
<text top="719" left="704" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="736" left="688" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="753" left="670" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="720" left="891" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="737" left="923" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="754" left="931" width="96" height="20" font="4"><b>Adverse Events </b></text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">32 </text>
<text top="107" left="98" width="105" height="20" font="1">Whelton SP, et al., </text>
<text top="124" left="98" width="56" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(62)</a> </text>
<text top="141" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15716684?dopt=Citation">15716684 </a></text>
<text top="107" left="216" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="124" left="216" width="141" height="20" font="1">dietary fiber intake on BP<b> </b></text>
<text top="141" left="216" width="3" height="20" font="1"> </text>
<text top="159" left="216" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="176" left="216" width="94" height="20" font="1">review and meta-</text>
<text top="193" left="216" width="48" height="20" font="1">analysis </text>
<text top="210" left="216" width="3" height="20" font="4"><b> </b></text>
<text top="227" left="216" width="32" height="20" font="4"><b>Size: </b></text>
<text top="247" left="216" width="7" height="18" font="1">•</text>
<text top="246" left="223" width="76" height="20" font="4"><b> </b>21 RCTs (25 </text>
<text top="263" left="216" width="137" height="20" font="1">comparisons) with 1,477 </text>
<text top="280" left="216" width="20" height="20" font="1">pts </text>
<text top="299" left="216" width="7" height="18" font="1">•</text>
<text top="299" left="223" width="120" height="20" font="4"><b> </b>20 of the RCTs were </text>
<text top="316" left="216" width="73" height="20" font="1">conducted in </text>
<text top="333" left="216" width="141" height="20" font="1">nonhypertensive persons </text>
<text top="352" left="216" width="7" height="18" font="1">•</text>
<text top="352" left="223" width="105" height="20" font="1"> 13 double-blind; 3 </text>
<text top="369" left="216" width="130" height="20" font="1">single blind and 9 open </text>
<text top="386" left="216" width="29" height="20" font="1">label </text>
<text top="107" left="371" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="126" left="371" width="7" height="18" font="1">•</text>
<text top="125" left="378" width="32" height="20" font="4"><b> </b>RCT </text>
<text top="144" left="371" width="7" height="18" font="1">•</text>
<text top="144" left="378" width="38" height="20" font="4"><b> </b>≥16 y </text>
<text top="163" left="371" width="7" height="18" font="1">•</text>
<text top="162" left="378" width="101" height="20" font="4"><b> </b>English language </text>
<text top="179" left="371" width="100" height="20" font="1">publication before </text>
<text top="197" left="371" width="59" height="20" font="1">Feb. 2004 </text>
<text top="216" left="371" width="7" height="18" font="1">•</text>
<text top="215" left="378" width="84" height="20" font="4"><b> </b>No concurrent </text>
<text top="232" left="371" width="73" height="20" font="1">interventions </text>
<text top="249" left="371" width="3" height="20" font="1"> </text>
<text top="267" left="371" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="284" left="371" width="95" height="20" font="1">Missing key data </text>
<text top="107" left="504" width="110" height="20" font="4"><b>Intervention:</b> Fiber </text>
<text top="124" left="504" width="97" height="20" font="1">supplementation, </text>
<text top="141" left="504" width="94" height="20" font="1">either as a pill (8 </text>
<text top="159" left="504" width="121" height="20" font="1">trials), cereal/fruit/veg </text>
<text top="176" left="504" width="110" height="20" font="1">(15 trials), Pectin (1 </text>
<text top="193" left="504" width="103" height="20" font="1">trial), Guar gum (1 </text>
<text top="210" left="504" width="27" height="20" font="1">trial) </text>
<text top="227" left="504" width="7" height="20" font="1">  </text>
<text top="245" left="504" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="262" left="504" width="59" height="20" font="1">or no fiber </text>
<text top="279" left="504" width="94" height="20" font="1">supplementation </text>
<text top="108" left="644" width="222" height="20" font="4"><b>1</b>°<b> endpoint:</b> In a pooled analysis of the </text>
<text top="125" left="644" width="176" height="20" font="1">overall group (hypertensive and </text>
<text top="143" left="644" width="204" height="20" font="1">normotensive persons), the mean for </text>
<text top="160" left="644" width="216" height="20" font="1">change in SBP was -1.15 mm Hg; 95% </text>
<text top="177" left="644" width="220" height="20" font="1">CI: -2.68–0.39 mm Hg and for DBP was </text>
<text top="194" left="644" width="219" height="20" font="1">-1.65 mm Hg; 95% CI: -2.70– -0.61 mm </text>
<text top="212" left="644" width="172" height="20" font="1">Hg. In the subgroup of 20 trials </text>
<text top="229" left="644" width="197" height="20" font="1">conducted in nonhypertensives, the </text>
<text top="246" left="644" width="222" height="20" font="1">mean change in SBP was -0.14 mm Hg; </text>
<text top="263" left="644" width="190" height="20" font="1">95% CI: -1.10–0.86 mm Hg. In the </text>
<text top="280" left="644" width="181" height="20" font="1">subgroup of 5 trials conducted in </text>
<text top="298" left="644" width="214" height="20" font="1">hypertensives, the mean change in BP </text>
<text top="315" left="644" width="224" height="20" font="1">was -5.95 mm Hg; 95% CI: -9.50– -2.40) </text>
<text top="332" left="644" width="46" height="20" font="1">mm Hg. </text>
<text top="349" left="644" width="3" height="20" font="4"><b> </b></text>
<text top="368" left="644" width="143" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A  </text>
<text top="107" left="882" width="172" height="20" font="1">● This is the most detailed and </text>
<text top="124" left="882" width="160" height="20" font="1">comprehensive review of the </text>
<text top="141" left="882" width="36" height="20" font="1">topic.  </text>
<text top="159" left="882" width="168" height="20" font="1">● It provides limited evidence, </text>
<text top="176" left="882" width="188" height="20" font="1">overall, that fiber supplementation </text>
<text top="193" left="882" width="178" height="20" font="1">results in a significant in BP and </text>
<text top="210" left="882" width="180" height="20" font="1">suggests no evidence in support </text>
<text top="228" left="882" width="164" height="20" font="1">of an effect in normotensives. </text>
<text top="404" left="98" width="87" height="20" font="1">Streppel MT, et </text>
<text top="421" left="98" width="76" height="20" font="1">al., 2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(63)</a> </text>
<text top="438" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15668359?dopt=Citation">15668359 </a></text>
<text top="404" left="216" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="421" left="216" width="138" height="20" font="1">fiber supplementation on </text>
<text top="438" left="216" width="20" height="20" font="1">BP<b> </b></text>
<text top="456" left="216" width="3" height="20" font="1"> </text>
<text top="473" left="216" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="490" left="216" width="94" height="20" font="1">review and meta-</text>
<text top="507" left="216" width="48" height="20" font="1">analysis </text>
<text top="524" left="216" width="3" height="20" font="4"><b> </b></text>
<text top="542" left="216" width="32" height="20" font="4"><b>Size: </b></text>
<text top="561" left="216" width="7" height="18" font="1">•</text>
<text top="560" left="223" width="76" height="20" font="1"> 23 RCTs (25 </text>
<text top="577" left="216" width="124" height="20" font="1">comparisons) in 1,404 </text>
<text top="594" left="216" width="20" height="20" font="1">pts </text>
<text top="613" left="216" width="7" height="18" font="1">•</text>
<text top="613" left="223" width="118" height="20" font="1"> Mean duration=9 wk </text>
<text top="632" left="216" width="7" height="18" font="1">•</text>
<text top="631" left="223" width="92" height="20" font="1"> Mean age=42 y </text>
<text top="650" left="216" width="7" height="18" font="1">•</text>
<text top="649" left="223" width="120" height="20" font="1"> 16 double-blind, with </text>
<text top="667" left="216" width="104" height="20" font="1">14 (67%) of the 21 </text>
<text top="684" left="216" width="133" height="20" font="1">comparisons conducted </text>
<text top="701" left="216" width="114" height="20" font="1">in normotensive pts  </text>
<text top="720" left="216" width="7" height="18" font="1">•</text>
<text top="719" left="223" width="127" height="20" font="1"> 3 trials based on plant </text>
<text top="737" left="216" width="141" height="20" font="1">protein and 4 trials based </text>
<text top="754" left="216" width="98" height="20" font="1">on animal protein<b> </b></text>
<text top="404" left="371" width="102" height="20" font="4"><b>Inclusion criteria </b></text>
<text top="423" left="371" width="7" height="18" font="1">•</text>
<text top="422" left="377" width="75" height="20" font="1"> Human RCT </text>
<text top="441" left="371" width="7" height="18" font="1">•</text>
<text top="441" left="377" width="70" height="20" font="1"> BP 1° or 2° </text>
<text top="458" left="371" width="51" height="20" font="1">outcome </text>
<text top="477" left="371" width="7" height="18" font="1">•</text>
<text top="476" left="377" width="73" height="20" font="1"> Publications </text>
<text top="493" left="371" width="97" height="20" font="1">between January </text>
<text top="511" left="371" width="112" height="20" font="1">1966–January 2003 </text>
<text top="528" left="371" width="3" height="20" font="1"> </text>
<text top="545" left="371" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="564" left="371" width="7" height="18" font="1">•</text>
<text top="563" left="377" width="68" height="20" font="1"> Inadequate </text>
<text top="581" left="371" width="114" height="20" font="1">reporting of the data </text>
<text top="600" left="371" width="7" height="18" font="1">•</text>
<text top="599" left="377" width="68" height="20" font="1"> Concurrent </text>
<text top="616" left="371" width="67" height="20" font="1">intervention<b> </b></text>
<text top="404" left="504" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="421" left="504" width="125" height="20" font="1">Fiber supplementation </text>
<text top="438" left="504" width="113" height="20" font="1">(average dose=11.5 </text>
<text top="456" left="504" width="111" height="20" font="1">g/d); soluble fiber in </text>
<text top="473" left="504" width="102" height="20" font="1">11 trials, insoluble </text>
<text top="490" left="504" width="118" height="20" font="1">fiber in 7 trials, and a </text>
<text top="507" left="504" width="77" height="20" font="1">mixture in the </text>
<text top="524" left="504" width="87" height="20" font="1">remaining trials </text>
<text top="542" left="504" width="3" height="20" font="1"> </text>
<text top="559" left="504" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="576" left="504" width="107" height="20" font="1">Placebo or no fiber </text>
<text top="593" left="504" width="94" height="20" font="1">supplementation<b> </b></text>
<text top="405" left="644" width="184" height="20" font="4"><b>1</b>°<b> endpoint:</b> In the overall group </text>
<text top="422" left="644" width="216" height="20" font="1">(hypertensive and normotensive pts), a </text>
<text top="440" left="644" width="192" height="20" font="1">pooled analysis identified a MD for </text>
<text top="457" left="644" width="223" height="20" font="1">change in SBP of -1.13 mm Hg; 95% CI: </text>
<text top="474" left="644" width="204" height="20" font="1">-2.49–0.23. In a subgroup of 17 trials </text>
<text top="491" left="644" width="220" height="20" font="1">conducted in “nonhypertensives” (mean </text>
<text top="508" left="644" width="206" height="20" font="1">baseline BP&lt;140/90 mm Hg or &lt;50% </text>
<text top="526" left="644" width="216" height="20" font="1">receiving antihypertensive medication), </text>
<text top="543" left="644" width="224" height="20" font="1">the mean treatment effect was -0.23 mm </text>
<text top="560" left="644" width="202" height="20" font="1">Hg; 95% CI: -1.43–0.98 in univariate </text>
<text top="577" left="644" width="201" height="20" font="1">analysis and -1.00 mm Hg; 95% CI: -</text>
<text top="594" left="644" width="188" height="20" font="1">1.94– -0.06 mm Hg in multivariate </text>
<text top="612" left="644" width="193" height="20" font="1">analysis that adjusted for age, sex, </text>
<text top="629" left="644" width="208" height="20" font="1">study design, duration of intervention, </text>
<text top="646" left="644" width="191" height="20" font="1">and fiber dose. The corresponding </text>
<text top="663" left="644" width="165" height="20" font="1">effects in 8 trials conducted in </text>
<text top="680" left="644" width="215" height="20" font="1">hypertensives were -4.53 mm Hg; 95% </text>
<text top="698" left="644" width="215" height="20" font="1">CI: -6.69– -2.38 mm Hg; and -2.42 mm </text>
<text top="715" left="644" width="182" height="20" font="1">Hg; 95% CI: -5.28–0.45 mm Hg.  </text>
<text top="732" left="644" width="3" height="20" font="1"> </text>
<text top="749" left="644" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="404" left="882" width="146" height="20" font="1">● Findings consistent with </text>
<text top="421" left="882" width="176" height="20" font="1">experience in the meta-analysis </text>
<text top="438" left="882" width="95" height="20" font="1">by Whelton et al. </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">33 </text>
<text top="107" left="98" width="95" height="20" font="1">Evans CE, et al., </text>
<text top="124" left="98" width="56" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(64)</a> </text>
<text top="141" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25668347?dopt=Citation">25668347 </a></text>
<text top="107" left="216" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="124" left="216" width="138" height="20" font="1">fiber supplementation on </text>
<text top="141" left="216" width="20" height="20" font="1">BP<b> </b></text>
<text top="159" left="216" width="3" height="20" font="1"> </text>
<text top="176" left="216" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="193" left="216" width="94" height="20" font="1">review and meta-</text>
<text top="210" left="216" width="48" height="20" font="1">analysis </text>
<text top="227" left="216" width="3" height="20" font="4"><b> </b></text>
<text top="245" left="216" width="123" height="20" font="4"><b>Size: </b>28 trials met the </text>
<text top="262" left="216" width="115" height="20" font="1">inclusion criteria and </text>
<text top="279" left="216" width="137" height="20" font="1">reported fiber intake and </text>
<text top="296" left="216" width="115" height="20" font="1">SBP and/or DBP. 18 </text>
<text top="314" left="216" width="132" height="20" font="1">trials were included in a </text>
<text top="331" left="216" width="83" height="20" font="1">meta-analysis.<b> </b></text>
<text top="107" left="371" width="102" height="20" font="4"><b>Inclusion criteria </b></text>
<text top="126" left="371" width="7" height="18" font="1">•</text>
<text top="125" left="377" width="102" height="20" font="1"> RCTs, in humans </text>
<text top="143" left="371" width="85" height="20" font="1">of at least 6 wk </text>
<text top="160" left="371" width="48" height="20" font="1">duration </text>
<text top="179" left="371" width="7" height="18" font="1">•</text>
<text top="178" left="377" width="88" height="20" font="1"> Fiber isolate or </text>
<text top="195" left="371" width="118" height="20" font="1">fiber-rich diet against </text>
<text top="213" left="371" width="115" height="20" font="1">a control or placebo  </text>
<text top="232" left="371" width="7" height="18" font="1">•</text>
<text top="231" left="377" width="111" height="20" font="1"> Published between </text>
<text top="248" left="371" width="112" height="20" font="1">1 January 1990 and </text>
<text top="266" left="371" width="105" height="20" font="1">1 December 2013. </text>
<text top="283" left="371" width="3" height="20" font="1"> </text>
<text top="300" left="371" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="317" left="371" width="24" height="20" font="1">N/A </text>
<text top="107" left="504" width="110" height="20" font="4"><b>Intervention:</b> Fiber </text>
<text top="124" left="504" width="94" height="20" font="1">supplementation </text>
<text top="141" left="504" width="117" height="20" font="1">(average dose =11.5 </text>
<text top="159" left="504" width="111" height="20" font="1">g/d) -soluble fiber in </text>
<text top="176" left="504" width="102" height="20" font="1">11 trials, insoluble </text>
<text top="193" left="504" width="118" height="20" font="1">fiber in 7 trials, and a </text>
<text top="210" left="504" width="77" height="20" font="1">mixture in the </text>
<text top="228" left="504" width="87" height="20" font="1">remaining trials </text>
<text top="245" left="504" width="3" height="20" font="1"> </text>
<text top="262" left="504" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="279" left="504" width="59" height="20" font="1">or no fiber </text>
<text top="296" left="504" width="94" height="20" font="1">supplementation </text>
<text top="108" left="644" width="217" height="20" font="4"><b>1</b>°<b> endpoint:</b> Studies were categorized </text>
<text top="125" left="644" width="207" height="20" font="1">into 1 of 12 fiber-type categories. The </text>
<text top="143" left="644" width="220" height="20" font="1">pooled estimates for all fiber types were </text>
<text top="160" left="644" width="215" height="20" font="1">-0.9 mm Hg (95% CI: -2.5–0.6 mm Hg) </text>
<text top="177" left="644" width="214" height="21" font="1">and -0.7 mm Hg (95% CI: -1.9–0.5  mm </text>
<text top="194" left="644" width="222" height="20" font="1">Hg) for SBP and DBP, respectively. The </text>
<text top="212" left="644" width="215" height="21" font="1">median difference in total fiber was 6 g. </text>
<text top="229" left="644" width="172" height="20" font="1">Analyses of specific fiber types </text>
<text top="246" left="644" width="223" height="20" font="1">concluded that diets rich in beta-glucans </text>
<text top="263" left="644" width="222" height="21" font="1">reduce SBP by 2.9 mm Hg (95% CI: 0.9, </text>
<text top="280" left="644" width="199" height="21" font="1">4.9 mm Hg) and DBP by 1.5  mm Hg </text>
<text top="298" left="644" width="216" height="21" font="1">(95% CI: 0.2–2.7  mm Hg) for a median </text>
<text top="315" left="644" width="183" height="21" font="1">difference in beta-glucans of 4  g. </text>
<text top="332" left="644" width="213" height="20" font="1">Heterogeneity for individual fiber types </text>
<text top="349" left="644" width="104" height="20" font="1">was generally low. </text>
<text top="367" left="644" width="3" height="20" font="1"> </text>
<text top="384" left="644" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="107" left="882" width="167" height="20" font="1">● Higher consumption of beta-</text>
<text top="124" left="882" width="167" height="20" font="1">glucan fiber is associated with </text>
<text top="141" left="882" width="120" height="20" font="1">lower SBP and DBP.  </text>
<text top="159" left="882" width="173" height="20" font="1">● The results of this review are </text>
<text top="176" left="882" width="185" height="20" font="1">consistent with recommendations </text>
<text top="193" left="882" width="184" height="20" font="1">to increase consumption of foods </text>
<text top="210" left="882" width="161" height="20" font="1">rich in dietary fiber, but some </text>
<text top="228" left="882" width="189" height="20" font="1">additional emphasis on sources of </text>
<text top="245" left="882" width="174" height="20" font="1">beta-glucans, such as oats and </text>
<text top="262" left="882" width="146" height="20" font="1">barley, may be warranted. </text>
<text top="402" left="108" width="3" height="20" font="4"><b> </b></text>
<text top="436" left="81" width="790" height="24" font="3"><b>Data Supplement 10. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Fish Oil) (Section 6.2) </b></text>
<text top="476" left="126" width="38" height="20" font="4"><b>Study </b></text>
<text top="493" left="115" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="510" left="121" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="528" left="99" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="476" left="231" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="493" left="235" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="510" left="229" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="476" left="369" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="476" left="515" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="493" left="547" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="510" left="515" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="528" left="550" width="55" height="20" font="4"><b>patients) </b></text>
<text top="476" left="715" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="493" left="699" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="510" left="680" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="477" left="895" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="494" left="927" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="512" left="935" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="546" left="98" width="83" height="20" font="1">Campbell F, et </text>
<text top="563" left="98" width="76" height="20" font="1">al., 2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(65)</a> </text>
<text top="580" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22345681?dopt=Citation">22345681 </a></text>
<text top="546" left="206" width="119" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="563" left="206" width="52" height="20" font="1">of fish oil </text>
<text top="580" left="206" width="131" height="20" font="1">supplementation on BP<b> </b></text>
<text top="597" left="206" width="3" height="20" font="1"> </text>
<text top="614" left="206" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="632" left="206" width="126" height="20" font="1">Systematic review and </text>
<text top="649" left="206" width="79" height="20" font="1">meta-analysis </text>
<text top="666" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="683" left="206" width="32" height="20" font="4"><b>Size: </b></text>
<text top="702" left="206" width="7" height="18" font="1">•</text>
<text top="702" left="213" width="76" height="20" font="1"> 17 RCTs (25 </text>
<text top="719" left="206" width="102" height="20" font="1">comparisons) with </text>
<text top="736" left="206" width="57" height="20" font="1">1,524 pts.<b> </b></text>
<text top="755" left="206" width="7" height="18" font="1">•</text>
<text top="755" left="213" width="73" height="20" font="1"> 9 trials were </text>
<text top="772" left="206" width="73" height="20" font="1">conducted in </text>
<text top="789" left="206" width="122" height="20" font="1">normotensives (1,049 </text>
<text top="546" left="352" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="565" left="352" width="7" height="18" font="1">•</text>
<text top="564" left="358" width="32" height="20" font="1"> RCT </text>
<text top="583" left="352" width="7" height="18" font="1">•</text>
<text top="582" left="358" width="101" height="20" font="1"> English language </text>
<text top="600" left="352" width="100" height="20" font="1">publication before </text>
<text top="617" left="352" width="78" height="20" font="1">January 2011 </text>
<text top="636" left="352" width="7" height="18" font="1">•</text>
<text top="635" left="358" width="90" height="20" font="1"> Duration ≥8 wk </text>
<text top="652" left="352" width="3" height="20" font="1"> </text>
<text top="670" left="352" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="546" left="511" width="120" height="20" font="4"><b>Intervention:</b> Fish oil </text>
<text top="563" left="511" width="123" height="20" font="1">given in capsule form, </text>
<text top="580" left="511" width="132" height="20" font="1">with doses varying from </text>
<text top="597" left="511" width="82" height="20" font="1">0.8–13.33 g/d. </text>
<text top="614" left="511" width="7" height="20" font="1">  </text>
<text top="632" left="511" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="649" left="511" width="121" height="20" font="1">(usually corn oil, olive </text>
<text top="666" left="511" width="109" height="20" font="1">oil, or safflower oil). </text>
<text top="547" left="657" width="202" height="20" font="4"><b>1</b>°<b> endpoint:</b> In a pooled analysis of </text>
<text top="564" left="657" width="206" height="20" font="1">the 8 trials conducted in hypertensive </text>
<text top="581" left="657" width="210" height="20" font="1">pts, the mean for change in SBP was -</text>
<text top="598" left="657" width="215" height="20" font="1">2.56 mm Hg; 95% CI: -4.53– -0.58 mm </text>
<text top="616" left="657" width="218" height="20" font="1">Hg. The corresponding SBP change for </text>
<text top="633" left="657" width="217" height="20" font="1">the 9 trials conducted in normotensives </text>
<text top="650" left="657" width="219" height="20" font="1">was -0.50 mm Hg; 95% CI: -1.44– 0.45. </text>
<text top="546" left="890" width="153" height="20" font="1">● This is the most recent of </text>
<text top="563" left="890" width="181" height="20" font="1">many that have been published.  </text>
<text top="580" left="890" width="177" height="20" font="1">● Previous meta-analyses have </text>
<text top="597" left="890" width="169" height="20" font="1">been conducted by Appel et al </text>
<text top="615" left="890" width="153" height="20" font="1">(1993), Morris et al. (1993), </text>
<text top="632" left="890" width="144" height="20" font="1">Geleijnse et al (2002) and </text>
<text top="649" left="890" width="133" height="20" font="1">Dickinson et al. (2006).  </text>
<text top="666" left="890" width="170" height="20" font="1">● In general, the findings have </text>
<text top="683" left="890" width="132" height="20" font="1">been fairly consistent in </text>
<text top="701" left="890" width="175" height="20" font="1">demonstrating a relatively small </text>
<text top="718" left="890" width="131" height="20" font="1">(2 3/4 mm Hg SBP) but </text>
<text top="735" left="890" width="164" height="20" font="1">significant effect, with most of </text>
<text top="752" left="890" width="154" height="20" font="1">this being attributable to the </text>
<text top="770" left="890" width="155" height="20" font="1">results in trials conducted in </text>
<text top="787" left="890" width="96" height="20" font="1">hypertensive pts. </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">34 </text>
<text top="107" left="206" width="117" height="20" font="1">pts with mean age of </text>
<text top="124" left="206" width="128" height="20" font="1">47 y). Follow-up varied </text>
<text top="141" left="206" width="56" height="20" font="1">2–26 wk.  </text>
<text top="159" left="98" width="60" height="20" font="1">Rodriguez-</text>
<text top="177" left="98" width="85" height="20" font="1">Leyva D, et al., </text>
<text top="194" left="98" width="56" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(66)</a> </text>
<text top="211" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24126178?dopt=Citation">24126178</a></text>
<text top="211" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24126178?dopt=Citation"> </a></text>
<text top="159" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="177" left="206" width="113" height="20" font="1">of flaxseed on BP in </text>
<text top="194" left="206" width="93" height="20" font="1">hypertensive pts<b> </b></text>
<text top="211" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="228" left="206" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="245" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="263" left="206" width="130" height="20" font="4"><b>Size: </b>110 pts with PAD<b> </b></text>
<text top="159" left="352" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="178" left="352" width="7" height="18" font="1">•</text>
<text top="178" left="358" width="41" height="20" font="1"> &gt;40 y  </text>
<text top="197" left="352" width="7" height="18" font="1">•</text>
<text top="196" left="358" width="114" height="20" font="1"> PAD for &gt;6 mo, ABI </text>
<text top="213" left="352" width="28" height="20" font="1">&lt;0.9 </text>
<text top="231" left="352" width="3" height="20" font="1"> </text>
<text top="248" left="352" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="265" left="352" width="126" height="20" font="1">Inability to walk, bowel </text>
<text top="282" left="352" width="118" height="20" font="1">disease, moderate to </text>
<text top="300" left="352" width="130" height="20" font="1">severe renal failure, life </text>
<text top="317" left="352" width="145" height="20" font="1">expectancy &lt;2 y with high </text>
<text top="334" left="352" width="145" height="20" font="1">cardiac risk, allergy to any </text>
<text top="351" left="352" width="141" height="20" font="1">of the study products, pts </text>
<text top="368" left="352" width="115" height="20" font="1">who plan to undergo </text>
<text top="386" left="352" width="143" height="20" font="1">surgery during the course </text>
<text top="403" left="352" width="133" height="20" font="1">of the trial, and no more </text>
<text top="420" left="352" width="136" height="20" font="1">than 2 fish meals per wk </text>
<text top="159" left="511" width="132" height="20" font="4"><b>Intervention:</b> Pts given </text>
<text top="177" left="511" width="127" height="20" font="1">1 food item per day for </text>
<text top="194" left="511" width="128" height="20" font="1">6 mo, containing either </text>
<text top="211" left="511" width="129" height="20" font="1">30 g of milled flax seed </text>
<text top="228" left="511" width="118" height="20" font="1">or placebo. Flaxseed </text>
<text top="246" left="511" width="128" height="20" font="1">contains omega-3 fatty </text>
<text top="263" left="511" width="105" height="20" font="1">acids, lignans, and </text>
<text top="280" left="511" width="31" height="20" font="1">fiber. </text>
<text top="297" left="511" width="3" height="20" font="1"> </text>
<text top="314" left="511" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="161" left="657" width="156" height="20" font="4"><b>1</b>°<b> endpoint:</b> SBP and DBP </text>
<text top="178" left="657" width="211" height="20" font="1">consistently decreased in the flaxseed </text>
<text top="195" left="657" width="194" height="20" font="1">group over the course of the study. </text>
<text top="212" left="657" width="209" height="20" font="1">After 6 mo, SBP in the flaxseed group </text>
<text top="229" left="657" width="218" height="20" font="1">dropped significantly to 136±22 mm Hg </text>
<text top="247" left="657" width="178" height="20" font="1">(p=0.04). On the contrary, in the </text>
<text top="264" left="657" width="195" height="20" font="1">placebo group, SBP rose slightly to </text>
<text top="281" left="657" width="166" height="20" font="1">146±21 mm Hg. After 6 mo of </text>
<text top="298" left="657" width="217" height="20" font="1">intervention, DBP in the flaxseed group </text>
<text top="316" left="657" width="175" height="20" font="1">fell to 72±11 mm Hg (p=0.004), </text>
<text top="333" left="657" width="194" height="20" font="1">whereas DBP in the placebo group </text>
<text top="350" left="657" width="202" height="20" font="1">remained the same (79±10 mm Hg). </text>
<text top="159" left="890" width="182" height="20" font="1">● Based on this 1 RCT, flaxseed </text>
<text top="177" left="890" width="167" height="20" font="1">appeared to have a significant </text>
<text top="194" left="890" width="103" height="20" font="1">BP lowering effect </text>
<text top="439" left="108" width="3" height="19" font="1"> </text>
<text top="474" left="81" width="980" height="24" font="3"><b>Data Supplement 11. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Potassium Supplementation to Placebo or Usual </b></text>
<text top="498" left="81" width="129" height="24" font="3"><b>Diet) (Section 6.2) </b></text>
<text top="537" left="126" width="38" height="20" font="4"><b>Study </b></text>
<text top="554" left="114" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="572" left="121" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="589" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="537" left="220" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="554" left="225" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="572" left="219" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="537" left="336" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="537" left="477" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="554" left="509" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="572" left="477" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="589" left="512" width="55" height="20" font="4"><b>patients) </b></text>
<text top="537" left="657" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="554" left="641" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="572" left="633" width="154" height="20" font="4"><b>P value; OR or RR; &amp; 95% </b></text>
<text top="589" left="700" width="20" height="20" font="4"><b>CI) </b></text>
<text top="538" left="852" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="556" left="885" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="573" left="892" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="607" left="98" width="85" height="20" font="1">Whelton PK, et </text>
<text top="624" left="98" width="76" height="20" font="1">al., 1997 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(67)</a> </text>
<text top="641" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9168293?dopt=Citation">9168293</a></text>
<text top="641" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9168293?dopt=Citation"> </a></text>
<text top="607" left="204" width="86" height="20" font="4"><b>Aim: </b>Study the </text>
<text top="624" left="204" width="107" height="20" font="1">effect of potassium </text>
<text top="641" left="204" width="111" height="20" font="1">supplementation on </text>
<text top="658" left="204" width="20" height="20" font="1">BP<b> </b></text>
<text top="676" left="204" width="3" height="20" font="1"> </text>
<text top="693" left="204" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="710" left="204" width="102" height="20" font="1">Systematic review </text>
<text top="727" left="204" width="103" height="20" font="1">and meta-analysis </text>
<text top="744" left="204" width="3" height="20" font="1"> </text>
<text top="762" left="204" width="32" height="20" font="4"><b>Size: </b></text>
<text top="607" left="332" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="626" left="332" width="7" height="18" font="1">•</text>
<text top="625" left="338" width="75" height="20" font="1"> Human RCT </text>
<text top="644" left="332" width="7" height="18" font="1">•</text>
<text top="643" left="338" width="77" height="20" font="1"> Without HTN </text>
<text top="663" left="332" width="7" height="18" font="1">•</text>
<text top="662" left="338" width="64" height="20" font="1"> Potassium </text>
<text top="679" left="332" width="113" height="20" font="1">supplementation vs. </text>
<text top="696" left="332" width="40" height="20" font="1">control </text>
<text top="715" left="332" width="7" height="18" font="1">•</text>
<text top="715" left="338" width="84" height="20" font="1"> No concurrent </text>
<text top="732" left="332" width="73" height="20" font="1">interventions </text>
<text top="749" left="332" width="3" height="20" font="4"><b> </b></text>
<text top="766" left="332" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="784" left="332" width="95" height="20" font="1">Missing key data<b> </b></text>
<text top="607" left="465" width="139" height="20" font="4"><b>Intervention:</b> Potassium </text>
<text top="624" left="465" width="141" height="20" font="1">supplementation in 1,049 </text>
<text top="641" left="465" width="130" height="20" font="1">pts (potassium chloride </text>
<text top="658" left="465" width="141" height="20" font="1">tabs in 10 RCTs with 618 </text>
<text top="676" left="465" width="144" height="20" font="1">pts and diet in 2 RCT with </text>
<text top="693" left="465" width="48" height="20" font="1">431 pts) </text>
<text top="710" left="465" width="3" height="20" font="1"> </text>
<text top="727" left="465" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="744" left="465" width="78" height="20" font="1">No potassium </text>
<text top="762" left="465" width="94" height="20" font="1">supplementation </text>
<text top="608" left="627" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="627" left="627" width="7" height="18" font="1">•</text>
<text top="626" left="633" width="154" height="20" font="1"> Significant reduction in BP. </text>
<text top="645" left="627" width="7" height="18" font="1">•</text>
<text top="645" left="633" width="153" height="20" font="1"> Overall (hypertensives and </text>
<text top="662" left="627" width="156" height="20" font="1">normotensives), mean: 3.11 </text>
<text top="679" left="627" width="163" height="20" font="1">mm Hg; 95% CI: -4.32– -1.91 </text>
<text top="696" left="627" width="46" height="20" font="1">mm Hg. </text>
<text top="715" left="627" width="7" height="18" font="1">•</text>
<text top="715" left="633" width="157" height="20" font="1"> In the 12 trials conducted in </text>
<text top="732" left="627" width="149" height="20" font="1">normotensives, mean: -1.8 </text>
<text top="749" left="627" width="150" height="20" font="1">mm Hg; 95% CI: -2.9– -0.6 </text>
<text top="766" left="627" width="161" height="20" font="1">mm Hg for SBP and -1.0 mm </text>
<text top="784" left="627" width="165" height="20" font="1">Hg; 95% CI: -2.1–0.0 for DBP </text>
<text top="609" left="806" width="7" height="18" font="1">•</text>
<text top="608" left="813" width="251" height="20" font="1"> This is the most comprehensive presentation </text>
<text top="625" left="806" width="239" height="20" font="1">of the effects of potassium on BP, including </text>
<text top="642" left="806" width="163" height="20" font="1">experience in normotensives. </text>
<text top="661" left="806" width="7" height="18" font="1">•</text>
<text top="661" left="813" width="256" height="20" font="1"> Significant reduction in SBP overall and in the </text>
<text top="678" left="806" width="185" height="20" font="1">subgroups with and without HTN. </text>
<text top="697" left="806" width="7" height="18" font="1">•</text>
<text top="696" left="813" width="237" height="20" font="1"> In a subsequent meta-analysis of 23 trials, </text>
<text top="713" left="806" width="262" height="20" font="1">Geleijnse JM, Kok FJ, and Grobbee DE (J Hum </text>
<text top="731" left="806" width="262" height="20" font="1">Hypertens. 2003;17:471-480) reported a similar </text>
<text top="748" left="806" width="192" height="20" font="1">effect of potassium on SBP in both </text>
<text top="765" left="806" width="259" height="20" font="1">hypertensives and nonhypertensives (mean of -</text>
<text top="782" left="806" width="195" height="20" font="1">3.2 and -1.4 mm Hg, respectively).  </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="11" size="12" family="Times" color="#0a0905"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">35 </text>
<text top="109" left="204" width="7" height="18" font="1">•</text>
<text top="108" left="211" width="95" height="20" font="1"> Overall, 33 RCT </text>
<text top="125" left="204" width="60" height="20" font="1">(n=2,609)  </text>
<text top="144" left="204" width="7" height="18" font="1">•</text>
<text top="144" left="211" width="105" height="20" font="1"> 2 RCTs (n=1,049) </text>
<text top="161" left="204" width="96" height="20" font="1">in normotensives<b> </b></text>
<text top="107" left="465" width="133" height="20" font="1">(placebo in 10 RCT and </text>
<text top="124" left="465" width="112" height="20" font="1">usual diet in 2 RCT)<b> </b></text>
<text top="109" left="627" width="7" height="18" font="1">•</text>
<text top="108" left="633" width="157" height="20" font="1"> In the 20 trials conducted in </text>
<text top="125" left="627" width="145" height="20" font="1">hypertensives, mean: -4.4 </text>
<text top="143" left="627" width="150" height="20" font="1">mm Hg; 95% CI: -6.6– -2.2 </text>
<text top="160" left="627" width="141" height="20" font="1">for SBP and -2.5 mm Hg; </text>
<text top="177" left="627" width="150" height="20" font="1">95% CI: -4.9– -0.1 for DBP </text>
<text top="194" left="627" width="3" height="20" font="1"> </text>
<text top="211" left="627" width="127" height="20" font="4"><b>Safety endpoint:</b> N/A  </text>
<text top="109" left="806" width="7" height="18" font="1">•</text>
<text top="108" left="813" width="244" height="20" font="1"> The 1 RCT conducted in African-Americans </text>
<text top="125" left="806" width="264" height="20" font="1">(n=87) identified a mean treatment effect size of </text>
<text top="143" left="806" width="4" height="20" font="1">-</text>
<text top="143" left="810" width="135" height="20" font="11">6.9 mm Hg; 95% CI: -9.3</text>
<text top="143" left="945" width="7" height="20" font="1">–</text>
<text top="143" left="952" width="74" height="20" font="11"> -4.4 for SBP </text>
<text top="160" left="806" width="220" height="20" font="11">(p&lt;0.001) and -2.5 mm Hg; 95% CI: -4.3</text>
<text top="160" left="1025" width="7" height="20" font="1">–</text>
<text top="160" left="1032" width="28" height="20" font="11"> -0.8 </text>
<text top="177" left="806" width="106" height="20" font="11">for DBP (p=0.004). </text>
<text top="196" left="806" width="7" height="18" font="1">•</text>
<text top="195" left="813" width="261" height="20" font="1"> In the entire cohort (trials conducted in pts with </text>
<text top="213" left="806" width="249" height="20" font="1">HTN and normotension), net changes in SBP </text>
<text top="230" left="806" width="263" height="20" font="1">and DBP were directly related to level of urinary </text>
<text top="247" left="806" width="181" height="20" font="1">sodium excretion during the trial. </text>
<text top="265" left="98" width="75" height="20" font="1">Aburto NJ, et </text>
<text top="282" left="98" width="76" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(68)</a> </text>
<text top="299" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23558164?dopt=Citation">23558164</a></text>
<text top="299" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23558164?dopt=Citation"> </a></text>
<text top="265" left="204" width="85" height="20" font="4"><b>Aim</b>: Study the </text>
<text top="282" left="204" width="107" height="20" font="1">effect of potassium </text>
<text top="299" left="204" width="111" height="20" font="1">supplementation on </text>
<text top="317" left="204" width="20" height="20" font="1">BP </text>
<text top="334" left="204" width="3" height="20" font="1"> </text>
<text top="351" left="204" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="368" left="204" width="102" height="20" font="1">Systematic review </text>
<text top="386" left="204" width="103" height="20" font="1">and meta-analysis </text>
<text top="403" left="204" width="3" height="20" font="1"> </text>
<text top="420" left="204" width="83" height="20" font="4"><b>Size</b>: 21 RCTs </text>
<text top="437" left="204" width="110" height="20" font="1">(n=1,892); 16 in pts </text>
<text top="454" left="204" width="100" height="20" font="1">with HTN (n=818) </text>
<text top="472" left="204" width="102" height="20" font="1">and 3 RCTs in pts </text>
<text top="489" left="204" width="71" height="20" font="1">without HTN </text>
<text top="506" left="204" width="49" height="20" font="1">(n=757)  </text>
<text top="265" left="332" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="284" left="332" width="7" height="18" font="1">•</text>
<text top="283" left="338" width="92" height="20" font="1"> RCT in humans </text>
<text top="303" left="332" width="7" height="18" font="1">•</text>
<text top="302" left="338" width="90" height="20" font="1"> Duration ≥4 wk </text>
<text top="321" left="332" width="7" height="18" font="1">•</text>
<text top="320" left="338" width="106" height="20" font="1"> 24-h collections of </text>
<text top="337" left="332" width="104" height="20" font="1">urinary potassium  </text>
<text top="356" left="332" width="7" height="18" font="1">•</text>
<text top="356" left="338" width="92" height="20" font="1"> No concomitant </text>
<text top="373" left="332" width="73" height="20" font="1">interventions </text>
<text top="390" left="332" width="3" height="20" font="1"> </text>
<text top="407" left="332" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="425" left="332" width="120" height="20" font="1">Pts who were acutely </text>
<text top="442" left="332" width="87" height="20" font="1">ill, HIV positive, </text>
<text top="459" left="332" width="110" height="20" font="1">hospitalized, or had </text>
<text top="476" left="332" width="92" height="20" font="1">impaired urinary </text>
<text top="493" left="332" width="67" height="20" font="1">excretion of </text>
<text top="511" left="332" width="63" height="20" font="1">potassium  </text>
<text top="265" left="465" width="138" height="20" font="4"><b>Intervention</b>: Potassium </text>
<text top="282" left="465" width="124" height="20" font="1">supplementation in 20 </text>
<text top="299" left="465" width="132" height="20" font="1">trials, supplements plus </text>
<text top="317" left="465" width="130" height="20" font="1">diet/education in 1 trial, </text>
<text top="334" left="465" width="137" height="20" font="1">and diet/education alone </text>
<text top="351" left="465" width="60" height="20" font="1">in 2 trials.  </text>
<text top="368" left="465" width="7" height="20" font="1">  </text>
<text top="386" left="465" width="96" height="20" font="4"><b>Comparator</b>: No </text>
<text top="403" left="465" width="59" height="20" font="1">potassium </text>
<text top="420" left="465" width="94" height="20" font="1">supplementation </text>
<text top="437" left="465" width="125" height="20" font="1">(placebo or usual diet) </text>
<text top="266" left="627" width="78" height="20" font="4"><b>1</b>°<b> endpoint</b>:  </text>
<text top="285" left="627" width="7" height="18" font="1">•</text>
<text top="285" left="633" width="138" height="20" font="1"> Overall change in SBP=-</text>
<text top="302" left="627" width="158" height="20" font="1">5.93; 95% CI: -10.15– -1.70. </text>
<text top="319" left="627" width="153" height="20" font="1">After removing outlier trials, </text>
<text top="336" left="627" width="145" height="20" font="1">the change was -3.49 mm </text>
<text top="354" left="627" width="163" height="20" font="1">Hg; 95% CI: -5.15– -1.82 mm </text>
<text top="371" left="627" width="22" height="20" font="1">Hg. </text>
<text top="390" left="627" width="7" height="18" font="1">•</text>
<text top="389" left="633" width="137" height="20" font="1"> In 16 trials conducted in </text>
<text top="406" left="627" width="139" height="20" font="1">hypertensives, change in </text>
<text top="423" left="627" width="159" height="20" font="1">SBP was -5.32 mm Hg; 95% </text>
<text top="441" left="627" width="92" height="20" font="1">CI: -7.20– -3.43. </text>
<text top="460" left="627" width="7" height="18" font="1">•</text>
<text top="459" left="633" width="150" height="20" font="1"> In the 3 trials conducted in </text>
<text top="476" left="627" width="165" height="20" font="1">persons without HTN, change </text>
<text top="493" left="627" width="140" height="20" font="1">in SBP was 0.09 mm Hg; </text>
<text top="511" left="627" width="113" height="20" font="1">95% CI: -0.77–0.95. </text>
<text top="528" left="627" width="3" height="20" font="1"> </text>
<text top="545" left="627" width="127" height="20" font="4"><b>Safety endpoint</b>: N/A  </text>
<text top="267" left="806" width="7" height="18" font="1">•</text>
<text top="266" left="813" width="233" height="20" font="1"> 1 trial (TOHP Phase I) incorrectly entered </text>
<text top="283" left="806" width="257" height="20" font="1">twice so only 2 trials really available. However, </text>
<text top="301" left="806" width="200" height="20" font="1">this does not change overall finding. </text>
<text top="320" left="806" width="7" height="18" font="1">•</text>
<text top="319" left="813" width="254" height="20" font="1"> The negative results for normotensives in this </text>
<text top="336" left="806" width="256" height="20" font="1">meta-analysis (and difference with the findings </text>
<text top="354" left="806" width="210" height="20" font="1">by Whelton et al) probably reflects the </text>
<text top="371" left="806" width="263" height="20" font="1">requirement for a duration of ≥4 wk and the fact </text>
<text top="388" left="806" width="221" height="20" font="1">that few trials of this duration have been </text>
<text top="405" left="806" width="160" height="20" font="1">conducted in normotensives. </text>
<text top="563" left="98" width="91" height="20" font="1">Geleijnse JM, et </text>
<text top="580" left="98" width="79" height="20" font="1">al., 2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(69)</a>  </text>
<text top="597" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12821954">12821954</a></text>
<text top="597" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12821954"> </a></text>
<text top="563" left="204" width="85" height="20" font="4"><b>Aim</b>: Study the </text>
<text top="580" left="204" width="107" height="20" font="1">effect of potassium </text>
<text top="597" left="204" width="111" height="20" font="1">supplementation on </text>
<text top="615" left="204" width="20" height="20" font="1">BP </text>
<text top="632" left="204" width="3" height="20" font="1"> </text>
<text top="649" left="204" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="666" left="204" width="102" height="20" font="1">Systematic review </text>
<text top="683" left="204" width="55" height="20" font="1">and meta-</text>
<text top="701" left="204" width="109" height="20" font="1">regression analysis </text>
<text top="718" left="204" width="3" height="20" font="1"> </text>
<text top="735" left="204" width="104" height="20" font="4"><b>Size</b>: 27 RCTs; 19 </text>
<text top="752" left="204" width="110" height="20" font="1">in pts with HTN and </text>
<text top="770" left="204" width="85" height="20" font="1">11 RCTs in pts </text>
<text top="787" left="204" width="71" height="20" font="1">without HTN </text>
<text top="563" left="332" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="582" left="332" width="7" height="18" font="1">•</text>
<text top="581" left="338" width="81" height="20" font="1"> RCT in adults </text>
<text top="600" left="332" width="7" height="18" font="1">•</text>
<text top="600" left="338" width="89" height="20" font="1"> Published after </text>
<text top="617" left="332" width="31" height="20" font="1">1966 </text>
<text top="636" left="332" width="7" height="18" font="1">•</text>
<text top="635" left="338" width="90" height="20" font="1"> Duration ≥2 wk </text>
<text top="654" left="332" width="7" height="18" font="1">•</text>
<text top="654" left="338" width="92" height="20" font="1"> No concomitant </text>
<text top="671" left="332" width="73" height="20" font="1">interventions </text>
<text top="688" left="332" width="3" height="20" font="1"> </text>
<text top="705" left="332" width="113" height="20" font="4"><b>Exclusion criteria</b>:  </text>
<text top="724" left="332" width="7" height="18" font="1">•</text>
<text top="724" left="338" width="51" height="20" font="1"> Disease </text>
<text top="743" left="332" width="7" height="18" font="1">•</text>
<text top="742" left="338" width="97" height="20" font="1"> Outlier results (1 </text>
<text top="759" left="332" width="27" height="20" font="1">trial) </text>
<text top="563" left="465" width="138" height="20" font="4"><b>Intervention</b>: Potassium </text>
<text top="580" left="465" width="97" height="20" font="1">supplementation  </text>
<text top="597" left="465" width="7" height="20" font="1">  </text>
<text top="615" left="465" width="96" height="20" font="4"><b>Comparator</b>: No </text>
<text top="632" left="465" width="59" height="20" font="1">potassium </text>
<text top="649" left="465" width="94" height="20" font="1">supplementation </text>
<text top="564" left="627" width="78" height="20" font="4"><b>1</b>°<b> endpoint</b>:  </text>
<text top="583" left="627" width="7" height="18" font="1">•</text>
<text top="583" left="633" width="138" height="20" font="1"> Overall change in SBP=-</text>
<text top="600" left="627" width="151" height="20" font="1">2.42; 95% CI: -3.75– -1.08  </text>
<text top="619" left="627" width="7" height="18" font="1">•</text>
<text top="618" left="633" width="157" height="20" font="1"> In the 19 trials conducted in </text>
<text top="635" left="627" width="139" height="20" font="1">hypertensives, change in </text>
<text top="653" left="627" width="159" height="20" font="1">SBP was -3.51 mm Hg; 95% </text>
<text top="670" left="627" width="89" height="20" font="1">CI: -5.31– -1.72 </text>
<text top="689" left="627" width="7" height="18" font="1">•</text>
<text top="688" left="633" width="150" height="20" font="1"> In the 3 trials conducted in </text>
<text top="705" left="627" width="165" height="20" font="1">persons without HTN, change </text>
<text top="723" left="627" width="140" height="20" font="1">in SBP was 0.97 mm Hg; </text>
<text top="740" left="627" width="109" height="20" font="1">95% CI: -3.07–1.14 </text>
<text top="757" left="627" width="3" height="20" font="1"> </text>
<text top="774" left="627" width="123" height="20" font="4"><b>Safety endpoint</b>: N/A </text>
<text top="565" left="806" width="7" height="18" font="1">•</text>
<text top="564" left="813" width="155" height="20" font="1"> Imputation for missing data </text>
<text top="583" left="806" width="7" height="18" font="1">•</text>
<text top="583" left="813" width="261" height="20" font="1"> In addition to the treatment effect difference by </text>
<text top="600" left="806" width="248" height="20" font="1">presence/absence of HTN, there was a trend </text>
<text top="617" left="806" width="242" height="20" font="1">toward a larger treatment effect in older age </text>
<text top="634" left="806" width="254" height="20" font="1">(≥45 y), and to a lesser extent higher baseline </text>
<text top="651" left="806" width="227" height="20" font="1">urinary Na (&gt;150 mmol/24 h) and greater </text>
<text top="669" left="806" width="209" height="20" font="1">increase in urinary K (&gt;44 mmol/24 h)<b> </b></text>
<text top="686" left="779" width="4" height="24" font="3"><b> </b></text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">36 </text>
<text top="108" left="108" width="3" height="19" font="1"> </text>
<text top="142" left="81" width="880" height="24" font="3"><b>Data Supplement 12. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Protein Intake on BP) (Section 6.2) </b></text>
<text top="182" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="199" left="128" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="216" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="182" left="245" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="199" left="250" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="216" left="244" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="182" left="386" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="182" left="534" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="199" left="566" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="216" left="535" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="233" left="570" width="55" height="20" font="4"><b>patients) </b></text>
<text top="182" left="737" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="199" left="720" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="216" left="726" width="129" height="20" font="4"><b>P value; OR or RR; &amp;  </b></text>
<text top="233" left="765" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="183" left="926" width="143" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="200" left="981" width="33" height="20" font="4"><b>any); </b></text>
<text top="217" left="942" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="235" left="949" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="253" left="98" width="108" height="20" font="1">Rebholz CM, et al., </text>
<text top="270" left="98" width="56" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(70)</a> </text>
<text top="287" left="98" width="62" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23035142?dopt=Citation">23035142  </a></text>
<text top="253" left="219" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="270" left="219" width="114" height="20" font="1">protein intake on BP<b> </b></text>
<text top="287" left="219" width="3" height="20" font="1"> </text>
<text top="304" left="219" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="321" left="219" width="94" height="20" font="1">review and meta-</text>
<text top="339" left="219" width="48" height="20" font="1">analysis </text>
<text top="356" left="219" width="3" height="20" font="4"><b> </b></text>
<text top="373" left="219" width="32" height="20" font="4"><b>Size: </b></text>
<text top="392" left="219" width="7" height="18" font="1">•</text>
<text top="391" left="226" width="76" height="20" font="1"> 40 RCTs (44 </text>
<text top="409" left="219" width="102" height="20" font="1">comparisons) with </text>
<text top="426" left="219" width="54" height="20" font="1">3,277 pts </text>
<text top="445" left="219" width="7" height="18" font="1">•</text>
<text top="444" left="226" width="107" height="20" font="1"> 32 comparisons of </text>
<text top="462" left="219" width="135" height="20" font="1">protein vs. carbohydrate </text>
<text top="481" left="219" width="7" height="18" font="1">•</text>
<text top="480" left="226" width="107" height="20" font="1"> 12 comparisons of </text>
<text top="497" left="219" width="115" height="20" font="1">vegetable vs. animal </text>
<text top="514" left="219" width="41" height="20" font="1">protein </text>
<text top="533" left="219" width="7" height="18" font="1">•</text>
<text top="533" left="226" width="120" height="20" font="1"> 35 of the RCTs were </text>
<text top="550" left="219" width="73" height="20" font="1">conducted in </text>
<text top="567" left="219" width="124" height="20" font="1">normotensive persons </text>
<text top="584" left="219" width="108" height="20" font="1">(28 with SBP in the </text>
<text top="602" left="219" width="130" height="20" font="1">prehypertensive range) </text>
<text top="253" left="368" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="272" left="368" width="7" height="18" font="1">•</text>
<text top="271" left="374" width="92" height="20" font="1"> RCT in humans </text>
<text top="290" left="368" width="7" height="18" font="1">•</text>
<text top="289" left="374" width="38" height="20" font="1"> ≥18 y </text>
<text top="308" left="368" width="7" height="18" font="1">•</text>
<text top="308" left="374" width="117" height="20" font="1"> Publication between </text>
<text top="325" left="368" width="140" height="20" font="1">January 1,1950 and April </text>
<text top="342" left="368" width="44" height="20" font="1">1, 2011 </text>
<text top="361" left="368" width="7" height="18" font="1">•</text>
<text top="361" left="374" width="84" height="20" font="1"> No concurrent </text>
<text top="378" left="368" width="73" height="20" font="1">interventions </text>
<text top="397" left="368" width="7" height="18" font="1">•</text>
<text top="396" left="374" width="109" height="20" font="1"> No more than 10% </text>
<text top="413" left="368" width="120" height="20" font="1">difference in calories, </text>
<text top="431" left="368" width="137" height="20" font="1">sodium, potassium, fiber </text>
<text top="448" left="368" width="126" height="20" font="1">between the treatment </text>
<text top="465" left="368" width="31" height="20" font="1">arms </text>
<text top="484" left="368" width="7" height="18" font="1">•</text>
<text top="483" left="374" width="90" height="20" font="1"> Duration ≥1 wk </text>
<text top="501" left="368" width="3" height="20" font="1"> </text>
<text top="518" left="368" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="535" left="368" width="95" height="20" font="1">Missing key data </text>
<text top="253" left="530" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="272" left="530" width="7" height="18" font="1">•</text>
<text top="271" left="536" width="82" height="20" font="1"> Protein intake </text>
<text top="290" left="530" width="7" height="18" font="1">•</text>
<text top="289" left="536" width="10" height="20" font="1"> 1</text>
<text top="291" left="547" width="6" height="13" font="6">st</text>
<text top="289" left="553" width="109" height="20" font="1"> meta-analysis: any </text>
<text top="307" left="530" width="134" height="20" font="1">source of protein, with a </text>
<text top="324" left="530" width="85" height="20" font="1">median protein </text>
<text top="341" left="530" width="124" height="20" font="1">supplementation dose </text>
<text top="358" left="530" width="118" height="20" font="1">of 40 g/d (20–66 g/d) </text>
<text top="377" left="530" width="7" height="18" font="1">•</text>
<text top="377" left="536" width="10" height="20" font="1"> 2</text>
<text top="378" left="547" width="9" height="13" font="6">nd</text>
<text top="377" left="556" width="86" height="20" font="1"> meta-analysis: </text>
<text top="394" left="530" width="134" height="20" font="1">specifically vegetable or </text>
<text top="411" left="530" width="81" height="20" font="1">animal protein </text>
<text top="428" left="530" width="7" height="20" font="1">  </text>
<text top="445" left="530" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="465" left="530" width="7" height="18" font="1">•</text>
<text top="464" left="536" width="10" height="20" font="1"> 1</text>
<text top="466" left="547" width="6" height="13" font="6">st</text>
<text top="464" left="553" width="86" height="20" font="1"> meta-analysis: </text>
<text top="481" left="530" width="75" height="20" font="1">carbohydrate </text>
<text top="500" left="530" width="7" height="18" font="1">•</text>
<text top="499" left="536" width="10" height="20" font="1"> 2</text>
<text top="501" left="547" width="9" height="13" font="6">nd</text>
<text top="499" left="556" width="86" height="20" font="1"> meta-analysis: </text>
<text top="517" left="530" width="111" height="20" font="1">vegetable or animal </text>
<text top="534" left="530" width="41" height="20" font="1">protein<b> </b></text>
<text top="254" left="678" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="273" left="678" width="7" height="18" font="1">•</text>
<text top="272" left="685" width="10" height="20" font="1"> 1</text>
<text top="274" left="695" width="6" height="13" font="6">st</text>
<text top="272" left="701" width="83" height="20" font="1"> meta-analysis </text>
<text top="289" left="678" width="212" height="20" font="1"> There was a fairly consistent trend for </text>
<text top="307" left="678" width="200" height="20" font="1">a small BP lowering effect of protein </text>
<text top="324" left="678" width="215" height="20" font="1">compared to carbohydrate intake (86% </text>
<text top="341" left="678" width="217" height="20" font="1">of the trials). In a pooled analysis of the </text>
<text top="358" left="678" width="176" height="20" font="1">overall group (hypertensive and </text>
<text top="375" left="678" width="204" height="20" font="1">normotensive persons), the mean for </text>
<text top="393" left="678" width="197" height="20" font="1">change in SBP was -1.76 (95% CI: -</text>
<text top="410" left="678" width="212" height="20" font="1">2.33– -1.20). In a subgroup of 15 trials </text>
<text top="427" left="678" width="209" height="20" font="1">in which none of the participants were </text>
<text top="444" left="678" width="212" height="20" font="1">receiving antihypertensive medication, </text>
<text top="462" left="678" width="196" height="20" font="1">the mean change in SBP was -1.95 </text>
<text top="479" left="678" width="128" height="20" font="1">(95% CI: -2.62– -1.29). </text>
<text top="498" left="678" width="7" height="18" font="1">•</text>
<text top="497" left="685" width="10" height="20" font="1"> 2</text>
<text top="499" left="695" width="9" height="13" font="6">nd</text>
<text top="497" left="704" width="83" height="20" font="1"> meta-analysis </text>
<text top="514" left="678" width="199" height="20" font="1">For the comparison of vegetable vs. </text>
<text top="532" left="678" width="211" height="20" font="1">animal protein, there was no evidence </text>
<text top="549" left="678" width="182" height="20" font="1">of a difference in BP. In a pooled </text>
<text top="566" left="678" width="156" height="20" font="1">analysis of the overall group </text>
<text top="583" left="678" width="203" height="20" font="1">(hypertensive and normotensive pts) </text>
<text top="600" left="678" width="196" height="20" font="1">the mean change in SBP was -0.10 </text>
<text top="618" left="678" width="188" height="20" font="1">(95% CI: -2.31–2.11) mm Hg. In a </text>
<text top="635" left="678" width="221" height="20" font="1">subgroup of 8 trials in which none of the </text>
<text top="652" left="678" width="195" height="20" font="1">pts were receiving antihypertensive </text>
<text top="669" left="678" width="206" height="20" font="1">medication, the mean change in SBP </text>
<text top="686" left="678" width="181" height="20" font="1">was -0.55 (95% CI: -3.06–1.96).  </text>
<text top="704" left="678" width="3" height="20" font="1"> </text>
<text top="722" left="678" width="143" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A  </text>
<text top="253" left="913" width="148" height="20" font="1">● This is the most detailed </text>
<text top="270" left="913" width="163" height="20" font="1">and comprehensive review of </text>
<text top="287" left="913" width="57" height="20" font="1">the topic.  </text>
<text top="304" left="913" width="163" height="20" font="1">● It provides strong evidence </text>
<text top="321" left="913" width="159" height="20" font="1">that protein supplementation </text>
<text top="339" left="913" width="141" height="20" font="1">results in a significant but </text>
<text top="356" left="913" width="154" height="20" font="1">modest reduction in BP and </text>
<text top="373" left="913" width="168" height="20" font="1">suggests that the effect size is </text>
<text top="390" left="913" width="90" height="20" font="1">similar following </text>
<text top="408" left="913" width="160" height="20" font="1">supplementation with protein </text>
<text top="425" left="913" width="158" height="20" font="1">from vegetables or animals.  </text>
<text top="740" left="98" width="99" height="20" font="1">Tielemans SM, et </text>
<text top="757" left="98" width="76" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(71)</a> </text>
<text top="774" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23514841?dopt=Citation">23514841</a></text>
<text top="774" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23514841?dopt=Citation"> </a></text>
<text top="740" left="219" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="757" left="219" width="114" height="20" font="1">protein intake on BP<b> </b></text>
<text top="774" left="219" width="3" height="20" font="1"> </text>
<text top="740" left="368" width="102" height="20" font="4"><b>Inclusion criteria </b></text>
<text top="759" left="368" width="7" height="18" font="1">•</text>
<text top="758" left="374" width="112" height="20" font="1"> RCTs, in “generally </text>
<text top="776" left="368" width="84" height="20" font="1">healthy adults” </text>
<text top="740" left="530" width="120" height="20" font="4"><b>Intervention:</b> Protein </text>
<text top="757" left="530" width="36" height="20" font="1">intake </text>
<text top="774" left="530" width="3" height="20" font="1"> </text>
<text top="741" left="678" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="760" left="678" width="7" height="18" font="1">•</text>
<text top="759" left="685" width="192" height="20" font="1"> At baseline, the mean for age and </text>
<text top="777" left="678" width="207" height="20" font="1">SBP were 50 (range: 31–74) and 128 </text>
<text top="742" left="913" width="7" height="18" font="1">•</text>
<text top="741" left="919" width="137" height="20" font="1"> Findings consistent with </text>
<text top="758" left="913" width="128" height="20" font="1">experience in the meta-</text>
<text top="776" left="913" width="143" height="20" font="1">analysis by Rebholz et al. </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">37 </text>
<text top="107" left="219" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="124" left="219" width="94" height="20" font="1">review and meta-</text>
<text top="141" left="219" width="48" height="20" font="1">analysis </text>
<text top="159" left="219" width="3" height="20" font="4"><b> </b></text>
<text top="176" left="219" width="106" height="20" font="4"><b>Size: </b>16 RCT (210 </text>
<text top="193" left="219" width="132" height="20" font="1">comparisons) of protein </text>
<text top="210" left="219" width="107" height="20" font="1">vs. carbohydrate in </text>
<text top="228" left="219" width="100" height="20" font="1">1,449 pts, with 14 </text>
<text top="245" left="219" width="87" height="20" font="1">(67%) of the 21 </text>
<text top="262" left="219" width="133" height="20" font="1">comparisons conducted </text>
<text top="279" left="219" width="117" height="20" font="1">in normotensive pts. <b> </b></text>
<text top="296" left="219" width="128" height="20" font="1">-3 trials based on plant </text>
<text top="314" left="219" width="105" height="20" font="1">protein and 4 trials </text>
<text top="331" left="219" width="135" height="20" font="1">based on animal protein<b> </b></text>
<text top="109" left="368" width="7" height="18" font="1">•</text>
<text top="108" left="374" width="123" height="20" font="1"> Publications between </text>
<text top="125" left="368" width="128" height="20" font="1">January 1966–January </text>
<text top="143" left="368" width="31" height="20" font="1">2012 </text>
<text top="160" left="368" width="3" height="20" font="1"> </text>
<text top="177" left="368" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="196" left="368" width="7" height="18" font="1">•</text>
<text top="195" left="374" width="134" height="20" font="1"> Inadequate reporting of </text>
<text top="213" left="368" width="48" height="20" font="1">the data </text>
<text top="232" left="368" width="7" height="18" font="1">•</text>
<text top="231" left="374" width="135" height="20" font="1"> Concurrent intervention<b> </b></text>
<text top="107" left="530" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="124" left="530" width="114" height="20" font="1">Carbohydrate intake </text>
<text top="107" left="678" width="215" height="20" font="1">(range: 112–144). During the trials, the </text>
<text top="124" left="678" width="218" height="20" font="1">MD in protein intake was 48 g/d (range: </text>
<text top="141" left="678" width="69" height="20" font="1">26–74 g/d).  </text>
<text top="160" left="678" width="7" height="18" font="1">•</text>
<text top="160" left="685" width="214" height="20" font="1"> In the overall group (hypertensive and </text>
<text top="177" left="678" width="202" height="20" font="1">normotensive participants), a pooled </text>
<text top="194" left="678" width="209" height="20" font="1">analysis of comparisons from 14 trials </text>
<text top="211" left="678" width="209" height="20" font="1">(1,208 pts) identified a MD for change </text>
<text top="229" left="678" width="204" height="20" font="1">in SBP of -2.11 (95% CI: -2.8– -1.37) </text>
<text top="246" left="678" width="215" height="20" font="1">for protein vs. carbohydrate. In 3 RCTs </text>
<text top="263" left="678" width="207" height="20" font="1">that employed plant protein (327 pts), </text>
<text top="280" left="678" width="200" height="20" font="1">the mean treatment effect was -1.95 </text>
<text top="298" left="678" width="207" height="20" font="1">(95% CI: -3.21– -0.69) and in 4 RCTs </text>
<text top="315" left="678" width="217" height="20" font="1">that employed animal protein (574 pts), </text>
<text top="332" left="678" width="216" height="20" font="1">the corresponding difference was -2.20 </text>
<text top="349" left="678" width="128" height="20" font="1">(95% CI: -3.36– -1.03). </text>
<text top="367" left="678" width="3" height="20" font="1"> </text>
<text top="384" left="678" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="402" left="98" width="87" height="20" font="1">Dong JY, et al., </text>
<text top="419" left="98" width="56" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(72)</a> </text>
<text top="436" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23829939?dopt=Citation">23829939 </a></text>
<text top="402" left="219" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="419" left="219" width="127" height="20" font="1">protein intake on BP in </text>
<text top="436" left="219" width="33" height="20" font="1">DM-2<b> </b></text>
<text top="453" left="219" width="3" height="20" font="1"> </text>
<text top="470" left="219" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="488" left="219" width="94" height="20" font="1">review and meta-</text>
<text top="505" left="219" width="48" height="20" font="1">analysis </text>
<text top="522" left="219" width="3" height="20" font="4"><b> </b></text>
<text top="539" left="219" width="126" height="20" font="4"><b>Size: </b>9 RCTs with 418 </text>
<text top="557" left="219" width="20" height="20" font="1">pts<b> </b></text>
<text top="402" left="368" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="421" left="368" width="7" height="18" font="1">•</text>
<text top="420" left="374" width="136" height="20" font="1"> RCTs in adults with DM-</text>
<text top="437" left="368" width="10" height="20" font="1">2 </text>
<text top="456" left="368" width="7" height="18" font="1">•</text>
<text top="456" left="374" width="104" height="20" font="1"> Publications up to </text>
<text top="473" left="368" width="73" height="20" font="1">August 2012 </text>
<text top="492" left="368" width="7" height="18" font="1">•</text>
<text top="491" left="374" width="96" height="20" font="1"> High protein diet </text>
<text top="508" left="368" width="120" height="20" font="1">intervention and ≥5% </text>
<text top="526" left="368" width="111" height="20" font="1">difference in dietary </text>
<text top="543" left="368" width="127" height="20" font="1">protein intake between </text>
<text top="560" left="368" width="131" height="20" font="1">intervention and control </text>
<text top="577" left="368" width="41" height="20" font="1">groups </text>
<text top="596" left="368" width="7" height="18" font="1">•</text>
<text top="596" left="374" width="116" height="20" font="1"> Trial duration ≥4 wk </text>
<text top="613" left="368" width="3" height="20" font="1"> </text>
<text top="630" left="368" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="647" left="368" width="131" height="20" font="1">Inadequate reporting of </text>
<text top="664" left="368" width="53" height="20" font="1">key data  </text>
<text top="402" left="530" width="107" height="20" font="4"><b>Intervention:</b> High </text>
<text top="419" left="530" width="131" height="20" font="1">protein diet intervention </text>
<text top="436" left="530" width="124" height="20" font="1">and ≥5% difference in </text>
<text top="453" left="530" width="118" height="20" font="1">dietary protein intake </text>
<text top="470" left="530" width="117" height="20" font="1">between intervention </text>
<text top="488" left="530" width="105" height="20" font="1">and control groups </text>
<text top="505" left="530" width="3" height="20" font="1"> </text>
<text top="522" left="530" width="101" height="20" font="4"><b>Comparator:</b> N/A </text>
<text top="403" left="678" width="215" height="20" font="4"><b>1</b>°<b> endpoint:</b> Pooled experience in the </text>
<text top="420" left="678" width="188" height="20" font="1">14 trials identified a nonsignificant </text>
<text top="437" left="678" width="207" height="20" font="1">reduction in mean SBP of -3.10 (95% </text>
<text top="454" left="678" width="100" height="20" font="1">CI: -4.63– -1.56).  </text>
<text top="472" left="678" width="3" height="20" font="1"> </text>
<text top="489" left="678" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="402" left="913" width="148" height="20" font="1">● Heterogeneous group of </text>
<text top="419" left="913" width="160" height="20" font="1">open label trials with a range </text>
<text top="436" left="913" width="139" height="20" font="1">of duration from 4–24 wk </text>
<text top="453" left="913" width="165" height="20" font="1">(median of 12 wk). In addition </text>
<text top="470" left="913" width="167" height="20" font="1">to DM-2, all of the participants </text>
<text top="488" left="913" width="148" height="20" font="1">were overweight or obese. </text>
<text top="505" left="913" width="139" height="20" font="1">● The quality of the trials </text>
<text top="522" left="913" width="162" height="20" font="1">varied, drop-out rates ranged </text>
<text top="539" left="913" width="161" height="20" font="1">from 0%–0%, and only 1 trial </text>
<text top="557" left="913" width="161" height="20" font="1">was analyzed using an intent </text>
<text top="574" left="913" width="100" height="20" font="1">to treat approach. </text>
<text top="682" left="98" width="87" height="20" font="1">Dong JY, et al., </text>
<text top="700" left="98" width="56" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(73)</a> </text>
<text top="717" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23823502?dopt=Citation">23823502</a></text>
<text top="717" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23823502?dopt=Citation"><b> </b></a></text>
<text top="682" left="219" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="700" left="219" width="134" height="20" font="1">probiotic fermented milk </text>
<text top="717" left="219" width="40" height="20" font="1">on BP.<b> </b></text>
<text top="734" left="219" width="3" height="20" font="4"><b> </b></text>
<text top="751" left="219" width="134" height="20" font="4"><b>Study type: </b>Systematic </text>
<text top="768" left="219" width="94" height="20" font="1">review and meta-</text>
<text top="786" left="219" width="99" height="20" font="1">analysis. All but 1 </text>
<text top="682" left="368" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="701" left="368" width="7" height="18" font="1">•</text>
<text top="701" left="374" width="38" height="20" font="1"> RCTs </text>
<text top="720" left="368" width="7" height="18" font="1">•</text>
<text top="719" left="374" width="108" height="20" font="1"> Placebo controlled </text>
<text top="738" left="368" width="7" height="18" font="1">•</text>
<text top="737" left="374" width="140" height="20" font="1"> Published prior to March </text>
<text top="755" left="368" width="31" height="20" font="1">2012 </text>
<text top="772" left="368" width="3" height="20" font="1"> </text>
<text top="789" left="368" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="682" left="530" width="129" height="20" font="4"><b>Intervention: </b>Probiotic </text>
<text top="700" left="530" width="116" height="20" font="1">fermented milk (100–</text>
<text top="717" left="530" width="49" height="20" font="1">450 g/d)<b> </b></text>
<text top="734" left="530" width="3" height="20" font="4"><b> </b></text>
<text top="751" left="530" width="100" height="20" font="4"><b>Comparator: </b>Not </text>
<text top="768" left="530" width="122" height="20" font="1">specified but all of the </text>
<text top="786" left="530" width="109" height="20" font="1">trials reported to be </text>
<text top="683" left="678" width="215" height="20" font="4"><b>1</b>°<b> endpoint: </b>Pooled experience in the </text>
<text top="701" left="678" width="181" height="20" font="1">9 trials identified a nonsignificant </text>
<text top="718" left="678" width="207" height="20" font="1">reduction in mean SBP of -3.59 (95% </text>
<text top="735" left="678" width="92" height="20" font="1">CI: -7.58–0.40). <b> </b></text>
<text top="752" left="678" width="3" height="20" font="4"><b> </b></text>
<text top="770" left="678" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A <b> </b></text>
<text top="682" left="913" width="161" height="20" font="1">● The most recent of several </text>
<text top="700" left="913" width="160" height="20" font="1">meta-analyses conducted by </text>
<text top="717" left="913" width="103" height="20" font="1">different groups of </text>
<text top="734" left="913" width="126" height="20" font="1">investigators that have </text>
<text top="751" left="913" width="157" height="20" font="1">reported a similar effect size </text>
<text top="768" left="913" width="145" height="20" font="1">following administration of </text>
<text top="786" left="913" width="157" height="20" font="1">lactopeptides, especially the </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">38 </text>
<text top="107" left="219" width="132" height="20" font="1">(cross-over) trial said to </text>
<text top="124" left="219" width="120" height="20" font="1">use a parallel design. </text>
<text top="141" left="219" width="122" height="20" font="1">Antihypertensive drug </text>
<text top="159" left="219" width="125" height="20" font="1">use reported in 3 trials </text>
<text top="176" left="219" width="120" height="20" font="1">and in an additional 3 </text>
<text top="193" left="219" width="91" height="20" font="1">trials mean SBP </text>
<text top="210" left="219" width="124" height="20" font="1">exceeded 150 mm Hg </text>
<text top="228" left="219" width="70" height="20" font="1">at baseline. <b> </b></text>
<text top="245" left="219" width="3" height="20" font="1"> </text>
<text top="262" left="219" width="133" height="20" font="4"><b>Size: </b>14 RCTs with 702 </text>
<text top="279" left="219" width="125" height="20" font="1">pts (median size=40). <b> </b></text>
<text top="109" left="368" width="7" height="18" font="1">•</text>
<text top="108" left="374" width="96" height="20" font="1"> Intervention with </text>
<text top="125" left="368" width="140" height="20" font="1">enzymatically<b> </b>hydrolysed </text>
<text top="143" left="368" width="25" height="20" font="1">milk </text>
<text top="162" left="368" width="7" height="18" font="1">•</text>
<text top="161" left="374" width="86" height="20" font="1"> Cointervention </text>
<text top="107" left="530" width="107" height="20" font="1">placebo controlled. </text>
<text top="124" left="530" width="131" height="20" font="1">However, 2 were single </text>
<text top="141" left="530" width="120" height="20" font="1">blind and 1 was open </text>
<text top="159" left="530" width="36" height="20" font="1">label. <b> </b></text>
<text top="107" left="913" width="124" height="20" font="1">lactotripeptides Valine-</text>
<text top="124" left="913" width="161" height="20" font="1">Proline-Proline and Isolucine-</text>
<text top="141" left="913" width="87" height="20" font="1">Proline-Proline. </text>
<text top="159" left="913" width="152" height="20" font="1">● These findings may have </text>
<text top="176" left="913" width="116" height="20" font="1">special relevance for </text>
<text top="193" left="913" width="156" height="20" font="1">countries, like Japan, where </text>
<text top="210" left="913" width="146" height="20" font="1">consumption of fermented </text>
<text top="228" left="913" width="146" height="20" font="1">milk products is common.<b>  </b></text>
<text top="299" left="108" width="3" height="19" font="1"> </text>
<text top="333" left="81" width="948" height="24" font="3"><b>Data Supplement 13. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Sodium Reduction to Placebo or Usual Diet) </b></text>
<text top="357" left="81" width="92" height="24" font="3"><b>(Section 6.2) </b></text>
<text top="397" left="99" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="414" left="125" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="431" left="102" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="397" left="232" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="414" left="237" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="431" left="230" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="397" left="363" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="397" left="504" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="414" left="536" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="431" left="504" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="448" left="540" width="55" height="20" font="4"><b>patients) </b></text>
<text top="397" left="713" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="414" left="697" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="431" left="679" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="398" left="899" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="415" left="932" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="432" left="939" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="466" left="98" width="76" height="20" font="4"><b>NUTRICODE</b> </text>
<text top="483" left="98" width="97" height="20" font="1">Mozaffarian D, et </text>
<text top="500" left="98" width="76" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(74)</a> </text>
<text top="518" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25119608?dopt=Citation">25119608</a></text>
<text top="518" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25119608?dopt=Citation"> </a></text>
<text top="466" left="212" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="483" left="212" width="111" height="20" font="1">of sodium reduction </text>
<text top="500" left="212" width="90" height="20" font="1">on BP and CVD </text>
<text top="518" left="212" width="50" height="20" font="1">mortality<b> </b></text>
<text top="535" left="212" width="3" height="20" font="1"> </text>
<text top="552" left="212" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="569" left="212" width="109" height="20" font="1">regression analysis </text>
<text top="587" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="604" left="212" width="119" height="20" font="4"><b>Size: </b>103 RCTs (107 </text>
<text top="621" left="212" width="102" height="20" font="1">comparisons) with </text>
<text top="638" left="212" width="109" height="20" font="1">6,970 pts; 38 of the </text>
<text top="655" left="212" width="97" height="20" font="1">107 comparisons </text>
<text top="673" left="212" width="103" height="20" font="1">were conducted in </text>
<text top="690" left="212" width="97" height="20" font="1">normotensive pts<b> </b></text>
<text top="466" left="347" width="135" height="20" font="4"><b>Inclusion criteria: </b>RCT </text>
<text top="483" left="347" width="130" height="20" font="1">in 2 previous Cochrane </text>
<text top="500" left="347" width="83" height="20" font="1">meta-analyses<b> </b></text>
<text top="518" left="347" width="3" height="20" font="1"> </text>
<text top="535" left="347" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="554" left="347" width="7" height="18" font="1">•</text>
<text top="553" left="354" width="89" height="20" font="1"> Duration &lt;1 wk </text>
<text top="572" left="347" width="7" height="18" font="1">•</text>
<text top="572" left="354" width="126" height="20" font="1"> Mean 24-h collections </text>
<text top="589" left="347" width="125" height="20" font="1">or estimates of urinary </text>
<text top="606" left="347" width="115" height="20" font="1">sodium reduced &lt;20 </text>
<text top="623" left="347" width="134" height="20" font="1">mmol in the intervention </text>
<text top="640" left="347" width="107" height="20" font="1">group compared to </text>
<text top="658" left="347" width="40" height="20" font="1">control </text>
<text top="677" left="347" width="7" height="18" font="1">•</text>
<text top="676" left="354" width="76" height="20" font="1"> Concomitant </text>
<text top="693" left="347" width="73" height="20" font="1">interventions </text>
<text top="466" left="503" width="123" height="20" font="4"><b>Intervention:</b> Sodium </text>
<text top="483" left="503" width="57" height="20" font="1">reduction  </text>
<text top="500" left="503" width="7" height="20" font="1">  </text>
<text top="518" left="503" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="535" left="503" width="97" height="20" font="1">sodium reduction </text>
<text top="467" left="644" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="486" left="644" width="7" height="18" font="1">•</text>
<text top="486" left="651" width="224" height="20" font="1"> Strong evidence for a linear relationship </text>
<text top="503" left="644" width="220" height="20" font="1">between reduction in sodium intake and </text>
<text top="520" left="644" width="226" height="20" font="1">lower levels of SBP throughout the entire </text>
<text top="537" left="644" width="226" height="20" font="1">distribution of sodium studied, with larger </text>
<text top="554" left="644" width="193" height="20" font="1">reductions in older persons, blacks </text>
<text top="572" left="644" width="221" height="20" font="1">(compared to whites) and hypertensives </text>
<text top="589" left="644" width="235" height="20" font="1">(compared to normotensives). For a white, </text>
<text top="606" left="644" width="235" height="20" font="1">normotensive population at age 50 y, each </text>
<text top="623" left="644" width="238" height="20" font="1">reduction of 100 mmol/d (2.3 g/d) in dietary </text>
<text top="640" left="644" width="241" height="20" font="1">sodium lowered SBP by a mean: 3.74 (95% </text>
<text top="658" left="644" width="85" height="20" font="1">CI: 5.18–2.29). </text>
<text top="677" left="644" width="7" height="18" font="1">•</text>
<text top="676" left="651" width="217" height="20" font="1"> Modeling based on global estimates of </text>
<text top="693" left="644" width="227" height="20" font="1">sodium intake, effect of sodium reduction </text>
<text top="710" left="644" width="232" height="20" font="1">on BP, and effect of BP reduction on CVD </text>
<text top="728" left="644" width="240" height="20" font="1">mortality attributed 1.65 million CVD deaths </text>
<text top="745" left="644" width="216" height="20" font="1">annually due sodium intake &gt;2 g/d. this </text>
<text top="762" left="644" width="229" height="20" font="1">would represent 9.5% (95% CI: 6.4–12.8) </text>
<text top="779" left="644" width="220" height="20" font="1">of all CVD mortality. Estimates were not </text>
<text top="466" left="899" width="133" height="20" font="1">● RCT meta-regression </text>
<text top="483" left="899" width="174" height="20" font="1">analysis that provides evidence </text>
<text top="500" left="899" width="148" height="20" font="1">for BP lowering following a </text>
<text top="518" left="899" width="150" height="20" font="1">reduction in dietary sodium </text>
<text top="535" left="899" width="116" height="20" font="1">intake, overall and in </text>
<text top="552" left="899" width="163" height="20" font="1">normotensive persons, with a </text>
<text top="569" left="899" width="146" height="20" font="1">more pronounced effect in </text>
<text top="587" left="899" width="156" height="20" font="1">those who were older, black </text>
<text top="604" left="899" width="168" height="20" font="1">and had a higher starting level </text>
<text top="621" left="899" width="40" height="20" font="1">of BP.  </text>
<text top="638" left="899" width="117" height="20" font="1">● These findings are </text>
<text top="655" left="899" width="164" height="20" font="1">consistent with other reports.  </text>
<text top="673" left="899" width="138" height="20" font="1">● The modeling analysis </text>
<text top="690" left="899" width="157" height="20" font="1">suggested sodium reduction </text>
<text top="707" left="899" width="119" height="20" font="1">would yield important </text>
<text top="724" left="899" width="164" height="20" font="1">population health benefits but </text>
<text top="741" left="899" width="163" height="20" font="1">did not specify the magnitude </text>
<text top="759" left="899" width="162" height="20" font="1">of the potential benefit for pts </text>
<text top="776" left="899" width="155" height="20" font="1">within the normal BP range. </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">39 </text>
<text top="107" left="644" width="226" height="20" font="1">provided separately for hypertensive and </text>
<text top="124" left="644" width="128" height="20" font="1">normotensive persons. </text>
<text top="141" left="644" width="3" height="20" font="4"><b> </b></text>
<text top="160" left="644" width="143" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A  </text>
<text top="193" left="98" width="95" height="20" font="1">Aburto NJ, et al., </text>
<text top="210" left="98" width="56" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(68)</a> </text>
<text top="227" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23558164?dopt=Citation">23558164</a></text>
<text top="227" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23558164?dopt=Citation"> </a></text>
<text top="193" left="212" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="210" left="212" width="111" height="20" font="1">of sodium reduction </text>
<text top="227" left="212" width="37" height="20" font="1">on BP<b> </b></text>
<text top="244" left="212" width="3" height="20" font="1"> </text>
<text top="262" left="212" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="279" left="212" width="102" height="20" font="1">Systematic review </text>
<text top="296" left="212" width="103" height="20" font="1">and meta-analysis </text>
<text top="313" left="212" width="3" height="20" font="1"> </text>
<text top="330" left="212" width="107" height="20" font="4"><b>Size: </b>Overall study </text>
<text top="348" left="212" width="117" height="20" font="1">included 36 trials (49 </text>
<text top="365" left="212" width="77" height="20" font="1">comparisons) </text>
<text top="382" left="212" width="107" height="20" font="1">conducted in 6,736 </text>
<text top="399" left="212" width="111" height="20" font="1">pts. Of these, 3,263 </text>
<text top="417" left="212" width="30" height="20" font="1">were </text>
<text top="434" left="212" width="122" height="20" font="1">nonhypertensive. The </text>
<text top="451" left="212" width="53" height="20" font="1">results in </text>
<text top="468" left="212" width="119" height="20" font="1">normotensives in this </text>
<text top="485" left="212" width="105" height="20" font="1">table are based on </text>
<text top="503" left="212" width="121" height="20" font="1">experience in 7 RCTs </text>
<text top="520" left="212" width="107" height="20" font="1">conducted in 3,067 </text>
<text top="537" left="212" width="100" height="20" font="1">normotensive pts.<b> </b></text>
<text top="193" left="347" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="212" left="347" width="7" height="18" font="1">•</text>
<text top="211" left="354" width="92" height="20" font="4"><b> </b>RCT in humans </text>
<text top="230" left="347" width="7" height="18" font="1">•</text>
<text top="230" left="354" width="115" height="20" font="4"><b> </b>Trial duration ≥4 wk </text>
<text top="249" left="347" width="7" height="18" font="1">•</text>
<text top="248" left="354" width="116" height="20" font="4"><b> </b>24-h urinary sodium </text>
<text top="265" left="347" width="107" height="20" font="1">≥40 mmol/d less in </text>
<text top="282" left="347" width="127" height="20" font="1">treatment compared to </text>
<text top="300" left="347" width="75" height="20" font="1">control group </text>
<text top="319" left="347" width="7" height="18" font="1">•</text>
<text top="318" left="354" width="84" height="20" font="4"><b> </b>No concurrent </text>
<text top="335" left="347" width="73" height="20" font="1">interventions </text>
<text top="354" left="347" width="7" height="18" font="1">•</text>
<text top="353" left="354" width="80" height="20" font="4"><b> </b>Not acutely ill </text>
<text top="371" left="347" width="3" height="20" font="1"> </text>
<text top="388" left="347" width="139" height="20" font="4"><b>Exclusion criteria:</b> Lack </text>
<text top="405" left="347" width="54" height="20" font="1">of above  </text>
<text top="193" left="503" width="123" height="20" font="4"><b>Intervention:</b> Sodium </text>
<text top="210" left="503" width="54" height="20" font="1">reduction </text>
<text top="227" left="503" width="3" height="20" font="1"> </text>
<text top="244" left="503" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="262" left="503" width="97" height="20" font="1">sodium reduction </text>
<text top="194" left="644" width="241" height="20" font="4"><b>1</b>°<b> endpoint:</b> In pooled analysis, the overall </text>
<text top="211" left="644" width="235" height="20" font="1">change in SBP was -3.39 (95% CI: -4.31– -</text>
<text top="228" left="644" width="210" height="20" font="1">2.46) mm Hg. In the pts with HTN, the </text>
<text top="246" left="644" width="229" height="20" font="1">change was -4.06 (95% CI: -5.15– -2.96). </text>
<text top="263" left="644" width="242" height="20" font="1">In the normotensives, the change was -1.38 </text>
<text top="280" left="644" width="121" height="20" font="1">(95% CI: -2.74–0.02). </text>
<text top="297" left="644" width="3" height="20" font="1"> </text>
<text top="314" left="644" width="225" height="20" font="4"><b>Safety endpoint:</b> In the small number of </text>
<text top="332" left="644" width="212" height="20" font="1">relevant trials, there was no significant </text>
<text top="349" left="644" width="221" height="20" font="1">effect of sodium reduction on lipid levels </text>
<text top="366" left="644" width="223" height="20" font="1">(Total cholesterol, LDL-cholesterol, HDL-</text>
<text top="383" left="644" width="233" height="20" font="1">cholesterol, triglyceride levels; 11 trials) or </text>
<text top="400" left="644" width="163" height="20" font="1">on plasma (7 trials) or urinary </text>
<text top="418" left="644" width="234" height="20" font="1">catecholamine levels (2 trials). Experience </text>
<text top="435" left="644" width="235" height="20" font="1">in 4 trials (3 which could not be included in </text>
<text top="452" left="644" width="230" height="20" font="1">the meta-analysis) suggested a beneficial </text>
<text top="469" left="644" width="203" height="20" font="1">effect of sodium reduction on urinary </text>
<text top="487" left="644" width="98" height="20" font="1">protein excretion. </text>
<text top="193" left="899" width="153" height="20" font="1">● Study inclusion/exclusion </text>
<text top="210" left="899" width="146" height="20" font="1">criteria designed to yield a </text>
<text top="227" left="899" width="137" height="20" font="1">group of trials that would </text>
<text top="244" left="899" width="137" height="20" font="1">provide results that have </text>
<text top="262" left="899" width="161" height="20" font="1">relevance for clinical practice </text>
<text top="279" left="899" width="136" height="20" font="1">and public health. In this </text>
<text top="296" left="899" width="174" height="20" font="1">context, reduced sodium intake </text>
<text top="313" left="899" width="133" height="20" font="1">resulted in a statistically </text>
<text top="330" left="899" width="165" height="20" font="1">significant but small reduction </text>
<text top="348" left="899" width="48" height="20" font="1">in SBP.  </text>
<text top="555" left="98" width="73" height="20" font="1">He FJ, et al., </text>
<text top="572" left="98" width="60" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#267">(75)</a> <b> </b></text>
<text top="589" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22437256?dopt=Citation">22437256</a></text>
<text top="589" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22437256?dopt=Citation"><b> </b></a></text>
<text top="555" left="212" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="572" left="212" width="111" height="20" font="1">of sodium reduction </text>
<text top="589" left="212" width="37" height="20" font="1">on BP<b> </b></text>
<text top="607" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="624" left="212" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="641" left="212" width="106" height="20" font="1">Systematic review, </text>
<text top="658" left="212" width="103" height="20" font="1">meta-analysis and </text>
<text top="676" left="212" width="92" height="20" font="1">meta-regression </text>
<text top="693" left="212" width="48" height="20" font="1">analysis<b> </b></text>
<text top="710" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="727" left="212" width="107" height="20" font="4"><b>Size: </b>Overall study </text>
<text top="744" left="212" width="117" height="20" font="1">included 34 trials (37 </text>
<text top="762" left="212" width="77" height="20" font="1">comparisons) </text>
<text top="779" left="212" width="107" height="20" font="1">conducted in 3,230 </text>
<text top="555" left="347" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="574" left="347" width="7" height="18" font="1">•</text>
<text top="573" left="354" width="38" height="20" font="4"><b> </b>RCTs </text>
<text top="592" left="347" width="7" height="18" font="1">•</text>
<text top="592" left="354" width="120" height="20" font="4"><b> </b>Healthy adults ≥18 y </text>
<text top="611" left="347" width="7" height="18" font="1">•</text>
<text top="610" left="354" width="115" height="20" font="4"><b> </b>Trial duration ≥4 wk </text>
<text top="629" left="347" width="7" height="18" font="1">•</text>
<text top="629" left="354" width="111" height="20" font="4"><b> </b>Sodium intake only </text>
<text top="646" left="347" width="107" height="20" font="1">difference between </text>
<text top="663" left="347" width="120" height="20" font="1">treatment and control </text>
<text top="680" left="347" width="35" height="20" font="1">group </text>
<text top="699" left="347" width="7" height="18" font="1">•</text>
<text top="699" left="354" width="131" height="20" font="4"><b> </b>24-h urine sodium ≥40 </text>
<text top="716" left="347" width="127" height="20" font="1">mmol less in treatment </text>
<text top="733" left="347" width="112" height="20" font="1">compared to control </text>
<text top="750" left="347" width="3" height="20" font="4"><b> </b></text>
<text top="767" left="347" width="139" height="20" font="4"><b>Exclusion criteria: </b>Lack </text>
<text top="785" left="347" width="51" height="20" font="1">of above<b> </b></text>
<text top="555" left="503" width="123" height="20" font="4"><b>Intervention: </b>Sodium </text>
<text top="572" left="503" width="57" height="20" font="1">reduction<b>  </b></text>
<text top="589" left="503" width="7" height="20" font="4"><b>  </b></text>
<text top="607" left="503" width="96" height="20" font="4"><b>Comparator: </b>No </text>
<text top="624" left="503" width="100" height="20" font="1">sodium reduction<b>  </b></text>
<text top="556" left="644" width="238" height="20" font="4"><b>1</b>°<b> endpoint: </b>In an overall pooled analysis, </text>
<text top="573" left="644" width="222" height="20" font="1">the change for SBP was -4.18 (95% CI: -</text>
<text top="591" left="644" width="241" height="20" font="1">5.18– -3.18) mm Hg. In the trials of persons </text>
<text top="608" left="644" width="213" height="20" font="1">with HTN, the mean change was -5.39 </text>
<text top="625" left="644" width="235" height="20" font="1">(95% CI: -6.62– -4.15) mm Hg. In the trials </text>
<text top="642" left="644" width="237" height="20" font="1">conducted in normotensives, the change in </text>
<text top="660" left="644" width="234" height="20" font="1">SBP was -2.42 (95% CI: -3.56– -1.29) mm </text>
<text top="677" left="644" width="22" height="20" font="1">Hg.<b> </b></text>
<text top="694" left="644" width="3" height="20" font="4"><b> </b></text>
<text top="713" left="644" width="7" height="18" font="1">•</text>
<text top="712" left="651" width="217" height="20" font="4"><b> </b>In meta-regression analysis, change in </text>
<text top="730" left="644" width="204" height="20" font="1">24-h urinary sodium was significantly </text>
<text top="747" left="644" width="231" height="20" font="1">associated with reduction in SBP (4.3 mm </text>
<text top="764" left="644" width="241" height="20" font="1">Hg for a 100 mmol reduction in 24-h urinary </text>
<text top="781" left="644" width="51" height="20" font="1">sodium).<b> </b></text>
<text top="555" left="899" width="153" height="20" font="1">● Study inclusion/exclusion </text>
<text top="572" left="899" width="146" height="20" font="1">criteria designed to yield a </text>
<text top="589" left="899" width="137" height="20" font="1">group of trials that would </text>
<text top="607" left="899" width="137" height="20" font="1">provide results that have </text>
<text top="624" left="899" width="161" height="20" font="1">relevance for clinical practice </text>
<text top="641" left="899" width="136" height="20" font="1">and public health. In this </text>
<text top="658" left="899" width="174" height="20" font="1">context, reduced sodium intake </text>
<text top="676" left="899" width="152" height="20" font="1">resulted in a significant and </text>
<text top="693" left="899" width="167" height="20" font="1">potentially important reduction </text>
<text top="710" left="899" width="44" height="20" font="1">in SBP. </text>
<text top="727" left="899" width="169" height="20" font="1">● The meta-regression results </text>
<text top="744" left="899" width="155" height="20" font="1">were consistent with a dose-</text>
<text top="762" left="899" width="133" height="20" font="1">response relationship in </text>
<text top="779" left="899" width="97" height="20" font="1">normotensive pts </text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">40 </text>
<text top="107" left="212" width="109" height="20" font="1">pts. 12 of the RCTs </text>
<text top="124" left="212" width="98" height="20" font="1">(14 comparisons) </text>
<text top="141" left="212" width="103" height="20" font="1">were conducted in </text>
<text top="159" left="212" width="111" height="20" font="1">2,240 normotensive </text>
<text top="176" left="212" width="23" height="20" font="1">pts.<b> </b></text>
<text top="107" left="644" width="3" height="20" font="4"><b> </b></text>
<text top="124" left="644" width="103" height="20" font="4"><b>Safety endpoint:  </b></text>
<text top="141" left="644" width="240" height="20" font="1">In the small number of relevant trials (which </text>
<text top="159" left="644" width="174" height="20" font="1">included both hypertensive and </text>
<text top="176" left="644" width="212" height="20" font="1">normotensive pts) that provided safety </text>
<text top="193" left="644" width="239" height="20" font="1">endpoint measurements (4–14 trials), there </text>
<text top="210" left="644" width="202" height="20" font="1">was no change in total, LDL- or HDL-</text>
<text top="228" left="644" width="217" height="20" font="1">cholesterol, or triglyceride levels. There </text>
<text top="245" left="644" width="232" height="20" font="1">were small significant increases in plasma </text>
<text top="262" left="644" width="170" height="20" font="1">renin activity, aldosterone, and </text>
<text top="279" left="644" width="198" height="20" font="1">noradrenaline levels but these were </text>
<text top="296" left="644" width="202" height="20" font="1">consistent with expected physiologic </text>
<text top="314" left="644" width="174" height="20" font="1">responses to sodium reduction.<b> </b></text>
<text top="332" left="98" width="85" height="20" font="1">Graudal NA, et </text>
<text top="349" left="98" width="76" height="20" font="1">al., 2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(76)</a><b> </b></text>
<text top="366" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22068710?dopt=Citation">22068710</a></text>
<text top="366" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22068710?dopt=Citation"><b> </b></a></text>
<text top="332" left="212" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="349" left="212" width="111" height="20" font="1">of sodium reduction </text>
<text top="366" left="212" width="37" height="20" font="1">on BP<b> </b></text>
<text top="383" left="212" width="3" height="20" font="1"> </text>
<text top="400" left="212" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="418" left="212" width="102" height="20" font="1">Systematic review </text>
<text top="435" left="212" width="103" height="20" font="1">and meta-analysis<b> </b></text>
<text top="452" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="469" left="212" width="107" height="20" font="4"><b>Size: </b>Overall study </text>
<text top="487" left="212" width="106" height="20" font="1">included 167 trials. </text>
<text top="504" left="212" width="105" height="20" font="1">Of these, 71 RCTs </text>
<text top="521" left="212" width="103" height="20" font="1">were conducted in </text>
<text top="538" left="212" width="111" height="20" font="1">5,577 normotensive </text>
<text top="555" left="212" width="120" height="20" font="1">pts, with the following </text>
<text top="573" left="212" width="85" height="20" font="1">characteristics:<b> </b></text>
<text top="592" left="212" width="7" height="18" font="1">•</text>
<text top="591" left="219" width="101" height="20" font="1"> Median age: 27 y </text>
<text top="608" left="212" width="55" height="20" font="1">(13–67 y) </text>
<text top="627" left="212" width="7" height="18" font="1">•</text>
<text top="626" left="219" width="70" height="20" font="1"> Median trial </text>
<text top="644" left="212" width="90" height="20" font="1">duration: 7 d (4–</text>
<text top="661" left="212" width="49" height="20" font="1">1,100 d) </text>
<text top="680" left="212" width="7" height="18" font="1">•</text>
<text top="679" left="219" width="100" height="20" font="4"><b> </b>5,292 Whites (71 </text>
<text top="697" left="212" width="46" height="20" font="1">studies) </text>
<text top="716" left="212" width="7" height="18" font="1">•</text>
<text top="715" left="219" width="81" height="20" font="4"><b> </b>268 Blacks (7 </text>
<text top="732" left="212" width="46" height="20" font="1">studies) </text>
<text top="751" left="212" width="7" height="18" font="1">•</text>
<text top="750" left="219" width="82" height="20" font="4"><b> </b>215 Asians (3 </text>
<text top="768" left="212" width="46" height="20" font="1">studies)<b> </b></text>
<text top="332" left="347" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="351" left="347" width="7" height="18" font="1">•</text>
<text top="350" left="354" width="38" height="20" font="4"><b> </b>RCTs </text>
<text top="369" left="347" width="7" height="18" font="1">•</text>
<text top="368" left="354" width="107" height="20" font="4"><b> </b>24-h collections or </text>
<text top="386" left="347" width="113" height="20" font="1">estimates from ≥8 h </text>
<text top="403" left="347" width="115" height="20" font="1">collections of urinary </text>
<text top="420" left="347" width="96" height="20" font="1">sodium excretion </text>
<text top="437" left="347" width="3" height="20" font="4"><b> </b></text>
<text top="454" left="347" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="472" left="347" width="119" height="20" font="1">Systematic studies in </text>
<text top="489" left="347" width="102" height="20" font="1">unhealthy pts with </text>
<text top="506" left="347" width="143" height="20" font="1">diseases other than HTN<b>  </b></text>
<text top="332" left="503" width="123" height="20" font="4"><b>Intervention: </b>Sodium </text>
<text top="349" left="503" width="57" height="20" font="1">reduction <b> </b></text>
<text top="366" left="503" width="7" height="20" font="4"><b>  </b></text>
<text top="383" left="503" width="96" height="20" font="4"><b>Comparator: </b>No </text>
<text top="400" left="503" width="97" height="20" font="1">sodium reduction<b> </b></text>
<text top="333" left="644" width="230" height="20" font="4"><b>1</b>°<b> endpoint: </b>The overall effect of sodium </text>
<text top="350" left="644" width="161" height="20" font="1">reduction was not presented.<b> </b></text>
<text top="367" left="644" width="3" height="20" font="1"> </text>
<text top="384" left="644" width="222" height="20" font="1">A forest plot of 71 comparisons (from 61 </text>
<text top="402" left="644" width="217" height="20" font="1">trials) in the 4,919 normotensive whites </text>
<text top="419" left="644" width="235" height="20" font="1">assigned to sodium reduction compared to </text>
<text top="436" left="644" width="206" height="20" font="1">usual sodium intake identified a trend </text>
<text top="453" left="644" width="194" height="20" font="1">towards lower SBP in 50 (70%), no </text>
<text top="470" left="644" width="240" height="20" font="1">difference in 8 (11%), and higher SBP in 13 </text>
<text top="488" left="644" width="198" height="20" font="1">(19%). In a pooled analysis, sodium </text>
<text top="505" left="644" width="238" height="20" font="1">reduction compared to usual sodium intake </text>
<text top="522" left="644" width="231" height="20" font="1">in the normotensives yielded the following </text>
<text top="539" left="644" width="73" height="20" font="1">MDs in SBP: </text>
<text top="558" left="644" width="7" height="18" font="1">•</text>
<text top="558" left="651" width="204" height="20" font="4"><b> </b>Whites: -1.27 (95% CI: -1.88– -0.66) </text>
<text top="577" left="644" width="7" height="18" font="1">•</text>
<text top="576" left="651" width="203" height="20" font="4"><b> </b>Blacks: -4.02 (95% CI: -7.37– -0.68) </text>
<text top="595" left="644" width="7" height="18" font="1">•</text>
<text top="594" left="651" width="204" height="20" font="4"><b> </b>Asians: -1.27 (95% CI: -3.07– -0.54) </text>
<text top="612" left="644" width="3" height="20" font="1"> </text>
<text top="629" left="644" width="174" height="20" font="1">A corresponding analysis in the </text>
<text top="646" left="644" width="125" height="20" font="1">hypertensives yielded  </text>
<text top="663" left="644" width="218" height="20" font="1">the normotensives yielded the following </text>
<text top="680" left="644" width="73" height="20" font="1">MDs in SBP: </text>
<text top="699" left="644" width="7" height="18" font="1">•</text>
<text top="699" left="651" width="204" height="20" font="4"><b> </b>Whites: -5.48 (95% CI: -6.53– -4.43) </text>
<text top="718" left="644" width="7" height="18" font="1">•</text>
<text top="717" left="651" width="203" height="20" font="4"><b> </b>Blacks: -6.44 (95% CI: -8.85– -4.03) </text>
<text top="736" left="644" width="7" height="18" font="1">•</text>
<text top="736" left="651" width="217" height="20" font="4"><b> </b>Asians: -10.21 (95% CI: -16.98– -3.44) </text>
<text top="753" left="644" width="3" height="20" font="4"><b> </b></text>
<text top="770" left="644" width="230" height="20" font="4"><b>Safety endpoint: </b>In the relevant trials (all </text>
<text top="787" left="644" width="179" height="20" font="1">cross-over studies and including </text>
<text top="332" left="899" width="149" height="20" font="1">● Heterogeneous group of </text>
<text top="349" left="899" width="168" height="20" font="1">trials that included many small </text>
<text top="366" left="899" width="148" height="20" font="1">studies of short duration in </text>
<text top="383" left="899" width="87" height="20" font="1">young persons. </text>
<text top="400" left="899" width="174" height="20" font="1">● Overall finding of lower BP in </text>
<text top="418" left="899" width="158" height="20" font="1">those assigned to a reduced </text>
<text top="435" left="899" width="162" height="20" font="1">intake of dietary sodium, with </text>
<text top="452" left="899" width="167" height="20" font="1">an apparently greater effect in </text>
<text top="469" left="899" width="152" height="20" font="1">Blacks compared to Whites </text>
<text top="487" left="899" width="68" height="20" font="1">and Asians.<b> </b></text>
<text top="504" left="899" width="174" height="20" font="1">● The hormone changes in this </text>
<text top="521" left="899" width="157" height="20" font="1">meta-analysis likely reflect a </text>
<text top="538" left="899" width="175" height="20" font="1">physiologic response to sodium </text>
<text top="555" left="899" width="170" height="20" font="1">reduction, especially in studies </text>
<text top="573" left="899" width="147" height="20" font="1">of short duration and rapid </text>
<text top="590" left="899" width="170" height="20" font="1">changes in sodium intake. The </text>
<text top="607" left="899" width="158" height="20" font="1">increases in total cholesterol </text>
<text top="624" left="899" width="172" height="20" font="1">and triglyceride levels were not </text>
<text top="641" left="899" width="151" height="20" font="1">noted in the meta-analyses </text>
<text top="659" left="899" width="170" height="20" font="1">conducted by Aburto et al. and </text>
<text top="676" left="899" width="53" height="20" font="1">He et al.  </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">41 </text>
<text top="107" left="644" width="211" height="20" font="1">comparisons in both hypertensive and </text>
<text top="124" left="644" width="222" height="20" font="1">normotensive participants) that provided </text>
<text top="141" left="644" width="233" height="20" font="1">safety endpoint measurements, significant </text>
<text top="159" left="644" width="224" height="20" font="1">increases in the standard MD for plasma </text>
<text top="176" left="644" width="219" height="20" font="1">renin activity (70 trials), aldosterone (51 </text>
<text top="193" left="644" width="235" height="20" font="1">trials), noradrenaline (31 trials), adrenaline </text>
<text top="210" left="644" width="202" height="20" font="1">(14 trials), and weighted MD for total </text>
<text top="228" left="644" width="229" height="20" font="1">cholesterol (24 trials), and triglyceride (18 </text>
<text top="245" left="644" width="241" height="20" font="1">trials) levels. There was no significant effect </text>
<text top="262" left="644" width="239" height="20" font="1">of sodium reduction on LDL-cholesterol (15 </text>
<text top="279" left="644" width="207" height="20" font="1">trials) and HDL-cholesterol (17 trials).<b> </b></text>
<text top="297" left="98" width="87" height="20" font="4"><b>DASH-Sodium </b></text>
<text top="314" left="98" width="29" height="20" font="4"><b>Trial </b></text>
<text top="332" left="98" width="95" height="20" font="1">Sacks FM, et al., </text>
<text top="349" left="98" width="56" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(77)</a> </text>
<text top="366" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11136953?dopt=Citation">11136953 </a></text>
<text top="297" left="212" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="314" left="212" width="111" height="20" font="1">of sodium reduction </text>
<text top="332" left="212" width="37" height="20" font="1">on BP<b> </b></text>
<text top="349" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="366" left="212" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="383" left="212" width="76" height="20" font="1">Randomized, </text>
<text top="400" left="212" width="113" height="20" font="1">controlled crossover </text>
<text top="418" left="212" width="27" height="20" font="1">trial <b> </b></text>
<text top="435" left="212" width="3" height="20" font="1"> </text>
<text top="452" left="212" width="107" height="20" font="4"><b>Size: </b>Overall study </text>
<text top="469" left="212" width="115" height="20" font="1">based on 412 pts, of </text>
<text top="487" left="212" width="90" height="20" font="1">whom 243 were </text>
<text top="504" left="212" width="77" height="20" font="1">normotensive<b> </b></text>
<text top="297" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="314" left="347" width="76" height="20" font="1">Adults ≥22 y <b> </b></text>
<text top="332" left="347" width="3" height="20" font="1"> </text>
<text top="349" left="347" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="366" left="347" width="133" height="20" font="1">Taking antihypertensive </text>
<text top="383" left="347" width="70" height="20" font="1">medication, <b> </b></text>
<text top="400" left="347" width="111" height="20" font="1">heart disease, renal </text>
<text top="418" left="347" width="86" height="20" font="1">disease, poorly </text>
<text top="435" left="347" width="139" height="20" font="1">controlled hyperlipidemia </text>
<text top="452" left="347" width="114" height="20" font="1">or DM, DM requiring </text>
<text top="469" left="347" width="124" height="20" font="1">insulin, special dietary </text>
<text top="487" left="347" width="103" height="20" font="1">requirements, &gt;14 </text>
<text top="504" left="347" width="55" height="20" font="1">drinks/wk<b> </b></text>
<text top="297" left="503" width="126" height="20" font="4"><b>Intervention: </b>Feeding </text>
<text top="314" left="503" width="100" height="20" font="1">study in which pts </text>
<text top="332" left="503" width="122" height="20" font="1">were randomized to a </text>
<text top="349" left="503" width="115" height="20" font="1">DASH or control diet </text>
<text top="366" left="503" width="125" height="20" font="1">at 3 levels of assigned </text>
<text top="383" left="503" width="120" height="20" font="1">dietary sodium intake </text>
<text top="401" left="503" width="108" height="20" font="1">(High=210 mmol/d; </text>
<text top="418" left="503" width="100" height="20" font="1">Intermediate=100 </text>
<text top="435" left="503" width="94" height="20" font="1">mmol/d; Low=50 </text>
<text top="452" left="503" width="48" height="20" font="1">mmol/d)<b> </b></text>
<text top="469" left="503" width="3" height="20" font="4"><b> </b></text>
<text top="487" left="503" width="122" height="20" font="4"><b>Comparator: </b>Each pt </text>
<text top="504" left="503" width="110" height="20" font="1">served as their own </text>
<text top="521" left="503" width="101" height="20" font="1">control (crossover </text>
<text top="538" left="503" width="44" height="20" font="1">design)<b> </b></text>
<text top="298" left="644" width="83" height="20" font="4"><b>1</b>°<b> endpoint:   </b></text>
<text top="317" left="644" width="7" height="18" font="1">•</text>
<text top="317" left="651" width="206" height="20" font="4"><b> </b>Reduced sodium intake resulted in a </text>
<text top="334" left="644" width="235" height="20" font="1">significant reduction in SBP, with a greater </text>
<text top="351" left="644" width="218" height="20" font="1">reduction during assignment to the Low </text>
<text top="368" left="644" width="207" height="20" font="1">compared to the Intermediate sodium </text>
<text top="386" left="644" width="237" height="20" font="1">intake diet. At every level of sodium intake, </text>
<text top="403" left="644" width="236" height="20" font="1">the achieved reduction in SBP was greater </text>
<text top="420" left="644" width="205" height="20" font="1">on the control group compared to the </text>
<text top="437" left="644" width="214" height="20" font="1">DASH diet and for Blacks compared to </text>
<text top="454" left="644" width="55" height="20" font="1">other pts. </text>
<text top="473" left="644" width="7" height="18" font="1">•</text>
<text top="473" left="651" width="227" height="20" font="4"><b> </b>Reducing sodium intake from the high to </text>
<text top="490" left="644" width="226" height="20" font="1">intermediate level decreased SBP by 2.1 </text>
<text top="507" left="644" width="221" height="20" font="1">mm Hg (p&lt;0.001) during the control diet </text>
<text top="524" left="644" width="233" height="20" font="1">and 1.3 mm Hg (p=0.03) during the DASH </text>
<text top="542" left="644" width="27" height="20" font="1">diet. </text>
<text top="561" left="644" width="7" height="18" font="1">•</text>
<text top="560" left="651" width="187" height="20" font="4"><b> </b>Reducing sodium intake from the </text>
<text top="577" left="644" width="237" height="20" font="1">intermediate low level decreased SBP by a </text>
<text top="594" left="644" width="217" height="20" font="1">further 4.6 mm Hg (p&lt;0.001) during the </text>
<text top="612" left="644" width="238" height="20" font="1">control diet and 1.7 mm Hg (p&lt;0.01) during </text>
<text top="629" left="644" width="85" height="20" font="1">the DASH diet. </text>
<text top="646" left="644" width="3" height="20" font="4"><b> </b></text>
<text top="663" left="644" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="297" left="899" width="159" height="20" font="1">● This trial provides the best </text>
<text top="314" left="899" width="153" height="20" font="1">(direct) evidence for a dose-</text>
<text top="332" left="899" width="176" height="20" font="1">response treatment relationship </text>
<text top="349" left="899" width="153" height="20" font="1">between sodium intake and </text>
<text top="366" left="899" width="69" height="20" font="1">level of BP.  </text>
<text top="383" left="899" width="165" height="20" font="1">● It also suggests the relative </text>
<text top="400" left="899" width="174" height="20" font="1">effect of reduced sodium intake </text>
<text top="418" left="899" width="150" height="20" font="1">is greater in persons with a </text>
<text top="435" left="899" width="130" height="20" font="1">typical U.S. diet but the </text>
<text top="452" left="899" width="126" height="20" font="1">combination of sodium </text>
<text top="469" left="899" width="175" height="20" font="1">reduction and consumption of a </text>
<text top="487" left="899" width="151" height="20" font="1">DASH-type diet results in a </text>
<text top="504" left="899" width="163" height="20" font="1">lower level of BP than can be </text>
<text top="521" left="899" width="152" height="20" font="1">achieved with either dietary </text>
<text top="538" left="899" width="131" height="20" font="1">modification on its own.<b> </b></text>
<text top="557" left="899" width="7" height="18" font="1">•</text>
<text top="556" left="906" width="151" height="20" font="1"> Consistent with other trials </text>
<text top="574" left="899" width="173" height="20" font="1">and meta-analyses, it suggests </text>
<text top="591" left="899" width="169" height="20" font="1">the effect of a reduced sodium </text>
<text top="608" left="899" width="143" height="20" font="1">intake is greater in Blacks </text>
<text top="625" left="899" width="170" height="20" font="1">compared to others, especially </text>
<text top="643" left="899" width="163" height="20" font="1">for those consuming a typical </text>
<text top="660" left="899" width="54" height="20" font="1">U.S. diet.<b> </b></text>
<text top="681" left="98" width="77" height="20" font="4"><b>TOHP II Trial </b></text>
<text top="698" left="98" width="53" height="20" font="4"><b>(Sodium </b></text>
<text top="716" left="98" width="74" height="20" font="4"><b>component) </b></text>
<text top="733" left="98" width="101" height="20" font="1">Kumanyika SK, et </text>
<text top="750" left="98" width="76" height="20" font="1">al., 2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(78)</a> </text>
<text top="767" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15372064?dopt=Citation">15372064</a></text>
<text top="767" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15372064?dopt=Citation"> </a></text>
<text top="681" left="212" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="698" left="212" width="111" height="20" font="1">of sodium reduction </text>
<text top="716" left="212" width="122" height="20" font="1">on BP and prevention </text>
<text top="733" left="212" width="46" height="20" font="1">of HTN.<b> </b></text>
<text top="750" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="767" left="212" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="784" left="212" width="76" height="20" font="1">Randomized, </text>
<text top="681" left="347" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="700" left="347" width="7" height="18" font="1">•</text>
<text top="700" left="354" width="112" height="20" font="4"><b> </b>Healthy community-</text>
<text top="717" left="347" width="131" height="20" font="1">dwelling adults 30–54 y </text>
<text top="736" left="347" width="7" height="18" font="1">•</text>
<text top="735" left="354" width="113" height="20" font="4"><b> </b>BMI between 110% </text>
<text top="752" left="347" width="126" height="20" font="1">and 165% of desirable </text>
<text top="770" left="347" width="69" height="20" font="1">body weight </text>
<text top="681" left="503" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="698" left="503" width="96" height="20" font="1">Behavior change </text>
<text top="716" left="503" width="118" height="20" font="1">intervention aimed at </text>
<text top="733" left="503" width="123" height="20" font="1">studying the effects of </text>
<text top="750" left="503" width="111" height="20" font="1">modest (25%–30%) </text>
<text top="767" left="503" width="113" height="20" font="1">reductions in dietary </text>
<text top="784" left="503" width="117" height="20" font="1">sodium intake during </text>
<text top="682" left="644" width="83" height="20" font="4"><b>1</b>°<b> endpoint:   </b></text>
<text top="700" left="644" width="92" height="20" font="4"><b>Change in SBP </b></text>
<text top="719" left="644" width="7" height="18" font="1">•</text>
<text top="718" left="651" width="205" height="20" font="4"><b> </b>Compared to usual care, the sodium </text>
<text top="735" left="644" width="228" height="20" font="1">reduction group experienced a significant </text>
<text top="752" left="644" width="239" height="20" font="1">mean reduction of 51 mmol for 24-h urinary </text>
<text top="770" left="644" width="197" height="20" font="1">excretion and -2.9 (SD: 0.5) mm Hg </text>
<text top="787" left="644" width="227" height="20" font="1">(p&lt;0.001) in SBP at 6 mo (-5.1 mm Hg in </text>
<text top="681" left="899" width="162" height="20" font="1">● This was the largest trial of </text>
<text top="698" left="899" width="139" height="20" font="1">sodium reduction in HTN </text>
<text top="716" left="899" width="161" height="20" font="1">prevention and also provides </text>
<text top="733" left="899" width="167" height="20" font="1">the longest duration of follow.  </text>
<text top="750" left="899" width="168" height="20" font="1">● The assumptions for a main </text>
<text top="767" left="899" width="134" height="20" font="1">effects factorial analysis </text>
<text top="784" left="899" width="119" height="20" font="1">(independence of the </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="12" size="12" family="Times" color="#4616f6"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">42 </text>
<text top="107" left="212" width="103" height="20" font="1">controlled factorial </text>
<text top="124" left="212" width="30" height="20" font="1">trial. <b> </b></text>
<text top="141" left="212" width="3" height="20" font="1"> </text>
<text top="159" left="212" width="103" height="20" font="4"><b>Size: </b>2,382 pts, of </text>
<text top="176" left="212" width="90" height="20" font="1">whom 594 were </text>
<text top="193" left="212" width="81" height="20" font="1">randomized to </text>
<text top="210" left="212" width="97" height="20" font="1">sodium reduction </text>
<text top="228" left="212" width="120" height="20" font="1">(alone) and 596 were </text>
<text top="245" left="212" width="114" height="20" font="1">randomized to usual </text>
<text top="262" left="212" width="31" height="20" font="1">care.<b> </b></text>
<text top="109" left="347" width="7" height="18" font="1">•</text>
<text top="108" left="354" width="132" height="20" font="4"><b> </b>Not taking BP-lowering </text>
<text top="125" left="347" width="63" height="20" font="1">medication </text>
<text top="144" left="347" width="7" height="18" font="1">•</text>
<text top="144" left="354" width="120" height="20" font="4"><b> </b>Mean SBP &lt;140 mm </text>
<text top="161" left="347" width="133" height="20" font="1">Hg and DBP 83–89 mm </text>
<text top="178" left="347" width="19" height="20" font="1">Hg </text>
<text top="195" left="347" width="3" height="20" font="1"> </text>
<text top="213" left="347" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="230" left="347" width="133" height="20" font="1">Taking antihypertensive </text>
<text top="247" left="347" width="70" height="20" font="1">medication, <b> </b></text>
<text top="264" left="347" width="113" height="20" font="1">Heart disease, renal </text>
<text top="281" left="347" width="86" height="20" font="1">disease, poorly </text>
<text top="299" left="347" width="139" height="20" font="1">controlled hyperlipidemia </text>
<text top="316" left="347" width="114" height="20" font="1">or DM, DM requiring </text>
<text top="333" left="347" width="124" height="20" font="1">insulin, special dietary </text>
<text top="350" left="347" width="103" height="20" font="1">requirements, &gt;14 </text>
<text top="368" left="347" width="58" height="20" font="1">drinks/wk.<b> </b></text>
<text top="107" left="503" width="126" height="20" font="1">up to 48 mo (minimum </text>
<text top="124" left="503" width="111" height="20" font="1">36 mo) of follow-up.<b> </b></text>
<text top="141" left="503" width="3" height="20" font="4"><b> </b></text>
<text top="159" left="503" width="112" height="20" font="4"><b>Comparator: </b>Usual </text>
<text top="176" left="503" width="62" height="20" font="1">care group<b> </b></text>
<text top="107" left="644" width="225" height="20" font="1">the sodium reduction group and -2.2 mm </text>
<text top="124" left="644" width="155" height="20" font="1">Hg in the usual care group). </text>
<text top="143" left="644" width="7" height="18" font="1">•</text>
<text top="143" left="651" width="226" height="20" font="4"><b> </b>A progressive reduction in effect size for </text>
<text top="160" left="644" width="241" height="20" font="1">urinary sodium excretion and BP was noted </text>
<text top="177" left="644" width="235" height="20" font="1">over time, with mean for SBP at 18, 36 mo </text>
<text top="194" left="644" width="222" height="20" font="1">and termination of -2.0 (SD: 0.5) mm Hg </text>
<text top="211" left="644" width="233" height="20" font="1">(p&lt;0.001), -1.2 (SD: 0.5) mm Hg (p=0.02), </text>
<text top="229" left="644" width="190" height="20" font="1">and -1.0 (SD: 0.5) mm Hg (p=0.5). </text>
<text top="246" left="644" width="3" height="20" font="1"> </text>
<text top="263" left="644" width="111" height="20" font="4"><b>Prevention of </b>HTN<b> </b></text>
<text top="282" left="644" width="7" height="18" font="1">•</text>
<text top="281" left="651" width="231" height="20" font="4"><b> </b>At 6 mo of follow-up the incidence of new </text>
<text top="299" left="644" width="202" height="20" font="1">onset HTN was 39% lower in the pts </text>
<text top="316" left="644" width="213" height="20" font="1">randomized to reduced dietary sodium </text>
<text top="333" left="644" width="224" height="20" font="1">intake compared to the usual care group </text>
<text top="350" left="644" width="53" height="20" font="1">(p=0.04). </text>
<text top="369" left="644" width="7" height="18" font="1">•</text>
<text top="369" left="651" width="209" height="20" font="4"><b> </b>During more prolonged follow-up, the </text>
<text top="386" left="644" width="195" height="20" font="1">effect size decreased but remained </text>
<text top="403" left="644" width="222" height="20" font="1">significant after 48 mo of follow-up (14% </text>
<text top="420" left="644" width="242" height="20" font="1">reduction; p=0.04). Overall, the incidence of </text>
<text top="438" left="644" width="206" height="20" font="1">HTN was reduced by 18% (p=0.048). </text>
<text top="455" left="644" width="3" height="20" font="4"><b> </b></text>
<text top="472" left="644" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A <b> </b></text>
<text top="107" left="899" width="128" height="20" font="1">interventions) were not </text>
<text top="124" left="899" width="140" height="20" font="1">demonstrated. Given this </text>
<text top="141" left="899" width="137" height="20" font="1">finding, the most reliable </text>
<text top="159" left="899" width="132" height="20" font="1">analysis of this trial was </text>
<text top="176" left="899" width="165" height="20" font="1">comparison of the experience </text>
<text top="193" left="899" width="145" height="20" font="1">in each active intervention </text>
<text top="210" left="899" width="141" height="20" font="1">group with the usual care </text>
<text top="228" left="899" width="128" height="20" font="1">group. This results in a </text>
<text top="245" left="899" width="165" height="20" font="1">reduction in statistical power.  </text>
<text top="262" left="899" width="174" height="20" font="1">● Consistent with the pattern in </text>
<text top="279" left="899" width="152" height="20" font="1">the proceeding TOHP I trial </text>
<text top="296" left="899" width="165" height="20" font="1">sodium reduction reduced BP </text>
<text top="314" left="899" width="163" height="20" font="1">and the incidence of HTN but </text>
<text top="331" left="899" width="146" height="20" font="1">the effect sizes for sodium </text>
<text top="348" left="899" width="176" height="20" font="1">reduction and BP as well as the </text>
<text top="365" left="899" width="148" height="20" font="1">difficulty of maintaining the </text>
<text top="383" left="899" width="172" height="20" font="1">intervention in highly motivated </text>
<text top="400" left="899" width="150" height="20" font="1">and extensively counselled </text>
<text top="417" left="899" width="158" height="20" font="1">participants underscores the </text>
<text top="434" left="899" width="160" height="20" font="1">difficulty of achieving sodium </text>
<text top="451" left="899" width="132" height="20" font="1">reduction in the general </text>
<text top="469" left="899" width="165" height="20" font="1">population without changes in </text>
<text top="486" left="899" width="114" height="20" font="1">food processing and </text>
<text top="503" left="899" width="175" height="20" font="1">restaurant/fast food preparation </text>
<text top="520" left="899" width="56" height="20" font="1">practices.<b> </b></text>
<text top="538" left="98" width="84" height="20" font="4"><b>TOHP Phase I </b></text>
<text top="555" left="98" width="60" height="20" font="1">1992 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(79)</a>  </text>
<text top="573" left="98" width="48" height="20" font="12"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation">1586398</a></text>
<text top="573" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation"> </a></text>
<text top="538" left="212" width="120" height="20" font="4"><b>Aim:</b> Study the effect </text>
<text top="555" left="212" width="111" height="20" font="1">of sodium reduction </text>
<text top="573" left="212" width="122" height="20" font="1">on BP and prevention </text>
<text top="590" left="212" width="42" height="20" font="1">of HTN </text>
<text top="607" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="624" left="212" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="641" left="212" width="76" height="20" font="1">Randomized, </text>
<text top="659" left="212" width="103" height="20" font="1">controlled factorial </text>
<text top="676" left="212" width="30" height="20" font="1">trial. <b> </b></text>
<text top="693" left="212" width="3" height="20" font="1"> </text>
<text top="710" left="212" width="112" height="20" font="4"><b>Size: </b>Overall,<b> </b>2,182 </text>
<text top="727" left="212" width="109" height="20" font="1">adults, with the 327 </text>
<text top="745" left="212" width="109" height="20" font="1">assigned to sodium </text>
<text top="762" left="212" width="112" height="20" font="1">reduction compared </text>
<text top="538" left="347" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="557" left="347" width="7" height="18" font="1">•</text>
<text top="556" left="354" width="118" height="20" font="1"> Community-dwelling </text>
<text top="574" left="347" width="83" height="20" font="1">adults 30–54 y </text>
<text top="593" left="347" width="7" height="18" font="1">•</text>
<text top="592" left="354" width="43" height="20" font="1"> Not on </text>
<text top="609" left="347" width="93" height="20" font="1">antihypertensive </text>
<text top="627" left="347" width="63" height="20" font="1">medication </text>
<text top="646" left="347" width="7" height="18" font="1">•</text>
<text top="645" left="354" width="110" height="20" font="1"> DBP 80-89 mm Hg </text>
<text top="664" left="347" width="7" height="18" font="1">•</text>
<text top="663" left="354" width="49" height="20" font="1"> Healthy </text>
<text top="680" left="347" width="3" height="20" font="1"> </text>
<text top="698" left="347" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="717" left="347" width="7" height="18" font="1">•</text>
<text top="716" left="354" width="51" height="20" font="1"> Disease </text>
<text top="735" left="347" width="7" height="18" font="1">•</text>
<text top="734" left="354" width="130" height="20" font="1"> Inability to comply with </text>
<text top="752" left="347" width="68" height="20" font="1">the protocol<b> </b></text>
<text top="538" left="503" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="555" left="503" width="96" height="20" font="1">Behavior change </text>
<text top="573" left="503" width="67" height="20" font="1">intervention </text>
<text top="590" left="503" width="3" height="20" font="1"> </text>
<text top="607" left="503" width="112" height="20" font="4"><b>Comparator: </b>Usual </text>
<text top="624" left="503" width="27" height="20" font="1">care<b> </b></text>
<text top="539" left="644" width="83" height="20" font="4"><b>1</b>°<b> endpoint:   </b></text>
<text top="557" left="644" width="88" height="20" font="1">Change in DBP </text>
<text top="574" left="644" width="3" height="20" font="1"> </text>
<text top="592" left="644" width="83" height="20" font="4"><b>2</b>°<b> endpoint:   </b></text>
<text top="609" left="644" width="87" height="20" font="1">Change in SBP </text>
<text top="627" left="644" width="3" height="20" font="4"><b> </b></text>
<text top="644" left="644" width="103" height="20" font="4"><b>Safety endpoint:  </b></text>
<text top="661" left="644" width="224" height="20" font="1">CVD events, symptoms and general and </text>
<text top="678" left="644" width="58" height="20" font="1">well being<b> </b></text>
<text top="540" left="899" width="7" height="18" font="1">•</text>
<text top="539" left="906" width="158" height="20" font="4"><b> </b>Significantly lower DBP (0.9 </text>
<text top="557" left="899" width="168" height="20" font="1">mm Hg; p&lt;0.05) and SBP (1.7 </text>
<text top="574" left="899" width="168" height="20" font="1">mm Hg; p&lt;0.01) in the sodium </text>
<text top="591" left="899" width="161" height="20" font="1">reduction group compared to </text>
<text top="608" left="899" width="60" height="20" font="1">usual care </text>
<text top="627" left="899" width="7" height="18" font="1">•</text>
<text top="626" left="906" width="99" height="20" font="4"><b> </b>Few CVD events </text>
<text top="646" left="899" width="7" height="18" font="1">•</text>
<text top="645" left="906" width="152" height="20" font="4"><b> </b>No difference in symptoms </text>
<text top="664" left="899" width="7" height="18" font="1">•</text>
<text top="663" left="906" width="151" height="20" font="4"><b> </b>Significant improvement in </text>
<text top="680" left="899" width="168" height="20" font="1">general well-being at 6 and 18 </text>
<text top="698" left="899" width="70" height="20" font="1">mo (p&lt;0.05)<b> </b></text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="13" size="12" family="Times" color="#ff0000"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">43 </text>
<text top="107" left="212" width="98" height="20" font="1">to 417 usual care </text>
<text top="124" left="212" width="46" height="20" font="1">controls<b> </b></text>
<text top="142" left="98" width="90" height="20" font="1">Cook NR, et al., </text>
<text top="159" left="98" width="56" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(80)</a> </text>
<text top="177" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17449506?dopt=Citation">17449506</a></text>
<text top="177" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17449506?dopt=Citation"> </a></text>
<text top="142" left="212" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="159" left="212" width="111" height="20" font="1">of sodium reduction </text>
<text top="177" left="212" width="100" height="20" font="1">on CVD morbidity </text>
<text top="194" left="212" width="77" height="20" font="1">and mortality.<b> </b></text>
<text top="211" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="228" left="212" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="245" left="212" width="98" height="20" font="1">10–15 y post-trial </text>
<text top="263" left="212" width="110" height="20" font="1">follow-up of TOHP I </text>
<text top="280" left="212" width="115" height="20" font="1">and TOPH II pts that </text>
<text top="297" left="212" width="122" height="20" font="1">took advantage of the </text>
<text top="314" left="212" width="91" height="20" font="1">randomized trial </text>
<text top="332" left="212" width="107" height="20" font="1">design. Vital status </text>
<text top="349" left="212" width="94" height="20" font="1">was obtained for </text>
<text top="366" left="212" width="113" height="20" font="1">100% of the pts and </text>
<text top="383" left="212" width="81" height="20" font="1">information on </text>
<text top="401" left="212" width="78" height="20" font="1">morbidity was </text>
<text top="418" left="212" width="113" height="20" font="1">obtained from 2,415 </text>
<text top="435" left="212" width="94" height="20" font="1">(77%) of the pts. </text>
<text top="452" left="212" width="3" height="20" font="1"> </text>
<text top="469" left="212" width="93" height="20" font="4"><b>Size: </b>744 TOHP </text>
<text top="487" left="212" width="103" height="20" font="1">Phase I and 2,382 </text>
<text top="504" left="212" width="109" height="20" font="1">TOHP Phase II pts <b> </b></text>
<text top="142" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="159" left="347" width="108" height="20" font="1">Assigned to dietary </text>
<text top="177" left="347" width="111" height="20" font="1">sodium reduction or </text>
<text top="194" left="347" width="136" height="20" font="1">control in TOHP Phase I </text>
<text top="211" left="347" width="104" height="20" font="1">or TOHP Phase II.<b> </b></text>
<text top="228" left="347" width="3" height="20" font="1"> </text>
<text top="245" left="347" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="263" left="347" width="33" height="20" font="1">None<b> </b></text>
<text top="142" left="503" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="159" left="503" width="96" height="20" font="1">Behavior change </text>
<text top="177" left="503" width="118" height="20" font="1">intervention aimed at </text>
<text top="194" left="503" width="123" height="20" font="1">studying the effects of </text>
<text top="211" left="503" width="111" height="20" font="1">modest (25%–30%) </text>
<text top="228" left="503" width="113" height="20" font="1">reductions in dietary </text>
<text top="246" left="503" width="117" height="20" font="1">sodium intake during </text>
<text top="263" left="503" width="97" height="20" font="1">TOHP Phase I or </text>
<text top="280" left="503" width="90" height="20" font="1">TOHP Phase II.<b> </b></text>
<text top="297" left="503" width="3" height="20" font="4"><b> </b></text>
<text top="314" left="503" width="96" height="20" font="4"><b>Comparator: </b>No </text>
<text top="332" left="503" width="97" height="20" font="1">sodium reduction </text>
<text top="349" left="503" width="74" height="20" font="1">intervention. <b> </b></text>
<text top="143" left="644" width="83" height="20" font="4"><b>1</b>°<b> endpoint:   </b></text>
<text top="162" left="644" width="7" height="18" font="1">•</text>
<text top="162" left="651" width="215" height="20" font="4"><b> </b>200 CVD events and 77 deaths during </text>
<text top="179" left="644" width="53" height="20" font="1">follow-up </text>
<text top="198" left="644" width="7" height="18" font="1">•</text>
<text top="197" left="651" width="200" height="20" font="4"><b> </b>Kaplan-Meier plots identified trends </text>
<text top="215" left="644" width="239" height="20" font="1">toward less morbidity and mortality in those </text>
<text top="232" left="644" width="205" height="20" font="1">who had been randomized to sodium </text>
<text top="249" left="644" width="225" height="20" font="1">reduction compared to usual care, with a </text>
<text top="266" left="644" width="207" height="20" font="1">consistent pattern for the TOHP I and </text>
<text top="284" left="644" width="114" height="20" font="1">TOHP II participants </text>
<text top="303" left="644" width="7" height="18" font="1">•</text>
<text top="302" left="651" width="232" height="20" font="4"><b> </b>Risk of a CVD event was 30% lower (RR: </text>
<text top="319" left="644" width="233" height="20" font="1">0.70; 95% CI: 0.53–0.94; p=0.018) among </text>
<text top="336" left="644" width="212" height="20" font="1">those randomized to sodium reduction </text>
<text top="354" left="644" width="227" height="20" font="1">compared to usual care, after adjustment </text>
<text top="371" left="644" width="212" height="20" font="1">for trial, clinic, age, race, sex, baseline </text>
<text top="388" left="644" width="159" height="20" font="1">weight and sodium excretion </text>
<text top="407" left="644" width="7" height="18" font="1">•</text>
<text top="406" left="651" width="223" height="20" font="4"><b> </b>RR for total mortality was 0.80 (95% CI: </text>
<text top="423" left="644" width="66" height="20" font="1">0.51–1.26). </text>
<text top="441" left="644" width="3" height="20" font="4"><b> </b></text>
<text top="458" left="644" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A <b> </b></text>
<text top="142" left="899" width="155" height="20" font="1">● Dietary sodium reduction, </text>
<text top="159" left="899" width="172" height="20" font="1">previously shown to reduce BP </text>
<text top="177" left="899" width="175" height="20" font="1">and prevent HTN in the TOHP I </text>
<text top="194" left="899" width="174" height="20" font="1">and TOHP II trials, appeared to </text>
<text top="211" left="899" width="148" height="20" font="1">reduce CVD events during </text>
<text top="228" left="899" width="171" height="20" font="1">extended post-trial follow-up of </text>
<text top="246" left="899" width="145" height="20" font="1">the pts from these 2 trials.<b> </b></text>
<text top="523" left="108" width="3" height="19" font="13"> </text>
<text top="557" left="81" width="857" height="24" font="3"><b>Data Supplement 14. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Stress Reduction) (Section 6.2) </b></text>
<text top="597" left="102" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="614" left="127" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="632" left="105" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="597" left="252" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="614" left="257" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="632" left="251" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="597" left="391" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="597" left="528" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="614" left="560" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="632" left="528" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="649" left="563" width="55" height="20" font="4"><b>patients) </b></text>
<text top="597" left="695" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="614" left="679" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="632" left="685" width="126" height="20" font="4"><b>P value; OR or RR; &amp; </b></text>
<text top="649" left="724" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="598" left="868" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="616" left="900" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="633" left="908" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="667" left="98" width="98" height="20" font="1">Canter PH, et al., </text>
<text top="684" left="98" width="56" height="20" font="1">2004 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(81)</a> </text>
<text top="701" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15480084?dopt=Citation">15480084 </a></text>
<text top="667" left="217" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="684" left="217" width="144" height="20" font="1">transcendental meditation </text>
<text top="701" left="217" width="37" height="20" font="1">on BP<b> </b></text>
<text top="718" left="217" width="3" height="20" font="1"> </text>
<text top="736" left="217" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="753" left="217" width="39" height="20" font="1">review </text>
<text top="770" left="217" width="3" height="20" font="4"><b> </b></text>
<text top="787" left="217" width="32" height="20" font="4"><b>Size: </b></text>
<text top="667" left="384" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="686" left="384" width="7" height="18" font="1">•</text>
<text top="685" left="391" width="92" height="20" font="1"> RCT in humans </text>
<text top="704" left="384" width="7" height="18" font="1">•</text>
<text top="704" left="391" width="103" height="20" font="1"> Publication in any </text>
<text top="721" left="384" width="107" height="20" font="1">language until May </text>
<text top="738" left="384" width="31" height="20" font="1">2004 </text>
<text top="757" left="384" width="7" height="18" font="1">•</text>
<text top="756" left="391" width="84" height="20" font="1"> No concurrent </text>
<text top="774" left="384" width="73" height="20" font="1">interventions </text>
<text top="667" left="522" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="686" left="522" width="7" height="18" font="1">•</text>
<text top="685" left="529" width="126" height="20" font="1"> Use of transcendental </text>
<text top="702" left="522" width="123" height="20" font="1">meditation techniques </text>
<text top="720" left="522" width="127" height="20" font="1">as taught by Maharishi </text>
<text top="737" left="522" width="75" height="20" font="1">Mahesh Yogi </text>
<text top="756" left="522" width="7" height="18" font="1">•</text>
<text top="755" left="529" width="127" height="20" font="1"> Practiced on a regular </text>
<text top="772" left="522" width="131" height="20" font="1">basis over an extended </text>
<text top="790" left="522" width="38" height="20" font="1">period </text>
<text top="668" left="672" width="141" height="20" font="4"><b>1</b>°<b> endpoint:</b> Statistically </text>
<text top="685" left="672" width="125" height="20" font="1">significant reduction in </text>
<text top="702" left="672" width="124" height="20" font="1">SBP reported in 3 of 5 </text>
<text top="720" left="672" width="133" height="20" font="1">trials that provided such </text>
<text top="737" left="672" width="71" height="20" font="1">information.  </text>
<text top="754" left="672" width="3" height="20" font="4"><b> </b></text>
<text top="772" left="672" width="143" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A  </text>
<text top="790" left="672" width="3" height="20" font="4"><b> </b></text>
<text top="667" left="836" width="224" height="20" font="1">● Only a handful of RCTs available from </text>
<text top="684" left="836" width="218" height="20" font="1">the large number of publications on this </text>
<text top="701" left="836" width="33" height="20" font="1">topic. </text>
<text top="718" left="836" width="227" height="20" font="1">● Trials had methodological weaknesses </text>
<text top="736" left="836" width="224" height="20" font="1">and were subject to potential bias due to </text>
<text top="753" left="836" width="165" height="20" font="1">the affiliation of authors to the </text>
<text top="770" left="836" width="218" height="20" font="1">transcendental meditation organization. </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">44 </text>
<text top="109" left="217" width="7" height="18" font="1">•</text>
<text top="108" left="224" width="137" height="20" font="1"> 6 RCTs with wide range </text>
<text top="125" left="217" width="130" height="20" font="1">of pts: young to elderly; </text>
<text top="143" left="217" width="117" height="20" font="1">healthy volunteers to </text>
<text top="160" left="217" width="97" height="20" font="1">Blacks with HTN. </text>
<text top="179" left="217" width="7" height="18" font="1">•</text>
<text top="178" left="224" width="75" height="20" font="1"> HTN: 2 trials </text>
<text top="197" left="217" width="7" height="18" font="1">•</text>
<text top="197" left="224" width="136" height="20" font="1"> High normal BP: 2 trials </text>
<text top="216" left="217" width="7" height="18" font="1">•</text>
<text top="215" left="224" width="120" height="20" font="1"> Normotensive: 1 trial </text>
<text top="234" left="217" width="7" height="18" font="1">•</text>
<text top="233" left="224" width="100" height="20" font="1"> Not stated: 1 trial </text>
<text top="252" left="217" width="7" height="18" font="1">•</text>
<text top="252" left="224" width="124" height="20" font="1"> Sample sizes ranging </text>
<text top="269" left="217" width="92" height="20" font="1">from 34–156 pts </text>
<text top="288" left="217" width="7" height="18" font="1">•</text>
<text top="287" left="224" width="142" height="20" font="1"> Follow-up from 2 mo–1 y </text>
<text top="107" left="384" width="3" height="20" font="1"> </text>
<text top="124" left="384" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="141" left="384" width="24" height="20" font="1">N/A </text>
<text top="107" left="522" width="7" height="20" font="1">  </text>
<text top="124" left="522" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="141" left="522" width="96" height="20" font="1">treatment, sham, </text>
<text top="159" left="522" width="116" height="20" font="1">alternative treatment </text>
<text top="107" left="836" width="230" height="20" font="1">● A few trials reported small reductions in </text>
<text top="124" left="836" width="217" height="20" font="1">SBP but clinical relevance of findings is </text>
<text top="141" left="836" width="47" height="20" font="1">unclear. </text>
<text top="159" left="836" width="218" height="20" font="1">● Most of the trials were underpowered </text>
<text top="176" left="836" width="198" height="20" font="1">and could have missed a significant </text>
<text top="193" left="836" width="43" height="20" font="1">finding. </text>
<text top="210" left="836" width="226" height="20" font="1">● The authors concluded that “there is at </text>
<text top="228" left="836" width="176" height="20" font="1">present insufficient good quality </text>
<text top="245" left="836" width="213" height="20" font="1">information to conclude whether or not </text>
<text top="262" left="836" width="178" height="20" font="1">transcendental meditation has a </text>
<text top="279" left="836" width="185" height="20" font="1">cumulative positive effect on BP”  </text>
<text top="307" left="108" width="3" height="19" font="1"> </text>
<text top="341" left="81" width="984" height="24" font="3"><b>Data Supplement 15. RCTs and Meta-analyses Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Patterns) (Section 6.2) </b></text>
<text top="381" left="126" width="38" height="20" font="4"><b>Study </b></text>
<text top="398" left="115" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="415" left="121" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="433" left="99" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="381" left="228" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="398" left="233" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="415" left="227" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="381" left="366" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="381" left="515" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="398" left="547" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="415" left="515" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="433" left="551" width="55" height="20" font="4"><b>patients) </b></text>
<text top="381" left="708" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="398" left="691" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="415" left="673" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="382" left="898" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="399" left="930" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="416" left="938" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="451" left="98" width="88" height="20" font="1">Appel LJ, et al., </text>
<text top="468" left="98" width="56" height="20" font="1">1997 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(82)</a><b> </b></text>
<text top="485" left="98" width="51" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9099655?dopt=Citation">9099655 </a></text>
<text top="451" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="468" left="206" width="119" height="20" font="1">of dietary patterns on </text>
<text top="485" left="206" width="20" height="20" font="1">BP<b> </b></text>
<text top="502" left="206" width="3" height="20" font="1"> </text>
<text top="519" left="206" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="538" left="206" width="7" height="18" font="1">•</text>
<text top="538" left="212" width="96" height="20" font="1"> Multicenter RCT </text>
<text top="557" left="206" width="7" height="18" font="1">•</text>
<text top="556" left="212" width="121" height="20" font="1"> 3 arm parallel design </text>
<text top="575" left="206" width="7" height="18" font="1">•</text>
<text top="574" left="212" width="54" height="20" font="1"> 3 wk pre-</text>
<text top="592" left="206" width="116" height="20" font="1">randomization run-in </text>
<text top="609" left="206" width="37" height="20" font="1">phase </text>
<text top="628" left="206" width="7" height="18" font="1">•</text>
<text top="627" left="212" width="120" height="20" font="1"> Feeding study with 8 </text>
<text top="644" left="206" width="103" height="20" font="1">wk of intervention  </text>
<text top="662" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="679" left="206" width="96" height="20" font="4"><b>Size: </b>459 adults, </text>
<text top="696" left="206" width="116" height="20" font="1">mean age 44 y. (326 </text>
<text top="713" left="206" width="81" height="20" font="1">normotensive) </text>
<text top="451" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="470" left="347" width="7" height="18" font="1">•</text>
<text top="469" left="354" width="76" height="20" font="1"> Adults ≥22 y </text>
<text top="488" left="347" width="7" height="18" font="1">•</text>
<text top="487" left="354" width="126" height="20" font="1"> SBP&lt;160 mm Hg and </text>
<text top="504" left="347" width="113" height="20" font="1">DBP 80–95 mm Hg  </text>
<text top="523" left="347" width="7" height="18" font="1">•</text>
<text top="523" left="354" width="115" height="20" font="1"> No antihypertensive </text>
<text top="540" left="347" width="63" height="20" font="1">medication </text>
<text top="557" left="347" width="3" height="20" font="1"> </text>
<text top="574" left="347" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="593" left="347" width="7" height="18" font="1">•</text>
<text top="593" left="354" width="132" height="20" font="1"> CVD event within 6 mo </text>
<text top="612" left="347" width="7" height="18" font="1">•</text>
<text top="611" left="354" width="135" height="20" font="1"> Poorly controlled DM or </text>
<text top="628" left="347" width="83" height="20" font="1">hyperlipidemia </text>
<text top="647" left="347" width="7" height="18" font="1">•</text>
<text top="647" left="354" width="54" height="20" font="1"> BMI ≥35 </text>
<text top="666" left="347" width="7" height="18" font="1">•</text>
<text top="665" left="354" width="129" height="20" font="1"> Pregnancy or lactation </text>
<text top="684" left="347" width="7" height="18" font="1">•</text>
<text top="683" left="354" width="111" height="20" font="1"> Chronic illness that </text>
<text top="701" left="347" width="109" height="20" font="1">would interfere with </text>
<text top="718" left="347" width="70" height="20" font="1">participation </text>
<text top="737" left="347" width="7" height="18" font="1">•</text>
<text top="736" left="354" width="122" height="20" font="1"> Unwillingness to stop </text>
<text top="753" left="347" width="132" height="20" font="1">taking vitamins, mineral </text>
<text top="771" left="347" width="110" height="20" font="1">supplements, Ca++ </text>
<text top="788" left="347" width="49" height="20" font="1">antacids </text>
<text top="451" left="509" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="470" left="509" width="7" height="18" font="1">•</text>
<text top="469" left="516" width="122" height="20" font="1"> Diet high in fruits and </text>
<text top="486" left="509" width="63" height="20" font="1">vegetables </text>
<text top="505" left="509" width="7" height="18" font="1">•</text>
<text top="504" left="516" width="107" height="20" font="1"> “Combination” diet </text>
<text top="522" left="509" width="73" height="20" font="1">high in fruits, </text>
<text top="539" left="509" width="136" height="20" font="1">vegetables, low-fat dairy </text>
<text top="556" left="509" width="126" height="20" font="1">products, and reduced </text>
<text top="573" left="509" width="119" height="20" font="1">total fat, saturated fat </text>
<text top="590" left="509" width="90" height="20" font="1">and cholesterol. </text>
<text top="608" left="509" width="7" height="20" font="1">  </text>
<text top="625" left="509" width="112" height="20" font="4"><b>Comparator:</b> Usual </text>
<text top="642" left="509" width="51" height="20" font="1">U.S. diet </text>
<text top="452" left="659" width="171" height="20" font="4"><b>1</b>°<b> endpoint:</b> Compared to the </text>
<text top="469" left="659" width="191" height="20" font="1">control diet, both intervention diets </text>
<text top="486" left="659" width="187" height="20" font="1">reduced BP, with an overall mean </text>
<text top="503" left="659" width="123" height="20" font="1">(95% CI) reduction of: </text>
<text top="522" left="659" width="7" height="18" font="1">•</text>
<text top="522" left="666" width="119" height="20" font="1"> Fruits and Veg. Diet: </text>
<text top="539" left="659" width="174" height="20" font="1">  SBP: -2.8 (95% CI: -4.7– -0.9) </text>
<text top="556" left="659" width="175" height="20" font="1">  DBP: -1.1 (95% CI: -2.4– -0.3) </text>
<text top="575" left="659" width="7" height="18" font="1">•</text>
<text top="574" left="666" width="105" height="20" font="1"> Combination Diet: </text>
<text top="592" left="659" width="174" height="20" font="1">  SBP: -5.5 (95% CI: -7.4– -3.7) </text>
<text top="609" left="659" width="175" height="20" font="1">  DBP: -3.0 (95% CI: -4.3– -1.6) </text>
<text top="626" left="659" width="3" height="20" font="1"> </text>
<text top="643" left="659" width="183" height="20" font="1">The BP changes in the subgroup </text>
<text top="660" left="659" width="87" height="20" font="1">with HTN were: </text>
<text top="679" left="659" width="7" height="18" font="1">•</text>
<text top="679" left="666" width="119" height="20" font="1"> Fruits and Veg. Diet: </text>
<text top="696" left="659" width="131" height="20" font="1">  SBP: -7.2 (-11.4, -3.0) </text>
<text top="713" left="659" width="124" height="20" font="1">  DBP: -2.8 (-5.4, -0.3) </text>
<text top="732" left="659" width="7" height="18" font="1">•</text>
<text top="732" left="666" width="105" height="20" font="1"> Combination Diet: </text>
<text top="749" left="659" width="137" height="20" font="1">  SBP: -11.4 (-15.9, -6.9) </text>
<text top="766" left="659" width="124" height="20" font="1">  DBP: -5.5 (-8.2, -2.7) </text>
<text top="783" left="659" width="3" height="20" font="1"> </text>
<text top="451" left="874" width="202" height="20" font="1">● This trial was the first of several to </text>
<text top="468" left="874" width="215" height="20" font="1">document the value of the combination </text>
<text top="485" left="874" width="196" height="20" font="1">diet (later renamed the DASH diet). </text>
<text top="502" left="874" width="197" height="20" font="1">● The BP reductions noted with the </text>
<text top="519" left="874" width="169" height="20" font="1">DASH (combination) diet were </text>
<text top="537" left="874" width="178" height="20" font="1">substantial and well maintained. </text>
<text top="554" left="874" width="222" height="20" font="1">● Generalizability was limited due to the </text>
<text top="571" left="874" width="187" height="20" font="1">nature of the intervention (feeding </text>
<text top="588" left="874" width="215" height="20" font="1">study) and the relatively short period of </text>
<text top="605" left="874" width="168" height="20" font="1">intervention experience (8 wk) </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">45 </text>
<text top="109" left="347" width="7" height="18" font="1">•</text>
<text top="108" left="354" width="94" height="20" font="1"> Consuming ≥14 </text>
<text top="125" left="347" width="116" height="20" font="1">alcoholic drinks with  </text>
<text top="144" left="347" width="7" height="18" font="1">•</text>
<text top="144" left="354" width="109" height="20" font="1"> Renal insufficiency </text>
<text top="107" left="659" width="189" height="20" font="1">The corresponding changes in the </text>
<text top="124" left="659" width="185" height="20" font="1">subgroup of normotensives were: </text>
<text top="143" left="659" width="7" height="18" font="1">•</text>
<text top="143" left="666" width="119" height="20" font="1"> Fruits and Veg. Diet: </text>
<text top="160" left="659" width="120" height="20" font="1">  SBP: -0.8 (-2.7, 1.1) </text>
<text top="177" left="659" width="120" height="20" font="1">  DBP: -0.3 (-1.9, 1.3) </text>
<text top="196" left="659" width="7" height="18" font="1">•</text>
<text top="195" left="666" width="105" height="20" font="1"> Combination Diet: </text>
<text top="213" left="659" width="124" height="20" font="1">  SBP: -3.5 (-5.3, -1.6) </text>
<text top="230" left="659" width="124" height="20" font="1">  DBP: -2.1 (-3.6, -0.5) </text>
<text top="247" left="659" width="3" height="20" font="1"> </text>
<text top="265" left="659" width="199" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> Infrequent and </text>
<text top="283" left="659" width="117" height="20" font="1">similar occurrence of </text>
<text top="300" left="659" width="189" height="20" font="1">gastrointestinal symptoms in each </text>
<text top="317" left="659" width="38" height="20" font="1">group  </text>
<text top="335" left="98" width="95" height="20" font="1">Sacks FM, et al., </text>
<text top="352" left="98" width="56" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(77)</a> </text>
<text top="370" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11136953?dopt=Citation">11136953</a></text>
<text top="370" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11136953?dopt=Citation"> </a></text>
<text top="335" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="352" left="206" width="110" height="20" font="1">of different levels of </text>
<text top="370" left="206" width="116" height="20" font="1">sodium intake on BP </text>
<text top="387" left="206" width="124" height="20" font="1">during consumption of </text>
<text top="404" left="206" width="122" height="20" font="1">a DASH or usual U.S. </text>
<text top="421" left="206" width="23" height="20" font="1">diet<b> </b></text>
<text top="438" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="456" left="206" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="475" left="206" width="7" height="18" font="1">•</text>
<text top="474" left="212" width="121" height="20" font="1"> Multicenter RCT with </text>
<text top="491" left="206" width="107" height="20" font="1">2 parallel diet arms </text>
<text top="508" left="206" width="112" height="20" font="1">(DASH diet or usual </text>
<text top="526" left="206" width="55" height="20" font="1">U.S. diet) </text>
<text top="545" left="206" width="7" height="18" font="1">•</text>
<text top="544" left="212" width="99" height="20" font="1"> Within each arm, </text>
<text top="561" left="206" width="128" height="20" font="1">randomized cross-over </text>
<text top="578" left="206" width="102" height="20" font="1">trial with 3 periods </text>
<text top="596" left="206" width="122" height="20" font="1">testing different levels </text>
<text top="613" left="206" width="114" height="20" font="1">of sodium intake (no </text>
<text top="630" left="206" width="53" height="20" font="1">washout) </text>
<text top="647" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="664" left="206" width="113" height="20" font="4"><b>Size: </b>412, with 59% </text>
<text top="682" left="206" width="66" height="20" font="1">(243) being </text>
<text top="699" left="206" width="81" height="20" font="1">normotensive <b> </b></text>
<text top="335" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="354" left="347" width="7" height="18" font="1">•</text>
<text top="353" left="354" width="76" height="20" font="1"> Adults ≥22 y </text>
<text top="373" left="347" width="7" height="18" font="1">•</text>
<text top="372" left="354" width="130" height="20" font="1"> Average SBP between </text>
<text top="389" left="347" width="118" height="20" font="1">120–159 mm Hg and </text>
<text top="406" left="347" width="126" height="20" font="1">average DBP between </text>
<text top="423" left="347" width="81" height="20" font="1">80–95 mm Hg </text>
<text top="442" left="347" width="7" height="18" font="1">•</text>
<text top="442" left="354" width="59" height="20" font="1"> No use of </text>
<text top="459" left="347" width="93" height="20" font="1">antihypertensive </text>
<text top="476" left="347" width="63" height="20" font="1">medication </text>
<text top="493" left="347" width="3" height="20" font="4"><b> </b></text>
<text top="511" left="347" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="528" left="347" width="113" height="20" font="1">Heart disease, renal </text>
<text top="545" left="347" width="111" height="20" font="1">insufficiency, poorly </text>
<text top="562" left="347" width="139" height="20" font="1">controlled hyperlipidemia </text>
<text top="580" left="347" width="114" height="20" font="1">or DM, DM requiring </text>
<text top="597" left="347" width="124" height="20" font="1">insulin, special dietary </text>
<text top="614" left="347" width="103" height="20" font="1">requirements, &gt;14 </text>
<text top="631" left="347" width="113" height="20" font="1">alcoholic drinks /wk. </text>
<text top="335" left="509" width="137" height="20" font="4"><b>Intervention:</b> 3 levels of </text>
<text top="352" left="509" width="115" height="20" font="1">dietary sodium while </text>
<text top="370" left="509" width="125" height="20" font="1">consuming a DASH or </text>
<text top="387" left="509" width="111" height="20" font="1">usual U.S. diet. The </text>
<text top="404" left="509" width="114" height="20" font="1">target sodium intake </text>
<text top="421" left="509" width="132" height="20" font="1">levels for a daily energy </text>
<text top="438" left="509" width="109" height="20" font="1">intake of 2,100 kcal </text>
<text top="456" left="509" width="33" height="20" font="1">were:<b> </b></text>
<text top="473" left="509" width="128" height="20" font="1">High: 150 mmol (3,450 </text>
<text top="490" left="509" width="35" height="20" font="1">mg)/d </text>
<text top="507" left="509" width="133" height="20" font="1">Intermediate: 100 mmol </text>
<text top="524" left="509" width="73" height="20" font="1">(2,300 mg)/d </text>
<text top="542" left="509" width="118" height="20" font="1">Low: 50 mmol (1,150 </text>
<text top="559" left="509" width="35" height="20" font="1">mg)/d </text>
<text top="576" left="509" width="3" height="20" font="1"> </text>
<text top="593" left="509" width="111" height="20" font="1">The mean achieved </text>
<text top="610" left="509" width="129" height="20" font="1">levels of sodium during </text>
<text top="628" left="509" width="122" height="20" font="1">the high, intermediate </text>
<text top="645" left="509" width="132" height="20" font="1">and low sodium periods </text>
<text top="662" left="509" width="122" height="20" font="1">were 144, 107 and 67 </text>
<text top="679" left="509" width="115" height="20" font="1">mmol/d in the DASH </text>
<text top="697" left="509" width="137" height="20" font="1">diet group and 141, 106, </text>
<text top="714" left="509" width="118" height="20" font="1">and 64 mmol/d in the </text>
<text top="731" left="509" width="125" height="20" font="1">usual U.S. diet group.  </text>
<text top="748" left="509" width="3" height="20" font="4"><b> </b></text>
<text top="765" left="509" width="102" height="20" font="4"><b>Comparator: </b>See </text>
<text top="783" left="509" width="100" height="20" font="1">description above<b> </b></text>
<text top="336" left="659" width="79" height="20" font="4"><b>1</b>°<b> endpoint:  </b></text>
<text top="355" left="659" width="7" height="18" font="1">•</text>
<text top="355" left="666" width="174" height="20" font="1"> At each level of sodium intake, </text>
<text top="372" left="659" width="181" height="20" font="1">SBP and DBP were lower during </text>
<text top="389" left="659" width="168" height="20" font="1">consumption of the DASH diet </text>
<text top="406" left="659" width="200" height="20" font="1">compared to the usual U.S. diet, the </text>
<text top="423" left="659" width="191" height="20" font="1">difference being greatest with high </text>
<text top="441" left="659" width="189" height="20" font="1">sodium intake and lowest with low </text>
<text top="458" left="659" width="191" height="20" font="1">sodium intake, with the mean SBP </text>
<text top="475" left="659" width="189" height="20" font="1">difference between the DASH and </text>
<text top="492" left="659" width="150" height="20" font="1">usual US diets during high, </text>
<text top="510" left="659" width="196" height="20" font="1">intermediate and low sodium intake </text>
<text top="527" left="659" width="198" height="20" font="1">being -5.9 (95% CI: -8.0– -3.7), -5.0 </text>
<text top="544" left="659" width="195" height="20" font="1">(95% CI: -7.6– -2.5), and -2.2 (95% </text>
<text top="561" left="659" width="189" height="20" font="1">CI: -4.4– -0.1). The corresponding </text>
<text top="578" left="659" width="197" height="20" font="1">differences for DBP were -2.9 (95% </text>
<text top="596" left="659" width="194" height="20" font="1">CI: -4.3– -1.5), -2.5 (95% CI: -4.1– -</text>
<text top="613" left="659" width="184" height="20" font="1">0.8), and -1.0 (95% CI: -2.5, 0.4).<b> </b></text>
<text top="632" left="659" width="7" height="18" font="1">•</text>
<text top="631" left="666" width="187" height="20" font="1"> In both the DASH and usual U.S. </text>
<text top="648" left="659" width="168" height="20" font="1">diet arms, SBP and DBP were </text>
<text top="666" left="659" width="137" height="20" font="1">significantly lower during </text>
<text top="683" left="659" width="170" height="20" font="1">intermediate compared to high </text>
<text top="700" left="659" width="166" height="20" font="1">sodium intake, and during low </text>
<text top="717" left="659" width="186" height="20" font="1">compared to intermediate sodium </text>
<text top="734" left="659" width="180" height="20" font="1">intake, with the decrement being </text>
<text top="752" left="659" width="159" height="20" font="1">greater for the latter change. </text>
<text top="771" left="659" width="7" height="18" font="1">•</text>
<text top="770" left="666" width="195" height="20" font="1"> In comparison to consumption of a </text>
<text top="787" left="659" width="187" height="20" font="1">usual U.S. diet at the high level of </text>
<text top="335" left="874" width="169" height="20" font="1">● This trial provided additional </text>
<text top="352" left="874" width="217" height="20" font="1">documentation of the effectiveness of a </text>
<text top="370" left="874" width="156" height="20" font="1">DASH diet in lowering BP in </text>
<text top="387" left="874" width="219" height="20" font="1">normotensives (and hypertensives) and </text>
<text top="404" left="874" width="162" height="20" font="1">the complementary benefit of </text>
<text top="421" left="874" width="217" height="20" font="1">consuming a reduced intake of sodium. </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="14" size="7" family="Times" color="#000000"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">46 </text>
<text top="107" left="659" width="180" height="20" font="1">sodium intake, the normotensive </text>
<text top="124" left="659" width="193" height="20" font="1">group consuming the DASH diet at </text>
<text top="141" left="659" width="198" height="20" font="1">the low level of sodium intake had a </text>
<text top="159" left="659" width="197" height="20" font="1">mean SBP difference of 7.1 mm Hg </text>
<text top="176" left="659" width="60" height="20" font="1">(p&lt;0.001). </text>
<text top="193" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="211" left="659" width="113" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b></text>
<text top="213" left="772" width="2" height="13" font="14"><b> </b></text>
<text top="211" left="774" width="67" height="20" font="1">Participants </text>
<text top="229" left="659" width="175" height="20" font="1">tended to report less symptoms </text>
<text top="246" left="659" width="186" height="20" font="1">during periods of reduced sodium </text>
<text top="263" left="659" width="196" height="20" font="1">intake, with a statistically significant </text>
<text top="280" left="659" width="180" height="20" font="1">reduction in reports of headache </text>
<text top="298" left="659" width="162" height="20" font="1">(p&lt;0.05) consistent with prior </text>
<text top="315" left="659" width="158" height="20" font="1">experience in the TONE trial.</text>
<text top="316" left="817" width="2" height="13" font="14"><b> </b></text>
<text top="333" left="98" width="63" height="20" font="4"><b>PREMIER</b>  </text>
<text top="350" left="98" width="88" height="20" font="1">Appel LJ, et al., </text>
<text top="367" left="98" width="56" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(83)</a> </text>
<text top="384" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12709466">12709466</a></text>
<text top="384" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12709466"> </a></text>
<text top="333" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="350" left="206" width="84" height="20" font="1">of 2 behavioral </text>
<text top="367" left="206" width="127" height="20" font="1">interventions, aimed at </text>
<text top="384" left="206" width="128" height="20" font="1">dietary change, on BP  </text>
<text top="402" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="419" left="206" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="438" left="206" width="7" height="18" font="1">•</text>
<text top="437" left="212" width="121" height="20" font="1"> Multicenter RCT with </text>
<text top="454" left="206" width="87" height="20" font="1">3 parallel arms: </text>
<text top="473" left="206" width="7" height="18" font="1">•</text>
<text top="473" left="212" width="71" height="20" font="1"> Established </text>
<text top="492" left="206" width="7" height="18" font="1">•</text>
<text top="491" left="212" width="96" height="20" font="1"> Established plus </text>
<text top="508" left="206" width="61" height="20" font="1">DASH diet </text>
<text top="527" left="206" width="7" height="18" font="1">•</text>
<text top="527" left="212" width="70" height="20" font="1"> Advice only </text>
<text top="544" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="561" left="206" width="32" height="20" font="4"><b>Size: </b></text>
<text top="578" left="206" width="117" height="20" font="1">810 adults, with 62% </text>
<text top="596" left="206" width="128" height="20" font="1">(506) normotensive. At </text>
<text top="613" left="206" width="114" height="20" font="1">baseline, mean age, </text>
<text top="630" left="206" width="106" height="20" font="1">BMI and SBP/DBP </text>
<text top="647" left="206" width="104" height="20" font="1">were 50 y, 33 kg/m</text>
<text top="649" left="309" width="4" height="13" font="6">2</text>
<text top="647" left="314" width="7" height="20" font="1">, </text>
<text top="664" left="206" width="111" height="20" font="1">and 135/85 mm Hg, </text>
<text top="682" left="206" width="72" height="20" font="1">respectively. </text>
<text top="699" left="206" width="3" height="20" font="1"> </text>
<text top="716" left="206" width="118" height="20" font="4"><b>Duration:</b> 6 mo, with </text>
<text top="733" left="206" width="121" height="20" font="1">observations at 3 and </text>
<text top="750" left="206" width="38" height="20" font="1">6 mo. <b> </b></text>
<text top="333" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="352" left="347" width="7" height="18" font="1">•</text>
<text top="351" left="354" width="73" height="20" font="1"> Adults ≥25y </text>
<text top="370" left="347" width="7" height="18" font="1">•</text>
<text top="370" left="354" width="130" height="20" font="1"> Average SBP between </text>
<text top="387" left="347" width="118" height="20" font="1">120–159 mm Hg and </text>
<text top="404" left="347" width="126" height="20" font="1">average DBP between </text>
<text top="421" left="347" width="81" height="20" font="1">80–95 mm Hg </text>
<text top="440" left="347" width="7" height="18" font="1">•</text>
<text top="440" left="354" width="59" height="20" font="1"> No use of </text>
<text top="457" left="347" width="93" height="20" font="1">antihypertensive </text>
<text top="474" left="347" width="63" height="20" font="1">medication </text>
<text top="493" left="347" width="7" height="18" font="1">•</text>
<text top="492" left="354" width="130" height="20" font="1"> BMI between 18.5 and </text>
<text top="510" left="347" width="44" height="20" font="1">45 kg/m</text>
<text top="511" left="391" width="4" height="13" font="6">2</text>
<text top="510" left="396" width="3" height="20" font="1"> </text>
<text top="527" left="347" width="3" height="20" font="4"><b> </b></text>
<text top="544" left="347" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="563" left="347" width="7" height="18" font="1">•</text>
<text top="562" left="354" width="121" height="20" font="1"> Regular use of drugs </text>
<text top="580" left="347" width="77" height="20" font="1">that affect BP </text>
<text top="599" left="347" width="7" height="18" font="1">•</text>
<text top="598" left="354" width="140" height="20" font="1"> Target organ damage or </text>
<text top="615" left="347" width="22" height="20" font="1">DM </text>
<text top="634" left="347" width="7" height="18" font="1">•</text>
<text top="633" left="354" width="141" height="20" font="1"> Use of weight-loss meds </text>
<text top="652" left="347" width="7" height="18" font="1">•</text>
<text top="652" left="354" width="85" height="20" font="1"> Hx CVD event </text>
<text top="671" left="347" width="7" height="18" font="1">•</text>
<text top="670" left="354" width="114" height="20" font="1"> HF, angina, cancer, </text>
<text top="687" left="347" width="55" height="20" font="1">within 2 y </text>
<text top="706" left="347" width="7" height="18" font="1">•</text>
<text top="706" left="354" width="117" height="20" font="1"> Consumption of &gt;21 </text>
<text top="723" left="347" width="109" height="20" font="1">alcoholic drinks /wk </text>
<text top="742" left="347" width="7" height="18" font="1">•</text>
<text top="741" left="354" width="116" height="20" font="1"> Pregnancy, planned </text>
<text top="759" left="347" width="114" height="20" font="1">pregnancy, lactation </text>
<text top="333" left="509" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="352" left="509" width="7" height="18" font="1">•</text>
<text top="351" left="516" width="124" height="20" font="1"> Structured behavioral </text>
<text top="368" left="509" width="127" height="20" font="1">interventions that used </text>
<text top="386" left="509" width="118" height="20" font="1">an identical format (4 </text>
<text top="403" left="509" width="131" height="20" font="1">individual and 14 group </text>
<text top="420" left="509" width="117" height="20" font="1">sessions) to facilitate </text>
<text top="437" left="509" width="64" height="20" font="1">adoption of </text>
<text top="454" left="509" width="114" height="20" font="1">“established” dietary </text>
<text top="472" left="509" width="119" height="20" font="1">recommendations for </text>
<text top="489" left="509" width="101" height="20" font="1">reduction in BP or </text>
<text top="506" left="509" width="120" height="20" font="1">“established” plus the </text>
<text top="523" left="509" width="89" height="20" font="1">DASH diet. The </text>
<text top="540" left="509" width="114" height="20" font="1">“established” dietary </text>
<text top="558" left="509" width="131" height="20" font="1">recommendations used </text>
<text top="575" left="509" width="117" height="20" font="1">in PREMIER were a) </text>
<text top="592" left="509" width="77" height="20" font="1">weight loss in </text>
<text top="609" left="509" width="132" height="20" font="1">overweight participants, </text>
<text top="627" left="509" width="115" height="20" font="1">b) sodium reduction, </text>
<text top="644" left="509" width="104" height="20" font="1">increased physical </text>
<text top="661" left="509" width="134" height="20" font="1">activity, reduced alcohol </text>
<text top="678" left="509" width="132" height="20" font="1">intake in pts consuming </text>
<text top="695" left="509" width="46" height="20" font="1">alcohol. </text>
<text top="714" left="509" width="7" height="18" font="1">•</text>
<text top="714" left="516" width="78" height="20" font="1"> Compared to </text>
<text top="731" left="509" width="136" height="20" font="1">experience in the advice </text>
<text top="748" left="509" width="113" height="20" font="1">only (control) group, </text>
<text top="765" left="509" width="126" height="20" font="1">there was only modest </text>
<text top="783" left="509" width="87" height="20" font="1">achievement of </text>
<text top="334" left="659" width="72" height="20" font="4"><b>1</b>°<b> endpoint </b></text>
<text top="353" left="659" width="7" height="18" font="1">•</text>
<text top="352" left="666" width="195" height="20" font="1"> Compared to control (advice only), </text>
<text top="370" left="659" width="178" height="20" font="1">SBP and DBP were significantly </text>
<text top="387" left="659" width="136" height="20" font="1">reduced with both active </text>
<text top="404" left="659" width="167" height="20" font="1">interventions but there was no </text>
<text top="421" left="659" width="183" height="20" font="1">significant difference in the effect </text>
<text top="438" left="659" width="141" height="20" font="1">size between the 2 active </text>
<text top="456" left="659" width="188" height="20" font="1">intervention groups. This was true </text>
<text top="473" left="659" width="167" height="20" font="1">for both the normotensive and </text>
<text top="490" left="659" width="201" height="20" font="1">hypertensive pts, with the effect size </text>
<text top="507" left="659" width="175" height="20" font="1">being larger in the hypertensive </text>
<text top="524" left="659" width="180" height="20" font="1">group. In the normotensives, the </text>
<text top="542" left="659" width="199" height="20" font="1">MD for change in SBP was identical </text>
<text top="559" left="659" width="184" height="20" font="1">for the “established” compared to </text>
<text top="576" left="659" width="163" height="20" font="1">“established plus DASH Diet” </text>
<text top="593" left="659" width="181" height="20" font="1">groups: -3.1 (95% CI: -5.1– -1.1) </text>
<text top="610" left="659" width="43" height="20" font="1">mm Hg </text>
<text top="628" left="659" width="174" height="20" font="1">The corresponding changes for </text>
<text top="645" left="659" width="195" height="20" font="1">DBP were -1.6 (95% CI: -2.9– -0.2) </text>
<text top="662" left="659" width="179" height="20" font="1">for the “established” intervention </text>
<text top="679" left="659" width="195" height="20" font="1">group and -2.0 (95% CI: -3.4– -0.6) </text>
<text top="697" left="659" width="201" height="20" font="1">for the “established intervention plus </text>
<text top="714" left="659" width="109" height="20" font="1">DASH Diet) group.  </text>
<text top="733" left="659" width="7" height="18" font="1">•</text>
<text top="732" left="666" width="193" height="20" font="1"> Overall, the incidence of HTN was </text>
<text top="749" left="659" width="195" height="20" font="1">lowest and the percent with optimal </text>
<text top="766" left="659" width="192" height="20" font="1">BP was highest in the “established </text>
<text top="784" left="659" width="201" height="20" font="1">plus DASH” diet but the incidence of </text>
<text top="333" left="874" width="200" height="20" font="1">● This was an interesting trial which </text>
<text top="350" left="874" width="216" height="20" font="1">employed a behavior change approach </text>
<text top="367" left="874" width="217" height="20" font="1">to implement both active interventions.  </text>
<text top="384" left="874" width="175" height="20" font="1">● The investigators goal was to </text>
<text top="402" left="874" width="192" height="20" font="1">determine the additive value of the </text>
<text top="419" left="874" width="218" height="20" font="1">DASH Diet in persons already following </text>
<text top="436" left="874" width="162" height="20" font="1">key elements of conventional </text>
<text top="453" left="874" width="193" height="20" font="1">(established) recommendations for </text>
<text top="470" left="874" width="217" height="20" font="1">nonpharmacologic intervention to lower </text>
<text top="488" left="874" width="27" height="20" font="1">BP.  </text>
<text top="505" left="874" width="218" height="20" font="1">● The intervention approach in this trial </text>
<text top="522" left="874" width="207" height="20" font="1">was less effective in achieving weight </text>
<text top="539" left="874" width="200" height="20" font="1">loss and reduction in dietary sodium </text>
<text top="557" left="874" width="174" height="20" font="1">compared to the corresponding </text>
<text top="574" left="874" width="196" height="20" font="1">experience in the TOHP and TONE </text>
<text top="591" left="874" width="194" height="20" font="1">trials and the DASH Diet effects on </text>
<text top="608" left="874" width="222" height="20" font="1">intermediate variables (such as fruit and </text>
<text top="625" left="874" width="212" height="20" font="1">vegetable consumption) was less than </text>
<text top="643" left="874" width="217" height="20" font="1">that achieved in the DASH Diet feeding </text>
<text top="660" left="874" width="49" height="20" font="1">studies.  </text>
<text top="677" left="874" width="189" height="20" font="1">● Despite the modest intervention </text>
<text top="694" left="874" width="181" height="20" font="1">effects, both SBP and DBP were </text>
<text top="711" left="874" width="161" height="20" font="1">significantly reduced with the </text>
<text top="729" left="874" width="211" height="20" font="1">conventional intervention approach (in </text>
<text top="746" left="874" width="209" height="20" font="1">normotensives as well as overall) and </text>
<text top="763" left="874" width="222" height="20" font="1">addition of the DASH diet did not have a </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">47 </text>
<text top="107" left="509" width="133" height="20" font="1">intervention goals in the </text>
<text top="124" left="509" width="112" height="20" font="1">“established” group, </text>
<text top="141" left="509" width="115" height="20" font="1">with a MDs of 3.8 kg </text>
<text top="159" left="509" width="96" height="20" font="1">(8.4 lbs) for body </text>
<text top="176" left="509" width="131" height="20" font="1">weight, 11.6 mmol (267 </text>
<text top="193" left="509" width="98" height="20" font="1">mg)/d) for urinary </text>
<text top="210" left="509" width="117" height="20" font="1">sodium excretion, no </text>
<text top="228" left="509" width="104" height="20" font="1">change in physical </text>
<text top="245" left="509" width="100" height="20" font="1">activity (but better </text>
<text top="262" left="509" width="131" height="20" font="1">fitness), and no change </text>
<text top="279" left="509" width="128" height="20" font="1">in alcohol consumption </text>
<text top="296" left="509" width="115" height="20" font="1">(but very low alcohol </text>
<text top="314" left="509" width="87" height="20" font="1">consumption at </text>
<text top="331" left="509" width="57" height="20" font="1">baseline). </text>
<text top="350" left="509" width="7" height="18" font="1">•</text>
<text top="349" left="516" width="96" height="20" font="1"> Weight loss was </text>
<text top="366" left="509" width="135" height="20" font="1">somewhat greater in the </text>
<text top="384" left="509" width="100" height="20" font="1">“established” plus </text>
<text top="401" left="509" width="134" height="20" font="1">DASH diet group, with a </text>
<text top="418" left="509" width="128" height="20" font="1">MD of 4.8 kg (10.6 lbs) </text>
<text top="435" left="509" width="117" height="20" font="1">for body weight. This </text>
<text top="453" left="509" width="124" height="20" font="1">group also manifested </text>
<text top="470" left="509" width="127" height="20" font="1">expected effects of the </text>
<text top="487" left="509" width="89" height="20" font="1">DASH diet, with </text>
<text top="504" left="509" width="105" height="20" font="1">significantly higher </text>
<text top="521" left="509" width="124" height="20" font="1">urinary potassium and </text>
<text top="539" left="509" width="113" height="20" font="1">phosphorous levels, </text>
<text top="556" left="509" width="129" height="20" font="1">greater consumption of </text>
<text top="573" left="509" width="120" height="20" font="1">fruits and vegetables, </text>
<text top="590" left="509" width="119" height="20" font="1">dietary calcium, dairy </text>
<text top="607" left="509" width="121" height="20" font="1">products, and a lower </text>
<text top="625" left="509" width="130" height="20" font="1">consumption of total fat </text>
<text top="642" left="509" width="99" height="20" font="1">and saturated fat. </text>
<text top="659" left="509" width="3" height="20" font="4"><b> </b></text>
<text top="676" left="509" width="117" height="20" font="4"><b>Comparator: </b>Advice </text>
<text top="693" left="509" width="26" height="20" font="1">only<b> </b></text>
<text top="107" left="659" width="191" height="20" font="1">HTN was significantly less and the </text>
<text top="124" left="659" width="196" height="20" font="1">percent with optimal BP was higher </text>
<text top="141" left="659" width="184" height="20" font="1">in both active intervention groups </text>
<text top="159" left="659" width="165" height="20" font="1">compared to advice only. The </text>
<text top="176" left="659" width="174" height="20" font="1">difference between the 2 active </text>
<text top="193" left="659" width="154" height="20" font="1">intervention groups was not </text>
<text top="210" left="659" width="182" height="20" font="1">significant. In the normotensives, </text>
<text top="228" left="659" width="177" height="20" font="1">there was a nonsignificant trend </text>
<text top="245" left="659" width="202" height="20" font="1">towards less HTN and a significantly </text>
<text top="262" left="659" width="183" height="20" font="1">higher percent with optimal BP in </text>
<text top="279" left="659" width="171" height="20" font="1">both active intervention groups </text>
<text top="296" left="659" width="182" height="20" font="1">compared to advice only, with no </text>
<text top="314" left="659" width="178" height="20" font="1">significant difference for percent </text>
<text top="331" left="659" width="167" height="20" font="1">with optimal BP in the 2 active </text>
<text top="348" left="659" width="111" height="20" font="1">intervention groups. </text>
<text top="365" left="659" width="3" height="20" font="1"> </text>
<text top="384" left="659" width="139" height="20" font="4"><b>1</b>°<b> Safety endpoint</b>: N/A<b> </b></text>
<text top="107" left="874" width="219" height="20" font="1">significant effect on reduction of SBP or </text>
<text top="124" left="874" width="35" height="20" font="1">DBP.  </text>
<text top="141" left="874" width="190" height="20" font="1">● There were some nonsignificant </text>
<text top="159" left="874" width="210" height="20" font="1">trends for slightly lower BP, less HTN, </text>
<text top="176" left="874" width="221" height="20" font="1">and more optimal BP in the “established </text>
<text top="193" left="874" width="200" height="20" font="1">plus DASH Diet” group compared to </text>
<text top="210" left="874" width="207" height="20" font="1">“established” group. The authors also </text>
<text top="228" left="874" width="217" height="20" font="1">cited use of the DASH Diet as a means </text>
<text top="245" left="874" width="223" height="20" font="1">to beneficially influence CVD risk factors </text>
<text top="262" left="874" width="96" height="20" font="1">in addition to BP. </text>
<text top="711" left="98" width="88" height="20" font="1">Appel LJ, et al., </text>
<text top="729" left="98" width="56" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(84)</a> </text>
<text top="746" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16287956?dopt=Citation">16287956</a></text>
<text top="746" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16287956?dopt=Citation"> </a></text>
<text top="711" left="206" width="124" height="20" font="4"><b>Aim:</b> Compare effects </text>
<text top="729" left="206" width="122" height="20" font="1">of 3 diets, each with a </text>
<text top="746" left="206" width="98" height="20" font="1">reduced intake of </text>
<text top="763" left="206" width="118" height="20" font="1">saturated fats, on BP </text>
<text top="780" left="206" width="96" height="20" font="1">and serum lipids  </text>
<text top="711" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="730" left="347" width="7" height="18" font="1">•</text>
<text top="730" left="354" width="76" height="20" font="1"> Adults ≥30 y </text>
<text top="749" left="347" width="7" height="18" font="1">•</text>
<text top="748" left="354" width="130" height="20" font="1"> Average SBP between </text>
<text top="765" left="347" width="118" height="20" font="1">120–159 mm Hg and </text>
<text top="711" left="509" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="730" left="509" width="7" height="18" font="1">•</text>
<text top="730" left="516" width="98" height="20" font="1"> High protein with </text>
<text top="747" left="509" width="137" height="20" font="1">reduced fat/saturated fat </text>
<text top="764" left="509" width="44" height="20" font="1">content </text>
<text top="713" left="659" width="13" height="20" font="4"><b>1</b>°</text>
<text top="714" left="672" width="2" height="13" font="14"><b> </b></text>
<text top="713" left="674" width="55" height="20" font="4"><b>endpoint </b></text>
<text top="730" left="659" width="133" height="20" font="1">Compared with the high </text>
<text top="747" left="659" width="190" height="20" font="1">carbohydrate diet, the high protein </text>
<text top="764" left="659" width="27" height="20" font="1">diet: </text>
<text top="711" left="874" width="205" height="20" font="1">● This clinical trial demonstrated that </text>
<text top="729" left="874" width="155" height="20" font="1">substituting either protein or </text>
<text top="746" left="874" width="176" height="20" font="1">monounsaturated fat in place of </text>
<text top="763" left="874" width="178" height="20" font="1">carbohydrate resulted in a small </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">48 </text>
<text top="107" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="124" left="206" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="143" left="206" width="7" height="18" font="1">•</text>
<text top="143" left="212" width="80" height="20" font="1"> 2 center RCT </text>
<text top="162" left="206" width="7" height="18" font="1">•</text>
<text top="161" left="212" width="108" height="20" font="1"> 3 period crossover </text>
<text top="178" left="206" width="40" height="20" font="1">design </text>
<text top="197" left="206" width="7" height="18" font="1">•</text>
<text top="197" left="212" width="101" height="20" font="1"> Each 8 wk period </text>
<text top="214" left="206" width="124" height="20" font="1">was separated by a 2–</text>
<text top="231" left="206" width="119" height="20" font="1">4 wk wash-out phase </text>
<text top="248" left="206" width="3" height="20" font="1"> </text>
<text top="265" left="206" width="83" height="20" font="4"><b>Size: </b>161–164 </text>
<text top="283" left="206" width="114" height="20" font="1">included in analyses </text>
<text top="300" left="206" width="123" height="20" font="1">(191 pts randomized). </text>
<text top="317" left="206" width="128" height="20" font="1">132 (80.5%) of the 164 </text>
<text top="334" left="206" width="102" height="20" font="1">included in the BP </text>
<text top="352" left="206" width="82" height="20" font="1">analyses were </text>
<text top="369" left="206" width="115" height="20" font="1">normotensive. Mean </text>
<text top="386" left="206" width="120" height="20" font="1">age and BMI were 54 </text>
<text top="403" left="206" width="87" height="20" font="1">y and 30.2 kg/m</text>
<text top="405" left="293" width="4" height="13" font="6">2</text>
<text top="403" left="298" width="7" height="20" font="1">, </text>
<text top="420" left="206" width="72" height="20" font="1">respectively.<b> </b></text>
<text top="107" left="347" width="126" height="20" font="1">average DBP between </text>
<text top="124" left="347" width="81" height="20" font="1">80–95 mm Hg </text>
<text top="143" left="347" width="7" height="18" font="1">•</text>
<text top="143" left="354" width="59" height="20" font="1"> No use of </text>
<text top="160" left="347" width="93" height="20" font="1">antihypertensive </text>
<text top="177" left="347" width="63" height="20" font="1">medication </text>
<text top="194" left="347" width="3" height="20" font="4"><b> </b></text>
<text top="211" left="347" width="136" height="20" font="4"><b>Exclusion criteria: </b>DM, </text>
<text top="229" left="347" width="148" height="20" font="1">CVD (current or H/O), LDL </text>
<text top="246" left="347" width="135" height="20" font="1">cholesterol &gt;220 mg/dL, </text>
<text top="263" left="347" width="140" height="20" font="1">fasting triglycerides &gt;750 </text>
<text top="280" left="347" width="131" height="20" font="1">mg/dL, weight &gt;350 lb., </text>
<text top="298" left="347" width="128" height="20" font="1">taking that effect BP or </text>
<text top="315" left="347" width="125" height="20" font="1">lipids, unwillingness to </text>
<text top="332" left="347" width="113" height="20" font="1">stop vitamin/mineral </text>
<text top="349" left="347" width="101" height="20" font="1">supplements, &gt;14 </text>
<text top="366" left="347" width="109" height="20" font="1">alcoholic drinks/wk.<b> </b></text>
<text top="109" left="509" width="7" height="18" font="1">•</text>
<text top="108" left="516" width="124" height="20" font="1"> High unsaturated fats </text>
<text top="125" left="509" width="85" height="20" font="1">(predominantly </text>
<text top="143" left="509" width="120" height="20" font="1">monounsaturated fat) </text>
<text top="160" left="509" width="119" height="20" font="1">with low saturated fat </text>
<text top="177" left="509" width="44" height="20" font="1">content </text>
<text top="194" left="509" width="3" height="20" font="4"><b> </b></text>
<text top="211" left="509" width="106" height="20" font="4"><b>Comparator: </b>High </text>
<text top="229" left="509" width="100" height="20" font="1">carbohydrate with </text>
<text top="246" left="509" width="137" height="20" font="1">reduced fat/saturated fat </text>
<text top="263" left="509" width="44" height="20" font="1">content<b> </b></text>
<text top="109" left="659" width="7" height="18" font="1">•</text>
<text top="108" left="666" width="168" height="20" font="1"> Reduced SBP by -1.4 mm Hg </text>
<text top="125" left="659" width="185" height="20" font="1">(p=0.002) overall and by -0.9 mm </text>
<text top="143" left="659" width="192" height="20" font="1">Hg (p=0.047) in the normotensives </text>
<text top="162" left="659" width="7" height="18" font="1">•</text>
<text top="161" left="666" width="182" height="20" font="1"> Reduced LDL cholesterol by 3.3 </text>
<text top="178" left="659" width="192" height="20" font="1">mg/dL (p=0.01) overall and by -2.1 </text>
<text top="195" left="659" width="121" height="20" font="1">mg/dL (p=0.14) in the </text>
<text top="213" left="659" width="83" height="20" font="1">normotensives </text>
<text top="232" left="659" width="7" height="18" font="1">•</text>
<text top="231" left="666" width="176" height="20" font="1"> Reduced HDL-C by -1.3 mg/dL </text>
<text top="248" left="659" width="89" height="20" font="1">(p=0.02) overall </text>
<text top="267" left="659" width="7" height="18" font="1">•</text>
<text top="267" left="666" width="187" height="20" font="1"> Reduced serum Triglycerides by -</text>
<text top="284" left="659" width="161" height="20" font="1">15.7 mg/dL (p&lt;0.001) overall </text>
<text top="301" left="659" width="3" height="20" font="1"> </text>
<text top="318" left="659" width="133" height="20" font="1">Compared with the high </text>
<text top="336" left="659" width="149" height="20" font="1">carbohydrate diet, the high </text>
<text top="353" left="659" width="112" height="20" font="1">unsaturated fat diet: </text>
<text top="372" left="659" width="7" height="18" font="1">•</text>
<text top="371" left="666" width="168" height="20" font="1"> Reduced SBP by -1.3 mm Hg </text>
<text top="388" left="659" width="161" height="20" font="1">(p=0.005) overall and by -0.9 </text>
<text top="406" left="659" width="166" height="20" font="1">(p=0.06) in the normotensives </text>
<text top="425" left="659" width="7" height="18" font="1">•</text>
<text top="424" left="666" width="186" height="20" font="1"> Reduced LDL cholesterol by -1.5 </text>
<text top="441" left="659" width="202" height="20" font="1">mg/dL (p=0.01) and by -2.1 (p=0.14) </text>
<text top="458" left="659" width="117" height="20" font="1">in the normotensives </text>
<text top="477" left="659" width="7" height="18" font="1">•</text>
<text top="477" left="666" width="176" height="20" font="1"> Increased HDL-C by 1.1 mg/dL </text>
<text top="494" left="659" width="89" height="20" font="1">(p=0.03) overall </text>
<text top="513" left="659" width="7" height="18" font="1">•</text>
<text top="512" left="666" width="187" height="20" font="1"> Reduced serum Triglycerides by -</text>
<text top="529" left="659" width="110" height="20" font="1">9.6 (p=0.02) overall </text>
<text top="107" left="874" width="206" height="20" font="1">reduction in SBP and improvement in </text>
<text top="124" left="874" width="69" height="20" font="1">lipid profile.  </text>
<text top="547" left="98" width="87" height="20" font="1">Bazzano LA, et </text>
<text top="565" left="98" width="76" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(85)</a> </text>
<text top="582" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25178568?dopt=Citation">25178568</a></text>
<text top="582" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25178568?dopt=Citation"> </a></text>
<text top="547" left="206" width="105" height="20" font="4"><b>Aim: </b>Compare the </text>
<text top="565" left="206" width="86" height="20" font="1">effects of a low-</text>
<text top="582" left="206" width="109" height="20" font="1">carbohydrate and a </text>
<text top="599" left="206" width="110" height="20" font="1">low-fat diet on body </text>
<text top="616" left="206" width="115" height="20" font="1">weight and CVD risk </text>
<text top="633" left="206" width="120" height="20" font="1">factors (including BP)<b> </b></text>
<text top="651" left="206" width="3" height="20" font="1"> </text>
<text top="668" left="206" width="108" height="20" font="4"><b>Study type: </b>Single </text>
<text top="685" left="206" width="105" height="20" font="1">center parallel arm </text>
<text top="702" left="206" width="111" height="20" font="1">RCT that compared </text>
<text top="719" left="206" width="125" height="20" font="1">the 2 diets over 12 mo </text>
<text top="737" left="206" width="84" height="20" font="1">of intervention.<b> </b></text>
<text top="754" left="206" width="3" height="20" font="1"> </text>
<text top="771" left="206" width="115" height="20" font="4"><b>Size: </b>148 pts, with a </text>
<text top="788" left="206" width="122" height="20" font="1">mean age of 46.8 y at </text>
<text top="547" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="566" left="347" width="7" height="18" font="1">•</text>
<text top="566" left="354" width="51" height="20" font="1"> 22–75 y </text>
<text top="585" left="347" width="7" height="18" font="1">•</text>
<text top="584" left="354" width="96" height="20" font="1"> BMI: 30–45 kg/m</text>
<text top="586" left="451" width="4" height="13" font="6">2</text>
<text top="584" left="455" width="3" height="20" font="1"> </text>
<text top="601" left="347" width="3" height="20" font="4"><b> </b></text>
<text top="619" left="347" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="638" left="347" width="7" height="18" font="1">•</text>
<text top="637" left="354" width="33" height="20" font="1"> CVD </text>
<text top="656" left="347" width="7" height="18" font="1">•</text>
<text top="655" left="354" width="37" height="20" font="1"> DM-2 </text>
<text top="674" left="347" width="7" height="18" font="1">•</text>
<text top="674" left="354" width="90" height="20" font="1"> Kidney disease </text>
<text top="693" left="347" width="7" height="18" font="1">•</text>
<text top="692" left="354" width="109" height="20" font="1"> Use of prescription </text>
<text top="709" left="347" width="142" height="20" font="1">weight loss meds/surgery </text>
<text top="728" left="347" width="7" height="18" font="1">•</text>
<text top="728" left="354" width="114" height="20" font="1"> Weight loss &gt;6.8 kg </text>
<text top="745" left="347" width="96" height="20" font="1">during prior 6 mo </text>
<text top="547" left="509" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="566" left="509" width="7" height="18" font="1">•</text>
<text top="566" left="516" width="105" height="20" font="1"> Low-carbohydrate </text>
<text top="583" left="509" width="107" height="20" font="1">diet, with digestible </text>
<text top="600" left="509" width="106" height="20" font="1">carbohydrate (total </text>
<text top="617" left="509" width="111" height="20" font="1">carbohydrate minus </text>
<text top="635" left="509" width="103" height="20" font="1">total fiber) &lt;40 g/d </text>
<text top="654" left="509" width="7" height="18" font="1">•</text>
<text top="653" left="516" width="130" height="20" font="1"> Behavioral counselling </text>
<text top="670" left="509" width="127" height="20" font="1">that employed a mix of </text>
<text top="687" left="509" width="131" height="20" font="1">20 individual and group </text>
<text top="705" left="509" width="57" height="20" font="1">meetings  </text>
<text top="722" left="509" width="3" height="20" font="4"><b> </b></text>
<text top="739" left="509" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="758" left="509" width="7" height="18" font="1">•</text>
<text top="757" left="516" width="98" height="20" font="1"> Low fat diet, with </text>
<text top="775" left="509" width="118" height="20" font="1">&lt;30% of daily energy </text>
<text top="549" left="659" width="76" height="20" font="4"><b>1</b>°<b> endpoint: </b></text>
<text top="568" left="659" width="7" height="18" font="1">•</text>
<text top="567" left="666" width="161" height="20" font="1"> Compared to the low-fat diet </text>
<text top="584" left="659" width="180" height="20" font="1">group, the low-carbohydrate diet </text>
<text top="601" left="659" width="188" height="20" font="1">group had a mean decrease at 12 </text>
<text top="619" left="659" width="38" height="20" font="1">mo of: </text>
<text top="636" left="659" width="185" height="20" font="1">Body weight: -3.5 (95% CI: -5.6– -</text>
<text top="653" left="659" width="41" height="20" font="1">1.4) kg </text>
<text top="670" left="659" width="194" height="20" font="1">Fat mass: -1.5 (95% CI: -2.6– -0.4) </text>
<text top="687" left="659" width="162" height="20" font="1">HDL-C: 7.0 (11.0–3.0) mg/dL </text>
<text top="705" left="659" width="190" height="20" font="1">Ratio total/HDL-C: -0.44 (95% CI: -</text>
<text top="722" left="659" width="70" height="20" font="1">0.71– -0.16) </text>
<text top="739" left="659" width="172" height="20" font="1">Sr. triglyceride: -14.1 (95% CI: -</text>
<text top="756" left="659" width="104" height="20" font="1">27.4– -0.8) mg/dL  </text>
<text top="547" left="874" width="197" height="20" font="1">● This clinical trial provides 1 of the </text>
<text top="565" left="874" width="220" height="20" font="1">longest follow-up experiences related to </text>
<text top="582" left="874" width="57" height="20" font="1">the topic.  </text>
<text top="599" left="874" width="202" height="20" font="1">● It suggests low carbohydrate diets </text>
<text top="616" left="874" width="222" height="20" font="1">may be somewhat better than traditional </text>
<text top="633" left="874" width="207" height="20" font="1">low fat diets in achievement of weight </text>
<text top="651" left="874" width="182" height="20" font="1">loss, improvement of lipid profile, </text>
<text top="668" left="874" width="160" height="20" font="1">inflammation, and CHD risk.  </text>
<text top="685" left="874" width="219" height="20" font="1">● Although the BP differences were not </text>
<text top="702" left="874" width="219" height="20" font="1">significant, there was a consistent trend </text>
<text top="719" left="874" width="155" height="20" font="1">toward lower BPs in the low-</text>
<text top="737" left="874" width="137" height="20" font="1">carbohydrate diet group. </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">49 </text>
<text top="107" left="206" width="87" height="20" font="1">baseline. Mean </text>
<text top="124" left="206" width="120" height="20" font="1">SBP/DBP at baseline </text>
<text top="141" left="206" width="116" height="20" font="1">were 124.9/79.4 and </text>
<text top="159" left="206" width="118" height="20" font="1">120.3/77.5 mm Hg in </text>
<text top="176" left="206" width="106" height="20" font="1">the low-fat and low-</text>
<text top="193" left="206" width="120" height="20" font="1">carbohydrate groups, </text>
<text top="210" left="206" width="96" height="20" font="1">respectively. The </text>
<text top="228" left="206" width="113" height="20" font="1">corresponding BMIs </text>
<text top="245" left="206" width="109" height="20" font="1">were 97.9 and 96.3 </text>
<text top="262" left="206" width="27" height="20" font="1">kg/m</text>
<text top="264" left="232" width="4" height="13" font="6">2</text>
<text top="262" left="237" width="98" height="20" font="1">. All 148 pts were </text>
<text top="279" left="206" width="83" height="20" font="1">included in the </text>
<text top="296" left="206" width="115" height="20" font="1">analysis (intention to </text>
<text top="314" left="206" width="32" height="20" font="1">treat) </text>
<text top="107" left="509" width="114" height="20" font="1">intake from fat (&lt;7% </text>
<text top="124" left="509" width="104" height="20" font="1">from saturated fat) </text>
<text top="143" left="509" width="7" height="18" font="1">•</text>
<text top="143" left="516" width="130" height="20" font="1"> Behavioral counselling </text>
<text top="160" left="509" width="102" height="20" font="1">that used identical </text>
<text top="177" left="509" width="133" height="20" font="1">format to that employed </text>
<text top="194" left="509" width="131" height="20" font="1">in the low carbohydrate </text>
<text top="211" left="509" width="35" height="20" font="1">group </text>
<text top="109" left="659" width="7" height="18" font="1">•</text>
<text top="108" left="666" width="185" height="20" font="1"> At 3, 6, and 12 mo, BP tended to </text>
<text top="125" left="659" width="181" height="20" font="1">be lower in the low-carbohydrate </text>
<text top="143" left="659" width="197" height="20" font="1">group but none of the differences in </text>
<text top="160" left="659" width="166" height="20" font="1">SBP or DBP were significant.  </text>
<text top="179" left="659" width="7" height="18" font="1">•</text>
<text top="178" left="666" width="169" height="20" font="1"> CRP was reduced in both diet </text>
<text top="195" left="659" width="195" height="20" font="1">groups but to a significantly greater </text>
<text top="213" left="659" width="168" height="20" font="1">extent in the low-carbohydrate </text>
<text top="230" left="659" width="38" height="20" font="1">group. </text>
<text top="249" left="659" width="7" height="18" font="1">•</text>
<text top="248" left="666" width="165" height="20" font="1"> At 6 and 12 mo pts in the low </text>
<text top="265" left="659" width="191" height="20" font="1">carbohydrate group experienced a </text>
<text top="283" left="659" width="200" height="20" font="1">significant improvement in their 10-y </text>
<text top="300" left="659" width="175" height="20" font="1">Framingham CHD risk score. In </text>
<text top="317" left="659" width="181" height="20" font="1">contrast, there was no change in </text>
<text top="334" left="659" width="198" height="20" font="1">Framingham CHD risk in the low-fat </text>
<text top="352" left="659" width="65" height="20" font="1">diet group.  </text>
<text top="369" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="387" left="659" width="178" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> No serious </text>
<text top="404" left="659" width="100" height="20" font="1">side effects noted </text>
<text top="422" left="98" width="82" height="20" font="1">Nordmann AJ, </text>
<text top="440" left="98" width="90" height="20" font="1">et al., 2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(86)</a> </text>
<text top="457" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16476868?dopt=Citation">16476868</a></text>
<text top="457" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16476868?dopt=Citation"> </a></text>
<text top="422" left="206" width="124" height="20" font="4"><b>Aim: </b>Compare effects </text>
<text top="440" left="206" width="111" height="20" font="1">of low-carbohydrate </text>
<text top="457" left="206" width="110" height="20" font="1">and low-fat diets on </text>
<text top="474" left="206" width="117" height="20" font="1">weight loss and CVD </text>
<text top="491" left="206" width="66" height="20" font="1">risk factors <b> </b></text>
<text top="508" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="526" left="206" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="545" left="206" width="7" height="18" font="1">•</text>
<text top="544" left="212" width="106" height="20" font="1"> Systematic review </text>
<text top="561" left="206" width="103" height="20" font="1">and meta-analysis </text>
<text top="580" left="206" width="7" height="18" font="1">•</text>
<text top="579" left="212" width="60" height="20" font="1"> Cochrane </text>
<text top="597" left="206" width="123" height="20" font="1">Collaboration strategy </text>
<text top="614" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="631" left="206" width="124" height="20" font="4"><b>Size:</b> 5 trials (447 pts)<b> </b></text>
<text top="422" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="441" left="347" width="7" height="18" font="1">•</text>
<text top="441" left="354" width="32" height="20" font="1"> RCT </text>
<text top="460" left="347" width="7" height="18" font="1">•</text>
<text top="459" left="354" width="76" height="20" font="1"> Adults ≥16 y </text>
<text top="478" left="347" width="7" height="18" font="1">•</text>
<text top="477" left="354" width="129" height="20" font="1"> Low-carbohydrate diet </text>
<text top="495" left="347" width="87" height="20" font="1">and low-fat diet </text>
<text top="512" left="347" width="77" height="20" font="1">interventions  </text>
<text top="531" left="347" width="7" height="18" font="1">•</text>
<text top="530" left="354" width="81" height="20" font="1"> BMI ≥25 kg/m</text>
<text top="532" left="435" width="4" height="13" font="6">2</text>
<text top="530" left="439" width="3" height="20" font="1"> </text>
<text top="549" left="347" width="7" height="18" font="1">•</text>
<text top="549" left="354" width="92" height="20" font="1"> Follow-up ≥6 m </text>
<text top="566" left="347" width="3" height="20" font="1"> </text>
<text top="583" left="347" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="602" left="347" width="7" height="18" font="1">•</text>
<text top="601" left="354" width="141" height="20" font="1"> Cross-over or sequential </text>
<text top="619" left="347" width="40" height="20" font="1">design </text>
<text top="638" left="347" width="7" height="18" font="1">•</text>
<text top="637" left="354" width="76" height="20" font="1"> Missing data </text>
<text top="422" left="509" width="105" height="20" font="4"><b>Intervention: </b>Low-</text>
<text top="440" left="509" width="102" height="20" font="1">carbohydrate diet: </text>
<text top="457" left="509" width="108" height="20" font="1">maximum of 60 g/d </text>
<text top="474" left="509" width="75" height="20" font="1">carbohydrate </text>
<text top="491" left="509" width="3" height="20" font="4"><b> </b></text>
<text top="508" left="509" width="121" height="20" font="4"><b>Comparator: </b>Low-fat </text>
<text top="526" left="509" width="125" height="20" font="1">diet: maximum of 30% </text>
<text top="543" left="509" width="86" height="20" font="1">energy from fat </text>
<text top="423" left="659" width="168" height="20" font="4"><b>1</b>°<b> endpoint: </b>At 6 mo, the low-</text>
<text top="441" left="659" width="194" height="20" font="1">carbohydrate diet pts, compared to </text>
<text top="458" left="659" width="187" height="20" font="1">the low-fat diet participants, had a </text>
<text top="475" left="659" width="194" height="20" font="1">mean reduction in body weight that </text>
<text top="492" left="659" width="196" height="20" font="1">was greater by -3.3 (95% CI: -5.3– -</text>
<text top="510" left="659" width="201" height="20" font="1">1.4) kg, and a more favorable profile </text>
<text top="527" left="659" width="196" height="20" font="1">for HDL-cholesterol and triglyceride </text>
<text top="544" left="659" width="178" height="20" font="1">levels. In contrast, the profile for </text>
<text top="561" left="659" width="143" height="20" font="1">total-cholesterol and HDL-</text>
<text top="578" left="659" width="187" height="20" font="1">cholesterol was more favorable in </text>
<text top="596" left="659" width="201" height="20" font="1">those assigned to a low-fat diet. The </text>
<text top="613" left="659" width="190" height="20" font="1">profile for SBP tended to be better </text>
<text top="630" left="659" width="194" height="20" font="1">in the low carbohydrate diet pts but </text>
<text top="647" left="659" width="196" height="20" font="1">the differences were not significant: </text>
<text top="664" left="659" width="199" height="20" font="1">MD at 6 mo: -2.4 (95% CI: -4.9–0.1) </text>
<text top="682" left="659" width="50" height="20" font="1">mm Hg. <b> </b></text>
<text top="699" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="717" left="659" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint: </b>N/A<b> </b></text>
<text top="422" left="874" width="219" height="20" font="1">● This systematic review/meta-analysis </text>
<text top="440" left="874" width="221" height="20" font="1">tends to suggest low-carbohydrate diets </text>
<text top="457" left="874" width="174" height="20" font="1">are somewhat more effective in </text>
<text top="474" left="874" width="212" height="20" font="1">reducing body weight compared to the </text>
<text top="491" left="874" width="224" height="20" font="1">traditionally recommended low-fat diets.  </text>
<text top="508" left="874" width="219" height="20" font="1">● Although the BP differences were not </text>
<text top="526" left="874" width="201" height="20" font="1">significant they would probably have </text>
<text top="543" left="874" width="173" height="20" font="1">reached a conventional level of </text>
<text top="560" left="874" width="199" height="20" font="1">significance had subsequent clinical </text>
<text top="577" left="874" width="215" height="20" font="1">trials (including the Bazzano et al. trial) </text>
<text top="594" left="874" width="168" height="20" font="1">been included in the analysis.  </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">50 </text>
<text top="107" left="98" width="82" height="20" font="1">Nordmann AJ, </text>
<text top="124" left="98" width="90" height="20" font="1">et al., 2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(87)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21854893?dopt=Citation">21854893</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21854893?dopt=Citation"> </a></text>
<text top="107" left="206" width="124" height="20" font="4"><b>Aim: </b>Compare effects </text>
<text top="124" left="206" width="120" height="20" font="1">of Mediterranean and </text>
<text top="141" left="206" width="125" height="20" font="1">low-fat diets on weight </text>
<text top="159" left="206" width="101" height="20" font="1">loss and CVD risk </text>
<text top="176" left="206" width="40" height="20" font="1">factors<b> </b></text>
<text top="193" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="210" left="206" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="229" left="206" width="7" height="18" font="1">•</text>
<text top="229" left="212" width="106" height="20" font="1"> Systematic review </text>
<text top="246" left="206" width="103" height="20" font="1">and meta-analysis </text>
<text top="265" left="206" width="7" height="18" font="1">•</text>
<text top="264" left="212" width="60" height="20" font="1"> Cochrane </text>
<text top="282" left="206" width="123" height="20" font="1">Collaboration strategy </text>
<text top="299" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="316" left="206" width="110" height="20" font="4"><b>Size:</b> 6 trials (2,650 </text>
<text top="333" left="206" width="24" height="20" font="1">pts)<b> </b></text>
<text top="107" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="126" left="347" width="7" height="18" font="1">•</text>
<text top="125" left="354" width="32" height="20" font="1"> RCT </text>
<text top="144" left="347" width="7" height="18" font="1">•</text>
<text top="144" left="354" width="127" height="20" font="1"> Intent to treat analysis </text>
<text top="163" left="347" width="7" height="18" font="1">•</text>
<text top="162" left="354" width="131" height="20" font="1"> Overweight/obese with </text>
<text top="179" left="347" width="139" height="20" font="1">at least 1 additional CVD </text>
<text top="197" left="347" width="57" height="20" font="1">risk factor </text>
<text top="216" left="347" width="7" height="18" font="1">•</text>
<text top="215" left="354" width="99" height="20" font="1"> Follow-up ≥6 mo </text>
<text top="232" left="347" width="3" height="20" font="4"><b> </b></text>
<text top="249" left="347" width="134" height="20" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="107" left="509" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="124" left="509" width="109" height="20" font="1">Mediterranean diet: </text>
<text top="141" left="509" width="109" height="20" font="1">moderate fat intake </text>
<text top="159" left="509" width="125" height="20" font="1">(main sources olive oil </text>
<text top="176" left="509" width="94" height="20" font="1">and nuts), rich in </text>
<text top="193" left="509" width="125" height="20" font="1">vegetables, and low in </text>
<text top="210" left="509" width="55" height="20" font="1">red meat. </text>
<text top="228" left="509" width="3" height="20" font="4"><b> </b></text>
<text top="245" left="509" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="262" left="509" width="70" height="20" font="1">Low fat diet: </text>
<text top="279" left="509" width="127" height="20" font="1">≤30% of energy intake </text>
<text top="296" left="509" width="45" height="20" font="1">from fat<b> </b></text>
<text top="108" left="659" width="193" height="20" font="4"><b>1</b>°<b> endpoint:</b> Compared to the low-</text>
<text top="125" left="659" width="170" height="20" font="1">fat diet, the Mediterranean diet </text>
<text top="143" left="659" width="106" height="20" font="1">resulted in MDs of:<b> </b></text>
<text top="162" left="659" width="7" height="18" font="1">•</text>
<text top="161" left="666" width="188" height="20" font="1"> Body weight: -2.2 (95% CI: -3.9 – </text>
<text top="178" left="659" width="45" height="20" font="1">-0.6) kg </text>
<text top="197" left="659" width="7" height="18" font="1">•</text>
<text top="197" left="666" width="168" height="20" font="1"> BMI: -0.6 (95% CI: -1.0– -0.1) </text>
<text top="214" left="659" width="27" height="20" font="1">kg/m</text>
<text top="216" left="686" width="4" height="13" font="6">2</text>
<text top="214" left="690" width="3" height="20" font="1"> </text>
<text top="233" left="659" width="7" height="18" font="1">•</text>
<text top="232" left="666" width="178" height="20" font="1"> SBP: -1.7 (95% CI: -3.3– -0.05) </text>
<text top="249" left="659" width="43" height="20" font="1">mm Hg </text>
<text top="268" left="659" width="7" height="18" font="1">•</text>
<text top="268" left="666" width="172" height="20" font="1"> DBP: -1.5 (95% CI: -2.1– -0.8) </text>
<text top="287" left="659" width="7" height="18" font="1">•</text>
<text top="286" left="666" width="168" height="20" font="1"> Fasting Plasma Glucose: -3.8 </text>
<text top="303" left="659" width="149" height="20" font="1">(95% CI: -7.0– -0.6) mg/dL </text>
<text top="322" left="659" width="7" height="18" font="1">•</text>
<text top="322" left="666" width="187" height="20" font="1"> Total-Cholesterol.: -7.4 (95% CI: -</text>
<text top="339" left="659" width="63" height="20" font="1">10.3– -4.4) </text>
<text top="358" left="659" width="7" height="18" font="1">•</text>
<text top="357" left="666" width="169" height="20" font="1"> CRP: -1.0 (95% CI: -1.5– -0.5)</text>
<text top="359" left="835" width="2" height="13" font="6"> </text>
<text top="375" left="659" width="3" height="20" font="1"> </text>
<text top="393" left="659" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A<b> </b></text>
<text top="107" left="874" width="187" height="20" font="1">● Overall, this study suggests the </text>
<text top="124" left="874" width="198" height="20" font="1">Mediterranean diet compared to the </text>
<text top="141" left="874" width="214" height="20" font="1">traditional low fat diet results in greater </text>
<text top="159" left="874" width="199" height="20" font="1">weight loss, a better CVD risk factor </text>
<text top="176" left="874" width="220" height="20" font="1">profile (including better BP control), and </text>
<text top="193" left="874" width="102" height="20" font="1">less inflammation. </text>
<text top="210" left="874" width="192" height="20" font="1">● The number of eligible trials was </text>
<text top="227" left="874" width="189" height="20" font="1">small and the study samples were </text>
<text top="245" left="874" width="165" height="20" font="1">heterogeneous (2 2º and 4 1° </text>
<text top="262" left="874" width="98" height="20" font="1">prevention trials). </text>
<text top="411" left="98" width="90" height="20" font="1">Yokoyama Y, et </text>
<text top="428" left="98" width="76" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(88)</a> </text>
<text top="445" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24566947?dopt=Citation">24566947</a></text>
<text top="445" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24566947?dopt=Citation"> </a></text>
<text top="411" left="206" width="105" height="20" font="4"><b>Aim: </b>Compare the </text>
<text top="428" left="206" width="114" height="20" font="1">effects of vegetarian </text>
<text top="445" left="206" width="120" height="20" font="1">and omnivorous diets </text>
<text top="463" left="206" width="37" height="20" font="1">on BP<b> </b></text>
<text top="480" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="497" left="206" width="71" height="20" font="4"><b>Study type: </b></text>
<text top="514" left="206" width="126" height="20" font="1">Systematic review and </text>
<text top="531" left="206" width="79" height="20" font="1">meta-analysis<b> </b></text>
<text top="549" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="566" left="206" width="32" height="20" font="4"><b>Size: </b></text>
<text top="585" left="206" width="7" height="18" font="1">•</text>
<text top="584" left="212" width="93" height="20" font="1"> 7 trials (n=311). </text>
<text top="603" left="206" width="7" height="18" font="1">•</text>
<text top="602" left="212" width="119" height="20" font="1"> 6 were RCT (n=198) </text>
<text top="622" left="206" width="7" height="18" font="1">•</text>
<text top="621" left="212" width="91" height="20" font="1"> 4 parallel and 3 </text>
<text top="638" left="206" width="107" height="20" font="1">cross-over designs </text>
<text top="657" left="206" width="7" height="18" font="1">•</text>
<text top="656" left="212" width="81" height="20" font="1"> All were open </text>
<text top="675" left="206" width="7" height="18" font="1">•</text>
<text top="675" left="212" width="97" height="20" font="1"> Follow-up ≥6 wk </text>
<text top="692" left="206" width="95" height="20" font="1">(mean=15.7 wk)  </text>
<text top="711" left="206" width="7" height="18" font="1">•</text>
<text top="710" left="212" width="102" height="20" font="1"> Mean age=44.5 y </text>
<text top="411" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="430" left="347" width="7" height="18" font="1">•</text>
<text top="429" left="354" width="76" height="20" font="1"> Adults ≥20 y </text>
<text top="448" left="347" width="7" height="18" font="1">•</text>
<text top="448" left="354" width="101" height="20" font="1"> English language </text>
<text top="465" left="347" width="141" height="20" font="1">publications between Jan </text>
<text top="482" left="347" width="87" height="20" font="1">1946-Nov 2013 </text>
<text top="499" left="347" width="3" height="20" font="4"><b> </b></text>
<text top="516" left="347" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="535" left="347" width="7" height="18" font="1">•</text>
<text top="535" left="354" width="89" height="20" font="1"> Twin pt studies </text>
<text top="554" left="347" width="7" height="18" font="1">•</text>
<text top="553" left="354" width="122" height="20" font="1"> Multiple interventions </text>
<text top="572" left="347" width="7" height="18" font="1">•</text>
<text top="572" left="354" width="115" height="20" font="1"> Only categorical BP </text>
<text top="589" left="347" width="43" height="20" font="1">results  </text>
<text top="411" left="509" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="430" left="509" width="7" height="18" font="1">•</text>
<text top="429" left="516" width="114" height="20" font="1"> Lacto-ovo in 4 trials </text>
<text top="448" left="509" width="7" height="18" font="1">•</text>
<text top="448" left="516" width="84" height="20" font="1"> Lacto in 1 trial </text>
<text top="467" left="509" width="7" height="18" font="1">•</text>
<text top="466" left="516" width="98" height="20" font="1"> Vegan in 2 trials <b> </b></text>
<text top="483" left="509" width="3" height="20" font="4"><b> </b></text>
<text top="500" left="509" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="518" left="509" width="121" height="20" font="1">Omnivorous diet in all </text>
<text top="535" left="509" width="29" height="20" font="1">trials<b> </b></text>
<text top="412" left="659" width="171" height="20" font="4"><b>1</b>°<b> endpoint: </b>Compared to the </text>
<text top="429" left="659" width="198" height="20" font="1">omnivorous diet, the vegetarian diet </text>
<text top="446" left="659" width="106" height="20" font="1">resulted in MDs of:<b> </b></text>
<text top="465" left="659" width="7" height="18" font="1">•</text>
<text top="465" left="666" width="195" height="20" font="1"> SBP: -4.8 (95% CI: -6.6– -3.1) mm </text>
<text top="482" left="659" width="19" height="20" font="1">Hg </text>
<text top="501" left="659" width="7" height="18" font="1">•</text>
<text top="500" left="666" width="172" height="20" font="1"> DBP: -2.2 (95% CI: -3.5– -1.0) </text>
<text top="518" left="659" width="3" height="20" font="1"> </text>
<text top="535" left="659" width="180" height="20" font="1">SBP was lower in the vegetarian </text>
<text top="552" left="659" width="155" height="20" font="1">diet group in 5 of the 7 trials </text>
<text top="569" left="659" width="200" height="20" font="1">(significant in 3) and DBP was lower </text>
<text top="586" left="659" width="194" height="20" font="1">in 6 of the 7 trials (significant in 2).  </text>
<text top="604" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="622" left="659" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A<b> </b></text>
<text top="411" left="874" width="214" height="20" font="1">● Overall, this meta-analysis of clinical </text>
<text top="428" left="874" width="214" height="20" font="1">trials suggested BP was lower in those </text>
<text top="445" left="874" width="180" height="20" font="1">who consumed a vegetarian diet </text>
<text top="463" left="874" width="197" height="20" font="1">compared to their counterparts who </text>
<text top="480" left="874" width="174" height="20" font="1">consumed an omnivorous diet.  </text>
<text top="497" left="874" width="201" height="20" font="1">● However, the trials were generally </text>
<text top="514" left="874" width="201" height="20" font="1">small, heterogeneous in their design </text>
<text top="531" left="874" width="185" height="20" font="1">and conduct, and of questionable </text>
<text top="549" left="874" width="42" height="20" font="1">quality. </text>
<text top="566" left="874" width="212" height="20" font="1">● Even greater reductions in SBP and </text>
<text top="583" left="874" width="169" height="20" font="1">DBP were noted in a MA of 32 </text>
<text top="600" left="874" width="122" height="20" font="1">observational studies. </text>
<text top="728" left="98" width="72" height="20" font="4"><b>PREDIMED</b>  </text>
<text top="746" left="98" width="89" height="20" font="1">Toledo E, et al., </text>
<text top="763" left="98" width="56" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(89)</a> </text>
<text top="780" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24050803?dopt=Citation">24050803</a></text>
<text top="780" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24050803?dopt=Citation"> </a></text>
<text top="728" left="206" width="105" height="20" font="4"><b>Aim:</b> Compare the </text>
<text top="746" left="206" width="64" height="20" font="1">effects of a </text>
<text top="763" left="206" width="107" height="20" font="1">Mediterranean and </text>
<text top="780" left="206" width="111" height="20" font="1">lower-fat diet on BP </text>
<text top="728" left="347" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="747" left="347" width="7" height="18" font="1">•</text>
<text top="747" left="354" width="119" height="20" font="1"> Adults, men 5,580 y, </text>
<text top="764" left="347" width="90" height="20" font="1">women 60–80 y </text>
<text top="783" left="347" width="7" height="18" font="1">•</text>
<text top="782" left="354" width="90" height="20" font="1"> Free from CVD </text>
<text top="728" left="509" width="99" height="20" font="4"><b>Intervention: </b>Pts </text>
<text top="746" left="509" width="117" height="20" font="1">assigned to a control </text>
<text top="763" left="509" width="97" height="20" font="1">group or to 1 of 2 </text>
<text top="780" left="509" width="116" height="20" font="1">Mediterranean diets. </text>
<text top="730" left="659" width="199" height="20" font="4"><b>1</b>°<b> endpoint: </b>The percentage of pts </text>
<text top="747" left="659" width="198" height="20" font="1">with controlled BP increased in all 3 </text>
<text top="764" left="659" width="174" height="20" font="1">intervention groups (p-value for </text>
<text top="781" left="659" width="201" height="20" font="1">within-group changes: p&lt;0.001). Pts </text>
<text top="728" left="874" width="201" height="20" font="1">● Both the traditional Mediterranean </text>
<text top="746" left="874" width="220" height="20" font="1">diet and a low-fat diet exerted beneficial </text>
<text top="763" left="874" width="189" height="20" font="1">effects on BP and could be part of </text>
<text top="780" left="874" width="176" height="20" font="1">advice to pts for controlling BP.  </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">51 </text>
<text top="107" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="124" left="206" width="103" height="20" font="4"><b>Study type: </b>RCT, </text>
<text top="141" left="206" width="96" height="20" font="1">single-blinded, in </text>
<text top="159" left="206" width="92" height="20" font="1">Spanish primary </text>
<text top="176" left="206" width="105" height="20" font="1">healthcare centers<b> </b></text>
<text top="193" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="210" left="206" width="118" height="20" font="4"><b>Size: </b>7,447 men (55–</text>
<text top="227" left="206" width="122" height="20" font="1">80 y) and women (60–</text>
<text top="245" left="206" width="111" height="20" font="1">80 y) at high risk for </text>
<text top="262" left="206" width="36" height="20" font="1">CVD. <b> </b></text>
<text top="109" left="347" width="7" height="18" font="1">•</text>
<text top="108" left="354" width="128" height="20" font="1"> DM or at least 3 major </text>
<text top="125" left="347" width="149" height="20" font="1">CVD risk factors (smoking, </text>
<text top="143" left="347" width="108" height="20" font="1">HTN, elevated LDL </text>
<text top="160" left="347" width="120" height="20" font="1">cholesterol, low HDL, </text>
<text top="177" left="347" width="139" height="20" font="1">overweight/obese, family </text>
<text top="194" left="347" width="121" height="20" font="1">history of early CHD)  </text>
<text top="211" left="347" width="3" height="20" font="4"><b> </b></text>
<text top="229" left="347" width="129" height="20" font="4"><b>Exclusion criteria: </b>Do </text>
<text top="246" left="347" width="124" height="20" font="1">not meet criteria listed </text>
<text top="263" left="347" width="37" height="20" font="1">above </text>
<text top="107" left="509" width="100" height="20" font="1">The control group </text>
<text top="124" left="509" width="124" height="20" font="1">received education on </text>
<text top="141" left="509" width="128" height="20" font="1">following a low-fat diet, </text>
<text top="159" left="509" width="110" height="20" font="1">while the groups on </text>
<text top="176" left="509" width="112" height="20" font="1">Mediterranean diets </text>
<text top="193" left="509" width="107" height="20" font="1">received nutritional </text>
<text top="210" left="509" width="131" height="20" font="1">education and also free </text>
<text top="227" left="509" width="135" height="20" font="1">foods; either extra virgin </text>
<text top="245" left="509" width="96" height="20" font="1">olive oil, or nuts. <b> </b></text>
<text top="262" left="509" width="3" height="20" font="4"><b> </b></text>
<text top="279" left="509" width="131" height="20" font="4"><b>Comparator: </b>Lower fat </text>
<text top="296" left="509" width="23" height="20" font="1">diet<b> </b></text>
<text top="107" left="659" width="145" height="20" font="1">allocated to either of the 2 </text>
<text top="124" left="659" width="171" height="20" font="1">Mediterranean diet groups had </text>
<text top="141" left="659" width="196" height="20" font="1">significantly lower DBP than the pts </text>
<text top="159" left="659" width="187" height="20" font="1">in the control group (-1.53 mm Hg </text>
<text top="176" left="659" width="163" height="20" font="1">(95% CI: -2.01– -1.04) for the </text>
<text top="193" left="659" width="187" height="20" font="1">Mediterranean diet supplemented </text>
<text top="210" left="659" width="192" height="20" font="1">with extra virgin olive oil, and -0.65 </text>
<text top="227" left="659" width="192" height="20" font="1">mm Hg (95% CI: -1.15– -0.15) mm </text>
<text top="245" left="659" width="163" height="20" font="1">Hg for the Mediterranean diet </text>
<text top="262" left="659" width="159" height="20" font="1">supplemented with nuts). No </text>
<text top="279" left="659" width="162" height="20" font="1">between-group differences in </text>
<text top="296" left="659" width="152" height="20" font="1">changes of SBP were seen<b> </b></text>
<text top="107" left="874" width="212" height="20" font="1">● However, lower values of DBP were </text>
<text top="124" left="874" width="191" height="20" font="1">noted in the 2 groups following the </text>
<text top="141" left="874" width="195" height="20" font="1">Mediterranean diet with extra virgin </text>
<text top="159" left="874" width="212" height="20" font="1">olive oil or with nuts than in the control </text>
<text top="176" left="874" width="38" height="20" font="1">group. </text>
<text top="316" left="108" width="3" height="19" font="1"> </text>
<text top="350" left="81" width="948" height="24" font="3"><b>Data Supplement 16. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Alcohol Reduction) </b></text>
<text top="374" left="81" width="92" height="24" font="3"><b>(Section 6.2) </b></text>
<text top="414" left="99" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="431" left="124" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="448" left="102" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="414" left="230" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="431" left="234" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="448" left="228" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="414" left="362" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="414" left="512" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="431" left="544" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="448" left="512" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="465" left="548" width="55" height="20" font="4"><b>patients) </b></text>
<text top="414" left="696" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="431" left="680" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="448" left="662" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="415" left="875" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="432" left="908" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="449" left="915" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="483" left="98" width="70" height="20" font="1">Xin X, et al., </text>
<text top="500" left="98" width="56" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(90)</a> </text>
<text top="518" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11711507?dopt=Citation">11711507</a></text>
<text top="518" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11711507?dopt=Citation"> </a></text>
<text top="483" left="211" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="500" left="211" width="110" height="20" font="1">of alcohol reduction </text>
<text top="518" left="211" width="37" height="20" font="1">on BP<b> </b></text>
<text top="535" left="211" width="3" height="20" font="1"> </text>
<text top="552" left="211" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="569" left="211" width="102" height="20" font="1">Systematic review </text>
<text top="587" left="211" width="103" height="20" font="1">and meta-analysis </text>
<text top="604" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="621" left="211" width="32" height="20" font="4"><b>Size: </b></text>
<text top="640" left="211" width="7" height="18" font="1">•</text>
<text top="639" left="218" width="76" height="20" font="1"> 15 RCTs (25 </text>
<text top="656" left="211" width="102" height="20" font="1">comparisons) with </text>
<text top="674" left="211" width="57" height="20" font="1">2,234 pts. </text>
<text top="693" left="211" width="7" height="18" font="1">•</text>
<text top="692" left="218" width="73" height="20" font="1"> 6 trials were </text>
<text top="709" left="211" width="73" height="20" font="1">conducted in </text>
<text top="726" left="211" width="111" height="20" font="1">normotensives (269 </text>
<text top="744" left="211" width="113" height="20" font="1">pts with a mean age </text>
<text top="761" left="211" width="103" height="20" font="1">ranging from 26.5–</text>
<text top="778" left="211" width="94" height="20" font="1">45.5 y). Average </text>
<text top="483" left="344" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="502" left="344" width="7" height="18" font="1">•</text>
<text top="502" left="351" width="92" height="20" font="1"> RCT in humans </text>
<text top="521" left="344" width="7" height="18" font="1">•</text>
<text top="520" left="351" width="117" height="20" font="1"> Publication between </text>
<text top="537" left="344" width="62" height="20" font="1">1966-1999 </text>
<text top="556" left="344" width="7" height="18" font="1">•</text>
<text top="556" left="351" width="90" height="20" font="1"> Duration ≥1 wk </text>
<text top="575" left="344" width="7" height="18" font="1">•</text>
<text top="574" left="351" width="102" height="20" font="1"> Only pts regularly </text>
<text top="591" left="344" width="109" height="20" font="1">consuming alcohol  </text>
<text top="610" left="344" width="7" height="18" font="1">•</text>
<text top="609" left="351" width="139" height="20" font="1"> Only difference between </text>
<text top="627" left="344" width="129" height="20" font="1">the comparison groups </text>
<text top="644" left="344" width="104" height="20" font="1">was alcohol intake </text>
<text top="661" left="344" width="3" height="20" font="1"> </text>
<text top="678" left="344" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="696" left="344" width="131" height="20" font="1">Comparison of different </text>
<text top="713" left="344" width="128" height="20" font="1">doses of alcohol intake </text>
<text top="483" left="504" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="500" left="504" width="114" height="20" font="1">Reduction in alcohol </text>
<text top="518" left="504" width="120" height="20" font="1">consumption. In most </text>
<text top="535" left="504" width="130" height="20" font="1">trials this was achieved </text>
<text top="552" left="504" width="111" height="20" font="1">by randomization to </text>
<text top="569" left="504" width="130" height="20" font="1">“light” alcohol but some </text>
<text top="587" left="504" width="123" height="20" font="1">RCT were based on a </text>
<text top="604" left="504" width="127" height="20" font="1">behavioral intervention </text>
<text top="621" left="504" width="122" height="20" font="1">aimed at reducing the </text>
<text top="638" left="504" width="95" height="20" font="1">number of drinks </text>
<text top="655" left="504" width="64" height="20" font="1">consumed. </text>
<text top="673" left="504" width="7" height="20" font="1">  </text>
<text top="690" left="504" width="112" height="20" font="4"><b>Comparator:</b> Usual </text>
<text top="707" left="504" width="129" height="20" font="1">consumption of alcohol </text>
<text top="484" left="659" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="503" left="659" width="7" height="18" font="1">•</text>
<text top="503" left="666" width="171" height="20" font="1"> Overall, alcohol reduction was </text>
<text top="520" left="659" width="156" height="20" font="1">associated with a significant </text>
<text top="537" left="659" width="174" height="20" font="1">reduction in mean SBP of -3.31 </text>
<text top="554" left="659" width="178" height="20" font="1">(95% CI: -4.10– -2.52) and DBP </text>
<text top="572" left="659" width="174" height="20" font="1">of -2.04 (95% CI: -2.58– -1.49). </text>
<text top="591" left="659" width="7" height="18" font="1">•</text>
<text top="590" left="666" width="164" height="20" font="1"> In the subgroup of 7 RCTs in </text>
<text top="607" left="659" width="159" height="20" font="1">persons with HTN, the mean </text>
<text top="624" left="659" width="174" height="20" font="1">changes in SBP and DBP were </text>
<text top="642" left="659" width="174" height="20" font="1">-3.9 (95% CI: -5.04– -2.76) and </text>
<text top="659" left="659" width="160" height="20" font="1">-2.41 (95% CI: -3.25– -1.57). </text>
<text top="678" left="659" width="7" height="18" font="1">•</text>
<text top="677" left="666" width="164" height="20" font="1"> In the subgroup of 6 RCTs in </text>
<text top="694" left="659" width="104" height="20" font="1">normotensives the </text>
<text top="712" left="659" width="172" height="20" font="1">corresponding changes in SBP </text>
<text top="729" left="659" width="162" height="20" font="1">and DBP were -3.5 (95% CI: -</text>
<text top="746" left="659" width="176" height="20" font="1">4.61– -2.51) and -1.80 (95% CI: </text>
<text top="763" left="659" width="77" height="20" font="1">-3.03– -0.58). </text>
<text top="485" left="851" width="7" height="18" font="1">•</text>
<text top="484" left="858" width="210" height="20" font="1"> This is the most recent meta-analysis </text>
<text top="502" left="851" width="223" height="20" font="1">of this topic. Although this meta-analysis </text>
<text top="519" left="851" width="205" height="20" font="1">reports % reduction in alcohol intake, </text>
<text top="536" left="851" width="181" height="20" font="1">most trials aimed at reducing the </text>
<text top="553" left="851" width="206" height="20" font="1">number of alcoholic drinks consumed </text>
<text top="570" left="851" width="175" height="20" font="1">achieved a reduction of about 3 </text>
<text top="588" left="851" width="50" height="20" font="1">drinks/d. </text>
<text top="607" left="851" width="7" height="18" font="1">•</text>
<text top="606" left="858" width="165" height="20" font="1"> The intervention results were </text>
<text top="623" left="851" width="213" height="20" font="1">consistent with the relationship alcohol </text>
<text top="640" left="851" width="219" height="20" font="1">and BP in observational epidemiology – </text>
<text top="658" left="851" width="185" height="20" font="1">about a 1 mm Hg higher SBP per </text>
<text top="675" left="851" width="158" height="20" font="1">alcoholic drink consumed. In </text>
<text top="692" left="851" width="205" height="20" font="1">observational studies, type of alcohol </text>
<text top="709" left="851" width="206" height="20" font="1">does not seem to matter and at lower </text>
<text top="726" left="851" width="186" height="20" font="1">levels of alcohol consumption (&lt;1 </text>
<text top="744" left="851" width="215" height="20" font="1">standard size alcoholic drink per day in </text>
<text top="761" left="851" width="211" height="20" font="1">women and &lt;2 in men) there does not </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">52 </text>
<text top="107" left="211" width="87" height="20" font="1">consumption of </text>
<text top="124" left="211" width="105" height="20" font="1">alcohol at baseline </text>
<text top="141" left="211" width="98" height="20" font="1">was not reported. </text>
<text top="159" left="211" width="94" height="20" font="1">Follow-up varied </text>
<text top="176" left="211" width="81" height="20" font="1">from 1–18 wk  </text>
<text top="109" left="659" width="7" height="18" font="1">•</text>
<text top="108" left="666" width="171" height="20" font="1"> In a meta-regression analysis, </text>
<text top="125" left="659" width="154" height="20" font="1">a dose-response was noted </text>
<text top="143" left="659" width="174" height="20" font="1">between % reduction in alcohol </text>
<text top="160" left="659" width="131" height="20" font="1">consumption and mean </text>
<text top="177" left="659" width="94" height="20" font="1">reduction in BP.  </text>
<text top="194" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="213" left="659" width="143" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A <b> </b></text>
<text top="107" left="851" width="191" height="20" font="1">seem to be an important biological </text>
<text top="124" left="851" width="130" height="20" font="1">effect of alcohol on BP. </text>
<text top="143" left="851" width="7" height="18" font="1">•</text>
<text top="143" left="858" width="187" height="20" font="1"> The relationship between alcohol </text>
<text top="160" left="851" width="217" height="20" font="1">consumption and BP is predictable and </text>
<text top="177" left="851" width="201" height="20" font="1">consistent in observational and RCT </text>
<text top="194" left="851" width="188" height="20" font="1">studies. However, the relationship </text>
<text top="211" left="851" width="219" height="20" font="1">between alcohol consumption and CVD </text>
<text top="229" left="851" width="164" height="20" font="1">is more complex as alcohol is </text>
<text top="246" left="851" width="221" height="20" font="1">associated with an apparently beneficial </text>
<text top="263" left="851" width="208" height="20" font="1">effect on CVD risk, possibly mediated </text>
<text top="280" left="851" width="191" height="20" font="1">by an increase in HDL-cholesterol. </text>
<text top="299" left="851" width="7" height="18" font="1">•</text>
<text top="299" left="858" width="201" height="20" font="1"> Pregnant women, pts with HTN and </text>
<text top="316" left="851" width="188" height="20" font="1">those at risk of a drinking problem </text>
<text top="333" left="851" width="203" height="20" font="1">should not drink alcohol. Established </text>
<text top="350" left="851" width="205" height="20" font="1">light drinkers (&lt;2 standard drinks/d in </text>
<text top="368" left="851" width="186" height="20" font="1">men and &lt;1/d in women) who are </text>
<text top="385" left="851" width="198" height="20" font="1">normotensive are in a favorable risk </text>
<text top="402" left="851" width="101" height="20" font="1">category for CVD. </text>
<text top="420" left="98" width="83" height="20" font="1">Stewart SH, et </text>
<text top="437" left="98" width="76" height="20" font="1">al., 2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(91)</a> </text>
<text top="454" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18821872">18821872</a></text>
<text top="454" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18821872"> </a></text>
<text top="420" left="211" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="437" left="211" width="104" height="20" font="1">of reduced alcohol </text>
<text top="454" left="211" width="77" height="20" font="1">intake on BP.<b> </b></text>
<text top="472" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="489" left="211" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="506" left="211" width="76" height="20" font="1">Randomized, </text>
<text top="523" left="211" width="103" height="20" font="1">controlled factorial </text>
<text top="540" left="211" width="30" height="20" font="1">trial. <b> </b></text>
<text top="558" left="211" width="3" height="20" font="1"> </text>
<text top="575" left="211" width="90" height="20" font="4"><b>Size:</b> 1,383 pts.<b> </b></text>
<text top="420" left="344" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="439" left="344" width="7" height="18" font="1">•</text>
<text top="438" left="351" width="122" height="20" font="1"> Alcohol dependence. </text>
<text top="457" left="344" width="7" height="18" font="1">•</text>
<text top="457" left="351" width="130" height="20" font="1"> 4—21 d of abstinence. </text>
<text top="476" left="344" width="7" height="18" font="1">•</text>
<text top="475" left="351" width="116" height="20" font="1"> Men: &gt;21 drinks/wk; </text>
<text top="492" left="344" width="128" height="20" font="1">Women &gt;14 drinks/wk. </text>
<text top="511" left="344" width="7" height="18" font="1">•</text>
<text top="511" left="351" width="94" height="20" font="1"> At least 2 heavy </text>
<text top="528" left="344" width="121" height="20" font="1">drinking days within a </text>
<text top="545" left="344" width="134" height="20" font="1">consecutive 30-d period </text>
<text top="562" left="344" width="107" height="20" font="1">during 90 d prior to </text>
<text top="580" left="344" width="53" height="20" font="1">baseline. </text>
<text top="597" left="344" width="3" height="20" font="1"> </text>
<text top="614" left="344" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="633" left="344" width="7" height="18" font="1">•</text>
<text top="632" left="351" width="138" height="20" font="1"> Other substance abuse. </text>
<text top="651" left="344" width="7" height="18" font="1">•</text>
<text top="651" left="351" width="114" height="20" font="1"> Psychiatric disorder </text>
<text top="668" left="344" width="118" height="20" font="1">requiring medication. </text>
<text top="687" left="344" width="7" height="18" font="1">•</text>
<text top="686" left="351" width="101" height="20" font="1"> Unstable medical </text>
<text top="703" left="344" width="53" height="20" font="1">condition<b> </b></text>
<text top="420" left="504" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="437" left="504" width="100" height="20" font="1">Pharmacotherapy </text>
<text top="454" left="504" width="68" height="20" font="1">(naltrexone, </text>
<text top="472" left="504" width="124" height="20" font="1">acamprosate, or both)<b> </b></text>
<text top="489" left="504" width="86" height="20" font="1">and counseling </text>
<text top="506" left="504" width="121" height="20" font="1">strategies (behavioral </text>
<text top="523" left="504" width="84" height="20" font="1">and/or medical </text>
<text top="540" left="504" width="83" height="20" font="1">management).<b> </b></text>
<text top="558" left="504" width="3" height="20" font="4"><b> </b></text>
<text top="575" left="504" width="129" height="20" font="4"><b>Comparator: </b>Placebo.<b> </b></text>
<text top="420" left="659" width="87" height="20" font="4"><b>Change in BP: </b></text>
<text top="439" left="659" width="7" height="18" font="1">•</text>
<text top="438" left="666" width="152" height="20" font="1"> Based on up to 5 repeated </text>
<text top="456" left="659" width="157" height="20" font="1">measures of BP over 16 wk. </text>
<text top="473" left="659" width="143" height="20" font="1">Data modeled to estimate </text>
<text top="490" left="659" width="134" height="20" font="1">change in BP over time. </text>
<text top="507" left="659" width="7" height="20" font="1">  </text>
<text top="526" left="659" width="7" height="18" font="1">•</text>
<text top="526" left="666" width="135" height="20" font="1"> For pts with higher than </text>
<text top="543" left="659" width="160" height="20" font="1">average baseline SBP (&gt;132 </text>
<text top="560" left="659" width="161" height="20" font="1">mm Hg), SBP declined by an </text>
<text top="577" left="659" width="159" height="20" font="1">average of 12 mm Hg (149—</text>
<text top="594" left="659" width="153" height="20" font="1">137) in the intervention arm </text>
<text top="612" left="659" width="157" height="20" font="1">compared to placebo, with a </text>
<text top="629" left="659" width="179" height="20" font="1">corresponding decline in DBP of </text>
<text top="646" left="659" width="148" height="20" font="1">8 mm Hg. For those with a </text>
<text top="663" left="659" width="152" height="20" font="1">baseline SBP ≤132 mm Hg </text>
<text top="680" left="659" width="158" height="20" font="1">there was no change in SBP </text>
<text top="698" left="659" width="154" height="20" font="1">(120—121 mm Hg) or DBP. </text>
<text top="715" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="732" left="659" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A <b> </b></text>
<text top="422" left="851" width="7" height="18" font="1">•</text>
<text top="421" left="858" width="195" height="20" font="4"><b> </b>This trial was designed to evaluate </text>
<text top="438" left="851" width="202" height="20" font="1">interventions for treatment of alcohol </text>
<text top="456" left="851" width="75" height="20" font="1">dependence. </text>
<text top="475" left="851" width="7" height="18" font="1">•</text>
<text top="474" left="858" width="158" height="20" font="4"><b> </b>BP measurements were not </text>
<text top="491" left="851" width="81" height="20" font="1">standardized.  </text>
<text top="510" left="851" width="7" height="18" font="1">•</text>
<text top="510" left="858" width="204" height="20" font="4"><b> </b>About 20% of the observations were </text>
<text top="527" left="851" width="202" height="20" font="1">missing and assumed to be random. </text>
<text top="750" left="98" width="100" height="20" font="1">Dickenson HO, et </text>
<text top="767" left="98" width="76" height="20" font="1">al., 2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(92)</a> </text>
<text top="784" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16508562">16508562</a></text>
<text top="784" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16508562"> </a></text>
<text top="750" left="211" width="65" height="20" font="4"><b>Aim: </b>Study </text>
<text top="767" left="211" width="89" height="20" font="1">effectiveness of </text>
<text top="784" left="211" width="44" height="20" font="1">lifestyle </text>
<text top="750" left="344" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="769" left="344" width="7" height="18" font="1">•</text>
<text top="768" left="351" width="108" height="20" font="1"> Only parallel trials  </text>
<text top="750" left="504" width="127" height="20" font="4"><b>Intervention: </b>Lifestyle </text>
<text top="767" left="504" width="142" height="20" font="1">change aimed at reduced </text>
<text top="784" left="504" width="129" height="20" font="1">consumption of alcohol </text>
<text top="751" left="659" width="79" height="20" font="4"><b>1</b>°<b> endpoint:  </b></text>
<text top="768" left="659" width="136" height="20" font="4"><b>-</b>Net reduction (95% CI): </text>
<text top="786" left="659" width="122" height="20" font="1">SBP -3.8 (-6.1— -1.4) </text>
<text top="752" left="851" width="7" height="18" font="1">•</text>
<text top="751" left="858" width="184" height="20" font="4"><b> </b>Relatively small number of trials  </text>
<text top="770" left="851" width="7" height="18" font="1">•</text>
<text top="769" left="858" width="136" height="20" font="4"><b> </b>Limited details provided </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">53 </text>
<text top="107" left="211" width="76" height="20" font="1">interventions, </text>
<text top="124" left="211" width="100" height="20" font="1">including reduced </text>
<text top="141" left="211" width="100" height="20" font="1">alcohol intake, for </text>
<text top="159" left="211" width="101" height="20" font="1">treatment of HTN. </text>
<text top="176" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="193" left="211" width="112" height="20" font="4"><b>Study type: </b>1 of 10 </text>
<text top="210" left="211" width="87" height="20" font="1">meta-analyses. </text>
<text top="227" left="211" width="3" height="20" font="1"> </text>
<text top="245" left="211" width="107" height="20" font="4"><b>Size: </b>4 trials which </text>
<text top="262" left="211" width="106" height="20" font="1">collectively studied </text>
<text top="279" left="211" width="44" height="20" font="1">305 pts<b> </b></text>
<text top="109" left="344" width="7" height="18" font="1">•</text>
<text top="108" left="351" width="107" height="20" font="1"> SBP ≥140 mm Hg </text>
<text top="125" left="344" width="135" height="20" font="1">and/or DBP ≥85 mm Hg </text>
<text top="144" left="344" width="7" height="18" font="1">•</text>
<text top="144" left="351" width="88" height="20" font="1"> ≥8 wk duration </text>
<text top="163" left="344" width="7" height="18" font="1">•</text>
<text top="162" left="351" width="74" height="20" font="1"> BP outcome </text>
<text top="179" left="344" width="3" height="20" font="1"> </text>
<text top="197" left="344" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="216" left="344" width="7" height="18" font="1">•</text>
<text top="215" left="351" width="138" height="20" font="1"> 2º HTN or renal disease </text>
<text top="234" left="344" width="7" height="18" font="1">•</text>
<text top="233" left="351" width="100" height="20" font="1"> Pregnant women </text>
<text top="252" left="344" width="7" height="18" font="1">•</text>
<text top="252" left="351" width="116" height="20" font="1"> Change in BP meds </text>
<text top="269" left="344" width="61" height="20" font="1">during trial<b> </b></text>
<text top="107" left="504" width="3" height="20" font="1"> </text>
<text top="124" left="504" width="139" height="20" font="4"><b>Comparator: </b>Usual care<b> </b></text>
<text top="107" left="659" width="123" height="20" font="1">DBP -3.2 (-5.0— -1.4) </text>
<text top="124" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="141" left="659" width="103" height="20" font="4"><b>Safety endpoint:  </b></text>
<text top="159" left="659" width="24" height="20" font="1">N/A<b> </b></text>
<text top="297" left="98" width="96" height="20" font="1">Wallace P, et al., </text>
<text top="314" left="98" width="56" height="20" font="1">1988 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(93)</a> </text>
<text top="332" left="98" width="48" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3052668">3052668</a></text>
<text top="332" left="145" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3052668"> </a></text>
<text top="297" left="211" width="65" height="20" font="4"><b>Aim: </b>Study </text>
<text top="314" left="211" width="89" height="20" font="1">effectiveness of </text>
<text top="332" left="211" width="109" height="20" font="1">general practitioner </text>
<text top="349" left="211" width="94" height="20" font="1">advice to reduce </text>
<text top="366" left="211" width="86" height="20" font="1">heavy drinking. </text>
<text top="383" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="400" left="211" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="420" left="211" width="7" height="18" font="1">•</text>
<text top="419" left="218" width="32" height="20" font="1"> RCT </text>
<text top="436" left="211" width="3" height="20" font="1"> </text>
<text top="453" left="211" width="92" height="20" font="4"><b>Size: </b>909 adults </text>
<text top="470" left="211" width="103" height="20" font="1">(641 men and 268 </text>
<text top="488" left="211" width="47" height="20" font="1">women)<b> </b></text>
<text top="297" left="344" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="314" left="344" width="141" height="20" font="1">Heavy drinking during wk </text>
<text top="332" left="344" width="98" height="20" font="1">prior to screening </text>
<text top="349" left="344" width="55" height="20" font="1">interview. </text>
<text top="366" left="344" width="3" height="20" font="1"> </text>
<text top="383" left="344" width="143" height="20" font="4"><b>Exclusion criteria: </b>None </text>
<text top="400" left="344" width="61" height="20" font="1">mentioned<b> </b></text>
<text top="297" left="504" width="134" height="20" font="4"><b>Intervention: </b>Physician </text>
<text top="314" left="504" width="115" height="20" font="1">counselling aimed at </text>
<text top="332" left="504" width="135" height="20" font="1">reduced consumption of </text>
<text top="349" left="504" width="46" height="20" font="1">alcohol. </text>
<text top="366" left="504" width="3" height="20" font="1"> </text>
<text top="383" left="504" width="139" height="20" font="4"><b>Comparator: </b>Usual care<b> </b></text>
<text top="297" left="659" width="71" height="20" font="4"><b>Endpoints:  </b></text>
<text top="316" left="659" width="7" height="18" font="1">•</text>
<text top="316" left="666" width="163" height="20" font="1"> 1° outcome was reduction in </text>
<text top="333" left="659" width="179" height="20" font="1">percent with heavy consumption </text>
<text top="350" left="659" width="115" height="20" font="1">of alcohol (mean net </text>
<text top="367" left="659" width="166" height="20" font="1">change=46%). Liver enzymes </text>
<text top="384" left="659" width="176" height="20" font="1">and BP also measured at 6 and </text>
<text top="402" left="659" width="41" height="20" font="1">12 mo. </text>
<text top="421" left="659" width="7" height="18" font="1">•</text>
<text top="420" left="666" width="78" height="20" font="1"> Pretreatment </text>
<text top="437" left="659" width="168" height="20" font="1">SBP/DBP=133.5/79.9 mm Hg. </text>
<text top="456" left="659" width="7" height="18" font="1">•</text>
<text top="456" left="666" width="143" height="20" font="1"> Net reduction SBP=-2.12 </text>
<text top="473" left="659" width="125" height="20" font="1">(95% CI: -4.19– -0.00)<b> </b></text>
<text top="490" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="507" left="659" width="100" height="20" font="4"><b>Safety endpoint: </b></text>
<text top="524" left="659" width="24" height="20" font="1">N/A<b> </b></text>
<text top="297" left="851" width="165" height="20" font="1">● The goal was to blind those </text>
<text top="314" left="851" width="217" height="20" font="1">conducting the outcome assessment to </text>
<text top="332" left="851" width="189" height="20" font="1">treatment assignment but by 6 mo </text>
<text top="349" left="851" width="224" height="20" font="1">assignment was known in 20-30% of the </text>
<text top="366" left="851" width="70" height="20" font="1">participants. </text>
<text top="383" left="851" width="222" height="20" font="1">● A reduction in SBP was noted despite </text>
<text top="400" left="851" width="161" height="20" font="1">use of a modest intervention. </text>
<text top="542" left="98" width="79" height="20" font="1">Lang T, et al., </text>
<text top="560" left="98" width="56" height="20" font="1">1995 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(94)</a> </text>
<text top="577" left="98" width="48" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8596098">8596098</a></text>
<text top="577" left="145" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8596098"> </a></text>
<text top="542" left="211" width="114" height="20" font="4"><b>Aim</b>: Worksite study </text>
<text top="560" left="211" width="104" height="20" font="1">of reduced alcohol </text>
<text top="577" left="211" width="120" height="20" font="1">intake effect on BP in </text>
<text top="594" left="211" width="109" height="20" font="1">heavy drinkers with </text>
<text top="611" left="211" width="32" height="20" font="1">HTN. </text>
<text top="628" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="646" left="211" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="663" left="211" width="3" height="20" font="1"> </text>
<text top="680" left="211" width="72" height="20" font="4"><b>Size: </b>14 site </text>
<text top="697" left="211" width="88" height="20" font="1">physicians; 129 </text>
<text top="714" left="211" width="100" height="20" font="1">adults (95% men)<b> </b></text>
<text top="542" left="344" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="561" left="344" width="7" height="18" font="1">•</text>
<text top="561" left="351" width="88" height="20" font="1"> Heavy drinking </text>
<text top="578" left="344" width="131" height="20" font="1">(documented by history </text>
<text top="595" left="344" width="96" height="20" font="1">and liver enzyme </text>
<text top="612" left="344" width="60" height="20" font="1">elevation). </text>
<text top="631" left="344" width="7" height="18" font="1">•</text>
<text top="631" left="351" width="93" height="20" font="1"> HTN (SBP/DBP </text>
<text top="648" left="344" width="95" height="20" font="1">&gt;140/90 mm Hg) </text>
<text top="665" left="344" width="3" height="20" font="1"> </text>
<text top="682" left="344" width="114" height="20" font="4"><b>Exclusion criteria:  </b></text>
<text top="701" left="344" width="7" height="18" font="1">•</text>
<text top="701" left="351" width="47" height="20" font="1"> 2º HTN </text>
<text top="720" left="344" width="7" height="18" font="1">•</text>
<text top="719" left="351" width="118" height="20" font="1"> Severe liver disease </text>
<text top="738" left="344" width="7" height="18" font="1">•</text>
<text top="737" left="351" width="52" height="20" font="1"> Planned </text>
<text top="755" left="344" width="96" height="20" font="1">move/retirement.<b> </b></text>
<text top="542" left="504" width="134" height="20" font="4"><b>Intervention: </b>Physician </text>
<text top="560" left="504" width="129" height="20" font="1">and worker counselling </text>
<text top="577" left="504" width="98" height="20" font="1">aimed at reduced </text>
<text top="594" left="504" width="133" height="20" font="1">consumption of alcohol. </text>
<text top="611" left="504" width="3" height="20" font="1"> </text>
<text top="628" left="504" width="81" height="20" font="4"><b>Comparator:  </b></text>
<text top="646" left="504" width="66" height="20" font="1">Usual care. </text>
<text top="663" left="504" width="3" height="20" font="1"> </text>
<text top="680" left="504" width="114" height="20" font="4"><b>Duration</b>: Follow-up </text>
<text top="697" left="504" width="126" height="20" font="1">visits at 1, 3, 6, and 18 </text>
<text top="714" left="504" width="24" height="20" font="1">mo.<b> </b></text>
<text top="542" left="659" width="71" height="20" font="4"><b>Endpoints:  </b></text>
<text top="561" left="659" width="7" height="18" font="1">•</text>
<text top="561" left="666" width="54" height="20" font="1"> Baseline </text>
<text top="578" left="659" width="177" height="20" font="1">SBP/DBP=162.5/98.0. Although </text>
<text top="595" left="659" width="178" height="20" font="1">all of the workers had HTN, only </text>
<text top="612" left="659" width="167" height="20" font="1">about 20% were being treated </text>
<text top="630" left="659" width="118" height="20" font="1">with antihypertensive </text>
<text top="647" left="659" width="135" height="20" font="1">medications at baseline. </text>
<text top="666" left="659" width="7" height="18" font="1">•</text>
<text top="665" left="666" width="140" height="20" font="1"> At 1 y, the net change in </text>
<text top="682" left="659" width="155" height="20" font="1">SBP=-5.5 (p&lt;0.05). When 5 </text>
<text top="700" left="659" width="170" height="20" font="1">sites with &lt;5 workers/site were </text>
<text top="717" left="659" width="154" height="20" font="1">excluded, the net change in </text>
<text top="734" left="659" width="152" height="20" font="1">SBP=-7.3 mm Hg (p&lt;0.01). </text>
<text top="753" left="659" width="7" height="18" font="1">•</text>
<text top="752" left="666" width="140" height="20" font="1"> At 2 y, the net change in </text>
<text top="770" left="659" width="109" height="20" font="1">SBP=-6.6 (p&lt;0.05).<b> </b></text>
<text top="787" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="542" left="851" width="223" height="20" font="1">● Behavioral intervention state of the art </text>
<text top="560" left="851" width="60" height="20" font="1">for its time </text>
<text top="577" left="851" width="207" height="20" font="1">● Careful measurements of BP using </text>
<text top="594" left="851" width="195" height="20" font="1">Hawksley RZ sphygmomanometer. </text>
<text top="611" left="851" width="209" height="20" font="1">● Main analyses do not seem to have </text>
<text top="628" left="851" width="164" height="20" font="1">accounted for cluster design.  </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">54 </text>
<text top="107" left="659" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="125" left="98" width="87" height="20" font="1">Roerecke M, et </text>
<text top="142" left="98" width="51" height="20" font="1">al., 2017 </text>
<text top="159" left="98" width="77" height="20" font="1">Lancet Public </text>
<text top="177" left="98" width="42" height="20" font="1">Health. </text>
<text top="194" left="98" width="103" height="20" font="1">2017;2:e108-120.  </text>
<text top="125" left="211" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="142" left="211" width="104" height="20" font="1">of reduced alcohol </text>
<text top="159" left="211" width="77" height="20" font="1">intake on BP. </text>
<text top="177" left="211" width="3" height="20" font="1"> </text>
<text top="194" left="211" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="211" left="211" width="102" height="20" font="1">Systematic review </text>
<text top="228" left="211" width="107" height="20" font="1">and meta-analysis. </text>
<text top="245" left="211" width="3" height="20" font="1"> </text>
<text top="263" left="211" width="102" height="20" font="4"><b>Size</b>: 36 RCT with </text>
<text top="280" left="211" width="101" height="20" font="1">2865 participants. </text>
<text top="297" left="211" width="3" height="20" font="1"> </text>
<text top="314" left="211" width="48" height="20" font="4"><b>Design</b>: </text>
<text top="333" left="211" width="7" height="18" font="1">•</text>
<text top="333" left="218" width="89" height="20" font="1"> 15 parallel-arm </text>
<text top="350" left="211" width="29" height="20" font="1">trials </text>
<text top="369" left="211" width="7" height="18" font="1">•</text>
<text top="368" left="218" width="107" height="20" font="1"> 21 crossover trials </text>
<text top="386" left="211" width="3" height="20" font="1"> </text>
<text top="403" left="211" width="49" height="20" font="4"><b>Setting</b>: </text>
<text top="422" left="211" width="7" height="18" font="1">•</text>
<text top="421" left="218" width="107" height="20" font="1"> 13 in hypertension </text>
<text top="440" left="211" width="7" height="18" font="1">•</text>
<text top="440" left="218" width="112" height="20" font="1"> 13 in normotension </text>
<text top="459" left="211" width="7" height="18" font="1">•</text>
<text top="458" left="218" width="96" height="20" font="1"> 12 HTN and NT  </text>
<text top="477" left="211" width="7" height="18" font="1">•</text>
<text top="476" left="218" width="72" height="20" font="1"> Only 3 trials </text>
<text top="493" left="211" width="103" height="20" font="1">presented data for </text>
<text top="511" left="211" width="46" height="20" font="1">women.<b> </b></text>
<text top="125" left="344" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="144" left="344" width="7" height="18" font="1">•</text>
<text top="143" left="351" width="122" height="20" font="1"> RCT in adult humans </text>
<text top="162" left="344" width="7" height="18" font="1">•</text>
<text top="162" left="351" width="137" height="20" font="1"> Publication on or before </text>
<text top="179" left="344" width="80" height="20" font="1">July 13, 2016. </text>
<text top="198" left="344" width="7" height="18" font="1">•</text>
<text top="197" left="351" width="96" height="20" font="1"> Full text articles. </text>
<text top="216" left="344" width="7" height="18" font="1">•</text>
<text top="216" left="351" width="105" height="20" font="1"> Change in alcohol </text>
<text top="233" left="344" width="91" height="20" font="1">intake for ≥1 wk<b> </b></text>
<text top="125" left="504" width="137" height="20" font="4"><b>Intervention:</b> Reduction </text>
<text top="142" left="504" width="132" height="20" font="1">in alcohol consumption. </text>
<text top="159" left="504" width="114" height="20" font="1">Strategy varied from </text>
<text top="177" left="504" width="107" height="20" font="1">controlled inpatient </text>
<text top="194" left="504" width="94" height="20" font="1">administration to </text>
<text top="211" left="504" width="128" height="20" font="1">randomization to “light” </text>
<text top="228" left="504" width="113" height="20" font="1">alcohol to pragmatic </text>
<text top="246" left="504" width="126" height="20" font="1">primary care trials with </text>
<text top="263" left="504" width="120" height="20" font="1">counselling to reduce </text>
<text top="280" left="504" width="82" height="20" font="1">alcohol intake. </text>
<text top="297" left="504" width="7" height="20" font="1">  </text>
<text top="314" left="504" width="142" height="20" font="4"><b>Duration</b>: Follow-up from </text>
<text top="332" left="504" width="120" height="20" font="1">1 wk to 2 y (median 4 </text>
<text top="349" left="504" width="26" height="20" font="1">wk).<b> </b></text>
<text top="126" left="659" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="145" left="659" width="7" height="18" font="1">•</text>
<text top="145" left="666" width="171" height="20" font="1"> Overall, alcohol reduction was </text>
<text top="162" left="659" width="156" height="20" font="1">associated with a significant </text>
<text top="179" left="659" width="174" height="20" font="1">reduction in mean SBP of -3.31 </text>
<text top="196" left="659" width="178" height="20" font="1">(95% CI: -4.10– -2.52) and DBP </text>
<text top="213" left="659" width="174" height="20" font="1">of -2.04 (95% CI: -2.58– -1.49). </text>
<text top="233" left="659" width="7" height="18" font="1">•</text>
<text top="232" left="666" width="164" height="20" font="1"> In the subgroup of 7 RCTs in </text>
<text top="249" left="659" width="159" height="20" font="1">persons with HTN, the mean </text>
<text top="266" left="659" width="174" height="20" font="1">changes in SBP and DBP were </text>
<text top="284" left="659" width="156" height="20" font="1">SBP: -3.13 (95% CI: -3.93– -</text>
<text top="301" left="659" width="31" height="20" font="1">2.32) </text>
<text top="318" left="659" width="157" height="20" font="1">DBP: -2.00 (95% CI: -2.65– -</text>
<text top="335" left="659" width="35" height="20" font="1">1.35). </text>
<text top="354" left="659" width="7" height="18" font="1">•</text>
<text top="353" left="666" width="161" height="20" font="1"> In meta-regression analysis, </text>
<text top="371" left="659" width="171" height="20" font="1">there was a strong relationship </text>
<text top="388" left="659" width="141" height="20" font="1">between the extent of BP </text>
<text top="405" left="659" width="158" height="20" font="1">reduction and change in BP, </text>
<text top="422" left="659" width="147" height="20" font="1">with no reduction in BP for </text>
<text top="440" left="659" width="146" height="20" font="1">those consuming 2 or less </text>
<text top="457" left="659" width="179" height="20" font="1">drinks at baseline but increasing </text>
<text top="474" left="659" width="169" height="20" font="1">reductions in BP for those with </text>
<text top="491" left="659" width="169" height="20" font="1">progressively higher intakes of </text>
<text top="508" left="659" width="131" height="20" font="1">alcohol at baseline. For </text>
<text top="526" left="659" width="162" height="20" font="1">instance, in those consuming </text>
<text top="543" left="659" width="152" height="20" font="1">≥6 drinks/day and reducing </text>
<text top="560" left="659" width="122" height="20" font="1">their alcohol intake by </text>
<text top="577" left="659" width="132" height="20" font="1">approximately 50%, the </text>
<text top="594" left="659" width="176" height="20" font="1">estimated reduction in SBP and </text>
<text top="612" left="659" width="62" height="20" font="1">DBP were: </text>
<text top="629" left="659" width="150" height="20" font="1">SBP: -5.5 (95% CI: -6.70– -</text>
<text top="646" left="659" width="31" height="20" font="1">4.30) </text>
<text top="663" left="659" width="157" height="20" font="1">DBP: -3.97 (95% CI: -4.70– -</text>
<text top="681" left="659" width="158" height="20" font="1">3.25). Similar patterns of the </text>
<text top="698" left="659" width="175" height="20" font="1">effect of baseline alcohol intake </text>
<text top="715" left="659" width="170" height="20" font="1">on treatment effect were noted </text>
<text top="732" left="659" width="149" height="20" font="1">for a variety of subgroups.  </text>
<text top="750" left="659" width="3" height="20" font="4"><b> </b></text>
<text top="768" left="659" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A<b> </b></text>
<text top="125" left="851" width="24" height="20" font="1">N/A </text>
<text top="787" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">55 </text>
<text top="106" left="81" width="999" height="24" font="3"><b>Data Supplement 17. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Calcium Supplementation) </b></text>
<text top="130" left="81" width="92" height="24" font="3"><b>(Section 6.2) </b></text>
<text top="170" left="125" width="38" height="20" font="4"><b>Study </b></text>
<text top="187" left="114" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="204" left="120" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="221" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="170" left="220" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="187" left="224" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="204" left="218" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="170" left="344" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="170" left="487" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="187" left="520" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="204" left="488" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="221" left="523" width="55" height="20" font="4"><b>patients) </b></text>
<text top="170" left="676" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="187" left="659" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="204" left="641" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="171" left="868" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="188" left="900" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="205" left="908" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="239" left="98" width="84" height="20" font="1">Van Mierlo LA, </text>
<text top="256" left="98" width="33" height="20" font="1">et al., </text>
<text top="274" left="98" width="56" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(95)</a> </text>
<text top="291" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16673011?dopt=Citation">16673011</a></text>
<text top="291" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16673011?dopt=Citation"> </a></text>
<text top="239" left="203" width="86" height="20" font="4"><b>Aim: </b>Study the </text>
<text top="256" left="203" width="92" height="20" font="1">effect of calcium </text>
<text top="274" left="203" width="111" height="20" font="1">supplementation on </text>
<text top="291" left="203" width="20" height="20" font="1">BP<b> </b></text>
<text top="308" left="203" width="3" height="20" font="1"> </text>
<text top="325" left="203" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="342" left="203" width="102" height="20" font="1">Systematic review </text>
<text top="360" left="203" width="103" height="20" font="1">and meta-analysis </text>
<text top="377" left="203" width="3" height="20" font="4"><b> </b></text>
<text top="394" left="203" width="36" height="20" font="4"><b>Size:  </b></text>
<text top="413" left="203" width="7" height="18" font="1">•</text>
<text top="412" left="210" width="80" height="20" font="1"> 40 RCTs with </text>
<text top="430" left="203" width="57" height="20" font="1">2,492 pts.<b> </b></text>
<text top="449" left="203" width="7" height="18" font="1">•</text>
<text top="448" left="210" width="88" height="20" font="1"> 27 RCTs in pts </text>
<text top="465" left="203" width="91" height="20" font="1">&lt;140/90 mm Hg </text>
<text top="482" left="203" width="56" height="20" font="1">(n=1,728) </text>
<text top="501" left="203" width="7" height="18" font="1">•</text>
<text top="501" left="210" width="97" height="20" font="1"> Follow-up varied </text>
<text top="518" left="203" width="84" height="20" font="1">from 3–208 wk </text>
<text top="535" left="203" width="95" height="20" font="1">(median=8.5 wk) </text>
<text top="554" left="203" width="7" height="18" font="1">•</text>
<text top="554" left="210" width="101" height="20" font="1"> Age range 11–77 </text>
<text top="571" left="203" width="93" height="20" font="1">y (mean=43.7 y) </text>
<text top="239" left="332" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="258" left="332" width="7" height="18" font="1">•</text>
<text top="258" left="339" width="92" height="20" font="1"> RCT in humans </text>
<text top="277" left="332" width="7" height="18" font="1">•</text>
<text top="276" left="339" width="117" height="20" font="1"> Publication between </text>
<text top="293" left="332" width="86" height="20" font="1">1996 and 2003 </text>
<text top="312" left="332" width="7" height="18" font="1">•</text>
<text top="311" left="339" width="78" height="20" font="1"> Nonpregnant </text>
<text top="329" left="332" width="111" height="20" font="1">normotensive pts or </text>
<text top="346" left="332" width="93" height="20" font="1">hypertensive pts </text>
<text top="365" left="332" width="7" height="18" font="1">•</text>
<text top="364" left="339" width="89" height="20" font="1"> Only difference </text>
<text top="382" left="332" width="70" height="20" font="1">between the </text>
<text top="399" left="332" width="133" height="20" font="1">comparison groups was </text>
<text top="416" left="332" width="103" height="20" font="1">magnesium intake </text>
<text top="435" left="332" width="7" height="18" font="1">•</text>
<text top="434" left="339" width="97" height="20" font="1"> Follow-up ≥2 wk </text>
<text top="452" left="332" width="3" height="20" font="1"> </text>
<text top="469" left="332" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="486" left="332" width="125" height="20" font="1">Study pts having renal </text>
<text top="503" left="332" width="60" height="20" font="1">disease or </text>
<text top="520" left="332" width="115" height="20" font="1">hyperparathyroidism </text>
<text top="239" left="481" width="136" height="20" font="4"><b>Intervention:</b> Increased </text>
<text top="256" left="481" width="120" height="20" font="1">calcium intake, with a </text>
<text top="274" left="481" width="125" height="20" font="1">range from 355–2,000 </text>
<text top="291" left="481" width="107" height="20" font="1">mg/d (mean=1,200 </text>
<text top="308" left="481" width="116" height="20" font="1">mg/d; median=1,055 </text>
<text top="325" left="481" width="115" height="20" font="1">mg/d), primarily as a </text>
<text top="342" left="481" width="129" height="20" font="1">gluconate or carbonate </text>
<text top="360" left="481" width="26" height="20" font="1">salt. </text>
<text top="377" left="481" width="7" height="20" font="1">  </text>
<text top="394" left="481" width="139" height="20" font="4"><b>Comparator:</b> Placebo or </text>
<text top="411" left="481" width="96" height="20" font="1">usual intake – 32 </text>
<text top="429" left="481" width="74" height="20" font="1">double-blind. </text>
<text top="240" left="633" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="259" left="633" width="7" height="18" font="1">•</text>
<text top="259" left="640" width="151" height="20" font="1"> Overall, increased calcium </text>
<text top="276" left="633" width="159" height="20" font="1">intake was associated with a </text>
<text top="293" left="633" width="187" height="20" font="1">significant reduction in mean SBP </text>
<text top="310" left="633" width="170" height="20" font="1">of -1.86 (95% CI: -2.91– -0.81) </text>
<text top="328" left="633" width="187" height="20" font="1">and DBP of -0.99 (95% CI: -1.61– </text>
<text top="345" left="633" width="42" height="20" font="1">-0.37).  </text>
<text top="364" left="633" width="7" height="18" font="1">•</text>
<text top="363" left="640" width="174" height="20" font="1"> The reduction was slightly less </text>
<text top="380" left="633" width="187" height="20" font="1">but still significant in the subset of </text>
<text top="398" left="633" width="156" height="20" font="1">32 double-blind trials, with a </text>
<text top="415" left="633" width="162" height="20" font="1">mean SBP of -1.67 (95% CI: -</text>
<text top="432" left="633" width="167" height="20" font="1">2.87– -0.47) and DBP of -0.93 </text>
<text top="449" left="633" width="132" height="20" font="1">(95% CIL -1.64– -0.22). </text>
<text top="468" left="633" width="7" height="18" font="1">•</text>
<text top="468" left="640" width="139" height="20" font="1"> There was no significant </text>
<text top="485" left="633" width="187" height="20" font="1">difference between the effect size </text>
<text top="502" left="633" width="163" height="20" font="1">in those with a baseline BP ≥ </text>
<text top="519" left="633" width="106" height="20" font="1">or&lt;140/90 mm Hg. </text>
<text top="536" left="633" width="175" height="20" font="1">- The mean change in SBP and </text>
<text top="554" left="633" width="165" height="20" font="1">DBP for those with a baseline </text>
<text top="571" left="633" width="130" height="20" font="1">BP≥140/90 mm Hg (23 </text>
<text top="588" left="633" width="185" height="20" font="1">comparisons) was -2.17 (95% CI: </text>
<text top="605" left="633" width="185" height="20" font="1">-3.78– -0.55) and -0.95 (95% CI: -</text>
<text top="623" left="633" width="145" height="20" font="1">1.89– -0.01), respectively. </text>
<text top="640" left="633" width="178" height="20" font="1">- The mean in SBP and DBP for </text>
<text top="657" left="633" width="186" height="20" font="1">those with a baseline BP &lt;140/90 </text>
<text top="674" left="633" width="189" height="20" font="1">mm Hg was -1.67 (95% CI: -3.01– </text>
<text top="691" left="633" width="185" height="20" font="1">-0.27) and -1.02 (95% CI: -1.85– -</text>
<text top="709" left="633" width="150" height="20" font="1">0.19) mm Hg, respectively. </text>
<text top="727" left="633" width="7" height="18" font="1">•</text>
<text top="727" left="640" width="163" height="20" font="1"> The authors reported slightly </text>
<text top="744" left="633" width="182" height="20" font="1">larger effect sizes in those with a </text>
<text top="761" left="633" width="162" height="20" font="1">lower initial calcium intake, in </text>
<text top="778" left="633" width="161" height="20" font="1">trials that employed a dietary </text>
<text top="241" left="836" width="7" height="18" font="1">•</text>
<text top="240" left="843" width="213" height="20" font="1"> This is the most recent SR/MA on this </text>
<text top="258" left="836" width="215" height="20" font="1">topic to include RCT conducted in both </text>
<text top="275" left="836" width="222" height="20" font="1">normotensive and hypertensive pts. The </text>
<text top="292" left="836" width="224" height="20" font="1">authors interpreted their results as being </text>
<text top="309" left="836" width="197" height="20" font="1">consistent with a beneficial effect of </text>
<text top="326" left="836" width="239" height="20" font="1">calcium supplementation on BP, with about </text>
<text top="344" left="836" width="207" height="20" font="1">a 2 mm Hg reduction in SBP for a 1 g </text>
<text top="361" left="836" width="230" height="20" font="1">increase in calcium intake. This is slighter </text>
<text top="378" left="836" width="211" height="20" font="1">larger effect size than noted in several </text>
<text top="395" left="836" width="124" height="20" font="1">earlier meta-analyses. </text>
<text top="414" left="836" width="7" height="18" font="1">•</text>
<text top="414" left="843" width="215" height="20" font="1"> A subsequent Cochrane Collaboration </text>
<text top="431" left="836" width="227" height="20" font="1">meta-analysis was confined to 13 RCT in </text>
<text top="448" left="836" width="237" height="20" font="1">485 adults (≥18 y) with HTN studied for ≥8 </text>
<text top="465" left="836" width="188" height="20" font="1">wk (Dickinson HO et al. Cochrane </text>
<text top="482" left="836" width="221" height="20" font="1">Database of Systematic Reviews. 2006; </text>
<text top="500" left="836" width="183" height="20" font="1">CD004639). The authors noted a </text>
<text top="517" left="836" width="230" height="20" font="1">significant reduction in mean of -2.5 (95% </text>
<text top="534" left="836" width="231" height="20" font="1">CI: -4.5– -0.6) for SBP but a more modest </text>
<text top="551" left="836" width="229" height="20" font="1">insignificant change of -0.8 (95% CI: -2.1–</text>
<text top="568" left="836" width="236" height="20" font="1">0.4) for DBP. Due to the poor quality of the </text>
<text top="586" left="836" width="228" height="20" font="1">RCT and heterogeneity of the results, the </text>
<text top="603" left="836" width="219" height="20" font="1">authors concluded the reduction in SBP </text>
<text top="620" left="836" width="184" height="20" font="1">was likely an artifact due to bias.  </text>
<text top="639" left="836" width="7" height="18" font="1">•</text>
<text top="639" left="843" width="200" height="20" font="1"> Although not included in most meta-</text>
<text top="656" left="836" width="217" height="20" font="1">analyses, calcium supplementation has </text>
<text top="673" left="836" width="227" height="20" font="1">been effective as a treatment in pregnant </text>
<text top="690" left="836" width="181" height="20" font="1">women at risk for pre-eclampsia. </text>
<text top="709" left="836" width="7" height="18" font="1">•</text>
<text top="708" left="843" width="222" height="20" font="1"> Several of the meta-analyses (including </text>
<text top="726" left="836" width="239" height="20" font="1">the 1 by van Mierlo et al) have suggested a </text>
<text top="743" left="836" width="225" height="20" font="1">bigger effect size in persons with a lower </text>
<text top="760" left="836" width="224" height="20" font="1">intake of calcium at baseline and in trials </text>
<text top="777" left="836" width="187" height="20" font="1">that utilized a dietary intervention. </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">56 </text>
<text top="107" left="633" width="153" height="20" font="1">intervention (compared to a </text>
<text top="124" left="633" width="172" height="20" font="1">supplement), and in the 4 trials </text>
<text top="141" left="633" width="117" height="20" font="1">conducted in Asians. </text>
<text top="159" left="633" width="3" height="20" font="4"><b> </b></text>
<text top="177" left="633" width="143" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A <b> </b></text>
<text top="109" left="836" width="7" height="18" font="1">•</text>
<text top="108" left="843" width="220" height="20" font="1"> Most of the trials were of short duration </text>
<text top="125" left="836" width="224" height="20" font="1">and did not (have the capacity) report on </text>
<text top="143" left="836" width="197" height="20" font="1">potential adverse effects such renal </text>
<text top="160" left="836" width="43" height="20" font="1">stones. </text>
<text top="179" left="836" width="7" height="18" font="1">•</text>
<text top="178" left="843" width="219" height="20" font="1"> In addition to being small, several trials </text>
<text top="195" left="836" width="140" height="20" font="1">were of uncertain quality. </text>
<text top="214" left="836" width="7" height="18" font="1">•</text>
<text top="214" left="843" width="230" height="20" font="1"> Overall, RCT experience provides limited </text>
<text top="231" left="836" width="216" height="20" font="1">and inconsistent evidence from trials of </text>
<text top="248" left="836" width="202" height="20" font="1">variable quality in support of calcium </text>
<text top="265" left="836" width="191" height="20" font="1">supplementation for prevention (or </text>
<text top="283" left="836" width="194" height="20" font="1">treatment) of HTN. Better evidence </text>
<text top="300" left="836" width="230" height="20" font="1">supports the role of calcium supplements, </text>
<text top="317" left="836" width="175" height="20" font="1">in conjunction with vitamin D, in </text>
<text top="334" left="836" width="155" height="20" font="1">strengthening bone density. </text>
<text top="354" left="108" width="3" height="19" font="4"><b> </b></text>
<text top="388" left="81" width="1002" height="24" font="3"><b>Data Supplement 18. RCTs and Meta-analyses RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Physical Activity) (Section </b></text>
<text top="412" left="81" width="29" height="24" font="3"><b>6.2) </b></text>
<text top="452" left="127" width="38" height="20" font="4"><b>Study </b></text>
<text top="469" left="115" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="486" left="122" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="503" left="99" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="452" left="231" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="469" left="236" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="486" left="230" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="452" left="357" width="256" height="20" font="4"><b>Patient Population  Study Intervention (# </b></text>
<text top="469" left="520" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="486" left="488" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="503" left="523" width="55" height="20" font="4"><b>patients) </b></text>
<text top="452" left="689" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="469" left="672" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="486" left="654" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="453" left="883" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="470" left="916" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="487" left="923" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="521" left="98" width="85" height="20" font="1">Whelton SP, et </text>
<text top="538" left="98" width="76" height="20" font="1">al., 2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(96)</a> </text>
<text top="556" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11926784?dopt=Citation">11926784</a></text>
<text top="556" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11926784?dopt=Citation"> </a></text>
<text top="521" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="538" left="206" width="124" height="20" font="1">of aerobic exercise on </text>
<text top="556" left="206" width="20" height="20" font="1">BP<b> </b></text>
<text top="573" left="206" width="3" height="20" font="1"> </text>
<text top="590" left="206" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="607" left="206" width="126" height="20" font="1">Systematic review and </text>
<text top="624" left="206" width="79" height="20" font="1">meta-analysis </text>
<text top="642" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="659" left="206" width="112" height="20" font="4"><b>Size: </b>38 reports (54 </text>
<text top="676" left="206" width="102" height="20" font="1">comparisons) with </text>
<text top="693" left="206" width="109" height="20" font="1">2,419 pts; 27 of the </text>
<text top="710" left="206" width="103" height="20" font="1">comparisons were </text>
<text top="728" left="206" width="73" height="20" font="1">conducted in </text>
<text top="745" left="206" width="97" height="20" font="1">normotensive pts<b> </b></text>
<text top="521" left="352" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="540" left="352" width="7" height="18" font="1">•</text>
<text top="539" left="359" width="101" height="20" font="1"> English language </text>
<text top="557" left="352" width="112" height="20" font="1">publication between </text>
<text top="574" left="352" width="65" height="20" font="1">1966–2001 </text>
<text top="593" left="352" width="7" height="18" font="1">•</text>
<text top="592" left="359" width="107" height="20" font="1"> RCT in adults ≥18 </text>
<text top="610" left="352" width="10" height="20" font="1">y </text>
<text top="629" left="352" width="7" height="18" font="1">•</text>
<text top="628" left="359" width="90" height="20" font="1"> Duration ≥2 wk </text>
<text top="647" left="352" width="7" height="18" font="1">•</text>
<text top="646" left="359" width="84" height="20" font="1"> No concurrent </text>
<text top="663" left="352" width="73" height="20" font="1">interventions </text>
<text top="681" left="352" width="3" height="20" font="1"> </text>
<text top="698" left="352" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="715" left="352" width="92" height="20" font="1">Missing BP data </text>
<text top="521" left="487" width="123" height="20" font="4"><b>Intervention:</b> Aerobic </text>
<text top="538" left="487" width="53" height="20" font="1">exercise  </text>
<text top="556" left="487" width="7" height="20" font="1">  </text>
<text top="573" left="487" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="590" left="487" width="110" height="20" font="1">exercise prescribed </text>
<text top="522" left="627" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="541" left="627" width="7" height="18" font="1">•</text>
<text top="541" left="634" width="174" height="20" font="1"> For the overall group, a pooled </text>
<text top="558" left="627" width="185" height="20" font="1">analysis of experience in 53 trials </text>
<text top="575" left="627" width="220" height="20" font="1">identified a mean net change in SBP of -</text>
<text top="592" left="627" width="224" height="20" font="1">3.84 (95% CI: -4.97– -2.72). In subgroup </text>
<text top="610" left="627" width="226" height="20" font="1">analysis, the effect was noted in different </text>
<text top="627" left="627" width="204" height="20" font="1">ethnic groups, in trials that employed </text>
<text top="644" left="627" width="222" height="20" font="1">different designs, durations, and sample </text>
<text top="661" left="627" width="220" height="20" font="1">sizes, in trials with obese, overweight or </text>
<text top="678" left="627" width="194" height="20" font="1">normal weight pts, and in trials that </text>
<text top="696" left="627" width="189" height="20" font="1">employed different types, intensity </text>
<text top="713" left="627" width="220" height="20" font="1">levels, and duration of aerobic exercise. </text>
<text top="732" left="627" width="7" height="18" font="1">•</text>
<text top="731" left="634" width="165" height="20" font="1"> In the subgroup of 15 trials in </text>
<text top="748" left="627" width="215" height="20" font="1">hypertensives, the mean net change in </text>
<text top="766" left="627" width="217" height="20" font="1">SBP was -4.94 (95% CI: -7.17– -2.70).<b>  </b></text>
<text top="521" left="867" width="189" height="20" font="1">● This meta-analysis provides the </text>
<text top="538" left="867" width="199" height="20" font="1">most comprehensive analysis of the </text>
<text top="556" left="867" width="201" height="20" font="1">effect of aerobic exercise on BP and </text>
<text top="573" left="867" width="198" height="20" font="1">provides strong evidence in support </text>
<text top="590" left="867" width="207" height="20" font="1">of aerobic exercise as an intervention </text>
<text top="607" left="867" width="170" height="20" font="1">to lower BP in normotensives.  </text>
<text top="624" left="867" width="207" height="20" font="1">● Recognizing this, many of the trials </text>
<text top="642" left="867" width="182" height="20" font="1">were small and of short duration. </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">57 </text>
<text top="109" left="627" width="7" height="18" font="1">•</text>
<text top="108" left="634" width="213" height="20" font="1"> In the subgroup of 27 trials conducted </text>
<text top="125" left="627" width="219" height="20" font="1">in normotensives, the mean net change </text>
<text top="143" left="627" width="230" height="20" font="1">in SBP was -4.04 (95% CI: -5.32– -2.75).<b>  </b></text>
<text top="160" left="627" width="3" height="20" font="4"><b> </b></text>
<text top="178" left="627" width="143" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A  </text>
<text top="196" left="98" width="91" height="20" font="1">Cornelissen VA, </text>
<text top="213" left="98" width="93" height="20" font="1">et al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(97)</a>  </text>
<text top="231" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23525435?dopt=Citation">23525435</a></text>
<text top="231" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23525435?dopt=Citation"> </a></text>
<text top="196" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="213" left="206" width="108" height="20" font="1">of different types of </text>
<text top="231" left="206" width="129" height="20" font="1">physical activity on BP <b> </b></text>
<text top="250" left="206" width="7" height="18" font="1">•</text>
<text top="249" left="213" width="98" height="20" font="1"> Dynamic aerobic </text>
<text top="266" left="206" width="62" height="20" font="1">endurance </text>
<text top="285" left="206" width="7" height="18" font="1">•</text>
<text top="285" left="213" width="112" height="20" font="1"> Resistance training </text>
<text top="302" left="206" width="59" height="20" font="1">- Dynamic </text>
<text top="319" left="206" width="107" height="20" font="1">- Static (Isometric)  </text>
<text top="336" left="206" width="3" height="20" font="1"> </text>
<text top="353" left="206" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="371" left="206" width="126" height="20" font="1">Systematic review and </text>
<text top="388" left="206" width="79" height="20" font="1">meta-analysis </text>
<text top="405" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="422" left="206" width="95" height="20" font="4"><b>Size: </b>Overall, 93 </text>
<text top="440" left="206" width="115" height="20" font="1">studies (&gt;5,000 pts) <b> </b></text>
<text top="459" left="206" width="7" height="18" font="1">•</text>
<text top="458" left="213" width="117" height="20" font="1"> 59 Dynamic Aerobic </text>
<text top="475" left="206" width="105" height="20" font="1">Endurance studies </text>
<text top="494" left="206" width="7" height="18" font="1">•</text>
<text top="493" left="213" width="72" height="20" font="1"> 13 Dynamic </text>
<text top="511" left="206" width="64" height="20" font="1">Resistance </text>
<text top="528" left="206" width="90" height="20" font="1">Training studies </text>
<text top="547" left="206" width="7" height="18" font="1">•</text>
<text top="546" left="213" width="124" height="20" font="1"> 5 Combined Dynamic </text>
<text top="563" left="206" width="69" height="20" font="1">Aerobic and </text>
<text top="581" left="206" width="108" height="20" font="1">Resistance training </text>
<text top="600" left="206" width="7" height="18" font="1">•</text>
<text top="599" left="213" width="109" height="20" font="1"> 4 Static (Isometric) </text>
<text top="616" left="206" width="64" height="20" font="1">Resistance </text>
<text top="635" left="206" width="7" height="18" font="1">•</text>
<text top="635" left="213" width="70" height="20" font="1"> 12 Different </text>
<text top="652" left="206" width="118" height="20" font="1">interventions within 1 </text>
<text top="669" left="206" width="23" height="20" font="1">trial </text>
<text top="196" left="352" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="215" left="352" width="7" height="18" font="1">•</text>
<text top="215" left="359" width="107" height="20" font="1"> Parallel arm RCTs </text>
<text top="234" left="352" width="7" height="18" font="1">•</text>
<text top="233" left="359" width="73" height="20" font="1"> Adults≥18 y </text>
<text top="252" left="352" width="7" height="18" font="1">•</text>
<text top="251" left="359" width="85" height="20" font="1"> Peer reviewed </text>
<text top="269" left="352" width="77" height="20" font="1">journals up to </text>
<text top="286" left="352" width="83" height="20" font="1">February 2012 </text>
<text top="305" left="352" width="7" height="18" font="1">•</text>
<text top="304" left="359" width="97" height="20" font="1"> Trial duration ≥4 </text>
<text top="321" left="352" width="19" height="20" font="1">wk </text>
<text top="339" left="352" width="3" height="20" font="1"> </text>
<text top="356" left="352" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="373" left="352" width="117" height="20" font="1">Inadequate reporting </text>
<text top="390" left="352" width="62" height="20" font="1">of the data<b> </b></text>
<text top="196" left="487" width="127" height="20" font="4"><b>Intervention:</b> Physical </text>
<text top="213" left="487" width="41" height="20" font="1">activity </text>
<text top="231" left="487" width="3" height="20" font="1"> </text>
<text top="248" left="487" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="265" left="487" width="81" height="20" font="1">prescription of </text>
<text top="282" left="487" width="89" height="20" font="1">physical activity </text>
<text top="197" left="627" width="165" height="20" font="4"><b>1</b>°<b> endpoint:</b> Overall (trials in </text>
<text top="215" left="627" width="188" height="20" font="1">hypertensives and normotensive), </text>
<text top="232" left="627" width="225" height="20" font="1">pooled experience identified a significant </text>
<text top="249" left="627" width="223" height="20" font="1">reduction in BP with all forms of physical </text>
<text top="266" left="627" width="188" height="20" font="1">activity (aerobic and both forms of </text>
<text top="283" left="627" width="170" height="20" font="1">resistance training), with mean </text>
<text top="301" left="627" width="182" height="20" font="1">reductions in SBP of -3.5 mm Hg </text>
<text top="318" left="627" width="208" height="20" font="1">following aerobic endurance training, -</text>
<text top="335" left="627" width="224" height="20" font="1">1.8 mm Hg following dynamic resistance </text>
<text top="352" left="627" width="197" height="20" font="1">training, and -10.9 mm Hg following </text>
<text top="370" left="627" width="196" height="20" font="1">static (isometric) resistance training </text>
<text top="387" left="627" width="219" height="20" font="1">(p&lt;0.001 for the difference between the </text>
<text top="404" left="627" width="226" height="20" font="1">effect size following static [isometric] and </text>
<text top="421" left="627" width="176" height="20" font="1">other forms of physical activity). </text>
<text top="438" left="627" width="213" height="20" font="1">In subgroup analysis, dynamic aerobic </text>
<text top="456" left="627" width="194" height="20" font="1">endurance and dynamic resistance </text>
<text top="473" left="627" width="216" height="20" font="1">training resulted in mean SBP changes </text>
<text top="490" left="627" width="205" height="20" font="1">of -2.1 (95% CI: -3.3– -0.83) and -4.3 </text>
<text top="507" left="628" width="227" height="20" font="1">(95% CI: -7.7– -0.90), respectively, in the </text>
<text top="524" left="628" width="166" height="20" font="1">pts with pre-HTN and smaller, </text>
<text top="542" left="628" width="172" height="20" font="1">nonsignificant reductions in the </text>
<text top="559" left="628" width="181" height="20" font="1">remaining pts with a normal BP.  </text>
<text top="576" left="628" width="3" height="20" font="1"> </text>
<text top="593" left="627" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="198" left="867" width="7" height="18" font="1">•</text>
<text top="197" left="874" width="144" height="20" font="1"> Most recent in a series of </text>
<text top="215" left="867" width="192" height="20" font="1">progressively updated publications </text>
<text top="232" left="867" width="161" height="20" font="1">from Dr. Cornelissen and her </text>
<text top="249" left="867" width="66" height="20" font="1">colleagues. </text>
<text top="268" left="867" width="7" height="18" font="1">•</text>
<text top="267" left="874" width="186" height="20" font="1"> The findings suggest a beneficial </text>
<text top="285" left="867" width="200" height="20" font="1">effect of all forms of physical activity </text>
<text top="302" left="867" width="207" height="20" font="1">on BP, with a disproportionately large </text>
<text top="319" left="867" width="191" height="20" font="1">effect of resistance training on BP. </text>
<text top="338" left="867" width="7" height="18" font="1">•</text>
<text top="337" left="874" width="188" height="20" font="1"> Many of the available RCTs have </text>
<text top="355" left="867" width="200" height="20" font="1">been small, of short duration, and of </text>
<text top="372" left="867" width="100" height="20" font="1">uncertain quality.  </text>
<text top="687" left="98" width="93" height="20" font="1">Rossi AM, et al., </text>
<text top="704" left="98" width="56" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(98)</a> </text>
<text top="721" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23541664?dopt=Citation">23541664</a></text>
<text top="721" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23541664?dopt=Citation"> </a></text>
<text top="687" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="704" left="206" width="122" height="20" font="1">of resistance exercise </text>
<text top="721" left="206" width="37" height="20" font="1">on BP<b> </b></text>
<text top="739" left="206" width="3" height="20" font="1"> </text>
<text top="756" left="206" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="773" left="206" width="126" height="20" font="1">Systematic review and </text>
<text top="790" left="206" width="79" height="20" font="1">meta-analysis </text>
<text top="687" left="352" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="706" left="352" width="7" height="18" font="1">•</text>
<text top="705" left="359" width="87" height="20" font="1"> RCTs in adults </text>
<text top="723" left="352" width="43" height="20" font="1">(≥18 y) </text>
<text top="742" left="352" width="7" height="18" font="1">•</text>
<text top="741" left="359" width="89" height="20" font="1"> BP-lowering 1° </text>
<text top="758" left="352" width="51" height="20" font="1">outcome </text>
<text top="687" left="487" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="704" left="487" width="111" height="20" font="1">Dynamic resistance </text>
<text top="721" left="487" width="104" height="20" font="1">training but overall </text>
<text top="739" left="487" width="125" height="20" font="1">reporting of the details </text>
<text top="756" left="487" width="57" height="20" font="1">was poor. </text>
<text top="773" left="487" width="3" height="20" font="1"> </text>
<text top="688" left="627" width="181" height="20" font="4"><b>1</b>°<b> endpoint:</b> Pooled experience </text>
<text top="705" left="627" width="203" height="20" font="1">(hypertensive and normotensive pts) </text>
<text top="723" left="627" width="177" height="20" font="1">identified a small, nonsignificant </text>
<text top="740" left="627" width="226" height="20" font="1">reduction in mean SBP of -1.03 (95% CI: </text>
<text top="757" left="627" width="215" height="20" font="1">-3.44–0.39). The corresponding finding </text>
<text top="689" left="867" width="7" height="18" font="1">•</text>
<text top="688" left="874" width="174" height="20" font="1"> Suggests resistance training is </text>
<text top="705" left="867" width="201" height="20" font="1">effective in lowering BP and was the </text>
<text top="723" left="867" width="157" height="20" font="1">basis for recommending this </text>
<text top="740" left="867" width="185" height="20" font="1">intervention in the Canadian HTN </text>
<text top="757" left="867" width="109" height="20" font="1">Education Program </text>
<text top="774" left="867" width="108" height="20" font="1">recommendations.  </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">58 </text>
<text top="107" left="206" width="3" height="20" font="1"> </text>
<text top="124" left="206" width="98" height="20" font="4"><b>Size: </b>9 RCTs (11 </text>
<text top="141" left="206" width="132" height="20" font="1">intervention groups and </text>
<text top="159" left="206" width="94" height="20" font="1">14 comparisons) </text>
<text top="176" left="206" width="120" height="20" font="1">conducted in 452 pts. </text>
<text top="193" left="206" width="104" height="20" font="1">10 (71%) of the 14 </text>
<text top="210" left="206" width="103" height="20" font="1">comparisons were </text>
<text top="228" left="206" width="73" height="20" font="1">conducted in </text>
<text top="245" left="206" width="83" height="20" font="1">normotensives<b> </b></text>
<text top="109" left="352" width="7" height="18" font="1">•</text>
<text top="108" left="359" width="97" height="20" font="1"> Trial duration ≥4 </text>
<text top="125" left="352" width="19" height="20" font="1">wk </text>
<text top="144" left="352" width="7" height="18" font="1">•</text>
<text top="144" left="359" width="111" height="20" font="1"> Resistance training </text>
<text top="161" left="352" width="93" height="20" font="1">only intervention </text>
<text top="178" left="352" width="3" height="20" font="1"> </text>
<text top="195" left="352" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="213" left="352" width="106" height="20" font="1">Handgrip/isometric </text>
<text top="230" left="352" width="53" height="20" font="1">exercise  </text>
<text top="107" left="487" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="124" left="487" width="124" height="20" font="1">resistance training but </text>
<text top="141" left="487" width="102" height="20" font="1">not detailed in this </text>
<text top="159" left="487" width="36" height="20" font="1">article </text>
<text top="107" left="627" width="197" height="20" font="1">for DBP was -2.19 (95% CI: -3.87– -</text>
<text top="124" left="627" width="38" height="20" font="1">0.51).  </text>
<text top="141" left="627" width="3" height="20" font="1"> </text>
<text top="159" left="627" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="109" left="867" width="7" height="18" font="1">•</text>
<text top="108" left="874" width="169" height="20" font="1"> The discrepancy in effect size </text>
<text top="125" left="867" width="206" height="20" font="1">between this meta-analysis and the 1 </text>
<text top="143" left="867" width="198" height="20" font="1">conducted by Cornelisson et al may </text>
<text top="160" left="867" width="206" height="20" font="1">have been due to the more restrictive </text>
<text top="177" left="867" width="170" height="20" font="1">requirement by Rossi et al that </text>
<text top="194" left="867" width="184" height="20" font="1">change in BP be the 1° outcome. </text>
<text top="263" left="98" width="94" height="20" font="1">Garcia-Hermosa </text>
<text top="280" left="98" width="79" height="20" font="1">A, et al., 2013 </text>
<text top="297" left="98" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(99)</a> </text>
<text top="314" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23786645?dopt=Citation">23786645</a></text>
<text top="314" left="152" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23786645?dopt=Citation"><b>  </b></a></text>
<text top="263" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="280" left="206" width="113" height="20" font="1">of exercise on BP in </text>
<text top="297" left="206" width="87" height="20" font="1">obese children.<b> </b></text>
<text top="314" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="332" left="206" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="349" left="206" width="126" height="20" font="1">Systematic review and </text>
<text top="366" left="206" width="86" height="20" font="1">meta-analysis. <b> </b></text>
<text top="383" left="206" width="3" height="20" font="1"> </text>
<text top="400" left="206" width="133" height="20" font="4"><b>Size: </b>9 RCTs (410 pts).<b> </b></text>
<text top="263" left="352" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="282" left="352" width="7" height="18" font="1">•</text>
<text top="281" left="359" width="113" height="20" font="1"> Children ≤14 y with </text>
<text top="298" left="352" width="42" height="20" font="1">obesity </text>
<text top="317" left="352" width="7" height="18" font="1">•</text>
<text top="317" left="359" width="32" height="20" font="1"> RCT </text>
<text top="336" left="352" width="7" height="18" font="1">•</text>
<text top="335" left="359" width="90" height="20" font="1"> Duration ≥8 wk </text>
<text top="354" left="352" width="7" height="18" font="1">•</text>
<text top="353" left="359" width="74" height="20" font="1"> 1° outcome: </text>
<text top="371" left="352" width="77" height="20" font="1">change in BP </text>
<text top="388" left="352" width="3" height="20" font="1"> </text>
<text top="405" left="352" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="422" left="352" width="72" height="20" font="1">Concomitant </text>
<text top="440" left="352" width="67" height="20" font="1">intervention </text>
<text top="263" left="487" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="280" left="487" width="94" height="20" font="1">Physical activity, </text>
<text top="297" left="487" width="102" height="20" font="1">principally aerobic </text>
<text top="314" left="487" width="53" height="20" font="1">exercise.<b> </b></text>
<text top="332" left="487" width="3" height="20" font="4"><b> </b></text>
<text top="349" left="487" width="96" height="20" font="4"><b>Comparator: </b>No </text>
<text top="366" left="487" width="100" height="20" font="1">physical exercise, </text>
<text top="383" left="487" width="125" height="20" font="1">nutrition, education, or </text>
<text top="400" left="487" width="97" height="20" font="1">dietary restriction </text>
<text top="418" left="487" width="67" height="20" font="1">intervention<b> </b></text>
<text top="264" left="627" width="221" height="20" font="4"><b>1</b>°<b> endpoint: </b>Change in SBP: In pooled </text>
<text top="281" left="627" width="220" height="20" font="1">analysis, mean change in SBP was -0.4 </text>
<text top="298" left="627" width="128" height="20" font="1">(95% CI: -0.66– -0.24).<b> </b></text>
<text top="316" left="627" width="3" height="20" font="4"><b> </b></text>
<text top="333" left="627" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A <b> </b></text>
<text top="265" left="867" width="7" height="18" font="1">•</text>
<text top="264" left="874" width="156" height="20" font="4"><b> </b>This meta-analysis focused </text>
<text top="281" left="867" width="195" height="20" font="1">specifically on the effect of physical </text>
<text top="298" left="867" width="163" height="20" font="1">activity on BP in children with </text>
<text top="316" left="867" width="177" height="20" font="1">obesity. Although it is not stated </text>
<text top="333" left="867" width="207" height="20" font="1">explicitly, it seems likely that all of the </text>
<text top="350" left="867" width="198" height="20" font="1">participants were normotensive and </text>
<text top="367" left="867" width="193" height="20" font="1">not receiving medication that could </text>
<text top="384" left="867" width="118" height="20" font="1">influence level of BP. </text>
<text top="403" left="867" width="7" height="18" font="1">•</text>
<text top="403" left="874" width="179" height="20" font="4"><b> </b>The findings are consistent with </text>
<text top="420" left="867" width="196" height="20" font="1">other meta-analyses of the effect of </text>
<text top="437" left="867" width="133" height="20" font="1">physical activity on BP.  </text>
<text top="456" left="867" width="7" height="18" font="1">•</text>
<text top="456" left="874" width="191" height="20" font="4"><b> </b>Only limited information regarding </text>
<text top="473" left="867" width="170" height="20" font="1">study details is provided in this </text>
<text top="490" left="867" width="194" height="20" font="1">publication. The interventions were </text>
<text top="507" left="867" width="204" height="20" font="1">heterogeneous in type, duration, and </text>
<text top="524" left="867" width="42" height="20" font="1">quality.<b> </b></text>
<text top="542" left="98" width="81" height="20" font="1">Carlson DJ, et </text>
<text top="560" left="98" width="83" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(100)</a> </text>
<text top="577" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24582191?dopt=Citation">24582191</a></text>
<text top="577" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24582191?dopt=Citation"><b> </b></a></text>
<text top="542" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="560" left="206" width="120" height="20" font="1">of physical activity on </text>
<text top="577" left="206" width="104" height="20" font="1">BP in children with </text>
<text top="594" left="206" width="46" height="20" font="1">obesity.<b> </b></text>
<text top="611" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="628" left="206" width="71" height="20" font="4"><b>Study type: </b></text>
<text top="646" left="206" width="126" height="20" font="1">Systematic review and </text>
<text top="663" left="206" width="86" height="20" font="1">meta-analysis. <b> </b></text>
<text top="680" left="206" width="3" height="20" font="1"> </text>
<text top="697" left="206" width="128" height="20" font="4"><b>Size: </b>9 RCTs (223 pts: </text>
<text top="714" left="206" width="132" height="20" font="1">127 intervention and 96 </text>
<text top="732" left="206" width="94" height="20" font="1">controls): 6 were </text>
<text top="749" left="206" width="73" height="20" font="1">conducted in </text>
<text top="766" left="206" width="87" height="20" font="1">normotensives.<b> </b></text>
<text top="542" left="352" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="561" left="352" width="7" height="18" font="1">•</text>
<text top="561" left="359" width="76" height="20" font="1"> Adults ≥18 y </text>
<text top="580" left="352" width="7" height="18" font="1">•</text>
<text top="579" left="359" width="87" height="20" font="1"> RCT, including </text>
<text top="596" left="352" width="94" height="20" font="1">cross-over trials. </text>
<text top="615" left="352" width="7" height="18" font="1">•</text>
<text top="615" left="359" width="90" height="20" font="1"> Duration ≥4 wk </text>
<text top="634" left="352" width="7" height="18" font="1">•</text>
<text top="633" left="359" width="112" height="20" font="1"> Published in a peer </text>
<text top="650" left="352" width="93" height="20" font="1">reviewed journal </text>
<text top="667" left="352" width="111" height="20" font="1">between January 1, </text>
<text top="685" left="352" width="100" height="20" font="1">1966 and July 31, </text>
<text top="702" left="352" width="31" height="20" font="1">2013 </text>
<text top="719" left="352" width="3" height="20" font="1"> </text>
<text top="736" left="352" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="753" left="352" width="68" height="20" font="1">Studies that </text>
<text top="771" left="352" width="80" height="20" font="1">employed any </text>
<text top="788" left="352" width="98" height="20" font="1">intervention other </text>
<text top="542" left="487" width="107" height="20" font="4"><b>Intervention: </b>Pure </text>
<text top="560" left="487" width="105" height="20" font="1">isometric exercise.<b> </b></text>
<text top="577" left="487" width="3" height="20" font="4"><b> </b></text>
<text top="594" left="487" width="126" height="20" font="4"><b>Comparator: </b>Use of a </text>
<text top="611" left="487" width="111" height="20" font="1">control group was a </text>
<text top="628" left="487" width="107" height="20" font="1">requirement but no </text>
<text top="646" left="487" width="100" height="20" font="1">additional specific </text>
<text top="663" left="487" width="118" height="20" font="1">information provided.<b> </b></text>
<text top="543" left="627" width="83" height="20" font="4"><b>1</b>°<b> endpoint:   </b></text>
<text top="563" left="627" width="7" height="18" font="1">•</text>
<text top="562" left="634" width="165" height="20" font="1"> In the overall pooled analysis </text>
<text top="579" left="627" width="215" height="20" font="1">(hypertensive and normotensive trials), </text>
<text top="596" left="627" width="227" height="20" font="1">mean change in SBP was -6.77 (95% CI: </text>
<text top="614" left="627" width="120" height="20" font="1">-7.93– -5.62) mm Hg. </text>
<text top="633" left="627" width="7" height="18" font="1">•</text>
<text top="632" left="634" width="171" height="20" font="1"> In the subgroup of 3 trials with </text>
<text top="649" left="627" width="223" height="20" font="1">hypertensive pts (all on antihypertensive </text>
<text top="666" left="627" width="210" height="20" font="1">medication), the mean change in SBP </text>
<text top="683" left="627" width="206" height="20" font="1">was -4.31 (95% CI: -6.42– -2.21) mm </text>
<text top="701" left="627" width="22" height="20" font="1">Hg. </text>
<text top="720" left="627" width="7" height="18" font="1">•</text>
<text top="719" left="634" width="171" height="20" font="1"> In the subgroup of 6 trials with </text>
<text top="736" left="627" width="212" height="20" font="1">normotensive pts, the mean change in </text>
<text top="754" left="627" width="210" height="20" font="1">SBP was -7.83 (95% CI: -9.21– -6.45) </text>
<text top="771" left="627" width="46" height="20" font="1">mm Hg. </text>
<text top="788" left="627" width="3" height="20" font="4"><b> </b></text>
<text top="544" left="867" width="7" height="18" font="1">•</text>
<text top="543" left="874" width="177" height="20" font="4"><b> </b>This study provides information </text>
<text top="561" left="867" width="204" height="20" font="1">regarding the effect of pure isometric </text>
<text top="578" left="867" width="172" height="20" font="1">exercise interventions on BP in </text>
<text top="595" left="867" width="40" height="20" font="1">adults. </text>
<text top="614" left="867" width="7" height="18" font="1">•</text>
<text top="613" left="874" width="193" height="20" font="4"><b> </b>The BP reductions reported in this </text>
<text top="631" left="867" width="197" height="20" font="1">meta-analysis are surprisingly large </text>
<text top="648" left="867" width="198" height="20" font="1">but the overall effect pattern is quite </text>
<text top="665" left="867" width="199" height="20" font="1">consistent with other meta-analyses </text>
<text top="682" left="867" width="119" height="20" font="1">of isometric exercise.<b> </b></text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">59 </text>
<text top="107" left="352" width="108" height="20" font="1">than pure isometric </text>
<text top="124" left="352" width="81" height="20" font="1">exercise (e.g., </text>
<text top="141" left="352" width="116" height="20" font="1">dynamic resistance) <b> </b></text>
<text top="107" left="627" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="159" left="98" width="91" height="20" font="1">Cornelissen VA, </text>
<text top="177" left="98" width="37" height="20" font="1">et al.,  </text>
<text top="194" left="98" width="63" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(101)</a> </text>
<text top="211" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21896934?dopt=Citation">21896934</a></text>
<text top="211" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21896934?dopt=Citation"><b> </b></a></text>
<text top="159" left="206" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="177" left="206" width="117" height="20" font="1">of resistance training </text>
<text top="194" left="206" width="40" height="20" font="1">on BP.<b> </b></text>
<text top="211" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="228" left="206" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="245" left="206" width="51" height="20" font="1">analysis <b> </b></text>
<text top="263" left="206" width="3" height="20" font="1"> </text>
<text top="280" left="206" width="120" height="20" font="4"><b>Size: </b>28 randomized, </text>
<text top="297" left="206" width="89" height="20" font="1">controlled trials, </text>
<text top="314" left="206" width="101" height="20" font="1">involving 33 study </text>
<text top="332" left="206" width="126" height="20" font="1">groups and 1,012 pts. <b> </b></text>
<text top="159" left="352" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="178" left="352" width="7" height="18" font="1">•</text>
<text top="178" left="359" width="76" height="20" font="1"> Adults ≥18 y </text>
<text top="197" left="352" width="7" height="18" font="1">•</text>
<text top="196" left="359" width="87" height="20" font="1"> RCT, including </text>
<text top="213" left="352" width="94" height="20" font="1">cross-over trials. </text>
<text top="232" left="352" width="7" height="18" font="1">•</text>
<text top="232" left="359" width="90" height="20" font="1"> Duration ≥4 wk </text>
<text top="251" left="352" width="7" height="18" font="1">•</text>
<text top="250" left="359" width="112" height="20" font="1"> Published in a peer </text>
<text top="267" left="352" width="110" height="20" font="1">reviewed journal up </text>
<text top="285" left="352" width="75" height="20" font="1">to June 2010 </text>
<text top="302" left="352" width="3" height="20" font="1"> </text>
<text top="319" left="352" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="336" left="352" width="105" height="20" font="1">Interventions other </text>
<text top="353" left="352" width="108" height="20" font="1">than pure isometric </text>
<text top="371" left="352" width="77" height="20" font="1">exercise (e.g. </text>
<text top="388" left="352" width="116" height="20" font="1">dynamic resistance) <b> </b></text>
<text top="159" left="487" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="177" left="487" width="111" height="20" font="1">Resistance training, </text>
<text top="194" left="487" width="104" height="20" font="1">including isometric </text>
<text top="211" left="487" width="73" height="20" font="1">and dynamic </text>
<text top="228" left="487" width="62" height="20" font="1">modalities.<b> </b></text>
<text top="245" left="487" width="3" height="20" font="4"><b> </b></text>
<text top="263" left="487" width="126" height="20" font="4"><b>Comparator: </b>Use of a </text>
<text top="280" left="487" width="111" height="20" font="1">control group was a </text>
<text top="297" left="487" width="107" height="20" font="1">requirement but no </text>
<text top="314" left="487" width="100" height="20" font="1">additional specific </text>
<text top="332" left="487" width="118" height="20" font="1">information provided.<b> </b></text>
<text top="161" left="627" width="184" height="20" font="4"><b>1</b>°<b> endpoint: </b>Resistance training </text>
<text top="178" left="627" width="226" height="20" font="1">induced a significant SBP/DBP reduction </text>
<text top="195" left="627" width="213" height="20" font="1">in 28 normotensive or prehypertensive </text>
<text top="212" left="627" width="206" height="20" font="1">study groups of -3.9 (-6.4, -1.2)/-3.9 (-</text>
<text top="229" left="628" width="220" height="20" font="1">5.6, -2.2] mm Hg). In the 5 hypertensive </text>
<text top="247" left="627" width="189" height="20" font="1">study groups, the change in mean </text>
<text top="264" left="627" width="222" height="20" font="1">SBP/DBP was -4.1 (95% CI: -0.63–1.4)/-</text>
<text top="281" left="628" width="213" height="20" font="1">1.5 (95% CI: -3.4–0.40) mm Hg. When </text>
<text top="298" left="628" width="224" height="20" font="1">the study groups were divided according </text>
<text top="316" left="628" width="182" height="20" font="1">to the mode of training, isometric </text>
<text top="333" left="628" width="219" height="20" font="1">handgrip training in 3 groups resulted in </text>
<text top="350" left="628" width="204" height="20" font="1">a larger decrease in SBP/DBP (-13.5 </text>
<text top="367" left="628" width="227" height="20" font="1">[95% CI: -16.5– -10.5]/-6.1[95% CI: -8.3– </text>
<text top="384" left="628" width="211" height="20" font="1">-3.9] mm Hg) than dynamic resistance </text>
<text top="402" left="628" width="226" height="20" font="1">training in 30 groups (-2.8 [95% CI: -4.3– </text>
<text top="419" left="628" width="213" height="20" font="1">-1.3]/-2.7 [95% CI: -3.8– -1.7] mm Hg).<b> </b></text>
<text top="436" left="627" width="3" height="20" font="4"><b> </b></text>
<text top="453" left="627" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A <b> </b></text>
<text top="159" left="867" width="190" height="20" font="1">● This meta-analysis supports the </text>
<text top="177" left="877" width="182" height="20" font="1">BP-lowering potential of dynamic </text>
<text top="194" left="877" width="180" height="20" font="1">resistance training and isometric </text>
<text top="211" left="877" width="102" height="20" font="1">handgrip training.  </text>
<text top="228" left="867" width="166" height="20" font="1">● Results further suggest that </text>
<text top="245" left="877" width="192" height="20" font="1">isometric handgrip training may be </text>
<text top="263" left="877" width="196" height="20" font="1">more effective for reducing BP than </text>
<text top="280" left="877" width="159" height="20" font="1">dynamic resistance training.  </text>
<text top="297" left="867" width="198" height="20" font="1">● However, given the small amount </text>
<text top="314" left="877" width="164" height="20" font="1">of isometric studies available, </text>
<text top="332" left="877" width="192" height="20" font="1">additional studies are warranted to </text>
<text top="349" left="877" width="109" height="20" font="1">confirm this finding.<b> </b></text>
<text top="473" left="135" width="3" height="19" font="1"> </text>
<text top="507" left="81" width="894" height="24" font="3"><b>Data Supplement 19. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Magnesium </b></text>
<text top="531" left="81" width="221" height="24" font="3"><b>Supplementation) (Section 6.2) </b></text>
<text top="570" left="111" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="588" left="136" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="605" left="114" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="570" left="260" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="588" left="265" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="605" left="258" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="570" left="387" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="570" left="521" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="588" left="553" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="605" left="521" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="622" left="556" width="55" height="20" font="4"><b>patients) </b></text>
<text top="570" left="697" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="588" left="681" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="605" left="673" width="154" height="20" font="4"><b>P value; OR or RR; &amp; 95% </b></text>
<text top="622" left="740" width="20" height="20" font="4"><b>CI) </b></text>
<text top="572" left="874" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="589" left="906" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="606" left="914" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="640" left="98" width="109" height="20" font="1">Kass L, et al., 2012 </text>
<text top="657" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(102)</a> </text>
<text top="674" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22318649?dopt=Citation">22318649</a></text>
<text top="674" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22318649?dopt=Citation"> </a></text>
<text top="640" left="235" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="657" left="235" width="81" height="20" font="1">of magnesium </text>
<text top="674" left="235" width="131" height="20" font="1">supplementation on BP<b> </b></text>
<text top="692" left="235" width="3" height="20" font="1"> </text>
<text top="709" left="235" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="726" left="235" width="126" height="20" font="1">Systematic review and </text>
<text top="743" left="235" width="79" height="20" font="1">meta-analysis </text>
<text top="760" left="235" width="3" height="20" font="4"><b> </b></text>
<text top="640" left="381" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="659" left="381" width="7" height="18" font="1">•</text>
<text top="658" left="388" width="92" height="20" font="1"> RCT in humans </text>
<text top="677" left="381" width="7" height="18" font="1">•</text>
<text top="677" left="388" width="96" height="20" font="1"> Parallel or cross-</text>
<text top="694" left="381" width="67" height="20" font="1">over design </text>
<text top="713" left="381" width="7" height="18" font="1">•</text>
<text top="712" left="388" width="105" height="20" font="1"> Publication before </text>
<text top="730" left="381" width="56" height="20" font="1">July 2010 </text>
<text top="749" left="381" width="7" height="18" font="1">•</text>
<text top="748" left="388" width="75" height="20" font="1"> Adults &gt;18 y </text>
<text top="767" left="381" width="7" height="18" font="1">•</text>
<text top="766" left="388" width="89" height="20" font="1"> Only difference </text>
<text top="784" left="381" width="70" height="20" font="1">between the </text>
<text top="640" left="517" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="657" left="517" width="124" height="20" font="1">Increased magnesium </text>
<text top="674" left="517" width="123" height="20" font="1">intake, with a range in </text>
<text top="692" left="517" width="124" height="20" font="1">elemental magnesium </text>
<text top="709" left="517" width="130" height="20" font="1">of 120 to 973 mg/d and </text>
<text top="726" left="517" width="116" height="20" font="1">a mean of 410 mg/d. </text>
<text top="743" left="517" width="7" height="20" font="1">  </text>
<text top="760" left="517" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="778" left="517" width="83" height="20" font="1">or usual intake<b> </b></text>
<text top="641" left="663" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="660" left="663" width="7" height="18" font="1">•</text>
<text top="660" left="670" width="106" height="20" font="1"> Overall, increased </text>
<text top="677" left="663" width="128" height="20" font="1">magnesium intake was </text>
<text top="694" left="663" width="130" height="20" font="1">associated with a small </text>
<text top="711" left="663" width="145" height="20" font="1">nonsignificant reduction in </text>
<text top="728" left="663" width="162" height="20" font="1">mean SBP of -0.32 (95% CI: -</text>
<text top="746" left="663" width="167" height="20" font="1">0.41– -0.23) and DBP of -0.36 </text>
<text top="763" left="663" width="128" height="20" font="1">(95% CI: -0.44– -0.27). </text>
<text top="642" left="849" width="7" height="18" font="1">•</text>
<text top="641" left="855" width="192" height="20" font="1"> This is the most recent systematic </text>
<text top="658" left="849" width="215" height="20" font="1">review/meta-analysis on this topic. The </text>
<text top="676" left="849" width="224" height="20" font="1">authors interpreted their results as being </text>
<text top="693" left="849" width="197" height="20" font="1">consistent with a beneficial effect of </text>
<text top="710" left="849" width="201" height="20" font="1">magnesium supplementation on BP. </text>
<text top="727" left="849" width="206" height="20" font="1">However, this interpretation seems at </text>
<text top="744" left="849" width="107" height="20" font="1">odds with the data. </text>
<text top="763" left="849" width="7" height="18" font="1">•</text>
<text top="763" left="855" width="211" height="20" font="1"> In an earlier meta-analysis of 20 RCT </text>
<text top="780" left="849" width="200" height="20" font="1">(6 in normotensives) by Jee Systolic </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">60 </text>
<text top="107" left="235" width="105" height="20" font="4"><b>Size: </b>22 RCTs (23 </text>
<text top="124" left="235" width="102" height="20" font="1">comparisons) with </text>
<text top="141" left="235" width="57" height="20" font="1">1,173 pts.<b> </b></text>
<text top="159" left="235" width="82" height="20" font="1">Data for RCTs </text>
<text top="176" left="235" width="73" height="20" font="1">conducted in </text>
<text top="193" left="235" width="127" height="20" font="1">normotensive pts were </text>
<text top="210" left="235" width="82" height="20" font="1">not presented. </text>
<text top="228" left="235" width="120" height="20" font="1">However, most RCTs </text>
<text top="245" left="235" width="103" height="20" font="1">were conducted in </text>
<text top="262" left="235" width="107" height="20" font="1">normotensives and </text>
<text top="279" left="235" width="105" height="20" font="1">only 6 of the RCTs </text>
<text top="296" left="235" width="121" height="20" font="1">included some (or all) </text>
<text top="314" left="235" width="109" height="20" font="1">pts who were being </text>
<text top="331" left="235" width="67" height="20" font="1">treated with </text>
<text top="348" left="235" width="93" height="20" font="1">antihypertensive </text>
<text top="365" left="235" width="109" height="20" font="1">medication. Overall </text>
<text top="383" left="235" width="121" height="20" font="1">mean age was ~50 y. </text>
<text top="400" left="235" width="122" height="20" font="1">Follow-up varied from </text>
<text top="417" left="235" width="122" height="20" font="1">3–24 wk, with a mean </text>
<text top="434" left="235" width="66" height="20" font="1">of 11.3 wk.  </text>
<text top="107" left="381" width="108" height="20" font="1">comparison groups </text>
<text top="124" left="381" width="92" height="20" font="1">was magnesium </text>
<text top="141" left="381" width="36" height="20" font="1">intake </text>
<text top="159" left="381" width="3" height="20" font="1"> </text>
<text top="176" left="381" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="193" left="381" width="83" height="20" font="1">Comparison of </text>
<text top="210" left="381" width="98" height="20" font="1">different doses of </text>
<text top="228" left="381" width="79" height="20" font="1">alcohol intake </text>
<text top="109" left="663" width="7" height="18" font="1">•</text>
<text top="108" left="670" width="122" height="20" font="1"> Forest plots revealed </text>
<text top="125" left="663" width="164" height="20" font="1">considerable heterogeneity in </text>
<text top="143" left="663" width="62" height="20" font="1">effect size. </text>
<text top="162" left="663" width="7" height="18" font="1">•</text>
<text top="161" left="670" width="163" height="20" font="1"> The authors reported slightly </text>
<text top="178" left="663" width="167" height="20" font="1">larger effect sizes in subgroup </text>
<text top="195" left="663" width="151" height="20" font="1">analysis of cross-over RCT </text>
<text top="213" left="663" width="143" height="20" font="1">and RCT that employed a </text>
<text top="230" left="663" width="142" height="20" font="1">dose of magnesium &gt;370 </text>
<text top="247" left="663" width="34" height="20" font="1">mg/d. </text>
<text top="264" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="283" left="663" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A<b> </b></text>
<text top="107" left="849" width="213" height="20" font="1">HTN et al (Am J Hyperts. 2002;15:691-</text>
<text top="124" left="849" width="189" height="20" font="1">696) magnesium supplementation </text>
<text top="141" left="849" width="221" height="20" font="1">resulted in small mean NS reductions of </text>
<text top="159" left="849" width="213" height="20" font="1">-0.6 (95% CI: -2.2–1.0) mm Hg in SBP </text>
<text top="176" left="849" width="211" height="20" font="1">and -0.8 (95% CI: -1.9–0.4) in DBP. In </text>
<text top="193" left="849" width="217" height="20" font="1">meta-regression analysis, there was an </text>
<text top="210" left="849" width="214" height="20" font="1">apparent dose-response with SBP and </text>
<text top="228" left="849" width="214" height="20" font="1">DBP reductions of -4.3 (95% CI: -6.3– -</text>
<text top="245" left="849" width="210" height="20" font="1">2.2) and -2.3 (95% CI: -4.9–0) mm Hg </text>
<text top="262" left="849" width="189" height="20" font="1">for each 10 mmol/d higher level of </text>
<text top="279" left="849" width="107" height="20" font="1">magnesium intake. </text>
<text top="298" left="849" width="7" height="18" font="1">•</text>
<text top="298" left="855" width="204" height="20" font="1"> A Cochrane systematic review/meta-</text>
<text top="315" left="849" width="222" height="20" font="1">analysis of magnesium supplementation </text>
<text top="332" left="849" width="226" height="20" font="1">for treatment of HTN in adults (Dickinson </text>
<text top="349" left="849" width="165" height="20" font="1">HO et al. Cochrane Database </text>
<text top="366" left="849" width="211" height="20" font="1">Systematic Review 2006: CD 004640) </text>
<text top="384" left="849" width="219" height="20" font="1">included 12 RCT (n=545) with follow-up </text>
<text top="401" left="849" width="198" height="20" font="1">of 8–26 wk. Overall, mean SBP and </text>
<text top="418" left="849" width="203" height="20" font="1">DBP were reduced by -1.3 (95% CI: -</text>
<text top="435" left="849" width="209" height="20" font="1">4.0–1.5) and -2.2 (95% CI: -3.4– -0.9) </text>
<text top="453" left="849" width="222" height="20" font="1">mm Hg, respectively. The authors noted </text>
<text top="470" left="849" width="202" height="20" font="1">the studies were of poor quality, with </text>
<text top="487" left="849" width="219" height="20" font="1">considerable heterogeneity, and felt the </text>
<text top="504" left="849" width="144" height="20" font="1">results were likely biased. </text>
<text top="523" left="849" width="7" height="18" font="1">•</text>
<text top="523" left="855" width="205" height="20" font="1"> Some authors have suggested there </text>
<text top="540" left="849" width="203" height="20" font="1">may be a greater BP effect when the </text>
<text top="557" left="849" width="217" height="20" font="1">intervention is by means of diet change </text>
<text top="574" left="849" width="221" height="20" font="1">but there is insufficient RCT evidence to </text>
<text top="591" left="849" width="116" height="20" font="1">support this position. </text>
<text top="610" left="849" width="7" height="18" font="1">•</text>
<text top="610" left="855" width="185" height="20" font="1"> Magnesium sulfate is the drug of </text>
<text top="627" left="849" width="214" height="20" font="1">choice for prevention of seizures in the </text>
<text top="644" left="849" width="213" height="20" font="1">pre-eclamptic woman, or prevention of </text>
<text top="661" left="849" width="214" height="20" font="1">recurrence of seizures in the eclamptic </text>
<text top="679" left="849" width="217" height="20" font="1">woman, as demonstrated in RCT and a </text>
<text top="696" left="849" width="206" height="20" font="1">2010 Cochrane review (Duley L et al. </text>
<text top="713" left="849" width="190" height="20" font="1">Cochrane Database of Systematic </text>
<text top="730" left="849" width="157" height="20" font="1">Reviews. CD000127, 2010). </text>
<text top="749" left="849" width="7" height="18" font="1">•</text>
<text top="749" left="855" width="192" height="20" font="1"> Overall, RCT experience provides </text>
<text top="766" left="849" width="220" height="20" font="1">insufficient evidence to recommend oral </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">61 </text>
<text top="107" left="849" width="187" height="20" font="1">magnesium supplementation as a </text>
<text top="124" left="849" width="181" height="20" font="1">means to prevent (or treat) HTN. </text>
<text top="194" left="108" width="3" height="19" font="1"> </text>
<text top="229" left="81" width="823" height="24" font="3"><b>Data Supplement 20. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Weight Loss) (Section 6.2) </b></text>
<text top="268" left="106" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="286" left="131" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="303" left="109" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="268" left="249" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="286" left="253" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="303" left="247" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="268" left="397" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="268" left="557" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="286" left="590" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="303" left="558" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="320" left="593" width="55" height="20" font="4"><b>patients) </b></text>
<text top="268" left="764" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="286" left="747" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="303" left="747" width="142" height="20" font="4"><b>P value; OR or RR; and  </b></text>
<text top="320" left="792" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="270" left="948" width="143" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="287" left="1003" width="33" height="20" font="4"><b>any); </b></text>
<text top="304" left="964" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="321" left="971" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="339" left="98" width="88" height="20" font="1">Neter JE, et al., </text>
<text top="356" left="98" width="66" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(103)</a>  </text>
<text top="374" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12975389?dopt=Citation">12975389</a></text>
<text top="374" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12975389?dopt=Citation"> </a></text>
<text top="339" left="226" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="356" left="226" width="115" height="20" font="1">of weight loss on BP<b> </b></text>
<text top="374" left="226" width="3" height="20" font="1"> </text>
<text top="391" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="408" left="226" width="126" height="20" font="1">Systematic review and </text>
<text top="425" left="226" width="79" height="20" font="1">meta-analysis </text>
<text top="442" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="460" left="226" width="105" height="20" font="4"><b>Size: </b>25 RCTs (34 </text>
<text top="477" left="226" width="102" height="20" font="1">comparisons) with </text>
<text top="494" left="226" width="109" height="20" font="1">4,874 pts; 17 of the </text>
<text top="511" left="226" width="103" height="20" font="1">comparisons were </text>
<text top="528" left="226" width="73" height="20" font="1">conducted in </text>
<text top="546" left="226" width="97" height="20" font="1">normotensive pts<b> </b></text>
<text top="339" left="368" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="358" left="368" width="7" height="18" font="1">•</text>
<text top="357" left="374" width="92" height="20" font="1"> RCT in humans </text>
<text top="376" left="368" width="7" height="18" font="1">•</text>
<text top="376" left="374" width="101" height="20" font="1"> English language </text>
<text top="393" left="368" width="146" height="20" font="1">publication between 1966–</text>
<text top="410" left="368" width="31" height="20" font="1">2002 </text>
<text top="429" left="368" width="7" height="18" font="1">•</text>
<text top="429" left="374" width="109" height="20" font="1"> Nonpharmacologic </text>
<text top="446" left="368" width="67" height="20" font="1">intervention </text>
<text top="463" left="368" width="3" height="20" font="1"> </text>
<text top="480" left="368" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="499" left="368" width="7" height="18" font="1">•</text>
<text top="499" left="374" width="89" height="20" font="1"> Duration &lt;8 wk </text>
<text top="518" left="368" width="7" height="18" font="1">•</text>
<text top="517" left="374" width="76" height="20" font="1"> Missing data </text>
<text top="536" left="368" width="7" height="18" font="1">•</text>
<text top="535" left="374" width="143" height="20" font="1"> Objective not weight loss </text>
<text top="555" left="368" width="7" height="18" font="1">•</text>
<text top="554" left="374" width="157" height="20" font="1"> Concomitant intervention(s) </text>
<text top="339" left="550" width="120" height="20" font="4"><b>Intervention:</b> Weight </text>
<text top="356" left="550" width="126" height="20" font="1">loss (calorie reduction, </text>
<text top="374" left="550" width="107" height="20" font="1">physical activity, or </text>
<text top="391" left="550" width="118" height="20" font="1">combination of both)  </text>
<text top="408" left="550" width="7" height="20" font="1">  </text>
<text top="425" left="550" width="135" height="20" font="4"><b>Comparator:</b> No weight </text>
<text top="442" left="550" width="96" height="20" font="1">loss prescription<b> </b> </text>
<text top="340" left="704" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="359" left="704" width="7" height="18" font="1">•</text>
<text top="359" left="710" width="207" height="20" font="1"> For the overall group, mean baseline </text>
<text top="376" left="704" width="196" height="20" font="1">body weight was 88.3 kg and mean </text>
<text top="393" left="704" width="198" height="20" font="1">change in body weight following the </text>
<text top="410" left="704" width="161" height="20" font="1">application of the weight loss </text>
<text top="427" left="704" width="211" height="20" font="1">intervention was -5.1 (95% CI: -6.03– -</text>
<text top="445" left="704" width="184" height="20" font="1">4.25) kg. This represents a mean </text>
<text top="462" left="704" width="144" height="20" font="1">percent change of -5.8%.  </text>
<text top="481" left="704" width="7" height="18" font="1">•</text>
<text top="480" left="710" width="202" height="20" font="1"> There was strong evidence for a BP </text>
<text top="498" left="704" width="201" height="20" font="1">lowering effect of weight loss on BP, </text>
<text top="515" left="704" width="212" height="20" font="1">overall and in normotensive subgroup. </text>
<text top="532" left="704" width="222" height="20" font="1">In the normotensive group, the mean for </text>
<text top="549" left="704" width="193" height="20" font="1">change in SBP was 4.08 (95% CI: -</text>
<text top="566" left="704" width="73" height="20" font="1">6.01– -2.16). </text>
<text top="586" left="704" width="7" height="18" font="1">•</text>
<text top="585" left="710" width="183" height="20" font="1"> Overall, a 1 kg reduction in body </text>
<text top="602" left="704" width="196" height="20" font="1">weight was associated with a mean </text>
<text top="619" left="704" width="220" height="20" font="1">change in SBP of -1.05 (95% CI: -1.43– </text>
<text top="637" left="704" width="82" height="20" font="1">-0.66) mm Hg. </text>
<text top="654" left="704" width="3" height="20" font="4"><b> </b></text>
<text top="672" left="704" width="143" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A  </text>
<text top="341" left="941" width="7" height="18" font="1">•</text>
<text top="340" left="948" width="148" height="20" font="1"> Substantial evidence for a </text>
<text top="357" left="941" width="154" height="20" font="1">reduction in BP, overall and </text>
<text top="375" left="941" width="100" height="20" font="1">in normotensives. </text>
<text top="394" left="941" width="7" height="18" font="1">•</text>
<text top="393" left="948" width="142" height="20" font="1"> With the exception of the </text>
<text top="410" left="941" width="149" height="20" font="1">mean (95% CI) changes in </text>
<text top="427" left="941" width="130" height="20" font="1">BP, this paper provides </text>
<text top="445" left="941" width="105" height="20" font="1">limited data for the </text>
<text top="462" left="941" width="112" height="20" font="1">normotensive group </text>
<text top="690" left="98" width="100" height="20" font="1">Ho M, et al., 2012 </text>
<text top="707" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(104)</a> </text>
<text top="724" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23166346?dopt=Citation">23166346</a></text>
<text top="724" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23166346?dopt=Citation"> </a></text>
<text top="690" left="226" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="707" left="226" width="122" height="20" font="1">of lifestyle weight loss </text>
<text top="724" left="226" width="86" height="20" font="1">interventions in </text>
<text top="742" left="226" width="100" height="20" font="1">obese/overweight </text>
<text top="759" left="226" width="102" height="20" font="1">children on weight </text>
<text top="690" left="368" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="709" left="368" width="7" height="18" font="1">•</text>
<text top="708" left="374" width="154" height="20" font="1"> RCTs, in obese/overweight </text>
<text top="726" left="368" width="165" height="20" font="1">children and adolescents ≤18 </text>
<text top="743" left="368" width="10" height="20" font="1">y </text>
<text top="690" left="550" width="127" height="20" font="4"><b>Intervention:</b> Lifestyle </text>
<text top="707" left="550" width="139" height="20" font="1">weight loss program with </text>
<text top="724" left="550" width="115" height="20" font="1">a dietary component </text>
<text top="742" left="550" width="3" height="20" font="1"> </text>
<text top="759" left="550" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="776" left="550" width="133" height="20" font="1">treatment, usual care or </text>
<text top="691" left="704" width="225" height="20" font="4"><b>1</b>°<b> endpoint:</b> Pooled experience in the 7 </text>
<text top="708" left="704" width="206" height="20" font="1">RCTs with BP experience identified a </text>
<text top="726" left="704" width="205" height="20" font="1">significant reduction in mean SBP of -</text>
<text top="743" left="704" width="221" height="20" font="1">3.40 (95% CI: -5.19– -1.61). The pooled </text>
<text top="760" left="704" width="201" height="20" font="1">SBP MD was -3.72 (95% CI: -4.74– -</text>
<text top="777" left="704" width="224" height="20" font="1">2.69) in the 3 RCTs with a duration &gt;1 y  </text>
<text top="692" left="941" width="7" height="18" font="1">•</text>
<text top="691" left="948" width="134" height="20" font="1"> Findings in children are </text>
<text top="708" left="941" width="148" height="20" font="1">consistent with experience </text>
<text top="726" left="941" width="150" height="20" font="1">in adult normotensives and </text>
<text top="743" left="941" width="102" height="20" font="1">with experience in </text>
<text top="760" left="941" width="96" height="20" font="1">hypertensive pts. </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">62 </text>
<text top="107" left="226" width="105" height="20" font="1">change and cardio-</text>
<text top="124" left="226" width="119" height="20" font="1">metabolic risk factors<b> </b></text>
<text top="141" left="226" width="3" height="20" font="1"> </text>
<text top="159" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="176" left="226" width="126" height="20" font="1">Systematic review and </text>
<text top="193" left="226" width="79" height="20" font="1">meta-analysis </text>
<text top="210" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="227" left="226" width="32" height="20" font="4"><b>Size: </b></text>
<text top="247" left="226" width="7" height="18" font="1">•</text>
<text top="246" left="233" width="109" height="20" font="1"> Overall, 38 studies </text>
<text top="265" left="226" width="7" height="18" font="1">•</text>
<text top="264" left="233" width="83" height="20" font="1"> 33 included in </text>
<text top="281" left="226" width="127" height="20" font="1">various meta-analyses </text>
<text top="301" left="226" width="7" height="18" font="1">•</text>
<text top="300" left="233" width="83" height="20" font="1"> Effect on SBP </text>
<text top="317" left="226" width="125" height="20" font="1">studied in 7 RCTs that </text>
<text top="334" left="226" width="93" height="20" font="1">included 554 pts<b> </b></text>
<text top="109" left="368" width="7" height="18" font="1">•</text>
<text top="108" left="374" width="98" height="20" font="1">English language </text>
<text top="125" left="368" width="152" height="20" font="1">publications between 1975–</text>
<text top="143" left="368" width="31" height="20" font="1">2010 </text>
<text top="162" left="368" width="7" height="18" font="1">•</text>
<text top="161" left="374" width="118" height="20" font="1"> Trial duration ≥2 mo </text>
<text top="178" left="368" width="3" height="20" font="1"> </text>
<text top="195" left="368" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="214" left="368" width="7" height="18" font="1">•</text>
<text top="214" left="374" width="120" height="20" font="1"> Studies that targeted </text>
<text top="231" left="368" width="100" height="20" font="1">prevention/weight </text>
<text top="248" left="368" width="74" height="20" font="1">maintenance </text>
<text top="267" left="368" width="7" height="18" font="1">•</text>
<text top="267" left="374" width="63" height="20" font="1"> Drug trials </text>
<text top="286" left="368" width="7" height="18" font="1">•</text>
<text top="285" left="374" width="139" height="20" font="1"> Trials in persons with an </text>
<text top="302" left="368" width="85" height="20" font="1">eating disorder </text>
<text top="321" left="368" width="7" height="18" font="1">•</text>
<text top="321" left="374" width="155" height="20" font="1"> Inadequate reporting of the </text>
<text top="338" left="368" width="27" height="20" font="1">data<b> </b></text>
<text top="107" left="550" width="96" height="20" font="1">written education </text>
<text top="124" left="550" width="53" height="20" font="1">materials </text>
<text top="107" left="704" width="3" height="20" font="1"> </text>
<text top="124" left="704" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="109" left="941" width="7" height="18" font="1">•</text>
<text top="108" left="948" width="79" height="20" font="1"> Considerable </text>
<text top="125" left="941" width="139" height="20" font="1">heterogeneity in the data </text>
<text top="356" left="98" width="73" height="20" font="1">Cai L, et al.,  </text>
<text top="373" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(105)</a> </text>
<text top="390" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24552832?dopt=Citation">24552832</a></text>
<text top="390" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24552832?dopt=Citation"> </a></text>
<text top="356" left="226" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="373" left="226" width="112" height="20" font="1">of childhood obesity </text>
<text top="390" left="226" width="116" height="20" font="1">prevention programs </text>
<text top="407" left="226" width="37" height="20" font="1">on BP<b> </b></text>
<text top="425" left="226" width="3" height="20" font="1"> </text>
<text top="442" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="459" left="226" width="126" height="20" font="1">Systematic review and </text>
<text top="476" left="226" width="79" height="20" font="1">meta-analysis </text>
<text top="493" left="226" width="3" height="20" font="1"> </text>
<text top="511" left="226" width="107" height="20" font="4"><b>Size: </b>Overall study </text>
<text top="528" left="226" width="109" height="20" font="1">included 23 studies </text>
<text top="545" left="226" width="98" height="20" font="1">(28 comparisons) </text>
<text top="562" left="226" width="114" height="20" font="1">conducted in 18,925 </text>
<text top="580" left="226" width="23" height="20" font="1">pts.<b> </b></text>
<text top="356" left="368" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="375" left="368" width="7" height="18" font="1">•</text>
<text top="374" left="374" width="149" height="20" font="1"> RCTs, quasi-experimental </text>
<text top="391" left="368" width="111" height="20" font="1">studies, and natural </text>
<text top="409" left="368" width="131" height="20" font="1">experiments in humans </text>
<text top="428" left="368" width="7" height="18" font="1">•</text>
<text top="427" left="374" width="146" height="20" font="1"> Children and adolescents </text>
<text top="444" left="368" width="44" height="20" font="1">2–18 y  </text>
<text top="463" left="368" width="7" height="18" font="1">•</text>
<text top="463" left="374" width="150" height="20" font="1"> Conducted in a developed </text>
<text top="480" left="368" width="44" height="20" font="1">country </text>
<text top="499" left="368" width="7" height="18" font="1">•</text>
<text top="498" left="374" width="101" height="20" font="1"> English language </text>
<text top="515" left="368" width="68" height="20" font="1">publications </text>
<text top="534" left="368" width="7" height="18" font="1">•</text>
<text top="534" left="374" width="150" height="20" font="1"> Trial duration ≥1 y (≥6 mo </text>
<text top="551" left="368" width="161" height="20" font="1">for school-based intervention </text>
<text top="568" left="368" width="46" height="20" font="1">studies) </text>
<text top="585" left="368" width="3" height="20" font="1"> </text>
<text top="603" left="368" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="622" left="368" width="7" height="18" font="1">•</text>
<text top="621" left="374" width="146" height="20" font="1"> Studies that only targeted </text>
<text top="638" left="368" width="161" height="20" font="1">obese/overweight children or </text>
<text top="655" left="368" width="168" height="20" font="1">those with a medical condition </text>
<text top="674" left="368" width="7" height="18" font="1">•</text>
<text top="674" left="374" width="155" height="20" font="1"> Inadequate reporting of the </text>
<text top="691" left="368" width="31" height="20" font="1">data  </text>
<text top="356" left="550" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="375" left="550" width="7" height="18" font="1">•</text>
<text top="374" left="557" width="71" height="20" font="1"> Weight loss </text>
<text top="393" left="550" width="7" height="18" font="1">•</text>
<text top="393" left="557" width="97" height="20" font="1"> 15 school-based </text>
<text top="412" left="550" width="7" height="18" font="1">•</text>
<text top="411" left="557" width="124" height="20" font="1"> 12 some combination </text>
<text top="428" left="550" width="129" height="20" font="1">of school, home and/or </text>
<text top="445" left="550" width="100" height="20" font="1">community-based </text>
<text top="464" left="550" width="7" height="18" font="1">•</text>
<text top="464" left="557" width="70" height="20" font="1"> 1 child care </text>
<text top="481" left="550" width="3" height="20" font="1"> </text>
<text top="498" left="550" width="135" height="20" font="4"><b>Comparator:</b> No weight </text>
<text top="515" left="550" width="25" height="20" font="1">loss </text>
<text top="357" left="704" width="211" height="20" font="4"><b>1</b>°<b> endpoint:</b> Pooled experience in 19 </text>
<text top="374" left="704" width="204" height="20" font="1">studies (20 comparisons) identified a </text>
<text top="391" left="704" width="212" height="20" font="1">small but significant reduction in mean </text>
<text top="409" left="704" width="202" height="20" font="1">SBP of -1.65 (95% CI: -2.56– -0.71). </text>
<text top="426" left="704" width="206" height="20" font="1">The effect size was greater in studies </text>
<text top="443" left="704" width="189" height="20" font="1">that employed an intervention that </text>
<text top="460" left="704" width="193" height="20" font="1">combined diet and physical activity </text>
<text top="477" left="704" width="219" height="20" font="1">(mean change in SBP of -2.11 mm Hg). </text>
<text top="495" left="704" width="3" height="20" font="1"> </text>
<text top="512" left="704" width="124" height="20" font="4"><b>Safety endpoint:</b> N/A<b> </b></text>
<text top="358" left="941" width="7" height="18" font="1">•</text>
<text top="357" left="948" width="134" height="20" font="1"> Study included a mix of </text>
<text top="374" left="941" width="97" height="20" font="1">RCTs (13), quasi-</text>
<text top="391" left="941" width="138" height="20" font="1">experimental studies (9), </text>
<text top="409" left="941" width="135" height="20" font="1">and natural experiments </text>
<text top="426" left="941" width="22" height="20" font="1">(1). </text>
<text top="445" left="941" width="7" height="18" font="1">•</text>
<text top="444" left="948" width="96" height="20" font="1"> Included studies </text>
<text top="461" left="941" width="131" height="20" font="1">conducted over several </text>
<text top="479" left="941" width="138" height="20" font="1">decades (1985–2012). A </text>
<text top="496" left="941" width="145" height="20" font="1">significant reduction in BP </text>
<text top="513" left="941" width="119" height="20" font="1">was only noted in the </text>
<text top="530" left="941" width="152" height="20" font="1">studies conducted between </text>
<text top="547" left="941" width="146" height="20" font="1">2000–2009: mean change </text>
<text top="565" left="941" width="141" height="20" font="1">in SBP of -3.73 (95% CI: -</text>
<text top="582" left="941" width="73" height="20" font="1">5.37– -2.09)  </text>
<text top="601" left="941" width="7" height="18" font="1">•</text>
<text top="600" left="948" width="97" height="20" font="1"> Findings of a BP </text>
<text top="617" left="941" width="123" height="20" font="1">reduction in childhood </text>
<text top="635" left="941" width="137" height="20" font="1">consistent with evidence </text>
<text top="652" left="941" width="133" height="20" font="1">from the publications by </text>
<text top="669" left="941" width="80" height="20" font="1">Neter and Ho. </text>
<text top="709" left="98" width="91" height="20" font="4"><b>TOHP, Phase II </b></text>
<text top="726" left="98" width="76" height="20" font="1">Hypertension </text>
<text top="743" left="98" width="62" height="20" font="1">Prevention </text>
<text top="760" left="98" width="75" height="20" font="1">Collaborative </text>
<text top="778" left="98" width="97" height="20" font="1">Research Group, </text>
<text top="709" left="226" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="726" left="226" width="115" height="20" font="1">of weight loss on BP </text>
<text top="743" left="226" width="98" height="20" font="1">and prevention of </text>
<text top="760" left="226" width="32" height="20" font="1">HTN.<b> </b></text>
<text top="778" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="709" left="368" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="728" left="368" width="7" height="18" font="1">•</text>
<text top="727" left="374" width="160" height="20" font="1"> Healthy community-dwelling </text>
<text top="744" left="368" width="87" height="20" font="1">adults 30–54 y  </text>
<text top="709" left="550" width="130" height="20" font="4"><b>Intervention: </b>Behavior </text>
<text top="726" left="550" width="111" height="20" font="1">change intervention </text>
<text top="743" left="550" width="111" height="20" font="1">(combination of diet </text>
<text top="760" left="550" width="115" height="20" font="1">change and physical </text>
<text top="778" left="550" width="96" height="20" font="1">activity) aimed at </text>
<text top="710" left="704" width="76" height="20" font="4"><b>1</b>°<b> endpoint: </b></text>
<text top="727" left="704" width="87" height="20" font="1">Change in SBP </text>
<text top="746" left="704" width="7" height="18" font="1">•</text>
<text top="746" left="710" width="201" height="20" font="1"> Compared to usual care, the weight </text>
<text top="763" left="704" width="199" height="20" font="1">loss group experienced a significant </text>
<text top="780" left="704" width="186" height="20" font="1">mean reduction of -4.5 kg in body </text>
<text top="711" left="941" width="7" height="18" font="1">•</text>
<text top="710" left="948" width="149" height="20" font="4"><b> </b>Largest trial of weight loss </text>
<text top="727" left="941" width="140" height="20" font="1">in prevention of HTN and </text>
<text top="744" left="941" width="139" height="20" font="1">also provides the longest </text>
<text top="762" left="941" width="114" height="20" font="1">duration of follow-up </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">63 </text>
<text top="107" left="98" width="63" height="20" font="1">1997 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(106)</a> </text>
<text top="124" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9080920?dopt=Citation">9080920</a></text>
<text top="124" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9080920?dopt=Citation"> </a></text>
<text top="107" left="226" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="124" left="226" width="76" height="20" font="1">Randomized, </text>
<text top="141" left="226" width="103" height="20" font="1">controlled factorial </text>
<text top="159" left="226" width="30" height="20" font="1">trial. <b> </b></text>
<text top="176" left="226" width="3" height="20" font="1"> </text>
<text top="193" left="226" width="103" height="20" font="4"><b>Size:</b> 2,382 pts, of </text>
<text top="210" left="226" width="100" height="20" font="1">whom 1,192 were </text>
<text top="227" left="226" width="92" height="20" font="1">randomized to a </text>
<text top="245" left="226" width="64" height="20" font="1">weight loss </text>
<text top="262" left="226" width="125" height="20" font="1">intervention and 1,190 </text>
<text top="279" left="226" width="122" height="20" font="1">were randomized to a </text>
<text top="296" left="226" width="81" height="20" font="1">no weight loss </text>
<text top="314" left="226" width="70" height="20" font="1">intervention.<b> </b></text>
<text top="109" left="368" width="7" height="18" font="1">•</text>
<text top="108" left="374" width="137" height="20" font="1"> BMI between 110% and </text>
<text top="125" left="368" width="132" height="20" font="1">165% of desirable body </text>
<text top="143" left="368" width="39" height="20" font="1">weight </text>
<text top="162" left="368" width="7" height="18" font="1">•</text>
<text top="161" left="374" width="132" height="20" font="1"> Not taking BP-lowering </text>
<text top="178" left="368" width="63" height="20" font="1">medication </text>
<text top="197" left="368" width="7" height="18" font="1">•</text>
<text top="197" left="374" width="140" height="20" font="1"> Mean SBP &lt;140 mm Hg </text>
<text top="214" left="368" width="130" height="20" font="1">and DBP 83-89 mm Hg </text>
<text top="231" left="368" width="3" height="20" font="1"> </text>
<text top="248" left="368" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="267" left="368" width="7" height="18" font="1">•</text>
<text top="267" left="374" width="137" height="20" font="1"> Taking antihypertensive </text>
<text top="284" left="368" width="63" height="20" font="1">medication </text>
<text top="303" left="368" width="7" height="18" font="1">•</text>
<text top="302" left="374" width="117" height="20" font="1"> Heart disease, renal </text>
<text top="319" left="368" width="143" height="20" font="1">disease, poorly controlled </text>
<text top="337" left="368" width="145" height="20" font="1">hyperlipidemia or DM, DM </text>
<text top="354" left="368" width="134" height="20" font="1">requiring insulin, special </text>
<text top="371" left="368" width="116" height="20" font="1">dietary requirements </text>
<text top="390" left="368" width="7" height="18" font="1">•</text>
<text top="389" left="374" width="82" height="20" font="1"> &gt;14 drinks/wk<b> </b></text>
<text top="107" left="550" width="133" height="20" font="1">studying the effects of a </text>
<text top="124" left="550" width="141" height="20" font="1">modest reduction in body </text>
<text top="141" left="550" width="124" height="20" font="1">weight during up to 48 </text>
<text top="159" left="550" width="133" height="20" font="1">mo (minimum 36 mo) of </text>
<text top="176" left="550" width="56" height="20" font="1">follow-up.<b> </b></text>
<text top="193" left="550" width="3" height="20" font="4"><b> </b></text>
<text top="210" left="550" width="139" height="20" font="4"><b>Comparator: </b>Usual care </text>
<text top="227" left="550" width="35" height="20" font="1">group<b> </b></text>
<text top="107" left="704" width="216" height="20" font="1">weight and -3.7 (SD: 0.5; p&lt;0.001) mm </text>
<text top="124" left="704" width="210" height="20" font="1">Hg in SBP at 6 mo (-6.0 mm Hg in the </text>
<text top="141" left="704" width="224" height="20" font="1">weight loss group and -2.2 mm Hg in the </text>
<text top="159" left="704" width="106" height="20" font="1">usual care group).  </text>
<text top="178" left="704" width="7" height="18" font="1">•</text>
<text top="177" left="710" width="203" height="20" font="1"> A progressive reduction in the effect </text>
<text top="194" left="704" width="222" height="20" font="1">sizes for body weight and BP was noted </text>
<text top="211" left="704" width="214" height="20" font="1">over time, with mean for SBP at 18, 36 </text>
<text top="229" left="704" width="199" height="20" font="1">mo and termination of -1.8 (SD: 0.5; </text>
<text top="246" left="704" width="209" height="20" font="1">p&lt;0.001), -1.3 (SD: 0.5; p=0.01), and -</text>
<text top="263" left="704" width="121" height="20" font="1">1.1 (SD: 0.5; p=0.04). </text>
<text top="280" left="704" width="3" height="20" font="4"><b> </b></text>
<text top="298" left="704" width="105" height="20" font="1">Prevention of HTN </text>
<text top="317" left="704" width="7" height="18" font="1">•</text>
<text top="316" left="710" width="205" height="20" font="1"> At 6 mo of follow-up the incidence of </text>
<text top="333" left="704" width="208" height="20" font="1">new onset HTN was 42% lower in the </text>
<text top="350" left="704" width="212" height="20" font="1">participants randomized to weight loss </text>
<text top="368" left="704" width="187" height="20" font="1">compared to the usual care group </text>
<text top="385" left="704" width="53" height="20" font="1">(p=0.02). </text>
<text top="404" left="704" width="7" height="18" font="1">•</text>
<text top="403" left="710" width="209" height="20" font="1"> During more prolonged follow-up, the </text>
<text top="420" left="704" width="195" height="20" font="1">effect size decreased but remained </text>
<text top="438" left="704" width="196" height="20" font="1">borderline significant after 48 mo of </text>
<text top="455" left="704" width="191" height="20" font="1">follow-up (13% reduction; p=0.06). </text>
<text top="472" left="704" width="189" height="20" font="1">Overall, the incidence of HTN was </text>
<text top="489" left="704" width="145" height="20" font="1">reduced by 21% (p=0.02). </text>
<text top="506" left="704" width="3" height="20" font="4"><b> </b></text>
<text top="524" left="704" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A <b> </b></text>
<text top="109" left="941" width="7" height="18" font="1">•</text>
<text top="108" left="948" width="129" height="20" font="4"><b> </b>The assumptions for a </text>
<text top="125" left="941" width="116" height="20" font="1">main effects factorial </text>
<text top="143" left="941" width="146" height="20" font="1">analysis (independence of </text>
<text top="160" left="941" width="148" height="20" font="1">the interventions) were not </text>
<text top="177" left="941" width="140" height="20" font="1">demonstrated. Given this </text>
<text top="194" left="941" width="137" height="20" font="1">finding, the most reliable </text>
<text top="212" left="941" width="132" height="20" font="1">analysis of this trial was </text>
<text top="229" left="941" width="101" height="20" font="1">comparison of the </text>
<text top="246" left="941" width="142" height="20" font="1">experience in each active </text>
<text top="263" left="941" width="148" height="20" font="1">intervention group with the </text>
<text top="280" left="941" width="125" height="20" font="1">usual care group. This </text>
<text top="298" left="941" width="130" height="20" font="1">results in a reduction in </text>
<text top="315" left="941" width="98" height="20" font="1">statistical power.  </text>
<text top="334" left="941" width="7" height="18" font="1">•</text>
<text top="333" left="948" width="111" height="20" font="4"><b> </b>Consistent with the </text>
<text top="350" left="941" width="140" height="20" font="1">pattern in the proceeding </text>
<text top="368" left="941" width="132" height="20" font="1">TOHP I trial weight loss </text>
<text top="385" left="941" width="112" height="20" font="1">reduced BP and the </text>
<text top="402" left="941" width="139" height="20" font="1">incidence of HTN but the </text>
<text top="419" left="941" width="147" height="20" font="1">effect sizes for weight loss </text>
<text top="437" left="941" width="121" height="20" font="1">and BP as well as the </text>
<text top="454" left="941" width="148" height="20" font="1">difficulty of maintaining the </text>
<text top="471" left="941" width="115" height="20" font="1">intervention in highly </text>
<text top="488" left="941" width="145" height="20" font="1">motivated and extensively </text>
<text top="505" left="941" width="128" height="20" font="1">counselled participants </text>
<text top="523" left="941" width="153" height="20" font="1">underscores the difficulty of </text>
<text top="540" left="941" width="145" height="20" font="1">achieving and maintaining </text>
<text top="557" left="941" width="132" height="20" font="1">ideal body weight in the </text>
<text top="574" left="941" width="121" height="20" font="1">general population by </text>
<text top="591" left="941" width="146" height="20" font="1">means of lifestyle change.<b> </b></text>
<text top="609" left="98" width="87" height="20" font="4"><b>TOHP, Phase I </b></text>
<text top="627" left="98" width="60" height="20" font="1">1992 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#268">(79)</a>  </text>
<text top="644" left="98" width="48" height="20" font="12"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation">1586398</a></text>
<text top="644" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation"> </a></text>
<text top="609" left="226" width="120" height="20" font="4"><b>Aim:</b> Study the effect </text>
<text top="627" left="226" width="115" height="20" font="1">of weight loss on BP </text>
<text top="644" left="226" width="127" height="20" font="1">and prevention of HTN </text>
<text top="661" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="678" left="226" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="695" left="226" width="76" height="20" font="1">Randomized, </text>
<text top="713" left="226" width="103" height="20" font="1">controlled factorial </text>
<text top="730" left="226" width="30" height="20" font="1">trial. <b> </b></text>
<text top="747" left="226" width="3" height="20" font="1"> </text>
<text top="764" left="226" width="112" height="20" font="4"><b>Size: </b>Overall,<b> </b>2,182 </text>
<text top="781" left="226" width="109" height="20" font="1">adults, with the 308 </text>
<text top="609" left="368" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="628" left="368" width="7" height="18" font="1">•</text>
<text top="628" left="374" width="73" height="20" font="1"> Community- </text>
<text top="645" left="368" width="131" height="20" font="1">dwelling adults 30–54 y </text>
<text top="664" left="368" width="7" height="18" font="1">•</text>
<text top="663" left="374" width="136" height="20" font="1"> Not on antihypertensive </text>
<text top="680" left="368" width="63" height="20" font="1">medication </text>
<text top="699" left="368" width="7" height="18" font="1">•</text>
<text top="699" left="374" width="110" height="20" font="1"> DBP 80-89 mm Hg </text>
<text top="718" left="368" width="7" height="18" font="1">•</text>
<text top="717" left="374" width="49" height="20" font="1"> Healthy </text>
<text top="734" left="368" width="3" height="20" font="1"> </text>
<text top="752" left="368" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="771" left="368" width="7" height="18" font="1">•</text>
<text top="770" left="374" width="51" height="20" font="1"> Disease </text>
<text top="609" left="550" width="130" height="20" font="4"><b>Intervention: </b>Behavior </text>
<text top="627" left="550" width="111" height="20" font="1">change intervention </text>
<text top="644" left="550" width="111" height="20" font="1">(combination of diet </text>
<text top="661" left="550" width="115" height="20" font="1">change and physical </text>
<text top="678" left="550" width="45" height="20" font="1">activity) </text>
<text top="695" left="550" width="3" height="20" font="4"><b> </b></text>
<text top="713" left="550" width="139" height="20" font="4"><b>Comparator: </b>Usual care<b> </b></text>
<text top="610" left="704" width="164" height="20" font="4"><b>1</b>°<b> endpoint: </b>Change in DBP </text>
<text top="628" left="704" width="3" height="20" font="1"> </text>
<text top="646" left="704" width="163" height="20" font="4"><b>2</b>°<b> endpoint: </b>Change in SBP </text>
<text top="663" left="704" width="3" height="20" font="4"><b> </b></text>
<text top="680" left="704" width="172" height="20" font="4"><b>Safety endpoint: </b>CVD events, </text>
<text top="698" left="704" width="210" height="20" font="1">symptoms and general and well being<b> </b></text>
<text top="611" left="941" width="7" height="18" font="1">•</text>
<text top="610" left="948" width="134" height="20" font="4"><b> </b>Significantly lower DBP </text>
<text top="628" left="941" width="141" height="20" font="1">(2.3 mm Hg; p&lt;0.01) and </text>
<text top="645" left="941" width="144" height="20" font="1">SBP (2.9 mm Hg; p&lt;0.01) </text>
<text top="662" left="941" width="132" height="20" font="1">in the weight loss group </text>
<text top="679" left="941" width="132" height="20" font="1">compared to usual care </text>
<text top="698" left="941" width="7" height="18" font="1">•</text>
<text top="698" left="948" width="99" height="20" font="4"><b> </b>Few CVD events </text>
<text top="717" left="941" width="7" height="18" font="1">•</text>
<text top="716" left="948" width="93" height="20" font="4"><b> </b>No difference in </text>
<text top="733" left="941" width="59" height="20" font="1">symptoms </text>
<text top="752" left="941" width="7" height="18" font="1">•</text>
<text top="752" left="948" width="138" height="20" font="4"><b> </b>Significant improvement </text>
<text top="769" left="941" width="140" height="20" font="1">in general well-being at 6 </text>
<text top="786" left="941" width="111" height="20" font="1">and 18 mo (p&lt;0.05)<b> </b></text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">64 </text>
<text top="107" left="226" width="105" height="20" font="1">assigned to weight </text>
<text top="124" left="226" width="121" height="20" font="1">loss compared to 256 </text>
<text top="141" left="226" width="107" height="20" font="1">usual care controls<b> </b></text>
<text top="109" left="368" width="7" height="18" font="1">•</text>
<text top="108" left="374" width="150" height="20" font="1"> Inability to comply with the </text>
<text top="125" left="368" width="47" height="20" font="1">protocol<b> </b></text>
<text top="193" left="98" width="38" height="20" font="4"><b>TONE </b></text>
<text top="211" left="98" width="105" height="20" font="1">Whelton PK, et al., </text>
<text top="228" left="98" width="63" height="20" font="1">1998 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(107)</a> </text>
<text top="245" left="98" width="48" height="20" font="12"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=Citation">9515998</a></text>
<text top="245" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=Citation"> </a></text>
<text top="193" left="226" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="211" left="226" width="115" height="20" font="1">of weight loss on BP </text>
<text top="228" left="226" width="73" height="20" font="1">and need for </text>
<text top="245" left="226" width="121" height="20" font="1">antihypertensive drug </text>
<text top="262" left="226" width="48" height="20" font="1">therapy<b>  </b></text>
<text top="279" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="297" left="226" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="314" left="226" width="118" height="20" font="1">RCT, factorial design </text>
<text top="331" left="226" width="3" height="20" font="1"> </text>
<text top="348" left="226" width="101" height="20" font="4"><b>Size: </b>585 (obese) </text>
<text top="365" left="226" width="66" height="20" font="1">participants<b> </b></text>
<text top="193" left="368" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="212" left="368" width="7" height="18" font="1">•</text>
<text top="212" left="374" width="154" height="20" font="1"> Community-dwelling adults </text>
<text top="229" left="368" width="47" height="20" font="1">60–80 y </text>
<text top="248" left="368" width="7" height="18" font="1">•</text>
<text top="247" left="374" width="158" height="20" font="1"> SBP &lt;145 mm Hg and DBP </text>
<text top="264" left="368" width="95" height="20" font="1">&lt;85 mm Hg on 1 </text>
<text top="282" left="368" width="159" height="20" font="1">antihypertensive medication  </text>
<text top="299" left="368" width="3" height="20" font="1"> </text>
<text top="316" left="368" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="335" left="368" width="7" height="18" font="1">•</text>
<text top="334" left="374" width="159" height="20" font="1"> Heart attack or stroke within </text>
<text top="352" left="368" width="31" height="20" font="1">6 mo </text>
<text top="371" left="368" width="7" height="18" font="1">•</text>
<text top="370" left="374" width="154" height="20" font="1"> Current angina, HF, insulin-</text>
<text top="387" left="368" width="84" height="20" font="1">dependent DM </text>
<text top="406" left="368" width="7" height="18" font="1">•</text>
<text top="406" left="374" width="130" height="20" font="1"> Inability to comply with </text>
<text top="423" left="368" width="47" height="20" font="1">protocol<b> </b></text>
<text top="193" left="550" width="130" height="20" font="4"><b>Intervention: </b>Behavior </text>
<text top="211" left="550" width="111" height="20" font="1">change intervention </text>
<text top="228" left="550" width="111" height="20" font="1">(combination of diet </text>
<text top="245" left="550" width="115" height="20" font="1">change and physical </text>
<text top="262" left="550" width="45" height="20" font="1">activity) </text>
<text top="279" left="550" width="3" height="20" font="1"> </text>
<text top="297" left="550" width="112" height="20" font="4"><b>Comparator: </b>Usual </text>
<text top="314" left="550" width="137" height="20" font="1">care, with similar level of </text>
<text top="331" left="550" width="115" height="20" font="1">contact compared to </text>
<text top="348" left="550" width="138" height="20" font="1">active intervention group<b> </b></text>
<text top="194" left="704" width="185" height="20" font="4"><b>1</b>°<b> endpoint: </b>Recurrence of HTN </text>
<text top="212" left="704" width="219" height="20" font="1">following withdrawal of antihypertensive </text>
<text top="229" left="704" width="148" height="20" font="1">medication (or CVD event) </text>
<text top="246" left="704" width="3" height="20" font="4"><b> </b></text>
<text top="264" left="704" width="169" height="20" font="4"><b>2</b>°<b> endpoint:</b> BP (while still on </text>
<text top="282" left="704" width="198" height="20" font="1">antihypertensive medication prior to </text>
<text top="299" left="704" width="132" height="20" font="1">tapering of medication)<b>  </b></text>
<text top="316" left="704" width="3" height="20" font="4"><b> </b></text>
<text top="333" left="704" width="172" height="20" font="4"><b>Safety endpoint: </b>CVD events, </text>
<text top="350" left="704" width="187" height="20" font="1">symptoms (including headaches), </text>
<text top="368" left="704" width="109" height="20" font="1">dietary composition<b> </b></text>
<text top="195" left="941" width="7" height="18" font="1">•</text>
<text top="194" left="948" width="130" height="20" font="4"><b> </b>Significant reduction in </text>
<text top="212" left="941" width="145" height="20" font="1">SBP prior to withdrawal of </text>
<text top="229" left="941" width="156" height="20" font="1">antihypertensive medication </text>
<text top="246" left="941" width="141" height="20" font="1">(mean±SE=-4.0±1.3 mm </text>
<text top="263" left="941" width="27" height="20" font="1">Hg)  </text>
<text top="282" left="941" width="7" height="18" font="1">•</text>
<text top="282" left="948" width="137" height="20" font="4"><b> </b>1° outcome significantly </text>
<text top="299" left="941" width="153" height="20" font="1">less common in weight loss </text>
<text top="316" left="941" width="140" height="20" font="1">group compared to usual </text>
<text top="333" left="941" width="146" height="20" font="1">care – Rel. HR: 0.70; 95% </text>
<text top="350" left="941" width="132" height="20" font="1">CI, 0.57–0.87; p&lt;0.001<b> </b> </text>
<text top="369" left="941" width="7" height="18" font="1">•</text>
<text top="369" left="948" width="124" height="20" font="4"><b> </b>No overt evidence for </text>
<text top="386" left="941" width="100" height="20" font="1">adverse effects of </text>
<text top="403" left="941" width="67" height="20" font="1">intervention<b> </b></text>
<text top="442" left="108" width="3" height="19" font="1"> </text>
<text top="477" left="81" width="964" height="24" font="3"><b>Data Supplement 21. RCTs and Systematic Reviews for RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Section 6.2) </b></text>
<text top="516" left="126" width="38" height="20" font="4"><b>Study </b></text>
<text top="534" left="115" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="551" left="121" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="568" left="99" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="516" left="215" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="534" left="220" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="551" left="213" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="516" left="336" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="516" left="484" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="534" left="516" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="551" left="484" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="568" left="519" width="55" height="20" font="4"><b>patients) </b></text>
<text top="516" left="678" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="534" left="662" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="551" left="644" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="517" left="879" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="535" left="912" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="552" left="919" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="586" left="98" width="41" height="20" font="4"><b>TOHP</b>, </text>
<text top="603" left="98" width="49" height="20" font="1">Phase II </text>
<text top="620" left="98" width="75" height="20" font="1">(Weight Loss </text>
<text top="638" left="98" width="68" height="20" font="1">component) </text>
<text top="655" left="98" width="49" height="20" font="1">1997 (1) </text>
<text top="672" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9080920?dopt=Citation">9080920</a></text>
<text top="672" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9080920?dopt=Citation"> </a></text>
<text top="586" left="206" width="86" height="20" font="4"><b>Aim: </b>Study the </text>
<text top="603" left="206" width="86" height="20" font="1">effect of weight </text>
<text top="620" left="206" width="86" height="20" font="1">loss on BP and </text>
<text top="638" left="206" width="75" height="20" font="1">prevention of </text>
<text top="655" left="206" width="32" height="20" font="1">HTN.<b> </b></text>
<text top="672" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="689" left="206" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="706" left="206" width="76" height="20" font="1">Randomized, </text>
<text top="724" left="206" width="57" height="20" font="1">controlled </text>
<text top="741" left="206" width="77" height="20" font="1">factorial trial. <b> </b></text>
<text top="758" left="206" width="3" height="20" font="1"> </text>
<text top="586" left="320" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="605" left="320" width="7" height="18" font="1">•</text>
<text top="604" left="327" width="112" height="20" font="1"> Healthy community-</text>
<text top="622" left="320" width="135" height="20" font="1">dwelling adults 30–54 y  </text>
<text top="641" left="320" width="7" height="18" font="1">•</text>
<text top="640" left="327" width="113" height="20" font="1"> BMI between 110% </text>
<text top="657" left="320" width="126" height="20" font="1">and 165% of desirable </text>
<text top="674" left="320" width="69" height="20" font="1">body weight </text>
<text top="693" left="320" width="7" height="18" font="1">•</text>
<text top="693" left="327" width="132" height="20" font="1"> Not taking BP-lowering </text>
<text top="710" left="320" width="63" height="20" font="1">medication </text>
<text top="729" left="320" width="7" height="18" font="1">•</text>
<text top="728" left="327" width="121" height="20" font="1"> Mean SBP &lt;140 mm </text>
<text top="746" left="320" width="130" height="20" font="1">Hg and DBP 83-89 mm </text>
<text top="763" left="320" width="19" height="20" font="1">Hg </text>
<text top="780" left="320" width="3" height="20" font="1"> </text>
<text top="586" left="476" width="130" height="20" font="4"><b>Intervention: </b>Behavior </text>
<text top="603" left="476" width="111" height="20" font="1">change intervention </text>
<text top="620" left="476" width="111" height="20" font="1">(combination of diet </text>
<text top="638" left="476" width="115" height="20" font="1">change and physical </text>
<text top="655" left="476" width="96" height="20" font="1">activity) aimed at </text>
<text top="672" left="476" width="133" height="20" font="1">studying the effects of a </text>
<text top="689" left="476" width="141" height="20" font="1">modest reduction in body </text>
<text top="707" left="476" width="124" height="20" font="1">weight during up to 48 </text>
<text top="724" left="476" width="133" height="20" font="1">mo (minimum 36 mo) of </text>
<text top="741" left="476" width="56" height="20" font="1">follow-up.<b> </b></text>
<text top="758" left="476" width="3" height="20" font="4"><b> </b></text>
<text top="587" left="631" width="83" height="20" font="4"><b>1</b>°<b> endpoint:   </b></text>
<text top="604" left="631" width="92" height="20" font="4"><b>Change in SBP </b></text>
<text top="623" left="631" width="7" height="18" font="1">•</text>
<text top="623" left="638" width="162" height="20" font="1"> Compared to usual care, the </text>
<text top="640" left="631" width="180" height="20" font="1">weight loss group experienced a </text>
<text top="657" left="631" width="181" height="20" font="1">significant mean (standard error) </text>
<text top="674" left="631" width="191" height="20" font="1">reduction of -4.5 kg in body weight </text>
<text top="692" left="631" width="190" height="20" font="1">and -3.7 (0.5) (p&lt;0.001) mm Hg in </text>
<text top="709" left="631" width="178" height="20" font="1">SBP at 6 mo (-6.0 mm Hg in the </text>
<text top="726" left="631" width="191" height="20" font="1">weight loss group and -2.2 mm Hg </text>
<text top="743" left="631" width="140" height="20" font="1">in the usual care group).  </text>
<text top="762" left="631" width="7" height="18" font="1">•</text>
<text top="762" left="638" width="170" height="20" font="1"> A progressive reduction in the </text>
<text top="779" left="631" width="195" height="20" font="1">effect sizes for body weight and BP </text>
<text top="588" left="843" width="7" height="18" font="1">•</text>
<text top="587" left="850" width="230" height="20" font="4"><b> </b>This was the largest trial of weight loss in </text>
<text top="604" left="843" width="224" height="20" font="1">prevention of HTN and also provides the </text>
<text top="622" left="843" width="157" height="20" font="1">longest duration of follow-up </text>
<text top="641" left="843" width="7" height="18" font="1">•</text>
<text top="640" left="850" width="198" height="20" font="4"><b> </b>The assumptions for a main effects </text>
<text top="657" left="843" width="213" height="20" font="1">factorial analysis (independence of the </text>
<text top="674" left="843" width="245" height="20" font="1">interventions) were not demonstrated. Given </text>
<text top="692" left="843" width="243" height="20" font="1">this finding, the most reliable analysis of this </text>
<text top="709" left="843" width="226" height="20" font="1">trial was comparison of the experience in </text>
<text top="726" left="843" width="246" height="20" font="1">each active intervention group with the usual </text>
<text top="743" left="843" width="222" height="20" font="1">care group. This results in a reduction in </text>
<text top="761" left="843" width="98" height="20" font="1">statistical power.  </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">65 </text>
<text top="107" left="206" width="89" height="20" font="4"><b>Size:</b> 2,382 pts, </text>
<text top="124" left="206" width="84" height="20" font="1">of whom 1,192 </text>
<text top="141" left="206" width="98" height="20" font="1">were randomized </text>
<text top="159" left="206" width="102" height="20" font="1">to weight loss and </text>
<text top="176" left="206" width="64" height="20" font="1">1,190 were </text>
<text top="193" left="206" width="98" height="20" font="1">randomized to no </text>
<text top="210" left="206" width="64" height="20" font="1">weight loss </text>
<text top="228" left="206" width="67" height="20" font="1">intervention<b> </b></text>
<text top="107" left="320" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="126" left="320" width="7" height="18" font="1">•</text>
<text top="125" left="327" width="44" height="20" font="1"> Taking </text>
<text top="143" left="320" width="93" height="20" font="1">antihypertensive </text>
<text top="160" left="320" width="63" height="20" font="1">medication </text>
<text top="179" left="320" width="7" height="18" font="1">•</text>
<text top="178" left="327" width="117" height="20" font="1"> Heart disease, renal </text>
<text top="195" left="320" width="86" height="20" font="1">disease, poorly </text>
<text top="213" left="320" width="139" height="20" font="1">controlled hyperlipidemia </text>
<text top="230" left="320" width="114" height="20" font="1">or DM, DM requiring </text>
<text top="247" left="320" width="124" height="20" font="1">insulin, special dietary </text>
<text top="264" left="320" width="75" height="20" font="1">requirements </text>
<text top="283" left="320" width="7" height="18" font="1">•</text>
<text top="283" left="327" width="96" height="20" font="1"> &gt;14 drinks/wk.<b>    </b></text>
<text top="107" left="476" width="139" height="20" font="4"><b>Comparator: </b>Usual care </text>
<text top="124" left="476" width="35" height="20" font="1">group<b> </b></text>
<text top="107" left="631" width="176" height="20" font="1">was noted over time, with mean </text>
<text top="124" left="631" width="25" height="20" font="9">(SD)</text>
<text top="124" left="656" width="145" height="20" font="1"> for SBP at 18, 36 mo and </text>
<text top="141" left="631" width="195" height="20" font="1">termination of -1.8 (0.5) (p&lt;0.001), -</text>
<text top="159" left="631" width="180" height="20" font="1">1.3 (0.5) (p=0.01), and -1.1 (0.5) </text>
<text top="176" left="631" width="53" height="20" font="1">(p=0.04). </text>
<text top="193" left="631" width="3" height="20" font="4"><b> </b></text>
<text top="210" left="631" width="111" height="20" font="4"><b>Prevention of </b>HTN<b> </b></text>
<text top="229" left="631" width="7" height="18" font="1">•</text>
<text top="229" left="638" width="192" height="20" font="1"> At 6 mo of follow-up the incidence </text>
<text top="246" left="631" width="188" height="20" font="1">of new onset HTN was 42% lower </text>
<text top="263" left="631" width="181" height="20" font="1">in the participants randomized to </text>
<text top="280" left="631" width="189" height="20" font="1">weight loss compared to the usual </text>
<text top="298" left="631" width="115" height="20" font="1">care group (p=0.02). </text>
<text top="317" left="631" width="7" height="18" font="1">•</text>
<text top="316" left="638" width="189" height="20" font="1"> During more prolonged follow-up, </text>
<text top="333" left="631" width="161" height="20" font="1">the effect size decreased but </text>
<text top="350" left="631" width="199" height="20" font="1">remained borderline significant after </text>
<text top="368" left="631" width="193" height="20" font="1">48 mo of follow-up (13% reduction; </text>
<text top="385" left="631" width="184" height="20" font="1">p=0.06). Overall, the incidence of </text>
<text top="402" left="631" width="206" height="20" font="1">HTN was reduced by 21% (p=0.02).   </text>
<text top="419" left="631" width="3" height="20" font="4"><b> </b></text>
<text top="436" left="631" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A <b> </b></text>
<text top="109" left="843" width="7" height="18" font="1">•</text>
<text top="108" left="850" width="186" height="20" font="4"><b> </b>Consistent with the pattern in the </text>
<text top="125" left="843" width="244" height="20" font="1">proceeding TOHP I trial weight loss reduced </text>
<text top="143" left="843" width="237" height="20" font="1">BP and the incidence of HTN but the effect </text>
<text top="160" left="843" width="235" height="20" font="1">sizes for weight loss and BP as well as the </text>
<text top="177" left="843" width="228" height="20" font="1">difficulty of maintaining the intervention in </text>
<text top="194" left="843" width="243" height="20" font="1">highly motivated and extensively counselled </text>
<text top="212" left="843" width="219" height="20" font="1">participants underscores the difficulty of </text>
<text top="229" left="843" width="244" height="20" font="1">achieving and maintaining ideal body weight </text>
<text top="246" left="843" width="209" height="20" font="1">in the general population by means of </text>
<text top="263" left="843" width="92" height="20" font="1">lifestyle change.<b> </b></text>
<text top="454" left="98" width="38" height="20" font="1">TONE </text>
<text top="472" left="98" width="75" height="20" font="1">(Weight Loss </text>
<text top="489" left="98" width="68" height="20" font="1">component) </text>
<text top="506" left="98" width="85" height="20" font="1">Whelton PK, et </text>
<text top="523" left="98" width="69" height="20" font="1">al., 1998 (3) </text>
<text top="540" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=Citation">9515998</a></text>
<text top="540" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=Citation"> </a></text>
<text top="454" left="206" width="86" height="20" font="4"><b>Aim: </b>Study the </text>
<text top="472" left="206" width="86" height="20" font="1">effect of weight </text>
<text top="489" left="206" width="86" height="20" font="1">loss on BP and </text>
<text top="506" left="206" width="49" height="20" font="1">need for </text>
<text top="523" left="206" width="93" height="20" font="1">antihypertensive </text>
<text top="540" left="206" width="76" height="20" font="1">drug therapy<b>  </b></text>
<text top="558" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="575" left="206" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="592" left="206" width="78" height="20" font="1">RCT, factorial </text>
<text top="609" left="206" width="40" height="20" font="1">design </text>
<text top="627" left="206" width="3" height="20" font="1"> </text>
<text top="644" left="206" width="101" height="20" font="4"><b>Size: </b>585 (obese) </text>
<text top="661" left="206" width="66" height="20" font="1">participants<b> </b></text>
<text top="454" left="320" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="473" left="320" width="7" height="18" font="1">•</text>
<text top="473" left="327" width="118" height="20" font="1"> Community-dwelling </text>
<text top="490" left="320" width="81" height="20" font="1">adults 60-80 y </text>
<text top="509" left="320" width="7" height="18" font="1">•</text>
<text top="508" left="327" width="129" height="20" font="1"> SBP &lt;145 mm Hg and </text>
<text top="526" left="320" width="123" height="20" font="1">DBP &lt;85 mm Hg on 1 </text>
<text top="543" left="320" width="93" height="20" font="1">antihypertensive </text>
<text top="560" left="320" width="66" height="20" font="1">medication  </text>
<text top="577" left="320" width="3" height="20" font="1"> </text>
<text top="594" left="320" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="613" left="320" width="7" height="18" font="1">•</text>
<text top="613" left="327" width="124" height="20" font="1"> Heart attack or stroke </text>
<text top="630" left="320" width="66" height="20" font="1">within 6 mo </text>
<text top="649" left="320" width="7" height="18" font="1">•</text>
<text top="648" left="327" width="115" height="20" font="1"> Current angina, HF, </text>
<text top="666" left="320" width="123" height="20" font="1">insulin-dependent DM </text>
<text top="685" left="320" width="7" height="18" font="1">•</text>
<text top="684" left="327" width="130" height="20" font="1"> Inability to comply with </text>
<text top="701" left="320" width="47" height="20" font="1">protocol<b> </b></text>
<text top="454" left="476" width="130" height="20" font="4"><b>Intervention: </b>Behavior </text>
<text top="472" left="476" width="111" height="20" font="1">change intervention </text>
<text top="489" left="476" width="111" height="20" font="1">(combination of diet </text>
<text top="506" left="476" width="115" height="20" font="1">change and physical </text>
<text top="523" left="476" width="45" height="20" font="1">activity) </text>
<text top="540" left="476" width="3" height="20" font="1"> </text>
<text top="558" left="476" width="112" height="20" font="4"><b>Comparator: </b>Usual </text>
<text top="575" left="476" width="137" height="20" font="1">care, with similar level of </text>
<text top="592" left="476" width="115" height="20" font="1">contact compared to </text>
<text top="609" left="476" width="138" height="20" font="1">active intervention group </text>
<text top="456" left="631" width="185" height="20" font="4"><b>1</b>°<b> endpoint: </b>Recurrence of HTN </text>
<text top="473" left="631" width="126" height="20" font="1">following withdrawal of </text>
<text top="490" left="631" width="174" height="20" font="1">antihypertensive medication (or </text>
<text top="507" left="631" width="67" height="20" font="1">CVD event) </text>
<text top="524" left="631" width="3" height="20" font="4"><b> </b></text>
<text top="543" left="631" width="169" height="20" font="4"><b>2</b>°<b> endpoint:</b> BP (while still on </text>
<text top="560" left="631" width="198" height="20" font="1">antihypertensive medication prior to </text>
<text top="577" left="631" width="128" height="20" font="1">tapering of medication)<b> </b></text>
<text top="594" left="631" width="3" height="20" font="4"><b> </b></text>
<text top="612" left="631" width="172" height="20" font="4"><b>Safety endpoint: </b>CVD events, </text>
<text top="629" left="631" width="187" height="20" font="1">symptoms (including headaches), </text>
<text top="646" left="631" width="109" height="20" font="1">dietary composition </text>
<text top="456" left="843" width="7" height="18" font="1">•</text>
<text top="456" left="850" width="200" height="20" font="4"><b> </b>Significant reduction in SBP prior to </text>
<text top="473" left="843" width="231" height="20" font="1">withdrawal of antihypertensive medication </text>
<text top="490" left="843" width="228" height="20" font="1">(mean±standard error=-4.0±1.3 mm Hg)  </text>
<text top="509" left="843" width="7" height="18" font="1">•</text>
<text top="508" left="850" width="226" height="20" font="4"><b> </b>1° outcome significantly less common in </text>
<text top="526" left="843" width="241" height="20" font="1">weight loss group compared to usual care – </text>
<text top="543" left="843" width="244" height="20" font="1">Rel. HR: 0.70; 95% CI: 0.57– 0.87; p&lt;0.001<b> </b> </text>
<text top="562" left="843" width="7" height="18" font="1">•</text>
<text top="561" left="850" width="224" height="20" font="4"><b> </b>No overt evidence for adverse effects of </text>
<text top="578" left="843" width="67" height="20" font="1">intervention<b> </b></text>
<text top="719" left="98" width="86" height="20" font="1">TOHP, Phase I </text>
<text top="736" left="98" width="75" height="20" font="1">(Weight Loss </text>
<text top="753" left="98" width="68" height="20" font="1">component) </text>
<text top="771" left="98" width="53" height="20" font="1">1992 (4)  </text>
<text top="788" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation">1586398</a></text>
<text top="788" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation"> </a></text>
<text top="719" left="206" width="86" height="20" font="4"><b>Aim:</b> Study the </text>
<text top="736" left="206" width="86" height="20" font="1">effect of weight </text>
<text top="753" left="206" width="86" height="20" font="1">loss on BP and </text>
<text top="771" left="206" width="75" height="20" font="1">prevention of </text>
<text top="788" left="206" width="29" height="20" font="1">HTN </text>
<text top="719" left="320" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="738" left="320" width="7" height="18" font="1">•</text>
<text top="737" left="327" width="118" height="20" font="1"> Community-dwelling </text>
<text top="755" left="320" width="83" height="20" font="1">adults 30–54 y </text>
<text top="719" left="476" width="130" height="20" font="4"><b>Intervention: </b>Behavior </text>
<text top="736" left="476" width="111" height="20" font="1">change intervention </text>
<text top="753" left="476" width="111" height="20" font="1">(combination of diet </text>
<text top="771" left="476" width="115" height="20" font="1">change and physical </text>
<text top="788" left="476" width="45" height="20" font="1">activity) </text>
<text top="720" left="631" width="164" height="20" font="4"><b>1</b>°<b> endpoint: </b>Change in DBP </text>
<text top="737" left="631" width="3" height="20" font="4"><b> </b></text>
<text top="756" left="631" width="163" height="20" font="4"><b>2</b>°<b> endpoint: </b>Change in SBP </text>
<text top="773" left="631" width="3" height="20" font="4"><b> </b></text>
<text top="721" left="843" width="7" height="18" font="1">•</text>
<text top="720" left="850" width="205" height="20" font="4"><b> </b>Significantly lower DBP (2.3 mm Hg; </text>
<text top="737" left="843" width="227" height="20" font="1">p&lt;0.01) and SBP (2.9 mm Hg; p&lt;0.01) in </text>
<text top="755" left="843" width="224" height="20" font="1">the weight loss group compared to usual </text>
<text top="772" left="843" width="27" height="20" font="1">care </text>
<text top="791" left="843" width="7" height="18" font="1">•</text>
<text top="790" left="850" width="99" height="20" font="4"><b> </b>Few CVD events </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">66 </text>
<text top="107" left="206" width="3" height="20" font="4"><b> </b></text>
<text top="124" left="206" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="141" left="206" width="76" height="20" font="1">Randomized, </text>
<text top="159" left="206" width="57" height="20" font="1">controlled </text>
<text top="176" left="206" width="77" height="20" font="1">factorial trial. <b> </b></text>
<text top="193" left="206" width="3" height="20" font="1"> </text>
<text top="210" left="206" width="78" height="20" font="4"><b>Size: </b>Overall,<b> </b></text>
<text top="227" left="206" width="99" height="20" font="1">2,182 adults, with </text>
<text top="245" left="206" width="97" height="20" font="1">the 308 assigned </text>
<text top="262" left="206" width="78" height="20" font="1">to weight loss </text>
<text top="279" left="206" width="96" height="20" font="1">compared to 256 </text>
<text top="296" left="206" width="60" height="20" font="1">usual care </text>
<text top="314" left="206" width="46" height="20" font="1">controls<b> </b></text>
<text top="109" left="320" width="7" height="18" font="1">•</text>
<text top="108" left="327" width="43" height="20" font="1"> Not on </text>
<text top="125" left="320" width="93" height="20" font="1">antihypertensive </text>
<text top="143" left="320" width="63" height="20" font="1">medication </text>
<text top="162" left="320" width="7" height="18" font="1">•</text>
<text top="161" left="327" width="110" height="20" font="1"> DBP 80-89 mm Hg </text>
<text top="180" left="320" width="7" height="18" font="1">•</text>
<text top="179" left="327" width="49" height="20" font="1"> Healthy </text>
<text top="197" left="320" width="3" height="20" font="1"> </text>
<text top="214" left="320" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="233" left="320" width="7" height="18" font="1">•</text>
<text top="232" left="327" width="51" height="20" font="1"> Disease </text>
<text top="251" left="320" width="7" height="18" font="1">•</text>
<text top="251" left="327" width="130" height="20" font="1"> Inability to comply with </text>
<text top="268" left="320" width="68" height="20" font="1">the protocol </text>
<text top="107" left="476" width="3" height="20" font="4"><b> </b></text>
<text top="124" left="476" width="143" height="20" font="4"><b>Comparator:</b> Usual care<b>  </b></text>
<text top="107" left="631" width="172" height="20" font="4"><b>Safety endpoint: </b>CVD events, </text>
<text top="124" left="631" width="176" height="20" font="1">symptoms and general and well </text>
<text top="141" left="631" width="33" height="20" font="1">being </text>
<text top="109" left="843" width="7" height="18" font="1">•</text>
<text top="108" left="850" width="152" height="20" font="4"><b> </b>No difference in symptoms </text>
<text top="127" left="843" width="7" height="18" font="1">•</text>
<text top="127" left="850" width="221" height="20" font="4"><b> </b>Significant improvement in general well-</text>
<text top="144" left="843" width="119" height="20" font="1">being at 6 and 18 mo </text>
<text top="333" left="108" width="3" height="19" font="1"> </text>
<text top="367" left="81" width="705" height="24" font="3"><b>Data Supplement 22. Observational Studies of CV Target Organ Damage Including LVH (Section 7.2) </b></text>
<text top="407" left="106" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="424" left="131" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="442" left="109" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="407" left="258" width="38" height="20" font="4"><b>Study </b></text>
<text top="424" left="237" width="81" height="20" font="4"><b>Type/Design; </b></text>
<text top="442" left="234" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="407" left="376" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="407" left="629" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="424" left="607" width="224" height="20" font="4"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="407" left="941" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="424" left="968" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="465" left="98" width="30" height="20" font="4"><b>LIFE </b></text>
<text top="482" left="98" width="113" height="20" font="1">Devereux RB, et al., </text>
<text top="499" left="98" width="63" height="20" font="1">2004 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(108)</a> </text>
<text top="516" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15547162?dopt=Citation">15547162</a></text>
<text top="516" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15547162?dopt=Citation"> </a></text>
<text top="465" left="226" width="96" height="20" font="4"><b>Study type: </b>Sub-</text>
<text top="482" left="226" width="91" height="20" font="1">study of pts with </text>
<text top="499" left="226" width="83" height="20" font="1">HTN and ECG </text>
<text top="516" left="226" width="27" height="20" font="1">LVH </text>
<text top="533" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="551" left="226" width="55" height="20" font="4"><b>Size</b>: 941 </text>
<text top="465" left="341" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="484" left="341" width="7" height="18" font="1">•</text>
<text top="483" left="347" width="51" height="20" font="1"> 55–80 y </text>
<text top="502" left="341" width="7" height="18" font="1">•</text>
<text top="501" left="347" width="162" height="20" font="1"> BP 160–200/95–115 mm Hg </text>
<text top="520" left="341" width="7" height="18" font="1">•</text>
<text top="520" left="347" width="157" height="20" font="1"> No MI or stroke within 6 mo </text>
<text top="539" left="341" width="7" height="18" font="1">•</text>
<text top="538" left="347" width="60" height="20" font="1"> Had echo </text>
<text top="557" left="341" width="7" height="18" font="1">•</text>
<text top="556" left="347" width="168" height="20" font="1"> Did not require treatment with </text>
<text top="574" left="341" width="174" height="20" font="1">BB, ACE or AT-1 antagonist for </text>
<text top="591" left="341" width="82" height="20" font="1">other reasons  </text>
<text top="608" left="341" width="3" height="20" font="1"> </text>
<text top="625" left="341" width="171" height="20" font="4"><b>Intervention: </b>Treatment to BP </text>
<text top="642" left="341" width="180" height="20" font="1">of 140/90 mm Hg beginning with </text>
<text top="660" left="341" width="163" height="20" font="1">pts randomized to losartan or </text>
<text top="677" left="341" width="50" height="20" font="1">atenolol  </text>
<text top="466" left="536" width="356" height="20" font="4"><b>1</b>°<b> endpoint:</b> Change in LV mass assessed by echo and change </text>
<text top="483" left="536" width="172" height="20" font="1">in BP in relation to CVD events </text>
<text top="500" left="536" width="3" height="20" font="1"> </text>
<text top="517" left="536" width="59" height="20" font="4"><b>Results:</b>   </text>
<text top="536" left="536" width="7" height="18" font="1">•</text>
<text top="536" left="543" width="358" height="20" font="1"> Composite endpoint of CV death, MI, or stroke reached in 104 in </text>
<text top="553" left="536" width="96" height="20" font="1">4.8 y of follow-up </text>
<text top="572" left="536" width="7" height="18" font="1">•</text>
<text top="571" left="543" width="302" height="20" font="1"> Reduction in 1° endpoint per SD reduction in LV mass </text>
<text top="588" left="536" width="359" height="20" font="1">independent of BP change OR: 0.74 (95% CI: 0.6–0.91; p=0.003) </text>
<text top="607" left="536" width="7" height="18" font="1">•</text>
<text top="607" left="543" width="341" height="20" font="1"> Reductions for each composite endpoint component and total </text>
<text top="624" left="536" width="349" height="20" font="1">mortality were also significant; results independent of change in </text>
<text top="641" left="536" width="57" height="20" font="1">ECG LVH </text>
<text top="466" left="914" width="7" height="18" font="1">•</text>
<text top="466" left="921" width="173" height="20" font="1"> Reduction in LV mass by echo </text>
<text top="483" left="914" width="164" height="20" font="1">independently related to CVD </text>
<text top="500" left="914" width="57" height="20" font="1">outcomes </text>
<text top="695" left="98" width="51" height="20" font="4"><b>CARDIA </b></text>
<text top="712" left="98" width="98" height="20" font="1">Armstrong AC, et </text>
<text top="729" left="98" width="83" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(109)</a> </text>
<text top="746" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24507735?dopt=Citation">24507735</a></text>
<text top="746" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24507735?dopt=Citation"> </a></text>
<text top="695" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="712" left="226" width="79" height="20" font="1">Observational </text>
<text top="729" left="226" width="46" height="20" font="1">study of </text>
<text top="746" left="226" width="98" height="20" font="1">population-based </text>
<text top="764" left="226" width="44" height="20" font="1">cohorts </text>
<text top="781" left="226" width="3" height="20" font="1"> </text>
<text top="695" left="341" width="148" height="20" font="4"><b>Inclusion criteria:</b> African </text>
<text top="712" left="341" width="163" height="20" font="1">American and white men and </text>
<text top="729" left="341" width="166" height="20" font="1">women stratified by education </text>
<text top="746" left="341" width="167" height="20" font="1">(above/below high school) 18–</text>
<text top="764" left="341" width="173" height="20" font="1">30 y at study start and followed </text>
<text top="781" left="341" width="177" height="20" font="1">for over 20 y; previously healthy </text>
<text top="696" left="536" width="249" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite of hard CVD events </text>
<text top="713" left="536" width="3" height="20" font="1"> </text>
<text top="730" left="536" width="59" height="20" font="4"><b>Results:</b>   </text>
<text top="749" left="536" width="7" height="18" font="1">•</text>
<text top="749" left="543" width="356" height="20" font="1"> LV mass indexed to body surface area or to height predicted CV </text>
<text top="766" left="536" width="342" height="20" font="1">events independently of the Framingham risk score (HR: 1.21; </text>
<text top="783" left="536" width="161" height="20" font="1">95% CI: 1.05–1.39; p&lt;0.007) </text>
<text top="697" left="914" width="7" height="18" font="1">•</text>
<text top="696" left="921" width="171" height="20" font="1"> LV mass measured at age 18–</text>
<text top="713" left="914" width="139" height="20" font="1">30 y leads to modest risk </text>
<text top="730" left="914" width="144" height="20" font="1">reclassification later in life </text>
<text top="749" left="914" width="7" height="18" font="1">•</text>
<text top="749" left="921" width="159" height="20" font="1"> Low number of events limits </text>
<text top="766" left="914" width="85" height="20" font="1">generalizability </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">67 </text>
<text top="107" left="226" width="66" height="20" font="4"><b>Size:</b> 3,980 </text>
<text top="109" left="536" width="7" height="18" font="1">•</text>
<text top="108" left="543" width="321" height="20" font="1"> Net reclassification improvement for LVM/height was 0.13 </text>
<text top="125" left="536" width="254" height="20" font="1">(p&lt;0.01) and for LVM/BSA was 0.11 (p=0.02). </text>
<text top="193" left="98" width="33" height="20" font="4"><b>ARIC </b></text>
<text top="211" left="98" width="113" height="20" font="1">Okwuosa TM, et al., </text>
<text top="228" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(110)</a> </text>
<text top="245" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25497261?dopt=Citation">25497261</a></text>
<text top="245" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25497261?dopt=Citation"> </a></text>
<text top="193" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="211" left="226" width="79" height="20" font="1">Observational </text>
<text top="228" left="226" width="46" height="20" font="1">study of </text>
<text top="245" left="226" width="98" height="20" font="1">population-based </text>
<text top="262" left="226" width="44" height="20" font="1">cohorts </text>
<text top="279" left="226" width="3" height="20" font="1"> </text>
<text top="297" left="226" width="77" height="20" font="4"><b>Size:</b> 14,489  </text>
<text top="193" left="341" width="148" height="20" font="4"><b>Inclusion criteria:</b> African </text>
<text top="211" left="341" width="163" height="20" font="1">American and white men and </text>
<text top="228" left="341" width="178" height="20" font="1">women population-based cohort </text>
<text top="245" left="341" width="174" height="20" font="1">mean age 54.7 ± 5.7 y at study </text>
<text top="262" left="341" width="175" height="20" font="1">start and followed for over 25 y; </text>
<text top="279" left="341" width="102" height="20" font="1">previously healthy </text>
<text top="194" left="536" width="339" height="20" font="4"><b>1</b>°<b> endpoint:</b> Pooled cohort CV events and 10-y Framingham </text>
<text top="212" left="536" width="69" height="20" font="1">CVD events </text>
<text top="229" left="536" width="3" height="20" font="1"> </text>
<text top="246" left="536" width="59" height="20" font="4"><b>Results:</b>   </text>
<text top="265" left="536" width="7" height="18" font="1">•</text>
<text top="264" left="543" width="351" height="20" font="1"> 792 (5.5%) 10-y Pooled Cohort CV events and 690 (4.8%) 10-y </text>
<text top="282" left="536" width="149" height="20" font="1">Framingham CHD events.  </text>
<text top="301" left="536" width="7" height="18" font="1">•</text>
<text top="300" left="543" width="350" height="20" font="1"> LVH was associated with CVD events (HR: 1.62; 95% CI: 1.38–</text>
<text top="317" left="536" width="297" height="20" font="1">1.90) and CHD events (HR: 1.56; 95% CIL 1.32–1.86. </text>
<text top="336" left="536" width="323" height="20" font="1"> • LVH by ECG did not significantly reclassify or improve C </text>
<text top="353" left="536" width="323" height="20" font="1">statistic compared with Framingham risk score (C statistics </text>
<text top="370" left="536" width="358" height="20" font="1">0.767/0.719; net reclassification index =0.001 [p=not significant]), </text>
<text top="387" left="536" width="302" height="20" font="1">compared with (C statistics 0.770/0.718), respectively.  </text>
<text top="195" left="914" width="7" height="18" font="1">•</text>
<text top="194" left="921" width="159" height="20" font="1"> ECG LVH does not improve </text>
<text top="212" left="914" width="107" height="20" font="1">risk reclassification </text>
<text top="405" left="98" width="39" height="20" font="4"><b>MESA </b></text>
<text top="422" left="98" width="102" height="20" font="1">Zalawadiya SK, et </text>
<text top="440" left="98" width="83" height="20" font="1">al., 2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(111)</a> </text>
<text top="457" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24699336?dopt=Citation">24699336</a></text>
<text top="457" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24699336?dopt=Citation"> </a></text>
<text top="405" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="422" left="226" width="79" height="20" font="1">Observational </text>
<text top="440" left="226" width="46" height="20" font="1">study of </text>
<text top="457" left="226" width="98" height="20" font="1">population-based </text>
<text top="474" left="226" width="44" height="20" font="1">cohorts </text>
<text top="491" left="226" width="3" height="20" font="1"> </text>
<text top="508" left="226" width="66" height="20" font="4"><b>Size:</b> 4,921 </text>
<text top="405" left="341" width="172" height="20" font="4"><b>Inclusion criteria:</b> Multi-ethnic </text>
<text top="422" left="341" width="146" height="20" font="1">cohort of men and women </text>
<text top="440" left="341" width="177" height="20" font="1">followed for a mean follow-up of </text>
<text top="457" left="341" width="30" height="20" font="1">4.5 y </text>
<text top="406" left="536" width="192" height="20" font="4"><b>1</b>°<b> endpoint:</b> Hard CVD endpoints </text>
<text top="424" left="536" width="3" height="20" font="1"> </text>
<text top="441" left="536" width="332" height="20" font="4"><b>Results:</b> MRI calculated LVH (indexed to BSA or height; &gt;95</text>
<text top="442" left="868" width="7" height="13" font="6">th</text>
<text top="441" left="875" width="3" height="20" font="1"> </text>
<text top="458" left="536" width="359" height="20" font="1">percentile) predicted hard CVD events (LVH-BSA: HR: 2.36; 95% </text>
<text top="475" left="536" width="361" height="20" font="1">CI: 1.37–4.04; p=0.002; LVH-height [1.7]: HR: 1.95; 95% CI: 1.17–</text>
<text top="492" left="536" width="338" height="20" font="1">3.26; p=0.01). but did not improve risk reclassification beyond </text>
<text top="510" left="536" width="135" height="20" font="1">conventional risk factors </text>
<text top="407" left="914" width="7" height="18" font="1">•</text>
<text top="406" left="921" width="170" height="20" font="1"> Though LVH predicted events </text>
<text top="424" left="914" width="120" height="20" font="1">it did not improve risk </text>
<text top="441" left="914" width="84" height="20" font="1">reclassification </text>
<text top="529" left="108" width="3" height="19" font="1"> </text>
<text top="563" left="81" width="738" height="24" font="3"><b>Data Supplement 23. RCTs on Use of Risk Estimation to Guide Treatment of Hypertension (Section 8.1.2) </b></text>
<text top="603" left="120" width="38" height="20" font="4"><b>Study </b></text>
<text top="620" left="109" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="638" left="115" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="655" left="124" width="30" height="20" font="4"><b>Year </b></text>
<text top="672" left="108" width="62" height="20" font="4"><b>Published </b></text>
<text top="603" left="216" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="620" left="221" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="638" left="215" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="603" left="371" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="603" left="546" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="620" left="578" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="638" left="546" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="655" left="582" width="55" height="20" font="4"><b>patients) </b></text>
<text top="603" left="746" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="620" left="729" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="638" left="735" width="129" height="20" font="4"><b>P value; OR or RR; &amp;  </b></text>
<text top="655" left="774" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="604" left="925" width="143" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="622" left="980" width="33" height="20" font="4"><b>any); </b></text>
<text top="639" left="941" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="656" left="949" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="673" left="967" width="59" height="20" font="4"><b>Summary </b></text>
<text top="691" left="98" width="76" height="20" font="1">Sundstrom J, </text>
<text top="708" left="98" width="64" height="20" font="1">et al., 2014 </text>
<text top="726" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(112)</a> </text>
<text top="743" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25131978?dopt=Citation">25131978</a></text>
<text top="743" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25131978?dopt=Citation"> </a></text>
<text top="691" left="194" width="103" height="20" font="4"><b>Aim:</b> We aimed to </text>
<text top="708" left="194" width="109" height="20" font="1">investigate whether </text>
<text top="726" left="194" width="101" height="20" font="1">the benefits of BP-</text>
<text top="743" left="194" width="105" height="20" font="1">lowering drugs are </text>
<text top="760" left="194" width="82" height="20" font="1">proportional to </text>
<text top="777" left="194" width="109" height="20" font="1">baseline CV risk, to </text>
<text top="691" left="335" width="160" height="20" font="4"><b>Inclusion criteria:</b> BPLTTC: </text>
<text top="708" left="335" width="182" height="20" font="1">trials were eligible if they met the </text>
<text top="726" left="335" width="134" height="20" font="1">original inclusion criteria </text>
<text top="743" left="335" width="177" height="20" font="1">specified in the protocol, 11 and </text>
<text top="760" left="335" width="142" height="20" font="1">were part of the subset of </text>
<text top="777" left="335" width="173" height="20" font="1">studies that randomly allocated </text>
<text top="691" left="531" width="148" height="20" font="4"><b>Intervention:</b> BP-lowering </text>
<text top="708" left="531" width="33" height="20" font="1">meds </text>
<text top="726" left="531" width="7" height="20" font="1">  </text>
<text top="743" left="531" width="139" height="20" font="4"><b>Comparator:</b> Placebo or </text>
<text top="760" left="531" width="133" height="20" font="1">less intensive treatment<b> </b></text>
<text top="692" left="700" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="711" left="700" width="7" height="18" font="1">•</text>
<text top="711" left="707" width="132" height="20" font="1"> Total major CV events, </text>
<text top="728" left="700" width="160" height="20" font="1">consisting of stroke (nonfatal </text>
<text top="745" left="700" width="114" height="20" font="1">stroke or death from </text>
<text top="762" left="700" width="174" height="20" font="1">cerebrovascular disease), CHD </text>
<text top="780" left="700" width="175" height="20" font="1">(nonfatal MI or death from CHD </text>
<text top="691" left="909" width="63" height="20" font="4"><b>Summary</b>: </text>
<text top="710" left="909" width="7" height="18" font="1">•</text>
<text top="710" left="916" width="165" height="20" font="1"> Lowering BP provides similar </text>
<text top="727" left="909" width="165" height="20" font="1">relative protection at all levels </text>
<text top="744" left="909" width="130" height="20" font="1">of baseline CV risk, but </text>
<text top="761" left="909" width="168" height="20" font="1">progressively greater absolute </text>
<text top="778" left="909" width="171" height="20" font="1">risk reductions as baseline risk </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">68 </text>
<text top="107" left="194" width="99" height="20" font="1">establish whether </text>
<text top="124" left="194" width="122" height="20" font="1">absolute risk could be </text>
<text top="141" left="194" width="81" height="20" font="1">used to inform </text>
<text top="159" left="194" width="128" height="20" font="1">treatment decisions for </text>
<text top="176" left="194" width="117" height="20" font="1">BP-lowering therapy, </text>
<text top="193" left="194" width="129" height="20" font="1">as is recommended for </text>
<text top="210" left="194" width="123" height="20" font="1">lipid-lowering therapy. </text>
<text top="227" left="194" width="3" height="20" font="1"> </text>
<text top="245" left="194" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="262" left="194" width="100" height="20" font="1">analysis of RCTs  </text>
<text top="279" left="194" width="3" height="20" font="1"> </text>
<text top="296" left="194" width="120" height="20" font="4"><b>Size:</b> 11 trials and 26 </text>
<text top="314" left="194" width="109" height="20" font="1">randomized groups </text>
<text top="331" left="194" width="86" height="20" font="1">with 67,475 pts </text>
<text top="348" left="194" width="92" height="20" font="1">(51,917 pts data </text>
<text top="365" left="194" width="90" height="20" font="1">available for the </text>
<text top="382" left="194" width="118" height="20" font="1">calculation of the risk </text>
<text top="400" left="194" width="61" height="20" font="1">equations) </text>
<text top="107" left="335" width="176" height="20" font="1">pts to either a BP-lowering drug </text>
<text top="124" left="335" width="134" height="20" font="1">or placebo, or to a more </text>
<text top="141" left="335" width="163" height="20" font="1">intensive or less intensive BP </text>
<text top="159" left="335" width="163" height="20" font="1">regimen. Trials had to have a </text>
<text top="176" left="335" width="139" height="20" font="1">minimum of 1,000 pt-y of </text>
<text top="193" left="335" width="143" height="20" font="1">planned follow-up in each </text>
<text top="210" left="335" width="170" height="20" font="1">randomized group, and should </text>
<text top="228" left="335" width="166" height="20" font="1">not have presented their main </text>
<text top="245" left="335" width="171" height="20" font="1">results before the protocol was </text>
<text top="262" left="335" width="125" height="20" font="1">finalized in July, 1995. </text>
<text top="279" left="335" width="3" height="20" font="1"> </text>
<text top="296" left="335" width="170" height="20" font="4"><b>Exclusion criteria:</b> Not stated </text>
<text top="107" left="700" width="157" height="20" font="1">including sudden death), HF </text>
<text top="124" left="700" width="188" height="20" font="1">(resulting in death or admission to </text>
<text top="141" left="700" width="145" height="20" font="1">hospital), or CV morbidity. </text>
<text top="160" left="700" width="7" height="18" font="1">•</text>
<text top="160" left="707" width="168" height="20" font="1"> The mean estimated baseline </text>
<text top="177" left="700" width="194" height="20" font="1">levels of 5-y CV risk for each of the </text>
<text top="194" left="700" width="195" height="20" font="1">4 risk groups were 6.0% (SD: 2–0), </text>
<text top="211" left="700" width="172" height="20" font="1">12.1% (1–5), 17.7% (1–7), and </text>
<text top="229" left="700" width="77" height="20" font="1">26.8% (5–4).  </text>
<text top="248" left="700" width="7" height="18" font="1">•</text>
<text top="247" left="707" width="176" height="20" font="1"> In each consecutive higher risk </text>
<text top="264" left="700" width="163" height="20" font="1">group, BP-lowering treatment </text>
<text top="282" left="700" width="165" height="20" font="1">reduced the risk of CV events </text>
<text top="299" left="700" width="186" height="20" font="1">relatively by 18% (95% CI: 7–27), </text>
<text top="316" left="700" width="178" height="20" font="1">15% (95% CI: 4–25), 13% (95% </text>
<text top="333" left="700" width="174" height="20" font="1">CI: 2–22), and 15% (95% CI: 5–</text>
<text top="350" left="700" width="193" height="20" font="1">24), respectively (p=0·30 for trend) </text>
<text top="368" left="700" width="173" height="20" font="1">in each group with BP-lowering </text>
<text top="385" left="700" width="190" height="20" font="1">treatment for 5 y would prevent 14 </text>
<text top="402" left="700" width="196" height="20" font="1">(95% CI: 8–21), 20 (95% CI: 8–31), </text>
<text top="419" left="700" width="180" height="20" font="1">24 (95% CI: 8–40), and 38 (95% </text>
<text top="437" left="700" width="193" height="20" font="1">CI: 16–61) CV events, respectively </text>
<text top="454" left="700" width="102" height="20" font="1">(p=0.04 for trend). </text>
<text top="107" left="909" width="137" height="20" font="1">increases. These results </text>
<text top="124" left="909" width="156" height="20" font="1">support the use of predicted </text>
<text top="141" left="909" width="172" height="20" font="1">baseline CVD risk equations to </text>
<text top="159" left="909" width="163" height="20" font="1">inform BP-lowering treatment </text>
<text top="176" left="909" width="58" height="20" font="1">decisions. </text>
<text top="195" left="909" width="7" height="18" font="1">•</text>
<text top="194" left="916" width="162" height="20" font="1"> Lowest risk group had &gt;83% </text>
<text top="211" left="909" width="156" height="20" font="1">with a risk that exceeds 4%. </text>
<text top="472" left="98" width="76" height="20" font="1">Sundstrom J, </text>
<text top="489" left="98" width="64" height="20" font="1">et al., 2015 </text>
<text top="506" left="98" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(19)</a> </text>
<text top="523" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25531552?dopt=Citation">25531552</a></text>
<text top="523" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25531552?dopt=Citation"> </a></text>
<text top="472" left="194" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="489" left="194" width="47" height="20" font="1">whether </text>
<text top="506" left="194" width="103" height="20" font="1">pharmacologic BP </text>
<text top="523" left="193" width="125" height="20" font="1">reduction prevents CV </text>
<text top="540" left="193" width="117" height="20" font="1">events and deaths in </text>
<text top="558" left="193" width="122" height="20" font="1">pts with grade 1 HTN. </text>
<text top="575" left="194" width="3" height="20" font="1"> </text>
<text top="592" left="194" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="609" left="194" width="96" height="20" font="1">analysis of RCTs </text>
<text top="627" left="194" width="3" height="20" font="1"> </text>
<text top="644" left="194" width="109" height="20" font="4"><b>Size:</b> 10 RTCs with </text>
<text top="661" left="194" width="61" height="20" font="1">15,266 pts </text>
<text top="472" left="335" width="141" height="20" font="4"><b>Inclusion criteria:</b> RCTs </text>
<text top="489" left="335" width="173" height="20" font="1">of at least 1 y duration; pts ≥18 </text>
<text top="506" left="335" width="158" height="20" font="1">y, at least 80% of whom had </text>
<text top="523" left="335" width="165" height="20" font="1">grade 1 HTN and no previous </text>
<text top="540" left="335" width="144" height="20" font="1">CVD (MI, angina pectoris, </text>
<text top="558" left="335" width="175" height="20" font="1">CABG, PCI, stroke, TIA, carotid </text>
<text top="575" left="335" width="147" height="20" font="1">surgery, peripheral arterial </text>
<text top="592" left="335" width="112" height="20" font="1">surgery, intermittent </text>
<text top="609" left="335" width="117" height="20" font="1">claudication, or renal </text>
<text top="627" left="335" width="144" height="20" font="1">failure); and compared an </text>
<text top="644" left="335" width="121" height="20" font="1">antihypertensive drug </text>
<text top="661" left="335" width="167" height="20" font="1">provided as monotherapy or a </text>
<text top="678" left="335" width="148" height="20" font="1">stepped-care algorithm vs. </text>
<text top="695" left="335" width="146" height="20" font="1">placebo or another control </text>
<text top="713" left="335" width="51" height="20" font="1">regimen. </text>
<text top="730" left="335" width="3" height="20" font="1"> </text>
<text top="747" left="335" width="164" height="20" font="4"><b>Exclusion criteria:</b> Excluded </text>
<text top="764" left="335" width="178" height="20" font="1">trials did not contribute an event </text>
<text top="472" left="531" width="148" height="20" font="4"><b>Intervention:</b> BP-lowering </text>
<text top="489" left="531" width="33" height="20" font="1">meds </text>
<text top="506" left="531" width="7" height="20" font="1">  </text>
<text top="523" left="531" width="81" height="20" font="4"><b>Comparator:</b> <b> </b></text>
<text top="542" left="531" width="7" height="18" font="1">•</text>
<text top="542" left="538" width="143" height="20" font="1"> Placebo or less intensive </text>
<text top="559" left="531" width="55" height="20" font="1">treatment </text>
<text top="578" left="531" width="7" height="18" font="1">•</text>
<text top="577" left="538" width="146" height="20" font="1"> The difference in average </text>
<text top="594" left="531" width="143" height="20" font="1">achieved BP between the </text>
<text top="612" left="531" width="141" height="20" font="1">active and control groups </text>
<text top="629" left="531" width="143" height="20" font="1">was 3.6/2.4 mm Hg in the </text>
<text top="646" left="531" width="109" height="20" font="1">BPLTTC (Appendix </text>
<text top="663" left="531" width="113" height="20" font="1">Table 2, available at </text>
<text top="680" left="531" width="128" height="20" font="1">www.annals.org) but is </text>
<text top="698" left="531" width="122" height="20" font="1">unknown for the other </text>
<text top="715" left="531" width="155" height="20" font="1">contributing trial subgroups. </text>
<text top="473" left="700" width="161" height="20" font="4"><b>1</b>°<b> endpoint:</b> Total major CV </text>
<text top="490" left="700" width="194" height="20" font="1">events, comprising stroke (nonfatal </text>
<text top="507" left="700" width="114" height="20" font="1">stroke or death from </text>
<text top="524" left="700" width="195" height="20" font="1">cerebrovascular disease), coronary </text>
<text top="542" left="700" width="185" height="20" font="1">events (nonfatal MI or death from </text>
<text top="559" left="700" width="191" height="20" font="1">CHD, including sudden death), HF </text>
<text top="576" left="700" width="161" height="20" font="1">(causing death or resulting in </text>
<text top="593" left="700" width="187" height="20" font="1">hospitalization), or CV death; OR: </text>
<text top="610" left="700" width="141" height="20" font="1">0.86 (95% CI: 0.74–1.01) </text>
<text top="628" left="700" width="3" height="20" font="1"> </text>
<text top="645" left="700" width="103" height="20" font="4"><b>Other endpoints: </b></text>
<text top="662" left="700" width="159" height="20" font="1">Each of the above outcomes </text>
<text top="679" left="700" width="181" height="20" font="1">independently; and total deaths.  </text>
<text top="698" left="700" width="7" height="18" font="1">•</text>
<text top="698" left="707" width="174" height="20" font="1"> CHD 0.91 (95% CI: 0.74–1.12) </text>
<text top="717" left="700" width="7" height="18" font="1">•</text>
<text top="716" left="707" width="183" height="20" font="1"> Stroke 0.72 (95% CI: 0.55–0.99) </text>
<text top="735" left="700" width="7" height="18" font="1">•</text>
<text top="734" left="707" width="164" height="20" font="1"> HF 0.80 (95% CI: 0.57–1.12) </text>
<text top="753" left="700" width="7" height="18" font="1">•</text>
<text top="753" left="707" width="183" height="20" font="1"> CVD deaths 0.75 (95% CI: 0.57–</text>
<text top="770" left="700" width="31" height="20" font="1">0.98) </text>
<text top="472" left="909" width="66" height="20" font="4"><b>Summary</b>:  </text>
<text top="491" left="909" width="7" height="18" font="1">•</text>
<text top="490" left="916" width="161" height="20" font="1"> BP-lowering therapy is likely </text>
<text top="507" left="909" width="166" height="20" font="1">to prevent stroke and death in </text>
<text top="524" left="909" width="173" height="20" font="1">pts with uncomplicated grade 1 </text>
<text top="542" left="909" width="32" height="20" font="1">HTN. </text>
<text top="561" left="909" width="7" height="18" font="1">•</text>
<text top="560" left="916" width="156" height="20" font="1"> 5 y risks in BPLTTC control </text>
<text top="577" left="909" width="41" height="20" font="1">groups </text>
<text top="594" left="909" width="100" height="20" font="1">CVD events 7.4% </text>
<text top="612" left="909" width="101" height="20" font="1">CVD deaths 3.1%<b> </b></text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">69 </text>
<text top="107" left="335" width="146" height="20" font="1">for any of the outcomes of </text>
<text top="124" left="335" width="51" height="20" font="1">interest.  </text>
<text top="109" left="700" width="7" height="18" font="1">•</text>
<text top="108" left="707" width="184" height="20" font="1"> Total deaths 0.78 (95% CI: 0.67–</text>
<text top="125" left="700" width="35" height="20" font="1">0.92)  </text>
<text top="143" left="700" width="3" height="20" font="1"> </text>
<text top="160" left="700" width="173" height="20" font="1">Only the first event for a pt was </text>
<text top="177" left="700" width="160" height="20" font="1">used for the analysis of each </text>
<text top="194" left="700" width="166" height="20" font="1">outcome, but a pt who had &gt;1 </text>
<text top="211" left="700" width="181" height="20" font="1">outcome type could contribute to </text>
<text top="229" left="700" width="177" height="20" font="1">more than 1 analysis. They also </text>
<text top="246" left="700" width="185" height="20" font="1">tabulated overall withdrawals and </text>
<text top="263" left="700" width="195" height="20" font="1">withdrawals due to adverse events. </text>
<text top="281" left="98" width="62" height="20" font="1">Thompson </text>
<text top="298" left="98" width="62" height="20" font="1">AM, et al.,  </text>
<text top="316" left="98" width="63" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(113)</a> </text>
<text top="333" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21364140?dopt=Citation">21364140</a></text>
<text top="333" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21364140?dopt=Citation"> </a></text>
<text top="281" left="194" width="119" height="20" font="4"><b>Aim:</b> To evaluate the </text>
<text top="298" left="194" width="47" height="20" font="1">effect of </text>
<text top="316" left="194" width="93" height="20" font="1">antihypertensive </text>
<text top="333" left="194" width="87" height="20" font="1">treatment on 2º </text>
<text top="350" left="194" width="104" height="20" font="1">prevention of CVD </text>
<text top="367" left="194" width="116" height="20" font="1">events and all-cause </text>
<text top="384" left="194" width="111" height="20" font="1">mortality among pts </text>
<text top="402" left="194" width="91" height="20" font="1">without clinically </text>
<text top="419" left="194" width="76" height="20" font="1">defined HTN. </text>
<text top="436" left="194" width="3" height="20" font="1"> </text>
<text top="453" left="194" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="470" left="194" width="96" height="20" font="1">analysis of RCTs </text>
<text top="488" left="194" width="3" height="20" font="1"> </text>
<text top="505" left="194" width="109" height="20" font="4"><b>Size:</b> 25 RCTs with </text>
<text top="522" left="194" width="61" height="20" font="1">64,162 pts </text>
<text top="281" left="335" width="180" height="20" font="4"><b>Inclusion criteria:</b> Studies were </text>
<text top="298" left="335" width="177" height="20" font="1">eligible for inclusion if they were </text>
<text top="316" left="335" width="141" height="20" font="1">RCTs of antihypertensive </text>
<text top="333" left="335" width="161" height="20" font="1">treatment among pts with BP </text>
<text top="350" left="335" width="180" height="20" font="1">&lt;140 mm Hg systolic or &lt;90 mm </text>
<text top="367" left="335" width="180" height="20" font="1">Hg diastolic for the prevention of </text>
<text top="384" left="335" width="161" height="20" font="1">CVD events (fatal or nonfatal </text>
<text top="402" left="335" width="181" height="20" font="1">stroke, fatal or nonfatal MI, CHF, </text>
<text top="419" left="335" width="101" height="20" font="1">or CVD mortality). </text>
<text top="436" left="335" width="3" height="20" font="1"> </text>
<text top="453" left="335" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="470" left="335" width="166" height="20" font="1">Studies were excluded if CVD </text>
<text top="488" left="335" width="156" height="20" font="1">events were not reported by </text>
<text top="505" left="335" width="144" height="20" font="1">HTN status in studies that </text>
<text top="522" left="335" width="161" height="20" font="1">included pts with and without </text>
<text top="539" left="335" width="165" height="20" font="1">HTN; the study population did </text>
<text top="557" left="335" width="161" height="20" font="1">not include pts with BP in the </text>
<text top="574" left="335" width="146" height="20" font="1">normal or prehypertensive </text>
<text top="591" left="335" width="178" height="20" font="1">ranges; the study population did </text>
<text top="608" left="335" width="171" height="20" font="1">not include pts with preexisting </text>
<text top="625" left="335" width="171" height="20" font="1">CVD or CVD equivalents, such </text>
<text top="643" left="335" width="163" height="20" font="1">as diabetes; antihypertensive </text>
<text top="660" left="335" width="160" height="20" font="1">treatment was not part of the </text>
<text top="677" left="335" width="181" height="20" font="1">intervention; treatment allocation </text>
<text top="694" left="335" width="170" height="20" font="1">was not random; a measure of </text>
<text top="711" left="335" width="178" height="20" font="1">variance (p-value or CI) was not </text>
<text top="729" left="335" width="134" height="20" font="1">reported or could not be </text>
<text top="746" left="335" width="172" height="20" font="1">calculated from the information </text>
<text top="763" left="335" width="157" height="20" font="1">provided; pts &lt;18 y; or there </text>
<text top="780" left="335" width="143" height="20" font="1">were differences between </text>
<text top="281" left="531" width="148" height="20" font="4"><b>Intervention:</b> BP-lowering </text>
<text top="298" left="531" width="134" height="20" font="1">meds, the majority were </text>
<text top="316" left="531" width="148" height="20" font="1">studies of ACEI, next most </text>
<text top="333" left="531" width="113" height="20" font="1">common were BBs.  </text>
<text top="350" left="531" width="7" height="20" font="1">  </text>
<text top="367" left="531" width="139" height="20" font="4"><b>Comparator:</b> Placebo or </text>
<text top="384" left="531" width="101" height="20" font="1">active comparator </text>
<text top="282" left="700" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="301" left="700" width="7" height="18" font="1">•</text>
<text top="301" left="707" width="187" height="20" font="1"> Composite CVD (fatal or nonfatal </text>
<text top="318" left="700" width="196" height="20" font="1">stroke, fatal or nonfatal MI, CHF, or </text>
<text top="335" left="700" width="90" height="20" font="1">CVD mortality):  </text>
<text top="354" left="700" width="7" height="18" font="1">•</text>
<text top="353" left="707" width="167" height="20" font="1"> CVD RR: 0.85 (95% CI: 0.80–</text>
<text top="371" left="700" width="165" height="20" font="1">0.90), absolute risk reduction: </text>
<text top="388" left="700" width="65" height="20" font="1">27.1/1,000. </text>
<text top="407" left="700" width="7" height="18" font="1">•</text>
<text top="406" left="707" width="187" height="20" font="1"> This implies that a 2.7% absolute </text>
<text top="423" left="700" width="179" height="20" font="1">risk reduction reflects a 15% RR </text>
<text top="441" left="700" width="184" height="20" font="1">reduction, so the baseline risk for </text>
<text top="458" left="700" width="191" height="20" font="1">CVD would have been about 18%, </text>
<text top="475" left="700" width="196" height="20" font="1">but the follow-up interval is unclear. </text>
<text top="492" left="700" width="3" height="20" font="1"> </text>
<text top="510" left="700" width="103" height="20" font="4"><b>Other endpoints: </b></text>
<text top="529" left="700" width="7" height="18" font="1">•</text>
<text top="528" left="707" width="176" height="20" font="1"> Stroke RR: 0.77 (95% CI: 0.61, </text>
<text top="545" left="700" width="31" height="20" font="1">0.98) </text>
<text top="564" left="700" width="7" height="18" font="1">•</text>
<text top="563" left="707" width="186" height="20" font="1"> MI RR: 0.80 (95% CI: 0.69, 0.93) </text>
<text top="582" left="700" width="7" height="18" font="1">•</text>
<text top="582" left="707" width="189" height="20" font="1"> HF RR: 0.71 (95% CI: 0.65, 0.77) </text>
<text top="601" left="700" width="7" height="18" font="1">•</text>
<text top="600" left="707" width="170" height="20" font="1"> CVD death RR: 0.83 (95% CI: </text>
<text top="617" left="700" width="62" height="20" font="1">0.69, 0.99) </text>
<text top="636" left="700" width="7" height="18" font="1">•</text>
<text top="636" left="707" width="178" height="20" font="1"> Total deaths RR: 0.87 (95% CI: </text>
<text top="653" left="700" width="62" height="20" font="1">0.80, 0.95) </text>
<text top="670" left="700" width="3" height="20" font="1"> </text>
<text top="687" left="700" width="167" height="20" font="4"><b>Other results:</b> Table 4 shows </text>
<text top="705" left="700" width="196" height="20" font="1">similar results for CVD from studies </text>
<text top="722" left="700" width="181" height="20" font="1">of pts with CAD vs. other, HF vs. </text>
<text top="739" left="700" width="192" height="20" font="1">other, and DM vs. non-DM. Similar </text>
<text top="756" left="700" width="175" height="20" font="1">results from studies of ACEI vs. </text>
<text top="773" left="700" width="177" height="20" font="1">other. These results support the </text>
<text top="281" left="909" width="151" height="20" font="4"><b>Summary:</b> Among pts with </text>
<text top="298" left="909" width="144" height="20" font="1">clinical history of CVD but </text>
<text top="316" left="909" width="167" height="20" font="1">without HTN, antihypertensive </text>
<text top="333" left="909" width="168" height="20" font="1">treatment was associated with </text>
<text top="350" left="909" width="169" height="20" font="1">decreased risk of stroke, CHF, </text>
<text top="367" left="909" width="156" height="20" font="1">composite CVD events, and </text>
<text top="384" left="909" width="106" height="20" font="1">all-cause mortality. </text>
<text top="402" left="909" width="3" height="20" font="4"><b> </b></text>
<text top="419" left="909" width="80" height="20" font="4"><b>Limitations:</b>   </text>
<text top="438" left="909" width="7" height="18" font="1">•</text>
<text top="437" left="916" width="148" height="20" font="1"> Difference in achieved BP </text>
<text top="454" left="909" width="98" height="20" font="1">was not reported. </text>
<text top="473" left="909" width="7" height="18" font="1">•</text>
<text top="473" left="916" width="150" height="20" font="1"> Average baseline SBP not </text>
<text top="490" left="909" width="174" height="20" font="1">reported. No information on the </text>
<text top="507" left="909" width="158" height="20" font="1">entry levels of BP other than </text>
<text top="524" left="909" width="154" height="20" font="1">not hypertensive. Difficult to </text>
<text top="542" left="909" width="154" height="20" font="1">use to establish a treatment </text>
<text top="559" left="909" width="98" height="20" font="1">threshold or goal. </text>
<text top="578" left="909" width="7" height="18" font="1">•</text>
<text top="577" left="916" width="157" height="20" font="1"> Many of these studies were </text>
<text top="594" left="909" width="170" height="20" font="1">designed to try to demonstrate </text>
<text top="612" left="909" width="154" height="20" font="1">specific drug benefits rather </text>
<text top="629" left="909" width="173" height="20" font="1">than BP-lowering benefits. Can </text>
<text top="646" left="909" width="168" height="20" font="1">we attribute the benefits to BP-</text>
<text top="663" left="909" width="163" height="20" font="1">lowering? We know these pts </text>
<text top="680" left="909" width="156" height="20" font="1">did not have HTN but we do </text>
<text top="698" left="909" width="165" height="20" font="1">not know the lower limit of the </text>
<text top="715" left="909" width="147" height="20" font="1">BP inclusion ranges or the </text>
<text top="732" left="909" width="118" height="20" font="1">treatment associated </text>
<text top="749" left="909" width="148" height="20" font="1">difference in SBP between </text>
<text top="767" left="909" width="149" height="20" font="1">groups making it difficult to </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">70 </text>
<text top="107" left="335" width="172" height="20" font="1">intervention and control groups </text>
<text top="124" left="335" width="152" height="20" font="1">other than antihypertensive </text>
<text top="141" left="335" width="59" height="20" font="1">treatment. </text>
<text top="107" left="700" width="182" height="20" font="1">conclusion that the effect is not a </text>
<text top="124" left="700" width="178" height="20" font="1">drug effect, but is a BP-lowering </text>
<text top="141" left="700" width="194" height="20" font="1">effect, and that the effect is seen in </text>
<text top="159" left="700" width="186" height="20" font="1">people with CVD broadly defined, </text>
<text top="176" left="700" width="99" height="20" font="1">not just in HF pts. </text>
<text top="107" left="909" width="166" height="20" font="1">establish a treatment initiation </text>
<text top="124" left="909" width="98" height="20" font="1">threshold or goal. </text>
<text top="194" left="98" width="70" height="20" font="1">Xie X, et al., </text>
<text top="211" left="98" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(21)</a> </text>
<text top="228" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation">26559744</a></text>
<text top="228" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation"> </a></text>
<text top="194" left="194" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="211" left="194" width="119" height="20" font="1">efficacy and safety of </text>
<text top="228" left="194" width="121" height="20" font="1">intensive BP-lowering </text>
<text top="246" left="194" width="60" height="20" font="1">strategies. </text>
<text top="263" left="194" width="3" height="20" font="1"> </text>
<text top="280" left="194" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="297" left="194" width="96" height="20" font="1">analysis of RCTs </text>
<text top="314" left="194" width="3" height="20" font="1"> </text>
<text top="332" left="194" width="109" height="20" font="4"><b>Size:</b> 19 RCTs with </text>
<text top="349" left="194" width="61" height="20" font="1">44,989 pts </text>
<text top="194" left="335" width="180" height="20" font="4"><b>Inclusion criteria:</b> RCTs with at </text>
<text top="211" left="335" width="137" height="20" font="1">least 6 mo follow-up that </text>
<text top="228" left="335" width="172" height="20" font="1">randomly assigned pts to more </text>
<text top="246" left="335" width="169" height="20" font="1">intensive vs. less intensive BP-</text>
<text top="263" left="335" width="181" height="20" font="1">lowering treatment, with different </text>
<text top="280" left="335" width="143" height="20" font="1">BP targets or different BP </text>
<text top="297" left="335" width="130" height="20" font="1">changes from baseline. </text>
<text top="314" left="335" width="165" height="20" font="1">Reference lists from identified </text>
<text top="332" left="335" width="165" height="20" font="1">trials and review articles were </text>
<text top="349" left="335" width="182" height="20" font="1">manually scanned to identify any </text>
<text top="366" left="335" width="128" height="20" font="1">other relevant studies.  </text>
<text top="383" left="335" width="3" height="20" font="1"> </text>
<text top="400" left="335" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="194" left="531" width="148" height="20" font="4"><b>Intervention:</b> BP-lowering </text>
<text top="211" left="531" width="37" height="20" font="1">meds  </text>
<text top="228" left="531" width="7" height="20" font="1">  </text>
<text top="245" left="531" width="84" height="20" font="4"><b>Comparator:</b>   </text>
<text top="265" left="531" width="7" height="18" font="1">•</text>
<text top="264" left="538" width="140" height="20" font="1"> Less intensive treatment </text>
<text top="283" left="531" width="7" height="18" font="1">•</text>
<text top="282" left="538" width="122" height="20" font="1"> BP difference 6.8/3.5 </text>
<text top="301" left="531" width="7" height="18" font="1">•</text>
<text top="301" left="538" width="135" height="20" font="1"> The mean follow-up BP </text>
<text top="318" left="531" width="145" height="20" font="1">levels in the less intensive </text>
<text top="335" left="531" width="70" height="20" font="1">BP-lowering </text>
<text top="352" left="531" width="154" height="20" font="1">regimen group were 140/81 </text>
<text top="370" left="531" width="130" height="20" font="1">mm Hg, compared with </text>
<text top="387" left="531" width="149" height="20" font="1">133/76 mm Hg in the more </text>
<text top="404" left="531" width="146" height="20" font="1">intensive treatment group. </text>
<text top="195" left="700" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="214" left="700" width="7" height="18" font="1">•</text>
<text top="213" left="707" width="165" height="20" font="1"> CVD, other major CV events, </text>
<text top="231" left="700" width="189" height="20" font="1">defined as a MI, stroke, HF, or CV </text>
<text top="248" left="700" width="182" height="20" font="1">death, separately and combined; </text>
<text top="265" left="700" width="146" height="20" font="1">nonvascular and all-cause </text>
<text top="282" left="700" width="165" height="20" font="1">mortality; ESKD, and adverse </text>
<text top="300" left="700" width="193" height="20" font="1">events. Progression of albuminuria </text>
<text top="317" left="700" width="171" height="20" font="1">(defined as new onset of micro-</text>
<text top="334" left="700" width="187" height="20" font="1">albuminuria/macro-albuminuria or </text>
<text top="351" left="700" width="183" height="20" font="1">a change from micro-albuminuria </text>
<text top="368" left="700" width="123" height="20" font="1">to macro-albuminuria) </text>
<text top="386" left="700" width="157" height="20" font="1">and retinopathy (retinopathy </text>
<text top="403" left="700" width="174" height="20" font="1">progression of 2 or more steps) </text>
<text top="420" left="700" width="179" height="20" font="1">were also recorded for trials that </text>
<text top="437" left="700" width="141" height="20" font="1">were done in pts with DM </text>
<text top="456" left="700" width="7" height="18" font="1">•</text>
<text top="456" left="707" width="167" height="20" font="1"> CVD RR: 0.86 (95% CI: 0.78–</text>
<text top="473" left="700" width="31" height="20" font="1">0.96) </text>
<text top="490" left="700" width="3" height="20" font="1"> </text>
<text top="507" left="700" width="103" height="20" font="4"><b>Other endpoints: </b></text>
<text top="524" left="700" width="182" height="20" font="1">MI RR: 0.87 (95% CI: 0.76–1.00; </text>
<text top="542" left="700" width="52" height="20" font="1">p=0.042) </text>
<text top="559" left="700" width="173" height="20" font="1">Stroke RR: 0.78 (95% CI: 0.68–</text>
<text top="576" left="700" width="31" height="20" font="1">0.90) </text>
<text top="593" left="700" width="185" height="20" font="1">HF RR: 0.85 (95% CI: 0.66–1.11) </text>
<text top="610" left="700" width="167" height="20" font="1">CVD death RR: 0.91 (95% CI: </text>
<text top="628" left="700" width="62" height="20" font="1">0.74–1.11) </text>
<text top="645" left="700" width="174" height="20" font="1">Total deaths RR: 0.91 (95% CI: </text>
<text top="662" left="700" width="62" height="20" font="1">0.81–1.03) </text>
<text top="679" left="700" width="3" height="20" font="1"> </text>
<text top="697" left="700" width="84" height="20" font="4"><b>Other results: </b></text>
<text top="716" left="700" width="7" height="18" font="1">•</text>
<text top="715" left="707" width="177" height="20" font="1"> Benefit for CVD not different by </text>
<text top="732" left="700" width="77" height="20" font="1">baseline SBP </text>
<text top="749" left="700" width="196" height="20" font="1">120–139: 0.89 (95% CI: 0.76–1.05) </text>
<text top="766" left="700" width="196" height="20" font="1">140–160: 0.83 (95% CI: 0.68–1.00) </text>
<text top="784" left="700" width="175" height="20" font="1">&gt;160: 0.89 (95% CI: 0.73–1.09) </text>
<text top="194" left="909" width="137" height="20" font="4"><b>Summary:</b> Intensive BP-</text>
<text top="211" left="909" width="173" height="20" font="1">lowering, including to &lt;130 mm </text>
<text top="228" left="909" width="165" height="20" font="1">Hg, provided greater vascular </text>
<text top="246" left="909" width="136" height="20" font="1">protection than standard </text>
<text top="263" left="909" width="144" height="20" font="1">regimens. In high-risk pts, </text>
<text top="280" left="909" width="155" height="20" font="1">there are additional benefits </text>
<text top="297" left="909" width="132" height="20" font="1">from more intensive BP-</text>
<text top="314" left="909" width="156" height="20" font="1">lowering, including for those </text>
<text top="332" left="909" width="141" height="20" font="1">with SPB &lt;140 mm Hg at </text>
<text top="349" left="909" width="148" height="20" font="1">baseline. The net absolute </text>
<text top="366" left="909" width="132" height="20" font="1">benefits of intensive BP-</text>
<text top="383" left="909" width="173" height="20" font="1">lowering in high-risk individuals </text>
<text top="401" left="909" width="55" height="20" font="1">are large. </text>
<text top="418" left="909" width="3" height="20" font="1"> </text>
<text top="435" left="909" width="80" height="20" font="4"><b>Limitations:</b>   </text>
<text top="454" left="909" width="7" height="18" font="1">•</text>
<text top="453" left="916" width="146" height="20" font="1"> Lack of individual pt data, </text>
<text top="470" left="909" width="156" height="20" font="1">which would have allowed a </text>
<text top="488" left="909" width="157" height="20" font="1">more reliable assessment of </text>
<text top="505" left="909" width="170" height="20" font="1">treatment effects in different pt </text>
<text top="522" left="909" width="44" height="20" font="1">groups. </text>
<text top="541" left="909" width="7" height="18" font="1">•</text>
<text top="540" left="916" width="135" height="20" font="1"> Interpretation: Supports </text>
<text top="558" left="909" width="150" height="20" font="1">treating pt with and without </text>
<text top="575" left="909" width="148" height="20" font="1">CVD at threshold of 130 to </text>
<text top="592" left="909" width="145" height="20" font="1">&lt;130. Supports treating at </text>
<text top="609" left="909" width="156" height="20" font="1">threshold of about 130 even </text>
<text top="627" left="909" width="158" height="20" font="1">down to a CVD event rate of </text>
<text top="644" left="909" width="66" height="20" font="1">0.9% per y. </text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">71 </text>
<text top="107" left="700" width="120" height="20" font="1">p-heterogeneity: 0.60 </text>
<text top="126" left="700" width="7" height="18" font="1">•</text>
<text top="125" left="707" width="179" height="20" font="1"> Benefit for CVD not different for </text>
<text top="143" left="700" width="185" height="20" font="1">more intensive and less intensive </text>
<text top="160" left="700" width="141" height="20" font="1">targets in intensive group </text>
<text top="177" left="700" width="183" height="20" font="1">&lt;140 or &lt;150 mm Hg: 0.76 (95% </text>
<text top="194" left="700" width="81" height="20" font="1">CI: 0.60–0.97) </text>
<text top="212" left="700" width="194" height="20" font="1">&lt;120– &lt;130 mm Hg: 0.91 (95% CI: </text>
<text top="229" left="700" width="62" height="20" font="1">0.84–1.00) </text>
<text top="246" left="700" width="80" height="20" font="1">p-hetero: 0.06 </text>
<text top="265" left="700" width="7" height="18" font="1">•</text>
<text top="264" left="707" width="131" height="20" font="1"> Absolute benefits were </text>
<text top="282" left="700" width="158" height="20" font="1">proportional to absolute risk. </text>
<text top="301" left="700" width="7" height="18" font="1">•</text>
<text top="300" left="707" width="162" height="20" font="1"> For trials in which all pts had </text>
<text top="317" left="700" width="193" height="20" font="1">vascular disease, renal disease, or </text>
<text top="334" left="700" width="157" height="20" font="1">DM at baseline, the average </text>
<text top="352" left="700" width="148" height="20" font="1">control group rate of major </text>
<text top="369" left="700" width="177" height="20" font="1">vascular events was 2·9% per y </text>
<text top="386" left="700" width="191" height="20" font="1">compared with 0·9% per y in other </text>
<text top="403" left="700" width="187" height="20" font="1">trials, and the numbers needed to </text>
<text top="420" left="700" width="188" height="20" font="1">treat were 94 (95% CI: 44–782) in </text>
<text top="438" left="700" width="185" height="20" font="1">these trials vs. 186 (95% CI: 107–</text>
<text top="455" left="700" width="121" height="20" font="1">708) in all other trials. </text>
<text top="474" left="700" width="7" height="18" font="1">•</text>
<text top="473" left="707" width="181" height="20" font="1"> Increase in severe hypotension: </text>
<text top="490" left="700" width="179" height="20" font="1">0.3% vs. 0.1% per person y OR: </text>
<text top="508" left="700" width="141" height="20" font="1">2.68 (95% CI: 1.21–5.89) </text>
<text top="526" left="98" width="75" height="20" font="1">Ettehad D, et </text>
<text top="543" left="98" width="76" height="20" font="1">al., 2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(17)</a> </text>
<text top="560" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178?dopt=Citation">26724178</a></text>
<text top="560" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178?dopt=Citation"> </a></text>
<text top="526" left="194" width="119" height="20" font="4"><b>Aim:</b> This systematic </text>
<text top="543" left="194" width="94" height="20" font="1">review and meta-</text>
<text top="560" left="194" width="91" height="20" font="1">analysis aims to </text>
<text top="577" left="194" width="121" height="20" font="1">combine data from all </text>
<text top="594" left="194" width="120" height="20" font="1">published large-scale </text>
<text top="612" left="194" width="113" height="20" font="1">BP-lowering trials to </text>
<text top="629" left="194" width="120" height="20" font="1">quantify the effects of </text>
<text top="646" left="194" width="111" height="20" font="1">BP reduction on CV </text>
<text top="663" left="194" width="115" height="20" font="1">outcomes and death </text>
<text top="680" left="194" width="83" height="20" font="1">across various </text>
<text top="698" left="194" width="107" height="20" font="1">baseline BP levels, </text>
<text top="715" left="194" width="113" height="20" font="1">major comorbidities, </text>
<text top="732" left="194" width="72" height="20" font="1">and different </text>
<text top="749" left="194" width="93" height="20" font="1">pharmacological </text>
<text top="766" left="194" width="77" height="20" font="1">interventions. </text>
<text top="784" left="194" width="3" height="20" font="1"> </text>
<text top="526" left="335" width="113" height="20" font="4"><b>Inclusion criteria:</b>   </text>
<text top="545" left="335" width="7" height="18" font="1">•</text>
<text top="544" left="342" width="121" height="20" font="1"> RCTs of BP-lowering </text>
<text top="561" left="335" width="139" height="20" font="1">treatment that included a </text>
<text top="578" left="335" width="174" height="20" font="1">minimum of 1,000 pt-y of follow-</text>
<text top="596" left="335" width="169" height="20" font="1">up in each study arm. No trials </text>
<text top="613" left="335" width="146" height="20" font="1">were excluded because of </text>
<text top="630" left="335" width="117" height="20" font="1">presence of baseline </text>
<text top="647" left="335" width="146" height="20" font="1">comorbidities, and trials of </text>
<text top="664" left="335" width="145" height="20" font="1">antihypertensive drugs for </text>
<text top="682" left="335" width="179" height="20" font="1">indications other than HTN were </text>
<text top="699" left="335" width="45" height="20" font="1">eligible. </text>
<text top="718" left="335" width="7" height="18" font="1">•</text>
<text top="717" left="342" width="141" height="20" font="1"> Eligible studies fell into 3 </text>
<text top="734" left="335" width="132" height="20" font="1">categories: 1st, random </text>
<text top="752" left="335" width="182" height="20" font="1">allocation of pts to a BP-lowering </text>
<text top="769" left="335" width="165" height="20" font="1">drug or placebo; 2nd, random </text>
<text top="786" left="335" width="171" height="20" font="1">allocation of pts to different BP-</text>
<text top="526" left="531" width="148" height="20" font="4"><b>Intervention:</b> BP-lowering </text>
<text top="543" left="531" width="37" height="20" font="1">meds  </text>
<text top="560" left="531" width="7" height="20" font="1">  </text>
<text top="577" left="531" width="128" height="20" font="4"><b>Comparator:</b> Placebo, </text>
<text top="594" left="531" width="141" height="20" font="1">active comparator or less </text>
<text top="612" left="531" width="107" height="20" font="1">intensive treatment </text>
<text top="527" left="700" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="546" left="700" width="7" height="18" font="1">•</text>
<text top="545" left="707" width="36" height="20" font="1"> CVD. </text>
<text top="564" left="700" width="7" height="18" font="1">•</text>
<text top="563" left="707" width="184" height="20" font="1"> Major CVD events, CHD, stroke, </text>
<text top="581" left="700" width="171" height="20" font="1">HF, renal failure, and all-cause </text>
<text top="598" left="700" width="53" height="20" font="1">mortality. </text>
<text top="617" left="700" width="7" height="18" font="1">•</text>
<text top="616" left="707" width="179" height="20" font="1"> Standardized RR for 10 mm Hg </text>
<text top="633" left="700" width="98" height="20" font="1">difference in SBP </text>
<text top="652" left="700" width="7" height="18" font="1">•</text>
<text top="652" left="707" width="167" height="20" font="1"> CVD RR: 0.80 (95% CI: 0.77–</text>
<text top="669" left="700" width="31" height="20" font="1">0.83) </text>
<text top="686" left="700" width="3" height="20" font="1"> </text>
<text top="703" left="700" width="103" height="20" font="4"><b>Other endpoints: </b></text>
<text top="722" left="700" width="7" height="18" font="1">•</text>
<text top="722" left="707" width="167" height="20" font="1"> CHD RR: 0.83 (95% CI: 0.78–</text>
<text top="739" left="700" width="31" height="20" font="1">0.88) </text>
<text top="758" left="700" width="7" height="18" font="1">•</text>
<text top="757" left="707" width="176" height="20" font="1"> Stroke RR: 0.73 (95% CI: 0.68–</text>
<text top="775" left="700" width="31" height="20" font="1">0.77) </text>
<text top="526" left="909" width="70" height="20" font="4"><b>Summary:</b>   </text>
<text top="545" left="909" width="7" height="18" font="1">•</text>
<text top="544" left="916" width="140" height="20" font="1"> BP-lowering significantly </text>
<text top="561" left="909" width="158" height="20" font="1">reduces vascular risk across </text>
<text top="578" left="909" width="171" height="20" font="1">various baseline BP levels and </text>
<text top="596" left="909" width="143" height="20" font="1">comorbidities. Our results </text>
<text top="613" left="909" width="144" height="20" font="1">provide strong support for </text>
<text top="630" left="909" width="166" height="20" font="1">lowering BP to SBP &lt;130 mm </text>
<text top="647" left="909" width="166" height="20" font="1">Hg and providing BP-lowering </text>
<text top="664" left="909" width="165" height="20" font="1">treatment to individuals with a </text>
<text top="682" left="909" width="160" height="20" font="1">history of CVD, CHD, stroke, </text>
<text top="699" left="909" width="106" height="20" font="1">DM, HF, and CKD. </text>
<text top="718" left="909" width="7" height="18" font="1">•</text>
<text top="717" left="916" width="167" height="20" font="1"> In stratified analyses, we saw </text>
<text top="734" left="909" width="131" height="20" font="1">no strong evidence that </text>
<text top="752" left="909" width="138" height="20" font="1">proportional effects were </text>
<text top="769" left="909" width="128" height="20" font="1">diminished in trials that </text>
<text top="786" left="909" width="148" height="20" font="1">included people with lower </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">72 </text>
<text top="107" left="194" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="124" left="194" width="96" height="20" font="1">analysis of RCTs </text>
<text top="141" left="194" width="3" height="20" font="1"> </text>
<text top="159" left="194" width="124" height="20" font="4"><b>Size:</b> 123 studies with </text>
<text top="176" left="194" width="68" height="20" font="1">613,815 pts </text>
<text top="107" left="335" width="141" height="20" font="1">lowering drugs; and third, </text>
<text top="124" left="335" width="148" height="20" font="1">random allocation of pts to </text>
<text top="141" left="335" width="162" height="20" font="1">different BP-lowering targets. </text>
<text top="159" left="335" width="3" height="20" font="1"> </text>
<text top="176" left="335" width="175" height="20" font="4"><b>Exclusion criteria:</b> &lt;1,000 pt-y </text>
<text top="193" left="335" width="165" height="20" font="1">of follow-up in each treatment </text>
<text top="210" left="335" width="38" height="20" font="1">group. </text>
<text top="109" left="700" width="7" height="18" font="1">•</text>
<text top="108" left="707" width="189" height="20" font="1"> HF RR: 0.72 (95% CI: 0.67–0.78) </text>
<text top="127" left="700" width="7" height="18" font="1">•</text>
<text top="127" left="707" width="178" height="20" font="1"> Total deaths RR: 0.87 (95% CI: </text>
<text top="144" left="700" width="62" height="20" font="1">0.84–0.91) </text>
<text top="161" left="700" width="3" height="20" font="1"> </text>
<text top="178" left="700" width="84" height="20" font="4"><b>Other results: </b></text>
<text top="197" left="700" width="7" height="18" font="1">•</text>
<text top="197" left="707" width="148" height="20" font="1"> Benefit for CVD and other </text>
<text top="214" left="700" width="191" height="20" font="1">endpoints not different by baseline </text>
<text top="231" left="700" width="184" height="20" font="1">SBP, including &lt;130 mm Hg fig 4 </text>
<text top="248" left="700" width="48" height="20" font="1">in paper </text>
<text top="265" left="700" width="172" height="20" font="1">CVD: 0.63; 95% CI: 0.50–0.80; </text>
<text top="283" left="700" width="41" height="20" font="1">p=0.22 </text>
<text top="300" left="700" width="173" height="20" font="1">CHD: 0.55; 95% CI: 0.42–0.72; </text>
<text top="317" left="700" width="41" height="20" font="1">p=0.93 </text>
<text top="334" left="700" width="182" height="20" font="1">Stroke: 0.65; 95% CI: 0.27–1.57; </text>
<text top="352" left="700" width="41" height="20" font="1">p=0.38 </text>
<text top="369" left="700" width="163" height="20" font="1">HF: 0.83; 95% CI: 0.41–1.70; </text>
<text top="386" left="700" width="41" height="20" font="1">p=0.27 </text>
<text top="403" left="700" width="183" height="20" font="1">Total deaths: 0.53; 95% CI: 0.37–</text>
<text top="420" left="700" width="72" height="20" font="1">0.76; p=0.79 </text>
<text top="439" left="700" width="7" height="18" font="1">•</text>
<text top="439" left="707" width="185" height="20" font="1"> More precision around estimates </text>
<text top="456" left="700" width="166" height="20" font="1">of benefits in SBP 130–139 at </text>
<text top="473" left="700" width="127" height="20" font="1">baseline, fig 4 in paper </text>
<text top="492" left="700" width="7" height="18" font="1">•</text>
<text top="492" left="707" width="183" height="20" font="1"> Results similar in trials of people </text>
<text top="509" left="700" width="184" height="20" font="1">with and without CVD at baseline </text>
<text top="526" left="700" width="44" height="20" font="1">figure 5 </text>
<text top="543" left="700" width="177" height="20" font="1">CVD+ 0.77 (95% CI: 0.71–0.81) </text>
<text top="560" left="700" width="174" height="20" font="1">CVD- 0.74 (95% CI: 0.67–0.83) </text>
<text top="578" left="700" width="71" height="20" font="1">Total deaths </text>
<text top="595" left="700" width="177" height="20" font="1">CVD+ 0.90 (95% CI: 0.83–0.98) </text>
<text top="612" left="700" width="178" height="20" font="1">CVD- 0.84 (95% CI: 0.75–0.93)  </text>
<text top="629" left="700" width="196" height="20" font="1">Other outcomes similarly in figure 5 </text>
<text top="648" left="700" width="7" height="18" font="1">•</text>
<text top="648" left="707" width="181" height="20" font="1"> In appendix, in general, benefits </text>
<text top="665" left="700" width="192" height="20" font="1">for CVD prevention seen in groups </text>
<text top="682" left="700" width="174" height="20" font="1">with and without baseline CHD, </text>
<text top="699" left="700" width="174" height="20" font="1">Stroke, DM, CKD and HF when </text>
<text top="716" left="700" width="158" height="20" font="1">examined separately, but no </text>
<text top="734" left="700" width="183" height="20" font="1">absolute risks provided to enable </text>
<text top="751" left="700" width="170" height="20" font="1">estimation of how far down the </text>
<text top="768" left="700" width="185" height="20" font="1">absolute risk curve these findings </text>
<text top="785" left="700" width="143" height="20" font="1">have been demonstrated. </text>
<text top="107" left="909" width="163" height="20" font="1">baseline SBP (&lt;130 mm Hg), </text>
<text top="124" left="909" width="148" height="20" font="1">and major CV events were </text>
<text top="141" left="909" width="169" height="20" font="1">clearly reduced in high-risk pts </text>
<text top="159" left="909" width="117" height="20" font="1">with various baseline </text>
<text top="176" left="909" width="155" height="20" font="1">comorbidities. Both of these </text>
<text top="193" left="909" width="168" height="20" font="1">major findings—the efficacy of </text>
<text top="210" left="909" width="172" height="20" font="1">BP-lowering below 130 mm Hg </text>
<text top="228" left="909" width="152" height="20" font="1">and the similar proportional </text>
<text top="245" left="909" width="102" height="20" font="1">effects in high risk </text>
<text top="262" left="909" width="155" height="20" font="1">populations—are consistent </text>
<text top="279" left="909" width="169" height="20" font="1">with and extend the findings of </text>
<text top="296" left="909" width="99" height="20" font="1">the SPRINT trial.  </text>
<text top="314" left="909" width="3" height="20" font="1"> </text>
<text top="331" left="909" width="80" height="20" font="4"><b>Limitations:</b>   </text>
<text top="350" left="909" width="7" height="18" font="1">•</text>
<text top="349" left="916" width="146" height="20" font="1"> Lack of individual pt data, </text>
<text top="366" left="909" width="156" height="20" font="1">which would have allowed a </text>
<text top="384" left="909" width="157" height="20" font="1">more reliable assessment of </text>
<text top="401" left="909" width="170" height="20" font="1">treatment effects in different pt </text>
<text top="418" left="909" width="44" height="20" font="1">groups. </text>
<text top="437" left="909" width="7" height="18" font="1">•</text>
<text top="436" left="916" width="150" height="20" font="1"> Interpretation: Lowering of </text>
<text top="454" left="909" width="126" height="20" font="1">BP into what has been </text>
<text top="471" left="909" width="150" height="20" font="1">regarded the normotensive </text>
<text top="488" left="909" width="144" height="20" font="1">range should therefore be </text>
<text top="505" left="909" width="152" height="20" font="1">routinely considered for the </text>
<text top="523" left="909" width="145" height="20" font="1">prevention of CVD among </text>
<text top="540" left="909" width="126" height="20" font="1">those deemed to be of </text>
<text top="557" left="909" width="128" height="20" font="1">sufficient absolute risk. </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">73 </text>
<text top="109" left="700" width="7" height="18" font="1">•</text>
<text top="108" left="707" width="179" height="20" font="1"> Some evidence of BB inferiority </text>
<text top="125" left="700" width="178" height="20" font="1">to other med classes in figure 6. </text>
<text top="144" left="700" width="7" height="18" font="1">•</text>
<text top="144" left="707" width="176" height="20" font="1"> Did not report absolute risks so </text>
<text top="161" left="700" width="180" height="20" font="1">do not know lower level of risk in </text>
<text top="178" left="700" width="111" height="20" font="1">treated populations. </text>
<text top="196" left="98" width="49" height="20" font="4"><b>SPRINT </b></text>
<text top="213" left="98" width="73" height="20" font="1">Wright JT Jr, </text>
<text top="231" left="98" width="64" height="20" font="1">et al., 2015 </text>
<text top="248" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(114)</a> </text>
<text top="265" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=Citation">26551272</a></text>
<text top="265" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=Citation"> </a></text>
<text top="196" left="194" width="92" height="20" font="4"><b>Aim:</b> To test the </text>
<text top="213" left="194" width="126" height="20" font="1">effectiveness of a goal </text>
<text top="231" left="194" width="128" height="20" font="1">SBP&lt;120 mm Hg vs. a </text>
<text top="248" left="193" width="125" height="20" font="1">goal SBP&lt;140 mm Hg </text>
<text top="265" left="194" width="113" height="20" font="1">for the prevention of </text>
<text top="282" left="194" width="87" height="20" font="1">CVD in pts with </text>
<text top="300" left="194" width="113" height="20" font="1">SBP≥130 mm Hg at </text>
<text top="317" left="194" width="53" height="20" font="1">baseline. </text>
<text top="334" left="194" width="3" height="20" font="1"> </text>
<text top="351" left="194" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="368" left="194" width="3" height="20" font="1"> </text>
<text top="386" left="194" width="83" height="20" font="4"><b>Size: </b>9361 pts </text>
<text top="403" left="194" width="106" height="20" font="1">followed median of </text>
<text top="420" left="194" width="40" height="20" font="1">3.26 y. </text>
<text top="196" left="335" width="163" height="20" font="4"><b>Inclusion criteria:</b> SBP≥130 </text>
<text top="213" left="335" width="175" height="20" font="1">mm Hg, with upper limit varying </text>
<text top="231" left="335" width="141" height="20" font="1">as number of pre-trial BP-</text>
<text top="248" left="335" width="143" height="20" font="1">lowering meds increased. </text>
<text top="265" left="335" width="62" height="20" font="1">age ≥50 y<b>  </b></text>
<text top="282" left="335" width="156" height="20" font="1">Presence of at least 1 of the </text>
<text top="300" left="335" width="55" height="20" font="1">following: </text>
<text top="319" left="335" width="7" height="18" font="1">•</text>
<text top="318" left="342" width="150" height="20" font="1"> Clinical or subclinical CVD </text>
<text top="337" left="335" width="7" height="18" font="1">•</text>
<text top="336" left="342" width="88" height="20" font="1"> CKD stage ≥3  </text>
<text top="355" left="335" width="7" height="18" font="1">•</text>
<text top="355" left="342" width="51" height="20" font="1"> Age≥75 </text>
<text top="374" left="335" width="7" height="18" font="1">•</text>
<text top="373" left="342" width="152" height="20" font="1"> Framingham General CVD </text>
<text top="390" left="335" width="98" height="20" font="1">risk≥15% in 10 y  </text>
<text top="407" left="335" width="3" height="20" font="1"> </text>
<text top="425" left="335" width="176" height="20" font="4"><b>Exclusion criteria: </b>DM, history </text>
<text top="442" left="335" width="160" height="20" font="1">of stroke, ESRD (eGFR &lt;20) </text>
<text top="196" left="531" width="151" height="20" font="4"><b>Intervention:</b> Intensive BP-</text>
<text top="213" left="531" width="145" height="20" font="1">lowering treatment to goal </text>
<text top="231" left="531" width="102" height="20" font="1">SBP &lt;120 mm Hg </text>
<text top="248" left="531" width="3" height="20" font="1"> </text>
<text top="265" left="531" width="83" height="20" font="4"><b>Comparison:  </b></text>
<text top="284" left="531" width="7" height="18" font="1">•</text>
<text top="283" left="538" width="126" height="20" font="1"> Standard BP-lowering </text>
<text top="301" left="531" width="151" height="20" font="1">treatment to goal SBP&lt;140 </text>
<text top="318" left="531" width="43" height="20" font="1">mm Hg </text>
<text top="337" left="531" width="7" height="18" font="1">•</text>
<text top="336" left="538" width="139" height="20" font="1"> Net treatment difference </text>
<text top="354" left="531" width="145" height="20" font="1">~3 drugs (2.8) on average </text>
<text top="371" left="531" width="109" height="20" font="1">vs. 2 drugs (1.8) on </text>
<text top="388" left="531" width="48" height="20" font="1">average </text>
<text top="407" left="531" width="7" height="18" font="1">•</text>
<text top="406" left="538" width="124" height="20" font="1"> During the trial, mean </text>
<text top="423" left="531" width="144" height="20" font="1">SBP was 121.5 vs. 134.6. </text>
<text top="196" left="700" width="162" height="20" font="1">1°<b> endpoint: </b>CVD (MI, ACS, </text>
<text top="213" left="700" width="135" height="20" font="1">stroke, HF, CVD death)  </text>
<text top="231" left="700" width="165" height="20" font="1">HR: 0.75 (95% CI: 0.64, 0.89) </text>
<text top="248" left="700" width="3" height="20" font="1"> </text>
<text top="265" left="700" width="103" height="20" font="4"><b>Other endpoints:</b> </text>
<text top="284" left="700" width="7" height="18" font="1">•</text>
<text top="283" left="707" width="178" height="20" font="1"> Total deaths HR: 0.73 (95% CI: </text>
<text top="301" left="700" width="62" height="20" font="1">0.60–0.90) </text>
<text top="320" left="700" width="7" height="18" font="1">•</text>
<text top="319" left="707" width="171" height="20" font="1"> 1° or death HR: 0.78 (95% CI: </text>
<text top="336" left="700" width="62" height="20" font="1">0.67–0.90) </text>
<text top="355" left="700" width="7" height="18" font="1">•</text>
<text top="355" left="707" width="166" height="20" font="1"> Components of 1° composite </text>
<text top="372" left="700" width="192" height="20" font="1">mostly consistent in direction other </text>
<text top="389" left="700" width="144" height="20" font="1">than ACS – no difference. </text>
<text top="406" left="700" width="3" height="20" font="1"> </text>
<text top="423" left="700" width="96" height="20" font="4"><b>CKD outcomes: </b></text>
<text top="442" left="700" width="7" height="18" font="1">•</text>
<text top="442" left="707" width="182" height="20" font="1"> 1° in CKD pts: reduction in GFR </text>
<text top="459" left="700" width="186" height="20" font="1">of ≥50% or ESRD HR: 0.89 (95% </text>
<text top="476" left="700" width="81" height="20" font="1">CI: 0.42, 1.87) </text>
<text top="495" left="700" width="7" height="18" font="1">•</text>
<text top="495" left="707" width="169" height="20" font="1"> Incident albuminuria HR: 0.72 </text>
<text top="512" left="700" width="94" height="20" font="1">(95% 0.48, 1.07) </text>
<text top="531" left="700" width="7" height="18" font="1">•</text>
<text top="530" left="707" width="179" height="20" font="1"> In pts without CKD: reduction in </text>
<text top="547" left="700" width="128" height="20" font="1">GFR ≥30% and to &lt;60 </text>
<text top="566" left="700" width="7" height="18" font="1">•</text>
<text top="566" left="707" width="169" height="20" font="1"> HR: 3.49 (95% CI: 2.44–5.10) </text>
<text top="585" left="700" width="7" height="18" font="1">•</text>
<text top="584" left="707" width="169" height="20" font="1"> Incident albuminuria HR: 0.81 </text>
<text top="601" left="700" width="114" height="20" font="1">(95% CI: 0.63–1.04) </text>
<text top="619" left="700" width="3" height="20" font="1"> </text>
<text top="636" left="700" width="98" height="20" font="4"><b>Adverse events:</b> </text>
<text top="655" left="700" width="7" height="18" font="1">•</text>
<text top="654" left="707" width="113" height="20" font="1"> SAEs: 1.04; p=0.25 </text>
<text top="673" left="700" width="7" height="18" font="1">•</text>
<text top="672" left="707" width="170" height="20" font="1"> Significant absolute increases </text>
<text top="690" left="700" width="148" height="20" font="1">seen in intensive group for </text>
<text top="707" left="700" width="195" height="20" font="1">hypotension (1%), syncope (0.6%), </text>
<text top="724" left="700" width="169" height="20" font="1">electrolyte abnormality (0.8%), </text>
<text top="741" left="700" width="169" height="20" font="1">acute kidney injury/acute renal </text>
<text top="759" left="700" width="157" height="20" font="1">failure (1.6%) over the study </text>
<text top="776" left="700" width="41" height="20" font="1">period. </text>
<text top="196" left="909" width="67" height="20" font="4"><b>Summary:</b>  </text>
<text top="215" left="909" width="7" height="18" font="1">•</text>
<text top="215" left="916" width="164" height="20" font="1"> More intensive SBP lowering </text>
<text top="232" left="909" width="164" height="20" font="1">to a goal of &lt;120 mm Hg with </text>
<text top="249" left="909" width="100" height="20" font="1">achieved mean of </text>
<text top="266" left="909" width="147" height="20" font="1">approximately 121 mm Hg </text>
<text top="283" left="909" width="172" height="20" font="1">resulted in less CVD and lower </text>
<text top="301" left="909" width="154" height="20" font="1">total mortality over 3.26 y in </text>
<text top="318" left="909" width="157" height="20" font="1">comparison with a goal SBP </text>
<text top="335" left="909" width="151" height="20" font="1">&lt;140 mm Hg and achieved </text>
<text top="352" left="909" width="119" height="20" font="1">SBP of ~135 mm Hg. </text>
<text top="371" left="909" width="7" height="18" font="1">•</text>
<text top="371" left="916" width="157" height="20" font="1"> There were small increases </text>
<text top="388" left="909" width="137" height="20" font="1">in some expected SAEs. </text>
<text top="405" left="909" width="172" height="20" font="1">Perhaps unexpected, a sizable </text>
<text top="422" left="909" width="160" height="20" font="1">increase in reduced eGFR in </text>
<text top="440" left="909" width="133" height="20" font="1">the non-CKD group and </text>
<text top="457" left="909" width="170" height="20" font="1">AKI/ARF overall was observed </text>
<text top="474" left="909" width="172" height="20" font="1">in the intensive group. While of </text>
<text top="491" left="909" width="124" height="20" font="1">uncertain etiology and </text>
<text top="508" left="909" width="115" height="20" font="1">significance, there is </text>
<text top="526" left="909" width="155" height="20" font="1">speculation this could be an </text>
<text top="543" left="909" width="150" height="20" font="1">acute hemodynamic effect, </text>
<text top="560" left="909" width="156" height="20" font="1">especially given the findings </text>
<text top="577" left="909" width="126" height="20" font="1">regarding albuminuria. </text>
<text top="594" left="909" width="3" height="20" font="1"> </text>
<text top="612" left="909" width="150" height="20" font="4"><b>Limitations:</b> Few pts were </text>
<text top="629" left="909" width="167" height="20" font="1">untreated at baseline ~9%, so </text>
<text top="646" left="909" width="156" height="20" font="1">SPRINT provides little if any </text>
<text top="663" left="909" width="152" height="20" font="1">insight at present regarding </text>
<text top="680" left="909" width="132" height="20" font="1">BP-lowering medication </text>
<text top="698" left="909" width="162" height="20" font="1">initiation for untreated people </text>
<text top="715" left="909" width="108" height="20" font="1">with SBP 130–139. </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">74 </text>
<text top="109" left="700" width="7" height="18" font="1">•</text>
<text top="108" left="707" width="172" height="20" font="1"> 1.7% fewer pts had orthostatic </text>
<text top="125" left="700" width="173" height="20" font="1">hypotension in intensive group; </text>
<text top="143" left="700" width="48" height="20" font="1">p=0.01.  </text>
<text top="161" left="98" width="78" height="20" font="1">Lawes MR, et </text>
<text top="178" left="98" width="83" height="20" font="1">al., 2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(115)</a> </text>
<text top="195" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16222626?dopt=Citation">16222626</a></text>
<text top="195" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16222626?dopt=Citation"> </a></text>
<text top="161" left="194" width="34" height="20" font="4"><b>Aim:  </b></text>
<text top="180" left="194" width="7" height="18" font="1">•</text>
<text top="179" left="200" width="100" height="20" font="1"> To determine the </text>
<text top="196" left="194" width="125" height="20" font="1">quantitative efficacy of </text>
<text top="213" left="194" width="106" height="20" font="1">different classes of </text>
<text top="231" left="194" width="117" height="20" font="1">BP-lowering drugs in </text>
<text top="248" left="194" width="115" height="20" font="1">preventing CHD and </text>
<text top="265" left="194" width="90" height="20" font="1">stroke, and who </text>
<text top="282" left="194" width="83" height="20" font="1">should receive </text>
<text top="300" left="194" width="59" height="20" font="1">treatment. </text>
<text top="319" left="194" width="7" height="18" font="1">•</text>
<text top="318" left="200" width="70" height="20" font="1"> 5 questions </text>
<text top="335" left="194" width="92" height="20" font="1">encapsulate this </text>
<text top="352" left="194" width="107" height="20" font="1">uncertainty. 1st, do </text>
<text top="370" left="194" width="108" height="20" font="1">BBs have a special </text>
<text top="387" left="194" width="122" height="20" font="1">effect over and above </text>
<text top="404" left="194" width="82" height="20" font="1">lowering BP in </text>
<text top="421" left="194" width="91" height="20" font="1">preventing CHD </text>
<text top="438" left="194" width="128" height="20" font="1">events in people with a </text>
<text top="456" left="194" width="97" height="20" font="1">history of CHD? 2</text>
<text top="457" left="290" width="9" height="13" font="6">nd</text>
<text top="456" left="299" width="7" height="20" font="1">, </text>
<text top="473" left="194" width="118" height="20" font="1">does the effect of BP-</text>
<text top="490" left="193" width="96" height="20" font="1">lowering drugs in </text>
<text top="507" left="193" width="115" height="20" font="1">preventing CHD and </text>
<text top="524" left="193" width="121" height="20" font="1">stroke differ in people </text>
<text top="542" left="193" width="102" height="20" font="1">with and without a </text>
<text top="559" left="193" width="122" height="20" font="1">history of CVD (i.e., is </text>
<text top="576" left="193" width="123" height="20" font="1">there a different effect </text>
<text top="593" left="193" width="69" height="20" font="1">in 2° and 1° </text>
<text top="610" left="193" width="79" height="20" font="1">prevention)? 3</text>
<text top="612" left="272" width="7" height="13" font="6">rd</text>
<text top="610" left="279" width="37" height="20" font="1">, does </text>
<text top="628" left="193" width="107" height="20" font="1">BP reduction alone </text>
<text top="645" left="193" width="110" height="20" font="1">explain the effect of </text>
<text top="662" left="193" width="117" height="20" font="1">BP-lowering drugs in </text>
<text top="679" left="193" width="115" height="20" font="1">preventing CHD and </text>
<text top="697" left="193" width="51" height="20" font="1">stroke? 4</text>
<text top="698" left="244" width="7" height="13" font="6">th</text>
<text top="697" left="251" width="67" height="20" font="1">, should the </text>
<text top="714" left="194" width="107" height="20" font="1">use of BP-lowering </text>
<text top="731" left="194" width="104" height="20" font="1">drugs be limited to </text>
<text top="748" left="194" width="112" height="20" font="1">people with high BP </text>
<text top="765" left="194" width="124" height="20" font="1">and not given to those </text>
<text top="783" left="194" width="106" height="20" font="1">at high risk of CVD </text>
<text top="161" left="335" width="131" height="20" font="4"><b>Inclusion criteria: </b>The </text>
<text top="178" left="335" width="178" height="20" font="1">database search (by MRL) used </text>
<text top="195" left="335" width="155" height="20" font="1">Medline (1966 to December </text>
<text top="212" left="335" width="172" height="20" font="1">2007; any language) to identify </text>
<text top="229" left="335" width="180" height="20" font="1">randomized trials of BP-lowering </text>
<text top="247" left="335" width="166" height="20" font="1">drugs in which CHD events or </text>
<text top="264" left="335" width="125" height="20" font="1">strokes were recorded </text>
<text top="281" left="335" width="151" height="20" font="1">(irrespective of whether BP </text>
<text top="298" left="335" width="163" height="20" font="1">reduction was considered the </text>
<text top="316" left="335" width="166" height="20" font="1">mechanism of action). Search </text>
<text top="333" left="335" width="161" height="20" font="1">terms were “antihypertensive </text>
<text top="350" left="335" width="167" height="20" font="1">agents” or “HTN” or “diuretics, </text>
<text top="367" left="335" width="158" height="20" font="1">thiazide” or “adrenergic beta-</text>
<text top="384" left="335" width="156" height="20" font="1">antagonists” or “angiotensin-</text>
<text top="402" left="335" width="178" height="20" font="1">converting enzyme inhibitors” or </text>
<text top="419" left="335" width="62" height="20" font="1">“receptors, </text>
<text top="436" left="335" width="144" height="20" font="1">angiotensin/antagonists &amp; </text>
<text top="453" left="335" width="150" height="20" font="1">inhibitors” or “tetrazoles” or </text>
<text top="470" left="335" width="173" height="20" font="1">“CCB s” or “vasodilator agents” </text>
<text top="488" left="335" width="174" height="20" font="1">or the names of all BP-lowering </text>
<text top="505" left="335" width="137" height="20" font="1">drugs listed in the British </text>
<text top="522" left="335" width="179" height="20" font="1">National Formulary as keywords </text>
<text top="539" left="335" width="143" height="20" font="1">or text words. Limits were </text>
<text top="557" left="335" width="180" height="20" font="1">Medline publication type “clinical </text>
<text top="574" left="335" width="170" height="20" font="1">trial” or “controlled clinical trial” </text>
<text top="591" left="335" width="178" height="20" font="1">or “RCT” or “meta-analysis”. We </text>
<text top="608" left="335" width="157" height="20" font="1">also searched the Cochrane </text>
<text top="625" left="335" width="142" height="20" font="1">Collaboration and Web of </text>
<text top="643" left="335" width="152" height="20" font="1">Science databases and the </text>
<text top="660" left="335" width="165" height="20" font="1">citations in trials and previous </text>
<text top="677" left="335" width="142" height="20" font="1">meta-analysis and review </text>
<text top="694" left="335" width="46" height="20" font="1">articles. </text>
<text top="711" left="335" width="3" height="20" font="1"> </text>
<text top="729" left="335" width="114" height="20" font="4"><b>Exclusion criteria: </b> </text>
<text top="746" left="335" width="163" height="20" font="1">We excluded nonrandomized </text>
<text top="763" left="335" width="172" height="20" font="1">trials and trials in which treated </text>
<text top="780" left="335" width="163" height="20" font="1">groups but not control groups </text>
<text top="161" left="531" width="148" height="20" font="4"><b>Intervention:</b> BP-lowering </text>
<text top="178" left="531" width="69" height="20" font="1">medications </text>
<text top="195" left="531" width="3" height="20" font="1"> </text>
<text top="212" left="531" width="141" height="20" font="4"><b>Comparison:</b> Placebo or </text>
<text top="229" left="531" width="133" height="20" font="1">less intensive treatment </text>
<text top="161" left="700" width="83" height="20" font="4"><b>1° endpoint: </b>  </text>
<text top="180" left="700" width="7" height="18" font="1">•</text>
<text top="179" left="707" width="128" height="20" font="1"> CHD and stroke co-1° </text>
<text top="198" left="700" width="7" height="18" font="1">•</text>
<text top="197" left="707" width="174" height="20" font="1"> Standardized to a 10/5 mm Hg </text>
<text top="215" left="700" width="74" height="20" font="1">BP reduction </text>
<text top="232" left="700" width="42" height="20" font="1">Overall </text>
<text top="249" left="700" width="174" height="20" font="1">CHD: 0.78 (95% CI: 0.73–0.83) </text>
<text top="266" left="700" width="183" height="20" font="1">Stroke: 0.59 (95% CI: 0.52–0.67) </text>
<text top="285" left="700" width="7" height="18" font="1">•</text>
<text top="285" left="707" width="176" height="20" font="1"> In absence of vascular disease </text>
<text top="302" left="700" width="174" height="20" font="1">CHD: 0.79 (95% CI: 0.72–0.86) </text>
<text top="319" left="700" width="183" height="20" font="1">Stroke: 0.54 (95% CI: 0.45–0.65) </text>
<text top="338" left="700" width="7" height="18" font="1">•</text>
<text top="337" left="707" width="89" height="20" font="1"> History of CHD </text>
<text top="355" left="700" width="174" height="20" font="1">CHD: 0.76 (95% CI: 0.68–0.86) </text>
<text top="372" left="700" width="183" height="20" font="1">Stroke: 0.65 (95% CI: 0.53–0.80) </text>
<text top="391" left="700" width="7" height="18" font="1">•</text>
<text top="390" left="707" width="96" height="20" font="1"> History of stroke </text>
<text top="407" left="700" width="174" height="20" font="1">CHD: 0.79 (95% CI: 0.62–1.00) </text>
<text top="425" left="700" width="183" height="20" font="1">Stroke: 0.66 (95% CI: 0.56–0.79) </text>
<text top="444" left="700" width="7" height="18" font="1">•</text>
<text top="443" left="707" width="181" height="20" font="1"> No big drug class effects except </text>
<text top="460" left="700" width="183" height="20" font="1">more benefit for BBs shortly after </text>
<text top="477" left="700" width="21" height="20" font="1">MI. </text>
<text top="496" left="700" width="7" height="18" font="1">•</text>
<text top="496" left="707" width="186" height="20" font="1"> Treatment benefits seen down to </text>
<text top="513" left="700" width="194" height="20" font="1">pre-treatment SBP of 110–119 mm </text>
<text top="530" left="700" width="191" height="20" font="1">Hg for CHD events RR: 0.78 (95% </text>
<text top="547" left="700" width="181" height="20" font="1">CI: 0.63–0.96) and 130–139 mm </text>
<text top="565" left="700" width="177" height="20" font="1">Hg for stroke RR: 0.75 (95% CI: </text>
<text top="582" left="700" width="62" height="20" font="1">0.63–0.89) </text>
<text top="161" left="909" width="156" height="20" font="4"><b>Summary: </b>The effect of BP-</text>
<text top="178" left="909" width="167" height="20" font="1">lowering drugs in reducing the </text>
<text top="195" left="909" width="152" height="20" font="1">risk of disease is entirely or </text>
<text top="212" left="909" width="154" height="20" font="1">largely due to BP reduction, </text>
<text top="229" left="909" width="135" height="20" font="1">with 1 main exception, a </text>
<text top="247" left="909" width="158" height="20" font="1">special extra effect of BBs in </text>
<text top="264" left="909" width="168" height="20" font="1">people who have had a recent </text>
<text top="281" left="909" width="164" height="20" font="1">MI The proportional reduction </text>
<text top="298" left="909" width="172" height="20" font="1">in CHD events and stroke for a </text>
<text top="316" left="909" width="140" height="20" font="1">given reduction in BP, an </text>
<text top="333" left="909" width="167" height="20" font="1">approximate halving in risk for </text>
<text top="350" left="909" width="138" height="20" font="1">each 10 mm Hg diastolic </text>
<text top="367" left="909" width="137" height="20" font="1">reduction, is the same in </text>
<text top="384" left="909" width="142" height="20" font="1">people with and without a </text>
<text top="402" left="909" width="172" height="20" font="1">history of vascular disease and </text>
<text top="419" left="909" width="158" height="20" font="1">in people without high BP as </text>
<text top="436" left="909" width="159" height="20" font="1">well as in those with high BP </text>
<text top="453" left="909" width="170" height="20" font="1">There is benefit in lowering BP </text>
<text top="470" left="909" width="165" height="20" font="1">in anyone at sufficient CV risk </text>
<text top="488" left="909" width="169" height="20" font="1">whatever their BP, so avoiding </text>
<text top="505" left="909" width="136" height="20" font="1">the need to measure BP </text>
<text top="522" left="909" width="53" height="20" font="1">routinely. </text>
<text top="539" left="909" width="3" height="20" font="1"> </text>
<text top="557" left="909" width="70" height="20" font="4"><b>Limitation:  </b></text>
<text top="576" left="909" width="7" height="18" font="1">•</text>
<text top="575" left="916" width="159" height="20" font="1"> Most of the pts without HTN </text>
<text top="592" left="909" width="172" height="20" font="1">were in the trials of people with </text>
<text top="609" left="909" width="170" height="20" font="1">pre-existing CVD; hence, most </text>
<text top="627" left="909" width="169" height="20" font="1">of the results of BP lowering in </text>
<text top="644" left="909" width="155" height="20" font="1">people with SBP&lt;140 are in </text>
<text top="661" left="909" width="98" height="20" font="1">people with CVD. </text>
<text top="680" left="909" width="7" height="18" font="1">•</text>
<text top="679" left="916" width="162" height="20" font="1"> No absolute risks or benefits </text>
<text top="697" left="909" width="139" height="20" font="1">provided. Not possible to </text>
<text top="714" left="909" width="169" height="20" font="1">estimate how far down the risk </text>
<text top="731" left="909" width="143" height="20" font="1">curve these results apply. </text>
<text top="748" left="909" width="3" height="20" font="1"> </text>
<text top="765" left="909" width="135" height="20" font="4"><b>Interpretation: </b>This MA </text>
<text top="783" left="909" width="161" height="20" font="1">provides stronger support for </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">75 </text>
<text top="107" left="194" width="126" height="20" font="1">who have a lower BP? </text>
<text top="124" left="194" width="121" height="20" font="1">A corollary is whether </text>
<text top="141" left="194" width="124" height="20" font="1">BP should be reduced </text>
<text top="159" left="194" width="100" height="20" font="1">to a limited extent </text>
<text top="176" left="194" width="116" height="20" font="1">only, a treat to target </text>
<text top="193" left="194" width="110" height="20" font="1">approach. Although </text>
<text top="210" left="194" width="38" height="20" font="1">cohort </text>
<text top="228" left="194" width="120" height="20" font="1">(prospective\observati</text>
<text top="245" left="194" width="111" height="20" font="1">onal) studies do not </text>
<text top="262" left="194" width="120" height="20" font="1">show a lower BP limit </text>
<text top="279" left="194" width="93" height="20" font="1">below which risk </text>
<text top="296" left="194" width="127" height="20" font="1">ceases to decline (“the </text>
<text top="314" left="194" width="122" height="20" font="1">lower the better”), this </text>
<text top="331" left="194" width="126" height="20" font="1">has not been shown in </text>
<text top="348" left="194" width="97" height="20" font="1">randomized trials </text>
<text top="365" left="194" width="127" height="20" font="1">across a wide range of </text>
<text top="383" left="194" width="23" height="20" font="1">BP. </text>
<text top="400" left="194" width="104" height="20" font="1">Finally, what is the </text>
<text top="417" left="194" width="113" height="20" font="1">quantitative effect of </text>
<text top="434" left="194" width="124" height="20" font="1">taking ≥1 BP-lowering </text>
<text top="451" left="194" width="116" height="20" font="1">drugs in lowering BP </text>
<text top="469" left="194" width="115" height="20" font="1">and preventing CHD </text>
<text top="486" left="194" width="100" height="20" font="1">events and stroke </text>
<text top="503" left="194" width="104" height="20" font="1">according to dose, </text>
<text top="520" left="194" width="120" height="20" font="1">pretreatment BP, and </text>
<text top="537" left="194" width="122" height="20" font="1">age? To date no such </text>
<text top="555" left="194" width="120" height="20" font="1">quantitative summary </text>
<text top="572" left="194" width="87" height="20" font="1">of effect, taking </text>
<text top="589" left="194" width="94" height="20" font="1">account of these </text>
<text top="606" left="194" width="111" height="20" font="1">determining factors, </text>
<text top="623" left="194" width="92" height="20" font="1">has been made. </text>
<text top="641" left="194" width="3" height="20" font="1"> </text>
<text top="658" left="194" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="675" left="194" width="96" height="20" font="1">analysis of RCTs </text>
<text top="692" left="194" width="3" height="20" font="1"> </text>
<text top="710" left="194" width="125" height="20" font="4"><b>Size:</b> 147 RCTs of BP-</text>
<text top="727" left="194" width="107" height="20" font="1">lowering meds and </text>
<text top="744" left="194" width="119" height="20" font="1">CHD events (22,000) </text>
<text top="761" left="194" width="114" height="20" font="1">and stroke (12,000). </text>
<text top="107" left="335" width="169" height="20" font="1">had other interventions as well </text>
<text top="124" left="335" width="139" height="20" font="1">as BP reduction, such as </text>
<text top="141" left="335" width="142" height="20" font="1">cholesterol reduction. We </text>
<text top="159" left="335" width="140" height="20" font="1">excluded trials in pts with </text>
<text top="176" left="335" width="161" height="20" font="1">chronic renal failure because </text>
<text top="193" left="335" width="177" height="20" font="1">these pts typically have high BP </text>
<text top="210" left="335" width="176" height="20" font="1">and high rates of CVD and their </text>
<text top="228" left="335" width="139" height="20" font="1">response to standard BP-</text>
<text top="245" left="335" width="179" height="20" font="1">lowering therapy may differ from </text>
<text top="262" left="335" width="176" height="20" font="1">other people. We also excluded </text>
<text top="279" left="335" width="178" height="20" font="1">trials in which fewer than 5 CHD </text>
<text top="296" left="335" width="137" height="20" font="1">events and strokes were </text>
<text top="314" left="335" width="149" height="20" font="1">recorded or the duration of </text>
<text top="331" left="335" width="167" height="20" font="1">treatment was less than 6 mo, </text>
<text top="348" left="335" width="170" height="20" font="1">as these data would contribute </text>
<text top="365" left="335" width="163" height="20" font="1">little to the overall results and </text>
<text top="383" left="335" width="141" height="20" font="1">substantially increase the </text>
<text top="400" left="335" width="151" height="20" font="1">complexity of the analyses. </text>
<text top="417" left="335" width="170" height="20" font="1">RCTs were otherwise included </text>
<text top="434" left="335" width="167" height="20" font="1">irrespective of pt age, disease </text>
<text top="451" left="335" width="171" height="20" font="1">status, BP before treatment, or </text>
<text top="469" left="335" width="106" height="20" font="1">use of other drugs. </text>
<text top="107" left="909" width="142" height="20" font="1">treating at levels &lt;140 for </text>
<text top="124" left="909" width="140" height="20" font="1">people with CVD than for </text>
<text top="141" left="909" width="116" height="20" font="1">people without CVD. </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">76 </text>
<text top="107" left="98" width="74" height="20" font="1">Lewington S, </text>
<text top="124" left="98" width="64" height="20" font="1">et al., 2002 </text>
<text top="141" left="98" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(16)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12493255?dopt=Citation">12493255</a></text>
<text top="159" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12493255?dopt=Citation"> </a></text>
<text top="107" left="194" width="119" height="20" font="4"><b>Aim:</b> To describe the </text>
<text top="124" left="194" width="126" height="20" font="1">age-specific relevance </text>
<text top="141" left="194" width="128" height="20" font="1">of BP to cause-specific </text>
<text top="159" left="193" width="50" height="20" font="1">mortality </text>
<text top="176" left="194" width="3" height="20" font="1"> </text>
<text top="193" left="194" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="210" left="194" width="99" height="20" font="1">analysis of cohort </text>
<text top="227" left="194" width="42" height="20" font="1">studies </text>
<text top="245" left="194" width="3" height="20" font="1"> </text>
<text top="262" left="194" width="115" height="20" font="4"><b>Size:</b> 61 prospective </text>
<text top="279" left="194" width="95" height="20" font="1">studies with 12.7 </text>
<text top="296" left="194" width="103" height="20" font="1">million person-y of </text>
<text top="314" left="194" width="111" height="20" font="1">observation, 56,000 </text>
<text top="331" left="194" width="123" height="20" font="1">vascular deaths in 40–</text>
<text top="348" left="194" width="30" height="20" font="1">89 y. </text>
<text top="107" left="335" width="182" height="20" font="4"><b>Inclusion criteria: </b>Collaboration </text>
<text top="124" left="335" width="114" height="20" font="1">was sought from the </text>
<text top="141" left="335" width="168" height="20" font="1">investigators of all prospective </text>
<text top="159" left="335" width="167" height="20" font="1">observational studies in which </text>
<text top="176" left="335" width="167" height="20" font="1">data on BP, blood cholesterol, </text>
<text top="193" left="335" width="165" height="20" font="1">date of birth (or age), and sex </text>
<text top="210" left="335" width="180" height="20" font="1">had been recorded at a baseline </text>
<text top="228" left="335" width="156" height="20" font="1">screening visit, and in which </text>
<text top="245" left="335" width="178" height="20" font="1">cause and date of death (or age </text>
<text top="262" left="335" width="157" height="20" font="1">at death) had been routinely </text>
<text top="279" left="335" width="158" height="20" font="1">sought for all screens during </text>
<text top="296" left="335" width="158" height="20" font="1">more than 5,000 person-y of </text>
<text top="314" left="335" width="148" height="20" font="1">follow-up (see appendix A; </text>
<text top="331" left="335" width="175" height="20" font="7"><a href="http://image.thelancet.com/extras/01art8300webappendixA.pdf">http://image.thelancet.com/extra</a></text>
<text top="348" left="335" width="166" height="20" font="7"><a href="http://image.thelancet.com/extras/01art8300webappendixA.pdf">s/01art8300webappendixA.pdf</a></text>
<text top="348" left="501" width="11" height="20" font="1"><a href="http://image.thelancet.com/extras/01art8300webappendixA.pdf">)</a>. </text>
<text top="365" left="335" width="177" height="20" font="1">Relevant studies were identified </text>
<text top="382" left="335" width="167" height="20" font="1">through computer searches of </text>
<text top="400" left="335" width="170" height="20" font="1">Medline and Embase, by hand-</text>
<text top="417" left="335" width="171" height="20" font="1">searches of meeting abstracts, </text>
<text top="434" left="335" width="163" height="20" font="1">and by extensive discussions </text>
<text top="451" left="335" width="105" height="20" font="1">with investigators.  </text>
<text top="469" left="335" width="3" height="20" font="1"> </text>
<text top="486" left="335" width="180" height="20" font="4"><b>Exclusion criteria:</b> To minimize </text>
<text top="503" left="335" width="169" height="20" font="1">the effects of reverse causality </text>
<text top="520" left="335" width="165" height="20" font="1">(whereby established disease </text>
<text top="537" left="335" width="157" height="20" font="1">could change the usual BP), </text>
<text top="555" left="335" width="161" height="20" font="1">studies were excluded if they </text>
<text top="572" left="335" width="176" height="20" font="1">had selected pts on the basis of </text>
<text top="589" left="335" width="160" height="20" font="1">a positive history of stroke or </text>
<text top="606" left="335" width="165" height="20" font="1">heart disease, and individuals </text>
<text top="623" left="335" width="167" height="20" font="1">from contributing studies were </text>
<text top="641" left="335" width="146" height="20" font="1">excluded from the present </text>
<text top="658" left="335" width="152" height="20" font="1">analyses if they had such a </text>
<text top="675" left="335" width="158" height="20" font="1">history recorded at baseline. </text>
<text top="107" left="531" width="105" height="20" font="4"><b>Intervention:</b> N/A  </text>
<text top="124" left="531" width="3" height="20" font="1"> </text>
<text top="141" left="531" width="101" height="20" font="4"><b>Comparator:</b> N/A </text>
<text top="159" left="531" width="3" height="20" font="1"> </text>
<text top="178" left="531" width="7" height="18" font="1">•</text>
<text top="177" left="538" width="146" height="20" font="1"> The exposures of interest </text>
<text top="194" left="531" width="145" height="20" font="1">were the level of SBP and </text>
<text top="211" left="531" width="116" height="20" font="1">DBP and age-group. </text>
<text top="229" left="531" width="3" height="20" font="1"> </text>
<text top="107" left="700" width="79" height="20" font="1">1°<b> endpoint:</b>  </text>
<text top="126" left="700" width="7" height="18" font="1">•</text>
<text top="125" left="707" width="181" height="20" font="1"> Not completely clear, but for our </text>
<text top="143" left="700" width="177" height="20" font="1">purposes, stroke and IHD death </text>
<text top="160" left="700" width="170" height="20" font="1">would be co-1°. Also looked at </text>
<text top="177" left="700" width="124" height="20" font="1">other vascular deaths. </text>
<text top="196" left="700" width="7" height="18" font="1">•</text>
<text top="195" left="707" width="181" height="20" font="1"> HRs for stroke mortality for a 20 </text>
<text top="213" left="700" width="180" height="20" font="1">mm Hg lower SBP by age-group </text>
<text top="230" left="700" width="182" height="20" font="1">40–49: 0.36 (95% CI: 0.32–0.40) </text>
<text top="247" left="700" width="182" height="20" font="1">50–59: 0.38 (95% CI: 0.35–0.40) </text>
<text top="264" left="700" width="182" height="20" font="1">60–69: 0.43 (95% CI: 0.41–0.45) </text>
<text top="282" left="700" width="182" height="20" font="1">70–79: 0.50 (95% CI: 0.48–0.52) </text>
<text top="299" left="700" width="182" height="20" font="1">80–89: 0.67 (95% CI: 0.63–0.71) </text>
<text top="318" left="700" width="7" height="18" font="1">•</text>
<text top="317" left="706" width="168" height="20" font="1"> HRs for IHD mortality for a 20 </text>
<text top="334" left="700" width="180" height="20" font="1">mm Hg lower SBP by age-group </text>
<text top="352" left="700" width="182" height="20" font="1">40–49: 0.49 (95% CI: 0.45–0.53) </text>
<text top="369" left="700" width="182" height="20" font="1">50–59: 0.50 (95% CI: 0.49–0.52) </text>
<text top="386" left="700" width="182" height="20" font="1">60–69: 0.54 (95% CI: 0.53–0.55) </text>
<text top="403" left="700" width="182" height="20" font="1">70–79: 0.60 (95% CI: 0.58–0.61) </text>
<text top="420" left="700" width="182" height="20" font="1">80–89: 0.67 (95% CI: 0.64–0.70) </text>
<text top="439" left="700" width="7" height="18" font="1">•</text>
<text top="439" left="706" width="179" height="20" font="1"> HRs for other vascular mortality </text>
<text top="456" left="700" width="190" height="20" font="1">for a 20 mm Hg lower SBP by age-</text>
<text top="473" left="700" width="35" height="20" font="1">group </text>
<text top="490" left="700" width="182" height="20" font="1">40–49: 0.43 (95% CI: 0.38–0.48) </text>
<text top="508" left="700" width="182" height="20" font="1">50–59: 0.50 (95% CI: 0.47–0.54) </text>
<text top="525" left="700" width="182" height="20" font="1">60–69: 0.53 (95% CI: 0.51–0.56) </text>
<text top="542" left="700" width="182" height="20" font="1">70–79: 0.64 (95% CI: 0.61–0.67) </text>
<text top="559" left="700" width="182" height="20" font="1">80–89: 0.70 (95% CI: 0.65–0.75) </text>
<text top="578" left="700" width="7" height="18" font="1">•</text>
<text top="578" left="706" width="169" height="20" font="1"> Similar results for DBP also in </text>
<text top="595" left="700" width="48" height="20" font="1">figure 1. </text>
<text top="614" left="700" width="7" height="18" font="1">•</text>
<text top="613" left="706" width="153" height="20" font="1"> Similar results for men and </text>
<text top="630" left="700" width="196" height="20" font="1">women separately for stroke, figure </text>
<text top="648" left="700" width="114" height="20" font="1">3, and IHD, figure 5. </text>
<text top="107" left="909" width="170" height="20" font="4"><b>Summary:</b> Throughout middle </text>
<text top="124" left="909" width="136" height="20" font="1">and old age, usual BP is </text>
<text top="141" left="909" width="167" height="20" font="1">strongly and directly related to </text>
<text top="159" left="909" width="174" height="20" font="1">vascular (and overall) mortality, </text>
<text top="176" left="909" width="142" height="20" font="1">without any evidence of a </text>
<text top="193" left="909" width="143" height="20" font="1">threshold down to at least </text>
<text top="210" left="909" width="87" height="20" font="1">115/75 mm Hg. </text>
<text top="693" left="98" width="78" height="20" font="1">Thomopoulos </text>
<text top="710" left="98" width="53" height="20" font="1">C, et al.,  </text>
<text top="727" left="98" width="56" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(20)</a> </text>
<text top="745" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25259547?dopt=Citation">25259547</a></text>
<text top="745" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25259547?dopt=Citation"> </a></text>
<text top="693" left="194" width="103" height="20" font="4"><b>Aim:</b> Investigating </text>
<text top="710" left="194" width="118" height="20" font="1">whether all grades of </text>
<text top="727" left="194" width="117" height="20" font="1">HTN benefit from BP-</text>
<text top="745" left="194" width="129" height="20" font="1">lowering treatment and </text>
<text top="762" left="194" width="111" height="20" font="1">which are the target </text>
<text top="693" left="335" width="166" height="20" font="4"><b>Inclusion criteria:</b> Intentional </text>
<text top="710" left="335" width="166" height="20" font="1">BP-lowering comparing active </text>
<text top="727" left="335" width="173" height="20" font="1">drug treatment with placebo, or </text>
<text top="745" left="335" width="180" height="20" font="1">less active treatment (intentional </text>
<text top="762" left="335" width="121" height="20" font="1">BP-lowering trials), or </text>
<text top="779" left="335" width="161" height="20" font="1">comparison of an active drug </text>
<text top="693" left="531" width="151" height="20" font="4"><b>Intervention/Comparator: </b></text>
<text top="710" left="531" width="137" height="20" font="1">Criteria of eligibility were </text>
<text top="727" left="531" width="129" height="20" font="1">intentional BP-lowering </text>
<text top="745" left="531" width="124" height="20" font="1">comparing active drug </text>
<text top="762" left="531" width="145" height="20" font="1">treatment with placebo, or </text>
<text top="779" left="531" width="116" height="20" font="1">less active treatment </text>
<text top="694" left="700" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="713" left="700" width="7" height="18" font="1">•</text>
<text top="713" left="707" width="185" height="20" font="1"> As some trials were done on low-</text>
<text top="730" left="700" width="184" height="20" font="1">risk pts, others on higher risk pts, </text>
<text top="747" left="700" width="163" height="20" font="1">no evaluation of absolute risk-</text>
<text top="764" left="700" width="182" height="20" font="1">reduction was made. However, a </text>
<text top="781" left="700" width="170" height="20" font="1">2º analysis was done including </text>
<text top="693" left="909" width="146" height="20" font="4"><b>Summary</b>: Meta-analyses </text>
<text top="710" left="909" width="156" height="20" font="1">favor BP-lowering treatment </text>
<text top="727" left="909" width="167" height="20" font="1">even in grade 1 HTN at low-to-</text>
<text top="745" left="909" width="154" height="20" font="1">moderate risk, and lowering </text>
<text top="762" left="909" width="165" height="20" font="1">SBP/DBP to &lt;140/90 mm Hg. </text>
<text top="779" left="909" width="148" height="20" font="1">Achieving &lt;130/80 mm Hg </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">77 </text>
<text top="107" left="194" width="124" height="20" font="1">BP levels to maximize </text>
<text top="124" left="194" width="108" height="20" font="1">outcome reduction. </text>
<text top="141" left="194" width="3" height="20" font="1"> </text>
<text top="159" left="194" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="176" left="194" width="96" height="20" font="1">analysis of RCTs </text>
<text top="193" left="194" width="3" height="20" font="1"> </text>
<text top="210" left="194" width="109" height="20" font="4"><b>Size:</b> 32 RCTs with </text>
<text top="227" left="194" width="71" height="20" font="1">104,359 pts  </text>
<text top="107" left="335" width="148" height="20" font="1">with placebo over baseline </text>
<text top="124" left="335" width="152" height="20" font="1">antihypertensive treatment, </text>
<text top="141" left="335" width="178" height="20" font="1">resulting in a BP difference of at </text>
<text top="159" left="335" width="172" height="20" font="1">least 2 mm Hg in either SBP or </text>
<text top="176" left="335" width="182" height="20" font="1">DBP (nonintentional BP-lowering </text>
<text top="193" left="335" width="174" height="20" font="1">trials); enrolling of hypertensive </text>
<text top="210" left="335" width="138" height="20" font="1">individuals only or a high </text>
<text top="228" left="335" width="152" height="20" font="1">proportion (at least 40%) of </text>
<text top="245" left="335" width="34" height="20" font="1">them. </text>
<text top="262" left="335" width="3" height="20" font="1"> </text>
<text top="279" left="335" width="134" height="20" font="4"><b>Exclusion criteria: </b>N/A </text>
<text top="107" left="531" width="133" height="20" font="1">(intentional BP-lowering </text>
<text top="124" left="531" width="149" height="20" font="1">trials), or comparison of an </text>
<text top="141" left="531" width="135" height="20" font="1">active drug with placebo </text>
<text top="159" left="531" width="76" height="20" font="1">over baseline </text>
<text top="176" left="531" width="152" height="20" font="1">antihypertensive treatment, </text>
<text top="193" left="531" width="150" height="20" font="1">resulting in a BP difference </text>
<text top="210" left="531" width="123" height="20" font="1">of at least 2 mm Hg in </text>
<text top="228" left="531" width="105" height="20" font="1">either SBP or DBP </text>
<text top="245" left="531" width="154" height="20" font="1">(nonintentional BP-lowering </text>
<text top="262" left="531" width="100" height="20" font="1">trials); enrolling of </text>
<text top="279" left="531" width="134" height="20" font="1">hypertensive individuals </text>
<text top="296" left="531" width="154" height="20" font="1">only or a high proportion (at </text>
<text top="314" left="531" width="143" height="20" font="1">least 40%) of them. Other </text>
<text top="331" left="531" width="132" height="20" font="1">inclusion criteria can be </text>
<text top="348" left="531" width="125" height="20" font="1">found in the preceding </text>
<text top="365" left="531" width="149" height="20" font="1">paper. 51 trials were found </text>
<text top="383" left="531" width="152" height="20" font="1">eligible either for assessing </text>
<text top="400" left="531" width="122" height="20" font="1">BP-lowering effects in </text>
<text top="417" left="531" width="150" height="20" font="1">different HTN grades or for </text>
<text top="434" left="531" width="132" height="20" font="1">assessing the effects of </text>
<text top="451" left="531" width="123" height="20" font="1">achieving different BP </text>
<text top="469" left="531" width="35" height="20" font="1">levels </text>
<text top="107" left="700" width="187" height="20" font="1">trials or trial subgroups with mean </text>
<text top="124" left="700" width="193" height="20" font="1">baseline SBP/DBP values in grade </text>
<text top="141" left="700" width="194" height="20" font="1">1 range and a low-to-moderate risk </text>
<text top="159" left="700" width="146" height="20" font="1">(&lt;5% CV deaths in 10 y in </text>
<text top="176" left="700" width="168" height="20" font="1">controls): FEVER stratum with </text>
<text top="193" left="700" width="177" height="20" font="1">baseline SBP below the median </text>
<text top="210" left="700" width="195" height="20" font="1">(&lt;153 mm Hg) (e7); HTN Detection </text>
<text top="228" left="700" width="176" height="20" font="1">and Follow-up Program stratum </text>
<text top="245" left="700" width="184" height="20" font="1">with baseline DBP 90–94 mm Hg </text>
<text top="262" left="700" width="172" height="20" font="1">and no CVD (e9); OSLO (e17); </text>
<text top="279" left="700" width="185" height="20" font="1">TOMHS (e28) and USPHS (e29). </text>
<text top="296" left="700" width="141" height="20" font="1">Risks of stroke, CHD, the </text>
<text top="314" left="700" width="192" height="20" font="1">composite of stroke and CHD, and </text>
<text top="331" left="700" width="184" height="20" font="1">all-cause death were significantly </text>
<text top="348" left="700" width="180" height="20" font="1">reduced by BP-lowering in these </text>
<text top="365" left="700" width="179" height="20" font="1">low-to-moderate risk pts (control </text>
<text top="383" left="700" width="188" height="20" font="1">group: average CV mortality 4.5% </text>
<text top="400" left="700" width="151" height="20" font="1">in10 y) with a moderate BP </text>
<text top="417" left="700" width="161" height="20" font="1">elevation (average SBP/DBP </text>
<text top="434" left="700" width="196" height="20" font="1">145.5/91 mm Hg) at randomization. </text>
<text top="451" left="700" width="188" height="20" font="1">Standardized risk ratio associated </text>
<text top="469" left="700" width="180" height="20" font="1">with 10/5 reduction in BP: stroke </text>
<text top="486" left="700" width="144" height="20" font="1">0.33 (95% CI: 0.11–0.98)  </text>
<text top="503" left="700" width="171" height="20" font="1">CHD 0.68 (95% CI: 0.48–0.95) </text>
<text top="520" left="700" width="173" height="20" font="1">CVD death 0.57 (95% CI: 0.32–</text>
<text top="537" left="700" width="183" height="20" font="1">1.02) total death 0.53 (95% 0.35–</text>
<text top="555" left="700" width="31" height="20" font="1">0.80) </text>
<text top="574" left="700" width="7" height="18" font="1">•</text>
<text top="573" left="707" width="187" height="20" font="1"> Compared outcomes of achieved </text>
<text top="590" left="700" width="160" height="20" font="1">on study SBP &lt;130 vs. ≥130 </text>
<text top="607" left="700" width="193" height="20" font="1">Standardized Risk ratio associated </text>
<text top="625" left="700" width="180" height="20" font="1">with 10/5 reduction in BP: stroke </text>
<text top="642" left="700" width="144" height="20" font="1">0.68 (95% CI: 0.57, 0.83)  </text>
<text top="659" left="700" width="171" height="20" font="1">CHD 0.87 (95% CI: 0.76, 1.00) </text>
<text top="676" left="700" width="161" height="20" font="1">HF 0.92 (95% CI: 0.47, 1.77) </text>
<text top="693" left="700" width="170" height="20" font="1">CVD 0.81 (95% CI: 0.67, 1.00) </text>
<text top="711" left="700" width="173" height="20" font="1">CVD death 0.88 (95% CI: 0.77, </text>
<text top="728" left="700" width="171" height="20" font="1">1.01) total death 0.88 (95% CI: </text>
<text top="745" left="700" width="62" height="20" font="1">0.77, 0.99) </text>
<text top="764" left="700" width="7" height="18" font="1">•</text>
<text top="763" left="707" width="179" height="20" font="1"> Outcomes of achieved on study </text>
<text top="781" left="700" width="131" height="20" font="1">SBP 130–139 vs. ≥140 </text>
<text top="107" left="909" width="154" height="20" font="1">appears safe, but only adds </text>
<text top="124" left="909" width="146" height="20" font="1">further reduction in stroke. </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">78 </text>
<text top="107" left="700" width="193" height="20" font="1">Standardized Risk ratio associated </text>
<text top="124" left="700" width="180" height="20" font="1">with 10/5 reduction in BP: stroke </text>
<text top="141" left="700" width="144" height="20" font="1">0.63 (95% CI: 0.52–0.77)  </text>
<text top="159" left="700" width="171" height="20" font="1">CHD 0.77 (95% CI: 0.70–0.86) </text>
<text top="176" left="700" width="161" height="20" font="1">HF 0.76 (95% CI: 0.47–1.25) </text>
<text top="193" left="700" width="170" height="20" font="1">CVD 0.74 (95% CI: 0.62–0.88) </text>
<text top="210" left="700" width="173" height="20" font="1">CVD death 0.81 (95% CI: 0.67–</text>
<text top="228" left="700" width="171" height="20" font="1">0.97) total death 0.87 (95% CI: </text>
<text top="245" left="700" width="62" height="20" font="1">0.75–1.00) </text>
<text top="264" left="700" width="7" height="18" font="1">•</text>
<text top="263" left="707" width="174" height="20" font="1"> Similar pattern of results for on </text>
<text top="280" left="700" width="87" height="20" font="1">treatment DBP.<b> </b></text>
<text top="298" left="98" width="70" height="20" font="1">Lonn EM, et </text>
<text top="316" left="98" width="83" height="20" font="1">al., 2016 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(116)</a> </text>
<text top="333" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27041480">27041480</a></text>
<text top="333" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27041480"> </a></text>
<text top="298" left="194" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="316" left="194" width="119" height="20" font="1">efficacy of fixed-dose </text>
<text top="333" left="194" width="93" height="20" font="1">antihypertensive </text>
<text top="350" left="194" width="119" height="20" font="1">therapy in adults with </text>
<text top="367" left="194" width="127" height="20" font="1">intermediate CVD risk. </text>
<text top="384" left="194" width="3" height="20" font="1"> </text>
<text top="402" left="194" width="113" height="20" font="4"><b>Study type</b>: Double-</text>
<text top="419" left="194" width="80" height="20" font="1">blind, placebo-</text>
<text top="436" left="194" width="89" height="20" font="1">controlled RCT, </text>
<text top="453" left="194" width="86" height="20" font="1">factorial design </text>
<text top="470" left="194" width="3" height="20" font="1"> </text>
<text top="488" left="194" width="92" height="20" font="4"><b>Size</b>: 12,705 pts </text>
<text top="298" left="335" width="168" height="20" font="4"><b>Inclusion criteria: </b>Men ≥55 y </text>
<text top="316" left="335" width="116" height="20" font="1">and women ≥60 y at </text>
<text top="333" left="335" width="163" height="20" font="1">intermediate risk for CVD. No </text>
<text top="350" left="335" width="86" height="20" font="1">BP restrictions. </text>
<text top="367" left="335" width="3" height="20" font="1"> </text>
<text top="384" left="335" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="403" left="335" width="7" height="18" font="1">•</text>
<text top="403" left="342" width="74" height="20" font="1"> Known CVD </text>
<text top="422" left="335" width="7" height="18" font="1">•</text>
<text top="421" left="342" width="176" height="20" font="1"> Indications or contraindications </text>
<text top="438" left="335" width="80" height="20" font="1">to study meds </text>
<text top="457" left="335" width="7" height="18" font="1">•</text>
<text top="457" left="342" width="117" height="20" font="1"> Mod/advanced CKD </text>
<text top="476" left="335" width="7" height="18" font="1">•</text>
<text top="475" left="342" width="148" height="20" font="1"> Symptomatic hypotension </text>
<text top="298" left="531" width="149" height="20" font="4"><b>Intervention: </b>FDC of ARB </text>
<text top="316" left="531" width="151" height="20" font="1">(candesartan 16 mg/d) and </text>
<text top="333" left="531" width="43" height="20" font="1">diuretic </text>
<text top="350" left="531" width="141" height="20" font="1">(hydrochlorothiazide 12.5 </text>
<text top="367" left="531" width="96" height="20" font="1">mg/d) or placebo </text>
<text top="384" left="531" width="3" height="20" font="1"> </text>
<text top="402" left="531" width="143" height="20" font="4"><b>Follow-up</b>: Median=5.6 y </text>
<text top="299" left="700" width="149" height="20" font="4"><b>1</b>°<b> endpoint: </b>1 co-1° CVD </text>
<text top="317" left="700" width="116" height="20" font="1">composite outcomes </text>
<text top="336" left="700" width="7" height="18" font="1">•</text>
<text top="335" left="707" width="154" height="20" font="1"> CVD mortality, nonfatal MI, </text>
<text top="352" left="700" width="84" height="20" font="1">nonfatal stroke<b> </b></text>
<text top="371" left="700" width="7" height="18" font="1">•</text>
<text top="371" left="707" width="172" height="20" font="1"> Above plus cardiac arrest, HF, </text>
<text top="388" left="700" width="96" height="20" font="1">revascularization<b> </b></text>
<text top="298" left="909" width="64" height="20" font="4"><b>Summary:</b> </text>
<text top="317" left="909" width="7" height="18" font="1">•</text>
<text top="317" left="916" width="128" height="20" font="1"> SBP/DBP reduction of </text>
<text top="334" left="909" width="84" height="20" font="1">6.0/3.0 mm Hg </text>
<text top="351" left="909" width="3" height="20" font="1"> </text>
<text top="370" left="909" width="7" height="18" font="1">•</text>
<text top="370" left="916" width="148" height="20" font="1"> No difference in treatment </text>
<text top="387" left="909" width="33" height="20" font="1">effect </text>
<text top="406" left="909" width="7" height="18" font="1">•</text>
<text top="405" left="916" width="57" height="20" font="1"> 1st co-1° </text>
<text top="422" left="909" width="97" height="20" font="1"> 0.93 (0.79–1.10) </text>
<text top="441" left="909" width="7" height="18" font="1">•</text>
<text top="441" left="916" width="61" height="20" font="1"> 2nd co-1° </text>
<text top="458" left="909" width="97" height="20" font="1"> 0.95 (0.81–1.11) </text>
<text top="475" left="909" width="3" height="20" font="1"> </text>
<text top="494" left="909" width="7" height="18" font="1">•</text>
<text top="493" left="916" width="147" height="20" font="1"> Suggestion of a subgroup </text>
<text top="511" left="909" width="169" height="20" font="1">effect in tertile with the highest </text>
<text top="528" left="909" width="150" height="20" font="1">baseline BP and increased </text>
<text top="545" left="909" width="59" height="20" font="1">CVD risk.  </text>
<text top="563" left="98" width="75" height="20" font="1">Neaton JD et </text>
<text top="580" left="98" width="54" height="20" font="1">al., 1993  </text>
<text top="597" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(117)</a> </text>
<text top="615" left="98" width="48" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8336373">8336373</a></text>
<text top="615" left="145" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8336373"> </a></text>
<text top="563" left="194" width="110" height="20" font="4"><b>Aim: </b>To compare 6 </text>
<text top="580" left="194" width="127" height="20" font="1">antihypertensive drugs </text>
<text top="597" left="194" width="124" height="20" font="1">(representing different </text>
<text top="615" left="194" width="80" height="20" font="1">drug classes)  </text>
<text top="632" left="194" width="3" height="20" font="4"><b> </b></text>
<text top="649" left="194" width="114" height="20" font="4"><b>Study type: </b>Double-</text>
<text top="666" left="194" width="80" height="20" font="1">blind, placebo-</text>
<text top="683" left="194" width="89" height="20" font="1">controlled RCT  </text>
<text top="701" left="194" width="3" height="20" font="4"><b> </b></text>
<text top="718" left="194" width="101" height="20" font="4"><b>Size: </b>902 pts with </text>
<text top="735" left="194" width="73" height="20" font="1">stage 1 HTN </text>
<text top="563" left="335" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="582" left="335" width="7" height="18" font="1">•</text>
<text top="581" left="342" width="145" height="20" font="1"> Men and women 45–69 y<b> </b></text>
<text top="600" left="335" width="7" height="18" font="1">•</text>
<text top="600" left="342" width="155" height="20" font="1"> Not taking antihypertensive </text>
<text top="617" left="335" width="164" height="20" font="1">medications, with DBP 90–99 </text>
<text top="634" left="335" width="43" height="20" font="1">mm Hg </text>
<text top="653" left="335" width="7" height="18" font="1">•</text>
<text top="653" left="342" width="147" height="20" font="1"> Taking 1 antihypertensive </text>
<text top="670" left="335" width="168" height="20" font="1">medication, with DBP &lt;95 mm </text>
<text top="687" left="335" width="173" height="20" font="1">Hg and between 85–99 mm Hg </text>
<text top="704" left="335" width="123" height="20" font="1">after withdrawal of BP </text>
<text top="721" left="335" width="69" height="20" font="1">medications </text>
<text top="563" left="531" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="580" left="531" width="116" height="20" font="1">Treatment (number): </text>
<text top="597" left="531" width="95" height="20" font="1">Once daily (AM): </text>
<text top="616" left="531" width="7" height="18" font="1">•</text>
<text top="616" left="538" width="84" height="20" font="1"> Placebo (234) </text>
<text top="635" left="531" width="7" height="18" font="1">•</text>
<text top="634" left="538" width="134" height="20" font="1"> Chlorthalidone 15 mg/d </text>
<text top="651" left="531" width="32" height="20" font="1">(136) </text>
<text top="670" left="531" width="7" height="18" font="1">•</text>
<text top="670" left="538" width="119" height="20" font="1"> Acebutolol 400 mg/d </text>
<text top="687" left="531" width="32" height="20" font="1">(132) </text>
<text top="706" left="531" width="7" height="18" font="1">•</text>
<text top="705" left="538" width="138" height="20" font="1"> Doxazosin 2 mg/d (134) </text>
<text top="724" left="531" width="7" height="18" font="1">•</text>
<text top="724" left="538" width="141" height="20" font="1"> Amlodipine 5 mg/d (131) </text>
<text top="743" left="531" width="7" height="18" font="1">•</text>
<text top="742" left="538" width="128" height="20" font="1"> Enalapril 5 mg/d (135) </text>
<text top="759" left="531" width="3" height="20" font="1"> </text>
<text top="776" left="531" width="143" height="20" font="4"><b>Follow-up</b>: Median=4.4 y </text>
<text top="564" left="700" width="155" height="20" font="4"><b>1</b>°<b> endpoint: </b>BP, QoL, side </text>
<text top="581" left="700" width="186" height="20" font="1">effects, chemistries, ECG, clinical </text>
<text top="599" left="700" width="43" height="20" font="1">events  </text>
<text top="563" left="909" width="64" height="20" font="4"><b>Summary:</b> </text>
<text top="582" left="909" width="7" height="18" font="1">•</text>
<text top="581" left="916" width="129" height="20" font="1"> Drugs (plus diet) more </text>
<text top="599" left="909" width="167" height="20" font="1">effective compared to placebo </text>
<text top="616" left="909" width="152" height="20" font="1">(plus diet) for control of BP. </text>
<text top="635" left="909" width="7" height="18" font="1">•</text>
<text top="634" left="916" width="163" height="20" font="1"> Minimal differences between </text>
<text top="651" left="909" width="82" height="20" font="1">drug regimens<b> </b></text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="15" size="12" family="Times" color="#292526"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">79 </text>
<text top="107" left="98" width="80" height="20" font="1">Van Dieren S, </text>
<text top="124" left="98" width="64" height="20" font="1">et al., 2012 </text>
<text top="141" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(118)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22677192?dopt=Citation">22677192</a></text>
<text top="159" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22677192?dopt=Citation"> </a></text>
<text top="107" left="194" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="124" left="194" width="76" height="20" font="1">differences in </text>
<text top="141" left="194" width="119" height="20" font="1">treatment effects of a </text>
<text top="159" left="194" width="113" height="20" font="1">fixed combination of </text>
<text top="176" left="194" width="64" height="20" font="1">perindopril–</text>
<text top="193" left="194" width="118" height="20" font="1">indapamide on major </text>
<text top="210" left="194" width="110" height="20" font="1">clinical outcomes in </text>
<text top="228" left="194" width="104" height="20" font="1">pts with type 2 DM </text>
<text top="245" left="194" width="114" height="20" font="1">across subgroups of </text>
<text top="262" left="194" width="46" height="20" font="1">CV risk. </text>
<text top="279" left="194" width="3" height="20" font="1"> </text>
<text top="296" left="194" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="314" left="194" width="3" height="20" font="1"> </text>
<text top="331" left="194" width="118" height="20" font="4"><b>Size:</b> 11,140 pts with </text>
<text top="348" left="194" width="85" height="20" font="1">DM-2, from the </text>
<text top="365" left="194" width="86" height="20" font="1">ADVANCE trial </text>
<text top="107" left="335" width="174" height="20" font="4"><b>Inclusion criteria:</b> DM-2, aged </text>
<text top="124" left="335" width="161" height="20" font="1">≥55 y, with a history of major </text>
<text top="141" left="335" width="177" height="20" font="1">macrovascular or microvascular </text>
<text top="159" left="335" width="171" height="20" font="1">disease, or at least 1 other risk </text>
<text top="176" left="335" width="147" height="20" font="1">factor for vascular disease </text>
<text top="193" left="335" width="3" height="20" font="1"> </text>
<text top="210" left="335" width="165" height="20" font="4"><b>Exclusion criteria:</b> A definite </text>
<text top="227" left="335" width="180" height="20" font="1">indication for, or contraindication </text>
<text top="245" left="335" width="183" height="20" font="1">to, any of the study treatments, a </text>
<text top="262" left="335" width="171" height="20" font="1">definite indication for long-term </text>
<text top="279" left="335" width="138" height="20" font="1">insulin treatment or were </text>
<text top="296" left="335" width="178" height="20" font="1">participating in any other clinical </text>
<text top="314" left="335" width="27" height="20" font="1">trial. </text>
<text top="107" left="531" width="144" height="20" font="4"><b>Intervention:</b> Perindopril–</text>
<text top="124" left="531" width="135" height="20" font="1">indapamide or matching </text>
<text top="141" left="531" width="46" height="20" font="1">placebo </text>
<text top="108" left="700" width="76" height="20" font="4"><b>1</b>°<b> endpoint: </b></text>
<text top="127" left="700" width="7" height="18" font="1">•</text>
<text top="127" left="707" width="176" height="20" font="1"> The Framingham equation was </text>
<text top="144" left="700" width="192" height="20" font="1">used to calculate 5-y CVD risk and </text>
<text top="161" left="700" width="172" height="20" font="1">to divide participants into 2 risk </text>
<text top="178" left="700" width="164" height="20" font="1">groups, moderate-to-high risk </text>
<text top="195" left="700" width="134" height="20" font="1">(&lt;25% and no history of </text>
<text top="213" left="700" width="190" height="20" font="1">macrovascular disease), very high </text>
<text top="230" left="700" width="153" height="20" font="1">risk (&gt;25% and/or history of </text>
<text top="247" left="700" width="137" height="20" font="1">macrovascular disease). </text>
<text top="266" left="700" width="7" height="18" font="1">•</text>
<text top="266" left="707" width="175" height="20" font="1"> Endpoints were macrovascular </text>
<text top="283" left="700" width="146" height="20" font="1">and microvascular events. </text>
<text top="107" left="909" width="164" height="20" font="4"><b>Summary</b>: Relative effects of </text>
<text top="124" left="909" width="159" height="20" font="1">BP-lowering with perindopril–</text>
<text top="141" left="909" width="161" height="20" font="1">indapamide on CV outcomes </text>
<text top="159" left="909" width="172" height="20" font="1">were similar across risk groups </text>
<text top="176" left="909" width="169" height="20" font="1">whilst absolute effects trended </text>
<text top="193" left="909" width="157" height="20" font="1">to be greater in the high-risk </text>
<text top="210" left="909" width="38" height="20" font="1">group. </text>
<text top="383" left="98" width="72" height="20" font="1">Montgomery </text>
<text top="400" left="98" width="60" height="20" font="1">AA, et al.,  </text>
<text top="418" left="98" width="66" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(119)</a>  </text>
<text top="435" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12923409?dopt=Citation">12923409</a></text>
<text top="435" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12923409?dopt=Citation"> </a></text>
<text top="383" left="194" width="119" height="20" font="4"><b>Aim:</b> To estimate the </text>
<text top="400" left="194" width="99" height="20" font="1">effectiveness and </text>
<text top="418" left="194" width="115" height="20" font="1">cost-effectiveness of </text>
<text top="435" left="194" width="125" height="20" font="1">BP-lowering treatment </text>
<text top="452" left="194" width="83" height="20" font="1">over a lifetime. </text>
<text top="469" left="194" width="3" height="20" font="1"> </text>
<text top="487" left="194" width="114" height="20" font="4"><b>Study type:</b> Markov </text>
<text top="504" left="194" width="96" height="20" font="1">decision analysis </text>
<text top="521" left="194" width="98" height="20" font="1">model comparing </text>
<text top="538" left="194" width="79" height="20" font="1">treatment and </text>
<text top="555" left="194" width="122" height="20" font="1">nontreatment of HTN. </text>
<text top="573" left="194" width="3" height="20" font="1"> </text>
<text top="590" left="194" width="103" height="20" font="4"><b>Size:</b> Hypothetical </text>
<text top="607" left="194" width="127" height="20" font="1">cohorts for 20 different </text>
<text top="624" left="194" width="122" height="20" font="1">strata of sex, age (30–</text>
<text top="641" left="194" width="115" height="20" font="1">79 y, in 10-y bands), </text>
<text top="659" left="194" width="117" height="20" font="1">and CV risk (low and </text>
<text top="676" left="194" width="31" height="20" font="1">high) </text>
<text top="383" left="335" width="172" height="20" font="4"><b>Inclusion criteria:</b> We created </text>
<text top="400" left="335" width="174" height="20" font="1">models for 20 different strata of </text>
<text top="418" left="335" width="165" height="20" font="1">sex, age (age 30–70 y in 10-y </text>
<text top="435" left="335" width="144" height="20" font="1">bands), and 2 risk profiles </text>
<text top="452" left="335" width="167" height="20" font="1">(designated as ‘low’ and ‘high’ </text>
<text top="469" left="335" width="140" height="20" font="1">risk). These example risk </text>
<text top="487" left="335" width="173" height="20" font="1">profiles represent the extremes </text>
<text top="504" left="335" width="164" height="20" font="1">of absolute CV risk, based on </text>
<text top="521" left="335" width="174" height="20" font="1">data from the Health Survey for </text>
<text top="538" left="335" width="115" height="20" font="1">England and using a </text>
<text top="555" left="335" width="167" height="20" font="1">Framingham risk function. We </text>
<text top="573" left="335" width="167" height="20" font="1">recognize that the risk of most </text>
<text top="590" left="335" width="176" height="20" font="1">individuals seen in primary care </text>
<text top="607" left="335" width="175" height="20" font="1">will be somewhere between the </text>
<text top="624" left="335" width="170" height="20" font="1">examples presented here. The </text>
<text top="641" left="335" width="167" height="20" font="1">data included were as follows: </text>
<text top="659" left="335" width="182" height="20" font="1">age- and sex-specific mean SBP </text>
<text top="676" left="335" width="155" height="20" font="1">of untreated individuals with </text>
<text top="693" left="335" width="169" height="20" font="1">SBP&gt;0.160 mm Hg were used </text>
<text top="710" left="335" width="164" height="20" font="1">for both high-risk and low-risk </text>
<text top="727" left="335" width="155" height="20" font="1">profiles. In addition, low-risk </text>
<text top="745" left="335" width="122" height="20" font="1">profile was defined as </text>
<text top="762" left="335" width="178" height="20" font="1">nonsmoker, 10th percentile total </text>
<text top="779" left="335" width="175" height="20" font="1">cholesterol 90th percentile HDL </text>
<text top="383" left="531" width="137" height="20" font="4"><b>Intervention:</b> Treatment </text>
<text top="400" left="531" width="146" height="20" font="1">and nontreatment of HTN. </text>
<text top="384" left="700" width="192" height="20" font="4"><b>1</b>°<b> endpoint:</b> Life expectancy, and </text>
<text top="402" left="700" width="172" height="20" font="1">incremental cost: effectiveness </text>
<text top="419" left="700" width="131" height="20" font="1">ratios for treatment and </text>
<text top="436" left="700" width="133" height="20" font="1">nontreatment strategies </text>
<text top="385" left="909" width="7" height="18" font="1">•</text>
<text top="384" left="916" width="167" height="20" font="1"> Probabilities of clinical events </text>
<text top="402" left="909" width="165" height="20" font="1">were obtained from published </text>
<text top="419" left="909" width="55" height="20" font="1">literature. </text>
<text top="436" left="909" width="3" height="20" font="1"> </text>
<text top="453" left="909" width="63" height="20" font="4"><b>Summary</b>: </text>
<text top="472" left="909" width="7" height="18" font="1">•</text>
<text top="472" left="916" width="158" height="20" font="1"> Incremental cost per quality-</text>
<text top="489" left="909" width="165" height="20" font="1">adjusted life y among low-risk </text>
<text top="506" left="909" width="166" height="20" font="1">groups ranged from £1,030 to </text>
<text top="523" left="909" width="149" height="20" font="1">£3,304. Cost-effectiveness </text>
<text top="540" left="909" width="152" height="20" font="1">results for low-risk pts were </text>
<text top="558" left="909" width="130" height="20" font="1">sensitive to the utility of </text>
<text top="575" left="909" width="145" height="20" font="1">receiving antihypertensive </text>
<text top="592" left="909" width="159" height="20" font="1">treatment. Treatment of high-</text>
<text top="609" left="909" width="171" height="20" font="1">risk individuals was highly cost-</text>
<text top="627" left="909" width="161" height="20" font="1">effective, such that it was the </text>
<text top="644" left="909" width="171" height="20" font="1">dominant strategy in the oldest </text>
<text top="661" left="909" width="146" height="20" font="1">age group, and resulted in </text>
<text top="678" left="909" width="160" height="20" font="1">incremental costs per quality-</text>
<text top="695" left="909" width="151" height="20" font="1">adjusted life y ranging from </text>
<text top="713" left="909" width="143" height="20" font="1">£34–£265 in younger age </text>
<text top="730" left="909" width="44" height="20" font="1">groups. </text>
<text top="749" left="909" width="7" height="18" font="1">•</text>
<text top="748" left="916" width="3" height="20" font="1"> </text>
<text top="748" left="919" width="160" height="20" font="15">Policy decisions about which </text>
<text top="765" left="909" width="170" height="20" font="15">pts to treat depend on whether </text>
<text top="783" left="909" width="137" height="20" font="15">a life-expectancy or cost-</text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="16" size="12" family="Times" color="#231f20"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">80 </text>
<text top="107" left="335" width="181" height="20" font="1">cholesterol, no DM, and no LVH, </text>
<text top="124" left="335" width="180" height="20" font="1">and high-risk profile was defined </text>
<text top="141" left="335" width="174" height="20" font="1">as smoker, 90th percentile total </text>
<text top="159" left="335" width="178" height="20" font="1">cholesterol, 10th percentile HDL </text>
<text top="176" left="335" width="147" height="20" font="1">cholesterol, DM, and LVH. </text>
<text top="193" left="335" width="3" height="20" font="4"><b> </b></text>
<text top="210" left="335" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="107" left="909" width="154" height="20" font="15">effectiveness perspective is </text>
<text top="124" left="909" width="172" height="20" font="15">taken. Treatment increases life </text>
<text top="141" left="909" width="170" height="20" font="15">expectancy in all strata of age, </text>
<text top="159" left="909" width="152" height="20" font="15">sex, and CV risk. However, </text>
<text top="176" left="909" width="156" height="20" font="15">younger individuals stand to </text>
<text top="193" left="909" width="171" height="20" font="15">gain proportionately more from </text>
<text top="210" left="909" width="140" height="20" font="15">BP treatment than do the </text>
<text top="228" left="909" width="131" height="20" font="15">elderly. In terms of cost-</text>
<text top="245" left="909" width="161" height="20" font="15">effectiveness, pts at high risk </text>
<text top="262" left="909" width="14" height="20" font="15">of </text>
<text top="262" left="923" width="26" height="20" font="1">CVD</text>
<text top="262" left="948" width="97" height="20" font="15"> are a highly cost-</text>
<text top="279" left="909" width="163" height="20" font="15">effective group to treat. In pts </text>
<text top="296" left="909" width="115" height="20" font="15">at lower risk of CVD, </text>
<text top="314" left="909" width="166" height="20" font="15">consideration should be given </text>
<text top="331" left="909" width="165" height="20" font="15">to issues of pt preference and </text>
<text top="348" left="909" width="29" height="20" font="15">cost. </text>
<text top="366" left="98" width="69" height="20" font="1">Kassai B, et </text>
<text top="383" left="98" width="83" height="20" font="1">al., 2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(120)</a> </text>
<text top="400" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17315403?dopt=Citation">17315403</a></text>
<text top="400" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17315403?dopt=Citation"> </a></text>
<text top="366" left="194" width="124" height="20" font="4"><b>Aim:</b> Consideration of </text>
<text top="383" left="194" width="126" height="20" font="1">absolute risk has been </text>
<text top="400" left="194" width="100" height="20" font="1">recommended for </text>
<text top="418" left="194" width="98" height="20" font="1">making decisions </text>
<text top="435" left="194" width="124" height="20" font="1">concerning preventive </text>
<text top="452" left="194" width="125" height="20" font="1">treatment in HTN. Aim </text>
<text top="469" left="194" width="124" height="20" font="1">to estimate the benefit </text>
<text top="487" left="194" width="107" height="20" font="1">of antihypertensive </text>
<text top="504" left="194" width="102" height="20" font="1">therapy over a life-</text>
<text top="521" left="194" width="30" height="20" font="1">time. </text>
<text top="538" left="194" width="3" height="20" font="1"> </text>
<text top="555" left="194" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="573" left="194" width="120" height="20" font="1">analysis on individual </text>
<text top="590" left="194" width="93" height="20" font="1">data in HTN and </text>
<text top="607" left="194" width="128" height="20" font="1">specific cause of death </text>
<text top="624" left="194" width="128" height="20" font="1">from national statistics. </text>
<text top="641" left="194" width="118" height="20" font="1">Disease-free survival </text>
<text top="659" left="194" width="101" height="20" font="1">curves until all pts </text>
<text top="676" left="194" width="113" height="20" font="1">have died were built </text>
<text top="693" left="194" width="111" height="20" font="1">using the “life-table” </text>
<text top="710" left="194" width="128" height="20" font="1">method. The treatment </text>
<text top="727" left="194" width="118" height="20" font="1">effect estimated from </text>
<text top="745" left="194" width="118" height="20" font="1">INDANA was applied </text>
<text top="762" left="194" width="120" height="20" font="1">to this curve to obtain </text>
<text top="779" left="194" width="92" height="20" font="1">the disease-free </text>
<text top="366" left="335" width="174" height="20" font="4"><b>Inclusion criteria:</b> To estimate </text>
<text top="383" left="335" width="143" height="20" font="1">the rate of cv and non-CV </text>
<text top="400" left="335" width="160" height="20" font="1">deaths in a hypothetical U.S. </text>
<text top="418" left="335" width="129" height="20" font="1">population of untreated </text>
<text top="435" left="335" width="166" height="20" font="1">hypertensive pts, we used the </text>
<text top="452" left="335" width="182" height="20" font="1">following procedure: age-specific </text>
<text top="469" left="335" width="170" height="20" font="1">death rates in the U.S. general </text>
<text top="487" left="335" width="169" height="20" font="1">population were obtained from </text>
<text top="504" left="335" width="165" height="20" font="1">national vital statistics (1994), </text>
<text top="521" left="335" width="165" height="20" font="1">and in untreated hypertensive </text>
<text top="538" left="335" width="167" height="20" font="1">population they were obtained </text>
<text top="555" left="335" width="164" height="20" font="1">from the control groups of the </text>
<text top="573" left="335" width="165" height="20" font="1">INDANA database. This latter </text>
<text top="590" left="335" width="147" height="20" font="1">group represents a unique </text>
<text top="607" left="335" width="162" height="20" font="1">cohort of 14 942 untreated or </text>
<text top="624" left="335" width="162" height="20" font="1">placebo-treated hypertensive </text>
<text top="641" left="335" width="161" height="20" font="1">pts, 26–96 y with an average </text>
<text top="659" left="335" width="90" height="20" font="1">follow-up of 5 y  </text>
<text top="676" left="335" width="3" height="20" font="1"> </text>
<text top="693" left="335" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="366" left="531" width="142" height="20" font="4"><b>Intervention:</b> The gain in </text>
<text top="383" left="531" width="127" height="20" font="1">life expectancy without </text>
<text top="400" left="531" width="118" height="20" font="1">stroke, CHD, and CV </text>
<text top="418" left="531" width="150" height="20" font="1">events was estimated from </text>
<text top="435" left="531" width="129" height="20" font="1">the area between the 2 </text>
<text top="452" left="531" width="140" height="20" font="1">survival curves of treated </text>
<text top="469" left="531" width="133" height="20" font="1">and control groups. The </text>
<text top="487" left="531" width="102" height="20" font="1">relative gain in life </text>
<text top="504" left="531" width="151" height="20" font="1">expectancy was defined as </text>
<text top="521" left="531" width="120" height="20" font="1">the ratio of gain in life </text>
<text top="538" left="531" width="98" height="20" font="1">expectancy to life </text>
<text top="555" left="531" width="69" height="20" font="1">expectancy.<b> </b></text>
<text top="367" left="700" width="186" height="20" font="4"><b>1</b>°<b> endpoint:</b> Stroke and CHD co-</text>
<text top="384" left="700" width="16" height="20" font="1">1° </text>
<text top="402" left="700" width="3" height="20" font="4"><b> </b></text>
<text top="419" left="700" width="52" height="20" font="4"><b>Results: </b></text>
<text top="436" left="700" width="26" height="20" font="1">CHD</text>
<text top="436" left="726" width="7" height="20" font="16"><b>  </b></text>
<text top="453" left="700" width="161" height="20" font="16"><b>Age         AB</b>b          <b>RGLE</b>e <b> </b></text>
<text top="470" left="700" width="176" height="20" font="16"><b>Y     RR</b>a <b>(%)  NNT</b>c <b>GLE</b>d <b>(%)  </b></text>
<text top="488" left="700" width="171" height="20" font="9">40   0.86  0.3  333        20  4.1  </text>
<text top="505" left="700" width="171" height="20" font="9">50   0.88  1.0  100        17  4.3  </text>
<text top="522" left="700" width="171" height="20" font="9">60   0.90  1.9   53         13  3.4  </text>
<text top="539" left="700" width="171" height="20" font="9">70   0.91  3.9   26         10  5.4  </text>
<text top="557" left="700" width="3" height="20" font="9"> </text>
<text top="574" left="700" width="42" height="20" font="16"><b>Stroke </b></text>
<text top="591" left="700" width="161" height="20" font="16"><b>Age         AB</b>b          <b>RGLE</b>e <b> </b></text>
<text top="608" left="700" width="176" height="20" font="16"><b>Y     RR</b>a  <b>(%) NNT</b>c <b>GLE</b>d <b>(%)  </b></text>
<text top="625" left="700" width="164" height="20" font="9">40   0.80  0.4  250       32  5.9 </text>
<text top="643" left="700" width="164" height="20" font="9">50   0.84  1.0  100       26  5.7 </text>
<text top="660" left="700" width="164" height="20" font="9">60   0.86  2.3   44        21  7.1 </text>
<text top="677" left="700" width="164" height="20" font="9">70   0.87  5.7   18        17  9.1 </text>
<text top="694" left="700" width="3" height="20" font="9"> </text>
<text top="711" left="700" width="10" height="20" font="9">a </text>
<text top="711" left="710" width="18" height="20" font="1">RR</text>
<text top="711" left="728" width="44" height="20" font="9"> at 10 y </text>
<text top="729" left="700" width="142" height="20" font="9">b Absolute benefit at 10 y </text>
<text top="746" left="700" width="10" height="20" font="9">c </text>
<text top="746" left="709" width="25" height="20" font="1">NNT</text>
<text top="746" left="735" width="97" height="20" font="9"> to avoid 1 event. </text>
<text top="763" left="700" width="171" height="20" font="9">d Gain in life expectancy in mo </text>
<text top="780" left="700" width="85" height="20" font="9">without events. </text>
<text top="366" left="909" width="160" height="20" font="4"><b>Summary</b>: Absolute gains in </text>
<text top="383" left="909" width="167" height="20" font="1">life expectancy are likely to be </text>
<text top="400" left="909" width="167" height="20" font="1">greater for younger, lower risk </text>
<text top="418" left="909" width="174" height="20" font="1">people with HTN than for older, </text>
<text top="435" left="909" width="158" height="20" font="1">higher risk people with HTN. </text>
<text top="452" left="909" width="163" height="20" font="1">However, the NNT to prevent </text>
<text top="469" left="909" width="161" height="20" font="1">an event will likely be greater </text>
<text top="487" left="909" width="163" height="20" font="1">especially in the short term in </text>
<text top="504" left="909" width="150" height="20" font="1">younger, lower risk people. </text>
<text top="521" left="909" width="128" height="20" font="1">This modeling analysis </text>
<text top="538" left="909" width="157" height="20" font="1">provides support for treating </text>
<text top="555" left="909" width="167" height="20" font="1">younger, lower risk individuals </text>
<text top="573" left="909" width="148" height="20" font="1">with HTN, but relies on the </text>
<text top="590" left="909" width="154" height="20" font="1">assumption that the relative </text>
<text top="607" left="909" width="122" height="20" font="1">benefits of treatments </text>
<text top="624" left="909" width="170" height="20" font="1">observed in short-term trials of </text>
<text top="641" left="909" width="163" height="20" font="1">higher risk individuals applies </text>
<text top="659" left="909" width="172" height="20" font="1">over a longer term to lower risk </text>
<text top="676" left="909" width="64" height="20" font="1">individuals. </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">81 </text>
<text top="107" left="194" width="113" height="20" font="1">survival curve of the </text>
<text top="124" left="194" width="88" height="20" font="1">life-long treated </text>
<text top="141" left="194" width="112" height="20" font="1">population. Gains in </text>
<text top="159" left="194" width="78" height="20" font="1">event-free life </text>
<text top="176" left="194" width="96" height="20" font="1">expectancy were </text>
<text top="193" left="194" width="85" height="20" font="1">estimated from </text>
<text top="210" left="194" width="100" height="20" font="1">survival curves. A </text>
<text top="228" left="194" width="104" height="20" font="1">sensitivity analysis </text>
<text top="245" left="194" width="98" height="20" font="1">was performed to </text>
<text top="262" left="194" width="115" height="20" font="1">assess the impact of </text>
<text top="279" left="194" width="83" height="20" font="1">possible death </text>
<text top="296" left="194" width="102" height="20" font="1">misclassifications. </text>
<text top="314" left="194" width="3" height="20" font="4"><b> </b></text>
<text top="331" left="194" width="129" height="20" font="4"><b>Size:</b> 6 RCTs, ~30,000 </text>
<text top="348" left="194" width="20" height="20" font="1">pts </text>
<text top="107" left="700" width="182" height="20" font="9">e Relative gain in life expectancy </text>
<text top="124" left="700" width="82" height="20" font="9">without events.</text>
<text top="124" left="782" width="3" height="20" font="4"><b> </b></text>
<text top="366" left="98" width="79" height="20" font="1">Czernichow S </text>
<text top="383" left="98" width="64" height="20" font="1">et al., 2011 </text>
<text top="400" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(121)</a> </text>
<text top="418" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20881867">20881867</a></text>
<text top="418" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20881867"> </a></text>
<text top="366" left="194" width="121" height="20" font="4"><b>Aim:</b> The objective of </text>
<text top="383" left="194" width="123" height="20" font="1">this systematic review </text>
<text top="400" left="194" width="128" height="20" font="1">and meta-analysis was </text>
<text top="418" left="194" width="129" height="20" font="1">to compare the relative </text>
<text top="435" left="194" width="96" height="20" font="1">reductions in risk </text>
<text top="452" left="194" width="126" height="20" font="1">achieved with different </text>
<text top="469" left="194" width="112" height="20" font="1">starting levels of BP </text>
<text top="487" left="194" width="84" height="20" font="1">(and treatment </text>
<text top="504" left="194" width="62" height="20" font="1">regimens). </text>
<text top="521" left="194" width="3" height="20" font="1"> </text>
<text top="538" left="194" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="555" left="194" width="96" height="20" font="1">analysis of RCTs </text>
<text top="573" left="194" width="3" height="20" font="1"> </text>
<text top="590" left="194" width="104" height="20" font="4"><b>Size:</b> 32 trials with </text>
<text top="607" left="194" width="113" height="20" font="1">201,566 pts (20,079 </text>
<text top="624" left="194" width="111" height="20" font="1">1° outcome events)<b> </b></text>
<text top="366" left="335" width="178" height="20" font="4"><b>Inclusion criteria:</b>  RCTs of BP-</text>
<text top="383" left="335" width="180" height="20" font="1">lowering (drug vs. control or less </text>
<text top="400" left="335" width="174" height="20" font="1">intensive treatment) or different </text>
<text top="418" left="335" width="154" height="20" font="1">classes of drug therapy that </text>
<text top="435" left="335" width="175" height="20" font="1">included a minimum of 1,000 pt-</text>
<text top="452" left="335" width="180" height="20" font="1">y of follow-up in each study arm. </text>
<text top="469" left="335" width="3" height="20" font="1"> </text>
<text top="487" left="335" width="175" height="20" font="4"><b>Exclusion criteria: </b>&lt;1,000 pt-y </text>
<text top="504" left="335" width="165" height="20" font="1">of follow-up in each treatment </text>
<text top="521" left="335" width="38" height="20" font="1">group.<b> </b></text>
<text top="366" left="531" width="148" height="20" font="4"><b>Intervention:</b> BP-lowering </text>
<text top="383" left="531" width="37" height="20" font="1">meds  </text>
<text top="400" left="531" width="7" height="20" font="1">  </text>
<text top="418" left="531" width="128" height="20" font="4"><b>Comparator:</b> Placebo, </text>
<text top="435" left="531" width="141" height="20" font="1">active comparator or less </text>
<text top="452" left="531" width="107" height="20" font="1">intensive treatment<b> </b></text>
<text top="367" left="700" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="386" left="700" width="7" height="18" font="1">•</text>
<text top="386" left="707" width="184" height="20" font="1"> Major CVD events (stroke, CHD, </text>
<text top="403" left="700" width="47" height="20" font="1">and HF. </text>
<text top="422" left="700" width="7" height="18" font="1">•</text>
<text top="421" left="707" width="186" height="20" font="1"> No evidence of differences in the </text>
<text top="438" left="700" width="195" height="20" font="1">ratio of risk across varying levels of </text>
<text top="456" left="700" width="193" height="20" font="1">baseline BP (with all classes of BP-</text>
<text top="473" left="700" width="129" height="20" font="1">lowering medications). <b> </b></text>
<text top="366" left="909" width="70" height="20" font="4"><b>Summary:</b>   </text>
<text top="385" left="909" width="7" height="18" font="1">•</text>
<text top="384" left="916" width="163" height="20" font="1"> Effectiveness of BP-lowering </text>
<text top="402" left="909" width="156" height="20" font="1">regiments in reducing RR of </text>
<text top="419" left="909" width="154" height="20" font="1">major CVD events does not </text>
<text top="436" left="909" width="140" height="20" font="1">seem to be influenced by </text>
<text top="453" left="909" width="109" height="20" font="1">starting level of BP. </text>
<text top="470" left="909" width="3" height="20" font="1"> </text>
<text top="488" left="909" width="80" height="20" font="4"><b>Limitations:</b>   </text>
<text top="507" left="909" width="7" height="18" font="1">•</text>
<text top="506" left="916" width="109" height="20" font="1"> The majority of the </text>
<text top="523" left="909" width="153" height="20" font="1">participants studied were at </text>
<text top="540" left="909" width="100" height="20" font="1">high risk for CVD. </text>
<text top="559" left="909" width="7" height="18" font="1">•</text>
<text top="559" left="916" width="160" height="20" font="1"> Information pertaining to the </text>
<text top="576" left="909" width="170" height="20" font="1">effect of treatment on absolute </text>
<text top="593" left="909" width="162" height="20" font="1">risk was not presented in this </text>
<text top="610" left="909" width="67" height="20" font="1">manuscript.<b> </b></text>
<text top="644" left="108" width="3" height="19" font="1"> </text>
<text top="678" left="81" width="517" height="24" font="3"><b>Data Supplement 24. Follow-Up After Initial BP Evaluation (Section 8.1.3)  </b></text>
<text top="718" left="99" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="735" left="125" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="752" left="102" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="718" left="220" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="735" left="225" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="752" left="219" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="718" left="343" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="718" left="493" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="735" left="509" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="752" left="493" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="769" left="514" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="718" left="649" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="735" left="633" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="752" left="625" width="154" height="20" font="4"><b>P value; OR or RR; &amp; 95% </b></text>
<text top="769" left="692" width="20" height="20" font="4"><b>CI) </b></text>
<text top="719" left="845" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="736" left="878" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="753" left="883" width="103" height="20" font="4"><b>Adverse Events;  </b></text>
<text top="771" left="904" width="59" height="20" font="4"><b>Summary </b></text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="17" size="12" family="Times" color="#2a2a2a"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">82 </text>
<text top="107" left="98" width="101" height="20" font="1">Ambrosius WT, et </text>
<text top="124" left="98" width="83" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(122)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24902920?dopt=Citation">24902920</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24902920?dopt=Citation"> </a></text>
<text top="107" left="212" width="98" height="20" font="4"><b>Aim:</b> To describe </text>
<text top="124" left="212" width="93" height="20" font="1">the study design </text>
<text top="141" left="212" width="83" height="20" font="1">of the SPRINT </text>
<text top="159" left="212" width="3" height="20" font="1"> </text>
<text top="176" left="212" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="193" left="212" width="77" height="20" font="1">SPRINT RCT </text>
<text top="107" left="325" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="124" left="325" width="124" height="20" font="1">Adults ≥50 y, average </text>
<text top="141" left="325" width="127" height="20" font="1">SBP ≥130 mm Hg and </text>
<text top="159" left="325" width="146" height="20" font="1">evidence of CVD, CKD, or </text>
<text top="176" left="325" width="122" height="20" font="1">10-y Framingham risk </text>
<text top="193" left="325" width="122" height="20" font="1">score ≥15%, or ≥75 y </text>
<text top="107" left="485" width="112" height="20" font="4"><b>Intervention:</b> 9,361 </text>
<text top="124" left="485" width="111" height="20" font="1">pts randomized to 2 </text>
<text top="141" left="485" width="103" height="20" font="1">treatment groups:  </text>
<text top="160" left="485" width="7" height="18" font="1">•</text>
<text top="160" left="492" width="112" height="20" font="1"> Standard treatment </text>
<text top="177" left="485" width="101" height="20" font="1">group, SBP target </text>
<text top="194" left="485" width="74" height="20" font="1">&lt;140 mm Hg </text>
<text top="213" left="485" width="7" height="18" font="1">•</text>
<text top="213" left="492" width="111" height="20" font="1"> Intensive treatment </text>
<text top="230" left="485" width="101" height="20" font="1">group: SBP target </text>
<text top="247" left="485" width="78" height="20" font="1">&lt;120 mm Hg.<b> </b></text>
<text top="108" left="625" width="128" height="20" font="4"><b>1</b>°<b> endpoint:</b> MI, ACS, </text>
<text top="125" left="625" width="145" height="20" font="1">stroke, HF, or CVD death. </text>
<text top="108" left="792" width="280" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> All-cause mortality, decline </text>
<text top="125" left="792" width="241" height="20" font="1">in kidney function or development of ESRD, </text>
<text top="143" left="792" width="260" height="20" font="1">incident dementia, decline in cognitive function, </text>
<text top="160" left="792" width="240" height="20" font="1">and small-vessel cerebral ischemic disease </text>
<text top="177" left="792" width="3" height="20" font="1"> </text>
<text top="194" left="792" width="249" height="20" font="4"><b>Summary:</b> This paper describes the protocol </text>
<text top="211" left="792" width="277" height="20" font="1">followed in the SPRINT trial that was successful in </text>
<text top="229" left="792" width="250" height="20" font="1">helping participants to attain and maintain BP </text>
<text top="246" left="792" width="230" height="20" font="1">targets in the study groups. Once treated, </text>
<text top="263" left="792" width="276" height="20" font="1">participants had follow-up visits to assessment BP </text>
<text top="280" left="792" width="279" height="20" font="1">control monthly until BP was at target. Medications </text>
<text top="298" left="792" width="254" height="20" font="1">were titrated and added as per protocol, when </text>
<text top="315" left="792" width="151" height="20" font="1">target BP was not attained.<b> </b></text>
<text top="333" left="98" width="97" height="20" font="1">Cushman WC, et </text>
<text top="350" left="98" width="83" height="20" font="1">al., 2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(123)</a> </text>
<text top="367" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17599425?dopt=Citation">17599425</a></text>
<text top="367" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17599425?dopt=Citation"> </a></text>
<text top="333" left="212" width="98" height="20" font="4"><b>Aim:</b> To describe </text>
<text top="350" left="212" width="93" height="20" font="1">the study design </text>
<text top="367" left="212" width="91" height="20" font="1">of the BP trial of </text>
<text top="384" left="212" width="77" height="20" font="1">the ACCORD </text>
<text top="402" left="212" width="27" height="20" font="1">Trial </text>
<text top="419" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="436" left="212" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="453" left="212" width="78" height="20" font="1">Description of </text>
<text top="470" left="212" width="96" height="20" font="1">study design and </text>
<text top="488" left="212" width="85" height="20" font="1">protocol for the </text>
<text top="505" left="212" width="85" height="20" font="1">ACCORD RCT<b> </b></text>
<text top="333" left="325" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="350" left="325" width="142" height="20" font="17">Adults with a diagnosis of </text>
<text top="367" left="325" width="125" height="20" font="17">DM-2 for at least 3 mo </text>
<text top="384" left="325" width="134" height="20" font="17">and at high risk for CVD </text>
<text top="402" left="325" width="120" height="20" font="17">events, who meet the </text>
<text top="419" left="325" width="133" height="20" font="17">following BP criteria: (1) </text>
<text top="436" left="325" width="48" height="20" font="17">SBP 130</text>
<text top="436" left="373" width="7" height="20" font="1">–</text>
<text top="436" left="380" width="91" height="20" font="17">160 mm Hg and </text>
<text top="453" left="325" width="43" height="20" font="17">taking 0</text>
<text top="453" left="368" width="7" height="20" font="1">–</text>
<text top="453" left="374" width="10" height="20" font="17">3 </text>
<text top="470" left="325" width="93" height="20" font="17">antihypertensive </text>
<text top="488" left="325" width="119" height="20" font="17">medications; (2) SBP </text>
<text top="505" left="325" width="20" height="20" font="17">161</text>
<text top="505" left="345" width="7" height="20" font="1">–</text>
<text top="505" left="352" width="72" height="20" font="17">170 and on 0</text>
<text top="505" left="424" width="7" height="20" font="1">–</text>
<text top="505" left="431" width="10" height="20" font="17">2 </text>
<text top="522" left="325" width="93" height="20" font="17">antihypertensive </text>
<text top="539" left="325" width="133" height="20" font="17">medications; or (3) SBP </text>
<text top="557" left="325" width="130" height="20" font="17">171-180 and taking 0-1 </text>
<text top="574" left="325" width="93" height="20" font="17">antihypertensive </text>
<text top="591" left="325" width="131" height="20" font="17">medication. Other entry </text>
<text top="608" left="325" width="147" height="20" font="17">criteria included spot urine </text>
<text top="625" left="325" width="132" height="20" font="17">sample &lt;2+, protein–Cr </text>
<text top="643" left="325" width="141" height="20" font="17">ratio &lt;700 mg protein/1 g </text>
<text top="660" left="325" width="103" height="20" font="17">Cr, or 24-h protein </text>
<text top="677" left="325" width="122" height="20" font="17">excretion &lt;1.0 g/24 h. </text>
<text top="333" left="485" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="352" left="485" width="7" height="18" font="1">•</text>
<text top="351" left="492" width="100" height="20" font="1"> Unmasked, open-</text>
<text top="368" left="485" width="122" height="20" font="1">label, factorial design, </text>
<text top="386" left="485" width="126" height="20" font="1">randomized trial with a </text>
<text top="403" left="485" width="116" height="20" font="1">sample size of 4,733 </text>
<text top="420" left="485" width="23" height="20" font="1">pts<b>  </b></text>
<text top="439" left="485" width="7" height="18" font="1">•</text>
<text top="438" left="492" width="106" height="20" font="1"> Pts randomized to </text>
<text top="456" left="485" width="120" height="20" font="1">intensive SBP control </text>
<text top="473" left="485" width="97" height="20" font="1">(&lt;120 mm Hg) or </text>
<text top="490" left="485" width="127" height="20" font="1">standard control (&lt;140 </text>
<text top="507" left="485" width="47" height="20" font="1">mm Hg) </text>
<text top="334" left="625" width="139" height="20" font="4"><b>1</b>°<b> endpoint:</b> Major CVD </text>
<text top="351" left="625" width="116" height="20" font="1">event (nonfatal MI or </text>
<text top="368" left="625" width="114" height="20" font="1">stroke, or CV death) </text>
<text top="334" left="792" width="273" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> Expanded macrovascular </text>
<text top="352" left="792" width="199" height="20" font="1">outcome (1° outcome plus coronary </text>
<text top="370" left="792" width="246" height="20" font="1">revascularization or HF hospitalization), total </text>
<text top="387" left="792" width="274" height="20" font="1">mortality, each of the separate components of the </text>
<text top="404" left="792" width="247" height="20" font="1">1° outcome, HF death or hospitalization, and </text>
<text top="421" left="792" width="278" height="20" font="1">composite microvascular disease outcome (kidney </text>
<text top="438" left="792" width="101" height="20" font="1">and eye disease). </text>
<text top="456" left="792" width="3" height="20" font="1"> </text>
<text top="473" left="792" width="249" height="20" font="4"><b>Summary:</b> This paper describes the protocol </text>
<text top="490" left="792" width="272" height="20" font="1">followed in the ACCORD trial that was successful </text>
<text top="507" left="792" width="263" height="20" font="1">in helping participants to attain and maintain BP </text>
<text top="524" left="792" width="230" height="20" font="1">targets in the study groups. Once treated, </text>
<text top="542" left="792" width="276" height="20" font="1">participants had follow-up visits to assessment BP </text>
<text top="559" left="792" width="279" height="20" font="1">control monthly until BP was at target. Medications </text>
<text top="576" left="792" width="254" height="20" font="1">were titrated and added as per protocol, when </text>
<text top="593" left="792" width="151" height="20" font="1">target BP was not attained.<b> </b></text>
<text top="696" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">83 </text>
<text top="106" left="81" width="901" height="24" font="3"><b>Data Supplement 25. RCTs for General Principles of Drug Therapy (Combination Therapies that Inhibit the RAAS) (Section 8.1.4) </b></text>
<text top="146" left="98" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="163" left="124" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="180" left="102" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="228" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="163" left="233" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="180" left="227" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="399" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="587" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="163" left="603" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="180" left="588" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="197" left="608" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="146" left="746" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="163" left="729" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="180" left="735" width="129" height="20" font="4"><b>P value; OR or RR; &amp;  </b></text>
<text top="197" left="774" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="147" left="895" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="164" left="927" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="181" left="935" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="217" left="98" width="98" height="20" font="4"><b>VA NEPHRON-D </b></text>
<text top="235" left="98" width="86" height="20" font="1">Fried LF, et al., </text>
<text top="252" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(124)</a> </text>
<text top="269" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24206457">24206457</a></text>
<text top="269" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24206457"> </a></text>
<text top="217" left="211" width="94" height="20" font="4"><b>Aim:</b> Assess the </text>
<text top="235" left="211" width="59" height="20" font="1">efficacy of </text>
<text top="252" left="211" width="100" height="20" font="1">combination of an </text>
<text top="269" left="211" width="102" height="20" font="1">ACEI and an ARB </text>
<text top="286" left="211" width="48" height="20" font="1">vs. ARB </text>
<text top="303" left="211" width="88" height="20" font="1">monotherapy in </text>
<text top="321" left="211" width="71" height="20" font="1">reducing the </text>
<text top="338" left="211" width="81" height="20" font="1">progression of </text>
<text top="355" left="211" width="107" height="20" font="1">proteinuric diabetic </text>
<text top="372" left="211" width="72" height="20" font="1">nephropathy </text>
<text top="390" left="211" width="3" height="20" font="1"> </text>
<text top="407" left="211" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="424" left="211" width="108" height="20" font="1">Multicenter, double-</text>
<text top="441" left="211" width="112" height="20" font="1">blind, RCT at 32 VA </text>
<text top="458" left="211" width="92" height="20" font="1">Medical Centers </text>
<text top="476" left="211" width="3" height="20" font="1"> </text>
<text top="493" left="211" width="83" height="20" font="4"><b>Size:</b> 1448 pts<b> </b></text>
<text top="217" left="343" width="215" height="20" font="4"><b>Inclusion criteria</b>: Pts with type 2 DM, </text>
<text top="235" left="343" width="211" height="20" font="1">a urinary albumin-to-creatinine ratio of </text>
<text top="252" left="343" width="171" height="20" font="1">≥300, and an eGFR 30.0–89.9 </text>
<text top="269" left="343" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="271" left="424" width="4" height="13" font="6">2</text>
<text top="269" left="428" width="3" height="20" font="1"> </text>
<text top="286" left="343" width="3" height="20" font="1"> </text>
<text top="303" left="343" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="322" left="343" width="7" height="18" font="1">•</text>
<text top="322" left="349" width="185" height="20" font="1"> Subjects with known nondiabetic </text>
<text top="339" left="343" width="85" height="20" font="1">kidney disease </text>
<text top="358" left="343" width="7" height="18" font="1">•</text>
<text top="357" left="349" width="133" height="20" font="1"> Serum K+ &gt;5.5 mmol/L </text>
<text top="376" left="343" width="7" height="18" font="1">•</text>
<text top="376" left="349" width="172" height="20" font="1"> Current treatment with sodium </text>
<text top="393" left="343" width="120" height="20" font="1">polystyrene sulfonate </text>
<text top="412" left="343" width="7" height="18" font="1">•</text>
<text top="411" left="349" width="213" height="20" font="1"> Inability to stop prescribed medication </text>
<text top="429" left="343" width="213" height="20" font="1">that increases the risk of hyperkalemia </text>
<text top="217" left="580" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="235" left="580" width="124" height="20" font="1">Losartan 100 mg daily </text>
<text top="252" left="580" width="111" height="20" font="1">plus lisinopril 10–40 </text>
<text top="269" left="580" width="95" height="20" font="1">mg daily (n=724) </text>
<text top="286" left="580" width="7" height="20" font="1">  </text>
<text top="303" left="580" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="321" left="580" width="124" height="20" font="1">Losartan 100 mg daily </text>
<text top="338" left="580" width="119" height="20" font="1">plus placebo (n=724)<b> </b></text>
<text top="218" left="719" width="116" height="20" font="4"><b>1</b>°<b> endpoint:</b> After a </text>
<text top="236" left="719" width="143" height="20" font="1">median follow-up of 2.2 y, </text>
<text top="253" left="719" width="156" height="20" font="1">the study was stopped early </text>
<text top="270" left="719" width="130" height="20" font="1">due to safety concerns. </text>
<text top="287" left="719" width="148" height="20" font="1">There was no difference in </text>
<text top="305" left="719" width="124" height="20" font="1">the 1° outcome of first </text>
<text top="322" left="719" width="135" height="20" font="1">occurrence of change in </text>
<text top="339" left="719" width="133" height="20" font="1">eGFR (decrease of ≥30 </text>
<text top="356" left="719" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="358" left="800" width="7" height="13" font="6">2 </text>
<text top="356" left="807" width="70" height="20" font="1">if initial GFR </text>
<text top="373" left="719" width="132" height="20" font="1">was ≥60 mL/min/1.73 m</text>
<text top="375" left="851" width="4" height="13" font="6">2</text>
<text top="373" left="855" width="18" height="20" font="1"> or </text>
<text top="391" left="719" width="143" height="20" font="1">a decline of ≥50% if initial </text>
<text top="408" left="719" width="157" height="20" font="1">eGFR was &lt;60 mL/min/1.73 </text>
<text top="425" left="719" width="10" height="20" font="1">m</text>
<text top="427" left="729" width="4" height="13" font="6">2</text>
<text top="425" left="734" width="125" height="20" font="1">), ESRD, or death (HR </text>
<text top="442" left="719" width="143" height="20" font="1">with combination therapy: </text>
<text top="460" left="719" width="139" height="20" font="1">0.88; 95% CI: 0.70–1.12; </text>
<text top="477" left="719" width="49" height="20" font="1">p=0.30). </text>
<text top="494" left="719" width="3" height="20" font="1"> </text>
<text top="511" left="719" width="100" height="20" font="4"><b>Safety endpoint:</b> </text>
<text top="528" left="719" width="117" height="20" font="1">Combination therapy </text>
<text top="546" left="719" width="113" height="20" font="1">increased the risk of </text>
<text top="563" left="719" width="157" height="20" font="1">hyperkalemia (HR: 2.8; 95% </text>
<text top="580" left="719" width="143" height="20" font="1">CI: 1.8–4.2; p&lt;0.001) and </text>
<text top="597" left="719" width="158" height="20" font="1">acute kidney injury (HR: 1.7; </text>
<text top="614" left="719" width="151" height="20" font="1">95% CI: 1.3–2.2; p&lt;0.001). </text>
<text top="218" left="890" width="153" height="20" font="4"><b>2</b>°<b> endpoint</b>: There was no </text>
<text top="236" left="890" width="170" height="20" font="1">difference in the 2º endpoint of </text>
<text top="253" left="890" width="158" height="20" font="1">first occurrence of change in </text>
<text top="270" left="890" width="175" height="20" font="1">eGFR or ESRD (HR: 0.78; 95% </text>
<text top="287" left="890" width="165" height="20" font="1">CI: 0.58–1.05; p=0.10). There </text>
<text top="305" left="890" width="161" height="20" font="1">were no differences between </text>
<text top="322" left="890" width="176" height="20" font="1">combination therapy or losartan </text>
<text top="339" left="890" width="184" height="20" font="1">monotherapy for the endpoints of </text>
<text top="356" left="890" width="172" height="20" font="1">ESRD, death, composite of MI, </text>
<text top="374" left="890" width="154" height="20" font="1">HF, or stroke, MI, CHF, and </text>
<text top="391" left="890" width="123" height="20" font="1">stroke (p&gt;0.05 for all). </text>
<text top="408" left="890" width="3" height="20" font="1"> </text>
<text top="425" left="890" width="180" height="20" font="4"><b>Summary</b>: Combination therapy </text>
<text top="442" left="890" width="175" height="20" font="1">of losartan plus lisinopril did not </text>
<text top="460" left="890" width="135" height="20" font="1">improve renal outcomes </text>
<text top="477" left="890" width="180" height="20" font="1">compared to losartan alone, and </text>
<text top="494" left="890" width="178" height="20" font="1">was associated with greater risk </text>
<text top="511" left="890" width="143" height="20" font="1">of acute kidney injury and </text>
<text top="528" left="890" width="80" height="20" font="1">hyperkalemia. </text>
<text top="632" left="98" width="64" height="20" font="4"><b>ALTITUDE </b></text>
<text top="650" left="98" width="83" height="20" font="1">Parving HH, et </text>
<text top="667" left="98" width="83" height="20" font="1">al., 2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(125)</a> </text>
<text top="684" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23121378">23121378</a></text>
<text top="684" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23121378"> </a></text>
<text top="632" left="211" width="100" height="20" font="4"><b>Aim:</b> Determine if </text>
<text top="650" left="211" width="109" height="20" font="1">addition of aliskiren </text>
<text top="667" left="211" width="107" height="20" font="1">as an adjunct to an </text>
<text top="684" left="211" width="75" height="20" font="1">ACEI or ARB </text>
<text top="701" left="211" width="104" height="20" font="1">reduces the risk of </text>
<text top="718" left="211" width="115" height="20" font="1">CV and renal events </text>
<text top="736" left="211" width="118" height="20" font="1">in pts with type 2 DM </text>
<text top="753" left="211" width="3" height="20" font="1"> </text>
<text top="632" left="343" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="651" left="343" width="7" height="18" font="1">•</text>
<text top="651" left="349" width="123" height="20" font="1"> ≥35 y with type 2 DM </text>
<text top="670" left="343" width="7" height="18" font="1">•</text>
<text top="669" left="349" width="98" height="20" font="1"> On ACEI or ARB </text>
<text top="688" left="343" width="7" height="18" font="1">•</text>
<text top="687" left="349" width="204" height="20" font="1"> At least 1 of the following: persistent </text>
<text top="705" left="343" width="213" height="20" font="1">macroalbuminuria (urine microalbumin </text>
<text top="722" left="343" width="189" height="20" font="1">to creatinine ratio ≥200 mg/g) and </text>
<text top="739" left="343" width="143" height="20" font="1">eGFR ≥30 mL/min/1.73 m</text>
<text top="741" left="485" width="4" height="13" font="6">2</text>
<text top="739" left="490" width="64" height="20" font="1">, persistent </text>
<text top="756" left="343" width="212" height="20" font="1">microalbuminuria (≥20 mg/g and &lt;200 </text>
<text top="774" left="343" width="213" height="20" font="1">mg/g) and a mean eGFR ≥30 and &lt;60 </text>
<text top="632" left="580" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="650" left="580" width="123" height="20" font="1">Aliskiren 300 mg daily </text>
<text top="667" left="580" width="124" height="20" font="1">added to conventional </text>
<text top="684" left="580" width="98" height="20" font="1">treatment with an </text>
<text top="701" left="580" width="75" height="20" font="1">ACEI or ARB </text>
<text top="718" left="580" width="56" height="20" font="1">(n=4,274) </text>
<text top="736" left="580" width="3" height="20" font="1"> </text>
<text top="753" left="580" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="770" left="580" width="56" height="20" font="1">(n=4,287) </text>
<text top="787" left="580" width="3" height="20" font="4"><b> </b></text>
<text top="634" left="719" width="116" height="20" font="4"><b>1</b>°<b> endpoint:</b> After a </text>
<text top="651" left="719" width="158" height="20" font="1">median follow-up of 32.9 mo </text>
<text top="668" left="719" width="126" height="20" font="1">the study was stopped </text>
<text top="685" left="719" width="111" height="20" font="1">early. There was no </text>
<text top="702" left="719" width="107" height="20" font="1">difference in the 1° </text>
<text top="720" left="719" width="144" height="20" font="1">composite outcome death </text>
<text top="737" left="719" width="128" height="20" font="1">from CV causes or first </text>
<text top="754" left="719" width="156" height="20" font="1">occurrence of cardiac arrest </text>
<text top="771" left="719" width="148" height="20" font="1">with resuscitation; nonfatal </text>
<text top="788" left="719" width="108" height="20" font="1">MI; nonfatal stroke; </text>
<text top="634" left="890" width="75" height="20" font="4"><b>2</b>°<b> endpoint</b>: </text>
<text top="653" left="890" width="7" height="18" font="1">•</text>
<text top="652" left="897" width="139" height="20" font="1"> There was no difference </text>
<text top="669" left="890" width="169" height="20" font="1">between aliskiren and placebo </text>
<text top="686" left="890" width="177" height="20" font="1">for the individual components of </text>
<text top="704" left="890" width="167" height="20" font="1">the composite 1° outcome (all </text>
<text top="721" left="890" width="182" height="20" font="1">p&gt;0.05) other than cardiac arrest </text>
<text top="738" left="890" width="161" height="20" font="1">with resuscitation, which was </text>
<text top="755" left="890" width="149" height="20" font="1">increased significantly with </text>
<text top="772" left="890" width="155" height="20" font="1">aliskiren (HR: 2.40; 95% CI: </text>
<text top="790" left="890" width="111" height="20" font="1">1.05–5.48; p=0.04). </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">84 </text>
<text top="107" left="211" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="124" left="211" width="83" height="20" font="1">Doubled-blind, </text>
<text top="141" left="211" width="92" height="20" font="1">multicenter RCT </text>
<text top="159" left="211" width="3" height="20" font="1"> </text>
<text top="176" left="211" width="63" height="20" font="4"><b>Size:</b> 8561<b> </b></text>
<text top="107" left="343" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="109" left="424" width="4" height="13" font="6">2</text>
<text top="107" left="428" width="135" height="20" font="1">, or history of CVD (e.g., </text>
<text top="124" left="343" width="200" height="20" font="1">MI, stroke, HF, or CAD) and a mean </text>
<text top="141" left="343" width="191" height="20" font="1">eGFR ≥30 and &lt;60 mL/min/1.73 m</text>
<text top="143" left="534" width="4" height="13" font="6">2</text>
<text top="141" left="538" width="3" height="20" font="1"> </text>
<text top="159" left="343" width="3" height="20" font="1"> </text>
<text top="176" left="343" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="195" left="343" width="7" height="18" font="1">•</text>
<text top="194" left="349" width="133" height="20" font="1"> Serum K+ &gt;5.0 mmol/L </text>
<text top="213" left="343" width="7" height="18" font="1">•</text>
<text top="213" left="349" width="67" height="20" font="1"> Type 1 DM </text>
<text top="232" left="343" width="7" height="18" font="1">•</text>
<text top="231" left="349" width="109" height="20" font="1"> Unstable serum Cr </text>
<text top="250" left="343" width="7" height="18" font="1">•</text>
<text top="249" left="349" width="214" height="20" font="1"> CV history (NYHA Class III or IV, SBP </text>
<text top="267" left="343" width="208" height="20" font="1">≥170 mm Hg or DBP ≥110 mm Hg or </text>
<text top="284" left="343" width="201" height="20" font="1">SBP ≥135 and &lt;170 mm Hg or DBP </text>
<text top="301" left="343" width="202" height="20" font="1">≥82 and &lt;100 mm Hg with at least 3 </text>
<text top="318" left="343" width="51" height="20" font="1">agents, 2</text>
<text top="320" left="393" width="9" height="13" font="6">nd</text>
<text top="318" left="402" width="154" height="20" font="1"> or third degree heart block, </text>
<text top="335" left="343" width="114" height="20" font="1">renal artery stenosis </text>
<text top="355" left="343" width="7" height="18" font="1">•</text>
<text top="354" left="349" width="170" height="20" font="1"> Surgical or medical conditions </text>
<text top="371" left="343" width="175" height="20" font="1">(malignancy in last 5 y, &lt;2 y life </text>
<text top="388" left="343" width="172" height="20" font="1">expectancy, renal transplant or </text>
<text top="406" left="343" width="161" height="20" font="1">immunosuppressive therapy, </text>
<text top="423" left="343" width="111" height="20" font="1">drug/alcohol abuse, </text>
<text top="440" left="343" width="217" height="20" font="1">hypersensitivity/allergy/contraindication </text>
<text top="457" left="343" width="149" height="20" font="1">to study drugs, pregnancy) </text>
<text top="476" left="343" width="7" height="18" font="1">•</text>
<text top="476" left="349" width="215" height="20" font="1"> Concomitant treatment with ≥2 agents </text>
<text top="493" left="343" width="108" height="20" font="1">blocking RAAS or K</text>
<text top="494" left="450" width="5" height="13" font="6">+</text>
<text top="493" left="455" width="101" height="20" font="1">-sparing diuretics.<b> </b></text>
<text top="107" left="719" width="142" height="20" font="1">unplanned hospitalization </text>
<text top="124" left="719" width="116" height="20" font="1">for HF; ESRD; death </text>
<text top="141" left="719" width="154" height="20" font="1">attributable to kidney failure </text>
<text top="159" left="719" width="94" height="20" font="1">or need for renal-</text>
<text top="176" left="719" width="158" height="20" font="1">replacement therapy with no </text>
<text top="193" left="719" width="142" height="20" font="1">dialysis or transplantation </text>
<text top="210" left="719" width="130" height="20" font="1">available or initiated; or </text>
<text top="228" left="719" width="133" height="20" font="1">doubling of the baseline </text>
<text top="245" left="719" width="152" height="20" font="1">serum Cr between aliskiren </text>
<text top="262" left="719" width="148" height="20" font="1">or placebo (HR: 1.08; 95% </text>
<text top="279" left="719" width="130" height="20" font="1">CI: 0.98–1.20; p=0.12). </text>
<text top="296" left="719" width="3" height="20" font="1"> </text>
<text top="314" left="719" width="125" height="20" font="4"><b>Safety endpoint:</b> The </text>
<text top="331" left="719" width="132" height="20" font="1">combination of aliskiren </text>
<text top="348" left="719" width="132" height="20" font="1">added to an ACEI or an </text>
<text top="365" left="719" width="141" height="20" font="1">ARB was associated with </text>
<text top="382" left="719" width="155" height="20" font="1">greater risk of hyperkalemia </text>
<text top="400" left="719" width="155" height="20" font="1">and hypotension (11.2% vs. </text>
<text top="417" left="719" width="148" height="20" font="1">7.2% and 12.8% vs. 8.3%; </text>
<text top="434" left="719" width="97" height="20" font="1">p&lt;0.001 for both, </text>
<text top="451" left="719" width="76" height="20" font="1">respectively).<b> </b></text>
<text top="109" left="890" width="7" height="18" font="1">•</text>
<text top="108" left="897" width="158" height="20" font="1"> There was no differences in </text>
<text top="125" left="890" width="165" height="20" font="1">CV composite outcome, renal </text>
<text top="143" left="890" width="162" height="20" font="1">composite outcome, or death </text>
<text top="160" left="890" width="171" height="20" font="1">from any cause (p&gt;0.05 for all) </text>
<text top="177" left="890" width="3" height="20" font="1"> </text>
<text top="194" left="890" width="164" height="20" font="4"><b>Summary</b>: Aliskiren added to </text>
<text top="211" left="890" width="154" height="20" font="1">background treatment of an </text>
<text top="229" left="890" width="169" height="20" font="1">ACEI or ARB did not decrease </text>
<text top="246" left="890" width="175" height="20" font="1">CV or renal outcomes, and was </text>
<text top="263" left="890" width="180" height="20" font="1">associated with increased risk of </text>
<text top="280" left="890" width="179" height="20" font="1">cardiac arrest with resuscitation, </text>
<text top="298" left="890" width="177" height="20" font="1">hyperkalemia, and hypotension. </text>
<text top="511" left="98" width="76" height="20" font="4"><b>ONTARGET  </b></text>
<text top="528" left="98" width="83" height="20" font="1">Yusuf S, et al., </text>
<text top="545" left="98" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(126)</a> </text>
<text top="562" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18378520">18378520</a></text>
<text top="562" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18378520"> </a></text>
<text top="511" left="211" width="82" height="20" font="4"><b>Aim:</b> Evaluate </text>
<text top="528" left="211" width="101" height="20" font="1">whether use of an </text>
<text top="545" left="211" width="115" height="20" font="1">ARB was noninferior </text>
<text top="562" left="211" width="73" height="20" font="1">to ACEI, and </text>
<text top="580" left="211" width="68" height="20" font="1">whether the </text>
<text top="597" left="211" width="95" height="20" font="1">combination was </text>
<text top="614" left="211" width="90" height="20" font="1">superior to ACE </text>
<text top="631" left="211" width="67" height="20" font="1">alone in the </text>
<text top="648" left="211" width="75" height="20" font="1">prevention of </text>
<text top="666" left="211" width="102" height="20" font="1">vascular events in </text>
<text top="683" left="211" width="111" height="20" font="1">pts with CVD or DM </text>
<text top="700" left="211" width="64" height="20" font="1">but not HF. </text>
<text top="717" left="211" width="3" height="20" font="1"> </text>
<text top="734" left="211" width="101" height="20" font="4"><b>Study type:</b> Multi-</text>
<text top="752" left="211" width="115" height="20" font="1">center, double-blind, </text>
<text top="769" left="211" width="29" height="20" font="1">RCT </text>
<text top="786" left="211" width="3" height="20" font="1"> </text>
<text top="511" left="343" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="530" left="343" width="7" height="18" font="1">•</text>
<text top="529" left="349" width="42" height="20" font="1"> ≥55 y  </text>
<text top="548" left="343" width="7" height="18" font="1">•</text>
<text top="547" left="349" width="137" height="20" font="1"> Coronary, peripheral, or </text>
<text top="565" left="343" width="199" height="20" font="1">cerebrovascular disease or DM with </text>
<text top="582" left="343" width="107" height="20" font="1">end-organ damage </text>
<text top="599" left="343" width="3" height="20" font="1"> </text>
<text top="616" left="343" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="635" left="343" width="7" height="18" font="1">•</text>
<text top="635" left="349" width="203" height="20" font="1"> Inability to discontinue ACEI or ARB </text>
<text top="654" left="343" width="7" height="18" font="1">•</text>
<text top="653" left="349" width="210" height="20" font="1"> Known hypersensitivity or intolerance </text>
<text top="670" left="343" width="89" height="20" font="1">to ACEI or ARB </text>
<text top="689" left="343" width="7" height="18" font="1">•</text>
<text top="689" left="349" width="180" height="20" font="1"> Selected CVDs (congestive HF, </text>
<text top="706" left="343" width="217" height="20" font="1">hemodynamically significant valvular or </text>
<text top="723" left="343" width="202" height="20" font="1">outflow tract obstruction, constrictive </text>
<text top="740" left="343" width="207" height="20" font="1">pericarditis, complex congenital heart </text>
<text top="757" left="343" width="220" height="20" font="1">disease, syncopal episodes of unknown </text>
<text top="775" left="343" width="222" height="20" font="1">etiology &lt;3 mo, planned cardiac surgery </text>
<text top="511" left="580" width="127" height="20" font="4"><b>Intervention:</b> Ramipril </text>
<text top="528" left="580" width="123" height="20" font="1">10 mg daily (n=8,576) </text>
<text top="545" left="580" width="3" height="20" font="1"> </text>
<text top="562" left="580" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="581" left="580" width="7" height="18" font="1">•</text>
<text top="581" left="586" width="109" height="20" font="1"> Telmisartan 80 mg </text>
<text top="598" left="580" width="85" height="20" font="1">daily (n=8,542) </text>
<text top="617" left="580" width="7" height="18" font="1">•</text>
<text top="616" left="586" width="89" height="20" font="1"> Combination of </text>
<text top="633" left="580" width="87" height="20" font="1">telmisartan and </text>
<text top="651" left="580" width="100" height="20" font="1">ramipril (n=8,502) </text>
<text top="512" left="719" width="116" height="20" font="4"><b>1</b>°<b> endpoint:</b> After a </text>
<text top="529" left="719" width="151" height="20" font="1">median follow-up of 56 mo, </text>
<text top="546" left="719" width="131" height="20" font="1">there was no difference </text>
<text top="563" left="719" width="113" height="20" font="1">between ramipril vs. </text>
<text top="581" left="719" width="148" height="20" font="1">telmisartan or combination </text>
<text top="598" left="719" width="157" height="20" font="1">therapy vs. ramipril in the 1° </text>
<text top="615" left="719" width="158" height="20" font="1">composite outcome of death </text>
<text top="632" left="719" width="155" height="20" font="1">from CV causes, MI, stroke, </text>
<text top="650" left="719" width="133" height="20" font="1">or hospitalization for HF </text>
<text top="667" left="719" width="137" height="20" font="1">(RR: 1.01; 95% CI: 0.94–</text>
<text top="684" left="719" width="154" height="20" font="1">1.09 and RR: 0.99; 95% CI: </text>
<text top="701" left="719" width="134" height="20" font="1">0.92–1.07, respectively) </text>
<text top="718" left="719" width="3" height="20" font="1"> </text>
<text top="736" left="719" width="103" height="20" font="4"><b>Safety endpoint:</b>  </text>
<text top="755" left="719" width="7" height="18" font="1">•</text>
<text top="754" left="726" width="145" height="20" font="1"> Combination therapy was </text>
<text top="771" left="719" width="152" height="20" font="1">associated with greater risk </text>
<text top="788" left="719" width="118" height="20" font="1">of hyperkalemia than </text>
<text top="512" left="890" width="75" height="20" font="4"><b>2</b>°<b> endpoint</b>: </text>
<text top="531" left="890" width="7" height="18" font="1">•</text>
<text top="530" left="897" width="152" height="20" font="1"> There was no difference in </text>
<text top="547" left="890" width="156" height="20" font="1">composite of death from CV </text>
<text top="565" left="890" width="151" height="20" font="1">causes, MI, or stroke in the </text>
<text top="582" left="890" width="167" height="20" font="1">ramipril vs. telmisartan groups </text>
<text top="599" left="890" width="161" height="20" font="1">RR: 0.99; 95% CI: 0.9–1.07); </text>
<text top="616" left="890" width="125" height="20" font="1">p=0.001 or ramipril vs. </text>
<text top="633" left="890" width="172" height="20" font="1">combination RR: 1.00; 95% CI: </text>
<text top="651" left="890" width="58" height="20" font="1">0.93–1.09 </text>
<text top="670" left="890" width="7" height="18" font="1">•</text>
<text top="669" left="897" width="150" height="20" font="1"> There were no differences </text>
<text top="686" left="890" width="176" height="20" font="1">between ramipril vs. telmisartan </text>
<text top="703" left="890" width="147" height="20" font="1">or ramipril vs. combination </text>
<text top="721" left="890" width="181" height="20" font="1">therapy in 2º outcomes including </text>
<text top="738" left="890" width="183" height="20" font="1">MI, stroke, hospitalization for HF, </text>
<text top="755" left="890" width="163" height="20" font="1">death from CV causes, death </text>
<text top="772" left="890" width="167" height="20" font="1">from non-CV causes, or death </text>
<text top="789" left="890" width="174" height="20" font="1">from any cause (p&gt;0.05 for all). </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">85 </text>
<text top="107" left="211" width="73" height="20" font="4"><b>Size:</b> 25,620 </text>
<text top="107" left="343" width="208" height="20" font="1">or PTCA &lt;3 mo, uncontrolled HTN on </text>
<text top="124" left="343" width="211" height="20" font="1">treatment [e.g., BP &gt;160/100 mm Hg], </text>
<text top="141" left="343" width="217" height="20" font="1">heart transplant recipient, stroke due to </text>
<text top="159" left="343" width="151" height="20" font="1">subarachnoid hemorrhage) </text>
<text top="178" left="343" width="7" height="18" font="1">•</text>
<text top="177" left="349" width="190" height="20" font="1"> Other conditions (significant renal </text>
<text top="194" left="343" width="196" height="20" font="1">artery disease, hepatic dysfunction, </text>
<text top="211" left="343" width="169" height="20" font="1">uncorrected volume or sodium </text>
<text top="229" left="343" width="187" height="20" font="1">depletion, 1° hyperaldosteronism, </text>
<text top="246" left="343" width="204" height="20" font="1">hereditary fructose intolerance, other </text>
<text top="263" left="343" width="217" height="20" font="1">major noncardiac illness or expected to </text>
<text top="280" left="343" width="198" height="20" font="1">reduce life expectancy or significant </text>
<text top="298" left="343" width="157" height="20" font="1">disability interfere with study </text>
<text top="315" left="343" width="194" height="20" font="1">participation, simultaneously taking </text>
<text top="332" left="343" width="205" height="20" font="1">another experimental drug, unable to </text>
<text top="349" left="343" width="189" height="20" font="1">provide written informed consent). </text>
<text top="107" left="719" width="147" height="20" font="1">ramipril monotherapy (480 </text>
<text top="124" left="719" width="139" height="20" font="1">pts vs. 283 pts; p&lt;0.001)<b> </b></text>
<text top="143" left="719" width="7" height="18" font="1">•</text>
<text top="143" left="726" width="134" height="20" font="1"> Hypotensive symptoms </text>
<text top="160" left="719" width="135" height="20" font="1">were cited as reason for </text>
<text top="177" left="719" width="137" height="20" font="1">permanent discontinuing </text>
<text top="194" left="719" width="127" height="20" font="1">more in telmisartan vs. </text>
<text top="211" left="719" width="156" height="20" font="1">ramipril (RR: 1.54; p&lt;0.001) </text>
<text top="229" left="719" width="157" height="20" font="1">and combination therapy vs. </text>
<text top="246" left="719" width="148" height="20" font="1">ramipril monotherapy (RR: </text>
<text top="263" left="719" width="83" height="20" font="1">2.75; p&lt;0.001)<b> </b></text>
<text top="282" left="719" width="7" height="18" font="1">•</text>
<text top="281" left="726" width="128" height="20" font="1"> Renal impairment was </text>
<text top="299" left="719" width="95" height="20" font="1">more common in </text>
<text top="316" left="719" width="133" height="20" font="1">combination therapy vs. </text>
<text top="333" left="719" width="143" height="20" font="1">ramipril monotherapy RR: </text>
<text top="350" left="719" width="129" height="20" font="1">1.33; 95% CI: 1.2–1.44<b> </b></text>
<text top="107" left="890" width="3" height="20" font="1"> </text>
<text top="124" left="890" width="180" height="20" font="4"><b>Summary</b>: Combination therapy </text>
<text top="141" left="890" width="176" height="20" font="1">with telmisartan and ramipril did </text>
<text top="159" left="890" width="152" height="20" font="1">not decrease the risk of CV </text>
<text top="176" left="890" width="135" height="20" font="1">events in pts at high risk </text>
<text top="193" left="890" width="172" height="20" font="1">compared to monotherapy with </text>
<text top="210" left="890" width="180" height="20" font="1">ramipril. In addition, combination </text>
<text top="228" left="890" width="157" height="20" font="1">therapy was associated with </text>
<text top="245" left="890" width="166" height="20" font="1">increased risk of hypotension, </text>
<text top="262" left="890" width="135" height="20" font="1">hyperkalemia, and renal </text>
<text top="279" left="890" width="68" height="20" font="1">impairment. </text>
<text top="370" left="108" width="3" height="19" font="1"> </text>
<text top="404" left="81" width="532" height="24" font="3"><b>Data Supplement 26. BP Goal for Patients with Hypertension (Section 8.1.5) </b></text>
<text top="444" left="98" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="461" left="104" width="86" height="20" font="4"><b>(if applicable)  </b></text>
<text top="478" left="123" width="44" height="20" font="4"><b>Author </b></text>
<text top="496" left="99" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="444" left="244" width="38" height="20" font="4"><b>Study </b></text>
<text top="461" left="222" width="81" height="20" font="4"><b>Type/Design; </b></text>
<text top="478" left="219" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="444" left="398" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="444" left="601" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="461" left="620" width="76" height="20" font="4"><b> (# patients)  </b></text>
<text top="478" left="601" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="496" left="622" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="444" left="746" width="131" height="20" font="4"><b>Primary Endpoint and </b></text>
<text top="461" left="788" width="48" height="20" font="4"><b>Results </b></text>
<text top="478" left="742" width="139" height="20" font="4"><b>(include P value; OR or </b></text>
<text top="496" left="769" width="85" height="20" font="4"><b>RR; &amp; 95% CI) </b></text>
<text top="444" left="922" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="461" left="950" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="514" left="98" width="78" height="20" font="1">Lawes CM, et </text>
<text top="531" left="98" width="76" height="20" font="1">al., 2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(50)</a> </text>
<text top="548" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12658016">12658016</a></text>
<text top="548" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12658016"> </a></text>
<text top="514" left="206" width="101" height="20" font="4"><b>Study type</b>: Meta-</text>
<text top="531" left="206" width="110" height="20" font="1">analysis of RCTs of </text>
<text top="548" left="206" width="109" height="20" font="1">BP drugs recording </text>
<text top="565" left="206" width="93" height="20" font="1">CHD events and </text>
<text top="582" left="206" width="43" height="20" font="1">strokes </text>
<text top="600" left="206" width="3" height="20" font="1"> </text>
<text top="617" left="206" width="99" height="20" font="4"><b>Size</b>: 464,000 pts </text>
<text top="514" left="332" width="24" height="20" font="1">N/A </text>
<text top="514" left="589" width="24" height="20" font="1">N/A </text>
<text top="515" left="737" width="7" height="18" font="1">•</text>
<text top="515" left="744" width="136" height="20" font="1"> CHD RR or 46% Stroke </text>
<text top="532" left="737" width="31" height="20" font="1">64%  </text>
<text top="515" left="899" width="7" height="18" font="1">•</text>
<text top="515" left="906" width="132" height="20" font="1"> All classes of BP meds </text>
<text top="532" left="899" width="167" height="20" font="1">confer benefit while BB confer </text>
<text top="549" left="899" width="154" height="20" font="1">greater benefit in those with </text>
<text top="566" left="899" width="29" height="20" font="1">CAD </text>
<text top="635" left="98" width="65" height="20" font="1">LV J, et al., </text>
<text top="652" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(127)</a> </text>
<text top="669" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459">23798459</a></text>
<text top="669" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459"> </a></text>
<text top="635" left="206" width="105" height="20" font="4"><b>Study type</b>: MA of </text>
<text top="652" left="206" width="107" height="20" font="1">RTC that randomly </text>
<text top="669" left="206" width="113" height="20" font="1">assigned individuals </text>
<text top="686" left="206" width="96" height="20" font="1">to different target </text>
<text top="704" left="206" width="58" height="20" font="1">BP levels  </text>
<text top="721" left="206" width="3" height="20" font="1"> </text>
<text top="738" left="206" width="78" height="20" font="4"><b>Size</b>: 15 trials </text>
<text top="755" left="206" width="102" height="20" font="1">including a total of </text>
<text top="772" left="206" width="61" height="20" font="1">37,348 pts </text>
<text top="635" left="332" width="24" height="20" font="1">N/A </text>
<text top="635" left="589" width="24" height="20" font="1">N/A </text>
<text top="635" left="737" width="104" height="20" font="1">7.5/4.5 mm Hg BP </text>
<text top="652" left="737" width="133" height="20" font="1">difference. Intensive BP </text>
<text top="669" left="737" width="109" height="20" font="1">lowering achieved.  </text>
<text top="686" left="737" width="42" height="20" font="1">RR for  </text>
<text top="705" left="737" width="7" height="18" font="1">•</text>
<text top="705" left="744" width="132" height="20" font="1"> Major CV events: 11%; </text>
<text top="722" left="737" width="104" height="20" font="1">95% CI: 1%–21%) </text>
<text top="741" left="737" width="7" height="18" font="1">•</text>
<text top="740" left="744" width="127" height="20" font="1"> MI: 13%; 95% CI: 0%–</text>
<text top="757" left="737" width="28" height="20" font="1">25% </text>
<text top="637" left="899" width="7" height="18" font="1">•</text>
<text top="636" left="906" width="152" height="20" font="1"> More intensive strategy for </text>
<text top="653" left="899" width="145" height="20" font="1">BP control reduced cardio-</text>
<text top="670" left="899" width="81" height="20" font="1">renal endpoint </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">86 </text>
<text top="109" left="737" width="7" height="18" font="1">•</text>
<text top="108" left="744" width="124" height="20" font="1"> Stroke: 24%; 95% CI: </text>
<text top="125" left="737" width="53" height="20" font="1">8%–37% </text>
<text top="144" left="737" width="7" height="18" font="1">•</text>
<text top="144" left="744" width="123" height="20" font="1"> ESRD: 11%; 95% CI: </text>
<text top="161" left="737" width="53" height="20" font="1">3%–18% </text>
<text top="180" left="737" width="7" height="18" font="1">•</text>
<text top="179" left="744" width="135" height="20" font="1"> Albuminuria: 10%; 95% </text>
<text top="197" left="737" width="75" height="20" font="1">CI: 4%–16%  </text>
<text top="216" left="737" width="7" height="18" font="1">•</text>
<text top="215" left="744" width="132" height="20" font="1"> Retinopathy 19%; 95% </text>
<text top="232" left="737" width="72" height="20" font="1">CI: 0%–34% </text>
<text top="249" left="737" width="52" height="20" font="1">p=0.051  </text>
<text top="267" left="98" width="70" height="20" font="1">Xie X, et al., </text>
<text top="285" left="98" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(21)</a> </text>
<text top="302" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation">26559744</a></text>
<text top="302" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation"><b> </b></a></text>
<text top="267" left="206" width="105" height="20" font="4"><b>Study type</b>: MA of </text>
<text top="285" left="206" width="107" height="20" font="1">RTC that randomly </text>
<text top="302" left="206" width="113" height="20" font="1">assigned individuals </text>
<text top="319" left="206" width="96" height="20" font="1">to different target </text>
<text top="336" left="206" width="55" height="20" font="1">BP levels </text>
<text top="353" left="206" width="3" height="20" font="1"> </text>
<text top="371" left="206" width="78" height="20" font="4"><b>Size</b>: 19 trials </text>
<text top="388" left="206" width="63" height="20" font="1">(n=44,989) </text>
<text top="267" left="332" width="24" height="20" font="1">N/A </text>
<text top="267" left="589" width="24" height="20" font="1">N/A </text>
<text top="267" left="737" width="74" height="20" font="1">Achieved BP </text>
<text top="285" left="737" width="144" height="20" font="1">133/76 mm Hg (intensive) </text>
<text top="302" left="737" width="118" height="20" font="1">140/81 (less intense) </text>
<text top="321" left="737" width="7" height="18" font="1">•</text>
<text top="320" left="744" width="132" height="20" font="1"> Major CV events: 14%; </text>
<text top="337" left="737" width="100" height="20" font="1">95% CI: 4%–22% </text>
<text top="356" left="737" width="7" height="18" font="1">•</text>
<text top="356" left="744" width="127" height="20" font="1"> MI: 13%; 95% CI: 0%–</text>
<text top="373" left="737" width="28" height="20" font="1">24% </text>
<text top="392" left="737" width="7" height="18" font="1">•</text>
<text top="391" left="744" width="125" height="20" font="1"> Stroke: 22%; 95% CI: </text>
<text top="409" left="737" width="60" height="20" font="1">10%–32% </text>
<text top="428" left="737" width="7" height="18" font="1">•</text>
<text top="427" left="744" width="135" height="20" font="1"> Albuminuria: 10%; 95% </text>
<text top="444" left="737" width="72" height="20" font="1">CI: 3%–16% </text>
<text top="463" left="737" width="7" height="18" font="1">•</text>
<text top="463" left="744" width="72" height="20" font="1"> Retinopathy </text>
<text top="480" left="737" width="131" height="20" font="1">progression: 19%; 95% </text>
<text top="497" left="737" width="79" height="20" font="1">CI: 0%–34%.  </text>
<text top="516" left="737" width="7" height="18" font="1">•</text>
<text top="515" left="744" width="128" height="20" font="1"> More intensive had no </text>
<text top="533" left="737" width="139" height="20" font="1">effects on HF: 15%; 95% </text>
<text top="550" left="737" width="83" height="20" font="1">CI: -11%–34% </text>
<text top="569" left="737" width="7" height="18" font="1">•</text>
<text top="568" left="744" width="137" height="20" font="1"> CV death: 9%; 95% CI: -</text>
<text top="585" left="737" width="60" height="20" font="1">11%–26% </text>
<text top="604" left="737" width="7" height="18" font="1">•</text>
<text top="604" left="744" width="140" height="20" font="1"> Total mortality: 9%; 95% </text>
<text top="621" left="737" width="76" height="20" font="1">CI: -3%–19% </text>
<text top="640" left="737" width="7" height="18" font="1">•</text>
<text top="639" left="744" width="126" height="20" font="1"> ESKD: 10%; 95% CI: -</text>
<text top="656" left="737" width="53" height="20" font="1">6%–23%<b> </b></text>
<text top="269" left="899" width="7" height="18" font="1">•</text>
<text top="269" left="906" width="141" height="20" font="1"> More intensive approach </text>
<text top="286" left="899" width="142" height="20" font="1">reduced major CV events </text>
<text top="303" left="899" width="153" height="20" font="1">(stroke and MI) except heat </text>
<text top="320" left="899" width="165" height="20" font="1">failure, CVD, ESRD, and total </text>
<text top="337" left="899" width="53" height="20" font="1">mortality. </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">87 </text>
<text top="107" left="98" width="90" height="20" font="1">Verdecchia P et </text>
<text top="124" left="98" width="54" height="20" font="1">al., 2016  </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27456518">27456518</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27456518"> </a></text>
<text top="107" left="206" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="124" left="206" width="96" height="20" font="1">Cumulative meta-</text>
<text top="141" left="206" width="110" height="20" font="1">analysis of RCTs to </text>
<text top="159" left="206" width="87" height="20" font="1">study benefit of </text>
<text top="176" left="206" width="76" height="20" font="1">more vs. less </text>
<text top="193" left="206" width="72" height="20" font="1">intensive BP </text>
<text top="210" left="206" width="49" height="20" font="1">lowering </text>
<text top="227" left="206" width="3" height="20" font="1"> </text>
<text top="245" left="206" width="78" height="20" font="4"><b>Size</b>: 18 trials </text>
<text top="262" left="206" width="63" height="20" font="1">(n=53,405) </text>
<text top="107" left="332" width="24" height="20" font="1">N/A </text>
<text top="107" left="589" width="24" height="20" font="1">N/A </text>
<text top="109" left="737" width="7" height="18" font="1">•</text>
<text top="108" left="744" width="119" height="20" font="1"> Stroke, MI, HF, CVD </text>
<text top="125" left="737" width="130" height="20" font="1">mortality, and all-cause </text>
<text top="143" left="737" width="50" height="20" font="1">mortality </text>
<text top="162" left="737" width="7" height="18" font="1">•</text>
<text top="161" left="744" width="129" height="20" font="1"> Difference in achieved </text>
<text top="178" left="737" width="145" height="20" font="1">SBP/DBP=7.6/4.5 mm Hg </text>
<text top="197" left="737" width="7" height="18" font="1">•</text>
<text top="197" left="744" width="124" height="20" font="1"> For stroke and MI the </text>
<text top="214" left="737" width="107" height="20" font="1">cumulative Z score </text>
<text top="231" left="737" width="112" height="20" font="1">crossed the efficacy </text>
<text top="248" left="737" width="143" height="20" font="1">boundary after addition of </text>
<text top="266" left="737" width="109" height="20" font="1">the SPRINT results </text>
<text top="285" left="737" width="7" height="18" font="1">•</text>
<text top="284" left="744" width="128" height="20" font="1"> For CVD mortality and </text>
<text top="301" left="737" width="117" height="20" font="1">HF, the cumulative Z </text>
<text top="318" left="737" width="100" height="20" font="1">curve crossed the </text>
<text top="336" left="737" width="140" height="20" font="1">conventional significance </text>
<text top="353" left="737" width="120" height="20" font="1">boundary (but not the </text>
<text top="370" left="737" width="120" height="20" font="1">sequential monitoring </text>
<text top="387" left="737" width="59" height="20" font="1">boundary) </text>
<text top="406" left="737" width="7" height="18" font="1">•</text>
<text top="406" left="744" width="131" height="20" font="1"> For all-cause mortality, </text>
<text top="423" left="737" width="147" height="20" font="1">the cumulative Z curve did </text>
<text top="440" left="737" width="147" height="20" font="1">not reside in the futility are </text>
<text top="457" left="737" width="114" height="20" font="1">but did not cross the </text>
<text top="474" left="737" width="140" height="20" font="1">conventional significance </text>
<text top="492" left="737" width="55" height="20" font="1">boundary </text>
<text top="109" left="899" width="7" height="18" font="1">•</text>
<text top="108" left="906" width="114" height="20" font="1"> The results strongly </text>
<text top="125" left="899" width="133" height="20" font="1">supported the benefit of </text>
<text top="143" left="899" width="143" height="20" font="1">intensive BP reduction for </text>
<text top="160" left="899" width="152" height="20" font="1">prevention of stroke and MI </text>
<text top="177" left="899" width="142" height="20" font="1">and suggested benefit for </text>
<text top="194" left="899" width="154" height="20" font="1">prevention of CVD mortality </text>
<text top="212" left="899" width="47" height="20" font="1">and HF  </text>
<text top="510" left="98" width="88" height="20" font="1">Bangalore S, et </text>
<text top="527" left="98" width="54" height="20" font="1">al., 2017  </text>
<text top="544" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28109971">28109971</a></text>
<text top="544" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28109971"> </a></text>
<text top="510" left="206" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="527" left="206" width="80" height="20" font="1">Network meta-</text>
<text top="544" left="206" width="96" height="20" font="1">analysis in which </text>
<text top="561" left="206" width="65" height="20" font="1">the authors </text>
<text top="578" left="206" width="72" height="20" font="1">attempted to </text>
<text top="596" left="206" width="72" height="20" font="1">compare the </text>
<text top="613" left="206" width="70" height="20" font="1">benefits and </text>
<text top="630" left="206" width="87" height="20" font="1">adverse effects </text>
<text top="647" left="206" width="78" height="20" font="1">resulting from </text>
<text top="664" left="206" width="106" height="20" font="1">intensive reduction </text>
<text top="682" left="206" width="41" height="20" font="1">in SBP </text>
<text top="699" left="206" width="3" height="20" font="1"> </text>
<text top="716" left="206" width="78" height="20" font="4"><b>Size</b>: 17 trials </text>
<text top="733" left="206" width="63" height="20" font="1">(n=55,163) </text>
<text top="510" left="332" width="24" height="20" font="1">N/A </text>
<text top="510" left="589" width="24" height="20" font="1">N/A </text>
<text top="511" left="737" width="7" height="18" font="1">•</text>
<text top="511" left="744" width="132" height="20" font="1"> There was a significant </text>
<text top="528" left="737" width="132" height="20" font="1">reduction in stroke (RR: </text>
<text top="545" left="737" width="133" height="20" font="1">0.54) and MI (RR: 0.68) </text>
<text top="564" left="737" width="7" height="18" font="1">•</text>
<text top="563" left="744" width="108" height="20" font="1"> The point estimate </text>
<text top="581" left="737" width="97" height="20" font="1">favored all-cause </text>
<text top="598" left="737" width="132" height="20" font="1">mortality, CVD mortality </text>
<text top="615" left="737" width="144" height="20" font="1">and HF but the results did </text>
<text top="632" left="737" width="134" height="20" font="1">not achieve significance </text>
<text top="651" left="737" width="7" height="18" font="1">•</text>
<text top="651" left="744" width="127" height="20" font="1"> SBP targets &lt;120 and </text>
<text top="668" left="737" width="132" height="20" font="1">&lt;130 mm Hg ranked #1 </text>
<text top="685" left="737" width="108" height="20" font="1">and #2 as the most </text>
<text top="702" left="737" width="62" height="20" font="1">efficacious </text>
<text top="721" left="737" width="7" height="18" font="1">•</text>
<text top="721" left="744" width="135" height="20" font="1"> Serious adverse effects </text>
<text top="738" left="737" width="136" height="20" font="1">were more common at a </text>
<text top="755" left="737" width="146" height="20" font="1">lower SBP (120 vs. 150 or </text>
<text top="772" left="737" width="71" height="20" font="1">140 mm Hg) </text>
<text top="511" left="899" width="7" height="18" font="1">•</text>
<text top="511" left="906" width="165" height="20" font="1"> Overall, the beneficial effects </text>
<text top="528" left="899" width="158" height="20" font="1">of treatment were consistent </text>
<text top="545" left="899" width="166" height="20" font="1">with other reports. The cluster </text>
<text top="562" left="899" width="158" height="20" font="1">plots of treatment benefit vs. </text>
<text top="580" left="899" width="172" height="20" font="1">risk are difficult to interpret due </text>
<text top="597" left="899" width="158" height="20" font="1">to limitations of the available </text>
<text top="614" left="899" width="149" height="20" font="1">data base and the authors’ </text>
<text top="631" left="899" width="156" height="20" font="1">decision to weight treatment </text>
<text top="648" left="899" width="167" height="20" font="1">benefits and potential adverse </text>
<text top="666" left="899" width="85" height="20" font="1">effects equally. </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">88 </text>
<text top="109" left="737" width="7" height="18" font="1">•</text>
<text top="108" left="744" width="93" height="20" font="1"> Cluster plots for </text>
<text top="125" left="737" width="126" height="20" font="1">combined efficacy and </text>
<text top="143" left="737" width="135" height="20" font="1">safety suggested a SBP </text>
<text top="160" left="737" width="111" height="20" font="1">&lt;130 mm Hg as the </text>
<text top="177" left="737" width="124" height="20" font="1">optimal target for SBP </text>
<text top="194" left="737" width="151" height="20" font="1">reduction during treatment  </text>
<text top="314" left="98" width="94" height="20" font="1">Bundy JD, et al., </text>
<text top="331" left="98" width="31" height="20" font="1">2017 </text>
<text top="348" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28564682">28564682</a></text>
<text top="348" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28564682"> </a></text>
<text top="314" left="206" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="331" left="206" width="102" height="20" font="1">Systematic review </text>
<text top="348" left="206" width="102" height="20" font="1">and network meta-</text>
<text top="365" left="206" width="103" height="20" font="1">analysis to assess </text>
<text top="382" left="206" width="81" height="20" font="1">the benefits of </text>
<text top="400" left="206" width="80" height="20" font="1">intensive SBP </text>
<text top="417" left="206" width="92" height="20" font="1">reduction during </text>
<text top="434" left="206" width="69" height="20" font="1">treatment of </text>
<text top="451" left="206" width="74" height="20" font="1">hypertension </text>
<text top="469" left="206" width="3" height="20" font="1"> </text>
<text top="486" left="206" width="78" height="20" font="4"><b>Size</b>: 42 trials </text>
<text top="503" left="206" width="70" height="20" font="1">(n=144,220) </text>
<text top="314" left="332" width="24" height="20" font="1">N/A </text>
<text top="314" left="589" width="24" height="20" font="1">N/A </text>
<text top="315" left="737" width="7" height="18" font="1">•</text>
<text top="315" left="744" width="127" height="20" font="1"> In general, there were </text>
<text top="332" left="737" width="104" height="20" font="1">linear associations </text>
<text top="349" left="737" width="130" height="20" font="1">between achieved SPB </text>
<text top="366" left="737" width="130" height="20" font="1">and risk of CVD and all-</text>
<text top="384" left="737" width="135" height="20" font="1">cause mortality, with the </text>
<text top="401" left="737" width="126" height="20" font="1">lowest risk at a SBP of </text>
<text top="418" left="737" width="98" height="20" font="1">120–124 mm Hg. </text>
<text top="315" left="899" width="7" height="18" font="1">•</text>
<text top="315" left="906" width="150" height="20" font="1"> This was by far the largest </text>
<text top="332" left="899" width="133" height="20" font="1">and best powered meta-</text>
<text top="349" left="899" width="124" height="20" font="1">analysis to assess the </text>
<text top="366" left="899" width="144" height="20" font="1">relationship between SBP </text>
<text top="384" left="899" width="169" height="20" font="1">reduction and major outcomes </text>
<text top="401" left="899" width="107" height="20" font="1">during treatment of </text>
<text top="418" left="899" width="148" height="20" font="1">hypertension. The findings </text>
<text top="435" left="899" width="159" height="20" font="1">provided strong evidence for </text>
<text top="453" left="899" width="163" height="20" font="1">the “lower is better” approach </text>
<text top="470" left="899" width="164" height="20" font="1">to treatment in patients with a </text>
<text top="487" left="899" width="165" height="20" font="1">high SBP who are at high risk </text>
<text top="504" left="899" width="51" height="20" font="1">for CVD. </text>
<text top="522" left="98" width="89" height="20" font="1">Lawes CMM, et </text>
<text top="539" left="98" width="51" height="20" font="1">al., 2002 </text>
<text top="557" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16222626">16222626</a></text>
<text top="557" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16222626"> </a></text>
<text top="522" left="206" width="113" height="20" font="4"><b>Study type</b>: Review </text>
<text top="539" left="206" width="90" height="20" font="1">of observational </text>
<text top="557" left="206" width="66" height="20" font="1">reports and </text>
<text top="574" left="206" width="68" height="20" font="1">randomized </text>
<text top="591" left="206" width="86" height="20" font="1">controlled trials </text>
<text top="522" left="332" width="24" height="20" font="1">N/A </text>
<text top="522" left="589" width="24" height="20" font="1">N/A </text>
<text top="524" left="737" width="7" height="18" font="1">•</text>
<text top="523" left="744" width="131" height="20" font="1"> The relative benefits of </text>
<text top="540" left="737" width="117" height="20" font="1">BP lowering for CHD </text>
<text top="558" left="737" width="122" height="20" font="1">prevention likely to be </text>
<text top="575" left="737" width="137" height="20" font="1">consistent across a wide </text>
<text top="592" left="737" width="96" height="20" font="1">range of different </text>
<text top="609" left="737" width="66" height="20" font="1">populations </text>
<text top="628" left="737" width="7" height="18" font="1">•</text>
<text top="628" left="744" width="142" height="20" font="1"> Likely to be considerable </text>
<text top="645" left="737" width="127" height="20" font="1">benefit for BP lowering </text>
<text top="662" left="737" width="100" height="20" font="1">beyond traditional </text>
<text top="679" left="737" width="134" height="20" font="1">thresholds, especially in </text>
<text top="697" left="737" width="144" height="20" font="1">those at high risk for CVD </text>
<text top="716" left="737" width="7" height="18" font="1">•</text>
<text top="715" left="744" width="129" height="20" font="1"> BP lowering is likely to </text>
<text top="732" left="737" width="131" height="20" font="1">be more important than </text>
<text top="749" left="737" width="118" height="20" font="1">choice of initial agent </text>
<text top="768" left="737" width="7" height="18" font="1">•</text>
<text top="768" left="744" width="106" height="20" font="1"> A large majority of </text>
<text top="785" left="737" width="140" height="20" font="1">patients being treated for </text>
<text top="524" left="899" width="7" height="18" font="1">•</text>
<text top="523" left="906" width="161" height="20" font="1"> Strongly supports lower BPs </text>
<text top="540" left="899" width="174" height="20" font="1">during BP treatment, especially </text>
<text top="558" left="899" width="152" height="20" font="1">in those at high risk of CVD </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">89 </text>
<text top="107" left="737" width="104" height="20" font="1">hypertension have </text>
<text top="124" left="737" width="147" height="20" font="1">suboptimal BPs. Initiatives </text>
<text top="141" left="737" width="132" height="20" font="1">to lower their BP further </text>
<text top="159" left="737" width="73" height="20" font="1">are essential </text>
<text top="314" left="108" width="3" height="20" font="1"> </text>
<text top="348" left="108" width="3" height="20" font="1"> </text>
<text top="384" left="99" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="401" left="124" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="418" left="102" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="384" left="229" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="401" left="233" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="418" left="227" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="384" left="373" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="384" left="560" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="401" left="576" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="418" left="560" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="436" left="581" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="384" left="754" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="401" left="734" width="144" height="20" font="4"><b>(include Absolute Event </b></text>
<text top="418" left="786" width="44" height="20" font="4"><b>Rates,  </b></text>
<text top="436" left="737" width="142" height="20" font="4"><b>P value; OR or RR; and  </b></text>
<text top="453" left="782" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="385" left="921" width="143" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="402" left="976" width="33" height="20" font="4"><b>any); </b></text>
<text top="420" left="937" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="437" left="944" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="471" left="98" width="73" height="20" font="1">Xie X, et al.,  </text>
<text top="488" left="98" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(21)</a> </text>
<text top="505" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation">26559744</a></text>
<text top="505" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation"> </a></text>
<text top="471" left="211" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="488" left="211" width="105" height="20" font="1">efficacy and safety </text>
<text top="505" left="211" width="86" height="20" font="1">of intensive BP-</text>
<text top="522" left="211" width="109" height="20" font="1">lowering strategies. </text>
<text top="540" left="211" width="3" height="20" font="1"> </text>
<text top="557" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="574" left="211" width="96" height="20" font="1">analysis of RCTs </text>
<text top="591" left="211" width="3" height="20" font="1"> </text>
<text top="608" left="211" width="109" height="20" font="4"><b>Size:</b> 19 RCTs with </text>
<text top="626" left="211" width="61" height="20" font="1">44,989 pts </text>
<text top="471" left="343" width="166" height="20" font="4"><b>Inclusion criteria:</b> RCTs with </text>
<text top="488" left="343" width="150" height="20" font="1">at least 6 mo follow-up that </text>
<text top="505" left="343" width="172" height="20" font="1">randomly assigned pts to more </text>
<text top="522" left="343" width="148" height="20" font="1">intensive vs. less intensive </text>
<text top="540" left="343" width="154" height="20" font="1">BP-lowering treatment, with </text>
<text top="557" left="343" width="171" height="20" font="1">different BP targets or different </text>
<text top="574" left="343" width="150" height="20" font="1">BP changes from baseline. </text>
<text top="591" left="343" width="165" height="20" font="1">Reference lists from identified </text>
<text top="608" left="343" width="165" height="20" font="1">trials and review articles were </text>
<text top="626" left="343" width="158" height="20" font="1">manually scanned to identify </text>
<text top="643" left="343" width="151" height="20" font="1">any other relevant studies.  </text>
<text top="660" left="343" width="3" height="20" font="1"> </text>
<text top="677" left="343" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="471" left="528" width="148" height="20" font="4"><b>Intervention:</b> BP-lowering </text>
<text top="488" left="528" width="37" height="20" font="1">meds  </text>
<text top="505" left="528" width="7" height="20" font="1">  </text>
<text top="522" left="528" width="84" height="20" font="4"><b>Comparator:</b>   </text>
<text top="541" left="528" width="7" height="18" font="1">•</text>
<text top="541" left="535" width="140" height="20" font="1"> Less intensive treatment </text>
<text top="560" left="528" width="7" height="18" font="1">•</text>
<text top="559" left="535" width="122" height="20" font="1"> BP difference 6.8/3.5 </text>
<text top="578" left="528" width="7" height="18" font="1">•</text>
<text top="577" left="535" width="135" height="20" font="1"> The mean follow-up BP </text>
<text top="595" left="528" width="166" height="20" font="1">levels in the less intensive BP-</text>
<text top="612" left="528" width="49" height="20" font="1">lowering </text>
<text top="629" left="528" width="154" height="20" font="1">regimen group were 140/81 </text>
<text top="646" left="528" width="130" height="20" font="1">mm Hg, compared with </text>
<text top="664" left="528" width="149" height="20" font="1">133/76 mm Hg in the more </text>
<text top="681" left="528" width="146" height="20" font="1">intensive treatment group. </text>
<text top="472" left="716" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="491" left="716" width="7" height="18" font="1">•</text>
<text top="490" left="723" width="165" height="20" font="1"> CVD, other major CV events, </text>
<text top="508" left="716" width="169" height="20" font="1">defined as a MI, stroke, HF, or </text>
<text top="525" left="716" width="142" height="20" font="1">CV death, separately and </text>
<text top="542" left="716" width="170" height="20" font="1">combined; nonvascular and all-</text>
<text top="559" left="716" width="154" height="20" font="1">cause mortality; ESKD, and </text>
<text top="576" left="716" width="173" height="20" font="1">adverse events. Progression of </text>
<text top="594" left="716" width="157" height="20" font="1">albuminuria (defined as new </text>
<text top="611" left="716" width="81" height="20" font="1">onset of micro-</text>
<text top="628" left="716" width="172" height="20" font="1">albuminuria/macro-albuminuria </text>
<text top="645" left="716" width="131" height="20" font="1">or a change from micro-</text>
<text top="662" left="716" width="119" height="20" font="1">albuminuria to macro-</text>
<text top="680" left="716" width="71" height="20" font="1">albuminuria) </text>
<text top="697" left="716" width="157" height="20" font="1">and retinopathy (retinopathy </text>
<text top="714" left="716" width="174" height="20" font="1">progression of 2 or more steps) </text>
<text top="731" left="716" width="179" height="20" font="1">were also recorded for trials that </text>
<text top="749" left="716" width="141" height="20" font="1">were done in pts with DM </text>
<text top="767" left="716" width="7" height="18" font="1">•</text>
<text top="767" left="723" width="167" height="20" font="1"> CVD RR: 0.86 (95% CI: 0.78–</text>
<text top="784" left="716" width="31" height="20" font="1">0.96) </text>
<text top="471" left="909" width="137" height="20" font="4"><b>Summary:</b> Intensive BP-</text>
<text top="488" left="909" width="149" height="20" font="1">lowering, including to &lt;130 </text>
<text top="505" left="909" width="140" height="20" font="1">mm Hg, provided greater </text>
<text top="522" left="909" width="134" height="20" font="1">vascular protection than </text>
<text top="540" left="909" width="150" height="20" font="1">standard regimens. In high-</text>
<text top="557" left="909" width="154" height="20" font="1">risk pts, there are additional </text>
<text top="574" left="909" width="158" height="20" font="1">benefits from more intensive </text>
<text top="591" left="909" width="143" height="20" font="1">BP-lowering, including for </text>
<text top="608" left="909" width="161" height="20" font="1">those with SPB &lt;140 mm Hg </text>
<text top="626" left="909" width="161" height="20" font="1">at baseline. The net absolute </text>
<text top="643" left="909" width="132" height="20" font="1">benefits of intensive BP-</text>
<text top="660" left="909" width="112" height="20" font="1">lowering in high-risk </text>
<text top="677" left="909" width="116" height="20" font="1">individuals are large. </text>
<text top="694" left="909" width="3" height="20" font="1"> </text>
<text top="712" left="909" width="80" height="20" font="4"><b>Limitations:</b>   </text>
<text top="731" left="909" width="7" height="18" font="1">•</text>
<text top="730" left="916" width="146" height="20" font="1"> Lack of individual pt data, </text>
<text top="747" left="909" width="156" height="20" font="1">which would have allowed a </text>
<text top="764" left="909" width="157" height="20" font="1">more reliable assessment of </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">90 </text>
<text top="107" left="716" width="3" height="20" font="1"> </text>
<text top="124" left="716" width="103" height="20" font="4"><b>Other endpoints: </b></text>
<text top="143" left="716" width="7" height="18" font="1">•</text>
<text top="143" left="723" width="154" height="20" font="1"> MI RR: 0.87 (95% CI: 0.76–</text>
<text top="160" left="716" width="80" height="20" font="1">1.00) p=0.042 </text>
<text top="179" left="716" width="7" height="18" font="1">•</text>
<text top="178" left="723" width="145" height="20" font="1"> Stroke RR: 0.78 (95% CI: </text>
<text top="195" left="716" width="62" height="20" font="1">0.68–0.90) </text>
<text top="214" left="716" width="7" height="18" font="1">•</text>
<text top="214" left="723" width="157" height="20" font="1"> HF RR: 0.85 (95% CI: 0.66–</text>
<text top="231" left="716" width="31" height="20" font="1">1.11) </text>
<text top="250" left="716" width="7" height="18" font="1">•</text>
<text top="249" left="723" width="170" height="20" font="1"> CVD death RR: 0.91 (95% CI: </text>
<text top="267" left="716" width="62" height="20" font="1">0.74–1.11) </text>
<text top="286" left="716" width="7" height="18" font="1">•</text>
<text top="285" left="723" width="159" height="20" font="1"> Total deaths RR: 0.91 (95% </text>
<text top="302" left="716" width="81" height="20" font="1">CI: 0.81–1.03) </text>
<text top="320" left="716" width="3" height="20" font="1"> </text>
<text top="337" left="716" width="84" height="20" font="4"><b>Other results: </b></text>
<text top="356" left="716" width="7" height="18" font="1">•</text>
<text top="355" left="723" width="161" height="20" font="1"> Benefit for CVD not different </text>
<text top="372" left="716" width="94" height="20" font="1">by baseline SBP </text>
<text top="390" left="716" width="164" height="20" font="1">120–139: 0.89 (95% CI: 0.76–</text>
<text top="407" left="716" width="31" height="20" font="1">1.05) </text>
<text top="424" left="716" width="164" height="20" font="1">140–160: 0.83 (95% CI: 0.68–</text>
<text top="441" left="716" width="31" height="20" font="1">1.00) </text>
<text top="458" left="716" width="176" height="20" font="1">&gt;160: 0.89 (95% CI: 0.73–1.09) </text>
<text top="476" left="716" width="120" height="20" font="1">p-heterogeneity: 0.60 </text>
<text top="495" left="716" width="7" height="18" font="1">•</text>
<text top="494" left="723" width="161" height="20" font="1"> Benefit for CVD not different </text>
<text top="511" left="716" width="150" height="20" font="1">for more intensive and less </text>
<text top="528" left="716" width="158" height="20" font="1">intensive targets in intensive </text>
<text top="546" left="716" width="35" height="20" font="1">group </text>
<text top="563" left="716" width="150" height="20" font="1">&lt;140 or &lt;150 mm Hg: 0.76 </text>
<text top="580" left="716" width="114" height="20" font="1">(95% CI: 0.60–0.97) </text>
<text top="597" left="716" width="175" height="20" font="1">&lt;120– &lt;130 mm Hg: 0.91 (95% </text>
<text top="614" left="716" width="165" height="20" font="1">CI: 0.84–1.00; p-hetero: 0.06) </text>
<text top="633" left="716" width="7" height="18" font="1">•</text>
<text top="633" left="723" width="131" height="20" font="1"> Absolute benefits were </text>
<text top="650" left="716" width="158" height="20" font="1">proportional to absolute risk. </text>
<text top="669" left="716" width="7" height="18" font="1">•</text>
<text top="668" left="723" width="162" height="20" font="1"> For trials in which all pts had </text>
<text top="686" left="716" width="178" height="20" font="1">vascular disease, renal disease, </text>
<text top="703" left="716" width="172" height="20" font="1">or DM at baseline, the average </text>
<text top="720" left="716" width="148" height="20" font="1">control group rate of major </text>
<text top="737" left="716" width="177" height="20" font="1">vascular events was 2·9% per y </text>
<text top="754" left="716" width="159" height="20" font="1">compared with 0·9% per y in </text>
<text top="772" left="716" width="160" height="20" font="1">other trials, and the numbers </text>
<text top="789" left="716" width="165" height="20" font="1">needed to treat were 94 (95% </text>
<text top="107" left="909" width="156" height="20" font="1">treatment effects in different </text>
<text top="124" left="909" width="58" height="20" font="1">pt groups. </text>
<text top="143" left="909" width="7" height="18" font="1">•</text>
<text top="143" left="916" width="135" height="20" font="1"> Interpretation: Supports </text>
<text top="160" left="909" width="150" height="20" font="1">treating pt with and without </text>
<text top="177" left="909" width="148" height="20" font="1">CVD at threshold of 130 to </text>
<text top="194" left="909" width="145" height="20" font="1">&lt;130. Supports treating at </text>
<text top="211" left="909" width="156" height="20" font="1">threshold of about 130 even </text>
<text top="229" left="909" width="158" height="20" font="1">down to a CVD event rate of </text>
<text top="246" left="909" width="66" height="20" font="1">0.9% per y. </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">91 </text>
<text top="107" left="716" width="163" height="20" font="1">CI: 44–782) in these trials vs. </text>
<text top="124" left="716" width="159" height="20" font="1">186 (95% CI: 107–708) in all </text>
<text top="141" left="716" width="64" height="20" font="1">other trials. </text>
<text top="160" left="716" width="7" height="18" font="1">•</text>
<text top="160" left="723" width="107" height="20" font="1"> Increase in severe </text>
<text top="177" left="716" width="176" height="20" font="1">hypotension: 0.3% vs. 0.1% per </text>
<text top="194" left="716" width="155" height="20" font="1">person y OR: 2.68 (95% CI: </text>
<text top="211" left="716" width="62" height="20" font="1">1.21–5.89) </text>
<text top="229" left="98" width="84" height="20" font="1">Julius S, et al., </text>
<text top="247" left="98" width="56" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(55)</a> </text>
<text top="264" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16537662">16537662</a></text>
<text top="264" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16537662"><b> </b></a></text>
<text top="229" left="211" width="111" height="20" font="4"><b>Study type</b>: RCT in </text>
<text top="247" left="211" width="85" height="20" font="1">pre-HTN16 mg </text>
<text top="264" left="211" width="90" height="20" font="1">candesartan vs. </text>
<text top="281" left="211" width="46" height="20" font="1">placebo </text>
<text top="298" left="211" width="3" height="20" font="1"> </text>
<text top="316" left="211" width="75" height="20" font="4"><b>Size</b>: 809 pts </text>
<text top="231" left="343" width="7" height="18" font="1">•</text>
<text top="231" left="350" width="59" height="20" font="1"> 58% men<b> </b></text>
<text top="229" left="528" width="24" height="20" font="1">N/A </text>
<text top="231" left="718" width="7" height="18" font="1">•</text>
<text top="231" left="725" width="139" height="20" font="1"> During the first 2 y, HTN </text>
<text top="251" left="718" width="176" height="20" font="1">developed in 154 (40.4%) pts in </text>
<text top="271" left="718" width="160" height="20" font="1">the placebo group compared </text>
<text top="290" left="718" width="175" height="20" font="1">with only 53 (13.6%) of those in </text>
<text top="310" left="718" width="158" height="20" font="1">the candesartan group, for a </text>
<text top="330" left="718" width="169" height="20" font="1">RR of 66.3% (p&lt;0.0001). After </text>
<text top="350" left="718" width="149" height="20" font="1">4 y, HTN developed in 240 </text>
<text top="369" left="718" width="161" height="20" font="1">(63.0%) in the placebo group </text>
<text top="389" left="718" width="149" height="20" font="1">vs. only 208 (53.2%) in the </text>
<text top="409" left="718" width="165" height="20" font="1">candesartan group RR 15.6% </text>
<text top="429" left="718" width="67" height="20" font="1">(p&lt;0.0069). </text>
<text top="231" left="909" width="7" height="18" font="1">•</text>
<text top="231" left="916" width="147" height="20" font="1"> 2/3 of those with pre-HTN </text>
<text top="251" left="909" width="133" height="20" font="1">develop HTN within 4 y. </text>
<text top="271" left="909" width="149" height="20" font="1">Candesartan interrupts the </text>
<text top="290" left="909" width="160" height="20" font="1">onset and reduced by 15.6% </text>
<text top="464" left="98" width="98" height="20" font="1">Lawes CM, et al., </text>
<text top="481" left="98" width="56" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(50)</a> </text>
<text top="499" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12658016">12658016</a></text>
<text top="499" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12658016"> </a></text>
<text top="464" left="211" width="101" height="20" font="4"><b>Study type</b>: Meta-</text>
<text top="481" left="211" width="110" height="20" font="1">analysis of RCTs of </text>
<text top="499" left="211" width="109" height="20" font="1">BP drugs recording </text>
<text top="516" left="211" width="93" height="20" font="1">CHD events and </text>
<text top="533" left="211" width="43" height="20" font="1">strokes </text>
<text top="550" left="211" width="3" height="20" font="1"> </text>
<text top="568" left="211" width="99" height="20" font="4"><b>Size</b>: 464,000 pts </text>
<text top="464" left="343" width="24" height="20" font="1">N/A </text>
<text top="464" left="528" width="24" height="20" font="1">N/A </text>
<text top="466" left="718" width="7" height="18" font="1">•</text>
<text top="465" left="725" width="323" height="20" font="1"> CHD RR or 46% Stroke 64%   • All classes of BP meds </text>
<text top="485" left="909" width="129" height="20" font="1">confer benefit while BB </text>
<text top="505" left="909" width="133" height="20" font="1">confer greater benefit in </text>
<text top="525" left="909" width="88" height="20" font="1">those with CAD </text>
<text top="586" left="98" width="93" height="20" font="1">Lonn EM, et al.,  </text>
<text top="603" left="98" width="63" height="20" font="1">2016 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(116)</a> </text>
<text top="620" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27041480">27041480</a></text>
<text top="620" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27041480"> </a></text>
<text top="586" left="211" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="603" left="211" width="119" height="20" font="1">efficacy of fixed-dose </text>
<text top="620" left="211" width="93" height="20" font="1">antihypertensive </text>
<text top="637" left="211" width="119" height="20" font="1">therapy in adults with </text>
<text top="654" left="211" width="100" height="20" font="1">intermediate CVD </text>
<text top="672" left="211" width="26" height="20" font="1">risk. </text>
<text top="689" left="211" width="3" height="20" font="1"> </text>
<text top="706" left="211" width="113" height="20" font="4"><b>Study type</b>: Double-</text>
<text top="723" left="211" width="80" height="20" font="1">blind, placebo-</text>
<text top="740" left="211" width="89" height="20" font="1">controlled RCT, </text>
<text top="758" left="211" width="86" height="20" font="1">factorial design </text>
<text top="775" left="211" width="3" height="20" font="1"> </text>
<text top="586" left="343" width="168" height="20" font="4"><b>Inclusion criteria: </b>Men ≥55 y </text>
<text top="603" left="343" width="116" height="20" font="1">and women ≥60 y at </text>
<text top="620" left="343" width="163" height="20" font="1">intermediate risk for CVD. No </text>
<text top="637" left="343" width="86" height="20" font="1">BP restrictions. </text>
<text top="654" left="343" width="3" height="20" font="1"> </text>
<text top="672" left="343" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="691" left="343" width="7" height="18" font="1">•</text>
<text top="690" left="350" width="74" height="20" font="1"> Known CVD </text>
<text top="709" left="343" width="7" height="18" font="1">•</text>
<text top="708" left="350" width="80" height="20" font="1"> Indications or </text>
<text top="726" left="343" width="142" height="20" font="1">contraindications to study </text>
<text top="743" left="343" width="33" height="20" font="1">meds </text>
<text top="762" left="343" width="7" height="18" font="1">•</text>
<text top="761" left="350" width="117" height="20" font="1"> Mod/advanced CKD </text>
<text top="780" left="343" width="7" height="18" font="1">•</text>
<text top="779" left="350" width="148" height="20" font="1"> Symptomatic hypotension </text>
<text top="586" left="528" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="603" left="528" width="163" height="20" font="1">FDC of ARB (candesartan 16 </text>
<text top="620" left="528" width="102" height="20" font="1">mg/d) and diuretic </text>
<text top="637" left="528" width="141" height="20" font="1">(hydrochlorothiazide 12.5 </text>
<text top="654" left="528" width="96" height="20" font="1">mg/d) or placebo </text>
<text top="672" left="528" width="3" height="20" font="1"> </text>
<text top="689" left="528" width="65" height="20" font="4"><b>Follow-up</b>: </text>
<text top="706" left="528" width="78" height="20" font="1">Median=5.6 y </text>
<text top="587" left="716" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="604" left="716" width="132" height="20" font="1">1 co-1° CVD composite </text>
<text top="621" left="716" width="57" height="20" font="1">outcomes </text>
<text top="640" left="716" width="7" height="18" font="1">•</text>
<text top="640" left="723" width="154" height="20" font="1"> CVD mortality, nonfatal MI, </text>
<text top="657" left="716" width="84" height="20" font="1">nonfatal stroke<b> </b></text>
<text top="676" left="716" width="7" height="18" font="1">•</text>
<text top="675" left="723" width="172" height="20" font="1"> Above plus cardiac arrest, HF, </text>
<text top="695" left="716" width="96" height="20" font="1">revascularization </text>
<text top="586" left="909" width="64" height="20" font="4"><b>Summary:</b> </text>
<text top="605" left="909" width="7" height="18" font="1">•</text>
<text top="604" left="916" width="128" height="20" font="1"> SBP/DBP reduction of </text>
<text top="621" left="909" width="84" height="20" font="1">6.0/3.0 mm Hg </text>
<text top="638" left="909" width="3" height="20" font="1"> </text>
<text top="657" left="909" width="7" height="18" font="1">•</text>
<text top="657" left="916" width="148" height="20" font="1"> No difference in treatment </text>
<text top="674" left="909" width="33" height="20" font="1">effect </text>
<text top="693" left="909" width="7" height="18" font="1">•</text>
<text top="692" left="916" width="57" height="20" font="1"> 1st co-1° </text>
<text top="710" left="909" width="97" height="20" font="1"> 0.93 (0.79–1.10) </text>
<text top="729" left="909" width="7" height="18" font="1">•</text>
<text top="728" left="916" width="61" height="20" font="1"> 2nd co-1° </text>
<text top="745" left="909" width="97" height="20" font="1"> 0.95 (0.81–1.11) </text>
<text top="762" left="909" width="3" height="20" font="1"> </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">92 </text>
<text top="107" left="211" width="92" height="20" font="4"><b>Size</b>: 12,705 pts </text>
<text top="109" left="909" width="7" height="18" font="1">•</text>
<text top="108" left="916" width="147" height="20" font="1"> Suggestion of a subgroup </text>
<text top="128" left="909" width="126" height="20" font="1">effect in tertile with the </text>
<text top="148" left="909" width="136" height="20" font="1">highest baseline BP and </text>
<text top="168" left="909" width="116" height="20" font="1">increased CVD risk.  </text>
<text top="203" left="98" width="98" height="20" font="1">Neaton JD, et al., </text>
<text top="220" left="98" width="63" height="20" font="1">1993 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(117)</a> </text>
<text top="238" left="98" width="48" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8336373">8336373</a></text>
<text top="238" left="145" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8336373"><b> </b></a></text>
<text top="203" left="211" width="110" height="20" font="4"><b>Aim: </b>To compare 6 </text>
<text top="220" left="211" width="93" height="20" font="1">antihypertensive </text>
<text top="238" left="211" width="110" height="20" font="1">drugs (representing </text>
<text top="255" left="211" width="76" height="20" font="1">different drug </text>
<text top="272" left="211" width="52" height="20" font="1">classes)  </text>
<text top="289" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="307" left="211" width="114" height="20" font="4"><b>Study type: </b>Double-</text>
<text top="324" left="211" width="80" height="20" font="1">blind, placebo-</text>
<text top="341" left="211" width="89" height="20" font="1">controlled RCT  </text>
<text top="358" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="375" left="211" width="101" height="20" font="4"><b>Size: </b>902 pts with </text>
<text top="393" left="211" width="73" height="20" font="1">stage 1 HTN<b> </b></text>
<text top="203" left="343" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="222" left="343" width="7" height="18" font="1">•</text>
<text top="222" left="350" width="145" height="20" font="1"> Men and women 45–69 y<b> </b></text>
<text top="241" left="343" width="7" height="18" font="1">•</text>
<text top="240" left="350" width="155" height="20" font="1"> Not taking antihypertensive </text>
<text top="257" left="343" width="164" height="20" font="1">medications, with DBP 90–99 </text>
<text top="274" left="343" width="43" height="20" font="1">mm Hg </text>
<text top="294" left="343" width="7" height="18" font="1">•</text>
<text top="293" left="350" width="147" height="20" font="1"> Taking 1 antihypertensive </text>
<text top="310" left="343" width="168" height="20" font="1">medication, with DBP &lt;95 mm </text>
<text top="327" left="343" width="154" height="20" font="1">Hg and between 85–99 mm </text>
<text top="345" left="343" width="142" height="20" font="1">Hg after withdrawal of BP </text>
<text top="362" left="343" width="69" height="20" font="1">medications<b> </b></text>
<text top="203" left="528" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="220" left="528" width="116" height="20" font="1">Treatment (number): </text>
<text top="238" left="528" width="95" height="20" font="1">Once daily (AM): </text>
<text top="257" left="528" width="7" height="18" font="1">•</text>
<text top="256" left="535" width="84" height="20" font="1"> Placebo (234) </text>
<text top="275" left="528" width="7" height="18" font="1">•</text>
<text top="274" left="535" width="166" height="20" font="1"> Chlorthalidone 15 mg/d (136) </text>
<text top="294" left="528" width="7" height="18" font="1">•</text>
<text top="293" left="535" width="151" height="20" font="1"> Acebutolol 400 mg/d (132) </text>
<text top="312" left="528" width="7" height="18" font="1">•</text>
<text top="311" left="535" width="138" height="20" font="1"> Doxazosin 2 mg/d (134) </text>
<text top="330" left="528" width="7" height="18" font="1">•</text>
<text top="330" left="535" width="141" height="20" font="1"> Amlodipine 5 mg/d (131) </text>
<text top="349" left="528" width="7" height="18" font="1">•</text>
<text top="348" left="535" width="128" height="20" font="1"> Enalapril 5 mg/d (135) </text>
<text top="365" left="528" width="3" height="20" font="1"> </text>
<text top="382" left="528" width="143" height="20" font="4"><b>Follow-up</b>: Median=4.4 y </text>
<text top="204" left="716" width="155" height="20" font="4"><b>1</b>°<b> endpoint: </b>BP, QoL, side </text>
<text top="222" left="716" width="145" height="20" font="1">effects, chemistries, ECG, </text>
<text top="239" left="716" width="83" height="20" font="1">clinical events  </text>
<text top="203" left="909" width="64" height="20" font="4"><b>Summary:</b> </text>
<text top="222" left="909" width="7" height="18" font="1">•</text>
<text top="222" left="916" width="129" height="20" font="1"> Drugs (plus diet) more </text>
<text top="239" left="909" width="121" height="20" font="1">effective compared to </text>
<text top="256" left="909" width="162" height="20" font="1">placebo (plus diet) for control </text>
<text top="273" left="909" width="37" height="20" font="1">of BP. </text>
<text top="292" left="909" width="7" height="18" font="1">•</text>
<text top="292" left="916" width="113" height="20" font="1"> Minimal differences </text>
<text top="312" left="909" width="132" height="20" font="1">between drug regimens </text>
<text top="418" left="108" width="3" height="20" font="1"> </text>
<text top="453" left="81" width="453" height="24" font="3"><b>Data Supplement 27. Choice of Initial Medication (Section 8.1.6)  </b></text>
<text top="492" left="100" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="509" left="126" width="47" height="20" font="4"><b>Author  </b></text>
<text top="527" left="102" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="492" left="227" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="509" left="231" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="527" left="225" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="492" left="371" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="492" left="560" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="509" left="576" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="527" left="561" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="544" left="581" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="492" left="756" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="509" left="739" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="527" left="721" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="493" left="922" width="143" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="511" left="977" width="33" height="20" font="4"><b>any); </b></text>
<text top="528" left="938" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="545" left="944" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="562" left="964" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="580" left="98" width="93" height="20" font="1">Psaty BM, et al., </text>
<text top="597" left="98" width="31" height="20" font="1">2003 </text>
<text top="615" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12759325">12759325</a></text>
<text top="615" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12759325"> </a></text>
<text top="580" left="211" width="71" height="20" font="4"><b>Study type: </b></text>
<text top="597" left="211" width="80" height="20" font="1">Network meta-</text>
<text top="615" left="211" width="113" height="20" font="1">analysis to compare </text>
<text top="632" left="211" width="94" height="20" font="1">value of different </text>
<text top="649" left="211" width="46" height="20" font="1">first-line </text>
<text top="666" left="211" width="93" height="20" font="1">antihypertensive </text>
<text top="683" left="211" width="108" height="20" font="1">drugs in prevention </text>
<text top="701" left="211" width="101" height="20" font="1">of major CVD and </text>
<text top="718" left="211" width="103" height="20" font="1">all-cause mortality </text>
<text top="735" left="211" width="3" height="20" font="1"> </text>
<text top="752" left="211" width="78" height="20" font="4"><b>Size</b>: 42 trials </text>
<text top="769" left="211" width="70" height="20" font="1">(n=192,478)<b> </b></text>
<text top="580" left="339" width="24" height="20" font="1">N/A<b> </b></text>
<text top="582" left="528" width="7" height="18" font="1">•</text>
<text top="581" left="535" width="154" height="20" font="1"> For all outcomes, low-dose </text>
<text top="599" left="528" width="141" height="20" font="1">diuretics were better than </text>
<text top="616" left="528" width="46" height="20" font="1">placebo </text>
<text top="635" left="528" width="7" height="18" font="1">•</text>
<text top="634" left="535" width="148" height="20" font="1"> None of the other first-line </text>
<text top="651" left="528" width="143" height="20" font="1">agents (β-blockers, ACEI, </text>
<text top="669" left="528" width="172" height="20" font="1">CCBs, α-receptor blockers and </text>
<text top="686" left="528" width="153" height="20" font="1">ARBs) were superior to low-</text>
<text top="703" left="528" width="79" height="20" font="1">dose diuretics </text>
<text top="722" left="528" width="7" height="18" font="1">•</text>
<text top="721" left="535" width="151" height="20" font="1"> For several outcomes, low-</text>
<text top="739" left="528" width="171" height="20" font="1">dose diuretics were superior to </text>
<text top="756" left="528" width="72" height="20" font="1">other agents<b> </b></text>
<text top="582" left="717" width="7" height="18" font="1">•</text>
<text top="581" left="724" width="139" height="20" font="1"> Low-dose diuretics were </text>
<text top="599" left="717" width="169" height="20" font="1">identified as the most effective </text>
<text top="616" left="717" width="181" height="20" font="1">first-line treatment for prevention </text>
<text top="633" left="717" width="169" height="20" font="1">of CVD and all-cause mortality </text>
<text top="650" left="717" width="181" height="20" font="1">during treatment of hypertension<b> </b></text>
<text top="580" left="913" width="24" height="20" font="1">N/A </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">93 </text>
<text top="107" left="98" width="91" height="20" font="1">Brunström M, et </text>
<text top="124" left="98" width="76" height="20" font="1">al., 2016 <a href="">(53)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26920333">26920333</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26920333"> </a></text>
<text top="107" left="211" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="124" left="211" width="110" height="20" font="1">analysis of levels of </text>
<text top="141" left="211" width="96" height="20" font="1">BP control in DM </text>
<text top="159" left="211" width="83" height="20" font="1">hypertensives. </text>
<text top="176" left="211" width="3" height="20" font="1"> </text>
<text top="193" left="211" width="92" height="20" font="4"><b>Size</b>: 73,738 pts </text>
<text top="109" left="339" width="7" height="18" font="1">•</text>
<text top="108" left="346" width="295" height="20" font="1"> 49 trials (most pts with DM-2)  Baseline SBP &gt;150  </text>
<text top="124" left="528" width="42" height="20" font="1">RR for  </text>
<text top="143" left="528" width="7" height="18" font="1">•</text>
<text top="143" left="535" width="163" height="20" font="1"> All death: 0.89; 95% CI:0.80–</text>
<text top="160" left="528" width="27" height="20" font="1">0.99 </text>
<text top="179" left="528" width="7" height="18" font="1">•</text>
<text top="178" left="535" width="145" height="20" font="1"> CVD: 0.75; 95% CI: 0.57–</text>
<text top="195" left="528" width="27" height="20" font="1">0.99 </text>
<text top="214" left="528" width="7" height="18" font="1">•</text>
<text top="214" left="535" width="160" height="20" font="1"> MI: 0.74; 95% CI: 0.63–0.87 </text>
<text top="233" left="528" width="7" height="18" font="1">•</text>
<text top="232" left="535" width="154" height="20" font="1"> Stroke: 0.77; 95% CI: 0.65–</text>
<text top="249" left="528" width="27" height="20" font="1">0.91 </text>
<text top="269" left="528" width="7" height="18" font="1">•</text>
<text top="268" left="535" width="153" height="20" font="1"> ESRD: 0.82; 95% CI: 0.71–</text>
<text top="285" left="528" width="27" height="20" font="1">0.94 </text>
<text top="302" left="528" width="3" height="20" font="1"> </text>
<text top="319" left="528" width="165" height="20" font="1">Baseline SBP140–150 RR of  </text>
<text top="339" left="528" width="7" height="18" font="1">•</text>
<text top="338" left="535" width="152" height="20" font="1"> Death: 0.87; 95% CI: 0.78–</text>
<text top="355" left="528" width="31" height="20" font="1">0.98) </text>
<text top="374" left="528" width="7" height="18" font="1">•</text>
<text top="373" left="535" width="157" height="20" font="1"> MI: 0.84; 95% CI: 0.76–0.9  </text>
<text top="392" left="528" width="7" height="18" font="1">•</text>
<text top="392" left="535" width="163" height="20" font="1"> HF: 0.80; 95% CI: 0.66–0.97 </text>
<text top="409" left="528" width="158" height="20" font="1">If baseline SBP,140 mm Hg, </text>
<text top="426" left="528" width="148" height="20" font="1">however, further treatment </text>
<text top="443" left="528" width="134" height="20" font="1">increased the risk of CV </text>
<text top="461" left="528" width="163" height="20" font="1">mortality (1.15; 95% CI: 1.00–</text>
<text top="478" left="528" width="27" height="20" font="1">1.32 </text>
<text top="109" left="717" width="7" height="18" font="1">•</text>
<text top="108" left="724" width="174" height="20" font="1"> BP lowering reduces major CV </text>
<text top="125" left="717" width="142" height="20" font="1">events in DM. Caution for </text>
<text top="143" left="717" width="169" height="20" font="1">initiating treatment in diabetics </text>
<text top="160" left="717" width="102" height="20" font="1">with SBP &lt;140/90 </text>
<text top="107" left="913" width="24" height="20" font="1">N/A<b> </b></text>
<text top="496" left="98" width="95" height="20" font="1">Ettehad D, et al., </text>
<text top="513" left="98" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(17)</a> </text>
<text top="530" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178">26724178</a></text>
<text top="530" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178"> </a></text>
<text top="496" left="211" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="513" left="211" width="92" height="20" font="1">analysis of large </text>
<text top="530" left="211" width="48" height="20" font="1">RTCs of </text>
<text top="547" left="211" width="93" height="20" font="1">antihypertensive </text>
<text top="565" left="211" width="55" height="20" font="1">treatment </text>
<text top="582" left="211" width="3" height="20" font="1"> </text>
<text top="599" left="211" width="98" height="20" font="4"><b>Size</b>: 123 studies </text>
<text top="616" left="211" width="76" height="20" font="1">(613,815 pts) </text>
<text top="496" left="339" width="24" height="20" font="1">N/A </text>
<text top="496" left="528" width="162" height="20" font="1">Every 10 mm Hg reduction in </text>
<text top="513" left="528" width="53" height="20" font="1">SBP RR: </text>
<text top="532" left="528" width="7" height="18" font="1">•</text>
<text top="531" left="535" width="160" height="20" font="1"> Major CV events: 0.80; 95% </text>
<text top="549" left="528" width="77" height="20" font="1">CI: 0.77–0.83 </text>
<text top="568" left="528" width="7" height="18" font="1">•</text>
<text top="567" left="535" width="145" height="20" font="1"> CHD: 0.83; 95% CI: 0.78–</text>
<text top="584" left="528" width="27" height="20" font="1">0.88 </text>
<text top="603" left="528" width="7" height="18" font="1">•</text>
<text top="602" left="535" width="154" height="20" font="1"> Stroke: 0.73; 95% CI: 0.68–</text>
<text top="620" left="528" width="148" height="20" font="1">0.77), HF (0.72, 0.67–0.78 </text>
<text top="639" left="528" width="7" height="18" font="1">•</text>
<text top="638" left="535" width="141" height="20" font="1"> All-cause mortality: 0.87; </text>
<text top="655" left="528" width="136" height="20" font="1">95% CI: 0.87; 0.84–0.91 </text>
<text top="674" left="528" width="7" height="18" font="1">•</text>
<text top="674" left="535" width="133" height="20" font="1"> ESRD: 0.95; 0.84–1.07 </text>
<text top="498" left="717" width="7" height="18" font="1">•</text>
<text top="497" left="724" width="163" height="20" font="1"> BP lowering reduces CV risk </text>
<text top="514" left="717" width="152" height="20" font="1">across various baseline BP </text>
<text top="531" left="717" width="138" height="20" font="1">levels and comorbidities. </text>
<text top="549" left="717" width="181" height="20" font="1">Suggest lowering SBP &lt;130 mm </text>
<text top="566" left="717" width="182" height="20" font="1">Hg and BP-lowering treatment to </text>
<text top="583" left="717" width="175" height="20" font="1">pts with a history of CVD, CHD, </text>
<text top="600" left="717" width="146" height="20" font="1">stroke, DM, HF, and CKD. </text>
<text top="496" left="913" width="24" height="20" font="1">N/A </text>
<text top="692" left="98" width="94" height="20" font="1">Thomopolous C, </text>
<text top="709" left="98" width="90" height="20" font="1">et al., 2016 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(54)</a> </text>
<text top="726" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26848994">26848994</a></text>
<text top="726" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26848994"> </a></text>
<text top="692" left="211" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="709" left="211" width="110" height="20" font="1">analysis of RTCs of </text>
<text top="726" left="211" width="76" height="20" font="1">more vs. less </text>
<text top="743" left="211" width="103" height="20" font="1">intense BP control </text>
<text top="693" left="339" width="7" height="18" font="1">•</text>
<text top="693" left="346" width="119" height="20" font="1"> 16 trials (52,235 pts) </text>
<text top="710" left="339" width="134" height="20" font="1">compared more vs. less </text>
<text top="727" left="339" width="98" height="20" font="1">intense treatment </text>
<text top="744" left="339" width="148" height="20" font="1">34 (138,127 pts) active vs. </text>
<text top="762" left="339" width="46" height="20" font="1">placebo </text>
<text top="692" left="528" width="98" height="20" font="1">More intense BP  </text>
<text top="711" left="528" width="7" height="18" font="1">•</text>
<text top="710" left="535" width="145" height="20" font="1"> Stroke RR: 0.71; 95% CI: </text>
<text top="727" left="528" width="62" height="20" font="1">0.60–0.84) </text>
<text top="746" left="528" width="7" height="18" font="1">•</text>
<text top="746" left="535" width="136" height="20" font="1"> CHD RR: 0.80; 95% CI: </text>
<text top="763" left="528" width="62" height="20" font="1">0.68–0.95) </text>
<text top="693" left="717" width="7" height="18" font="1">•</text>
<text top="693" left="724" width="133" height="20" font="1">  Intensive BP reduction </text>
<text top="710" left="717" width="130" height="20" font="1">improves CV outcomes </text>
<text top="727" left="717" width="140" height="20" font="1">compared to less intense </text>
<text top="746" left="717" width="7" height="18" font="1">•</text>
<text top="746" left="724" width="173" height="20" font="1">  Achieved BP &lt;130/80 may be </text>
<text top="763" left="717" width="152" height="20" font="1">associated with CV benefit. </text>
<text top="692" left="913" width="24" height="20" font="1">N/A </text>
</page>
<page number="94" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">94 </text>
<text top="109" left="528" width="7" height="18" font="1">•</text>
<text top="108" left="535" width="153" height="20" font="1"> Major CV events RR: 0.75; </text>
<text top="125" left="528" width="105" height="20" font="1">95% CI: 0.68–0.85 </text>
<text top="144" left="528" width="7" height="18" font="1">•</text>
<text top="144" left="535" width="157" height="20" font="1"> CV mortality RR: 0.79; 95% </text>
<text top="161" left="528" width="77" height="20" font="1">CI: 0.63–0.97 </text>
<text top="178" left="528" width="3" height="20" font="1"> </text>
<text top="195" left="528" width="152" height="20" font="1">Stratification of SBP cutoffs </text>
<text top="213" left="528" width="147" height="20" font="1">(150,140 and 130 mm Hg) </text>
<text top="230" left="528" width="137" height="20" font="1">showed that a SBP/DBP </text>
<text top="247" left="528" width="141" height="20" font="1">difference of 10/5 mm Hg </text>
<text top="264" left="528" width="174" height="20" font="1">across each cutoff reduced risk </text>
<text top="281" left="528" width="86" height="20" font="1">of all outcomes </text>
<text top="299" left="98" width="84" height="20" font="1">Julius S, et al., </text>
<text top="317" left="98" width="56" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(55)</a> </text>
<text top="334" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16537662">16537662</a></text>
<text top="334" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16537662"> </a></text>
<text top="299" left="211" width="112" height="20" font="4"><b>Study type: </b>RCT in </text>
<text top="317" left="211" width="51" height="20" font="1">pre-HTN </text>
<text top="334" left="211" width="109" height="20" font="1">16 mg candesartan </text>
<text top="351" left="211" width="66" height="20" font="1">vs. placebo </text>
<text top="368" left="211" width="3" height="20" font="1"> </text>
<text top="386" left="211" width="75" height="20" font="4"><b>Size</b>: 809 pts </text>
<text top="301" left="339" width="7" height="18" font="1">•</text>
<text top="301" left="346" width="59" height="20" font="1"> 58% men </text>
<text top="301" left="528" width="7" height="18" font="1">•</text>
<text top="301" left="535" width="139" height="20" font="1"> During the first 2 y, HTN </text>
<text top="318" left="528" width="163" height="20" font="1">developed in 154 (40.4%) pts </text>
<text top="335" left="528" width="173" height="20" font="1">in the placebo group compared </text>
<text top="352" left="528" width="175" height="20" font="1">with only 53 (13.6%) of those in </text>
<text top="370" left="528" width="158" height="20" font="1">the candesartan group, for a </text>
<text top="387" left="528" width="169" height="20" font="1">RR of 66.3% (p&lt;0.0001). After </text>
<text top="404" left="528" width="149" height="20" font="1">4 y, HTN developed in 240 </text>
<text top="421" left="528" width="161" height="20" font="1">(63.0%) in the placebo group </text>
<text top="438" left="528" width="149" height="20" font="1">vs. only 208 (53.2%) in the </text>
<text top="456" left="528" width="165" height="20" font="1">candesartan group RR 15.6% </text>
<text top="473" left="528" width="67" height="20" font="1">(p&lt;0.0069). </text>
<text top="301" left="717" width="7" height="18" font="1">•</text>
<text top="301" left="724" width="147" height="20" font="1"> 2/3 of those with pre-HTN </text>
<text top="318" left="717" width="133" height="20" font="1">develop HTN within 4 y. </text>
<text top="335" left="717" width="183" height="20" font="1">Candesartan interrupts the onset </text>
<text top="352" left="717" width="127" height="20" font="1">and reduced by 15.6% </text>
<text top="299" left="913" width="24" height="20" font="1">N/A </text>
<text top="491" left="98" width="85" height="20" font="1">Ference BA, et </text>
<text top="508" left="98" width="76" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(56)</a> </text>
<text top="525" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24591335">24591335</a></text>
<text top="525" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24591335"> </a></text>
<text top="491" left="211" width="71" height="20" font="4"><b>Study type: </b></text>
<text top="508" left="211" width="112" height="20" font="1">Evaluated the effect </text>
<text top="525" left="211" width="31" height="20" font="1">of 12 </text>
<text top="542" left="211" width="86" height="20" font="1">polymorphisms </text>
<text top="560" left="211" width="91" height="20" font="1">(associated with </text>
<text top="577" left="211" width="105" height="20" font="1">BP) on the odds of </text>
<text top="594" left="211" width="112" height="20" font="1">CHD and compared </text>
<text top="611" left="211" width="102" height="20" font="1">it with the effect of </text>
<text top="628" left="211" width="115" height="20" font="1">lower SBP observed </text>
<text top="646" left="211" width="107" height="20" font="1">in both prospective </text>
<text top="663" left="211" width="104" height="20" font="1">cohort studies and </text>
<text top="680" left="211" width="69" height="20" font="1">BP-lowering </text>
<text top="697" left="211" width="97" height="20" font="1">randomized trials </text>
<text top="714" left="211" width="3" height="20" font="1"> </text>
<text top="732" left="211" width="112" height="20" font="4"><b>Size</b>: 199,477 pts in </text>
<text top="749" left="211" width="60" height="20" font="1">63 studies </text>
<text top="491" left="339" width="24" height="20" font="1">N/A </text>
<text top="493" left="528" width="7" height="18" font="1">•</text>
<text top="492" left="535" width="133" height="20" font="1">12 polymorphisms were </text>
<text top="509" left="528" width="168" height="20" font="1">associated with a 0.32 mm Hg </text>
<text top="526" left="528" width="124" height="20" font="1">lower SBP (p=1.79×10</text>
<text top="528" left="651" width="7" height="13" font="6">-7</text>
<text top="526" left="659" width="42" height="20" font="1">) and a </text>
<text top="544" left="528" width="161" height="20" font="1">0.093-mm Hg/decade slower </text>
<text top="561" left="528" width="130" height="20" font="1">age-related rise in SBP </text>
<text top="578" left="528" width="63" height="20" font="1">(p=3.05×10</text>
<text top="580" left="591" width="7" height="13" font="6">-5</text>
<text top="578" left="598" width="83" height="20" font="1">). The effect of </text>
<text top="595" left="528" width="156" height="20" font="1">long-term exposure to lower </text>
<text top="612" left="528" width="145" height="20" font="1">SBP on CHD mediated by </text>
<text top="630" left="528" width="156" height="20" font="1">these polymorphisms was 2-</text>
<text top="647" left="528" width="171" height="20" font="1">fold greater than that observed </text>
<text top="664" left="528" width="159" height="20" font="1">in prospective cohort studies </text>
<text top="681" left="528" width="157" height="20" font="1">(p=0.006) and 3-fold greater </text>
<text top="698" left="528" width="150" height="20" font="1">than that observed in short-</text>
<text top="716" left="528" width="132" height="20" font="1">term BP treatment trials </text>
<text top="733" left="528" width="63" height="20" font="1">(p=0.001).  </text>
<text top="493" left="717" width="7" height="18" font="1">•</text>
<text top="492" left="724" width="123" height="20" font="1"> SBP may be causally </text>
<text top="509" left="717" width="182" height="20" font="1">associated with the rate of rise in </text>
<text top="526" left="717" width="135" height="20" font="1">SBP with age and has a </text>
<text top="544" left="717" width="169" height="20" font="1">cumulative effect on the risk of </text>
<text top="561" left="717" width="33" height="20" font="1">CHD. </text>
<text top="491" left="913" width="24" height="20" font="1">N/A </text>
<text top="767" left="108" width="3" height="20" font="1"> </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">95 </text>
<text top="106" left="81" width="661" height="24" font="3"><b>Data Supplement 28. Follow-Up After Initiating Antihypertensive Drug Therapy (Section 8.3.1)  </b></text>
<text top="146" left="100" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="163" left="126" width="47" height="20" font="4"><b>Author  </b></text>
<text top="180" left="102" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="227" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="163" left="231" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="180" left="225" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="371" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="560" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="163" left="576" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="180" left="561" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="197" left="581" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="146" left="756" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="163" left="739" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="180" left="721" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="147" left="922" width="143" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="164" left="977" width="33" height="20" font="4"><b>any); </b></text>
<text top="181" left="938" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="199" left="944" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="216" left="964" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="234" left="98" width="87" height="20" font="1">Ambrosius WT, </text>
<text top="251" left="98" width="96" height="20" font="1">et al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(122)</a> </text>
<text top="268" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24902920?dopt=Citation">24902920</a></text>
<text top="268" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24902920?dopt=Citation"> </a></text>
<text top="234" left="211" width="98" height="20" font="4"><b>Aim:</b> To describe </text>
<text top="251" left="211" width="107" height="20" font="1">the study design of </text>
<text top="268" left="211" width="92" height="20" font="1">the SPRINT trial </text>
<text top="285" left="211" width="3" height="20" font="1"> </text>
<text top="303" left="211" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="320" left="211" width="109" height="20" font="1">description of study </text>
<text top="337" left="211" width="111" height="20" font="1">design and protocol </text>
<text top="354" left="211" width="87" height="20" font="1">for the SPRINT </text>
<text top="372" left="211" width="29" height="20" font="1">RCT<b> </b></text>
<text top="234" left="339" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="251" left="339" width="152" height="20" font="1">Adults ≥50 y, average SBP </text>
<text top="268" left="339" width="165" height="20" font="1">≥130 mm Hg and evidence of </text>
<text top="285" left="339" width="107" height="20" font="1">CVD, CKD, or 10-y </text>
<text top="303" left="339" width="168" height="20" font="1">Framingham risk score ≥15%, </text>
<text top="320" left="339" width="73" height="20" font="1">or age ≥75 y<b> </b></text>
<text top="234" left="528" width="175" height="20" font="4"><b>Intervention:</b> 9361 participants </text>
<text top="251" left="528" width="147" height="20" font="1">randomized to 2 treatment </text>
<text top="268" left="528" width="172" height="20" font="1">groups: (1) Standard treatment </text>
<text top="285" left="528" width="156" height="20" font="1">group, SBP target &lt;140 mm </text>
<text top="303" left="528" width="173" height="20" font="1">Hg, and (2) Intensive treatment </text>
<text top="320" left="528" width="156" height="20" font="1">group: SBP target &lt;120 mm </text>
<text top="337" left="528" width="22" height="20" font="1">Hg. </text>
<text top="235" left="717" width="169" height="20" font="4"><b>1</b>°<b> endpoint:</b> MI, ACS, stroke, </text>
<text top="252" left="717" width="105" height="20" font="1">HF, or CVD death. </text>
<text top="235" left="913" width="148" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> All-</text>
<text top="252" left="913" width="145" height="20" font="1">cause mortality, decline in </text>
<text top="269" left="913" width="100" height="20" font="1">kidney function or </text>
<text top="287" left="913" width="128" height="20" font="1">development of ESRD, </text>
<text top="304" left="913" width="158" height="20" font="1">incident dementia, decline in </text>
<text top="321" left="913" width="159" height="20" font="1">cognitive function, and small-</text>
<text top="338" left="913" width="137" height="20" font="1">vessel cerebral ischemic </text>
<text top="356" left="913" width="46" height="20" font="1">disease </text>
<text top="373" left="913" width="3" height="20" font="1"> </text>
<text top="390" left="913" width="125" height="20" font="4"><b>Summary:</b> This paper </text>
<text top="407" left="913" width="124" height="20" font="1">describes the protocol </text>
<text top="424" left="913" width="154" height="20" font="1">followed in the SPRINT trial </text>
<text top="442" left="913" width="123" height="20" font="1">that was successful in </text>
<text top="459" left="913" width="156" height="20" font="1">helping participants to attain </text>
<text top="476" left="913" width="148" height="20" font="1">and maintain BP targets in </text>
<text top="493" left="913" width="131" height="20" font="1">the study groups. Once </text>
<text top="510" left="913" width="135" height="20" font="1">treated, participants had </text>
<text top="528" left="913" width="97" height="20" font="1">follow-up visits to </text>
<text top="545" left="913" width="129" height="20" font="1">assessment BP control </text>
<text top="562" left="913" width="131" height="20" font="1">monthly until BP was at </text>
<text top="579" left="913" width="137" height="20" font="1">target. Medications were </text>
<text top="596" left="913" width="140" height="20" font="1">titrated and added as per </text>
<text top="614" left="913" width="138" height="20" font="1">protocol, when target BP </text>
<text top="631" left="913" width="96" height="20" font="1">was not attained. </text>
<text top="649" left="98" width="97" height="20" font="1">Cushman WC, et </text>
<text top="666" left="98" width="83" height="20" font="1">al., 2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(123)</a> </text>
<text top="683" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17599425?dopt=Citation">17599425</a></text>
<text top="683" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17599425?dopt=Citation"> </a></text>
<text top="649" left="211" width="98" height="20" font="4"><b>Aim:</b> To describe </text>
<text top="666" left="211" width="107" height="20" font="1">the study design of </text>
<text top="683" left="211" width="98" height="20" font="1">the BP trial of the </text>
<text top="700" left="211" width="83" height="20" font="1">ACCORD trial. </text>
<text top="718" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="735" left="211" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="752" left="211" width="109" height="20" font="1">description of study </text>
<text top="769" left="211" width="111" height="20" font="1">design and protocol </text>
<text top="649" left="339" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="666" left="339" width="169" height="20" font="17">Adults with a diagnosis of type </text>
<text top="683" left="339" width="162" height="20" font="17">2 DM for at least 3 mo and at </text>
<text top="700" left="339" width="165" height="20" font="17">high risk for CVD events, who </text>
<text top="718" left="339" width="166" height="20" font="17">meet the following BP criteria: </text>
<text top="735" left="339" width="67" height="20" font="17">(1) SBP 130</text>
<text top="735" left="406" width="7" height="20" font="1">–</text>
<text top="735" left="412" width="91" height="20" font="17">160 mm Hg and </text>
<text top="752" left="339" width="43" height="20" font="17">taking 0</text>
<text top="752" left="382" width="7" height="20" font="1">–</text>
<text top="752" left="389" width="103" height="20" font="17">3 antihypertensive </text>
<text top="769" left="339" width="139" height="20" font="17">medications; (2) SBP 161</text>
<text top="769" left="478" width="7" height="20" font="1">–</text>
<text top="769" left="485" width="24" height="20" font="17">170 </text>
<text top="786" left="339" width="48" height="20" font="17">and on 0</text>
<text top="786" left="387" width="7" height="20" font="1">–</text>
<text top="786" left="394" width="103" height="20" font="17">2 antihypertensive </text>
<text top="649" left="528" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="668" left="528" width="7" height="18" font="1">•</text>
<text top="667" left="535" width="133" height="20" font="1"> Unmasked, open-label, </text>
<text top="684" left="528" width="157" height="20" font="1">factorial design, randomized </text>
<text top="702" left="528" width="175" height="20" font="1">trial with a sample size of 4,733 </text>
<text top="719" left="528" width="23" height="20" font="1">pts<b>  </b></text>
<text top="738" left="528" width="7" height="18" font="1">•</text>
<text top="737" left="535" width="163" height="20" font="1"> Patients were randomized to </text>
<text top="754" left="528" width="156" height="20" font="1">intensive SBP control (&lt;120 </text>
<text top="772" left="528" width="153" height="20" font="1">mm Hg) or standard control </text>
<text top="789" left="528" width="82" height="20" font="1">(&lt;140 mm Hg) </text>
<text top="650" left="717" width="173" height="20" font="4"><b>1</b>°<b> endpoint:</b> Major CVD event </text>
<text top="667" left="717" width="158" height="20" font="1">(nonfatal MI or stroke, or CV </text>
<text top="684" left="717" width="38" height="20" font="1">death) </text>
<text top="650" left="913" width="130" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> </text>
<text top="667" left="913" width="142" height="20" font="1">Expanded macrovascular </text>
<text top="684" left="913" width="147" height="20" font="1">outcome (1° outcome plus </text>
<text top="702" left="913" width="161" height="20" font="1">coronary revascularization or </text>
<text top="719" left="913" width="135" height="20" font="1">HF hospitalization), total </text>
<text top="736" left="913" width="118" height="20" font="1">mortality, each of the </text>
<text top="753" left="913" width="156" height="20" font="1">separate components of the </text>
<text top="770" left="913" width="139" height="20" font="1">1° outcome, HF death or </text>
<text top="788" left="913" width="109" height="20" font="1">hospitalization, and </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">96 </text>
<text top="107" left="211" width="95" height="20" font="1">for the ACCORD </text>
<text top="124" left="211" width="29" height="20" font="1">RCT<b> </b></text>
<text top="107" left="339" width="154" height="20" font="17">medications; or (3) SBP 171</text>
<text top="107" left="492" width="7" height="20" font="1">–</text>
<text top="124" left="339" width="91" height="20" font="17">180 and taking 0</text>
<text top="124" left="430" width="7" height="20" font="1">–</text>
<text top="124" left="436" width="10" height="20" font="17">1 </text>
<text top="141" left="339" width="159" height="20" font="17">antihypertensive medication. </text>
<text top="159" left="339" width="154" height="20" font="17">Other entry criteria included </text>
<text top="176" left="339" width="129" height="20" font="17">spot urine sample &lt;2+, </text>
<text top="193" left="339" width="140" height="20" font="17">protein–Cr ratio &lt;700 mg </text>
<text top="210" left="339" width="164" height="20" font="17">protein/1 g creatinine, or 24-h </text>
<text top="228" left="339" width="160" height="20" font="17">protein excretion &lt;1.0 g/24 h.</text>
<text top="228" left="498" width="3" height="20" font="4"><b> </b></text>
<text top="107" left="913" width="139" height="20" font="1">composite microvascular </text>
<text top="124" left="913" width="139" height="20" font="1">disease outcome (kidney </text>
<text top="141" left="913" width="101" height="20" font="1">and eye disease). </text>
<text top="159" left="913" width="3" height="20" font="1"> </text>
<text top="176" left="913" width="125" height="20" font="4"><b>Summary:</b> This paper </text>
<text top="193" left="913" width="124" height="20" font="1">describes the protocol </text>
<text top="210" left="913" width="162" height="20" font="1">followed in the ACCORD trial </text>
<text top="228" left="913" width="123" height="20" font="1">that was successful in </text>
<text top="245" left="913" width="134" height="20" font="1">helping pts to attain and </text>
<text top="262" left="913" width="144" height="20" font="1">maintain BP targets in the </text>
<text top="279" left="913" width="155" height="20" font="1">study groups. Once treated, </text>
<text top="296" left="913" width="141" height="20" font="1">pts had follow-up visits to </text>
<text top="314" left="913" width="129" height="20" font="1">assessment BP control </text>
<text top="331" left="913" width="131" height="20" font="1">monthly until BP was at </text>
<text top="348" left="913" width="137" height="20" font="1">target. Medications were </text>
<text top="365" left="913" width="140" height="20" font="1">titrated and added as per </text>
<text top="383" left="913" width="138" height="20" font="1">protocol, when target BP </text>
<text top="400" left="913" width="96" height="20" font="1">was not attained. </text>
<text top="418" left="98" width="70" height="20" font="1">Xu W, et al., </text>
<text top="435" left="98" width="66" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(128)</a>  </text>
<text top="452" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25655523?dopt=Citation">25655523</a></text>
<text top="452" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25655523?dopt=Citation"> </a></text>
<text top="418" left="211" width="109" height="20" font="4"><b>Aim: </b>Retrospective </text>
<text top="435" left="211" width="103" height="20" font="1">assessment of the </text>
<text top="452" left="211" width="106" height="20" font="1">impact of follow-up </text>
<text top="469" left="211" width="73" height="20" font="1">intervals and </text>
<text top="487" left="211" width="55" height="20" font="1">treatment </text>
<text top="504" left="211" width="78" height="20" font="1">intensification </text>
<text top="521" left="211" width="107" height="20" font="1">thresholds on CVD </text>
<text top="538" left="211" width="40" height="20" font="1">events </text>
<text top="555" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="573" left="211" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="590" left="211" width="78" height="20" font="1">Retrospective </text>
<text top="607" left="211" width="41" height="20" font="1">cohort  </text>
<text top="624" left="211" width="3" height="20" font="1"> </text>
<text top="641" left="211" width="103" height="20" font="4"><b>Size:</b> 88,756 adult </text>
<text top="659" left="211" width="102" height="20" font="1">pts with HTN from </text>
<text top="676" left="211" width="64" height="20" font="1">The Health </text>
<text top="693" left="211" width="75" height="20" font="1">Improvement </text>
<text top="710" left="211" width="103" height="20" font="1">Network database </text>
<text top="418" left="339" width="152" height="20" font="4"><b>Inclusion criteria: </b>Primary </text>
<text top="435" left="339" width="144" height="20" font="1">care practices in the U.K., </text>
<text top="452" left="339" width="68" height="20" font="1">1986–2010. </text>
<text top="418" left="528" width="24" height="20" font="1">N/A<b> </b></text>
<text top="420" left="717" width="7" height="18" font="1">•</text>
<text top="419" left="724" width="161" height="20" font="1"> Median follow-up of 37.4 mo </text>
<text top="436" left="717" width="151" height="20" font="1">after the treatment strategy </text>
<text top="453" left="717" width="110" height="20" font="1">assessment period  </text>
<text top="472" left="717" width="7" height="18" font="1">•</text>
<text top="472" left="724" width="145" height="20" font="1"> 9,985 (11.3%) pts had an </text>
<text top="489" left="717" width="135" height="20" font="1">acute CV event or died.  </text>
<text top="508" left="717" width="7" height="18" font="1">•</text>
<text top="507" left="724" width="150" height="20" font="1"> No difference in risk of the </text>
<text top="524" left="717" width="120" height="20" font="1">outcome with systolic </text>
<text top="542" left="717" width="165" height="20" font="1">intensification thresholds 130–</text>
<text top="559" left="717" width="161" height="20" font="1">150 mm Hg, but HR: 1.21 for </text>
<text top="576" left="717" width="138" height="20" font="1">thresholds &gt;150 mm Hg  </text>
<text top="595" left="717" width="7" height="18" font="1">•</text>
<text top="594" left="724" width="136" height="20" font="1"> Outcome risk increased </text>
<text top="612" left="717" width="163" height="20" font="1">progressively from the lowest </text>
<text top="629" left="717" width="147" height="20" font="1">(0–1.4 mo) to the highest 5</text>
<text top="630" left="864" width="7" height="13" font="6">th</text>
<text top="629" left="870" width="17" height="20" font="1"> of </text>
<text top="646" left="717" width="181" height="20" font="1">time to medication intensification </text>
<text top="663" left="717" width="168" height="20" font="1">(HR: 1.12; 95% CI: 1.05–1.20; </text>
<text top="680" left="717" width="148" height="20" font="1">p=0.009) for intensification </text>
<text top="698" left="717" width="163" height="20" font="1">between 1.4 and 4.7 mo after </text>
<text top="715" left="717" width="169" height="20" font="1">detection of elevated BP). The </text>
<text top="732" left="717" width="173" height="20" font="1">highest fifth of time to follow-up </text>
<text top="749" left="717" width="170" height="20" font="1">(&gt;2.7 mo) was also associated </text>
<text top="766" left="717" width="180" height="20" font="1">with increased outcome risk HR: </text>
<text top="420" left="913" width="7" height="18" font="1">•</text>
<text top="419" left="919" width="130" height="20" font="1"> Increased risk of acute </text>
<text top="436" left="913" width="140" height="20" font="1">CVD event or death with: </text>
<text top="455" left="913" width="7" height="18" font="1">•</text>
<text top="454" left="919" width="127" height="20" font="1"> Systolic intensification </text>
<text top="472" left="913" width="134" height="20" font="1">thresholds &gt;150 mm Hg </text>
<text top="491" left="913" width="7" height="18" font="1">•</text>
<text top="490" left="919" width="145" height="20" font="1"> Delays of &gt;1.4 mo before </text>
<text top="507" left="913" width="141" height="20" font="1">medication intensification </text>
<text top="524" left="913" width="112" height="20" font="1">after SBP elevation  </text>
<text top="543" left="913" width="7" height="18" font="1">•</text>
<text top="543" left="919" width="145" height="20" font="1"> Delays of &gt;2.7 mo before </text>
<text top="560" left="913" width="100" height="20" font="1">BP follow-up after </text>
<text top="577" left="913" width="156" height="20" font="1">antihypertensive medication </text>
<text top="594" left="913" width="81" height="20" font="1">intensification  </text>
<text top="613" left="913" width="7" height="18" font="1">•</text>
<text top="613" left="919" width="89" height="20" font="1"> Timely medical </text>
<text top="630" left="913" width="152" height="20" font="1">management and follow-up </text>
<text top="647" left="913" width="136" height="20" font="1">impacts outcomes in the </text>
<text top="664" left="913" width="146" height="20" font="1">treatment of pts with HTN. </text>
<text top="683" left="913" width="7" height="18" font="1">•</text>
<text top="683" left="919" width="139" height="20" font="1"> Retrospective study, but </text>
<text top="700" left="913" width="155" height="20" font="1">still sheds important light on </text>
<text top="717" left="913" width="126" height="20" font="1">the impact of follow-up </text>
<text top="734" left="913" width="42" height="20" font="1">actions </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">97 </text>
<text top="107" left="717" width="139" height="20" font="1">1.18; 95% CI: 1.11–1.25; </text>
<text top="124" left="717" width="48" height="20" font="1">p&lt;0.001 </text>
<text top="142" left="98" width="97" height="20" font="1">Birtwhistle RV, et </text>
<text top="159" left="98" width="83" height="20" font="1">al., 2004 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(129)</a> </text>
<text top="177" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14726370?dopt=Citation">14726370</a></text>
<text top="177" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14726370?dopt=Citation"> </a></text>
<text top="142" left="211" width="113" height="20" font="4"><b>Aim:</b> Assess impact </text>
<text top="159" left="211" width="66" height="20" font="1">of follow-up </text>
<text top="177" left="211" width="86" height="20" font="1">intervals on BP </text>
<text top="194" left="211" width="93" height="20" font="1">control in stable, </text>
<text top="211" left="211" width="87" height="20" font="1">treated pts with </text>
<text top="228" left="211" width="29" height="20" font="1">HTN </text>
<text top="245" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="263" left="211" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="280" left="211" width="3" height="20" font="4"><b> </b></text>
<text top="297" left="211" width="100" height="20" font="4"><b>Size:</b> 609 pts, 30–</text>
<text top="314" left="211" width="104" height="20" font="1">74 y with essential </text>
<text top="332" left="211" width="77" height="20" font="1">HTN, on drug </text>
<text top="349" left="211" width="113" height="20" font="1">treatment, with HTN </text>
<text top="366" left="211" width="114" height="20" font="1">controlled for ≥3 mo </text>
<text top="383" left="211" width="96" height="20" font="1">prior to entry into </text>
<text top="400" left="211" width="36" height="20" font="1">study. </text>
<text top="142" left="339" width="159" height="20" font="4"><b>Inclusion criteria: </b>50 family </text>
<text top="159" left="339" width="140" height="20" font="1">practices in southeastern </text>
<text top="177" left="339" width="97" height="20" font="1">Ontario, Canada.<b> </b></text>
<text top="144" left="528" width="7" height="18" font="1">•</text>
<text top="143" left="535" width="164" height="20" font="1"> 302 pts randomized to follow-</text>
<text top="161" left="528" width="109" height="20" font="1">up every 3 mo, 307 </text>
<text top="178" left="528" width="167" height="20" font="1">randomized to follow-up every </text>
<text top="195" left="528" width="34" height="20" font="1">6 mo. </text>
<text top="144" left="717" width="7" height="18" font="1">•</text>
<text top="143" left="724" width="144" height="20" font="1"> Pts in both groups visited </text>
<text top="161" left="717" width="181" height="20" font="1">doctor more frequently than their </text>
<text top="178" left="717" width="103" height="20" font="1">assigned interval.  </text>
<text top="197" left="717" width="7" height="18" font="1">•</text>
<text top="196" left="724" width="155" height="20" font="1"> Mean BP was similar in the </text>
<text top="213" left="717" width="176" height="20" font="1">groups, as was control of HTN.  </text>
<text top="232" left="717" width="7" height="18" font="1">•</text>
<text top="232" left="724" width="169" height="20" font="1"> Pt satisfaction and adherence </text>
<text top="249" left="717" width="172" height="20" font="1">to treatment were similar in the </text>
<text top="266" left="717" width="48" height="20" font="1">groups.  </text>
<text top="285" left="717" width="7" height="18" font="1">•</text>
<text top="285" left="724" width="143" height="20" font="1"> About 20% of pts in each </text>
<text top="302" left="717" width="173" height="20" font="1">group had BPs that were out of </text>
<text top="319" left="717" width="135" height="20" font="1">control during the study. </text>
<text top="144" left="913" width="7" height="18" font="1">•</text>
<text top="143" left="919" width="151" height="20" font="1"> Study addresses follow-up </text>
<text top="161" left="913" width="151" height="20" font="1">interval for pts with treated, </text>
<text top="178" left="913" width="152" height="20" font="1">stable, and controlled HTN. </text>
<text top="195" left="913" width="150" height="20" font="1">No difference in BP control </text>
<text top="212" left="913" width="153" height="20" font="1">or pt satisfaction between 3 </text>
<text top="229" left="913" width="152" height="20" font="1">and 6 mo follow-up groups. </text>
<text top="249" left="913" width="7" height="18" font="1">•</text>
<text top="248" left="919" width="112" height="20" font="1"> May be helpful with </text>
<text top="265" left="913" width="139" height="20" font="1">recommendations for pts </text>
<text top="282" left="913" width="139" height="20" font="1">with treated, stable HTN. </text>
<text top="420" left="108" width="3" height="19" font="1"> </text>
<text top="454" left="81" width="887" height="24" font="3"><b>Data Supplement 29. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP (Section 8.3.2)    </b></text>
<text top="494" left="126" width="38" height="20" font="4"><b>Study </b></text>
<text top="511" left="116" width="57" height="20" font="4"><b>Acronym </b></text>
<text top="528" left="123" width="47" height="20" font="4"><b>Author  </b></text>
<text top="546" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="494" left="242" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="511" left="247" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="528" left="241" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="494" left="405" width="44" height="20" font="4"><b>Patient </b></text>
<text top="511" left="394" width="67" height="20" font="4"><b>Population </b></text>
<text top="494" left="502" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="511" left="518" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="528" left="502" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="546" left="523" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="494" left="685" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="511" left="645" width="187" height="20" font="4"><b>(include Absolute Event Rates,  </b></text>
<text top="528" left="650" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="495" left="874" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="512" left="906" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="530" left="912" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="547" left="932" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="565" left="98" width="78" height="20" font="1">Brennan T, et </text>
<text top="582" left="98" width="83" height="20" font="1">al., 2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(130)</a> </text>
<text top="599" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20415618?dopt=Citation">20415618</a></text>
<text top="599" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20415618?dopt=Citation"> </a></text>
<text top="565" left="204" width="127" height="20" font="4"><b>Aim:</b> Assess impact of </text>
<text top="582" left="204" width="137" height="20" font="1">follow-up and monitoring </text>
<text top="599" left="204" width="148" height="20" font="1">system including home BP </text>
<text top="616" left="204" width="144" height="20" font="1">monitoring and telephonic </text>
<text top="634" left="204" width="156" height="20" font="1">nurse case management on </text>
<text top="651" left="204" width="152" height="20" font="1">BP control in pts treated for </text>
<text top="668" left="204" width="29" height="20" font="1">HTN </text>
<text top="685" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="702" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="720" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="737" left="204" width="153" height="20" font="4"><b>Size:</b> 638 African American </text>
<text top="754" left="204" width="130" height="20" font="1">pts with high BP from a </text>
<text top="771" left="204" width="157" height="20" font="1">national health maintenance </text>
<text top="788" left="204" width="97" height="20" font="1">organization plan </text>
<text top="565" left="377" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="582" left="377" width="77" height="20" font="4"><b>criteria: </b>HTN </text>
<text top="565" left="491" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="582" left="491" width="103" height="20" font="1">Intervention group </text>
<text top="599" left="491" width="109" height="20" font="1">received telephonic </text>
<text top="616" left="491" width="64" height="20" font="1">nurse case </text>
<text top="634" left="491" width="92" height="20" font="1">management, pt </text>
<text top="651" left="491" width="113" height="20" font="1">education materials, </text>
<text top="668" left="491" width="134" height="20" font="1">lifestyle counseling, and </text>
<text top="685" left="491" width="109" height="20" font="1">a home BP monitor </text>
<text top="702" left="491" width="3" height="20" font="1"> </text>
<text top="720" left="491" width="120" height="20" font="4"><b>Comparator: </b>Control </text>
<text top="737" left="491" width="129" height="20" font="1">group received a home </text>
<text top="754" left="491" width="90" height="20" font="1">BP monitor only </text>
<text top="567" left="638" width="7" height="18" font="1">•</text>
<text top="566" left="645" width="159" height="20" font="1"> Intervention group achieved </text>
<text top="583" left="638" width="176" height="20" font="1">lower SBP (123.6 vs. 126.7 mm </text>
<text top="600" left="638" width="177" height="20" font="1">Hg, p=0.03) and was 50% more </text>
<text top="618" left="638" width="167" height="20" font="1">likely than the control group to </text>
<text top="635" left="638" width="190" height="20" font="1">achieve BP control OR: 1.50; 95% </text>
<text top="652" left="638" width="136" height="20" font="1">CI: 0.997–2.27; p=0.052<b> </b></text>
<text top="567" left="849" width="7" height="18" font="1">•</text>
<text top="566" left="856" width="204" height="20" font="1"> Combination of home BP monitoring </text>
<text top="583" left="849" width="219" height="20" font="1">and nurse case management controlled </text>
<text top="600" left="849" width="179" height="20" font="1">HTN better than home BP alone<b> </b></text>
</page>
<page number="98" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">98 </text>
<text top="107" left="98" width="91" height="20" font="1">Bosworth, et al., </text>
<text top="124" left="98" width="66" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(131)</a>  </text>
<text top="141" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19920269?dopt=Citation">19920269 </a></text>
<text top="107" left="204" width="127" height="20" font="4"><b>Aim: </b>Assess impact of </text>
<text top="124" left="204" width="110" height="20" font="1">telephone follow-up </text>
<text top="141" left="204" width="159" height="20" font="1">intervention and/or home BP </text>
<text top="159" left="204" width="151" height="20" font="1">monitoring on BP control in </text>
<text top="176" left="204" width="116" height="20" font="1">pts with treated HTN </text>
<text top="193" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="210" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="227" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="245" left="204" width="106" height="20" font="4"><b>Size:</b> 636 pts were </text>
<text top="262" left="204" width="115" height="20" font="1">randomized; 475 pts </text>
<text top="279" left="204" width="159" height="20" font="1">completed the trial, including </text>
<text top="296" left="204" width="132" height="20" font="1">24-mo follow-up period. </text>
<text top="107" left="377" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="124" left="377" width="95" height="20" font="4"><b>criteria: </b>Pts with </text>
<text top="141" left="377" width="70" height="20" font="1">HTN, from 2 </text>
<text top="159" left="377" width="56" height="20" font="1">university-</text>
<text top="176" left="377" width="94" height="20" font="1">affiliated primary </text>
<text top="193" left="377" width="68" height="20" font="1">care clinics. </text>
<text top="109" left="491" width="7" height="18" font="1">•</text>
<text top="108" left="497" width="115" height="20" font="1"> 636 pts randomized </text>
<text top="125" left="491" width="122" height="20" font="1">to usual care or 1 of 3 </text>
<text top="143" left="491" width="130" height="20" font="1">intervention groups: (1) </text>
<text top="160" left="491" width="111" height="20" font="1">Nurse-administered </text>
<text top="177" left="491" width="124" height="20" font="1">telephone intervention </text>
<text top="194" left="491" width="125" height="20" font="1">targeting HTN -related </text>
<text top="212" left="491" width="133" height="20" font="1">behaviors, (2) home BP </text>
<text top="229" left="491" width="104" height="20" font="1">monitoring 3 times </text>
<text top="246" left="491" width="114" height="20" font="1">weekly, and (3) both </text>
<text top="263" left="491" width="73" height="20" font="1">interventions<b> </b></text>
<text top="109" left="638" width="7" height="18" font="1">•</text>
<text top="108" left="645" width="182" height="20" font="1"> 475 pts (75%) completed the 24-</text>
<text top="125" left="638" width="100" height="20" font="1">mo BP follow-up.  </text>
<text top="144" left="638" width="7" height="18" font="1">•</text>
<text top="144" left="645" width="174" height="20" font="1"> At 24 mo, improvements in the </text>
<text top="161" left="638" width="178" height="20" font="1">proportion of pts with BP control </text>
<text top="178" left="638" width="172" height="20" font="1">relative to the usual care group </text>
<text top="195" left="638" width="194" height="20" font="1">were 4.3% (95% CI: -4.5%, 12.9%) </text>
<text top="213" left="638" width="161" height="20" font="1">in the behavioral intervention </text>
<text top="230" left="638" width="160" height="20" font="1">group, 7.6% (95% CI: -1.9%, </text>
<text top="247" left="638" width="191" height="20" font="1">17.0%) in the home BP monitoring </text>
<text top="264" left="638" width="187" height="20" font="1">group, and 11.0% (95% CI: 1.9%, </text>
<text top="281" left="638" width="132" height="20" font="1">19.8%) in the combined </text>
<text top="299" left="638" width="109" height="20" font="1">intervention group.  </text>
<text top="318" left="638" width="7" height="18" font="1">•</text>
<text top="317" left="645" width="187" height="20" font="1"> Relative to usual care, the 24-mo </text>
<text top="334" left="638" width="187" height="20" font="1">difference in SBP was 0.6 mm Hg </text>
<text top="352" left="638" width="185" height="20" font="1">(95% CI: -2.2, 3.4 mm Hg) for the </text>
<text top="369" left="638" width="190" height="20" font="1">behavioral intervention group, -0.6 </text>
<text top="386" left="638" width="190" height="20" font="1">mm Hg (95% CI: -3.6, 2.3 mm Hg) </text>
<text top="403" left="638" width="185" height="20" font="1">for the BP monitoring group, and -</text>
<text top="420" left="638" width="195" height="20" font="1">3.9 mm Hg (95% CI: -6.9– -0.9 mm </text>
<text top="438" left="638" width="185" height="20" font="1">Hg) for the combined intervention </text>
<text top="455" left="638" width="173" height="20" font="1">group; patterns were similar for </text>
<text top="472" left="638" width="29" height="20" font="1">DBP </text>
<text top="109" left="849" width="7" height="18" font="1">•</text>
<text top="108" left="856" width="188" height="20" font="1"> Home BP monitoring and tailored </text>
<text top="125" left="849" width="185" height="20" font="1">behavioral telephone intervention </text>
<text top="143" left="849" width="215" height="20" font="1">improved BP control, SBP, and DBP at </text>
<text top="160" left="849" width="217" height="20" font="1">24 mo relative to usual care. Combined </text>
<text top="177" left="849" width="199" height="20" font="1">therapy was significantly better than </text>
<text top="194" left="849" width="116" height="20" font="1">either therapy alone. </text>
<text top="490" left="98" width="91" height="20" font="1">Bosworth, et al., </text>
<text top="507" left="98" width="66" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(132)</a>  </text>
<text top="524" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21747013?dopt=Citation">21747013</a></text>
<text top="524" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21747013?dopt=Citation"> </a></text>
<text top="490" left="204" width="127" height="20" font="4"><b>Aim:</b> Assess impact of </text>
<text top="507" left="204" width="110" height="20" font="1">telephone follow-up </text>
<text top="524" left="204" width="150" height="20" font="1">interventions on BP control </text>
<text top="542" left="204" width="128" height="20" font="1">in pts with treated HTN </text>
<text top="559" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="576" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="593" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="610" left="204" width="144" height="20" font="4"><b>Size:</b> Of 1551 eligible pts, </text>
<text top="628" left="204" width="92" height="20" font="1">593 randomized </text>
<text top="490" left="377" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="507" left="377" width="94" height="20" font="4"><b>criteria: </b>Primary </text>
<text top="524" left="377" width="88" height="20" font="1">care clinics at a </text>
<text top="542" left="377" width="66" height="20" font="1">VA Medical </text>
<text top="559" left="377" width="40" height="20" font="1">Center </text>
<text top="492" left="491" width="7" height="18" font="1">•</text>
<text top="491" left="497" width="115" height="20" font="1"> 593 pts randomized </text>
<text top="508" left="491" width="122" height="20" font="1">to either usual care or </text>
<text top="526" left="491" width="105" height="20" font="1">to 1 of 3 telephone </text>
<text top="543" left="491" width="115" height="20" font="1">follow-up groups: (1) </text>
<text top="560" left="491" width="109" height="20" font="1">nurse-administered </text>
<text top="577" left="491" width="60" height="20" font="1">behavioral </text>
<text top="594" left="491" width="97" height="20" font="1">management, (2) </text>
<text top="612" left="491" width="117" height="20" font="1">nurse- and physician-</text>
<text top="629" left="491" width="74" height="20" font="1">administered </text>
<text top="646" left="491" width="63" height="20" font="1">medication </text>
<text top="663" left="491" width="122" height="20" font="1">management, or (3) a </text>
<text top="680" left="491" width="111" height="20" font="1">combination of both </text>
<text top="492" left="638" width="7" height="18" font="1">•</text>
<text top="491" left="645" width="134" height="20" font="1"> 1° endpoint: BP control </text>
<text top="508" left="638" width="178" height="20" font="1">measured every 6 mo for 18 mo </text>
<text top="527" left="638" width="7" height="18" font="1">•</text>
<text top="527" left="645" width="164" height="20" font="1"> Behavioral management and </text>
<text top="544" left="638" width="172" height="20" font="1">medication management alone </text>
<text top="561" left="638" width="185" height="20" font="1">showed significant improvements </text>
<text top="578" left="638" width="176" height="20" font="1">at 12 mo-12.8% (95% CI: 1.6%, </text>
<text top="596" left="638" width="191" height="20" font="1">24.1%) and 12.5% (95% CI: 1.3%, </text>
<text top="613" left="638" width="187" height="20" font="1">23.6%), respectively-but not at 18 </text>
<text top="630" left="638" width="27" height="20" font="1">mo.  </text>
<text top="649" left="638" width="7" height="18" font="1">•</text>
<text top="648" left="645" width="168" height="20" font="1"> In subgroup analyses, among </text>
<text top="666" left="638" width="156" height="20" font="1">those with poor baseline BP </text>
<text top="683" left="638" width="166" height="20" font="1">control, SBP decreased in the </text>
<text top="700" left="638" width="175" height="20" font="1">combined intervention group by </text>
<text top="717" left="638" width="185" height="20" font="1">14.8 mm Hg (95% CI: -21.8– -7.8 </text>
<text top="734" left="638" width="186" height="20" font="1">mm Hg) at 12 mo and 8.0 mm Hg </text>
<text top="752" left="638" width="192" height="20" font="1">(95% CI: -15.5– -0.5 mm Hg) at 18 </text>
<text top="769" left="638" width="144" height="20" font="1">mo, relative to usual care.<b> </b></text>
<text top="492" left="849" width="7" height="18" font="1">•</text>
<text top="491" left="856" width="207" height="20" font="1"> Telephone-based case management </text>
<text top="508" left="849" width="221" height="20" font="1">for high BP control effectively lowers BP </text>
<text top="526" left="849" width="180" height="20" font="1">for up to 1 y, but then BP control </text>
<text top="543" left="849" width="55" height="20" font="1">slackens. </text>
<text top="562" left="849" width="7" height="18" font="1">•</text>
<text top="561" left="856" width="209" height="20" font="1"> Interventions had the most impact on </text>
<text top="578" left="849" width="219" height="20" font="1">pts with worst BP control at study entry. </text>
<text top="597" left="849" width="7" height="18" font="1">•</text>
<text top="597" left="856" width="192" height="20" font="1">  Study carried out in the Veteran’s </text>
<text top="614" left="849" width="189" height="20" font="1">Administration outpatient practice; </text>
<text top="631" left="849" width="207" height="20" font="1">unclear if results would apply to other </text>
<text top="648" left="849" width="96" height="20" font="1">practice settings.<b> </b></text>
</page>
<page number="99" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1066" width="17" height="20" font="1">99 </text>
<text top="107" left="98" width="74" height="20" font="1">Green BB, et </text>
<text top="124" left="98" width="83" height="20" font="1">al., 2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(133)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18577730?dopt=Citation">18577730</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18577730?dopt=Citation"> </a></text>
<text top="107" left="204" width="127" height="20" font="4"><b>Aim:</b> Assess impact of </text>
<text top="124" left="204" width="137" height="20" font="1">follow-up and monitoring </text>
<text top="141" left="204" width="148" height="20" font="1">system including home BP </text>
<text top="159" left="204" width="147" height="20" font="1">monitoring, Internet-based </text>
<text top="176" left="204" width="145" height="20" font="1">BP management tool, and </text>
<text top="193" left="204" width="91" height="20" font="1">pharmacist care </text>
<text top="210" left="204" width="152" height="20" font="1">management on BP control </text>
<text top="228" left="204" width="121" height="20" font="1">in pts treated for HTN </text>
<text top="245" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="262" left="204" width="141" height="20" font="4"><b>Study type:</b> Cluster RCT </text>
<text top="279" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="296" left="204" width="158" height="20" font="4"><b>Size:</b> 778 pts from 16 clinics </text>
<text top="314" left="204" width="152" height="20" font="1">in integrated group practice </text>
<text top="331" left="204" width="115" height="20" font="1">in Washington state. </text>
<text top="107" left="377" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="124" left="377" width="48" height="20" font="4"><b>criteria: </b></text>
<text top="141" left="377" width="72" height="20" font="1">Uncontrolled </text>
<text top="159" left="377" width="98" height="20" font="1">HTN and Internet </text>
<text top="176" left="377" width="42" height="20" font="1">access </text>
<text top="109" left="491" width="7" height="18" font="1">•</text>
<text top="108" left="497" width="129" height="20" font="1"> 2 intervention groups:  </text>
<text top="125" left="491" width="103" height="20" font="1">one with home BP </text>
<text top="143" left="491" width="130" height="20" font="1">monitoring and Internet </text>
<text top="160" left="491" width="128" height="20" font="1">tool, and the other with </text>
<text top="177" left="491" width="118" height="20" font="1">home BP monitoring, </text>
<text top="194" left="491" width="96" height="20" font="1">Internet tool, and </text>
<text top="212" left="491" width="91" height="20" font="1">pharmacist care </text>
<text top="229" left="491" width="75" height="20" font="1">management </text>
<text top="248" left="491" width="7" height="18" font="1">•</text>
<text top="247" left="497" width="104" height="20" font="1"> Compare to usual </text>
<text top="264" left="491" width="27" height="20" font="1">care </text>
<text top="283" left="491" width="7" height="18" font="1">•</text>
<text top="283" left="497" width="76" height="20" font="1"> 1 y follow-up </text>
<text top="109" left="638" width="7" height="18" font="1">•</text>
<text top="108" left="645" width="147" height="20" font="1"> Intervention group with all </text>
<text top="125" left="638" width="178" height="20" font="1">components achieved better BP </text>
<text top="143" left="638" width="120" height="20" font="1">control vs. usual care </text>
<text top="162" left="638" width="7" height="18" font="1">•</text>
<text top="161" left="645" width="161" height="20" font="1"> 56% (95% CI: 49%–62%) or </text>
<text top="178" left="638" width="172" height="20" font="1">combination intervention group </text>
<text top="195" left="638" width="192" height="20" font="1">achieved BP control vs. usual care </text>
<text top="213" left="638" width="173" height="20" font="1">(p&lt;0.001) and intervention with </text>
<text top="230" left="638" width="194" height="20" font="1">only home BP monitor and Internet </text>
<text top="247" left="638" width="80" height="20" font="1">tool (p&lt;0.001)<b> </b></text>
<text top="109" left="849" width="7" height="18" font="1">•</text>
<text top="108" left="856" width="208" height="20" font="1"> Combination of home BP monitoring, </text>
<text top="125" left="849" width="211" height="20" font="1">Internet-based BP management tools, </text>
<text top="143" left="849" width="192" height="20" font="1">and pharmacist case management </text>
<text top="160" left="849" width="204" height="20" font="1">helped control HTN better than usual </text>
<text top="177" left="849" width="218" height="20" font="1">care and better than BP monitoring and </text>
<text top="194" left="849" width="143" height="20" font="1">Internet-based tool alone.<b> </b></text>
<text top="349" left="98" width="92" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Heisler%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22570370">Heisler M, e</a>t al., </text>
<text top="366" left="98" width="66" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(134)</a>  </text>
<text top="383" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22570370?dopt=Citation">22570370</a></text>
<text top="383" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22570370?dopt=Citation"> </a></text>
<text top="349" left="204" width="127" height="20" font="4"><b>Aim:</b> Assess impact of </text>
<text top="366" left="204" width="143" height="20" font="1">follow-up pharmacist care </text>
<text top="383" left="204" width="154" height="20" font="1">management system on BP </text>
<text top="400" left="204" width="133" height="20" font="1">control in pts treated for </text>
<text top="418" left="204" width="29" height="20" font="1">HTN </text>
<text top="435" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="452" left="204" width="141" height="20" font="4"><b>Study type:</b> Cluster RCT </text>
<text top="469" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="487" left="204" width="154" height="20" font="4"><b>Size:</b> 1797 intervention and </text>
<text top="504" left="204" width="136" height="20" font="1">2303 control pts from 16 </text>
<text top="521" left="204" width="132" height="20" font="1">primary care clinics at 5 </text>
<text top="538" left="204" width="158" height="20" font="1">medical centers (3 VA and 2 </text>
<text top="555" left="204" width="113" height="20" font="1">Kaiser Permanente) </text>
<text top="349" left="377" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="366" left="377" width="48" height="20" font="4"><b>criteria: </b></text>
<text top="383" left="377" width="72" height="20" font="1">Uncontrolled </text>
<text top="400" left="377" width="98" height="20" font="1">HTN and Internet </text>
<text top="418" left="377" width="42" height="20" font="1">access </text>
<text top="351" left="491" width="7" height="18" font="1">•</text>
<text top="350" left="497" width="109" height="20" font="1"> 14-mo intervention </text>
<text top="367" left="491" width="38" height="20" font="1">period </text>
<text top="386" left="491" width="7" height="18" font="1">•</text>
<text top="386" left="497" width="120" height="20" font="1"> BP 6 mo prior to and </text>
<text top="403" left="491" width="126" height="20" font="1">6 mo after intervention </text>
<text top="420" left="491" width="126" height="20" font="1">period were compared </text>
<text top="437" left="491" width="104" height="20" font="1">in intervention and </text>
<text top="454" left="491" width="81" height="20" font="1">control groups </text>
<text top="351" left="638" width="7" height="18" font="1">•</text>
<text top="350" left="645" width="187" height="20" font="1"> Mean SBP was 2.4 mm Hg lower </text>
<text top="367" left="638" width="197" height="20" font="1">(95% CI: -3.4– -1.5), p&lt;0.001 in the </text>
<text top="384" left="638" width="171" height="20" font="1">intervention group immediately </text>
<text top="402" left="638" width="157" height="20" font="1">after the intervention period, </text>
<text top="419" left="638" width="168" height="20" font="1">compared to the control group </text>
<text top="436" left="638" width="3" height="20" font="1"> </text>
<text top="453" left="638" width="187" height="20" font="1">BP decrease was the same in the </text>
<text top="470" left="638" width="187" height="20" font="1">intervention and control groups (9 </text>
<text top="488" left="638" width="51" height="20" font="1">mm Hg). </text>
<text top="505" left="638" width="3" height="20" font="4"><b> </b></text>
<text top="522" left="638" width="3" height="20" font="4"><b> </b></text>
<text top="351" left="849" width="7" height="18" font="1">•</text>
<text top="350" left="856" width="213" height="20" font="1"> Pharmacist care management system </text>
<text top="367" left="849" width="185" height="20" font="1">in a “real world” setting was more </text>
<text top="384" left="849" width="219" height="20" font="1">effective than usual care in lowering BP </text>
<text top="402" left="849" width="217" height="20" font="1">in the short-term, but in the longer-term </text>
<text top="419" left="849" width="219" height="20" font="1">follow-up did not differ significantly from </text>
<text top="436" left="849" width="64" height="20" font="1">usual care. </text>
<text top="455" left="849" width="7" height="18" font="1">•</text>
<text top="454" left="856" width="218" height="20" font="1"> This study is one of very few studies to </text>
<text top="472" left="849" width="213" height="20" font="1">show no significant longer term impact </text>
<text top="489" left="849" width="206" height="20" font="1">of a care management system on BP </text>
<text top="506" left="849" width="130" height="20" font="1">control in pts with HTN. </text>
<text top="523" left="849" width="3" height="20" font="4"><b> </b></text>
<text top="573" left="98" width="85" height="20" font="1">Margolis KL, et </text>
<text top="591" left="98" width="76" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(25)</a> </text>
<text top="608" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23821088?dopt=Citation">23821088</a></text>
<text top="608" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23821088?dopt=Citation"> </a></text>
<text top="573" left="204" width="127" height="20" font="4"><b>Aim:</b> Assess impact of </text>
<text top="591" left="204" width="137" height="20" font="1">follow-up and monitoring </text>
<text top="608" left="204" width="148" height="20" font="1">system including home BP </text>
<text top="625" left="204" width="109" height="20" font="1">tele-monitoring and </text>
<text top="642" left="204" width="93" height="20" font="1">pharmacist case </text>
<text top="659" left="204" width="152" height="20" font="1">management on BP control </text>
<text top="677" left="204" width="121" height="20" font="1">in pts treated for HTN </text>
<text top="694" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="711" left="204" width="141" height="20" font="4"><b>Study type:</b> Cluster RCT </text>
<text top="728" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="745" left="204" width="158" height="20" font="4"><b>Size:</b> 450 pts from 16 clinics </text>
<text top="763" left="204" width="150" height="20" font="1">in integrated health system </text>
<text top="780" left="204" width="108" height="20" font="1">in Minneapolis, MN<b> </b></text>
<text top="573" left="377" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="591" left="377" width="48" height="20" font="4"><b>criteria: </b></text>
<text top="608" left="377" width="72" height="20" font="1">Uncontrolled </text>
<text top="625" left="377" width="29" height="20" font="1">HTN<b> </b></text>
<text top="575" left="491" width="7" height="18" font="1">•</text>
<text top="574" left="497" width="115" height="20" font="1"> 222 pts randomized </text>
<text top="592" left="491" width="121" height="20" font="1">to 8 usual care clinics </text>
<text top="609" left="491" width="129" height="20" font="1">and 228 randomized to </text>
<text top="626" left="491" width="114" height="20" font="1">8 intervention clinics </text>
<text top="645" left="491" width="7" height="18" font="1">•</text>
<text top="644" left="497" width="120" height="20" font="1"> Intervention included </text>
<text top="662" left="491" width="129" height="20" font="1">12 mo of home BP tele-</text>
<text top="679" left="491" width="85" height="20" font="1">monitoring and </text>
<text top="696" left="491" width="93" height="20" font="1">pharmacist case </text>
<text top="713" left="491" width="114" height="20" font="1">management, with 6 </text>
<text top="730" left="491" width="87" height="20" font="1">mo of follow-up </text>
<text top="748" left="491" width="55" height="20" font="1">afterward </text>
<text top="575" left="638" width="7" height="18" font="1">•</text>
<text top="574" left="645" width="159" height="20" font="1"> Intervention group achieved </text>
<text top="592" left="638" width="167" height="20" font="1">better BP control compared to </text>
<text top="609" left="638" width="149" height="20" font="1">usual care during 12 mo of </text>
<text top="626" left="638" width="195" height="20" font="1">intervention and persisting during 6 </text>
<text top="643" left="638" width="87" height="20" font="1">mo of follow-up </text>
<text top="662" left="638" width="7" height="18" font="1">•</text>
<text top="662" left="645" width="188" height="20" font="1"> SBP was &lt;140/90 in 57.2% (95% </text>
<text top="679" left="638" width="184" height="20" font="1">CI: 44.8%, 68.7%) of intervention </text>
<text top="696" left="638" width="185" height="20" font="1">pts at 6 and 12 mo vs. 30% (95% </text>
<text top="713" left="638" width="176" height="20" font="1">CI: 23.2%, 37.8%) in usual care </text>
<text top="730" left="638" width="56" height="20" font="1">(p=0.001) </text>
<text top="575" left="849" width="7" height="18" font="1">•</text>
<text top="574" left="856" width="167" height="20" font="1"> Combination of home BP tele-</text>
<text top="592" left="849" width="178" height="20" font="1">monitoring and pharmacist case </text>
<text top="609" left="849" width="220" height="20" font="1">management helped control HTN better </text>
<text top="626" left="849" width="197" height="20" font="1">than usual care at 6, 12, and 18 mo </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">100 </text>
<text top="108" left="108" width="3" height="19" font="7"> </text>
<text top="144" left="108" width="3" height="19" font="1"> </text>
<text top="144" left="304" width="3" height="19" font="1"> </text>
<text top="178" left="81" width="583" height="24" font="3"><b>Data Supplement 30. RCTs Comparing Stable Ischemic Heart Disease (Section 9.1) </b></text>
<text top="218" left="125" width="38" height="20" font="4"><b>Study </b></text>
<text top="235" left="114" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="252" left="120" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="270" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="218" left="223" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="235" left="228" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="252" left="222" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="218" left="352" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="218" left="497" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="235" left="513" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="252" left="497" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="270" left="518" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="218" left="651" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="235" left="635" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="252" left="641" width="126" height="20" font="4"><b>P value; OR or RR; &amp; </b></text>
<text top="270" left="680" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="219" left="853" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="236" left="885" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="253" left="891" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="271" left="911" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="289" left="98" width="51" height="20" font="4"><b>INVEST  </b></text>
<text top="306" left="98" width="88" height="20" font="1">Bangalore S, et </text>
<text top="323" left="98" width="83" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(135)</a> </text>
<text top="340" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25145522?dopt=Citation">25145522</a></text>
<text top="340" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25145522?dopt=Citation"><b> </b></a></text>
<text top="289" left="204" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="306" left="204" width="121" height="20" font="1">optimal BP in pts ≥60 </text>
<text top="323" left="204" width="116" height="20" font="1">y with CAD and SBP </text>
<text top="340" left="204" width="116" height="20" font="1">&gt;150 mm Hg treated </text>
<text top="357" left="204" width="118" height="20" font="1">with antihypertensive </text>
<text top="375" left="204" width="34" height="20" font="1">drugs </text>
<text top="392" left="204" width="3" height="20" font="1"> </text>
<text top="409" left="204" width="99" height="20" font="4"><b>Study type:</b> Post-</text>
<text top="426" left="204" width="85" height="20" font="1">hoc analysis of </text>
<text top="443" left="204" width="122" height="20" font="1">PROBE trial (INVEST </text>
<text top="461" left="204" width="42" height="20" font="1">study—</text>
<text top="478" left="204" width="97" height="20" font="1">atenolol/HCTZ or </text>
<text top="495" left="204" width="57" height="20" font="1">verapamil-</text>
<text top="512" left="204" width="89" height="20" font="1">SR/trandolapril) </text>
<text top="530" left="204" width="3" height="20" font="1"> </text>
<text top="547" left="204" width="86" height="20" font="4"><b>Size:</b> 8,354 pts </text>
<text top="289" left="339" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="306" left="339" width="113" height="20" font="1">≥60 y with CAD and </text>
<text top="323" left="339" width="102" height="20" font="1">SBP &gt;150 mm Hg </text>
<text top="340" left="339" width="67" height="20" font="1">treated with </text>
<text top="357" left="339" width="93" height="20" font="1">antihypertensive </text>
<text top="375" left="339" width="44" height="20" font="1">therapy </text>
<text top="392" left="339" width="3" height="20" font="1"> </text>
<text top="409" left="339" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="289" left="489" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="308" left="489" width="7" height="18" font="1">•</text>
<text top="307" left="496" width="94" height="20" font="1"> 4,787 pts (57%) </text>
<text top="324" left="489" width="108" height="20" font="1">achieved SBP&lt;140 </text>
<text top="341" left="489" width="96" height="20" font="1">mm Hg (group 1) </text>
<text top="360" left="489" width="7" height="18" font="1">•</text>
<text top="360" left="496" width="109" height="20" font="1"> SBP achieved was </text>
<text top="377" left="489" width="113" height="20" font="1">&lt;140 mm Hg (group </text>
<text top="394" left="489" width="14" height="20" font="1">1) </text>
<text top="411" left="489" width="7" height="20" font="1">  </text>
<text top="429" left="489" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="448" left="489" width="7" height="18" font="1">•</text>
<text top="447" left="496" width="94" height="20" font="1"> 1,747 pts (21%) </text>
<text top="464" left="489" width="121" height="20" font="1">achieved SBP of 140–</text>
<text top="481" left="489" width="124" height="20" font="1">149 mm Hg (group 2); </text>
<text top="499" left="489" width="90" height="20" font="1">1,820 pts (22%) </text>
<text top="516" left="489" width="113" height="20" font="1">achieved SBP ≥150 </text>
<text top="533" left="489" width="96" height="20" font="1">mm Hg (group 3) </text>
<text top="552" left="489" width="7" height="18" font="1">•</text>
<text top="552" left="496" width="109" height="20" font="1"> SBP achieved was </text>
<text top="569" left="489" width="94" height="20" font="1">140–149 mm Hg </text>
<text top="586" left="489" width="125" height="20" font="1">(group 2) and 150 mm </text>
<text top="603" left="489" width="124" height="20" font="1">Hg or higher (group 3)<b> </b></text>
<text top="290" left="629" width="130" height="20" font="4"><b>1</b>°<b> endpoint:</b> All-cause </text>
<text top="307" left="629" width="120" height="20" font="1">death, nonfatal MI, or </text>
<text top="324" left="629" width="133" height="20" font="1">nonfatal stroke. Multiple </text>
<text top="341" left="629" width="144" height="20" font="1">propensity score-adjusted </text>
<text top="359" left="629" width="136" height="20" font="1">1° outcome showed that </text>
<text top="376" left="629" width="132" height="20" font="1">compared with group 1, </text>
<text top="393" left="629" width="123" height="20" font="1">the risk of 1° outcome </text>
<text top="410" left="629" width="134" height="20" font="1">adjusted HR: 1.12 (95% </text>
<text top="428" left="629" width="53" height="20" font="1">CI: 0.95– </text>
<text top="445" left="629" width="143" height="20" font="1">1.32; p=0.19); for group 2 </text>
<text top="462" left="629" width="134" height="20" font="1">adjusted HR: 1.85 (95% </text>
<text top="479" left="629" width="143" height="20" font="1">CI: 1.59, 2.14), p&lt;0.0001; </text>
<text top="496" left="629" width="137" height="20" font="1">for group 3 adjusted HR: </text>
<text top="514" left="629" width="144" height="20" font="1">1.64 (95% CI: 1.40, 1.93), </text>
<text top="531" left="629" width="48" height="20" font="1">p&lt;.0001 </text>
<text top="548" left="629" width="3" height="20" font="1"> </text>
<text top="566" left="629" width="135" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> No </text>
<text top="584" left="629" width="115" height="20" font="1">significant difference </text>
<text top="601" left="629" width="122" height="20" font="1">between the 3 groups </text>
<text top="290" left="791" width="270" height="20" font="4"><b>Relevant 2</b>°<b> endpoint: </b>Multiple propensity score-</text>
<text top="307" left="791" width="101" height="20" font="1">adjusted analysis: </text>
<text top="326" left="791" width="7" height="18" font="1">•</text>
<text top="325" left="798" width="280" height="20" font="1">Compared with group 1, no significant difference in </text>
<text top="343" left="791" width="290" height="20" font="1">all-cause mortality in group 2 but increased all-cause </text>
<text top="360" left="791" width="276" height="20" font="1">mortality in group 3 (HR: 1.64; 95% CI: 1.40–1.93; </text>
<text top="377" left="791" width="63" height="20" font="1">p&lt;0.0001). </text>
<text top="396" left="791" width="7" height="18" font="1">•</text>
<text top="395" left="798" width="271" height="20" font="1"> Compared with group 1, increase CV mortality in </text>
<text top="413" left="791" width="296" height="20" font="1">group 2 (HR: 1.34; 95% CI: 1.01–1.77; p=0.04) and in </text>
<text top="430" left="791" width="279" height="20" font="1">group 3 (HR: 2.29; 95% CI: 1.79–2.93; p&lt;0.0001).  </text>
<text top="449" left="791" width="7" height="18" font="1">•</text>
<text top="448" left="798" width="265" height="20" font="1"> Compared with group 1, total MI was in group 2 </text>
<text top="465" left="791" width="260" height="20" font="1">(HR: 1.20; 95% CI: 0.90–1.60; p=0.21) but was </text>
<text top="483" left="791" width="280" height="20" font="1">increased in group 3 (HR: 2.39; 95% CI: 1.87-3.05; </text>
<text top="500" left="791" width="66" height="20" font="1">p&lt;0.0001).  </text>
<text top="519" left="791" width="7" height="18" font="1">•</text>
<text top="518" left="798" width="271" height="20" font="1"> Compared with group 1, no significant difference </text>
<text top="536" left="791" width="293" height="20" font="1">with group 2 but an increase in nonfatal MI in group 3 </text>
<text top="553" left="791" width="284" height="20" font="1">(adjusted HR: 2.45; 95% CI: 1.02–3.71; p&lt;0.0001).  </text>
<text top="572" left="791" width="7" height="18" font="1">•</text>
<text top="571" left="798" width="282" height="20" font="1"> Compared with group 1, an increase in total stroke </text>
<text top="588" left="791" width="279" height="20" font="1">in group 2 (HR: 1.89; 95% CI: 1.26–2.82; p=0.002) </text>
<text top="606" left="791" width="250" height="20" font="1">and in group 3 (HR: 2.93; 95% CI: 2.01–4.27; </text>
<text top="623" left="791" width="59" height="20" font="1">p&lt;0.001).  </text>
<text top="642" left="791" width="7" height="18" font="1">•</text>
<text top="641" left="798" width="265" height="20" font="1"> Compared with group 1, an increase in nonfatal </text>
<text top="658" left="791" width="263" height="20" font="1">stroke in group 2 (HR: 1.70; 95% CI: 1.06–2.72; </text>
<text top="676" left="791" width="296" height="20" font="1">p=0.03) and in group 3 (HR: 2.78; 95% CI: 1.80–4.30; </text>
<text top="693" left="791" width="56" height="20" font="1">p&lt;0.001). </text>
<text top="712" left="791" width="7" height="18" font="1">•</text>
<text top="711" left="798" width="222" height="20" font="1"> HF and revascularization not significant </text>
<text top="728" left="791" width="3" height="20" font="1"> </text>
<text top="746" left="791" width="294" height="20" font="4"><b>Study limitations and adverse events:</b> The present </text>
<text top="763" left="791" width="296" height="20" font="1">study was not designed to test whether pts ≥60 y with </text>
<text top="780" left="791" width="275" height="20" font="1">CAD and a SBP of 140–149 mm Hg would benefit </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">101 </text>
<text top="107" left="791" width="286" height="20" font="1">from antihypertensive treatment. No adverse events </text>
<text top="124" left="791" width="83" height="20" font="1">were reported. </text>
<text top="141" left="791" width="3" height="20" font="1"> </text>
<text top="159" left="791" width="281" height="20" font="4"><b>Summary</b>: The optimal SBP in pts ≥60 y with CAD </text>
<text top="176" left="791" width="286" height="20" font="1">and SBP &gt;150 mm Hg treated with antihypertensive </text>
<text top="193" left="791" width="144" height="20" font="1">therapy was &lt;140 mm Hg </text>
<text top="211" left="98" width="89" height="20" font="1">Law MR, et al.,  </text>
<text top="228" left="98" width="56" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(18)</a> </text>
<text top="245" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation">19454737</a></text>
<text top="245" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation"><b> </b></a></text>
<text top="211" left="204" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="228" left="204" width="98" height="20" font="1">analysis of use of </text>
<text top="245" left="204" width="117" height="20" font="1">BP-lowering drugs in </text>
<text top="263" left="204" width="104" height="20" font="1">prevention of CVD </text>
<text top="280" left="204" width="120" height="20" font="1">from 147 randomized </text>
<text top="297" left="204" width="29" height="20" font="1">trials </text>
<text top="314" left="204" width="3" height="20" font="1"> </text>
<text top="332" left="204" width="72" height="20" font="4"><b>Size:</b> Of 147 </text>
<text top="349" left="204" width="111" height="20" font="1">randomized trials of </text>
<text top="366" left="204" width="118" height="20" font="1">464,000 pts, 37 trials </text>
<text top="383" left="204" width="82" height="20" font="1">of BBs in CAD </text>
<text top="400" left="204" width="113" height="20" font="1">included 38,892 pts, </text>
<text top="418" left="204" width="116" height="20" font="1">and 37 trials of other </text>
<text top="435" left="204" width="93" height="20" font="1">antihypertensive </text>
<text top="452" left="204" width="76" height="20" font="1">drugs in CAD </text>
<text top="469" left="204" width="110" height="20" font="1">included 85,395 pts<b> </b></text>
<text top="211" left="339" width="131" height="20" font="4"><b>Inclusion criteria:</b> The </text>
<text top="228" left="339" width="124" height="20" font="1">database search used </text>
<text top="245" left="339" width="124" height="20" font="1">Medline (1966 to Dec. </text>
<text top="263" left="339" width="91" height="20" font="1">2007) to identify </text>
<text top="280" left="339" width="131" height="20" font="1">randomized trials of BP-</text>
<text top="297" left="339" width="131" height="20" font="1">lowering drugs in which </text>
<text top="314" left="339" width="126" height="20" font="1">CAD events or strokes </text>
<text top="332" left="339" width="110" height="20" font="1">were recorded. The </text>
<text top="349" left="339" width="115" height="20" font="1">search also included </text>
<text top="366" left="339" width="77" height="20" font="1">the Cochrane </text>
<text top="383" left="339" width="128" height="20" font="1">Collaboration and Web </text>
<text top="401" left="339" width="121" height="20" font="1">of Science databases </text>
<text top="418" left="339" width="96" height="20" font="1">and the citations  </text>
<text top="435" left="339" width="116" height="20" font="1">in trials and previous </text>
<text top="452" left="339" width="107" height="20" font="1">meta-analyses and </text>
<text top="469" left="339" width="88" height="20" font="1">review articles.  </text>
<text top="487" left="339" width="3" height="20" font="1"> </text>
<text top="504" left="339" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="521" left="339" width="126" height="20" font="1">Trials were excluded if </text>
<text top="538" left="339" width="108" height="20" font="1">there were &lt;5 CAD </text>
<text top="555" left="339" width="131" height="20" font="1">events and strokes or if </text>
<text top="573" left="339" width="129" height="20" font="1">treatment duration was </text>
<text top="590" left="339" width="41" height="20" font="1">&lt;6 mo. </text>
<text top="211" left="487" width="24" height="20" font="1">N/A </text>
<text top="212" left="629" width="148" height="20" font="4"><b>1</b>°<b> endpoint:</b> CAD events; </text>
<text top="229" left="629" width="37" height="20" font="1">stroke </text>
<text top="247" left="629" width="3" height="20" font="1"> </text>
<text top="264" left="629" width="146" height="20" font="4"><b>Results:</b> In 37 trials of pts </text>
<text top="281" left="629" width="147" height="20" font="1">with a history of CAD, BBs </text>
<text top="298" left="629" width="145" height="20" font="1">reduced CAD events 29% </text>
<text top="316" left="629" width="149" height="20" font="1">(95% CI: 22%, 34%). In 27 </text>
<text top="333" left="629" width="133" height="20" font="1">trials in which BBs were </text>
<text top="350" left="629" width="138" height="20" font="1">used after acute MI, BBs </text>
<text top="367" left="629" width="145" height="20" font="1">reduced CAD events 31% </text>
<text top="384" left="629" width="142" height="20" font="1">(95% CI: 24%–38%), and </text>
<text top="402" left="629" width="133" height="20" font="1">in 11 trials in which BBs </text>
<text top="419" left="629" width="144" height="20" font="1">were used after long-term </text>
<text top="436" left="629" width="135" height="20" font="1">CAD, BBs insignificantly </text>
<text top="453" left="629" width="148" height="20" font="1">reduced CAD events 13%. </text>
<text top="470" left="629" width="130" height="20" font="1">In 7 trials, BBs reduced </text>
<text top="488" left="629" width="141" height="20" font="1">stroke 17% (95% CI: 1%–</text>
<text top="505" left="629" width="134" height="20" font="1">30%). CAD events were </text>
<text top="522" left="629" width="127" height="20" font="1">reduced 14% (95% CI: </text>
<text top="539" left="629" width="130" height="20" font="1">2%–25%) in 11 trials of </text>
<text top="557" left="629" width="126" height="20" font="1">thiazide diuretics, 17% </text>
<text top="574" left="629" width="145" height="20" font="1">(95% CI: 11%–22%) in 21 </text>
<text top="591" left="629" width="85" height="20" font="1">trials of ACEIs, </text>
<text top="608" left="629" width="128" height="20" font="1">insignificantly 14% in 4 </text>
<text top="625" left="629" width="109" height="20" font="1">trials of angiotensin </text>
<text top="643" left="629" width="125" height="20" font="1">receptor blockers, and </text>
<text top="660" left="629" width="149" height="20" font="1">15% (95% CI: 8%–22%) in </text>
<text top="677" left="629" width="138" height="20" font="1">22 trials of CCBs. Stroke </text>
<text top="694" left="629" width="133" height="20" font="1">was reduced 38% (95% </text>
<text top="711" left="629" width="142" height="20" font="1">CI: 28%–47%) in 10 trials </text>
<text top="729" left="629" width="140" height="20" font="1">of thiazide diuretics, 22% </text>
<text top="746" left="629" width="138" height="20" font="1">(95% CI: 8%–34%) in 13 </text>
<text top="763" left="629" width="137" height="20" font="1">trials of ACEIs, and 34% </text>
<text top="213" left="791" width="7" height="18" font="1">•</text>
<text top="212" left="798" width="277" height="20" font="1"> With the exception of the extra protective effect of </text>
<text top="229" left="791" width="289" height="20" font="1">BBs given shortly after a MI and the minor additional </text>
<text top="247" left="791" width="291" height="20" font="1">effect of CCBs in preventing stroke, all the classes of </text>
<text top="264" left="791" width="280" height="20" font="1">BP-lowering drugs have a similar effect in reducing </text>
<text top="281" left="791" width="281" height="20" font="1">CAD events and stroke for a given reduction in BP. </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">102 </text>
<text top="107" left="629" width="138" height="20" font="1">(95% CI: 25%–42%) in 9 </text>
<text top="124" left="629" width="82" height="20" font="1">trials of CCBs. </text>
<text top="193" left="98" width="42" height="20" font="4"><b>HOPE  </b></text>
<text top="210" left="98" width="87" height="20" font="1">Yusuf S, et al.,  </text>
<text top="227" left="98" width="63" height="20" font="1">2000 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(136)</a> </text>
<text top="244" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10639539?dopt=Citation">10639539</a></text>
<text top="244" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10639539?dopt=Citation"> </a></text>
<text top="193" left="204" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="210" left="204" width="83" height="20" font="1">effect of ACE-I </text>
<text top="227" left="204" width="111" height="20" font="1">(Ramipril 10 mg) on </text>
<text top="244" left="204" width="100" height="20" font="1">CV events in high </text>
<text top="262" left="204" width="115" height="20" font="1">risk pts. over 5y with </text>
<text top="279" left="204" width="109" height="20" font="1">a mean entry BP of </text>
<text top="296" left="204" width="97" height="20" font="1">139/79 mm Hg in </text>
<text top="313" left="204" width="68" height="20" font="1">both groups </text>
<text top="330" left="204" width="3" height="20" font="1"> </text>
<text top="348" left="204" width="103" height="20" font="4"><b>Study type:</b> RCT, </text>
<text top="365" left="204" width="111" height="20" font="1">2×2 factorial design </text>
<text top="382" left="204" width="3" height="20" font="1"> </text>
<text top="399" left="204" width="66" height="20" font="4"><b>Size:</b> 9,297 </text>
<text top="193" left="339" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="210" left="339" width="113" height="20" font="1">≥55 y with history of </text>
<text top="227" left="339" width="116" height="20" font="1">CAD, stroke, PVD or </text>
<text top="244" left="339" width="114" height="20" font="1">DM with either HTN, </text>
<text top="262" left="339" width="76" height="20" font="1">elevated total </text>
<text top="279" left="339" width="114" height="20" font="1">cholesterol, low LDL </text>
<text top="296" left="339" width="133" height="20" font="1">cholesterol, smoking, or </text>
<text top="313" left="339" width="104" height="20" font="1">micro albuminuria. </text>
<text top="330" left="339" width="3" height="20" font="1"> </text>
<text top="348" left="339" width="133" height="20" font="4"><b>Exclusion criteria:</b> HF, </text>
<text top="365" left="339" width="125" height="20" font="1">&lt;0.40 EF, on ACE-I or </text>
<text top="382" left="339" width="130" height="20" font="1">Vitamin E, uncontrolled </text>
<text top="399" left="339" width="63" height="20" font="1">HTN /overt </text>
<text top="417" left="339" width="133" height="20" font="1">nephropathy, Had MI or </text>
<text top="434" left="339" width="73" height="20" font="1">stroke &lt;4 wk </text>
<text top="193" left="489" width="127" height="20" font="4"><b>Intervention:</b> Ramipril </text>
<text top="210" left="489" width="88" height="20" font="1">(10 mg) (4,645) </text>
<text top="227" left="489" width="3" height="20" font="1"> </text>
<text top="244" left="489" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="262" left="489" width="42" height="20" font="1">(4,652) </text>
<text top="194" left="629" width="138" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite </text>
<text top="211" left="629" width="139" height="20" font="1">of MI, stroke, or mortality </text>
<text top="228" left="629" width="94" height="20" font="1">from CV causes. </text>
<text top="246" left="629" width="3" height="20" font="1"> </text>
<text top="263" left="629" width="104" height="20" font="4"><b>Results: </b>Endpoint </text>
<text top="280" left="629" width="137" height="20" font="1">reduction Ramipril group </text>
<text top="297" left="629" width="118" height="20" font="1">vs. Placebo (14% vs. </text>
<text top="314" left="629" width="116" height="20" font="1">17.8%; RR: 0.78; CI: </text>
<text top="332" left="629" width="114" height="20" font="1">0.70–0.86; p&lt;0.001) </text>
<text top="195" left="791" width="7" height="18" font="1">•</text>
<text top="194" left="798" width="291" height="20" font="1"> Death from cardiac causes reduced (6.1% vs. 8.1%; </text>
<text top="211" left="791" width="52" height="20" font="1">p&lt;0.001) </text>
<text top="230" left="791" width="7" height="18" font="1">•</text>
<text top="230" left="798" width="282" height="20" font="1"> Death from MI reduced (9.9% vs. 12.3%; p&lt;0.001) </text>
<text top="249" left="791" width="7" height="18" font="1">•</text>
<text top="248" left="798" width="286" height="20" font="1"> Death from any cause (10.4 % vs. 12.2%; p=0.005) </text>
<text top="452" left="98" width="40" height="20" font="4"><b>SAVE  </b></text>
<text top="469" left="98" width="74" height="20" font="1">Pfeffer M., et </text>
<text top="486" left="98" width="83" height="20" font="1">al., 1992 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(137)</a> </text>
<text top="503" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1386652?dopt=Citation">1386652</a></text>
<text top="503" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1386652?dopt=Citation"> </a></text>
<text top="452" left="204" width="100" height="20" font="4"><b>Aim:</b> To assess if </text>
<text top="469" left="204" width="104" height="20" font="1">captopril decrease </text>
<text top="486" left="204" width="77" height="20" font="1">morbidity and </text>
<text top="503" left="204" width="108" height="20" font="1">mortality in pts with </text>
<text top="521" left="204" width="112" height="20" font="1">LV dysfunction after </text>
<text top="538" left="204" width="21" height="20" font="1">MI. </text>
<text top="555" left="204" width="3" height="20" font="1"> </text>
<text top="572" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="589" left="204" width="3" height="20" font="1"> </text>
<text top="607" left="204" width="66" height="20" font="4"><b>Size:</b> 2,231 </text>
<text top="452" left="339" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="469" left="339" width="128" height="20" font="1">(21–80 y) surviving 3 d </text>
<text top="486" left="339" width="104" height="20" font="1">after MI, EF≤40%. </text>
<text top="503" left="339" width="3" height="20" font="1"> </text>
<text top="521" left="339" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="538" left="339" width="109" height="20" font="1">Pts not randomized </text>
<text top="555" left="339" width="111" height="20" font="1">within 16 d after MI, </text>
<text top="572" left="339" width="117" height="20" font="1">contra. to ACE-I use, </text>
<text top="589" left="339" width="128" height="20" font="1">Serum Cr. &gt;2.5 mg/dL, </text>
<text top="607" left="339" width="120" height="20" font="1">severe comorbidities, </text>
<text top="624" left="339" width="107" height="20" font="1">unstable infarction, </text>
<text top="641" left="339" width="49" height="20" font="1">need for </text>
<text top="658" left="339" width="96" height="20" font="1">revascularization </text>
<text top="452" left="489" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="469" left="489" width="98" height="20" font="1">Captopril (titrated </text>
<text top="486" left="489" width="73" height="20" font="1">doses) (115) </text>
<text top="503" left="489" width="3" height="20" font="1"> </text>
<text top="521" left="489" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="538" left="489" width="39" height="20" font="1">(1116) </text>
<text top="453" left="629" width="145" height="20" font="4"><b>1</b>°<b> endpoint and results:</b> </text>
<text top="470" left="629" width="135" height="20" font="1">All-cause mortality: 20% </text>
<text top="487" left="629" width="134" height="20" font="1">vs. 25%, RR: 19%; 95% </text>
<text top="505" left="629" width="123" height="20" font="1">CI: 3%–32%; p=0.019 </text>
<text top="522" left="629" width="3" height="20" font="1"> </text>
<text top="539" left="629" width="133" height="20" font="4"><b>Other endpoints:</b> Fatal </text>
<text top="556" left="629" width="126" height="20" font="1">and nonfatal major CV </text>
<text top="573" left="629" width="131" height="20" font="1">events were reduced in </text>
<text top="591" left="629" width="109" height="20" font="1">the captopril group. </text>
<text top="454" left="791" width="7" height="18" font="1">•</text>
<text top="453" left="798" width="268" height="20" font="1"> Captopril vs. Placebo group BP at 1 y (125±18 / </text>
<text top="470" left="791" width="294" height="20" font="1">77±10 mm Hg for placebo vs. 119±18/74±10 mm Hg </text>
<text top="487" left="791" width="123" height="20" font="1">for captopril; p&lt;0.001) </text>
<text top="506" left="791" width="7" height="18" font="1">•</text>
<text top="506" left="798" width="273" height="20" font="1"> Dizziness, alteration in taste, cough and diarrhea </text>
<text top="523" left="791" width="296" height="20" font="1">were reported significantly more in the captopril group </text>
<text top="542" left="791" width="7" height="18" font="1">•</text>
<text top="541" left="798" width="278" height="20" font="1"> Ventricular size on Echo studies was independent </text>
<text top="559" left="791" width="189" height="20" font="1">predictor of adverse CV outcomes </text>
<text top="676" left="98" width="59" height="20" font="4"><b>EUROPA  </b></text>
<text top="694" left="98" width="86" height="20" font="1">Fox KM, et al.,  </text>
<text top="711" left="98" width="63" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(138)</a> </text>
<text top="728" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13678872?dopt=Citation">13678872</a></text>
<text top="728" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13678872?dopt=Citation"> </a></text>
<text top="676" left="204" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="694" left="204" width="120" height="20" font="1">efficacy of perindopril </text>
<text top="711" left="204" width="106" height="20" font="1">in CV events in pts </text>
<text top="728" left="204" width="94" height="20" font="1">with stable CAD. </text>
<text top="745" left="204" width="3" height="20" font="1"> </text>
<text top="762" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="780" left="204" width="3" height="20" font="1"> </text>
<text top="676" left="339" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="694" left="339" width="111" height="20" font="1">≥18 y (women) with </text>
<text top="711" left="339" width="95" height="20" font="1">CAD &gt;mo before </text>
<text top="728" left="339" width="60" height="20" font="1">screening, </text>
<text top="745" left="339" width="134" height="20" font="1">revascularization &gt;6 mo </text>
<text top="762" left="339" width="135" height="20" font="1">before screening, ≥70% </text>
<text top="780" left="339" width="105" height="20" font="1">narrowing of major </text>
<text top="676" left="489" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="694" left="489" width="105" height="20" font="1">Perindopril (6,110) </text>
<text top="711" left="489" width="3" height="20" font="1"> </text>
<text top="728" left="489" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="745" left="489" width="42" height="20" font="1">(6,108) </text>
<text top="677" left="629" width="138" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite </text>
<text top="695" left="629" width="139" height="20" font="1">of CV death, nonfatal MI, </text>
<text top="712" left="629" width="103" height="20" font="1">cardiac arrest with </text>
<text top="729" left="629" width="90" height="20" font="1">successful CPR </text>
<text top="746" left="629" width="3" height="20" font="1"> </text>
<text top="764" left="629" width="133" height="20" font="4"><b>Results: </b>RR 20%; 95% </text>
<text top="781" left="629" width="119" height="20" font="1">CI: 9%–29; p=0.0003 </text>
<text top="678" left="791" width="7" height="18" font="1">•</text>
<text top="677" left="798" width="289" height="20" font="1"> Perindopril resulted reduction in all these outcomes: </text>
<text top="695" left="791" width="267" height="20" font="1">composite of total mortality, nonfatal MI, hospital </text>
<text top="712" left="791" width="288" height="20" font="1">admission for UA, and cardiac arrest with successful </text>
<text top="729" left="791" width="270" height="20" font="1">CPR; CV mortality and nonfatal MI, the individual </text>
<text top="746" left="791" width="284" height="20" font="1">components these outcomes and revascularization, </text>
<text top="764" left="791" width="161" height="20" font="1">stroke, and admission for HF </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">103 </text>
<text top="107" left="204" width="93" height="20" font="4"><b>Size:</b> 12,218 pts </text>
<text top="107" left="339" width="117" height="20" font="1">coronary artery. Men </text>
<text top="124" left="339" width="111" height="20" font="1">with history of chest </text>
<text top="141" left="339" width="109" height="20" font="1">pain, positive ECG, </text>
<text top="159" left="339" width="111" height="20" font="1">echo or nuclear test </text>
<text top="176" left="339" width="3" height="20" font="1"> </text>
<text top="193" left="339" width="133" height="20" font="4"><b>Exclusion criteria: </b>HF, </text>
<text top="210" left="339" width="47" height="20" font="1">planned </text>
<text top="227" left="339" width="130" height="20" font="1">revascularization, &lt;110 </text>
<text top="245" left="339" width="74" height="20" font="1">mm Hg SBP, </text>
<text top="262" left="339" width="134" height="20" font="1">uncontrolled HTN, &gt;100 </text>
<text top="279" left="339" width="133" height="20" font="1">mm Hg DBP, &lt;I mo use </text>
<text top="296" left="339" width="136" height="20" font="1">of ACEI or ARB, Cr&gt;150 </text>
<text top="314" left="339" width="119" height="20" font="1">µmol/L, serum K&gt;5.5 </text>
<text top="331" left="339" width="47" height="20" font="1">mmol/L  </text>
<text top="349" left="98" width="66" height="20" font="4"><b>MERIT-HF  </b></text>
<text top="366" left="98" width="84" height="20" font="1">Goldstein S, et </text>
<text top="383" left="98" width="83" height="20" font="1">al., 1999 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(139)</a> </text>
<text top="400" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10526701?dopt=Citation">10526701</a></text>
<text top="400" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10526701?dopt=Citation"> </a></text>
<text top="349" left="204" width="120" height="20" font="4"><b>Aim:</b> To investigate if </text>
<text top="366" left="204" width="109" height="20" font="1">metoprolol (CR/XL) </text>
<text top="383" left="204" width="107" height="20" font="1">once daily with std. </text>
<text top="400" left="204" width="94" height="20" font="1">treatment lowers </text>
<text top="418" left="204" width="108" height="20" font="1">mortality in pts with </text>
<text top="435" left="204" width="40" height="20" font="1">HF<i>r</i>EF </text>
<text top="452" left="204" width="3" height="20" font="1"> </text>
<text top="469" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="487" left="204" width="3" height="20" font="1"> </text>
<text top="504" left="204" width="86" height="20" font="4"><b>Size: </b>3,991 pts </text>
<text top="349" left="339" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="366" left="339" width="131" height="20" font="1">Pts 40–80 y with NYHA </text>
<text top="383" left="339" width="126" height="20" font="1">class II-IV HF for 3 mo </text>
<text top="400" left="339" width="119" height="20" font="1">before randomization </text>
<text top="418" left="339" width="92" height="20" font="1">and on standard </text>
<text top="435" left="339" width="122" height="20" font="1">treatment 2 wk before </text>
<text top="452" left="339" width="113" height="20" font="1">entry, Stable clinical </text>
<text top="469" left="339" width="119" height="20" font="1">condition during 2 wk </text>
<text top="487" left="339" width="133" height="20" font="1">run-in phase, EF ≤0.40. </text>
<text top="504" left="339" width="3" height="20" font="1"> </text>
<text top="521" left="339" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="538" left="339" width="124" height="20" font="1">Acute MI, UA &lt;28 d of </text>
<text top="555" left="339" width="113" height="20" font="1">entry, contra to beta </text>
<text top="573" left="339" width="114" height="20" font="1">blockade &lt;6 mo, HF </text>
<text top="590" left="339" width="89" height="20" font="1">due to systemic </text>
<text top="607" left="339" width="128" height="20" font="1">disease/alcohol abuse, </text>
<text top="624" left="339" width="89" height="20" font="1">heart transplant </text>
<text top="641" left="339" width="135" height="20" font="1">candidate, ICD, planned </text>
<text top="659" left="339" width="135" height="20" font="1">revascularization in past </text>
<text top="676" left="339" width="125" height="20" font="1">4 mo, decompensated </text>
<text top="693" left="339" width="118" height="20" font="1">heart, SBP &lt;100 mm </text>
<text top="710" left="339" width="111" height="20" font="1">Hg, CCB treatment, </text>
<text top="727" left="339" width="137" height="20" font="1">amiodarone use within 6 </text>
<text top="745" left="339" width="21" height="20" font="1">mo </text>
<text top="349" left="489" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="366" left="489" width="100" height="20" font="1">Metoprolol CR/XL </text>
<text top="383" left="489" width="42" height="20" font="1">(1,990) </text>
<text top="400" left="489" width="3" height="20" font="1"> </text>
<text top="418" left="489" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="435" left="489" width="42" height="20" font="1">(2,001) </text>
<text top="350" left="629" width="130" height="20" font="4"><b>1</b>°<b> endpoint:</b> All-cause </text>
<text top="367" left="629" width="130" height="20" font="1">mortality in the intent to </text>
<text top="384" left="629" width="31" height="20" font="1">treat  </text>
<text top="402" left="629" width="3" height="20" font="1"> </text>
<text top="419" left="629" width="119" height="20" font="4"><b>Results:</b> 145 vs. 217 </text>
<text top="439" left="629" width="144" height="20" font="1">deaths [11.0 %], RR: 0.66 </text>
<text top="458" left="629" width="113" height="20" font="1">(95% CI: 0.53–0.81; </text>
<text top="478" left="629" width="148" height="20" font="1">p=0.00009) or adjusted for </text>
<text top="498" left="629" width="92" height="20" font="1">interim analyses </text>
<text top="518" left="629" width="58" height="20" font="1">p=0.0062. </text>
<text top="351" left="791" width="7" height="18" font="1">•</text>
<text top="350" left="798" width="255" height="20" font="1"> Fewer sudden deaths in the metoprolol group </text>
<text top="367" left="791" width="63" height="20" font="1">(p=0.0002) </text>
<text top="386" left="791" width="7" height="18" font="1">•</text>
<text top="386" left="798" width="281" height="20" font="1"> Lesser deaths from HF<i>r</i>EF in the metoprolol group </text>
<text top="403" left="791" width="56" height="20" font="1">(p=0.002) </text>
<text top="422" left="791" width="7" height="18" font="1">•</text>
<text top="421" left="798" width="289" height="20" font="1"> Metoprolol improved survival and was well tolerated </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">104 </text>
<text top="107" left="98" width="92" height="20" font="1">Packer M, et al., </text>
<text top="124" left="98" width="63" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(140)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11386263?dopt=Citation">11386263</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11386263?dopt=Citation"> </a></text>
<text top="107" left="204" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="124" left="204" width="98" height="20" font="1">survival in severe </text>
<text top="141" left="204" width="120" height="20" font="1">chronic HF pts by the </text>
<text top="159" left="204" width="96" height="20" font="1">use of carvedilol. </text>
<text top="176" left="204" width="3" height="20" font="1"> </text>
<text top="193" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="210" left="204" width="3" height="20" font="1"> </text>
<text top="227" left="204" width="86" height="20" font="4"><b>Size:</b> 2,289 pts </text>
<text top="107" left="339" width="126" height="20" font="4"><b>Inclusion criteria:</b> HF </text>
<text top="124" left="339" width="45" height="20" font="1">pts with </text>
<text top="141" left="339" width="125" height="20" font="1">dyspnea/exertion for 2 </text>
<text top="159" left="339" width="107" height="20" font="1">mo at least and left </text>
<text top="176" left="339" width="94" height="20" font="1">EF&lt;25% despite </text>
<text top="193" left="339" width="104" height="20" font="1">treatment clinically </text>
<text top="210" left="339" width="124" height="20" font="1">euvolemic; allowed on </text>
<text top="228" left="339" width="95" height="20" font="1">digitalis, nitrates, </text>
<text top="245" left="339" width="70" height="20" font="1">hydralazine, </text>
<text top="262" left="339" width="101" height="20" font="1">spironolactone, or </text>
<text top="279" left="339" width="72" height="20" font="1">amiodarone. </text>
<text top="296" left="339" width="132" height="20" font="1">Hospitalized pts with no </text>
<text top="314" left="339" width="75" height="20" font="1">acute illness. </text>
<text top="331" left="339" width="3" height="20" font="1"> </text>
<text top="348" left="339" width="130" height="20" font="4"><b>Exclusion criteria:</b> HF </text>
<text top="365" left="339" width="137" height="20" font="1">due to uncorrected prim. </text>
<text top="382" left="339" width="106" height="20" font="1">valvular disease or </text>
<text top="400" left="339" width="57" height="20" font="1">reversible </text>
<text top="417" left="339" width="133" height="20" font="1">cardiomyopathy cardiac </text>
<text top="434" left="339" width="135" height="20" font="1">transplant pts., coronary </text>
<text top="451" left="339" width="135" height="20" font="1">revasc. &lt;2 mo, acute MI </text>
<text top="469" left="339" width="115" height="20" font="1">or stroke, ventricular </text>
<text top="486" left="339" width="120" height="20" font="1">tachycardia, on alpha </text>
<text top="503" left="339" width="118" height="20" font="1">blocker or CCB or on </text>
<text top="520" left="339" width="136" height="20" font="1">antiarrythmics class I &lt;4 </text>
<text top="537" left="339" width="120" height="20" font="1">wk, SBP &lt;85 mm Hg, </text>
<text top="555" left="339" width="123" height="20" font="1">serum Cr &gt;2.8 mg/dL, </text>
<text top="572" left="339" width="126" height="20" font="1">change in body weight </text>
<text top="589" left="339" width="82" height="20" font="1">&gt;1.5 kg during </text>
<text top="606" left="339" width="60" height="20" font="1">screening. </text>
<text top="107" left="489" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="124" left="489" width="100" height="20" font="1">Carvedilol (1,156) </text>
<text top="141" left="489" width="3" height="20" font="1"> </text>
<text top="159" left="489" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="176" left="489" width="42" height="20" font="1">(1,133) </text>
<text top="108" left="629" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="125" left="629" width="136" height="20" font="1">● Death from any cause </text>
<text top="143" left="629" width="132" height="20" font="1">130 vs. 190 deaths RR: </text>
<text top="160" left="629" width="141" height="20" font="1">35%; 95% CI: 19%–48%; </text>
<text top="177" left="629" width="65" height="20" font="1">p=0.00013  </text>
<text top="194" left="629" width="108" height="20" font="1">● Combined risk of </text>
<text top="212" left="629" width="148" height="20" font="1">death/hospitalization (24% </text>
<text top="229" left="629" width="147" height="20" font="1">lower risk in the carvedilol; </text>
<text top="246" left="629" width="114" height="20" font="1">(95% CI: 13%–33%; </text>
<text top="263" left="629" width="48" height="20" font="1">p&lt;0.001 </text>
<text top="280" left="629" width="3" height="20" font="1"> </text>
<text top="298" left="629" width="140" height="20" font="4"><b>Safety endpoint:</b> Lesser </text>
<text top="315" left="629" width="123" height="20" font="1">pts in carvedilol group </text>
<text top="332" left="629" width="111" height="20" font="1">required permanent </text>
<text top="349" left="629" width="149" height="20" font="1">discontinuation because of </text>
<text top="366" left="629" width="119" height="20" font="1">adverse events or for </text>
<text top="384" left="629" width="140" height="20" font="1">reasons other than death </text>
<text top="401" left="629" width="49" height="20" font="1">(p=0.02) </text>
<text top="109" left="791" width="7" height="18" font="1">•</text>
<text top="108" left="798" width="285" height="20" font="1"> Study stopped early (1.3-y follow-up) due to benefit </text>
<text top="125" left="791" width="62" height="20" font="1">on survival </text>
<text top="144" left="791" width="7" height="18" font="1">•</text>
<text top="144" left="798" width="210" height="20" font="1"> Long-term treatment is very valuable. </text>
<text top="163" left="791" width="7" height="18" font="1">•</text>
<text top="162" left="798" width="276" height="20" font="1"> Not all the pts with severe HF were allowed in the </text>
<text top="179" left="791" width="33" height="20" font="1">study </text>
<text top="624" left="98" width="81" height="20" font="4"><b>CAPRICORN  </b></text>
<text top="641" left="98" width="75" height="20" font="1">Dargie HJ, et </text>
<text top="659" left="98" width="83" height="20" font="1">al., 2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(141)</a> </text>
<text top="676" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11356434?dopt=Citation">11356434</a></text>
<text top="676" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11356434?dopt=Citation"><b> </b></a></text>
<text top="624" left="204" width="111" height="20" font="4"><b>Aim: </b>To investigate </text>
<text top="641" left="204" width="85" height="20" font="1">outcomes after </text>
<text top="659" left="204" width="113" height="20" font="1">carvedilol after MI in </text>
<text top="676" left="204" width="63" height="20" font="1">pts with LV </text>
<text top="693" left="204" width="69" height="20" font="1">dysfunction. </text>
<text top="710" left="204" width="3" height="20" font="1"> </text>
<text top="727" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="745" left="204" width="3" height="20" font="1"> </text>
<text top="762" left="204" width="86" height="20" font="4"><b>Size: </b>1,959 pts </text>
<text top="624" left="339" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="641" left="339" width="131" height="20" font="1">≥18 y, MI within 3–21 d </text>
<text top="659" left="339" width="118" height="20" font="1">of entry, LVEF≤40%, </text>
<text top="676" left="339" width="130" height="20" font="1">concurrent ACEI stable </text>
<text top="693" left="339" width="122" height="20" font="1">dose for at least 24 h, </text>
<text top="710" left="339" width="105" height="20" font="1">HF pts treated and </text>
<text top="727" left="339" width="114" height="20" font="1">controlled with ACEI </text>
<text top="745" left="339" width="114" height="20" font="1">and diuretics but not </text>
<text top="762" left="339" width="57" height="20" font="1">inotropes. </text>
<text top="779" left="339" width="3" height="20" font="4"><b> </b></text>
<text top="624" left="489" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="641" left="489" width="90" height="20" font="1">Carvedilol (975) </text>
<text top="659" left="489" width="3" height="20" font="4"><b> </b></text>
<text top="676" left="489" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="693" left="489" width="32" height="20" font="1">(984) </text>
<text top="625" left="629" width="130" height="20" font="4"><b>1</b>°<b> endpoint: </b>All-cause </text>
<text top="643" left="629" width="110" height="20" font="1">mortality or hospital </text>
<text top="660" left="629" width="141" height="20" font="1">admissions for CV issues </text>
<text top="677" left="629" width="3" height="20" font="1"> </text>
<text top="694" left="629" width="131" height="20" font="4"><b>Results: </b>12% vs. 15%; </text>
<text top="711" left="629" width="134" height="20" font="1">RR: 23%; 95% CI: 0.60–</text>
<text top="729" left="629" width="72" height="20" font="1">0.98; p=0.03 </text>
<text top="746" left="629" width="126" height="20" font="1">No difference between </text>
<text top="763" left="629" width="128" height="20" font="1">groups for death or CV </text>
<text top="780" left="629" width="111" height="20" font="1">hospital admissions </text>
<text top="626" left="791" width="7" height="18" font="1">•</text>
<text top="625" left="798" width="278" height="20" font="1"> CV mortality, nonfatal MI reduced in the carvedilol </text>
<text top="643" left="791" width="35" height="20" font="1">group<b> </b></text>
<text top="662" left="791" width="7" height="18" font="1">•</text>
<text top="661" left="798" width="283" height="20" font="1"> No difference between groups SCD and admission </text>
<text top="678" left="791" width="61" height="20" font="1">due to HF<b>  </b></text>
</page>
<page number="105" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">105 </text>
<text top="107" left="339" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="124" left="339" width="95" height="20" font="1">SBP&lt;90 mm Hg, </text>
<text top="141" left="339" width="102" height="20" font="1">uncontrolled HTN, </text>
<text top="159" left="339" width="110" height="20" font="1">bradycardia, insulin-</text>
<text top="176" left="339" width="134" height="20" font="1">dependent DM, BBs not </text>
<text top="193" left="339" width="130" height="20" font="1">for HF, Beta-2 agonists </text>
<text top="210" left="339" width="70" height="20" font="1">and steroids<b> </b></text>
<text top="228" left="98" width="94" height="20" font="4"><b>MERIT-HF HTN</b>  </text>
<text top="245" left="98" width="85" height="20" font="1">Herlitz J, et al., </text>
<text top="263" left="98" width="63" height="20" font="1">2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(142)</a> </text>
<text top="280" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11862577?dopt=Citation">11862577</a></text>
<text top="280" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11862577?dopt=Citation"><b> </b></a></text>
<text top="228" left="204" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="245" left="204" width="100" height="20" font="1">metoprolol CR/XL </text>
<text top="263" left="204" width="120" height="20" font="1">influence on mortality </text>
<text top="280" left="204" width="111" height="20" font="1">and hospitalizations </text>
<text top="297" left="204" width="109" height="20" font="1">in HF and HTN pts. </text>
<text top="314" left="204" width="7" height="20" font="1">  </text>
<text top="332" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="349" left="204" width="3" height="20" font="1"> </text>
<text top="366" left="204" width="86" height="20" font="4"><b>Size: </b>1,747 pts </text>
<text top="228" left="339" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="245" left="339" width="131" height="20" font="1">Same as above MERIT-</text>
<text top="263" left="339" width="120" height="20" font="1">HF, 1999 study (HTN </text>
<text top="280" left="339" width="62" height="20" font="1">subgroup)  </text>
<text top="297" left="339" width="3" height="20" font="1"> </text>
<text top="314" left="339" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="332" left="339" width="131" height="20" font="1">Same as above MERIT-</text>
<text top="349" left="339" width="20" height="20" font="1">HF </text>
<text top="228" left="489" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="245" left="489" width="100" height="20" font="1">Metoprolol CR/XL </text>
<text top="263" left="489" width="32" height="20" font="1">(871) </text>
<text top="280" left="489" width="3" height="20" font="4"><b> </b></text>
<text top="297" left="489" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="314" left="489" width="32" height="20" font="1">(876) </text>
<text top="229" left="629" width="107" height="20" font="4"><b>1</b>°<b> endpoint: </b>Total </text>
<text top="247" left="629" width="50" height="20" font="1">mortality </text>
<text top="264" left="629" width="3" height="20" font="1"> </text>
<text top="281" left="629" width="135" height="20" font="4"><b>Results: </b>RR: 0.61; 95% </text>
<text top="298" left="629" width="135" height="20" font="1">Cl: 0.44–0.84; p=0.0022 </text>
<text top="230" left="791" width="7" height="18" font="1">•</text>
<text top="229" left="798" width="284" height="20" font="1"> Total mortality reduction was driven by reduction in </text>
<text top="247" left="791" width="215" height="20" font="1">the SCD and death from worsening HF<b> </b></text>
<text top="266" left="791" width="7" height="18" font="1">•</text>
<text top="265" left="798" width="269" height="20" font="1"> 12.5% pts had earlier discontinuation due to any </text>
<text top="282" left="791" width="263" height="20" font="1">cause. Lesser no. of pts in the metoprolol group </text>
<text top="300" left="791" width="229" height="20" font="1">(n=21) discontinued due to worsening HF </text>
<text top="317" left="791" width="292" height="20" font="1">The mean reduction in BP (adjusted) was 1.7 mm Hg </text>
<text top="334" left="791" width="271" height="20" font="1">in the metoprolol group vs. 4.8 mm Hg in placebo </text>
<text top="351" left="791" width="98" height="20" font="1">group (p=0.0001)<b> </b></text>
<text top="384" left="98" width="51" height="20" font="4"><b>CIBIS-II</b>  </text>
<text top="401" left="98" width="66" height="20" font="1">1999 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(143)</a>  </text>
<text top="418" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10023943?dopt=Citation">10023943</a></text>
<text top="418" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10023943?dopt=Citation"><b> </b></a></text>
<text top="384" left="204" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="401" left="204" width="115" height="20" font="1">efficacy of bisoprolol </text>
<text top="418" left="204" width="113" height="20" font="1">in reducing mortality </text>
<text top="436" left="204" width="79" height="20" font="1">in chronic HF. </text>
<text top="453" left="204" width="3" height="20" font="1"> </text>
<text top="470" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="487" left="204" width="3" height="20" font="1"> </text>
<text top="504" left="204" width="86" height="20" font="4"><b>Size: </b>2,647 pts<b> </b></text>
<text top="384" left="339" width="127" height="20" font="4"><b>Inclusion criteria: </b>18–</text>
<text top="401" left="339" width="100" height="20" font="1">80 y, LVEF≤35%, </text>
<text top="418" left="339" width="116" height="20" font="1">dyspnea, orthopnea, </text>
<text top="436" left="339" width="127" height="20" font="1">fatigue, NYHA class III-</text>
<text top="453" left="339" width="15" height="20" font="1">IV </text>
<text top="470" left="339" width="3" height="20" font="1"> </text>
<text top="487" left="339" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="504" left="339" width="125" height="20" font="1">Uncontrolled HTN, MI, </text>
<text top="522" left="339" width="58" height="20" font="1">UA &lt;3 mo </text>
<text top="539" left="339" width="99" height="20" font="1">revascularization. </text>
<text top="556" left="339" width="90" height="20" font="1">treatment, heart </text>
<text top="573" left="339" width="130" height="20" font="1">transplant, AV block &lt;1 </text>
<text top="591" left="339" width="128" height="20" font="1">degree, SBP &lt;100 mm </text>
<text top="608" left="339" width="94" height="20" font="1">Hg, renal failure, </text>
<text top="625" left="339" width="120" height="20" font="1">reversible obstructive </text>
<text top="642" left="339" width="73" height="20" font="1">lung disease </text>
<text top="384" left="489" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="401" left="489" width="100" height="20" font="1">Bisoprolol (1,327) </text>
<text top="418" left="489" width="3" height="20" font="4"><b> </b></text>
<text top="436" left="489" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="453" left="489" width="42" height="20" font="1">(1,320) </text>
<text top="385" left="629" width="130" height="20" font="4"><b>1</b>°<b> endpoint: </b>All-cause </text>
<text top="402" left="629" width="50" height="20" font="1">mortality </text>
<text top="420" left="629" width="3" height="20" font="1"> </text>
<text top="437" left="629" width="148" height="20" font="4"><b>Results: </b>11.8% vs. 17.3% </text>
<text top="454" left="629" width="131" height="20" font="1">deaths with a RR: 0.66; </text>
<text top="471" left="629" width="109" height="20" font="1">95% CI: 0.54–0.81; </text>
<text top="488" left="629" width="55" height="20" font="1">p&lt;0.0001 </text>
<text top="386" left="791" width="7" height="18" font="1">•</text>
<text top="385" left="798" width="210" height="20" font="1"> The trial stopped early due to benefit.<b> </b></text>
<text top="402" left="791" width="256" height="20" font="1">Bisoprolol group had significantly fewer SCDs.<b> </b></text>
<text top="421" left="791" width="7" height="18" font="1">•</text>
<text top="421" left="798" width="278" height="20" font="1"> Mean age was 61 y so more data on elderly pts is </text>
<text top="438" left="791" width="44" height="20" font="1">needed </text>
<text top="660" left="98" width="80" height="20" font="1">Elkayam U, et </text>
<text top="677" left="98" width="83" height="20" font="1">al., 1990 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(144)</a> </text>
<text top="694" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2242521?dopt=Citation">2242521</a></text>
<text top="694" left="145" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2242521?dopt=Citation"><b> </b></a></text>
<text top="660" left="204" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="677" left="204" width="115" height="20" font="1">comparative efficacy </text>
<text top="694" left="204" width="74" height="20" font="1">and safety of </text>
<text top="712" left="204" width="113" height="20" font="1">nifedipine and ISDN </text>
<text top="729" left="204" width="78" height="20" font="1">alone and the </text>
<text top="746" left="204" width="87" height="20" font="1">combination for </text>
<text top="763" left="204" width="105" height="20" font="1">treating for chronic </text>
<text top="781" left="204" width="32" height="20" font="1">CHF. </text>
<text top="660" left="339" width="127" height="20" font="4"><b>Inclusion criteria: </b>18–</text>
<text top="677" left="339" width="107" height="20" font="1">75 y HF pts, NYHA </text>
<text top="694" left="339" width="83" height="20" font="1">class II and III, </text>
<text top="712" left="339" width="118" height="20" font="1">LVEF&lt;40%, clinically </text>
<text top="729" left="339" width="113" height="20" font="1">stable, maintenance </text>
<text top="746" left="339" width="114" height="20" font="1">dose of Digitalis and </text>
<text top="763" left="339" width="56" height="20" font="1">diuretics.  </text>
<text top="781" left="339" width="3" height="20" font="1"> </text>
<text top="660" left="489" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="677" left="489" width="120" height="20" font="1">Nifedipine (21), ISDN </text>
<text top="694" left="489" width="123" height="20" font="1">(20), Nifedipine+ISDN </text>
<text top="712" left="489" width="25" height="20" font="1">(23) </text>
<text top="729" left="489" width="3" height="20" font="4"><b> </b></text>
<text top="746" left="489" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="660" left="629" width="141" height="20" font="4"><b>Endpoints and Results: </b></text>
<text top="677" left="629" width="107" height="20" font="1">HF-worsening: 9 in </text>
<text top="694" left="629" width="135" height="20" font="1">Nifedipine group vs. 3 in </text>
<text top="712" left="629" width="145" height="20" font="1">ISDN group (p&lt;0.09); and </text>
<text top="729" left="629" width="120" height="20" font="1">21 in nifedipine-ISDN </text>
<text top="746" left="629" width="106" height="20" font="1">group (p&lt;0.001 vs. </text>
<text top="763" left="629" width="134" height="20" font="1">nifedipine, p&lt;0.0001 vs. </text>
<text top="781" left="629" width="37" height="20" font="1">ISDN) </text>
<text top="662" left="791" width="7" height="18" font="1">•</text>
<text top="661" left="798" width="280" height="20" font="1"> In clinical deterioration nifedipine pts (8) vs. rest of </text>
<text top="678" left="791" width="200" height="20" font="1">the pts (No difference in LVEF or VO</text>
<text top="680" left="991" width="7" height="13" font="6">2 </text>
<text top="678" left="998" width="31" height="20" font="1">max<b>) </b></text>
<text top="697" left="791" width="7" height="18" font="1">•</text>
<text top="697" left="798" width="287" height="20" font="1"> Although all the 3 drug regimens improved exercise </text>
<text top="714" left="791" width="294" height="20" font="1">capacity, nifedipine treatment alone or in combination </text>
<text top="731" left="791" width="298" height="20" font="1">resulted in clinical deterioration and worsening of CHF<b> </b></text>
</page>
<page number="106" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">106 </text>
<text top="107" left="204" width="3" height="20" font="1"> </text>
<text top="124" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="141" left="204" width="92" height="20" font="1">with a crossover </text>
<text top="159" left="204" width="40" height="20" font="1">design<b> </b></text>
<text top="176" left="204" width="3" height="20" font="1"> </text>
<text top="193" left="204" width="69" height="20" font="4"><b>Size: </b>28 pts<b> </b></text>
<text top="107" left="339" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="124" left="339" width="113" height="20" font="1">Pregnancy, nursing, </text>
<text top="141" left="339" width="108" height="20" font="1">history of MI &lt;1 mo </text>
<text top="159" left="339" width="118" height="20" font="1">before entry, valvular </text>
<text top="176" left="339" width="94" height="20" font="1">disease, Angina, </text>
<text top="193" left="339" width="122" height="20" font="1">significant pulmonary, </text>
<text top="210" left="339" width="101" height="20" font="1">hepatic, renal and </text>
<text top="228" left="339" width="119" height="20" font="1">hematologic disease, </text>
<text top="245" left="339" width="119" height="20" font="1">unable to walk on the </text>
<text top="262" left="339" width="53" height="20" font="1">treadmill, </text>
<text top="279" left="339" width="90" height="20" font="1">noncompliance  </text>
<text top="107" left="629" width="3" height="20" font="1"> </text>
<text top="124" left="629" width="126" height="20" font="4"><b>Clinical deterioration </b></text>
<text top="141" left="629" width="98" height="20" font="4"><b>discontinuation</b>: </text>
<text top="159" left="629" width="138" height="20" font="1">Nifedipine 29% vs. ISDN </text>
<text top="176" left="629" width="106" height="20" font="1">group 5% (p&lt;0.05) </text>
<text top="193" left="629" width="3" height="20" font="1"> </text>
<text top="210" left="629" width="139" height="20" font="4"><b>DBP</b>: Nifedipine alone or </text>
<text top="227" left="629" width="128" height="20" font="1">combination with ISDN </text>
<text top="245" left="629" width="107" height="20" font="1">(reduction, p&lt;0.05) </text>
<text top="297" left="98" width="88" height="20" font="1">The Multicenter </text>
<text top="314" left="98" width="57" height="20" font="1">Dilitiazem </text>
<text top="332" left="98" width="78" height="20" font="1">Postinfarction </text>
<text top="349" left="98" width="56" height="20" font="1">Research </text>
<text top="366" left="98" width="41" height="20" font="1">Group  </text>
<text top="383" left="98" width="63" height="20" font="1">1988 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(145)</a> </text>
<text top="400" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2899840?dopt=Citation">2899840</a></text>
<text top="400" left="145" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2899840?dopt=Citation"><b> </b></a></text>
<text top="297" left="204" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="314" left="204" width="105" height="20" font="1">dilitiazem effect on </text>
<text top="332" left="204" width="106" height="20" font="1">recurrent infarction </text>
<text top="349" left="204" width="120" height="20" font="1">and death after acute </text>
<text top="366" left="204" width="17" height="20" font="1">MI </text>
<text top="383" left="204" width="3" height="20" font="1"> </text>
<text top="400" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="418" left="204" width="3" height="20" font="1"> </text>
<text top="435" left="204" width="86" height="20" font="4"><b>Size: </b>2,466 pts </text>
<text top="297" left="339" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="314" left="339" width="111" height="20" font="1">25–75 y admitted to </text>
<text top="332" left="339" width="122" height="20" font="1">CCU, MI with enzyme </text>
<text top="349" left="339" width="74" height="20" font="1">confirmation. </text>
<text top="366" left="339" width="3" height="20" font="1"> </text>
<text top="383" left="339" width="114" height="20" font="4"><b>Exclusion criteria:  </b></text>
<text top="402" left="339" width="7" height="18" font="1">•</text>
<text top="402" left="346" width="115" height="20" font="1"> Cardiogenic shock,  </text>
<text top="421" left="339" width="7" height="18" font="1">•</text>
<text top="420" left="346" width="78" height="20" font="1"> Symptomatic </text>
<text top="437" left="339" width="77" height="20" font="1">hypotension,  </text>
<text top="456" left="339" width="7" height="18" font="1">•</text>
<text top="456" left="346" width="103" height="20" font="1"> PH with right HF,  </text>
<text top="475" left="339" width="7" height="18" font="1">•</text>
<text top="474" left="346" width="122" height="20" font="1"> 2nd/3rd degree heart </text>
<text top="491" left="339" width="39" height="20" font="1">block,  </text>
<text top="510" left="339" width="7" height="18" font="1">•</text>
<text top="510" left="346" width="83" height="20" font="1"> HR &lt;50 bpm,  </text>
<text top="529" left="339" width="7" height="18" font="1">•</text>
<text top="528" left="346" width="96" height="20" font="1"> Contraceptives,  </text>
<text top="547" left="339" width="7" height="18" font="1">•</text>
<text top="546" left="346" width="103" height="20" font="1"> WPW syndrome,  </text>
<text top="565" left="339" width="7" height="18" font="1">•</text>
<text top="565" left="346" width="46" height="20" font="1"> CCBs,  </text>
<text top="584" left="339" width="7" height="18" font="1">•</text>
<text top="583" left="346" width="121" height="20" font="1"> Severe comorbidities </text>
<text top="600" left="339" width="18" height="20" font="1">or  </text>
<text top="619" left="339" width="7" height="18" font="1">•</text>
<text top="619" left="346" width="94" height="20" font="1"> Cardiac surgery </text>
<text top="297" left="489" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="314" left="489" width="101" height="20" font="1">Dilitiazem 240 mg </text>
<text top="332" left="489" width="42" height="20" font="1">(1,234) </text>
<text top="349" left="489" width="3" height="20" font="4"><b> </b></text>
<text top="366" left="489" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="383" left="489" width="42" height="20" font="1">(1,232) </text>
<text top="298" left="629" width="104" height="20" font="4"><b>1</b>°<b> endpoints and </b></text>
<text top="316" left="629" width="51" height="20" font="4"><b>results:  </b></text>
<text top="335" left="629" width="7" height="18" font="1">•</text>
<text top="334" left="636" width="136" height="20" font="1"> Total mortality: identical </text>
<text top="351" left="629" width="81" height="20" font="1">in both groups </text>
<text top="370" left="629" width="7" height="18" font="1">•</text>
<text top="370" left="636" width="107" height="20" font="1"> Cardiac death and </text>
<text top="387" left="629" width="142" height="20" font="1">nonfatal MI: 11% fewer in </text>
<text top="404" left="629" width="132" height="20" font="1">dilitiazem but difference </text>
<text top="421" left="629" width="46" height="20" font="1">was NS </text>
<text top="299" left="791" width="7" height="18" font="1">•</text>
<text top="298" left="798" width="284" height="20" font="1"> No combined benefit from dilitiazem on mortality or </text>
<text top="316" left="791" width="83" height="20" font="1">cardiac events </text>
<text top="636" left="98" width="42" height="20" font="4"><b>MDPIT </b></text>
<text top="654" left="98" width="93" height="20" font="1">Goldstein RE, et </text>
<text top="671" left="98" width="83" height="20" font="1">al., 1991 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(146)</a> </text>
<text top="688" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1984898?dopt=Citation">1984898</a></text>
<text top="688" left="145" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1984898?dopt=Citation"><b> </b></a></text>
<text top="636" left="204" width="116" height="20" font="4"><b>Aim: </b>To determine if </text>
<text top="654" left="204" width="111" height="20" font="1">dilitiazem increases </text>
<text top="671" left="204" width="98" height="20" font="1">late onset CHF in </text>
<text top="688" left="204" width="120" height="20" font="1">post-MI pts with early </text>
<text top="705" left="204" width="78" height="20" font="1">decline in EF. </text>
<text top="723" left="204" width="7" height="20" font="1">  </text>
<text top="740" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="757" left="204" width="3" height="20" font="1"> </text>
<text top="774" left="204" width="86" height="20" font="4"><b>Size: </b>2,466 pts </text>
<text top="636" left="339" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="654" left="339" width="89" height="20" font="1">Same as above </text>
<text top="671" left="339" width="3" height="20" font="1"> </text>
<text top="688" left="339" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="705" left="339" width="89" height="20" font="1">Same as above </text>
<text top="636" left="489" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="654" left="489" width="101" height="20" font="1">Dilitiazem 240 mg </text>
<text top="671" left="489" width="42" height="20" font="1">(1,234) </text>
<text top="688" left="489" width="3" height="20" font="4"><b> </b></text>
<text top="705" left="489" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="723" left="489" width="42" height="20" font="1">(1,232) </text>
<text top="638" left="629" width="145" height="20" font="4"><b>1</b>°<b> endpoint and results: </b></text>
<text top="655" left="629" width="89" height="20" font="1">Same as above </text>
<text top="672" left="629" width="3" height="20" font="1"> </text>
<text top="689" left="629" width="117" height="20" font="4"><b>Follow-up Results:  </b></text>
<text top="706" left="629" width="142" height="20" font="1">Pts with BL EF&lt;0.40, late </text>
<text top="724" left="629" width="126" height="20" font="1">CHF in Dilitizam group </text>
<text top="741" left="629" width="139" height="20" font="1">(21%) vs. Placebo (12%) </text>
<text top="758" left="629" width="62" height="20" font="1">[p=0.004].  </text>
<text top="638" left="791" width="7" height="18" font="1">•</text>
<text top="638" left="798" width="290" height="20" font="1"> Life table analysis confirmed increased frequency of </text>
<text top="655" left="791" width="239" height="20" font="1">late CHF in pts taking dilitiazem (p=0.0017)<b> </b></text>
<text top="674" left="791" width="7" height="18" font="1">•</text>
<text top="673" left="798" width="280" height="20" font="1"> Dilitiazem related CHF exclusively associated with </text>
<text top="690" left="791" width="179" height="20" font="1">systolic LVD with or without BBs </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">107 </text>
<text top="107" left="98" width="81" height="20" font="1">Freemantle N, </text>
<text top="124" left="98" width="64" height="20" font="1">et al., 1999 </text>
<text top="141" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(147)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10381708?dopt=Citation">10381708</a></text>
<text top="159" left="152" width="7" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10381708?dopt=Citation"><b>  </b></a></text>
<text top="107" left="204" width="98" height="20" font="4"><b>Aim: </b>To evaluate </text>
<text top="124" left="204" width="119" height="20" font="1">BBs effectiveness for </text>
<text top="141" left="204" width="115" height="20" font="1">short-term treatment </text>
<text top="160" left="204" width="96" height="20" font="1">and long-term 2° </text>
<text top="177" left="204" width="107" height="20" font="1">prevention in acute </text>
<text top="194" left="204" width="21" height="20" font="1">MI. </text>
<text top="211" left="204" width="3" height="20" font="1"> </text>
<text top="229" left="204" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="246" left="204" width="96" height="20" font="1">analysis of RCTs </text>
<text top="263" left="204" width="3" height="20" font="1"> </text>
<text top="280" left="204" width="114" height="20" font="4"><b>Size: </b>54,234 pts (82 </text>
<text top="298" left="204" width="39" height="20" font="1">RCTs) </text>
<text top="107" left="339" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="124" left="339" width="115" height="20" font="1">RCTs with treatment </text>
<text top="141" left="339" width="116" height="20" font="1">lasting &gt;1 d and with </text>
<text top="159" left="339" width="116" height="20" font="1">follow-ups on clinical </text>
<text top="176" left="339" width="133" height="20" font="1">effectiveness in pts with </text>
<text top="193" left="339" width="17" height="20" font="1">MI </text>
<text top="210" left="339" width="3" height="20" font="1"> </text>
<text top="227" left="339" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="245" left="339" width="98" height="20" font="1">Cross-over RCTs </text>
<text top="107" left="489" width="104" height="20" font="4"><b>Intervention: </b>BBs </text>
<text top="124" left="489" width="111" height="20" font="1">(mostly propranolol, </text>
<text top="141" left="489" width="107" height="20" font="1">timolol, metoprolol) </text>
<text top="159" left="489" width="3" height="20" font="4"><b> </b></text>
<text top="176" left="489" width="126" height="20" font="4"><b>Comparator: </b>Controls </text>
<text top="193" left="489" width="82" height="20" font="1">(placebo/other </text>
<text top="210" left="489" width="59" height="20" font="1">treatment) </text>
<text top="108" left="629" width="130" height="20" font="4"><b>1</b>°<b> endpoint: </b>All-cause </text>
<text top="125" left="629" width="50" height="20" font="1">mortality </text>
<text top="143" left="629" width="3" height="20" font="1"> </text>
<text top="160" left="629" width="59" height="20" font="4"><b>Results:   </b></text>
<text top="179" left="629" width="7" height="18" font="1">•</text>
<text top="178" left="636" width="113" height="20" font="1"> Long-term trials RR </text>
<text top="195" left="629" width="137" height="20" font="1">reduction: 23% (95% CI: </text>
<text top="213" left="629" width="64" height="20" font="1">15%–31%) </text>
<text top="232" left="629" width="7" height="18" font="1">•</text>
<text top="231" left="636" width="115" height="20" font="1"> Short-term trials RR </text>
<text top="248" left="629" width="133" height="20" font="1">reduction: 4%; 95% CI: -</text>
<text top="265" left="629" width="46" height="20" font="1">8%–5% </text>
<text top="109" left="791" width="7" height="18" font="1">•</text>
<text top="108" left="798" width="284" height="20" font="4"><b> </b>Meta-regression<b> </b>in long-term trials indicated a near </text>
<text top="125" left="791" width="281" height="20" font="1">significant trend for decreased benefit in drugs with </text>
<text top="143" left="791" width="27" height="20" font="1">ISA.<b> </b></text>
<text top="162" left="791" width="7" height="18" font="1">•</text>
<text top="161" left="798" width="273" height="20" font="4"><b> </b>NS in withdrawal between BBs of different cardio </text>
<text top="178" left="791" width="60" height="20" font="1">selectivity.<b> </b></text>
<text top="316" left="98" width="82" height="20" font="1">de Peuter OR, </text>
<text top="333" left="98" width="37" height="20" font="1">et al.,  </text>
<text top="350" left="98" width="63" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(148)</a> </text>
<text top="367" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19841485?dopt=Citation">19841485</a></text>
<text top="367" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19841485?dopt=Citation"> </a></text>
<text top="316" left="204" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="333" left="204" width="105" height="20" font="1">influence of beta-2 </text>
<text top="350" left="204" width="112" height="20" font="1">blockade in addition </text>
<text top="367" left="204" width="105" height="20" font="1">to beta-1 blockade </text>
<text top="384" left="204" width="79" height="20" font="1">for preventing </text>
<text top="402" left="204" width="121" height="20" font="1">vascular events in pts </text>
<text top="419" left="204" width="92" height="20" font="1">with ACS or HF. </text>
<text top="436" left="204" width="3" height="20" font="1"> </text>
<text top="453" left="204" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="470" left="204" width="96" height="20" font="1">analysis of RCTs </text>
<text top="488" left="204" width="3" height="20" font="1"> </text>
<text top="505" left="204" width="114" height="20" font="4"><b>Size:</b> 34,360 pts (33 </text>
<text top="522" left="204" width="39" height="20" font="1">RCTs) </text>
<text top="316" left="339" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="333" left="339" width="108" height="20" font="1">● RCTs comparing </text>
<text top="350" left="339" width="134" height="20" font="1">Beta-1 blockers vs. BBs </text>
<text top="367" left="339" width="92" height="20" font="1">1 + 2 directly (5) </text>
<text top="384" left="339" width="108" height="20" font="1">● RCTs comparing </text>
<text top="402" left="339" width="137" height="20" font="1">Beta-1 blockers vs. Beta </text>
<text top="419" left="339" width="116" height="20" font="1">1 + 2 blockers with a </text>
<text top="436" left="339" width="100" height="20" font="1">control group (28) </text>
<text top="453" left="339" width="3" height="20" font="1"> </text>
<text top="470" left="339" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="488" left="339" width="87" height="20" font="1">Studies not pre-</text>
<text top="505" left="339" width="134" height="20" font="1">specifying total mortality </text>
<text top="522" left="339" width="123" height="20" font="1">and vascular event as </text>
<text top="539" left="339" width="130" height="20" font="1">outcomes &lt;3 mo follow-</text>
<text top="557" left="339" width="127" height="20" font="1">up, duplicate data, sub </text>
<text top="574" left="339" width="46" height="20" font="1">studies. </text>
<text top="316" left="489" width="118" height="20" font="4"><b>Intervention: </b>Beta-1 </text>
<text top="333" left="489" width="49" height="20" font="1">blockers </text>
<text top="350" left="489" width="3" height="20" font="1"> </text>
<text top="367" left="489" width="103" height="20" font="4"><b>Comparator: </b>BBs </text>
<text top="384" left="489" width="106" height="20" font="1">1+2 with or without </text>
<text top="402" left="489" width="75" height="20" font="1">control group </text>
<text top="317" left="629" width="107" height="20" font="4"><b>1</b>°<b> endpoint: </b>Total </text>
<text top="334" left="629" width="146" height="20" font="1">mortality, vascular events. </text>
<text top="351" left="629" width="3" height="20" font="1"> </text>
<text top="368" left="629" width="59" height="20" font="4"><b>Results:  </b> </text>
<text top="386" left="629" width="94" height="20" font="1">ACS Population: </text>
<text top="403" left="629" width="142" height="20" font="1">1 study with different BBs </text>
<text top="420" left="629" width="133" height="20" font="1">underpowered to detect </text>
<text top="437" left="629" width="120" height="20" font="1">difference. Beta-1 vs. </text>
<text top="454" left="629" width="116" height="20" font="1">Placebo NS reduced </text>
<text top="472" left="629" width="113" height="20" font="1">mortality or vascular </text>
<text top="489" left="629" width="40" height="20" font="1">events </text>
<text top="506" left="629" width="3" height="20" font="1"> </text>
<text top="523" left="629" width="83" height="20" font="1">HF population: </text>
<text top="540" left="629" width="128" height="20" font="1">Beta 1 + 2 blockers vs. </text>
<text top="558" left="629" width="149" height="20" font="1">Beta 1 blockers decreased </text>
<text top="575" left="629" width="133" height="20" font="1">mortality RR: 0.86; 95% </text>
<text top="592" left="629" width="77" height="20" font="1">CI: 0.78–0.94 </text>
<text top="609" left="629" width="116" height="20" font="1">Beta 1 and Beta 1+2 </text>
<text top="627" left="629" width="141" height="20" font="1">decreased total mortality. </text>
<text top="644" left="629" width="131" height="20" font="1">Only Beta 1+2 blockers </text>
<text top="661" left="629" width="140" height="20" font="1">reduced vascular events. </text>
<text top="317" left="791" width="7" height="18" font="1">•</text>
<text top="317" left="798" width="255" height="20" font="1"> Supplementary beta 2 blockade may be more </text>
<text top="334" left="791" width="59" height="20" font="1">beneficial. </text>
<text top="353" left="791" width="7" height="18" font="1">•</text>
<text top="352" left="798" width="263" height="20" font="1"> Indirect comparisons and heterogeneity among </text>
<text top="370" left="791" width="42" height="20" font="1">studies </text>
<text top="679" left="98" width="89" height="20" font="1">Leon MB, et al., </text>
<text top="696" left="98" width="63" height="20" font="1">1981 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(149)</a> </text>
<text top="713" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7246435?dopt=Citation">7246435</a></text>
<text top="713" left="145" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7246435?dopt=Citation"><b> </b></a></text>
<text top="679" left="204" width="98" height="20" font="4"><b>Aim: </b>To evaluate </text>
<text top="696" left="204" width="89" height="20" font="1">effectiveness of </text>
<text top="713" left="204" width="119" height="20" font="1">verapamil as a single </text>
<text top="730" left="204" width="71" height="20" font="1">agent and in </text>
<text top="748" left="204" width="95" height="20" font="1">combination with </text>
<text top="765" left="204" width="98" height="20" font="1">propranolol in pts </text>
<text top="782" left="204" width="85" height="20" font="1">with stable AP. </text>
<text top="679" left="339" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="696" left="339" width="115" height="20" font="1">Symptomatic angina </text>
<text top="713" left="339" width="73" height="20" font="1">pectoris pts,  </text>
<text top="730" left="339" width="96" height="20" font="1">1) not sufficiently </text>
<text top="748" left="339" width="124" height="20" font="1">controlled on BBs and </text>
<text top="765" left="339" width="131" height="20" font="1">nitrates and noncardiac </text>
<text top="679" left="489" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="696" left="489" width="70" height="20" font="1">Propranolol, </text>
<text top="713" left="489" width="60" height="20" font="1">verapamil, </text>
<text top="730" left="489" width="86" height="20" font="1">Combination of </text>
<text top="748" left="489" width="89" height="20" font="1">propranolol and </text>
<text top="765" left="489" width="57" height="20" font="1">verapamil </text>
<text top="782" left="489" width="3" height="20" font="4"><b> </b></text>
<text top="679" left="629" width="117" height="20" font="4"><b>Results: </b>Large dose </text>
<text top="696" left="629" width="124" height="20" font="1">verapamil significantly </text>
<text top="713" left="629" width="136" height="20" font="1">lowered BP. Propranolol </text>
<text top="730" left="629" width="137" height="20" font="1">and verapamil combined </text>
<text top="748" left="629" width="118" height="20" font="1">(at best dose) further </text>
<text top="765" left="629" width="124" height="20" font="1">lowered BP, improved </text>
<text top="681" left="791" width="7" height="18" font="1">•</text>
<text top="680" left="798" width="283" height="20" font="1"> HR and pressure-rate product lowered significantly </text>
<text top="697" left="791" width="131" height="20" font="1">on combination therapy<b> </b></text>
<text top="716" left="791" width="7" height="18" font="1">•</text>
<text top="716" left="798" width="269" height="20" font="1"> PR interval increased on combination treatment<b>  </b></text>
<text top="733" left="791" width="289" height="20" font="1">Regarding antianginal properties, verapamil seemed </text>
<text top="750" left="791" width="207" height="20" font="1">to be more effective than propranolol.<b> </b></text>
</page>
<page number="108" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">108 </text>
<text top="107" left="204" width="3" height="20" font="1"> </text>
<text top="124" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="141" left="204" width="95" height="20" font="1">(triple crossover) </text>
<text top="159" left="204" width="3" height="20" font="1"> </text>
<text top="176" left="204" width="69" height="20" font="4"><b>Size: </b>11 pts </text>
<text top="107" left="339" width="133" height="20" font="1">effects from propranolol </text>
<text top="124" left="339" width="109" height="20" font="1">hindering treatment </text>
<text top="141" left="339" width="128" height="20" font="1">2) who could stay 4 wk </text>
<text top="159" left="339" width="59" height="20" font="1">in hospital </text>
<text top="176" left="339" width="3" height="20" font="1"> </text>
<text top="193" left="339" width="137" height="20" font="4"><b>Exclusion criteria: </b>LVD </text>
<text top="210" left="339" width="134" height="20" font="1">with CHF or LVEF&lt;30% </text>
<text top="227" left="339" width="114" height="20" font="1">at rest and &lt;25% for </text>
<text top="245" left="339" width="131" height="20" font="1">exercise, HR&lt;50 b/min, </text>
<text top="262" left="339" width="137" height="20" font="1">≥first degree heart block </text>
<text top="107" left="489" width="285" height="20" font="4"><b>Comparator: </b>Placebo   exercise time by 4.7 ± 0.7 </text>
<text top="124" left="629" width="80" height="20" font="1">min (p&lt;0.001) </text>
<text top="280" left="98" width="89" height="20" font="1">Staessen JA, et </text>
<text top="297" left="98" width="83" height="20" font="1">al., 1997 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(150)</a> </text>
<text top="314" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9297994?dopt=Citation">9297994</a></text>
<text top="314" left="145" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9297994?dopt=Citation"><b> </b></a></text>
<text top="280" left="204" width="116" height="20" font="4"><b>Aim: </b>To determine if </text>
<text top="297" left="204" width="91" height="20" font="1">active treatment </text>
<text top="314" left="204" width="47" height="20" font="1">reduces </text>
<text top="332" left="204" width="106" height="20" font="1">complications from </text>
<text top="349" left="204" width="118" height="20" font="1">isolated systolic HTN </text>
<text top="366" left="204" width="77" height="20" font="1">in the elderly. </text>
<text top="383" left="204" width="3" height="20" font="1"> </text>
<text top="400" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="418" left="204" width="3" height="20" font="1"> </text>
<text top="435" left="204" width="86" height="20" font="4"><b>Size: </b>4,965 pts </text>
<text top="280" left="339" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="297" left="339" width="129" height="20" font="1">≥60 y, sitting SPB 160–</text>
<text top="314" left="339" width="134" height="20" font="1">219 mm Hg, sitting DBP </text>
<text top="332" left="339" width="87" height="20" font="1">95 mm Hg, and </text>
<text top="349" left="339" width="134" height="20" font="1">standing SBP ≥140 mm </text>
<text top="366" left="339" width="22" height="20" font="1">Hg. </text>
<text top="383" left="339" width="3" height="20" font="1"> </text>
<text top="400" left="339" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="418" left="339" width="122" height="20" font="1">Systolic HTN 2nd to a </text>
<text top="435" left="339" width="88" height="20" font="1">disorder, retinal </text>
<text top="452" left="339" width="125" height="20" font="1">hemorrhages/papillede</text>
<text top="469" left="339" width="123" height="20" font="1">ma, CHF, aneurysms, </text>
<text top="487" left="339" width="132" height="20" font="1">serum Cr ≥180 µmol/L, </text>
<text top="504" left="339" width="117" height="20" font="1">history of nosebleed, </text>
<text top="521" left="339" width="88" height="20" font="1">stroke, MI &lt;1 y, </text>
<text top="538" left="339" width="117" height="20" font="1">dementia, substance </text>
<text top="555" left="339" width="81" height="20" font="1">abuse, severe </text>
<text top="573" left="339" width="76" height="20" font="1">comorbidities </text>
<text top="280" left="489" width="115" height="20" font="4"><b>Intervention: </b>Active </text>
<text top="297" left="489" width="98" height="20" font="1">treatment (2,398) </text>
<text top="314" left="489" width="3" height="20" font="4"><b> </b></text>
<text top="332" left="489" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="349" left="489" width="42" height="20" font="1">(2,297) </text>
<text top="281" left="629" width="130" height="20" font="4"><b>1</b>°<b> endpoint: </b>Fatal and </text>
<text top="298" left="629" width="90" height="20" font="1">nonfatal strokes </text>
<text top="316" left="629" width="60" height="20" font="1">combined. </text>
<text top="333" left="629" width="3" height="20" font="1"> </text>
<text top="350" left="629" width="119" height="20" font="4"><b>Results: </b>13.7 vs. 7.9 </text>
<text top="367" left="629" width="124" height="20" font="1">endpoints/ 1,000 pts-y </text>
<text top="384" left="629" width="142" height="20" font="1">(42% reduction; p=0.003) </text>
<text top="282" left="791" width="7" height="18" font="1">•</text>
<text top="281" left="798" width="291" height="20" font="1"> All fatal and nonfatal cardiac endpoints (with sudden </text>
<text top="298" left="791" width="259" height="20" font="1">death) decreased in the active treatment group </text>
<text top="316" left="791" width="49" height="20" font="1">(p=0.03)<b> </b></text>
<text top="335" left="791" width="7" height="18" font="1">•</text>
<text top="334" left="798" width="269" height="20" font="1"> Cardiac mortality was lower in active treatment (-</text>
<text top="351" left="791" width="282" height="20" font="1">27%; p=0.07)<b>. </b>All-cause mortality was not different.<b> </b></text>
<text top="370" left="791" width="7" height="18" font="1">•</text>
<text top="370" left="798" width="184" height="20" font="1"> Nitrendipine used for active arm.<b> </b></text>
<text top="591" left="98" width="93" height="20" font="1">Wright JT, et al., </text>
<text top="608" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(114)</a> </text>
<text top="625" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=Citation">26551272</a></text>
<text top="625" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=Citation"> </a></text>
<text top="591" left="204" width="113" height="20" font="4"><b>Aim: </b>To compare in </text>
<text top="608" left="204" width="97" height="20" font="1">pts with a SBP of </text>
<text top="625" left="204" width="118" height="20" font="1">130–180 mm Hg and </text>
<text top="642" left="204" width="117" height="20" font="1">an increased CV risk </text>
<text top="659" left="204" width="106" height="20" font="1">but without DM the </text>
<text top="677" left="204" width="120" height="20" font="1">effect of a target SBP </text>
<text top="694" left="204" width="117" height="20" font="1">of &lt;140 mm Hg vs. a </text>
<text top="711" left="204" width="108" height="20" font="1">target SBP of &lt;120 </text>
<text top="728" left="204" width="97" height="20" font="1">mm Hg on the 1° </text>
<text top="745" left="204" width="110" height="20" font="1">composite outcome </text>
<text top="763" left="204" width="104" height="20" font="1">of MI, other ACSs, </text>
<text top="591" left="339" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="608" left="339" width="129" height="20" font="1">9,361 pts, mean 67.9 y </text>
<text top="625" left="339" width="119" height="20" font="1">(28.2% ≥75 y; 35.6% </text>
<text top="642" left="339" width="109" height="20" font="1">women; 57.7% non-</text>
<text top="659" left="339" width="124" height="20" font="1">Hispanic white; 31.5% </text>
<text top="677" left="339" width="100" height="20" font="1">African American; </text>
<text top="694" left="339" width="128" height="20" font="1">10.5% Hispanic) with a </text>
<text top="711" left="339" width="136" height="20" font="1">SBP of 130–180 mm Hg </text>
<text top="728" left="339" width="118" height="20" font="1">and an increased CV </text>
<text top="745" left="339" width="111" height="20" font="1">risk but without DM, </text>
<text top="763" left="339" width="94" height="20" font="1">history of stroke, </text>
<text top="780" left="339" width="127" height="20" font="1">symptomatic HF within </text>
<text top="591" left="489" width="112" height="20" font="4"><b>Intervention: </b>4,678 </text>
<text top="608" left="489" width="118" height="20" font="1">pts were randomized </text>
<text top="625" left="489" width="85" height="20" font="1">to intensive BP </text>
<text top="642" left="489" width="59" height="20" font="1">treatment  </text>
<text top="659" left="489" width="3" height="20" font="1"> </text>
<text top="677" left="489" width="111" height="20" font="4"><b>Comparator: </b>4,683 </text>
<text top="694" left="489" width="118" height="20" font="1">pts were randomized </text>
<text top="711" left="489" width="85" height="20" font="1">to standard BP </text>
<text top="728" left="489" width="55" height="20" font="1">treatment </text>
<text top="592" left="629" width="83" height="20" font="4"><b>1</b>°<b> endpoint:   </b></text>
<text top="611" left="629" width="7" height="18" font="1">•</text>
<text top="610" left="636" width="124" height="20" font="1"> At 1 y, the mean SBP </text>
<text top="627" left="629" width="128" height="20" font="1">was 121.4 mm Hg with </text>
<text top="644" left="629" width="146" height="20" font="1">intensive treatment (mean </text>
<text top="662" left="629" width="59" height="20" font="1">number of </text>
<text top="679" left="629" width="127" height="20" font="1">antihypertensive drugs </text>
<text top="696" left="629" width="132" height="20" font="1">was 2.8) and 136.2 mm </text>
<text top="713" left="629" width="96" height="20" font="1">Hg with standard </text>
<text top="730" left="629" width="139" height="20" font="1">treatment (mean number </text>
<text top="748" left="629" width="141" height="20" font="1">of antihypertensive drugs </text>
<text top="765" left="629" width="50" height="20" font="1">was 1.8) </text>
<text top="592" left="791" width="7" height="18" font="1">•</text>
<text top="592" left="798" width="291" height="20" font="1"> At 3.26-y median follow-up, compared with standard </text>
<text top="609" left="791" width="270" height="20" font="1">BP treatment, intensive BP treatment reduced all-</text>
<text top="626" left="791" width="282" height="20" font="1">cause mortality 27% (p=0.003), HF 38% (p=0.002), </text>
<text top="643" left="791" width="278" height="20" font="1">CV mortality 43% (p=0.005), and the 1° composite </text>
<text top="660" left="791" width="184" height="20" font="1">outcome or death 22% (p&lt;0.001) </text>
<text top="679" left="791" width="7" height="18" font="1">•</text>
<text top="679" left="798" width="275" height="20" font="1"> Intensive BP treatment reduced the 1° composite </text>
<text top="696" left="791" width="271" height="20" font="1">endpoint 33% (14% to 49%) in pts aged 75 y and </text>
<text top="713" left="791" width="234" height="20" font="1">older and 20% (0% to 36%) in pts 50–74 y </text>
<text top="732" left="791" width="7" height="18" font="1">•</text>
<text top="732" left="798" width="245" height="20" font="1"> Serious adverse events were similar in both </text>
<text top="749" left="791" width="282" height="20" font="1">treatment groups. However, intensive BP treatment </text>
<text top="766" left="791" width="289" height="20" font="1">caused more hypotension (2.4% vs. 1.4%; p=0.001), </text>
<text top="783" left="791" width="251" height="20" font="1">more syncope (2.3% vs. 1.7%; p=0.05), more </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">109 </text>
<text top="107" left="204" width="98" height="20" font="1">stroke, HF, or CV </text>
<text top="124" left="204" width="34" height="20" font="1">death </text>
<text top="107" left="339" width="134" height="20" font="1">past 6 mo, LVEF &lt;35%, </text>
<text top="124" left="339" width="84" height="20" font="1">and eGFR &lt;20 </text>
<text top="141" left="339" width="92" height="20" font="1">mL/min/1.73 mm</text>
<text top="143" left="430" width="4" height="13" font="6">2</text>
<text top="141" left="435" width="36" height="20" font="1">; CVD </text>
<text top="159" left="339" width="124" height="20" font="1">was present in 20.1%, </text>
<text top="176" left="339" width="117" height="20" font="1">and the Framingham </text>
<text top="193" left="339" width="113" height="20" font="1">10-y CVD risk score </text>
<text top="210" left="339" width="126" height="20" font="1">was ≥15% in 61.3% of </text>
<text top="227" left="339" width="23" height="20" font="1">pts  </text>
<text top="109" left="629" width="7" height="18" font="1">•</text>
<text top="108" left="636" width="135" height="20" font="1"> At 3.26-y median follow-</text>
<text top="125" left="629" width="117" height="20" font="1">up, the 1° composite </text>
<text top="143" left="629" width="124" height="20" font="1">outcome was reduced </text>
<text top="160" left="629" width="101" height="20" font="1">25% (p&lt;0.001) by </text>
<text top="177" left="629" width="127" height="20" font="1">intensive BP treatment </text>
<text top="107" left="791" width="289" height="20" font="1">electrolyte abnormality (3.1% vs. 2.3%; p=0.02), and </text>
<text top="124" left="791" width="288" height="20" font="1">more acute kidney injury or acute renal failure (4.1% </text>
<text top="141" left="791" width="275" height="20" font="1">vs. 2.5%; p&lt;0.001). The incidence of bradycardia, </text>
<text top="159" left="791" width="257" height="20" font="1">injurious falls, and orthostatic hypotension with </text>
<text top="176" left="791" width="255" height="20" font="1">dizziness was similar in both treatment groups </text>
<text top="245" left="98" width="50" height="20" font="1">ALLHAT </text>
<text top="263" left="98" width="75" height="20" font="1">Collaborative </text>
<text top="280" left="98" width="56" height="20" font="1">Research </text>
<text top="297" left="98" width="72" height="20" font="1">Group, 2003 </text>
<text top="314" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12925554">12925554</a></text>
<text top="314" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12925554"> </a></text>
<text top="245" left="204" width="107" height="20" font="4"><b>Aim: </b>In a follow-up </text>
<text top="263" left="204" width="116" height="20" font="1">analysis, to compare </text>
<text top="280" left="204" width="96" height="20" font="1">diuretic vs. alpha-</text>
<text top="297" left="204" width="109" height="20" font="1">blocker as first step </text>
<text top="314" left="204" width="69" height="20" font="1">treatment of </text>
<text top="332" left="204" width="77" height="20" font="1">hypertension.<b> </b></text>
<text top="245" left="339" width="133" height="20" font="4"><b>Inclusion criteria: </b>Men </text>
<text top="263" left="339" width="131" height="20" font="1">and women ≥ 55 y with </text>
<text top="280" left="339" width="126" height="20" font="1">BP ≥140/90 mm Hg or </text>
<text top="297" left="339" width="104" height="20" font="1">on medications for </text>
<text top="314" left="339" width="113" height="20" font="1">hypertension with at </text>
<text top="332" left="339" width="132" height="20" font="1">least one additional risk </text>
<text top="349" left="339" width="135" height="20" font="1">factor for coronary heart </text>
<text top="366" left="339" width="49" height="20" font="1">disease.<b> </b></text>
<text top="245" left="489" width="119" height="20" font="4"><b>Intervention: </b>15,255 </text>
<text top="263" left="489" width="76" height="20" font="1">patients were </text>
<text top="280" left="489" width="81" height="20" font="1">randomized to </text>
<text top="297" left="489" width="104" height="20" font="1">chlorthalidone and </text>
<text top="314" left="489" width="107" height="20" font="1">9,061 to doxazosin </text>
<text top="332" left="489" width="124" height="20" font="1">and followed for 3.2 y.<b> </b></text>
<text top="245" left="629" width="109" height="20" font="4"><b>Primary endpoint:</b> </text>
<text top="263" left="629" width="137" height="20" font="1">Combined fatal coronary </text>
<text top="280" left="629" width="143" height="20" font="1">heart disease or non-fatal </text>
<text top="297" left="629" width="139" height="20" font="1">MI, analyzed by intention </text>
<text top="314" left="629" width="45" height="20" font="1">to treat.<b> </b></text>
<text top="247" left="791" width="7" height="18" font="1">•</text>
<text top="247" left="798" width="247" height="20" font="1"> There was no difference in primary outcome </text>
<text top="264" left="791" width="274" height="20" font="1">between the arms (RR: 1.02; 95% CI: 0.94–1.13). </text>
<text top="283" left="791" width="7" height="18" font="1">•</text>
<text top="282" left="798" width="267" height="20" font="1"> However, the doxazosin arm compared with the </text>
<text top="299" left="791" width="282" height="20" font="1">chlorthalidone arm had a higher risk for stroke (RR: </text>
<text top="317" left="791" width="221" height="20" font="1">1.26; 95% CI: 1.10–1.46) and combined </text>
<text top="334" left="791" width="266" height="20" font="1">cardiovascular disease (RR: 1.20; 95% CI: 1.13–</text>
<text top="351" left="791" width="35" height="20" font="1">1.27). </text>
<text top="370" left="791" width="7" height="18" font="1">•</text>
<text top="370" left="798" width="269" height="20" font="1"> The findings confirmed the superiority of diuretic-</text>
<text top="387" left="791" width="271" height="20" font="1">based over alpha blocker based antihypertensive </text>
<text top="404" left="791" width="295" height="20" font="1">treatment in the prevention of cardiovascular disease. </text>
<text top="422" left="98" width="83" height="20" font="1">Zanchetti A, et </text>
<text top="439" left="98" width="51" height="20" font="1">al., 2006 </text>
<text top="456" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17053536">17053536</a></text>
<text top="456" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17053536"> </a></text>
<text top="422" left="204" width="92" height="20" font="4"><b>Aim: </b>To provide </text>
<text top="439" left="204" width="121" height="20" font="1">additional analyses of </text>
<text top="456" left="204" width="116" height="20" font="1">the primary endpoint </text>
<text top="474" left="204" width="104" height="20" font="1">in the VALUE trial, </text>
<text top="491" left="204" width="105" height="20" font="1">including sex, age, </text>
<text top="508" left="204" width="95" height="20" font="1">race, geographic </text>
<text top="525" left="204" width="90" height="20" font="1">region, smoking </text>
<text top="542" left="204" width="76" height="20" font="1">status, type 2 </text>
<text top="560" left="204" width="80" height="20" font="1">diabetes, total </text>
<text top="577" left="204" width="86" height="20" font="1">cholesterol, left </text>
<text top="594" left="204" width="60" height="20" font="1">ventricular </text>
<text top="611" left="204" width="72" height="20" font="1">hypertrophy, </text>
<text top="628" left="204" width="103" height="20" font="1">proteinuria, serum </text>
<text top="646" left="204" width="113" height="20" font="1">creatinine, history of </text>
<text top="663" left="204" width="83" height="20" font="1">coronary heart </text>
<text top="680" left="204" width="100" height="20" font="1">disease, stroke or </text>
<text top="697" left="204" width="102" height="20" font="1">transient ischemic </text>
<text top="714" left="204" width="113" height="20" font="1">attack and history of </text>
<text top="732" left="204" width="93" height="20" font="1">peripheral artery </text>
<text top="749" left="204" width="49" height="20" font="1">disease.<b> </b></text>
<text top="422" left="339" width="131" height="20" font="4"><b>Inclusion criteria: </b>The </text>
<text top="439" left="339" width="87" height="20" font="1">15,245 patients </text>
<text top="456" left="339" width="126" height="20" font="1">participating in VALUE </text>
<text top="474" left="339" width="96" height="20" font="1">were divided into </text>
<text top="491" left="339" width="131" height="20" font="1">subgroups according to </text>
<text top="508" left="339" width="135" height="20" font="1">baseline characteristics.<b> </b></text>
<text top="422" left="489" width="118" height="20" font="4"><b>Statistical analysis: </b></text>
<text top="439" left="489" width="117" height="20" font="1">Subgroup interaction </text>
<text top="456" left="489" width="82" height="20" font="1">analyses were </text>
<text top="474" left="489" width="122" height="20" font="1">conducted by the Cox </text>
<text top="491" left="489" width="100" height="20" font="1">proportion hazard </text>
<text top="508" left="489" width="108" height="20" font="1">model. Within each </text>
<text top="525" left="489" width="114" height="20" font="1">subgroup, treatment </text>
<text top="542" left="489" width="125" height="20" font="1">effects were assessed </text>
<text top="560" left="489" width="115" height="20" font="1">by hazard ratios and </text>
<text top="577" left="489" width="53" height="20" font="1">95% CIs.<b> </b></text>
<text top="422" left="629" width="3" height="20" font="4"><b> </b></text>
<text top="424" left="791" width="7" height="18" font="1">•</text>
<text top="423" left="798" width="245" height="20" font="1"> For cardiac morbidity and mortality, the only </text>
<text top="440" left="791" width="284" height="20" font="1">significant subgroup by treatment interaction was of </text>
<text top="457" left="791" width="289" height="20" font="1">sex (p=0.016) with HR indicating a relative excess of </text>
<text top="475" left="791" width="272" height="20" font="1">cardiac events in women but not in men, but SBP </text>
<text top="492" left="791" width="269" height="20" font="1">differences in favor of amlodipine were greater in </text>
<text top="509" left="791" width="46" height="20" font="1">women. </text>
<text top="528" left="791" width="7" height="18" font="1">•</text>
<text top="527" left="798" width="268" height="20" font="1"> In the VALUE cohort, in no subgroup of patients </text>
<text top="545" left="791" width="248" height="20" font="1">were there differences in the incidence of the </text>
<text top="562" left="791" width="256" height="20" font="1">composite cardiac endpoint with valsartan and </text>
<text top="579" left="791" width="290" height="20" font="1">amlodipine treatment despite greater BP reduction in </text>
<text top="596" left="791" width="122" height="20" font="1">the amlodipine group. </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">110 </text>
<text top="107" left="98" width="90" height="20" font="1">Leenen FHH, et </text>
<text top="124" left="98" width="54" height="20" font="1">al., 2006  </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16864749">16864749</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16864749"> </a></text>
<text top="107" left="204" width="120" height="20" font="4"><b>Aim: </b>To compare the </text>
<text top="124" left="204" width="98" height="20" font="1">long-term relative </text>
<text top="141" left="204" width="117" height="20" font="1">safety and outcomes </text>
<text top="159" left="204" width="117" height="20" font="1">of ACE inhibitor- and </text>
<text top="176" left="204" width="121" height="20" font="1">CCB-based regimens </text>
<text top="193" left="204" width="117" height="20" font="1">in older hypertensive </text>
<text top="210" left="204" width="74" height="20" font="1">individuals in </text>
<text top="228" left="204" width="53" height="20" font="1">ALLHAT.<b> </b></text>
<text top="107" left="339" width="133" height="20" font="4"><b>Inclusion criteria: </b>men </text>
<text top="124" left="339" width="126" height="20" font="1">and women age ≥55 y </text>
<text top="141" left="339" width="132" height="20" font="1">with untreated (BP 140–</text>
<text top="159" left="339" width="130" height="20" font="1">180/90–110 mm Hg) or </text>
<text top="176" left="339" width="116" height="20" font="1">treated hypertension </text>
<text top="193" left="339" width="123" height="20" font="1">(BP ≤160/100 mm Hg </text>
<text top="210" left="339" width="129" height="20" font="1">on ≤2 antihypertensive </text>
<text top="228" left="339" width="86" height="20" font="1">drugs) with ≥ 1 </text>
<text top="245" left="339" width="130" height="20" font="1">additional risk factor for </text>
<text top="262" left="339" width="132" height="20" font="1">coronary heart disease.<b> </b></text>
<text top="107" left="489" width="126" height="20" font="4"><b>Intervention: </b>Patients </text>
<text top="124" left="489" width="116" height="20" font="1">(were randomized to </text>
<text top="141" left="489" width="120" height="20" font="1">amlodipine (9,048) or </text>
<text top="159" left="489" width="98" height="20" font="1">Lisinopril (9,054).<b> </b></text>
<text top="107" left="629" width="108" height="20" font="4"><b>Primary outcome: </b></text>
<text top="124" left="629" width="137" height="20" font="1">Combined fatal coronary </text>
<text top="141" left="629" width="143" height="20" font="1">heart disease or non-fatal </text>
<text top="159" left="629" width="139" height="20" font="1">MI, analyzed by intention </text>
<text top="176" left="629" width="45" height="20" font="1">to treat. </text>
<text top="193" left="629" width="3" height="20" font="1"> </text>
<text top="210" left="629" width="95" height="20" font="4"><b>Follow-up</b>: 4.9 y<b> </b></text>
<text top="109" left="791" width="7" height="18" font="1">•</text>
<text top="108" left="798" width="287" height="20" font="1"> Risk of coronary heart disease was similar between </text>
<text top="125" left="791" width="139" height="20" font="1">amlodipine and Lisinopril </text>
<text top="144" left="791" width="7" height="18" font="1">•</text>
<text top="144" left="798" width="254" height="20" font="1"> For stroke, combined cardiovascular disease, </text>
<text top="161" left="791" width="284" height="20" font="1">gastrointestinal bleeding and angioedema, risks are </text>
<text top="178" left="791" width="253" height="20" font="1">higher with Lisinopril compared to amlodipine. </text>
<text top="197" left="791" width="7" height="18" font="1">•</text>
<text top="197" left="798" width="273" height="20" font="1"> For heart failure, risks are higher with amlodipine </text>
<text top="214" left="791" width="127" height="20" font="1">compared to Lisinopril. </text>
<text top="280" left="135" width="3" height="20" font="4"><b> </b></text>
<text top="314" left="81" width="530" height="24" font="3"><b>Data Supplement 31. Meta-analyses of ischemic heart disease (Section 9.1) </b></text>
<text top="354" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="371" left="128" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="389" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="354" left="257" width="38" height="20" font="4"><b>Study </b></text>
<text top="371" left="235" width="81" height="20" font="4"><b>Type/Design; </b></text>
<text top="389" left="243" width="66" height="20" font="4"><b>Study Size </b></text>
<text top="354" left="386" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="354" left="570" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="371" left="555" width="209" height="20" font="4"><b>(include P value; OR or RR; and CI) </b></text>
<text top="354" left="874" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="371" left="901" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="407" left="98" width="94" height="20" font="1">Bundy JD, et al., </text>
<text top="424" left="98" width="31" height="20" font="1">2017 </text>
<text top="441" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28564682">28564682</a></text>
<text top="441" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28564682"> </a></text>
<text top="407" left="219" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="424" left="219" width="80" height="20" font="1">Network meta-</text>
<text top="441" left="219" width="51" height="20" font="1">analysis  </text>
<text top="458" left="219" width="3" height="20" font="1"> </text>
<text top="475" left="219" width="79" height="20" font="4"><b>Size</b>: 144,220 </text>
<text top="493" left="219" width="115" height="20" font="1">patients in 42 RCTs. </text>
<text top="407" left="347" width="109" height="20" font="4"><b>Inclusion criteria</b>:  </text>
<text top="426" left="347" width="7" height="18" font="1">•</text>
<text top="425" left="354" width="149" height="20" font="1"> Random allocation into an </text>
<text top="442" left="347" width="159" height="20" font="1">antihypertensive medication, </text>
<text top="459" left="347" width="145" height="20" font="1">control or treatment target </text>
<text top="478" left="347" width="7" height="18" font="1">•</text>
<text top="478" left="354" width="170" height="20" font="1"> Allocation to antihypertensive  </text>
<text top="495" left="347" width="175" height="20" font="1">Antihypertensive treatment was </text>
<text top="512" left="347" width="172" height="20" font="1">independent of other treatment </text>
<text top="529" left="347" width="54" height="20" font="1">regimens </text>
<text top="548" left="347" width="7" height="18" font="1">•</text>
<text top="548" left="354" width="181" height="20" font="1"> ≥100 patients in each treatment </text>
<text top="565" left="347" width="35" height="20" font="1">group </text>
<text top="584" left="347" width="7" height="18" font="1">•</text>
<text top="583" left="354" width="121" height="20" font="1"> Trial duration ≥ 6 mo </text>
<text top="602" left="347" width="7" height="18" font="1">•</text>
<text top="602" left="354" width="163" height="20" font="1"> One or more events for each </text>
<text top="619" left="347" width="139" height="20" font="1">treatment group reported </text>
<text top="638" left="347" width="7" height="18" font="1">•</text>
<text top="637" left="354" width="181" height="20" font="1"> Minimum 5 mm Hg difference in </text>
<text top="655" left="347" width="137" height="20" font="1">SBP level between the 2 </text>
<text top="672" left="347" width="96" height="20" font="1">treatment groups </text>
<text top="691" left="347" width="7" height="18" font="1">•</text>
<text top="690" left="354" width="179" height="20" font="1"> Outcomes included major CVD, </text>
<text top="707" left="347" width="184" height="20" font="1">stroke, CHD, CVD mortality or all-</text>
<text top="725" left="347" width="86" height="20" font="1">cause mortality </text>
<text top="408" left="551" width="7" height="18" font="1">•</text>
<text top="408" left="557" width="174" height="20" font="1"> There were linear associations </text>
<text top="425" left="551" width="211" height="20" font="1">between mean achieved SBP and risk </text>
<text top="442" left="551" width="166" height="20" font="1">of cardiovascular disease and </text>
<text top="459" left="551" width="211" height="20" font="1">mortality, with the lowest risk at 120 to </text>
<text top="477" left="551" width="209" height="20" font="1">124 mm Hg. Randomized groups with </text>
<text top="494" left="551" width="200" height="20" font="1">a mean achieved SBP of 120 to 124 </text>
<text top="511" left="551" width="193" height="20" font="1">mm Hg had a hazard ratio (HR) for </text>
<text top="528" left="551" width="204" height="20" font="1">major cardiovascular disease of 0.71 </text>
<text top="545" left="551" width="197" height="20" font="1">(95% CI: 0.60–0.83) compared with </text>
<text top="563" left="551" width="178" height="20" font="1">randomized groups with a mean </text>
<text top="580" left="551" width="202" height="20" font="1">achieved SBP of 130 to 134 mm Hg, </text>
<text top="597" left="551" width="193" height="20" font="1">an HR of 0.58 (95% CI: 0.48–0.72) </text>
<text top="614" left="551" width="187" height="20" font="1">compared with those with a mean </text>
<text top="632" left="551" width="202" height="20" font="1">achieved SBP of 140 to 144 mm Hg, </text>
<text top="649" left="551" width="193" height="20" font="1">an HR of 0.46 (95% CI: 0.34–0.63) </text>
<text top="666" left="551" width="187" height="20" font="1">compared with those with a mean </text>
<text top="683" left="551" width="202" height="20" font="1">achieved SBP of 150 to 154 mm Hg, </text>
<text top="700" left="551" width="217" height="20" font="1">and an HR of 0.36 (95% CI: 0.26–0.51) </text>
<text top="718" left="551" width="187" height="20" font="1">compared with those with a mean </text>
<text top="735" left="551" width="211" height="20" font="1">achieved SBP of 160 mm Hg or more.<b> </b></text>
<text top="408" left="782" width="7" height="18" font="1">•</text>
<text top="408" left="789" width="267" height="20" font="1"> This study suggests that reducing SBP to levels </text>
<text top="425" left="782" width="276" height="20" font="1">below currently recommended targets significantly </text>
<text top="442" left="782" width="273" height="20" font="1">reduces the risk of cardiovascular disease and all-</text>
<text top="459" left="782" width="284" height="20" font="1">cause mortality and strongly support more intensive </text>
<text top="477" left="782" width="262" height="20" font="1">control of SBP among adults with hypertension. </text>
<text top="754" left="108" width="3" height="19" font="1"> </text>
<text top="790" left="108" width="3" height="19" font="4"><b> </b></text>
</page>
<page number="111" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">111 </text>
<text top="106" left="81" width="880" height="24" font="3"><b>Data Supplement 32. Nonrandomized Trials, Observational Studies, and/or Registries of Ischemic Heart Disease (Section 9.1) </b></text>
<text top="146" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="163" left="128" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="180" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="257" width="38" height="20" font="4"><b>Study </b></text>
<text top="163" left="235" width="81" height="20" font="4"><b>Type/Design; </b></text>
<text top="180" left="233" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="383" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="605" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="163" left="576" width="237" height="20" font="4"><b>(include P value; OR or RR; and 95% CI) </b></text>
<text top="146" left="900" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="163" left="928" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="198" left="98" width="110" height="20" font="4"><b>PROVE IT-TIMI 22</b>  </text>
<text top="215" left="98" width="108" height="20" font="1">Bangalore S, et al., </text>
<text top="233" left="98" width="63" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(151)</a> </text>
<text top="250" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21060068?dopt=Citation">21060068</a></text>
<text top="250" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21060068?dopt=Citation"> </a></text>
<text top="198" left="219" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="215" left="219" width="90" height="20" font="1">Nonrandomized </text>
<text top="233" left="219" width="100" height="20" font="1">trial of optimal BP </text>
<text top="250" left="219" width="57" height="20" font="1">after ACS </text>
<text top="267" left="219" width="3" height="20" font="1"> </text>
<text top="284" left="219" width="86" height="20" font="4"><b>Size:</b> 4,162 pts </text>
<text top="198" left="345" width="186" height="20" font="4"><b>Inclusion criteria:</b> Pts with acute </text>
<text top="215" left="345" width="164" height="20" font="1">MI or high-risk UA within 10 d </text>
<text top="233" left="345" width="159" height="20" font="1">randomized to pravastatin or </text>
<text top="250" left="345" width="184" height="20" font="1">atorvastatin and to gatifloxacin or </text>
<text top="267" left="345" width="165" height="20" font="1">placebo treated with standard </text>
<text top="284" left="345" width="146" height="20" font="1">medical and interventional </text>
<text top="302" left="345" width="102" height="20" font="1">treatment for ACS </text>
<text top="319" left="345" width="3" height="20" font="1"> </text>
<text top="336" left="345" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="199" left="545" width="283" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite of all-cause death, MI, UA </text>
<text top="217" left="545" width="288" height="20" font="1">requiring rehospitalization, revascularization after 30 </text>
<text top="234" left="545" width="248" height="20" font="1">d, and stroke with a mean follow-up of 24 mo </text>
<text top="251" left="545" width="3" height="20" font="1"> </text>
<text top="268" left="545" width="273" height="20" font="4"><b>Results:</b> The relationship between SBP and DBP </text>
<text top="285" left="545" width="288" height="20" font="1">followed a J- or U-shaped curve association with the </text>
<text top="303" left="545" width="282" height="20" font="1">1° outcome with increased events rates at both low </text>
<text top="320" left="545" width="272" height="20" font="1">and high BP values. A nonlinear Cox proportional </text>
<text top="337" left="545" width="269" height="20" font="1">hazards model showed a nadir of 136/85 mm Hg </text>
<text top="354" left="545" width="244" height="20" font="1">(range 130–140/80–90 mm Hg) at which the </text>
<text top="372" left="545" width="274" height="20" font="1">incidence of 1° outcome was lowest. There was a </text>
<text top="389" left="545" width="283" height="20" font="1">relatively flat curve for SBP of 110–130 mm Hg and </text>
<text top="406" left="545" width="285" height="20" font="1">for DBP of 70–90 mm Hg, suggesting a BP &lt;110/70 </text>
<text top="423" left="545" width="152" height="20" font="1">mm Hg may be dangerous. </text>
<text top="200" left="856" width="7" height="18" font="1">•</text>
<text top="199" left="863" width="177" height="20" font="1"> After an ACS, a J- or U-shaped </text>
<text top="217" left="856" width="201" height="20" font="1">association existed between BP and </text>
<text top="234" left="856" width="204" height="20" font="1">the incidence of new CV events. The </text>
<text top="251" left="856" width="219" height="20" font="1">lowest incidence of CV events occurred </text>
<text top="268" left="856" width="201" height="20" font="1">with a BP of 130–140/80–90 mm Hg </text>
<text top="285" left="856" width="199" height="20" font="1">and a relatively flat curve for SBP of </text>
<text top="303" left="856" width="212" height="20" font="1">110–130 mm Hg and of DBP of 70–90 </text>
<text top="320" left="856" width="212" height="20" font="1">mm Hg, suggesting a BP &lt;110/70 mm </text>
<text top="337" left="856" width="128" height="20" font="1">Hg may be dangerous. </text>
<text top="441" left="98" width="89" height="20" font="1">Law MR, et al.,  </text>
<text top="458" left="98" width="56" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(18)</a> </text>
<text top="476" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation">19454737</a></text>
<text top="476" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation"> </a></text>
<text top="441" left="219" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="458" left="219" width="98" height="20" font="1">analysis of use of </text>
<text top="476" left="219" width="104" height="20" font="1">BP-lowering drugs </text>
<text top="493" left="219" width="87" height="20" font="1">in prevention of </text>
<text top="510" left="219" width="81" height="20" font="1">CVD from 147 </text>
<text top="527" left="219" width="97" height="20" font="1">randomized trials </text>
<text top="544" left="219" width="3" height="20" font="1"> </text>
<text top="562" left="219" width="72" height="20" font="4"><b>Size:</b> Of 147 </text>
<text top="579" left="219" width="111" height="20" font="1">randomized trials of </text>
<text top="596" left="219" width="88" height="20" font="1">464,000 pts, 37 </text>
<text top="613" left="219" width="111" height="20" font="1">trials of BBs in CAD </text>
<text top="630" left="219" width="90" height="20" font="1">included 38,892 </text>
<text top="648" left="219" width="107" height="20" font="1">pts, and 37 trials of </text>
<text top="665" left="219" width="31" height="20" font="1">other </text>
<text top="682" left="219" width="93" height="20" font="1">antihypertensive </text>
<text top="699" left="219" width="76" height="20" font="1">drugs in CAD </text>
<text top="716" left="219" width="110" height="20" font="1">included 85,395 pts </text>
<text top="441" left="345" width="185" height="20" font="4"><b>Inclusion criteria:</b> The database </text>
<text top="458" left="345" width="165" height="20" font="1">search used Medline (1966 to </text>
<text top="476" left="345" width="187" height="20" font="1">Dec. 2007) to identify randomized </text>
<text top="493" left="345" width="160" height="20" font="1">trials of BP-lowering drugs in </text>
<text top="510" left="345" width="161" height="20" font="1">which CAD events or strokes </text>
<text top="527" left="345" width="176" height="20" font="1">were recorded. The search also </text>
<text top="544" left="345" width="126" height="20" font="1">included the Cochrane </text>
<text top="562" left="345" width="142" height="20" font="1">Collaboration and Web of </text>
<text top="579" left="345" width="152" height="20" font="1">Science databases and the </text>
<text top="596" left="345" width="165" height="20" font="1">citations in trials and previous </text>
<text top="613" left="345" width="146" height="20" font="1">meta-analyses and review </text>
<text top="630" left="345" width="49" height="20" font="1">articles.  </text>
<text top="648" left="345" width="3" height="20" font="1"> </text>
<text top="665" left="345" width="174" height="20" font="4"><b>Exclusion criteria:</b> Trials were </text>
<text top="682" left="345" width="170" height="20" font="1">excluded if there were &lt;5 CAD </text>
<text top="699" left="345" width="186" height="20" font="1">events and strokes or if treatment </text>
<text top="716" left="345" width="114" height="20" font="1">duration was &lt;6 mo. </text>
<text top="442" left="545" width="185" height="20" font="4"><b>1</b>°<b> endpoint:</b> CAD events; stroke </text>
<text top="460" left="545" width="3" height="20" font="1"> </text>
<text top="477" left="545" width="293" height="20" font="4"><b>Results:</b> In 37 trials of pts with a history of CAD, BBs </text>
<text top="494" left="545" width="294" height="20" font="1">reduced CAD events 29% (95% CI: 22%, 34%). In 27 </text>
<text top="511" left="545" width="271" height="20" font="1">trials in which BBs were used after acute MI, BBs </text>
<text top="528" left="545" width="287" height="20" font="1">reduced CAD events 31% (95% CI: 24%–38%), and </text>
<text top="546" left="545" width="277" height="20" font="1">in 11 trials in which BBs were used after long-term </text>
<text top="563" left="545" width="297" height="20" font="1">CAD, BBs insignificantly reduced CAD events 13%. In </text>
<text top="580" left="545" width="293" height="20" font="1">7 trials, BBs reduced stroke 17% (95% CI: 1%–30%). </text>
<text top="597" left="545" width="296" height="20" font="1">CAD events were reduced 14% (95% CI: 2%–25%) in </text>
<text top="614" left="545" width="269" height="20" font="1">11 trials of thiazide diuretics, 17% (95% CI: 11%–</text>
<text top="632" left="545" width="275" height="20" font="1">22%) in 21 trials of ACEIs, insignificantly 14% in 4 </text>
<text top="649" left="545" width="295" height="20" font="1">trials of angiotensin receptor blockers, and 15% (95% </text>
<text top="666" left="545" width="252" height="20" font="1">CI: 8%–22%) in 22 trials of CCBs. Stroke was </text>
<text top="683" left="545" width="264" height="20" font="1">reduced 38% (95% CI: 28%–47%) in 10 trials of </text>
<text top="700" left="545" width="294" height="20" font="1">thiazide diuretics, 22% (95% CI: 8%–34%) in 13 trials </text>
<text top="718" left="545" width="288" height="20" font="1">of ACEIs, and 34% (95% CI: 25%–42%) in 9 trials of </text>
<text top="735" left="545" width="39" height="20" font="1">CCBs. </text>
<text top="443" left="856" width="7" height="18" font="1">•</text>
<text top="442" left="863" width="173" height="20" font="1"> With the exception of the extra </text>
<text top="460" left="856" width="202" height="20" font="1">protective effect of BBs given shortly </text>
<text top="477" left="856" width="190" height="20" font="1">after a MI and the minor additional </text>
<text top="494" left="856" width="213" height="20" font="1">effect of CCBs in preventing stroke, all </text>
<text top="511" left="856" width="213" height="20" font="1">the classes of BP-lowering drugs have </text>
<text top="528" left="856" width="215" height="20" font="1">a similar effect in reducing CAD events </text>
<text top="546" left="856" width="212" height="20" font="1">and stroke for a given reduction in BP. </text>
<text top="753" left="135" width="3" height="20" font="1"> </text>
</page>
<page number="112" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">112 </text>
<text top="106" left="81" width="460" height="24" font="3"><b>Data Supplement 33. RCTs Comparing Heart Failure (Section 9.2) </b></text>
<text top="146" left="104" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="163" left="109" width="86" height="20" font="4"><b>(if applicable)  </b></text>
<text top="180" left="129" width="44" height="20" font="4"><b>Author </b></text>
<text top="197" left="105" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="227" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="163" left="243" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="399" width="44" height="20" font="4"><b>Patient </b></text>
<text top="163" left="387" width="70" height="20" font="4"><b>Population  </b></text>
<text top="146" left="577" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="163" left="548" width="237" height="20" font="4"><b>(include P value; OR or RR; and 95% CI) </b></text>
<text top="146" left="910" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="163" left="937" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="215" left="98" width="65" height="20" font="1">LV J, et al., </text>
<text top="233" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(127)</a> </text>
<text top="250" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459">23798459</a></text>
<text top="250" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459"> </a></text>
<text top="215" left="217" width="134" height="20" font="4"><b>Study type</b>: MA of RTC </text>
<text top="233" left="217" width="131" height="20" font="1">that randomly assigned </text>
<text top="250" left="217" width="122" height="20" font="1">individuals to different </text>
<text top="267" left="217" width="93" height="20" font="1">target BP levels  </text>
<text top="284" left="217" width="3" height="20" font="1"> </text>
<text top="301" left="217" width="92" height="20" font="4"><b>Size</b>: 37,348 pts </text>
<text top="217" left="368" width="7" height="18" font="1">•</text>
<text top="217" left="374" width="53" height="20" font="1">15 trials   </text>
<text top="215" left="487" width="346" height="20" font="1">7.5/4.5 mm Hg BP difference. Intensive BP lowering achieved.  </text>
<text top="233" left="487" width="42" height="20" font="1">RR for  </text>
<text top="252" left="487" width="7" height="18" font="1">•</text>
<text top="251" left="494" width="237" height="20" font="1"> Major CV events: 11%; 95% CI: 1%–21%) </text>
<text top="270" left="487" width="7" height="18" font="1">•</text>
<text top="269" left="494" width="155" height="20" font="1"> MI: 13%; 95% CI: 0%–25% </text>
<text top="288" left="487" width="7" height="18" font="1">•</text>
<text top="288" left="494" width="177" height="20" font="1"> Stroke: 24%; 95% CI: 8%–37% </text>
<text top="307" left="487" width="7" height="18" font="1">•</text>
<text top="306" left="494" width="176" height="20" font="1"> ESRD: 11%; 95% CI: 3%–18% </text>
<text top="325" left="487" width="7" height="18" font="1">•</text>
<text top="325" left="494" width="210" height="20" font="1"> Albuminuria: 10%; 95% CI: 4%–16%  </text>
<text top="344" left="487" width="7" height="18" font="1">•</text>
<text top="343" left="494" width="204" height="20" font="1"> Retinopathy 19%; 95% CI: 0%–34% </text>
<text top="360" left="487" width="52" height="20" font="1">p=0.051  </text>
<text top="217" left="859" width="7" height="18" font="1">•</text>
<text top="217" left="865" width="212" height="20" font="1"> More intensive strategy for BP control </text>
<text top="234" left="859" width="167" height="20" font="1">reduced cardio-renal endpoint </text>
<text top="378" left="98" width="100" height="20" font="1">Xie X, et al., 2015 </text>
<text top="395" left="98" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(21)</a> </text>
<text top="413" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation">26559744</a></text>
<text top="413" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation"><b> </b></a></text>
<text top="378" left="217" width="134" height="20" font="4"><b>Study type</b>: MA of RTC </text>
<text top="395" left="217" width="131" height="20" font="1">that randomly assigned </text>
<text top="413" left="217" width="122" height="20" font="1">individuals to different </text>
<text top="430" left="217" width="90" height="20" font="1">target BP levels </text>
<text top="447" left="217" width="3" height="20" font="1"> </text>
<text top="464" left="217" width="92" height="20" font="4"><b>Size</b>: 44,989 pts </text>
<text top="380" left="368" width="7" height="18" font="1">•</text>
<text top="379" left="374" width="53" height="20" font="1"> 19 trials  </text>
<text top="378" left="487" width="74" height="20" font="1">Achieved BP </text>
<text top="395" left="487" width="262" height="20" font="1">133/76 mm Hg (intensive) 140/81 (less intense) </text>
<text top="414" left="487" width="7" height="18" font="1">•</text>
<text top="414" left="494" width="233" height="20" font="1"> Major CV events: 14%; 95% CI: 4%–22% </text>
<text top="433" left="487" width="7" height="18" font="1">•</text>
<text top="432" left="494" width="155" height="20" font="1"> MI: 13%; 95% CI: 0%–24% </text>
<text top="451" left="487" width="7" height="18" font="1">•</text>
<text top="450" left="494" width="184" height="20" font="1"> Stroke: 22%; 95% CI: 10%–32% </text>
<text top="469" left="487" width="7" height="18" font="1">•</text>
<text top="469" left="494" width="207" height="20" font="1"> Albuminuria: 10%; 95% CI: 3%–16% </text>
<text top="488" left="487" width="7" height="18" font="1">•</text>
<text top="487" left="494" width="282" height="20" font="1"> Retinopathy progression: 19%; 95% CI: 0%–34%.  </text>
<text top="506" left="487" width="7" height="18" font="1">•</text>
<text top="505" left="494" width="350" height="20" font="1"> More intensive had no effects on HF: 15%; 95% CI: -11%–34% </text>
<text top="524" left="487" width="7" height="18" font="1">•</text>
<text top="524" left="494" width="197" height="20" font="1"> CV death: 9%; 95% CI: -11%–26% </text>
<text top="543" left="487" width="7" height="18" font="1">•</text>
<text top="542" left="494" width="216" height="20" font="1"> Total mortality: 9%; 95% CI: -3%–19% </text>
<text top="561" left="487" width="7" height="18" font="1">•</text>
<text top="561" left="494" width="179" height="20" font="1"> ESKD: 10%; 95% CI: -6%–23%<b> </b></text>
<text top="380" left="859" width="7" height="18" font="1">•</text>
<text top="379" left="865" width="224" height="20" font="1"> More intensive approach reduced major </text>
<text top="396" left="859" width="213" height="20" font="1">CV events (stroke and MI) except heat </text>
<text top="414" left="859" width="218" height="20" font="1">failure, CVD, ESRD, and total mortality. </text>
<text top="585" left="98" width="94" height="20" font="1">Thomopolous C, </text>
<text top="602" left="98" width="90" height="20" font="1">et al., 2016 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#266">(54)</a> </text>
<text top="619" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26848994">26848994</a></text>
<text top="619" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26848994"> </a></text>
<text top="585" left="217" width="101" height="20" font="4"><b>Study type</b>: Meta-</text>
<text top="602" left="217" width="110" height="20" font="1">analysis of RTCs of </text>
<text top="619" left="217" width="119" height="20" font="1">more vs. less intense </text>
<text top="636" left="217" width="60" height="20" font="1">BP control </text>
<text top="653" left="217" width="3" height="20" font="1"> </text>
<text top="586" left="368" width="7" height="18" font="1">•</text>
<text top="586" left="374" width="50" height="20" font="1"> 16 trials </text>
<text top="603" left="368" width="69" height="20" font="1">(52,235 pts) </text>
<text top="620" left="368" width="90" height="20" font="1">compared more </text>
<text top="637" left="368" width="87" height="20" font="1">vs. less intense </text>
<text top="655" left="368" width="55" height="20" font="1">treatment </text>
<text top="672" left="368" width="69" height="20" font="1">34 (138,127 </text>
<text top="689" left="368" width="79" height="20" font="1">pts) active vs. </text>
<text top="706" left="368" width="46" height="20" font="1">placebo </text>
<text top="585" left="487" width="98" height="20" font="1">More intense BP  </text>
<text top="604" left="487" width="7" height="18" font="1">•</text>
<text top="603" left="494" width="207" height="20" font="1"> Stroke RR: 0.71; 95% CI: 0.60–0.84) </text>
<text top="622" left="487" width="7" height="18" font="1">•</text>
<text top="621" left="494" width="198" height="20" font="1"> CHD RR: 0.80; 95% CI: 0.68–0.95) </text>
<text top="640" left="487" width="7" height="18" font="1">•</text>
<text top="640" left="494" width="258" height="20" font="1"> Major CV events RR: 0.75; 95% CI: 0.68–0.85 </text>
<text top="659" left="487" width="7" height="18" font="1">•</text>
<text top="658" left="494" width="235" height="20" font="1"> CV mortality RR: 0.79; 95% CI: 0.63–0.97 </text>
<text top="675" left="487" width="3" height="20" font="1"> </text>
<text top="692" left="487" width="345" height="20" font="1">Stratification of SBP cutoffs (150,140 and 130 mm Hg) showed </text>
<text top="710" left="487" width="336" height="20" font="1">that a SBP/DBP difference of 10/5 mm Hg across each cutoff </text>
<text top="727" left="487" width="70" height="20" font="1">reduced risk </text>
<text top="744" left="487" width="86" height="20" font="1">of all outcomes </text>
<text top="586" left="859" width="7" height="18" font="1">•</text>
<text top="586" left="865" width="204" height="20" font="1"> Intensive BP reduction improves CV </text>
<text top="603" left="859" width="197" height="20" font="1">outcomes compared to less intense </text>
<text top="620" left="859" width="228" height="20" font="1">Achieved BP &lt;130/80 may be associated </text>
<text top="637" left="859" width="90" height="20" font="1">with CV benefit. </text>
<text top="762" left="108" width="3" height="20" font="1"> </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="18" size="16" family="Times" color="#000000"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">113 </text>
<text top="106" left="81" width="427" height="24" font="3"><b>Data Supplement 34. RCTs Comparing HF<i>r</i></b><b>EF (Section 9.2.1) </b></text>
<text top="146" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="163" left="128" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="180" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="242" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="163" left="247" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="180" left="240" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="397" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="565" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="163" left="581" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="180" left="566" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="197" left="586" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="146" left="731" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="163" left="714" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="180" left="706" width="154" height="20" font="4"><b>P value; OR or RR; &amp; 95% </b></text>
<text top="197" left="773" width="20" height="20" font="4"><b>CI) </b></text>
<text top="147" left="898" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="164" left="931" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="181" left="936" width="103" height="20" font="4"><b>Adverse Events;  </b></text>
<text top="199" left="957" width="59" height="20" font="4"><b>Summary </b></text>
<text top="217" left="98" width="85" height="20" font="1">Herlitz J, et al., </text>
<text top="234" left="98" width="63" height="20" font="1">2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(142)</a> </text>
<text top="251" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11862577?dopt=Citation">11862577</a></text>
<text top="251" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11862577?dopt=Citation"> </a></text>
<text top="217" left="219" width="119" height="20" font="4"><b>Aim:</b> To see effect of </text>
<text top="234" left="219" width="126" height="20" font="1">metoprolol vs. placebo </text>
<text top="251" left="219" width="91" height="20" font="1">on mortality and </text>
<text top="268" left="219" width="128" height="20" font="1">hospitalizations among </text>
<text top="285" left="219" width="127" height="20" font="1">pts with history of HTN </text>
<text top="303" left="219" width="117" height="20" font="1">and HF with reduced </text>
<text top="320" left="219" width="34" height="20" font="1">LVEF </text>
<text top="337" left="219" width="3" height="20" font="1"> </text>
<text top="354" left="219" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="371" left="219" width="3" height="20" font="1"> </text>
<text top="389" left="219" width="86" height="20" font="4"><b>Size:</b> 1,747 pts </text>
<text top="217" left="361" width="175" height="20" font="4"><b>Inclusion criteria:</b> NYHA class </text>
<text top="234" left="361" width="179" height="20" font="1">II–IV HF with LVEF ≤40% within </text>
<text top="251" left="361" width="148" height="20" font="1">3 mo of enrollment; supine </text>
<text top="268" left="361" width="154" height="20" font="1">resting HR ≥68 bpm; stable </text>
<text top="285" left="361" width="93" height="20" font="1">clinical condition </text>
<text top="303" left="361" width="3" height="20" font="1"> </text>
<text top="320" left="361" width="176" height="20" font="4"><b>Exclusion criteria:</b> Acute MI or </text>
<text top="337" left="361" width="180" height="20" font="1">UA within 28 d of randomization; </text>
<text top="354" left="361" width="177" height="20" font="1">indication or contraindication for </text>
<text top="372" left="361" width="180" height="20" font="1">treatment with BBs or drugs with </text>
<text top="389" left="361" width="166" height="20" font="1">beta-blocking properties; poor </text>
<text top="406" left="361" width="166" height="20" font="1">compliance; CABG surgery or </text>
<text top="423" left="361" width="107" height="20" font="1">PTCA in past 4 mo </text>
<text top="217" left="557" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="236" left="557" width="7" height="18" font="1">•</text>
<text top="235" left="563" width="98" height="20" font="1"> Administration of </text>
<text top="252" left="557" width="64" height="20" font="1">metoprolol  </text>
<text top="271" left="557" width="7" height="18" font="1">•</text>
<text top="271" left="563" width="115" height="20" font="1"> 871 pts randomized </text>
<text top="288" left="557" width="75" height="20" font="1">to metoprolol </text>
<text top="305" left="557" width="7" height="20" font="1">  </text>
<text top="322" left="557" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="341" left="557" width="7" height="18" font="1">•</text>
<text top="341" left="563" width="98" height="20" font="1"> Administration of </text>
<text top="358" left="557" width="46" height="20" font="1">placebo </text>
<text top="377" left="557" width="7" height="18" font="1">•</text>
<text top="376" left="563" width="115" height="20" font="1"> 876 pts randomized </text>
<text top="393" left="557" width="60" height="20" font="1">to placebo </text>
<text top="218" left="698" width="167" height="20" font="4"><b>1</b>°<b> endpoint:</b> At 1-y follow-up, </text>
<text top="235" left="698" width="133" height="20" font="1">compared with placebo, </text>
<text top="252" left="698" width="161" height="20" font="1">metoprolol reduced all-cause </text>
<text top="269" left="698" width="161" height="20" font="1">mortality 39% (95% CI: 16%–</text>
<text top="287" left="698" width="160" height="20" font="1">56%; p=0.002) and all-cause </text>
<text top="304" left="698" width="117" height="20" font="1">mortality or all-cause </text>
<text top="321" left="698" width="161" height="20" font="1">hospitalization 24% (95% CI: </text>
<text top="338" left="698" width="122" height="20" font="1">11%–35%; p=0.0007) </text>
<text top="355" left="698" width="3" height="20" font="1"> </text>
<text top="374" left="698" width="148" height="20" font="4"><b>1</b>°<b> Safety endpoint: </b>Early </text>
<text top="391" left="698" width="159" height="20" font="1">permanent cessation of drug </text>
<text top="408" left="698" width="166" height="20" font="1">was 12.5% for metoprolol and </text>
<text top="426" left="698" width="162" height="20" font="1">15.9% for placebo (p=0.048); </text>
<text top="443" left="698" width="156" height="20" font="1">21 pts on metoprolol and 35 </text>
<text top="460" left="698" width="137" height="20" font="1">pts on placebo had early </text>
<text top="477" left="698" width="119" height="20" font="1">cessation because of </text>
<text top="494" left="698" width="59" height="20" font="1">worsening </text>
<text top="218" left="881" width="201" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> At 1-y follow-</text>
<text top="235" left="881" width="154" height="20" font="1">up, compared with placebo, </text>
<text top="252" left="881" width="191" height="20" font="1">metoprolol reduced CV death 41% </text>
<text top="269" left="881" width="204" height="20" font="1">(95% CI: 17%–57%; p=0.002), death </text>
<text top="287" left="881" width="187" height="20" font="1">from HF: 51% (95% CI: 1%–75%; </text>
<text top="304" left="881" width="205" height="20" font="1">p=0.042), sudden cardiac death 49% </text>
<text top="321" left="881" width="186" height="20" font="1">(95% CI: 21%–67%; p=0.002), all-</text>
<text top="338" left="881" width="202" height="20" font="1">cause mortality or HF hospitalization </text>
<text top="356" left="881" width="198" height="20" font="1">28% (95% CI: 11%–42%; p=0.002), </text>
<text top="373" left="881" width="196" height="20" font="1">and cardiac death or nonfatal acute </text>
<text top="390" left="881" width="159" height="20" font="1">MI 44% (95% CI: 23%–60%; </text>
<text top="407" left="881" width="59" height="20" font="1">p=0.0003) </text>
<text top="424" left="881" width="3" height="20" font="1"> </text>
<text top="442" left="881" width="178" height="20" font="4"><b>Study limitations and adverse </b></text>
<text top="459" left="881" width="209" height="20" font="4"><b>events:</b> Early permanent cessation of </text>
<text top="476" left="881" width="194" height="20" font="1">drug was 12.5% for metoprolol and </text>
<text top="493" left="881" width="199" height="20" font="1">15.9% for placebo (p=0.048); 21 pts </text>
<text top="510" left="881" width="209" height="20" font="1">on M and 35 pts on placebo had early </text>
<text top="528" left="881" width="202" height="20" font="1">cessation because of worsening HF; </text>
<text top="545" left="881" width="204" height="20" font="1">all-cause withdrawals were 22% less </text>
<text top="562" left="881" width="197" height="20" font="1">with metoprolol; (p=0.048); adverse </text>
<text top="579" left="881" width="209" height="20" font="1">events were 28% less with metoprolol </text>
<text top="596" left="881" width="192" height="20" font="1">(p=0.026); worsening HF was 41% </text>
<text top="614" left="881" width="168" height="20" font="1">less with metoprolol (p=0.056) </text>
<text top="631" left="881" width="3" height="20" font="1"> </text>
<text top="648" left="881" width="202" height="20" font="4"><b>Summary:</b> In an RCT of pts with HF </text>
<text top="665" left="881" width="180" height="20" font="1">with reduced EF and a history of </text>
<text top="683" left="881" width="165" height="20" font="1">HTN, compared with placebo, </text>
<text top="700" left="881" width="180" height="20" font="1">metoprolol succinate reduced all-</text>
<text top="717" left="881" width="163" height="20" font="1">cause mortality and all-cause </text>
<text top="734" left="881" width="198" height="20" font="1">mortality or all-cause hospitalization<b> </b></text>
<text top="752" left="98" width="92" height="20" font="1">Packer M, et al., </text>
<text top="769" left="98" width="63" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(140)</a> </text>
<text top="787" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11386263?dopt=Citation">11386263</a></text>
<text top="787" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11386263?dopt=Citation"> </a></text>
<text top="752" left="219" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="769" left="219" width="98" height="20" font="1">survival in severe </text>
<text top="752" left="361" width="171" height="20" font="4"><b>Inclusion criteria:</b> HF pts with </text>
<text top="769" left="361" width="159" height="20" font="1">dyspnea/exertion for 2 mo at </text>
<text top="787" left="361" width="167" height="20" font="1">least and left EF&lt;25% despite </text>
<text top="752" left="557" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="769" left="557" width="100" height="20" font="1">Carvedilol (1,156) </text>
<text top="787" left="557" width="3" height="20" font="1"> </text>
<text top="753" left="698" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="770" left="698" width="160" height="20" font="1">● Death from any cause 130 </text>
<text top="788" left="698" width="144" height="20" font="1">vs. 190 deaths (RR: 35%; </text>
<text top="754" left="881" width="7" height="18" font="1">•</text>
<text top="753" left="887" width="185" height="20" font="1"> Study stopped early (1.3 y follow-</text>
<text top="770" left="881" width="161" height="20" font="1">up) due to benefit on survival </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">114 </text>
<text top="107" left="219" width="120" height="20" font="1">chronic HF pts by the </text>
<text top="124" left="219" width="96" height="20" font="1">use of carvedilol. </text>
<text top="141" left="219" width="3" height="20" font="1"> </text>
<text top="159" left="219" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="176" left="219" width="3" height="20" font="1"> </text>
<text top="193" left="219" width="86" height="20" font="4"><b>Size:</b> 2,289 pts </text>
<text top="107" left="361" width="167" height="20" font="1">treatment clinically euvolemic; </text>
<text top="124" left="361" width="157" height="20" font="1">allowed on digitalis, nitrates, </text>
<text top="141" left="361" width="171" height="20" font="1">hydralazine, spironolactone, or </text>
<text top="159" left="361" width="162" height="20" font="1">amiodarone. Hospitalized pts </text>
<text top="176" left="361" width="117" height="20" font="1">with no acute illness. </text>
<text top="193" left="361" width="3" height="20" font="1"> </text>
<text top="210" left="361" width="167" height="20" font="4"><b>Exclusion criteria:</b> HF due to </text>
<text top="227" left="361" width="145" height="20" font="1">uncorrected prim. valvular </text>
<text top="245" left="361" width="117" height="20" font="1">disease or reversible </text>
<text top="262" left="361" width="137" height="20" font="1">cardiomyopathy, cardiac </text>
<text top="279" left="361" width="178" height="20" font="1">transplant pts., coronary revasc. </text>
<text top="296" left="361" width="147" height="20" font="1">&lt;2 mo, acute MI or stroke, </text>
<text top="314" left="361" width="180" height="20" font="1">ventricular tachycardia, on alpha </text>
<text top="331" left="361" width="118" height="20" font="1">blocker or CCB or on </text>
<text top="348" left="361" width="158" height="20" font="1">antiarrythmics class I &lt;4 wk, </text>
<text top="365" left="361" width="180" height="20" font="1">SBP &lt;85 mm Hg, serum Cr &gt;2.8 </text>
<text top="383" left="361" width="167" height="20" font="1">mg/dL, change in body weight </text>
<text top="400" left="361" width="142" height="20" font="1">&gt;1.5 kg during screening. </text>
<text top="107" left="557" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="124" left="557" width="42" height="20" font="1">(1,133) </text>
<text top="107" left="698" width="110" height="20" font="1">95% CI: 19%–48%; </text>
<text top="124" left="698" width="69" height="20" font="1">p=0.00013)  </text>
<text top="141" left="698" width="108" height="20" font="1">● Combined risk of </text>
<text top="159" left="698" width="148" height="20" font="1">death/hospitalization (24% </text>
<text top="176" left="698" width="147" height="20" font="1">lower risk in the carvedilol; </text>
<text top="193" left="698" width="162" height="20" font="1">95% CI: 13%–33%; p&lt;0.001) </text>
<text top="210" left="698" width="3" height="20" font="1"> </text>
<text top="227" left="698" width="163" height="20" font="4"><b>Safety endpoint:</b>  Lesser pts </text>
<text top="245" left="698" width="152" height="20" font="1">in carvedilol group required </text>
<text top="262" left="698" width="148" height="20" font="1">permanent discontinuation </text>
<text top="279" left="698" width="165" height="20" font="1">because of adverse events or </text>
<text top="296" left="698" width="158" height="20" font="1">for reasons other than death </text>
<text top="314" left="698" width="49" height="20" font="1">(p=0.02) </text>
<text top="109" left="881" width="7" height="18" font="1">•</text>
<text top="108" left="887" width="157" height="20" font="1"> Long-term treatment is very </text>
<text top="125" left="881" width="53" height="20" font="1">valuable. </text>
<text top="144" left="881" width="7" height="18" font="1">•</text>
<text top="144" left="887" width="198" height="20" font="1"> Not all the pts with severe HF were </text>
<text top="161" left="881" width="111" height="20" font="1">allowed in the study </text>
<text top="418" left="98" width="78" height="20" font="4"><b>CAPRICORN </b></text>
<text top="435" left="98" width="95" height="20" font="1">Dargie HJ, et al., </text>
<text top="452" left="98" width="63" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(141)</a> </text>
<text top="469" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11356434?dopt=Citation">11356434</a></text>
<text top="469" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11356434?dopt=Citation"><b> </b></a></text>
<text top="418" left="219" width="111" height="20" font="4"><b>Aim: </b>To investigate </text>
<text top="435" left="219" width="85" height="20" font="1">outcomes after </text>
<text top="452" left="219" width="113" height="20" font="1">carvedilol after MI in </text>
<text top="469" left="219" width="63" height="20" font="1">pts with LV </text>
<text top="487" left="219" width="69" height="20" font="1">dysfunction. </text>
<text top="504" left="219" width="3" height="20" font="1"> </text>
<text top="521" left="219" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="538" left="219" width="3" height="20" font="1"> </text>
<text top="555" left="219" width="86" height="20" font="4"><b>Size: </b>1,959 pts </text>
<text top="418" left="361" width="183" height="20" font="4"><b>Inclusion criteria: </b>Pts ≥18 y, MI </text>
<text top="435" left="361" width="158" height="20" font="1">within 3–21 d of entry, LVEF </text>
<text top="452" left="361" width="169" height="20" font="1">≤40%, concurrent ACEI stable </text>
<text top="469" left="361" width="161" height="20" font="1">dose for at least 24 h, HF pts </text>
<text top="487" left="361" width="180" height="20" font="1">treated and controlled with ACEI </text>
<text top="504" left="361" width="172" height="20" font="1">and diuretics but not inotropes. </text>
<text top="521" left="361" width="3" height="20" font="4"><b> </b></text>
<text top="538" left="361" width="162" height="20" font="4"><b>Exclusion criteria: </b>SBP &lt;90 </text>
<text top="555" left="361" width="149" height="20" font="1">mm Hg, uncontrolled HTN, </text>
<text top="573" left="361" width="172" height="20" font="1">bradycardia, insulin-dependent </text>
<text top="590" left="361" width="153" height="20" font="1">DM, BBs not for HF, Beta-2 </text>
<text top="607" left="361" width="123" height="20" font="1">agonists, and steroids<b> </b></text>
<text top="418" left="557" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="435" left="557" width="90" height="20" font="1">Carvedilol (975) </text>
<text top="452" left="557" width="3" height="20" font="4"><b> </b></text>
<text top="469" left="557" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="487" left="557" width="32" height="20" font="1">(984) </text>
<text top="419" left="698" width="130" height="20" font="4"><b>1</b>°<b> endpoint: </b>All-cause </text>
<text top="436" left="698" width="110" height="20" font="1">mortality or hospital </text>
<text top="453" left="698" width="141" height="20" font="1">admissions for CV issues </text>
<text top="470" left="698" width="3" height="20" font="1"> </text>
<text top="488" left="698" width="155" height="20" font="4"><b>Results: </b>12% vs. 15%; RR: </text>
<text top="505" left="698" width="141" height="20" font="1">23% (95% CI: 0.60–0.98; </text>
<text top="522" left="698" width="46" height="20" font="1">p=0.03) </text>
<text top="539" left="698" width="167" height="20" font="1">No difference between groups </text>
<text top="557" left="698" width="132" height="20" font="1">for death or CV hospital </text>
<text top="574" left="698" width="65" height="20" font="1">admissions </text>
<text top="420" left="881" width="7" height="18" font="1">•</text>
<text top="419" left="888" width="202" height="20" font="4"><b> </b>CV mortality, nonfatal MI reduced in </text>
<text top="436" left="881" width="111" height="20" font="1">the carvedilol group<b> </b></text>
<text top="455" left="881" width="7" height="18" font="1">•</text>
<text top="454" left="888" width="171" height="20" font="4"><b> </b>No difference between groups </text>
<text top="472" left="881" width="198" height="20" font="1">sudden death and admission due to </text>
<text top="489" left="881" width="23" height="20" font="1">HF<b>  </b></text>
<text top="625" left="98" width="100" height="20" font="1">Elkayam U, et al., </text>
<text top="642" left="98" width="63" height="20" font="1">1990 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(144)</a> </text>
<text top="659" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2242521?dopt=Citation">2242521</a></text>
<text top="659" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2242521?dopt=Citation"> </a></text>
<text top="625" left="219" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="642" left="219" width="115" height="20" font="1">comparative efficacy </text>
<text top="659" left="219" width="74" height="20" font="1">and safety of </text>
<text top="677" left="219" width="113" height="20" font="1">nifedipine and ISDN </text>
<text top="694" left="219" width="78" height="20" font="1">alone and the </text>
<text top="711" left="219" width="87" height="20" font="1">combination for </text>
<text top="728" left="219" width="105" height="20" font="1">treating for chronic </text>
<text top="745" left="219" width="32" height="20" font="1">CHF. </text>
<text top="763" left="219" width="3" height="20" font="1"> </text>
<text top="625" left="361" width="173" height="20" font="4"><b>Inclusion criteria: </b>18–75 y old </text>
<text top="642" left="361" width="163" height="20" font="1">HF pts, NYHA class II and III, </text>
<text top="659" left="361" width="158" height="20" font="1">LVEF&lt;40%, clinically stable, </text>
<text top="677" left="361" width="164" height="20" font="1">maintenance dose of Digitalis </text>
<text top="694" left="361" width="80" height="20" font="1">and diuretics.  </text>
<text top="711" left="361" width="3" height="20" font="1"> </text>
<text top="728" left="361" width="175" height="20" font="4"><b>Exclusion criteria: </b>Pregnancy, </text>
<text top="745" left="361" width="156" height="20" font="1">nursing, history of MI &lt;1 mo </text>
<text top="763" left="361" width="167" height="20" font="1">before entry, valvular disease, </text>
<text top="780" left="361" width="166" height="20" font="1">angina, significant pulmonary, </text>
<text top="625" left="557" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="642" left="557" width="120" height="20" font="1">Nifedipine (21), ISDN </text>
<text top="659" left="557" width="123" height="20" font="1">(20), Nifedipine+ISDN </text>
<text top="677" left="557" width="25" height="20" font="1">(23) </text>
<text top="694" left="557" width="3" height="20" font="4"><b> </b></text>
<text top="711" left="557" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="625" left="698" width="148" height="20" font="4"><b>Endpoints and Results:   </b></text>
<text top="644" left="698" width="7" height="18" font="1">•</text>
<text top="643" left="705" width="110" height="20" font="4"><b> </b>HF-worsening: 9 in<b> </b></text>
<text top="660" left="698" width="168" height="20" font="1">Nifedipine group vs. 3 in ISDN </text>
<text top="678" left="698" width="112" height="20" font="1">group (p&lt;0.09); and </text>
<text top="695" left="698" width="154" height="20" font="1">21 in nifedipine-ISDN group </text>
<text top="712" left="698" width="131" height="20" font="1">(p&lt;0.001 vs. nifedipine, </text>
<text top="729" left="698" width="111" height="20" font="1">p&lt;0.0001 vs. ISDN) </text>
<text top="748" left="698" width="7" height="18" font="1">•</text>
<text top="748" left="705" width="118" height="20" font="4"><b> </b>Clinical deterioration </text>
<text top="765" left="698" width="89" height="20" font="1">discontinuation: </text>
<text top="627" left="881" width="7" height="18" font="1">•</text>
<text top="626" left="888" width="185" height="20" font="4"><b> </b>In clinical deterioration nifedipine </text>
<text top="643" left="881" width="159" height="20" font="1">pts (8) vs. rest of the pts (No </text>
<text top="660" left="881" width="137" height="20" font="1">difference in LVEF or VO</text>
<text top="662" left="1017" width="4" height="13" font="6">2</text>
<text top="660" left="1022" width="38" height="20" font="1"> max.<b>) </b></text>
<text top="679" left="881" width="7" height="18" font="1">•</text>
<text top="679" left="888" width="184" height="20" font="4"><b> </b>Although all the 3 drug regimens </text>
<text top="696" left="881" width="211" height="20" font="1">improved exercise capacity, nifedipine </text>
<text top="713" left="881" width="186" height="20" font="1">treatment alone or in combination </text>
<text top="730" left="881" width="196" height="20" font="1">resulted in clinical deterioration and </text>
<text top="748" left="881" width="102" height="20" font="1">worsening of CHF<b> </b></text>
</page>
<page number="115" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">115 </text>
<text top="107" left="219" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="124" left="219" width="92" height="20" font="1">Crossover RCT <b> </b></text>
<text top="141" left="219" width="3" height="20" font="1"> </text>
<text top="159" left="219" width="69" height="20" font="4"><b>Size: </b>28 pts </text>
<text top="107" left="361" width="171" height="20" font="1">hepatic, renal and hematologic </text>
<text top="124" left="361" width="172" height="20" font="1">disease., unable to walk on the </text>
<text top="141" left="361" width="143" height="20" font="1">treadmill, noncompliance  </text>
<text top="107" left="698" width="138" height="20" font="1">Nifedipine 29% vs. ISDN </text>
<text top="124" left="698" width="106" height="20" font="1">group 5% (p&lt;0.05) </text>
<text top="143" left="698" width="7" height="18" font="1">•</text>
<text top="143" left="705" width="141" height="20" font="4"><b> </b>DBP: Nifedipine alone or </text>
<text top="160" left="698" width="128" height="20" font="1">combination with ISDN </text>
<text top="177" left="698" width="107" height="20" font="1">(reduction, p&lt;0.05) </text>
<text top="195" left="98" width="42" height="20" font="4"><b>MDPIT </b></text>
<text top="212" left="98" width="93" height="20" font="1">Goldstein RE, et </text>
<text top="229" left="98" width="83" height="20" font="1">al., 1991 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(146)</a> </text>
<text top="247" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1984898?dopt=Citation">1984898</a></text>
<text top="247" left="145" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1984898?dopt=Citation"><b> </b></a></text>
<text top="195" left="219" width="116" height="20" font="4"><b>Aim: </b>To determine if </text>
<text top="212" left="219" width="111" height="20" font="1">dilitiazem increases </text>
<text top="229" left="219" width="98" height="20" font="1">late onset CHF in </text>
<text top="247" left="219" width="120" height="20" font="1">post-MI pts with early </text>
<text top="264" left="219" width="78" height="20" font="1">decline in EF. </text>
<text top="281" left="219" width="7" height="20" font="1">  </text>
<text top="298" left="219" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="316" left="219" width="3" height="20" font="1"> </text>
<text top="333" left="219" width="86" height="20" font="4"><b>Size: </b>2,466 pts </text>
<text top="195" left="361" width="173" height="20" font="4"><b>Inclusion criteria: </b>18–75 y HF </text>
<text top="212" left="361" width="178" height="20" font="1">pts, NYHA class II and III, LVEF </text>
<text top="229" left="361" width="127" height="20" font="1">&lt;40%, clinically stable, </text>
<text top="247" left="361" width="162" height="20" font="1">maintenance dose of digitalis </text>
<text top="264" left="361" width="80" height="20" font="1">and diuretics.  </text>
<text top="281" left="361" width="3" height="20" font="1"> </text>
<text top="298" left="361" width="175" height="20" font="4"><b>Exclusion criteria: </b>Pregnancy, </text>
<text top="316" left="361" width="156" height="20" font="1">nursing, history of MI &lt;1 mo </text>
<text top="333" left="361" width="167" height="20" font="1">before entry, valvular disease, </text>
<text top="350" left="361" width="167" height="20" font="1">Angina, significant pulmonary, </text>
<text top="367" left="361" width="171" height="20" font="1">hepatic, renal and hematologic </text>
<text top="384" left="361" width="172" height="20" font="1">disease., unable to walk on the </text>
<text top="402" left="361" width="143" height="20" font="1">treadmill, noncompliance  </text>
<text top="195" left="557" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="212" left="557" width="101" height="20" font="1">Dilitiazem 240 mg </text>
<text top="229" left="557" width="42" height="20" font="1">(1,234) </text>
<text top="247" left="557" width="3" height="20" font="4"><b> </b></text>
<text top="264" left="557" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="281" left="557" width="42" height="20" font="1">(1,232) </text>
<text top="196" left="698" width="152" height="20" font="4"><b>1</b>°<b> endpoint and results:   </b></text>
<text top="215" left="698" width="7" height="18" font="1">•</text>
<text top="215" left="705" width="110" height="20" font="4"><b> </b>HF-worsening: 9 in<b> </b></text>
<text top="232" left="698" width="168" height="20" font="1">Nifedipine group vs. 3 in ISDN </text>
<text top="249" left="698" width="112" height="20" font="1">group (p&lt;0.09); and </text>
<text top="266" left="698" width="154" height="20" font="1">21 in nifedipine-ISDN group </text>
<text top="283" left="698" width="131" height="20" font="1">(p&lt;0.001 vs. nifedipine, </text>
<text top="301" left="698" width="111" height="20" font="1">p&lt;0.0001 vs. ISDN) </text>
<text top="320" left="698" width="7" height="18" font="1">•</text>
<text top="319" left="705" width="118" height="20" font="4"><b> </b>Clinical deterioration </text>
<text top="336" left="698" width="89" height="20" font="1">discontinuation: </text>
<text top="353" left="698" width="138" height="20" font="1">Nifedipine 29% vs. ISDN </text>
<text top="371" left="698" width="106" height="20" font="1">group 5% (p&lt;0.05) </text>
<text top="390" left="698" width="7" height="18" font="1">•</text>
<text top="389" left="705" width="141" height="20" font="4"><b> </b>DBP: Nifedipine alone or </text>
<text top="406" left="698" width="128" height="20" font="1">combination with ISDN </text>
<text top="423" left="698" width="107" height="20" font="1">(reduction, p&lt;0.05) </text>
<text top="441" left="698" width="3" height="20" font="1"> </text>
<text top="458" left="698" width="160" height="20" font="4"><b>Follow-up Results: </b>Pts with </text>
<text top="475" left="698" width="137" height="20" font="1">BL EF&lt;0.40, late CHF in </text>
<text top="492" left="698" width="140" height="20" font="1">Dilitizam group (21%) vs. </text>
<text top="510" left="698" width="139" height="20" font="1">Placebo (12%) p=0.004.  </text>
<text top="197" left="881" width="7" height="18" font="1">•</text>
<text top="196" left="888" width="162" height="20" font="4"><b> </b>Life table analysis confirmed </text>
<text top="213" left="881" width="193" height="20" font="1">increased frequency of late CHF in </text>
<text top="231" left="881" width="174" height="20" font="1">pts taking dilitiazem (p=0.0017)<b> </b></text>
<text top="250" left="881" width="7" height="18" font="1">•</text>
<text top="249" left="888" width="193" height="20" font="4"><b> </b>Dilitiazem related CHF exclusively </text>
<text top="266" left="881" width="198" height="20" font="1">associated with systolic LVD with or </text>
<text top="283" left="881" width="72" height="20" font="1">without BB s </text>
<text top="527" left="98" width="88" height="20" font="1">Cohn JN, et al., </text>
<text top="545" left="98" width="63" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(152)</a> </text>
<text top="562" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11759645?dopt=Citation">11759645</a></text>
<text top="562" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11759645?dopt=Citation"> </a></text>
<text top="527" left="219" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="545" left="219" width="120" height="20" font="1">effect of valsartan vs. </text>
<text top="562" left="219" width="113" height="20" font="1">placebo on mortality </text>
<text top="579" left="219" width="112" height="20" font="1">plus morbidity in pts </text>
<text top="596" left="219" width="65" height="20" font="1">with HF<i>r</i>EF </text>
<text top="527" left="361" width="163" height="20" font="4"><b>Inclusion criteria: </b>5,010 pts, </text>
<text top="545" left="361" width="182" height="20" font="1">mean age 63 y, with NYHA class </text>
<text top="562" left="361" width="69" height="20" font="1">II-IV HF<i>r</i>EF  </text>
<text top="527" left="557" width="121" height="20" font="4"><b>Intervention/Compar</b></text>
<text top="545" left="557" width="102" height="20" font="4"><b>ator: </b>5,010 pts on </text>
<text top="562" left="557" width="114" height="20" font="1">standard therapy for </text>
<text top="579" left="557" width="118" height="20" font="1">HF were randomized </text>
<text top="596" left="557" width="128" height="20" font="1">to valsartan or placebo </text>
<text top="529" left="698" width="152" height="20" font="4"><b>1</b>°<b> endpoint and results:   </b></text>
<text top="548" left="698" width="7" height="18" font="1">•</text>
<text top="547" left="705" width="113" height="20" font="4"><b> </b>At 23-mo follow-up, </text>
<text top="564" left="698" width="147" height="20" font="1">mortality was similar in pts </text>
<text top="581" left="698" width="135" height="20" font="1">treated with valsartan or </text>
<text top="599" left="698" width="46" height="20" font="1">placebo </text>
<text top="618" left="698" width="7" height="18" font="1">•</text>
<text top="617" left="705" width="149" height="20" font="4"><b> </b>The combined endpoint of </text>
<text top="634" left="698" width="154" height="20" font="1">mortality plus morbidity was </text>
<text top="651" left="698" width="159" height="20" font="1">reduced 13.2% (p=0.009) by </text>
<text top="669" left="698" width="160" height="20" font="1">valsartan because of a lower </text>
<text top="686" left="698" width="157" height="20" font="1">rate of HF hospitalization for </text>
<text top="703" left="698" width="123" height="20" font="1">HF (13.8% vs. 18.2%; </text>
<text top="720" left="698" width="52" height="20" font="1">p&lt;0.001) </text>
<text top="529" left="881" width="7" height="18" font="1">•</text>
<text top="529" left="887" width="202" height="20" font="1"> Treatment with valsartan resulted in </text>
<text top="546" left="881" width="204" height="20" font="1">improvements in NYHA class, LVEF, </text>
<text top="563" left="881" width="176" height="20" font="1">signs and symptoms of HF, and </text>
<text top="580" left="881" width="202" height="20" font="1">quality of life compared with placebo </text>
<text top="597" left="881" width="53" height="20" font="1">(p&lt;0.01). </text>
<text top="738" left="98" width="45" height="20" font="1">SOLVD </text>
<text top="755" left="98" width="107" height="20" font="1">Investigators, 1991 </text>
<text top="773" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(153)</a> </text>
<text top="790" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2057034?dopt=Citation">2057034</a></text>
<text top="790" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2057034?dopt=Citation"> </a></text>
<text top="738" left="219" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="755" left="219" width="116" height="20" font="1">effect of enalapril vs. </text>
<text top="773" left="219" width="113" height="20" font="1">placebo on mortality </text>
<text top="790" left="219" width="117" height="20" font="1">and on mortality plus </text>
<text top="738" left="361" width="163" height="20" font="4"><b>Inclusion criteria: </b>2,569 pts, </text>
<text top="755" left="361" width="153" height="20" font="1">mean age 61 y, with HF<i>r</i>EF </text>
<text top="773" left="361" width="174" height="20" font="1">(90% with NYHA class II and III </text>
<text top="790" left="361" width="24" height="20" font="1">HF) </text>
<text top="738" left="557" width="121" height="20" font="4"><b>Intervention/Compar</b></text>
<text top="755" left="557" width="102" height="20" font="4"><b>ator: </b>2,569 pts on </text>
<text top="773" left="557" width="114" height="20" font="1">standard therapy for </text>
<text top="739" left="698" width="160" height="20" font="4"><b>1</b>°<b> endpoint and results: </b>At </text>
<text top="757" left="698" width="163" height="20" font="1">41.4-mo follow-up, compared </text>
<text top="774" left="698" width="125" height="20" font="1">with placebo, enalapril </text>
<text top="740" left="881" width="7" height="18" font="1">•</text>
<text top="739" left="887" width="181" height="20" font="1"> At 41.4-mo follow-up, compared </text>
<text top="757" left="881" width="173" height="20" font="1">with placebo, enalapril reduced </text>
<text top="774" left="881" width="158" height="20" font="1">mortality by 16% (p=0.0036) </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">116 </text>
<text top="107" left="219" width="119" height="20" font="1">hospitalization for HF </text>
<text top="124" left="219" width="98" height="20" font="1">in pts with HF<i>r</i>EF </text>
<text top="107" left="557" width="118" height="20" font="1">HF were randomized </text>
<text top="124" left="557" width="124" height="20" font="1">to enalapril or placebo </text>
<text top="107" left="698" width="112" height="20" font="1">reduced mortality or </text>
<text top="124" left="698" width="158" height="20" font="1">hospitalization for worsening </text>
<text top="141" left="698" width="128" height="20" font="1">HF by 26% (p&lt;0.0001) </text>
<text top="159" left="98" width="63" height="20" font="1">1993 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(154)</a> </text>
<text top="177" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8104270?dopt=Citation">8104270</a></text>
<text top="177" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8104270?dopt=Citation"> </a></text>
<text top="159" left="219" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="177" left="219" width="110" height="20" font="1">effect of ramipril vs. </text>
<text top="194" left="219" width="126" height="20" font="1">placebo on mortality in </text>
<text top="211" left="219" width="85" height="20" font="1">pts with HF<i>r</i>EF </text>
<text top="159" left="361" width="163" height="20" font="4"><b>Inclusion criteria: </b>2,006 pts, </text>
<text top="177" left="361" width="181" height="20" font="1">mean age 65 y, with HF<i>r</i>EF after </text>
<text top="194" left="361" width="179" height="20" font="1">MI and without NYHA class0HF  </text>
<text top="159" left="557" width="121" height="20" font="4"><b>Intervention/Compar</b></text>
<text top="177" left="557" width="115" height="20" font="4"><b>ator: </b>2,006 pts were </text>
<text top="194" left="557" width="125" height="20" font="1">randomized to ramipril </text>
<text top="211" left="557" width="61" height="20" font="1">or placebo </text>
<text top="161" left="698" width="160" height="20" font="4"><b>1</b>°<b> endpoint and results: </b>At </text>
<text top="178" left="698" width="128" height="20" font="1">15-mo mean follow-up, </text>
<text top="195" left="698" width="133" height="20" font="1">compared with placebo, </text>
<text top="212" left="698" width="144" height="20" font="1">ramipril reduced all-cause </text>
<text top="229" left="698" width="134" height="20" font="1">mortality 27% (p=0.002) </text>
<text top="161" left="881" width="7" height="18" font="1">•</text>
<text top="161" left="887" width="151" height="20" font="1"> Analysis of prespecified 2º </text>
<text top="178" left="881" width="170" height="20" font="1">outcomes showed that ramipril </text>
<text top="195" left="881" width="195" height="20" font="1">reduced the first validated outcome </text>
<text top="212" left="881" width="190" height="20" font="1">(death, severe/resistant HF, MI, or </text>
<text top="229" left="881" width="145" height="20" font="1">stroke) by 19% (p=0.008). </text>
<text top="247" left="98" width="80" height="20" font="1">Garg R, et al., </text>
<text top="265" left="98" width="63" height="20" font="1">1995 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(155)</a> </text>
<text top="282" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7654275?dopt=Citation">7654275</a></text>
<text top="282" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7654275?dopt=Citation"> </a></text>
<text top="247" left="219" width="122" height="20" font="4"><b>Aim: </b>A meta-analysis </text>
<text top="265" left="219" width="98" height="20" font="1">was performed to </text>
<text top="282" left="219" width="126" height="20" font="1">determine the effect of </text>
<text top="299" left="219" width="121" height="20" font="1">ACEIs vs. placebo on </text>
<text top="316" left="219" width="91" height="20" font="1">mortality and on </text>
<text top="334" left="219" width="76" height="20" font="1">mortality plus </text>
<text top="351" left="219" width="119" height="20" font="1">hospitalization for HF </text>
<text top="368" left="219" width="98" height="20" font="1">in pts with HF<i>r</i>EF </text>
<text top="247" left="361" width="162" height="20" font="4"><b>Inclusion criteria: </b>The meta-</text>
<text top="265" left="361" width="157" height="20" font="1">analysis included 32 trials of </text>
<text top="282" left="361" width="161" height="20" font="1">7,105 pts with HF<i>r</i>EF treated </text>
<text top="299" left="361" width="129" height="20" font="1">with ACEIs vs. placebo </text>
<text top="247" left="557" width="121" height="20" font="4"><b>Intervention/Compar</b></text>
<text top="265" left="557" width="114" height="20" font="4"><b>ator: </b>In 25 trials, pts </text>
<text top="282" left="557" width="97" height="20" font="1">were treated with </text>
<text top="299" left="557" width="81" height="20" font="1">digoxin and/or </text>
<text top="316" left="557" width="118" height="20" font="1">diuretics, 4 trials only </text>
<text top="334" left="557" width="116" height="20" font="1">used diuretics, 1 trial </text>
<text top="351" left="557" width="126" height="20" font="1">used only digoxin, and </text>
<text top="368" left="557" width="87" height="20" font="1">2 trials used no </text>
<text top="385" left="557" width="112" height="20" font="1">background therapy </text>
<text top="249" left="698" width="145" height="20" font="4"><b>1</b>°<b> endpoint and results: </b></text>
<text top="266" left="698" width="136" height="20" font="1">Compared with placebo, </text>
<text top="283" left="698" width="139" height="20" font="1">ACEIs reduced all-cause </text>
<text top="300" left="698" width="158" height="20" font="1">mortality 23% (p&lt;0.001) and </text>
<text top="318" left="698" width="117" height="20" font="1">all-cause mortality or </text>
<text top="335" left="698" width="147" height="20" font="1">hospitalization for HF 35% </text>
<text top="352" left="698" width="60" height="20" font="1">(p&lt;0.001). </text>
<text top="249" left="881" width="7" height="18" font="1">•</text>
<text top="249" left="887" width="170" height="20" font="1"> The reduction in mortality was </text>
<text top="266" left="881" width="197" height="20" font="1">primarily due to a 31% (17%–42%)  </text>
<text top="283" left="881" width="196" height="20" font="1">reduction in death from progressive </text>
<text top="300" left="881" width="23" height="20" font="1">HF. </text>
<text top="403" left="98" width="98" height="20" font="1">Pfeffer MA, et al., </text>
<text top="420" left="98" width="63" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(156)</a> </text>
<text top="438" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14610160?dopt=Citation">14610160</a></text>
<text top="438" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14610160?dopt=Citation"> </a></text>
<text top="403" left="219" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="420" left="219" width="104" height="20" font="1">effect of valsartan, </text>
<text top="438" left="219" width="112" height="20" font="1">captopril, or both on </text>
<text top="455" left="219" width="125" height="20" font="1">mortality in pts with MI </text>
<text top="472" left="219" width="127" height="20" font="1">complicated by HF, LV </text>
<text top="489" left="219" width="111" height="20" font="1">dysfunction, or both </text>
<text top="403" left="361" width="170" height="20" font="4"><b>Inclusion criteria:</b> 14,703 pts, </text>
<text top="420" left="361" width="131" height="20" font="1">mean age 65 y, with MI </text>
<text top="438" left="361" width="127" height="20" font="1">complicated by HF, LV </text>
<text top="455" left="361" width="111" height="20" font="1">dysfunction, or both </text>
<text top="403" left="557" width="112" height="20" font="4"><b>Intervention:</b> 4,909 </text>
<text top="420" left="557" width="118" height="20" font="1">pts were randomized </text>
<text top="438" left="557" width="124" height="20" font="1">to valsartan, 4,909 pts </text>
<text top="455" left="557" width="111" height="20" font="1">were randomized to </text>
<text top="472" left="557" width="50" height="20" font="1">captopril </text>
<text top="489" left="557" width="3" height="20" font="1"> </text>
<text top="506" left="557" width="111" height="20" font="4"><b>Comparator: </b>4,885 </text>
<text top="524" left="557" width="118" height="20" font="1">pts were randomized </text>
<text top="541" left="557" width="93" height="20" font="1">to valsartan plus </text>
<text top="558" left="557" width="53" height="20" font="1">captopril.<b> </b></text>
<text top="404" left="698" width="160" height="20" font="4"><b>1</b>°<b> endpoint and results: </b>At </text>
<text top="421" left="698" width="148" height="20" font="1">24.7-mo median follow-up, </text>
<text top="439" left="698" width="158" height="20" font="1">mortality was similar in the 3 </text>
<text top="456" left="698" width="100" height="20" font="1">treatment groups. </text>
<text top="405" left="881" width="7" height="18" font="1">•</text>
<text top="404" left="887" width="184" height="20" font="1"> The incidence of adverse events </text>
<text top="421" left="881" width="198" height="20" font="1">causing discontinuation of drug was </text>
<text top="439" left="881" width="170" height="20" font="1">5.8% with valsartan, 7.7% with </text>
<text top="456" left="881" width="191" height="20" font="1">captopril, and 9.0 % with valsartan </text>
<text top="473" left="881" width="182" height="20" font="1">plus captopril (p&lt;0.05 comparing </text>
<text top="490" left="881" width="206" height="20" font="1">valsartan with captopril and valsartan </text>
<text top="508" left="881" width="159" height="20" font="1">plus captopril with captopril). </text>
<text top="576" left="98" width="90" height="20" font="1">Maggioni AP, et </text>
<text top="593" left="98" width="83" height="20" font="1">al., 2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(157)</a> </text>
<text top="610" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12392830?dopt=Citation">12392830</a></text>
<text top="610" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12392830?dopt=Citation"> </a></text>
<text top="576" left="219" width="97" height="20" font="4"><b>Aim: </b>A subgroup </text>
<text top="593" left="219" width="104" height="20" font="1">analysis of the Val-</text>
<text top="610" left="219" width="92" height="20" font="1">HeFT study was </text>
<text top="628" left="219" width="73" height="20" font="1">performed to </text>
<text top="645" left="219" width="126" height="20" font="1">determine the effect of </text>
<text top="662" left="219" width="119" height="20" font="1">valsartan vs. placebo </text>
<text top="679" left="219" width="111" height="20" font="1">on mortality  and on </text>
<text top="696" left="219" width="76" height="20" font="1">mortality plus </text>
<text top="714" left="219" width="111" height="20" font="1">morbidity in pts with </text>
<text top="731" left="219" width="113" height="20" font="1">HF<i>r</i>EF not receiving </text>
<text top="748" left="219" width="38" height="20" font="1">ACEIs </text>
<text top="576" left="361" width="153" height="20" font="4"><b>Inclusion criteria:</b> 366 pts, </text>
<text top="593" left="361" width="173" height="20" font="1">mean age 67 y, with HF<i>r</i>EF not </text>
<text top="610" left="361" width="91" height="20" font="1">receiving ACEIs </text>
<text top="576" left="557" width="121" height="20" font="4"><b>Intervention/Compar</b></text>
<text top="593" left="557" width="105" height="20" font="4"><b>ator:</b> 185 pts were </text>
<text top="610" left="557" width="81" height="20" font="1">randomized to </text>
<text top="628" left="557" width="121" height="20" font="1">valsartan and 181 pts </text>
<text top="645" left="557" width="111" height="20" font="1">were randomized to </text>
<text top="662" left="557" width="46" height="20" font="1">placebo </text>
<text top="577" left="698" width="145" height="20" font="4"><b>1</b>°<b> endpoint and results: </b></text>
<text top="594" left="698" width="136" height="20" font="1">Compared with placebo, </text>
<text top="611" left="698" width="151" height="20" font="1">valsartan reduced mortality </text>
<text top="629" left="698" width="158" height="20" font="1">33% (p=0.017) and mortality </text>
<text top="646" left="698" width="167" height="20" font="1">plus morbidity 44% (p&lt;0.001). </text>
<text top="578" left="881" width="7" height="18" font="1">•</text>
<text top="577" left="887" width="193" height="20" font="1"> Compared with placebo, valsartan </text>
<text top="594" left="881" width="194" height="20" font="1">reduced first hospital admission for </text>
<text top="611" left="881" width="114" height="20" font="1">HF 53% (p=0.0006). </text>
</page>
<page number="117" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">117 </text>
<text top="107" left="98" width="106" height="20" font="1">Granger CB, et al., </text>
<text top="124" left="98" width="63" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(158)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13678870?dopt=Citation">13678870</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13678870?dopt=Citation"> </a></text>
<text top="107" left="219" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="124" left="219" width="118" height="20" font="1">effect of candesartan </text>
<text top="141" left="219" width="83" height="20" font="1">vs. placebo on </text>
<text top="159" left="219" width="108" height="20" font="1">mortality in pts with </text>
<text top="176" left="219" width="107" height="20" font="1">HF<i>r</i>EF intolerant to </text>
<text top="193" left="219" width="38" height="20" font="1">ACEIs </text>
<text top="107" left="361" width="163" height="20" font="4"><b>Inclusion criteria:</b> 2,028 pts, </text>
<text top="124" left="361" width="153" height="20" font="1">mean age 67 y, with HF<i>r</i>EF </text>
<text top="141" left="361" width="106" height="20" font="1">intolerant to ACEIs </text>
<text top="107" left="557" width="121" height="20" font="4"><b>Intervention/Compar</b></text>
<text top="124" left="557" width="115" height="20" font="4"><b>ator:</b> 1,013 pts were </text>
<text top="141" left="557" width="81" height="20" font="1">randomized to </text>
<text top="159" left="557" width="95" height="20" font="1">candesartan and </text>
<text top="176" left="557" width="84" height="20" font="1">1,015 pts were </text>
<text top="193" left="557" width="128" height="20" font="1">randomized to placebo </text>
<text top="108" left="698" width="160" height="20" font="4"><b>1</b>°<b> endpoint and results: </b>At </text>
<text top="125" left="698" width="148" height="20" font="1">33.7-mo median follow-up, </text>
<text top="143" left="698" width="154" height="20" font="1">compared with placebo, the </text>
<text top="160" left="698" width="150" height="20" font="1">1° endpoint of CV death or </text>
<text top="177" left="698" width="167" height="20" font="1">hospital admission for HF was </text>
<text top="194" left="698" width="163" height="20" font="1">reduced 30% by candesartan </text>
<text top="211" left="698" width="67" height="20" font="1">(p&lt;0.0001). </text>
<text top="109" left="881" width="7" height="18" font="1">•</text>
<text top="108" left="887" width="139" height="20" font="1"> Compared with placebo, </text>
<text top="125" left="881" width="177" height="20" font="1">candesartan reduced CV death, </text>
<text top="143" left="881" width="206" height="20" font="1">hospital admission for HF, MI, stroke, </text>
<text top="160" left="881" width="189" height="20" font="1">or coronary revascularization 24% </text>
<text top="177" left="881" width="70" height="20" font="1">(p&lt;0.0001).  </text>
<text top="229" left="98" width="100" height="20" font="1">Pitt B, et al., 2003 </text>
<text top="247" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(159)</a> </text>
<text top="264" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12668699?dopt=Citation">12668699</a></text>
<text top="264" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12668699?dopt=Citation"> </a></text>
<text top="229" left="219" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="247" left="219" width="112" height="20" font="1">effect of eplerenone </text>
<text top="264" left="219" width="83" height="20" font="1">vs. placebo on </text>
<text top="281" left="219" width="111" height="20" font="1">mortality and on CV </text>
<text top="298" left="219" width="49" height="20" font="1">death or </text>
<text top="316" left="219" width="120" height="20" font="1">hospitalization for CV </text>
<text top="333" left="219" width="115" height="20" font="1">events in pts with MI </text>
<text top="350" left="219" width="125" height="20" font="1">complicated by HF<i>r</i>EF </text>
<text top="229" left="361" width="163" height="20" font="4"><b>Inclusion criteria:</b> 6,632 pts, </text>
<text top="247" left="361" width="181" height="20" font="1">mean age 64 y, with HF<i>r</i>EF after </text>
<text top="264" left="361" width="17" height="20" font="1">MI </text>
<text top="229" left="557" width="121" height="20" font="4"><b>Intervention/Compar</b></text>
<text top="247" left="557" width="115" height="20" font="4"><b>ator:</b> 3,313 pts were </text>
<text top="264" left="557" width="81" height="20" font="1">randomized to </text>
<text top="281" left="557" width="123" height="20" font="1">eplerenone and 3,319 </text>
<text top="298" left="557" width="118" height="20" font="1">pts were randomized </text>
<text top="316" left="557" width="60" height="20" font="1">to placebo </text>
<text top="231" left="698" width="160" height="20" font="4"><b>1</b>°<b> endpoint and results:</b> At </text>
<text top="248" left="698" width="128" height="20" font="1">16-mo mean follow-up, </text>
<text top="265" left="698" width="163" height="20" font="1">eplerenone reduced mortality </text>
<text top="282" left="698" width="163" height="20" font="1">15% (p=0.008) and CV death </text>
<text top="300" left="698" width="134" height="20" font="1">or hospitalization for CV </text>
<text top="317" left="698" width="128" height="20" font="1">events 17% (p=0.005). </text>
<text top="231" left="881" width="7" height="18" font="1">•</text>
<text top="231" left="887" width="139" height="20" font="1"> Compared with placebo, </text>
<text top="248" left="881" width="198" height="20" font="1">eplerenone reduced death from any </text>
<text top="265" left="881" width="176" height="20" font="1">cause or any hospitalization 8% </text>
<text top="282" left="881" width="195" height="20" font="1">(p=0.02) and sudden cardiac death </text>
<text top="300" left="881" width="201" height="20" font="1">21% (p=0.03), reduced hypokalemia </text>
<text top="317" left="881" width="195" height="20" font="1">from 13.1% to 8.4% (p&lt;0.001), and </text>
<text top="334" left="881" width="204" height="20" font="1">increased serious hyperkalemia from </text>
<text top="351" left="881" width="130" height="20" font="1">3.9%–5.5% (p=0.002).  </text>
<text top="369" left="98" width="93" height="20" font="1">Taylor AL, et al., </text>
<text top="386" left="98" width="63" height="20" font="1">2004 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(160)</a> </text>
<text top="404" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15533851?dopt=Citation">15533851</a></text>
<text top="404" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15533851?dopt=Citation"> </a></text>
<text top="369" left="219" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="386" left="219" width="106" height="20" font="1">effect of ISDN plus </text>
<text top="404" left="219" width="85" height="20" font="1">hydralazine vs. </text>
<text top="421" left="219" width="117" height="20" font="1">placebo on mortality, </text>
<text top="438" left="219" width="122" height="20" font="1">first hospitalization for </text>
<text top="455" left="219" width="104" height="20" font="1">HF, and change in </text>
<text top="472" left="219" width="117" height="20" font="1">quality of life in black </text>
<text top="490" left="219" width="88" height="20" font="1">pts with HF<i>r</i>EF  </text>
<text top="369" left="361" width="182" height="20" font="4"><b>Inclusion criteria:</b> 1,050 African </text>
<text top="386" left="361" width="167" height="20" font="1">American pts, mean age 57 y, </text>
<text top="404" left="361" width="171" height="20" font="1">with HF<i>r</i>EF and NYHA class III </text>
<text top="421" left="361" width="53" height="20" font="1">or IV HF. </text>
<text top="369" left="557" width="121" height="20" font="4"><b>Intervention/Compar</b></text>
<text top="386" left="557" width="105" height="20" font="4"><b>ator:</b> 518 pts were </text>
<text top="404" left="557" width="114" height="20" font="1">randomized to ISDN </text>
<text top="421" left="557" width="116" height="20" font="1">plus hydralazine and </text>
<text top="438" left="557" width="74" height="20" font="1">532 pts were </text>
<text top="455" left="557" width="128" height="20" font="1">randomized to placebo </text>
<text top="370" left="698" width="160" height="20" font="4"><b>1</b>°<b> endpoint and results:</b> At </text>
<text top="387" left="698" width="128" height="20" font="1">10-mo mean follow-up, </text>
<text top="405" left="698" width="154" height="20" font="1">compared with placebo, the </text>
<text top="422" left="698" width="168" height="20" font="1">mean 1° endpoint of mortality, </text>
<text top="439" left="698" width="145" height="20" font="1">first hospitalization for HF, </text>
<text top="456" left="698" width="152" height="20" font="1">and change in quality of life </text>
<text top="474" left="698" width="148" height="20" font="1">was reduced by ISDN plus </text>
<text top="491" left="698" width="119" height="20" font="1">hydralazine (p=0.01). </text>
<text top="371" left="881" width="7" height="18" font="1">•</text>
<text top="370" left="887" width="198" height="20" font="1"> Compared with placebo, ISDN plus </text>
<text top="387" left="881" width="192" height="20" font="1">hydralazine reduced mortality from </text>
<text top="405" left="881" width="168" height="20" font="1">10.2%–6.2% (p=0.02) causing </text>
<text top="422" left="881" width="126" height="20" font="1">cessation of the study. </text>
<text top="441" left="881" width="7" height="18" font="1">•</text>
<text top="440" left="887" width="198" height="20" font="1"> Compared with placebo, ISDN plus </text>
<text top="457" left="881" width="167" height="20" font="1">hydralazine reduced all-cause </text>
<text top="475" left="881" width="204" height="20" font="1">mortality 43% (first hospitalization for </text>
<text top="492" left="881" width="186" height="20" font="1">HF 33% (p=0.001), and improved </text>
<text top="509" left="881" width="125" height="20" font="1">quality of life (p=0.02). </text>
<text top="527" left="98" width="88" height="20" font="1">The Multicenter </text>
<text top="544" left="98" width="57" height="20" font="1">Dilitiazem </text>
<text top="561" left="98" width="78" height="20" font="1">Postinfarction </text>
<text top="579" left="98" width="100" height="20" font="1">Research Group,  </text>
<text top="596" left="98" width="63" height="20" font="1">1988 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#271">(145)</a> </text>
<text top="613" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2899840?dopt=Citation">2899840</a></text>
<text top="613" left="145" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2899840?dopt=Citation"><b> </b></a></text>
<text top="527" left="219" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="544" left="219" width="105" height="20" font="1">dilitiazem effect on </text>
<text top="561" left="219" width="106" height="20" font="1">recurrent infarction </text>
<text top="579" left="219" width="120" height="20" font="1">and death after acute </text>
<text top="596" left="219" width="17" height="20" font="1">MI </text>
<text top="613" left="219" width="3" height="20" font="1"> </text>
<text top="630" left="219" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="647" left="219" width="3" height="20" font="1"> </text>
<text top="665" left="219" width="86" height="20" font="4"><b>Size: </b>2,466 pts </text>
<text top="682" left="219" width="3" height="20" font="1"> </text>
<text top="527" left="361" width="153" height="20" font="4"><b>Inclusion criteria: </b>25–75 y </text>
<text top="544" left="361" width="140" height="20" font="1">admitted to CCU, MI with </text>
<text top="561" left="361" width="120" height="20" font="1">enzyme confirmation. </text>
<text top="579" left="361" width="7" height="20" font="1">  </text>
<text top="596" left="361" width="179" height="20" font="4"><b>Exclusion criteria: </b>Cardiogenic </text>
<text top="613" left="361" width="111" height="20" font="1">shock, symptomatic </text>
<text top="630" left="361" width="169" height="20" font="1">hypotension, PH with right HF, </text>
<text top="647" left="361" width="175" height="20" font="1">2nd/3rd degree heart block, HR </text>
<text top="665" left="361" width="176" height="20" font="1">&lt;50 bpm, contraceptives, WPW </text>
<text top="682" left="361" width="140" height="20" font="1">syndrome, CCBs, severe </text>
<text top="699" left="361" width="178" height="20" font="1">comorbidities or cardiac surgery </text>
<text top="527" left="557" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="544" left="557" width="101" height="20" font="1">Dilitiazem 240 mg </text>
<text top="561" left="557" width="42" height="20" font="1">(1,234) </text>
<text top="579" left="557" width="3" height="20" font="4"><b> </b></text>
<text top="596" left="557" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="613" left="557" width="42" height="20" font="1">(1,232) </text>
<text top="528" left="698" width="158" height="20" font="4"><b>1</b>°<b> endpoints and results:   </b></text>
<text top="547" left="698" width="7" height="18" font="1">•</text>
<text top="547" left="705" width="149" height="20" font="1"> Total mortality: identical in </text>
<text top="564" left="698" width="68" height="20" font="1">both groups </text>
<text top="583" left="698" width="7" height="18" font="1">•</text>
<text top="582" left="705" width="154" height="20" font="1"> Cardiac death and nonfatal </text>
<text top="599" left="698" width="150" height="20" font="1">MI: 11% fewer in dilitiazem </text>
<text top="617" left="698" width="124" height="20" font="1">but difference was NS </text>
<text top="529" left="881" width="7" height="18" font="1">•</text>
<text top="528" left="887" width="203" height="20" font="1"> No combined benefit from dilitiazem </text>
<text top="545" left="881" width="164" height="20" font="1">on mortality or cardiac events </text>
<text top="717" left="98" width="72" height="20" font="4"><b>ONTARGET </b></text>
<text top="734" left="98" width="90" height="20" font="1">Investigators, et </text>
<text top="751" left="98" width="83" height="20" font="1">al., 2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(126)</a> </text>
<text top="769" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18378520">18378520</a></text>
<text top="769" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18378520"> </a></text>
<text top="717" left="219" width="82" height="20" font="4"><b>Aim:</b> Evaluate </text>
<text top="734" left="219" width="101" height="20" font="1">whether use of an </text>
<text top="751" left="219" width="115" height="20" font="1">ARB was noninferior </text>
<text top="769" left="219" width="120" height="20" font="1">to ACEI, and whether </text>
<text top="786" left="219" width="115" height="20" font="1">the combination was </text>
<text top="717" left="361" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="736" left="361" width="7" height="18" font="1">•</text>
<text top="735" left="368" width="42" height="20" font="1"> ≥55 y  </text>
<text top="754" left="361" width="7" height="18" font="1">•</text>
<text top="754" left="368" width="137" height="20" font="1"> Coronary, peripheral, or </text>
<text top="771" left="361" width="174" height="20" font="1">cerebrovascular disease or DM </text>
<text top="717" left="557" width="127" height="20" font="4"><b>Intervention:</b> Ramipril </text>
<text top="734" left="557" width="123" height="20" font="1">10 mg daily (n=8,576) </text>
<text top="751" left="557" width="3" height="20" font="1"> </text>
<text top="769" left="557" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="718" left="698" width="159" height="20" font="4"><b>1</b>°<b> endpoint:</b> After a median </text>
<text top="735" left="698" width="164" height="20" font="1">follow-up of 56 mo, there was </text>
<text top="753" left="698" width="168" height="20" font="1">no difference between ramipril </text>
<text top="770" left="698" width="167" height="20" font="1">vs. telmisartan or combination </text>
<text top="787" left="698" width="157" height="20" font="1">therapy vs. ramipril in the 1° </text>
<text top="719" left="881" width="7" height="18" font="1">•</text>
<text top="718" left="887" width="169" height="20" font="1"> Telmisartan was equivalent to </text>
<text top="735" left="881" width="211" height="20" font="1">ramipril in pts with vascular disease or </text>
<text top="753" left="881" width="209" height="20" font="1">high-risk DM and was associated with </text>
<text top="770" left="881" width="208" height="20" font="1">less angioedema. The combination of </text>
<text top="787" left="881" width="210" height="20" font="1">the 2 drugs was associated with more </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">118 </text>
<text top="107" left="219" width="124" height="20" font="1">superior to ACE alone </text>
<text top="124" left="219" width="108" height="20" font="1">in the prevention of </text>
<text top="141" left="219" width="121" height="20" font="1">vascular events in pts </text>
<text top="159" left="219" width="112" height="20" font="1">with CVD or DM but </text>
<text top="176" left="219" width="44" height="20" font="1">not HF. </text>
<text top="193" left="219" width="3" height="20" font="1"> </text>
<text top="210" left="219" width="101" height="20" font="4"><b>Study type:</b> Multi-</text>
<text top="227" left="219" width="115" height="20" font="1">center, double-blind, </text>
<text top="245" left="219" width="29" height="20" font="1">RCT </text>
<text top="262" left="219" width="3" height="20" font="1"> </text>
<text top="279" left="219" width="93" height="20" font="4"><b>Size:</b> 25,620 pts </text>
<text top="107" left="361" width="133" height="20" font="1">with end-organ damage </text>
<text top="124" left="361" width="3" height="20" font="1"> </text>
<text top="141" left="361" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="160" left="361" width="7" height="18" font="1">•</text>
<text top="160" left="368" width="174" height="20" font="1"> Inability to discontinue ACEI or </text>
<text top="177" left="361" width="29" height="20" font="1">ARB </text>
<text top="196" left="361" width="7" height="18" font="1">•</text>
<text top="195" left="368" width="146" height="20" font="1"> Known hypersensitivity or </text>
<text top="213" left="361" width="152" height="20" font="1">intolerance to ACEI or ARB </text>
<text top="232" left="361" width="7" height="18" font="1">•</text>
<text top="231" left="368" width="156" height="20" font="1"> Selected CVDs (congestive </text>
<text top="248" left="361" width="180" height="20" font="1">HF, hemodynamically significant </text>
<text top="265" left="361" width="130" height="20" font="1">valvular or outflow tract </text>
<text top="283" left="361" width="132" height="20" font="1">obstruction, constrictive </text>
<text top="300" left="361" width="175" height="20" font="1">pericarditis, complex congenital </text>
<text top="317" left="361" width="132" height="20" font="1">heart disease, syncopal </text>
<text top="334" left="361" width="182" height="20" font="1">episodes of unknown etiology &lt;3 </text>
<text top="352" left="361" width="173" height="20" font="1">mo, planned cardiac surgery or </text>
<text top="369" left="361" width="177" height="20" font="1">PTCA &lt;3 mo, uncontrolled HTN </text>
<text top="386" left="361" width="178" height="20" font="1">on treatment [e.g., BP &gt;160/100 </text>
<text top="403" left="361" width="139" height="20" font="1">mm Hg], heart transplant </text>
<text top="420" left="361" width="128" height="20" font="1">recipient, stroke due to </text>
<text top="438" left="361" width="151" height="20" font="1">subarachnoid hemorrhage) </text>
<text top="457" left="361" width="7" height="18" font="1">•</text>
<text top="456" left="368" width="159" height="20" font="1"> Other conditions (significant </text>
<text top="473" left="361" width="158" height="20" font="1">renal artery disease, hepatic </text>
<text top="490" left="361" width="180" height="20" font="1">dysfunction, uncorrected volume </text>
<text top="508" left="361" width="130" height="20" font="1">or sodium depletion, 1° </text>
<text top="525" left="361" width="172" height="20" font="1">hyperaldosteronism, hereditary </text>
<text top="542" left="361" width="180" height="20" font="1">fructose intolerance, other major </text>
<text top="559" left="361" width="182" height="20" font="1">noncardiac illness or expected to </text>
<text top="576" left="361" width="140" height="20" font="1">reduce life expectancy or </text>
<text top="594" left="361" width="182" height="20" font="1">significant disability interfere with </text>
<text top="611" left="361" width="106" height="20" font="1">study participation, </text>
<text top="628" left="361" width="166" height="20" font="1">simultaneously taking another </text>
<text top="645" left="361" width="159" height="20" font="1">experimental drug, unable to </text>
<text top="663" left="361" width="135" height="20" font="1">provide written informed </text>
<text top="680" left="361" width="54" height="20" font="1">consent). </text>
<text top="109" left="557" width="7" height="18" font="1">•</text>
<text top="108" left="563" width="109" height="20" font="1"> Telmisartan 80 mg </text>
<text top="125" left="557" width="85" height="20" font="1">daily (n=8,542) </text>
<text top="144" left="557" width="7" height="18" font="1">•</text>
<text top="144" left="563" width="89" height="20" font="1"> Combination of </text>
<text top="161" left="557" width="87" height="20" font="1">telmisartan and </text>
<text top="178" left="557" width="100" height="20" font="1">ramipril (n=8,502) </text>
<text top="107" left="698" width="158" height="20" font="1">composite outcome of death </text>
<text top="124" left="698" width="155" height="20" font="1">from CV causes, MI, stroke, </text>
<text top="141" left="698" width="162" height="20" font="1">or hospitalization for HF (RR: </text>
<text top="159" left="698" width="160" height="20" font="1">1.01; 95% CI: 0.94–1.09 and </text>
<text top="176" left="698" width="164" height="20" font="1">RR: 0.99; 95% CI: 0.92–1.07, </text>
<text top="193" left="698" width="73" height="20" font="1">respectively) </text>
<text top="210" left="698" width="3" height="20" font="1"> </text>
<text top="227" left="698" width="107" height="20" font="4"><b>Safety endpoint:</b>   </text>
<text top="247" left="698" width="7" height="18" font="1">•</text>
<text top="246" left="705" width="145" height="20" font="1"> Combination therapy was </text>
<text top="263" left="698" width="166" height="20" font="1">associated with greater risk of </text>
<text top="280" left="698" width="148" height="20" font="1">hyperkalemia than ramipril </text>
<text top="298" left="698" width="166" height="20" font="1">monotherapy (480 pts vs. 283 </text>
<text top="315" left="698" width="76" height="20" font="1">pts; p&lt;0.001)<b> </b></text>
<text top="334" left="698" width="7" height="18" font="1">•</text>
<text top="333" left="705" width="134" height="20" font="1"> Hypotensive symptoms </text>
<text top="350" left="698" width="135" height="20" font="1">were cited as reason for </text>
<text top="368" left="698" width="169" height="20" font="1">permanent discontinuing more </text>
<text top="385" left="698" width="168" height="20" font="1">in telmisartan vs. ramipril (RR: </text>
<text top="402" left="698" width="107" height="20" font="1">1.54; p&lt;0.001) and </text>
<text top="419" left="698" width="133" height="20" font="1">combination therapy vs. </text>
<text top="437" left="698" width="148" height="20" font="1">ramipril monotherapy (RR: </text>
<text top="454" left="698" width="83" height="20" font="1">2.75; p&lt;0.001)<b> </b></text>
<text top="473" left="698" width="7" height="18" font="1">•</text>
<text top="472" left="705" width="160" height="20" font="1"> Renal impairment was more </text>
<text top="489" left="698" width="133" height="20" font="1">common in combination </text>
<text top="506" left="698" width="107" height="20" font="1">therapy vs. ramipril </text>
<text top="524" left="698" width="163" height="20" font="1">monotherapy (RR: 1.33; 95% </text>
<text top="541" left="698" width="81" height="20" font="1">CI: 1.22–1.44)<b> </b></text>
<text top="107" left="881" width="209" height="20" font="1">adverse events without an increase in </text>
<text top="124" left="881" width="40" height="20" font="1">benefit </text>
<text top="699" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">119 </text>
<text top="106" left="81" width="430" height="24" font="3"><b>Data Supplement 35. RCTs Comparing HF<i>p</i></b><b>EF (Section 9.2.2) </b></text>
<text top="146" left="126" width="38" height="20" font="4"><b>Study </b></text>
<text top="163" left="114" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="180" left="121" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="197" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="220" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="163" left="225" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="180" left="219" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="336" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="492" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="163" left="508" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="180" left="492" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="197" left="513" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="146" left="693" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="163" left="676" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="180" left="682" width="129" height="20" font="4"><b>P value; OR or RR; &amp;  </b></text>
<text top="197" left="721" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="147" left="880" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="164" left="912" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="181" left="917" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="199" left="938" width="59" height="20" font="4"><b>Summary </b></text>
<text top="217" left="98" width="57" height="20" font="4"><b>TOPCAT  </b></text>
<text top="234" left="98" width="78" height="20" font="1">Pfeffer MA, et </text>
<text top="251" left="98" width="83" height="20" font="1">al., 2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(161)</a> </text>
<text top="268" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25406305?dopt=Citation">25406305</a></text>
<text top="268" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25406305?dopt=Citation"><b> </b></a></text>
<text top="217" left="204" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="234" left="204" width="107" height="20" font="1">variation in pts and </text>
<text top="251" left="204" width="64" height="20" font="1">outcome in </text>
<text top="268" left="204" width="103" height="20" font="1">TOPCAT between </text>
<text top="285" left="204" width="68" height="20" font="1">pts from the </text>
<text top="303" left="204" width="74" height="20" font="1">Americas vs. </text>
<text top="320" left="204" width="88" height="20" font="1">Russia/Georgia </text>
<text top="337" left="204" width="3" height="20" font="1"> </text>
<text top="354" left="204" width="99" height="20" font="4"><b>Study type:</b> Post-</text>
<text top="371" left="204" width="85" height="20" font="1">hoc analysis of </text>
<text top="389" left="204" width="111" height="20" font="1">prospective, double-</text>
<text top="406" left="204" width="62" height="20" font="1">blind, RCT </text>
<text top="423" left="204" width="3" height="20" font="1"> </text>
<text top="440" left="204" width="86" height="20" font="4"><b>Size:</b> 3,445 pts </text>
<text top="217" left="331" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="234" left="331" width="117" height="20" font="1">NYHA class II–IV HF </text>
<text top="251" left="331" width="96" height="20" font="1">with LVEF ≤40% </text>
<text top="268" left="331" width="79" height="20" font="1">within 3 mo of </text>
<text top="285" left="331" width="104" height="20" font="1">enrollment; supine </text>
<text top="303" left="331" width="96" height="20" font="1">resting heart rate </text>
<text top="320" left="331" width="92" height="20" font="1">≥68 bpm; stable </text>
<text top="337" left="331" width="93" height="20" font="1">clinical condition </text>
<text top="354" left="331" width="3" height="20" font="1"> </text>
<text top="371" left="331" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="389" left="331" width="87" height="20" font="1">Acute MI or UA </text>
<text top="406" left="331" width="76" height="20" font="1">within 28 d of </text>
<text top="423" left="331" width="84" height="20" font="1">randomization; </text>
<text top="440" left="331" width="70" height="20" font="1">indication or </text>
<text top="458" left="331" width="107" height="20" font="1">contraindication for </text>
<text top="475" left="331" width="107" height="20" font="1">treatment with BBs </text>
<text top="492" left="331" width="102" height="20" font="1">or drugs with beta-</text>
<text top="509" left="331" width="110" height="20" font="1">blocking properties; </text>
<text top="527" left="331" width="97" height="20" font="1">poor compliance; </text>
<text top="544" left="331" width="97" height="20" font="1">CABG surgery or </text>
<text top="561" left="331" width="107" height="20" font="1">PTCA in past 4 mo </text>
<text top="217" left="465" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="236" left="465" width="7" height="18" font="1">•</text>
<text top="235" left="472" width="99" height="20" font="1"> Americas 886 on </text>
<text top="252" left="465" width="87" height="20" font="1">spironolactone  </text>
<text top="271" left="465" width="7" height="18" font="1">•</text>
<text top="271" left="472" width="132" height="20" font="1"> Russia/Georgia 836 on </text>
<text top="288" left="465" width="83" height="20" font="1">spironolactone </text>
<text top="307" left="465" width="7" height="18" font="1">•</text>
<text top="306" left="472" width="147" height="20" font="1"> Spironolactone 15–45 mg </text>
<text top="323" left="465" width="29" height="20" font="1">daily </text>
<text top="341" left="465" width="7" height="20" font="1">  </text>
<text top="358" left="465" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="377" left="465" width="7" height="18" font="1">•</text>
<text top="376" left="472" width="146" height="20" font="1"> Americas 881 on placebo </text>
<text top="395" left="465" width="7" height="18" font="1">•</text>
<text top="395" left="472" width="132" height="20" font="1"> Russia/Georgia 842 on </text>
<text top="412" left="465" width="46" height="20" font="1">placebo </text>
<text top="431" left="465" width="7" height="18" font="1">•</text>
<text top="430" left="472" width="51" height="20" font="1"> Placebo </text>
<text top="218" left="643" width="172" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite of CV </text>
<text top="235" left="643" width="198" height="20" font="1">death, aborted cardiac arrest, or HF </text>
<text top="252" left="643" width="178" height="20" font="1">hospitalization at 3.3 y follow-up </text>
<text top="269" left="643" width="143" height="20" font="1">was: Americas: 27.3% for </text>
<text top="287" left="643" width="163" height="20" font="1">spironolactone and 31.8% for </text>
<text top="304" left="643" width="180" height="20" font="1">placebo HR: 0.82; 95% CI: 0.69–</text>
<text top="321" left="643" width="202" height="20" font="1">0.98; p=0.026; Russia/Georgia 9.3% </text>
<text top="338" left="643" width="174" height="20" font="1">for spironolactone and 8.4% for </text>
<text top="356" left="643" width="180" height="20" font="1">placebo HR: 1.10; 95% CI: 0.79–</text>
<text top="373" left="643" width="72" height="20" font="1">1.51; p=0.58 </text>
<text top="390" left="643" width="3" height="20" font="1"> </text>
<text top="408" left="643" width="120" height="20" font="4"><b>1</b>°<b> Safety endpoint: </b> </text>
<text top="427" left="643" width="7" height="18" font="1">•</text>
<text top="427" left="650" width="167" height="20" font="1"> Doubling of serum creatinine: </text>
<text top="444" left="643" width="198" height="20" font="1">Americas: 17.8% for spironolactone </text>
<text top="461" left="643" width="182" height="20" font="1">and 11.6% for placebo HR: 1.60; </text>
<text top="478" left="643" width="157" height="20" font="1">95% CI: 1.25–2.05; p&lt;0.001 </text>
<text top="497" left="643" width="7" height="18" font="1">•</text>
<text top="497" left="650" width="176" height="20" font="1"> Russia/Georgia 2.0% for S and </text>
<text top="514" left="643" width="193" height="20" font="1">2.1% for p HR: 0.95; 95% CI: 0.49–</text>
<text top="531" left="643" width="72" height="20" font="1">1.85; p=0.89 </text>
<text top="550" left="643" width="7" height="18" font="1">•</text>
<text top="549" left="650" width="128" height="20" font="1"> Creatinine &gt;3.0 mg/dL </text>
<text top="569" left="643" width="7" height="18" font="1">•</text>
<text top="568" left="650" width="191" height="20" font="1"> Americas 9.8% for spironolactone </text>
<text top="585" left="643" width="203" height="20" font="1">and 9.1% for placebo HR: 1.10; 95% </text>
<text top="602" left="643" width="122" height="20" font="1">CI: 0.81–1.49; p=0.55 </text>
<text top="621" left="643" width="7" height="18" font="1">•</text>
<text top="621" left="650" width="141" height="20" font="1"> Russia/Georgia 0.2% for </text>
<text top="638" left="643" width="203" height="20" font="1">spironolactone and 0.4% for placebo </text>
<text top="655" left="643" width="199" height="20" font="1">HR: 0.5; 95% CI: 0.09–2.75; p=0.43 </text>
<text top="674" left="643" width="7" height="18" font="1">•</text>
<text top="673" left="650" width="173" height="20" font="1"> Hyperkalemia (potassium &gt;5.5 </text>
<text top="691" left="643" width="48" height="20" font="1">mmol/L) </text>
<text top="710" left="643" width="7" height="18" font="1">•</text>
<text top="709" left="650" width="114" height="20" font="1"> Americas 25.2% for </text>
<text top="726" left="643" width="203" height="20" font="1">spironolactone and 8.9% for placebo </text>
<text top="743" left="643" width="165" height="20" font="1">OR: 3.46; 95% CI: 2.62–4.56; </text>
<text top="761" left="643" width="48" height="20" font="1">p&lt;0.001 </text>
<text top="218" left="860" width="204" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> CV mortality: </text>
<text top="235" left="860" width="194" height="20" font="1">Americas 10.8% for spironolactone </text>
<text top="252" left="860" width="210" height="20" font="1">and 14.4% for placebo HR: 0.74; 95% </text>
<text top="269" left="860" width="129" height="20" font="1">CI 0.57–0.97; p=0.027; </text>
<text top="287" left="860" width="137" height="20" font="1">Russia/Georgia 7.7% for </text>
<text top="304" left="860" width="203" height="20" font="1">spironolactone and 5.8% for placebo </text>
<text top="321" left="860" width="209" height="20" font="1">HR: 1.31; 95% CI: 0.91–1.90; p=0.15. </text>
<text top="338" left="860" width="198" height="20" font="1">Aborted cardiac arrest: NS between </text>
<text top="356" left="860" width="205" height="20" font="1">groups. HF hospitalization: 20.8% for </text>
<text top="373" left="860" width="210" height="20" font="1">spironolactone and 24.5% for placebo </text>
<text top="390" left="860" width="164" height="20" font="1">HR: 0.82; 95% CI: 0.67–0.99; </text>
<text top="407" left="860" width="189" height="20" font="1">p=0.042; Russia/Georgia 2.6% for </text>
<text top="424" left="860" width="203" height="20" font="1">spironolactone and 3.4% for placebo </text>
<text top="442" left="860" width="164" height="20" font="1">HR: 0.76; 95% CI: 0.44–1.32; </text>
<text top="459" left="860" width="214" height="20" font="1">p=0.327; Recurrent HF: 361 events for </text>
<text top="476" left="860" width="189" height="20" font="1">spironolactone and 438 events for </text>
<text top="493" left="860" width="187" height="20" font="1">placebo (IRR: 0.75; 95% CI: 0.58–</text>
<text top="510" left="860" width="188" height="20" font="1">0.96; p=0.024) Russia/Georgia 33 </text>
<text top="528" left="860" width="182" height="20" font="1">events for spironolactone and 37 </text>
<text top="545" left="860" width="214" height="20" font="1">events for placebo (IRR: 0.83; 95% CI: </text>
<text top="562" left="860" width="214" height="20" font="1">0.42–1.62; p=0.58) All-cause mortality: </text>
<text top="579" left="860" width="203" height="20" font="1">NS between groups in Americas and </text>
<text top="596" left="860" width="145" height="20" font="1">Russia/Georgia. All-cause </text>
<text top="614" left="860" width="209" height="20" font="1">hospitalization: NS between groups in </text>
<text top="631" left="860" width="211" height="20" font="1">Americas and Russia/Georgia. MI: NS </text>
<text top="648" left="860" width="207" height="20" font="1">between groups; Stroke: NS between </text>
<text top="665" left="860" width="41" height="20" font="1">groups </text>
<text top="683" left="860" width="3" height="20" font="1"> </text>
<text top="700" left="860" width="178" height="20" font="4"><b>Study limitations and adverse </b></text>
<text top="717" left="860" width="151" height="20" font="4"><b>events:</b> The pts enrolled in </text>
<text top="734" left="860" width="198" height="20" font="1">Russia/Georgia in the TOPCAT trial </text>
<text top="751" left="860" width="167" height="20" font="1">did not demonstrate either the </text>
<text top="769" left="860" width="180" height="20" font="1">expected morbidity and mortality </text>
<text top="786" left="860" width="194" height="20" font="1">associated with symptomatic HF or </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">120 </text>
<text top="109" left="643" width="7" height="18" font="1">•</text>
<text top="108" left="650" width="148" height="20" font="1"> Russia/Georgia 11.8% for </text>
<text top="125" left="643" width="203" height="20" font="1">spironolactone and 9.4% for placebo </text>
<text top="143" left="643" width="165" height="20" font="1">OR: 1.30; 95% CI: 0.95–1.77; </text>
<text top="160" left="643" width="41" height="20" font="1">p=0.10 </text>
<text top="179" left="643" width="7" height="18" font="1">•</text>
<text top="178" left="650" width="169" height="20" font="1"> Hypokalemia (potassium &lt;3.5 </text>
<text top="195" left="643" width="158" height="20" font="1">mmol/L) Americas 15.2% for </text>
<text top="213" left="643" width="163" height="20" font="1">spironolactone and 26.2% for </text>
<text top="230" left="643" width="191" height="20" font="1">placebo) 0.51 (95% CI: 0.40–0.64; </text>
<text top="247" left="643" width="52" height="20" font="1">p&lt;0.001) </text>
<text top="266" left="643" width="7" height="18" font="1">•</text>
<text top="265" left="650" width="183" height="20" font="1"> Russia/Georgia 17.2% for S and </text>
<text top="283" left="643" width="170" height="20" font="1">19.4% for p OR: 0.87 (95% CI: </text>
<text top="300" left="643" width="107" height="20" font="1">0.68–1.11; p=0.26) </text>
<text top="107" left="860" width="197" height="20" font="1">most pharmacological responses to </text>
<text top="124" left="860" width="83" height="20" font="1">spironolactone </text>
<text top="141" left="860" width="3" height="20" font="1"> </text>
<text top="159" left="860" width="167" height="20" font="4"><b>Summary</b>: In pts with HF with </text>
<text top="176" left="860" width="212" height="20" font="1">preserved EF, spironolactone reduced </text>
<text top="193" left="860" width="195" height="20" font="1">the 1° endpoint of composite of CV </text>
<text top="210" left="860" width="198" height="20" font="1">death, aborted cardiac arrest, or HF </text>
<text top="228" left="860" width="204" height="20" font="1">hospitalization in the Americas group </text>
<text top="245" left="860" width="201" height="20" font="1">but not in the Russia/Georgia group. </text>
<text top="262" left="860" width="213" height="20" font="1">The pts enrolled in the Russia/Georgia </text>
<text top="279" left="860" width="202" height="20" font="1">group did not demonstrate either the </text>
<text top="296" left="860" width="180" height="20" font="1">expected morbidity and mortality </text>
<text top="314" left="860" width="205" height="20" font="1">associated with symptomatic HF with </text>
<text top="331" left="860" width="215" height="20" font="1">preserved EF or most pharmacological </text>
<text top="348" left="860" width="157" height="20" font="1">responses to spironolactone </text>
<text top="366" left="98" width="85" height="20" font="1">Aronow WS, et </text>
<text top="383" left="98" width="83" height="20" font="1">al., 1997 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(162)</a> </text>
<text top="400" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9230162?dopt=Citation">9230162</a></text>
<text top="400" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9230162?dopt=Citation"> </a></text>
<text top="366" left="204" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="383" left="204" width="112" height="20" font="1">effect of propranolol </text>
<text top="400" left="204" width="101" height="20" font="1">vs. no propranolol </text>
<text top="418" left="204" width="93" height="20" font="1">on mortality plus </text>
<text top="435" left="204" width="97" height="20" font="1">nonfatal MI in pts </text>
<text top="452" left="204" width="94" height="20" font="1">with prior MI and </text>
<text top="469" left="204" width="42" height="20" font="1">HF<i>p</i>EF </text>
<text top="366" left="331" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="383" left="331" width="98" height="20" font="1">Pts ≥62 y with MI </text>
<text top="400" left="331" width="118" height="20" font="1">and LVEF ≥40% and </text>
<text top="418" left="331" width="113" height="20" font="1">HF NYHA class II or </text>
<text top="435" left="331" width="81" height="20" font="1">III treated with </text>
<text top="452" left="331" width="111" height="20" font="1">diuretics and ACEIs </text>
<text top="469" left="331" width="49" height="20" font="1">for 2 mo </text>
<text top="366" left="465" width="145" height="20" font="4"><b>Intervention:</b> 79 pts were </text>
<text top="383" left="465" width="162" height="20" font="1">randomized to treatment with </text>
<text top="400" left="465" width="68" height="20" font="1">propranolol  </text>
<text top="418" left="465" width="3" height="20" font="1"> </text>
<text top="435" left="465" width="144" height="20" font="4"><b>Comparator:</b> 79 pts were </text>
<text top="452" left="465" width="98" height="20" font="1">randomized to no </text>
<text top="469" left="465" width="72" height="20" font="1">propranolol.  </text>
<text top="487" left="465" width="3" height="20" font="1"> </text>
<text top="506" left="465" width="7" height="18" font="1">•</text>
<text top="505" left="472" width="143" height="20" font="1">  All pts continued diuretic </text>
<text top="522" left="465" width="104" height="20" font="1">and ACEI therapy. </text>
<text top="367" left="643" width="199" height="20" font="4"><b>1</b>°<b> endpoint:</b> At 32-mo mean follow-</text>
<text top="384" left="643" width="173" height="20" font="1">up, multivariate Cox regression </text>
<text top="402" left="643" width="201" height="20" font="1">analysis showed that compared with </text>
<text top="419" left="643" width="198" height="20" font="1">no propranolol, propranolol reduced </text>
<text top="436" left="643" width="201" height="20" font="1">mortality 35% (p=0.03) and mortality </text>
<text top="453" left="643" width="175" height="20" font="1">plus nonfatal MI 37% (p=0.018) </text>
<text top="367" left="860" width="201" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> At 1-y follow-</text>
<text top="384" left="860" width="153" height="20" font="1">up, LVEF was increased by </text>
<text top="402" left="860" width="163" height="20" font="1">propranolol from 57% to 63% </text>
<text top="419" left="860" width="157" height="20" font="1">(p&lt;0.001) and LV mass was </text>
<text top="436" left="860" width="194" height="20" font="1">decreased by propranolol from 312 </text>
<text top="453" left="860" width="169" height="20" font="1">grams to 278 grams (p=0.001) </text>
<text top="470" left="860" width="203" height="20" font="1">Propranolol was stopped because of </text>
<text top="488" left="860" width="204" height="20" font="1">adverse effects in 11 of 79 pts (14%) </text>
<text top="540" left="98" width="91" height="20" font="1">Kostis JB, et al., </text>
<text top="557" left="98" width="63" height="20" font="1">1997 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(163)</a> </text>
<text top="574" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9218667?dopt=Citation">9218667</a></text>
<text top="574" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9218667?dopt=Citation"> </a></text>
<text top="540" left="204" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="557" left="204" width="68" height="20" font="1">the effect of </text>
<text top="574" left="204" width="93" height="20" font="1">antihypertensive </text>
<text top="592" left="204" width="92" height="20" font="1">drug therapy vs. </text>
<text top="609" left="204" width="59" height="20" font="1">placebo in </text>
<text top="626" left="204" width="107" height="20" font="1">prevention of HF in </text>
<text top="643" left="204" width="91" height="20" font="1">pts with isolated </text>
<text top="660" left="204" width="72" height="20" font="1">systolic HTN </text>
<text top="540" left="331" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="557" left="331" width="81" height="20" font="1">Pts ≥60 y with </text>
<text top="574" left="331" width="118" height="20" font="1">isolated systolic HTN </text>
<text top="592" left="331" width="120" height="20" font="1">in the SHEP program </text>
<text top="540" left="465" width="151" height="20" font="4"><b>Intervention/Comparator:</b> </text>
<text top="557" left="465" width="152" height="20" font="1">4,736 pts were randomized </text>
<text top="574" left="465" width="135" height="20" font="1">to antihypertensive drug </text>
<text top="592" left="465" width="105" height="20" font="1">therapy or placebo </text>
<text top="541" left="643" width="204" height="20" font="4"><b>1</b>°<b> endpoint:</b> At 4.5-y follow-up, fatal </text>
<text top="558" left="643" width="182" height="20" font="1">or nonfatal HF was reduced 49% </text>
<text top="576" left="643" width="194" height="20" font="1">(p&lt;0.001) by antihypertensive drug </text>
<text top="593" left="643" width="179" height="20" font="1">therapy (NNT to prevent 1 event </text>
<text top="610" left="643" width="28" height="20" font="1">=48) </text>
<text top="541" left="860" width="201" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> CV mortality </text>
<text top="558" left="860" width="185" height="20" font="1">and nonfatal hospitalized HF was </text>
<text top="576" left="860" width="149" height="20" font="1">reduced 30% (p=0.002) by </text>
<text top="593" left="860" width="165" height="20" font="1">antihypertensive drug therapy </text>
<text top="678" left="98" width="82" height="20" font="1">Beckett NS, et </text>
<text top="696" left="98" width="83" height="20" font="1">al., 2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(164)</a> </text>
<text top="713" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18378519?dopt=Citation">18378519</a></text>
<text top="713" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18378519?dopt=Citation"> </a></text>
<text top="678" left="204" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="696" left="204" width="68" height="20" font="1">the effect of </text>
<text top="713" left="204" width="93" height="20" font="1">antihypertensive </text>
<text top="730" left="204" width="90" height="20" font="1">drug therapy on </text>
<text top="747" left="204" width="88" height="20" font="1">fatal or nonfatal </text>
<text top="764" left="204" width="108" height="20" font="1">stroke in pts ≥80 y  </text>
<text top="678" left="331" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="696" left="331" width="91" height="20" font="1">Pts ≥80 y with a </text>
<text top="713" left="331" width="103" height="20" font="1">SBP≥160 mm Hg  </text>
<text top="678" left="465" width="151" height="20" font="4"><b>Intervention/Comparator:</b> </text>
<text top="696" left="465" width="152" height="20" font="1">3,845 pts were randomized </text>
<text top="713" left="465" width="135" height="20" font="1">to antihypertensive drug </text>
<text top="730" left="465" width="105" height="20" font="1">therapy or placebo </text>
<text top="680" left="643" width="181" height="20" font="4"><b>1</b>°<b> endpoint:</b> The 1° endpoint of </text>
<text top="697" left="643" width="198" height="20" font="1">fatal or nonfatal stroke was reduced </text>
<text top="714" left="643" width="187" height="20" font="1">30% (p=0.06) by antihypertensive </text>
<text top="731" left="643" width="73" height="20" font="1">drug therapy </text>
<text top="680" left="860" width="130" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> </text>
<text top="697" left="860" width="215" height="20" font="1">Antihypertensive drug therapy reduced </text>
<text top="714" left="860" width="207" height="20" font="1">HF 64% (p&lt;0.001) all-cause mortality </text>
<text top="731" left="860" width="187" height="20" font="1">21% (p=0.02), and CV death 23% </text>
<text top="748" left="860" width="49" height="20" font="1">(p=0.06) </text>
</page>
<page number="121" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">121 </text>
<text top="107" left="98" width="89" height="20" font="1">Van Veldhuisen </text>
<text top="124" left="98" width="86" height="20" font="1">DJ, et al., 2009 </text>
<text top="141" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(165)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19497441?dopt=Citation">19497441</a></text>
<text top="159" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19497441?dopt=Citation"> </a></text>
<text top="107" left="204" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="124" left="204" width="68" height="20" font="1">the effect of </text>
<text top="141" left="204" width="71" height="20" font="1">nebivolol vs. </text>
<text top="159" left="204" width="104" height="20" font="1">placebo in pts with </text>
<text top="176" left="204" width="106" height="20" font="1">HF<i>r</i>EF and HF<i>p</i>EF </text>
<text top="107" left="331" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="124" left="331" width="113" height="20" font="1">Pts ≥70 y, history of </text>
<text top="141" left="331" width="101" height="20" font="1">HF, and HF<i>r</i>EF or </text>
<text top="159" left="331" width="42" height="20" font="1">HF<i>p</i>EF </text>
<text top="107" left="465" width="151" height="20" font="4"><b>Intervention/Comparator:</b> </text>
<text top="124" left="465" width="143" height="20" font="1">1,359 pts with a history of </text>
<text top="141" left="465" width="143" height="20" font="1">HF<i>r</i>EF and 752 pts with a </text>
<text top="159" left="465" width="126" height="20" font="1">history of HF<i>p</i>EF were </text>
<text top="176" left="465" width="161" height="20" font="1">randomized to nebivolol or to </text>
<text top="193" left="465" width="46" height="20" font="1">placebo </text>
<text top="108" left="643" width="185" height="20" font="4"><b>1</b>°<b> endpoint:</b> At 21-mo follow-up, </text>
<text top="125" left="643" width="204" height="20" font="1">the 1° endpoint of all-cause mortality </text>
<text top="143" left="643" width="189" height="20" font="1">or CV hospitalization was reduced </text>
<text top="160" left="643" width="178" height="20" font="1">by nebivolol 14% (95% CI: 0.72–</text>
<text top="177" left="643" width="181" height="20" font="1">1.04) in pts with HF<i>r</i>EF and 19% </text>
<text top="194" left="643" width="172" height="20" font="1">(95% CI: 0.63, 1.04) in pts with </text>
<text top="211" left="643" width="42" height="20" font="1">HF<i>p</i>EF </text>
<text top="108" left="860" width="169" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> HR for </text>
<text top="125" left="860" width="187" height="20" font="1">reduction of all-cause mortality by </text>
<text top="143" left="860" width="214" height="20" font="1">nebivolol: 0.84 (95% CI: 0.86–1.08) for </text>
<text top="160" left="860" width="204" height="20" font="1">HF<i>r</i>EF and 0.91 (95% CI: 0.62–1.33) </text>
<text top="177" left="860" width="60" height="20" font="1">for HF<i>p</i>EF </text>
<text top="229" left="98" width="83" height="20" font="1">Yusef S, et al., </text>
<text top="247" left="98" width="63" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(166)</a> </text>
<text top="264" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13678871?dopt=Citation">13678871</a></text>
<text top="264" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13678871?dopt=Citation"> </a></text>
<text top="229" left="204" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="247" left="204" width="74" height="20" font="1">the effects of </text>
<text top="264" left="204" width="90" height="20" font="1">candesartan vs. </text>
<text top="281" left="204" width="104" height="20" font="1">placebo in pts with </text>
<text top="298" left="204" width="42" height="20" font="1">HF<i>p</i>EF </text>
<text top="229" left="331" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="247" left="331" width="116" height="20" font="1">3,032 pts, mean age </text>
<text top="264" left="331" width="98" height="20" font="1">67 y, with HF<i>p</i>EF </text>
<text top="281" left="331" width="119" height="20" font="1">and NYHA class II-IV </text>
<text top="298" left="331" width="20" height="20" font="1">HF </text>
<text top="229" left="465" width="151" height="20" font="4"><b>Intervention/Comparator:</b> </text>
<text top="247" left="465" width="152" height="20" font="1">3,032 pts were randomized </text>
<text top="264" left="465" width="146" height="20" font="1">to candesartan or placebo </text>
<text top="231" left="643" width="188" height="20" font="4"><b>1</b>°<b> endpoint:</b> At 36.6 m follow-up, </text>
<text top="248" left="643" width="170" height="20" font="1">the 1° outcome of CV death or </text>
<text top="265" left="643" width="192" height="20" font="1">hospitalization for HF was reduced </text>
<text top="282" left="643" width="172" height="20" font="1">11% (p=0.118) by candesartan </text>
<text top="231" left="860" width="214" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> Hospitalization </text>
<text top="248" left="860" width="174" height="20" font="1">was reduced 16% (p=0.047) by </text>
<text top="265" left="860" width="71" height="20" font="1">candesartan </text>
<text top="316" left="98" width="81" height="20" font="1">Massie BM, et </text>
<text top="334" left="98" width="83" height="20" font="1">al., 2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(167)</a> </text>
<text top="351" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19001508?dopt=Citation">19001508</a></text>
<text top="351" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19001508?dopt=Citation"> </a></text>
<text top="316" left="204" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="334" left="204" width="68" height="20" font="1">the effect of </text>
<text top="351" left="204" width="77" height="20" font="1">irbesartan vs. </text>
<text top="368" left="204" width="80" height="20" font="1">placebo on all-</text>
<text top="385" left="204" width="100" height="20" font="1">cause mortality or </text>
<text top="402" left="204" width="109" height="20" font="1">hospitalization for a </text>
<text top="420" left="204" width="89" height="20" font="1">CV cause in pts </text>
<text top="437" left="204" width="68" height="20" font="1">with HF<i>p</i>EF </text>
<text top="316" left="331" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="334" left="331" width="102" height="20" font="1">Pts 60 y and older </text>
<text top="351" left="331" width="91" height="20" font="1">with HF<i>p</i>EF and </text>
<text top="368" left="331" width="114" height="20" font="1">NYHA class II, III, or </text>
<text top="385" left="331" width="35" height="20" font="1">IV HF </text>
<text top="316" left="465" width="147" height="20" font="4"><b>Intervention/Comparator</b> </text>
<text top="334" left="465" width="152" height="20" font="1">4,128 pts were randomized </text>
<text top="351" left="465" width="133" height="20" font="1">to irbesartan or placebo </text>
<text top="317" left="643" width="195" height="20" font="4"><b>1</b>°<b> endpoint:</b> At 49.5-mo follow-up, </text>
<text top="335" left="643" width="204" height="20" font="1">the 1° outcome of all-cause mortality </text>
<text top="352" left="643" width="195" height="20" font="1">or hospitalization for CV cause was </text>
<text top="369" left="643" width="193" height="20" font="1">reduced 5% by irbesartan (p=0.35) </text>
<text top="317" left="860" width="209" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> Irbesartan did </text>
<text top="335" left="860" width="164" height="20" font="1">not significantly reduce the 2º </text>
<text top="352" left="860" width="167" height="20" font="1">outcomes of death from HF or </text>
<text top="369" left="860" width="208" height="20" font="1">hospitalization for HF, death from any </text>
<text top="386" left="860" width="178" height="20" font="1">cause and from CV causes, and </text>
<text top="404" left="860" width="72" height="20" font="1">quality of life </text>
<text top="455" left="98" width="86" height="20" font="1">Piller LB, et al., </text>
<text top="472" left="98" width="63" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#272">(168)</a> </text>
<text top="489" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21969009?dopt=Citation">21969009</a></text>
<text top="489" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21969009?dopt=Citation"> </a></text>
<text top="455" left="204" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="472" left="204" width="113" height="20" font="1">mortality rates in pts </text>
<text top="489" left="204" width="106" height="20" font="1">who developed HF </text>
<text top="506" left="204" width="63" height="20" font="1">in ALLHAT </text>
<text top="455" left="331" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="472" left="331" width="116" height="20" font="1">1,761 pts, mean age </text>
<text top="489" left="331" width="110" height="20" font="1">70 y, developed HF </text>
<text top="506" left="331" width="87" height="20" font="1">during ALLHAT </text>
<text top="455" left="465" width="162" height="20" font="4"><b>Intervention/Comparator</b> At </text>
<text top="472" left="465" width="155" height="20" font="1">8.9-y mean follow-up, 1,348 </text>
<text top="489" left="465" width="149" height="20" font="1">of 1,761 pts (77%) with HF </text>
<text top="506" left="465" width="27" height="20" font="1">died </text>
<text top="456" left="643" width="177" height="20" font="4"><b>1</b>°<b> endpoint:</b> Post-HF all-cause </text>
<text top="473" left="643" width="193" height="20" font="1">mortality was similar for pts treated </text>
<text top="490" left="643" width="199" height="20" font="1">with chlorthalidone, amlodipine, and </text>
<text top="508" left="643" width="177" height="20" font="1">lisinopril. 10-y adjusted rates for </text>
<text top="525" left="643" width="192" height="20" font="1">mortality were 86% for amlodipine, </text>
<text top="542" left="643" width="167" height="20" font="1">87% for lisinopril, and 83% for </text>
<text top="559" left="643" width="80" height="20" font="1">chlorthalidone </text>
<text top="456" left="860" width="184" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> All-cause </text>
<text top="473" left="860" width="201" height="20" font="1">mortality rates were similar for those </text>
<text top="490" left="860" width="202" height="20" font="1">with HF<i>r</i>EF (84%) and for those with </text>
<text top="508" left="860" width="179" height="20" font="1">HF<i>p</i>EF (81%) with no significant </text>
<text top="525" left="860" width="203" height="20" font="1">differences by randomized treatment </text>
<text top="542" left="860" width="25" height="20" font="1">arm </text>
<text top="577" left="98" width="85" height="20" font="1">Law MR, et al., </text>
<text top="594" left="98" width="56" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(18)</a> </text>
<text top="611" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation">19454737</a></text>
<text top="611" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation"> </a></text>
<text top="577" left="204" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="594" left="204" width="98" height="20" font="1">analysis of use of </text>
<text top="611" left="204" width="104" height="20" font="1">BP-lowering drugs </text>
<text top="629" left="204" width="87" height="20" font="1">in prevention of </text>
<text top="646" left="204" width="81" height="20" font="1">CVD from 147 </text>
<text top="663" left="204" width="97" height="20" font="1">randomized trials </text>
<text top="680" left="204" width="3" height="20" font="1"> </text>
<text top="698" left="204" width="72" height="20" font="4"><b>Size:</b> Of 147 </text>
<text top="715" left="204" width="111" height="20" font="1">randomized trials of </text>
<text top="732" left="204" width="88" height="20" font="1">464,000 pts, 37 </text>
<text top="749" left="204" width="111" height="20" font="1">trials of BBs in CAD </text>
<text top="766" left="204" width="113" height="20" font="1">included 38,892 pts, </text>
<text top="784" left="204" width="84" height="20" font="1">and 37 trials of </text>
<text top="577" left="331" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="594" left="331" width="119" height="20" font="1">The database search </text>
<text top="611" left="331" width="112" height="20" font="1">used Medline (1966-</text>
<text top="629" left="331" width="96" height="20" font="1">Dec. 2007 in any </text>
<text top="646" left="331" width="114" height="20" font="1">language) to identify </text>
<text top="663" left="331" width="111" height="20" font="1">randomized trials of </text>
<text top="680" left="331" width="117" height="20" font="1">BP-lowering drugs in </text>
<text top="698" left="331" width="118" height="20" font="1">which CAD events or </text>
<text top="715" left="331" width="73" height="20" font="1">strokes were </text>
<text top="732" left="331" width="120" height="20" font="1">recorded. The search </text>
<text top="749" left="331" width="96" height="20" font="1">also included the </text>
<text top="766" left="331" width="57" height="20" font="1">Cochrane </text>
<text top="784" left="331" width="100" height="20" font="1">Collaboration and </text>
<text top="578" left="465" width="148" height="20" font="4"><b>1</b>°<b> endpoint:</b> CAD events; </text>
<text top="595" left="465" width="37" height="20" font="1">stroke </text>
<text top="613" left="465" width="3" height="20" font="1"> </text>
<text top="630" left="465" width="146" height="20" font="4"><b>Results:</b> In 37 trials of pts </text>
<text top="647" left="465" width="147" height="20" font="1">with a history of CAD, BBs </text>
<text top="664" left="465" width="145" height="20" font="1">reduced CAD events 29% </text>
<text top="681" left="465" width="149" height="20" font="1">(95% CI: 22%–34%). In 27 </text>
<text top="699" left="465" width="163" height="20" font="1">trials in which BBs were used </text>
<text top="716" left="465" width="156" height="20" font="1">after acute MI, BBs reduced </text>
<text top="733" left="465" width="148" height="20" font="1">CAD events 31% (95% CI: </text>
<text top="750" left="465" width="163" height="20" font="1">24%–38%), and in 11 trials in </text>
<text top="768" left="465" width="149" height="20" font="1">which BBs were used after </text>
<text top="785" left="465" width="114" height="20" font="1">long-term CAD, BBs </text>
<text top="579" left="643" width="7" height="18" font="1">•</text>
<text top="578" left="650" width="173" height="20" font="1"> With the exception of the extra </text>
<text top="595" left="643" width="202" height="20" font="1">protective effect of BBs given shortly </text>
<text top="613" left="643" width="190" height="20" font="1">after a MI and the minor additional </text>
<text top="630" left="643" width="197" height="20" font="1">effect of CCBs in preventing stroke, </text>
<text top="647" left="643" width="198" height="20" font="1">all the classes of BP-lowering drugs </text>
<text top="664" left="643" width="176" height="20" font="1">have a similar effect in reducing </text>
<text top="681" left="643" width="191" height="20" font="1">CAD events and stroke for a given </text>
<text top="699" left="643" width="90" height="20" font="1">reduction in BP. </text>
<text top="577" left="860" width="24" height="20" font="1">N/A </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">122 </text>
<text top="107" left="204" width="31" height="20" font="1">other </text>
<text top="124" left="204" width="93" height="20" font="1">antihypertensive </text>
<text top="141" left="204" width="76" height="20" font="1">drugs in CAD </text>
<text top="159" left="204" width="110" height="20" font="1">included 85,395 pts </text>
<text top="107" left="331" width="89" height="20" font="1">Web of Science </text>
<text top="124" left="331" width="105" height="20" font="1">databases and the </text>
<text top="141" left="331" width="115" height="20" font="1">citations in trials and </text>
<text top="159" left="331" width="81" height="20" font="1">previous meta-</text>
<text top="176" left="331" width="115" height="20" font="1">analyses and review </text>
<text top="193" left="331" width="49" height="20" font="1">articles.  </text>
<text top="210" left="331" width="3" height="20" font="1"> </text>
<text top="227" left="331" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="245" left="331" width="116" height="20" font="1">Trials were excluded </text>
<text top="262" left="331" width="118" height="20" font="1">if there were &lt;5 CAD </text>
<text top="279" left="331" width="107" height="20" font="1">events and strokes </text>
<text top="296" left="331" width="79" height="20" font="1">or if treatment </text>
<text top="314" left="331" width="114" height="20" font="1">duration was &lt;6 mo. </text>
<text top="107" left="465" width="154" height="20" font="1">insignificantly reduced CAD </text>
<text top="124" left="465" width="154" height="20" font="1">events 13%. In 7 trials, BBs </text>
<text top="141" left="465" width="164" height="20" font="1">reduced stroke 17% (95% CI: </text>
<text top="159" left="465" width="159" height="20" font="1">1%–30%). CAD events were </text>
<text top="176" left="465" width="152" height="20" font="1">reduced 14% (95% CI: 2%–</text>
<text top="193" left="465" width="151" height="20" font="1">25%) in 11 trials of thiazide </text>
<text top="210" left="465" width="132" height="20" font="1">diuretics, 17% (95% CI: </text>
<text top="228" left="465" width="137" height="20" font="1">11%–22%) in 21 trials of </text>
<text top="245" left="465" width="159" height="20" font="1">ACEIs, insignificantly 14% in </text>
<text top="262" left="465" width="120" height="20" font="1">4 trials of angiotensin </text>
<text top="279" left="465" width="153" height="20" font="1">receptor blockers, and 15% </text>
<text top="296" left="465" width="138" height="20" font="1">(95% CI: 8%–22%) in 22 </text>
<text top="314" left="465" width="146" height="20" font="1">trials of CCBs. Stroke was </text>
<text top="331" left="465" width="158" height="20" font="1">reduced 38% (95% CI: 28%–</text>
<text top="348" left="465" width="151" height="20" font="1">47%) in 10 trials of thiazide </text>
<text top="365" left="465" width="156" height="20" font="1">diuretics, 22% (95% CI: 8%–</text>
<text top="383" left="465" width="147" height="20" font="1">34%) in 13 trials of ACEIs, </text>
<text top="400" left="465" width="134" height="20" font="1">and 34% (95% CI: 25%–</text>
<text top="417" left="465" width="137" height="20" font="1">42%) in 9 trials of CCBs. </text>
<text top="436" left="108" width="3" height="19" font="1"> </text>
<text top="471" left="81" width="779" height="24" font="3"><b>Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries of HF<i>p</i></b><b>EF (Section 9.2.2)  </b></text>
<text top="510" left="109" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="528" left="134" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="545" left="112" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="510" left="236" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="528" left="252" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="510" left="415" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="510" left="662" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="528" left="640" width="224" height="20" font="4"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="510" left="942" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="528" left="969" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="563" left="104" width="85" height="20" font="1">Law MR, et al., </text>
<text top="580" left="104" width="56" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(18)</a> </text>
<text top="597" left="104" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation">19454737</a></text>
<text top="597" left="159" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation"> </a></text>
<text top="563" left="224" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="580" left="224" width="119" height="20" font="1">analysis of use of BP-</text>
<text top="597" left="224" width="96" height="20" font="1">lowering drugs in </text>
<text top="615" left="224" width="132" height="20" font="1">prevention of CVD from </text>
<text top="632" left="224" width="121" height="20" font="1">147 randomized trials </text>
<text top="649" left="224" width="3" height="20" font="1"> </text>
<text top="666" left="224" width="140" height="20" font="4"><b>Size:</b> Of 147 randomized </text>
<text top="683" left="224" width="131" height="20" font="1">trials of 464,000 pts, 37 </text>
<text top="701" left="224" width="111" height="20" font="1">trials of BBs in CAD </text>
<text top="718" left="224" width="137" height="20" font="1">included 38,892 pts, and </text>
<text top="735" left="224" width="92" height="20" font="1">37 trials of other </text>
<text top="752" left="224" width="140" height="20" font="1">antihypertensive drugs in </text>
<text top="769" left="224" width="139" height="20" font="1">CAD included 85,395 pts </text>
<text top="563" left="378" width="185" height="20" font="4"><b>Inclusion criteria:</b> The database </text>
<text top="580" left="378" width="184" height="20" font="1">search used Medline (1966–Dec. </text>
<text top="597" left="378" width="181" height="20" font="1">2007 in any language) to identify </text>
<text top="615" left="378" width="180" height="20" font="1">randomized trials of BP-lowering </text>
<text top="632" left="378" width="165" height="20" font="1">drugs in which CAD events or </text>
<text top="649" left="378" width="153" height="20" font="1">strokes were recorded. The </text>
<text top="666" left="378" width="136" height="20" font="1">search also included the </text>
<text top="683" left="378" width="185" height="20" font="1">Cochrane Collaboration and Web </text>
<text top="701" left="378" width="165" height="20" font="1">of Science databases and the </text>
<text top="718" left="378" width="165" height="20" font="1">citations in trials and previous </text>
<text top="735" left="378" width="146" height="20" font="1">meta-analyses and review </text>
<text top="752" left="378" width="49" height="20" font="1">articles.  </text>
<text top="769" left="378" width="3" height="20" font="1"> </text>
<text top="564" left="577" width="185" height="20" font="4"><b>1</b>°<b> endpoint:</b> CAD events; stroke </text>
<text top="581" left="577" width="3" height="20" font="1"> </text>
<text top="598" left="577" width="341" height="20" font="4"><b>Results:</b> In 37 trials of pts with a history of CAD, BBs reduced </text>
<text top="616" left="577" width="349" height="20" font="1">CAD events 29% (95% CI: 22%, 34%). In 27 trials in which BBs </text>
<text top="633" left="577" width="345" height="20" font="1">were used after acute MI, BBs reduced CAD events 31% (95% </text>
<text top="650" left="577" width="331" height="20" font="1">CI: 24%, 38%), and in 11 trials in which BBs were used after </text>
<text top="667" left="577" width="339" height="20" font="1">long-term CAD, BBs insignificantly reduced CAD events 13%. </text>
<text top="685" left="577" width="337" height="20" font="1">In 7 trials, BBs reduced stroke 17% (95% CI: 1%–30%). CAD </text>
<text top="702" left="577" width="327" height="20" font="1">events were reduced 14% (95% CI: 2%–25%) in 11 trials of </text>
<text top="719" left="577" width="314" height="20" font="1">thiazide diuretics, 17% (95% CI: 11%–22%) in 21 trials of </text>
<text top="736" left="577" width="327" height="20" font="1">ACEIs, insignificantly 14% in 4 trials of angiotensin receptor </text>
<text top="753" left="577" width="325" height="20" font="1">blockers, and 15% (95% CI: 8%–22%) in 22 trials of CCBs. </text>
<text top="771" left="577" width="328" height="20" font="1">Stroke was reduced 38% (95% CI: 28%–47%) in 10 trials of </text>
<text top="565" left="939" width="7" height="18" font="1">•</text>
<text top="564" left="946" width="122" height="20" font="1"> With the exception of </text>
<text top="581" left="939" width="108" height="20" font="1">the extra protective </text>
<text top="598" left="939" width="106" height="20" font="1">effect of BBs given </text>
<text top="616" left="939" width="119" height="20" font="1">shortly after a MI and </text>
<text top="633" left="939" width="111" height="20" font="1">the minor additional </text>
<text top="650" left="939" width="96" height="20" font="1">effect of CCBs in </text>
<text top="667" left="939" width="117" height="20" font="1">preventing stroke, all </text>
<text top="685" left="939" width="99" height="20" font="1">the classes of BP-</text>
<text top="702" left="939" width="124" height="20" font="1">lowering drugs have a </text>
<text top="719" left="939" width="85" height="20" font="1">similar effect in </text>
<text top="736" left="939" width="120" height="20" font="1">reducing CAD events </text>
<text top="753" left="939" width="122" height="20" font="1">and stroke for a given </text>
<text top="771" left="939" width="90" height="20" font="1">reduction in BP. </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">123 </text>
<text top="107" left="378" width="174" height="20" font="4"><b>Exclusion criteria:</b> Trials were </text>
<text top="124" left="378" width="170" height="20" font="1">excluded if there were &lt;5 CAD </text>
<text top="141" left="378" width="186" height="20" font="1">events and strokes or if treatment </text>
<text top="159" left="378" width="114" height="20" font="1">duration was &lt;6 mo. </text>
<text top="107" left="577" width="349" height="20" font="1">thiazide diuretics, 22% (95% CI: 8%–34%) in 13 trials of ACEIs, </text>
<text top="124" left="577" width="272" height="20" font="1">and 34% (95% CI: 25%–42%) in 9 trials of CCBs. </text>
<text top="177" left="108" width="3" height="20" font="1"> </text>
<text top="211" left="81" width="402" height="24" font="3"><b>Data Supplement 37. RCTs Comparing CKD (Section 9.3) </b></text>
<text top="251" left="106" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="268" left="131" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="285" left="109" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="251" left="249" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="268" left="254" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="285" left="248" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="251" left="384" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="251" left="540" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="268" left="555" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="285" left="540" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="303" left="561" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="251" left="742" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="268" left="725" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="285" left="707" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="252" left="927" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="269" left="959" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="287" left="935" width="159" height="20" font="4"><b>Adverse Events; Summary </b></text>
<text top="321" left="98" width="43" height="20" font="4"><b>MDRD  </b></text>
<text top="339" left="98" width="84" height="20" font="1">Klahr S, et al.,  </text>
<text top="357" left="98" width="63" height="20" font="1">1994 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(169)</a> </text>
<text top="376" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8114857?dopt=Citation">8114857</a></text>
<text top="376" left="145" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8114857?dopt=Citation"><b> </b></a></text>
<text top="321" left="226" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="338" left="226" width="101" height="20" font="1">whether restricted </text>
<text top="355" left="226" width="129" height="20" font="1">protein intake or tighter </text>
<text top="372" left="226" width="104" height="20" font="1">HTN control would </text>
<text top="389" left="226" width="114" height="20" font="1">delay progression of </text>
<text top="407" left="226" width="29" height="20" font="1">CKD </text>
<text top="422" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="439" left="226" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="456" left="226" width="72" height="20" font="1">Randomized </text>
<text top="474" left="226" width="125" height="20" font="1">management to low or </text>
<text top="491" left="226" width="103" height="20" font="1">usual BP goal and </text>
<text top="508" left="226" width="121" height="20" font="1">usual, low or very low </text>
<text top="525" left="226" width="77" height="20" font="1">protein intake </text>
<text top="542" left="226" width="3" height="20" font="1"> </text>
<text top="560" left="226" width="32" height="20" font="4"><b>Size: </b></text>
<text top="579" left="226" width="7" height="18" font="1">•</text>
<text top="578" left="233" width="72" height="20" font="1"> Total n=840 </text>
<text top="595" left="226" width="83" height="20" font="1">Study 1 n=585 </text>
<text top="613" left="226" width="83" height="20" font="1">Study 2 n=255 </text>
<text top="632" left="226" width="7" height="18" font="1">•</text>
<text top="631" left="233" width="120" height="20" font="1"> Mean follow-up 2.2 y </text>
<text top="650" left="226" width="7" height="18" font="1">•</text>
<text top="649" left="233" width="114" height="20" font="1"> Mean MAP, mm Hg </text>
<text top="667" left="226" width="25" height="20" font="9">(SD)</text>
<text top="667" left="251" width="7" height="20" font="1">: </text>
<text top="684" left="226" width="91" height="20" font="1">Study 1: 98 (11) </text>
<text top="701" left="226" width="91" height="20" font="1">Study 2: 98 (11) </text>
<text top="720" left="226" width="7" height="18" font="1">•</text>
<text top="719" left="233" width="112" height="20" font="1"> Mean SBP, mm Hg </text>
<text top="737" left="226" width="25" height="20" font="9">(SD)</text>
<text top="737" left="251" width="7" height="20" font="1">: </text>
<text top="754" left="226" width="98" height="20" font="1">Study 1: 131 (18) </text>
<text top="771" left="226" width="98" height="20" font="1">Study 2: 133 (18) </text>
<text top="321" left="369" width="144" height="20" font="4"><b>Inclusion criteria: </b>Adults </text>
<text top="338" left="369" width="107" height="20" font="1">18–70 y, with renal </text>
<text top="355" left="369" width="128" height="20" font="1">insufficiency (serum Cr </text>
<text top="372" left="369" width="138" height="20" font="1">1.2–7.0 mg/dL in women </text>
<text top="389" left="369" width="119" height="20" font="1">and 1.4–7.0 mg/dL in </text>
<text top="407" left="369" width="138" height="20" font="1">men or CrCl &lt;70 mL/min </text>
<text top="424" left="369" width="94" height="20" font="1">per 1.73 m²) and </text>
<text top="441" left="369" width="102" height="20" font="1">MAP≤125 mm Hg </text>
<text top="458" left="369" width="141" height="20" font="1">(normotensives included)<b> </b></text>
<text top="475" left="369" width="3" height="20" font="1"> </text>
<text top="493" left="369" width="113" height="20" font="4"><b>Exclusion criteria:  </b></text>
<text top="510" left="369" width="134" height="20" font="1">Pregnancy, body weight </text>
<text top="527" left="369" width="105" height="20" font="1">&lt;80% or &gt;160% of </text>
<text top="544" left="369" width="129" height="20" font="1">standard, DM requiring </text>
<text top="562" left="369" width="138" height="20" font="1">insulin, urine protein &gt;10 </text>
<text top="579" left="369" width="108" height="20" font="1">g/d, history of renal </text>
<text top="596" left="369" width="104" height="20" font="1">transplant, chronic </text>
<text top="613" left="369" width="108" height="20" font="1">medical conditions, </text>
<text top="630" left="369" width="96" height="20" font="1">doubts regarding </text>
<text top="648" left="369" width="69" height="20" font="1">compliance. </text>
<text top="321" left="524" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="340" left="524" width="7" height="18" font="1">•</text>
<text top="339" left="531" width="98" height="20" font="1"> Study 1 included </text>
<text top="356" left="524" width="141" height="20" font="1">subjects with GFR 25–55 </text>
<text top="373" left="524" width="142" height="20" font="1">mL/min 1.73 m² (n=585);  </text>
<text top="392" left="524" width="7" height="18" font="1">•</text>
<text top="392" left="531" width="98" height="20" font="1"> Study 2 included </text>
<text top="409" left="524" width="141" height="20" font="1">subjects with GFR 13–24 </text>
<text top="426" left="524" width="135" height="20" font="1">mL/min 1.73 m² (n=255) </text>
<text top="445" left="524" width="7" height="18" font="1">•</text>
<text top="445" left="531" width="135" height="20" font="1"> Low MAP goal ≤92 mm </text>
<text top="462" left="524" width="121" height="20" font="1">Hg for those 18–60 y; </text>
<text top="479" left="524" width="115" height="20" font="1">≤98 for those ≥61 y  </text>
<text top="498" left="524" width="7" height="18" font="1">•</text>
<text top="497" left="531" width="131" height="20" font="1"> Usual: MAP goal ≤107 </text>
<text top="515" left="524" width="135" height="20" font="1">mm Hg for those 18–60; </text>
<text top="532" left="524" width="128" height="20" font="1">MAP ≤113 for subjects </text>
<text top="549" left="524" width="25" height="20" font="1">≥61 </text>
<text top="568" left="524" width="7" height="18" font="1">•</text>
<text top="567" left="531" width="60" height="20" font="1"> 2 studies: </text>
<text top="585" left="524" width="138" height="20" font="1">Study 1: above BP goals </text>
<text top="602" left="524" width="136" height="20" font="1">plus usual or low protein </text>
<text top="619" left="524" width="141" height="20" font="1">diet (1.3 or 0.58 g protein </text>
<text top="636" left="524" width="138" height="20" font="1">per kg of body weight/d)  </text>
<text top="653" left="524" width="138" height="20" font="1">Study 2: above BP goals </text>
<text top="671" left="524" width="111" height="20" font="1">plus low or very low </text>
<text top="688" left="524" width="138" height="20" font="1">protein diet (0.58 or 0.28 </text>
<text top="705" left="524" width="62" height="20" font="1">g per kg/d) </text>
<text top="724" left="524" width="7" height="18" font="1">•</text>
<text top="723" left="531" width="89" height="20" font="1"> Between group </text>
<text top="741" left="524" width="128" height="20" font="1">difference in MAP, mm </text>
<text top="758" left="524" width="91" height="20" font="1">Hg 4.7; p&lt;0.001 </text>
<text top="775" left="524" width="3" height="20" font="1"> </text>
<text top="321" left="680" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="339" left="680" width="230" height="20" font="1">Rate of decline in GFR, mL/min (95% CI)  </text>
<text top="358" left="680" width="7" height="18" font="1">•</text>
<text top="358" left="686" width="52" height="20" font="1"> Study 1  </text>
<text top="375" left="680" width="129" height="20" font="1">From baseline to 4 mo  </text>
<text top="392" left="680" width="145" height="20" font="1">Low: 3.4; 95% CI: 2.6–4.1 </text>
<text top="409" left="680" width="154" height="20" font="1">Usual: 1.9; 95% CI: 1.1–2.7 </text>
<text top="427" left="680" width="48" height="20" font="1">p=0.010 </text>
<text top="444" left="680" width="108" height="20" font="1">4 mo to study end,  </text>
<text top="461" left="680" width="145" height="20" font="1">Low: 2.8; 95% CI: 2.2–3.3 </text>
<text top="478" left="680" width="154" height="20" font="1">Usual: 3.9; 95% CI: 3.3–4.5 </text>
<text top="496" left="680" width="48" height="20" font="1">p=0.006 </text>
<text top="513" left="680" width="87" height="20" font="1">Baseline to 3 y, </text>
<text top="530" left="680" width="159" height="20" font="1">Low: 10.7; 95% CI: 9.1–12.4 </text>
<text top="547" left="680" width="174" height="20" font="1">Usual: 12.3; 95% CI: 10.6–14.0 </text>
<text top="565" left="680" width="41" height="20" font="1">p=0.18 </text>
<text top="584" left="680" width="7" height="18" font="1">•</text>
<text top="583" left="686" width="49" height="20" font="1"> Study 2 </text>
<text top="600" left="680" width="172" height="20" font="1">From baseline to end of study,  </text>
<text top="617" left="680" width="145" height="20" font="1">Low: 3.7; 95% CI: 3.1–4.3 </text>
<text top="635" left="680" width="154" height="20" font="1">Usual: 4.2; 95% CI: 3.6–4.9 </text>
<text top="651" left="680" width="41" height="20" font="1">p=0.28 </text>
<text top="668" left="680" width="90" height="20" font="1">ESRD or death: </text>
<text top="687" left="680" width="7" height="18" font="1">•</text>
<text top="687" left="686" width="49" height="20" font="1"> Study 2 </text>
<text top="704" left="680" width="225" height="20" font="1">RR for low vs. usual: 0.85; 95% CI: 0.60–</text>
<text top="721" left="680" width="27" height="20" font="1">1.22 </text>
<text top="738" left="680" width="35" height="20" font="1">p=NR </text>
<text top="319" left="921" width="76" height="20" font="4"><b>Limitations</b>:  </text>
<text top="335" left="921" width="7" height="18" font="1">•</text>
<text top="335" left="928" width="124" height="20" font="1"> Drug therapy was not </text>
<text top="350" left="921" width="161" height="20" font="1">randomized.  Recommended </text>
<text top="365" left="921" width="167" height="20" font="1">ACEI ± diuretic then CCB and </text>
<text top="380" left="921" width="176" height="20" font="1">others. More subjects in the low </text>
<text top="395" left="921" width="175" height="20" font="1">BP goal groups received ACEIs </text>
<text top="410" left="921" width="139" height="20" font="1">(48%, 51% also reported </text>
<text top="425" left="921" width="156" height="20" font="1">elsewhere) compared to the </text>
<text top="440" left="921" width="178" height="20" font="1">usual BP goal group (28%, 32% </text>
<text top="455" left="921" width="174" height="20" font="1">also reported e/w) (not noted in </text>
<text top="470" left="921" width="163" height="20" font="1">1° manuscript but reported in </text>
<text top="485" left="921" width="179" height="20" font="1">Peterson JC, et al., 1995 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(170)</a>). </text>
<text top="500" left="921" width="175" height="20" font="1">1.9% study 1, 1.2% study 2 lost </text>
<text top="515" left="921" width="70" height="20" font="1">to follow-up. </text>
<text top="532" left="921" width="7" height="18" font="1">•</text>
<text top="531" left="928" width="143" height="20" font="1"> Rate of GFR decline was </text>
<text top="546" left="921" width="153" height="20" font="1">slower than expected in the </text>
<text top="561" left="921" width="151" height="20" font="1">control groups and was not </text>
<text top="576" left="921" width="53" height="20" font="1">constant. </text>
<text top="591" left="921" width="3" height="20" font="1"> </text>
<text top="609" left="921" width="188" height="20" font="4"><b>Summary:</b> No significant benefits </text>
<text top="626" left="921" width="179" height="20" font="1">overall from either low protein or </text>
<text top="643" left="921" width="162" height="20" font="1">lower BP target. There was a </text>
<text top="660" left="921" width="168" height="20" font="1">significant interaction between </text>
<text top="677" left="921" width="185" height="20" font="1">baseline urinary protein excretion </text>
<text top="695" left="921" width="167" height="20" font="1">and BP interventions (p=0.01) </text>
<text top="712" left="921" width="160" height="20" font="1">indicating that low BP was of </text>
<text top="729" left="921" width="156" height="20" font="1">benefit to subjects with &gt;1 g </text>
<text top="746" left="921" width="126" height="20" font="1">proteinuria with slower </text>
<text top="763" left="921" width="150" height="20" font="1">progression of loss of GFR </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">124 </text>
<text top="109" left="226" width="7" height="18" font="1">•</text>
<text top="108" left="233" width="113" height="20" font="1"> Mean DBP, mm Hg </text>
<text top="125" left="226" width="25" height="20" font="9">(SD)</text>
<text top="125" left="251" width="7" height="20" font="1">: </text>
<text top="143" left="226" width="91" height="20" font="1">Study 1: 81 (10) </text>
<text top="160" left="226" width="91" height="20" font="1">Study 2: 81 (10) </text>
<text top="107" left="524" width="142" height="20" font="4"><b>Comparator: </b> By BP and </text>
<text top="124" left="524" width="110" height="20" font="1">protein intake goals </text>
<text top="281" left="98" width="43" height="20" font="4"><b>REIN-2 </b></text>
<text top="296" left="98" width="107" height="20" font="1">Ruggeneti P, et al., </text>
<text top="312" left="98" width="62" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(171)</a> </text>
<text top="327" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15766995?dopt=Citation">15766995</a></text>
<text top="327" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15766995?dopt=Citation"> </a></text>
<text top="281" left="226" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="296" left="226" width="119" height="20" font="1">whether intensive BP </text>
<text top="312" left="226" width="107" height="20" font="1">control will achieve </text>
<text top="327" left="226" width="121" height="20" font="1">further renoprotection </text>
<text top="342" left="226" width="118" height="20" font="1">(delayed progression </text>
<text top="358" left="226" width="127" height="20" font="1">to ESRD) compared to </text>
<text top="373" left="226" width="124" height="20" font="1">standard BP control in </text>
<text top="388" left="226" width="88" height="20" font="1">pts with chronic </text>
<text top="404" left="226" width="81" height="20" font="1">nephropathies </text>
<text top="419" left="226" width="3" height="20" font="1"> </text>
<text top="436" left="226" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="454" left="226" width="126" height="20" font="1">Multicenter RCT of pts </text>
<text top="471" left="226" width="104" height="20" font="1">all placed on ACEI </text>
<text top="488" left="226" width="122" height="20" font="1">(ramipril) at maximum </text>
<text top="505" left="226" width="95" height="20" font="1">dose tolerated to </text>
<text top="522" left="226" width="126" height="20" font="1">achieve DBP &lt;90 then </text>
<text top="540" left="226" width="66" height="20" font="1">assigned to </text>
<text top="557" left="226" width="87" height="20" font="1">conventional or </text>
<text top="574" left="226" width="122" height="20" font="1">intensified BP control. </text>
<text top="591" left="226" width="96" height="20" font="1">Add-on drug was </text>
<text top="609" left="226" width="87" height="20" font="1">dihydropyridine </text>
<text top="626" left="226" width="118" height="20" font="1">felodipine 5–10 mg/d </text>
<text top="643" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="660" left="226" width="130" height="20" font="4"><b>Size: </b>335 (median time </text>
<text top="677" left="226" width="42" height="20" font="1">19 mo) </text>
<text top="281" left="369" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="300" left="369" width="7" height="18" font="1">•</text>
<text top="299" left="376" width="119" height="20" font="1"> Adults, age 18–70 y, </text>
<text top="316" left="369" width="91" height="20" font="1">with nondiabetic </text>
<text top="334" left="369" width="132" height="20" font="1">nephropathy, persistent </text>
<text top="351" left="369" width="107" height="20" font="1">proteinuria (urinary </text>
<text top="368" left="369" width="139" height="20" font="1">protein excretion &gt;1 g/24 </text>
<text top="385" left="369" width="133" height="20" font="1">h for ≥3 mo) and not on </text>
<text top="402" left="369" width="130" height="20" font="1">ACEIs in previous 6 wk </text>
<text top="421" left="369" width="7" height="18" font="1">•</text>
<text top="421" left="376" width="135" height="20" font="1"> Pts with proteinuria 1–3 </text>
<text top="438" left="369" width="124" height="20" font="1">g/24 h included if CrCl </text>
<text top="455" left="369" width="106" height="20" font="1">&lt;70 mL/min/1.73 m</text>
<text top="457" left="475" width="4" height="13" font="6">2</text>
<text top="455" left="479" width="7" height="20" font="1">  </text>
<text top="474" left="369" width="7" height="18" font="1">•</text>
<text top="474" left="376" width="129" height="20" font="1"> For overall population, </text>
<text top="491" left="369" width="109" height="20" font="1">mean SBP, mm Hg </text>
<text top="491" left="478" width="25" height="20" font="9">(SD)</text>
<text top="491" left="503" width="7" height="20" font="1">: </text>
<text top="508" left="369" width="126" height="20" font="1">Intensive: 137.0 (16.7) </text>
<text top="525" left="369" width="113" height="20" font="1">Conventional: 136.4 </text>
<text top="542" left="369" width="36" height="20" font="1">(17.0) </text>
<text top="561" left="369" width="7" height="18" font="1">•</text>
<text top="561" left="376" width="129" height="20" font="1"> For overall population, </text>
<text top="578" left="369" width="109" height="20" font="1">mean DBP, mm Hg </text>
<text top="578" left="478" width="25" height="20" font="9">(SD)</text>
<text top="578" left="503" width="7" height="20" font="1">: </text>
<text top="595" left="369" width="112" height="20" font="1">Intensive: 84.3 (9.0) </text>
<text top="613" left="369" width="141" height="20" font="1">Conventional: 83.9 (10.4) </text>
<text top="647" left="369" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="664" left="369" width="123" height="20" font="1">Urinary tract infection, </text>
<text top="681" left="369" width="96" height="20" font="1">CHF class III–IV, </text>
<text top="698" left="369" width="81" height="20" font="1">treatment with </text>
<text top="716" left="369" width="137" height="20" font="1">corticosteroids, NSAIDs, </text>
<text top="733" left="369" width="117" height="20" font="1">immunosuppression, </text>
<text top="750" left="369" width="143" height="20" font="1">acute MI or stroke in prior </text>
<text top="767" left="369" width="75" height="20" font="1">6 mo, severe </text>
<text top="784" left="369" width="102" height="20" font="1">uncontrolled HTN, </text>
<text top="281" left="524" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="300" left="524" width="7" height="18" font="1">•</text>
<text top="299" left="531" width="106" height="20" font="1"> Intensive: BP goal </text>
<text top="316" left="524" width="91" height="20" font="1">&lt;130/80 mm Hg </text>
<text top="335" left="524" width="7" height="18" font="1">•</text>
<text top="335" left="531" width="111" height="20" font="1"> Conventional: DBP </text>
<text top="352" left="524" width="97" height="20" font="1">goal &lt;90 mm Hg, </text>
<text top="369" left="524" width="111" height="20" font="1">irrespective of SBP  </text>
<text top="388" left="524" width="7" height="18" font="1">•</text>
<text top="388" left="531" width="75" height="20" font="1"> For baseline </text>
<text top="405" left="524" width="126" height="20" font="1">proteinuria subgroups, </text>
<text top="422" left="524" width="117" height="20" font="1">result BP values NR  </text>
<text top="441" left="524" width="7" height="18" font="1">•</text>
<text top="440" left="531" width="85" height="20" font="1"> For the overall </text>
<text top="458" left="524" width="139" height="20" font="1">population, achieved BP, </text>
<text top="475" left="524" width="43" height="20" font="1">mm Hg </text>
<text top="475" left="567" width="25" height="20" font="9">(SD)</text>
<text top="475" left="593" width="3" height="20" font="1"> </text>
<text top="492" left="524" width="118" height="20" font="1">Intensive: 129.6/79.5 </text>
<text top="509" left="524" width="56" height="20" font="1">(10.9/5.3) </text>
<text top="526" left="524" width="140" height="20" font="1">Conventional: 133.7/82.3 </text>
<text top="544" left="524" width="56" height="20" font="1">(12.6/7.1) </text>
<text top="561" left="524" width="103" height="20" font="1">p=0.0019/&lt;0.0001 </text>
<text top="580" left="524" width="7" height="18" font="1">•</text>
<text top="579" left="531" width="85" height="20" font="1"> For the overall </text>
<text top="596" left="524" width="64" height="20" font="1">population, </text>
<text top="614" left="524" width="123" height="20" font="1">change in BP, mm Hg </text>
<text top="631" left="524" width="105" height="20" font="1">Intensive: -7.4/-4.8 </text>
<text top="648" left="524" width="128" height="20" font="1">Conventional: -2.7/-1.6 </text>
<text top="665" left="524" width="35" height="20" font="1">p=NR </text>
<text top="684" left="524" width="7" height="18" font="1">•</text>
<text top="684" left="531" width="85" height="20" font="1"> For the overall </text>
<text top="701" left="524" width="64" height="20" font="1">population, </text>
<text top="718" left="524" width="127" height="20" font="1">BP difference between </text>
<text top="735" left="524" width="87" height="20" font="1">groups, mm Hg </text>
<text top="753" left="524" width="41" height="20" font="1">4.1/2.8 </text>
<text top="768" left="524" width="35" height="20" font="1">p=NR </text>
<text top="784" left="524" width="3" height="20" font="1"> </text>
<text top="283" left="680" width="72" height="20" font="4"><b>1° endpoint </b></text>
<text top="303" left="680" width="7" height="18" font="1">•</text>
<text top="302" left="686" width="208" height="20" font="1"> Time to ESRD; over 36 mo follow-up, </text>
<text top="320" left="680" width="80" height="20" font="1">median 19 mo </text>
<text top="337" left="680" width="215" height="20" font="1">1° outcome: ESRD in pts with baseline </text>
<text top="354" left="680" width="123" height="20" font="1">proteinuria 1–3 g/24 h </text>
<text top="371" left="680" width="217" height="20" font="1">HR (95% CI): 1.06 (95% CI: 0.51–2.20) </text>
<text top="388" left="680" width="41" height="20" font="1">p=0.89 </text>
<text top="407" left="680" width="7" height="18" font="1">•</text>
<text top="407" left="686" width="210" height="20" font="1"> ESRD in pts with baseline proteinuria </text>
<text top="424" left="680" width="55" height="20" font="1">&gt;3 g/24 h </text>
<text top="441" left="680" width="217" height="20" font="1">HR (95% CI): 1.09 (95% CI: 0.55–2.19) </text>
<text top="458" left="680" width="41" height="20" font="1">p=0.81 </text>
<text top="478" left="680" width="7" height="18" font="1">•</text>
<text top="477" left="686" width="163" height="20" font="1"> 23% of intensive and 20% of </text>
<text top="494" left="680" width="219" height="20" font="1">conventional control groups progressed </text>
<text top="511" left="680" width="55" height="20" font="1">to ESRD. </text>
<text top="530" left="680" width="7" height="18" font="1">•</text>
<text top="530" left="686" width="161" height="20" font="1"> Median rate of GFR decline, </text>
<text top="547" left="680" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="549" left="761" width="4" height="13" font="6">2</text>
<text top="547" left="765" width="115" height="20" font="1">/mo (IQR) in pts with </text>
<text top="564" left="679" width="162" height="20" font="1">baseline proteinuria &lt;3 g/24:  </text>
<text top="581" left="679" width="197" height="20" font="1">Intensive: 0.18 (95% CI: 0.03–0.49) </text>
<text top="598" left="679" width="82" height="20" font="1">Conventional:  </text>
<text top="616" left="679" width="145" height="20" font="1">0.21 (95% CI: -0.03–0.40) </text>
<text top="633" left="679" width="41" height="20" font="1">p=0.89 </text>
<text top="652" left="679" width="7" height="18" font="1">•</text>
<text top="651" left="686" width="161" height="20" font="1"> Median rate of GFR decline, </text>
<text top="669" left="679" width="197" height="20" font="1">mL/min/1.73 m/mo (IQR) in pts with </text>
<text top="686" left="680" width="163" height="20" font="1">baseline proteinuria ≥3 g/24:  </text>
<text top="703" left="680" width="192" height="20" font="1">Intensive: 0.51; 95% CI: 0.16–1.05 </text>
<text top="720" left="680" width="208" height="20" font="1">Conventional: 0.39; 95% CI: 0.030.98 </text>
<text top="738" left="680" width="41" height="20" font="1">p=0.39 </text>
<text top="281" left="921" width="156" height="20" font="4"><b>Limitations: </b>The study was </text>
<text top="296" left="921" width="88" height="20" font="1">stopped at the 1</text>
<text top="298" left="1009" width="6" height="13" font="6">st</text>
<text top="296" left="1015" width="92" height="20" font="1"> interim analysis </text>
<text top="311" left="921" width="164" height="20" font="1">for futility. Median time 19 mo </text>
<text top="327" left="921" width="3" height="20" font="4"><b> </b></text>
<text top="344" left="921" width="170" height="20" font="4"><b>Summary:</b> In pts with non-DM </text>
<text top="361" left="921" width="142" height="20" font="1">proteinuric nephropathies </text>
<text top="378" left="921" width="152" height="20" font="1">receiving background ACEI </text>
<text top="395" left="921" width="167" height="20" font="1">therapy, no additional benefits </text>
<text top="413" left="921" width="157" height="20" font="1">from further BP reduction by </text>
<text top="430" left="921" width="148" height="20" font="1">felodipine could be shown. </text>
<text top="447" left="921" width="162" height="20" font="1">Dihydropyridine CCBs do not </text>
<text top="464" left="921" width="180" height="20" font="1">offer additional renoprotection to </text>
<text top="482" left="921" width="91" height="20" font="1">ACEIs or ARBs. </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">125 </text>
<text top="107" left="369" width="72" height="20" font="1">suspicion for </text>
<text top="124" left="369" width="123" height="20" font="1">renovascular disease, </text>
<text top="141" left="369" width="118" height="20" font="1">obstructive uropathy, </text>
<text top="159" left="369" width="135" height="20" font="1">DM-1, collagen vascular </text>
<text top="176" left="369" width="143" height="20" font="1">disease, cancer, elevated </text>
<text top="193" left="369" width="135" height="20" font="1">aspartate transaminase, </text>
<text top="210" left="369" width="137" height="20" font="1">chronic cough, history of </text>
<text top="228" left="369" width="136" height="20" font="1">allergy or poor tolerance </text>
<text top="245" left="369" width="126" height="20" font="1">to study meds, alcohol </text>
<text top="262" left="369" width="105" height="20" font="1">abuse, pregnancy, </text>
<text top="279" left="369" width="140" height="20" font="1">breastfeeding, ineffective </text>
<text top="296" left="369" width="81" height="20" font="1">contraception.<b> </b></text>
<text top="107" left="524" width="115" height="20" font="4"><b>Comparator:</b> By BP </text>
<text top="124" left="524" width="33" height="20" font="1">goals </text>
<text top="313" left="98" width="38" height="20" font="4"><b>AASK </b></text>
<text top="328" left="98" width="92" height="20" font="1">Wright JT, et al., </text>
<text top="343" left="98" width="62" height="20" font="1">2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(172)</a> </text>
<text top="359" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12435255?dopt=Citation">12435255</a></text>
<text top="359" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12435255?dopt=Citation"> </a></text>
<text top="313" left="226" width="120" height="20" font="4"><b>Aim: </b>To compare the </text>
<text top="328" left="226" width="112" height="20" font="1">effects of 2 levels of </text>
<text top="343" left="226" width="54" height="20" font="1">BP and 3 </text>
<text top="359" left="226" width="121" height="20" font="1">antihypertensive drug </text>
<text top="374" left="226" width="91" height="20" font="1">classes on GFR </text>
<text top="389" left="226" width="84" height="20" font="1">decline in HTN </text>
<text top="405" left="226" width="3" height="20" font="1"> </text>
<text top="422" left="226" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="441" left="226" width="7" height="18" font="1">•</text>
<text top="440" left="233" width="100" height="20" font="1"> Randomized 3×2 </text>
<text top="458" left="226" width="70" height="20" font="1">factorial trial </text>
<text top="477" left="226" width="7" height="18" font="1">•</text>
<text top="476" left="233" width="116" height="20" font="1"> Measured GFR with </text>
<text top="493" left="226" width="67" height="20" font="1">iothalamate </text>
<text top="510" left="226" width="3" height="20" font="1"> </text>
<text top="528" left="226" width="66" height="20" font="4"><b>Size: </b>1,094<b> </b></text>
<text top="313" left="369" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="331" left="369" width="7" height="18" font="1">•</text>
<text top="331" left="376" width="77" height="20" font="1"> Adult African-</text>
<text top="348" left="369" width="137" height="20" font="1">Americans,18–70 y, with </text>
<text top="365" left="369" width="115" height="20" font="1">HTN (DBP ≥95) and </text>
<text top="382" left="369" width="81" height="20" font="1">GFR of 20–65 </text>
<text top="400" left="369" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="401" left="450" width="4" height="13" font="6">2</text>
<text top="400" left="455" width="46" height="20" font="1">, no DM </text>
<text top="419" left="369" width="7" height="18" font="1">•</text>
<text top="418" left="376" width="120" height="20" font="1"> At entry: mean MAP, </text>
<text top="435" left="369" width="46" height="20" font="1">mm Hg: </text>
<text top="453" left="369" width="79" height="20" font="1">Low: 115 (27) </text>
<text top="470" left="369" width="87" height="20" font="1">Usual: 113 (15) </text>
<text top="489" left="369" width="7" height="18" font="1">•</text>
<text top="488" left="376" width="112" height="20" font="1"> Mean SBP, mm Hg </text>
<text top="505" left="369" width="25" height="20" font="9">(SD)</text>
<text top="505" left="394" width="7" height="20" font="1">: </text>
<text top="523" left="369" width="75" height="20" font="1">Low:152 (25) </text>
<text top="540" left="369" width="87" height="20" font="1">Usual: 149 (23) </text>
<text top="559" left="369" width="7" height="18" font="1">•</text>
<text top="558" left="376" width="116" height="20" font="1"> Mean DBP, mm Hg: </text>
<text top="575" left="369" width="72" height="20" font="1">Low: 96 (15) </text>
<text top="593" left="369" width="81" height="20" font="1">Usual: 95 (14) </text>
<text top="608" left="369" width="3" height="20" font="1"> </text>
<text top="625" left="369" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="642" left="369" width="132" height="20" font="1">DBP&lt;95, history of DM, </text>
<text top="660" left="369" width="141" height="20" font="1">Urinary protein/creatinine </text>
<text top="677" left="369" width="140" height="20" font="1">ratio &gt;2.5, accelerated or </text>
<text top="694" left="369" width="133" height="20" font="1">malignant HTN, non-BP </text>
<text top="711" left="369" width="124" height="20" font="1">related cause of CKD, </text>
<text top="728" left="369" width="143" height="20" font="1">serious systemic disease, </text>
<text top="746" left="369" width="117" height="20" font="1">clinical CHF, specific </text>
<text top="763" left="369" width="70" height="20" font="1">indication or </text>
<text top="780" left="369" width="118" height="20" font="1">contraindication for a </text>
<text top="313" left="524" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="331" left="524" width="7" height="18" font="1">•</text>
<text top="331" left="531" width="115" height="20" font="1"> Low: MAP goal ≤92 </text>
<text top="348" left="524" width="43" height="20" font="1">mm Hg </text>
<text top="365" left="524" width="122" height="20" font="1">Usual: MAP goal 102–</text>
<text top="382" left="524" width="70" height="20" font="1">107 mm Hg  </text>
<text top="402" left="524" width="7" height="18" font="1">•</text>
<text top="401" left="531" width="126" height="20" font="1"> Initial treatment with a </text>
<text top="418" left="524" width="129" height="20" font="1">B Blocker (metoprolol), </text>
<text top="435" left="524" width="133" height="20" font="1">and ACEI (ramipril) or a </text>
<text top="453" left="524" width="87" height="20" font="1">dihydropyridine </text>
<text top="470" left="524" width="127" height="20" font="1">(amlodipine) with open </text>
<text top="487" left="524" width="121" height="20" font="1">label agents added to </text>
<text top="504" left="524" width="98" height="20" font="1">achieve BP goals </text>
<text top="521" left="524" width="7" height="18" font="1">•</text>
<text top="520" left="531" width="90" height="20" font="1"> Study duration: </text>
<text top="537" left="524" width="44" height="20" font="1">3–6.4 y </text>
<text top="553" left="524" width="7" height="18" font="1">•</text>
<text top="552" left="531" width="130" height="20" font="1"> BP similar across drug </text>
<text top="568" left="524" width="134" height="20" font="1">groups except 2 mm Hg </text>
<text top="583" left="524" width="109" height="20" font="1">lower in amlodipine </text>
<text top="598" left="524" width="35" height="20" font="1">group </text>
<text top="616" left="524" width="7" height="18" font="1">•</text>
<text top="616" left="531" width="110" height="20" font="1"> Mean from 3 mo to </text>
<text top="633" left="524" width="57" height="20" font="1">study end </text>
<text top="652" left="524" width="7" height="18" font="1">•</text>
<text top="651" left="531" width="80" height="20" font="1"> MAP, mm Hg </text>
<text top="651" left="611" width="25" height="20" font="9">(SD)</text>
<text top="651" left="636" width="3" height="20" font="1"> </text>
<text top="669" left="524" width="75" height="20" font="1">Low: 95.8 (8) </text>
<text top="686" left="524" width="81" height="20" font="1">Usual: 104 (7) </text>
<text top="705" left="524" width="7" height="18" font="1">•</text>
<text top="704" left="531" width="107" height="20" font="1"> SBP/DBP, mm Hg </text>
<text top="704" left="638" width="25" height="20" font="9">(SD)</text>
<text top="704" left="663" width="3" height="20" font="1"> </text>
<text top="721" left="524" width="106" height="20" font="1">Low: 128/78 (12/8) </text>
<text top="739" left="524" width="115" height="20" font="1">Usual: 141/85 (12/7) </text>
<text top="758" left="524" width="7" height="18" font="1">•</text>
<text top="757" left="531" width="124" height="20" font="1"> MAP change, mm Hg </text>
<text top="774" left="524" width="51" height="20" font="1">Low: -20 </text>
<text top="314" left="680" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="333" left="680" width="7" height="18" font="1">•</text>
<text top="333" left="686" width="221" height="20" font="1"> 1° outcome: difference in mean slopes, </text>
<text top="350" left="680" width="180" height="20" font="1">acute GFR slope, mL/min/1.73 m</text>
<text top="352" left="860" width="4" height="13" font="6">2</text>
<text top="350" left="865" width="34" height="20" font="1">/3 mo </text>
<text top="367" left="679" width="35" height="20" font="1">(SE):  </text>
<text top="386" left="679" width="7" height="18" font="1">•</text>
<text top="386" left="686" width="156" height="20" font="1"> 1.82 (0.54) in low BP group </text>
<text top="403" left="679" width="48" height="20" font="1">p&lt;0.001 </text>
<text top="422" left="679" width="7" height="18" font="1">•</text>
<text top="421" left="686" width="221" height="20" font="1"> 1° outcome: difference in mean slopes, </text>
<text top="438" left="679" width="190" height="20" font="1">chronic GFR slope, mL/min/1.73 m</text>
<text top="440" left="870" width="4" height="13" font="6">2</text>
<text top="438" left="874" width="13" height="20" font="1">/y </text>
<text top="456" left="680" width="98" height="20" font="1">(SE): 0.21 (0.22)  </text>
<text top="473" left="680" width="62" height="20" font="1">p=0.33 NS </text>
<text top="492" left="680" width="7" height="18" font="1">•</text>
<text top="491" left="686" width="209" height="20" font="1"> Difference in mean slopes, total GFR </text>
<text top="508" left="680" width="118" height="20" font="1">slope, mL/min/1.73 m</text>
<text top="510" left="797" width="4" height="13" font="6">2</text>
<text top="508" left="802" width="48" height="20" font="1">/y (SE):  </text>
<text top="526" left="679" width="67" height="20" font="1">-0.25 (0.22) </text>
<text top="543" left="679" width="41" height="20" font="1">p=0.24 </text>
<text top="562" left="679" width="7" height="18" font="1">•</text>
<text top="561" left="686" width="202" height="20" font="1"> Main 2º clinical composite outcome: </text>
<text top="578" left="679" width="159" height="20" font="1">GFR event, ESRD, or death, </text>
<text top="596" left="679" width="212" height="20" font="1">% risk reduction (95% CI): 2 (95% CI: -</text>
<text top="613" left="679" width="42" height="20" font="1">22–21) </text>
<text top="630" left="679" width="41" height="20" font="1">p=0.85 </text>
<text top="649" left="679" width="7" height="18" font="1">•</text>
<text top="648" left="686" width="122" height="20" font="1"> GFR event or ESRD, </text>
<text top="666" left="680" width="214" height="20" font="1">% Risk Reduction: -2; 95% CI: -31–20; </text>
<text top="683" left="680" width="41" height="20" font="1">p=0.87 </text>
<text top="702" left="680" width="7" height="18" font="1">•</text>
<text top="701" left="686" width="93" height="20" font="1"> ESRD or death, </text>
<text top="718" left="680" width="207" height="20" font="1">% risk reduction: 12; 95% CI: -13–32; </text>
<text top="736" left="680" width="41" height="20" font="1">p=0.31 </text>
<text top="755" left="680" width="7" height="18" font="1">•</text>
<text top="754" left="686" width="78" height="20" font="1"> ESRD alone, </text>
<text top="771" left="680" width="200" height="20" font="1">% risk reduction: 6; 95% CI: -29–31; </text>
<text top="788" left="680" width="41" height="20" font="1">p=0.72 </text>
<text top="315" left="921" width="73" height="20" font="4"><b>Limitations: </b></text>
<text top="335" left="921" width="7" height="18" font="1">•</text>
<text top="334" left="928" width="98" height="20" font="1"> Based on DSMD </text>
<text top="352" left="921" width="186" height="20" font="1">recommendation, amlodipine arm </text>
<text top="369" left="921" width="144" height="20" font="1">halted early and those pts </text>
<text top="386" left="921" width="147" height="20" font="1">switched to open label Rx, </text>
<text top="403" left="921" width="166" height="20" font="1">continued study schedule and </text>
<text top="420" left="921" width="86" height="20" font="1">same BP goals </text>
<text top="438" left="921" width="3" height="20" font="1"> </text>
<text top="456" left="921" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="475" left="921" width="7" height="18" font="1">•</text>
<text top="474" left="928" width="165" height="20" font="1"> No difference in GFR decline </text>
<text top="491" left="921" width="145" height="20" font="1">with lower BP goal and no </text>
<text top="508" left="921" width="170" height="20" font="1">difference in composite clinical </text>
<text top="526" left="921" width="57" height="20" font="1">endpoints </text>
<text top="545" left="921" width="7" height="18" font="1">•</text>
<text top="544" left="928" width="173" height="20" font="1"> Average rate of GFR decline 2 </text>
<text top="561" left="921" width="185" height="20" font="1">mL/min/y is similar or slower than </text>
<text top="579" left="921" width="92" height="20" font="1">previous reports </text>
<text top="598" left="921" width="7" height="18" font="1">•</text>
<text top="597" left="928" width="174" height="20" font="1"> There was a trend favoring the </text>
<text top="614" left="921" width="166" height="20" font="1">lower BP goal in subjects with </text>
<text top="631" left="921" width="172" height="20" font="1">higher baseline proteinuria and </text>
<text top="649" left="921" width="153" height="20" font="1">the opposite trend for those </text>
<text top="666" left="921" width="104" height="20" font="1">without proteinuria </text>
<text top="683" left="921" width="175" height="20" font="1">● Ramipril treatment group had </text>
<text top="700" left="921" width="165" height="20" font="1">slower progression compared </text>
<text top="717" left="921" width="173" height="20" font="1">with metoprolol and amlodipine </text>
<text top="735" left="921" width="178" height="20" font="1">combined, less evident between </text>
<text top="752" left="921" width="128" height="20" font="1">ramipril and metoprolol </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">126 </text>
<text top="107" left="369" width="134" height="20" font="1">study drug or procedure </text>
<text top="107" left="524" width="53" height="20" font="1">Usual: -9 </text>
<text top="126" left="524" width="7" height="18" font="1">•</text>
<text top="125" left="531" width="131" height="20" font="1"> SBP/DBP change, mm </text>
<text top="143" left="524" width="19" height="20" font="1">Hg </text>
<text top="160" left="524" width="65" height="20" font="1">Low: -24/-8 </text>
<text top="177" left="524" width="81" height="20" font="1">Usual: -18/-10 </text>
<text top="196" left="524" width="7" height="18" font="1">•</text>
<text top="195" left="531" width="111" height="20" font="1"> Achieved mean BP </text>
<text top="213" left="524" width="107" height="20" font="1">difference between </text>
<text top="230" left="524" width="87" height="20" font="1">groups, mm Hg </text>
<text top="247" left="524" width="51" height="20" font="1">MAP: 11 </text>
<text top="264" left="524" width="49" height="20" font="1">SBP: 16 </text>
<text top="282" left="524" width="42" height="20" font="1">DBP: 8 </text>
<text top="299" left="524" width="3" height="20" font="1"> </text>
<text top="316" left="524" width="101" height="20" font="4"><b>Comparator: </b>N/A<b> </b></text>
<text top="110" left="680" width="7" height="18" font="1">•</text>
<text top="109" left="686" width="197" height="20" font="1"> 2º outcome: urine protein excretion </text>
<text top="127" left="680" width="3" height="20" font="1"> </text>
<text top="144" left="680" width="103" height="20" font="4"><b>Safety endpoint:</b>  </text>
<text top="161" left="680" width="209" height="20" font="1">● Acute and chronic rate of change in </text>
<text top="179" left="680" width="74" height="20" font="1">GFR (slope): </text>
<text top="196" left="680" width="178" height="20" font="1">NS for chronic and total slope in </text>
<text top="213" left="680" width="172" height="20" font="1">subgroup analyses by baseline </text>
<text top="230" left="680" width="99" height="20" font="1">proteinuria strata  </text>
<text top="248" left="680" width="203" height="20" font="1">● Acute slope: p=0.08 for interaction </text>
<text top="265" left="680" width="199" height="20" font="1">● Total slope: p=0.04 for interaction </text>
<text top="282" left="680" width="214" height="20" font="1">● Chronic slope: p=0.16 for interaction </text>
<text top="299" left="680" width="217" height="20" font="1">● Clinical composite outcome: includes </text>
<text top="316" left="680" width="189" height="20" font="1">reduction in GFR by 50% or by 25 </text>
<text top="334" left="680" width="177" height="20" font="1">mL/min/m², ESRD, death, NS in </text>
<text top="351" left="680" width="172" height="20" font="1">subgroup analyses by baseline </text>
<text top="368" left="680" width="225" height="20" font="1">proteinuria strata; p=0.007 for interaction </text>
<text top="385" left="680" width="214" height="20" font="1">● For above outcomes, trends favored </text>
<text top="402" left="680" width="220" height="20" font="1">the lower BP goal over the usual goal in </text>
<text top="420" left="680" width="178" height="20" font="1">participants with higher baseline </text>
<text top="437" left="680" width="186" height="20" font="1">proteinuria and opposite trends in </text>
<text top="454" left="680" width="210" height="20" font="1">participants with little or no proteinuria </text>
<text top="471" left="680" width="217" height="20" font="1">Within each drug group, risk reductions </text>
<text top="488" left="680" width="222" height="20" font="1">for any 2º clinical outcome of the low vs. </text>
<text top="506" left="680" width="197" height="20" font="1">usual BP goal were not significantly </text>
<text top="523" left="680" width="223" height="20" font="1">different between pts with baseline urine </text>
<text top="540" left="680" width="198" height="20" font="1">protein to creatinine ratio ≤0.22 and </text>
<text top="557" left="680" width="77" height="20" font="1">&gt;0.22 (p=NS) </text>
<text top="575" left="98" width="106" height="20" font="1">Contreras G, et al., </text>
<text top="592" left="98" width="62" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(173)</a> </text>
<text top="610" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15897360?dopt=Citation">15897360</a></text>
<text top="610" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15897360?dopt=Citation"> </a></text>
<text top="575" left="226" width="118" height="20" font="4"><b>Aim: </b>Within AASK to </text>
<text top="592" left="226" width="118" height="20" font="1">examine the effect of </text>
<text top="610" left="226" width="87" height="20" font="1">BP intervention </text>
<text top="627" left="226" width="104" height="20" font="1">separately in the 3 </text>
<text top="644" left="226" width="124" height="20" font="1">drug treatment groups </text>
<text top="660" left="226" width="3" height="20" font="1"> </text>
<text top="677" left="226" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="694" left="226" width="109" height="20" font="1">● Randomized 3×2 </text>
<text top="711" left="226" width="70" height="20" font="1">factorial trial </text>
<text top="728" left="226" width="125" height="20" font="1">● Measured GFR with </text>
<text top="746" left="226" width="67" height="20" font="1">iothalamate </text>
<text top="763" left="226" width="3" height="20" font="1"> </text>
<text top="780" left="226" width="66" height="20" font="4"><b>Size: </b>1,094 </text>
<text top="575" left="369" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="592" left="369" width="85" height="20" font="1">● Adult African </text>
<text top="610" left="369" width="136" height="20" font="1">Americans, ages 18–70, </text>
<text top="627" left="369" width="140" height="20" font="1">with HTN (DBP ≥95) and </text>
<text top="644" left="369" width="81" height="20" font="1">GFR of 20–65 </text>
<text top="661" left="369" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="663" left="450" width="4" height="13" font="6">2</text>
<text top="661" left="455" width="46" height="20" font="1">, no DM </text>
<text top="678" left="369" width="114" height="20" font="1">Mean MAP, mm Hg: </text>
<text top="696" left="369" width="131" height="20" font="1">Low, Amlodipine: 115.3 </text>
<text top="713" left="369" width="36" height="20" font="1">(18.3) </text>
<text top="730" left="369" width="140" height="20" font="1">Usual, Amlodipine: 112.7 </text>
<text top="747" left="369" width="36" height="20" font="1">(14.7) </text>
<text top="764" left="369" width="128" height="20" font="1">Low, Metoprolol: 114.5 </text>
<text top="782" left="369" width="36" height="20" font="1">(17.5) </text>
<text top="575" left="524" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="592" left="524" width="138" height="20" font="1">● Analysis by initial drug </text>
<text top="610" left="524" width="90" height="20" font="1">treatment group </text>
<text top="627" left="524" width="139" height="20" font="1">● Low, Amlodipine: MAP </text>
<text top="644" left="524" width="98" height="20" font="1">goal ≤92 mm Hg, </text>
<text top="661" left="524" width="138" height="20" font="1">Amlodipine (5–10 mg/d)  </text>
<text top="678" left="524" width="136" height="20" font="1">Usual, Amlodipine: MAP </text>
<text top="696" left="524" width="124" height="20" font="1">goal 102–107 mm Hg, </text>
<text top="713" left="524" width="138" height="20" font="1">Amlodipine (5–10 mg/d)  </text>
<text top="730" left="524" width="136" height="20" font="1">● Low, Metoprolol: MAP </text>
<text top="747" left="524" width="98" height="20" font="1">goal ≤92 mm Hg, </text>
<text top="764" left="524" width="109" height="20" font="1">Metoprolol (50–200 </text>
<text top="782" left="524" width="38" height="20" font="1">mg/d)  </text>
<text top="576" left="680" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="593" left="680" width="210" height="20" font="1">● GFR event, ESRD, or death prior to </text>
<text top="611" left="680" width="224" height="20" font="1">dialysis, Amlodipine, Low vs. Usual Goal </text>
<text top="628" left="680" width="190" height="20" font="1">RR: 32%; 95% CI: -14–60; p=0.14 </text>
<text top="645" left="680" width="211" height="20" font="1">● Metoprolol, Low vs. Usual Goal RR: </text>
<text top="662" left="679" width="158" height="20" font="1">4%; 95% CI: -39–33; p=0.84 </text>
<text top="679" left="680" width="227" height="20" font="1">● Ramipril, Low vs. Usual Goal RR: -8%; </text>
<text top="697" left="680" width="134" height="20" font="1">95% CI: -93–15; p=0.24 </text>
<text top="714" left="680" width="119" height="20" font="1">p for interaction=0.17 </text>
<text top="731" left="680" width="131" height="20" font="1">● GFR event or ESRD, </text>
<text top="748" left="680" width="202" height="20" font="1">Amlodipine, Low vs. Usual Goal RR: </text>
<text top="765" left="680" width="165" height="20" font="1">26%; 95% CI: -33–58; p=0.32 </text>
<text top="575" left="921" width="176" height="20" font="4"><b>Limitations: </b>Post-hoc analysis, </text>
<text top="592" left="921" width="174" height="20" font="1">effects on GFR may have been </text>
<text top="610" left="921" width="175" height="20" font="1">obscured by early rise and later </text>
<text top="627" left="921" width="163" height="20" font="1">fall with amlodipine, follow-up </text>
<text top="644" left="921" width="180" height="20" font="1">only 3–6.4 y, many comparisons </text>
<text top="661" left="921" width="177" height="20" font="1">so risk for type I error, unable to </text>
<text top="678" left="921" width="124" height="20" font="1">test ACEI – DHP CCB </text>
<text top="696" left="921" width="73" height="20" font="1">combination. </text>
<text top="713" left="921" width="3" height="20" font="1"> </text>
<text top="730" left="921" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="747" left="921" width="171" height="20" font="1">● BP effect was similar among </text>
<text top="764" left="921" width="173" height="20" font="1">drug groups for GFR slope and </text>
<text top="782" left="921" width="133" height="20" font="1">main clinical composite. </text>
</page>
<page number="127" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">127 </text>
<text top="107" left="369" width="137" height="20" font="1">Usual, Metoprolol: 112.4 </text>
<text top="124" left="369" width="36" height="20" font="1">(14.1) </text>
<text top="141" left="369" width="115" height="20" font="1">Low, Ramipril: 115.2 </text>
<text top="159" left="369" width="36" height="20" font="1">(15.2) </text>
<text top="176" left="369" width="124" height="20" font="1">Usual, Ramipril: 114.0 </text>
<text top="193" left="369" width="36" height="20" font="1">(16.7) </text>
<text top="210" left="369" width="125" height="20" font="1">● Mean SBP, mm Hg: </text>
<text top="228" left="369" width="131" height="20" font="1">Low, Amlodipine: 152.2 </text>
<text top="245" left="369" width="36" height="20" font="1">(28.2) </text>
<text top="262" left="369" width="140" height="20" font="1">Usual, Amlodipine: 147.7 </text>
<text top="279" left="369" width="36" height="20" font="1">(21.9) </text>
<text top="296" left="369" width="128" height="20" font="1">Low, Metoprolol: 152.0 </text>
<text top="314" left="369" width="36" height="20" font="1">(25.7) </text>
<text top="331" left="369" width="137" height="20" font="1">Usual, Metoprolol: 147.7 </text>
<text top="348" left="369" width="39" height="20" font="1">(21.4)  </text>
<text top="365" left="369" width="115" height="20" font="1">Low, Ramipril: 151.0 </text>
<text top="383" left="369" width="36" height="20" font="1">(22.5) </text>
<text top="400" left="369" width="124" height="20" font="1">Usual, Ramipril: 150.9 </text>
<text top="417" left="369" width="36" height="20" font="1">(24.1) </text>
<text top="434" left="369" width="125" height="20" font="1">● Mean DBP, mm Hg: </text>
<text top="451" left="369" width="131" height="20" font="1">Low, Amlodipine: 96.55 </text>
<text top="469" left="369" width="39" height="20" font="1">(15.1)  </text>
<text top="486" left="369" width="140" height="20" font="1">Usual, Amlodipine: 94.87 </text>
<text top="503" left="369" width="36" height="20" font="1">(12.9) </text>
<text top="520" left="369" width="128" height="20" font="1">Low, Metoprolol: 95.45 </text>
<text top="537" left="369" width="36" height="20" font="1">(15.4) </text>
<text top="555" left="369" width="137" height="20" font="1">Usual, Metoprolol: 94.47 </text>
<text top="572" left="369" width="36" height="20" font="1">(12.5) </text>
<text top="589" left="369" width="115" height="20" font="1">Low, Ramipril: 96.90 </text>
<text top="606" left="369" width="36" height="20" font="1">(13.6) </text>
<text top="623" left="369" width="124" height="20" font="1">Usual, Ramipril: 95.12 </text>
<text top="641" left="369" width="36" height="20" font="1">(15.3) </text>
<text top="658" left="369" width="3" height="20" font="1"> </text>
<text top="675" left="369" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="692" left="369" width="132" height="20" font="1">DBP&lt;95, history of DM, </text>
<text top="710" left="369" width="141" height="20" font="1">Urinary protein/creatinine </text>
<text top="727" left="369" width="140" height="20" font="1">ratio &gt;2.5, accelerated or </text>
<text top="744" left="369" width="133" height="20" font="1">malignant HTN, non-BP </text>
<text top="761" left="369" width="124" height="20" font="1">related cause of CKD, </text>
<text top="778" left="369" width="94" height="20" font="1">serious systemic </text>
<text top="107" left="524" width="133" height="20" font="1">Usual, Metoprolol: MAP </text>
<text top="124" left="524" width="124" height="20" font="1">goal 102–107 mm Hg, </text>
<text top="141" left="524" width="109" height="20" font="1">Metoprolol (50–200 </text>
<text top="159" left="524" width="38" height="20" font="1">mg/d)  </text>
<text top="176" left="524" width="124" height="20" font="1">● Low, Ramipril: MAP </text>
<text top="193" left="524" width="98" height="20" font="1">goal ≤92 mm Hg, </text>
<text top="210" left="524" width="132" height="20" font="1">Ramipril (2.5–10 mg/d)  </text>
<text top="228" left="524" width="120" height="20" font="1">Usual, Ramipril: MAP </text>
<text top="245" left="524" width="124" height="20" font="1">goal 102–107 mm Hg, </text>
<text top="262" left="524" width="132" height="20" font="1">Ramipril (2.5–10 mg/d)  </text>
<text top="279" left="524" width="140" height="20" font="1">● Note: Amlodipine arms </text>
<text top="296" left="524" width="111" height="20" font="1">terminated 1 y early </text>
<text top="314" left="524" width="96" height="20" font="1">● Achieved MAP </text>
<text top="331" left="524" width="107" height="20" font="1">difference between </text>
<text top="348" left="524" width="87" height="20" font="1">groups, mm Hg </text>
<text top="365" left="524" width="113" height="20" font="1">Amlodipine, Low vs. </text>
<text top="383" left="524" width="69" height="20" font="1">Usual:12.89 </text>
<text top="400" left="524" width="109" height="20" font="1">Metoprolol, Low vs. </text>
<text top="417" left="524" width="73" height="20" font="1">Usual: 11.11 </text>
<text top="434" left="524" width="135" height="20" font="1">Ramipril, Low vs. Usual: </text>
<text top="451" left="524" width="34" height="20" font="1">10.12 </text>
<text top="469" left="524" width="35" height="20" font="1">p=NR </text>
<text top="486" left="524" width="94" height="20" font="1">● Achieved SBP </text>
<text top="503" left="524" width="107" height="20" font="1">difference between </text>
<text top="520" left="524" width="87" height="20" font="1">groups, mm Hg </text>
<text top="537" left="524" width="113" height="20" font="1">Amlodipine, Low vs. </text>
<text top="555" left="524" width="66" height="20" font="1">Usual: 18.4 </text>
<text top="572" left="524" width="109" height="20" font="1">Metoprolol, Low vs. </text>
<text top="589" left="524" width="66" height="20" font="1">Usual: 15.4 </text>
<text top="606" left="524" width="135" height="20" font="1">Ramipril, Low vs. Usual: </text>
<text top="623" left="524" width="27" height="20" font="1">12.6 </text>
<text top="641" left="524" width="35" height="20" font="1">p=NR </text>
<text top="658" left="524" width="3" height="20" font="1"> </text>
<text top="675" left="524" width="95" height="20" font="1">● Achieved DBP </text>
<text top="692" left="524" width="107" height="20" font="1">difference between </text>
<text top="710" left="524" width="87" height="20" font="1">groups, mm Hg </text>
<text top="727" left="524" width="113" height="20" font="1">Amlodipine, Low vs. </text>
<text top="744" left="524" width="73" height="20" font="1">Usual: 10.14 </text>
<text top="761" left="524" width="109" height="20" font="1">Metoprolol, Low vs. </text>
<text top="778" left="524" width="66" height="20" font="1">Usual: 8.86 </text>
<text top="107" left="680" width="211" height="20" font="1">● Metoprolol, Low vs. Usual Goal RR: </text>
<text top="124" left="680" width="158" height="20" font="1">7%; 95% CI: -42–39; p=0.74 </text>
<text top="141" left="680" width="198" height="20" font="1">● Ramipril, Low vs. Usual Goal RR: </text>
<text top="159" left="680" width="179" height="20" font="1"> -42%; 95% CI: -126–11; p=0.14 </text>
<text top="176" left="679" width="119" height="20" font="1">p for interaction=0.20 </text>
<text top="193" left="679" width="188" height="20" font="1">● ESRD or death prior to dialysis, </text>
<text top="210" left="679" width="202" height="20" font="1">Amlodipine, Low vs. Usual Goal RR: </text>
<text top="228" left="679" width="168" height="20" font="1">51%; 95% CI: 13–73; p=0.016 </text>
<text top="245" left="680" width="211" height="20" font="1">● Metoprolol, Low vs. Usual Goal RR: </text>
<text top="262" left="679" width="165" height="20" font="1">11%; 95% CI: -40–44; p=0.61 </text>
<text top="279" left="679" width="202" height="20" font="1">● Ramipril, Low vs. Usual Goal RR:  </text>
<text top="296" left="679" width="176" height="20" font="1">-32%; 95% CI: -114–18; p=0.26 </text>
<text top="314" left="679" width="126" height="20" font="1">p for interaction=0.035 </text>
<text top="331" left="679" width="179" height="20" font="1">● Death alone (prior to dialysis), </text>
<text top="348" left="679" width="202" height="20" font="1">Amlodipine, Low vs. Usual Goal RR: </text>
<text top="365" left="679" width="165" height="20" font="1">48%; 95% CI: -59–83; p=0.25 </text>
<text top="383" left="679" width="228" height="20" font="1">● Metoprolol, Low vs. Usual Goal RR: -1; </text>
<text top="400" left="679" width="134" height="20" font="1">95% CI: -110–5; p=0.97 </text>
<text top="417" left="679" width="198" height="20" font="1">● Ramipril, Low vs. Usual Goal RR: </text>
<text top="434" left="679" width="197" height="20" font="1">21%; 95% CI: -92–67; p=0.61; p for </text>
<text top="451" left="679" width="91" height="20" font="1">interaction=0.61 </text>
<text top="469" left="679" width="3" height="20" font="1"> </text>
<text top="486" left="680" width="103" height="20" font="4"><b>Safety endpoint:  </b></text>
<text top="503" left="680" width="200" height="20" font="1">● ESRD alone, Amlodipine, Low vs. </text>
<text top="520" left="679" width="205" height="20" font="1">Usual Goal: RR: 54%; 95% CI: 8–77; </text>
<text top="537" left="680" width="48" height="20" font="1">p=0.028 </text>
<text top="555" left="680" width="211" height="20" font="1">● Metoprolol, Low vs. Usual Goal RR: </text>
<text top="572" left="679" width="165" height="20" font="1">11%; 95% CI: -60–50; p=0.70 </text>
<text top="589" left="679" width="198" height="20" font="1">● Ramipril, Low vs. Usual Goal RR: </text>
<text top="606" left="679" width="204" height="20" font="1"> -65%; 95% CI: -195–8; p=0.09; p for </text>
<text top="623" left="680" width="98" height="20" font="1">interaction=0.021 </text>
<text top="642" left="680" width="179" height="20" font="1">● Death alone (prior to dialysis), </text>
<text top="660" left="680" width="205" height="20" font="1">Amlodipine, Low vs. Usual Goal: RR: </text>
<text top="677" left="680" width="165" height="20" font="1">48%; 95% CI: -59–83; p=0.25 </text>
<text top="695" left="680" width="218" height="20" font="1">● Metoprolol, Low vs. Usual Goal: RR: -</text>
<text top="712" left="680" width="147" height="20" font="1">1; 95% CI: -110–5; p=0.97 </text>
<text top="730" left="680" width="198" height="20" font="1">● Ramipril, Low vs. Usual Goal RR: </text>
<text top="748" left="680" width="197" height="20" font="1">21%; 95% CI: -92–67; p=0.61; p for </text>
<text top="765" left="680" width="91" height="20" font="1">interaction=0.61 </text>
<text top="107" left="921" width="179" height="20" font="1">● BP effect differed among drug </text>
<text top="124" left="921" width="184" height="20" font="1">groups for composite of ESRD or </text>
<text top="141" left="921" width="133" height="20" font="1">death and ESRD alone. </text>
<text top="159" left="921" width="134" height="20" font="1">● Higher event rates for </text>
<text top="176" left="921" width="166" height="20" font="1">amlodipine and usual BP goal </text>
<text top="193" left="921" width="163" height="20" font="1">compared with other groups.  </text>
<text top="210" left="921" width="172" height="20" font="1">● Low BP goal associated with </text>
<text top="228" left="921" width="170" height="20" font="1">reduced risk of ESRD or death </text>
<text top="245" left="921" width="183" height="20" font="1">and ESRD for amlodipine but not </text>
<text top="262" left="921" width="156" height="20" font="1">for other drug groups (in the </text>
<text top="279" left="921" width="159" height="20" font="1">absence of ACEI treatment). </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">128 </text>
<text top="107" left="369" width="122" height="20" font="1">disease, clinical CHF, </text>
<text top="124" left="369" width="114" height="20" font="1">specific indication or </text>
<text top="141" left="369" width="118" height="20" font="1">contraindication for a </text>
<text top="159" left="369" width="134" height="20" font="1">study drug or procedure </text>
<text top="107" left="524" width="135" height="20" font="1">Ramipril, Low vs. Usual: </text>
<text top="124" left="524" width="27" height="20" font="1">8.96 </text>
<text top="141" left="524" width="35" height="20" font="1">p=NR </text>
<text top="159" left="524" width="3" height="20" font="1"> </text>
<text top="176" left="524" width="101" height="20" font="4"><b>Comparator: </b>N/A<b> </b></text>
<text top="107" left="680" width="207" height="20" font="1">● Proteinuria within each drug group, </text>
<text top="125" left="680" width="180" height="20" font="1">risk reductions for any 2° clinical </text>
<text top="143" left="680" width="205" height="20" font="1">outcome of the low vs. usual BP goal </text>
<text top="160" left="680" width="215" height="20" font="1">were not significantly different between </text>
<text top="177" left="680" width="180" height="20" font="1">pts with baseline urine protein to </text>
<text top="194" left="680" width="221" height="20" font="1">creatinine ratio ≤0.22 and &gt;0.22 (p=NS) </text>
<text top="212" left="98" width="87" height="20" font="1">Norris K, et al.,  </text>
<text top="229" left="98" width="62" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(174)</a> </text>
<text top="247" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17059993?dopt=Citation">17059993</a></text>
<text top="247" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17059993?dopt=Citation"> </a></text>
<text top="212" left="226" width="125" height="20" font="4"><b>Aim: </b>Compared effect </text>
<text top="229" left="226" width="107" height="20" font="1">of treatment on CV </text>
<text top="247" left="226" width="130" height="20" font="1">event rate during mean </text>
<text top="264" left="226" width="113" height="20" font="1">follow-up of 4.1 y by </text>
<text top="281" left="226" width="126" height="20" font="1">drug class and level of </text>
<text top="298" left="226" width="64" height="20" font="1">BP control. </text>
<text top="316" left="226" width="116" height="20" font="1">Determined baseline </text>
<text top="333" left="226" width="125" height="20" font="1">factors that predict CV </text>
<text top="350" left="226" width="57" height="20" font="1">outcomes </text>
<text top="366" left="226" width="3" height="20" font="1"> </text>
<text top="383" left="226" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="400" left="226" width="97" height="20" font="1">Randomized 3×2 </text>
<text top="417" left="226" width="70" height="20" font="1">factorial trial </text>
<text top="434" left="226" width="113" height="20" font="1">Measured GFR with </text>
<text top="451" left="226" width="67" height="20" font="1">iothalamate </text>
<text top="469" left="226" width="3" height="20" font="1"> </text>
<text top="486" left="226" width="32" height="20" font="4"><b>Size: </b></text>
<text top="503" left="226" width="34" height="20" font="1">1,094 </text>
<text top="212" left="369" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="229" left="369" width="85" height="20" font="1">● Adult African </text>
<text top="247" left="369" width="141" height="20" font="1">Americans, 18–70 y, with </text>
<text top="264" left="369" width="115" height="20" font="1">HTN (DBP ≥95) and </text>
<text top="281" left="369" width="81" height="20" font="1">GFR of 20–65 </text>
<text top="298" left="369" width="132" height="20" font="1">mL/min/1.73 m², no DM </text>
<text top="316" left="369" width="127" height="20" font="1">● Mean MAP, mm Hg: </text>
<text top="333" left="369" width="49" height="20" font="1">114 (16) </text>
<text top="350" left="369" width="124" height="20" font="1">● Mean SBP, mm Hg: </text>
<text top="367" left="369" width="49" height="20" font="1">150 (24) </text>
<text top="384" left="369" width="79" height="20" font="1">● Mean DBP, </text>
<text top="402" left="369" width="64" height="20" font="1">mm Hg: 96 </text>
<text top="419" left="369" width="25" height="20" font="1">(14) </text>
<text top="436" left="369" width="3" height="20" font="4"><b> </b></text>
<text top="453" left="369" width="134" height="20" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="212" left="524" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="229" left="524" width="127" height="20" font="1">● Achieved SBP/DBP, </text>
<text top="247" left="524" width="43" height="20" font="1">mm Hg </text>
<text top="247" left="567" width="25" height="20" font="9">(SD)</text>
<text top="247" left="593" width="3" height="20" font="1"> </text>
<text top="264" left="524" width="74" height="20" font="1">Low: 128/78  </text>
<text top="281" left="524" width="79" height="20" font="1">Usual: 141/85 </text>
<text top="298" left="524" width="35" height="20" font="1">p=NR </text>
<text top="316" left="524" width="140" height="20" font="1">● SBP/DBP change, mm </text>
<text top="333" left="524" width="19" height="20" font="1">Hg </text>
<text top="350" left="524" width="72" height="20" font="1">Low: -23/-19 </text>
<text top="367" left="524" width="67" height="20" font="1">Usual: -8/-9 </text>
<text top="384" left="524" width="35" height="20" font="1">p=NR </text>
<text top="402" left="524" width="120" height="20" font="1">● Achieved mean BP </text>
<text top="419" left="524" width="107" height="20" font="1">difference between </text>
<text top="436" left="524" width="87" height="20" font="1">groups, mm Hg </text>
<text top="453" left="524" width="49" height="20" font="1">SBP: 15 </text>
<text top="470" left="524" width="49" height="20" font="1">DBP: 10 </text>
<text top="488" left="524" width="35" height="20" font="1">p=NR </text>
<text top="505" left="524" width="3" height="20" font="1"> </text>
<text top="522" left="524" width="101" height="20" font="4"><b>Comparator: </b>N/A<b> </b></text>
<text top="212" left="680" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="229" left="680" width="217" height="20" font="1">● Number of deaths before ESRD, n of </text>
<text top="247" left="680" width="40" height="20" font="1">events </text>
<text top="264" left="680" width="46" height="20" font="1">Low: 38 </text>
<text top="281" left="680" width="94" height="20" font="1">Usual: 47; p=NR </text>
<text top="298" left="680" width="212" height="20" font="1">● Major CAD events, n of events (rate </text>
<text top="316" left="680" width="76" height="20" font="1">per person-y) </text>
<text top="333" left="680" width="89" height="20" font="1">Low: 19 (0.008) </text>
<text top="350" left="680" width="136" height="20" font="1">Usual: 23 (0.010); p=NS </text>
<text top="367" left="680" width="222" height="20" font="1">● Stroke events, number of events (rate </text>
<text top="384" left="680" width="76" height="20" font="1">per person-y) </text>
<text top="402" left="680" width="89" height="20" font="1">Low: 26 (0.011) </text>
<text top="419" left="680" width="136" height="20" font="1">Usual: 29 (0.013); p=NS </text>
<text top="436" left="680" width="189" height="20" font="1">● HF events, n of events (rate per </text>
<text top="453" left="680" width="55" height="20" font="1">person-y) </text>
<text top="470" left="680" width="89" height="20" font="1">Low: 27 (0.012) </text>
<text top="488" left="680" width="98" height="20" font="1">Usual: 23 (0.010) </text>
<text top="506" left="680" width="35" height="20" font="1">p=NS </text>
<text top="523" left="680" width="210" height="20" font="1">● CV composite outcome, n of events </text>
<text top="540" left="680" width="105" height="20" font="1">(rate per person-y) </text>
<text top="558" left="680" width="89" height="20" font="1">Low: 71 (0.032) </text>
<text top="575" left="680" width="136" height="20" font="1">Usual: 78 (0.035); p=NS </text>
<text top="592" left="680" width="205" height="20" font="1">● Composite outcome or ESRD, n of </text>
<text top="609" left="680" width="145" height="20" font="1">events (rate per person-y) </text>
<text top="626" left="680" width="96" height="20" font="1">Low: 143 (0.064) </text>
<text top="644" left="680" width="105" height="20" font="1">Usual: 159 (0.072) </text>
<text top="661" left="680" width="35" height="20" font="1">p=NS </text>
<text top="678" left="680" width="220" height="20" font="1">● Overall rate of CV events, n of events </text>
<text top="695" left="680" width="105" height="20" font="1">(rate per person-y) </text>
<text top="712" left="680" width="96" height="20" font="1">Low: 108 (0.048) </text>
<text top="730" left="680" width="136" height="20" font="1">Usual: 94 (0.042); p=NS </text>
<text top="747" left="680" width="184" height="20" font="1">● CV death, n of events (rate per </text>
<text top="764" left="680" width="55" height="20" font="1">person-y) </text>
<text top="781" left="680" width="89" height="20" font="1">Low: 16 (0.007) </text>
<text top="212" left="921" width="73" height="20" font="4"><b>Limitations: </b></text>
<text top="229" left="921" width="166" height="20" font="1">● Limited power, only 202 CV </text>
<text top="247" left="921" width="151" height="20" font="1">events – low incidence. CV </text>
<text top="264" left="921" width="172" height="20" font="1">outcomes were 2º endpoints of </text>
<text top="281" left="921" width="148" height="20" font="1">high priority (prespecified). </text>
<text top="298" left="921" width="167" height="20" font="1">● &gt;50% had a history of heart </text>
<text top="316" left="921" width="174" height="20" font="1">disease at entry, 40% with LVH </text>
<text top="333" left="921" width="163" height="20" font="1">by ECG. 1/3 smokers, almost </text>
<text top="350" left="921" width="131" height="20" font="1">50% had income &lt;15K. </text>
<text top="367" left="921" width="3" height="20" font="1"> </text>
<text top="384" left="921" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="402" left="921" width="154" height="20" font="1">● CV outcome rate was not </text>
<text top="419" left="921" width="122" height="20" font="1">related to randomized </text>
<text top="436" left="921" width="173" height="20" font="1">interventions, either drug or BP </text>
<text top="453" left="921" width="38" height="20" font="1">target. </text>
<text top="470" left="921" width="165" height="20" font="1">● 7 baseline risk factors were </text>
<text top="488" left="921" width="167" height="20" font="1">independently associated with </text>
<text top="505" left="921" width="177" height="20" font="1">increased risk for CV composite </text>
<text top="522" left="921" width="188" height="20" font="1">outcome in multivariable analyses </text>
<text top="539" left="921" width="159" height="20" font="1">after controlling for age, sex, </text>
<text top="557" left="921" width="131" height="20" font="1">baseline GFR, baseline </text>
<text top="574" left="921" width="182" height="20" font="1">proteinuria: PP, duration of HTN, </text>
<text top="591" left="921" width="159" height="20" font="1">protein/creatinine ratio, urine </text>
<text top="608" left="921" width="154" height="20" font="1">sodium-potassium ratio and </text>
<text top="625" left="921" width="135" height="20" font="1">annual income &lt;15,000. </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">129 </text>
<text top="107" left="680" width="136" height="20" font="1">Usual: 15 (0.006); p=NS </text>
<text top="125" left="98" width="106" height="20" font="1">Amlodipine Versus </text>
<text top="142" left="98" width="100" height="20" font="1">Enalapril in Renal </text>
<text top="159" left="98" width="112" height="20" font="1">Failure<b> (AVER trial) </b></text>
<text top="177" left="98" width="98" height="20" font="1">Esnault VL, et al., </text>
<text top="194" left="98" width="62" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(175)</a> </text>
<text top="211" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18405787?dopt=Citation">18405787</a></text>
<text top="211" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18405787?dopt=Citation"> </a></text>
<text top="125" left="226" width="31" height="20" font="4"><b>Aim: </b></text>
<text top="142" left="226" width="98" height="20" font="1">To compare GFR </text>
<text top="159" left="226" width="125" height="20" font="1">decline in nondiabetic, </text>
<text top="177" left="226" width="111" height="20" font="1">nonnephrotic adults </text>
<text top="194" left="226" width="78" height="20" font="1">with HTN and </text>
<text top="211" left="226" width="122" height="20" font="1">estimated CrCl 20–60 </text>
<text top="228" left="226" width="122" height="20" font="1">mL/min/1.73 m² when </text>
<text top="246" left="226" width="121" height="20" font="1">randomized to a CCB </text>
<text top="263" left="226" width="101" height="20" font="1">(amlodipine, 5–10 </text>
<text top="280" left="226" width="98" height="20" font="1">mg/d) or an ACEI </text>
<text top="297" left="226" width="127" height="20" font="1">(enalapril, 5–20 mg/d). </text>
<text top="313" left="226" width="3" height="20" font="1"> </text>
<text top="330" left="226" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="364" left="226" width="32" height="20" font="4"><b>Size: </b></text>
<text top="381" left="226" width="92" height="20" font="1">Amlodipine: 132 </text>
<text top="398" left="226" width="79" height="20" font="1">Enalapril: 131 </text>
<text top="125" left="369" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="142" left="369" width="60" height="20" font="1">● 18–80 y </text>
<text top="159" left="369" width="78" height="20" font="1">● CrCl 20–60 </text>
<text top="177" left="369" width="89" height="20" font="1">mL/min/1.73 m² </text>
<text top="194" left="369" width="97" height="20" font="1">(Cockcroft-Gault) </text>
<text top="211" left="369" width="81" height="20" font="1">● Nondiabetic </text>
<text top="228" left="369" width="132" height="20" font="1">● Enrollment confirmed </text>
<text top="246" left="369" width="127" height="20" font="1">at end of 4-wk placebo </text>
<text top="263" left="369" width="109" height="20" font="1">run-in if sitting DBP </text>
<text top="280" left="369" width="139" height="20" font="1">between 90 and 119 mm </text>
<text top="297" left="369" width="19" height="20" font="1">Hg </text>
<text top="314" left="369" width="121" height="20" font="1">● Mean SBP, mm Hg </text>
<text top="332" left="369" width="25" height="20" font="9">(SD)</text>
<text top="332" left="394" width="7" height="20" font="1">: </text>
<text top="349" left="369" width="141" height="20" font="1">Amlodipine: 165.1 (15.4)  </text>
<text top="366" left="369" width="124" height="20" font="1">Enalapril: 165.2 (16.6) </text>
<text top="383" left="369" width="122" height="20" font="1">● Mean DBP, mm Hg </text>
<text top="401" left="369" width="25" height="20" font="9">(SD)</text>
<text top="401" left="394" width="7" height="20" font="1">: </text>
<text top="418" left="369" width="131" height="20" font="1">Amlodipine: 102.0 (6.7) </text>
<text top="435" left="369" width="118" height="20" font="1">Enalapril: 102.5 (7.1) </text>
<text top="452" left="369" width="142" height="20" font="1">● Mean serum Cr, mg/dL </text>
<text top="469" left="369" width="25" height="20" font="9">(SD)</text>
<text top="469" left="394" width="7" height="20" font="1">: </text>
<text top="487" left="369" width="124" height="20" font="1">Amlodipine: 2.00 (0.8) </text>
<text top="504" left="369" width="111" height="20" font="1">Enalapril: 2.05 (0.7) </text>
<text top="521" left="369" width="3" height="20" font="1"> </text>
<text top="538" left="369" width="114" height="20" font="4"><b>Exclusion criteria:  </b></text>
<text top="555" left="369" width="130" height="20" font="1">● Nephrotic proteinuria </text>
<text top="573" left="369" width="127" height="20" font="1">● 2º or malignant HTN </text>
<text top="590" left="369" width="111" height="20" font="1">(DBP &gt;120 mm Hg) </text>
<text top="607" left="369" width="112" height="20" font="1">● A major CV event </text>
<text top="624" left="369" width="66" height="20" font="1">within 3 mo </text>
<text top="641" left="369" width="101" height="20" font="1">● Angina pectoris </text>
<text top="659" left="369" width="109" height="20" font="1">● Congestive heart </text>
<text top="676" left="369" width="118" height="20" font="1">disease (NYHA II-IV) </text>
<text top="693" left="369" width="85" height="20" font="1">● Uncontrolled </text>
<text top="710" left="369" width="68" height="20" font="1">arrhythmias </text>
<text top="727" left="369" width="89" height="20" font="1">● II-III AV block </text>
<text top="745" left="369" width="106" height="20" font="1">● Need for serious </text>
<text top="762" left="369" width="113" height="20" font="1">steroids, NSAIDS or </text>
<text top="779" left="369" width="85" height="20" font="1">cytotoxic drugs </text>
<text top="125" left="524" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="142" left="524" width="142" height="20" font="1">● Amlodipine: 5–10 mg/d </text>
<text top="159" left="524" width="132" height="20" font="1">● Enalapril: 5–20 mg/d  </text>
<text top="177" left="524" width="120" height="20" font="1">Therapy initiated with </text>
<text top="194" left="524" width="118" height="20" font="1">amlodipine 5 mg/d or </text>
<text top="211" left="524" width="131" height="20" font="1">enalapril 5 mg/d. Drugs </text>
<text top="228" left="524" width="135" height="20" font="1">up-titrated to amlodipine </text>
<text top="246" left="524" width="129" height="20" font="1">10 mg/d or enalapril 20 </text>
<text top="263" left="524" width="124" height="20" font="1">mg/d at wk 8 and 12 if </text>
<text top="280" left="524" width="100" height="20" font="1">DBP &gt;90 mm Hg. </text>
<text top="297" left="524" width="127" height="20" font="1">After 18 wk, if maximal </text>
<text top="314" left="524" width="128" height="20" font="1">tolerated dose of study </text>
<text top="332" left="524" width="142" height="20" font="1">drug did not decrease BP </text>
<text top="349" left="524" width="117" height="20" font="1">to target, add on anti-</text>
<text top="366" left="524" width="141" height="20" font="1">HTN treatments were the </text>
<text top="383" left="524" width="126" height="20" font="1">following: atenolol (50–</text>
<text top="401" left="524" width="138" height="20" font="1">100 mg/d), loop diuretics </text>
<text top="418" left="524" width="113" height="20" font="1">(furosemide 20–500 </text>
<text top="435" left="524" width="120" height="20" font="1">mg/d or torsemide, 5–</text>
<text top="452" left="524" width="96" height="20" font="1">200 mg/d), alpha </text>
<text top="469" left="524" width="141" height="20" font="1">blockers (prazosin, 2.4–5 </text>
<text top="487" left="524" width="138" height="20" font="1">mg/d or doxazosin, 1–16 </text>
<text top="504" left="524" width="108" height="20" font="1">mg/d) and centrally </text>
<text top="521" left="524" width="137" height="20" font="1">acting drugs (rilmenidine </text>
<text top="538" left="524" width="73" height="20" font="1">(1–2 mg/d or </text>
<text top="555" left="524" width="122" height="20" font="1">methyldopa, 250–500 </text>
<text top="573" left="524" width="38" height="20" font="1">mg/d). </text>
<text top="590" left="524" width="3" height="20" font="1"> </text>
<text top="607" left="524" width="66" height="20" font="1">● BP goal:  </text>
<text top="624" left="524" width="140" height="20" font="1">Amlodipine: &lt;130/85 mm </text>
<text top="641" left="524" width="19" height="20" font="1">Hg </text>
<text top="659" left="524" width="127" height="20" font="1">Enalapril: &lt;130/85 mm </text>
<text top="676" left="524" width="19" height="20" font="1">Hg </text>
<text top="693" left="524" width="122" height="20" font="1">Duration of treatment: </text>
<text top="710" left="524" width="133" height="20" font="1">Median follow-up 2.93 y </text>
<text top="728" left="524" width="141" height="20" font="1">in amlodipine group; 2.95 </text>
<text top="745" left="524" width="107" height="20" font="1">y in enalapril group<b> </b></text>
<text top="126" left="680" width="193" height="20" font="4"><b>1° endpoint:</b> Change in GFR from </text>
<text top="143" left="680" width="158" height="20" font="1">baseline to final assessment </text>
<text top="161" left="680" width="3" height="20" font="1"> </text>
<text top="178" left="680" width="224" height="20" font="4"><b>2° Outcome: </b>Clinical composite of renal </text>
<text top="196" left="680" width="204" height="20" font="1">replacement therapy, discontinuation </text>
<text top="213" left="680" width="204" height="20" font="1">due to deterioration of renal function, </text>
<text top="230" left="680" width="192" height="20" font="1">50% decrease in GFR, doubling of </text>
<text top="247" left="680" width="207" height="20" font="1">serum Cr, hospitalization for transient </text>
<text top="265" left="680" width="175" height="20" font="1">renal failure. &#34;Other 2º outcome </text>
<text top="282" left="680" width="215" height="20" font="1">measures&#34; included: changes in serum </text>
<text top="299" left="680" width="199" height="20" font="1">Cr, sitting DBP and SBP, heart rate, </text>
<text top="316" left="680" width="214" height="20" font="1">total and HDL cholesterol, 24-h urinary </text>
<text top="333" left="680" width="182" height="20" font="1">protein excretion, ambulatory BP </text>
<text top="351" left="680" width="185" height="20" font="1">monitoring, and safety measures. </text>
<text top="368" left="680" width="180" height="20" font="1">Composite Outcomes: 2º clinical </text>
<text top="385" left="680" width="60" height="20" font="1">composite<b> </b></text>
<text top="403" left="680" width="3" height="20" font="1"> </text>
<text top="420" left="680" width="221" height="20" font="4"><b>Safety endpoint: </b>Proteinuria subgroup, </text>
<text top="438" left="680" width="221" height="20" font="1">&gt;1 g/d: protein excretion rate decreased </text>
<text top="455" left="680" width="212" height="20" font="1">significantly in pts taking enalapril plus </text>
<text top="472" left="680" width="206" height="20" font="1">diuretic (median -270 mg/d; p&lt;0.001) </text>
<text top="489" left="680" width="199" height="20" font="1">but not in pts taking amlodipine plus </text>
<text top="506" left="680" width="163" height="20" font="1">diuretic (-25 mg/d) at last obs </text>
<text top="125" left="921" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="142" left="921" width="175" height="20" font="1">● No difference in GFR change </text>
<text top="159" left="921" width="170" height="20" font="1">or serum creatinine at trial end </text>
<text top="177" left="921" width="188" height="20" font="1">Last observation: mean change in </text>
<text top="194" left="921" width="122" height="20" font="1">GFR, mL/min/1.73 m² </text>
<text top="194" left="1083" width="3" height="20" font="1"> </text>
<text top="211" left="921" width="185" height="20" font="1">Amlodipine -4.92, Enalapril -3.98; </text>
<text top="228" left="921" width="35" height="20" font="1">p=NS </text>
<text top="246" left="921" width="188" height="20" font="1">● Last observation: mean change </text>
<text top="263" left="921" width="185" height="20" font="1">in Serum Cr from baseline (mg/d) </text>
<text top="280" left="921" width="153" height="20" font="1">Amlodipine +0.57, Enalapril </text>
<text top="297" left="921" width="73" height="20" font="1">+0.47; p=NS </text>
<text top="314" left="921" width="176" height="20" font="1">● No difference in composite 2º </text>
<text top="332" left="921" width="60" height="20" font="1">endpoints. </text>
<text top="349" left="921" width="184" height="20" font="1">● Mean BP (mm Hg): baseline to </text>
<text top="366" left="921" width="90" height="20" font="1">last observation </text>
<text top="383" left="921" width="146" height="20" font="1">Amlodipine 164.8/101.8 to </text>
<text top="401" left="921" width="154" height="20" font="1">140.1/85.4, delta -24.7/16.4 </text>
<text top="418" left="921" width="133" height="20" font="1">Enalapril 165.0/102.5 to </text>
<text top="435" left="921" width="154" height="20" font="1">140.3/86.4, delta -24.7/16.1 </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">130 </text>
<text top="107" left="369" width="101" height="20" font="1">● Women of child-</text>
<text top="124" left="369" width="115" height="20" font="1">bearing potential not </text>
<text top="141" left="369" width="98" height="20" font="1">using appropriate </text>
<text top="159" left="369" width="83" height="20" font="1">contraceptives </text>
<text top="176" left="369" width="139" height="20" font="1">● Any disease that could </text>
<text top="193" left="369" width="128" height="20" font="1">limit the ability of pts to </text>
<text top="210" left="369" width="115" height="20" font="1">comply with protocol </text>
<text top="227" left="369" width="75" height="20" font="1">requirements </text>
<text top="245" left="98" width="56" height="20" font="4"><b>ESPIRAL </b></text>
<text top="263" left="98" width="85" height="20" font="1">Marin R, et al.,  </text>
<text top="280" left="98" width="62" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(176)</a> </text>
<text top="297" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11593109?dopt=Citation">11593109 </a></text>
<text top="297" left="155" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11593109?dopt=Citation"> </a></text>
<text top="245" left="226" width="124" height="20" font="4"><b>Aim:</b> To investigate in </text>
<text top="263" left="226" width="122" height="20" font="1">a random comparison </text>
<text top="280" left="226" width="100" height="20" font="1">the capacity of an </text>
<text top="297" left="226" width="126" height="20" font="1">angiotensin converting </text>
<text top="314" left="226" width="93" height="20" font="1">enzyme inhibitor </text>
<text top="332" left="226" width="126" height="20" font="1">(fosinopril), and that of </text>
<text top="349" left="226" width="74" height="20" font="1">a long-acting </text>
<text top="366" left="226" width="83" height="20" font="1">dihydropiridine </text>
<text top="383" left="226" width="110" height="20" font="1">(nifedipine GITS) to </text>
<text top="401" left="226" width="109" height="20" font="1">modify the decay in </text>
<text top="418" left="226" width="110" height="20" font="1">renal function in pts </text>
<text top="435" left="226" width="100" height="20" font="1">with primary renal </text>
<text top="452" left="226" width="115" height="20" font="1">disease, exhibiting a </text>
<text top="469" left="226" width="130" height="20" font="1">progressive increase in </text>
<text top="487" left="226" width="112" height="20" font="1">serum Cr during the </text>
<text top="504" left="226" width="73" height="20" font="1">previous 2 y. </text>
<text top="521" left="226" width="3" height="20" font="1"> </text>
<text top="539" left="226" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="556" left="226" width="103" height="20" font="1">Randomized open </text>
<text top="573" left="226" width="53" height="20" font="1">label trial </text>
<text top="590" left="226" width="3" height="20" font="1"> </text>
<text top="607" left="226" width="55" height="20" font="4"><b>Size</b>: 241 </text>
<text top="625" left="226" width="118" height="20" font="1">Nifedipine GITS: 112 </text>
<text top="642" left="226" width="84" height="20" font="1">Fosinopril: 129 </text>
<text top="245" left="369" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="263" left="369" width="60" height="20" font="1">● 18–75 y </text>
<text top="280" left="369" width="139" height="20" font="1">● Serum Cr between 1.5 </text>
<text top="297" left="369" width="127" height="20" font="1">and 5 mg/dL (133–442 </text>
<text top="314" left="369" width="42" height="20" font="1">µmol/l) </text>
<text top="332" left="369" width="121" height="20" font="1">● HTN defined as BP </text>
<text top="349" left="369" width="122" height="20" font="1">&gt;140/90 mm Hg or by </text>
<text top="366" left="369" width="57" height="20" font="1">the use of </text>
<text top="383" left="369" width="141" height="20" font="1">antihypertensive agent(s) </text>
<text top="401" left="369" width="136" height="20" font="1">● Proven progression of </text>
<text top="418" left="369" width="124" height="20" font="1">chronic renal failure in </text>
<text top="435" left="369" width="137" height="20" font="1">the previous 2 y, defined </text>
<text top="452" left="369" width="132" height="20" font="1">by increase by &gt;25% or </text>
<text top="469" left="369" width="139" height="20" font="1">&gt;0.5 mg/dL (44.2 µmol/l) </text>
<text top="487" left="369" width="67" height="20" font="1">in serum Cr </text>
<text top="504" left="369" width="121" height="20" font="1">● Mean SBP, mm Hg </text>
<text top="521" left="369" width="25" height="20" font="9">(SD)</text>
<text top="521" left="394" width="10" height="20" font="1">:  </text>
<text top="538" left="369" width="128" height="20" font="1">Nifedipine GITS: 157.5 </text>
<text top="555" left="369" width="25" height="20" font="1">(20) </text>
<text top="573" left="369" width="109" height="20" font="1">Fosinopril: 155 (17) </text>
<text top="590" left="369" width="122" height="20" font="1">● Mean DBP, mm Hg </text>
<text top="607" left="369" width="25" height="20" font="9">(SD)</text>
<text top="607" left="394" width="7" height="20" font="1">: </text>
<text top="624" left="369" width="136" height="20" font="1">Nifedipine GITS: 96 (11) </text>
<text top="641" left="369" width="96" height="20" font="1">Fosinopril: 96 (8) </text>
<text top="659" left="369" width="3" height="20" font="1"> </text>
<text top="676" left="369" width="114" height="20" font="4"><b>Exclusion criteria:  </b></text>
<text top="693" left="369" width="35" height="20" font="1">● DM </text>
<text top="710" left="369" width="141" height="20" font="1">● Previous recent history </text>
<text top="727" left="369" width="122" height="20" font="1">of CVD (stroke, MI, or </text>
<text top="745" left="369" width="24" height="20" font="1">HF) </text>
<text top="762" left="369" width="122" height="20" font="1">● Taking concomitant </text>
<text top="779" left="369" width="126" height="20" font="1">medications that could </text>
<text top="245" left="524" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="263" left="524" width="127" height="20" font="1">● Nifedipine GITS: 30–</text>
<text top="280" left="524" width="59" height="20" font="1">60 mg QD </text>
<text top="299" left="524" width="86" height="20" font="1">● Fosinopril: 10</text>
<text top="298" left="610" width="8" height="21" font="0">–</text>
<text top="299" left="619" width="38" height="20" font="1">30 mg </text>
<text top="317" left="524" width="25" height="20" font="1">QD  </text>
<text top="334" left="524" width="127" height="20" font="1">● Drugs added in step-</text>
<text top="352" left="524" width="130" height="20" font="1">wise fashion to achieve </text>
<text top="369" left="524" width="50" height="20" font="1">BP goal. </text>
<text top="386" left="524" width="127" height="20" font="1">● Step 1: Randomized </text>
<text top="403" left="524" width="28" height="20" font="1">drug </text>
<text top="420" left="524" width="123" height="20" font="1">● Step 2: Furosemide </text>
<text top="438" left="524" width="83" height="20" font="1">(up to 100 mg) </text>
<text top="455" left="524" width="138" height="20" font="1">● Step 3: Atenolol (up to </text>
<text top="472" left="524" width="49" height="20" font="1">100 mg) </text>
<text top="489" left="524" width="137" height="20" font="1">● Step 4: Doxazosin (up </text>
<text top="507" left="524" width="55" height="20" font="1">to 12 mg) </text>
<text top="524" left="524" width="66" height="20" font="1">● BP goal:  </text>
<text top="541" left="524" width="142" height="20" font="1">Nifedipine GITS: &lt;140/90 </text>
<text top="558" left="524" width="43" height="20" font="1">mm Hg </text>
<text top="576" left="524" width="132" height="20" font="1">Fosinopril: &lt;140/90 mm </text>
<text top="593" left="524" width="19" height="20" font="1">Hg </text>
<text top="610" left="524" width="135" height="20" font="1">● Duration of treatment: </text>
<text top="627" left="524" width="111" height="20" font="1">mean follow-up NR; </text>
<text top="644" left="524" width="133" height="20" font="1">authors report minimum </text>
<text top="662" left="524" width="132" height="20" font="1">follow-up of 3 y and this </text>
<text top="679" left="524" width="126" height="20" font="1">is when most outcome </text>
<text top="696" left="524" width="107" height="20" font="1">measures reported </text>
<text top="713" left="524" width="3" height="20" font="1"> </text>
<text top="245" left="680" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="263" left="680" width="226" height="20" font="1">● 1° Outcome: Time elapsed until serum </text>
<text top="280" left="679" width="227" height="20" font="1">Cr values doubled, or the need to enter a </text>
<text top="297" left="679" width="93" height="20" font="1">dialysis program </text>
<text top="314" left="679" width="221" height="20" font="1">● 2º Outcome: CV events (including MI, </text>
<text top="332" left="679" width="211" height="20" font="1">stroke, angina, and death), proteinuria </text>
<text top="349" left="679" width="131" height="20" font="1">evolution and serum Cr </text>
<text top="366" left="679" width="3" height="20" font="1"> </text>
<text top="383" left="680" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="245" left="921" width="73" height="20" font="4"><b>Limitations: </b></text>
<text top="263" left="921" width="165" height="20" font="1">● SBP was 4–6 mm Hg lower </text>
<text top="280" left="921" width="149" height="20" font="1">with ACEI which may have </text>
<text top="297" left="921" width="167" height="20" font="1">impacted improved outcomes. </text>
<text top="314" left="921" width="163" height="20" font="1">Still positive effects remained </text>
<text top="332" left="921" width="176" height="20" font="1">from fosinopril after adjusted for </text>
<text top="349" left="921" width="58" height="20" font="1">BP levels. </text>
<text top="366" left="921" width="171" height="20" font="1">● Sodium restriction may have </text>
<text top="383" left="921" width="135" height="20" font="1">favored the ACEI group. </text>
<text top="401" left="921" width="3" height="20" font="1"> </text>
<text top="418" left="921" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="435" left="921" width="185" height="20" font="1">● Renal survival was significantly </text>
<text top="452" left="921" width="167" height="20" font="1">better if fosinopril used as first </text>
<text top="469" left="921" width="171" height="20" font="1">agent, unrelated to the primary </text>
<text top="487" left="921" width="80" height="20" font="1">renal disease. </text>
<text top="504" left="921" width="181" height="20" font="1">● Proteinuria decreased by 57% </text>
<text top="521" left="921" width="145" height="20" font="1">in the fosinopril group and </text>
<text top="538" left="921" width="184" height="20" font="1">increased by 7% in the nifedipine </text>
<text top="555" left="921" width="178" height="20" font="1">GITS group while BP control did </text>
<text top="573" left="921" width="157" height="20" font="1">not differ between treatment </text>
<text top="590" left="921" width="91" height="20" font="1">groups for DBP. </text>
<text top="607" left="921" width="86" height="20" font="1">● 3-y follow-up </text>
<text top="624" left="921" width="182" height="20" font="1">Doubling of serum Cr or entering </text>
<text top="641" left="921" width="79" height="20" font="1">dialysis N (%) </text>
<text top="659" left="921" width="144" height="20" font="1">Nifedipine GITS 40 (36%) </text>
<text top="676" left="921" width="110" height="20" font="1">Fosinopril 27 (21%) </text>
<text top="693" left="921" width="164" height="20" font="1">OR: 0.47 (0.26–0.84); p=0.01 </text>
<text top="710" left="921" width="156" height="20" font="1">● Decrease in SBP, mm Hg </text>
<text top="710" left="1077" width="25" height="20" font="9">(SD)</text>
<text top="710" left="1102" width="3" height="20" font="1"> </text>
<text top="727" left="921" width="153" height="20" font="1">Nifedipine GITS 14.0 (22.5) </text>
<text top="745" left="921" width="154" height="20" font="1">Fosinopril 19.8 (19.6), p NR </text>
<text top="762" left="921" width="144" height="20" font="1">Decrease in DBP, mm Hg </text>
<text top="762" left="1065" width="25" height="20" font="9">(SD)</text>
<text top="762" left="1091" width="3" height="20" font="1"> </text>
<text top="779" left="921" width="153" height="20" font="1">Nifedipine GITS 14.9 (11.8) </text>
</page>
<page number="131" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">131 </text>
<text top="107" left="369" width="107" height="20" font="1">interfere with study </text>
<text top="124" left="369" width="94" height="20" font="1">results (steroids, </text>
<text top="141" left="369" width="114" height="20" font="1">immunosuppressant </text>
<text top="159" left="369" width="105" height="20" font="1">drugs, or NSAIDS) </text>
<text top="176" left="369" width="138" height="20" font="1">● Presenting intolerance </text>
<text top="193" left="369" width="137" height="20" font="1">to fosinopril or nifedipine </text>
<text top="107" left="921" width="158" height="20" font="1">Fosinopril 12.7 (11.6); p=NS </text>
<text top="211" left="98" width="85" height="20" font="4"><b>ACCOMPLISH </b></text>
<text top="228" left="98" width="93" height="20" font="1">Bakris GL, et al., </text>
<text top="245" left="98" width="62" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(177)</a> </text>
<text top="263" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20170948?dopt=Citation">20170948</a></text>
<text top="263" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20170948?dopt=Citation"> </a></text>
<text top="211" left="226" width="119" height="20" font="4"><b>Aim: </b>To examine the </text>
<text top="228" left="226" width="78" height="20" font="1">effect of initial </text>
<text top="245" left="226" width="93" height="20" font="1">antihypertensive </text>
<text top="263" left="226" width="130" height="20" font="1">therapy with benazepril </text>
<text top="280" left="226" width="89" height="20" font="1">plus amlodipine </text>
<text top="297" left="226" width="72" height="20" font="1">compared to </text>
<text top="314" left="226" width="86" height="20" font="1">benazepril plus </text>
<text top="332" left="226" width="127" height="20" font="1">hydrochlorothiazide on </text>
<text top="349" left="226" width="111" height="20" font="1">progression of CKD </text>
<text top="366" left="226" width="3" height="20" font="1"> </text>
<text top="383" left="226" width="103" height="20" font="4"><b>Study type:</b> RCT, </text>
<text top="400" left="226" width="109" height="20" font="1">forced drug titration </text>
<text top="418" left="226" width="3" height="20" font="1"> </text>
<text top="435" left="226" width="32" height="20" font="4"><b>Size: </b></text>
<text top="452" left="226" width="55" height="20" font="1">● Overall </text>
<text top="469" left="226" width="86" height="20" font="1">benazepril plus </text>
<text top="487" left="226" width="111" height="20" font="1">amlodipine n=5,744 </text>
<text top="504" left="226" width="86" height="20" font="1">benazepril plus </text>
<text top="521" left="226" width="110" height="20" font="1">hydrochlorothiazide </text>
<text top="538" left="226" width="48" height="20" font="1">n=5,762 </text>
<text top="555" left="226" width="88" height="20" font="1">● Pts with CKD </text>
<text top="573" left="226" width="86" height="20" font="1">benazepril plus </text>
<text top="590" left="226" width="101" height="20" font="1">amlodipine n=561 </text>
<text top="607" left="226" width="86" height="20" font="1">benazepril plus </text>
<text top="624" left="226" width="110" height="20" font="1">hydrochlorothiazide </text>
<text top="641" left="226" width="38" height="20" font="1">n=532 </text>
<text top="659" left="226" width="105" height="20" font="1">● Pts without CKD </text>
<text top="676" left="226" width="86" height="20" font="1">benazepril plus </text>
<text top="693" left="226" width="111" height="20" font="1">amlodipine n=5,171 </text>
<text top="710" left="226" width="86" height="20" font="1">benazepril plus </text>
<text top="727" left="226" width="110" height="20" font="1">hydrochlorothiazide </text>
<text top="745" left="226" width="48" height="20" font="1">n=5,218 </text>
<text top="211" left="369" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="228" left="369" width="135" height="20" font="1">● Males or females ≥55 </text>
<text top="245" left="369" width="140" height="20" font="1">y, with HTN, high CV risk </text>
<text top="263" left="369" width="109" height="20" font="1">(history of coronary </text>
<text top="280" left="369" width="64" height="20" font="1">events, MI, </text>
<text top="297" left="369" width="139" height="20" font="1">revascularization, stroke, </text>
<text top="314" left="369" width="122" height="20" font="1">CKD, PAD, LVH, DM) </text>
<text top="332" left="369" width="127" height="20" font="1">● Entry BP for pts with </text>
<text top="349" left="369" width="29" height="20" font="1">CKD </text>
<text top="366" left="369" width="86" height="20" font="1">benazepril plus </text>
<text top="383" left="369" width="66" height="20" font="1">amlodipine: </text>
<text top="401" left="369" width="125" height="20" font="1">145.1/78.6 (20.2/11.2) </text>
<text top="418" left="369" width="86" height="20" font="1">benazepril plus </text>
<text top="435" left="369" width="114" height="20" font="1">hydrochlorothiazide: </text>
<text top="452" left="369" width="125" height="20" font="1">145.0/78.1 (20.5/10.7) </text>
<text top="469" left="369" width="124" height="20" font="1">● Rate of DM same in </text>
<text top="487" left="369" width="127" height="20" font="1">CKD and non-CKD pts </text>
<text top="504" left="369" width="103" height="20" font="1">(58.9% vs. 60.5%; </text>
<text top="521" left="369" width="48" height="20" font="1">p=0.302 </text>
<text top="538" left="369" width="3" height="20" font="1"> </text>
<text top="555" left="369" width="134" height="20" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="211" left="524" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="228" left="524" width="138" height="20" font="1">● Initial antihypertensive </text>
<text top="245" left="524" width="130" height="20" font="1">therapy with benazepril </text>
<text top="263" left="524" width="89" height="20" font="1">plus amlodipine </text>
<text top="280" left="524" width="132" height="20" font="1">compared to benazepril </text>
<text top="297" left="524" width="136" height="20" font="1">plus hydrochlorothiazide </text>
<text top="314" left="524" width="90" height="20" font="1">● BP after dose </text>
<text top="332" left="524" width="64" height="20" font="1">adjustment </text>
<text top="349" left="524" width="86" height="20" font="1">benazepril plus </text>
<text top="366" left="524" width="128" height="20" font="1">amlodipine: 131.6/73.3 </text>
<text top="383" left="524" width="118" height="20" font="1">(18.2/10.3 SD), 4119 </text>
<text top="401" left="524" width="93" height="20" font="1">(75%) controlled </text>
<text top="418" left="524" width="100" height="20" font="1">● Benazepril plus </text>
<text top="435" left="524" width="113" height="20" font="1">hydrochlorothiazide: </text>
<text top="452" left="524" width="120" height="20" font="1">132.5/74.4 (17.9/11.2 </text>
<text top="469" left="524" width="95" height="20" font="1">SD), 3963 (72%) </text>
<text top="487" left="524" width="57" height="20" font="1">controlled </text>
<text top="504" left="524" width="55" height="20" font="1">p&lt;0.0013 </text>
<text top="521" left="524" width="111" height="20" font="1">Target &lt;140/90 and </text>
<text top="538" left="524" width="132" height="20" font="1">&lt;130/80 for DM or CKD </text>
<text top="555" left="524" width="3" height="20" font="1"> </text>
<text top="573" left="524" width="101" height="20" font="4"><b>Comparator: </b>N/A<b> </b></text>
<text top="212" left="680" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="230" left="680" width="229" height="20" font="1">● Overall: time to first event of composite </text>
<text top="247" left="680" width="148" height="20" font="1">CV morbidity and mortality </text>
<text top="265" left="680" width="208" height="20" font="1">● Progression of CKD, a prespeciﬁed </text>
<text top="282" left="680" width="203" height="20" font="1">endpoint, was deﬁned as doubling of </text>
<text top="299" left="680" width="223" height="20" font="1">serum creatinine concentration or ESRD </text>
<text top="316" left="680" width="218" height="20" font="1">(estimated glomerular ﬁltration rate &lt;15 </text>
<text top="333" left="680" width="204" height="20" font="1">mL/min/1·73 m² or need for dialysis). </text>
<text top="351" left="680" width="209" height="20" font="1">● All randomized pts were included in </text>
<text top="368" left="680" width="200" height="20" font="1">the intention-to-treat analysis. There </text>
<text top="385" left="680" width="207" height="20" font="1">were 113 (2.0% x 0%) events of CKD </text>
<text top="402" left="680" width="191" height="20" font="1">progression in the benazepril  plus </text>
<text top="419" left="680" width="205" height="20" font="1">amlodipine group compared with 215 </text>
<text top="437" left="680" width="190" height="20" font="1">(3.7% x 7%) in the benazepril plus </text>
<text top="454" left="680" width="200" height="20" font="1">hydrochlorothiazide group HR: 0.52, </text>
<text top="471" left="680" width="172" height="20" font="1">(95% CI: 0.41–0.65), p&lt;0.0001 </text>
<text top="488" left="680" width="87" height="20" font="1">● 2º endpoints: </text>
<text top="506" left="679" width="220" height="20" font="1">CKD plus death, change in albuminuria, </text>
<text top="523" left="679" width="93" height="20" font="1">change in eGFR </text>
<text top="540" left="679" width="197" height="20" font="1">● Subset with more advanced CKD </text>
<text top="557" left="679" width="176" height="20" font="1">analyzed for rate of progression </text>
<text top="575" left="679" width="3" height="20" font="1"> </text>
<text top="593" left="680" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="211" left="921" width="73" height="20" font="4"><b>Limitations: </b></text>
<text top="228" left="921" width="170" height="20" font="1">● Trial terminated early (mean </text>
<text top="245" left="921" width="185" height="20" font="1">follow-up 2.9 y [SD 0.4]) because </text>
<text top="263" left="921" width="182" height="21" font="1">of superior eﬃcacy of benazepril </text>
<text top="280" left="921" width="172" height="20" font="1">plus amlodipine compared with </text>
<text top="297" left="921" width="86" height="20" font="1">benazepril plus </text>
<text top="314" left="921" width="163" height="20" font="1">hydrochlorothiazide with 20% </text>
<text top="332" left="921" width="79" height="20" font="1">lower CV risk. </text>
<text top="349" left="921" width="178" height="20" font="1">● Very small proportion of study </text>
<text top="366" left="921" width="188" height="20" font="1">population had albuminuria above </text>
<text top="383" left="921" width="163" height="20" font="1">33.9 mg/mmol combined with </text>
<text top="401" left="921" width="172" height="20" font="1">early trial termination to reduce </text>
<text top="418" left="921" width="74" height="20" font="1">renal events. </text>
<text top="435" left="921" width="126" height="20" font="1">● Funded by Novartis. </text>
<text top="452" left="924" width="3" height="20" font="1"> </text>
<text top="469" left="921" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="487" left="921" width="138" height="20" font="1">● Initial antihypertensive </text>
<text top="504" left="921" width="167" height="20" font="1">treatment with benazepril plus </text>
<text top="521" left="921" width="186" height="20" font="1">amlodipine slowed progression of </text>
<text top="538" left="921" width="175" height="20" font="1">nephropathy to a greater extent </text>
<text top="555" left="921" width="158" height="20" font="1">compared to benazepril plus </text>
<text top="573" left="921" width="114" height="20" font="1">hydrochlorothiazide. </text>
<text top="763" left="98" width="42" height="20" font="4"><b>AVOID </b></text>
<text top="781" left="98" width="103" height="20" font="1">Parving HH, et al., </text>
<text top="763" left="226" width="124" height="20" font="4"><b>Aim:</b> Compare effects </text>
<text top="780" left="226" width="107" height="20" font="1">of dual blockade of </text>
<text top="763" left="369" width="110" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="780" left="369" width="129" height="20" font="1">Pts with HTN, 18–85 y, </text>
<text top="763" left="524" width="112" height="20" font="4"><b>Intervention: </b>All on </text>
<text top="780" left="524" width="137" height="20" font="1">losartan then aliskiren or </text>
<text top="764" left="680" width="79" height="20" font="4"><b>1</b>° <b>endpoint:  </b></text>
<text top="782" left="680" width="220" height="20" font="1">● Ratio of albumin to creatinine at 6 mo </text>
<text top="764" left="921" width="180" height="20" font="4"><b>Limitations:</b> No renal endpoints </text>
<text top="781" left="921" width="174" height="20" font="1">regarding function, survival, CV </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">132 </text>
<text top="107" left="98" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(178)</a> </text>
<text top="125" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18525041?dopt=Citation">18525041</a></text>
<text top="125" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18525041?dopt=Citation"> </a></text>
<text top="107" left="226" width="126" height="20" font="1">RAAS by aliskiren 300 </text>
<text top="124" left="226" width="131" height="20" font="1">mg/d added to maximal </text>
<text top="141" left="226" width="101" height="20" font="1">dose losartan 100 </text>
<text top="159" left="226" width="126" height="20" font="1">mg/d and optimal HTN </text>
<text top="176" left="226" width="44" height="20" font="1">therapy </text>
<text top="191" left="226" width="3" height="20" font="1"> </text>
<text top="209" left="226" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="226" left="226" width="119" height="20" font="1">RCT, double-blinded, </text>
<text top="243" left="226" width="104" height="20" font="1">duration was 6 mo </text>
<text top="260" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="277" left="226" width="32" height="20" font="4"><b>Size: </b></text>
<text top="295" left="226" width="100" height="20" font="1">805 entered open </text>
<text top="312" left="226" width="128" height="20" font="1">label, 599 randomized, </text>
<text top="329" left="226" width="87" height="20" font="1">524 completed. </text>
<text top="107" left="369" width="81" height="20" font="1">and DM-2 and </text>
<text top="124" left="369" width="106" height="20" font="1">nephropathy (early </text>
<text top="141" left="369" width="130" height="20" font="1">morning alb/creat &gt;300 </text>
<text top="159" left="369" width="137" height="20" font="1">mg/g or &gt;200 mg/g in on </text>
<text top="176" left="369" width="124" height="20" font="1">RAAS blocker already </text>
<text top="193" left="369" width="3" height="20" font="4"><b> </b></text>
<text top="210" left="369" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="227" left="369" width="137" height="20" font="1">Non-DM kidney disease, </text>
<text top="245" left="369" width="112" height="20" font="1">&gt;3,500 mg/g alb/ Cr </text>
<text top="262" left="369" width="87" height="20" font="1">ratio, eGFR, 30 </text>
<text top="279" left="369" width="118" height="20" font="1">mL/min/BSA, chronic </text>
<text top="296" left="369" width="127" height="20" font="1">urinary tract infections, </text>
<text top="314" left="369" width="87" height="20" font="1">baseline serum </text>
<text top="331" left="369" width="131" height="20" font="1">potassium &gt;5.1, severe </text>
<text top="348" left="369" width="137" height="20" font="1">HTN, major CVD in prior </text>
<text top="365" left="369" width="31" height="20" font="1">6 mo </text>
<text top="107" left="524" width="84" height="20" font="1">placebo added<b> </b></text>
<text top="124" left="524" width="3" height="20" font="4"><b> </b></text>
<text top="141" left="524" width="111" height="20" font="4"><b>Comparator: </b>All on </text>
<text top="159" left="524" width="113" height="20" font="1">losartan, aliskiren or </text>
<text top="176" left="524" width="84" height="20" font="1">placebo added </text>
<text top="108" left="680" width="213" height="20" font="1">● 2º: decline in eGFR, development of </text>
<text top="125" left="680" width="195" height="20" font="1">renal dysfunction (serum creatinine </text>
<text top="142" left="680" width="167" height="20" font="1">&gt;176.8 micromol/l (2.0 mg/dL) </text>
<text top="161" left="680" width="3" height="20" font="4"><b> </b></text>
<text top="179" left="680" width="100" height="20" font="4"><b>Safety endpoint: </b></text>
<text top="197" left="680" width="200" height="20" font="1">Hyperkalemia 5% in aliskiren group, </text>
<text top="214" left="680" width="178" height="20" font="1">5.7% in placebo group but more </text>
<text top="231" left="680" width="203" height="20" font="1">frequent individual elevations &gt;5.5 in </text>
<text top="248" left="680" width="83" height="20" font="1">aliskiren group </text>
<text top="107" left="921" width="172" height="20" font="1">events, BP 2/1 mm Hg lower in </text>
<text top="124" left="921" width="161" height="20" font="1">aliskiren group; supported by </text>
<text top="141" left="921" width="49" height="20" font="1">Novartis<b> </b></text>
<text top="157" left="921" width="3" height="20" font="4"><b> </b></text>
<text top="174" left="921" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="191" left="921" width="146" height="20" font="1">● Outcome was degree of </text>
<text top="209" left="921" width="168" height="20" font="1">albuminuria. Aliskiren reduced </text>
<text top="226" left="921" width="163" height="20" font="1">urinary alb/creat ratio by 20% </text>
<text top="243" left="921" width="134" height="20" font="1">(95% CI 9–30; p&lt;0.001) </text>
<text top="260" left="921" width="146" height="20" font="1">● From post hoc analysis: </text>
<text top="278" left="921" width="180" height="20" font="1">Antiproteinuric effects consistent </text>
<text top="295" left="921" width="176" height="20" font="1">across CKD stages (19%, 22%, </text>
<text top="312" left="921" width="178" height="20" font="1">and 18% for stages 3, 2, and 1). </text>
<text top="329" left="921" width="161" height="20" font="1">For CKD 3, renal dysfunction </text>
<text top="347" left="921" width="174" height="20" font="1">more frequent in placebo group </text>
<text top="364" left="921" width="145" height="20" font="1">(29.3 vs. 13.6%; p=0.032) </text>
<text top="381" left="921" width="163" height="20" font="1">● No differences in deaths or </text>
<text top="398" left="921" width="173" height="20" font="1">acute renal failure by treatment </text>
<text top="415" left="921" width="115" height="20" font="1">group (0.7% in both) </text>
<text top="433" left="98" width="98" height="20" font="4"><b>VA NEPHRON-D </b></text>
<text top="450" left="98" width="88" height="20" font="1">Fried LF, et al.,  </text>
<text top="468" left="98" width="66" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(124)</a>  </text>
<text top="485" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20728887?dopt=Citation">20728887</a></text>
<text top="485" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20728887?dopt=Citation"><b> </b></a></text>
<text top="433" left="226" width="92" height="20" font="4"><b>Aim: </b>To test the </text>
<text top="450" left="226" width="79" height="20" font="1">efficacy of the </text>
<text top="468" left="226" width="83" height="20" font="1">combination of </text>
<text top="485" left="226" width="120" height="20" font="1">losartan with lisinopril </text>
<text top="502" left="226" width="100" height="20" font="1">as compared with </text>
<text top="519" left="226" width="107" height="20" font="1">standard treatment </text>
<text top="537" left="226" width="119" height="20" font="1">with losartan alone in </text>
<text top="554" left="226" width="65" height="20" font="1">slowing the </text>
<text top="571" left="226" width="81" height="20" font="1">progression of </text>
<text top="588" left="226" width="107" height="20" font="1">proteinuric diabetic </text>
<text top="605" left="226" width="85" height="20" font="1">kidney disease<b> </b></text>
<text top="623" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="640" left="226" width="102" height="20" font="4"><b>Study type: </b>RCT, </text>
<text top="657" left="226" width="112" height="20" font="1">multi-center, double-</text>
<text top="674" left="226" width="29" height="20" font="1">blind<b> </b></text>
<text top="691" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="709" left="226" width="93" height="20" font="4"><b>Size: </b>1448 were </text>
<text top="726" left="226" width="68" height="20" font="1">randomized<b> </b></text>
<text top="433" left="369" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="450" left="369" width="129" height="20" font="1">without adverse events </text>
<text top="468" left="369" width="114" height="20" font="1">on full dose losartan </text>
<text top="485" left="369" width="121" height="20" font="1">DM-2, eGFR 30–89.9 </text>
<text top="502" left="369" width="116" height="20" font="1">mL/min/1.73 m² by 4 </text>
<text top="519" left="369" width="134" height="20" font="1">variable MDRD formula, </text>
<text top="537" left="369" width="41" height="20" font="1">urinary </text>
<text top="554" left="369" width="131" height="20" font="1">albumin/creatinine ratio </text>
<text top="571" left="369" width="114" height="20" font="1">of ≥300 in a random </text>
<text top="588" left="369" width="43" height="20" font="1">sample </text>
<text top="605" left="369" width="3" height="20" font="1"> </text>
<text top="623" left="369" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="640" left="369" width="127" height="20" font="1">Known non-DM kidney </text>
<text top="657" left="369" width="87" height="20" font="1">disease, serum </text>
<text top="674" left="369" width="134" height="20" font="1">potassium &gt;5.5 mmol/L, </text>
<text top="691" left="369" width="122" height="20" font="1">current treatment with </text>
<text top="709" left="369" width="109" height="20" font="1">sodium polystyrene </text>
<text top="726" left="369" width="126" height="20" font="1">sulfonate or inability to </text>
<text top="743" left="369" width="87" height="20" font="1">stop prescribed </text>
<text top="760" left="369" width="128" height="20" font="1">medications increasing </text>
<text top="777" left="369" width="116" height="20" font="1">risk of hyperkalemia.<b> </b></text>
<text top="433" left="524" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="450" left="524" width="136" height="20" font="1">● Pts with DM-2 already </text>
<text top="468" left="524" width="138" height="20" font="1">taking losartan 100 mg/d </text>
<text top="485" left="524" width="142" height="20" font="1">with albumin to creatinine </text>
<text top="502" left="524" width="103" height="20" font="1">ratio of ≥300 were </text>
<text top="519" left="524" width="116" height="20" font="1">randomized to either </text>
<text top="537" left="524" width="130" height="20" font="1">lisinopril 10–40 mg/d or </text>
<text top="554" left="524" width="50" height="20" font="1">placebo.<b> </b></text>
<text top="571" left="524" width="122" height="20" font="1">● 132 1° endpoints in </text>
<text top="588" left="524" width="135" height="20" font="1">the combination therapy </text>
<text top="605" left="524" width="111" height="20" font="1">group; No benefit to </text>
<text top="623" left="524" width="128" height="20" font="1">mortality or CV events. </text>
<text top="640" left="524" width="117" height="20" font="1">Combination therapy </text>
<text top="657" left="524" width="86" height="20" font="1">increase risk of </text>
<text top="674" left="524" width="97" height="20" font="1">hyperkalemia 6.3 </text>
<text top="691" left="524" width="134" height="20" font="1">events/100 person-y vs. </text>
<text top="709" left="524" width="135" height="20" font="1">2.6 events/100 person-y </text>
<text top="726" left="524" width="114" height="20" font="1">(p&lt;0.001) and acute </text>
<text top="743" left="524" width="139" height="20" font="1">kidney injury 12.2 vs. 6.7 </text>
<text top="760" left="524" width="115" height="20" font="1">events/100 person-y </text>
<text top="777" left="524" width="56" height="20" font="1">(p&lt;0.001) </text>
<text top="433" left="680" width="191" height="20" font="4"><b>1° endpoint:</b> First occurrence of a </text>
<text top="450" left="680" width="189" height="20" font="1">change in eGFR (a decline of ≥30 </text>
<text top="468" left="680" width="209" height="20" font="1">mL/min/1.73 m² if initial GFR ≥60 or a </text>
<text top="485" left="680" width="197" height="20" font="1">decline of ≥50% if initial eGFR &lt;60, </text>
<text top="502" left="680" width="86" height="20" font="1">ESRD or death </text>
<text top="519" left="680" width="218" height="20" font="1">2° endpoint: First occurrence of decline </text>
<text top="537" left="680" width="101" height="20" font="1">in eGFR or ESRD </text>
<text top="554" left="680" width="3" height="20" font="1"> </text>
<text top="571" left="680" width="153" height="20" font="4"><b>Safety endpoint:</b> mortality, </text>
<text top="588" left="680" width="185" height="20" font="1">hyperkalemia, acute kidney injury </text>
<text top="433" left="921" width="176" height="20" font="4"><b>Summary:</b> Study stopped early </text>
<text top="450" left="921" width="130" height="20" font="1">due to safety concerns.<b> </b></text>
<text top="468" left="921" width="171" height="20" font="1">Combination of ACEI and ARB </text>
<text top="485" left="921" width="169" height="20" font="1">was associated with increased </text>
<text top="502" left="921" width="184" height="20" font="1">risk of adverse events among pts </text>
<text top="519" left="921" width="143" height="20" font="1">with diabetic nephropathy<b> </b></text>
</page>
<page number="133" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">133 </text>
<text top="107" left="524" width="3" height="20" font="1"> </text>
<text top="124" left="524" width="101" height="20" font="4"><b>Comparator: </b>152 </text>
<text top="141" left="524" width="114" height="20" font="1">primary endpoints in </text>
<text top="159" left="524" width="110" height="20" font="1">monotherapy group<b> </b></text>
<text top="178" left="108" width="3" height="19" font="1"> </text>
<text top="212" left="81" width="747" height="24" font="3"><b>Data Supplement 38. Nonrandomized Trials, Observational Studies, and/or Registries of CKD (Section 9.3) </b></text>
<text top="252" left="99" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="269" left="125" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="287" left="102" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="252" left="215" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="269" left="231" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="252" left="407" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="252" left="610" width="131" height="20" font="4"><b>Primary Endpoint and </b></text>
<text top="269" left="601" width="149" height="20" font="4"><b>Results (include P value; </b></text>
<text top="287" left="614" width="123" height="20" font="4"><b>OR or RR; &amp; 95% CI) </b></text>
<text top="252" left="888" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="269" left="915" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="306" left="98" width="87" height="20" font="1">Upadhyay A, et </text>
<text top="323" left="98" width="83" height="20" font="1">al., 2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(179)</a> </text>
<text top="341" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21403055?dopt=Citation">21403055</a></text>
<text top="341" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21403055?dopt=Citation"> </a></text>
<text top="305" left="212" width="112" height="20" font="4"><b>Aim:</b> To summarize </text>
<text top="322" left="212" width="123" height="20" font="1">trials comparing lower </text>
<text top="339" left="212" width="118" height="20" font="1">vs. higher BP targets </text>
<text top="356" left="212" width="91" height="20" font="1">in pts with CKD; </text>
<text top="373" left="212" width="111" height="20" font="1">focus on proteinuria </text>
<text top="391" left="212" width="114" height="20" font="1">as an effect modifier </text>
<text top="408" left="212" width="3" height="20" font="1"> </text>
<text top="425" left="212" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="442" left="212" width="103" height="20" font="1">Systematic review </text>
<text top="460" left="212" width="3" height="20" font="1"> </text>
<text top="477" left="212" width="66" height="20" font="4"><b>Size:</b> 2,272 </text>
<text top="305" left="349" width="208" height="20" font="4"><b>Inclusion criteria: </b>&gt;50 pts/group, 1 y </text>
<text top="322" left="349" width="203" height="20" font="1">follow-up, outcomes of death, kidney </text>
<text top="339" left="349" width="200" height="20" font="1">failure, CV events, change in kidney </text>
<text top="356" left="349" width="202" height="20" font="1">function, number of antihypertensive </text>
<text top="373" left="349" width="134" height="20" font="1">agents, adverse events.<b> </b></text>
<text top="391" left="349" width="184" height="20" font="1">3 trials (MDRD, AASK, REIN-2; 8 </text>
<text top="408" left="349" width="46" height="20" font="1">reports) </text>
<text top="305" left="590" width="164" height="20" font="4"><b>Results: </b>Overall trials did not </text>
<text top="323" left="590" width="124" height="20" font="1">show that BP target of </text>
<text top="340" left="590" width="136" height="20" font="1">&lt;125/75–130/80 is more </text>
<text top="357" left="590" width="141" height="20" font="1">beneficial than a target of </text>
<text top="374" left="590" width="127" height="20" font="1">&lt;140/90. Lower quality </text>
<text top="391" left="590" width="137" height="20" font="1">evidence suggests a low </text>
<text top="409" left="590" width="147" height="20" font="1">target may be beneficial in </text>
<text top="426" left="590" width="148" height="20" font="1">subgroups with proteinuria </text>
<text top="443" left="590" width="79" height="20" font="1">&gt;300–1,000/d </text>
<text top="305" left="774" width="346" height="20" font="4"><b>Limitations</b>: No pts with DM-1 included. Duration (mean follow-</text>
<text top="323" left="774" width="326" height="20" font="1">up 2–4 y) may be too short to detect differences in clinically </text>
<text top="340" left="774" width="341" height="20" font="1">important outcomes. Reporting of adverse events not uniform. </text>
<text top="358" left="774" width="3" height="20" font="1"> </text>
<text top="376" left="774" width="358" height="20" font="4"><b>Summary:</b> Available evidence is inconclusive but does not prove </text>
<text top="393" left="774" width="333" height="20" font="1">a BP target &lt;130/80 improves clinical outcomes more than a </text>
<text top="411" left="774" width="204" height="20" font="1">target of &lt;140/90 in adults with CKD. </text>
<text top="493" left="98" width="57" height="20" font="1">Lv, et al.,  </text>
<text top="508" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(127)</a> </text>
<text top="526" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459?dopt=Citation">23798459</a></text>
<text top="526" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459?dopt=Citation"> </a></text>
<text top="493" left="212" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="508" left="212" width="115" height="20" font="1">renal and CV effects </text>
<text top="523" left="212" width="85" height="20" font="1">of intensive BP </text>
<text top="538" left="212" width="102" height="20" font="1">lowering in people </text>
<text top="553" left="212" width="55" height="20" font="1">with CKD </text>
<text top="569" left="212" width="3" height="20" font="1"> </text>
<text top="585" left="212" width="71" height="20" font="4"><b>Study type: </b></text>
<text top="600" left="212" width="103" height="20" font="1">Systematic review </text>
<text top="615" left="212" width="3" height="20" font="1"> </text>
<text top="631" left="212" width="111" height="20" font="4"><b>Size:</b> 9,287 pts with </text>
<text top="646" left="212" width="87" height="20" font="1">CKD and 1,264 </text>
<text top="661" left="212" width="119" height="20" font="1">kidney failure events  </text>
<text top="493" left="349" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="509" left="349" width="7" height="18" font="1">•</text>
<text top="508" left="356" width="193" height="20" font="1"> Randomized trials of pts with CKD </text>
<text top="524" left="349" width="193" height="20" font="1">assigned to different target BP that </text>
<text top="539" left="349" width="213" height="20" font="1">reported kidney failure and CV events.<b> </b></text>
<text top="555" left="349" width="7" height="18" font="1">•</text>
<text top="555" left="356" width="200" height="20" font="1"> 11 trials on 9,287 pts with CKD and </text>
<text top="570" left="349" width="217" height="20" font="1">1,264 kidney failure events (doubling of </text>
<text top="585" left="349" width="225" height="20" font="1">serum creatinine, 50% decline in GFR or </text>
<text top="600" left="349" width="41" height="20" font="1">ESKD) </text>
<text top="616" left="349" width="7" height="18" font="1">•</text>
<text top="615" left="356" width="215" height="20" font="1"> Included AASK, REIN-2, MDRD, Wuhl </text>
<text top="631" left="349" width="223" height="20" font="1">(children), Toto, Schrier plus 5 trials with </text>
<text top="646" left="349" width="213" height="20" font="1">CKD subgroups, also included the late </text>
<text top="661" left="349" width="201" height="20" font="1">nonrandomized follow-up studies for </text>
<text top="676" left="349" width="100" height="20" font="1">AASK and MDRD </text>
<text top="692" left="349" width="7" height="18" font="1">•</text>
<text top="691" left="356" width="172" height="20" font="1"> BP targets varied substantially </text>
<text top="706" left="349" width="225" height="20" font="1">between trials. 2 trials targeted mean BP </text>
<text top="721" left="349" width="213" height="20" font="1">&lt;92 mm Hg for the intensive treatment </text>
<text top="736" left="349" width="204" height="20" font="1">arm, and 107 mm Hg in the standard </text>
<text top="751" left="349" width="172" height="20" font="1">treatment arm. 1 trial aimed for </text>
<text top="766" left="349" width="220" height="20" font="1">BP&lt;130/80 mm Hg vs. a DBP of 90 mm </text>
<text top="781" left="349" width="224" height="20" font="1">Hg, 1 study targeted &lt;120/80 mm Hg vs. </text>
<text top="495" left="590" width="138" height="20" font="4"><b>Results: </b>Compared with </text>
<text top="513" left="590" width="140" height="20" font="1">standard regimens, more </text>
<text top="530" left="590" width="121" height="20" font="1">intensive BP lowering </text>
<text top="547" left="590" width="143" height="20" font="1">reduced risk of composite </text>
<text top="564" left="590" width="153" height="20" font="1">endpoint HR: 0.82; 95% CI: </text>
<text top="582" left="590" width="147" height="20" font="1">0.68–0.98, and ESKD HR: </text>
<text top="599" left="590" width="139" height="20" font="1">0.79; 95% CI: 0.67–0.93. </text>
<text top="616" left="590" width="126" height="20" font="1">Effect was modified by </text>
<text top="633" left="590" width="142" height="20" font="1">proteinuria (p=0.006) and </text>
<text top="650" left="590" width="127" height="20" font="1">markers of trial quality. </text>
<text top="668" left="590" width="121" height="20" font="1">Intensive BP lowering </text>
<text top="685" left="590" width="143" height="20" font="1">reduced the risk of kidney </text>
<text top="702" left="590" width="139" height="20" font="1">failure HR: 0.73; 95% CI: </text>
<text top="719" left="590" width="132" height="20" font="1">0.62–0.86 but not in pts </text>
<text top="736" left="590" width="167" height="20" font="1">without proteinuria at baseline </text>
<text top="754" left="590" width="164" height="20" font="1">HR: 1.12; 95% CI: 0.67–1.87. </text>
<text top="771" left="590" width="160" height="20" font="1">No clear effect on CV events </text>
<text top="788" left="590" width="52" height="20" font="1">or death.<b> </b></text>
<text top="494" left="774" width="332" height="20" font="4"><b>Limitations</b>: All trials used open label, in 2 pts were blinded, </text>
<text top="509" left="774" width="335" height="20" font="1">substantial variability in design quality. There was substantial </text>
<text top="525" left="774" width="347" height="20" font="1">variability in BP targets by MAP, systolic and DBP or only DBP. </text>
<text top="540" left="774" width="318" height="20" font="1">Most trials did not include pts with diabetic kidney disease </text>
<text top="558" left="774" width="3" height="20" font="1"> </text>
<text top="577" left="774" width="67" height="20" font="4"><b>Summary:  </b></text>
<text top="597" left="774" width="7" height="18" font="1">•</text>
<text top="596" left="781" width="334" height="20" font="1"> Renal outcomes: 7 trials (N=5,308) recorded a total of 1,264 </text>
<text top="613" left="774" width="355" height="20" font="1">kidney failure events. A -7.7 mm Hg difference in SBP and a -4.9 </text>
<text top="631" left="774" width="358" height="20" font="1">mm Hg difference in DBP seen between treatment arms. Overall, </text>
<text top="648" left="774" width="324" height="20" font="1">a more intensive regimen reduced risk of composite kidney </text>
<text top="665" left="774" width="353" height="20" font="1">failure events by 17% HR: 0.82; 95% CI: 0.68–0.98, reduced the </text>
<text top="682" left="774" width="354" height="20" font="1">risk of ESKD alone by 18% (pooled HR for composite outcomes: </text>
<text top="699" left="774" width="144" height="20" font="1">0.79; 95% CI: 0.67–0.93).<b> </b></text>
<text top="720" left="774" width="7" height="18" font="1">•</text>
<text top="719" left="781" width="352" height="20" font="1"> Intensive BP lowering had no effect on kidney failure in pts who </text>
<text top="736" left="774" width="336" height="20" font="1">did not have proteinuria (3 trials involving 1,218 pts HR: 1.12; </text>
<text top="753" left="774" width="327" height="20" font="1">95% CI: 0.67–1.87), but it did reduce the risk of progressive </text>
<text top="771" left="774" width="353" height="20" font="1">kidney failure by 27% (5 trials involving 1,703 pts HR: 0.73; 95% </text>
<text top="788" left="774" width="338" height="20" font="1">CI: 0.62–0.86 in people who did have proteinuria at baseline.  </text>
</page>
<page number="134" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">134 </text>
<text top="105" left="349" width="212" height="20" font="1">135–140/85–90 mm Hg, and 4 studies </text>
<text top="120" left="349" width="222" height="20" font="1">had DBP&lt;75–80 mm Hg vs. from 80–90 </text>
<text top="135" left="349" width="202" height="20" font="1">mm Hg. A trial involving pediatric pts </text>
<text top="150" left="349" width="193" height="20" font="1">targeted a 24-h mean BP&lt;the 50th </text>
<text top="165" left="349" width="205" height="20" font="1">percentile, compared with the 50th to </text>
<text top="180" left="349" width="213" height="20" font="1">95th percentiles in the control group. 2 </text>
<text top="195" left="349" width="180" height="20" font="1">trials had more liberal targets for </text>
<text top="210" left="349" width="213" height="20" font="1">intensive treatment (&lt;140–150 mm Hg </text>
<text top="225" left="349" width="159" height="20" font="1">systolic, 85 mm Hg diastolic) </text>
<text top="110" left="774" width="7" height="18" font="1">•</text>
<text top="109" left="781" width="329" height="20" font="1"> CV outcomes: major CV events reported in 5 trials (472 CV </text>
<text top="127" left="774" width="331" height="20" font="1">events in 5,308 pts with CKD). Intensive BP lowering did not </text>
<text top="144" left="774" width="346" height="20" font="1">reduce risk of CV events in pts with CKD, but the CIs remained </text>
<text top="161" left="774" width="319" height="20" font="1">wide RR: 1.09; 95% CI: 0.83–1.42. 6 trials reported stroke </text>
<text top="178" left="774" width="333" height="20" font="1">outcomes (197 events in 5,411 pts), 5 trials reported MI (138 </text>
<text top="195" left="774" width="328" height="20" font="1">events in 4,317 pts), and 5 trials reported HF (118 events in </text>
<text top="213" left="774" width="336" height="20" font="1">5,308 pts). They saw no clear effect of intensive treatment on </text>
<text top="230" left="774" width="183" height="20" font="1">any of these vascular outcomes.  </text>
<text top="250" left="774" width="7" height="18" font="1">•</text>
<text top="249" left="781" width="315" height="20" font="1"> Death: 10 trials involving 6,788 participants reported 846 </text>
<text top="267" left="774" width="337" height="20" font="1">deaths. There was no clear effect of intensive BP lowering on </text>
<text top="284" left="774" width="357" height="20" font="1">risk of all-cause death RR: 0.94; 95% CI: 0.84–1.05) or CV death </text>
<text top="301" left="774" width="161" height="20" font="1">RR: 1.20; 95% CI: 0.82–1.75 </text>
<text top="320" left="98" width="91" height="20" font="1">Jafar TH, et al.,  </text>
<text top="338" left="98" width="63" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(180)</a> </text>
<text top="356" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12965979?dopt=Citation">12965979</a></text>
<text top="356" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12965979?dopt=Citation"> </a></text>
<text top="317" left="212" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="333" left="212" width="113" height="20" font="1">the levels of BP and </text>
<text top="348" left="212" width="72" height="20" font="1">urine protein </text>
<text top="363" left="212" width="115" height="20" font="1">excretion associated </text>
<text top="379" left="212" width="104" height="20" font="1">with lowest risk for </text>
<text top="394" left="212" width="111" height="20" font="1">progression of CKD </text>
<text top="409" left="212" width="38" height="20" font="1">during </text>
<text top="425" left="212" width="93" height="20" font="1">antihypertensive </text>
<text top="440" left="212" width="94" height="20" font="1">therapy with and </text>
<text top="456" left="212" width="84" height="20" font="1">without ACEIs.<b> </b></text>
<text top="471" left="212" width="3" height="20" font="1"> </text>
<text top="488" left="212" width="122" height="20" font="4"><b>Study type: </b>11 RCTs </text>
<text top="506" left="212" width="58" height="20" font="1">in pts with </text>
<text top="523" left="212" width="81" height="20" font="1">predominantly </text>
<text top="540" left="212" width="105" height="20" font="1">nondiabetic kidney </text>
<text top="557" left="212" width="46" height="20" font="1">disease<b> </b></text>
<text top="574" left="212" width="3" height="20" font="4"><b> </b></text>
<text top="592" left="212" width="120" height="20" font="4"><b>Size: </b>1,860 pooled in </text>
<text top="609" left="212" width="74" height="20" font="1">pt level meta-</text>
<text top="626" left="212" width="85" height="20" font="1">analysis;<b> </b>mean </text>
<text top="643" left="212" width="114" height="20" font="1">duration of follow-up </text>
<text top="660" left="212" width="30" height="20" font="1">2.2 y </text>
<text top="317" left="349" width="109" height="20" font="4"><b>Inclusion criteria</b>:  </text>
<text top="333" left="349" width="7" height="18" font="1">•</text>
<text top="333" left="356" width="215" height="20" font="1"> Pt-level meta-analysis using data from </text>
<text top="348" left="349" width="202" height="20" font="1">the AIPRD Study Group database to </text>
<text top="363" left="349" width="200" height="20" font="1">assess relationships among pts with </text>
<text top="379" left="349" width="230" height="20" font="1">nondiabetic kidney disease across a wide </text>
<text top="394" left="349" width="213" height="20" font="1">range of urine protein excretion values </text>
<text top="409" left="349" width="224" height="20" font="1">during antihypertensive therapy with and </text>
<text top="425" left="349" width="84" height="20" font="1">without ACEIs. </text>
<text top="441" left="349" width="7" height="18" font="1">•</text>
<text top="441" left="355" width="196" height="20" font="1"> The AIPRD Study Group database </text>
<text top="456" left="349" width="195" height="20" font="1">included 1,860 pts with nondiabetic </text>
<text top="471" left="349" width="211" height="20" font="1">kidney disease enrolled in 11 RCTs of </text>
<text top="486" left="349" width="221" height="20" font="1">ACEIs to slow the progression of kidney </text>
<text top="501" left="349" width="185" height="20" font="1">disease. The database contained </text>
<text top="516" left="349" width="176" height="20" font="1">information on BP, urine protein </text>
<text top="531" left="349" width="226" height="20" font="1">excretion, serum creatinine, and onset of </text>
<text top="546" left="349" width="192" height="20" font="1">kidney failure during 22,610 visits.  </text>
<text top="562" left="349" width="7" height="18" font="1">•</text>
<text top="561" left="355" width="216" height="20" font="1"> Included only randomized trials (with a </text>
<text top="576" left="349" width="212" height="20" font="1">minimum 1 y follow-up) that compared </text>
<text top="591" left="349" width="221" height="20" font="1">the effects of antihypertensive regimens </text>
<text top="606" left="349" width="211" height="20" font="1">that included ACEIs with the effects of </text>
<text top="621" left="349" width="202" height="20" font="1">regimens that did not include ACEIs. </text>
<text top="636" left="349" width="215" height="20" font="1">HTN or decreased kidney function was </text>
<text top="651" left="349" width="182" height="20" font="1">required for entry into all studies. </text>
<text top="667" left="349" width="3" height="20" font="1"> </text>
<text top="684" left="349" width="192" height="20" font="4"><b>Exclusion criteria</b>: Common to all </text>
<text top="701" left="349" width="214" height="20" font="1">studies: acute kidney failure, treatment </text>
<text top="718" left="349" width="224" height="20" font="1">with immunosuppressive meds, clinically </text>
<text top="736" left="349" width="187" height="20" font="1">significant chronic HF, obstructive </text>
<text top="753" left="349" width="208" height="20" font="1">uropathy, renal artery stenosis, active </text>
<text top="770" left="349" width="191" height="20" font="1">systemic disease, DM-1, history of </text>
<text top="787" left="349" width="194" height="20" font="1">transplantation, history of allergy to </text>
<text top="320" left="590" width="158" height="20" font="4"><b>1° endpoint: </b>Progression of </text>
<text top="337" left="590" width="153" height="20" font="1">CKD defined as doubling of </text>
<text top="354" left="590" width="156" height="20" font="1">serum creatinine or onset of </text>
<text top="371" left="590" width="76" height="20" font="1">kidney failure<b> </b></text>
<text top="389" left="590" width="3" height="20" font="1"> </text>
<text top="407" left="590" width="138" height="20" font="4"><b>Results</b>: Kidney disease </text>
<text top="424" left="590" width="152" height="20" font="1">progression documented in </text>
<text top="442" left="590" width="151" height="20" font="1">311 pts, 124 (13.2%) in the </text>
<text top="459" left="590" width="161" height="20" font="1">ACEI group and 187 (20.5%) </text>
<text top="476" left="590" width="169" height="20" font="1">in the control group (p=0.001). </text>
<text top="493" left="590" width="163" height="20" font="1">176 (9.5%) developed kidney </text>
<text top="510" left="590" width="163" height="20" font="1">failure: 70 (7.4%) in the ACEI </text>
<text top="528" left="590" width="163" height="20" font="1">group and 106 (11.6%) in the </text>
<text top="545" left="590" width="138" height="20" font="1">control group (p=0.002).  </text>
<text top="563" left="590" width="160" height="20" font="1">SBP of 110–129 mm Hg and </text>
<text top="580" left="590" width="153" height="20" font="1">urine protein excretion &lt;2.0 </text>
<text top="597" left="590" width="138" height="20" font="1">g/d were associated with </text>
<text top="615" left="590" width="163" height="20" font="1">lowest risk for kidney disease </text>
<text top="632" left="590" width="158" height="20" font="1">progression. ACEI beneficial </text>
<text top="649" left="590" width="153" height="20" font="1">after adjustment for BP and </text>
<text top="666" left="590" width="154" height="20" font="1">urine protein excretion (RR: </text>
<text top="683" left="590" width="168" height="20" font="1">0.67; 95% CI: 0.53–0.84). The </text>
<text top="701" left="590" width="136" height="20" font="1">increased risk for kidney </text>
<text top="718" left="590" width="147" height="20" font="1">progression at higher SBP </text>
<text top="735" left="590" width="161" height="20" font="1">levels was greater in pts with </text>
<text top="752" left="590" width="153" height="20" font="1">urine protein excretion &gt;1.0 </text>
<text top="770" left="590" width="80" height="20" font="1">g/d (p&lt;0.006). </text>
<text top="320" left="774" width="347" height="20" font="4"><b>Limitations: </b>Studies included were not designed to assess the </text>
<text top="337" left="774" width="321" height="20" font="1">effect of lowering BP and urine protein excretion on kidney </text>
<text top="354" left="774" width="117" height="20" font="1">disease progression.<b> </b></text>
<text top="372" left="774" width="3" height="20" font="1"> </text>
<text top="390" left="774" width="344" height="20" font="4"><b>Conclusions:</b> Although reverse causation cannot be excluded </text>
<text top="407" left="774" width="342" height="20" font="1">with certainty, SBP goal between 110 and 129 mm Hg may be </text>
<text top="424" left="774" width="294" height="20" font="1">beneficial in pts with urine protein excretion &gt;1.0 g/d.  </text>
<text top="443" left="774" width="350" height="20" font="1">SBP &lt;110 mm Hg may be associated with higher risk for kidney </text>
<text top="460" left="774" width="117" height="20" font="1">disease progression. </text>
</page>
<page number="135" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">135 </text>
<text top="107" left="349" width="130" height="20" font="1">ACEIs, and pregnancy. </text>
<text top="125" left="98" width="89" height="20" font="1">Giatras I, et al.,  </text>
<text top="142" left="98" width="62" height="20" font="1">1997 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(181)</a> </text>
<text top="159" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9273824?dopt=Citation">9273824</a></text>
<text top="159" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9273824?dopt=Citation"> </a></text>
<text top="125" left="212" width="102" height="20" font="4"><b>Aim: </b>To use meta-</text>
<text top="142" left="212" width="102" height="20" font="1">analysis to assess </text>
<text top="159" left="212" width="104" height="20" font="1">effects if ACEIs on </text>
<text top="177" left="212" width="87" height="20" font="1">development of </text>
<text top="194" left="212" width="116" height="20" font="1">ESRD in nondiabetic </text>
<text top="211" left="212" width="20" height="20" font="1">pts </text>
<text top="228" left="212" width="3" height="20" font="1"> </text>
<text top="245" left="212" width="101" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="263" left="212" width="47" height="20" font="1">analysis </text>
<text top="280" left="212" width="7" height="20" font="1">  </text>
<text top="297" left="212" width="113" height="20" font="4"><b>Size:</b> 1,594 pts from </text>
<text top="314" left="212" width="59" height="20" font="1">10 studies </text>
<text top="125" left="349" width="188" height="20" font="4"><b>Inclusion criteria: </b>All randomized </text>
<text top="142" left="349" width="197" height="20" font="1">studies comparing ACEIs with other </text>
<text top="159" left="349" width="222" height="20" font="1">antihypertensive agents, with at least 1 y </text>
<text top="177" left="349" width="65" height="20" font="1">of follow-up<b> </b></text>
<text top="194" left="349" width="3" height="20" font="1"> </text>
<text top="211" left="349" width="212" height="20" font="4"><b>Exclusion criteria: </b>Studies of diabetic </text>
<text top="228" left="349" width="225" height="20" font="1">renal disease and renal transplants were </text>
<text top="245" left="349" width="56" height="20" font="1">excluded.<b> </b></text>
<text top="125" left="590" width="51" height="20" font="4"><b>Results: </b></text>
<text top="144" left="590" width="7" height="18" font="1">•</text>
<text top="143" left="597" width="142" height="20" font="1"> Among 806 pts receiving </text>
<text top="161" left="590" width="158" height="20" font="1">ACEIs, 52 (6.4%) developed </text>
<text top="178" left="590" width="148" height="20" font="1">ESRD and 17 (2.1%) died.<b> </b></text>
<text top="197" left="590" width="7" height="18" font="1">•</text>
<text top="196" left="597" width="148" height="20" font="1"> In 788 controls, 72 (9.1%) </text>
<text top="213" left="590" width="139" height="20" font="1">developed ESRD and 12 </text>
<text top="231" left="590" width="156" height="20" font="1">(1.5%) died. The pooled RR </text>
<text top="248" left="590" width="166" height="20" font="1">were 0.70; 95% CI: 0.51–0.97 </text>
<text top="265" left="590" width="160" height="20" font="1">for ESRD and 1.24; CI: 0.55–</text>
<text top="282" left="590" width="83" height="20" font="1">2.83 for death. </text>
<text top="301" left="590" width="7" height="18" font="1">•</text>
<text top="301" left="597" width="154" height="20" font="1"> The decreases in weighted </text>
<text top="318" left="590" width="137" height="20" font="1">mean systolic and DBPs </text>
<text top="335" left="590" width="165" height="20" font="1">during follow-up were 4.9 and </text>
<text top="352" left="590" width="109" height="20" font="1">1.2 mm Hg greater, </text>
<text top="370" left="590" width="151" height="20" font="1">respectively, in the pts who </text>
<text top="387" left="590" width="92" height="20" font="1">received ACEIs. </text>
<text top="125" left="774" width="349" height="20" font="4"><b>Limitations: </b>Included studies through 5/1996, published (7) and </text>
<text top="142" left="774" width="353" height="20" font="1">nonpublished (3) study results. Did not require that pts have HTN </text>
<text top="159" left="774" width="356" height="20" font="1">or renal insufficiency at baseline. Did not report results by severity </text>
<text top="177" left="774" width="350" height="20" font="1">of proteinuria related to the diseases included many of which are </text>
<text top="194" left="774" width="177" height="20" font="1">not characterized by proteinuria.<b> </b></text>
<text top="211" left="774" width="3" height="20" font="1"> </text>
<text top="228" left="774" width="355" height="20" font="4"><b>Summary:</b> ACEIs<b> </b>are more effective than other antihypertensive </text>
<text top="245" left="774" width="336" height="20" font="1">agents in reducing the development of end-stage nondiabetic </text>
<text top="263" left="774" width="352" height="20" font="1">renal disease, and they do not increase mortality. It could not be </text>
<text top="280" left="774" width="336" height="20" font="1">determined whether this beneficial effect is due to the greater </text>
<text top="297" left="774" width="272" height="20" font="1">decline in BP or to other effects of ACE inhibition. </text>
<text top="405" left="98" width="72" height="20" font="4"><b>ONTARGET </b></text>
<text top="422" left="98" width="90" height="20" font="1">Investigators, et </text>
<text top="439" left="98" width="83" height="20" font="1">al., 2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(126)</a> </text>
<text top="456" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18378520">18378520</a></text>
<text top="456" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18378520"> </a></text>
<text top="405" left="212" width="82" height="20" font="4"><b>Aim:</b> Evaluate </text>
<text top="422" left="212" width="101" height="20" font="1">whether use of an </text>
<text top="439" left="212" width="115" height="20" font="1">ARB was noninferior </text>
<text top="456" left="212" width="120" height="20" font="1">to ACEI, and whether </text>
<text top="474" left="212" width="115" height="20" font="1">the combination was </text>
<text top="491" left="212" width="90" height="20" font="1">superior to ACE </text>
<text top="508" left="212" width="67" height="20" font="1">alone in the </text>
<text top="525" left="212" width="75" height="20" font="1">prevention of </text>
<text top="542" left="212" width="121" height="20" font="1">vascular events in pts </text>
<text top="560" left="212" width="112" height="20" font="1">with CVD or DM but </text>
<text top="577" left="212" width="44" height="20" font="1">not HF. </text>
<text top="594" left="212" width="3" height="20" font="1"> </text>
<text top="611" left="212" width="101" height="20" font="4"><b>Study type:</b> Multi-</text>
<text top="628" left="212" width="115" height="20" font="1">center, double-blind, </text>
<text top="646" left="212" width="29" height="20" font="1">RCT </text>
<text top="663" left="212" width="3" height="20" font="1"> </text>
<text top="680" left="212" width="93" height="20" font="4"><b>Size:</b> 25,620 pts </text>
<text top="405" left="349" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="424" left="349" width="7" height="18" font="1">•</text>
<text top="423" left="356" width="38" height="20" font="1"> ≥55 y </text>
<text top="442" left="349" width="7" height="18" font="1">•</text>
<text top="441" left="356" width="137" height="20" font="1"> Coronary, peripheral, or </text>
<text top="459" left="349" width="224" height="20" font="1">cerebrovascular disease or DM with end-</text>
<text top="476" left="349" width="83" height="20" font="1">organ damage </text>
<text top="493" left="349" width="3" height="20" font="1"> </text>
<text top="510" left="349" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="529" left="349" width="7" height="18" font="1">•</text>
<text top="529" left="356" width="203" height="20" font="1"> Inability to discontinue ACEI or ARB </text>
<text top="548" left="349" width="7" height="18" font="1">•</text>
<text top="547" left="356" width="210" height="20" font="1"> Known hypersensitivity or intolerance </text>
<text top="564" left="349" width="89" height="20" font="1">to ACEI or ARB </text>
<text top="583" left="349" width="7" height="18" font="1">•</text>
<text top="583" left="356" width="180" height="20" font="1"> Selected CVDs (congestive HF, </text>
<text top="600" left="349" width="217" height="20" font="1">hemodynamically significant valvular or </text>
<text top="617" left="349" width="202" height="20" font="1">outflow tract obstruction, constrictive </text>
<text top="634" left="349" width="207" height="20" font="1">pericarditis, complex congenital heart </text>
<text top="651" left="349" width="220" height="20" font="1">disease, syncopal episodes of unknown </text>
<text top="669" left="349" width="222" height="20" font="1">etiology &lt;3 mo, planned cardiac surgery </text>
<text top="686" left="349" width="208" height="20" font="1">or PTCA &lt;3 mo, uncontrolled HTN on </text>
<text top="703" left="349" width="211" height="20" font="1">treatment [e.g., BP &gt;160/100 mm Hg], </text>
<text top="720" left="349" width="217" height="20" font="1">heart transplant recipient, stroke due to </text>
<text top="737" left="349" width="151" height="20" font="1">subarachnoid hemorrhage) </text>
<text top="756" left="349" width="7" height="18" font="1">•</text>
<text top="756" left="356" width="190" height="20" font="1"> Other conditions (significant renal </text>
<text top="773" left="349" width="196" height="20" font="1">artery disease, hepatic dysfunction, </text>
<text top="790" left="349" width="226" height="20" font="1">uncorrected volume or sodium depletion, </text>
<text top="405" left="590" width="164" height="20" font="4"><b>Intervention:</b> Ramipril 10 mg </text>
<text top="422" left="590" width="85" height="20" font="1">daily (n=8,576) </text>
<text top="439" left="590" width="3" height="20" font="1"> </text>
<text top="456" left="590" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="475" left="590" width="7" height="18" font="1">•</text>
<text top="475" left="597" width="137" height="20" font="1"> Telmisartan 80 mg daily </text>
<text top="492" left="590" width="56" height="20" font="1">(n=8,542) </text>
<text top="511" left="590" width="7" height="18" font="1">•</text>
<text top="510" left="597" width="153" height="20" font="1"> Combination of telmisartan </text>
<text top="527" left="590" width="124" height="20" font="1">and ramipril (n=8,502) </text>
<text top="406" left="774" width="340" height="20" font="4"><b>1</b>°<b> endpoint:</b> After a median follow-up of 56 mo, there was no </text>
<text top="423" left="774" width="318" height="20" font="1">difference between ramipril vs. telmisartan or combination </text>
<text top="440" left="774" width="343" height="20" font="1">therapy vs. ramipril in the 1° composite outcome of death from </text>
<text top="457" left="774" width="344" height="20" font="1">CV causes, MI, stroke, or hospitalization for HF RR: 1.01; 95% </text>
<text top="475" left="774" width="334" height="20" font="1">CI: 0.94–1.09 and RR: 0.99; 95% CI: 0.92–1.07, respectively </text>
<text top="492" left="774" width="3" height="20" font="1"> </text>
<text top="509" left="774" width="107" height="20" font="4"><b>Safety endpoint:</b>   </text>
<text top="528" left="774" width="7" height="18" font="1">•</text>
<text top="527" left="781" width="312" height="20" font="1"> Combination therapy was associated with greater risk of </text>
<text top="545" left="774" width="337" height="20" font="1">hyperkalemia than ramipril monotherapy (480 pts vs. 283 pts; </text>
<text top="562" left="774" width="52" height="20" font="1">p&lt;0.001)<b> </b></text>
<text top="581" left="774" width="7" height="18" font="1">•</text>
<text top="580" left="781" width="331" height="20" font="1"> Hypotensive symptoms were cited as reason for permanent </text>
<text top="597" left="774" width="350" height="20" font="1">discontinuing more in telmisartan vs. ramipril RR: 1.54; p&lt;0.001 </text>
<text top="615" left="774" width="332" height="20" font="1">and combination therapy vs. ramipril monotherapy RR: 2.75; </text>
<text top="632" left="774" width="48" height="20" font="1">p&lt;0.001<b> </b></text>
<text top="651" left="774" width="7" height="18" font="1">•</text>
<text top="650" left="781" width="338" height="20" font="1"> Renal impairment was more common in combination therapy </text>
<text top="667" left="774" width="306" height="20" font="1">vs. ramipril monotherapy RR: 1.33; 95% CI: 1.22–1.44).<b> </b></text>
</page>
<page number="136" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">136 </text>
<text top="107" left="349" width="188" height="20" font="1">1° hyperaldosteronism, hereditary </text>
<text top="124" left="349" width="180" height="20" font="1">fructose intolerance, other major </text>
<text top="141" left="349" width="224" height="20" font="1">noncardiac illness or expected to reduce </text>
<text top="159" left="349" width="208" height="20" font="1">life expectancy or significant disability </text>
<text top="176" left="349" width="180" height="20" font="1">interfere with study participation, </text>
<text top="193" left="349" width="166" height="20" font="1">simultaneously taking another </text>
<text top="210" left="349" width="203" height="20" font="1">experimental drug, unable to provide </text>
<text top="227" left="349" width="145" height="20" font="1">written informed consent). </text>
<text top="245" left="98" width="56" height="20" font="4"><b>VALIANT </b></text>
<text top="263" left="98" width="92" height="20" font="1">White HD, et al., </text>
<text top="280" left="98" width="62" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(182)</a> </text>
<text top="297" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16301343?dopt=Citation">16301343</a></text>
<text top="297" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16301343?dopt=Citation"> </a></text>
<text top="245" left="212" width="82" height="20" font="4"><b>Aim:</b> Evaluate </text>
<text top="263" left="212" width="101" height="20" font="1">whether use of an </text>
<text top="280" left="212" width="63" height="20" font="1">ARB or the </text>
<text top="297" left="212" width="100" height="20" font="1">combination of an </text>
<text top="314" left="212" width="102" height="20" font="1">ACEI and an ARB </text>
<text top="332" left="212" width="97" height="20" font="1">was superior to a </text>
<text top="349" left="212" width="120" height="20" font="1">proven effective dose </text>
<text top="366" left="212" width="116" height="20" font="1">of an ACEI after AMI </text>
<text top="383" left="212" width="116" height="20" font="1">in pts with HF and/or </text>
<text top="401" left="212" width="73" height="20" font="1">LVEF &lt;40%. </text>
<text top="418" left="212" width="3" height="20" font="1"> </text>
<text top="435" left="212" width="101" height="20" font="4"><b>Study type:</b> Multi-</text>
<text top="452" left="212" width="115" height="20" font="1">center, double-blind, </text>
<text top="469" left="212" width="29" height="20" font="1">RCT </text>
<text top="487" left="212" width="3" height="20" font="1"> </text>
<text top="504" left="212" width="93" height="20" font="4"><b>Size:</b> 14,703 pts </text>
<text top="245" left="349" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="265" left="349" width="7" height="18" font="1">•</text>
<text top="264" left="356" width="38" height="20" font="1"> ≥18 y </text>
<text top="283" left="349" width="7" height="18" font="1">•</text>
<text top="282" left="356" width="187" height="20" font="1"> Between 12 h and 10 d after AMI </text>
<text top="301" left="349" width="7" height="18" font="1">•</text>
<text top="301" left="356" width="192" height="20" font="1"> Clinical or radiological signs of HF </text>
<text top="318" left="349" width="228" height="20" font="1">and/or evidence of depressed LV systolic </text>
<text top="335" left="349" width="215" height="20" font="1">function with EF&lt;40% or reduced echo </text>
<text top="352" left="349" width="101" height="20" font="1">wall motion index  </text>
<text top="370" left="349" width="3" height="20" font="1"> </text>
<text top="387" left="349" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="406" left="349" width="7" height="18" font="1">•</text>
<text top="405" left="356" width="108" height="20" font="1"> Cardiogenic shock </text>
<text top="424" left="349" width="7" height="18" font="1">•</text>
<text top="423" left="356" width="165" height="20" font="1"> Serum creatinine &gt;2.5 mg/dL </text>
<text top="442" left="349" width="7" height="18" font="1">•</text>
<text top="442" left="356" width="210" height="20" font="1"> Known hypersensitivity or intolerance </text>
<text top="459" left="349" width="89" height="20" font="1">to ACEI or ARB </text>
<text top="478" left="349" width="7" height="18" font="1">•</text>
<text top="477" left="356" width="102" height="20" font="1"> SBP&lt;100 mm Hg </text>
<text top="496" left="349" width="7" height="18" font="1">•</text>
<text top="496" left="356" width="196" height="20" font="1"> Known or suspected bilateral renal </text>
<text top="513" left="349" width="83" height="20" font="1">artery stenosis </text>
<text top="532" left="349" width="7" height="18" font="1">•</text>
<text top="531" left="356" width="195" height="20" font="1"> Stroke or TIA within previous 3 mo </text>
<text top="550" left="349" width="7" height="18" font="1">•</text>
<text top="550" left="356" width="185" height="20" font="1"> Refractory ventricular arrhythmia </text>
<text top="569" left="349" width="7" height="18" font="1">•</text>
<text top="568" left="356" width="104" height="20" font="1"> Refractory angina </text>
<text top="587" left="349" width="7" height="18" font="1">•</text>
<text top="586" left="356" width="113" height="20" font="1"> Right ventricular MI </text>
<text top="605" left="349" width="7" height="18" font="1">•</text>
<text top="605" left="356" width="198" height="20" font="1"> Mitral stenosis, mitral regurgitation, </text>
<text top="622" left="349" width="204" height="20" font="1">aortic stenosis, aortic regurgitation of </text>
<text top="639" left="349" width="148" height="20" font="1">hemodynamic significance </text>
<text top="658" left="349" width="7" height="18" font="1">•</text>
<text top="658" left="356" width="159" height="20" font="1"> Obstructive cardiomyopathy </text>
<text top="677" left="349" width="7" height="18" font="1">•</text>
<text top="676" left="356" width="181" height="20" font="1"> Previous major organ transplant </text>
<text top="695" left="349" width="7" height="18" font="1">•</text>
<text top="694" left="356" width="178" height="20" font="1"> Conditions likely to lead to poor </text>
<text top="712" left="349" width="62" height="20" font="1">adherence </text>
<text top="245" left="590" width="157" height="20" font="4"><b>Intervention:</b> Valsartan 160 </text>
<text top="263" left="590" width="40" height="20" font="1">mg bid </text>
<text top="280" left="590" width="3" height="20" font="1"> </text>
<text top="297" left="590" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="316" left="590" width="7" height="18" font="1">•</text>
<text top="316" left="597" width="110" height="20" font="1"> Captopril 50 mg tid </text>
<text top="335" left="590" width="7" height="18" font="1">•</text>
<text top="334" left="597" width="156" height="20" font="1"> Combination of captopril 50 </text>
<text top="351" left="590" width="159" height="20" font="1">mg tid and valsartan 160 mg </text>
<text top="368" left="590" width="20" height="20" font="1">bid </text>
<text top="387" left="590" width="7" height="18" font="1">•</text>
<text top="387" left="597" width="143" height="20" font="1"> Analyzed by prespecified </text>
<text top="404" left="590" width="79" height="20" font="1">age groups of </text>
<text top="421" left="590" width="87" height="20" font="1">&lt;65 y (n=6988) </text>
<text top="438" left="590" width="100" height="20" font="1">65–74 y (n=4555) </text>
<text top="456" left="590" width="100" height="20" font="1">75–84 y (n=2777) </text>
<text top="473" left="590" width="81" height="20" font="1">≥85 y (n=383) </text>
<text top="247" left="774" width="180" height="20" font="4"><b>1</b>°<b> endpoint:</b> All-cause mortality </text>
<text top="264" left="774" width="3" height="20" font="1"> </text>
<text top="281" left="774" width="76" height="21" font="4"><b>2ᵒ endpoint:</b> </text>
<text top="300" left="774" width="7" height="18" font="1">•</text>
<text top="299" left="781" width="298" height="20" font="1"> Composite of CV mortality or emergency treatment or </text>
<text top="317" left="774" width="354" height="20" font="1">hospitalization for new or worsening HF, reinfarction, stroke, and </text>
<text top="334" left="774" width="148" height="20" font="1">resuscitated cardiac arrest </text>
<text top="353" left="774" width="7" height="18" font="1">•</text>
<text top="352" left="781" width="324" height="20" font="1"> On 3-y multivariable analysis, each 10-y age increase was </text>
<text top="370" left="774" width="329" height="20" font="1">associated with HR: 1.49; 95% CI: 1.43–1.56); p&lt;0.0001 for </text>
<text top="387" left="774" width="329" height="20" font="1">mortality and an OR: 1.38; 95% CI: 1.31–1.46; p&lt;0.0001 for </text>
<text top="404" left="774" width="118" height="20" font="1">readmission with HF. </text>
<text top="423" left="774" width="7" height="18" font="1">•</text>
<text top="422" left="781" width="349" height="20" font="1"> Similar but slightly smaller trend for composite endpoint, higher </text>
<text top="440" left="774" width="147" height="20" font="1">mainly in the oldest group. </text>
<text top="457" left="774" width="319" height="20" font="1">Valsartan was at least as effective as captopril in reducing </text>
<text top="474" left="774" width="327" height="20" font="1">mortality and other adverse outcomes in all age groups and </text>
<text top="491" left="774" width="329" height="20" font="1">combination therapy with both agents added no incremental </text>
<text top="508" left="774" width="44" height="20" font="1">benefit. </text>
<text top="527" left="774" width="7" height="18" font="1">•</text>
<text top="527" left="781" width="314" height="20" font="1"> Combination therapy increased the incidence of adverse </text>
<text top="544" left="774" width="279" height="20" font="1">effects leading to discontinuation in all age groups  </text>
<text top="561" left="774" width="3" height="20" font="1"> </text>
<text top="578" left="774" width="107" height="20" font="4"><b>Safety endpoint:</b>   </text>
<text top="597" left="774" width="7" height="18" font="1">•</text>
<text top="597" left="781" width="336" height="20" font="1"> Adverse events associated with captopril and valsartan were </text>
<text top="614" left="774" width="334" height="20" font="1">more common in the elderly and in pts receiving combination </text>
<text top="631" left="774" width="51" height="20" font="1">therapy.  </text>
<text top="650" left="774" width="7" height="18" font="1">•</text>
<text top="650" left="781" width="316" height="20" font="1"> Renal dysfunction was more common with older age and </text>
<text top="667" left="774" width="118" height="20" font="1">combination therapy. </text>
<text top="731" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">137 </text>
<text top="106" left="81" width="672" height="24" font="3"><b>Data Supplement 39. RCTs Comparing Hypertension after Renal Transplantation (Section 9.3.1) </b></text>
<text top="146" left="100" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="163" left="125" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="180" left="103" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="260" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="163" left="265" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="180" left="259" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="428" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="606" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="163" left="622" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="180" left="607" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="197" left="628" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="146" left="792" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="163" left="776" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="180" left="782" width="129" height="20" font="4"><b>P value; OR or RR; &amp;  </b></text>
<text top="197" left="820" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="147" left="948" width="143" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="164" left="1004" width="33" height="20" font="4"><b>any); </b></text>
<text top="181" left="965" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="199" left="970" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="216" left="990" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="235" left="98" width="97" height="20" font="1">Midtvedt K, et al., </text>
<text top="252" left="98" width="62" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(183)</a> </text>
<text top="270" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11468543?dopt=Citation">11468543</a></text>
<text top="270" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11468543?dopt=Citation"> </a></text>
<text top="234" left="214" width="168" height="20" font="4"><b>Aim:</b> To compare the effect of </text>
<text top="251" left="214" width="170" height="20" font="1">an ACEI (lisinopril) with a CCB </text>
<text top="268" left="214" width="165" height="20" font="1">(controlled release nifedipine) </text>
<text top="285" left="214" width="130" height="20" font="1">in the treatment of post-</text>
<text top="303" left="214" width="152" height="20" font="1">transplant HTN focusing on </text>
<text top="320" left="214" width="94" height="20" font="1">changes in LVH. </text>
<text top="337" left="214" width="3" height="20" font="1"> </text>
<text top="355" left="214" width="165" height="20" font="4"><b>Study type:</b> prospective RCT </text>
<text top="372" left="214" width="3" height="20" font="1"> </text>
<text top="389" left="214" width="73" height="20" font="4"><b>Size:</b>154 pts<b> </b></text>
<text top="406" left="214" width="174" height="20" font="1">123 completed 1 y good quality </text>
<text top="424" left="214" width="164" height="20" font="1">echo data for 116 at 2 and 12 </text>
<text top="441" left="214" width="103" height="20" font="1">mo post treatment </text>
<text top="234" left="403" width="149" height="20" font="4"><b>Inclusion criteria: </b>All RTx </text>
<text top="251" left="403" width="157" height="20" font="1">pts with HTN by DBP ≥95 in </text>
<text top="268" left="403" width="138" height="20" font="1">first 3 wk after transplant<b> </b></text>
<text top="285" left="403" width="3" height="20" font="1"> </text>
<text top="303" left="403" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="320" left="403" width="128" height="20" font="1">Normotensive, isolated </text>
<text top="337" left="403" width="119" height="20" font="1">systolic HTN, refusal, </text>
<text top="354" left="403" width="156" height="20" font="1">requirement of ACEI for HF. </text>
<text top="234" left="578" width="113" height="20" font="4"><b>Intervention: </b>Renal </text>
<text top="251" left="578" width="167" height="20" font="1">transplant recipients with HTN </text>
<text top="268" left="578" width="162" height="20" font="1">(DBP ≥95 mm Hg) in the first </text>
<text top="285" left="578" width="148" height="20" font="1">3 wk after Transplant were </text>
<text top="303" left="578" width="152" height="20" font="1">randomized to double-blind </text>
<text top="320" left="578" width="129" height="20" font="1">nifedipine CR 30 mg or </text>
<text top="337" left="578" width="118" height="20" font="1">lisinopril 10 mg daily.<b> </b></text>
<text top="354" left="578" width="3" height="20" font="1"> </text>
<text top="371" left="578" width="142" height="20" font="4"><b>Comparator</b>: 2 treatment </text>
<text top="389" left="578" width="31" height="20" font="1">arms </text>
<text top="235" left="759" width="165" height="20" font="4"><b>1° endpoint: </b>BP controlled in </text>
<text top="252" left="759" width="142" height="20" font="1">both groups (mean 140 ± </text>
<text top="269" left="759" width="165" height="20" font="1">16/87 ± 8 with nifedipine, 136 </text>
<text top="286" left="759" width="144" height="20" font="1">± 17/85 ± 8 with lisinopril, </text>
<text top="303" left="759" width="171" height="20" font="1">NS). LV mass reduced by 15% </text>
<text top="321" left="759" width="170" height="20" font="1">(p&lt;0.001) in both groups (from </text>
<text top="338" left="759" width="140" height="20" font="1">153 ± 43 to 131 ± 38 g/m</text>
<text top="340" left="899" width="4" height="13" font="6">2</text>
<text top="338" left="903" width="3" height="20" font="1"> </text>
<text top="355" left="759" width="169" height="20" font="1">with nifedipine and from 142 ± </text>
<text top="372" left="759" width="104" height="20" font="1">35 to 121 ± 34 g/m</text>
<text top="374" left="863" width="4" height="13" font="6">2</text>
<text top="372" left="868" width="29" height="20" font="1"> with </text>
<text top="389" left="759" width="152" height="20" font="1">lisinopril) with no difference </text>
<text top="407" left="759" width="168" height="20" font="1">between groups at baseline or </text>
<text top="424" left="759" width="70" height="20" font="1">at follow-up.<b> </b></text>
<text top="235" left="943" width="108" height="20" font="4"><b>Summary: </b>In renal </text>
<text top="252" left="943" width="131" height="20" font="1">transplant pts with HTN </text>
<text top="269" left="943" width="130" height="20" font="1">with well-controlled BP, </text>
<text top="286" left="943" width="137" height="20" font="1">there is regression of LV </text>
<text top="304" left="943" width="92" height="20" font="1">mass after renal </text>
<text top="321" left="943" width="131" height="20" font="1">transplantation which is </text>
<text top="338" left="943" width="137" height="20" font="1">observed to be similar in </text>
<text top="355" left="943" width="149" height="20" font="1">pts treated with lisinopril or </text>
<text top="372" left="943" width="60" height="20" font="1">nifedipine.<b> </b></text>
<text top="460" left="98" width="97" height="20" font="1">Midtvedt K, et al., </text>
<text top="477" left="98" width="66" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(184)</a>  </text>
<text top="495" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11740389?dopt=Citation">11740389</a></text>
<text top="495" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11740389?dopt=Citation"> </a></text>
<text top="459" left="214" width="174" height="20" font="4"><b>Aim:</b> To examine whether graft </text>
<text top="476" left="214" width="174" height="20" font="1">function as determined by GFR </text>
<text top="493" left="214" width="159" height="20" font="1">was better maintained with a </text>
<text top="510" left="214" width="134" height="20" font="1">CCB (controlled release </text>
<text top="528" left="214" width="165" height="20" font="1">nifedipine) as compared to an </text>
<text top="545" left="214" width="174" height="20" font="1">ACEI (lisinopril) in hypertensive </text>
<text top="562" left="214" width="144" height="20" font="1">renal transplant recipients </text>
<text top="579" left="214" width="142" height="20" font="1">treated with cyclosporine. </text>
<text top="597" left="214" width="3" height="20" font="1"> </text>
<text top="614" left="214" width="167" height="20" font="4"><b>Study type:</b> Prospective RCT </text>
<text top="631" left="214" width="3" height="20" font="1"> </text>
<text top="649" left="214" width="73" height="20" font="4"><b>Size:</b>154 pts<b> </b></text>
<text top="666" left="214" width="147" height="20" font="1">● 123 completed 1 y good </text>
<text top="683" left="214" width="162" height="20" font="1">quality echo data for 116 at 2 </text>
<text top="700" left="214" width="154" height="20" font="1">and 12 mo post-Transplant  </text>
<text top="717" left="214" width="158" height="20" font="1">● 64 recruited to complete a </text>
<text top="735" left="214" width="33" height="20" font="1">2nd y </text>
<text top="459" left="403" width="154" height="20" font="4"><b>Inclusion criteria: </b>All renal </text>
<text top="476" left="403" width="147" height="20" font="1">transplant pts with HTN by </text>
<text top="493" left="403" width="147" height="20" font="1">DBP ≥95 in first 3 wk after </text>
<text top="510" left="403" width="57" height="20" font="1">transplant<b> </b></text>
<text top="528" left="403" width="3" height="20" font="1"> </text>
<text top="545" left="403" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="562" left="403" width="128" height="20" font="1">Normotensive, isolated </text>
<text top="579" left="403" width="119" height="20" font="1">systolic HTN, refusal, </text>
<text top="597" left="403" width="156" height="20" font="1">requirement of ACEI for HF. </text>
<text top="459" left="578" width="113" height="20" font="4"><b>Intervention: </b>Renal </text>
<text top="476" left="578" width="164" height="20" font="1">transplant pts with HTN (DBP </text>
<text top="493" left="578" width="158" height="20" font="1">≥95 mm Hg) in the first 3 wk </text>
<text top="510" left="578" width="116" height="20" font="1">after transplant were </text>
<text top="528" left="578" width="152" height="20" font="1">randomized to double-blind </text>
<text top="545" left="578" width="129" height="20" font="1">nifedipine CR 30 mg or </text>
<text top="562" left="578" width="118" height="20" font="1">lisinopril 10 mg daily.<b> </b></text>
<text top="579" left="578" width="3" height="20" font="1"> </text>
<text top="596" left="578" width="143" height="20" font="4"><b>Comparator:</b> 2 treatment </text>
<text top="614" left="578" width="31" height="20" font="1">arms </text>
<text top="459" left="759" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="476" left="759" width="147" height="20" font="1">● GFR baseline at 3–5 wk </text>
<text top="493" left="759" width="154" height="20" font="1">after entry, and at 1 and 2 y </text>
<text top="510" left="759" width="152" height="20" font="1">● Nifedipine: baseline GFR </text>
<text top="528" left="759" width="115" height="20" font="1">46 mL/min, at 1 y 56 </text>
<text top="545" left="759" width="167" height="20" font="1">● Lisinopril: baseline GFR 43, </text>
<text top="562" left="759" width="51" height="20" font="1">at 1 y 44 </text>
<text top="579" left="759" width="141" height="20" font="1">● delta N vs. L: 9.6 at 1 y </text>
<text top="597" left="759" width="150" height="20" font="1">(95% CI: 5.5–13.7 mL/min; </text>
<text top="614" left="759" width="155" height="20" font="1">p=0.0001), 10.3 at 2 y (95% </text>
<text top="631" left="759" width="118" height="20" font="1">CI: 4.0–16.6 mL/min; </text>
<text top="648" left="759" width="59" height="20" font="1">p=0.0017) </text>
<text top="665" left="759" width="135" height="20" font="1">● Baseline GFR similar, </text>
<text top="683" left="759" width="144" height="20" font="1">change in GFR significant </text>
<text top="700" left="759" width="127" height="20" font="1">after 1 y and remained </text>
<text top="717" left="759" width="169" height="20" font="1">statistically significant after 2 y </text>
<text top="460" left="943" width="148" height="20" font="4"><b>Summary: </b>Both nifedipine </text>
<text top="477" left="943" width="152" height="20" font="1">and lisinopril were safe and </text>
<text top="494" left="943" width="131" height="20" font="1">effective in treatment of </text>
<text top="511" left="943" width="150" height="20" font="1">HTN in renal transplant pts </text>
<text top="528" left="943" width="142" height="20" font="1">treated with cyclosporine. </text>
<text top="546" left="943" width="150" height="20" font="1">Pts receiving nifedipine but </text>
<text top="563" left="943" width="146" height="20" font="1">not lisinopril had improved </text>
<text top="580" left="943" width="128" height="20" font="1">renal function over 2 y.<b> </b></text>
</page>
<page number="138" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">138 </text>
<text top="108" left="98" width="103" height="20" font="1">Suwelack B, et al., </text>
<text top="125" left="98" width="62" height="20" font="1">2000 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(185)</a> </text>
<text top="143" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11009288?dopt=Citation">11009288</a></text>
<text top="143" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11009288?dopt=Citation"> </a></text>
<text top="107" left="214" width="174" height="20" font="4"><b>Aim:</b> To compare the structural </text>
<text top="124" left="214" width="173" height="20" font="1">and functional cardiac changes </text>
<text top="141" left="214" width="129" height="20" font="1">of quinapril vs. atenolol </text>
<text top="159" left="214" width="161" height="20" font="1">administered to hypertensive </text>
<text top="176" left="214" width="152" height="20" font="1">kidney transplant recipients </text>
<text top="193" left="214" width="3" height="20" font="1"> </text>
<text top="211" left="214" width="167" height="20" font="4"><b>Study type:</b> Prospective RCT </text>
<text top="228" left="214" width="3" height="20" font="1"> </text>
<text top="245" left="214" width="163" height="20" font="4"><b>Size: </b>31 cyclosporine treated </text>
<text top="262" left="214" width="164" height="20" font="1">stable function recipients with </text>
<text top="280" left="214" width="167" height="20" font="1">HTN 6–12 wk after transplant <b> </b></text>
<text top="105" left="403" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="121" left="403" width="112" height="20" font="1">Cyclosporine-based </text>
<text top="136" left="403" width="153" height="20" font="1">immunosuppression, stable </text>
<text top="151" left="403" width="137" height="20" font="1">graft function with serum </text>
<text top="167" left="403" width="125" height="20" font="1">creatinine &lt;2.5 mg/dL.<b> </b></text>
<text top="182" left="403" width="3" height="20" font="1"> </text>
<text top="199" left="403" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="217" left="403" width="135" height="20" font="1">Pts with severe aortic or </text>
<text top="234" left="403" width="145" height="20" font="1">mitral regurgitation or with </text>
<text top="251" left="403" width="150" height="20" font="1">heart rates &gt;100 beats/min </text>
<text top="107" left="578" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="124" left="578" width="165" height="20" font="1">● Cyclosporine treated stable </text>
<text top="141" left="578" width="151" height="20" font="1">function pts with HTN 6–12 </text>
<text top="159" left="578" width="104" height="20" font="1">wk after transplant </text>
<text top="176" left="578" width="165" height="20" font="1">randomized to double-blinded </text>
<text top="193" left="578" width="159" height="20" font="1">quinapril or atenolol to target </text>
<text top="210" left="578" width="56" height="20" font="1">DBP&lt;90.  </text>
<text top="228" left="578" width="143" height="20" font="1">● Echo within 24 h of first </text>
<text top="245" left="578" width="105" height="20" font="1">dose and at 24 mo </text>
<text top="262" left="578" width="162" height="20" font="1">● Stepwise increase in dose, </text>
<text top="279" left="578" width="148" height="20" font="1">could then add furosemide </text>
<text top="296" left="578" width="152" height="20" font="1">40–80 mg/d, third-line CCB </text>
<text top="312" left="578" width="3" height="20" font="1"> </text>
<text top="329" left="578" width="143" height="20" font="4"><b>Comparator:</b> 2 treatment </text>
<text top="346" left="578" width="31" height="20" font="1">arms </text>
<text top="108" left="759" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="126" left="759" width="124" height="20" font="1">● BP was lower in the </text>
<text top="143" left="759" width="154" height="20" font="1">atenolol group, delta 10.7 ± </text>
<text top="160" left="759" width="159" height="20" font="1">3.4 mm Hg vs. 4.5 ± 2.9 mm </text>
<text top="177" left="759" width="94" height="20" font="1">Hg with quinapril </text>
<text top="195" left="759" width="118" height="20" font="1">● E/A ratio (impaired </text>
<text top="213" left="759" width="118" height="20" font="1">relaxation) increased </text>
<text top="230" left="759" width="151" height="20" font="1">(improved) only in quinapril </text>
<text top="247" left="759" width="147" height="20" font="1">group (+0.11; p&lt;0.05) and </text>
<text top="264" left="759" width="150" height="20" font="1">decreased by 0.03 (p&gt;0.05 </text>
<text top="282" left="759" width="153" height="20" font="1">vs. start of treatment) in the </text>
<text top="299" left="759" width="157" height="20" font="1">atenolol group. Difference in </text>
<text top="316" left="759" width="136" height="20" font="1">E/A ratio alterations was </text>
<text top="333" left="759" width="111" height="20" font="1">significant (p&lt;0.05). </text>
<text top="351" left="759" width="157" height="20" font="1">● LV mass index decreased </text>
<text top="368" left="759" width="124" height="20" font="1">only in quinapril group </text>
<text top="385" left="759" width="163" height="20" font="1">(p&lt;0.05) from entry to 24 mo. </text>
<text top="108" left="943" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="125" left="943" width="130" height="20" font="1">● In hypertensive renal </text>
<text top="142" left="943" width="107" height="20" font="1">allograft recipients, </text>
<text top="159" left="943" width="124" height="20" font="1">quinapril in contrast to </text>
<text top="177" left="943" width="107" height="20" font="1">atenolol provided a </text>
<text top="194" left="943" width="146" height="20" font="1">sufficient reduction in LVH </text>
<text top="211" left="943" width="104" height="20" font="1">and a concomitant </text>
<text top="228" left="943" width="154" height="20" font="1">improvement in LV diastolic </text>
<text top="246" left="943" width="124" height="20" font="1">cardiac relaxation and </text>
<text top="263" left="943" width="124" height="20" font="1">these effects occurred </text>
<text top="280" left="943" width="128" height="20" font="1">independently from BP </text>
<text top="297" left="943" width="57" height="20" font="1">reduction. </text>
<text top="314" left="943" width="154" height="20" font="1">● While the conclusion was </text>
<text top="332" left="943" width="130" height="20" font="1">that quinapril showed a </text>
<text top="349" left="943" width="116" height="20" font="1">benefit not seen with </text>
<text top="366" left="943" width="107" height="20" font="1">atenolol, the actual </text>
<text top="383" left="943" width="131" height="20" font="1">numbers are very close </text>
<text top="401" left="943" width="148" height="20" font="1">(14.1 ± 10.1 atenolol, 15.8 </text>
<text top="418" left="943" width="90" height="20" font="1">± 7.7 quinapril). </text>
<text top="435" left="943" width="143" height="20" font="1">● BP reduction was twice </text>
<text top="452" left="943" width="128" height="20" font="1">as great in the atenolol </text>
<text top="469" left="943" width="135" height="20" font="1">group as in the quinapril </text>
<text top="487" left="943" width="141" height="20" font="1">group. Arterial BP did not </text>
<text top="504" left="943" width="152" height="20" font="1">correlate with cardiac mass </text>
<text top="521" left="943" width="57" height="20" font="1">reduction. </text>
<text top="540" left="98" width="92" height="20" font="1">Paoletti E, et al., </text>
<text top="557" left="98" width="62" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(186)</a> </text>
<text top="575" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17591533?dopt=Citation">17591533</a></text>
<text top="575" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17591533?dopt=Citation"> </a></text>
<text top="539" left="214" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="556" left="214" width="140" height="20" font="1">effectiveness of ACEIs in </text>
<text top="573" left="214" width="172" height="20" font="1">regressing LVH persisting after </text>
<text top="591" left="214" width="170" height="20" font="1">renal transplantation during an </text>
<text top="608" left="214" width="150" height="20" font="1">18-mo observation period.  </text>
<text top="625" left="214" width="133" height="20" font="1">To assess the impact of </text>
<text top="642" left="214" width="163" height="20" font="1">cyclosporine vs. tacrolimus in </text>
<text top="659" left="214" width="131" height="20" font="1">affecting LVH outcome. </text>
<text top="677" left="214" width="3" height="20" font="1"> </text>
<text top="694" left="214" width="167" height="20" font="4"><b>Study type:</b> Prospective RCT </text>
<text top="712" left="214" width="3" height="20" font="1"> </text>
<text top="729" left="214" width="137" height="20" font="4"><b>Size:</b> 70 renal transplant </text>
<text top="746" left="214" width="142" height="20" font="1">recipients at 3–6 mo after </text>
<text top="763" left="214" width="64" height="20" font="1">transplant.  </text>
<text top="539" left="403" width="110" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="556" left="403" width="151" height="20" font="1">● Renal transplant pts with </text>
<text top="573" left="403" width="163" height="20" font="1">serum creatinine &lt;2.5 mg/dL, </text>
<text top="591" left="403" width="146" height="20" font="1">urine protein excretion not </text>
<text top="608" left="403" width="139" height="20" font="1">exceeding 1 g/d and with </text>
<text top="625" left="403" width="142" height="20" font="1">persistent LVH at 3–6 mo </text>
<text top="642" left="403" width="92" height="20" font="1">after transplant.  </text>
<text top="659" left="403" width="154" height="20" font="1">● Previously randomized to </text>
<text top="677" left="403" width="120" height="20" font="1">either cyclosporine or </text>
<text top="694" left="403" width="59" height="20" font="1">tacrolimus </text>
<text top="711" left="403" width="117" height="20" font="1">immunosuppression. </text>
<text top="728" left="403" width="150" height="20" font="1">● All were pts of deceased </text>
<text top="746" left="403" width="102" height="20" font="1">donor transplants. </text>
<text top="763" left="403" width="3" height="20" font="1"> </text>
<text top="780" left="403" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="539" left="578" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="556" left="578" width="151" height="20" font="1">● RCT Lisinopril (n=36) vs. </text>
<text top="573" left="578" width="145" height="20" font="1">placebo (n=34), also used </text>
<text top="591" left="578" width="142" height="20" font="1">other agents to treat HTN </text>
<text top="608" left="578" width="148" height="20" font="1">● Endpoint LVMI at 18 mo </text>
<text top="625" left="578" width="157" height="20" font="1">● Echo at 3–6 mo and at 18 </text>
<text top="642" left="578" width="21" height="20" font="1">mo </text>
<text top="659" left="578" width="3" height="20" font="1"> </text>
<text top="677" left="578" width="156" height="20" font="4"><b>Comparator:</b> Treatment vs. </text>
<text top="694" left="578" width="46" height="20" font="1">placebo </text>
<text top="539" left="759" width="79" height="20" font="4"><b>1° endpoint:  </b></text>
<text top="556" left="759" width="156" height="20" font="1">● Change in LV mass index </text>
<text top="573" left="759" width="55" height="20" font="1">at 18 mo. </text>
<text top="591" left="759" width="133" height="20" font="1">● BP decreased in both </text>
<text top="608" left="759" width="168" height="20" font="1">groups (p=NS, between group </text>
<text top="625" left="759" width="148" height="20" font="1">differences SBP -1.7 ± 3.3 </text>
<text top="642" left="759" width="145" height="20" font="1">mm Hg; 95% CI: -4.8–8.2; </text>
<text top="659" left="759" width="152" height="20" font="1">and DBP 0.3 ± 2.2 mm Hg; </text>
<text top="677" left="759" width="103" height="20" font="1">95% CI: -4.8–4.1). </text>
<text top="694" left="759" width="147" height="20" font="1">● LVMI regressed more in </text>
<text top="711" left="759" width="159" height="20" font="1">ACEI group (-9.1 ± 13.3 g/m </text>
<text top="728" left="759" width="136" height="20" font="1">2.7; p&lt;0.001) but only in </text>
<text top="746" left="759" width="122" height="20" font="1">those on cyclosporine </text>
<text top="763" left="759" width="117" height="20" font="1">immunosuppression. </text>
<text top="780" left="759" width="164" height="20" font="1">Interaction of LVMI effect and </text>
<text top="540" left="943" width="154" height="20" font="4"><b>Summary: </b>LVMI regressed </text>
<text top="557" left="943" width="132" height="20" font="1">more in ACEI group but </text>
<text top="574" left="943" width="89" height="20" font="1">only in those on </text>
<text top="591" left="943" width="72" height="20" font="1">cyclosporine </text>
<text top="609" left="943" width="120" height="20" font="1">immunosuppression. <b> </b></text>
<text top="626" left="943" width="140" height="20" font="1">Interaction of LVMI effect </text>
<text top="643" left="943" width="135" height="20" font="1">and cyclosporine in post </text>
<text top="660" left="943" width="75" height="20" font="1">hoc analysis. </text>
</page>
<page number="139" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">139 </text>
<text top="107" left="403" width="121" height="20" font="1">● No DM, HF, severe </text>
<text top="124" left="403" width="145" height="20" font="1">valvular disease, previous </text>
<text top="141" left="403" width="163" height="20" font="1">renal artery stenosis blocking </text>
<text top="159" left="403" width="146" height="20" font="1">agents, acute rejections in </text>
<text top="176" left="403" width="162" height="20" font="1">prior 3 mo or significant renal </text>
<text top="193" left="403" width="90" height="20" font="1">artery stenosis.  </text>
<text top="210" left="403" width="161" height="20" font="1">● Pts receiving a preemptive </text>
<text top="227" left="403" width="137" height="20" font="1">2nd transplant or a living </text>
<text top="245" left="403" width="122" height="20" font="1">donor transplant were </text>
<text top="262" left="403" width="56" height="20" font="1">excluded. </text>
<text top="107" left="759" width="134" height="20" font="1">cyclosporine in post hoc </text>
<text top="124" left="759" width="51" height="20" font="1">analysis. </text>
<text top="141" left="759" width="146" height="20" font="1">● 74/104 had LVMI above </text>
<text top="159" left="759" width="44" height="20" font="1">normal. </text>
<text top="176" left="759" width="161" height="20" font="1">● Change in LVMI ACEIs vs. </text>
<text top="193" left="759" width="95" height="20" font="1">controls p&lt;0.001 </text>
<text top="210" left="759" width="162" height="20" font="1">Number of meds comparable </text>
<text top="227" left="759" width="92" height="20" font="1">● Number using </text>
<text top="245" left="759" width="161" height="20" font="1">CCB/BBs/diuretic/others was </text>
<text top="262" left="759" width="169" height="20" font="1">17/21/2/9 for ACEI, 24/26/3/15 </text>
<text top="279" left="759" width="46" height="20" font="1">controls </text>
<text top="297" left="98" width="98" height="20" font="4"><b>VA NEPHRON-D </b></text>
<text top="314" left="98" width="85" height="20" font="1">Fried LF, et al., </text>
<text top="332" left="98" width="66" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(124)</a>  </text>
<text top="349" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20728887?dopt=Citation">20728887</a></text>
<text top="349" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20728887?dopt=Citation"><b> </b></a></text>
<text top="297" left="214" width="172" height="20" font="4"><b>Aim: </b>To test the efficacy of the </text>
<text top="314" left="214" width="156" height="20" font="1">combination of losartan with </text>
<text top="332" left="214" width="147" height="20" font="1">lisinopril as compared with </text>
<text top="349" left="214" width="132" height="20" font="1">standard treatment with </text>
<text top="366" left="214" width="158" height="20" font="1">losartan alone in slowing the </text>
<text top="383" left="214" width="142" height="20" font="1">progression of proteinuric </text>
<text top="401" left="214" width="131" height="20" font="1">diabetic kidney disease<b> </b></text>
<text top="418" left="214" width="3" height="20" font="4"><b> </b></text>
<text top="435" left="214" width="173" height="20" font="4"><b>Study type: </b>RCT, multi-center, </text>
<text top="452" left="214" width="70" height="20" font="1">double-blind </text>
<text top="469" left="214" width="3" height="20" font="4"><b> </b></text>
<text top="487" left="214" width="164" height="20" font="4"><b>Size: </b>1,448 were randomized<b> </b></text>
<text top="297" left="403" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="314" left="403" width="146" height="20" font="1">without adverse events on </text>
<text top="332" left="403" width="96" height="20" font="1">full dose losartan </text>
<text top="349" left="403" width="121" height="20" font="1">DM-2, eGFR 30–89.9 </text>
<text top="366" left="403" width="162" height="20" font="1">mL/min/1.73 m² by 4 variable </text>
<text top="383" left="403" width="129" height="20" font="1">MDRD formula, urinary </text>
<text top="400" left="403" width="144" height="20" font="1">albumin/creatinine ratio of </text>
<text top="418" left="403" width="144" height="20" font="1">≥300 in a random sample </text>
<text top="435" left="403" width="3" height="20" font="1"> </text>
<text top="452" left="403" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="469" left="403" width="146" height="20" font="1">Known nondiabetic kidney </text>
<text top="487" left="403" width="146" height="20" font="1">disease, serum potassium </text>
<text top="504" left="403" width="117" height="20" font="1">&gt;5.5 mmol/L, current </text>
<text top="521" left="403" width="124" height="20" font="1">treatment with sodium </text>
<text top="538" left="403" width="134" height="20" font="1">polystyrene sulfonate or </text>
<text top="555" left="403" width="145" height="20" font="1">inability to stop prescribed </text>
<text top="573" left="403" width="151" height="20" font="1">medications increasing risk </text>
<text top="590" left="403" width="94" height="20" font="1">of hyperkalemia. </text>
<text top="297" left="578" width="81" height="20" font="4"><b>Intervention:  </b></text>
<text top="314" left="578" width="136" height="20" font="1">● Pts with DM-2 already </text>
<text top="332" left="578" width="163" height="20" font="1">taking losartan 100 mg/d with </text>
<text top="349" left="578" width="158" height="20" font="1">albumin to creatinine ratio of </text>
<text top="366" left="578" width="144" height="20" font="1">≥300 were randomized to </text>
<text top="383" left="578" width="165" height="20" font="1">either lisinopril 10–40 mg/d or </text>
<text top="401" left="578" width="50" height="20" font="1">placebo.<b> </b></text>
<text top="418" left="578" width="143" height="20" font="1">● 132 1° endpoints in the </text>
<text top="435" left="578" width="149" height="20" font="1">combination therapy group </text>
<text top="452" left="578" width="158" height="20" font="1">No benefit to mortality or CV </text>
<text top="469" left="578" width="43" height="20" font="1">events. </text>
<text top="487" left="578" width="129" height="20" font="1">● Combination therapy </text>
<text top="504" left="578" width="163" height="20" font="1">increase risk of hyperkalemia </text>
<text top="521" left="578" width="154" height="20" font="1">6.3 events/100 person-y vs. </text>
<text top="538" left="578" width="135" height="20" font="1">2.6 events/100 person-y </text>
<text top="555" left="578" width="153" height="20" font="1">(p&lt;0.001) and acute kidney </text>
<text top="573" left="578" width="163" height="20" font="1">injury 12.2 vs. 6.7 events/100 </text>
<text top="590" left="578" width="108" height="20" font="1">person-y (p&lt;0.001) </text>
<text top="607" left="578" width="3" height="20" font="1"> </text>
<text top="624" left="578" width="117" height="20" font="4"><b>Comparator: </b>152 1° </text>
<text top="641" left="578" width="145" height="20" font="1">endpoints in monotherapy </text>
<text top="659" left="578" width="35" height="20" font="1">group<b> </b></text>
<text top="297" left="759" width="167" height="20" font="4"><b>1° endpoint:</b> First occurrence </text>
<text top="314" left="759" width="131" height="20" font="1">of a change in eGFR (a </text>
<text top="332" left="759" width="170" height="20" font="1">decline of ≥30 mL/min/1.73 m² </text>
<text top="349" left="759" width="163" height="20" font="1">if initial GFR ≥60 or a decline </text>
<text top="366" left="759" width="155" height="20" font="1">of ≥50% if initial eGFR &lt;60, </text>
<text top="383" left="759" width="86" height="20" font="1">ESRD or death </text>
<text top="400" left="759" width="3" height="20" font="1"> </text>
<text top="418" left="759" width="167" height="20" font="4"><b>2° endpoint</b>: First occurrence </text>
<text top="435" left="759" width="157" height="20" font="1">of decline in eGFR or ESRD </text>
<text top="452" left="759" width="3" height="20" font="1"> </text>
<text top="469" left="759" width="153" height="20" font="4"><b>Safety endpoint:</b> Mortality, </text>
<text top="487" left="759" width="152" height="20" font="1">hyperkalemia, acute kidney </text>
<text top="504" left="759" width="33" height="20" font="1">injury </text>
<text top="521" left="759" width="3" height="20" font="1"> </text>
<text top="538" left="926" width="3" height="20" font="1"> </text>
<text top="297" left="943" width="146" height="20" font="4"><b>Summary:</b> Study stopped </text>
<text top="314" left="943" width="104" height="20" font="1">early due to safety </text>
<text top="332" left="943" width="143" height="20" font="1">concerns.<b> </b>Combination of </text>
<text top="349" left="943" width="110" height="20" font="1">ACEI and ARB was </text>
<text top="366" left="943" width="144" height="20" font="1">associated with increased </text>
<text top="383" left="943" width="123" height="20" font="1">risk of adverse events </text>
<text top="401" left="943" width="132" height="20" font="1">among pts with diabetic </text>
<text top="418" left="943" width="72" height="20" font="1">nephropathy<b> </b></text>
<text top="678" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">140 </text>
<text top="106" left="81" width="981" height="24" font="3"><b>Data Supplement 40. Nonrandomized Trials, Observational Studies, and/or Registries for Hypertension after Renal Transplantation (Section </b></text>
<text top="130" left="81" width="42" height="24" font="3"><b>9.3.1) </b></text>
<text top="170" left="100" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="187" left="125" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="204" left="103" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="170" left="222" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="187" left="238" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="170" left="416" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="170" left="607" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="187" left="609" width="176" height="20" font="4"><b>(include P value; OR or RR; &amp; </b></text>
<text top="204" left="673" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="170" left="888" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="187" left="916" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="222" left="98" width="92" height="20" font="1">Cross NB, et al., </text>
<text top="239" left="98" width="62" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(187)</a> </text>
<text top="257" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19588343?dopt=Citation">19588343</a></text>
<text top="257" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19588343?dopt=Citation"> </a></text>
<text top="222" left="214" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="239" left="214" width="73" height="20" font="1">Comparative </text>
<text top="256" left="214" width="113" height="20" font="1">assessment by drug </text>
<text top="274" left="214" width="123" height="20" font="1">class using RCTs and </text>
<text top="291" left="214" width="121" height="20" font="1">quasi-RCTs lasting at </text>
<text top="308" left="214" width="110" height="20" font="1">least 2 wk in kidney </text>
<text top="325" left="214" width="77" height="20" font="1">transplant pts </text>
<text top="342" left="214" width="3" height="20" font="4"><b> </b></text>
<text top="360" left="214" width="36" height="20" font="4"><b>Size:  </b></text>
<text top="377" left="214" width="133" height="20" font="1">● 60 studies, 3,802 pts, </text>
<text top="394" left="214" width="66" height="20" font="1">most taking </text>
<text top="411" left="214" width="109" height="20" font="1">cyclosporine based </text>
<text top="429" left="214" width="114" height="20" font="1">immunosuppression </text>
<text top="446" left="214" width="128" height="20" font="1">● 29 studies (n=2,262) </text>
<text top="463" left="214" width="101" height="20" font="1">compared CCB to </text>
<text top="480" left="214" width="113" height="20" font="1">placebo, 10 (n=445) </text>
<text top="497" left="214" width="106" height="20" font="1">ACEI to placebo, 7 </text>
<text top="515" left="214" width="121" height="20" font="1">(n=405) CCB to ACEI </text>
<text top="222" left="361" width="215" height="20" font="4"><b>Inclusion criteria: </b>21 studies for HTN, </text>
<text top="239" left="361" width="212" height="20" font="1">6 for erythrocytosis, 2 CAN, 2 LVH, 30 </text>
<text top="256" left="361" width="73" height="20" font="1">not specified </text>
<text top="274" left="361" width="3" height="20" font="1"> </text>
<text top="291" left="361" width="134" height="20" font="4"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="223" left="595" width="135" height="20" font="4"><b>1</b>° <b>endpoint: </b>To assess </text>
<text top="240" left="595" width="124" height="20" font="1">comparative effects of </text>
<text top="257" left="595" width="185" height="20" font="1">antihypertensive agents in kidney </text>
<text top="274" left="595" width="77" height="20" font="1">transplant pts </text>
<text top="293" left="595" width="3" height="20" font="1"> </text>
<text top="311" left="595" width="200" height="20" font="4"><b>Results: </b>Used random effects meta-</text>
<text top="328" left="595" width="198" height="20" font="1">analysis, risk ratios for dichotomous </text>
<text top="345" left="595" width="184" height="20" font="1">outcomes and MD for continuous </text>
<text top="362" left="595" width="160" height="20" font="1">outcomes, both with 95% CI. </text>
<text top="380" left="595" width="159" height="20" font="1">Stratified analyses and meta-</text>
<text top="397" left="595" width="137" height="20" font="1">regression to investigate </text>
<text top="414" left="595" width="81" height="20" font="1">heterogeneity. </text>
<text top="222" left="811" width="278" height="20" font="1">● CCBs vs. placebo or no treatment had strongest </text>
<text top="239" left="811" width="275" height="20" font="1">results: improved GFR MD: 4.45 mL min (95% CI: </text>
<text top="256" left="811" width="273" height="20" font="1">2.22–6.68), reduced graft loss RR: 0.75, (95% CI: </text>
<text top="274" left="811" width="69" height="20" font="1">0.57–0.99).  </text>
<text top="291" left="811" width="258" height="20" font="1">● ACEI vs. placebo inconclusive for GFR MD: -</text>
<text top="308" left="811" width="284" height="20" font="1">8.07 mL/min (95% CI: -18.57–2.43) and variable for </text>
<text top="325" left="811" width="62" height="20" font="1">graft loss.  </text>
<text top="342" left="811" width="272" height="20" font="1">● Compared to CCB, ACEI decreased GFR MD: -</text>
<text top="360" left="811" width="267" height="20" font="1">11.48 mL/min; 95% CI: -5.75– -7.21), proteinuria </text>
<text top="377" left="811" width="250" height="20" font="1">MD: -0.28 g/24 h (95% CI: -0.47– -0.10), also </text>
<text top="394" left="811" width="255" height="20" font="1">reduced hemoglobin MD: -12.96 g/L (95% CI: -</text>
<text top="411" left="811" width="258" height="20" font="1">5.72– -10.21) and increased hyperkalemia RR: </text>
<text top="429" left="811" width="261" height="20" font="1">3.74 (95% CI: 1.89– 7.43). Graft loss data were </text>
<text top="446" left="811" width="77" height="20" font="1">inconclusive.  </text>
<text top="463" left="811" width="276" height="20" font="1">● CCB may be preferred as first line for HTN after </text>
<text top="480" left="811" width="222" height="20" font="1">kidney transplant. ACEI may have some </text>
<text top="497" left="811" width="280" height="20" font="1">detrimental effects. There were not enough studies </text>
<text top="515" left="811" width="101" height="20" font="1">with other agents. </text>
<text top="533" left="98" width="89" height="20" font="1">Jennings DL, et </text>
<text top="551" left="98" width="83" height="20" font="1">al., 2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(188)</a> </text>
<text top="569" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18094340?dopt=Citation">18094340</a></text>
<text top="569" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18094340?dopt=Citation"> </a></text>
<text top="531" left="214" width="126" height="20" font="4"><b>Study type: </b>Literature </text>
<text top="546" left="214" width="39" height="20" font="1">review<b> </b></text>
<text top="562" left="214" width="3" height="20" font="1"> </text>
<text top="579" left="214" width="120" height="20" font="4"><b>Size: </b>5 studies with 3 </text>
<text top="596" left="214" width="88" height="20" font="1">reporting safety </text>
<text top="613" left="214" width="91" height="20" font="1">endpoints and 2 </text>
<text top="631" left="214" width="92" height="20" font="1">reporting clinical </text>
<text top="648" left="214" width="102" height="20" font="1">efficacy endpoints<b> </b></text>
<text top="531" left="361" width="218" height="20" font="4"><b>Inclusion criteria:</b> Studies using either </text>
<text top="546" left="361" width="217" height="20" font="1">ACEI or ARB initiated within the first 12 </text>
<text top="562" left="361" width="135" height="20" font="1">wk after renal transplant </text>
<text top="533" left="595" width="174" height="20" font="4"><b>1° endpoint: </b>Safety or efficacy<b> </b></text>
<text top="551" left="595" width="3" height="20" font="1"> </text>
<text top="569" left="595" width="52" height="20" font="4"><b>Results: </b></text>
<text top="587" left="595" width="190" height="20" font="1">● No significant increase in serum </text>
<text top="605" left="595" width="200" height="20" font="1">creatinine or potassium after up to 9 </text>
<text top="622" left="595" width="39" height="20" font="1">mo Rx </text>
<text top="640" left="595" width="182" height="20" font="1">● Early initiation of ACEI may be </text>
<text top="657" left="595" width="192" height="20" font="1">more effective than BB in reducing </text>
<text top="675" left="595" width="178" height="20" font="1">LVH and proteinuria after 24 mo </text>
<text top="692" left="595" width="55" height="20" font="1">treatment </text>
<text top="533" left="811" width="244" height="20" font="4"><b>Conclusion: </b>Reasonable to consider RAAS </text>
<text top="551" left="811" width="281" height="20" font="1">inhibitors as first-line treatment in pts with HTN and </text>
<text top="568" left="811" width="264" height="20" font="1">compelling indications i.e., DM, HF in first 12 wk </text>
<text top="585" left="811" width="120" height="20" font="1">after renal transplant.<b> </b></text>
<text top="711" left="98" width="101" height="20" font="1">Ninomiya T, et al., </text>
<text top="728" left="98" width="62" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(189)</a> </text>
<text top="745" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24092942?dopt=Citation">24092942</a></text>
<text top="745" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24092942?dopt=Citation"> </a></text>
<text top="710" left="214" width="105" height="20" font="4"><b>Aim:</b> To define CV </text>
<text top="727" left="214" width="134" height="20" font="1">effects of lowering BP in </text>
<text top="744" left="214" width="74" height="20" font="1">pts with CKD </text>
<text top="761" left="214" width="3" height="20" font="1"> </text>
<text top="778" left="214" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="710" left="361" width="217" height="20" font="4"><b>Inclusion criteria</b>: Had to meet 1 of the </text>
<text top="727" left="361" width="205" height="20" font="1">following criteria: Pts randomized to a </text>
<text top="744" left="361" width="208" height="20" font="1">BP-lowering drug/regimen or a control </text>
<text top="761" left="361" width="194" height="20" font="1">group (placebo or less intensive BP </text>
<text top="778" left="361" width="200" height="20" font="1">lowering regimen) or pts randomized </text>
<text top="710" left="595" width="186" height="20" font="4"><b>Results: </b>Compared with placebo, </text>
<text top="727" left="595" width="189" height="20" font="1">BP lowering regimens reduced the </text>
<text top="744" left="595" width="189" height="20" font="1">risk of major CV events by about a </text>
<text top="761" left="595" width="196" height="20" font="1">sixth per 5 mm Hg reduction in SBP </text>
<text top="778" left="595" width="200" height="20" font="1">in individuals with (HR: 0.83; 95% CI </text>
<text top="710" left="811" width="75" height="20" font="4"><b>Limitations</b>:  </text>
<text top="727" left="811" width="276" height="20" font="1">● Limited numbers with CKD and most were stage </text>
<text top="744" left="811" width="20" height="20" font="1">3a: </text>
<text top="761" left="811" width="266" height="20" font="1">● There were 121,995 pts (80%) with eGFR ≥60 </text>
<text top="778" left="811" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="780" left="892" width="4" height="13" font="6">2</text>
<text top="778" left="896" width="139" height="20" font="1"> (mean eGFR 81 (SD 17) </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">141 </text>
<text top="107" left="214" width="105" height="20" font="1">● Meta-analysis of </text>
<text top="124" left="214" width="35" height="20" font="1">RCTs<b> </b></text>
<text top="141" left="214" width="107" height="20" font="1">● Individual pt data </text>
<text top="159" left="214" width="118" height="20" font="1">available for 23 trials, </text>
<text top="176" left="214" width="133" height="20" font="1">with summary data from </text>
<text top="193" left="214" width="89" height="20" font="1">another 3. Meta-</text>
<text top="210" left="214" width="131" height="20" font="1">analysis was performed </text>
<text top="228" left="214" width="118" height="20" font="1">according to baseline </text>
<text top="245" left="214" width="91" height="20" font="1">kidney function.  </text>
<text top="262" left="214" width="3" height="20" font="1"> </text>
<text top="279" left="214" width="129" height="20" font="4"><b>Size: </b>26 trials (152,290 </text>
<text top="296" left="214" width="119" height="20" font="1">pts), including 30,295 </text>
<text top="314" left="214" width="131" height="20" font="1">pts<b> </b>with reduced eGFR, </text>
<text top="331" left="214" width="120" height="20" font="1">defined as eGFR &lt;60 </text>
<text top="348" left="214" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="350" left="294" width="4" height="13" font="6">2</text>
<text top="348" left="299" width="7" height="20" font="1">.<b> </b></text>
<text top="107" left="361" width="203" height="20" font="1">between regimens based on different </text>
<text top="124" left="361" width="193" height="20" font="1">classes of drugs to lower BP. Trials </text>
<text top="141" left="361" width="205" height="20" font="1">required to have at least 1,000 pt-y of </text>
<text top="159" left="361" width="208" height="20" font="1">planned follow-up in each randomized </text>
<text top="176" left="361" width="183" height="20" font="1">arm and not to have presented or </text>
<text top="193" left="361" width="189" height="20" font="1">published their main results before </text>
<text top="210" left="361" width="205" height="20" font="1">finalization of the overview protocol in </text>
<text top="228" left="361" width="59" height="20" font="1">July 1995. </text>
<text top="245" left="361" width="3" height="20" font="1"> </text>
<text top="262" left="361" width="208" height="20" font="4"><b>Exclusion criteria:</b> Trials prior to July </text>
<text top="279" left="361" width="34" height="20" font="1">1995. </text>
<text top="107" left="595" width="174" height="20" font="1">0.76–0.90) and without reduced </text>
<text top="124" left="595" width="172" height="20" font="1">eGFR (HR: 0.83; 95% CI: 0.79–</text>
<text top="141" left="595" width="169" height="20" font="1">0.88), with no evidence for any </text>
<text top="159" left="595" width="102" height="20" font="1">difference in effect<b> </b></text>
<text top="176" left="595" width="167" height="20" font="1">(p=1.00 for homogeneity). The </text>
<text top="193" left="595" width="186" height="20" font="1">results were similar irrespective of </text>
<text top="210" left="595" width="155" height="20" font="1">whether BP was reduced by </text>
<text top="228" left="595" width="193" height="20" font="1">regimens based on ACEIs, calcium </text>
<text top="245" left="595" width="161" height="20" font="1">antagonists, or diuretics/BBs. </text>
<text top="262" left="595" width="173" height="20" font="1">There was no evidence that the </text>
<text top="279" left="595" width="188" height="20" font="1">effects of different drug classes on </text>
<text top="296" left="595" width="199" height="20" font="1">major CV events varied between pts </text>
<text top="314" left="595" width="186" height="20" font="1">with different eGFR (all p&gt;0.60 for </text>
<text top="331" left="595" width="80" height="20" font="1">homogeneity). </text>
<text top="107" left="811" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="109" left="892" width="4" height="13" font="6">2</text>
<text top="107" left="896" width="188" height="20" font="1">) and 30,295 pts (20%) with eGFR </text>
<text top="124" left="811" width="105" height="20" font="1">&lt;60 mL/min/1.73 m</text>
<text top="126" left="916" width="4" height="13" font="6">2</text>
<text top="124" left="920" width="166" height="20" font="1"> (mean 52 (SD 7) mL/min/1.73 </text>
<text top="142" left="811" width="10" height="20" font="1">m</text>
<text top="143" left="822" width="4" height="13" font="6">2</text>
<text top="142" left="826" width="264" height="22" font="1">) at baseline (table 4⇓). Only 439 pts (0.3%) had </text>
<text top="159" left="811" width="140" height="20" font="1">eGFR &lt;30 mL/min/1.73 m</text>
<text top="161" left="952" width="4" height="13" font="6">2</text>
<text top="159" left="956" width="72" height="20" font="1"> at baseline.  </text>
<text top="176" left="811" width="284" height="20" font="1">● Limited numbers had proteinuria, present in 2,500 </text>
<text top="193" left="811" width="206" height="20" font="1">(7%) of 37161 pts with data available. </text>
<text top="211" left="811" width="3" height="20" font="1"> </text>
<text top="228" left="811" width="66" height="20" font="4"><b>Summary:  </b></text>
<text top="245" left="811" width="282" height="20" font="1">● These analyses provided compelling evidence for </text>
<text top="262" left="811" width="276" height="20" font="1">the CV benefits of reduction in BP in pts with stage </text>
<text top="280" left="811" width="256" height="20" font="1">1–3 CKD. The proportional reductions in risk of </text>
<text top="297" left="811" width="284" height="20" font="1">major CV events were similar in pts with and without </text>
<text top="314" left="811" width="281" height="20" font="1">evidence of CKD, however those with CKD stood to </text>
<text top="331" left="811" width="281" height="20" font="1">gain larger absolute benefits because their baseline </text>
<text top="348" left="811" width="121" height="20" font="1">risk was much higher.<b> </b></text>
<text top="366" left="811" width="283" height="20" font="1">● BP-lowering is an effective strategy for preventing </text>
<text top="383" left="811" width="255" height="20" font="1">CV events among pts with moderately reduced </text>
<text top="400" left="811" width="281" height="20" font="1">eGFR. There is little evidence from these overviews </text>
<text top="417" left="811" width="274" height="20" font="1">to support the preferential choice of particular drug </text>
<text top="434" left="811" width="260" height="20" font="1">classes for the prevention of CV events in CKD. </text>
<text top="452" left="98" width="72" height="20" font="4"><b>ONTARGET </b></text>
<text top="470" left="98" width="90" height="20" font="1">Investigators, et </text>
<text top="487" left="98" width="83" height="20" font="1">al., 2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(126)</a> </text>
<text top="504" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18378520">18378520</a></text>
<text top="504" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18378520"> </a></text>
<text top="452" left="214" width="129" height="20" font="4"><b>Aim:</b> Evaluate whether </text>
<text top="470" left="214" width="108" height="20" font="1">use of an ARB was </text>
<text top="487" left="214" width="110" height="20" font="1">noninferior to ACEI, </text>
<text top="504" left="214" width="92" height="20" font="1">and whether the </text>
<text top="521" left="214" width="95" height="20" font="1">combination was </text>
<text top="539" left="214" width="124" height="20" font="1">superior to ACE alone </text>
<text top="556" left="214" width="108" height="20" font="1">in the prevention of </text>
<text top="573" left="214" width="121" height="20" font="1">vascular events in pts </text>
<text top="590" left="214" width="132" height="20" font="1">with CVD or DM but not </text>
<text top="607" left="214" width="23" height="20" font="1">HF. </text>
<text top="625" left="214" width="3" height="20" font="1"> </text>
<text top="642" left="214" width="101" height="20" font="4"><b>Study type:</b> Multi-</text>
<text top="659" left="214" width="115" height="20" font="1">center, double-blind, </text>
<text top="676" left="214" width="29" height="20" font="1">RCT </text>
<text top="693" left="214" width="3" height="20" font="1"> </text>
<text top="711" left="214" width="73" height="20" font="4"><b>Size:</b> 25,620 </text>
<text top="452" left="361" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="471" left="361" width="7" height="18" font="1">•</text>
<text top="471" left="368" width="38" height="20" font="1"> ≥55 y </text>
<text top="490" left="361" width="7" height="18" font="1">•</text>
<text top="489" left="368" width="137" height="20" font="1"> Coronary, peripheral, or </text>
<text top="506" left="361" width="199" height="20" font="1">cerebrovascular disease or DM with </text>
<text top="524" left="361" width="107" height="20" font="1">end-organ damage </text>
<text top="541" left="361" width="3" height="20" font="1"> </text>
<text top="558" left="361" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="577" left="361" width="7" height="18" font="1">•</text>
<text top="576" left="368" width="203" height="20" font="1"> Inability to discontinue ACEI or ARB </text>
<text top="595" left="361" width="7" height="18" font="1">•</text>
<text top="595" left="368" width="210" height="20" font="1"> Known hypersensitivity or intolerance </text>
<text top="612" left="361" width="89" height="20" font="1">to ACEI or ARB </text>
<text top="631" left="361" width="7" height="18" font="1">•</text>
<text top="630" left="368" width="180" height="20" font="1"> Selected CVDs (congestive HF, </text>
<text top="648" left="361" width="217" height="20" font="1">hemodynamically significant valvular or </text>
<text top="665" left="361" width="202" height="20" font="1">outflow tract obstruction, constrictive </text>
<text top="682" left="361" width="207" height="20" font="1">pericarditis, complex congenital heart </text>
<text top="699" left="361" width="220" height="20" font="1">disease, syncopal episodes of unknown </text>
<text top="716" left="361" width="177" height="20" font="1">etiology &lt;3 mo, planned cardiac </text>
<text top="734" left="361" width="207" height="20" font="1">surgery or PTCA &lt;3 mo, uncontrolled </text>
<text top="751" left="361" width="207" height="20" font="1">HTN on treatment [e.g., BP &gt;160/100 </text>
<text top="768" left="361" width="192" height="20" font="1">mm Hg], heart transplant recipient, </text>
<text top="452" left="595" width="193" height="20" font="4"><b>Intervention:</b> Ramipril 10 mg daily </text>
<text top="470" left="595" width="56" height="20" font="1">(n=8,576) </text>
<text top="487" left="595" width="3" height="20" font="1"> </text>
<text top="504" left="595" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="523" left="595" width="7" height="18" font="1">•</text>
<text top="522" left="602" width="194" height="20" font="1"> Telmisartan 80 mg daily (n=8,542) </text>
<text top="541" left="595" width="7" height="18" font="1">•</text>
<text top="541" left="602" width="177" height="20" font="1"> Combination of telmisartan and </text>
<text top="558" left="595" width="100" height="20" font="1">ramipril (n=8,502) </text>
<text top="454" left="811" width="284" height="20" font="4"><b>1</b>°<b> endpoint:</b> After a median follow-up of 56 mo, no </text>
<text top="471" left="811" width="248" height="20" font="1">difference between ramipril vs. telmisartan or </text>
<text top="489" left="811" width="227" height="20" font="1">combination therapy vs. ramipril in the 1° </text>
<text top="506" left="811" width="273" height="20" font="1">composite outcome of death from CV causes, MI, </text>
<text top="524" left="811" width="277" height="20" font="1">stroke, or hospitalization for HF RR: 1.01 (95% CI: </text>
<text top="541" left="811" width="255" height="20" font="1">0.94–1.09) and RR: 0.99 (95% CI: 0.92–1.07), </text>
<text top="558" left="811" width="72" height="20" font="1">respectively. </text>
<text top="575" left="811" width="3" height="20" font="1"> </text>
<text top="592" left="811" width="107" height="20" font="4"><b>Safety endpoint:</b>   </text>
<text top="611" left="811" width="7" height="18" font="1">•</text>
<text top="611" left="818" width="276" height="20" font="1"> Combination therapy was associated with greater </text>
<text top="628" left="811" width="259" height="20" font="1">risk of hyperkalemia than ramipril monotherapy </text>
<text top="645" left="811" width="166" height="20" font="1">(480 pts vs. 283 pts; p&lt;0.001)<b> </b></text>
<text top="664" left="811" width="7" height="18" font="1">•</text>
<text top="664" left="818" width="269" height="20" font="1"> Hypotensive symptoms were cited as reason for </text>
<text top="681" left="811" width="265" height="20" font="1">permanent discontinuing more in telmisartan vs. </text>
<text top="698" left="811" width="244" height="20" font="1">ramipril RR: 1.54, p&lt;0.001; and combination </text>
<text top="715" left="811" width="238" height="20" font="1">therapy vs. ramipril monotherapy RR: 2.75, </text>
<text top="732" left="811" width="48" height="20" font="1">p&lt;0.001<b> </b></text>
<text top="751" left="811" width="7" height="18" font="1">•</text>
<text top="751" left="818" width="224" height="20" font="1"> Renal impairment was more common in </text>
<text top="768" left="811" width="277" height="20" font="1">combination therapy vs. ramipril monotherapy RR: </text>
<text top="785" left="811" width="136" height="20" font="1">1.33; 95% CI: 1.22–1.44<b> </b></text>
</page>
<page number="142" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">142 </text>
<text top="107" left="361" width="152" height="20" font="1">stroke due to subarachnoid </text>
<text top="124" left="361" width="74" height="20" font="1">hemorrhage) </text>
<text top="143" left="361" width="7" height="18" font="1">•</text>
<text top="143" left="368" width="190" height="20" font="1"> Other conditions (significant renal </text>
<text top="160" left="361" width="196" height="20" font="1">artery disease, hepatic dysfunction, </text>
<text top="177" left="361" width="169" height="20" font="1">uncorrected volume or sodium </text>
<text top="194" left="361" width="187" height="20" font="1">depletion, 1° hyperaldosteronism, </text>
<text top="211" left="361" width="204" height="20" font="1">hereditary fructose intolerance, other </text>
<text top="229" left="361" width="217" height="20" font="1">major noncardiac illness or expected to </text>
<text top="246" left="361" width="198" height="20" font="1">reduce life expectancy or significant </text>
<text top="263" left="361" width="157" height="20" font="1">disability interfere with study </text>
<text top="280" left="361" width="194" height="20" font="1">participation, simultaneously taking </text>
<text top="298" left="361" width="205" height="20" font="1">another experimental drug, unable to </text>
<text top="315" left="361" width="189" height="20" font="1">provide written informed consent). </text>
<text top="333" left="98" width="56" height="20" font="4"><b>VALIANT </b></text>
<text top="350" left="98" width="92" height="20" font="1">White HD, et al., </text>
<text top="367" left="98" width="62" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(182)</a> </text>
<text top="384" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16301343?dopt=Citation">16301343</a></text>
<text top="384" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16301343?dopt=Citation"> </a></text>
<text top="333" left="214" width="129" height="20" font="4"><b>Aim:</b> Evaluate whether </text>
<text top="350" left="214" width="118" height="20" font="1">use of an ARB or the </text>
<text top="367" left="214" width="132" height="20" font="1">combination of an ACEI </text>
<text top="384" left="214" width="95" height="20" font="1">and an ARB was </text>
<text top="402" left="214" width="113" height="20" font="1">superior to a proven </text>
<text top="419" left="214" width="110" height="20" font="1">effective dose of an </text>
<text top="436" left="214" width="118" height="20" font="1">ACEI after AMI in pts </text>
<text top="453" left="214" width="118" height="20" font="1">with HF and/or LVEF </text>
<text top="470" left="214" width="39" height="20" font="1">&lt;40%. </text>
<text top="488" left="214" width="3" height="20" font="1"> </text>
<text top="505" left="214" width="101" height="20" font="4"><b>Study type:</b> Multi-</text>
<text top="522" left="214" width="115" height="20" font="1">center, double-blind, </text>
<text top="539" left="214" width="29" height="20" font="1">RCT </text>
<text top="557" left="214" width="3" height="20" font="1"> </text>
<text top="574" left="214" width="73" height="20" font="4"><b>Size:</b> 14,703 </text>
<text top="333" left="361" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="352" left="361" width="7" height="18" font="1">•</text>
<text top="351" left="368" width="38" height="20" font="1"> ≥18 y </text>
<text top="370" left="361" width="7" height="18" font="1">•</text>
<text top="370" left="368" width="187" height="20" font="1"> Between 12 h and 10 d after AMI </text>
<text top="389" left="361" width="7" height="18" font="1">•</text>
<text top="388" left="368" width="192" height="20" font="1"> Clinical or radiological signs of HF </text>
<text top="405" left="361" width="184" height="20" font="1">and/or evidence of depressed LV </text>
<text top="422" left="361" width="181" height="20" font="1">systolic function with EF&lt;40% or </text>
<text top="440" left="361" width="179" height="20" font="1">reduced echo wall motion index  </text>
<text top="457" left="361" width="3" height="20" font="1"> </text>
<text top="474" left="361" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="493" left="361" width="7" height="18" font="1">•</text>
<text top="492" left="368" width="108" height="20" font="1"> Cardiogenic shock </text>
<text top="511" left="361" width="7" height="18" font="1">•</text>
<text top="511" left="368" width="165" height="20" font="1"> Serum creatinine &gt;2.5 mg/dL </text>
<text top="530" left="361" width="7" height="18" font="1">•</text>
<text top="529" left="368" width="210" height="20" font="1"> Known hypersensitivity or intolerance </text>
<text top="546" left="361" width="89" height="20" font="1">to ACEI or ARB </text>
<text top="565" left="361" width="7" height="18" font="1">•</text>
<text top="565" left="368" width="102" height="20" font="1"> SBP&lt;100 mm Hg </text>
<text top="584" left="361" width="7" height="18" font="1">•</text>
<text top="583" left="368" width="196" height="20" font="1"> Known or suspected bilateral renal </text>
<text top="600" left="361" width="83" height="20" font="1">artery stenosis </text>
<text top="619" left="361" width="7" height="18" font="1">•</text>
<text top="619" left="368" width="195" height="20" font="1"> Stroke or TIA within previous 3 mo </text>
<text top="638" left="361" width="7" height="18" font="1">•</text>
<text top="637" left="368" width="185" height="20" font="1"> Refractory ventricular arrhythmia </text>
<text top="656" left="361" width="7" height="18" font="1">•</text>
<text top="655" left="368" width="104" height="20" font="1"> Refractory angina </text>
<text top="674" left="361" width="7" height="18" font="1">•</text>
<text top="674" left="368" width="113" height="20" font="1"> Right ventricular MI </text>
<text top="693" left="361" width="7" height="18" font="1">•</text>
<text top="692" left="368" width="198" height="20" font="1"> Mitral stenosis, mitral regurgitation, </text>
<text top="709" left="361" width="204" height="20" font="1">aortic stenosis, aortic regurgitation of </text>
<text top="726" left="361" width="148" height="20" font="1">hemodynamic significance </text>
<text top="746" left="361" width="7" height="18" font="1">•</text>
<text top="745" left="368" width="159" height="20" font="1"> Obstructive cardiomyopathy </text>
<text top="764" left="361" width="7" height="18" font="1">•</text>
<text top="763" left="368" width="181" height="20" font="1"> Previous major organ transplant </text>
<text top="333" left="595" width="198" height="20" font="4"><b>Intervention:</b> Valsartan 160 mg bid </text>
<text top="350" left="595" width="3" height="20" font="1"> </text>
<text top="367" left="595" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="386" left="595" width="7" height="18" font="1">•</text>
<text top="386" left="602" width="110" height="20" font="1"> Captopril 50 mg tid </text>
<text top="405" left="595" width="7" height="18" font="1">•</text>
<text top="404" left="602" width="194" height="20" font="1"> Combination of captopril 50 mg tid </text>
<text top="421" left="595" width="142" height="20" font="1">and valsartan 160 mg bid </text>
<text top="440" left="595" width="7" height="18" font="1">•</text>
<text top="440" left="602" width="167" height="20" font="1"> Analyzed by prespecified age </text>
<text top="457" left="595" width="55" height="20" font="1">groups of </text>
<text top="474" left="595" width="81" height="20" font="1">&lt;65 (n=6,988) </text>
<text top="491" left="595" width="104" height="20" font="1">65 to 74 (n=4,555) </text>
<text top="508" left="595" width="104" height="20" font="1">75 to 84 (n=2,777) </text>
<text top="526" left="595" width="81" height="20" font="1">≥85 y (n=383) </text>
<text top="334" left="811" width="180" height="20" font="4"><b>1</b>°<b> endpoint:</b> All-cause mortality </text>
<text top="351" left="811" width="3" height="20" font="1"> </text>
<text top="370" left="811" width="76" height="20" font="4"><b>2</b>°<b> endpoint:</b> </text>
<text top="389" left="811" width="7" height="18" font="1">•</text>
<text top="388" left="818" width="228" height="20" font="1"> Composite of CV mortality or emergency </text>
<text top="405" left="811" width="269" height="20" font="1">treatment or hospitalization for new or worsening </text>
<text top="422" left="811" width="268" height="20" font="1">HF, reinfarction, stroke, and resuscitated cardiac </text>
<text top="440" left="811" width="35" height="20" font="1">arrest </text>
<text top="459" left="811" width="7" height="18" font="1">•</text>
<text top="458" left="818" width="275" height="20" font="1"> On 3-y multivariable analysis, each 10-y increase </text>
<text top="475" left="811" width="282" height="20" font="1">was associated with HR: 1.49 (95% CI: 1.43–1.56), </text>
<text top="492" left="811" width="251" height="20" font="1">p&lt;0.0001 for mortality and OR: 1.38 (95% CI: </text>
<text top="510" left="811" width="257" height="20" font="1">1.31–1.46; p&lt;0.0001) for readmission with HF. </text>
<text top="529" left="811" width="7" height="18" font="1">•</text>
<text top="528" left="818" width="258" height="20" font="1"> Similar but slightly smaller trend for composite </text>
<text top="545" left="811" width="242" height="20" font="1">endpoint, higher mainly in the oldest group.  </text>
<text top="562" left="811" width="269" height="20" font="1">Valsartan was at least as effective as captopril in </text>
<text top="580" left="811" width="273" height="20" font="1">reducing mortality and other adverse outcomes in </text>
<text top="597" left="811" width="271" height="20" font="1">all age groups and combination therapy with both </text>
<text top="614" left="811" width="206" height="20" font="1">agents added no incremental benefit. </text>
<text top="631" left="811" width="263" height="20" font="1">Combination therapy increased the incidence of </text>
<text top="648" left="811" width="282" height="20" font="1">adverse effects leading to discontinuation in all age </text>
<text top="666" left="811" width="44" height="20" font="1">groups  </text>
<text top="683" left="811" width="3" height="20" font="1"> </text>
<text top="700" left="811" width="107" height="20" font="4"><b>Safety endpoint:</b>   </text>
<text top="719" left="811" width="7" height="18" font="1">•</text>
<text top="718" left="818" width="253" height="20" font="1"> Adverse events associated with captopril and </text>
<text top="736" left="811" width="275" height="20" font="1">valsartan were more common in the elderly and in </text>
<text top="753" left="811" width="194" height="20" font="1">pts receiving combination therapy.  </text>
<text top="772" left="811" width="7" height="18" font="1">•</text>
<text top="771" left="818" width="268" height="20" font="1"> Renal dysfunction was more common with older </text>
<text top="788" left="811" width="166" height="20" font="1">age and combination therapy. </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="19" size="12" family="Times" color="#121212"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">143 </text>
<text top="109" left="361" width="7" height="18" font="1">•</text>
<text top="108" left="368" width="178" height="20" font="1"> Conditions likely to lead to poor </text>
<text top="125" left="361" width="62" height="20" font="1">adherence </text>
<text top="143" left="98" width="87" height="20" font="1">SPRINT Senior </text>
<text top="161" left="98" width="98" height="20" font="1">Williamson JD, et </text>
<text top="178" left="98" width="51" height="20" font="1">al., 2016 </text>
<text top="195" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(190)</a> </text>
<text top="212" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27195814">27195814</a></text>
<text top="212" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27195814"> </a></text>
<text top="143" left="214" width="111" height="20" font="4"><b>Aim: </b>Intensive SBP </text>
<text top="161" left="214" width="124" height="20" font="1">goal &lt;120 mm Hg) vs. </text>
<text top="178" left="214" width="110" height="20" font="1">standard (SBP goal </text>
<text top="195" left="214" width="35" height="20" font="1">&lt;140) </text>
<text top="212" left="214" width="3" height="20" font="1"> </text>
<text top="229" left="214" width="102" height="20" font="4"><b>Study type:</b> RCT  </text>
<text top="247" left="214" width="3" height="20" font="1"> </text>
<text top="264" left="214" width="121" height="20" font="4"><b>Size:</b> 2,636; 30% met </text>
<text top="281" left="214" width="92" height="20" font="1">criteria for being </text>
<text top="298" left="214" width="70" height="20" font="1">classified as </text>
<text top="316" left="214" width="87" height="20" font="1">ambulatory frail </text>
<text top="333" left="214" width="3" height="20" font="1"> </text>
<text top="350" left="214" width="123" height="20" font="4"><b>Mean follow-up</b>:3.1 y </text>
<text top="143" left="361" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="161" left="361" width="94" height="20" font="1">Men and women </text>
<text top="178" left="361" width="110" height="20" font="1">age 75+; mean age </text>
<text top="195" left="361" width="115" height="20" font="1">79.8 y; 38% women; </text>
<text top="212" left="361" width="91" height="20" font="1">17% black, 74% </text>
<text top="229" left="361" width="62" height="20" font="1">Caucasian </text>
<text top="247" left="361" width="3" height="20" font="1"> </text>
<text top="264" left="361" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="281" left="361" width="80" height="20" font="1">Nursing home </text>
<text top="298" left="361" width="111" height="20" font="1">residents; prevalent </text>
<text top="316" left="361" width="100" height="20" font="1">DM, stroke, Class </text>
<text top="333" left="361" width="106" height="20" font="1">III/IV HF, dementia </text>
<text top="143" left="491" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="161" left="491" width="69" height="20" font="1">Medications </text>
<text top="178" left="491" width="64" height="20" font="1">and dietary </text>
<text top="195" left="491" width="53" height="20" font="1">advice to </text>
<text top="212" left="491" width="87" height="20" font="1">achieve SBP of </text>
<text top="229" left="491" width="74" height="20" font="1">&lt;120 mm Hg </text>
<text top="247" left="491" width="3" height="20" font="1"> </text>
<text top="264" left="491" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="281" left="491" width="69" height="20" font="1">Medications </text>
<text top="298" left="491" width="64" height="20" font="1">and dietary </text>
<text top="316" left="491" width="53" height="20" font="1">advice to </text>
<text top="333" left="491" width="87" height="20" font="1">achieve SBP of </text>
<text top="350" left="491" width="74" height="20" font="1">&lt;140 mm Hg </text>
<text top="367" left="491" width="3" height="20" font="1"> </text>
<text top="384" left="491" width="91" height="20" font="4"><b>Achieved SBP: </b></text>
<text top="402" left="491" width="60" height="20" font="1">Intensive= </text>
<text top="419" left="491" width="77" height="20" font="1">123.4 mm Hg </text>
<text top="436" left="491" width="60" height="20" font="1">Standard= </text>
<text top="453" left="491" width="77" height="20" font="1">134.8 mm Hg </text>
<text top="145" left="595" width="167" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite CVD </text>
<text top="162" left="595" width="200" height="20" font="1">outcome (AMI, non-MI ACS, Stroke, </text>
<text top="179" left="595" width="90" height="20" font="1">HF, CVD death. </text>
<text top="196" left="595" width="3" height="20" font="1"> </text>
<text top="213" left="595" width="55" height="20" font="4"><b>Results</b>:  </text>
<text top="232" left="595" width="7" height="18" font="1">•</text>
<text top="232" left="602" width="3" height="20" font="1"> </text>
<text top="232" left="606" width="149" height="20" font="10">102 events in the intensive </text>
<text top="249" left="595" width="186" height="20" font="10">treatment group vs. 148 events in </text>
<text top="266" left="595" width="190" height="20" font="10">the standard treatment group; HR: </text>
<text top="283" left="595" width="176" height="20" font="10">0.66; 95% CI: 0.51–0.85 and all-</text>
<text top="301" left="595" width="191" height="20" font="10">cause mortality (73 deaths vs. 107 </text>
<text top="318" left="595" width="199" height="20" font="10">deaths, respectively; HR: 0.67; 95% </text>
<text top="335" left="595" width="199" height="20" font="10">CI: 0.49–0.91. No difference in falls, </text>
<text top="352" left="595" width="187" height="20" font="10">orthostatic hypotension, or overall </text>
<text top="370" left="595" width="38" height="20" font="10">SAEs. </text>
<text top="389" left="595" width="7" height="18" font="1">•</text>
<text top="388" left="602" width="3" height="20" font="1"> </text>
<text top="388" left="606" width="46" height="20" font="10">NNT for </text>
<text top="388" left="652" width="13" height="20" font="1">1°</text>
<text top="388" left="665" width="128" height="20" font="10"> outcome=27 and NNT </text>
<text top="405" left="595" width="138" height="20" font="10">for all-cause mortality=41</text>
<text top="405" left="733" width="3" height="20" font="1"> </text>
<text top="143" left="811" width="284" height="20" font="4"><b>Limitations</b>: Does not apply to nursing home pts or </text>
<text top="161" left="811" width="177" height="20" font="1">those with dementia or advance </text>
<text top="178" left="811" width="3" height="20" font="1"> </text>
<text top="195" left="811" width="274" height="20" font="4"><b>Conclusions: </b>Intensive SBP is safe and effective </text>
<text top="212" left="811" width="249" height="20" font="1">for lowering CVD events and total mortality in </text>
<text top="229" left="811" width="75" height="20" font="1">adults ≥75 y <b> </b></text>
<text top="473" left="108" width="3" height="19" font="1"> </text>
<text top="507" left="81" width="684" height="24" font="3"><b>Data Supplement 41. RCTs Comparing Acute Intracerebral Hemorrhage Outcomes (Section 9.4.1) </b></text>
<text top="547" left="96" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="564" left="122" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="581" left="99" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="547" left="246" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="564" left="251" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="581" left="244" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="547" left="391" width="44" height="20" font="4"><b>Patient </b></text>
<text top="564" left="380" width="67" height="20" font="4"><b>Population </b></text>
<text top="547" left="497" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="564" left="513" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="581" left="498" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="598" left="518" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="547" left="712" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="564" left="695" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="581" left="677" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="548" left="909" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="565" left="941" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="582" left="917" width="159" height="20" font="4"><b>Adverse Events; Summary </b></text>
<text top="616" left="82" width="72" height="20" font="4"><b>INTERACT2 </b></text>
<text top="634" left="82" width="117" height="20" font="1">Anderson CS, et al.,  </text>
<text top="651" left="82" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(191)</a> </text>
<text top="668" left="82" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23713578?dopt=Citation">23713578</a></text>
<text top="668" left="137" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23713578?dopt=Citation"> </a></text>
<text top="616" left="222" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="634" left="222" width="127" height="20" font="1">whether rapid lowering </text>
<text top="651" left="222" width="119" height="20" font="1">of elevated BP would </text>
<text top="668" left="222" width="118" height="20" font="1">improve the outcome </text>
<text top="685" left="222" width="86" height="20" font="1">in pts with ICH. </text>
<text top="702" left="222" width="3" height="20" font="1"> </text>
<text top="720" left="222" width="122" height="20" font="4"><b>Study type: </b>Phase III </text>
<text top="737" left="222" width="32" height="20" font="1">RCT<b>  </b></text>
<text top="754" left="222" width="3" height="20" font="4"><b> </b></text>
<text top="771" left="222" width="122" height="20" font="4"><b>Study size: </b>2,839 pts<b> </b></text>
<text top="616" left="366" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="634" left="366" width="49" height="20" font="4"><b>criteria:</b> </text>
<text top="651" left="366" width="46" height="20" font="1">Pts with </text>
<text top="668" left="366" width="74" height="20" font="1">spontaneous </text>
<text top="685" left="366" width="80" height="20" font="1">ICH within the </text>
<text top="702" left="366" width="70" height="20" font="1">previous 6 h </text>
<text top="720" left="366" width="75" height="20" font="1">with elevated </text>
<text top="737" left="366" width="28" height="20" font="1">SBP<b> </b></text>
<text top="616" left="474" width="157" height="20" font="4"><b>Design: </b>Intensive treatment </text>
<text top="634" left="474" width="141" height="20" font="1">to lower BP (with a target </text>
<text top="651" left="474" width="141" height="20" font="1">systolic level of &lt;140 mm </text>
<text top="668" left="474" width="151" height="20" font="1">Hg within 1 h) vs. guideline-</text>
<text top="685" left="474" width="138" height="20" font="1">recommended treatment </text>
<text top="702" left="474" width="157" height="20" font="1">(with a target SBP &lt;180 mm </text>
<text top="720" left="474" width="137" height="20" font="1">Hg) among pts with SBP </text>
<text top="737" left="474" width="146" height="20" font="1">between 150 and 220 mm </text>
<text top="754" left="474" width="107" height="20" font="1">using agents of the </text>
<text top="771" left="474" width="119" height="20" font="1">physician's choosing.<b> </b></text>
<text top="617" left="645" width="210" height="20" font="4"><b>1</b>°<b> outcome: </b>Death or major disability </text>
<text top="635" left="645" width="215" height="20" font="1">(score of 3 to 6 on the modified Rankin </text>
<text top="652" left="645" width="81" height="20" font="1">scale) at 90 d. </text>
<text top="669" left="645" width="3" height="20" font="1"> </text>
<text top="686" left="645" width="197" height="20" font="4"><b>Pre-specified 2º outcome: </b>Ordinal </text>
<text top="704" left="645" width="211" height="20" font="1">analysis of the modified Rankin score. </text>
<text top="721" left="645" width="3" height="20" font="1"> </text>
<text top="738" left="645" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="755" left="645" width="220" height="20" font="1">● Among the 2,794 pts for whom the 1° </text>
<text top="772" left="645" width="206" height="20" font="1">outcome could be determined, 719 of </text>
<text top="790" left="645" width="200" height="20" font="1">1,382 participants (52.0%) receiving </text>
<text top="616" left="896" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="634" left="896" width="201" height="20" font="1">● In pts with ICH, intensive lowering </text>
<text top="651" left="896" width="189" height="20" font="1">of BP did not result in a significant </text>
<text top="668" left="896" width="174" height="20" font="1">reduction in the rate of death or </text>
<text top="685" left="896" width="98" height="20" font="1">severe disability.  </text>
<text top="702" left="896" width="197" height="20" font="1">● However, there may be improved </text>
<text top="720" left="896" width="190" height="20" font="1">functional outcomes with intensive </text>
<text top="737" left="896" width="86" height="20" font="1">lowering of BP. </text>
<text top="754" left="896" width="196" height="20" font="19">● INTERACT-2 is so far the largest </text>
<text top="771" left="896" width="194" height="20" font="19">(and only phase 3) RCT evaluating </text>
<text top="788" left="896" width="187" height="20" font="19">efficacy of intensive BP lowering.  </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">144 </text>
<text top="107" left="645" width="202" height="20" font="1">intensive treatment, vs. 785 of 1,412 </text>
<text top="124" left="645" width="235" height="20" font="1">(55.6%) receiving guideline-recommended </text>
<text top="141" left="645" width="197" height="20" font="1">treatment, had a 1° outcome event; </text>
<text top="159" left="645" width="211" height="20" font="1">intensive treatment OR: 0.87; 95% CI: </text>
<text top="176" left="645" width="110" height="20" font="1">0.75–1.01; p=0.06.  </text>
<text top="193" left="645" width="238" height="20" font="1">● The ordinal analysis showed significantly </text>
<text top="210" left="645" width="189" height="20" font="1">lower modified Rankin scores with </text>
<text top="228" left="645" width="193" height="20" font="1">intensive treatment. OR for greater </text>
<text top="245" left="645" width="242" height="20" font="1">disability: 0.87; 95% CI: 0.77–1.00; p=0.04.  </text>
<text top="262" left="645" width="194" height="20" font="1">● Mortality was 11.9% in the group </text>
<text top="279" left="645" width="235" height="20" font="1">receiving intensive treatment and 12.0% in </text>
<text top="296" left="645" width="161" height="20" font="1">the group receiving guideline-</text>
<text top="314" left="645" width="144" height="20" font="1">recommended treatment.  </text>
<text top="331" left="645" width="192" height="20" font="1">● Nonfatal serious adverse events </text>
<text top="348" left="645" width="232" height="20" font="1">occurred in 23.3% and 23.6% of the pts in </text>
<text top="365" left="645" width="147" height="20" font="1">the 2 groups, respectively. </text>
<text top="107" left="896" width="178" height="20" font="19">● No clear relationship between </text>
<text top="124" left="896" width="176" height="20" font="19">outcome and time from onset of </text>
<text top="141" left="896" width="191" height="20" font="19">ICH to commencing treatment and </text>
<text top="159" left="896" width="195" height="20" font="19">no significant effect of intensive BP-</text>
<text top="176" left="896" width="183" height="20" font="19">lowering treatment on hematoma </text>
<text top="193" left="896" width="47" height="20" font="19">growth.  </text>
<text top="210" left="896" width="153" height="20" font="19">● Of note, only1 third of pts </text>
<text top="227" left="896" width="200" height="20" font="19">achieved the target SBP level within </text>
<text top="245" left="896" width="201" height="20" font="19">1 h (half achieved the target by 6 h), </text>
<text top="262" left="896" width="200" height="20" font="19">and most (75%) presented with mild </text>
<text top="279" left="896" width="147" height="20" font="19">to moderate size (&lt;20 mL) </text>
<text top="296" left="896" width="75" height="20" font="19">hematomas.  </text>
<text top="383" left="82" width="61" height="20" font="4"><b>ATACH-1  </b></text>
<text top="400" left="82" width="63" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(192)</a> </text>
<text top="418" left="82" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19770736?dopt=Citation">19770736</a></text>
<text top="418" left="137" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19770736?dopt=Citation"><b> </b></a></text>
<text top="383" left="222" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="400" left="222" width="111" height="20" font="1">feasibility and acute </text>
<text top="418" left="222" width="130" height="20" font="1">(i.e., within 72 h) safety </text>
<text top="435" left="222" width="100" height="20" font="1">of 3 levels of SBP </text>
<text top="452" left="222" width="115" height="20" font="1">reduction in subjects </text>
<text top="469" left="222" width="128" height="20" font="1">with supratentorial ICH </text>
<text top="487" left="222" width="125" height="20" font="1">treated within 6 h after </text>
<text top="504" left="222" width="90" height="20" font="1">symptom onset. </text>
<text top="521" left="222" width="3" height="20" font="1"> </text>
<text top="538" left="222" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="555" left="222" width="79" height="20" font="1">Phase I, dose-</text>
<text top="573" left="222" width="126" height="20" font="1">escalation, multicenter </text>
<text top="590" left="222" width="103" height="20" font="1">prospective study. </text>
<text top="607" left="222" width="3" height="20" font="1"> </text>
<text top="624" left="222" width="85" height="20" font="4"><b>Study size: </b>60<b> </b></text>
<text top="383" left="366" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="400" left="366" width="49" height="20" font="4"><b>criteria:</b> </text>
<text top="418" left="366" width="71" height="20" font="1">Pts with ICH </text>
<text top="435" left="366" width="75" height="20" font="1">with elevated </text>
<text top="452" left="366" width="84" height="20" font="1">SBP ≥170 mm </text>
<text top="469" left="366" width="45" height="20" font="1">Hg who </text>
<text top="487" left="366" width="92" height="20" font="1">presented to the </text>
<text top="504" left="366" width="89" height="20" font="1">ED within 6 h of </text>
<text top="521" left="366" width="90" height="20" font="1">symptom onset.<b> </b></text>
<text top="383" left="474" width="49" height="20" font="4"><b>Design:</b> </text>
<text top="400" left="474" width="145" height="20" font="1">● IV nicardipine to reduce </text>
<text top="418" left="474" width="107" height="20" font="1">SBP to a target of:  </text>
<text top="435" left="474" width="148" height="20" font="1">#1: 170–200 mm Hg in the </text>
<text top="452" left="474" width="94" height="20" font="1">first cohort of pts </text>
<text top="469" left="474" width="148" height="20" font="1">#2: 140–170 mm Hg in the </text>
<text top="487" left="474" width="62" height="20" font="1">2nd cohort </text>
<text top="504" left="474" width="148" height="20" font="1">#3: 110–140 mm Hg in the </text>
<text top="521" left="474" width="68" height="20" font="1">third cohort. </text>
<text top="538" left="474" width="111" height="20" font="1">● Each subject was </text>
<text top="555" left="474" width="129" height="20" font="1">followed-up for 3 mo to </text>
<text top="573" left="474" width="111" height="20" font="1">preliminarily assess </text>
<text top="590" left="474" width="134" height="20" font="1">mortality and the clinical </text>
<text top="607" left="474" width="153" height="20" font="1">outcomes. A total of 18, 20, </text>
<text top="624" left="474" width="151" height="20" font="1">and 22 pts were enrolled in </text>
<text top="641" left="474" width="130" height="20" font="1">the respective 3 tiers of </text>
<text top="659" left="474" width="120" height="20" font="1">SBP treatment goals.<b> </b></text>
<text top="384" left="645" width="188" height="20" font="4"><b>1</b>°<b> outcome: </b>Treatment feasibility </text>
<text top="402" left="645" width="231" height="20" font="1">(achieving and maintaining the SBP goals </text>
<text top="419" left="645" width="70" height="20" font="1">for 18–24 h) </text>
<text top="436" left="645" width="3" height="20" font="1"> </text>
<text top="454" left="645" width="82" height="20" font="4"><b>2</b>°<b> outcomes:</b> </text>
<text top="472" left="645" width="224" height="20" font="1">#1: Neurologic deterioration within 24 h;  </text>
<text top="489" left="645" width="218" height="20" font="1">#2: Serious adverse events within 72 h. </text>
<text top="506" left="645" width="3" height="20" font="1"> </text>
<text top="523" left="645" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="540" left="645" width="199" height="20" font="1">● Overall, 9 of 60 pts had treatment </text>
<text top="558" left="645" width="209" height="20" font="1">failures (all in the last tier). A total of 7 </text>
<text top="575" left="645" width="236" height="20" font="1">subjects with neurologic deterioration were </text>
<text top="592" left="645" width="234" height="20" font="1">observed: 1 (6%), 2 (10%), and 4 (18%) in </text>
<text top="609" left="645" width="161" height="20" font="1">tier 1, 2, and 3, respectively.  </text>
<text top="627" left="645" width="229" height="20" font="1">● Serious adverse events were observed </text>
<text top="644" left="645" width="231" height="20" font="1">in1 subject (5%) in tier 2 and in 3 subjects </text>
<text top="661" left="645" width="195" height="20" font="1">(14%) in tier 3. However, the safety </text>
<text top="678" left="645" width="222" height="20" font="1">stopping rule was not activated in any of </text>
<text top="695" left="645" width="54" height="20" font="1">the tiers.  </text>
<text top="713" left="645" width="231" height="20" font="1">● 3 (17%), 2 (10%), and 5 (23%) subjects </text>
<text top="730" left="645" width="234" height="20" font="1">in tiers1, 2, and 3, respectively, died within </text>
<text top="747" left="645" width="31" height="20" font="1">3 mo<b> </b></text>
<text top="383" left="896" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="400" left="896" width="148" height="20" font="1">● Observed proportions of </text>
<text top="418" left="896" width="199" height="20" font="1">neurologic deterioration and serious </text>
<text top="435" left="896" width="173" height="20" font="1">adverse events were below the </text>
<text top="452" left="896" width="194" height="20" font="1">prespecified safety thresholds, and </text>
<text top="469" left="896" width="185" height="20" font="1">the 3-mo mortality rate was lower </text>
<text top="487" left="896" width="168" height="20" font="1">than expected in all SBP tiers.<b> </b></text>
<text top="765" left="82" width="80" height="20" font="4"><b>INTERACT-1  </b></text>
<text top="765" left="222" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="782" left="222" width="128" height="20" font="1">safety and efficiency of </text>
<text top="765" left="366" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="782" left="366" width="95" height="20" font="4"><b>criteria: </b>Pts with </text>
<text top="765" left="474" width="132" height="20" font="4"><b>Design:</b> Early intensive </text>
<text top="782" left="474" width="150" height="20" font="1">lowering of BP (target SBP </text>
<text top="766" left="645" width="202" height="20" font="4"><b>1</b>°<b> outcome:</b> Proportional change in </text>
<text top="783" left="645" width="149" height="20" font="1">hematoma volume at 24 h. </text>
<text top="765" left="896" width="167" height="20" font="4"><b>Summary: </b>Early intensive BP-</text>
<text top="782" left="896" width="166" height="20" font="1">lowering treatment is clinically </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">145 </text>
<text top="107" left="82" width="113" height="20" font="1">Anderson CS, et al., </text>
<text top="124" left="82" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(193)</a> </text>
<text top="141" left="82" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18396107?dopt=Citation">18396107</a></text>
<text top="141" left="137" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18396107?dopt=Citation"><b> </b></a></text>
<text top="107" left="222" width="108" height="20" font="1">this treatment, as a </text>
<text top="124" left="222" width="131" height="20" font="1">run-in phase to a larger </text>
<text top="141" left="222" width="27" height="20" font="1">trial. </text>
<text top="159" left="222" width="3" height="20" font="1"> </text>
<text top="176" left="222" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="193" left="222" width="122" height="20" font="1">Randomized pilot trial<b> </b></text>
<text top="210" left="222" width="3" height="20" font="1"> </text>
<text top="227" left="222" width="92" height="20" font="4"><b>Study size: </b>404<b> </b></text>
<text top="107" left="366" width="33" height="20" font="1">acute </text>
<text top="124" left="366" width="74" height="20" font="1">spontaneous </text>
<text top="141" left="366" width="85" height="20" font="1">ICH diagnosed </text>
<text top="159" left="366" width="91" height="20" font="1">by CT within 6 h </text>
<text top="176" left="366" width="51" height="20" font="1">of onset, </text>
<text top="193" left="366" width="78" height="20" font="1">elevated SBP </text>
<text top="210" left="366" width="79" height="20" font="1">(150–220 mm </text>
<text top="228" left="366" width="68" height="20" font="1">Hg), and no </text>
<text top="245" left="366" width="43" height="20" font="1">definite </text>
<text top="262" left="366" width="70" height="20" font="1">indication or </text>
<text top="279" left="366" width="89" height="20" font="1">contraindication </text>
<text top="296" left="366" width="69" height="20" font="1">to treatment<b> </b></text>
<text top="107" left="474" width="132" height="20" font="1">140 mm Hg; n=203) vs. </text>
<text top="124" left="474" width="141" height="20" font="1">standard guideline-based </text>
<text top="141" left="474" width="148" height="20" font="1">management of BP (target </text>
<text top="159" left="474" width="144" height="20" font="1">SBP 180 mm Hg; n=201).<b> </b></text>
<text top="107" left="645" width="3" height="20" font="1"> </text>
<text top="125" left="645" width="181" height="20" font="4"><b>2</b>°<b> outcomes:</b> Measurements of </text>
<text top="143" left="645" width="111" height="20" font="1">hematoma volume.  </text>
<text top="160" left="645" width="3" height="20" font="1"> </text>
<text top="177" left="645" width="233" height="20" font="4"><b>Safety and clinical outcomes:</b> Assessed </text>
<text top="194" left="645" width="83" height="20" font="1">for up to 90 d.  </text>
<text top="211" left="645" width="3" height="20" font="1"> </text>
<text top="229" left="645" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="246" left="645" width="231" height="20" font="1">● Mean hematoma volumes were smaller </text>
<text top="263" left="645" width="228" height="20" font="1">in the guideline group (12.7 mL, SD 11.6) </text>
<text top="280" left="645" width="224" height="20" font="1">than in the intensive group (14.2 mL, SD </text>
<text top="298" left="645" width="38" height="20" font="1">14.5).  </text>
<text top="315" left="645" width="225" height="20" font="1">● From randomization to 1 h, mean SBP </text>
<text top="332" left="645" width="237" height="20" font="1">was 153 mm Hg in the intensive group and </text>
<text top="349" left="645" width="188" height="20" font="1">167 mm Hg in the guideline group </text>
<text top="366" left="645" width="239" height="20" font="1">(difference 13.3 mm Hg (95% CI: 8.9–17.6) </text>
<text top="384" left="645" width="222" height="20" font="1">mm Hg; p&lt;0.0001); from 1 h to 24 h, BP </text>
<text top="401" left="645" width="237" height="20" font="1">was 146 mm Hg in the intensive group and </text>
<text top="418" left="645" width="220" height="20" font="1">157 mm Hg in the guideline group (10.8 </text>
<text top="435" left="645" width="192" height="20" font="1">mm Hg; 95% CI: 7.7–13.9 mm Hg; </text>
<text top="453" left="645" width="66" height="20" font="1">p&lt;0.0001).  </text>
<text top="470" left="645" width="217" height="20" font="1">● Mean proportional hematoma growth </text>
<text top="487" left="645" width="209" height="20" font="1">was 36.3% in the guideline group and </text>
<text top="504" left="645" width="220" height="20" font="1">13.7% in the intensive group (difference </text>
<text top="521" left="645" width="225" height="20" font="1">22.6%; 95% CI: 0.6%–44.5%; p=0.04) at </text>
<text top="539" left="645" width="34" height="20" font="1">24 h.  </text>
<text top="556" left="645" width="216" height="20" font="1">● After adjustment for initial hematoma </text>
<text top="573" left="645" width="236" height="20" font="1">volume and time from onset to CT, median </text>
<text top="590" left="645" width="217" height="20" font="1">hematoma growth differed between the </text>
<text top="607" left="645" width="181" height="20" font="1">groups with p=0.06; the absolute </text>
<text top="625" left="645" width="230" height="20" font="1">difference in volume between groups was </text>
<text top="642" left="645" width="228" height="20" font="1">1.7 mL (95% CI: -0.5–3.9; p=0.13). RR of </text>
<text top="659" left="645" width="234" height="20" font="1">hematoma growth ≥33% or ≥12.5 mL was </text>
<text top="676" left="645" width="227" height="20" font="1">36% lower (95% CI: 0%–59%; p=0.05) in </text>
<text top="693" left="645" width="221" height="20" font="1">the intensive group than in the guideline </text>
<text top="711" left="645" width="226" height="20" font="1">group. Adjusted RR: 8% (95% CI: -1.0%–</text>
<text top="728" left="645" width="84" height="20" font="1">17%; p=0.05).  </text>
<text top="745" left="645" width="231" height="20" font="1">● Intensive BP-lowering treatment did not </text>
<text top="763" left="645" width="208" height="20" font="1">alter the risks of adverse events or 2° </text>
<text top="781" left="645" width="141" height="20" font="1">clinical outcomes at 90 d.<b> </b></text>
<text top="107" left="896" width="186" height="20" font="1">feasible, well tolerated, and might </text>
<text top="124" left="896" width="187" height="20" font="1">reduce hematoma growth in ICH. <b> </b></text>
</page>
<page number="146" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="20" size="14" family="Times" color="#000000"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">146 </text>
<text top="107" left="82" width="111" height="20" font="1">Tsivgoulis G, et al.,  </text>
<text top="124" left="82" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(194)</a> </text>
<text top="141" left="82" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25239836?dopt=Citation">25239836</a></text>
<text top="141" left="137" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25239836?dopt=Citation"> </a></text>
<text top="107" left="222" width="119" height="20" font="4"><b>Aim: </b>To evaluate the </text>
<text top="124" left="222" width="119" height="20" font="1">safety and efficacy of </text>
<text top="141" left="222" width="126" height="20" font="1">intensive BP reduction </text>
<text top="159" left="222" width="126" height="20" font="1">in pts with acute-onset </text>
<text top="176" left="222" width="25" height="20" font="1">ICH </text>
<text top="193" left="222" width="3" height="20" font="1"> </text>
<text top="210" left="222" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="227" left="222" width="126" height="20" font="1">Systematic review and </text>
<text top="245" left="222" width="93" height="20" font="1">meta-analysis of </text>
<text top="262" left="222" width="38" height="20" font="1">RCTs. </text>
<text top="279" left="222" width="3" height="20" font="1"> </text>
<text top="296" left="222" width="120" height="20" font="4"><b>Study size: </b>4 eligible </text>
<text top="314" left="222" width="108" height="20" font="1">studies, including a </text>
<text top="331" left="222" width="94" height="20" font="1">total of 3,315 pts<b> </b></text>
<text top="107" left="366" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="124" left="366" width="95" height="20" font="4"><b>criteria: </b>Pts with </text>
<text top="141" left="366" width="58" height="20" font="1">acute ICH </text>
<text top="159" left="366" width="81" height="20" font="1">randomized to </text>
<text top="176" left="366" width="86" height="20" font="1">either intensive </text>
<text top="193" left="366" width="87" height="20" font="1">or guideline BP-</text>
<text top="210" left="366" width="54" height="20" font="1">reduction </text>
<text top="228" left="366" width="57" height="20" font="1">protocols.<b> </b></text>
<text top="107" left="474" width="115" height="20" font="1">● Intensive early BP </text>
<text top="124" left="474" width="135" height="20" font="1">lowering after acute ICH </text>
<text top="141" left="474" width="117" height="20" font="1">onset compared with </text>
<text top="159" left="474" width="146" height="20" font="1">guideline-based treatment<b> </b></text>
<text top="107" left="645" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="124" left="645" width="188" height="20" font="1">● Death rates similar between pts </text>
<text top="141" left="645" width="203" height="20" font="1">randomized to intensive BP-lowering </text>
<text top="159" left="645" width="218" height="20" font="1">treatment and those receiving guideline </text>
<text top="176" left="645" width="228" height="20" font="1">BP-lowering treatment OR: 1.01; 95% CI: </text>
<text top="193" left="645" width="110" height="20" font="1">0.83–1.23; p=0.914 </text>
<text top="210" left="645" width="190" height="20" font="1">● Intensive BP-lowering treatment </text>
<text top="228" left="645" width="236" height="20" font="1">associated with strong trend towards lower </text>
<text top="245" left="645" width="222" height="20" font="1">3-mo death or dependency vs. guideline </text>
<text top="262" left="645" width="220" height="20" font="1">treatment OR: 0.87; 95% CI: 0.76–1.01; </text>
<text top="279" left="645" width="55" height="20" font="1">p=0.062.  </text>
<text top="296" left="645" width="190" height="20" font="1">● Intensive BP reduction was also </text>
<text top="314" left="645" width="218" height="20" font="1">associated with a greater attenuation of </text>
<text top="331" left="645" width="193" height="20" font="1">absolute hematoma growth at 24 h </text>
<text top="348" left="645" width="231" height="20" font="1">(standardized MD± standard error: -0.110 </text>
<text top="365" left="645" width="105" height="20" font="1">± 0.053; p=0.038). </text>
<text top="107" left="896" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="124" left="896" width="193" height="20" font="1">● Intensive BP management in pts </text>
<text top="141" left="896" width="129" height="20" font="1">with acute ICH is safe.  </text>
<text top="159" left="896" width="160" height="20" font="1">● Intensively treated ICH pts </text>
<text top="176" left="896" width="181" height="20" font="1">tended to have more favorable 3-</text>
<text top="193" left="896" width="134" height="20" font="1">mo functional outcome.  </text>
<text top="210" left="896" width="139" height="20" font="1">● Intensive BP reduction </text>
<text top="228" left="896" width="140" height="20" font="1">associated with a greater </text>
<text top="245" left="896" width="190" height="20" font="1">attenuation of absolute hematoma </text>
<text top="262" left="896" width="85" height="20" font="1">growth at 24 h. </text>
<text top="279" left="896" width="151" height="20" font="1">● Starting antihypertensive </text>
<text top="296" left="896" width="190" height="20" font="1">treatment in the initial 5–10 d after </text>
<text top="314" left="896" width="190" height="20" font="1">ICH may have a different outcome </text>
<text top="331" left="896" width="178" height="20" font="1">from that seen after an ischemic </text>
<text top="348" left="896" width="156" height="20" font="1">stroke because of 2º edema </text>
<text top="365" left="896" width="159" height="20" font="1">formation and hemodynamic </text>
<text top="382" left="896" width="50" height="20" font="1">changes </text>
<text top="400" left="82" width="53" height="20" font="4"><b>ATACH2 </b></text>
<text top="418" left="82" width="98" height="20" font="1">Qureshi AI, et al., </text>
<text top="435" left="82" width="31" height="20" font="1">2016 </text>
<text top="452" left="82" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27276234">27276234</a></text>
<text top="452" left="137" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27276234"> </a></text>
<text top="400" left="222" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="418" left="222" width="102" height="20" font="1">relative efficacy of </text>
<text top="435" left="222" width="122" height="20" font="1">intensive vs. standard </text>
<text top="452" left="222" width="93" height="20" font="1">antihypertensive </text>
<text top="469" left="222" width="105" height="20" font="1">treatment that was </text>
<text top="487" left="222" width="113" height="20" font="1">initiated within 4.5 H </text>
<text top="504" left="222" width="115" height="20" font="1">after symptom onset </text>
<text top="521" left="222" width="119" height="20" font="1">and continued for the </text>
<text top="538" left="222" width="115" height="20" font="1">next 24 H in patients </text>
<text top="555" left="222" width="99" height="20" font="1">with spontaneous </text>
<text top="573" left="222" width="78" height="20" font="1">supratentorial </text>
<text top="590" left="222" width="72" height="20" font="1">intracerebral </text>
<text top="607" left="222" width="70" height="20" font="1">hemorrhage </text>
<text top="624" left="222" width="3" height="20" font="1"> </text>
<text top="641" left="222" width="122" height="20" font="4"><b>Study type: </b>Phase III </text>
<text top="659" left="222" width="32" height="20" font="1">RCT<b>  </b></text>
<text top="676" left="222" width="3" height="20" font="4"><b> </b></text>
<text top="693" left="222" width="122" height="20" font="4"><b>Study size: </b>1,000 pts<b> </b></text>
<text top="400" left="366" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="418" left="366" width="95" height="20" font="4"><b>criteria: </b>Pts with </text>
<text top="435" left="366" width="74" height="20" font="1">spontaneous </text>
<text top="452" left="366" width="75" height="20" font="1">ICH (volume, </text>
<text top="469" left="366" width="89" height="20" font="1">&lt;60 cm3) and a </text>
<text top="487" left="366" width="87" height="20" font="1">Glasgow Coma </text>
<text top="504" left="366" width="72" height="20" font="1">Scale (GCS) </text>
<text top="521" left="366" width="72" height="20" font="1">score of 5 or </text>
<text top="538" left="366" width="31" height="20" font="1">more<b> </b></text>
<text top="400" left="474" width="116" height="20" font="4"><b>Design: </b>Intravenous </text>
<text top="418" left="474" width="137" height="20" font="1">nicardipine administered </text>
<text top="435" left="474" width="149" height="20" font="1">within 4.5 H after symptom </text>
<text top="452" left="474" width="152" height="20" font="1">onset and continued for the </text>
<text top="469" left="474" width="126" height="20" font="1">next 24 H to lower BP  </text>
<text top="402" left="645" width="234" height="20" font="4"><b>1</b>°<b> outcome: </b>Moderately severe or severe </text>
<text top="419" left="645" width="237" height="20" font="1">disability or who had died (modified Rankin </text>
<text top="436" left="645" width="175" height="20" font="1">scale score, 4 to 6) at 3 months </text>
<text top="453" left="645" width="3" height="20" font="1"> </text>
<text top="470" left="645" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="488" left="645" width="225" height="20" font="1">● Among 1,000 participants with a mean </text>
<text top="505" left="645" width="237" height="20" font="1">(±SD) systolic BP of 200.6±27.0 mm Hg at </text>
<text top="522" left="645" width="225" height="20" font="1">baseline, 500 were assigned to intensive </text>
<text top="539" left="645" width="227" height="20" font="1">treatment and 500 to standard treatment. </text>
<text top="557" left="645" width="237" height="20" font="1">Enrollment was stopped because of futility  </text>
<text top="574" left="645" width="230" height="20" font="1">● Death or disability occurred in 38.7% of </text>
<text top="591" left="645" width="223" height="20" font="1">patients in the intensive-treatment group </text>
<text top="608" left="645" width="203" height="20" font="1">and 37.7% in the standard-treatment </text>
<text top="625" left="645" width="199" height="20" font="1">group. RR: 1.04; 95%CI: 0.85–1.27. </text>
<text top="643" left="645" width="233" height="20" font="1">● Serious adverse events occurring within </text>
<text top="660" left="645" width="230" height="20" font="1">72 H after randomization were reported in </text>
<text top="677" left="645" width="198" height="20" font="1">1.6% of the patients in the intensive-</text>
<text top="694" left="645" width="226" height="20" font="1">treatment group and 1.2% of those in the </text>
<text top="711" left="645" width="149" height="20" font="1">standard-treatment group.  </text>
<text top="729" left="645" width="218" height="20" font="1">● Renal adverse events within 7 d after </text>
<text top="746" left="645" width="228" height="20" font="1">randomization were significantly higher in </text>
<text top="763" left="645" width="224" height="20" font="1">the intensive-treatment group than in the </text>
<text top="400" left="896" width="183" height="20" font="4"><b>Summary: </b>Treatment of patients </text>
<text top="418" left="896" width="194" height="20" font="1">with spontaneous ICH to achieve a </text>
<text top="435" left="896" width="198" height="20" font="1">target systolic BP of 110 to 139 mm </text>
<text top="452" left="896" width="187" height="20" font="1">Hg did not result in a lower rate of </text>
<text top="469" left="896" width="171" height="20" font="1">death or disability compared to </text>
<text top="487" left="896" width="199" height="20" font="1">conventional reduction to a target of </text>
<text top="504" left="896" width="172" height="20" font="1">140–179 mm Hg. Furthermore, </text>
<text top="521" left="896" width="167" height="20" font="1">there was more than twice the </text>
<text top="538" left="896" width="189" height="20" font="1">frequency of renal adverse events </text>
<text top="555" left="896" width="192" height="20" font="1">in the more intensively treated arm </text>
<text top="573" left="896" width="195" height="20" font="1">within a week of treatment initiation.</text>
<text top="572" left="1091" width="4" height="21" font="20"><b> </b></text>
</page>
<page number="147" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">147 </text>
<text top="107" left="645" width="232" height="20" font="1">standard-treatment group (9.0% vs. 4.0%, </text>
<text top="124" left="645" width="56" height="20" font="1">p=0.002). </text>
<text top="144" left="108" width="3" height="19" font="1"> </text>
<text top="178" left="81" width="617" height="24" font="3"><b>Data Supplement 42. RCTs Comparing Acute Ischemic Stroke Outcomes (Section 9.4.2) </b></text>
<text top="218" left="106" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="235" left="131" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="252" left="109" width="92" height="20" font="4"><b>Year Published</b> </text>
<text top="218" left="239" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="235" left="244" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="252" left="238" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="218" left="357" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="218" left="501" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="235" left="519" width="76" height="20" font="4"><b>(# patients) / </b></text>
<text top="252" left="501" width="111" height="20" font="4"><b>Study Comparator </b></text>
<text top="269" left="522" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="218" left="709" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="235" left="693" width="137" height="20" font="4"><b>(Absolute Event Rates, </b></text>
<text top="252" left="674" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="219" left="913" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="236" left="945" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="253" left="921" width="159" height="20" font="4"><b>Adverse Events; Summary </b></text>
<text top="287" left="98" width="64" height="20" font="4"><b>COSSACS </b></text>
<text top="305" left="98" width="113" height="20" font="1">Robinson TG, et al., </text>
<text top="322" left="98" width="27" height="20" font="1">2010</text>
<text top="324" left="125" width="2" height="13" font="6"> </text>
<text top="339" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20621562%5Buid%5D">20621562</a></text>
<text top="339" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20621562%5Buid%5D"> </a></text>
<text top="287" left="226" width="94" height="20" font="4"><b>Aim: </b>Assess the </text>
<text top="305" left="226" width="105" height="20" font="1">efficacy and safety </text>
<text top="322" left="226" width="87" height="20" font="1">of continuing or </text>
<text top="339" left="226" width="72" height="20" font="1">stopping pre-</text>
<text top="356" left="226" width="45" height="20" font="1">existing </text>
<text top="373" left="226" width="93" height="20" font="1">antihypertensive </text>
<text top="391" left="226" width="47" height="20" font="1">drugs in </text>
<text top="408" left="226" width="105" height="20" font="1">patients with acute </text>
<text top="425" left="226" width="37" height="20" font="1">stroke<b> </b></text>
<text top="442" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="460" left="226" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="477" left="226" width="3" height="20" font="1"> </text>
<text top="494" left="226" width="56" height="20" font="4"><b>Size:</b> 763<b> </b></text>
<text top="287" left="348" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="305" left="348" width="123" height="20" font="1">Acute ischemic stroke </text>
<text top="322" left="348" width="82" height="20" font="1">(or ICH) within </text>
<text top="339" left="348" width="77" height="20" font="1">previous 48 h </text>
<text top="356" left="348" width="3" height="20" font="1"> </text>
<text top="373" left="348" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="393" left="348" width="7" height="18" font="1">•</text>
<text top="392" left="355" width="97" height="20" font="1"> Impaired level of </text>
<text top="409" left="348" width="84" height="20" font="1">consciousness </text>
<text top="428" left="348" width="7" height="18" font="1">•</text>
<text top="427" left="355" width="106" height="20" font="1"> Unable to swallow </text>
<text top="447" left="348" width="7" height="18" font="1">•</text>
<text top="446" left="355" width="75" height="20" font="1">Hypertensive </text>
<text top="463" left="348" width="64" height="20" font="1">emergency </text>
<text top="482" left="348" width="7" height="18" font="1">•</text>
<text top="481" left="355" width="121" height="20" font="1"> BP &gt;200/120 mm Hg </text>
<text top="500" left="348" width="7" height="18" font="1">•</text>
<text top="500" left="355" width="114" height="20" font="1"> Premorbid disability </text>
<text top="519" left="348" width="7" height="18" font="1">•</text>
<text top="518" left="355" width="71" height="20" font="1"> Intravenous </text>
<text top="535" left="348" width="53" height="20" font="1">alteplase<b> </b></text>
<text top="287" left="490" width="131" height="20" font="4"><b>Intervention:</b> Continue </text>
<text top="305" left="490" width="50" height="20" font="1">previous </text>
<text top="322" left="490" width="93" height="20" font="1">antihypertensive </text>
<text top="339" left="490" width="119" height="20" font="1">medication/s (n=379) </text>
<text top="356" left="490" width="3" height="20" font="1"> </text>
<text top="373" left="490" width="106" height="20" font="4"><b>Comparator:</b> Stop </text>
<text top="391" left="490" width="50" height="20" font="1">previous </text>
<text top="408" left="490" width="93" height="20" font="1">antihypertensive </text>
<text top="425" left="490" width="119" height="20" font="1">medication/s (n=384) </text>
<text top="289" left="637" width="246" height="20" font="4"><b>1</b>°<b> endpoint:</b> Death or major disability (mRS </text>
<text top="306" left="637" width="237" height="20" font="1">3–6) at 14 d: RR: 0.86 (95% CI: 0.65–1.14; </text>
<text top="323" left="637" width="39" height="20" font="1">p=0.3) </text>
<text top="340" left="637" width="3" height="20" font="1"> </text>
<text top="357" left="637" width="226" height="20" font="4"><b>Safety endpoint: </b>Adverse events, minor </text>
<text top="375" left="637" width="145" height="20" font="1">and serious: p&gt;0.05 for all<b> </b></text>
<text top="289" left="899" width="126" height="20" font="4"><b>Relevant 2</b>°<b> endpoint</b> </text>
<text top="308" left="899" width="7" height="18" font="1">•</text>
<text top="307" left="905" width="172" height="20" font="1"> 2-wk NIHSS: p=0.46 and 2-wk </text>
<text top="324" left="899" width="121" height="20" font="1">Barthel Index: p=0.30 </text>
<text top="343" left="899" width="7" height="18" font="1">•</text>
<text top="343" left="905" width="190" height="20" font="1"> 2-wk BP: significantly lower in the </text>
<text top="360" left="899" width="188" height="20" font="1">continue arm (mean difference of -</text>
<text top="377" left="899" width="196" height="20" font="1">13 mm Hg in SBP and -8 mm Hg in </text>
<text top="394" left="899" width="88" height="20" font="1">DBP) p&lt;0.0001 </text>
<text top="413" left="899" width="7" height="18" font="1">•</text>
<text top="413" left="905" width="161" height="20" font="1"> 6-month mortality: p=0.98; 6-</text>
<text top="430" left="899" width="130" height="20" font="1">month disability p&lt;0.05<b> </b></text>
<text top="447" left="899" width="3" height="20" font="1"> </text>
<text top="464" left="899" width="106" height="20" font="4"><b>Study limitations  </b></text>
<text top="483" left="899" width="7" height="18" font="1">•</text>
<text top="483" left="905" width="148" height="20" font="1"> Trial was terminated early </text>
<text top="500" left="899" width="184" height="20" font="1">because of slow recruitment, and </text>
<text top="517" left="899" width="193" height="20" font="1">consequently it was underpowered </text>
<text top="536" left="899" width="7" height="18" font="1">•</text>
<text top="535" left="905" width="190" height="20" font="1"> Treatment was not homogeneous </text>
<text top="553" left="899" width="171" height="20" font="1">(different drugs, no specific BP </text>
<text top="570" left="899" width="39" height="20" font="1">target) </text>
<text top="589" left="899" width="7" height="18" font="1">•</text>
<text top="588" left="905" width="167" height="20" font="1"> No differences when analysis </text>
<text top="605" left="899" width="191" height="20" font="1">restricted to patients with ischemic </text>
<text top="623" left="899" width="37" height="20" font="1">stroke<b> </b></text>
<text top="640" left="899" width="3" height="20" font="1"> </text>
<text top="657" left="899" width="135" height="20" font="4"><b>Summary/conclusions </b></text>
<text top="676" left="899" width="7" height="18" font="1">•</text>
<text top="675" left="905" width="108" height="20" font="1"> Early reinitiation of </text>
<text top="693" left="899" width="187" height="20" font="1">antihypertensive medications was </text>
<text top="710" left="899" width="198" height="20" font="1">safe but ineffective to prevent death </text>
<text top="727" left="899" width="85" height="20" font="1">or dependency </text>
<text top="746" left="899" width="7" height="18" font="1">•</text>
<text top="745" left="905" width="108" height="20" font="1"> Early reinitiation of </text>
<text top="763" left="899" width="187" height="20" font="1">antihypertensives was associated </text>
<text top="780" left="899" width="163" height="20" font="1">with better BP control at 2 wk<b> </b></text>
</page>
<page number="148" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">148 </text>
<text top="107" left="98" width="40" height="20" font="4"><b>CATIS </b></text>
<text top="124" left="98" width="96" height="20" font="1">He J, et al., 2014 </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24240777%5Buid%5D">24240777</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24240777%5Buid%5D"> </a></text>
<text top="107" left="226" width="82" height="20" font="4"><b>Aim: </b>Evaluate </text>
<text top="124" left="226" width="107" height="20" font="1">whether immediate </text>
<text top="141" left="226" width="85" height="20" font="1">blood pressure </text>
<text top="159" left="226" width="67" height="20" font="1">reduction in </text>
<text top="176" left="226" width="105" height="20" font="1">patients with acute </text>
<text top="193" left="226" width="88" height="20" font="1">ischemic stroke </text>
<text top="210" left="226" width="76" height="20" font="1">would reduce </text>
<text top="228" left="226" width="92" height="20" font="1">death and major </text>
<text top="245" left="226" width="106" height="20" font="1">disability at 14 d or </text>
<text top="262" left="226" width="103" height="20" font="1">hospital discharg<b>e </b></text>
<text top="279" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="296" left="226" width="98" height="20" font="4"><b>Study type</b>: RCT<b> </b></text>
<text top="314" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="331" left="226" width="63" height="20" font="4"><b>Size: </b>4071<b> </b></text>
<text top="107" left="348" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="126" left="348" width="7" height="18" font="1">•</text>
<text top="125" left="355" width="63" height="20" font="1"> Age &gt;22 y </text>
<text top="144" left="348" width="7" height="18" font="1">•</text>
<text top="144" left="355" width="89" height="20" font="1"> Acute ischemic </text>
<text top="161" left="348" width="121" height="20" font="1">stroke within previous </text>
<text top="178" left="348" width="27" height="20" font="1">24 h </text>
<text top="195" left="348" width="3" height="20" font="1"> </text>
<text top="213" left="348" width="114" height="20" font="4"><b>Exclusion criteria:  </b></text>
<text top="232" left="348" width="7" height="18" font="1">•</text>
<text top="231" left="355" width="97" height="20" font="1"> Impaired level of </text>
<text top="248" left="348" width="84" height="20" font="1">consciousness </text>
<text top="267" left="348" width="7" height="18" font="1">•</text>
<text top="267" left="355" width="78" height="20" font="1"> Hypertensive </text>
<text top="284" left="348" width="64" height="20" font="1">emergency </text>
<text top="303" left="348" width="7" height="18" font="1">•</text>
<text top="302" left="355" width="78" height="20" font="1"> BP &gt;220/120 </text>
<text top="321" left="348" width="7" height="18" font="1">•</text>
<text top="321" left="355" width="90" height="20" font="1"> Atrial fibrillation </text>
<text top="340" left="348" width="7" height="18" font="1">•</text>
<text top="339" left="355" width="71" height="20" font="1"> Intravenous </text>
<text top="356" left="348" width="53" height="20" font="1">alteplase<b> </b></text>
<text top="107" left="490" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="124" left="490" width="94" height="20" font="1">Antihypertensive </text>
<text top="141" left="490" width="126" height="20" font="1">medication to maintain </text>
<text top="159" left="490" width="129" height="20" font="1">BP &lt;140/90 for the first </text>
<text top="176" left="490" width="71" height="20" font="1">wk (n=2038)<b> </b></text>
<text top="193" left="490" width="3" height="20" font="4"><b> </b></text>
<text top="210" left="490" width="96" height="20" font="4"><b>Comparator</b>: No </text>
<text top="227" left="490" width="93" height="20" font="1">antihypertensive </text>
<text top="245" left="490" width="124" height="20" font="1">medication for the first </text>
<text top="262" left="490" width="71" height="20" font="1">wk (n=2033) </text>
<text top="108" left="637" width="245" height="20" font="4"><b>1</b>°<b> endpoint</b>: Death or major disability (mRS </text>
<text top="125" left="637" width="231" height="20" font="1">3–6) at 14 d: OR: 1.0 (95% CI: 0.88–1.14; </text>
<text top="143" left="637" width="46" height="20" font="1">p=0.98) </text>
<text top="160" left="637" width="3" height="20" font="1"> </text>
<text top="177" left="637" width="103" height="20" font="4"><b>Safety endpoint:  </b></text>
<text top="196" left="637" width="7" height="18" font="1">•</text>
<text top="195" left="644" width="181" height="20" font="4"><b> </b>Vascular disease events p=0.28 </text>
<text top="214" left="637" width="7" height="18" font="1">•</text>
<text top="214" left="644" width="139" height="20" font="1"> Recurrent stroke p=0.07<b> </b></text>
<text top="108" left="899" width="126" height="20" font="4"><b>Relevant 2</b>°<b> endpoint</b> </text>
<text top="127" left="899" width="7" height="18" font="1">•</text>
<text top="127" left="905" width="187" height="20" font="1"> Death or major disability (mRS 3–</text>
<text top="144" left="899" width="194" height="20" font="1">5) at 90 d: OR: 0.99 (95% CI: 0.86–</text>
<text top="161" left="899" width="76" height="20" font="1">1.15; p=0.93) </text>
<text top="180" left="899" width="7" height="18" font="1">•</text>
<text top="179" left="905" width="166" height="20" font="1"> Lower blood pressure at 14 d </text>
<text top="197" left="899" width="190" height="20" font="1">(mean difference of -8.6 mm Hg in </text>
<text top="214" left="899" width="165" height="20" font="1">SBP and -3.9 mm Hg in DBP; </text>
<text top="231" left="899" width="156" height="20" font="1">p&lt;0.001) and at 90 d (mean </text>
<text top="248" left="899" width="180" height="20" font="1">difference of -2.9 mm Hg in SBP </text>
<text top="266" left="899" width="202" height="20" font="1">and -1.4 mm Hg in DBP; p&lt;0.001) in </text>
<text top="283" left="899" width="81" height="20" font="1">the active arm </text>
<text top="300" left="899" width="3" height="20" font="1"> </text>
<text top="317" left="899" width="106" height="20" font="4"><b>Study limitations  </b></text>
<text top="334" left="899" width="188" height="20" font="1">Antihypertensive regimen was not </text>
<text top="352" left="899" width="74" height="20" font="1">standardized </text>
<text top="369" left="899" width="3" height="20" font="1"> </text>
<text top="386" left="899" width="135" height="20" font="4"><b>Summary/conclusions </b></text>
<text top="405" left="899" width="7" height="18" font="1">•</text>
<text top="404" left="905" width="178" height="20" font="1"> Early treatment of hypertension </text>
<text top="422" left="899" width="189" height="20" font="1">was safe but ineffective to prevent </text>
<text top="439" left="899" width="119" height="20" font="1">death or dependency </text>
<text top="458" left="899" width="7" height="18" font="1">•</text>
<text top="457" left="905" width="121" height="20" font="1"> Early initiation of anti-</text>
<text top="474" left="899" width="192" height="20" font="1">hypertensives was associated with </text>
<text top="492" left="899" width="138" height="20" font="1">better BP control at 2 wk<b> </b></text>
<text top="510" left="98" width="88" height="20" font="1">Wang H, et al.,  </text>
<text top="527" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(195)</a> </text>
<text top="544" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24853087?dopt=Citation">24853087</a></text>
<text top="544" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24853087?dopt=Citation"> </a></text>
<text top="510" left="226" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="527" left="226" width="104" height="20" font="1">the effects of early </text>
<text top="544" left="226" width="86" height="20" font="1">BP lowering on </text>
<text top="561" left="226" width="109" height="20" font="1">early and long-term </text>
<text top="578" left="226" width="85" height="20" font="1">outcomes after </text>
<text top="596" left="226" width="74" height="20" font="1">acute stroke. </text>
<text top="613" left="226" width="3" height="20" font="1"> </text>
<text top="630" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="647" left="226" width="102" height="20" font="1">Systematic review </text>
<text top="664" left="226" width="103" height="20" font="1">and meta-analysis </text>
<text top="682" left="226" width="52" height="20" font="1">of RCTs. </text>
<text top="699" left="226" width="3" height="20" font="1"> </text>
<text top="716" left="226" width="85" height="20" font="4"><b>Study size: </b>17 </text>
<text top="733" left="226" width="89" height="20" font="1">trials (n=13,236 </text>
<text top="750" left="226" width="24" height="20" font="1">pts)<b> </b></text>
<text top="510" left="348" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="527" left="348" width="116" height="20" font="1">Prospective RCTs of </text>
<text top="544" left="348" width="113" height="20" font="1">pts ≥18 y with acute </text>
<text top="561" left="348" width="66" height="20" font="1">ischemic or </text>
<text top="578" left="348" width="112" height="20" font="1">hemorrhagic stroke; </text>
<text top="596" left="348" width="125" height="20" font="1">intervention compared </text>
<text top="613" left="348" width="97" height="20" font="1">with placebo was </text>
<text top="630" left="348" width="115" height="20" font="1">initiated within 7 d of </text>
<text top="647" left="348" width="74" height="20" font="1">stroke onset; </text>
<text top="664" left="348" width="118" height="20" font="1">intervention aimed to </text>
<text top="682" left="348" width="67" height="20" font="1">lower BP or </text>
<text top="699" left="348" width="120" height="20" font="1">intervention achieved </text>
<text top="716" left="348" width="98" height="20" font="1">BP reduction;1 or </text>
<text top="733" left="348" width="88" height="20" font="1">more functional </text>
<text top="750" left="348" width="109" height="20" font="1">outcomes reported, </text>
<text top="768" left="348" width="94" height="20" font="1">such as death or </text>
<text top="785" left="348" width="74" height="20" font="1">dependency. </text>
<text top="510" left="490" width="113" height="20" font="1">● Early BP lowering </text>
<text top="527" left="490" width="132" height="20" font="1">after acute stroke onset </text>
<text top="544" left="490" width="130" height="20" font="1">compared with placebo </text>
<text top="511" left="637" width="235" height="20" font="4"><b>1</b>°<b> outcomes: </b>Early (within 30 d) and long-</text>
<text top="528" left="637" width="119" height="20" font="1">term (from 3–12 mo).<b> </b></text>
<text top="545" left="637" width="3" height="20" font="1"> </text>
<text top="562" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="580" left="637" width="245" height="20" font="1">● Early BP lowering after acute stroke onset </text>
<text top="597" left="637" width="215" height="20" font="1">associated with more death within 30 d </text>
<text top="614" left="637" width="232" height="20" font="1">compared with placebo RR: 1.34; 95% CI: </text>
<text top="631" left="637" width="109" height="21" font="1">1.02–1.74; p = 0.03. </text>
<text top="648" left="637" width="245" height="20" font="1">● Early BP lowering after acute stroke onset </text>
<text top="666" left="637" width="208" height="20" font="1">not associated with early neurological </text>
<text top="683" left="637" width="226" height="20" font="1">deterioration, early death within 7 d, long-</text>
<text top="700" left="637" width="249" height="20" font="1">term death, early and long-term dependency, </text>
<text top="717" left="637" width="241" height="20" font="1">early and long-term combination of death or </text>
<text top="734" left="637" width="232" height="20" font="1">dependency, long-term stroke recurrence, </text>
<text top="752" left="637" width="184" height="20" font="1">long-term MI and long-term CVE.<b> </b></text>
<text top="510" left="899" width="190" height="20" font="4"><b>Summary: </b>Results do not support </text>
<text top="527" left="899" width="201" height="20" font="1">early BP lowering after acute stroke. </text>
<text top="544" left="899" width="144" height="20" font="1">Early BP lowering may be </text>
<text top="561" left="899" width="200" height="20" font="1">associated with greater risk of death </text>
<text top="578" left="899" width="164" height="20" font="1">within 30 d after acute stroke.<b> </b></text>
</page>
<page number="149" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="21" size="12" family="Times" color="#303030"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">149 </text>
<text top="107" left="348" width="3" height="20" font="1"> </text>
<text top="124" left="348" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="141" left="348" width="124" height="20" font="1">Studies with the pts of </text>
<text top="159" left="348" width="77" height="20" font="1">subarachnoid </text>
<text top="176" left="348" width="116" height="20" font="1">hemorrhage, studies </text>
<text top="193" left="348" width="114" height="20" font="1">without available full-</text>
<text top="210" left="348" width="116" height="20" font="1">text or relevant data, </text>
<text top="228" left="348" width="124" height="20" font="1">studies about ongoing </text>
<text top="245" left="348" width="126" height="20" font="1">trials and those written </text>
<text top="262" left="348" width="105" height="20" font="1">in languages other </text>
<text top="279" left="348" width="75" height="20" font="1">than English.<b> </b></text>
<text top="297" left="98" width="84" height="20" font="1">Zhao R, et al.,  </text>
<text top="314" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(196)</a> </text>
<text top="332" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26061309?dopt=Citation">26061309</a></text>
<text top="332" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26061309?dopt=Citation"> </a></text>
<text top="297" left="226" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="314" left="226" width="96" height="20" font="1">whether lowering </text>
<text top="332" left="226" width="78" height="20" font="1">BP during the </text>
<text top="349" left="226" width="101" height="20" font="1">acute phase of an </text>
<text top="366" left="226" width="88" height="20" font="1">ischemic stroke </text>
<text top="383" left="226" width="88" height="20" font="1">improves short- </text>
<text top="401" left="226" width="79" height="20" font="1">and long-term </text>
<text top="418" left="226" width="60" height="20" font="1">outcomes. </text>
<text top="435" left="226" width="3" height="20" font="1"> </text>
<text top="452" left="226" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="469" left="226" width="102" height="20" font="1">Systematic review </text>
<text top="487" left="226" width="103" height="20" font="1">and meta-analysis </text>
<text top="504" left="226" width="52" height="20" font="1">of RCTs. </text>
<text top="521" left="226" width="3" height="20" font="1"> </text>
<text top="538" left="226" width="85" height="20" font="4"><b>Study size: </b>22 </text>
<text top="555" left="226" width="35" height="20" font="1">RCTs<b> </b></text>
<text top="297" left="348" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="314" left="348" width="96" height="20" font="1">with acute stroke </text>
<text top="332" left="348" width="70" height="20" font="1">(ischemic or </text>
<text top="349" left="348" width="118" height="20" font="1">hemorrhagic) treated </text>
<text top="366" left="348" width="42" height="20" font="1">with an </text>
<text top="383" left="348" width="127" height="20" font="1">antihypertensive agent </text>
<text top="401" left="348" width="64" height="20" font="1">or placebo. </text>
<text top="418" left="348" width="3" height="20" font="1"> </text>
<text top="435" left="348" width="111" height="20" font="4"><b>Groups: </b>Treatment </text>
<text top="452" left="348" width="119" height="20" font="1">groups were n=5,672 </text>
<text top="469" left="348" width="122" height="20" font="1">(range, 6–2,308), and </text>
<text top="487" left="348" width="115" height="20" font="1">in the control groups </text>
<text top="504" left="348" width="116" height="20" font="1">was 5,416 (range, 6–</text>
<text top="521" left="348" width="38" height="20" font="1">2033).<b> </b></text>
<text top="538" left="348" width="3" height="20" font="1"> </text>
<text top="555" left="348" width="112" height="20" font="4"><b>Follow-up: </b>Ranged </text>
<text top="573" left="348" width="90" height="20" font="1">from 5 d–12 mo<b> </b></text>
<text top="297" left="490" width="113" height="20" font="1">● Early BP lowering </text>
<text top="314" left="490" width="132" height="20" font="1">after acute stroke onset </text>
<text top="332" left="490" width="80" height="20" font="1">compared with</text>
<text top="332" left="570" width="46" height="20" font="21"> placebo</text>
<text top="332" left="616" width="3" height="20" font="4"><b> </b></text>
<text top="298" left="637" width="222" height="20" font="4"><b>1</b>°<b> outcomes:</b> Change in SBP and DBP </text>
<text top="316" left="637" width="222" height="20" font="1">after treatment and short- and long-term </text>
<text top="333" left="637" width="179" height="20" font="1">dependency and mortality rates. </text>
<text top="350" left="637" width="3" height="20" font="1"> </text>
<text top="367" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="384" left="637" width="244" height="20" font="1">● Treatment groups had a greater decrease </text>
<text top="402" left="637" width="225" height="20" font="1">in BP than control groups, and this effect </text>
<text top="419" left="637" width="187" height="20" font="1">was seen with different classes of </text>
<text top="436" left="637" width="134" height="20" font="1">antihypertensive drugs.  </text>
<text top="453" left="637" width="224" height="20" font="1">● Short-term and long-term dependency </text>
<text top="470" left="637" width="229" height="20" font="1">rates were similar between treatment and </text>
<text top="488" left="637" width="219" height="20" font="1">control groups (short-term dependency: </text>
<text top="505" left="637" width="224" height="21" font="1">pooled OR: 1.041; 95% CI: 0.936–1.159; </text>
<text top="522" left="637" width="222" height="21" font="1">p= 0.457; long-term dependency: pooled </text>
<text top="539" left="637" width="244" height="21" font="1">OR: 1.013; 95% CI: 0.915–1.120; p= 0.806).  </text>
<text top="557" left="637" width="219" height="20" font="1">● Short-term or long-term mortality was </text>
<text top="574" left="637" width="229" height="20" font="1">similar between the treatment and control </text>
<text top="591" left="637" width="224" height="20" font="1">groups (short-term mortality: pooled OR: </text>
<text top="608" left="637" width="219" height="21" font="1">1.020 (95% CI: 0.749–1.388; p =0 .902); </text>
<text top="625" left="637" width="241" height="20" font="1">long-term mortality: pooled OR: 1.039 (95% </text>
<text top="643" left="637" width="153" height="21" font="1">CI: 0.883–1.222; p = 0.644).<b> </b></text>
<text top="297" left="899" width="198" height="20" font="4"><b>Summary: </b>Antihypertensive agents </text>
<text top="314" left="899" width="177" height="20" font="1">effectively reduce BP during the </text>
<text top="332" left="899" width="193" height="20" font="1">acute phase of an ischemic stroke, </text>
<text top="349" left="899" width="188" height="20" font="1">but seem to confer no benefit with </text>
<text top="366" left="899" width="167" height="20" font="1">regard to short- and long-term </text>
<text top="383" left="899" width="148" height="20" font="1">dependency and mortality. </text>
<text top="661" left="98" width="95" height="20" font="1">Ahmed N, et al.,  </text>
<text top="678" left="98" width="63" height="20" font="1">2000 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(197)</a> </text>
<text top="695" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10835440?dopt=Citation">10835440</a></text>
<text top="695" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10835440?dopt=Citation"><b> </b></a></text>
<text top="661" left="226" width="49" height="20" font="4"><b>Aim: </b>To </text>
<text top="678" left="226" width="62" height="20" font="1">investigate </text>
<text top="695" left="226" width="64" height="20" font="1">outcome in </text>
<text top="712" left="226" width="51" height="20" font="1">INWEST </text>
<text top="730" left="226" width="86" height="20" font="1">subgroups with </text>
<text top="747" left="226" width="108" height="20" font="1">increasing levels of </text>
<text top="764" left="226" width="77" height="20" font="1">BP reduction. </text>
<text top="781" left="226" width="3" height="20" font="1"> </text>
<text top="661" left="348" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="678" left="348" width="104" height="20" font="1">with a diagnosis of </text>
<text top="695" left="348" width="121" height="20" font="1">ischemic stroke in the </text>
<text top="712" left="348" width="120" height="20" font="1">carotid artery territory </text>
<text top="730" left="348" width="66" height="20" font="1">within 24 h. </text>
<text top="661" left="490" width="88" height="20" font="4"><b>Interventions:</b>  </text>
<text top="678" left="490" width="109" height="20" font="1">● Nimodipine as IV </text>
<text top="695" left="490" width="129" height="20" font="1">infusion of 1 mg/h for 5 </text>
<text top="712" left="490" width="129" height="20" font="1">d followed by oral dose </text>
<text top="730" left="490" width="115" height="20" font="1">of 120 mg daily for a </text>
<text top="747" left="490" width="133" height="20" font="1">total treatment period of </text>
<text top="764" left="490" width="73" height="20" font="1">21 d (n=101) </text>
<text top="662" left="637" width="246" height="20" font="4"><b>1</b>°<b> outcomes:</b> Neurological outcome per the </text>
<text top="679" left="637" width="241" height="20" font="1">Orgogozo scale and functional outcome per </text>
<text top="696" left="637" width="136" height="20" font="1">the Barthel scale at d 21 </text>
<text top="713" left="637" width="3" height="20" font="1"> </text>
<text top="731" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="748" left="637" width="203" height="20" font="1">● Nimodipine treatment resulted in a </text>
<text top="765" left="637" width="241" height="20" font="1">significant reduction in BP from baseline vs. </text>
<text top="782" left="637" width="168" height="20" font="1">placebo during the first few d.  </text>
<text top="661" left="899" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="678" left="899" width="196" height="20" font="1">● DBP, but not SBP, reduction was </text>
<text top="695" left="899" width="157" height="20" font="1">associated with neurological </text>
<text top="712" left="899" width="180" height="20" font="1">worsening after the IV high-dose </text>
<text top="730" left="899" width="168" height="20" font="1">nimodipine after acute stroke.  </text>
<text top="747" left="899" width="174" height="20" font="1">● For low-dose nimodipine, the </text>
<text top="764" left="899" width="147" height="20" font="1">results were inconclusive.  </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">150 </text>
<text top="107" left="226" width="99" height="20" font="4"><b>Study type:</b> Post-</text>
<text top="124" left="226" width="85" height="20" font="1">hoc analysis of </text>
<text top="141" left="226" width="29" height="20" font="1">RCT </text>
<text top="159" left="226" width="3" height="20" font="1"> </text>
<text top="176" left="226" width="56" height="20" font="4"><b>Size: </b>265 </text>
<text top="107" left="490" width="109" height="20" font="1">● Nimodipine as IV </text>
<text top="124" left="490" width="129" height="20" font="1">infusion of 2 mg/h for 5 </text>
<text top="141" left="490" width="129" height="20" font="1">d followed by oral dose </text>
<text top="159" left="490" width="115" height="20" font="1">of 120 mg daily for a </text>
<text top="176" left="490" width="133" height="20" font="1">total treatment period of </text>
<text top="193" left="490" width="67" height="20" font="1">21 d (n=94) </text>
<text top="210" left="490" width="3" height="20" font="4"><b> </b></text>
<text top="227" left="490" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="245" left="490" width="94" height="20" font="1">Placebo (n=100)<b> </b></text>
<text top="107" left="637" width="221" height="20" font="1">● A significant correlation between DBP </text>
<text top="124" left="637" width="241" height="20" font="1">reduction and worsening of the neurological </text>
<text top="141" left="637" width="224" height="20" font="1">score was found for the high-dose group </text>
<text top="159" left="637" width="122" height="20" font="1">(beta=0.49; p=0.048). </text>
<text top="176" left="637" width="235" height="20" font="1">● Pts with a DBP reduction of ≥20% in the </text>
<text top="193" left="637" width="194" height="20" font="1">high-dose group had a significantly </text>
<text top="210" left="637" width="195" height="20" font="1">increased adjusted OR for death or </text>
<text top="228" left="637" width="248" height="20" font="1">dependency (n/N=25/26, OR: 10.16; 95% CI: </text>
<text top="245" left="637" width="229" height="20" font="1">1.02–101.74) and death alone (n/N=9/26, </text>
<text top="262" left="637" width="228" height="20" font="1">OR: 4.336; 95% CI: 1.131–16.619) vs. all </text>
<text top="279" left="637" width="193" height="20" font="1">placebo pts (n/N=62/92 and 14/92, </text>
<text top="296" left="637" width="234" height="20" font="1">respectively). No correlation between SBP </text>
<text top="314" left="637" width="122" height="20" font="1">change and outcome. </text>
<text top="332" left="98" width="91" height="20" font="1">Bath PM, et al.,  </text>
<text top="349" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(198)</a> </text>
<text top="366" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25353321?dopt=Citation">25353321</a></text>
<text top="366" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25353321?dopt=Citation"> </a></text>
<text top="332" left="226" width="89" height="20" font="4"><b>Aim</b>: To assess </text>
<text top="349" left="226" width="61" height="20" font="1">the clinical </text>
<text top="366" left="226" width="89" height="20" font="1">effectiveness of </text>
<text top="383" left="226" width="96" height="20" font="1">altering BP in pts </text>
<text top="400" left="226" width="99" height="20" font="1">with acute stroke, </text>
<text top="418" left="226" width="92" height="20" font="1">and the effect of </text>
<text top="435" left="226" width="48" height="20" font="1">different </text>
<text top="452" left="226" width="96" height="20" font="1">vasoactive drugs </text>
<text top="469" left="226" width="83" height="20" font="1">on BP in acute </text>
<text top="487" left="226" width="97" height="20" font="1">stroke. Update of </text>
<text top="504" left="226" width="59" height="20" font="1">previously </text>
<text top="521" left="226" width="56" height="20" font="1">published </text>
<text top="538" left="226" width="102" height="20" font="1">Cochrane reviews </text>
<text top="555" left="226" width="96" height="20" font="1">(1997, 2001, and </text>
<text top="573" left="226" width="38" height="20" font="1">2008). </text>
<text top="590" left="226" width="3" height="20" font="1"> </text>
<text top="607" left="226" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="624" left="226" width="96" height="20" font="1">analysis of<b> </b>RCTs </text>
<text top="641" left="226" width="87" height="20" font="1">of interventions </text>
<text top="659" left="226" width="102" height="20" font="1">that aimed to alter </text>
<text top="676" left="226" width="92" height="20" font="1">BP vs. control in </text>
<text top="693" left="226" width="97" height="20" font="1">pts within 1 wk of </text>
<text top="710" left="226" width="99" height="20" font="1">acute ischemic or </text>
<text top="727" left="226" width="72" height="20" font="1">hemorrhagic </text>
<text top="745" left="226" width="40" height="20" font="1">stroke. </text>
<text top="762" left="226" width="3" height="20" font="1"> </text>
<text top="332" left="348" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="349" left="348" width="121" height="20" font="1">RCTs of interventions </text>
<text top="366" left="348" width="121" height="20" font="1">that aimed to alter BP </text>
<text top="383" left="348" width="124" height="20" font="1">compared with control </text>
<text top="400" left="348" width="100" height="20" font="1">in pts with 1 wk of </text>
<text top="418" left="348" width="99" height="20" font="1">acute ischemic or </text>
<text top="435" left="348" width="109" height="20" font="1">hemorrhagic stroke<b> </b></text>
<text top="332" left="490" width="109" height="20" font="1">● BP lowering after </text>
<text top="349" left="490" width="104" height="20" font="1">acute stroke onset </text>
<text top="366" left="490" width="130" height="20" font="1">compared with placebo<b> </b></text>
<text top="333" left="637" width="186" height="20" font="4"><b>1</b>°<b> outcome: </b>Functional outcome<b> </b></text>
<text top="350" left="637" width="3" height="20" font="4"><b> </b></text>
<text top="367" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="384" left="637" width="211" height="20" font="1">● At 24 h after randomization #1: Oral </text>
<text top="402" left="637" width="249" height="20" font="1">ACEIs reduced SBP MD: -8 mm Hg (95% CI: </text>
<text top="419" left="637" width="244" height="20" font="1">-17–1) and DBP MD: -3 mm Hg (95% CI: -9–</text>
<text top="436" left="637" width="221" height="20" font="1">2), sublingual ACEIs reduced SBP MD: -</text>
<text top="453" left="637" width="246" height="20" font="1">12.00 mm Hg (95% CI: -26–2) and DBP MD: </text>
<text top="470" left="637" width="111" height="20" font="1">-2 (95% CI: -10–6).  </text>
<text top="488" left="637" width="220" height="20" font="1">● Oral angiotensin receptor antagonists </text>
<text top="505" left="637" width="243" height="20" font="1">reduced SBP MD: -1 mm Hg (95% CI: -3–2) </text>
<text top="522" left="637" width="223" height="20" font="1">and DBP MD: -1 mm Hg (95% CI: -3–1). </text>
<text top="539" left="637" width="231" height="20" font="1">● Oral BBs reduced SBP MD: -14 mm Hg </text>
<text top="557" left="637" width="234" height="20" font="1">(95% CI: -27– -1) and DBP MD: -1 mm Hg </text>
<text top="574" left="637" width="244" height="20" font="1">(95% CI: -9–7), IV BBs reduced SBP MD: -5 </text>
<text top="591" left="637" width="226" height="20" font="1">mm Hg (95% CI: -18–8) and DBP MD: -5 </text>
<text top="608" left="637" width="140" height="20" font="1">mm Hg (95% CI: -13–3).  </text>
<text top="625" left="637" width="241" height="20" font="1">● Oral CCBs reduced SBP MD: -13 mm Hg </text>
<text top="643" left="637" width="233" height="20" font="1">(95% CI: -43–17) and DBP MD: -6 mm Hg </text>
<text top="660" left="637" width="246" height="20" font="1">(95% CI: -14–2), IV CCBs reduced SBP MD: </text>
<text top="677" left="637" width="237" height="20" font="1">-32 mm Hg (95% CI: -65–1) and DBP MD: -</text>
<text top="694" left="637" width="114" height="20" font="1">13 (95% CI: -31–6).  </text>
<text top="711" left="637" width="241" height="20" font="1">● Nitric oxide donors reduced SBP MD: -12 </text>
<text top="729" left="637" width="234" height="20" font="1">mm Hg (95% CI: -19– -5) and DBP MD: -3 </text>
<text top="746" left="637" width="94" height="20" font="1">(95% CI: -4– -2). </text>
<text top="332" left="899" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="349" left="899" width="199" height="20" font="1">● No current evidence showing that </text>
<text top="366" left="899" width="198" height="20" font="1">lowering BP during the acute phase </text>
<text top="383" left="899" width="160" height="20" font="1">of stroke improves functional </text>
<text top="400" left="899" width="57" height="20" font="1">outcome.  </text>
<text top="418" left="899" width="189" height="20" font="1">● It seems reasonable to withhold </text>
<text top="435" left="899" width="171" height="20" font="1">BP-lowering drugs until pts are </text>
<text top="452" left="899" width="197" height="20" font="1">medically and neurologically stable, </text>
<text top="469" left="899" width="165" height="20" font="1">after which drugs can then be </text>
<text top="487" left="899" width="79" height="20" font="1">reintroduced.  </text>
<text top="504" left="899" width="202" height="20" font="1">● CCBs, ACEI, angiotensin receptor </text>
<text top="521" left="899" width="182" height="20" font="1">antagonists, BBs and nitric oxide </text>
<text top="538" left="899" width="170" height="20" font="1">donors each lower BP in acute </text>
<text top="555" left="899" width="197" height="20" font="1">stroke while phenylephrine appears </text>
<text top="573" left="899" width="87" height="20" font="1">to increase BP.<b> </b></text>
</page>
<page number="151" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">151 </text>
<text top="107" left="226" width="78" height="20" font="4"><b>Size: </b>26 trials </text>
<text top="124" left="226" width="92" height="20" font="1">involving 17,011 </text>
<text top="141" left="226" width="108" height="20" font="1">pts (8,497 pts were </text>
<text top="159" left="226" width="88" height="20" font="1">assigned active </text>
<text top="176" left="226" width="103" height="20" font="1">therapy and 8,514 </text>
<text top="193" left="226" width="70" height="20" font="1">pts received </text>
<text top="210" left="226" width="94" height="20" font="1">placebo/control). </text>
<text top="228" left="226" width="68" height="20" font="1">Not all trials </text>
<text top="245" left="226" width="108" height="20" font="1">contributed to each </text>
<text top="262" left="226" width="54" height="20" font="1">outcome.<b> </b></text>
<text top="107" left="637" width="242" height="20" font="1">● Phenylephrine, nonsignificantly increased </text>
<text top="124" left="637" width="235" height="20" font="1">SBP MD: 21 mm Hg (95% CI: -13–55) and </text>
<text top="141" left="637" width="209" height="20" font="1">DBP MD: 1 mm Hg (95% CI: -15–16). </text>
<text top="159" left="637" width="212" height="20" font="1">● BP lowering did not reduce death or </text>
<text top="176" left="637" width="233" height="20" font="1">dependency either by drug class OR: 0.98 </text>
<text top="193" left="637" width="233" height="20" font="1">(95% CI: 0.92–1.05), stroke type OR: 0.98 </text>
<text top="210" left="637" width="249" height="20" font="1">(95% CI: 0.92–1.05) or time to treatment OR: </text>
<text top="228" left="637" width="148" height="20" font="1">0.98 (95% CI: 0.92–1.05).  </text>
<text top="245" left="637" width="233" height="20" font="1">● Treatment within 6 h of stroke appeared </text>
<text top="262" left="637" width="232" height="20" font="1">effective in reducing death or dependency </text>
<text top="279" left="637" width="241" height="20" font="1">OR: 0.86 (95% CI: 0.76–0.99) but not death </text>
<text top="296" left="637" width="237" height="20" font="1">OR: 0.70 (95% CI: 0.38–1.26) by trial end.  </text>
<text top="314" left="637" width="237" height="20" font="1">● While death or dependency did not differ </text>
<text top="331" left="637" width="211" height="20" font="1">between pts who continued pre-stroke </text>
<text top="348" left="637" width="227" height="20" font="1">antihypertensive treatment vs. those who </text>
<text top="365" left="637" width="237" height="20" font="1">stopped it temporarily (worse outcome with </text>
<text top="382" left="637" width="218" height="20" font="1">continuing treatment OR: 1.06; 95% CI: </text>
<text top="400" left="637" width="248" height="20" font="1">0.91–1.24), disability scores at the end of the </text>
<text top="417" left="637" width="204" height="20" font="1">trial were worse in pts randomized to </text>
<text top="434" left="637" width="236" height="20" font="1">continue treatment (Barthel Index MD: -3.2 </text>
<text top="451" left="637" width="115" height="20" font="1">(95% CI: -5.8– -0.6). </text>
<text top="469" left="98" width="63" height="20" font="4"><b>SITS-ISTR </b></text>
<text top="487" left="98" width="91" height="20" font="1">Ahmed N, et al., </text>
<text top="504" left="98" width="63" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(199)</a> </text>
<text top="521" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19461022?dopt=Citation">19461022</a></text>
<text top="521" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19461022?dopt=Citation"> </a></text>
<text top="469" left="226" width="107" height="20" font="4"><b>Aim:</b> To<b> </b>determine </text>
<text top="487" left="226" width="99" height="20" font="1">the association of </text>
<text top="504" left="226" width="44" height="20" font="1">BP and </text>
<text top="521" left="226" width="93" height="20" font="1">antihypertensive </text>
<text top="538" left="226" width="70" height="20" font="1">therapy with </text>
<text top="555" left="226" width="97" height="20" font="1">clinical outcomes </text>
<text top="573" left="226" width="100" height="20" font="1">after thrombolysis </text>
<text top="590" left="226" width="102" height="20" font="1">for acute ischemic </text>
<text top="607" left="226" width="37" height="20" font="1">stroke </text>
<text top="624" left="226" width="3" height="20" font="1"> </text>
<text top="641" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="659" left="226" width="78" height="20" font="1">Retrospective </text>
<text top="676" left="226" width="61" height="20" font="1">analysis of </text>
<text top="693" left="226" width="75" height="20" font="1">prospectively </text>
<text top="710" left="226" width="64" height="20" font="1">maintained </text>
<text top="727" left="226" width="72" height="20" font="1">thrombolysis </text>
<text top="745" left="226" width="47" height="20" font="1">registry. </text>
<text top="762" left="226" width="3" height="20" font="1"> </text>
<text top="469" left="348" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="487" left="348" width="92" height="20" font="1">● Pts with acute </text>
<text top="504" left="348" width="88" height="20" font="1">ischemic stroke </text>
<text top="521" left="348" width="113" height="20" font="1">treated with IV rtPA  </text>
<text top="538" left="348" width="101" height="20" font="1">● BP values were </text>
<text top="555" left="348" width="129" height="20" font="1">recorded at baseline, 2 </text>
<text top="573" left="348" width="93" height="20" font="1">h, and 24 h after </text>
<text top="590" left="348" width="79" height="20" font="1">thrombolysis.  </text>
<text top="607" left="348" width="3" height="20" font="4"><b> </b></text>
<text top="624" left="348" width="71" height="20" font="4"><b>Categories: </b></text>
<text top="641" left="348" width="124" height="20" font="1">By history of HTN and </text>
<text top="659" left="348" width="93" height="20" font="1">antihypertensive </text>
<text top="676" left="348" width="128" height="20" font="1">therapy within 7 d after </text>
<text top="693" left="348" width="76" height="20" font="1">thrombolysis: </text>
<text top="710" left="348" width="92" height="20" font="1">● Group 1, HTN </text>
<text top="727" left="348" width="67" height="20" font="1">treated with </text>
<text top="745" left="348" width="99" height="20" font="1">antihypertensives </text>
<text top="762" left="348" width="56" height="20" font="1">(n=5,612) </text>
<text top="469" left="490" width="131" height="20" font="1">● Various categories of </text>
<text top="487" left="490" width="90" height="20" font="1">HTN treatments </text>
<text top="470" left="637" width="209" height="20" font="4"><b>1</b>°<b> outcomes: </b>Symptomatic (National </text>
<text top="488" left="637" width="212" height="20" font="1">Institutes of Health Stroke Scale score </text>
<text top="505" left="637" width="241" height="20" font="1">deterioration ≥4) ICH Type 2, mortality, and </text>
<text top="522" left="637" width="236" height="20" font="1">independence at (modified Rankin Score 0 </text>
<text top="539" left="637" width="62" height="20" font="1">to 2) 3 mo.<b> </b></text>
<text top="557" left="637" width="3" height="20" font="1"> </text>
<text top="574" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="591" left="637" width="237" height="20" font="1">● High SBP 2–24 h after thrombolysis as a </text>
<text top="608" left="637" width="222" height="20" font="1">continuous variable was associated with </text>
<text top="625" left="637" width="194" height="20" font="1">worse outcome (p&lt;0.001) and as a </text>
<text top="643" left="637" width="242" height="20" font="1">categorical variable had a linear association </text>
<text top="660" left="637" width="215" height="20" font="1">with symptomatic hemorrhage and a U-</text>
<text top="677" left="637" width="208" height="20" font="1">shaped association with mortality and </text>
<text top="694" left="637" width="228" height="20" font="1">independence with SBP 141–150 mm Hg </text>
<text top="711" left="637" width="235" height="20" font="1">associated with most favorable outcomes.  </text>
<text top="729" left="637" width="244" height="20" font="1">● No difference in symptomatic hemorrhage </text>
<text top="746" left="637" width="235" height="20" font="1">OR: 1.09 (95% CI: 0.83–1.51; p=0.58) and </text>
<text top="763" left="637" width="246" height="20" font="1">independence OR: 1.03 (95% CI: 0.93–1.10; </text>
<text top="780" left="637" width="234" height="20" font="1">p=0.80) but lower mortality OR: 0.82 (95% </text>
<text top="469" left="899" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="487" left="899" width="185" height="20" font="1">● Strong association of high SBP </text>
<text top="504" left="899" width="154" height="20" font="1">after thrombolysis with poor </text>
<text top="521" left="899" width="57" height="20" font="1">outcome.  </text>
<text top="538" left="899" width="195" height="20" font="1">● Higher BPs during the initial 24 h </text>
<text top="555" left="899" width="196" height="20" font="1">were associated with greater risk of </text>
<text top="573" left="899" width="131" height="20" font="1">ICH in a linear fashion.  </text>
<text top="590" left="899" width="197" height="20" font="1">● U-shaped relation found between </text>
<text top="607" left="899" width="189" height="20" font="1">BP during initial 24 h and death or </text>
<text top="624" left="899" width="170" height="20" font="1">dependency at 3 mo, with best </text>
<text top="641" left="899" width="186" height="20" font="1">outcomes associated with SBP of </text>
<text top="659" left="899" width="98" height="20" font="1">141–150 mm Hg.<b> </b></text>
</page>
<page number="152" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">152 </text>
<text top="107" left="226" width="68" height="20" font="4"><b>Study size: </b></text>
<text top="124" left="226" width="89" height="20" font="1">11,080 pts from </text>
<text top="141" left="226" width="68" height="20" font="1">2002–2006.<b> </b></text>
<text top="107" left="348" width="92" height="20" font="1">● Group 2, HTN </text>
<text top="124" left="348" width="65" height="20" font="1">withholding </text>
<text top="141" left="348" width="99" height="20" font="1">antihypertensives </text>
<text top="159" left="348" width="56" height="20" font="1">(n=1,573) </text>
<text top="176" left="348" width="106" height="20" font="1">● Group 3, without </text>
<text top="193" left="348" width="124" height="20" font="1">history of HTN treated </text>
<text top="210" left="348" width="124" height="20" font="1">with antihypertensives </text>
<text top="228" left="348" width="46" height="20" font="1">(n=995) </text>
<text top="245" left="348" width="106" height="20" font="1">● Group 4, without </text>
<text top="262" left="348" width="102" height="20" font="1">history of HTN not </text>
<text top="279" left="348" width="67" height="20" font="1">treated with </text>
<text top="296" left="348" width="99" height="20" font="1">antihypertensives </text>
<text top="314" left="348" width="60" height="20" font="1">(n=2,632). </text>
<text top="107" left="637" width="225" height="20" font="1">CI: 0.73–0.92; p=0.0007) for Group 1 vs. </text>
<text top="124" left="637" width="55" height="20" font="1">Group 4.  </text>
<text top="141" left="637" width="205" height="20" font="1">● Group 2 had a higher symptomatic </text>
<text top="159" left="637" width="239" height="20" font="1">hemorrhage (OR: 1.86; 95% CI: 1.34–2.68; </text>
<text top="176" left="637" width="240" height="20" font="1">p=0.0004) and mortality (OR: 1.62; 95% CI: </text>
<text top="193" left="637" width="177" height="20" font="1">1.41–1.85; p&lt;0.0001) and lower </text>
<text top="210" left="637" width="219" height="20" font="1">independence (OR: 0.89; 95% CI: 0.80–</text>
<text top="228" left="637" width="244" height="20" font="1">0.99; p=0.04) vs. with Group 4. Group 3 had </text>
<text top="245" left="637" width="146" height="20" font="1">similar results as Group 1.<b> </b></text>
<text top="332" left="98" width="58" height="20" font="4"><b>ACCESS  </b></text>
<text top="349" left="98" width="100" height="20" font="1">Schrader J, et al., </text>
<text top="366" left="98" width="63" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(200)</a> </text>
<text top="383" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12817109?dopt=Citation">12817109</a></text>
<text top="383" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12817109?dopt=Citation"> </a></text>
<text top="332" left="226" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="349" left="226" width="94" height="20" font="1">safety of modest </text>
<text top="366" left="226" width="90" height="20" font="1">BP reduction by </text>
<text top="383" left="226" width="84" height="20" font="1">candesartan in </text>
<text top="400" left="226" width="99" height="20" font="1">early treatment of </text>
<text top="418" left="226" width="108" height="20" font="1">stroke; and provide </text>
<text top="435" left="226" width="101" height="20" font="1">an estimate of the </text>
<text top="452" left="226" width="94" height="20" font="1">number of cases </text>
<text top="469" left="226" width="108" height="20" font="1">required to perform </text>
<text top="487" left="226" width="96" height="20" font="1">a larger phase III </text>
<text top="504" left="226" width="81" height="20" font="1">efficacy study. </text>
<text top="521" left="226" width="3" height="20" font="1"> </text>
<text top="538" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="555" left="226" width="71" height="20" font="1">Prospective, </text>
<text top="573" left="226" width="106" height="20" font="1">double-blind, RCT; </text>
<text top="590" left="226" width="100" height="20" font="1">multicenter phase </text>
<text top="607" left="226" width="46" height="20" font="1">II study. </text>
<text top="624" left="226" width="3" height="20" font="1"> </text>
<text top="641" left="226" width="75" height="20" font="4"><b>Size</b>: 342 pts </text>
<text top="332" left="348" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="349" left="348" width="84" height="20" font="1">Motor deficit, a </text>
<text top="366" left="348" width="97" height="20" font="1">cerebral CT scan </text>
<text top="383" left="348" width="107" height="20" font="1">excluding ICH, and </text>
<text top="400" left="348" width="125" height="20" font="1">necessity to treat HTN </text>
<text top="418" left="348" width="77" height="20" font="1">per prevailing </text>
<text top="435" left="348" width="95" height="20" font="1">recommendation </text>
<text top="452" left="348" width="3" height="20" font="1"> </text>
<text top="469" left="348" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="487" left="348" width="104" height="20" font="1">&gt;85 y, disorders in </text>
<text top="504" left="348" width="84" height="20" font="1">consciousness </text>
<text top="521" left="348" width="122" height="20" font="1">preventing acquisition </text>
<text top="538" left="348" width="118" height="20" font="1">of consent, occlusion </text>
<text top="555" left="348" width="112" height="20" font="1">or &gt;70% stenosis of </text>
<text top="573" left="348" width="105" height="20" font="1">the internal carotid </text>
<text top="590" left="348" width="127" height="20" font="1">artery, malignant HTN, </text>
<text top="607" left="348" width="93" height="20" font="1">manifest cardiac </text>
<text top="624" left="348" width="103" height="20" font="1">failure, high-grade </text>
<text top="641" left="348" width="81" height="20" font="1">aortic or mitral </text>
<text top="659" left="348" width="122" height="20" font="1">stenosis, UA pectoris, </text>
<text top="676" left="348" width="110" height="20" font="1">or contraindications </text>
<text top="693" left="348" width="118" height="20" font="1">against candesartan. </text>
<text top="332" left="490" width="79" height="20" font="4"><b>Design: </b>4 mg </text>
<text top="349" left="490" width="114" height="20" font="1">candesartan daily or </text>
<text top="366" left="490" width="131" height="20" font="1">placebo on d 1. On d 2, </text>
<text top="383" left="490" width="126" height="20" font="1">dosage was increased </text>
<text top="400" left="490" width="76" height="20" font="1">to 8 or 16 mg </text>
<text top="418" left="490" width="132" height="20" font="1">candesartan or placebo </text>
<text top="435" left="490" width="125" height="20" font="1">if BP &gt;60 mm Hg SPB </text>
<text top="452" left="490" width="113" height="20" font="1">or 100 mm Hg DBP. </text>
<text top="469" left="490" width="133" height="20" font="1">Treatment was targeted </text>
<text top="487" left="490" width="103" height="20" font="1">to a 10%–15% BP </text>
<text top="504" left="490" width="123" height="20" font="1">reduction within 24 h. <b> </b></text>
<text top="333" left="637" width="243" height="20" font="4"><b>1</b>°<b> outcome:</b> Trial was stopped prematurely </text>
<text top="350" left="637" width="192" height="20" font="1">when 342 pts (339 valid) had been </text>
<text top="367" left="637" width="221" height="20" font="1">randomized because of an imbalance in </text>
<text top="384" left="637" width="60" height="20" font="1">endpoints. </text>
<text top="402" left="637" width="3" height="20" font="1"> </text>
<text top="419" left="637" width="234" height="20" font="4"><b>Key findings: </b>Cumulative 12 mo mortality </text>
<text top="436" left="637" width="237" height="20" font="1">and the number of vascular events differed </text>
<text top="453" left="637" width="216" height="20" font="1">significantly in favor of the candesartan </text>
<text top="470" left="637" width="230" height="20" font="1">cilexetil group (OR: 0.475; 95% CI: 0.252–</text>
<text top="488" left="637" width="42" height="20" font="1">0.895).<b> </b></text>
<text top="332" left="899" width="188" height="20" font="4"><b>Summary: </b>Early antihypertensive </text>
<text top="349" left="899" width="202" height="20" font="1">therapy with candesartan might be a </text>
<text top="366" left="899" width="174" height="20" font="1">safe therapeutic option in acute </text>
<text top="383" left="899" width="189" height="20" font="1">stroke, but study sample size very </text>
<text top="400" left="899" width="35" height="20" font="1">small.<b> </b></text>
<text top="711" left="98" width="45" height="20" font="4"><b>SCAST </b></text>
<text top="728" left="98" width="106" height="20" font="1">Sandset EC, et al., </text>
<text top="745" left="98" width="63" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(201)</a> </text>
<text top="763" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21316752?dopt=Citation">21316752</a></text>
<text top="763" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21316752?dopt=Citation"> </a></text>
<text top="711" left="226" width="98" height="20" font="4"><b>Aim:</b> To examine </text>
<text top="728" left="226" width="87" height="20" font="1">whether careful </text>
<text top="745" left="226" width="69" height="20" font="1">BP-lowering </text>
<text top="763" left="226" width="101" height="20" font="1">treatment with the </text>
<text top="780" left="226" width="83" height="20" font="1">candesartan is </text>
<text top="711" left="348" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="728" left="348" width="93" height="20" font="1">&gt;18 y with acute </text>
<text top="745" left="348" width="107" height="20" font="1">stroke (ischemic or </text>
<text top="763" left="348" width="128" height="20" font="1">hemorrhagic) and SBP </text>
<text top="780" left="348" width="120" height="21" font="1">of ≥140 mm Hg were </text>
<text top="711" left="490" width="70" height="20" font="4"><b>Design:</b> Pts </text>
<text top="728" left="490" width="81" height="20" font="1">randomized to </text>
<text top="745" left="490" width="128" height="20" font="1">candesartan (n=1,017) </text>
<text top="763" left="490" width="132" height="20" font="1">or placebo (1,012) (1:1) </text>
<text top="780" left="490" width="103" height="20" font="1">for 7 d, with doses </text>
<text top="712" left="637" width="238" height="20" font="4"><b>1</b>°<b> effect variables:</b> Composite of vascular </text>
<text top="729" left="637" width="249" height="20" font="1">death, MI, or stroke during the first 6 mo; and </text>
<text top="747" left="637" width="246" height="20" font="1">functional outcome at 6 mo, as measured by </text>
<text top="764" left="637" width="150" height="20" font="1">the modified Rankin Scale. </text>
<text top="712" left="899" width="134" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:  </b></text>
<text top="729" left="899" width="196" height="20" font="1">● Similar effects for all prespecified </text>
<text top="747" left="899" width="75" height="20" font="1">2º endpoints. </text>
<text top="764" left="899" width="185" height="20" font="1">● During follow-up, 9 (1%) pts on </text>
<text top="781" left="899" width="159" height="20" font="1">candesartan and 5 (&lt;1%) on </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">153 </text>
<text top="107" left="226" width="88" height="20" font="1">beneficial in pts </text>
<text top="124" left="226" width="96" height="20" font="1">with acute stroke </text>
<text top="141" left="226" width="84" height="20" font="1">and raised BP. </text>
<text top="159" left="226" width="3" height="20" font="1"> </text>
<text top="176" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="193" left="226" width="101" height="20" font="1">Double-blind RCT </text>
<text top="210" left="226" width="3" height="20" font="1"> </text>
<text top="227" left="226" width="103" height="20" font="4"><b>Study size:</b> 2,029 </text>
<text top="245" left="226" width="20" height="20" font="1">pts </text>
<text top="107" left="348" width="125" height="20" font="1">included within 30 h of </text>
<text top="124" left="348" width="90" height="20" font="1">symptom onset. </text>
<text top="107" left="490" width="118" height="20" font="1">increasing from 4 mg </text>
<text top="124" left="490" width="133" height="20" font="1">on d 1–16 mg on d 3–7. </text>
<text top="107" left="637" width="228" height="20" font="1">Data for status at 6 mo were available for </text>
<text top="124" left="637" width="233" height="20" font="1">2,004 pts (99%; 1,000 candesartan, 1,004 </text>
<text top="141" left="637" width="54" height="20" font="1">placebo). </text>
<text top="159" left="637" width="3" height="20" font="1"> </text>
<text top="176" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="193" left="637" width="224" height="20" font="1">● BPs significantly lower in pts allocated </text>
<text top="210" left="637" width="216" height="20" font="1">candesartan vs. placebo (mean 147/82 </text>
<text top="228" left="637" width="245" height="21" font="1">mm Hg [SD 23/14] in the candesartan group </text>
<text top="245" left="637" width="216" height="21" font="1">on d 7 vs. 152/84 mm Hg [22/14] in the </text>
<text top="262" left="637" width="147" height="20" font="1">placebo group; p&lt;0.0001). </text>
<text top="279" left="637" width="233" height="20" font="1">● Risk of the composite vascular endpoint </text>
<text top="296" left="637" width="217" height="20" font="1">did not differ between treatment groups </text>
<text top="314" left="637" width="239" height="20" font="1">(candesartan, 120 events, vs. placebo, 111 </text>
<text top="331" left="637" width="226" height="20" font="1">events; adjusted HR: 1.09; 95% CI: 0.84–</text>
<text top="348" left="637" width="79" height="20" font="1">1.41; p=0.52.  </text>
<text top="365" left="637" width="242" height="20" font="1">● Analysis of functional outcome suggested </text>
<text top="382" left="637" width="196" height="20" font="1">a higher risk of poor outcome in the </text>
<text top="400" left="637" width="244" height="20" font="1">candesartan group (adjusted OR: 1.17; 95% </text>
<text top="417" left="637" width="132" height="20" font="1">CI: 1.00–1.38; p=0.048.<b> </b></text>
<text top="107" left="899" width="143" height="20" font="1">placebo had symptomatic </text>
<text top="124" left="899" width="190" height="20" font="1">hypotension, and renal failure was </text>
<text top="141" left="899" width="169" height="20" font="1">reported for 18 (2%) pts taking </text>
<text top="159" left="899" width="194" height="20" font="1">candesartan and 13 (1%) allocated </text>
<text top="176" left="899" width="50" height="20" font="1">placebo. </text>
<text top="193" left="899" width="3" height="20" font="1"> </text>
<text top="210" left="899" width="176" height="20" font="4"><b>Summary:</b> Careful BP-lowering </text>
<text top="227" left="899" width="198" height="20" font="1">treatment with candesartan was not </text>
<text top="245" left="899" width="184" height="20" font="1">beneficial in pts with acute stroke </text>
<text top="262" left="899" width="185" height="20" font="1">and raised BP. Indeed, there was </text>
<text top="279" left="899" width="189" height="20" font="1">the suggestion of a harmful effect. </text>
<text top="435" left="98" width="44" height="20" font="4"><b>CATIS  </b></text>
<text top="452" left="98" width="69" height="20" font="1">He J, et al.,  </text>
<text top="469" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(202)</a> </text>
<text top="487" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24240777?dopt=Citation">24240777</a></text>
<text top="487" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24240777?dopt=Citation"> </a></text>
<text top="435" left="226" width="98" height="20" font="4"><b>Aim:</b> To evaluate </text>
<text top="452" left="226" width="107" height="20" font="1">whether immediate </text>
<text top="469" left="226" width="107" height="20" font="1">BP reduction in pts </text>
<text top="487" left="226" width="59" height="20" font="1">with acute </text>
<text top="504" left="226" width="88" height="20" font="1">ischemic stroke </text>
<text top="521" left="226" width="76" height="20" font="1">would reduce </text>
<text top="538" left="226" width="92" height="20" font="1">death and major </text>
<text top="555" left="226" width="106" height="20" font="1">disability at 14 d or </text>
<text top="573" left="226" width="106" height="20" font="1">hospital discharge. </text>
<text top="590" left="226" width="3" height="20" font="1"> </text>
<text top="607" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="624" left="226" width="71" height="20" font="1">Single-blind, </text>
<text top="641" left="226" width="104" height="20" font="1">blinded end-points </text>
<text top="659" left="226" width="35" height="20" font="1">RCT.  </text>
<text top="676" left="226" width="3" height="20" font="1"> </text>
<text top="693" left="226" width="103" height="20" font="4"><b>Study size: </b>4,071 </text>
<text top="710" left="226" width="20" height="20" font="1">pts </text>
<text top="435" left="348" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="452" left="348" width="46" height="20" font="1">Pts with </text>
<text top="469" left="348" width="98" height="20" font="1">nonthrombolysed </text>
<text top="487" left="348" width="123" height="20" font="1">ischemic stroke within </text>
<text top="504" left="348" width="98" height="20" font="1">48 h of onset and </text>
<text top="521" left="348" width="78" height="20" font="1">elevated SBP<b> </b></text>
<text top="435" left="490" width="126" height="20" font="4"><b>Design:</b> Pts (n=2,038) </text>
<text top="452" left="490" width="81" height="20" font="1">randomized to </text>
<text top="469" left="490" width="93" height="20" font="1">antihypertensive </text>
<text top="487" left="490" width="110" height="20" font="1">treatment (aimed at </text>
<text top="504" left="490" width="121" height="20" font="1">lowering SBP by 10% </text>
<text top="521" left="490" width="130" height="20" font="1">to 25% within first 24 h, </text>
<text top="538" left="490" width="123" height="20" font="1">achieving BP &lt;140/90 </text>
<text top="555" left="490" width="126" height="20" font="1">mm Hg within 7 d, and </text>
<text top="573" left="490" width="117" height="20" font="1">maintaining this level </text>
<text top="590" left="490" width="123" height="20" font="1">during hospitalization) </text>
<text top="607" left="490" width="114" height="20" font="1">vs. to discontinue all </text>
<text top="624" left="490" width="93" height="20" font="1">antihypertensive </text>
<text top="642" left="490" width="118" height="20" font="1">medications (control) </text>
<text top="659" left="490" width="119" height="20" font="1">during hospitalization </text>
<text top="676" left="490" width="60" height="20" font="1">(n=2,033). </text>
<text top="436" left="637" width="219" height="20" font="4"><b>1</b>°<b> outcome:</b> Combination of death and </text>
<text top="453" left="637" width="248" height="20" font="1">major disability (modified Rankin Scale score </text>
<text top="470" left="637" width="184" height="20" font="1">≥3) at 14 d or hospital discharge. </text>
<text top="488" left="637" width="3" height="20" font="1"> </text>
<text top="505" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="522" left="637" width="234" height="20" font="1">● Mean SBP was reduced from 166.7 mm </text>
<text top="539" left="637" width="236" height="20" font="1">Hg to 144.7 mm Hg (-12.7%) within 24 h in </text>
<text top="557" left="637" width="228" height="20" font="1">the antihypertensive treatment group and </text>
<text top="574" left="637" width="240" height="20" font="1">from 165.6 mm Hg to 152.9 mm Hg (-7.2%) </text>
<text top="591" left="637" width="199" height="20" font="1">in the control group within 24 h after </text>
<text top="608" left="637" width="236" height="20" font="1">randomization (difference, -5.5% (95% CI: -</text>
<text top="625" left="637" width="249" height="20" font="1">4.9– -6.1%); absolute difference, -9.1 mm Hg </text>
<text top="643" left="637" width="181" height="20" font="1">(95% CI: -10.2– -8.1), p&lt;0.001).  </text>
<text top="660" left="637" width="200" height="20" font="1">● 1° outcome did not differ between </text>
<text top="677" left="637" width="235" height="20" font="1">treatment groups (OR: 1.00; 95% CI: 0.88–</text>
<text top="694" left="637" width="241" height="20" font="1">1.14; p=0.98) at 14 d or hospital discharge.  </text>
<text top="713" left="637" width="7" height="18" font="1">•</text>
<text top="713" left="644" width="232" height="20" font="1"> BP at 14 d and 90 d: significantly lower in </text>
<text top="730" left="637" width="239" height="20" font="1">the active arm (mean difference of -2.9 mm </text>
<text top="747" left="637" width="248" height="20" font="1">Hg in systolic BP and -1.4 mm Hg in diastolic </text>
<text top="764" left="637" width="24" height="20" font="1">BP) </text>
<text top="436" left="899" width="191" height="20" font="4"><b>Relevant 2</b>°<b> endpoint: </b>Death and </text>
<text top="453" left="899" width="130" height="20" font="1">major disability at 3-mo </text>
<text top="470" left="899" width="202" height="20" font="1">posttreatment follow-up did not differ </text>
<text top="488" left="899" width="174" height="20" font="1">between treatment groups (500 </text>
<text top="505" left="899" width="195" height="20" font="1">events [antihypertensive treatment] </text>
<text top="522" left="899" width="189" height="20" font="1">vs. 502 events [control]; OR: 0.99; </text>
<text top="539" left="899" width="158" height="20" font="1">95% CI: 0.86–1.15; p=0.93). </text>
<text top="557" left="899" width="3" height="20" font="4"><b> </b></text>
<text top="574" left="899" width="185" height="20" font="4"><b>Summary:</b> Among pts with acute </text>
<text top="591" left="899" width="191" height="20" font="1">ischemic stroke, BP reduction with </text>
<text top="608" left="899" width="185" height="20" font="1">antihypertensive medications, vs. </text>
<text top="625" left="899" width="203" height="20" font="1">absence of hypertensive medication, </text>
<text top="643" left="899" width="170" height="20" font="1">did not reduce the likelihood of </text>
<text top="660" left="899" width="198" height="20" font="1">death and major disability at 14 d or </text>
<text top="677" left="899" width="106" height="20" font="1">hospital discharge. </text>
<text top="694" left="899" width="3" height="20" font="1"> </text>
<text top="712" left="899" width="106" height="20" font="1">● Early initiation of </text>
<text top="729" left="899" width="187" height="20" font="1">antihypertensives was associated </text>
<text top="746" left="899" width="163" height="20" font="1">with better BP control at 2 wk </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">154 </text>
<text top="107" left="98" width="68" height="20" font="4"><b>COSSACS  </b></text>
<text top="124" left="98" width="113" height="20" font="1">Robinson TG, et al., </text>
<text top="141" left="98" width="63" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(203)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20621562?dopt=Citation">20621562</a></text>
<text top="159" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20621562?dopt=Citation"> </a></text>
<text top="107" left="226" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="124" left="226" width="89" height="20" font="1">the efficacy and </text>
<text top="141" left="226" width="50" height="20" font="1">safety of </text>
<text top="159" left="226" width="74" height="20" font="1">continuing or </text>
<text top="176" left="226" width="72" height="20" font="1">stopping pre-</text>
<text top="193" left="226" width="45" height="20" font="1">existing </text>
<text top="210" left="226" width="93" height="20" font="1">antihypertensive </text>
<text top="228" left="226" width="93" height="20" font="1">drugs in pts who </text>
<text top="245" left="226" width="81" height="20" font="1">recently had a </text>
<text top="262" left="226" width="40" height="20" font="1">stroke. </text>
<text top="279" left="226" width="3" height="20" font="1"> </text>
<text top="296" left="226" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="314" left="226" width="67" height="20" font="1">Multicenter, </text>
<text top="331" left="226" width="70" height="20" font="1">prospective, </text>
<text top="348" left="226" width="105" height="20" font="1">randomized, open, </text>
<text top="365" left="226" width="94" height="20" font="1">blinded-endpoint </text>
<text top="382" left="226" width="27" height="20" font="1">trial. </text>
<text top="400" left="226" width="3" height="20" font="1"> </text>
<text top="417" left="226" width="68" height="20" font="4"><b>Study size: </b></text>
<text top="434" left="226" width="44" height="20" font="1">763 pts </text>
<text top="107" left="348" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="124" left="348" width="70" height="20" font="1">&gt;18 y taking </text>
<text top="141" left="348" width="127" height="20" font="1">antihypertensive drugs </text>
<text top="159" left="348" width="123" height="20" font="1">enrolled within 48 h of </text>
<text top="176" left="348" width="127" height="20" font="1">stroke and last dose of </text>
<text top="193" left="348" width="124" height="20" font="1">antihypertensive drug. </text>
<text top="107" left="490" width="101" height="20" font="4"><b>Design:</b> Continue </text>
<text top="124" left="490" width="134" height="20" font="1">(n=379) or stop (n=384) </text>
<text top="141" left="490" width="67" height="20" font="1">pre-existing </text>
<text top="159" left="490" width="127" height="20" font="1">antihypertensive drugs </text>
<text top="176" left="490" width="50" height="20" font="1">for 2 wk. </text>
<text top="108" left="637" width="242" height="20" font="4"><b>1</b>°<b> outcome:</b> Death or dependency at 2 wk. </text>
<text top="125" left="637" width="3" height="20" font="1"> </text>
<text top="143" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="160" left="637" width="246" height="20" font="1">● 72 of 379 pts in the continue group and 82 </text>
<text top="177" left="637" width="237" height="20" font="1">of 384 pts in the stop group reached the 1° </text>
<text top="194" left="637" width="215" height="20" font="1">endpoint RR: 0.86; 95% CI: 0.65–1.14; </text>
<text top="211" left="637" width="38" height="20" font="1">p=0.3. </text>
<text top="229" left="637" width="226" height="20" font="1">● Difference in SBP at 2 wk between the </text>
<text top="246" left="637" width="233" height="20" font="1">continue group and the stop group was 13 </text>
<text top="263" left="637" width="238" height="20" font="1">mm Hg (95% CI: 10–17) and the difference </text>
<text top="280" left="637" width="216" height="20" font="1">in DBP was 8 mm Hg (6–10; difference </text>
<text top="298" left="637" width="160" height="20" font="1">between groups; p&lt;0.0001).  </text>
<text top="315" left="637" width="242" height="20" font="1">● No substantial differences were observed </text>
<text top="332" left="637" width="239" height="20" font="1">between groups in rates of serious adverse </text>
<text top="349" left="637" width="240" height="20" font="1">events, 6-mo mortality, or major CV events. </text>
<text top="107" left="899" width="67" height="20" font="4"><b>Summary:</b>  </text>
<text top="124" left="899" width="192" height="20" font="1">● Continuation of antihypertensive </text>
<text top="141" left="899" width="193" height="20" font="1">drugs did not reduce 2-wk death or </text>
<text top="159" left="899" width="170" height="20" font="1">dependency, CV event rate, or </text>
<text top="176" left="899" width="94" height="20" font="1">mortality at 6 mo </text>
<text top="193" left="899" width="117" height="20" font="1">● Early reinitiation of </text>
<text top="210" left="899" width="187" height="20" font="1">antihypertensives was associated </text>
<text top="228" left="899" width="163" height="20" font="1">with better BP control at 2 wk </text>
<text top="245" left="899" width="176" height="20" font="1">● Lower BP levels in those who </text>
<text top="262" left="899" width="150" height="20" font="1">continued antihypertensive </text>
<text top="279" left="899" width="180" height="20" font="1">treatment after acute mild stroke </text>
<text top="296" left="899" width="155" height="20" font="1">were not associated with an </text>
<text top="314" left="899" width="157" height="20" font="1">increase in adverse events.  </text>
<text top="331" left="899" width="179" height="20" font="1">● Of note, COSSACS was likely </text>
<text top="348" left="899" width="150" height="20" font="1">underpowered due to early </text>
<text top="365" left="899" width="125" height="20" font="1">termination of the trial. </text>
<text top="452" left="98" width="53" height="20" font="4"><b>CHHIPS  </b></text>
<text top="469" left="98" width="90" height="20" font="1">Potter JF, et al., </text>
<text top="487" left="98" width="63" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(204)</a> </text>
<text top="504" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19058760?dopt=Citation">19058760</a></text>
<text top="504" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19058760?dopt=Citation"> </a></text>
<text top="452" left="226" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="469" left="226" width="97" height="20" font="1">feasibility, safety, </text>
<text top="487" left="226" width="87" height="20" font="1">and effects of 2 </text>
<text top="504" left="226" width="72" height="20" font="1">regimens for </text>
<text top="521" left="226" width="102" height="20" font="1">lowering BP in pts </text>
<text top="538" left="226" width="85" height="20" font="1">who with acute </text>
<text top="555" left="226" width="40" height="20" font="1">stroke. </text>
<text top="573" left="226" width="3" height="20" font="1"> </text>
<text top="590" left="226" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="607" left="226" width="98" height="20" font="1">Double-blind pilot </text>
<text top="624" left="226" width="27" height="20" font="1">trial. </text>
<text top="641" left="226" width="3" height="20" font="1"> </text>
<text top="659" left="226" width="92" height="20" font="4"><b>Study size: </b>179 </text>
<text top="676" left="226" width="20" height="20" font="1">pts<b> </b></text>
<text top="452" left="348" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="469" left="348" width="126" height="20" font="1">with cerebral infarction </text>
<text top="487" left="348" width="62" height="20" font="1">or cerebral </text>
<text top="504" left="348" width="126" height="20" font="1">hemorrhage who were </text>
<text top="521" left="348" width="101" height="20" font="1">hypertensive SBP </text>
<text top="538" left="348" width="82" height="20" font="1">&gt;160 mm Hg)  </text>
<text top="452" left="490" width="49" height="20" font="4"><b>Design:</b> </text>
<text top="469" left="490" width="91" height="20" font="1">● Within 36 h of </text>
<text top="487" left="490" width="90" height="20" font="1">symptom onset: </text>
<text top="504" left="490" width="100" height="20" font="1">#1: Oral labetalol, </text>
<text top="521" left="490" width="123" height="20" font="1">lisinopril vs. placebo if </text>
<text top="538" left="490" width="57" height="20" font="1">they were </text>
<text top="555" left="490" width="83" height="20" font="1">nondysphagic; </text>
<text top="573" left="490" width="88" height="20" font="1">#2: IV labetalol, </text>
<text top="590" left="490" width="124" height="20" font="1">sublingual lisinopril, or </text>
<text top="607" left="490" width="107" height="20" font="1">placebo if they had </text>
<text top="624" left="490" width="63" height="20" font="1">dysphagia. </text>
<text top="641" left="490" width="109" height="20" font="1">● Labetalol (n=58), </text>
<text top="659" left="490" width="105" height="20" font="1">lisinopril (n=58), or </text>
<text top="676" left="490" width="89" height="20" font="1">placebo (n=63). </text>
<text top="693" left="490" width="122" height="20" font="1">● Doses were titrated </text>
<text top="710" left="490" width="127" height="20" font="1">up if target BP was not </text>
<text top="727" left="490" width="55" height="20" font="1">reached.  </text>
<text top="453" left="637" width="242" height="20" font="4"><b>1</b>°<b> outcome: </b>Death or dependency at 2 wk. </text>
<text top="470" left="637" width="3" height="20" font="1"> </text>
<text top="488" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="505" left="637" width="231" height="20" font="1">● 1° outcome occurred in 61% (69) of the </text>
<text top="522" left="637" width="224" height="20" font="1">active vs. 59% (35) of the placebo group </text>
<text top="539" left="637" width="214" height="20" font="1">(RR: 1.03; 95% CI: 0.80–1.33; p=0.82) </text>
<text top="557" left="637" width="198" height="20" font="1">● No evidence of early neurological </text>
<text top="574" left="637" width="248" height="20" font="1">deterioration with active treatment (RR: 1.22; </text>
<text top="591" left="637" width="240" height="20" font="1">95% CI: 0.33–4.54; p=0.76) despite greater </text>
<text top="608" left="637" width="246" height="20" font="1">drop in SBP within the first 24 h in this group </text>
<text top="625" left="637" width="248" height="20" font="1">vs. placebo (21 [17–25] mm Hg vs. 11 [5–17] </text>
<text top="643" left="637" width="102" height="20" font="1">mm Hg; p=0.004). </text>
<text top="660" left="637" width="223" height="20" font="1">● No rise in serious adverse events with </text>
<text top="677" left="637" width="228" height="20" font="1">active treatment (RR: 0.91; 95% CI: 0.69–</text>
<text top="694" left="637" width="243" height="20" font="1">1.12; p=0.50) but 3-mo mortality was halved </text>
<text top="711" left="637" width="247" height="20" font="1">(9.7% vs. 20.3%; HR: 0.40; 95% CI: 0.2–1.0; </text>
<text top="729" left="637" width="49" height="20" font="1">p=0.05).<b> </b></text>
<text top="452" left="899" width="70" height="20" font="4"><b>Summary:</b>   </text>
<text top="469" left="899" width="159" height="20" font="1">● Labetalol and lisinopril are </text>
<text top="487" left="899" width="189" height="20" font="1">effective antihypertensive drugs in </text>
<text top="504" left="899" width="198" height="20" font="1">acute stroke that do not raise risk of </text>
<text top="521" left="899" width="137" height="20" font="1">serious adverse events.  </text>
<text top="538" left="899" width="200" height="20" font="1">● Early lowering of BP with lisinopril </text>
<text top="555" left="899" width="198" height="20" font="1">and labetalol after acute stroke may </text>
<text top="573" left="899" width="185" height="20" font="1">be a promising approach to lower </text>
<text top="590" left="899" width="131" height="20" font="1">mortality and disability.  </text>
<text top="607" left="899" width="183" height="20" font="1">● However, pilot nature and very </text>
<text top="624" left="899" width="126" height="20" font="1">small sample size limit </text>
<text top="641" left="899" width="92" height="20" font="1">generalizability. <b> </b></text>
<text top="747" left="98" width="87" height="20" font="1">Bath PM, et al., </text>
<text top="764" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(205)</a> </text>
<text top="781" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25465108?dopt=Citation">25465108</a></text>
<text top="781" left="152" width="4" height="21" font="0"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25465108?dopt=Citation"> </a></text>
<text top="747" left="226" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="764" left="226" width="85" height="20" font="1">outcomes after </text>
<text top="781" left="226" width="102" height="20" font="1">stroke in pts given </text>
<text top="747" left="348" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="764" left="348" width="110" height="20" font="1">admitted to hospital </text>
<text top="781" left="348" width="127" height="20" font="1">with an acute ischemic </text>
<text top="747" left="490" width="49" height="20" font="4"><b>Design:</b> </text>
<text top="764" left="490" width="115" height="20" font="1">● 7 d of transdermal </text>
<text top="781" left="490" width="128" height="20" font="1">glyceryl trinitrate (5 mg </text>
<text top="748" left="637" width="230" height="20" font="4"><b>1</b>°<b> outcome:</b> Function, assessed with the </text>
<text top="765" left="637" width="167" height="20" font="1">modified Rankin Scale at 90 d </text>
<text top="782" left="637" width="3" height="20" font="1"> </text>
<text top="747" left="899" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="764" left="899" width="192" height="20" font="1">● In pts with acute stroke and high </text>
<text top="781" left="899" width="181" height="20" font="1">BP transdermal glyceryl trinitrate </text>
</page>
<page number="155" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">155 </text>
<text top="107" left="226" width="108" height="20" font="1">drugs to lower their </text>
<text top="124" left="226" width="23" height="20" font="1">BP. </text>
<text top="141" left="226" width="3" height="20" font="1"> </text>
<text top="159" left="226" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="176" left="226" width="67" height="20" font="1">Multicenter, </text>
<text top="193" left="226" width="105" height="20" font="1">randomized partial-</text>
<text top="210" left="226" width="70" height="20" font="1">factorial trial </text>
<text top="228" left="226" width="3" height="20" font="1"> </text>
<text top="245" left="226" width="103" height="20" font="4"><b>Study size: </b>4,011 </text>
<text top="262" left="226" width="20" height="20" font="1">pts<b> </b></text>
<text top="107" left="348" width="123" height="20" font="1">or hemorrhagic stroke </text>
<text top="124" left="348" width="120" height="20" font="1">and raised SBP (140–</text>
<text top="141" left="348" width="71" height="20" font="1">220 mm Hg) </text>
<text top="159" left="348" width="3" height="20" font="4"><b> </b></text>
<text top="107" left="490" width="132" height="20" font="1">per d), started within 48 </text>
<text top="124" left="490" width="132" height="20" font="1">h of stroke onset vs. No </text>
<text top="141" left="490" width="93" height="20" font="1">glyceryl trinitrate </text>
<text top="159" left="490" width="87" height="20" font="1">(control group). </text>
<text top="176" left="490" width="70" height="20" font="1">● Pts taking </text>
<text top="193" left="490" width="127" height="20" font="1">antihypertensive drugs </text>
<text top="210" left="490" width="108" height="20" font="1">before index stroke </text>
<text top="228" left="490" width="120" height="20" font="1">randomly assigned to </text>
<text top="245" left="490" width="132" height="20" font="1">continue vs. stop taking </text>
<text top="262" left="490" width="71" height="20" font="1">these drugs. </text>
<text top="107" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="124" left="637" width="225" height="20" font="1">● Mean BP was 167 (SD: 19) mm Hg/90 </text>
<text top="141" left="637" width="231" height="20" font="1">(13) mm Hg at baseline (median 26 h (16–</text>
<text top="159" left="637" width="243" height="20" font="1">37) after stroke onset), and was significantly </text>
<text top="176" left="637" width="219" height="20" font="1">reduced on d 1 in 2,000 pts allocated to </text>
<text top="193" left="637" width="193" height="20" font="1">glyceryl trinitrate vs. 2,011 controls </text>
<text top="210" left="637" width="245" height="20" font="1">(difference -7.0 (95% CI: -8.5– -5.6) mm Hg/-</text>
<text top="228" left="637" width="245" height="20" font="1">3.5 [-4·4– -2·6] mm Hg; both p&lt;0.0001), and </text>
<text top="245" left="637" width="221" height="20" font="1">on d 7 in 1,053 pts allocated to continue </text>
<text top="262" left="637" width="245" height="20" font="1">antihypertensive drugs compared with 1,044 </text>
<text top="279" left="637" width="249" height="20" font="1">pts randomized to stop them (difference: -9·5 </text>
<text top="296" left="637" width="249" height="20" font="1">(95% CI: -11.8– -7.2) mm Hg/-5.0 [-6.4– -3.7] </text>
<text top="314" left="637" width="140" height="20" font="1">mm Hg; both p&lt;0.0001).  </text>
<text top="331" left="637" width="233" height="20" font="1">● D-90 functional outcome did not differ in </text>
<text top="348" left="637" width="202" height="20" font="1">either treatment comparison-glyceryl </text>
<text top="365" left="637" width="237" height="20" font="1">trinitrate vs. no glyceryl trinitrate (OR: 1.01; </text>
<text top="382" left="637" width="204" height="20" font="1">95% CI 0.91–1.13; p=0·83), and with </text>
<text top="400" left="637" width="223" height="20" font="1">continue vs. stop antihypertensive drugs </text>
<text top="417" left="637" width="218" height="20" font="1">(OR: 1.05; 95% CI: 0.90–1.22; p=0.55). </text>
<text top="107" left="899" width="191" height="20" font="1">lowered BP with acceptable safety </text>
<text top="124" left="899" width="164" height="20" font="1">but did not improve functional </text>
<text top="141" left="899" width="57" height="20" font="1">outcome.  </text>
<text top="159" left="899" width="129" height="20" font="1">● Continuing prestroke </text>
<text top="176" left="899" width="174" height="20" font="1">antihypertensive drugs in acute </text>
<text top="193" left="899" width="187" height="20" font="1">stroke pts in the first few d did not </text>
<text top="210" left="899" width="81" height="20" font="1">confer benefit. </text>
<text top="435" left="98" width="61" height="20" font="4"><b>ATACH-1  </b></text>
<text top="452" left="98" width="63" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(192)</a> </text>
<text top="469" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19770736?dopt=Citation">19770736</a></text>
<text top="469" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19770736?dopt=Citation"> </a></text>
<text top="435" left="226" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="452" left="226" width="98" height="20" font="1">the feasibility and </text>
<text top="469" left="226" width="96" height="20" font="1">acute (i.e., within </text>
<text top="487" left="226" width="92" height="20" font="1">72 h) safety of 3 </text>
<text top="504" left="226" width="76" height="20" font="1">levels of SBP </text>
<text top="521" left="226" width="67" height="20" font="1">reduction in </text>
<text top="538" left="226" width="74" height="20" font="1">subjects with </text>
<text top="555" left="226" width="102" height="20" font="1">supratentorial ICH </text>
<text top="573" left="226" width="97" height="20" font="1">treated within 6 h </text>
<text top="590" left="226" width="81" height="20" font="1">after symptom </text>
<text top="607" left="226" width="37" height="20" font="1">onset. </text>
<text top="624" left="226" width="3" height="20" font="1"> </text>
<text top="641" left="226" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="659" left="226" width="79" height="20" font="1">Phase I, dose-</text>
<text top="676" left="226" width="62" height="20" font="1">escalation, </text>
<text top="693" left="226" width="64" height="20" font="1">multicenter </text>
<text top="710" left="226" width="103" height="20" font="1">prospective study. </text>
<text top="727" left="226" width="3" height="20" font="1"> </text>
<text top="745" left="226" width="85" height="20" font="4"><b>Study size: </b>60<b> </b></text>
<text top="435" left="348" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="452" left="348" width="96" height="20" font="1">Pts with ICH with </text>
<text top="469" left="348" width="110" height="20" font="1">elevated SBP ≥170 </text>
<text top="487" left="348" width="127" height="20" font="1">mm Hg who presented </text>
<text top="504" left="348" width="124" height="20" font="1">to the ED within 6 h of </text>
<text top="521" left="348" width="90" height="20" font="1">symptom onset. </text>
<text top="538" left="348" width="3" height="20" font="4"><b> </b></text>
<text top="435" left="490" width="49" height="20" font="4"><b>Design:</b> </text>
<text top="452" left="490" width="104" height="20" font="1">● IV nicardipine to </text>
<text top="469" left="490" width="128" height="20" font="1">reduce SBP to a target </text>
<text top="487" left="490" width="21" height="20" font="1">of:  </text>
<text top="504" left="490" width="128" height="20" font="1">#1: 170–200 mm Hg in </text>
<text top="521" left="490" width="115" height="20" font="1">the first cohort of pts </text>
<text top="538" left="490" width="128" height="20" font="1">#2: 140–170 mm Hg in </text>
<text top="555" left="490" width="82" height="20" font="1">the 2nd cohort </text>
<text top="573" left="490" width="128" height="20" font="1">#3: 110–140 mm Hg in </text>
<text top="590" left="490" width="89" height="20" font="1">the third cohort. </text>
<text top="607" left="490" width="111" height="20" font="1">● Each subject was </text>
<text top="624" left="490" width="129" height="20" font="1">followed-up for 3 mo to </text>
<text top="641" left="490" width="111" height="20" font="1">preliminarily assess </text>
<text top="659" left="490" width="94" height="20" font="1">mortality and the </text>
<text top="676" left="490" width="112" height="20" font="1">clinical outcomes. A </text>
<text top="693" left="490" width="122" height="20" font="1">total of 18, 20, and 22 </text>
<text top="710" left="490" width="131" height="20" font="1">pts were enrolled in the </text>
<text top="727" left="490" width="110" height="20" font="1">respective 3 tiers of </text>
<text top="745" left="490" width="120" height="20" font="1">SBP treatment goals.<b> </b></text>
<text top="436" left="637" width="248" height="20" font="4"><b>1</b>°<b> outcome: </b>Treatment feasibility (achieving </text>
<text top="453" left="637" width="242" height="20" font="1">and maintaining the SBP goals for 18–24 h) </text>
<text top="470" left="637" width="3" height="20" font="1"> </text>
<text top="489" left="637" width="82" height="20" font="4"><b>2</b>°<b> outcomes:</b> </text>
<text top="506" left="637" width="224" height="20" font="1">#1: Neurologic deterioration within 24 h;  </text>
<text top="523" left="637" width="218" height="20" font="1">#2: Serious adverse events within 72 h. </text>
<text top="540" left="637" width="3" height="20" font="1"> </text>
<text top="558" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="575" left="637" width="242" height="20" font="1">● Overall, 9 of 60 pts had treatment failures </text>
<text top="592" left="637" width="240" height="20" font="1">(all in the last tier). A total of 7 subjects with </text>
<text top="609" left="637" width="230" height="20" font="1">neurologic deterioration were observed: 1 </text>
<text top="627" left="637" width="238" height="20" font="1">(6%), 2 (10%), and 4 (18%) in tier 1, 2, and </text>
<text top="644" left="637" width="89" height="20" font="1">3, respectively.  </text>
<text top="661" left="637" width="248" height="20" font="1">● Serious adverse events were observed in1 </text>
<text top="678" left="637" width="247" height="20" font="1">subject (5%) in tier 2 and in 3 subjects (14%) </text>
<text top="695" left="637" width="233" height="20" font="1">in tier 3. However, the safety stopping rule </text>
<text top="713" left="637" width="203" height="20" font="1">was not activated in any of the tiers.  </text>
<text top="730" left="637" width="244" height="20" font="1">● 3 (17%), 2 (10%), and 5 (23%) subjects in </text>
<text top="747" left="637" width="232" height="20" font="1">tiers1, 2, and 3, respectively, died within 3 </text>
<text top="764" left="637" width="21" height="20" font="1">mo<b> </b></text>
<text top="435" left="899" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="452" left="899" width="148" height="20" font="1">● Observed proportions of </text>
<text top="469" left="899" width="199" height="20" font="1">neurologic deterioration and serious </text>
<text top="487" left="899" width="173" height="20" font="1">adverse events were below the </text>
<text top="504" left="899" width="194" height="20" font="1">prespecified safety thresholds, and </text>
<text top="521" left="899" width="185" height="20" font="1">the 3-mo mortality rate was lower </text>
<text top="538" left="899" width="171" height="20" font="1">than expected in all SBP tiers.  </text>
<text top="555" left="899" width="182" height="20" font="1">● Results formed the basis of an </text>
<text top="573" left="899" width="173" height="20" font="1">ongoing larger randomized trial </text>
<text top="590" left="899" width="193" height="20" font="1">(ATACH-2) addressing the efficacy </text>
<text top="607" left="899" width="182" height="20" font="1">of SBP reduction in pts with ICH.<b> </b></text>
</page>
<page number="156" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="22" size="12" family="Times" color="#212121"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">156 </text>
<text top="107" left="98" width="80" height="20" font="4"><b>INTERACT-1  </b></text>
<text top="124" left="98" width="113" height="20" font="1">Anderson CS, et al., </text>
<text top="141" left="98" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(193)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18396107?dopt=Citation">18396107</a></text>
<text top="159" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18396107?dopt=Citation"> </a></text>
<text top="107" left="226" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="124" left="226" width="81" height="20" font="1">the safety and </text>
<text top="141" left="226" width="91" height="20" font="1">efficiency of this </text>
<text top="159" left="226" width="85" height="20" font="1">treatment, as a </text>
<text top="176" left="226" width="96" height="20" font="1">run-in phase to a </text>
<text top="193" left="226" width="62" height="20" font="1">larger trial. </text>
<text top="210" left="226" width="3" height="20" font="1"> </text>
<text top="227" left="226" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="245" left="226" width="98" height="20" font="1">Randomized pilot </text>
<text top="262" left="226" width="23" height="20" font="1">trial<b> </b></text>
<text top="279" left="226" width="3" height="20" font="1"> </text>
<text top="296" left="226" width="92" height="20" font="4"><b>Study size: </b>404<b> </b></text>
<text top="107" left="348" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="124" left="348" width="59" height="20" font="1">with acute </text>
<text top="141" left="348" width="98" height="20" font="1">spontaneous ICH </text>
<text top="159" left="348" width="96" height="20" font="1">diagnosed by CT </text>
<text top="176" left="348" width="106" height="20" font="1">within 6 h of onset, </text>
<text top="193" left="348" width="109" height="20" font="1">elevated SBP (150–</text>
<text top="210" left="348" width="116" height="20" font="1">220 mm Hg), and no </text>
<text top="228" left="348" width="113" height="20" font="1">definite indication or </text>
<text top="245" left="348" width="103" height="20" font="1">contraindication to </text>
<text top="262" left="348" width="55" height="20" font="1">treatment<b> </b></text>
<text top="107" left="490" width="132" height="20" font="4"><b>Design:</b> Early intensive </text>
<text top="124" left="490" width="122" height="20" font="1">lowering of BP (target </text>
<text top="141" left="490" width="98" height="20" font="1">SBP 140 mm Hg; </text>
<text top="159" left="490" width="112" height="20" font="1">n=203) vs. standard </text>
<text top="176" left="490" width="90" height="20" font="1">guideline-based </text>
<text top="193" left="490" width="109" height="20" font="1">management of BP </text>
<text top="210" left="490" width="115" height="20" font="1">(target SBP 180 mm </text>
<text top="228" left="490" width="68" height="20" font="1">Hg; n=201).<b> </b></text>
<text top="108" left="637" width="202" height="20" font="4"><b>1</b>°<b> outcome:</b> Proportional change in </text>
<text top="125" left="637" width="149" height="20" font="1">hematoma volume at 24 h. </text>
<text top="143" left="637" width="3" height="20" font="1"> </text>
<text top="161" left="637" width="242" height="20" font="4"><b>2</b>°<b> outcomes:</b> Measurements of hematoma </text>
<text top="178" left="637" width="50" height="20" font="1">volume.  </text>
<text top="195" left="637" width="3" height="20" font="1"> </text>
<text top="213" left="637" width="233" height="20" font="4"><b>Safety and clinical outcomes:</b> Assessed </text>
<text top="230" left="637" width="83" height="20" font="1">for up to 90 d.  </text>
<text top="247" left="637" width="3" height="20" font="1"> </text>
<text top="264" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="281" left="637" width="244" height="20" font="1">● Mean hematoma volumes were smaller in </text>
<text top="299" left="637" width="243" height="20" font="1">the guideline group (12.7 mL, SD 11.6) than </text>
<text top="316" left="637" width="235" height="20" font="1">in the intensive group (14.2 mL, SD 14.5).  </text>
<text top="333" left="637" width="225" height="20" font="1">● From randomization to 1 h, mean SBP </text>
<text top="350" left="637" width="237" height="20" font="1">was 153 mm Hg in the intensive group and </text>
<text top="368" left="637" width="188" height="20" font="1">167 mm Hg in the guideline group </text>
<text top="385" left="637" width="239" height="20" font="1">(difference 13.3 mm Hg (95% CI: 8.9–17.6) </text>
<text top="402" left="637" width="247" height="20" font="1">mm Hg; p&lt;0.0001); from 1 h to 24 h, BP was </text>
<text top="419" left="637" width="235" height="20" font="1">146 mm Hg in the intensive group and 157 </text>
<text top="437" left="637" width="242" height="20" font="1">mm Hg in the guideline group (10.8 mm Hg; </text>
<text top="454" left="637" width="211" height="20" font="1">95% CI: 7.7–13.9 mm Hg; p&lt;0.0001).  </text>
<text top="471" left="637" width="242" height="20" font="1">● Mean proportional hematoma growth was </text>
<text top="488" left="637" width="234" height="20" font="1">36.3% in the guideline group and 13.7% in </text>
<text top="505" left="637" width="239" height="20" font="1">the intensive group (difference 22.6%; 95% </text>
<text top="523" left="637" width="189" height="20" font="1">CI: 0.6%–44.5%; p=0.04) at 24 h.  </text>
<text top="540" left="637" width="216" height="20" font="1">● After adjustment for initial hematoma </text>
<text top="557" left="637" width="236" height="20" font="1">volume and time from onset to CT, median </text>
<text top="574" left="637" width="217" height="20" font="1">hematoma growth differed between the </text>
<text top="591" left="637" width="239" height="20" font="1">groups with p=0.06; the absolute difference </text>
<text top="609" left="637" width="245" height="20" font="1">in volume between groups was 1.7 mL (95% </text>
<text top="626" left="637" width="216" height="20" font="1">CI: -0.5–3.9; p=0.13). RR of hematoma </text>
<text top="643" left="637" width="233" height="20" font="1">growth ≥33% or ≥12.5 mL was 36% lower </text>
<text top="660" left="637" width="238" height="20" font="1">(95% CI: 0%–59%; p=0.05) in the intensive </text>
<text top="677" left="637" width="238" height="20" font="1">group than in the guideline group. Adjusted </text>
<text top="695" left="637" width="220" height="20" font="1">RR: 8% (95% CI: -1.0%–17%; p=0.05).  </text>
<text top="712" left="637" width="231" height="20" font="1">● Intensive BP-lowering treatment did not </text>
<text top="730" left="637" width="248" height="20" font="1">alter the risks of adverse events or 2° clinical </text>
<text top="747" left="637" width="101" height="20" font="1">outcomes at 90 d. </text>
<text top="107" left="899" width="167" height="20" font="4"><b>Summary: </b>Early intensive BP-</text>
<text top="124" left="899" width="166" height="20" font="1">lowering treatment is clinically </text>
<text top="141" left="899" width="200" height="20" font="1">feasible, well tolerated, and appears </text>
<text top="159" left="899" width="201" height="20" font="1">to reduce hematoma growth in ICH. <b> </b></text>
<text top="765" left="98" width="87" height="20" font="1">Hack W, et al.,  </text>
<text top="783" left="98" width="66" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(206)</a>  </text>
<text top="765" left="226" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="783" left="226" width="89" height="20" font="1">the efficacy and </text>
<text top="765" left="348" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="783" left="348" width="7" height="20" font="1">1</text>
<text top="783" left="355" width="7" height="20" font="22">8</text>
<text top="783" left="362" width="7" height="20" font="1">–</text>
<text top="783" left="369" width="80" height="20" font="22">80 y, who had </text>
<text top="765" left="490" width="52" height="20" font="4"><b>Design:</b>  </text>
<text top="766" left="637" width="248" height="20" font="4"><b>1</b>°<b> outcome:</b> Disability at 90 d, dichotomized </text>
<text top="784" left="637" width="245" height="20" font="1">as a favorable outcome (a score of 0 or 1 on </text>
<text top="765" left="899" width="200" height="20" font="4"><b>Summary: </b>Compared with placebo, </text>
<text top="783" left="899" width="202" height="20" font="1">IV alteplase administered between 3 </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="23" size="12" family="Times" color="#212121"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">157 </text>
<text top="107" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18815396?dopt=Citation">18815396</a></text>
<text top="107" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18815396?dopt=Citation"> </a></text>
<text top="107" left="226" width="102" height="20" font="1">safety of alteplase </text>
<text top="124" left="226" width="74" height="20" font="1">administered </text>
<text top="141" left="226" width="105" height="20" font="1">between 3 and 4.5 </text>
<text top="159" left="226" width="106" height="20" font="1">h after the onset of </text>
<text top="176" left="226" width="51" height="20" font="1">a stroke. </text>
<text top="193" left="226" width="3" height="20" font="1"> </text>
<text top="210" left="226" width="99" height="20" font="4"><b>Study type: </b>RCT<b> </b></text>
<text top="227" left="226" width="3" height="20" font="1"> </text>
<text top="245" left="226" width="92" height="20" font="4"><b>Study size: </b>821 </text>
<text top="262" left="226" width="20" height="20" font="1">pts </text>
<text top="107" left="348" width="100" height="20" font="22">received a clinical </text>
<text top="124" left="348" width="102" height="20" font="22">diagnosis of acute </text>
<text top="141" left="348" width="115" height="20" font="22">ischemic stroke, and </text>
<text top="159" left="348" width="113" height="20" font="22">were able to receive </text>
<text top="176" left="348" width="116" height="20" font="22">the study drug within </text>
<text top="193" left="348" width="7" height="20" font="22">3</text>
<text top="193" left="355" width="7" height="20" font="1">–</text>
<text top="193" left="362" width="103" height="20" font="22">4 h after the onset </text>
<text top="210" left="348" width="76" height="20" font="22">of symptoms. </text>
<text top="227" left="348" width="3" height="20" font="22"> </text>
<text top="245" left="348" width="110" height="20" font="23"><b>Exclusion criteria:</b> </text>
<text top="262" left="348" width="116" height="20" font="22">SBP &gt;185 mm Hg or </text>
<text top="279" left="348" width="117" height="20" font="22">DBP &gt;110 mm Hg or </text>
<text top="296" left="348" width="118" height="20" font="22">aggressive treatment </text>
<text top="314" left="348" width="4" height="20" font="22">(</text>
<text top="314" left="352" width="12" height="20" font="1">IV</text>
<text top="314" left="364" width="70" height="20" font="22"> medication) </text>
<text top="331" left="348" width="114" height="20" font="22">necessary to reduce </text>
<text top="348" left="348" width="95" height="20" font="22">BP to these limits</text>
<text top="348" left="443" width="3" height="20" font="1"> </text>
<text top="365" left="348" width="3" height="20" font="1"> </text>
<text top="107" left="490" width="12" height="20" font="1">● </text>
<text top="107" left="502" width="93" height="20" font="22">Eligible pts were </text>
<text top="124" left="490" width="127" height="20" font="22">randomly assigned 1:1 </text>
<text top="141" left="490" width="111" height="20" font="22">to receive 0.9 mg of </text>
<text top="159" left="490" width="94" height="20" font="22">alteplase per kg, </text>
<text top="176" left="490" width="74" height="20" font="22">administered </text>
<text top="176" left="564" width="12" height="20" font="1">IV</text>
<text top="176" left="575" width="33" height="20" font="22"> (with </text>
<text top="193" left="490" width="108" height="20" font="22">an upper limit of 90 </text>
<text top="210" left="490" width="92" height="20" font="22">mg), or placebo. </text>
<text top="227" left="490" width="12" height="20" font="1">● </text>
<text top="227" left="502" width="74" height="20" font="22">418 pts were </text>
<text top="245" left="490" width="109" height="20" font="22">assigned to receive </text>
<text top="262" left="490" width="120" height="20" font="22">alteplase and 403 pts </text>
<text top="279" left="490" width="96" height="20" font="22">were assigned to </text>
<text top="296" left="490" width="86" height="20" font="22">receive placebo</text>
<text top="296" left="576" width="3" height="20" font="1"> </text>
<text top="107" left="637" width="216" height="20" font="1">the modified Rankin scale, which has a </text>
<text top="124" left="637" width="243" height="20" font="1">range of 0–6, with 0 indicating no symptoms </text>
<text top="141" left="637" width="189" height="20" font="1">at all and 6 indicating death) or an </text>
<text top="159" left="637" width="241" height="20" font="1">unfavorable outcome (a score of 2–6 on the </text>
<text top="176" left="637" width="135" height="20" font="1">modified Rankin scale).  </text>
<text top="193" left="637" width="3" height="20" font="1"> </text>
<text top="210" left="637" width="232" height="20" font="4"><b>2º outcome:</b> global outcome analysis of 4 </text>
<text top="227" left="637" width="238" height="20" font="1">neurologic and disability scores combined.  </text>
<text top="245" left="637" width="3" height="20" font="1"> </text>
<text top="262" left="637" width="216" height="20" font="4"><b>Safety outcomes:</b> death, symptomatic </text>
<text top="279" left="637" width="235" height="20" font="1">intracranial hemorrhage, and other serious </text>
<text top="296" left="637" width="90" height="20" font="1">adverse events. </text>
<text top="314" left="637" width="3" height="20" font="1"> </text>
<text top="331" left="637" width="85" height="20" font="4"><b>Key findings:  </b></text>
<text top="348" left="637" width="228" height="20" font="1">● More pts had a favorable outcome with </text>
<text top="365" left="637" width="213" height="20" font="1">alteplase than with placebo (52.4% vs. </text>
<text top="382" left="637" width="206" height="20" font="1">45.2%; OR: 1.34; 95% CI: 1.02–1.76; </text>
<text top="400" left="637" width="48" height="20" font="1">p=0.04. <b> </b></text>
<text top="417" left="637" width="248" height="20" font="1">● Incidence of ICH was higher with alteplase </text>
<text top="434" left="637" width="229" height="20" font="1">than with placebo (for any ICH, 27.0% vs. </text>
<text top="451" left="637" width="247" height="20" font="1">17.6%; p=0.001; for symptomatic intracranial </text>
<text top="469" left="637" width="218" height="20" font="1">hemorrhage, 2.4% vs. 0.2%; p=0.008).  </text>
<text top="486" left="637" width="201" height="20" font="1">● Mortality did not differ significantly </text>
<text top="503" left="637" width="235" height="20" font="1">between the alteplase and placebo groups </text>
<text top="520" left="637" width="219" height="20" font="1">(7.7% and 8.4%, respectively; p=0.68).  </text>
<text top="537" left="637" width="219" height="20" font="1">● No significant difference in the rate of </text>
<text top="555" left="637" width="165" height="20" font="1">other serious adverse events. </text>
<text top="107" left="899" width="150" height="20" font="1">and 4.5 h after the onset of </text>
<text top="124" left="899" width="180" height="20" font="1">symptoms significantly improved </text>
<text top="141" left="899" width="189" height="20" font="1">clinical outcomes in pts with acute </text>
<text top="159" left="899" width="201" height="20" font="1">ischemic stroke; alteplase was more </text>
<text top="176" left="899" width="145" height="20" font="1">frequently associated with </text>
<text top="193" left="899" width="100" height="20" font="1">symptomatic ICH. </text>
<text top="573" left="98" width="112" height="20" font="1">NINDS rt-PA Stroke </text>
<text top="590" left="98" width="107" height="20" font="1">Study Group, 1995 </text>
<text top="607" left="98" width="36" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(207)</a>  </text>
<text top="624" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7477192?dopt=Citation">7477192</a></text>
<text top="624" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7477192?dopt=Citation"> </a></text>
<text top="573" left="226" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="590" left="226" width="20" height="20" font="1">the </text>
<text top="590" left="246" width="70" height="20" font="22">difference in </text>
<text top="607" left="226" width="85" height="20" font="22">clinical efficacy </text>
<text top="624" left="226" width="65" height="20" font="22">between IV </text>
<text top="624" left="291" width="24" height="20" font="1">t-PA</text>
<text top="624" left="315" width="3" height="20" font="22"> </text>
<text top="641" left="226" width="70" height="20" font="22">and placebo </text>
<text top="659" left="226" width="103" height="20" font="22">among pts with an </text>
<text top="676" left="226" width="85" height="20" font="22">acute ischemic </text>
<text top="693" left="226" width="33" height="20" font="22">stroke</text>
<text top="693" left="259" width="3" height="20" font="1"> </text>
<text top="710" left="226" width="3" height="20" font="1"> </text>
<text top="727" left="226" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="745" left="226" width="101" height="20" font="1">Double-blind RCT<b> </b></text>
<text top="762" left="226" width="3" height="20" font="1"> </text>
<text top="573" left="348" width="114" height="20" font="4"><b>Inclusion criteria: </b>P</text>
<text top="573" left="462" width="13" height="20" font="22">ts </text>
<text top="590" left="348" width="93" height="20" font="22">with an ischemic </text>
<text top="607" left="348" width="111" height="20" font="22">stroke with a clearly </text>
<text top="624" left="348" width="118" height="20" font="22">defined time of onset </text>
<text top="641" left="348" width="85" height="20" font="22">(&lt;3 h), a deficit </text>
<text top="659" left="348" width="105" height="20" font="22">measurable on the </text>
<text top="676" left="348" width="90" height="20" font="1">NIH stroke scale</text>
<text top="676" left="438" width="31" height="20" font="22">, and </text>
<text top="693" left="348" width="126" height="20" font="22">a base-line CT scan of </text>
<text top="710" left="348" width="121" height="20" font="22">the brain that showed </text>
<text top="727" left="348" width="111" height="20" font="22">no evidence of ICH. </text>
<text top="745" left="348" width="3" height="20" font="22"> </text>
<text top="762" left="348" width="110" height="20" font="23"><b>Exclusion criteria: </b></text>
<text top="573" left="490" width="102" height="20" font="4"><b>Design:</b> RCT with </text>
<text top="590" left="490" width="121" height="20" font="1">acute ischemic stroke </text>
<text top="607" left="490" width="128" height="20" font="1">pts randomized to t-PA </text>
<text top="624" left="490" width="66" height="20" font="1">vs. placebo </text>
<text top="574" left="637" width="217" height="20" font="4"><b>1</b>°<b> outcome:</b> Clinical outcome at 3 mo, </text>
<text top="591" left="637" width="226" height="20" font="1">according to scores on the Barthel index, </text>
<text top="608" left="637" width="229" height="20" font="1">modified Rankin scale, Glasgow outcome </text>
<text top="625" left="637" width="157" height="20" font="1">scale, and NIH stroke scale: </text>
<text top="643" left="637" width="3" height="20" font="1"> </text>
<text top="660" left="637" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="677" left="637" width="236" height="20" font="1">● As compared with pts given placebo, pts </text>
<text top="694" left="637" width="227" height="20" font="1">treated with t-PA were at least 30% more </text>
<text top="711" left="637" width="247" height="20" font="1">likely to have minimal or no disability at 3 mo </text>
<text top="729" left="637" width="152" height="20" font="1">on the assessment scales.  </text>
<text top="746" left="637" width="222" height="20" font="1">● Symptomatic ICH within 36 h after the </text>
<text top="763" left="637" width="246" height="20" font="1">onset of stroke occurred in 6.4% of pts given </text>
<text top="573" left="899" width="182" height="20" font="4"><b>Summary: </b>Despite an increased </text>
<text top="590" left="899" width="169" height="20" font="1">incidence of symptomatic ICH, </text>
<text top="607" left="899" width="192" height="20" font="1">treatment with IV t-PA within 3 h of </text>
<text top="624" left="899" width="156" height="20" font="1">the onset of ischemic stroke </text>
<text top="641" left="899" width="189" height="20" font="1">improved clinical outcome at 3 mo </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="24" size="12" family="Times" color="#121212"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">158 </text>
<text top="107" left="226" width="92" height="20" font="4"><b>Study size: </b>624 </text>
<text top="124" left="226" width="20" height="20" font="1">pts </text>
<text top="107" left="348" width="116" height="20" font="22">SBP &gt;185 mm Hg or </text>
<text top="124" left="348" width="99" height="20" font="22">DBP &gt;110 mm Hg</text>
<text top="124" left="448" width="3" height="20" font="1"> </text>
<text top="107" left="637" width="218" height="20" font="1">t-PA but only 0.6% of pts given placebo </text>
<text top="124" left="637" width="63" height="20" font="1">(p&lt;0.001).  </text>
<text top="141" left="637" width="221" height="20" font="1">● Mortality at 3 mo was 17% in the t-PA </text>
<text top="159" left="637" width="248" height="20" font="1">group and 2% in the placebo group (p=0.30). </text>
<text top="178" left="108" width="3" height="19" font="1"> </text>
<text top="212" left="81" width="588" height="24" font="3"><b>Data Supplement 43. RCTs Comparing Secondary Stroke Prevention (Section 9.4.3) </b></text>
<text top="252" left="100" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="269" left="125" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="287" left="103" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="252" left="238" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="269" left="243" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="287" left="237" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="252" left="381" width="44" height="20" font="4"><b>Patient </b></text>
<text top="269" left="370" width="67" height="20" font="4"><b>Population </b></text>
<text top="252" left="464" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="269" left="480" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="287" left="464" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="304" left="485" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="252" left="654" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="269" left="638" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="287" left="620" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="253" left="871" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="271" left="904" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="288" left="880" width="163" height="20" font="4"><b>Adverse Events; Summary  </b></text>
<text top="322" left="98" width="66" height="20" font="1">Post-stroke </text>
<text top="339" left="98" width="94" height="20" font="1">Antihypertensive </text>
<text top="356" left="98" width="94" height="20" font="1">Treatment Study<b> </b></text>
<text top="373" left="98" width="75" height="20" font="4"><b>(PATS) </b>1995 </text>
<text top="391" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(208)</a> </text>
<text top="408" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8575241?dopt=Citation">8575241</a></text>
<text top="408" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8575241?dopt=Citation"> </a></text>
<text top="322" left="214" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="339" left="214" width="116" height="20" font="1">whether lowering BP </text>
<text top="356" left="214" width="71" height="20" font="1">prevents the </text>
<text top="373" left="214" width="126" height="20" font="1">recurrence of stroke in </text>
<text top="391" left="214" width="93" height="20" font="1">Chinese pts with </text>
<text top="408" left="214" width="53" height="20" font="1">history of </text>
<text top="425" left="214" width="91" height="20" font="1">cerebrovascular </text>
<text top="442" left="214" width="46" height="20" font="1">disease </text>
<text top="460" left="214" width="3" height="20" font="1"> </text>
<text top="477" left="214" width="114" height="20" font="4"><b>Study type:</b> Double-</text>
<text top="494" left="214" width="62" height="20" font="1">blind RCT  </text>
<text top="511" left="214" width="3" height="20" font="1"> </text>
<text top="528" left="214" width="86" height="20" font="4"><b>Size:</b> 5,665 pts </text>
<text top="322" left="359" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="339" left="359" width="70" height="20" font="4"><b>criteria:</b> Pts </text>
<text top="356" left="359" width="78" height="20" font="1">with history of </text>
<text top="373" left="359" width="74" height="20" font="1">stroke or TIA </text>
<text top="391" left="359" width="3" height="20" font="1"> </text>
<text top="408" left="359" width="62" height="20" font="4"><b>Exclusion </b></text>
<text top="425" left="359" width="73" height="20" font="4"><b>criteria:</b> N/A </text>
<text top="322" left="460" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="339" left="460" width="109" height="20" font="1">Indapamide 2.5 mg </text>
<text top="356" left="460" width="105" height="20" font="1">daily (n=2,840 pts) </text>
<text top="373" left="460" width="3" height="20" font="1"> </text>
<text top="391" left="460" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="408" left="460" width="100" height="20" font="1">Placebo (n=2,825 </text>
<text top="425" left="460" width="24" height="20" font="1">pts) </text>
<text top="323" left="592" width="196" height="20" font="4"><b>1</b>°<b> outcome</b>: Recurrence of fatal or </text>
<text top="340" left="592" width="87" height="20" font="1">nonfatal stroke. </text>
<text top="357" left="592" width="3" height="20" font="4"><b> </b></text>
<text top="375" left="592" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="392" left="592" width="226" height="20" font="1">Average SBP/DBP at randomization was </text>
<text top="409" left="592" width="219" height="20" font="1">153.8/92.8 mm Hg. At median follow-up </text>
<text top="426" left="592" width="226" height="20" font="1">(2 y), BP was 6.8/3.3 mm Hg lower in pts </text>
<text top="444" left="592" width="115" height="20" font="1">on active treatment.  </text>
<text top="461" left="592" width="208" height="20" font="1">143 pts on indapamide vs. 219 pts on </text>
<text top="478" left="592" width="226" height="20" font="1">placebo had recurrent strokes (HR: 0.69; </text>
<text top="495" left="592" width="168" height="20" font="1">95% CI: 0.54–0.89; p&lt;0.001).  </text>
<text top="323" left="835" width="78" height="20" font="4"><b>2</b>°<b> outcome</b>:  </text>
<text top="340" left="835" width="205" height="20" font="1">● Major fatal and nonfatal CV events </text>
<text top="357" left="835" width="239" height="20" font="1">In addition, 199 pts on indapamide and 258 </text>
<text top="375" left="835" width="231" height="20" font="1">pts on placebo had a CV event (HR: 0.75; </text>
<text top="392" left="835" width="165" height="20" font="1">95% CI: 0.89–0.62; p=0.002). </text>
<text top="409" left="835" width="231" height="20" font="1">● 2,825 pts received a placebo and 2,840 </text>
<text top="426" left="835" width="77" height="20" font="1">pts received.  </text>
<text top="444" left="835" width="3" height="20" font="1"> </text>
<text top="461" left="835" width="245" height="20" font="4"><b>Summary</b>: For pts with a history of stroke or </text>
<text top="478" left="835" width="243" height="20" font="1">TIA, BP reduction of 5/2 mm Hg with 2.5 mg </text>
<text top="495" left="835" width="240" height="20" font="1">of indapamide lowered the first incidence of </text>
<text top="512" left="835" width="228" height="20" font="1">fatal and nonfatal stroke by 29%, with 3-y </text>
<text top="530" left="835" width="239" height="20" font="1">absolute benefit of 29 events per 1,000 pts. </text>
<text top="557" left="98" width="73" height="20" font="24"><b>PROGRESS </b></text>
<text top="574" left="98" width="63" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(209)</a> </text>
<text top="591" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11589932?dopt=Citation">11589932</a></text>
<text top="591" left="152" width="7" height="20" font="19"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11589932?dopt=Citation">  </a></text>
<text top="557" left="214" width="106" height="20" font="4"><b>Aim</b>: To determine </text>
<text top="574" left="214" width="84" height="20" font="1">effects of a BP-</text>
<text top="591" left="214" width="110" height="20" font="1">lowering regimen in </text>
<text top="608" left="214" width="97" height="20" font="1">hypertensive and </text>
<text top="625" left="214" width="113" height="20" font="1">nonhypertensive pts </text>
<text top="643" left="214" width="126" height="20" font="1">with a history of stroke </text>
<text top="660" left="214" width="40" height="20" font="1">or TIA. </text>
<text top="677" left="214" width="3" height="20" font="1"> </text>
<text top="694" left="214" width="114" height="20" font="4"><b>Study type:</b> Double-</text>
<text top="711" left="214" width="80" height="20" font="1">blind, placebo-</text>
<text top="729" left="214" width="80" height="20" font="1">controlled trial </text>
<text top="746" left="214" width="3" height="20" font="1"> </text>
<text top="763" left="214" width="66" height="20" font="4"><b>Size:</b> 6,105 </text>
<text top="557" left="359" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="574" left="359" width="70" height="20" font="4"><b>criteria:</b> Pts </text>
<text top="591" left="359" width="79" height="20" font="1">with history of </text>
<text top="608" left="359" width="37" height="20" font="1">stroke </text>
<text top="625" left="359" width="87" height="20" font="1">(evidence of an </text>
<text top="643" left="359" width="33" height="20" font="1">acute </text>
<text top="660" left="359" width="81" height="20" font="1">disturbance of </text>
<text top="677" left="359" width="29" height="20" font="1">focal </text>
<text top="694" left="359" width="70" height="20" font="1">neurological </text>
<text top="711" left="359" width="72" height="20" font="1">function with </text>
<text top="729" left="359" width="59" height="20" font="1">symptoms </text>
<text top="746" left="359" width="70" height="20" font="1">lasting more </text>
<text top="763" left="359" width="79" height="20" font="1">than 24 h and </text>
<text top="557" left="460" width="115" height="20" font="4"><b>Intervention:</b> Active </text>
<text top="574" left="460" width="116" height="20" font="1">treatment comprised </text>
<text top="591" left="460" width="100" height="20" font="1">a flexible regimen </text>
<text top="608" left="460" width="107" height="20" font="1">based on the ACEI </text>
<text top="625" left="460" width="96" height="20" font="1">perindopril (4 mg </text>
<text top="643" left="460" width="108" height="20" font="1">daily), with addition </text>
<text top="660" left="460" width="57" height="20" font="1">of diuretic </text>
<text top="677" left="460" width="81" height="20" font="1">indapamide at </text>
<text top="694" left="460" width="114" height="20" font="1">discretion of treating </text>
<text top="711" left="460" width="117" height="20" font="1">physicians (n=3,051) </text>
<text top="729" left="460" width="3" height="20" font="1"> </text>
<text top="746" left="460" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="763" left="460" width="104" height="20" font="1">Placebo (n=3,054) </text>
<text top="558" left="592" width="188" height="20" font="4"><b>1</b>°<b> outcome:</b> Total stroke (fatal or </text>
<text top="575" left="592" width="51" height="20" font="1">nonfatal) </text>
<text top="592" left="592" width="3" height="20" font="4"><b> </b></text>
<text top="609" left="592" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="627" left="592" width="223" height="20" font="1">● Over 4 y of follow-up, active treatment </text>
<text top="644" left="592" width="211" height="20" font="1">reduced BP by 9/4 mm Hg. 307 (10%) </text>
<text top="661" left="592" width="222" height="20" font="1">pts assigned active treatment suffered a </text>
<text top="678" left="592" width="219" height="20" font="1">stroke, vs. 420 (14%) assigned placebo </text>
<text top="695" left="592" width="207" height="20" font="1">(RR reduction: 28% (95% CI: 17, 38), </text>
<text top="713" left="592" width="66" height="20" font="1">p&lt;0.0001).  </text>
<text top="730" left="592" width="215" height="20" font="1">● Combination therapy with perindopril </text>
<text top="747" left="592" width="228" height="20" font="1">plus indapamide reduced BP by 12/5 mm </text>
<text top="764" left="592" width="198" height="20" font="1">Hg and stroke risk by 43% (95% CI: </text>
<text top="781" left="592" width="226" height="20" font="1">30%–54%). Single-drug therapy reduced </text>
<text top="558" left="835" width="134" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:  </b></text>
<text top="575" left="835" width="223" height="20" font="1">Active treatment also reduced the risk of </text>
<text top="592" left="835" width="234" height="20" font="1">total major vascular events (26% [16–34]). </text>
<text top="609" left="835" width="235" height="20" font="1">There were similar reductions in the risk of </text>
<text top="627" left="835" width="241" height="20" font="1">stroke in hypertensive and nonhypertensive </text>
<text top="644" left="835" width="130" height="20" font="1">subgroups (all p&lt;0.01). </text>
<text top="661" left="835" width="3" height="20" font="1"> </text>
<text top="678" left="835" width="66" height="20" font="4"><b>Summary</b>:  </text>
<text top="695" left="835" width="248" height="20" font="1">● This BP-lowering regimen reduced the risk </text>
<text top="713" left="835" width="216" height="20" font="1">of stroke among both hypertensive and </text>
<text top="730" left="835" width="239" height="20" font="1">nonhypertensive pts with a history of stroke </text>
<text top="747" left="835" width="243" height="20" font="1">or TIA. Combination therapy with perindopril </text>
<text top="764" left="835" width="200" height="20" font="1">and indapamide produced larger BP </text>
</page>
<page number="159" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">159 </text>
<text top="107" left="359" width="75" height="20" font="1">thought to be </text>
<text top="124" left="359" width="76" height="20" font="1">due to ICH or </text>
<text top="141" left="359" width="70" height="20" font="1">ischemia) or </text>
<text top="159" left="359" width="78" height="20" font="1">TIA within the </text>
<text top="176" left="359" width="73" height="20" font="1">previous 5 y. </text>
<text top="193" left="359" width="3" height="20" font="1"> </text>
<text top="210" left="359" width="62" height="20" font="4"><b>Exclusion </b></text>
<text top="227" left="359" width="73" height="20" font="4"><b>criteria:</b> N/A </text>
<text top="245" left="359" width="3" height="20" font="1"> </text>
<text top="262" left="359" width="83" height="20" font="1">● Pts clinically </text>
<text top="279" left="359" width="68" height="20" font="1">stable for at </text>
<text top="296" left="359" width="86" height="20" font="1">least 2 wk after </text>
<text top="314" left="359" width="57" height="20" font="1">their most </text>
<text top="331" left="359" width="87" height="20" font="1">recent vascular </text>
<text top="348" left="359" width="72" height="20" font="1">event before </text>
<text top="365" left="359" width="65" height="20" font="1">entry to the </text>
<text top="382" left="359" width="36" height="20" font="1">study. </text>
<text top="107" left="592" width="196" height="20" font="1">BP by 5/3 mm Hg and produced no </text>
<text top="124" left="592" width="190" height="20" font="1">discernable reduction in the risk of </text>
<text top="141" left="592" width="40" height="20" font="1">stroke. </text>
<text top="107" left="835" width="229" height="20" font="1">reductions and larger risk reductions than </text>
<text top="124" left="835" width="235" height="20" font="1">single drug therapy with perindopril alone.  </text>
<text top="141" left="835" width="209" height="20" font="1">● This trial showed the benefits of BP </text>
<text top="159" left="835" width="241" height="20" font="1">lowering in both hypertensive pts. However, </text>
<text top="176" left="835" width="215" height="20" font="1">based on older definitions, presence of </text>
<text top="193" left="835" width="220" height="20" font="1">baseline HTN in the trial was defined as </text>
<text top="210" left="835" width="96" height="20" font="1">≥160/90 mm Hg. </text>
<text top="400" left="98" width="48" height="20" font="4"><b>MOSES </b></text>
<text top="418" left="98" width="100" height="20" font="1">Schrader J, et al., </text>
<text top="435" left="98" width="63" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(210)</a> </text>
<text top="452" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15879332?dopt=Citation">15879332</a></text>
<text top="452" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15879332?dopt=Citation"> </a></text>
<text top="400" left="214" width="131" height="20" font="4"><b>Aim:</b> To assess among </text>
<text top="418" left="214" width="110" height="20" font="1">hypertensive stroke </text>
<text top="435" left="214" width="109" height="20" font="1">pts, whether for the </text>
<text top="452" left="214" width="96" height="20" font="1">same level of BP </text>
<text top="469" left="214" width="106" height="20" font="1">control, eprosartan </text>
<text top="487" left="214" width="84" height="20" font="1">would be more </text>
<text top="504" left="214" width="76" height="20" font="1">effective than </text>
<text top="521" left="214" width="131" height="20" font="1">nitrendipine in reducing </text>
<text top="538" left="214" width="115" height="20" font="1">cerebrovascular and </text>
<text top="555" left="214" width="98" height="20" font="1">CV morbidity and </text>
<text top="573" left="214" width="53" height="20" font="1">mortality. </text>
<text top="590" left="214" width="3" height="20" font="1"> </text>
<text top="607" left="214" width="117" height="20" font="4"><b>Study type:</b> PROBE </text>
<text top="624" left="214" width="40" height="20" font="1">design </text>
<text top="641" left="214" width="3" height="20" font="1"> </text>
<text top="659" left="214" width="66" height="20" font="4"><b>Size:</b> 1,405<b> </b></text>
<text top="400" left="359" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="418" left="359" width="78" height="20" font="4"><b>criteria:</b> High-</text>
<text top="435" left="359" width="22" height="20" font="1">risk </text>
<text top="452" left="359" width="79" height="20" font="1">hypertensives </text>
<text top="469" left="359" width="73" height="20" font="1">with cerebral </text>
<text top="487" left="359" width="71" height="20" font="1">event during </text>
<text top="504" left="359" width="81" height="20" font="1">the last 24 mo </text>
<text top="521" left="359" width="62" height="20" font="1">(proven by </text>
<text top="538" left="359" width="68" height="20" font="1">cerebral CT </text>
<text top="555" left="359" width="87" height="20" font="1">scan or nuclear </text>
<text top="573" left="359" width="53" height="20" font="1">magnetic </text>
<text top="590" left="359" width="65" height="20" font="1">resonance) </text>
<text top="607" left="359" width="3" height="20" font="1"> </text>
<text top="624" left="359" width="62" height="20" font="4"><b>Exclusion </b></text>
<text top="641" left="359" width="48" height="20" font="4"><b>criteria:</b> </text>
<text top="659" left="359" width="85" height="20" font="1">Internal carotid </text>
<text top="676" left="359" width="35" height="20" font="1">artery </text>
<text top="693" left="359" width="69" height="20" font="1">occlusion or </text>
<text top="710" left="359" width="87" height="20" font="1">stenosis &gt;70%, </text>
<text top="727" left="359" width="70" height="20" font="1">manifest HF </text>
<text top="745" left="359" width="76" height="20" font="1">(NYHA grade </text>
<text top="762" left="359" width="88" height="20" font="1">III–IV), age &gt;85 </text>
<text top="779" left="359" width="84" height="20" font="1">y at the time of </text>
<text top="400" left="460" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="418" left="460" width="108" height="20" font="1">Eprosartan 600 mg </text>
<text top="435" left="460" width="46" height="20" font="1">(n=681) </text>
<text top="452" left="460" width="3" height="20" font="1"> </text>
<text top="469" left="460" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="487" left="460" width="107" height="20" font="1">Nitrendipine 10 mg </text>
<text top="504" left="460" width="46" height="20" font="1">(n=671) </text>
<text top="402" left="592" width="228" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite of total mortality </text>
<text top="419" left="592" width="218" height="20" font="1">and all CV and cerebrovascular events, </text>
<text top="436" left="592" width="163" height="20" font="1">including all recurrent events. </text>
<text top="453" left="592" width="3" height="20" font="4"><b> </b></text>
<text top="470" left="592" width="163" height="20" font="4"><b>Key findings: </b>BP reduced to </text>
<text top="488" left="592" width="205" height="20" font="1">comparable extent without significant </text>
<text top="505" left="592" width="202" height="20" font="1">differences between 2 groups during </text>
<text top="522" left="592" width="188" height="20" font="1">study period (150.7/84 mm Hg vs. </text>
<text top="539" left="592" width="216" height="20" font="1">152.0/87.2 mm Hg with eprosartan and </text>
<text top="557" left="592" width="230" height="20" font="1">nitrendipine therapy to 137.5/80.8 mm Hg </text>
<text top="574" left="592" width="208" height="20" font="1">and 136.0/80.2 mm Hg, respectively). </text>
<text top="591" left="592" width="216" height="20" font="1">75.5% reached values &lt;140/90 mm Hg </text>
<text top="608" left="592" width="223" height="20" font="1">with eprosartan regimen and 77.7% with </text>
<text top="625" left="592" width="206" height="20" font="1">nitrendipine. During follow-up, 461 1° </text>
<text top="643" left="592" width="228" height="20" font="1">events occurred: 206 eprosartan and 255 </text>
<text top="660" left="592" width="208" height="20" font="1">nitrendipine (IDR: 0.79; 95% CI: 0.66–</text>
<text top="677" left="592" width="86" height="20" font="1">0.96; p=0.014.  </text>
<text top="402" left="835" width="241" height="20" font="4"><b>Relevant 2</b>°<b> endpoint: </b>CV events were: 77 </text>
<text top="419" left="835" width="240" height="20" font="1">eprosartan and 101 nitrendipine (IDR: 0.75; </text>
<text top="436" left="835" width="249" height="20" font="1">95% CI: 0.55–1.02; p=0.06); cerebrovascular </text>
<text top="453" left="835" width="241" height="20" font="1">events: 102 eprosartan and134 nitrendipine </text>
<text top="470" left="835" width="221" height="20" font="1">(IDR: 0.75; 95% CI: 0.58–0.97; p=0.03). </text>
<text top="488" left="835" width="3" height="20" font="4"><b> </b></text>
<text top="505" left="835" width="63" height="20" font="4"><b>Summary</b>: </text>
<text top="522" left="835" width="186" height="20" font="1">● The combined 1° endpoint was </text>
<text top="539" left="835" width="234" height="20" font="1">significantly lower in the eprosartan group. </text>
<text top="557" left="835" width="233" height="20" font="1">● However, it was a reduction in TIAs that </text>
<text top="574" left="835" width="196" height="20" font="1">accounted for most of the benefit in </text>
<text top="591" left="835" width="234" height="20" font="1">cerebrovascular events, with no significant </text>
<text top="608" left="835" width="172" height="20" font="1">difference in ischemic strokes.  </text>
<text top="625" left="835" width="240" height="20" font="1">● Also a more traditional analysis of time to </text>
<text top="643" left="835" width="230" height="20" font="1">first cerebrovascular event did not show a </text>
<text top="660" left="835" width="120" height="20" font="1">benefit of eprosartan.<b> </b></text>
</page>
<page number="160" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">160 </text>
<text top="107" left="359" width="20" height="20" font="1">the </text>
<text top="124" left="359" width="83" height="20" font="1">cerebrovascula</text>
<text top="141" left="359" width="64" height="20" font="1">r event, pts </text>
<text top="159" left="359" width="67" height="20" font="1">treated with </text>
<text top="176" left="359" width="83" height="20" font="1">anticoagulants </text>
<text top="193" left="359" width="71" height="20" font="1">for a cardiac </text>
<text top="210" left="359" width="65" height="20" font="1">arrhythmia, </text>
<text top="228" left="359" width="62" height="20" font="1">high-grade </text>
<text top="245" left="359" width="81" height="20" font="1">aortic or mitral </text>
<text top="262" left="359" width="84" height="20" font="1">valve stenosis, </text>
<text top="279" left="359" width="85" height="20" font="1">or UA pectoris.<b> </b></text>
<text top="297" left="98" width="62" height="20" font="4"><b>PROFESS </b></text>
<text top="314" left="98" width="83" height="20" font="1">Yusuf S, et al., </text>
<text top="332" left="98" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(211)</a> </text>
<text top="349" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18753639?dopt=Citation">18753639</a></text>
<text top="349" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18753639?dopt=Citation"> </a></text>
<text top="349" left="156" width="3" height="20" font="19"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18753639?dopt=Citation"> </a></text>
<text top="297" left="214" width="119" height="20" font="4"><b>Aim:</b> To evaluate the </text>
<text top="314" left="214" width="123" height="20" font="1">effects of therapy with </text>
<text top="332" left="214" width="116" height="20" font="1">an ARB, telmisartan, </text>
<text top="349" left="214" width="114" height="20" font="1">initiated early after a </text>
<text top="366" left="214" width="37" height="20" font="1">stroke </text>
<text top="383" left="214" width="3" height="20" font="1"> </text>
<text top="400" left="214" width="114" height="20" font="4"><b>Study type:</b> Double-</text>
<text top="418" left="214" width="62" height="20" font="1">blind RCT  </text>
<text top="435" left="214" width="3" height="20" font="1"> </text>
<text top="452" left="214" width="93" height="20" font="4"><b>Size:</b> 20,332 pts<b> </b></text>
<text top="297" left="359" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="314" left="359" width="70" height="20" font="4"><b>criteria:</b> Pts </text>
<text top="332" left="359" width="77" height="20" font="1">≥55 y with an </text>
<text top="349" left="359" width="88" height="20" font="1">ischemic stroke </text>
<text top="366" left="359" width="73" height="20" font="1">&lt;90 d before </text>
<text top="383" left="359" width="81" height="20" font="1">randomization </text>
<text top="400" left="359" width="3" height="20" font="1"> </text>
<text top="418" left="359" width="62" height="20" font="4"><b>Exclusion </b></text>
<text top="435" left="359" width="65" height="20" font="4"><b>criteria:</b> 1° </text>
<text top="452" left="359" width="72" height="20" font="1">hemorrhagic </text>
<text top="469" left="359" width="81" height="20" font="1">stroke, severe </text>
<text top="487" left="359" width="78" height="20" font="1">disability after </text>
<text top="504" left="359" width="76" height="20" font="1">the qualifying </text>
<text top="521" left="359" width="37" height="20" font="1">stroke<b> </b></text>
<text top="297" left="460" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="314" left="460" width="105" height="20" font="1">Telmisartan 80 mg </text>
<text top="332" left="460" width="92" height="20" font="1">daily (n=10,146) </text>
<text top="349" left="460" width="3" height="20" font="1"> </text>
<text top="366" left="460" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="383" left="460" width="111" height="20" font="1">Placebo (n=10,186)<b> </b></text>
<text top="298" left="592" width="170" height="20" font="4"><b>1</b>°<b> endpoint:</b> Recurrent stroke </text>
<text top="316" left="592" width="3" height="20" font="4"><b> </b></text>
<text top="333" left="592" width="221" height="20" font="4"><b>Key findings: </b>During mean follow-up of </text>
<text top="350" left="592" width="230" height="20" font="1">2.5 y, mean BP was 3.8/2.0 mm Hg lower </text>
<text top="367" left="592" width="215" height="20" font="1">in telmisartan group vs. placebo group. </text>
<text top="384" left="592" width="214" height="20" font="1">880 pts (8.7%) in telmisartan group vs. </text>
<text top="402" left="592" width="212" height="20" font="1">934 pts (9.2%) in placebo group had a </text>
<text top="419" left="592" width="210" height="20" font="1">subsequent stroke (HR: 0.95; 95% CI: </text>
<text top="436" left="592" width="114" height="20" font="1">0.86–1.04; p=0.23). <b> </b></text>
<text top="298" left="835" width="224" height="20" font="4"><b>Relevant 2</b>°<b> endpoint</b>: Major CV events </text>
<text top="316" left="835" width="246" height="20" font="1">(death from CV causes, recurrent stroke, MI, </text>
<text top="333" left="835" width="237" height="20" font="1">or new or worsening HF) occurred in 1,367 </text>
<text top="350" left="835" width="231" height="20" font="1">pts (13.5%) in telmisartan group vs. 1,463 </text>
<text top="367" left="835" width="248" height="20" font="1">pts (14.4%) in placebo group (HR: 0.94; 95% </text>
<text top="384" left="835" width="133" height="20" font="1">CI: 0.87–1.01; p=0.11).  </text>
<text top="402" left="835" width="3" height="20" font="1"> </text>
<text top="419" left="835" width="63" height="20" font="4"><b>Summary</b>: </text>
<text top="436" left="835" width="226" height="20" font="1">● Therapy with telmisartan initiated soon </text>
<text top="453" left="835" width="245" height="20" font="1">after ischemic stroke and continued for 2.5 y </text>
<text top="470" left="835" width="236" height="20" font="1">did not significantly lower Rate of recurrent </text>
<text top="488" left="835" width="152" height="20" font="1">stroke, or major CV events. </text>
<text top="505" left="835" width="237" height="20" font="1">● Impact of treatment with telmisartan may </text>
<text top="522" left="835" width="210" height="20" font="1">have been affected by the high rate of </text>
<text top="539" left="835" width="217" height="20" font="1">discontinuation of treatment medication </text>
<text top="557" left="835" width="248" height="20" font="1">because of hypotensive symptoms, syncope, </text>
<text top="574" left="835" width="224" height="20" font="1">diarrhea, and nausea experienced in the </text>
<text top="591" left="835" width="227" height="20" font="1">telmisartan arm and the more aggressive </text>
<text top="608" left="835" width="163" height="20" font="1">treatment with other standard </text>
<text top="625" left="835" width="227" height="20" font="1">antihypertensive therapies in the placebo </text>
<text top="643" left="835" width="203" height="20" font="1">arm. Thus, adverse side effects from </text>
<text top="660" left="835" width="237" height="20" font="1">treatment medications may affect quality of </text>
<text top="677" left="835" width="222" height="20" font="1">life and thus medication adherence after </text>
<text top="694" left="835" width="40" height="20" font="1">stroke. </text>
<text top="712" left="98" width="39" height="20" font="24"><b>SPS-3 </b></text>
<text top="729" left="98" width="101" height="20" font="1">Benavente OR, et </text>
<text top="747" left="98" width="83" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(212)</a> </text>
<text top="764" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23726159?dopt=Citation">23726159</a></text>
<text top="764" left="152" width="3" height="20" font="19"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23726159?dopt=Citation"> </a></text>
<text top="712" left="214" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="729" left="214" width="121" height="20" font="1">effects of different BP </text>
<text top="747" left="214" width="96" height="20" font="1">targets on rate of </text>
<text top="764" left="214" width="122" height="20" font="1">recurrent stroke in pts </text>
<text top="712" left="359" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="729" left="359" width="70" height="20" font="4"><b>criteria:</b> Pts </text>
<text top="747" left="359" width="66" height="20" font="1">with recent, </text>
<text top="764" left="359" width="70" height="20" font="1">MRI-defined </text>
<text top="781" left="359" width="72" height="20" font="1">symptomatic </text>
<text top="712" left="460" width="106" height="20" font="4"><b>Intervention:</b> SBP </text>
<text top="729" left="460" width="100" height="20" font="1">target of 130–149 </text>
<text top="747" left="460" width="100" height="20" font="1">mm Hg (n=1,519) </text>
<text top="764" left="460" width="3" height="20" font="1"> </text>
<text top="713" left="592" width="185" height="20" font="4"><b>1</b>°<b> outcome:</b> All stroke (including </text>
<text top="730" left="592" width="182" height="20" font="1">ischemic strokes and intracranial </text>
<text top="748" left="592" width="83" height="20" font="1">hemorrhages). </text>
<text top="765" left="592" width="3" height="20" font="4"><b> </b></text>
<text top="782" left="592" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="713" left="835" width="243" height="20" font="4"><b>2</b>°<b> outcomes:</b> No difference between target </text>
<text top="730" left="835" width="247" height="20" font="1">groups in disabling or fatal stroke 0.81, (95% </text>
<text top="748" left="835" width="200" height="20" font="1">CI: 0.53–1.23; p=0.32) or composite </text>
<text top="765" left="835" width="239" height="20" font="1">outcome of MI or vascular death 0.84 (95% </text>
<text top="782" left="835" width="185" height="20" font="1">CI: 0.68–1.04; p=0.32). However, </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="25" size="7" family="Times" color="#0000ff"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">161 </text>
<text top="107" left="214" width="107" height="20" font="1">with recent lacunar </text>
<text top="124" left="214" width="40" height="20" font="1">stroke. </text>
<text top="141" left="214" width="3" height="20" font="1"> </text>
<text top="159" left="214" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="176" left="214" width="104" height="20" font="1">Randomized open-</text>
<text top="193" left="214" width="53" height="20" font="1">label trial </text>
<text top="210" left="214" width="3" height="20" font="1"> </text>
<text top="227" left="214" width="86" height="20" font="4"><b>Size:</b> 3,020 pts<b> </b></text>
<text top="107" left="359" width="44" height="20" font="1">lacunar </text>
<text top="124" left="359" width="63" height="20" font="1">infarctions. </text>
<text top="141" left="359" width="3" height="20" font="1"> </text>
<text top="159" left="359" width="62" height="20" font="4"><b>Exclusion </b></text>
<text top="176" left="359" width="70" height="20" font="4"><b>criteria: </b>Pts </text>
<text top="193" left="359" width="68" height="20" font="1">with cortical </text>
<text top="210" left="359" width="46" height="20" font="1">strokes, </text>
<text top="228" left="359" width="79" height="20" font="1">cardioembolic </text>
<text top="245" left="359" width="64" height="20" font="1">disease, or </text>
<text top="262" left="359" width="40" height="20" font="1">carotid </text>
<text top="279" left="359" width="78" height="20" font="1">stenosis were </text>
<text top="296" left="359" width="56" height="20" font="1">excluded.<b> </b></text>
<text top="107" left="460" width="105" height="20" font="4"><b>Comparator:</b> SBP </text>
<text top="124" left="460" width="104" height="20" font="1">target of &lt;130 mm </text>
<text top="141" left="460" width="76" height="20" font="1">Hg (n=1,501) </text>
<text top="107" left="592" width="220" height="20" font="1">● After 1 y, mean SBP was 138 mm Hg </text>
<text top="124" left="592" width="213" height="20" font="1">(95% CI: 137–139) in the higher-target </text>
<text top="141" left="592" width="204" height="20" font="1">group and 127 mm Hg (95% CI: 126–</text>
<text top="159" left="592" width="172" height="20" font="1">128) in the lower-target group.  </text>
<text top="176" left="592" width="223" height="20" font="1">● Recurrent stroke was observed in 152 </text>
<text top="193" left="592" width="230" height="20" font="1">pts assigned to higher-target group (2.8% </text>
<text top="210" left="592" width="198" height="20" font="1">per y) vs. 125 assigned to the lower-</text>
<text top="228" left="592" width="223" height="20" font="1">target group (2.3% per y; HR: 0.81; 95% </text>
<text top="245" left="592" width="85" height="20" font="1">CI: 0.64–1.03). </text>
<text top="107" left="835" width="210" height="20" font="1">hemorrhagic stroke occurred in 16 pts </text>
<text top="124" left="835" width="237" height="20" font="1">assigned to the higher-target group (0.29% </text>
<text top="141" left="835" width="220" height="20" font="1">per y) vs. 6 assigned to the lower-target </text>
<text top="159" left="835" width="245" height="20" font="1">group (0.11% per y; HR: 0.37 (95% CI: 0.15–</text>
<text top="176" left="835" width="241" height="20" font="1">0.95). Serious complications of hypotension </text>
<text top="193" left="835" width="221" height="20" font="1">were observed in 15 pts assigned to the </text>
<text top="210" left="835" width="226" height="20" font="1">higher-target group (0.26% per y) and 23 </text>
<text top="228" left="835" width="232" height="20" font="1">assigned to the lower-target group (0.40% </text>
<text top="245" left="835" width="202" height="20" font="1">per y; HR: 1.53; 95% CI: 0.80–2.93). </text>
<text top="262" left="835" width="3" height="20" font="1"> </text>
<text top="279" left="835" width="241" height="20" font="4"><b>Summary</b>: Use of a SBP target of less than </text>
<text top="296" left="835" width="242" height="20" font="1">130 mm Hg was not significantly better than </text>
<text top="314" left="835" width="232" height="20" font="1">a target of 130–149 mm Hg for preventing </text>
<text top="331" left="835" width="225" height="20" font="1">any recurrent stroke. However, the lower </text>
<text top="348" left="835" width="200" height="20" font="1">target appeared to confer benefit for </text>
<text top="365" left="835" width="187" height="20" font="1">prevention of hemorrhagic stroke. </text>
<text top="385" left="135" width="3" height="19" font="1"> </text>
<text top="419" left="81" width="934" height="24" font="3"><b>Data Supplement 44. Nonrandomized Trials, Observational Studies, and/or Registries of Secondary Stroke Prevention (Section 9.4.3) </b></text>
<text top="459" left="100" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="476" left="125" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="493" left="103" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="459" left="252" width="38" height="20" font="4"><b>Study </b></text>
<text top="476" left="230" width="81" height="20" font="4"><b>Type/Design; </b></text>
<text top="493" left="228" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="459" left="376" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="459" left="579" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="476" left="556" width="224" height="20" font="4"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="459" left="890" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="476" left="917" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="511" left="98" width="90" height="20" font="1">Rashid P, et al., </text>
<text top="528" left="98" width="63" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(213)</a> </text>
<text top="546" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14576382?dopt=Citation">14576382</a></text>
<text top="546" left="152" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14576382?dopt=Citation">  </a></text>
<text top="511" left="214" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="528" left="214" width="96" height="20" font="1">analysis of RCTs </text>
<text top="546" left="214" width="3" height="20" font="1"> </text>
<text top="563" left="214" width="77" height="20" font="4"><b>Size:</b> 7 RCTs </text>
<text top="511" left="341" width="163" height="20" font="4"><b>Inclusion criteria:</b> Pts with a </text>
<text top="528" left="341" width="171" height="20" font="1">history of ischemic stroke, TIA, </text>
<text top="546" left="341" width="39" height="20" font="1">or ICH </text>
<text top="563" left="341" width="3" height="20" font="1"> </text>
<text top="580" left="341" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="512" left="536" width="169" height="20" font="4"><b>1</b>°<b> outcome:</b> Recurrent stroke </text>
<text top="530" left="536" width="3" height="20" font="1"> </text>
<text top="547" left="536" width="248" height="20" font="4"><b>Key findings: </b>Antihypertensive drug therapy </text>
<text top="564" left="536" width="246" height="20" font="1">associated with a 24% reduction in recurrent </text>
<text top="581" left="536" width="228" height="20" font="1">stroke risk (RR: 0.76; 95% CI: 0.63–0.92) </text>
<text top="598" left="536" width="241" height="20" font="1">Recurrent stroke risk reduction seen in both </text>
<text top="616" left="536" width="255" height="20" font="1">hypertensive and normotensive (as defined by </text>
<text top="633" left="536" width="206" height="20" font="1">the respective trials) pts and linked to </text>
<text top="650" left="536" width="170" height="20" font="1">magnitude of reduction in SBP </text>
<text top="512" left="813" width="272" height="20" font="4"><b>2</b>°<b> outcomes:</b> Nonfatal stroke OR: 0.79 (95% CI: </text>
<text top="530" left="813" width="276" height="20" font="1">0.65–0.95), MI OR: 0.79 (95% CI: 0.63, 0.98), and </text>
<text top="547" left="813" width="250" height="20" font="1">total vascular events OR: 0.79 (95% CI: 0.66–</text>
<text top="564" left="813" width="251" height="20" font="1">0.95). No effect seen on vascular or all-cause </text>
<text top="581" left="813" width="252" height="20" font="1">mortality. ACEIs and diuretics separately, and </text>
<text top="598" left="813" width="255" height="20" font="1">particularly together, reduced vascular events, </text>
<text top="616" left="813" width="282" height="20" font="1">while beta-receptor antagonists had no discernable </text>
<text top="633" left="813" width="33" height="20" font="1">effect.</text>
<text top="635" left="847" width="2" height="13" font="25"> </text>
<text top="650" left="813" width="3" height="20" font="4"><b> </b></text>
<text top="667" left="813" width="282" height="20" font="4"><b>Summary</b>: Use of antihypertensive agents to lower </text>
<text top="684" left="813" width="280" height="20" font="1">BP for the prevention of vascular events in pts with </text>
<text top="702" left="813" width="204" height="20" font="1">previous stroke or TIA is efficacious.  </text>
<text top="720" left="98" width="100" height="20" font="1">Lakhan SE, et al., </text>
<text top="737" left="98" width="63" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(214)</a> </text>
<text top="754" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19843330?dopt=Citation">19843330</a></text>
<text top="754" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19843330?dopt=Citation"> </a></text>
<text top="720" left="214" width="98" height="20" font="4"><b>Aim: </b>To examine </text>
<text top="737" left="214" width="78" height="20" font="1">the role of BP </text>
<text top="754" left="214" width="87" height="20" font="1">reduction using </text>
<text top="771" left="214" width="93" height="20" font="1">antihypertensive </text>
<text top="720" left="341" width="163" height="20" font="4"><b>Inclusion criteria:</b> Pts with a </text>
<text top="737" left="341" width="171" height="20" font="1">history of ischemic stroke, TIA, </text>
<text top="754" left="341" width="39" height="20" font="1">or ICH </text>
<text top="771" left="341" width="3" height="20" font="1"> </text>
<text top="788" left="341" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="721" left="536" width="169" height="20" font="4"><b>1</b>°<b> outcome:</b> Recurrent stroke </text>
<text top="738" left="536" width="3" height="20" font="1"> </text>
<text top="755" left="536" width="248" height="20" font="1">BP-lowering agents reduced recurrent stroke </text>
<text top="772" left="536" width="249" height="20" font="1">OR: 0.71 (95% CI: 0.59–0.86; p=0.0004) and </text>
<text top="721" left="813" width="283" height="20" font="4"><b>2</b>°<b>outcomes:</b> BP-lowering agents did not affect the </text>
<text top="738" left="813" width="176" height="20" font="1">rate of MI or all-cause mortality. </text>
<text top="755" left="813" width="3" height="20" font="4"><b> </b></text>
</page>
<page number="162" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">162 </text>
<text top="107" left="214" width="98" height="20" font="1">agents to prevent </text>
<text top="124" left="214" width="93" height="20" font="1">recurrent stroke.<b> </b></text>
<text top="141" left="214" width="3" height="20" font="4"><b> </b></text>
<text top="159" left="214" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="176" left="214" width="102" height="20" font="1">Systematic review </text>
<text top="193" left="214" width="103" height="20" font="1">and meta-analysis </text>
<text top="210" left="214" width="3" height="20" font="1"> </text>
<text top="227" left="214" width="84" height="20" font="4"><b>Size:</b> 10 RCTs<b> </b></text>
<text top="107" left="536" width="226" height="20" font="1">CV events OR: 0.69 (95% CI: 0.57–0.85; </text>
<text top="124" left="536" width="236" height="20" font="1">p=0.0004) in pts with a prior stroke or TIA. <b> </b></text>
<text top="107" left="813" width="241" height="20" font="4"><b>Summary: </b>BP lowering agents reduced the </text>
<text top="124" left="813" width="269" height="20" font="1">occurrence of subsequent stroke and CV events. </text>
<text top="141" left="813" width="280" height="20" font="1">Rate of MI and all-cause mortality was unchanged. </text>
<text top="245" left="98" width="98" height="20" font="1">Liu L, et al., 2009 </text>
<text top="263" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(215)</a> </text>
<text top="280" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19798097?dopt=Citation">19798097</a></text>
<text top="280" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19798097?dopt=Citation"> </a></text>
<text top="245" left="214" width="98" height="20" font="4"><b>Aim: </b>To examine </text>
<text top="263" left="214" width="111" height="20" font="1">role of BP reduction </text>
<text top="280" left="214" width="33" height="20" font="1">using </text>
<text top="297" left="214" width="93" height="20" font="1">antihypertensive </text>
<text top="314" left="214" width="98" height="20" font="1">agents to prevent </text>
<text top="332" left="214" width="93" height="20" font="1">recurrent stroke.<b> </b></text>
<text top="349" left="214" width="3" height="20" font="4"><b> </b></text>
<text top="366" left="214" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="383" left="214" width="102" height="20" font="1">Systematic review </text>
<text top="400" left="214" width="103" height="20" font="1">and meta-analysis </text>
<text top="418" left="214" width="3" height="20" font="1"> </text>
<text top="435" left="214" width="84" height="20" font="4"><b>Size:</b> 10 RCTs<b> </b></text>
<text top="245" left="341" width="163" height="20" font="4"><b>Inclusion criteria:</b> Pts with a </text>
<text top="263" left="341" width="171" height="20" font="1">history of ischemic stroke, TIA, </text>
<text top="280" left="341" width="39" height="20" font="1">or ICH </text>
<text top="297" left="341" width="117" height="20" font="1">Followed up 2 to 5 y. </text>
<text top="314" left="341" width="3" height="20" font="1"> </text>
<text top="332" left="341" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="247" left="536" width="169" height="20" font="4"><b>1</b>°<b> outcome:</b> Recurrent stroke </text>
<text top="264" left="536" width="3" height="20" font="1"> </text>
<text top="281" left="536" width="210" height="20" font="4"><b>Key findings: </b>Antihypertensive drugs </text>
<text top="298" left="536" width="213" height="20" font="1">associated with significant reduction in </text>
<text top="316" left="536" width="233" height="20" font="1">recurrent strokes (RR: 0.78; 95% CI: 0.68–</text>
<text top="333" left="536" width="35" height="20" font="1">0.90). </text>
<text top="350" left="536" width="231" height="20" font="1">Impact of antihypertensive treatment after </text>
<text top="367" left="536" width="230" height="20" font="1">ischemic stroke was similar in a restricted </text>
<text top="384" left="536" width="224" height="20" font="1">group of subjects with HTN and when all </text>
<text top="402" left="536" width="261" height="20" font="1">subjects, including those with and without HTN, </text>
<text top="419" left="536" width="83" height="20" font="1">were included. </text>
<text top="436" left="536" width="207" height="20" font="1">Pooled OR: 0.63 (95% CI: 0.54–0.73; </text>
<text top="453" left="536" width="233" height="20" font="1">p&lt;0.0001) for trials involving diuretics as a </text>
<text top="470" left="536" width="256" height="20" font="1">component of therapy and 0.93 (95% CI: 0.87–</text>
<text top="488" left="536" width="234" height="20" font="1">1.01; p=0.086) for trials in which treatment </text>
<text top="505" left="536" width="252" height="20" font="1">included renin system inhibitors (p&lt;0.0001 for </text>
<text top="522" left="536" width="89" height="20" font="1">heterogeneity).  </text>
<text top="247" left="813" width="262" height="20" font="4"><b>2</b>°<b> outcomes:</b> Significant reduction in recurrent </text>
<text top="264" left="813" width="276" height="20" font="1">stroke seen with diuretics (alone or in combination </text>
<text top="281" left="813" width="248" height="20" font="1">with ACEIs) but not with renal artery stenosis </text>
<text top="298" left="813" width="256" height="20" font="1">inhibitors, BBs, or CCBs used alone; however, </text>
<text top="316" left="813" width="260" height="20" font="1">statistical power was limited, particularly for the </text>
<text top="333" left="813" width="172" height="20" font="1">assessment of BBs and CCBs. </text>
<text top="350" left="813" width="3" height="20" font="4"><b> </b></text>
<text top="367" left="813" width="228" height="20" font="4"><b>Summary: </b>In conclusion, BP lowering by </text>
<text top="384" left="813" width="267" height="20" font="1">indapamide treatment reduced the recurrence of </text>
<text top="402" left="813" width="272" height="20" font="1">stroke and the incidence of CV events in Chinese </text>
<text top="419" left="813" width="235" height="20" font="1">pts with cerebrovascular disease. Whether </text>
<text top="436" left="813" width="269" height="20" font="1">prevention of stroke recurrence depends on drug </text>
<text top="453" left="813" width="249" height="20" font="1">class, degree of BP lowering or both requires </text>
<text top="470" left="813" width="114" height="20" font="1">further investigation. </text>
<text top="540" left="98" width="75" height="20" font="1">Lee M, et al., </text>
<text top="557" left="98" width="63" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(216)</a> </text>
<text top="574" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21796663?dopt=Citation">21796663</a></text>
<text top="574" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21796663?dopt=Citation"> </a></text>
<text top="540" left="214" width="100" height="20" font="4"><b>Aim:</b> To compare </text>
<text top="557" left="214" width="109" height="20" font="1">impact of achieving </text>
<text top="574" left="214" width="107" height="20" font="1">tight vs. usual SBP </text>
<text top="592" left="214" width="94" height="20" font="1">control on stroke </text>
<text top="609" left="214" width="64" height="20" font="1">prevention  </text>
<text top="626" left="214" width="3" height="20" font="1"> </text>
<text top="643" left="214" width="68" height="20" font="4"><b>Study size: </b></text>
<text top="660" left="214" width="85" height="20" font="1">11 studies with </text>
<text top="678" left="214" width="109" height="20" font="1">42,572 pts and 794 </text>
<text top="695" left="214" width="80" height="20" font="1">stroke events.<b> </b></text>
<text top="540" left="341" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="557" left="341" width="171" height="20" font="4"><b>(</b>1) Achieved SBP&lt;130 mm Hg </text>
<text top="574" left="341" width="180" height="20" font="1">in an active treatment group and </text>
<text top="592" left="341" width="149" height="20" font="1">SBP 130 to 39 mm Hg in a </text>
<text top="609" left="341" width="162" height="20" font="1">comparator group by trial; (2) </text>
<text top="626" left="341" width="148" height="20" font="1">trial duration at least 6 mo; </text>
<text top="643" left="341" width="148" height="20" font="1">(3) total pts and number of </text>
<text top="660" left="341" width="126" height="20" font="1">stroke events reported </text>
<text top="678" left="341" width="169" height="20" font="1">separately for active treatment </text>
<text top="695" left="341" width="134" height="20" font="1">and comparator groups. </text>
<text top="712" left="341" width="3" height="20" font="1"> </text>
<text top="729" left="341" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="747" left="341" width="160" height="20" font="1">(1) Nonrandomized trials; (2) </text>
<text top="764" left="341" width="132" height="20" font="1">trials in which either the </text>
<text top="541" left="536" width="75" height="20" font="4"><b>1</b>°<b> outcome:</b> </text>
<text top="541" left="612" width="174" height="20" font="9">Association of future stroke risk </text>
<text top="558" left="536" width="251" height="20" font="9">and achieved level of different SBP (intensive </text>
<text top="576" left="536" width="56" height="20" font="9">vs. usual) </text>
<text top="593" left="536" width="3" height="20" font="1"> </text>
<text top="610" left="536" width="85" height="20" font="4"><b>Key findings:  </b></text>
<text top="629" left="536" width="7" height="18" font="1">•</text>
<text top="628" left="543" width="234" height="20" font="1"> Final SBPs, weighted for trial size, were a </text>
<text top="646" left="536" width="211" height="20" font="1">mean of 126.5 mm Hg in the intensive </text>
<text top="663" left="536" width="221" height="20" font="1">treatment arms and 132.6 mm Hg in the </text>
<text top="680" left="536" width="248" height="20" font="1">conventional arms (mean SBP reduction, 6.1 </text>
<text top="697" left="536" width="51" height="20" font="1">mm Hg). </text>
<text top="716" left="536" width="7" height="18" font="1">•</text>
<text top="716" left="543" width="252" height="20" font="1"> In subgroup analyses, those with established </text>
<text top="733" left="536" width="258" height="20" font="1">(symptomatic) CVD at entry did not experience </text>
<text top="750" left="536" width="241" height="20" font="1">stroke risk reduction with tight control (0.92; </text>
<text top="767" left="536" width="113" height="20" font="1">95% CI: 0.83–1.03). </text>
<text top="540" left="813" width="259" height="20" font="4"><b>Summary: </b>Achieving an SBP &lt;130 mm Hg vs. </text>
<text top="557" left="813" width="256" height="20" font="1">130–139 mm Hg appears to provide additional </text>
<text top="574" left="813" width="269" height="20" font="1">stroke protection only among pts with risk factors </text>
<text top="592" left="813" width="136" height="20" font="1">but no established CVD. </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">163 </text>
<text top="107" left="341" width="181" height="20" font="1">comparator or the active therapy </text>
<text top="124" left="341" width="35" height="20" font="1">group </text>
<text top="141" left="341" width="161" height="20" font="1">received additional treatment </text>
<text top="159" left="341" width="153" height="20" font="1">that other group did not; (3) </text>
<text top="176" left="341" width="150" height="20" font="1">majority of participants had </text>
<text top="193" left="341" width="41" height="20" font="1">ESRD; </text>
<text top="210" left="341" width="169" height="20" font="1">(4) &lt;10 stroke events in a trial, </text>
<text top="227" left="341" width="177" height="20" font="1">because stroke was not a major </text>
<text top="245" left="341" width="121" height="20" font="1">endpoint; (5) SBP not </text>
<text top="262" left="341" width="165" height="20" font="1">significantly different between </text>
<text top="279" left="341" width="180" height="20" font="1">active and comparator groups at </text>
<text top="296" left="341" width="179" height="20" font="1">trial end; (6) Achieved SBP&lt;130 </text>
<text top="314" left="341" width="170" height="20" font="1">mm Hg in a comparator group. </text>
<text top="332" left="98" width="75" height="20" font="1">Lee M, et al., </text>
<text top="349" left="98" width="63" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(217)</a> </text>
<text top="366" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22052520?dopt=Citation">22052520</a></text>
<text top="366" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22052520?dopt=Citation"> </a></text>
<text top="332" left="214" width="99" height="20" font="4"><b>Aim: To </b>evaluate </text>
<text top="349" left="214" width="84" height="20" font="1">whether use of </text>
<text top="366" left="214" width="81" height="20" font="1">ACEIs or ARB </text>
<text top="383" left="214" width="82" height="20" font="1">reduces future </text>
<text top="400" left="214" width="102" height="20" font="1">vascular events in </text>
<text top="418" left="214" width="100" height="20" font="1">persons with prior </text>
<text top="435" left="214" width="40" height="20" font="1">stroke. </text>
<text top="452" left="214" width="102" height="20" font="4"><b>Size:</b> 8 RCTs with </text>
<text top="469" left="214" width="61" height="20" font="1">29,667 pts<b> </b></text>
<text top="332" left="341" width="153" height="20" font="4"><b>Inclusion criteria: </b>(1) RCT </text>
<text top="349" left="341" width="169" height="20" font="1">design; (2) pts had a history of </text>
<text top="366" left="341" width="131" height="20" font="1">stroke or TIA; (3) active </text>
<text top="383" left="341" width="177" height="20" font="1">treatment consisted of ACEIs or </text>
<text top="400" left="341" width="171" height="20" font="1">ARBs; (4) follow-up duration at </text>
<text top="418" left="341" width="152" height="20" font="1">least 6 mo; (5) total pts and </text>
<text top="435" left="341" width="177" height="20" font="1">number of future major vascular </text>
<text top="452" left="341" width="168" height="20" font="1">events and/or recurrent stroke </text>
<text top="469" left="341" width="157" height="20" font="1">were reported separately for </text>
<text top="487" left="341" width="181" height="20" font="1">active treatment and comparator </text>
<text top="504" left="341" width="44" height="20" font="1">groups. </text>
<text top="521" left="341" width="3" height="20" font="1"> </text>
<text top="538" left="341" width="128" height="20" font="4"><b>Exclusion criteria: </b>(1) </text>
<text top="555" left="341" width="173" height="20" font="1">mandatory ACEI or ARB use in </text>
<text top="573" left="341" width="136" height="20" font="1">control groups; (2) study </text>
<text top="590" left="341" width="182" height="20" font="1">purpose was to examine efficacy </text>
<text top="607" left="341" width="159" height="20" font="1">of ACEIs or ARBs in pts with </text>
<text top="624" left="341" width="74" height="20" font="1">acute stroke  </text>
<text top="333" left="536" width="243" height="20" font="4"><b>1</b>°<b> outcome:</b> Major vascular event (nonfatal </text>
<text top="350" left="536" width="251" height="20" font="1">stroke, nonfatal MI, or death from CV causes) </text>
<text top="367" left="536" width="197" height="20" font="1">or stroke (ischemic or hemorrhagic) </text>
<text top="384" left="536" width="3" height="20" font="1"> </text>
<text top="402" left="536" width="221" height="20" font="4"><b>Key findings: </b>Use of ACEIs or ARBs in </text>
<text top="419" left="536" width="250" height="20" font="1">persons with prior stroke was associated with </text>
<text top="436" left="536" width="258" height="20" font="1">lower risks of future major vascular events RR: </text>
<text top="453" left="536" width="246" height="20" font="1">0.91 (95% CI: 0.87–0.97; p=0.001); NNT=71 </text>
<text top="470" left="536" width="247" height="20" font="1">and recurrent stroke RR: 0.93 (95% CI: 0.86–</text>
<text top="488" left="536" width="139" height="20" font="1">0.99; p=0.03); NNT=143.<b> </b></text>
<text top="332" left="813" width="274" height="20" font="4"><b>Summary:</b> Treatment with an ACEI or ARB has a </text>
<text top="349" left="813" width="280" height="20" font="1">clear but rather modest effect on reducing vascular </text>
<text top="366" left="813" width="176" height="20" font="1">risk in persons with prior stroke. </text>
<text top="642" left="98" width="85" height="20" font="1">Arima H, et al., </text>
<text top="659" left="98" width="63" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(218)</a> </text>
<text top="677" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16685221?dopt=Citation">16685221</a></text>
<text top="677" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16685221?dopt=Citation"> </a></text>
<text top="642" left="214" width="38" height="20" font="4"><b>Aims:</b> </text>
<text top="659" left="214" width="100" height="20" font="1">#1: To investigate </text>
<text top="677" left="214" width="74" height="20" font="1">the effects of </text>
<text top="694" left="214" width="68" height="20" font="1">randomized </text>
<text top="711" left="214" width="73" height="20" font="1">treatment on </text>
<text top="728" left="214" width="106" height="20" font="1">recurrent stroke by </text>
<text top="745" left="214" width="104" height="20" font="1">baseline BP levels </text>
<text top="763" left="214" width="100" height="20" font="1">#2: To investigate </text>
<text top="780" left="214" width="65" height="20" font="1">association </text>
<text top="642" left="341" width="152" height="20" font="4"><b>Inclusion criteria: </b>Pts with<b> </b></text>
<text top="659" left="341" width="178" height="20" font="1">history of cerebrovascular event </text>
<text top="677" left="341" width="137" height="20" font="1">(stroke or TIA) within the </text>
<text top="694" left="341" width="70" height="20" font="1">previous 5 y </text>
<text top="711" left="341" width="3" height="20" font="1"> </text>
<text top="728" left="341" width="51" height="20" font="4"><b>Groups: </b></text>
<text top="745" left="341" width="179" height="20" font="1">Defined by baseline BP of &lt;120, </text>
<text top="763" left="341" width="181" height="20" font="1">120–139, 140–159, and 160 mm </text>
<text top="780" left="341" width="76" height="20" font="1">Hg or greater </text>
<text top="643" left="536" width="239" height="20" font="4"><b>1</b>°<b> outcome:</b> Total stroke (fatal or nonfatal) </text>
<text top="660" left="536" width="3" height="20" font="1"> </text>
<text top="678" left="536" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="695" left="536" width="246" height="20" font="1">● Smaller BP differences between active vs. </text>
<text top="712" left="536" width="256" height="20" font="1">placebo groups (p&lt;0.0001) and corresponding </text>
<text top="729" left="536" width="36" height="20" font="1">lesser </text>
<text top="747" left="536" width="222" height="20" font="1">risk reductions (p trend=0.05) with lower </text>
<text top="764" left="536" width="75" height="20" font="1">baseline BPs </text>
<text top="781" left="536" width="250" height="20" font="1">Association of stroke incidence with achieved </text>
<text top="642" left="813" width="64" height="20" font="4"><b>Summary: </b></text>
<text top="659" left="813" width="283" height="20" font="1">● These analyses provide no evidence of a J-curve </text>
<text top="677" left="813" width="248" height="20" font="1">relationship between BP level and stroke risk </text>
<text top="694" left="813" width="282" height="20" font="1">among pts with cerebrovascular disease. However, </text>
<text top="711" left="813" width="279" height="20" font="1">ischemic stroke, TIA, and hemorrhagic pts were all </text>
<text top="728" left="813" width="226" height="20" font="1">enrolled and within 5 y of the index event </text>
<text top="745" left="813" width="224" height="20" font="1">suggesting that these pts were generally </text>
<text top="763" left="813" width="265" height="20" font="1">neurologically stable and not acknowledging the </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">164 </text>
<text top="107" left="214" width="102" height="20" font="1">between achieved </text>
<text top="124" left="214" width="107" height="20" font="1">follow-up BP levels </text>
<text top="141" left="214" width="114" height="20" font="1">and recurrent stroke </text>
<text top="159" left="214" width="26" height="20" font="1">risk. </text>
<text top="176" left="214" width="3" height="20" font="1"> </text>
<text top="193" left="214" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="210" left="214" width="113" height="20" font="1">Post-hoc analysis of </text>
<text top="227" left="214" width="100" height="20" font="1">PROGRESS trial. </text>
<text top="245" left="214" width="3" height="20" font="1"> </text>
<text top="262" left="214" width="86" height="20" font="4"><b>Size:</b> 6,105 pts<b> </b></text>
<text top="107" left="536" width="259" height="20" font="1">follow-up SBP level was strong and continuous </text>
<text top="124" left="536" width="42" height="20" font="1">with no </text>
<text top="141" left="536" width="255" height="20" font="1">evidence of a J-curve in the range of achieved </text>
<text top="159" left="536" width="53" height="20" font="1">follow-up </text>
<text top="176" left="536" width="244" height="20" font="1">SBP from 112–168 mm Hg (p trend &lt;0.0001 </text>
<text top="193" left="536" width="246" height="20" font="1">RR of study treatment on the discontinuation </text>
<text top="210" left="536" width="194" height="20" font="1">of randomized treatment increased </text>
<text top="228" left="536" width="76" height="20" font="1">progressively </text>
<text top="245" left="536" width="256" height="20" font="1">across the subgroups with lower baseline SBP </text>
<text top="262" left="536" width="35" height="20" font="1">levels </text>
<text top="279" left="536" width="223" height="20" font="1">at entry (p trend=0.04), but there was no </text>
<text top="296" left="536" width="205" height="20" font="1">corresponding difference in effects of </text>
<text top="314" left="536" width="252" height="20" font="1">randomized treatment on the risks of death or </text>
<text top="331" left="536" width="224" height="20" font="1">hospital admission (both p trend &gt;0.2) or </text>
<text top="348" left="536" width="233" height="20" font="1">hypotension, renal dysfunction, electrolyte </text>
<text top="365" left="536" width="217" height="20" font="1">disturbance, hip fracture, or depression </text>
<text top="383" left="536" width="261" height="20" font="1">between pts with different levels of baseline BP </text>
<text top="400" left="536" width="160" height="20" font="1">at baseline (all p trend &gt;0.1)  </text>
<text top="417" left="536" width="250" height="20" font="1">● Minor side-effects were progressively more </text>
<text top="434" left="536" width="155" height="20" font="1">common at lower BP levels  </text>
<text top="451" left="536" width="127" height="20" font="1">(p homogeneity=0.04). </text>
<text top="107" left="813" width="238" height="20" font="1">differences in pathophysiologic mechanism </text>
<text top="124" left="813" width="123" height="20" font="1">between stroke types. </text>
<text top="141" left="813" width="267" height="20" font="1">● First analysis showed that the effectiveness of </text>
<text top="159" left="813" width="279" height="20" font="1">antihypertensive treatment for 2º stroke prevention </text>
<text top="176" left="813" width="271" height="20" font="1">diminished as baseline BP declined (relative RRs </text>
<text top="193" left="813" width="278" height="20" font="1">were 39%, 31%, 14%, and 0%, respectively, in the </text>
<text top="210" left="813" width="223" height="20" font="1">groups defined previously). This trend of </text>
<text top="228" left="813" width="280" height="20" font="1">decreasing effect was despite successful reduction </text>
<text top="245" left="813" width="246" height="20" font="1">of mean SBP in each active-treatment group </text>
<text top="262" left="813" width="281" height="20" font="1">compared with placebo (11.1, 9.2, 7.6, and 7.4 mm </text>
<text top="279" left="813" width="273" height="20" font="1">Hg reductions, respectively, in the groups defined </text>
<text top="296" left="813" width="235" height="20" font="1">previously). Also of note, 40% of pts with a </text>
<text top="314" left="813" width="206" height="20" font="1">baseline BP&lt;140 mm Hg were taking </text>
<text top="331" left="813" width="204" height="20" font="1">antihypertensive therapy at baseline. </text>
<text top="469" left="98" width="91" height="20" font="1">White CL, et al., </text>
<text top="487" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(219)</a> </text>
<text top="504" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25850462?dopt=Citation">25850462</a></text>
<text top="504" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25850462?dopt=Citation"> </a></text>
<text top="469" left="214" width="106" height="20" font="4"><b>Aim</b>: To determine </text>
<text top="487" left="214" width="60" height="20" font="1">safety and </text>
<text top="504" left="214" width="72" height="20" font="1">tolerability of </text>
<text top="521" left="214" width="113" height="20" font="1">lowering BP in older </text>
<text top="538" left="214" width="105" height="20" font="1">adults with lacunar </text>
<text top="555" left="214" width="37" height="20" font="1">stroke </text>
<text top="573" left="214" width="3" height="20" font="1"> </text>
<text top="590" left="214" width="99" height="20" font="4"><b>Study type:</b> Post-</text>
<text top="607" left="214" width="85" height="20" font="1">hoc analysis of </text>
<text top="624" left="214" width="91" height="20" font="1">randomized trial </text>
<text top="641" left="214" width="3" height="20" font="1"> </text>
<text top="659" left="214" width="114" height="20" font="4"><b>Study Size:</b> 494 pts </text>
<text top="469" left="341" width="152" height="20" font="4"><b>Inclusion criteria: </b>Pts with </text>
<text top="487" left="341" width="116" height="20" font="1">lacunar stroke ≥75 y </text>
<text top="470" left="536" width="245" height="20" font="4"><b>1</b>°<b> outcome:</b> Rates of side effects related to </text>
<text top="488" left="536" width="81" height="20" font="1">lowering SBP  </text>
<text top="505" left="536" width="3" height="20" font="1"> </text>
<text top="523" left="536" width="262" height="20" font="4"><b>2</b>°<b> outcome:</b> Stroke recurrence and death from </text>
<text top="540" left="536" width="92" height="20" font="1">vascular causes </text>
<text top="558" left="536" width="3" height="20" font="1"> </text>
<text top="575" left="536" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="592" left="536" width="234" height="20" font="1">● Older pts achieved SBP levels similar to </text>
<text top="609" left="536" width="260" height="20" font="1">younger pts (mean SBP of 125 mm Hg in lower </text>
<text top="627" left="536" width="239" height="20" font="1">SBP target group and 137 mm Hg in higher </text>
<text top="644" left="536" width="74" height="20" font="1">target group) </text>
<text top="661" left="536" width="109" height="20" font="1">● 3.5 y of follow-up </text>
<text top="678" left="536" width="233" height="20" font="1">21% reported dizziness and 15% reported </text>
<text top="695" left="536" width="263" height="20" font="1">lightheadedness when standing; only significant </text>
<text top="713" left="536" width="251" height="20" font="1">difference between younger and older groups </text>
<text top="730" left="536" width="235" height="20" font="1">was unsteadiness when standing (23% vs. </text>
<text top="747" left="536" width="229" height="20" font="1">32%, p&lt;0.001). No difference in recurrent </text>
<text top="764" left="536" width="237" height="20" font="1">stroke by target SBP level among the older </text>
<text top="781" left="536" width="262" height="20" font="1">subjects (HR: 1.01; 95% CI: 0.59–1.73), but the </text>
<text top="469" left="813" width="273" height="20" font="4"><b>Summary: </b>Pts ≥75 y with a recent lacunar stroke </text>
<text top="487" left="813" width="267" height="20" font="1">who achieved a lower SBP target (&lt;130 mm Hg) </text>
<text top="504" left="813" width="209" height="20" font="1">were significantly more likely to report </text>
<text top="521" left="813" width="246" height="20" font="1">unsteadiness on standing than their younger </text>
<text top="538" left="813" width="251" height="20" font="1">counterparts. Lower SBP was not related to a </text>
<text top="555" left="813" width="277" height="20" font="1">decrease in recurrent stroke risk in elderly pts with </text>
<text top="573" left="813" width="275" height="20" font="1">lacunar stroke but there was a potential protective </text>
<text top="590" left="813" width="179" height="20" font="1">advantage from vascular death.  </text>
</page>
<page number="165" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">165 </text>
<text top="107" left="536" width="255" height="20" font="1">lower target SBP group in older pts was linked </text>
<text top="124" left="536" width="261" height="20" font="1">to a significant reduction in vascular death (HR: </text>
<text top="141" left="536" width="195" height="20" font="1">0.42; 95% CI: 0.18–0.98; p=0.049). </text>
<text top="159" left="98" width="87" height="20" font="1">Ovbiagele B, et </text>
<text top="177" left="98" width="83" height="20" font="1">al., 2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(220)</a> </text>
<text top="194" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22089721?dopt=Citation">22089721</a></text>
<text top="194" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22089721?dopt=Citation"> </a></text>
<text top="159" left="214" width="111" height="20" font="4"><b>Aim: </b>To assess the </text>
<text top="177" left="214" width="78" height="20" font="1">association of </text>
<text top="194" left="214" width="89" height="20" font="1">maintaining low-</text>
<text top="211" left="214" width="87" height="20" font="1">normal vs. high-</text>
<text top="228" left="214" width="104" height="20" font="1">normal SBP levels </text>
<text top="246" left="214" width="61" height="20" font="1">with risk of </text>
<text top="263" left="214" width="93" height="20" font="1">recurrent stroke. </text>
<text top="280" left="214" width="3" height="20" font="1"> </text>
<text top="297" left="214" width="99" height="20" font="4"><b>Study type:</b> Post </text>
<text top="314" left="214" width="95" height="20" font="1">hoc analysis of a </text>
<text top="332" left="214" width="87" height="20" font="1">multicenter trial </text>
<text top="349" left="214" width="112" height="20" font="1">involving 20,330 pts </text>
<text top="366" left="214" width="92" height="20" font="1">(age ≥50 y) with </text>
<text top="383" left="214" width="38" height="20" font="1">recent </text>
<text top="401" left="214" width="100" height="20" font="1">noncardioembolic </text>
<text top="418" left="214" width="88" height="20" font="1">ischemic stroke </text>
<text top="435" left="214" width="114" height="20" font="1">followed up for 2.5 y </text>
<text top="452" left="214" width="3" height="20" font="1"> </text>
<text top="469" left="214" width="111" height="20" font="4"><b>Study Size: </b>20,330 </text>
<text top="487" left="214" width="20" height="20" font="1">pts<b> </b></text>
<text top="159" left="341" width="168" height="20" font="4"><b>Inclusion criteria:</b> Pts 55 y or </text>
<text top="177" left="341" width="161" height="20" font="1">older with an ischemic stroke </text>
<text top="194" left="341" width="154" height="20" font="1">&lt;90 d before randomization </text>
<text top="211" left="341" width="3" height="20" font="1"> </text>
<text top="228" left="341" width="161" height="20" font="4"><b>Categories:</b> Based on mean </text>
<text top="245" left="341" width="172" height="20" font="1">SBP level was very low-normal </text>
<text top="263" left="341" width="149" height="20" font="1">(&lt;120 mm Hg), low-normal </text>
<text top="280" left="341" width="176" height="20" font="1">(120≤130 mm Hg), high-normal </text>
<text top="297" left="341" width="134" height="20" font="1">(130≤140 mm Hg), high </text>
<text top="314" left="341" width="158" height="20" font="1">(140≤150 mm Hg), and very </text>
<text top="332" left="341" width="114" height="20" font="1">high (≥150 mm Hg). </text>
<text top="349" left="341" width="3" height="20" font="1"> </text>
<text top="366" left="341" width="157" height="20" font="1">● 1° outcome was recurrent </text>
<text top="383" left="341" width="182" height="20" font="1">stroke and the 2º outcome was a </text>
<text top="400" left="341" width="166" height="20" font="1">composite of recurrent stroke, </text>
<text top="418" left="341" width="165" height="20" font="1">MI, and death due to vascular </text>
<text top="435" left="341" width="42" height="20" font="1">causes </text>
<text top="452" left="341" width="3" height="20" font="4"><b> </b></text>
<text top="161" left="536" width="252" height="20" font="4"><b>1</b>°<b> outcome:</b> First recurrence of stroke of any </text>
<text top="178" left="536" width="30" height="20" font="1">type  </text>
<text top="195" left="536" width="3" height="20" font="1"> </text>
<text top="213" left="536" width="260" height="20" font="4"><b>2</b>°<b> outcome:</b> Composite of stroke, MI, or death </text>
<text top="231" left="536" width="123" height="20" font="1">from vascular causes. </text>
<text top="248" left="536" width="3" height="20" font="1"> </text>
<text top="265" left="536" width="237" height="20" font="4"><b>Key findings: </b>Recurrent stroke rates were </text>
<text top="282" left="536" width="241" height="20" font="1">8.0% (95% CI: 6.8%–9.2%) for the very low-</text>
<text top="299" left="536" width="253" height="20" font="1">normal SBP level group, 7.2% (95% CI: 6.4%–</text>
<text top="317" left="536" width="235" height="20" font="1">8.0%) for the low-normal SBP group, 6.8% </text>
<text top="334" left="536" width="256" height="20" font="1">(95% CI: 6.1%–7.4%) for the high-normal SBP </text>
<text top="351" left="536" width="256" height="20" font="1">group, 8.7% (95% CI: 7.9%–9.5%) for the high </text>
<text top="368" left="536" width="264" height="20" font="1">SBP group, and 14.1% (95% CI: 13.0%–15.2%) </text>
<text top="386" left="536" width="264" height="20" font="1">for the very high SBP group. Compared with pts </text>
<text top="403" left="536" width="241" height="20" font="1">in the high-normal SBP group, the risk of 1° </text>
<text top="420" left="536" width="234" height="20" font="1">outcome was higher for pts in the very low-</text>
<text top="437" left="536" width="246" height="20" font="1">normal SBP group AHR: 1.29 (95% CI: 1.07–</text>
<text top="454" left="536" width="250" height="20" font="1">1.56), in the high SBP group AHR: 1.23 (95% </text>
<text top="472" left="536" width="258" height="20" font="1">CI: 1.07–1.41), and in the very high SBP group </text>
<text top="489" left="536" width="181" height="20" font="1">AHR: 2.08 (95% CI: 1.83–2.37). <b> </b></text>
<text top="161" left="813" width="270" height="20" font="4"><b>Relevant 2</b>°<b> endpoint: </b>Compared with pts in the </text>
<text top="178" left="813" width="282" height="20" font="1">high-normal SBP group, the risk of 2º outcome was </text>
<text top="195" left="813" width="262" height="20" font="1">higher for pts in the very low-normal SBP group </text>
<text top="212" left="813" width="274" height="20" font="1">AHR: 1.31 (95% CI: 1.13–1.52), in the low-normal </text>
<text top="229" left="813" width="274" height="20" font="1">SBP group AHR: 1.16 (95% CI: 1.03–1.31), in the </text>
<text top="247" left="813" width="267" height="20" font="1">high SBP group AHR: 1.24 (95% CI: 1.11–1.39), </text>
<text top="264" left="813" width="266" height="20" font="1">and in the very high SBP group AHR: 1.94 (95% </text>
<text top="281" left="813" width="85" height="20" font="1">CI: 1.74–2.16).<b> </b></text>
<text top="298" left="813" width="3" height="20" font="4"><b> </b></text>
<text top="316" left="813" width="189" height="20" font="4"><b>Summary: </b>Among pts with recent </text>
<text top="333" left="813" width="254" height="20" font="1">noncardioembolic ischemic stroke, SBP levels </text>
<text top="350" left="813" width="273" height="20" font="1">during follow-up in the very low-normal (&lt;120 mm </text>
<text top="367" left="813" width="272" height="20" font="1">Hg), high (140–≤150 mm Hg), or very high (≥150 </text>
<text top="384" left="813" width="279" height="20" font="1">mm Hg) range were associated with increased risk </text>
<text top="402" left="813" width="107" height="20" font="1">of recurrent stroke. </text>
<text top="507" left="98" width="87" height="20" font="1">Ovbiagele B, et </text>
<text top="524" left="98" width="83" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(221)</a> </text>
<text top="541" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22244715?dopt=Citation">22244715</a></text>
<text top="541" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22244715?dopt=Citation"> </a></text>
<text top="507" left="214" width="90" height="20" font="4"><b>Aim: </b>To assess </text>
<text top="524" left="214" width="78" height="20" font="1">association of </text>
<text top="541" left="214" width="89" height="20" font="1">maintaining low-</text>
<text top="558" left="214" width="87" height="20" font="1">normal vs. high-</text>
<text top="576" left="214" width="104" height="20" font="1">normal SBP levels </text>
<text top="593" left="214" width="61" height="20" font="1">with risk of </text>
<text top="610" left="214" width="93" height="20" font="1">recurrent stroke. </text>
<text top="627" left="214" width="3" height="20" font="1"> </text>
<text top="644" left="214" width="99" height="20" font="4"><b>Study type:</b> Post </text>
<text top="662" left="214" width="95" height="20" font="1">hoc analysis of a </text>
<text top="679" left="214" width="87" height="20" font="1">multicenter trial </text>
<text top="696" left="214" width="105" height="20" font="1">involving 3,680 pts </text>
<text top="713" left="214" width="63" height="20" font="1">with recent </text>
<text top="730" left="214" width="100" height="20" font="1">noncardioembolic </text>
<text top="748" left="214" width="88" height="20" font="1">ischemic stroke </text>
<text top="765" left="214" width="103" height="20" font="1">followed up for 2 y<b> </b></text>
<text top="507" left="341" width="169" height="20" font="4"><b>Inclusion criteria:</b> Pts with an </text>
<text top="524" left="341" width="168" height="20" font="1">ischemic stroke &lt;120 d before </text>
<text top="541" left="341" width="81" height="20" font="1">randomization </text>
<text top="558" left="341" width="3" height="20" font="1"> </text>
<text top="576" left="341" width="71" height="20" font="4"><b>Categories:</b> </text>
<text top="593" left="341" width="167" height="20" font="1">● Based on mean in-trial SBP </text>
<text top="610" left="341" width="181" height="20" font="1">value was low-normal (&lt;120 mm </text>
<text top="627" left="341" width="168" height="20" font="1">Hg), high-normal (120 to &lt;140 </text>
<text top="644" left="341" width="181" height="20" font="1">mm Hg), or high (&gt;140 mm Hg).  </text>
<text top="663" left="341" width="141" height="20" font="1">● 1° outcome was stroke<b> </b></text>
<text top="508" left="536" width="252" height="20" font="4"><b>1</b>°<b> outcome:</b> First recurrence of stroke of any </text>
<text top="525" left="536" width="30" height="20" font="1">type  </text>
<text top="542" left="536" width="3" height="20" font="1"> </text>
<text top="560" left="536" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="577" left="536" width="245" height="20" font="1">Rate of recurrent stroke was 9.1% in the low-</text>
<text top="594" left="536" width="251" height="20" font="1">normal group, 6.7% in the high-normal group, </text>
<text top="611" left="536" width="223" height="20" font="1">and 10% in the high group. Difference in </text>
<text top="628" left="536" width="252" height="20" font="1">recurrent stroke rate between low-normal and </text>
<text top="646" left="536" width="259" height="20" font="1">high-normal groups was more prominent within </text>
<text top="663" left="536" width="252" height="20" font="1">the first 6 mo (low-normal, 4.5%; high-normal, </text>
<text top="680" left="536" width="249" height="20" font="1">2.5%; high, 3.4%) vs. after 6 mo (low-normal, </text>
<text top="697" left="536" width="241" height="20" font="1">4.6%; high-normal, 4.2%; high, 6.6%). Over </text>
<text top="714" left="536" width="246" height="20" font="1">study period, compared with the high-normal </text>
<text top="732" left="536" width="258" height="20" font="1">group, risk of the 1° outcome trended higher in </text>
<text top="749" left="536" width="230" height="20" font="1">the low-normal group AHR: 1.47 (95% CI: </text>
<text top="766" left="536" width="254" height="20" font="1">0.94–2.29; p=0.09) and was higher in the high </text>
<text top="783" left="536" width="257" height="20" font="1">group AHR: 1.39 (95% CI: 1.08–1.79; p=0.01).<b> </b></text>
<text top="507" left="813" width="267" height="20" font="4"><b>Summary: </b>Results support a possible pattern of </text>
<text top="524" left="813" width="263" height="20" font="1">increased risk of recurrent stroke in pts with low-</text>
<text top="541" left="813" width="274" height="20" font="1">normal SBP levels, especially within the first 6 mo </text>
<text top="558" left="813" width="279" height="20" font="1">after first stroke. However, this study likely was not </text>
<text top="576" left="813" width="269" height="20" font="1">sufficiently powered to detect more than a strong </text>
<text top="593" left="813" width="238" height="20" font="1">statistical trend underlying this relationship. </text>
<text top="610" left="813" width="3" height="20" font="19"> </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">166 </text>
<text top="107" left="98" width="78" height="20" font="1">Lin MP, et al., </text>
<text top="124" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(222)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25765723?dopt=Citation">25765723</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25765723?dopt=Citation"> </a></text>
<text top="107" left="214" width="112" height="20" font="4"><b>Aim:</b> To assess link </text>
<text top="124" left="214" width="102" height="20" font="1">between SBP and </text>
<text top="141" left="214" width="78" height="20" font="1">mortality after </text>
<text top="159" left="214" width="40" height="20" font="1">stroke. </text>
<text top="176" left="214" width="3" height="20" font="1"> </text>
<text top="193" left="214" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="210" left="214" width="67" height="20" font="1">Analyses of </text>
<text top="227" left="214" width="55" height="20" font="1">nationally </text>
<text top="245" left="214" width="81" height="20" font="1">representative </text>
<text top="262" left="214" width="67" height="20" font="1">survey data </text>
<text top="279" left="214" width="63" height="20" font="1">(NHANES) </text>
<text top="296" left="214" width="3" height="20" font="1"> </text>
<text top="314" left="214" width="114" height="20" font="4"><b>Study Size:</b> 455 pts </text>
<text top="107" left="341" width="178" height="20" font="4"><b>Inclusion criteria: </b>Adults ≥20 y </text>
<text top="124" left="341" width="138" height="20" font="1">with self-reported stroke. </text>
<text top="141" left="341" width="3" height="20" font="1"> </text>
<text top="159" left="341" width="175" height="20" font="4"><b>Categories: </b>Baseline SBP was </text>
<text top="176" left="341" width="178" height="21" font="1">as low to normal (&lt;120 mm Hg), </text>
<text top="193" left="341" width="171" height="21" font="1">normal (120–140 mm Hg), and </text>
<text top="210" left="341" width="113" height="21" font="1">high (≥140 mm Hg). </text>
<text top="228" left="341" width="3" height="20" font="4"><b> </b></text>
<text top="108" left="536" width="259" height="20" font="4"><b>1</b>°<b> outcomes:</b> All-cause and vascular mortality </text>
<text top="125" left="536" width="3" height="20" font="1"> </text>
<text top="143" left="536" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="160" left="536" width="245" height="20" font="1">2 y after assessment, the low to normal SBP </text>
<text top="177" left="536" width="245" height="20" font="1">group tended to have the highest cumulative </text>
<text top="194" left="536" width="236" height="20" font="1">all-cause mortality (11.5%), compared with </text>
<text top="211" left="536" width="256" height="20" font="1">mortality rates of 8.5% and 7.5% in the normal </text>
<text top="229" left="536" width="236" height="20" font="1">and high SBP groups, respectively. Similar </text>
<text top="246" left="536" width="236" height="20" font="1">patterns were seen with vascular mortality. </text>
<text top="263" left="536" width="246" height="20" font="1">After adjusting for covariates, compared with </text>
<text top="280" left="536" width="246" height="20" font="1">the high SBP group, the low to normal group </text>
<text top="298" left="536" width="257" height="20" font="1">had higher all-cause mortality AHR: 1.96 (95% </text>
<text top="315" left="536" width="242" height="20" font="1">CI: 1.13–3.39; p=0.017) and trended toward </text>
<text top="332" left="536" width="248" height="20" font="1">higher vascular mortality AHR: 2.08 (95% CI: </text>
<text top="349" left="536" width="258" height="20" font="1">0.93–4.6; p=0.075). Compared with the normal </text>
<text top="367" left="536" width="241" height="20" font="1">BP group, the risk of all-cause and vascular </text>
<text top="384" left="536" width="242" height="20" font="1">mortality trended higher in low to normal BP </text>
<text top="401" left="536" width="196" height="20" font="1">group but did not achieve statistical </text>
<text top="418" left="536" width="71" height="20" font="1">significance. </text>
<text top="107" left="813" width="278" height="20" font="4"><b>Summary: </b>After stroke, compared with SBP in the </text>
<text top="124" left="813" width="275" height="20" font="1">high range, low to normal SBP may be associated </text>
<text top="141" left="813" width="264" height="20" font="1">with poorer mortality outcomes. Study limited by </text>
<text top="159" left="813" width="252" height="20" font="1">self-reported nature and retrospective design. </text>
<text top="436" left="98" width="75" height="20" font="1">Kim J, et al.,  </text>
<text top="453" left="98" width="66" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(223)</a>  </text>
<text top="470" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24509123?dopt=Citation">24509123</a></text>
<text top="470" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24509123?dopt=Citation"> </a></text>
<text top="436" left="214" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="453" left="214" width="85" height="20" font="1">the association </text>
<text top="470" left="214" width="94" height="20" font="1">between BP and </text>
<text top="488" left="214" width="106" height="20" font="1">vascular events up </text>
<text top="505" left="214" width="109" height="20" font="1">to 10 y after stroke. </text>
<text top="522" left="214" width="3" height="20" font="1"> </text>
<text top="539" left="214" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="557" left="214" width="63" height="20" font="1">Analysis of </text>
<text top="574" left="214" width="97" height="20" font="1">population based </text>
<text top="591" left="214" width="98" height="20" font="1">study (North East </text>
<text top="608" left="214" width="100" height="20" font="1">Melbourne Stroke </text>
<text top="625" left="214" width="91" height="20" font="1">Incidence Study </text>
<text top="643" left="214" width="67" height="20" font="1">(NEMESIS)<b> </b></text>
<text top="436" left="341" width="179" height="20" font="4"><b>Inclusion criteria: </b>5-y survivors </text>
<text top="453" left="341" width="51" height="20" font="1">of stroke<b> </b></text>
<text top="470" left="341" width="3" height="20" font="4"><b> </b></text>
<text top="488" left="341" width="71" height="20" font="4"><b>Categories: </b></text>
<text top="505" left="341" width="179" height="20" font="1">Stratification by quartiles of SBP </text>
<text top="522" left="341" width="3" height="20" font="4"><b> </b></text>
<text top="539" left="341" width="132" height="20" font="4"><b>Follow-up: </b>Annually by </text>
<text top="557" left="341" width="166" height="20" font="1">telephone at 6, 8, and 9 y and </text>
<text top="574" left="341" width="168" height="20" font="1">face-to-face interview at 7 and </text>
<text top="591" left="341" width="95" height="20" font="1">10 y after stroke.<b> </b></text>
<text top="437" left="536" width="259" height="20" font="4"><b>1</b>°<b> outcomes:</b> Composite of all-cause death or </text>
<text top="454" left="536" width="258" height="20" font="1">nonfatal vascular event (stroke or AMI); and all-</text>
<text top="472" left="536" width="107" height="20" font="1">cause death alone. </text>
<text top="489" left="536" width="3" height="20" font="1"> </text>
<text top="506" left="536" width="222" height="20" font="4"><b>Key findings: </b>In 5-y survivors of stroke, </text>
<text top="523" left="536" width="263" height="20" font="1">compared to a SBP of 131–141 mm Hg, SBP of </text>
<text top="540" left="536" width="258" height="20" font="1">120 mm Hg or less was associated with a 61% </text>
<text top="558" left="536" width="256" height="20" font="1">greater risk of stroke, acute MI and death (HR: </text>
<text top="575" left="536" width="198" height="21" font="1">1.61; 95% CI: 1.08–2.41; p = 0.019). </text>
<text top="592" left="536" width="243" height="20" font="1">Compared to the reference category of SBP </text>
<text top="609" left="536" width="254" height="21" font="1">131–141  mm Hg, there were no differences in </text>
<text top="627" left="536" width="253" height="21" font="1">outcome in the pts with SBP 121–130  mm Hg </text>
<text top="644" left="536" width="231" height="21" font="1">(p = 0.491) or 142–210  mm Hg (p = 0.313). </text>
<text top="661" left="536" width="249" height="20" font="1">Findings were not modified after adjusting for </text>
<text top="678" left="536" width="198" height="20" font="1">antihypertensive drug prescriptions.<b> </b></text>
<text top="436" left="813" width="267" height="20" font="4"><b>Summary: </b>There appears to be a greater risk of </text>
<text top="453" left="813" width="275" height="20" font="1">poor outcome in long-term survivors of stroke with </text>
<text top="470" left="813" width="258" height="20" font="1">low SBP. This is further evidence that low SBP </text>
<text top="488" left="813" width="161" height="20" font="1">may result in poor prognosis. </text>
<text top="488" left="975" width="3" height="20" font="19"> </text>
<text top="696" left="98" width="95" height="20" font="1">Wang WT, et al., </text>
<text top="713" left="98" width="63" height="20" font="1">2016 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#275">(224)</a> </text>
<text top="731" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27082571">27082571</a></text>
<text top="731" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27082571"> </a></text>
<text top="696" left="214" width="111" height="20" font="4"><b>Aim: </b>To investigate </text>
<text top="713" left="214" width="103" height="20" font="1">the relative effects </text>
<text top="731" left="214" width="83" height="20" font="1">of BP-lowering </text>
<text top="748" left="214" width="93" height="20" font="1">therapies [ACEI, </text>
<text top="765" left="214" width="94" height="20" font="1">ARB, BB, CCBs, </text>
<text top="782" left="214" width="76" height="20" font="1">diuretics, and </text>
<text top="696" left="341" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="715" left="341" width="7" height="18" font="1">•</text>
<text top="715" left="347" width="173" height="20" font="1"> RCTs comparing the effects of </text>
<text top="732" left="341" width="157" height="20" font="1">any of the 6 most commonly </text>
<text top="749" left="341" width="172" height="20" font="1">used BP-lowering drug classes </text>
<text top="766" left="341" width="175" height="20" font="1">[ACEI, ARB, alpha-blocker, BB, </text>
<text top="784" left="341" width="175" height="20" font="1">diuretics, and CCB] vs. placebo </text>
<text top="697" left="536" width="75" height="20" font="4"><b>1</b>°<b> outcome:</b> </text>
<text top="697" left="612" width="94" height="20" font="9">Recurrent stroke </text>
<text top="715" left="536" width="3" height="20" font="9"> </text>
<text top="733" left="536" width="180" height="20" font="4"><b>2</b>°<b> outcome:</b> CHD, and MACCE </text>
<text top="750" left="536" width="3" height="20" font="1"> </text>
<text top="767" left="536" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="786" left="536" width="7" height="18" font="1">•</text>
<text top="786" left="543" width="241" height="20" font="1"> Compared with placebo, ACEI plus diuretic </text>
<text top="698" left="813" width="7" height="18" font="1">•</text>
<text top="697" left="820" width="243" height="20" font="1"> Virtually all BP-lowering medication classes </text>
<text top="715" left="813" width="285" height="20" font="1">reduced vascular events including recurrent stroke.  </text>
<text top="734" left="813" width="7" height="18" font="1">•</text>
<text top="733" left="820" width="258" height="20" font="1"> The higher the average BP reduction between </text>
<text top="750" left="813" width="275" height="20" font="1">the treatment vs. control groups the larger the risk </text>
<text top="767" left="813" width="271" height="20" font="1">reduction in recurrent stroke events and MACCE. </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">167 </text>
<text top="107" left="214" width="100" height="20" font="1">combinations of 3 </text>
<text top="124" left="214" width="106" height="20" font="1">drugs] in pts with a </text>
<text top="141" left="214" width="105" height="20" font="1">prior stroke history </text>
<text top="159" left="214" width="3" height="20" font="1"> </text>
<text top="176" left="214" width="68" height="20" font="4"><b>Study size: </b></text>
<text top="193" left="214" width="112" height="20" font="1">15 RCTs composed </text>
<text top="210" left="214" width="55" height="20" font="1">of 39,329 </text>
<text top="228" left="214" width="66" height="20" font="1">participants </text>
<text top="245" left="214" width="87" height="20" font="1">previous stroke<b> </b></text>
<text top="107" left="341" width="126" height="20" font="1">or comparing 1 type of </text>
<text top="124" left="341" width="152" height="20" font="1">antihypertensive agent with </text>
<text top="141" left="341" width="165" height="20" font="1">another type on pts who have </text>
<text top="159" left="341" width="159" height="20" font="1">suffered from stroke or TIA s </text>
<text top="178" left="341" width="7" height="18" font="1">•</text>
<text top="177" left="347" width="161" height="20" font="1"> RCTs reporting outcomes of </text>
<text top="194" left="341" width="177" height="20" font="1">interest with a follow-up of more </text>
<text top="211" left="341" width="79" height="20" font="1">than a month.<b> </b></text>
<text top="107" left="536" width="245" height="20" font="1">reduced recurrent stroke (OR: 0.54; 95% CI: </text>
<text top="124" left="536" width="66" height="20" font="1">0.33–0.90). </text>
<text top="143" left="536" width="7" height="18" font="1">•</text>
<text top="143" left="543" width="250" height="20" font="1"> ACEI plus diuretic had a higher probability of </text>
<text top="160" left="536" width="227" height="20" font="1">being at the best ranking position (31%).  </text>
<text top="177" left="536" width="213" height="20" font="1">Compared with regimens not including </text>
<text top="194" left="536" width="261" height="20" font="1">diuretics, diuretics-based treatments resulted in </text>
<text top="211" left="536" width="252" height="21" font="1">a significantly larger reduction in BP (12.0 mm </text>
<text top="229" left="536" width="128" height="20" font="1">Hg; 95% CI: 7.0–16.9), </text>
<text top="246" left="536" width="261" height="20" font="1">● Treatment regimens including diuretics had a </text>
<text top="263" left="536" width="214" height="20" font="1">RR of 0.619 (95% CI: 0.515–0.743) for </text>
<text top="280" left="536" width="253" height="20" font="1">recurrent stroke, which was significantly lower </text>
<text top="298" left="536" width="245" height="20" font="1">than treatments that did not include diuretics </text>
<text top="315" left="536" width="238" height="21" font="1">(RR = 0.882; 95% CI: 0.800–0.973) with a p </text>
<text top="332" left="536" width="169" height="20" font="1">value for interaction of 0.0008. </text>
<text top="349" left="536" width="231" height="20" font="1">● None of the between-drug comparisons </text>
<text top="366" left="536" width="231" height="20" font="1">showed significant differences in effect on </text>
<text top="384" left="536" width="57" height="20" font="1">outcomes<b> </b></text>
<text top="109" left="813" width="7" height="18" font="1">•</text>
<text top="108" left="820" width="251" height="20" font="1"> Diuretic-based treatments lowered the risk of </text>
<text top="125" left="813" width="274" height="20" font="1">recurrent stroke more than treatments that did not </text>
<text top="143" left="813" width="95" height="20" font="1">include diuretics. </text>
<text top="162" left="813" width="7" height="18" font="1">•</text>
<text top="161" left="820" width="271" height="20" font="1"> There were no significant differences in effect on </text>
<text top="178" left="813" width="274" height="20" font="1">2º stroke reduction between the various individual </text>
<text top="195" left="813" width="204" height="20" font="1">antihypertensive medication classes.<b> </b></text>
<text top="402" left="98" width="92" height="20" font="1">Katsanos AH, et </text>
<text top="419" left="98" width="83" height="20" font="1">al., 2017 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(225)</a> </text>
<text top="436" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27802419">27802419</a></text>
<text top="436" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27802419"> </a></text>
<text top="402" left="214" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="419" left="214" width="98" height="20" font="1">association of BP </text>
<text top="436" left="214" width="79" height="20" font="1">reduction with </text>
<text top="453" left="214" width="114" height="20" font="1">recurrent stroke and </text>
<text top="471" left="214" width="93" height="20" font="1">CV events using </text>
<text top="488" left="214" width="108" height="20" font="1">available RCT data </text>
<text top="505" left="214" width="69" height="20" font="1">on 2º stroke </text>
<text top="522" left="214" width="61" height="20" font="1">prevention </text>
<text top="539" left="214" width="3" height="20" font="1"> </text>
<text top="557" left="214" width="85" height="20" font="4"><b>Study size: </b>14 </text>
<text top="574" left="214" width="109" height="20" font="1">studies with 42,736 </text>
<text top="591" left="214" width="23" height="20" font="1">pts <b> </b></text>
<text top="402" left="341" width="154" height="20" font="4"><b>Inclusion criteria: </b>RCTs of </text>
<text top="419" left="341" width="168" height="20" font="1">antihypertensives for 2º stroke </text>
<text top="436" left="341" width="154" height="20" font="1">prevention pts that reported </text>
<text top="453" left="341" width="169" height="20" font="1">achieved BP values during the </text>
<text top="471" left="341" width="94" height="20" font="1">follow-up period. </text>
<text top="488" left="341" width="3" height="20" font="1"> </text>
<text top="505" left="341" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="522" left="341" width="154" height="20" font="1">Observational studies, case </text>
<text top="539" left="341" width="162" height="20" font="1">series, case reports, RCTs in </text>
<text top="557" left="341" width="150" height="20" font="1">non-IS/TIA population, and </text>
<text top="574" left="341" width="159" height="20" font="1">studies not reporting data on </text>
<text top="591" left="341" width="146" height="20" font="1">finally achieved BP values<b> </b></text>
<text top="403" left="536" width="75" height="20" font="4"><b>1</b>°<b> outcome:</b> </text>
<text top="403" left="612" width="94" height="20" font="9">Recurrent stroke </text>
<text top="420" left="536" width="3" height="20" font="9"> </text>
<text top="438" left="536" width="245" height="20" font="4"><b>2</b>°<b> outcome:</b> MI, death from any cause, and </text>
<text top="456" left="536" width="91" height="20" font="1">risk of CV death </text>
<text top="456" left="627" width="3" height="20" font="9"> </text>
<text top="473" left="536" width="3" height="20" font="1"> </text>
<text top="490" left="536" width="81" height="20" font="4"><b>Key findings: </b></text>
<text top="507" left="536" width="257" height="20" font="1">● SBP reduction linearly associated with lower </text>
<text top="524" left="536" width="258" height="20" font="1">risk of recurrent stroke (regression slope, 0.02; </text>
<text top="542" left="536" width="247" height="20" font="1">95% CI: 0.01–0.04; p=0.049), MI (regression </text>
<text top="559" left="536" width="252" height="20" font="1">slope, 0.022; 95% CI: 0.002–0.041; p=0.024), </text>
<text top="576" left="536" width="254" height="20" font="1">death from any cause (regression slope, 0.02; </text>
<text top="593" left="536" width="243" height="20" font="1">95% CI: 0.01–0.03; p=0.001), and CV death </text>
<text top="611" left="536" width="241" height="20" font="1">(regression slope, 0.05; 95% CI: 0.03–0.07; </text>
<text top="628" left="536" width="59" height="20" font="1">p&lt;0.001).  </text>
<text top="645" left="536" width="225" height="20" font="1">● No relation was observed between the </text>
<text top="662" left="536" width="218" height="20" font="1">degree of SBP reduction and the risk of </text>
<text top="679" left="536" width="231" height="20" font="1">disabling or fatal stroke (regression slope, </text>
<text top="697" left="536" width="226" height="20" font="1">0.001; 95% CI: −0.024–0.022; p=0.944).  </text>
<text top="714" left="536" width="247" height="20" font="1">● Relation of SBP reduction with ischemic or </text>
<text top="731" left="536" width="248" height="20" font="1">hemorrhagic stroke was not assessed due to </text>
<text top="748" left="536" width="258" height="20" font="1">the small number of studies with available data </text>
<text top="765" left="536" width="36" height="20" font="1">(&lt;10).<b> </b></text>
<text top="402" left="813" width="279" height="20" font="4"><b>Summary: </b>BP reduction is linearly associated with </text>
<text top="419" left="813" width="237" height="20" font="1">the magnitude of risk reduction in recurrent </text>
<text top="436" left="813" width="262" height="20" font="1">cerebrovascular and CV events, but optimal BP </text>
<text top="453" left="813" width="116" height="20" font="1">target not evaluated.<b> </b></text>
<text top="785" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="168" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">168 </text>
<text top="106" left="81" width="532" height="24" font="3"><b>Data Supplement 45. RCTs and Meta-analysis Comparing PAD (Section 9.5) </b></text>
<text top="146" left="109" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="163" left="135" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="180" left="113" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="256" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="163" left="260" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="180" left="254" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="402" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="563" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="163" left="578" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="180" left="563" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="197" left="584" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="146" left="732" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="163" left="716" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="180" left="707" width="154" height="20" font="4"><b>P value; OR or RR; &amp; 95% </b></text>
<text top="197" left="774" width="20" height="20" font="4"><b>CI) </b></text>
<text top="147" left="906" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="164" left="940" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="181" left="948" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="215" left="104" width="42" height="20" font="4"><b>HOPE  </b></text>
<text top="233" left="104" width="105" height="20" font="1">Östergren J, et al., </text>
<text top="250" left="104" width="63" height="20" font="1">2004 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(226)</a> </text>
<text top="267" left="104" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14683738">14683738</a></text>
<text top="267" left="159" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14683738"> </a> </text>
<text top="215" left="226" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="233" left="226" width="97" height="20" font="1">impact of ramipril </text>
<text top="250" left="226" width="135" height="20" font="1">compared to placebo on </text>
<text top="267" left="226" width="129" height="20" font="1">the prevention of major </text>
<text top="284" left="226" width="134" height="20" font="1">CV events in PAD pts in </text>
<text top="301" left="226" width="98" height="20" font="1">the HOPE study.  </text>
<text top="319" left="226" width="3" height="20" font="1"> </text>
<text top="336" left="226" width="137" height="20" font="4"><b>Study type:</b> Multicenter, </text>
<text top="353" left="226" width="99" height="20" font="1">double-blind RCT </text>
<text top="370" left="226" width="3" height="20" font="1"> </text>
<text top="388" left="226" width="134" height="20" font="4"><b>Size:</b> 9,541 randomized </text>
<text top="405" left="226" width="89" height="20" font="1">in HOPE (1,725 </text>
<text top="422" left="226" width="118" height="20" font="1">randomized who had </text>
<text top="439" left="226" width="141" height="20" font="1">baseline PAD, defined by </text>
<text top="456" left="226" width="134" height="20" font="1">ABI with pulse detection </text>
<text top="474" left="226" width="111" height="20" font="1">by either Doppler or </text>
<text top="491" left="226" width="61" height="20" font="1">palpation)  </text>
<text top="215" left="381" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="234" left="381" width="7" height="18" font="1">•</text>
<text top="234" left="388" width="38" height="20" font="1"> ≥55 y </text>
<text top="253" left="381" width="7" height="18" font="1">•</text>
<text top="252" left="388" width="116" height="20" font="1"> Existing CVD (CAD, </text>
<text top="269" left="381" width="152" height="20" font="1">stroke, PAD) or DM with an </text>
<text top="287" left="381" width="142" height="20" font="1">additional CVD risk factor </text>
<text top="304" left="381" width="89" height="20" font="1">(smoking, HTN, </text>
<text top="321" left="381" width="145" height="20" font="1">hypercholesterolemia, low </text>
<text top="338" left="381" width="136" height="20" font="1">HDL, microalbuminuria)  </text>
<text top="356" left="381" width="3" height="20" font="1"> </text>
<text top="373" left="381" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="392" left="381" width="7" height="18" font="1">•</text>
<text top="391" left="388" width="105" height="20" font="1"> Received ACEI or </text>
<text top="408" left="381" width="92" height="20" font="1">vitamin E or had </text>
<text top="426" left="381" width="103" height="20" font="1">uncontrolled HTN  </text>
<text top="445" left="381" width="7" height="18" font="1">•</text>
<text top="444" left="388" width="122" height="20" font="1"> HF or LV dysfunction </text>
<text top="461" left="381" width="3" height="20" font="1"> </text>
<text top="478" left="381" width="135" height="20" font="1">*All eligible pts had 7- to </text>
<text top="496" left="381" width="104" height="20" font="1">10-d run-in period, </text>
<text top="513" left="381" width="135" height="20" font="1">received 2.5 mg ramipril </text>
<text top="530" left="381" width="143" height="20" font="1">daily; those who tolerated </text>
<text top="547" left="381" width="110" height="20" font="1">were then assigned </text>
<text top="564" left="381" width="136" height="20" font="1">placebo for 10–14 d and </text>
<text top="582" left="381" width="146" height="20" font="1">then were randomized to1 </text>
<text top="599" left="381" width="126" height="20" font="1">of intervention arms or </text>
<text top="616" left="381" width="40" height="20" font="1">control </text>
<text top="215" left="548" width="127" height="20" font="4"><b>Intervention: </b>Ramipril </text>
<text top="233" left="548" width="94" height="20" font="1">(10 mg/d): 4,645 </text>
<text top="250" left="548" width="68" height="20" font="1">randomized<b> </b></text>
<text top="267" left="548" width="129" height="20" font="4"><b>Intervention: </b>Placebo: </text>
<text top="284" left="548" width="105" height="20" font="1">4,652 randomized <b> </b></text>
<text top="217" left="701" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="236" left="701" width="7" height="18" font="1">•</text>
<text top="235" left="708" width="121" height="20" font="1"> Combined CV death, </text>
<text top="252" left="701" width="152" height="20" font="1">nonfatal MI, nonfatal stroke </text>
<text top="271" left="701" width="7" height="18" font="1">•</text>
<text top="271" left="708" width="115" height="20" font="1"> In pts with history of </text>
<text top="288" left="701" width="165" height="20" font="1">symptomatic PAD, comparing </text>
<text top="305" left="701" width="163" height="20" font="1">ramipril to placebo: RR: 0.75; </text>
<text top="322" left="701" width="109" height="20" font="1">95% CI: 0.61–0.92  </text>
<text top="341" left="701" width="7" height="18" font="1">•</text>
<text top="341" left="708" width="132" height="20" font="1"> In pts with no history of </text>
<text top="358" left="701" width="165" height="20" font="1">symptomatic PAD, but severe </text>
<text top="375" left="701" width="150" height="20" font="1">subclinical disease defined </text>
<text top="392" left="701" width="131" height="20" font="1">as ABI &lt;0.6, comparing </text>
<text top="409" left="701" width="163" height="20" font="1">ramipril to placebo: RR: 0.77; </text>
<text top="427" left="701" width="109" height="20" font="1">95% CI: 0.55–1.09  </text>
<text top="446" left="701" width="7" height="18" font="1">•</text>
<text top="445" left="708" width="132" height="20" font="1"> In pts with no history of </text>
<text top="462" left="701" width="125" height="20" font="1">symptomatic PAD, but </text>
<text top="479" left="701" width="161" height="20" font="1">moderate subclinical disease </text>
<text top="497" left="701" width="131" height="20" font="1">defined as ABI 0.6–0.9, </text>
<text top="514" left="701" width="118" height="20" font="1">comparing ramipril to </text>
<text top="531" left="701" width="152" height="20" font="1">placebo: RR: 0.72; 95% CI: </text>
<text top="548" left="701" width="58" height="20" font="1">0.56–0.92 </text>
<text top="566" left="701" width="3" height="20" font="1"> </text>
<text top="584" left="701" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A </text>
<text top="601" left="701" width="3" height="20" font="1"> </text>
<text top="618" left="701" width="112" height="20" font="4"><b>Summary:</b> Ramipril </text>
<text top="635" left="701" width="151" height="20" font="1">prevented clinical events in </text>
<text top="653" left="701" width="152" height="20" font="1">pts with clinical evidence of </text>
<text top="670" left="701" width="133" height="20" font="1">PAD as well as in those </text>
<text top="687" left="701" width="142" height="20" font="1">without PAD. The relative </text>
<text top="704" left="701" width="137" height="20" font="1">benefit was similar in pts </text>
<text top="722" left="701" width="145" height="20" font="1">classified by levels of ABI, </text>
<text top="739" left="701" width="165" height="20" font="1">even though event rates were </text>
<text top="756" left="701" width="156" height="20" font="1">higher in pts with subclinical </text>
<text top="773" left="701" width="91" height="20" font="1">and clinical ABI. </text>
<text top="217" left="880" width="134" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:  </b></text>
<text top="236" left="880" width="7" height="18" font="1">•</text>
<text top="235" left="887" width="203" height="20" font="1"> Individual components of composite </text>
<text top="252" left="880" width="160" height="20" font="1">endpoint, all-cause mortality, </text>
<text top="269" left="880" width="229" height="20" font="1">hospitalizations for HF, DM complications<b> </b></text>
<text top="288" left="880" width="7" height="18" font="1">•</text>
<text top="288" left="887" width="220" height="20" font="1"> In pts with history of symptomatic PAD, </text>
<text top="305" left="880" width="206" height="20" font="1">comparing ramipril to placebo: for MI, </text>
<text top="322" left="880" width="227" height="20" font="1">RR: 0.75 (95% CI: 0.58–0.98); for stroke, </text>
<text top="339" left="880" width="216" height="20" font="1">RR: 0.72 (95% CI: 0.50–1.05); for CVD </text>
<text top="357" left="880" width="222" height="20" font="1">mortality, RR: 0.75 (95% CI: 0.56–0.99); </text>
<text top="374" left="880" width="201" height="20" font="1">for total mortality, RR: 0.85 (95% CI: </text>
<text top="391" left="880" width="212" height="20" font="1">0.68–1.07); for DM complications, RR: </text>
<text top="408" left="880" width="210" height="20" font="1">0.87 (95% CI: 0.74–1.09); for HF, RR: </text>
<text top="426" left="880" width="141" height="20" font="1">0.81 (95% CI: 0.53–1.24)<b> </b></text>
<text top="445" left="880" width="7" height="18" font="1">•</text>
<text top="444" left="887" width="205" height="20" font="1"> In pts with no history of symptomatic </text>
<text top="461" left="880" width="199" height="20" font="1">PAD, but severe subclinical disease </text>
<text top="478" left="880" width="219" height="20" font="1">defined as ABI &lt;0.6, comparing ramipril </text>
<text top="496" left="880" width="205" height="20" font="1">to placebo: for MI, RR: 0.73 (95% CI: </text>
<text top="513" left="880" width="227" height="20" font="1">0.48–1.11); for stroke, RR: 0.99 (95% CI: </text>
<text top="530" left="880" width="218" height="20" font="1">0.52–1.89); for CVD mortality, RR: 0.76 </text>
<text top="547" left="880" width="215" height="20" font="1">(95% CI: 0.46–1.25); for total mortality, </text>
<text top="564" left="880" width="213" height="20" font="1">RR: 0.81 (95% CI: 0.55–1.19); for DM, </text>
<text top="582" left="880" width="210" height="20" font="1">RR: 0.83 (95% CI: 0.50–1.39); for HF, </text>
<text top="599" left="880" width="165" height="20" font="1">RR: 0.66 (95% CI: 0.34–1.28) </text>
<text top="618" left="880" width="7" height="18" font="1">•</text>
<text top="617" left="887" width="205" height="20" font="1"> In pts with no history of symptomatic </text>
<text top="634" left="880" width="214" height="20" font="1">PAD, but moderate subclinical disease </text>
<text top="652" left="880" width="192" height="20" font="1">defined as ABI 0.6–0.9, comparing </text>
<text top="669" left="880" width="230" height="20" font="1">ramipril to placebo: for MI, RR: 0.81 (95% </text>
<text top="686" left="880" width="227" height="20" font="1">CI: 0.60–1.09); for stroke, RR: 0.44 (95% </text>
<text top="703" left="880" width="210" height="20" font="1">CI: 0.26–0.77); for CVD mortality, RR: </text>
<text top="720" left="880" width="189" height="20" font="1">0.62 (95% CI: 0.42–0.90); for total </text>
<text top="738" left="880" width="222" height="20" font="1">mortality, RR: 0.58 (95% CI: 0.42–0.79); </text>
<text top="755" left="880" width="229" height="20" font="1">for diabetic complications, RR: 0.80 (95% </text>
<text top="772" left="880" width="229" height="20" font="1">CI: 0.53–1.21); for HF, RR: 0.69 (95% CI: </text>
<text top="789" left="880" width="62" height="20" font="1">0.38–1.23) </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">169 </text>
<text top="107" left="880" width="3" height="20" font="1"> </text>
<text top="124" left="880" width="228" height="20" font="4"><b>Study limitations and adverse events:</b>  </text>
<text top="141" left="880" width="192" height="20" font="1">ABI not measured by Doppler gold </text>
<text top="159" left="880" width="51" height="20" font="1">standard </text>
<text top="193" left="104" width="100" height="20" font="1">Overlack A, et al., </text>
<text top="210" left="104" width="63" height="20" font="1">1994 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(227)</a> </text>
<text top="227" left="104" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8059778">8059778</a></text>
<text top="227" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8059778"> </a></text>
<text top="193" left="226" width="127" height="20" font="4"><b>Aim:</b> To determine the </text>
<text top="210" left="226" width="108" height="20" font="1">effect of perindopril </text>
<text top="227" left="226" width="135" height="20" font="1">compared to placebo on </text>
<text top="244" left="226" width="140" height="20" font="1">various clinical outcomes </text>
<text top="262" left="226" width="94" height="20" font="1">in pt subgroups.  </text>
<text top="279" left="226" width="3" height="20" font="1"> </text>
<text top="296" left="226" width="137" height="20" font="4"><b>Study type:</b> Multicenter, </text>
<text top="313" left="226" width="127" height="20" font="1">double-blinded RCT (3 </text>
<text top="330" left="226" width="141" height="20" font="1">wk placebo run-in period, </text>
<text top="348" left="226" width="140" height="20" font="1">6 wk double-blind phase) </text>
<text top="365" left="226" width="3" height="20" font="1"> </text>
<text top="382" left="226" width="135" height="20" font="4"><b>Size:</b> 490 (54 with PAD) </text>
<text top="193" left="381" width="113" height="20" font="4"><b>Inclusion criteria:</b>   </text>
<text top="212" left="381" width="7" height="18" font="1">•</text>
<text top="211" left="388" width="124" height="20" font="1"> Mild newly diagnosed </text>
<text top="228" left="381" width="140" height="20" font="1">essential HTN in addition </text>
<text top="246" left="381" width="145" height="20" font="1">to 1 concomitant diseases </text>
<text top="263" left="381" width="72" height="20" font="1">or therapies: </text>
<text top="280" left="381" width="151" height="20" font="1">hyperlipidemia, DM-2, IHD, </text>
<text top="297" left="381" width="146" height="20" font="1">cardiac arrhythmias, PAD, </text>
<text top="314" left="381" width="97" height="20" font="1">nephropathy with </text>
<text top="332" left="381" width="121" height="20" font="1">proteinuria, COPD, or </text>
<text top="349" left="381" width="143" height="20" font="1">degenerative join disease </text>
<text top="366" left="381" width="72" height="20" font="1">with NSAIDs </text>
<text top="385" left="381" width="7" height="18" font="1">•</text>
<text top="385" left="388" width="54" height="20" font="1"> 40–75 y  </text>
<text top="402" left="381" width="3" height="20" font="1"> </text>
<text top="419" left="381" width="99" height="20" font="1">*Antihypertensive </text>
<text top="436" left="381" width="138" height="20" font="1">treatment was stopped 1 </text>
<text top="453" left="381" width="144" height="20" font="1">wk prior to randomization, </text>
<text top="471" left="381" width="145" height="20" font="1">required DBP 95–104 mm </text>
<text top="488" left="381" width="22" height="20" font="1">Hg  </text>
<text top="505" left="381" width="3" height="20" font="1"> </text>
<text top="522" left="381" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="193" left="548" width="140" height="20" font="4"><b>Intervention: </b>Perindopril </text>
<text top="210" left="548" width="77" height="20" font="1">(4 mg/d): 253 </text>
<text top="227" left="548" width="68" height="20" font="1">randomized </text>
<text top="244" left="548" width="3" height="20" font="1"> </text>
<text top="262" left="548" width="128" height="20" font="4"><b>Comparator: </b>Placebo: </text>
<text top="279" left="548" width="95" height="20" font="1">237 randomized  </text>
<text top="194" left="701" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="213" left="701" width="7" height="18" font="1">•</text>
<text top="212" left="708" width="151" height="20" font="1"> ABI measured by Doppler  </text>
<text top="231" left="701" width="7" height="18" font="1">•</text>
<text top="231" left="708" width="143" height="20" font="1"> In pts with baseline PAD, </text>
<text top="248" left="701" width="144" height="20" font="1">there was no difference in </text>
<text top="265" left="701" width="163" height="20" font="1">post-treatment Doppler Index </text>
<text top="282" left="701" width="165" height="20" font="1">between perindopril (0.75) vs. </text>
<text top="300" left="701" width="127" height="20" font="1">placebo (0.75); p&gt;0.05 </text>
<text top="317" left="701" width="3" height="20" font="1"> </text>
<text top="335" left="701" width="116" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> </text>
<text top="352" left="701" width="160" height="20" font="1">Spontaneously reported side </text>
<text top="370" left="701" width="121" height="20" font="1">effects: 5.5% of pts in </text>
<text top="387" left="701" width="142" height="20" font="1">perindopril, 3.8% of pts in </text>
<text top="404" left="701" width="50" height="20" font="1">placebo  </text>
<text top="421" left="701" width="3" height="20" font="1"> </text>
<text top="438" left="701" width="154" height="20" font="4"><b>Summary</b>: In pts with PAD, </text>
<text top="456" left="701" width="142" height="20" font="1">Doppler index at baseline </text>
<text top="473" left="701" width="164" height="20" font="1">was not different between the </text>
<text top="490" left="701" width="130" height="20" font="1">2 groups and remained </text>
<text top="507" left="701" width="161" height="20" font="1">unchanged during treatment. </text>
<text top="525" left="701" width="126" height="20" font="1">Pain-free and maximal </text>
<text top="542" left="701" width="156" height="20" font="1">walking distances increased </text>
<text top="559" left="701" width="159" height="20" font="1">from baseline but there were </text>
<text top="576" left="701" width="160" height="20" font="1">no significant between group </text>
<text top="593" left="701" width="67" height="20" font="1">differences. </text>
<text top="194" left="880" width="134" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b>  </text>
<text top="213" left="880" width="7" height="18" font="1">•</text>
<text top="212" left="887" width="176" height="20" font="1"> Pain-free walking distance (m), </text>
<text top="230" left="880" width="143" height="20" font="1">maximal walking distance </text>
<text top="249" left="880" width="7" height="18" font="1">•</text>
<text top="248" left="887" width="217" height="20" font="1"> In pts with baseline PAD, there was no </text>
<text top="265" left="880" width="223" height="20" font="1">difference in change in pain-free walking </text>
<text top="282" left="880" width="228" height="20" font="1">distance (m) between perindopril (+11 m) </text>
<text top="300" left="880" width="157" height="20" font="1">vs. placebo (+11 m); p&gt;0.05 </text>
<text top="319" left="880" width="7" height="18" font="1">•</text>
<text top="318" left="887" width="217" height="20" font="1"> In pts with baseline PAD, there was no </text>
<text top="335" left="880" width="221" height="20" font="1">difference in change in maximal walking </text>
<text top="352" left="880" width="213" height="20" font="1">distance between perindopril (pre-trial: </text>
<text top="370" left="880" width="210" height="20" font="1">318 m (SD: 45), post-trial: 323 m (SD: </text>
<text top="387" left="880" width="230" height="20" font="1">43) vs. placebo (pre-trial: 333 m (SD: 43), </text>
<text top="404" left="880" width="141" height="20" font="1">post-trial: 369 m (SD: 46) </text>
<text top="421" left="880" width="3" height="20" font="1"> </text>
<text top="438" left="880" width="228" height="20" font="4"><b>Study limitations and adverse events:</b>  </text>
<text top="456" left="880" width="213" height="20" font="1">Short follow-up, unable to assess hard </text>
<text top="473" left="880" width="97" height="20" font="1">clinical outcomes </text>
<text top="611" left="104" width="107" height="20" font="1">Schweizer J, et al., </text>
<text top="629" left="104" width="63" height="20" font="1">1998 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(228)</a> </text>
<text top="646" left="104" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9581724">9581724</a></text>
<text top="646" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9581724"> </a></text>
<text top="611" left="226" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="629" left="226" width="128" height="20" font="1">whether treatment with </text>
<text top="646" left="226" width="113" height="20" font="1">high dose verapamil </text>
<text top="663" left="226" width="123" height="20" font="1">prevents restenosis in </text>
<text top="680" left="226" width="137" height="20" font="1">pts with PAD at high risk </text>
<text top="697" left="226" width="121" height="20" font="1">for reoccurrence after </text>
<text top="715" left="226" width="100" height="20" font="1">successful PTCA. </text>
<text top="732" left="226" width="3" height="20" font="1"> </text>
<text top="749" left="226" width="114" height="20" font="4"><b>Study type:</b> Double-</text>
<text top="766" left="226" width="93" height="20" font="1">blind RCT (6 mo </text>
<text top="784" left="226" width="52" height="20" font="1">duration) </text>
<text top="611" left="381" width="113" height="20" font="4"><b>Inclusion criteria:</b>   </text>
<text top="630" left="381" width="7" height="18" font="1">•</text>
<text top="630" left="388" width="131" height="20" font="1"> PAD (based on arterial </text>
<text top="647" left="381" width="126" height="20" font="1">angiography and color-</text>
<text top="664" left="381" width="141" height="20" font="1">coded duplex ultrasound) </text>
<text top="681" left="381" width="100" height="20" font="1">present for &gt;6 mo </text>
<text top="700" left="381" width="7" height="18" font="1">•</text>
<text top="700" left="388" width="111" height="20" font="1"> Primary success of </text>
<text top="717" left="381" width="132" height="20" font="1">PTCA treatment (≥30% </text>
<text top="734" left="381" width="136" height="20" font="1">reduction of initial lumen </text>
<text top="751" left="381" width="70" height="20" font="1">constriction) </text>
<text top="770" left="381" width="7" height="18" font="1">•</text>
<text top="770" left="388" width="132" height="20" font="1"> Stable angina pectoris, </text>
<text top="787" left="381" width="128" height="20" font="1">mild HTN and at least1 </text>
<text top="611" left="548" width="137" height="20" font="4"><b>Intervention:</b> Verapamil </text>
<text top="629" left="548" width="115" height="20" font="1">(240 mg/twice/d): 49 </text>
<text top="646" left="548" width="68" height="20" font="1">randomized<b> </b></text>
<text top="663" left="548" width="3" height="20" font="1"> </text>
<text top="680" left="548" width="128" height="20" font="4"><b>Comparator: </b>Placebo: </text>
<text top="697" left="548" width="88" height="20" font="1">49 randomized <b> </b></text>
<text top="613" left="701" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="632" left="701" width="7" height="18" font="1">•</text>
<text top="631" left="708" width="135" height="20" font="1"> Percentage of diameter </text>
<text top="648" left="701" width="52" height="20" font="1">stenosis  </text>
<text top="667" left="701" width="7" height="18" font="1">•</text>
<text top="667" left="708" width="150" height="20" font="1"> At 6 wk, mean % diameter </text>
<text top="684" left="701" width="153" height="20" font="1">stenosis in verapamil group </text>
<text top="701" left="701" width="131" height="20" font="1">was 46.8 (SD: 14.1) vs. </text>
<text top="718" left="701" width="159" height="20" font="1">placebo was 55.5 (SD: 10.0) </text>
<text top="737" left="701" width="7" height="18" font="1">•</text>
<text top="737" left="708" width="152" height="20" font="1"> At 6 mo, mean % diameter </text>
<text top="754" left="701" width="153" height="20" font="1">stenosis in verapamil group </text>
<text top="771" left="701" width="131" height="20" font="1">was 48.0 (SD: 11.5) vs. </text>
<text top="613" left="880" width="137" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b>   </text>
<text top="632" left="880" width="7" height="18" font="1">•</text>
<text top="631" left="887" width="202" height="20" font="1"> Intima/media thickness was 1.2 mm </text>
<text top="648" left="880" width="221" height="20" font="1">(SD: 0.31) in verapamil vs. 1.9 mm (SD: </text>
<text top="665" left="880" width="87" height="20" font="1">0.47), p&lt;0.001  </text>
<text top="684" left="880" width="7" height="18" font="1">•</text>
<text top="684" left="887" width="201" height="20" font="1"> Septal thickness was 10.2 mm (SD: </text>
<text top="701" left="880" width="221" height="20" font="1">1.1) in verapamil vs. 11.9 mm (SD: 2.3), </text>
<text top="718" left="880" width="48" height="20" font="1">p&lt;0.001 </text>
<text top="737" left="880" width="7" height="18" font="1">•</text>
<text top="737" left="887" width="212" height="20" font="1"> Crurobrachial ratio dorsalis pedis was </text>
<text top="754" left="880" width="222" height="20" font="1">0.76 (SD: 0.10) in verapamil vs. placebo </text>
<text top="771" left="880" width="112" height="20" font="1">was 0.72 (SD: 0.08) </text>
</page>
<page number="170" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">170 </text>
<text top="107" left="226" width="3" height="20" font="1"> </text>
<text top="124" left="226" width="69" height="20" font="4"><b>Size:</b> 98 pts </text>
<text top="107" left="381" width="142" height="20" font="1">additional risk factor: DM, </text>
<text top="124" left="381" width="148" height="20" font="1">hyperlipoproteinemia, total </text>
<text top="141" left="381" width="110" height="20" font="1">or subtotal vascular </text>
<text top="159" left="381" width="108" height="20" font="1">occlusion of dilated </text>
<text top="176" left="381" width="120" height="20" font="1">segmented, eccentric </text>
<text top="193" left="381" width="147" height="20" font="1">stenosis, residual stenosis </text>
<text top="210" left="381" width="151" height="20" font="1">of at least 30%, or stenosis </text>
<text top="228" left="381" width="117" height="20" font="1">localized in the distal </text>
<text top="245" left="381" width="138" height="20" font="1">superficial femoral artery </text>
<text top="262" left="381" width="3" height="20" font="1"> </text>
<text top="279" left="381" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="298" left="381" width="7" height="18" font="1">•</text>
<text top="298" left="388" width="146" height="20" font="1"> History of pelvic stenosis  </text>
<text top="317" left="381" width="7" height="18" font="1">•</text>
<text top="316" left="388" width="105" height="20" font="1"> Previous adjuvant </text>
<text top="333" left="381" width="115" height="20" font="1">therapy with calcium </text>
<text top="350" left="381" width="109" height="20" font="1">antagonists or beta-</text>
<text top="368" left="381" width="154" height="20" font="1">adrenergic blocking agents  </text>
<text top="387" left="381" width="7" height="18" font="1">•</text>
<text top="386" left="388" width="63" height="20" font="1"> Age &gt;75 y </text>
<text top="405" left="381" width="7" height="18" font="1">•</text>
<text top="404" left="388" width="142" height="20" font="1"> Prior revascularization of </text>
<text top="422" left="381" width="65" height="20" font="1">same area  </text>
<text top="441" left="381" width="7" height="18" font="1">•</text>
<text top="440" left="388" width="145" height="20" font="1"> 1st, 2nd, or 3rd AV block, </text>
<text top="457" left="381" width="140" height="20" font="1">sinoatrial block, diseases </text>
<text top="474" left="381" width="151" height="20" font="1">of supporting or connective </text>
<text top="492" left="381" width="141" height="20" font="1">tissues, moderate arterial </text>
<text top="509" left="381" width="137" height="20" font="1">HTN with SBP &gt;170 mm </text>
<text top="526" left="381" width="143" height="20" font="1">Hg and DBP &gt;95 mm Hg  </text>
<text top="545" left="381" width="7" height="18" font="1">•</text>
<text top="544" left="388" width="124" height="20" font="1"> Pts requiring stent for </text>
<text top="562" left="381" width="141" height="20" font="1">large anatomic segments </text>
<text top="579" left="381" width="105" height="20" font="1">or elastic stenosis <b> </b></text>
<text top="107" left="701" width="162" height="20" font="1">placebo was 69.6 (SD: 12.2), </text>
<text top="124" left="701" width="41" height="20" font="1">p&lt;0.01 </text>
<text top="141" left="701" width="3" height="20" font="1"> </text>
<text top="160" left="701" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A </text>
<text top="177" left="701" width="3" height="20" font="1"> </text>
<text top="194" left="701" width="165" height="20" font="4"><b>Summary:</b> In pts with PAD at </text>
<text top="211" left="701" width="160" height="20" font="1">increased risk for restenosis, </text>
<text top="229" left="701" width="141" height="20" font="1">the administration of high </text>
<text top="246" left="701" width="145" height="20" font="1">dose verapamil prevented </text>
<text top="263" left="701" width="150" height="20" font="1">recurrent stenosis for 6 mo </text>
<text top="280" left="701" width="147" height="20" font="1">after successful peripheral </text>
<text top="298" left="701" width="139" height="20" font="1">angioplasty and was well </text>
<text top="315" left="701" width="55" height="20" font="1">tolerated.<b> </b></text>
<text top="109" left="880" width="7" height="18" font="1">•</text>
<text top="108" left="887" width="197" height="20" font="1"> Crurobrachial ratio tibial artery was </text>
<text top="125" left="880" width="222" height="20" font="1">0.76 (SD: 0.09) in verapamil vs. placebo </text>
<text top="143" left="880" width="112" height="20" font="1">was 0.70 (SD: 0.10) </text>
<text top="162" left="880" width="7" height="18" font="1">•</text>
<text top="161" left="887" width="206" height="20" font="1"> Arterial pressure was 134/87 mm Hg </text>
<text top="178" left="880" width="208" height="20" font="1">(SD: 5.2/4.2) in verapamil vs. placebo </text>
<text top="195" left="880" width="210" height="20" font="1">was 165/97 mm Hg (6.5/4.4), p&lt;0.001 </text>
<text top="214" left="880" width="7" height="18" font="1">•</text>
<text top="214" left="887" width="221" height="20" font="1"> Total vessel diameter was 8.3 mm (SD: </text>
<text top="231" left="880" width="214" height="20" font="1">0.3) in verapamil vs. 7.5 mm (SD: 0.3), </text>
<text top="248" left="880" width="48" height="20" font="1">p&lt;0.001 </text>
<text top="266" left="880" width="3" height="20" font="1"> </text>
<text top="283" left="880" width="228" height="20" font="4"><b>Study limitations and adverse events:</b>  </text>
<text top="300" left="880" width="213" height="20" font="1">Short follow-up, unable to assess hard </text>
<text top="317" left="880" width="97" height="20" font="1">clinical outcomes </text>
<text top="597" left="104" width="50" height="20" font="4"><b>NORMA </b></text>
<text top="614" left="104" width="98" height="20" font="1">Espinola-Klein C, </text>
<text top="631" left="104" width="100" height="20" font="1">et al., 2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(229)</a>  </text>
<text top="648" left="104" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21646599">21646599</a></text>
<text top="648" left="159" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21646599"> </a></text>
<text top="597" left="226" width="142" height="20" font="4"><b>Aim:</b> Evaluate the effects </text>
<text top="614" left="226" width="115" height="20" font="1">of treatment with the </text>
<text top="631" left="226" width="133" height="20" font="1">endothelium-dependent </text>
<text top="648" left="226" width="107" height="20" font="1">vasodilating beta 1-</text>
<text top="666" left="226" width="94" height="20" font="1">selective blocker </text>
<text top="683" left="226" width="130" height="20" font="1">nebivolol, as compared </text>
<text top="700" left="226" width="135" height="20" font="1">with the nonvasodilating </text>
<text top="717" left="226" width="132" height="20" font="1">beta 1-selective blocker </text>
<text top="734" left="226" width="122" height="20" font="1">metoprolol, on clinical </text>
<text top="752" left="226" width="132" height="20" font="1">parameters of PAD and </text>
<text top="769" left="226" width="137" height="20" font="1">endothelial function, and </text>
<text top="786" left="226" width="85" height="20" font="1">to compare the </text>
<text top="597" left="381" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="616" left="381" width="7" height="18" font="1">•</text>
<text top="615" left="388" width="106" height="20" font="1"> Stable intermittent </text>
<text top="632" left="381" width="149" height="20" font="1">claudication for ≥6 mo and </text>
<text top="650" left="381" width="82" height="20" font="1">an ABI of &lt;0.9 </text>
<text top="669" left="381" width="7" height="18" font="1">•</text>
<text top="668" left="388" width="119" height="20" font="1"> Stage 1 arterial HTN </text>
<text top="685" left="381" width="133" height="20" font="1">(SBP: 140–159 mm Hg, </text>
<text top="702" left="381" width="113" height="20" font="1">DBP: 90–99 mm Hg </text>
<text top="719" left="381" width="149" height="20" font="1">untreated, or treated stage </text>
<text top="737" left="381" width="87" height="20" font="1">1 arterial HTN)  </text>
<text top="756" left="381" width="7" height="18" font="1">•</text>
<text top="755" left="388" width="146" height="20" font="1"> SBP at time of enrollment </text>
<text top="772" left="381" width="94" height="20" font="1">100–160 mm Hg </text>
<text top="597" left="548" width="114" height="20" font="4"><b>Intervention arms:  </b></text>
<text top="616" left="548" width="7" height="18" font="1">•</text>
<text top="615" left="555" width="127" height="20" font="1"> Nebivolol (5 mg/d): 65 </text>
<text top="632" left="548" width="71" height="20" font="1">randomized  </text>
<text top="651" left="548" width="7" height="18" font="1">•</text>
<text top="651" left="555" width="124" height="20" font="1"> Metoprolol (95 mg/d): </text>
<text top="668" left="548" width="85" height="20" font="1">63 randomized<b> </b></text>
<text top="598" left="701" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="617" left="701" width="7" height="18" font="1">•</text>
<text top="616" left="708" width="144" height="20" font="1"> Change in ABI measured </text>
<text top="633" left="701" width="66" height="20" font="1">by Doppler  </text>
<text top="652" left="701" width="7" height="18" font="1">•</text>
<text top="652" left="708" width="154" height="20" font="1"> In nebivolol: initial ABI 0.62 </text>
<text top="669" left="701" width="146" height="20" font="1">(SD: 0.16), post-treatment </text>
<text top="686" left="701" width="157" height="20" font="1">ABI 0.68 (SD: 0.20), p-value </text>
<text top="703" left="701" width="99" height="20" font="1">for change: 0.002 </text>
<text top="722" left="701" width="7" height="18" font="1">•</text>
<text top="722" left="708" width="136" height="20" font="1"> In metoprolol: initial ABI </text>
<text top="739" left="701" width="117" height="20" font="1">0.63 (SD: 0.17), post-</text>
<text top="756" left="701" width="134" height="20" font="1">treatment ABI 0.67 (SD: </text>
<text top="598" left="880" width="134" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b>  </text>
<text top="617" left="880" width="7" height="18" font="1">•</text>
<text top="616" left="887" width="181" height="20" font="1"> Change in absolute claudication </text>
<text top="633" left="880" width="201" height="20" font="1">distance were 32.7 m in nebivolol (p-</text>
<text top="651" left="880" width="213" height="20" font="1">value 0.03) vs. 39.7 m in metoprolol (p-</text>
<text top="668" left="880" width="223" height="20" font="1">value 0.01), but no difference between 2 </text>
<text top="685" left="880" width="120" height="20" font="1">groups (p-value 0.54) </text>
<text top="704" left="880" width="7" height="18" font="1">•</text>
<text top="703" left="887" width="208" height="20" font="1"> Changes in SBP were -5.2 mm Hg in </text>
<text top="721" left="880" width="213" height="20" font="1">nebivolol (p=0.001) and -3.9 mm Hg in </text>
<text top="738" left="880" width="188" height="20" font="1">metoprolol (p=0.01), no difference </text>
<text top="755" left="880" width="91" height="20" font="1">between groups </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">171 </text>
<text top="107" left="226" width="134" height="20" font="1">tolerability of both drugs </text>
<text top="124" left="226" width="90" height="20" font="1">in pts with PAD  </text>
<text top="141" left="226" width="3" height="20" font="1"> </text>
<text top="159" left="226" width="114" height="20" font="4"><b>Study type:</b> Double-</text>
<text top="176" left="226" width="116" height="20" font="1">blinded RCT (48 wk) </text>
<text top="193" left="226" width="3" height="20" font="1"> </text>
<text top="210" left="226" width="56" height="20" font="4"><b>Size:</b> 128 </text>
<text top="109" left="381" width="7" height="18" font="1">•</text>
<text top="108" left="388" width="86" height="20" font="1"> DBP at time of </text>
<text top="125" left="381" width="135" height="20" font="1">enrollment &lt;100 mm Hg </text>
<text top="143" left="381" width="3" height="20" font="1"> </text>
<text top="160" left="381" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="179" left="381" width="7" height="18" font="1">•</text>
<text top="178" left="388" width="136" height="20" font="1"> Premenopausal women </text>
<text top="197" left="381" width="7" height="18" font="1">•</text>
<text top="197" left="388" width="122" height="20" font="1"> Critical limb ischemia </text>
<text top="214" left="381" width="132" height="20" font="1">with rest pain, leg ulcer, </text>
<text top="231" left="381" width="140" height="20" font="1">gangrene, severe angina </text>
<text top="248" left="381" width="151" height="20" font="1">pectoris that limits exercise </text>
<text top="265" left="381" width="136" height="20" font="1">capacity, severe HF that </text>
<text top="283" left="381" width="133" height="20" font="1">limits exercise capacity, </text>
<text top="300" left="381" width="130" height="20" font="1">hyperthyroidism, poorly </text>
<text top="317" left="381" width="79" height="20" font="1">controlled DM </text>
<text top="334" left="381" width="80" height="20" font="1">(HbA1c&gt;10%) </text>
<text top="353" left="381" width="7" height="18" font="1">•</text>
<text top="353" left="388" width="146" height="20" font="1"> Contraindications for BBs </text>
<text top="372" left="381" width="7" height="18" font="1">•</text>
<text top="371" left="388" width="121" height="20" font="1"> Acute MI within 6 mo </text>
<text top="388" left="381" width="95" height="20" font="1">before screening </text>
<text top="407" left="381" width="7" height="18" font="1">•</text>
<text top="407" left="388" width="135" height="20" font="1"> Previous treatment with </text>
<text top="424" left="381" width="122" height="20" font="1">nebivolol or carvedilol </text>
<text top="441" left="381" width="3" height="20" font="1"> </text>
<text top="458" left="381" width="132" height="20" font="1">*Concomitant treatment </text>
<text top="476" left="381" width="140" height="20" font="1">with calcium antagonists, </text>
<text top="493" left="381" width="145" height="20" font="1">ACEIs, angiotensin II type </text>
<text top="510" left="381" width="129" height="20" font="1">1 receptor antagonists, </text>
<text top="527" left="381" width="152" height="20" font="1">aspirin, clopidogrel, statins, </text>
<text top="544" left="381" width="147" height="20" font="1">estrogens was permitted if </text>
<text top="562" left="381" width="141" height="20" font="1">no change in dosage had </text>
<text top="579" left="381" width="148" height="20" font="1">been made in the previous </text>
<text top="596" left="381" width="126" height="20" font="1">3 mo before screening<b> </b></text>
<text top="107" left="701" width="144" height="20" font="1">0.21), p-value for change: </text>
<text top="124" left="701" width="27" height="20" font="1">0.04 </text>
<text top="143" left="701" width="7" height="18" font="1">•</text>
<text top="143" left="708" width="147" height="20" font="1"> Comparing ABI change in </text>
<text top="160" left="701" width="157" height="20" font="1">nebivolol to metoprolol: 0.02 </text>
<text top="177" left="701" width="53" height="20" font="1">(p=0.69). </text>
<text top="194" left="701" width="3" height="20" font="1"> </text>
<text top="211" left="701" width="7" height="20" font="4"><b>1</b></text>
<text top="213" left="708" width="7" height="13" font="14"><b>st</b></text>
<text top="211" left="715" width="126" height="20" font="4"><b> safety endpoint:</b> N/A </text>
<text top="229" left="701" width="3" height="20" font="1"> </text>
<text top="246" left="701" width="153" height="20" font="4"><b>Summary:</b> BB therapy was </text>
<text top="263" left="701" width="134" height="20" font="1">well tolerated in pts with </text>
<text top="280" left="701" width="156" height="20" font="1">intermittent claudication and </text>
<text top="298" left="701" width="132" height="20" font="1">HTN during a treatment </text>
<text top="315" left="701" width="142" height="20" font="1">period of 1 y. In the direct </text>
<text top="332" left="701" width="144" height="20" font="1">comparison, there was no </text>
<text top="349" left="701" width="165" height="20" font="1">significant difference between </text>
<text top="366" left="701" width="140" height="20" font="1">nebivolol and metoprolol.<b> </b></text>
<text top="109" left="880" width="7" height="18" font="1">•</text>
<text top="108" left="887" width="212" height="20" font="1"> No change in flow-mediated dilatation </text>
<text top="125" left="880" width="132" height="20" font="1">in either group (p=0.16) </text>
<text top="143" left="880" width="3" height="20" font="1"> </text>
<text top="160" left="880" width="228" height="20" font="4"><b>Study limitations and adverse events:</b>  </text>
<text top="179" left="880" width="7" height="18" font="1">•</text>
<text top="178" left="887" width="153" height="20" font="1"> Absence of placebo group  </text>
<text top="197" left="880" width="7" height="18" font="1">•</text>
<text top="197" left="887" width="223" height="20" font="1"> 21 total adverse events, 10 in nebivolol, </text>
<text top="214" left="880" width="185" height="20" font="1">11 in metoprolol (adverse events: </text>
<text top="231" left="880" width="221" height="20" font="1">bradycardia, tachycardia, blurred vision, </text>
<text top="248" left="880" width="195" height="20" font="1">worsening HTN, edema, worsening </text>
<text top="265" left="880" width="195" height="20" font="1">claudication, blurred vision, erectile </text>
<text top="283" left="880" width="216" height="20" font="1">dysfunction, edema, vertigo, temporary </text>
<text top="300" left="880" width="222" height="20" font="1">dysesthesia of the hands, dyspnea, skin </text>
<text top="317" left="880" width="219" height="20" font="1">irritation, headache, moderate diarrhea)<b> </b></text>
<text top="614" left="104" width="48" height="20" font="4"><b>INVEST </b></text>
<text top="631" left="104" width="91" height="20" font="1">Bavry AA, et al., </text>
<text top="648" left="104" width="66" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(230)</a>  </text>
<text top="666" left="104" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19996066">19996066</a></text>
<text top="666" left="159" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19996066"> </a></text>
<text top="614" left="226" width="119" height="20" font="4"><b>Aim:</b> To examine the </text>
<text top="631" left="226" width="137" height="20" font="1">effect of average treated </text>
<text top="648" left="226" width="141" height="20" font="1">BP on adverse outcomes </text>
<text top="666" left="226" width="140" height="20" font="1">in PAD pts with CAD and </text>
<text top="683" left="226" width="75" height="20" font="1">to compare 2 </text>
<text top="700" left="226" width="93" height="20" font="1">antihypertensive </text>
<text top="717" left="226" width="69" height="20" font="1">medications </text>
<text top="734" left="226" width="3" height="20" font="1"> </text>
<text top="752" left="226" width="122" height="20" font="4"><b>Study type:</b> Post hoc </text>
<text top="769" left="226" width="132" height="20" font="1">analysis of international </text>
<text top="614" left="381" width="113" height="20" font="4"><b>Inclusion criteria:</b>   </text>
<text top="633" left="381" width="7" height="18" font="1">•</text>
<text top="632" left="388" width="42" height="20" font="1"> ≥50 y  </text>
<text top="651" left="381" width="7" height="18" font="1">•</text>
<text top="651" left="388" width="121" height="20" font="1"> HTN, clinically stable </text>
<text top="668" left="381" width="33" height="20" font="1">CAD  </text>
<text top="687" left="381" width="7" height="18" font="1">•</text>
<text top="686" left="388" width="96" height="20" font="1"> Pt reported PAD </text>
<text top="703" left="381" width="3" height="20" font="1"> </text>
<text top="721" left="381" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="738" left="381" width="132" height="20" font="1">Contraindications to the </text>
<text top="755" left="381" width="96" height="20" font="1">treatment groups<b> </b></text>
<text top="614" left="548" width="88" height="20" font="4"><b>Interventions:  </b></text>
<text top="631" left="548" width="121" height="20" font="1">● Calcium antagonist-</text>
<text top="648" left="548" width="88" height="20" font="1">based strategy<b>: </b></text>
<text top="666" left="548" width="139" height="20" font="1">verapamil with or without </text>
<text top="683" left="548" width="68" height="20" font="1">trandolapril  </text>
<text top="700" left="548" width="121" height="20" font="1">● BB-based strategy<b>: </b></text>
<text top="717" left="548" width="128" height="20" font="1">atenolol with or without </text>
<text top="734" left="548" width="110" height="20" font="1">hydrochlorothiazide </text>
<text top="752" left="548" width="3" height="20" font="4"><b> </b></text>
<text top="769" left="548" width="114" height="20" font="1">*2º medications only </text>
<text top="786" left="548" width="126" height="20" font="1">given to achieve BP of </text>
<text top="615" left="701" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="634" left="701" width="7" height="18" font="1">•</text>
<text top="633" left="708" width="136" height="20" font="1"> Composite outcome: all-</text>
<text top="651" left="701" width="141" height="20" font="1">cause death, nonfatal MI, </text>
<text top="668" left="701" width="87" height="20" font="1">nonfatal stroke  </text>
<text top="687" left="701" width="7" height="18" font="1">•</text>
<text top="686" left="708" width="143" height="20" font="1"> No statistically significant </text>
<text top="703" left="701" width="146" height="20" font="1">difference in composite 1° </text>
<text top="721" left="701" width="154" height="20" font="1">outcome OR: 0.90 (95% CI: </text>
<text top="738" left="701" width="123" height="20" font="1">0.76, 1.07) comparing </text>
<text top="755" left="701" width="142" height="20" font="1">calcium antagonist based </text>
<text top="772" left="701" width="153" height="20" font="1">group to BB based group in </text>
<text top="789" left="701" width="116" height="20" font="1">fully adjusted model  </text>
<text top="615" left="880" width="154" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> N/A </text>
<text top="634" left="880" width="7" height="18" font="1">•</text>
<text top="633" left="887" width="187" height="20" font="1"> This trial also notes the J-shaped </text>
<text top="651" left="880" width="213" height="20" font="1">relationship between BP achieved and </text>
<text top="668" left="880" width="97" height="20" font="1">clinical outcomes </text>
<text top="687" left="880" width="7" height="18" font="1">•</text>
<text top="686" left="887" width="215" height="20" font="1"> Risk of 1° outcome was reduced most </text>
<text top="703" left="880" width="217" height="20" font="1">when SBP was treated to 130–140 mm </text>
<text top="721" left="880" width="194" height="20" font="1">Hg and DBP 60–90, as opposed to </text>
<text top="738" left="880" width="214" height="20" font="1">&lt;130/80 as 2005 guidelines suggest in </text>
<text top="755" left="880" width="49" height="20" font="1">PAD pts </text>
<text top="772" left="880" width="3" height="20" font="1"> </text>
<text top="789" left="880" width="228" height="20" font="4"><b>Study limitations and adverse events:</b>  </text>
</page>
<page number="172" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">172 </text>
<text top="107" left="226" width="115" height="20" font="1">randomized, blinded-</text>
<text top="124" left="226" width="118" height="20" font="1">endpoint trial (48 wk) </text>
<text top="141" left="226" width="3" height="20" font="1"> </text>
<text top="159" left="226" width="136" height="20" font="4"><b>Size:</b> 22,576 in total trial </text>
<text top="176" left="226" width="128" height="20" font="1">(2,699 with PAD in this </text>
<text top="193" left="226" width="52" height="20" font="1">analysis) </text>
<text top="107" left="548" width="120" height="20" font="1">&lt;140/90 mm Hg in all </text>
<text top="124" left="548" width="124" height="20" font="1">participants except for </text>
<text top="141" left="548" width="89" height="20" font="1">those with renal </text>
<text top="159" left="548" width="105" height="20" font="1">impairment or DM, </text>
<text top="176" left="548" width="108" height="20" font="1">BP&lt;130/85 mm Hg </text>
<text top="109" left="701" width="7" height="18" font="1">•</text>
<text top="108" left="708" width="150" height="20" font="1"> Kaplan–Meier curve for 1° </text>
<text top="125" left="701" width="163" height="20" font="1">outcome shows slightly lower </text>
<text top="143" left="701" width="130" height="20" font="1">cumulative incidence in </text>
<text top="160" left="701" width="164" height="20" font="1">calcium antagonist group (log </text>
<text top="177" left="701" width="76" height="20" font="1">rank p=0.26)  </text>
<text top="194" left="701" width="3" height="20" font="1"> </text>
<text top="211" left="701" width="7" height="20" font="4"><b>1</b></text>
<text top="213" left="708" width="7" height="13" font="14"><b>st</b></text>
<text top="211" left="715" width="126" height="20" font="4"><b> safety endpoint:</b> N/A </text>
<text top="229" left="701" width="3" height="20" font="4"><b> </b></text>
<text top="246" left="701" width="158" height="20" font="4"><b>Summary: </b>Among PAD pts, </text>
<text top="263" left="701" width="126" height="20" font="1">the incidence of the 1° </text>
<text top="280" left="701" width="163" height="20" font="1">outcome was not significantly </text>
<text top="298" left="701" width="153" height="20" font="1">different between treatment </text>
<text top="315" left="701" width="44" height="20" font="1">groups.<b> </b></text>
<text top="109" left="880" width="7" height="18" font="1">•</text>
<text top="108" left="887" width="204" height="20" font="1"> PAD was not uniformly measured or </text>
<text top="125" left="880" width="204" height="20" font="1">adjudicated (only based on pt report) </text>
<text top="144" left="880" width="7" height="18" font="1">•</text>
<text top="144" left="887" width="210" height="20" font="1"> Asymptomatic PAD was not captured<b> </b></text>
<text top="333" left="104" width="45" height="20" font="4"><b>VALUE </b></text>
<text top="350" left="104" width="102" height="20" font="1">Zanchetti A, et al., </text>
<text top="367" left="104" width="63" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(231)</a> </text>
<text top="384" left="104" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17053536">17053536</a></text>
<text top="384" left="159" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17053536"> </a></text>
<text top="333" left="226" width="119" height="20" font="4"><b>Aim:</b> To examine the </text>
<text top="350" left="226" width="120" height="20" font="1">effect of valsartan vs. </text>
<text top="367" left="226" width="123" height="20" font="1">amlodipine on cardiac </text>
<text top="384" left="226" width="140" height="20" font="1">morbidity and mortality in </text>
<text top="402" left="226" width="133" height="20" font="1">hypertensive pts at high </text>
<text top="419" left="226" width="43" height="20" font="1">CV risk </text>
<text top="436" left="226" width="3" height="20" font="1"> </text>
<text top="453" left="226" width="141" height="20" font="4"><b>Study type:</b> Prespecified </text>
<text top="470" left="226" width="122" height="20" font="1">additional analyses of </text>
<text top="488" left="226" width="141" height="20" font="1">international randomized, </text>
<text top="505" left="226" width="117" height="20" font="1">double-blind, parallel-</text>
<text top="522" left="226" width="58" height="20" font="1">group trial </text>
<text top="539" left="226" width="3" height="20" font="1"> </text>
<text top="557" left="226" width="136" height="20" font="4"><b>Size:</b> 15,245 in total trial </text>
<text top="574" left="226" width="96" height="20" font="1">(2,114 with PAD) </text>
<text top="333" left="381" width="113" height="20" font="4"><b>Inclusion criteria:</b>   </text>
<text top="352" left="381" width="7" height="18" font="1">•</text>
<text top="351" left="388" width="42" height="20" font="1"> ≥50 y  </text>
<text top="370" left="381" width="7" height="18" font="1">•</text>
<text top="370" left="388" width="122" height="20" font="1"> HTN (untreated: 160–</text>
<text top="387" left="381" width="147" height="20" font="1">210/&lt;115 mm Hg, treated: </text>
<text top="404" left="381" width="109" height="20" font="1">&lt;210/&lt;115 mm Hg) </text>
<text top="423" left="381" width="7" height="18" font="1">•</text>
<text top="422" left="388" width="115" height="20" font="1"> High risk for cardiac </text>
<text top="440" left="381" width="143" height="20" font="1">events (male sex, verified </text>
<text top="457" left="381" width="147" height="20" font="1">DM, current smoking, high </text>
<text top="474" left="381" width="153" height="20" font="1">cholesterol, LV hypertrophy </text>
<text top="491" left="381" width="128" height="20" font="1">by ECG, proteinuria on </text>
<text top="508" left="381" width="142" height="20" font="1">dipstick, serum creatinine </text>
<text top="526" left="381" width="118" height="20" font="1">150–265 micromol/L, </text>
<text top="543" left="381" width="97" height="20" font="1">coronary disease </text>
<text top="560" left="381" width="150" height="20" font="1">diagnosis, cerebrovascular </text>
<text top="577" left="381" width="148" height="20" font="1">disease diagnosis, or PAD </text>
<text top="594" left="381" width="60" height="20" font="1">diagnosis) </text>
<text top="612" left="381" width="3" height="20" font="1"> </text>
<text top="629" left="381" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="648" left="381" width="7" height="18" font="1">•</text>
<text top="647" left="388" width="122" height="20" font="1"> Renal artery stenosis </text>
<text top="666" left="381" width="7" height="18" font="1">•</text>
<text top="666" left="388" width="66" height="20" font="1"> Pregnancy </text>
<text top="685" left="381" width="7" height="18" font="1">•</text>
<text top="684" left="388" width="83" height="20" font="1"> AMI, coronary </text>
<text top="701" left="381" width="131" height="20" font="1">angioplasty or CABG in </text>
<text top="718" left="381" width="53" height="20" font="1">last 3 mo </text>
<text top="737" left="381" width="7" height="18" font="1">•</text>
<text top="737" left="388" width="135" height="20" font="1"> Severe hepatic disease </text>
<text top="756" left="381" width="7" height="18" font="1">•</text>
<text top="755" left="388" width="120" height="20" font="1"> Severe chronic renal </text>
<text top="772" left="381" width="40" height="20" font="1">failure  </text>
<text top="333" left="548" width="88" height="20" font="4"><b>Interventions:  </b></text>
<text top="352" left="548" width="7" height="18" font="1">•</text>
<text top="351" left="555" width="123" height="20" font="1"> Valsartan: 7,649 total </text>
<text top="370" left="548" width="7" height="18" font="1">•</text>
<text top="370" left="555" width="136" height="20" font="1"> Amlodipine: 7,596 total  </text>
<text top="387" left="548" width="98" height="20" font="1">*No PAD-specific </text>
<text top="404" left="548" width="107" height="20" font="1">numbers available  </text>
<text top="334" left="701" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="353" left="701" width="7" height="18" font="1">•</text>
<text top="352" left="708" width="123" height="20" font="1"> Composite of sudden </text>
<text top="370" left="701" width="162" height="20" font="1">cardiac death, fatal MI, death </text>
<text top="387" left="701" width="144" height="20" font="1">during/after percutaneous </text>
<text top="404" left="701" width="133" height="20" font="1">coronary intervention or </text>
<text top="421" left="701" width="113" height="20" font="1">CABG, HF requiring </text>
<text top="438" left="701" width="152" height="20" font="1">hospitalization, nonfatal MI, </text>
<text top="456" left="701" width="151" height="20" font="1">or emergency procedure to </text>
<text top="473" left="701" width="62" height="20" font="1">prevent MI </text>
<text top="492" left="701" width="7" height="18" font="1">•</text>
<text top="491" left="708" width="139" height="20" font="1"> There was no significant </text>
<text top="508" left="701" width="158" height="20" font="1">difference in the 1° outcome </text>
<text top="526" left="701" width="163" height="20" font="1">by treatment group among all </text>
<text top="543" left="701" width="128" height="20" font="1">pts and by PAD status. </text>
<text top="560" left="701" width="156" height="20" font="1">Among pts with PAD, the 1° </text>
<text top="577" left="701" width="153" height="20" font="1">outcome occurred in 13.4% </text>
<text top="594" left="701" width="138" height="20" font="1">of valsartan vs. 13.6% of </text>
<text top="612" left="701" width="148" height="20" font="1">amlodipine pts. Among pts </text>
<text top="629" left="701" width="95" height="20" font="1">without PAD, the </text>
<text top="646" left="701" width="164" height="20" font="1">corresponding % were 10.1% </text>
<text top="663" left="701" width="62" height="20" font="1">and 9.9%.  </text>
<text top="680" left="701" width="3" height="20" font="1"> </text>
<text top="698" left="701" width="7" height="20" font="4"><b>1</b></text>
<text top="699" left="708" width="7" height="13" font="14"><b>st</b></text>
<text top="698" left="715" width="118" height="20" font="4"><b> safety endpoint:</b> --- </text>
<text top="715" left="701" width="3" height="20" font="1"> </text>
<text top="732" left="701" width="141" height="20" font="4"><b>Summary:</b> The effects of </text>
<text top="749" left="701" width="157" height="20" font="1">treatments on occurrence of </text>
<text top="766" left="701" width="128" height="20" font="1">the 1° outcome did not </text>
<text top="784" left="701" width="133" height="20" font="1">different by PAD status.<b> </b></text>
<text top="334" left="880" width="154" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:</b> N/A </text>
<text top="351" left="880" width="3" height="20" font="1"> </text>
<text top="368" left="880" width="228" height="20" font="4"><b>Study limitations and adverse events:</b>  </text>
<text top="387" left="880" width="7" height="18" font="1">•</text>
<text top="387" left="887" width="199" height="20" font="1"> Limited subgroup analyses, only 1° </text>
<text top="404" left="880" width="103" height="20" font="1">outcome reported  </text>
<text top="423" left="880" width="7" height="18" font="1">•</text>
<text top="422" left="887" width="147" height="20" font="1"> High-risk population limits </text>
<text top="440" left="880" width="85" height="20" font="1">generalizability<b> </b></text>
</page>
<page number="173" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">173 </text>
<text top="109" left="381" width="7" height="18" font="1">•</text>
<text top="108" left="388" width="139" height="20" font="1"> Congestive HF requiring </text>
<text top="125" left="381" width="80" height="20" font="1">ACEI therapy  </text>
<text top="144" left="381" width="7" height="18" font="1">•</text>
<text top="144" left="388" width="142" height="20" font="1"> Pts on monotherapy with </text>
<text top="161" left="381" width="134" height="20" font="1">3 blockers for both CAD </text>
<text top="178" left="381" width="56" height="20" font="1">and HTN  </text>
<text top="196" left="104" width="86" height="20" font="1">Piller LB, et al., </text>
<text top="213" left="104" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(232)</a> </text>
<text top="231" left="104" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25002161">25002161</a></text>
<text top="231" left="159" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25002161"> </a> </text>
<text top="196" left="226" width="120" height="20" font="4"><b>Aim:</b> To compare, by </text>
<text top="213" left="226" width="123" height="20" font="1">randomized treatment </text>
<text top="231" left="226" width="111" height="20" font="1">groups (amlodipine, </text>
<text top="248" left="226" width="135" height="20" font="1">lisinopril, chlorthalidone) </text>
<text top="265" left="226" width="83" height="20" font="1">hospitalized or </text>
<text top="282" left="226" width="142" height="20" font="1">revascularized PAD rates </text>
<text top="300" left="226" width="91" height="20" font="1">and subsequent </text>
<text top="317" left="226" width="134" height="20" font="1">morbidity and mortality.  </text>
<text top="334" left="226" width="3" height="20" font="1"> </text>
<text top="351" left="226" width="122" height="20" font="4"><b>Study type:</b> Post-hoc </text>
<text top="368" left="226" width="131" height="20" font="1">analysis of prospective, </text>
<text top="386" left="226" width="112" height="20" font="1">randomized, double-</text>
<text top="403" left="226" width="119" height="20" font="1">blinded active-control </text>
<text top="420" left="226" width="119" height="20" font="1">trial (ALLHAT study—</text>
<text top="437" left="226" width="114" height="20" font="1">amlodipine, lisinopril </text>
<text top="454" left="226" width="72" height="20" font="1">compared to </text>
<text top="472" left="226" width="120" height="20" font="1">chlorthalidone control </text>
<text top="489" left="226" width="29" height="20" font="1">arm) </text>
<text top="506" left="226" width="3" height="20" font="1"> </text>
<text top="523" left="226" width="93" height="20" font="4"><b>Size:</b> 33,357 pts </text>
<text top="196" left="381" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="215" left="381" width="7" height="18" font="1">•</text>
<text top="215" left="388" width="133" height="20" font="1"> BP of 140–180/90–110 </text>
<text top="232" left="381" width="142" height="20" font="1">for untreated, 160/100 for </text>
<text top="249" left="381" width="62" height="20" font="1">treated pts </text>
<text top="268" left="381" width="7" height="18" font="1">•</text>
<text top="267" left="388" width="64" height="20" font="1"> Age ≥55 y </text>
<text top="286" left="381" width="7" height="18" font="1">•</text>
<text top="286" left="388" width="128" height="20" font="1"> Have at least1 CV risk </text>
<text top="303" left="381" width="124" height="20" font="1">factor (risk factors: old </text>
<text top="320" left="381" width="150" height="20" font="1">myocardial injury or stroke, </text>
<text top="337" left="381" width="105" height="20" font="1">history of coronary </text>
<text top="355" left="381" width="96" height="20" font="1">revascularization </text>
<text top="372" left="381" width="94" height="20" font="1">procedure, other </text>
<text top="389" left="381" width="71" height="20" font="1">documented </text>
<text top="406" left="381" width="145" height="20" font="1">atherosclerotic CVD PAD, </text>
<text top="423" left="381" width="118" height="20" font="1">history of intermittent </text>
<text top="441" left="381" width="130" height="20" font="1">claudication, peripheral </text>
<text top="458" left="381" width="145" height="20" font="1">artery revascularization or </text>
<text top="475" left="381" width="93" height="20" font="1">peripheral artery </text>
<text top="492" left="381" width="148" height="20" font="1">angioplasty, DM-2, current </text>
<text top="510" left="381" width="131" height="20" font="1">cigarette smoking, HDL </text>
<text top="527" left="381" width="147" height="20" font="1">&lt;0.90 mmol/L, LVH, major </text>
<text top="544" left="381" width="130" height="20" font="1">ST depression, T-wave </text>
<text top="561" left="381" width="57" height="20" font="1">inversion) </text>
<text top="578" left="381" width="3" height="20" font="1"> </text>
<text top="596" left="381" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="615" left="381" width="7" height="18" font="1">•</text>
<text top="614" left="388" width="133" height="20" font="1"> Canadian pts for whom </text>
<text top="631" left="381" width="141" height="20" font="1">outcome measures could </text>
<text top="648" left="381" width="139" height="20" font="1">not be assessed (n=533)<b> </b></text>
<text top="196" left="548" width="114" height="20" font="4"><b>Intervention arms:  </b></text>
<text top="215" left="548" width="7" height="18" font="1">•</text>
<text top="215" left="555" width="105" height="20" font="1"> Amlodipine: 8,898 </text>
<text top="232" left="548" width="68" height="20" font="1">randomized </text>
<text top="251" left="548" width="7" height="18" font="1">•</text>
<text top="250" left="555" width="93" height="20" font="1"> Lisinopril: 8,904 </text>
<text top="267" left="548" width="71" height="20" font="1">randomized  </text>
<text top="285" left="548" width="3" height="20" font="1"> </text>
<text top="302" left="548" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="319" left="548" width="127" height="20" font="1">Chlorthalidone:<b> </b>15,002 </text>
<text top="336" left="548" width="71" height="20" font="1">randomized  </text>
<text top="353" left="548" width="3" height="20" font="4"><b> </b></text>
<text top="371" left="548" width="127" height="20" font="1">*Goal BP was &lt;140/90 </text>
<text top="388" left="548" width="111" height="20" font="1">in each randomized </text>
<text top="405" left="548" width="124" height="20" font="1">group (achieved using </text>
<text top="422" left="548" width="122" height="20" font="1">study drug but adding </text>
<text top="440" left="548" width="115" height="20" font="1">open-label agents at </text>
<text top="457" left="548" width="111" height="20" font="1">physician discretion </text>
<text top="474" left="548" width="96" height="20" font="1">when necessary)<b> </b></text>
<text top="197" left="701" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="216" left="701" width="7" height="18" font="1">•</text>
<text top="216" left="708" width="83" height="20" font="1"> PAD requiring </text>
<text top="233" left="701" width="153" height="20" font="1">hospitalization or outpatient </text>
<text top="250" left="701" width="155" height="20" font="1">revascularization procedure </text>
<text top="269" left="701" width="7" height="18" font="1">•</text>
<text top="269" left="708" width="153" height="20" font="1"> 830 cases of PAD over 8.8 </text>
<text top="286" left="701" width="141" height="20" font="1">y follow-up; no significant </text>
<text top="303" left="701" width="163" height="20" font="1">difference between treatment </text>
<text top="320" left="701" width="133" height="20" font="1">groups after adjustment </text>
<text top="339" left="701" width="7" height="18" font="1">•</text>
<text top="339" left="708" width="148" height="20" font="1"> HR comparing amlodipine </text>
<text top="356" left="701" width="156" height="20" font="1">to chlorthalidone: 0.86 (95% </text>
<text top="373" left="701" width="129" height="20" font="1">CI: 0.72, 1.03) after full </text>
<text top="390" left="701" width="148" height="20" font="1">adjustment, p-value: 0.099 </text>
<text top="409" left="701" width="7" height="18" font="1">•</text>
<text top="409" left="708" width="147" height="20" font="1"> HR comparing lisinopril to </text>
<text top="426" left="701" width="162" height="20" font="1">chlorthalidone: 0.98 (95% CI: </text>
<text top="443" left="701" width="109" height="20" font="1">0.83, 1.17) after full </text>
<text top="460" left="701" width="152" height="20" font="1">adjustment, p-value: 0.847  </text>
<text top="479" left="701" width="7" height="18" font="1">•</text>
<text top="479" left="708" width="138" height="20" font="1"> Kaplan Meier: Y-to-PAD </text>
<text top="496" left="701" width="145" height="20" font="1">was longer amlodipine vs. </text>
<text top="513" left="701" width="159" height="20" font="1">chlorthalidone (no difference </text>
<text top="530" left="701" width="121" height="20" font="1">between lisinopril and </text>
<text top="547" left="701" width="87" height="20" font="1">chlorthalidone)  </text>
<text top="565" left="701" width="3" height="20" font="1"> </text>
<text top="583" left="701" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A<b> </b></text>
<text top="197" left="880" width="134" height="20" font="4"><b>Relevant 2</b>°<b> endpoint:  </b></text>
<text top="216" left="880" width="7" height="18" font="1">•</text>
<text top="216" left="887" width="192" height="20" font="1"> Post-PAD morbidity and mortality  </text>
<text top="235" left="880" width="7" height="18" font="1">•</text>
<text top="234" left="887" width="143" height="20" font="1"> Comparing amlodipine to </text>
<text top="251" left="880" width="227" height="20" font="1">chlorthalidone, no difference in post-PAD </text>
<text top="269" left="880" width="226" height="20" font="1">morbidity or mortality: MI, HR: 0.82 (95% </text>
<text top="286" left="880" width="230" height="20" font="1">CI: 0.48, 1.40); Stroke, HR: 0.86 (95% CI: </text>
<text top="303" left="880" width="215" height="20" font="1">0.41, 1.79); Cardiac Revascularization, </text>
<text top="320" left="880" width="213" height="20" font="1">HR: 1.39 (95% CI: 0.81, 2.39); HF, HR </text>
<text top="337" left="880" width="228" height="20" font="1">1.32 (95% CI: 0.79, 2.18); Total Mortality, </text>
<text top="355" left="880" width="165" height="20" font="1">HR: 0.92 (95% CI: 0.74, 1.15) </text>
<text top="374" left="880" width="7" height="18" font="1">•</text>
<text top="373" left="887" width="212" height="20" font="1"> Comparing lisinopril to chlorthalidone, </text>
<text top="390" left="880" width="211" height="20" font="1">no difference in post-PAD morbidity or </text>
<text top="407" left="880" width="208" height="20" font="1">mortality: MI, HR: 0.74 (95% CI: 0.44, </text>
<text top="425" left="880" width="211" height="20" font="1">1.25); Stroke, HR: 0.94 (95% CI: 0.48, </text>
<text top="442" left="880" width="209" height="20" font="1">1.86); Cardiac Revascularization, HR: </text>
<text top="459" left="880" width="219" height="20" font="1">1.25 (95% CI: 0.73, 2.13); HF, HR: 1.08 </text>
<text top="476" left="880" width="225" height="20" font="1">(95% CI: 0.65, 1.80); Total Mortality, HR: </text>
<text top="493" left="880" width="141" height="20" font="1">0.95 (95% CI: 0.77, 1.18) </text>
<text top="511" left="880" width="3" height="20" font="1"> </text>
<text top="528" left="880" width="228" height="20" font="4"><b>Study limitations and adverse events:</b>  </text>
<text top="547" left="880" width="7" height="18" font="1">•</text>
<text top="546" left="887" width="181" height="20" font="1"> PAD not specifically collected at </text>
<text top="563" left="880" width="193" height="20" font="1">baseline, thus cannot detect actual </text>
<text top="581" left="880" width="194" height="20" font="1">incidence (however, randomization </text>
<text top="598" left="880" width="220" height="20" font="1">presumably resulted in equal number of </text>
<text top="615" left="880" width="196" height="20" font="1">baseline PAD cases in each group) </text>
<text top="634" left="880" width="7" height="18" font="1">•</text>
<text top="633" left="887" width="186" height="20" font="1"> Asymptomatic PAD likely missed </text>
<text top="651" left="880" width="209" height="20" font="1">(definition used in this study based on </text>
<text top="668" left="880" width="222" height="20" font="1">hospitalization, likely only capturing very </text>
<text top="685" left="880" width="80" height="20" font="1">severe cases) </text>
<text top="703" left="104" width="100" height="20" font="1">Thompson AM, et </text>
<text top="720" left="104" width="86" height="20" font="1">al., 2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(113)</a>  </text>
<text top="737" left="104" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21364140?dopt=Citation">21364140</a></text>
<text top="737" left="159" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21364140?dopt=Citation"> </a></text>
<text top="703" left="226" width="119" height="20" font="4"><b>Aim:</b> To evaluate the </text>
<text top="720" left="226" width="140" height="20" font="1">effect of antihypertensive </text>
<text top="737" left="226" width="87" height="20" font="1">treatment on 2º </text>
<text top="755" left="226" width="104" height="20" font="1">prevention of CVD </text>
<text top="772" left="226" width="116" height="20" font="1">events and all-cause </text>
<text top="789" left="226" width="111" height="20" font="1">mortality among pts </text>
<text top="703" left="381" width="141" height="20" font="4"><b>Inclusion criteria: </b>RCTs </text>
<text top="720" left="381" width="107" height="20" font="1">of antihypertensive </text>
<text top="737" left="381" width="141" height="20" font="1">treatment among pts with </text>
<text top="755" left="381" width="149" height="20" font="1">BP &lt;140/90 mm Hg for the </text>
<text top="772" left="381" width="147" height="20" font="1">prevention of CVD events. </text>
<text top="789" left="381" width="3" height="20" font="1"> </text>
<text top="703" left="548" width="109" height="20" font="4"><b>Interventions</b>: Any </text>
<text top="720" left="548" width="127" height="20" font="1">antihypertensive agent </text>
<text top="737" left="548" width="130" height="20" font="1">compared with placebo </text>
<text top="755" left="548" width="90" height="20" font="1">or no treatment. </text>
<text top="703" left="701" width="137" height="20" font="4"><b>Results</b>: Compared with </text>
<text top="720" left="701" width="122" height="20" font="1">controls, pts receiving </text>
<text top="737" left="701" width="162" height="20" font="1">antihypertensive medications </text>
<text top="755" left="701" width="137" height="20" font="1">had a pooled RR of 0.77 </text>
<text top="772" left="701" width="131" height="20" font="1">(95% CI: 0.61, 0.77) for </text>
<text top="789" left="701" width="150" height="20" font="1">stroke: 0.80 (95% CI: 0.69, </text>
<text top="703" left="880" width="231" height="20" font="4"><b> Study limitations and adverse events:</b>  </text>
<text top="722" left="880" width="7" height="18" font="1">•</text>
<text top="721" left="887" width="181" height="20" font="1"> PAD not specifically collected at </text>
<text top="739" left="880" width="193" height="20" font="1">baseline, thus cannot detect actual </text>
<text top="756" left="880" width="194" height="20" font="1">incidence (however, randomization </text>
<text top="773" left="880" width="220" height="20" font="1">presumably resulted in equal number of </text>
<text top="790" left="880" width="196" height="20" font="1">baseline PAD cases in each group) </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">174 </text>
<text top="107" left="226" width="135" height="20" font="1">without clinically defined </text>
<text top="124" left="226" width="35" height="20" font="1">HTN.  </text>
<text top="141" left="226" width="3" height="20" font="1"> </text>
<text top="159" left="226" width="101" height="20" font="4"><b>Study type</b>: Meta-</text>
<text top="176" left="226" width="117" height="20" font="1">analysis including 25 </text>
<text top="193" left="226" width="35" height="20" font="1">RCTs </text>
<text top="210" left="226" width="3" height="20" font="1"> </text>
<text top="227" left="226" width="135" height="20" font="4"><b>Size</b>: 64,162 pts without </text>
<text top="245" left="226" width="32" height="20" font="1">HTN. </text>
<text top="107" left="381" width="139" height="20" font="4"><b>Exclusion criteria</b>: CVD </text>
<text top="124" left="381" width="140" height="20" font="1">events were not reported </text>
<text top="141" left="381" width="105" height="20" font="1">by HTN status that </text>
<text top="159" left="381" width="141" height="20" font="1">included participants with </text>
<text top="176" left="381" width="131" height="20" font="1">and without HTN; study </text>
<text top="193" left="381" width="143" height="20" font="1">population did not include </text>
<text top="210" left="381" width="126" height="20" font="1">persons with BP in the </text>
<text top="228" left="381" width="146" height="20" font="1">normal or prehypertensive </text>
<text top="245" left="381" width="137" height="20" font="1">ranges; study population </text>
<text top="262" left="381" width="130" height="20" font="1">did not include persons </text>
<text top="279" left="381" width="132" height="20" font="1">with preexisting CVD or </text>
<text top="296" left="381" width="144" height="20" font="1">CVD equivalents, such as </text>
<text top="314" left="381" width="119" height="20" font="1">DM; antihypertensive </text>
<text top="331" left="381" width="143" height="20" font="1">medication was not a part </text>
<text top="348" left="381" width="105" height="20" font="1">of the intervention; </text>
<text top="365" left="381" width="136" height="20" font="1">treatment allocation was </text>
<text top="383" left="381" width="134" height="20" font="1">not random; measure of </text>
<text top="400" left="381" width="123" height="20" font="1">variance not reported; </text>
<text top="417" left="381" width="134" height="20" font="1">participants were &lt;18 y; </text>
<text top="434" left="381" width="125" height="20" font="1">there were differences </text>
<text top="451" left="381" width="141" height="20" font="1">between intervention and </text>
<text top="469" left="381" width="140" height="20" font="1">control groups other than </text>
<text top="486" left="381" width="152" height="20" font="1">antihypertensive treatment. </text>
<text top="503" left="381" width="143" height="20" font="1">Preexisting CVD included </text>
<text top="520" left="381" width="32" height="20" font="1">PAD.<b> </b></text>
<text top="107" left="701" width="148" height="20" font="1">0.93) for MI: 0.71 (95% CI: </text>
<text top="124" left="701" width="140" height="20" font="1">0.65, 0.77) for CHF: 0.85 </text>
<text top="141" left="701" width="131" height="20" font="1">(95% CI: 0.80, 0.90) for </text>
<text top="159" left="701" width="159" height="20" font="1">composite CVD events: 0.83 </text>
<text top="176" left="701" width="161" height="20" font="1">(95% CI: 0.69, 0.99) for CVD </text>
<text top="193" left="701" width="152" height="20" font="1">mortality and 0.87 (95% CI: </text>
<text top="210" left="701" width="133" height="20" font="1">0.80, 0.95) for all-cause </text>
<text top="228" left="701" width="157" height="20" font="1">mortality from random effect </text>
<text top="245" left="701" width="162" height="20" font="1">models. Results did not differ </text>
<text top="262" left="701" width="94" height="20" font="1">according to trial </text>
<text top="279" left="701" width="157" height="20" font="1">characteristics or subgroups </text>
<text top="296" left="701" width="143" height="20" font="1">defined by clinical history, </text>
<text top="314" left="701" width="141" height="20" font="1">although no specific PAD </text>
<text top="331" left="701" width="127" height="20" font="1">subgroup was defined. </text>
<text top="348" left="701" width="3" height="20" font="1"> </text>
<text top="365" left="701" width="150" height="20" font="4"><b>Summary</b>: Among pts with </text>
<text top="382" left="701" width="126" height="20" font="1">clinical history of CVD, </text>
<text top="400" left="701" width="147" height="20" font="1">including PAD, but without </text>
<text top="417" left="701" width="125" height="20" font="1">HTN, antihypertensive </text>
<text top="434" left="701" width="143" height="20" font="1">treatment was associated </text>
<text top="451" left="701" width="150" height="20" font="1">with reduced risk of stroke, </text>
<text top="469" left="701" width="161" height="20" font="1">CHF, composite CVD events </text>
<text top="486" left="701" width="130" height="20" font="1">and all-cause mortality. </text>
<text top="109" left="880" width="7" height="18" font="1">•</text>
<text top="108" left="887" width="186" height="20" font="1"> Asymptomatic PAD likely missed </text>
<text top="125" left="880" width="209" height="20" font="1">(definition used in this study based on </text>
<text top="143" left="880" width="222" height="20" font="1">hospitalization, likely only capturing very </text>
<text top="160" left="880" width="80" height="20" font="1">severe cases) </text>
<text top="540" left="108" width="3" height="19" font="1"> </text>
<text top="574" left="81" width="627" height="24" font="3"><b>Data Supplement 46. RCTs and Meta-analyses Comparing BP Targets in DM (Section 9.6) </b></text>
<text top="614" left="105" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="631" left="131" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="648" left="109" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="614" left="242" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="631" left="247" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="648" left="241" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="614" left="366" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="614" left="503" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="631" left="534" width="54" height="20" font="4"><b> (# pts) /  </b></text>
<text top="648" left="504" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="665" left="539" width="40" height="20" font="4"><b>(# pts) </b></text>
<text top="614" left="703" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="631" left="686" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="648" left="668" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="615" left="907" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="632" left="940" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="649" left="945" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="667" left="965" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="684" left="98" width="64" height="20" font="4"><b>ADVANCE </b></text>
<text top="702" left="98" width="101" height="20" font="1">Kaplan NM, et al., </text>
<text top="719" left="98" width="63" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(233)</a> </text>
<text top="736" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17765962?dopt=Citation">17765962</a></text>
<text top="736" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17765962?dopt=Citation"> </a></text>
<text top="684" left="225" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="702" left="225" width="102" height="20" font="1">effects of an ACEI </text>
<text top="719" left="225" width="95" height="20" font="1">perindopril and a </text>
<text top="736" left="225" width="110" height="20" font="1">diuretic indapamide </text>
<text top="753" left="225" width="87" height="20" font="1">combination on </text>
<text top="771" left="225" width="92" height="20" font="1">serious vascular </text>
<text top="788" left="225" width="98" height="20" font="1">events in pts with </text>
<text top="684" left="356" width="104" height="20" font="1">DM-2 pts 30–55 y. </text>
<text top="702" left="356" width="3" height="20" font="4"><b> </b></text>
<text top="719" left="356" width="120" height="20" font="4"><b>Inclusion criteria</b>: At </text>
<text top="736" left="356" width="128" height="20" font="1">least 1 of the following: </text>
<text top="753" left="356" width="120" height="20" font="1">history of major CVD, </text>
<text top="771" left="356" width="124" height="20" font="1">(stroke, MI, admission </text>
<text top="788" left="356" width="119" height="20" font="1">for TIA, UA, coronary </text>
<text top="686" left="501" width="7" height="18" font="1">•</text>
<text top="686" left="508" width="107" height="20" font="1"> Fixed combination </text>
<text top="703" left="501" width="98" height="20" font="1">of perindopril and </text>
<text top="720" left="501" width="67" height="20" font="1">indapamide </text>
<text top="737" left="501" width="83" height="20" font="1">compared with </text>
<text top="754" left="501" width="85" height="20" font="1">perindopril and </text>
<text top="772" left="501" width="50" height="20" font="1">placebo. </text>
<text top="686" left="630" width="216" height="20" font="4"><b>1</b>°<b> endpoints</b>: Composite of CV death, </text>
<text top="703" left="630" width="196" height="20" font="1">nonfatal MI, nonfatal stroke, new or </text>
<text top="720" left="630" width="217" height="20" font="1">worsening nephropathy, or retinopathy. </text>
<text top="737" left="630" width="3" height="20" font="1"> </text>
<text top="754" left="630" width="239" height="20" font="4"><b>Results</b>: After 4.3 y follow-up, pts assigned </text>
<text top="772" left="630" width="237" height="20" font="1">to active therapy had a reduction of SBP of </text>
<text top="789" left="630" width="230" height="20" font="1">5.6 mm Hg.  RR of major macro- or micro-</text>
<text top="684" left="893" width="66" height="20" font="4"><b>Summary</b>:  </text>
<text top="703" left="893" width="7" height="18" font="1">•</text>
<text top="703" left="900" width="192" height="20" font="1"> This large RCT provides evidence </text>
<text top="720" left="893" width="188" height="20" font="1">that routine administration of fixed </text>
<text top="737" left="893" width="199" height="20" font="1">combination ACEI and thiazide-type </text>
<text top="754" left="893" width="171" height="20" font="1">diuretic therapy reduces risk of </text>
<text top="772" left="893" width="180" height="20" font="1">major CV events in those with at </text>
<text top="789" left="893" width="100" height="20" font="1">least 1 risk factor. </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">175 </text>
<text top="107" left="225" width="102" height="20" font="1">DM irrespective of </text>
<text top="124" left="225" width="100" height="20" font="1">initial BP levels or </text>
<text top="141" left="225" width="109" height="20" font="1">the use of other BP-</text>
<text top="159" left="225" width="87" height="20" font="1">lowering drugs. </text>
<text top="176" left="225" width="3" height="20" font="1"> </text>
<text top="193" left="225" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="210" left="225" width="3" height="20" font="1"> </text>
<text top="227" left="225" width="117" height="20" font="4"><b>Size:</b> 11,140 pts, 4.3 </text>
<text top="245" left="225" width="66" height="20" font="1">y follow-up  </text>
<text top="107" left="356" width="113" height="20" font="1">revascularization, or </text>
<text top="124" left="356" width="129" height="20" font="1">amputation for PVD) or </text>
<text top="141" left="356" width="107" height="20" font="1">at least 1 other risk </text>
<text top="159" left="356" width="92" height="20" font="1">factor (history of </text>
<text top="176" left="356" width="128" height="20" font="1">microvascular disease, </text>
<text top="193" left="356" width="100" height="20" font="1">microalbuminuria, </text>
<text top="210" left="356" width="113" height="20" font="1">proliferative diabetic </text>
<text top="228" left="356" width="105" height="20" font="1">retinopathy, retinal </text>
<text top="245" left="356" width="97" height="20" font="1">photocoagulation </text>
<text top="262" left="356" width="95" height="20" font="1">therapy, macular </text>
<text top="279" left="356" width="103" height="20" font="1">edema, blindness, </text>
<text top="296" left="356" width="130" height="20" font="1">cigarette smoking, high </text>
<text top="314" left="356" width="116" height="20" font="1">cholesterol, low HDL </text>
<text top="331" left="356" width="121" height="20" font="1">cholesterol, diagnosis </text>
<text top="348" left="356" width="106" height="20" font="1">of DM at least 10 y </text>
<text top="365" left="356" width="114" height="20" font="1">before enrollment or </text>
<text top="384" left="356" width="8" height="18" font="1">≥</text>
<text top="384" left="364" width="71" height="20" font="1">65 y at entry </text>
<text top="401" left="356" width="3" height="20" font="1"> </text>
<text top="418" left="356" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="436" left="356" width="129" height="20" font="1">HbA1c target ≤6.5% or </text>
<text top="454" left="356" width="115" height="20" font="1">indication for insulin. </text>
<text top="107" left="630" width="247" height="20" font="1">vascular events decreased by 9% (HR: 0.91; </text>
<text top="124" left="630" width="230" height="20" font="1">(95% CI: 0.83, 1.00), p&lt;0.04). Death from </text>
<text top="141" left="630" width="241" height="20" font="1">CVD decreased by 18%; RR: 0.82 (95% CI: </text>
<text top="159" left="630" width="208" height="20" font="1">0.68, 0.98) and death from any cause </text>
<text top="176" left="630" width="243" height="20" font="1">decreased by 14%; RR: 0.86 (95% CI: 0.75, </text>
<text top="193" left="630" width="245" height="20" font="1">0.98).  The effects of study treatment did not </text>
<text top="210" left="630" width="219" height="20" font="1">differ by initial BP or concomitant use of </text>
<text top="228" left="630" width="245" height="20" font="1">other treatments at baseline.  The pts had at </text>
<text top="245" left="630" width="120" height="20" font="1">least 1 CV risk factor. </text>
<text top="109" left="893" width="7" height="18" font="1">•</text>
<text top="108" left="900" width="186" height="20" font="1"> The ADVANCE trial included DM </text>
<text top="125" left="893" width="185" height="20" font="1">pts both with and without HTN. In </text>
<text top="143" left="893" width="186" height="20" font="1">this RCT, pts were randomized to </text>
<text top="160" left="893" width="187" height="20" font="1">active treatment or placebo rather </text>
<text top="177" left="893" width="199" height="20" font="1">than to a different BP goal, so that it </text>
<text top="194" left="893" width="193" height="20" font="1">is impossible to determine whether </text>
<text top="212" left="893" width="200" height="20" font="1">the benefit was due to the treatment </text>
<text top="229" left="893" width="83" height="20" font="1">of HTN <i>per se</i>. </text>
<text top="472" left="98" width="57" height="20" font="4"><b>ACCORD </b></text>
<text top="489" left="98" width="97" height="20" font="1">Cushman WC, et </text>
<text top="506" left="98" width="83" height="20" font="1">al., 2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(234)</a> </text>
<text top="523" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20228401?dopt=Citation">20228401</a></text>
<text top="523" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20228401?dopt=Citation"> </a></text>
<text top="472" left="225" width="89" height="20" font="4"><b>Aim</b>: To assess </text>
<text top="489" left="225" width="92" height="20" font="1">whether therapy </text>
<text top="506" left="225" width="92" height="20" font="1">targeting normal </text>
<text top="523" left="225" width="110" height="20" font="1">SBP (&lt;120 mm Hg) </text>
<text top="540" left="225" width="102" height="20" font="1">reduces major CV </text>
<text top="558" left="225" width="100" height="20" font="1">events in DM-2 at </text>
<text top="575" left="225" width="87" height="20" font="1">high risk for CV </text>
<text top="592" left="225" width="43" height="20" font="1">events. </text>
<text top="609" left="225" width="3" height="20" font="1"> </text>
<text top="627" left="225" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="644" left="225" width="3" height="20" font="1"> </text>
<text top="661" left="225" width="109" height="20" font="4"><b>Size</b>: 4,733 pts, 4.7 </text>
<text top="678" left="225" width="62" height="20" font="1">y follow-up </text>
<text top="472" left="356" width="128" height="20" font="4"><b>Inclusion criteria</b>: DM-</text>
<text top="490" left="356" width="126" height="20" font="1">2 with HgbA1c ≥7.5%; </text>
<text top="509" left="356" width="8" height="18" font="1">≥</text>
<text top="508" left="364" width="121" height="20" font="1">40 y with CVD or ≥55 </text>
<text top="526" left="356" width="98" height="20" font="1">y with anatomical </text>
<text top="543" left="356" width="66" height="20" font="1">evidence of </text>
<text top="560" left="356" width="89" height="20" font="1">atherosclerosis, </text>
<text top="577" left="356" width="115" height="20" font="1">albuminuria, LVH, or </text>
<text top="594" left="356" width="97" height="20" font="1">≥2 additional risk </text>
<text top="612" left="356" width="91" height="20" font="1">factors for CVD. </text>
<text top="629" left="356" width="3" height="20" font="1"> </text>
<text top="646" left="356" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="664" left="356" width="92" height="20" font="1">BMI ≥45, serum </text>
<text top="682" left="356" width="112" height="20" font="1">creatinine &gt;1.5, and </text>
<text top="699" left="356" width="116" height="20" font="1">other serious illness. </text>
<text top="473" left="501" width="7" height="18" font="1">•</text>
<text top="473" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="490" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="507" left="501" width="110" height="20" font="1">to intensive therapy </text>
<text top="524" left="501" width="102" height="20" font="1">SBP &lt;120 mm Hg </text>
<text top="542" left="501" width="110" height="20" font="1">or standard therapy </text>
<text top="559" left="501" width="106" height="20" font="1">SBP &lt;140 mm Hg. </text>
<text top="473" left="630" width="239" height="20" font="4"><b>1</b>°<b> outcomes</b>: Nonfatal MI, nonfatal stroke, </text>
<text top="490" left="630" width="73" height="20" font="1">or CV death. </text>
<text top="507" left="630" width="3" height="20" font="1"> </text>
<text top="524" left="630" width="243" height="20" font="4"><b>Results</b>: Mean SBP in the intensive therapy </text>
<text top="542" left="630" width="246" height="20" font="1">group was 119.3 mm Hg and in the standard </text>
<text top="559" left="630" width="250" height="20" font="1">therapy group was 133.5 mm Hg. The annual </text>
<text top="576" left="630" width="235" height="20" font="1">1° outcome 1.87% in the intensive therapy </text>
<text top="593" left="630" width="226" height="20" font="1">group and 2.09% in the standard therapy </text>
<text top="610" left="630" width="206" height="20" font="1">group HR: 0.88; 95% CI: 0.073–1.06; </text>
<text top="628" left="630" width="240" height="20" font="1">p=0.20. The annual rates of death from any </text>
<text top="645" left="630" width="211" height="20" font="1">cause were 1.28% and 1.19% in the 2 </text>
<text top="662" left="630" width="219" height="20" font="1">groups, respectively (HR: 0.59; 95% CI: </text>
<text top="679" left="630" width="242" height="20" font="1">0.39–0.89; p=0.01). Serious adverse events </text>
<text top="697" left="630" width="217" height="20" font="1">attributed to antihypertensive treatment </text>
<text top="714" left="630" width="226" height="20" font="1">occurred in 3.3% of the intensive therapy </text>
<text top="731" left="630" width="220" height="20" font="1">group and 1.3% of the standard therapy </text>
<text top="748" left="630" width="95" height="20" font="1">group (p&lt;0.001). </text>
<text top="472" left="893" width="194" height="20" font="4"><b>Limitations</b>: This trial had an open </text>
<text top="489" left="893" width="183" height="20" font="1">label design. The rate of adverse </text>
<text top="506" left="893" width="204" height="20" font="1">events in the standard therapy group </text>
<text top="523" left="893" width="204" height="20" font="1">was less than expected. Pts younger </text>
<text top="540" left="893" width="204" height="20" font="1">than 40 y or older than 79 y were not </text>
<text top="558" left="893" width="53" height="20" font="1">included. </text>
<text top="575" left="893" width="3" height="20" font="1"> </text>
<text top="592" left="893" width="179" height="20" font="4"><b>Summary</b>: In pts with DM-2 and </text>
<text top="609" left="893" width="182" height="20" font="1">high risk for CV events, targeting </text>
<text top="627" left="893" width="204" height="20" font="1">SBP of &lt;120 as compared with &lt;140 </text>
<text top="644" left="893" width="183" height="20" font="1">mm Hg did not reduce the rate of </text>
<text top="661" left="893" width="174" height="20" font="1">composite outcome of fatal and </text>
<text top="678" left="893" width="191" height="20" font="1">nonfatal major CV events and was </text>
<text top="695" left="893" width="170" height="20" font="1">associated with greater risk for </text>
<text top="713" left="893" width="90" height="20" font="1">adverse events. </text>
</page>
<page number="176" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">176 </text>
<text top="107" left="98" width="102" height="20" font="1">Margolis KL et al., </text>
<text top="124" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(235)</a><b> </b></text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24595629?dopt=Citation">24595629</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24595629?dopt=Citation"> </a></text>
<text top="107" left="225" width="100" height="20" font="4"><b>Aim: </b>To compare </text>
<text top="124" left="225" width="53" height="20" font="1">effects of </text>
<text top="141" left="225" width="89" height="20" font="1">combinations of </text>
<text top="159" left="225" width="75" height="20" font="1">standard and </text>
<text top="176" left="225" width="107" height="20" font="1">intensive treatment </text>
<text top="193" left="225" width="109" height="20" font="1">of glycemia and BP </text>
<text top="210" left="225" width="117" height="20" font="1">in the ACCORD trial. </text>
<text top="227" left="225" width="3" height="20" font="1"> </text>
<text top="245" left="225" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="262" left="225" width="3" height="20" font="1"> </text>
<text top="279" left="225" width="109" height="20" font="4"><b>Size</b>: 4,733 pts, 4.7 </text>
<text top="296" left="225" width="62" height="20" font="1">y follow-up </text>
<text top="314" left="225" width="3" height="20" font="4"><b> </b></text>
<text top="107" left="356" width="109" height="20" font="4"><b>Inclusion criteria</b>:  </text>
<text top="124" left="356" width="89" height="20" font="1">Type 2 DM with </text>
<text top="143" left="356" width="125" height="20" font="1">HgbA1c ≥7.5%; ≥40 y </text>
<text top="161" left="356" width="129" height="20" font="1">with CVD or ≥55 y with </text>
<text top="178" left="356" width="129" height="20" font="1">anatomical evidence of </text>
<text top="195" left="356" width="89" height="20" font="1">atherosclerosis, </text>
<text top="213" left="356" width="129" height="20" font="1">albuminuria, LVH, or at </text>
<text top="230" left="356" width="118" height="20" font="1">least 2 additional risk </text>
<text top="247" left="356" width="91" height="20" font="1">factors for CVD. </text>
<text top="264" left="356" width="3" height="20" font="1"> </text>
<text top="281" left="356" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="300" left="356" width="92" height="20" font="1">BMI ≥45, serum </text>
<text top="317" left="356" width="112" height="20" font="1">creatinine &gt;1.5, and </text>
<text top="334" left="356" width="116" height="20" font="1">other serious illness.<b> </b></text>
<text top="109" left="501" width="7" height="18" font="1">•</text>
<text top="108" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="125" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="143" left="501" width="110" height="20" font="1">to intensive therapy </text>
<text top="160" left="501" width="113" height="20" font="1">SBP&lt;120 mm Hg or </text>
<text top="177" left="501" width="96" height="20" font="1">standard therapy </text>
<text top="194" left="501" width="102" height="20" font="1">SBP&lt;140 mm Hg. </text>
<text top="108" left="630" width="239" height="20" font="4"><b>1</b>°<b> outcomes</b>: Nonfatal MI, nonfatal stroke, </text>
<text top="125" left="630" width="73" height="20" font="1">or CV death. </text>
<text top="143" left="630" width="3" height="20" font="1"> </text>
<text top="160" left="630" width="205" height="20" font="4"><b>Results</b>: In the BP trial, risk of the 1° </text>
<text top="177" left="630" width="244" height="20" font="1">outcome was lower in the groups intensively </text>
<text top="194" left="630" width="245" height="20" font="1">treated for glycemia HR: 0.67 (95% CI: 0.50, </text>
<text top="211" left="630" width="238" height="20" font="1">0.91), BP HR: 0.74 (95% CI: 0.55, 1.00), or </text>
<text top="229" left="630" width="193" height="20" font="1">both HR: 0.71 (95% CI: 0.52, 0.96) </text>
<text top="246" left="630" width="235" height="20" font="1">compared with combined standard BP and </text>
<text top="263" left="630" width="250" height="20" font="1">glycemia treatment. For 2º outcomes, MI was </text>
<text top="280" left="630" width="235" height="20" font="1">significantly reduced by intensive glycemia </text>
<text top="298" left="630" width="204" height="20" font="1">treatment and stroke by intensive BP </text>
<text top="315" left="630" width="233" height="20" font="1">treatment; most other HRs were neutral or </text>
<text top="332" left="630" width="196" height="20" font="1">favored intensive treatment groups. </text>
<text top="108" left="893" width="180" height="20" font="4"><b>Limitations: </b>2° analysis; results </text>
<text top="125" left="893" width="199" height="20" font="1">analyzed across individual cells of a </text>
<text top="143" left="893" width="189" height="20" font="1">factorial design with shorter follow-</text>
<text top="160" left="893" width="198" height="20" font="1">up than originally intended reducing </text>
<text top="177" left="893" width="151" height="20" font="1">power to detect meaningful </text>
<text top="194" left="893" width="197" height="20" font="1">differences and interactions; results </text>
<text top="212" left="893" width="196" height="20" font="1">may not apply to younger, healthier </text>
<text top="229" left="893" width="55" height="20" font="1">diabetics.<b> </b></text>
<text top="246" left="893" width="3" height="20" font="4"><b> </b></text>
<text top="263" left="893" width="203" height="20" font="4"><b>Conclusions: </b>Either intensive BP or </text>
<text top="280" left="893" width="204" height="20" font="1">glycemia control reduced major CVD </text>
<text top="298" left="893" width="192" height="20" font="1">compared with combined standard </text>
<text top="315" left="893" width="195" height="20" font="1">treatment, but the combination was </text>
<text top="332" left="893" width="154" height="20" font="1">no better than the individual </text>
<text top="349" left="893" width="129" height="20" font="1">intensive interventions.<b> </b></text>
<text top="367" left="98" width="100" height="20" font="1">Soliman EZ et al., </text>
<text top="384" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(236)</a> </text>
<text top="402" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26459421?dopt=Citation">26459421</a></text>
<text top="402" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26459421?dopt=Citation"> </a></text>
<text top="367" left="225" width="100" height="20" font="4"><b>Aim: </b>To compare </text>
<text top="384" left="225" width="53" height="20" font="1">effects of </text>
<text top="402" left="225" width="89" height="20" font="1">combinations of </text>
<text top="419" left="225" width="75" height="20" font="1">standard and </text>
<text top="436" left="225" width="106" height="20" font="1">intensive control of </text>
<text top="453" left="225" width="94" height="20" font="1">BP on the risk of </text>
<text top="470" left="225" width="117" height="20" font="1">LVH in the ACCORD </text>
<text top="488" left="225" width="27" height="20" font="1">trial. </text>
<text top="505" left="225" width="3" height="20" font="1"> </text>
<text top="522" left="225" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="539" left="225" width="3" height="20" font="1"> </text>
<text top="557" left="225" width="109" height="20" font="4"><b>Size</b>: 4,331 pts, 4.7 </text>
<text top="574" left="225" width="62" height="20" font="1">y follow-up<b> </b></text>
<text top="367" left="356" width="128" height="20" font="4"><b>Inclusion criteria</b>: DM-</text>
<text top="386" left="356" width="126" height="20" font="1">2 with HgbA1c ≥7.5%; </text>
<text top="405" left="356" width="8" height="18" font="1">≥</text>
<text top="404" left="364" width="121" height="20" font="1">40 y with CVD or ≥55 </text>
<text top="421" left="356" width="98" height="20" font="1">y with anatomical </text>
<text top="438" left="356" width="66" height="20" font="1">evidence of </text>
<text top="456" left="356" width="89" height="20" font="1">atherosclerosis, </text>
<text top="473" left="356" width="129" height="20" font="1">albuminuria, LVH, or at </text>
<text top="490" left="356" width="118" height="20" font="1">least 2 additional risk </text>
<text top="507" left="356" width="91" height="20" font="1">factors for CVD. </text>
<text top="524" left="356" width="3" height="20" font="1"> </text>
<text top="542" left="356" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="560" left="356" width="92" height="20" font="1">BMI ≥45, serum </text>
<text top="577" left="356" width="112" height="20" font="1">creatinine &gt;1.5, and </text>
<text top="594" left="356" width="116" height="20" font="1">other serious illness.<b> </b></text>
<text top="369" left="501" width="7" height="18" font="1">•</text>
<text top="368" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="386" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="403" left="501" width="110" height="20" font="1">to intensive therapy </text>
<text top="420" left="501" width="113" height="20" font="1">SBP&lt;120 mm Hg or </text>
<text top="437" left="501" width="96" height="20" font="1">standard therapy </text>
<text top="454" left="501" width="102" height="20" font="1">SBP&lt;140 mm Hg. </text>
<text top="368" left="630" width="239" height="20" font="4"><b>1</b>°<b> outcomes</b>: Nonfatal MI, nonfatal stroke, </text>
<text top="386" left="630" width="73" height="20" font="1">or CV death. </text>
<text top="403" left="630" width="3" height="20" font="4"><b> </b></text>
<text top="420" left="630" width="214" height="20" font="4"><b>Results</b>: The outcome measures were </text>
<text top="437" left="630" width="244" height="20" font="1">electrocardiographic LVH defined by Cornell </text>
<text top="454" left="630" width="235" height="20" font="1">voltage (binary variable) and mean Cornell </text>
<text top="472" left="630" width="228" height="20" font="1">index (continuous variable). The baseline </text>
<text top="489" left="630" width="240" height="20" font="1">prevalence of LVH (5.3% vs. 5.4%; p=0.91) </text>
<text top="506" left="630" width="245" height="20" font="1">and the mean Cornell index (1,456 vs. 1,470 </text>
<text top="523" left="630" width="224" height="20" font="1">µV; p=0.45) were similar in the intensive </text>
<text top="540" left="630" width="208" height="20" font="1">(n=2,154) and standard (n=2,177) BP-</text>
<text top="558" left="630" width="239" height="20" font="1">lowering arms, respectively. However, after </text>
<text top="575" left="630" width="199" height="20" font="1">median follow-up of 4.4 y, intensive, </text>
<text top="592" left="630" width="232" height="20" font="1">compared with standard, BP lowering was </text>
<text top="609" left="630" width="222" height="20" font="1">associated with a 39% lower risk of LVH </text>
<text top="627" left="630" width="245" height="20" font="1">(OR: 0.61; 95% CI: 0.43–0.88; p=0.008) and </text>
<text top="644" left="630" width="237" height="20" font="1">a significantly lower adjusted mean Cornell </text>
<text top="661" left="630" width="229" height="20" font="1">index (1,352 vs. 1,447 µV; p&lt;0.001). The </text>
<text top="678" left="630" width="236" height="20" font="1">lower risk of LVH associated with intensive </text>
<text top="695" left="630" width="248" height="20" font="1">BP lowering during follow-up was because of </text>
<text top="713" left="630" width="239" height="20" font="1">more regression of baseline LVH and lower </text>
<text top="730" left="630" width="241" height="20" font="1">rate of developing new LVH, compared with </text>
<text top="747" left="630" width="226" height="20" font="1">standard BP lowering. No interactions by </text>
<text top="764" left="630" width="183" height="20" font="1">age, sex, or race were observed.<b> </b></text>
<text top="367" left="893" width="200" height="20" font="4"><b>Limitations: </b>2º analysis; open-label </text>
<text top="384" left="893" width="184" height="20" font="1">design; LVH defined by EKG and </text>
<text top="402" left="893" width="194" height="20" font="1">not by echo or cardiac MRI; results </text>
<text top="419" left="893" width="196" height="20" font="1">may not apply to younger, healthier </text>
<text top="436" left="893" width="55" height="20" font="1">diabetics. </text>
<text top="453" left="893" width="3" height="20" font="4"><b> </b></text>
<text top="470" left="893" width="188" height="20" font="4"><b>Conclusions</b>: Targeting a SBP of </text>
<text top="488" left="893" width="190" height="20" font="1">&lt;120 mm Hg when compared with </text>
<text top="505" left="893" width="185" height="20" font="1">&lt;140 mm Hg in pts with HTN and </text>
<text top="522" left="893" width="196" height="20" font="1">DM produces a greater reduction in </text>
<text top="539" left="893" width="27" height="20" font="1">LVH </text>
</page>
<page number="177" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">177 </text>
<text top="107" left="98" width="73" height="20" font="1">Xie X, et al.,  </text>
<text top="124" left="98" width="56" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(21)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation">26559744</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation"> </a></text>
<text top="107" left="225" width="111" height="20" font="4"><b>Aim: </b>To assess the </text>
<text top="124" left="225" width="105" height="20" font="1">efficacy and safety </text>
<text top="141" left="225" width="85" height="20" font="1">of intensive BP </text>
<text top="159" left="225" width="109" height="20" font="1">lowering strategies. </text>
<text top="176" left="225" width="3" height="20" font="1"> </text>
<text top="193" left="225" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="210" left="225" width="102" height="20" font="1">Systematic review </text>
<text top="227" left="225" width="103" height="20" font="1">and meta-analysis </text>
<text top="245" left="225" width="3" height="20" font="1"> </text>
<text top="262" left="225" width="103" height="20" font="4"><b>Size</b>: 19 trials with </text>
<text top="279" left="225" width="108" height="20" font="1">44,989 pts; 3.8 y of </text>
<text top="296" left="225" width="56" height="20" font="1">follow-up.<b> </b></text>
<text top="107" left="356" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="124" left="356" width="128" height="20" font="1">RCTs with different BP </text>
<text top="141" left="356" width="123" height="20" font="1">targets or different BP </text>
<text top="159" left="356" width="131" height="20" font="1">changes between more </text>
<text top="176" left="356" width="132" height="20" font="1">vs. less intense therapy </text>
<text top="193" left="356" width="99" height="20" font="1">with at least 6 mo </text>
<text top="210" left="356" width="56" height="20" font="1">follow-up. </text>
<text top="227" left="356" width="3" height="20" font="1"> </text>
<text top="245" left="356" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="262" left="356" width="98" height="20" font="1">Trials that did not </text>
<text top="279" left="356" width="100" height="20" font="1">assess a different </text>
<text top="296" left="356" width="96" height="20" font="1">target or relevant </text>
<text top="314" left="356" width="54" height="20" font="1">outcome.<b> </b></text>
<text top="109" left="501" width="7" height="18" font="1">•</text>
<text top="108" left="508" width="87" height="20" font="1"> 5 RCTs (6,960 </text>
<text top="125" left="501" width="97" height="20" font="1">pts) enrolled only </text>
<text top="143" left="501" width="102" height="20" font="1">pts with DM and 6 </text>
<text top="160" left="501" width="92" height="20" font="1">trials (2,809 pts) </text>
<text top="177" left="501" width="114" height="20" font="1">specifically recruited </text>
<text top="194" left="501" width="78" height="20" font="1">pts with CKD. </text>
<text top="108" left="630" width="239" height="20" font="4"><b>1</b>°<b> outcomes</b>: Major CV events, defined as </text>
<text top="125" left="630" width="237" height="20" font="1">MI, stroke, HF or CV death, separately and </text>
<text top="143" left="630" width="206" height="20" font="1">combined; nonvascular and all-cause </text>
<text top="160" left="630" width="234" height="20" font="1">mortality; ESKD; and adverse events; new </text>
<text top="177" left="630" width="246" height="20" font="1">onset microalbuminuria/macroalbuminuria or </text>
<text top="194" left="630" width="248" height="20" font="1">change from micro- to macroalbuminuria and </text>
<text top="212" left="630" width="148" height="20" font="1">retinopathy in pts with DM. </text>
<text top="229" left="630" width="3" height="20" font="1"> </text>
<text top="246" left="630" width="210" height="20" font="4"><b>Results</b>: Pts in the more intensive BP-</text>
<text top="263" left="630" width="217" height="20" font="1">lowering treatment group had mean BP </text>
<text top="280" left="630" width="233" height="20" font="1">133/76 mm Hg compared with 140/81 mm </text>
<text top="298" left="630" width="241" height="20" font="1">Hg in the less intensive group. Intensive BP-</text>
<text top="315" left="630" width="239" height="20" font="1">lowering treatment achieved RR reductions </text>
<text top="332" left="630" width="233" height="20" font="1">for major CV events: 14% (95% CI: 4–22), </text>
<text top="349" left="630" width="238" height="20" font="1">MI: 13% (95% CI: 0–24), stroke: 22% (95% </text>
<text top="366" left="630" width="228" height="20" font="1">CI: 10–32), albuminuria: 10% (95% CI: 3–</text>
<text top="384" left="630" width="244" height="20" font="1">16), and retinopathy progression: 19% (95% </text>
<text top="401" left="630" width="196" height="20" font="1">CI: 0–34). However, more intensive </text>
<text top="418" left="630" width="231" height="20" font="1">treatment had no clear effects on HF: RR: </text>
<text top="435" left="630" width="236" height="20" font="1">15% (95% CI: -11–34), CV death: 9% (-11–</text>
<text top="453" left="630" width="234" height="20" font="1">26), total mortality: 9% (95% CI: -3–19), or </text>
<text top="470" left="630" width="241" height="20" font="1">ESKD: 10% (95% CI: -6–23). The reduction </text>
<text top="487" left="630" width="245" height="20" font="1">in major CV events was consistent across pt </text>
<text top="504" left="630" width="228" height="20" font="1">groups, and additional BP lowering had a </text>
<text top="521" left="630" width="242" height="20" font="1">clear benefit even in pts with SBP &lt;140 mm </text>
<text top="539" left="630" width="235" height="20" font="1">Hg. The absolute benefits were greatest in </text>
<text top="556" left="630" width="233" height="20" font="1">trials in which all enrolled pts had vascular </text>
<text top="573" left="630" width="215" height="20" font="1">disease, renal disease, or DM. Serious </text>
<text top="590" left="630" width="243" height="20" font="1">adverse events associated with BP lowering </text>
<text top="607" left="630" width="226" height="20" font="1">were only reported by 6 trials and had an </text>
<text top="625" left="630" width="233" height="20" font="1">event rate of 1%–2% per y in intensive BP </text>
<text top="642" left="630" width="235" height="20" font="1">lowering group pts, compared with 0.9% in </text>
<text top="659" left="630" width="247" height="20" font="1">the less intensive treatment group (RR: 1.35; </text>
<text top="676" left="630" width="250" height="20" font="1">95% CI: 0.93–1.97). Severe hypotension was </text>
<text top="693" left="630" width="197" height="20" font="1">more frequent in the more intensive </text>
<text top="711" left="630" width="240" height="20" font="1">treatment regimen (RR: 2.68; 95% CI: 1.21–</text>
<text top="728" left="630" width="245" height="20" font="1">5.89; p=0·015), but the absolute excess was </text>
<text top="745" left="630" width="250" height="20" font="1">small (0.3% vs. 0.1% per pt-y for the duration </text>
<text top="762" left="630" width="74" height="20" font="1">of follow-up).<b> </b></text>
<text top="107" left="893" width="189" height="20" font="4"><b>Study limitations</b>: Only 6,960 pts </text>
<text top="124" left="893" width="187" height="20" font="1">with DM were included in the total </text>
<text top="141" left="893" width="136" height="20" font="1">study size of 44,989 pts. </text>
<text top="159" left="893" width="3" height="20" font="1"> </text>
<text top="176" left="893" width="176" height="20" font="4"><b>Conclusions</b>: The absolute CV </text>
<text top="193" left="893" width="180" height="20" font="1">benefits were greatest in trials in </text>
<text top="210" left="893" width="191" height="20" font="1">which all enrolled pts had vascular </text>
<text top="228" left="893" width="166" height="20" font="1">disease, renal disease or DM. </text>
<text top="245" left="893" width="191" height="20" font="1">However, only 6,960 of the 44,989 </text>
<text top="262" left="893" width="197" height="20" font="1">pts had DM and no sub-analysis for </text>
<text top="279" left="893" width="176" height="20" font="1">DM was provided; however, the </text>
<text top="296" left="893" width="195" height="20" font="1">outcome benefits were qualitatively </text>
<text top="314" left="893" width="191" height="20" font="1">most striking for pts with DM, CKD </text>
<text top="331" left="893" width="137" height="20" font="1">and/or vascular disease.<b> </b></text>
</page>
<page number="178" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">178 </text>
<text top="107" left="98" width="86" height="20" font="4"><b>ACCOMPLISH </b></text>
<text top="124" left="98" width="98" height="20" font="1">Weber MA, et al., </text>
<text top="141" left="98" width="63" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(237)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20620720?dopt=Citation">20620720</a></text>
<text top="159" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20620720?dopt=Citation"> </a></text>
<text top="107" left="225" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="124" left="225" width="104" height="20" font="1">which combination </text>
<text top="141" left="225" width="102" height="20" font="1">therapy in pts with </text>
<text top="159" left="225" width="105" height="20" font="1">HTN and DM most </text>
<text top="176" left="225" width="118" height="20" font="1">effectively decreases </text>
<text top="193" left="225" width="64" height="20" font="1">CV events. </text>
<text top="210" left="225" width="3" height="20" font="1"> </text>
<text top="227" left="225" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="245" left="225" width="3" height="20" font="1"> </text>
<text top="262" left="225" width="111" height="20" font="4"><b>Size:</b> 2,842 pts with </text>
<text top="279" left="225" width="71" height="20" font="1">DM from the </text>
<text top="296" left="225" width="117" height="20" font="1">ACCOMPLISH study </text>
<text top="314" left="225" width="109" height="20" font="1">of 6,946 pts; 30 mo </text>
<text top="331" left="225" width="53" height="20" font="1">follow-up </text>
<text top="107" left="356" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="124" left="356" width="127" height="20" font="1">HTN and DM with high </text>
<text top="141" left="356" width="104" height="20" font="1">risk for CV events. </text>
<text top="159" left="356" width="3" height="20" font="1"> </text>
<text top="176" left="356" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="193" left="356" width="107" height="20" font="1">BMI &gt;45; serum Cr </text>
<text top="210" left="356" width="106" height="20" font="1">&gt;1.5; other serious </text>
<text top="228" left="356" width="38" height="20" font="1">illness </text>
<text top="109" left="501" width="7" height="18" font="1">•</text>
<text top="108" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="125" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="143" left="501" width="100" height="20" font="1">to benazepril plus </text>
<text top="160" left="501" width="77" height="20" font="1">amlodipine or </text>
<text top="177" left="501" width="86" height="20" font="1">benazepril plus </text>
<text top="194" left="501" width="113" height="20" font="1">hydrochlorothiazide. </text>
<text top="212" left="501" width="111" height="20" font="1">BPs were 145/79 at </text>
<text top="229" left="501" width="53" height="20" font="1">baseline. </text>
<text top="108" left="630" width="240" height="20" font="4"><b>1</b>°<b> outcomes</b>: Composite of death from CV </text>
<text top="125" left="630" width="201" height="20" font="1">causes, nonfatal MI, nonfatal stroke, </text>
<text top="143" left="630" width="244" height="20" font="1">hospitalization for angina, resuscitation after </text>
<text top="160" left="630" width="200" height="20" font="1">sudden cardiac arrest, and coronary </text>
<text top="177" left="630" width="99" height="20" font="1">revascularization. </text>
<text top="194" left="630" width="3" height="20" font="1"> </text>
<text top="211" left="630" width="208" height="20" font="4"><b>Results</b>: The mean achieved BP was </text>
<text top="229" left="630" width="250" height="20" font="1">131.5/72.6 and 132.7/73.7 in the B + A and B </text>
<text top="246" left="630" width="249" height="20" font="1">+ H groups, respectively, during the 30 mo of </text>
<text top="263" left="630" width="221" height="20" font="1">follow-up. There were 8.8% and 11% 1° </text>
<text top="280" left="630" width="218" height="20" font="1">events, respectively (HR: 0.79; 95% CI: </text>
<text top="298" left="630" width="226" height="20" font="1">0.684–0.92; p=0.003). In the pts with DM </text>
<text top="315" left="630" width="237" height="20" font="1">there were clear coronary benefits with B + </text>
<text top="332" left="630" width="208" height="20" font="1">A, including both acute clinical events </text>
<text top="349" left="630" width="238" height="20" font="1">(p=0.013 and revascularizations (p=0.024). </text>
<text top="366" left="630" width="240" height="20" font="1">There were no unexpected adverse events. </text>
<text top="107" left="893" width="200" height="20" font="4"><b>Summary</b>: In pts with DM and HTN, </text>
<text top="124" left="893" width="177" height="20" font="1">combining an ACEI with a CCB, </text>
<text top="141" left="893" width="197" height="20" font="1">compared with hydrochlorothiazide, </text>
<text top="159" left="893" width="200" height="20" font="1">was superior in reducing CV events. </text>
<text top="384" left="98" width="50" height="20" font="4"><b>ASCOT  </b></text>
<text top="402" left="98" width="105" height="20" font="1">Ostergren J, et al., </text>
<text top="419" left="98" width="66" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(238)</a>  </text>
<text top="436" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18854748?dopt=Citation">18854748</a></text>
<text top="436" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18854748?dopt=Citation"> </a></text>
<text top="384" left="225" width="100" height="20" font="4"><b>Aim:</b> To compare </text>
<text top="402" left="225" width="91" height="20" font="1">the effects of an </text>
<text top="419" left="225" width="100" height="20" font="1">amlodipine-based </text>
<text top="436" left="225" width="91" height="20" font="1">regimen vs. and </text>
<text top="453" left="225" width="84" height="20" font="1">atenolol-based </text>
<text top="470" left="225" width="85" height="20" font="1">regimen on CV </text>
<text top="488" left="225" width="115" height="20" font="1">outcomes in pts with </text>
<text top="505" left="225" width="22" height="20" font="1">DM </text>
<text top="522" left="225" width="3" height="20" font="1"> </text>
<text top="539" left="225" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="557" left="225" width="111" height="20" font="1">(BP lowering arm of </text>
<text top="574" left="225" width="50" height="20" font="1">ASCOT) </text>
<text top="591" left="225" width="3" height="20" font="1"> </text>
<text top="608" left="225" width="111" height="20" font="4"><b>Size:</b> 5,137 pts with </text>
<text top="625" left="225" width="99" height="20" font="1">DM, minimum 4 y </text>
<text top="643" left="225" width="53" height="20" font="1">follow-up </text>
<text top="384" left="356" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="402" left="356" width="101" height="20" font="1">40–65 y with HTN </text>
<text top="419" left="356" width="121" height="20" font="1">(&gt;160/100 mm Hg) or </text>
<text top="436" left="356" width="117" height="20" font="1">treated HTN and DM </text>
<text top="453" left="356" width="113" height="20" font="1">plus 2 additional CV </text>
<text top="470" left="356" width="98" height="20" font="1">risk factors: PAD, </text>
<text top="488" left="356" width="127" height="20" font="1">previous stroke or TIA, </text>
<text top="505" left="356" width="94" height="20" font="1">male sex, ≥55 y, </text>
<text top="522" left="356" width="100" height="20" font="1">microalbuminuria, </text>
<text top="539" left="356" width="79" height="20" font="1">smoking, total </text>
<text top="557" left="356" width="132" height="20" font="1">cholesterol to HDL ratio </text>
<text top="574" left="356" width="125" height="20" font="1">≥6, or family history of </text>
<text top="591" left="356" width="33" height="20" font="1">CHD.<b> </b></text>
<text top="386" left="501" width="7" height="18" font="1">•</text>
<text top="386" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="403" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="420" left="501" width="94" height="20" font="1">to an amlodipine-</text>
<text top="437" left="501" width="110" height="20" font="1">based regimen with </text>
<text top="454" left="501" width="60" height="20" font="1">addition of </text>
<text top="472" left="501" width="77" height="20" font="1">perindopril as </text>
<text top="489" left="501" width="80" height="20" font="1">required or an </text>
<text top="506" left="501" width="84" height="20" font="1">atenolol-based </text>
<text top="523" left="501" width="73" height="20" font="1">regimen with </text>
<text top="540" left="501" width="70" height="20" font="1">addition of a </text>
<text top="558" left="501" width="111" height="20" font="1">thiazide as required </text>
<text top="575" left="501" width="109" height="20" font="1">and therapy titrated </text>
<text top="592" left="501" width="79" height="20" font="1">as required to </text>
<text top="609" left="501" width="114" height="20" font="1">achieve target BP of </text>
<text top="627" left="501" width="87" height="20" font="1">130/80 mm Hg. </text>
<text top="386" left="630" width="234" height="20" font="4"><b>1</b>°<b> outcomes:</b> Fatal CHD and nonfatal MI. </text>
<text top="403" left="630" width="3" height="20" font="1"> </text>
<text top="420" left="630" width="239" height="20" font="4"><b>Results</b>: BPs were 136/75 (amlodipine and </text>
<text top="437" left="630" width="239" height="20" font="1">137/76 (atenolol) at the end of study. There </text>
<text top="454" left="630" width="212" height="20" font="1">was a 3/1.9 mm Hg lower BP in pts on </text>
<text top="472" left="630" width="239" height="20" font="1">amlodipine. The amlodipine-based regimen </text>
<text top="489" left="630" width="197" height="20" font="1">reduced CV events and procedures </text>
<text top="506" left="630" width="249" height="20" font="1">compared to the atenolol-based regimen (HR </text>
<text top="523" left="630" width="247" height="20" font="1">0.86; 0.76-0.98; p=0.026). Fatal and nonfatal </text>
<text top="540" left="630" width="225" height="20" font="1">strokes were reduced by 25% (p=0.017), </text>
<text top="558" left="630" width="225" height="20" font="1">PAD by 48% (p=0.004) and noncoronary </text>
<text top="575" left="630" width="194" height="20" font="1">vascularization procedures by 57% </text>
<text top="592" left="630" width="60" height="20" font="1">(p=0.001).<b> </b></text>
<text top="384" left="893" width="151" height="20" font="4"><b>Summary: </b>In the large DM </text>
<text top="402" left="893" width="197" height="20" font="1">subgroup of the BP-lowering arm of </text>
<text top="419" left="893" width="147" height="20" font="1">ASCOT, the benefits of an </text>
<text top="436" left="893" width="156" height="20" font="1">amlodipine-based treatment </text>
<text top="453" left="893" width="185" height="20" font="1">compared with an atenolol-based </text>
<text top="470" left="893" width="189" height="20" font="1">treatment on the incidence of total </text>
<text top="488" left="893" width="174" height="20" font="1">CV events and procedures was </text>
<text top="505" left="893" width="62" height="20" font="1">significant.<b> </b></text>
<text top="660" left="98" width="37" height="20" font="4"><b>SHEP </b></text>
<text top="678" left="98" width="95" height="20" font="1">Kostis JB, et al.,  </text>
<text top="695" left="98" width="66" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(239)</a>  </text>
<text top="712" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15619390?dopt=Citation">15619390</a></text>
<text top="712" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15619390?dopt=Citation"> </a></text>
<text top="660" left="225" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="678" left="225" width="105" height="20" font="1">long-term mortality </text>
<text top="695" left="225" width="106" height="20" font="1">rate of pts with DM </text>
<text top="712" left="225" width="113" height="20" font="1">pts in the SHEP trial </text>
<text top="729" left="225" width="107" height="20" font="1">randomly assigned </text>
<text top="747" left="225" width="113" height="20" font="1">to stepped care with </text>
<text top="764" left="225" width="94" height="20" font="1">chlorthalidone or </text>
<text top="781" left="225" width="50" height="20" font="1">placebo. </text>
<text top="660" left="356" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="678" left="356" width="119" height="20" font="1">Isolated systolic HTN </text>
<text top="695" left="356" width="130" height="20" font="1">(SBP 160–219 mm Hg) </text>
<text top="712" left="356" width="125" height="20" font="1">with DBP &lt;90 mm Hg. </text>
<text top="729" left="356" width="3" height="20" font="1"> </text>
<text top="747" left="356" width="131" height="20" font="4"><b>Exclusion criteria</b>: Pts </text>
<text top="764" left="356" width="128" height="20" font="1">with insulin–dependent </text>
<text top="781" left="356" width="106" height="20" font="1">DM and those who </text>
<text top="662" left="501" width="7" height="18" font="1">•</text>
<text top="662" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="679" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="696" left="501" width="108" height="20" font="1">to chlorthalidone or </text>
<text top="713" left="501" width="80" height="20" font="1">placebo. If BP </text>
<text top="730" left="501" width="92" height="20" font="1">remained above </text>
<text top="748" left="501" width="91" height="20" font="1">goal, atenolol or </text>
<text top="765" left="501" width="113" height="20" font="1">placebo was added. </text>
<text top="662" left="630" width="177" height="20" font="4"><b>1</b>°<b> outcomes: </b>CV mortality rate </text>
<text top="679" left="630" width="3" height="20" font="1"> </text>
<text top="696" left="630" width="233" height="20" font="4"><b>Results</b>: BP was 11.1/3.4 mm Hg lower in </text>
<text top="713" left="630" width="239" height="20" font="1">the active treatment group at the end of the </text>
<text top="730" left="630" width="243" height="20" font="1">study. Diuretic treatment in pts with DM was </text>
<text top="748" left="630" width="210" height="20" font="1">strongly associated with long-term CV </text>
<text top="765" left="630" width="234" height="20" font="1">mortality rate (AHR: 0.668 (95% CI: 0.526, </text>
<text top="660" left="893" width="184" height="20" font="4"><b>Summary: </b>Chlorthalidone-based </text>
<text top="678" left="893" width="165" height="20" font="1">treatment improved long-term </text>
<text top="695" left="893" width="141" height="20" font="1">outcomes in pts with DM.<b> </b></text>
</page>
<page number="179" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">179 </text>
<text top="107" left="225" width="3" height="20" font="1"> </text>
<text top="124" left="225" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="141" left="225" width="3" height="20" font="1"> </text>
<text top="159" left="225" width="89" height="20" font="4"><b>Size:</b> 4,732 pts; </text>
<text top="176" left="225" width="90" height="20" font="1">follow-up 14.3 y </text>
<text top="107" left="356" width="92" height="20" font="1">required diuretic </text>
<text top="124" left="356" width="48" height="20" font="1">therapy. </text>
<text top="107" left="630" width="233" height="20" font="1">0.848) and total mortality rate: 0.805 (95% </text>
<text top="124" left="630" width="98" height="20" font="1">CI: 0.680, 0.952).<b> </b></text>
<text top="194" left="98" width="67" height="20" font="4"><b>ROADMAP </b></text>
<text top="211" left="98" width="91" height="20" font="1">Menne J, et al.,  </text>
<text top="228" left="98" width="66" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(240)</a>  </text>
<text top="246" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22418908?dopt=Citation">22418908</a></text>
<text top="245" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22418908?dopt=Citation"> </a></text>
<text top="194" left="225" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="211" left="225" width="111" height="20" font="1">whether olmesartan </text>
<text top="228" left="225" width="118" height="20" font="1">compared to placebo </text>
<text top="246" left="225" width="107" height="20" font="1">delays the onset of </text>
<text top="263" left="225" width="100" height="20" font="1">albuminuria in pts </text>
<text top="280" left="225" width="104" height="20" font="1">with DM and HTN. </text>
<text top="297" left="225" width="3" height="20" font="1"> </text>
<text top="314" left="225" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="332" left="225" width="3" height="20" font="1"> </text>
<text top="349" left="225" width="89" height="20" font="4"><b>Size:</b> 4,020 pts; </text>
<text top="366" left="225" width="83" height="20" font="1">follow-up 3.2 y </text>
<text top="194" left="356" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="211" left="356" width="114" height="20" font="1">with HTN defined as </text>
<text top="228" left="356" width="112" height="20" font="1">BP ≥130/80 mm Hg </text>
<text top="246" left="356" width="120" height="20" font="1">and at least 1 CV risk </text>
<text top="263" left="356" width="38" height="20" font="1">factor.<b> </b></text>
<text top="196" left="501" width="7" height="18" font="1">•</text>
<text top="195" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="212" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="229" left="501" width="92" height="20" font="1">to olmesartan or </text>
<text top="247" left="501" width="107" height="20" font="1">placebo. Additional </text>
<text top="264" left="501" width="93" height="20" font="1">antihypertensive </text>
<text top="281" left="501" width="102" height="20" font="1">therapy except for </text>
<text top="298" left="501" width="107" height="20" font="1">ACEs and ARBs to </text>
<text top="316" left="501" width="56" height="20" font="1">lower BP. </text>
<text top="195" left="630" width="167" height="20" font="4"><b>1</b>°<b> outcome: </b>Time to onset of </text>
<text top="212" left="630" width="100" height="20" font="1">microalbuminuria. </text>
<text top="229" left="630" width="3" height="20" font="1"> </text>
<text top="247" left="630" width="231" height="20" font="4"><b>Results</b>: Average BP was 126.3/74.7 and </text>
<text top="264" left="630" width="216" height="20" font="1">129.5/76.6, respectively (significant not </text>
<text top="281" left="630" width="226" height="20" font="1">stated). Olmesartan delayed the onset of </text>
<text top="298" left="630" width="223" height="20" font="1">microalbuminuria by 25% (0.75; 95% CI: </text>
<text top="316" left="630" width="208" height="20" font="1">0.61–0.92; p=0.007). CV events were </text>
<text top="333" left="630" width="156" height="20" font="1">comparable in the 2 groups.<b> </b></text>
<text top="194" left="893" width="165" height="20" font="4"><b>Summary: </b>Pts with better BP </text>
<text top="211" left="893" width="192" height="20" font="1">reduction are less likely to develop </text>
<text top="228" left="893" width="202" height="20" font="1">microalbuminuria. Treatment with an </text>
<text top="246" left="893" width="143" height="20" font="1">ARB delayed the onset of </text>
<text top="263" left="893" width="191" height="20" font="1">microalbuminuria independently of </text>
<text top="280" left="893" width="168" height="20" font="1">baseline BP and degree of BP </text>
<text top="297" left="893" width="57" height="20" font="1">reduction.<b> </b></text>
<text top="384" left="98" width="39" height="20" font="4"><b>ABCD </b></text>
<text top="401" left="98" width="102" height="20" font="1">Estacio RO, et al., </text>
<text top="418" left="98" width="66" height="20" font="1">1998 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(241)</a>  </text>
<text top="436" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9486993?dopt=Citation">9486993</a></text>
<text top="436" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9486993?dopt=Citation"> </a></text>
<text top="384" left="225" width="100" height="20" font="4"><b>Aim:</b> To compare </text>
<text top="401" left="225" width="74" height="20" font="1">the effects of </text>
<text top="418" left="225" width="118" height="20" font="1">“intensive” compared </text>
<text top="436" left="225" width="109" height="20" font="1">with “moderate” BP </text>
<text top="453" left="225" width="101" height="20" font="1">treatment on 24-h </text>
<text top="470" left="225" width="113" height="20" font="1">creatinine clearance </text>
<text top="487" left="225" width="118" height="20" font="1">(GFR) in pts with DM </text>
<text top="504" left="225" width="56" height="20" font="1">and HTN. </text>
<text top="522" left="225" width="3" height="20" font="1"> </text>
<text top="539" left="225" width="109" height="20" font="4"><b>Study type</b>: RCT – </text>
<text top="556" left="225" width="60" height="20" font="1">open label </text>
<text top="573" left="225" width="3" height="20" font="1"> </text>
<text top="591" left="225" width="115" height="20" font="4"><b>Size:</b> 472 pts; follow-</text>
<text top="608" left="225" width="37" height="20" font="1">up 5 y </text>
<text top="384" left="356" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="401" left="356" width="114" height="20" font="1">with HTN defined as </text>
<text top="418" left="356" width="121" height="20" font="1">DBP ≥90 mm Hg and </text>
<text top="436" left="356" width="33" height="20" font="1">DM-2<b> </b></text>
<text top="386" left="501" width="7" height="18" font="1">•</text>
<text top="385" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="402" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="420" left="501" width="74" height="20" font="1">to “intensive” </text>
<text top="437" left="501" width="109" height="20" font="1">treatment (DBP&lt;75 </text>
<text top="454" left="501" width="67" height="20" font="1">mm Hg and </text>
<text top="471" left="501" width="63" height="20" font="1">“moderate” </text>
<text top="488" left="501" width="109" height="20" font="1">treatment (DBP 80–</text>
<text top="506" left="501" width="100" height="20" font="1">89 mm Hg) with a </text>
<text top="523" left="501" width="83" height="20" font="1">combination of </text>
<text top="540" left="501" width="85" height="20" font="1">nisoldipine and </text>
<text top="557" left="501" width="87" height="20" font="1">enalapril as the </text>
<text top="574" left="501" width="31" height="20" font="1">initial </text>
<text top="592" left="501" width="93" height="20" font="1">antihypertensive </text>
<text top="609" left="501" width="66" height="20" font="1">medication. </text>
<text top="385" left="630" width="219" height="20" font="4"><b>1</b>°<b> outcome: </b>Change in 24-h creatinine </text>
<text top="402" left="630" width="60" height="20" font="1">clearance. </text>
<text top="420" left="630" width="3" height="20" font="1"> </text>
<text top="437" left="630" width="55" height="20" font="4"><b>Results</b>:  </text>
<text top="456" left="630" width="7" height="18" font="1">•</text>
<text top="455" left="636" width="235" height="20" font="1"> The mean BP achieved was 132/78 in the </text>
<text top="472" left="630" width="241" height="20" font="1">intensive group and 138/86 in the moderate </text>
<text top="490" left="630" width="212" height="20" font="1">control group. During the 5-y follow-up </text>
<text top="507" left="630" width="215" height="20" font="1">period, there was no difference in GFR </text>
<text top="524" left="630" width="211" height="20" font="1">between the groups. After the first y of </text>
<text top="541" left="630" width="249" height="20" font="1">antihypertensive treatment, GFR stabilized in </text>
<text top="558" left="630" width="246" height="20" font="1">both the intensive and moderate groups with </text>
<text top="576" left="630" width="155" height="20" font="1">normal albumin excretion or </text>
<text top="593" left="630" width="241" height="20" font="1">microalbuminuria. In contrast, pts with overt </text>
<text top="610" left="630" width="241" height="20" font="1">albuminuria demonstrated steady decline in </text>
<text top="627" left="630" width="215" height="20" font="1">GFR whether on intensive or moderate </text>
<text top="644" left="630" width="216" height="20" font="1">therapy. Neither was there a significant </text>
<text top="662" left="630" width="241" height="20" font="1">difference in the progression from normal to </text>
<text top="679" left="630" width="201" height="20" font="1">micro- or micro-to overt albuminuria. </text>
<text top="698" left="630" width="7" height="18" font="1">•</text>
<text top="697" left="636" width="222" height="20" font="1"> Intensive therapy demonstrated a lower </text>
<text top="714" left="630" width="245" height="20" font="1">overall incidence of deaths, 5.5% vs. 10.7%; </text>
<text top="733" left="630" width="127" height="20" font="1">p=0.037 (2° endpoint).<b> </b></text>
<text top="384" left="893" width="200" height="20" font="4"><b>Limitations: </b>Open-label design; the </text>
<text top="401" left="893" width="198" height="20" font="1">definition of DM was 2 fasting blood </text>
<text top="418" left="893" width="199" height="20" font="1">glucose measurements &gt;140 mg/dL </text>
<text top="436" left="893" width="192" height="20" font="1">as opposed to &gt;126 today; serious </text>
<text top="453" left="893" width="196" height="20" font="1">side effects were not reported. Risk </text>
<text top="470" left="893" width="203" height="20" font="1">of bias due to a greater proportion of </text>
<text top="487" left="893" width="203" height="20" font="1">pts with established CVD at baseline </text>
<text top="504" left="893" width="196" height="20" font="1">assigned to the standard BP target.<b> </b></text>
<text top="522" left="893" width="3" height="20" font="4"><b> </b></text>
<text top="539" left="893" width="193" height="20" font="4"><b>Summary: </b>BP control of 138/86 or </text>
<text top="556" left="893" width="176" height="20" font="1">132/78 with either nisoldipine or </text>
<text top="573" left="893" width="118" height="20" font="1">enalapril as the initial </text>
<text top="591" left="893" width="196" height="20" font="1">antihypertensive agent appeared to </text>
<text top="608" left="893" width="187" height="20" font="1">stabilize renal function in HTN pts </text>
<text top="625" left="893" width="158" height="20" font="1">with type 2 DM without overt </text>
<text top="642" left="893" width="188" height="20" font="1">albuminuria over a 5-y period. For </text>
<text top="659" left="893" width="175" height="20" font="1">the ABCD trials, only ABDC (H) </text>
<text top="677" left="893" width="185" height="20" font="1">included strictly pts with HTN and </text>
<text top="694" left="893" width="190" height="20" font="1">DM. The quality of evidence is low </text>
<text top="711" left="893" width="193" height="20" font="1">due to imprecision and risk of bias.<b> </b></text>
<text top="751" left="98" width="82" height="20" font="4"><b>Hypertension </b></text>
<text top="768" left="98" width="112" height="20" font="4"><b>Optimal Treatment </b></text>
<text top="785" left="98" width="64" height="20" font="4"><b>(HOT trial) </b></text>
<text top="751" left="225" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="768" left="225" width="114" height="20" font="1">optimum target DBP </text>
<text top="751" left="356" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="768" left="356" width="114" height="20" font="1">with HTN defined as </text>
<text top="753" left="501" width="7" height="18" font="1">•</text>
<text top="752" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="769" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="786" left="501" width="111" height="20" font="1">to 1 of 3 DBP target </text>
<text top="752" left="630" width="240" height="20" font="4"><b>1</b>°<b> outcomes: </b>Major CV events, MI, stroke, </text>
<text top="769" left="630" width="174" height="20" font="1">CV mortality and total mortality. </text>
<text top="786" left="630" width="3" height="20" font="1"> </text>
<text top="751" left="893" width="200" height="20" font="4"><b>Limitations: </b>Open-label design; the </text>
<text top="768" left="893" width="173" height="20" font="1">definition of DM-2 fasting blood </text>
<text top="785" left="893" width="199" height="20" font="1">glucose measurements &gt;140 mg/dL </text>
</page>
<page number="180" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">180 </text>
<text top="107" left="98" width="99" height="20" font="1">Hansson L, et al., </text>
<text top="124" left="98" width="66" height="20" font="1">1998 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(242)</a>  </text>
<text top="141" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9635947?dopt=Citation">9635947</a></text>
<text top="141" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9635947?dopt=Citation"> </a></text>
<text top="107" left="225" width="103" height="20" font="1">in the treatment of </text>
<text top="124" left="225" width="32" height="20" font="1">HTN. </text>
<text top="141" left="225" width="3" height="20" font="1"> </text>
<text top="159" left="225" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="176" left="225" width="3" height="20" font="1"> </text>
<text top="193" left="225" width="99" height="20" font="4"><b>Size:</b> 1,501 pts in </text>
<text top="210" left="225" width="101" height="20" font="1">the DM subgroup; </text>
<text top="227" left="225" width="83" height="20" font="1">follow-up 3.8 y </text>
<text top="107" left="356" width="123" height="20" font="1">DBP 100–115 mm Hg </text>
<text top="124" left="356" width="50" height="20" font="1">and DM.<b> </b></text>
<text top="107" left="501" width="102" height="20" font="1">groups: ≤90, ≤85, </text>
<text top="124" left="501" width="86" height="20" font="1">or ≤80 mm Hg. </text>
<text top="107" left="630" width="227" height="20" font="4"><b>Results</b>: In the group randomized to ≤80 </text>
<text top="124" left="630" width="223" height="20" font="1">mm Hg, the risk of major CV events was </text>
<text top="141" left="630" width="238" height="20" font="1">halved in comparison to the target ≤90. CV </text>
<text top="159" left="630" width="202" height="20" font="1">mortality was lower in the ≤80 group </text>
<text top="176" left="630" width="168" height="20" font="1">compared to the other groups. </text>
<text top="107" left="893" width="192" height="20" font="1">as opposed to &gt;126 today; serious </text>
<text top="124" left="893" width="169" height="20" font="1">side effects were not reported; </text>
<text top="141" left="893" width="168" height="20" font="1">potential bias due to subgroup </text>
<text top="159" left="893" width="51" height="20" font="1">analysis.<b> </b></text>
<text top="176" left="893" width="3" height="20" font="4"><b> </b></text>
<text top="193" left="893" width="201" height="20" font="4"><b>Summary:</b> In pts with DM and HTN, </text>
<text top="210" left="893" width="160" height="20" font="1">intensive lowering of BP was </text>
<text top="227" left="893" width="178" height="20" font="1">associated with a low rate of CV </text>
<text top="245" left="893" width="185" height="20" font="1">events. The quality of evidence is </text>
<text top="262" left="893" width="187" height="20" font="1">low to very low due to imprecision </text>
<text top="279" left="893" width="90" height="20" font="1">and risk of bias.<b> </b></text>
<text top="297" left="98" width="46" height="20" font="4"><b>UKPDS </b></text>
<text top="314" left="98" width="63" height="20" font="1">1998 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(243)</a> </text>
<text top="332" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9732337?dopt=Citation">9732337</a></text>
<text top="332" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9732337?dopt=Citation"> </a></text>
<text top="297" left="225" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="314" left="225" width="114" height="20" font="1">whether tight control </text>
<text top="332" left="225" width="84" height="20" font="1">of BP prevents </text>
<text top="349" left="225" width="107" height="20" font="1">macrovascular and </text>
<text top="366" left="225" width="79" height="20" font="1">microvascular </text>
<text top="383" left="225" width="111" height="20" font="1">complications in pts </text>
<text top="401" left="225" width="62" height="20" font="1">with DM-2. </text>
<text top="418" left="225" width="3" height="20" font="1"> </text>
<text top="435" left="225" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="452" left="225" width="3" height="20" font="1"> </text>
<text top="469" left="225" width="65" height="20" font="4"><b>Size</b>: 1,148 </text>
<text top="487" left="225" width="118" height="20" font="1">hypertensive pts with </text>
<text top="504" left="225" width="59" height="20" font="1">type 2 DM </text>
<text top="521" left="225" width="3" height="20" font="1"> </text>
<text top="538" left="225" width="95" height="20" font="4"><b>Follow-up</b>: 8.4 y<b> </b></text>
<text top="297" left="356" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="314" left="356" width="132" height="20" font="1">Fasting plasma glucose </text>
<text top="332" left="356" width="95" height="20" font="1">concentration &gt;6 </text>
<text top="349" left="356" width="120" height="20" font="1">mmol/l in 2 mornings. </text>
<text top="366" left="356" width="3" height="20" font="1"> </text>
<text top="383" left="356" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="400" left="356" width="116" height="20" font="1">Ketonuria &gt;3 mmol/l; </text>
<text top="418" left="356" width="104" height="20" font="1">history of MI in the </text>
<text top="435" left="356" width="105" height="20" font="1">previous y; current </text>
<text top="452" left="356" width="130" height="20" font="1">angina or HF; &gt;1 major </text>
<text top="469" left="356" width="99" height="20" font="1">vascular episode; </text>
<text top="487" left="356" width="94" height="20" font="1">serum creatinine </text>
<text top="504" left="356" width="108" height="20" font="1">concentration &gt;175 </text>
<text top="521" left="356" width="106" height="20" font="1">µmol/l; retinopathy </text>
<text top="538" left="356" width="81" height="20" font="1">requiring laser </text>
<text top="555" left="356" width="116" height="20" font="1">treatment; malignant </text>
<text top="573" left="356" width="118" height="20" font="1">HTN; an uncorrected </text>
<text top="590" left="356" width="128" height="20" font="1">endocrine abnormality; </text>
<text top="607" left="356" width="104" height="20" font="1">an occupation that </text>
<text top="624" left="356" width="124" height="20" font="1">would preclude insulin </text>
<text top="641" left="356" width="109" height="20" font="1">treatment; a severe </text>
<text top="659" left="356" width="102" height="20" font="1">concurrent illness; </text>
<text top="676" left="356" width="64" height="20" font="1">inadequate </text>
<text top="693" left="356" width="96" height="20" font="1">understanding or </text>
<text top="710" left="356" width="121" height="20" font="1">unwillingness to enter </text>
<text top="727" left="356" width="57" height="20" font="1">the study.<b> </b></text>
<text top="299" left="501" width="7" height="18" font="1">•</text>
<text top="298" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="316" left="501" width="108" height="20" font="1">randomized to tight </text>
<text top="333" left="501" width="99" height="20" font="1">BP control (target </text>
<text top="350" left="501" width="112" height="20" font="1">BP&lt;150/85 mm Hg) </text>
<text top="367" left="501" width="86" height="20" font="1">or less tight BP </text>
<text top="384" left="501" width="79" height="20" font="1">control (target </text>
<text top="402" left="501" width="106" height="20" font="1">&lt;180/105 mm Hg), </text>
<text top="298" left="630" width="85" height="20" font="4"><b>1</b>°<b> outcomes:</b>  </text>
<text top="316" left="630" width="210" height="20" font="1">1) First clinical endpoint related to DM </text>
<text top="333" left="630" width="245" height="20" font="1">(sudden death, death from hyperglycemia or </text>
<text top="350" left="630" width="235" height="20" font="1">hypoglycemia, fatal or nonfatal MI, angina, </text>
<text top="367" left="630" width="249" height="20" font="1">HF, stroke, renal failure, amputation, vitreous </text>
<text top="384" left="630" width="211" height="20" font="1">hemorrhage, retinal photocoagulation, </text>
<text top="402" left="630" width="231" height="20" font="1">blindness in 1 eye or cataract extraction).  </text>
<text top="419" left="630" width="131" height="20" font="1">2) Death related to DM. </text>
<text top="436" left="630" width="144" height="20" font="1">3) Death from all causes.  </text>
<text top="453" left="630" width="3" height="20" font="1"> </text>
<text top="470" left="630" width="226" height="20" font="4"><b>Results</b>: BP in the tight BP control group </text>
<text top="488" left="630" width="205" height="20" font="1">was 144/82 compared with the group </text>
<text top="505" left="630" width="198" height="20" font="1">assigned less tight control (154/87), </text>
<text top="522" left="630" width="228" height="20" font="1">p&lt;0.0001. Reductions in risk in the group </text>
<text top="539" left="630" width="223" height="20" font="1">assigned tight BP control compared with </text>
<text top="557" left="630" width="225" height="20" font="1">those of the less tight control group were </text>
<text top="574" left="630" width="230" height="20" font="1">24% (95% CI: 8%–38%; p=0.0046) in DM </text>
<text top="591" left="630" width="237" height="20" font="1">related endpoints; 32% in deaths related to </text>
<text top="608" left="630" width="222" height="20" font="1">DM (95% CI: 6%–51%; p&lt;0.019; 44% in </text>
<text top="625" left="630" width="233" height="20" font="1">strokes (95% CI: 11%–65%; p&lt;0.013; and </text>
<text top="643" left="630" width="210" height="20" font="1">37% (95% CI: 11%–36%; p&lt;0.0092 in </text>
<text top="660" left="630" width="244" height="20" font="1">microvascular endpoints, predominantly due </text>
<text top="677" left="630" width="191" height="20" font="1">to risk of retinal photocoagulation. <b> </b></text>
<text top="297" left="893" width="199" height="20" font="4"><b>Limitations</b>: DBP targets were high </text>
<text top="314" left="893" width="200" height="20" font="1">(85 mm Hg in the tight control group </text>
<text top="332" left="893" width="176" height="20" font="1">and 105 mm Hg in the less tight </text>
<text top="349" left="893" width="176" height="20" font="1">control group) and similar to the </text>
<text top="366" left="893" width="192" height="20" font="1">cutoffs for the no treatment groups </text>
<text top="383" left="893" width="201" height="20" font="1">in trials comparing treatment with no </text>
<text top="401" left="893" width="161" height="20" font="1">treatment. UKPDS evaluated </text>
<text top="418" left="893" width="195" height="20" font="1">lowering both SBP and DBP so it is </text>
<text top="435" left="893" width="204" height="20" font="1">impossible to separate the outcomes </text>
<text top="452" left="893" width="166" height="20" font="1">effects of DBP. Therefore, the </text>
<text top="469" left="893" width="143" height="20" font="1">evidence is of low quality. </text>
<text top="487" left="893" width="3" height="20" font="1"> </text>
<text top="504" left="893" width="187" height="20" font="4"><b>Summary</b>: Tight BP control in pts </text>
<text top="521" left="893" width="174" height="20" font="1">with HTN and DM-2 achieved a </text>
<text top="538" left="893" width="192" height="20" font="1">clinically important reduction in the </text>
<text top="555" left="893" width="151" height="20" font="1">risk of death related to DM, </text>
<text top="573" left="893" width="158" height="20" font="1">complications related to DM, </text>
<text top="590" left="893" width="192" height="20" font="1">progression of DM retinopathy and </text>
<text top="607" left="893" width="200" height="20" font="1">deterioration of visual acuity, but the </text>
<text top="624" left="893" width="143" height="20" font="1">quality of evidence is low.<b> </b></text>
<text top="745" left="98" width="111" height="20" font="1">Arguedas JA, et al., </text>
<text top="763" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(244)</a> </text>
<text top="780" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24170669?dopt=Citation">24170669</a></text>
<text top="780" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24170669?dopt=Citation"> </a></text>
<text top="745" left="225" width="116" height="20" font="4"><b>Aim: </b>To determine if </text>
<text top="763" left="225" width="102" height="20" font="1">“lower” BP targets </text>
<text top="780" left="225" width="111" height="20" font="1">(any target &lt;130/85 </text>
<text top="745" left="356" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="763" left="356" width="82" height="20" font="1">RCTs in which </text>
<text top="780" left="356" width="91" height="20" font="1">individuals were </text>
<text top="747" left="501" width="7" height="18" font="1">•</text>
<text top="747" left="508" width="102" height="20" font="1"> Pts with HTN and </text>
<text top="764" left="501" width="107" height="20" font="1">DM were randomly </text>
<text top="781" left="501" width="87" height="20" font="1">assigned to the </text>
<text top="747" left="630" width="235" height="20" font="4"><b>1</b>°<b> outcomes</b>: Total mortality, total serious </text>
<text top="764" left="630" width="248" height="20" font="1">adverse events, MI, stroke, CHF, and ESRD. </text>
<text top="781" left="630" width="3" height="20" font="1"> </text>
<text top="745" left="893" width="198" height="20" font="4"><b>Conclusions: </b>Evidence from RCTs </text>
<text top="763" left="893" width="189" height="20" font="1">does not support BP targets lower </text>
</page>
<page number="181" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">181 </text>
<text top="107" left="225" width="68" height="20" font="1">mm Hg) are </text>
<text top="124" left="225" width="87" height="20" font="1">associated with </text>
<text top="141" left="225" width="117" height="20" font="1">reduction in mortality </text>
<text top="159" left="225" width="77" height="20" font="1">and morbidity </text>
<text top="176" left="225" width="72" height="20" font="1">compared to </text>
<text top="193" left="225" width="79" height="20" font="1">“standard” BP </text>
<text top="210" left="225" width="80" height="20" font="1">targets (&lt;140–</text>
<text top="228" left="225" width="116" height="20" font="1">160/90–100 mm Hg) </text>
<text top="245" left="225" width="84" height="20" font="1">in pts with DM. </text>
<text top="262" left="225" width="3" height="20" font="4"><b> </b></text>
<text top="279" left="225" width="101" height="20" font="4"><b>Study type</b>: Meta-</text>
<text top="296" left="225" width="100" height="20" font="1">analysis of RCTs. </text>
<text top="314" left="225" width="3" height="20" font="1"> </text>
<text top="331" left="225" width="76" height="20" font="4"><b>Size</b>: 5 RCTs </text>
<text top="348" left="225" width="105" height="20" font="1">recruiting a total of </text>
<text top="365" left="225" width="54" height="20" font="1">7,314 ps. </text>
<text top="382" left="225" width="3" height="20" font="4"><b> </b></text>
<text top="400" left="225" width="117" height="20" font="4"><b>Mean follow-up</b>: 4.5 </text>
<text top="417" left="225" width="10" height="20" font="1">y </text>
<text top="107" left="356" width="133" height="20" font="1">randomized to a “lower” </text>
<text top="124" left="356" width="94" height="20" font="1">compared with a </text>
<text top="141" left="356" width="121" height="20" font="1">“standard” BP target.  </text>
<text top="159" left="356" width="3" height="20" font="4"><b> </b></text>
<text top="176" left="356" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="193" left="356" width="109" height="20" font="1">Studies that did not </text>
<text top="210" left="356" width="102" height="20" font="1">meet the inclusion </text>
<text top="228" left="356" width="98" height="20" font="1">criteria. Excluded </text>
<text top="245" left="356" width="118" height="20" font="1">studies were UKPDS </text>
<text top="262" left="356" width="128" height="20" font="1">1998, HTN in Diabetes </text>
<text top="279" left="356" width="130" height="20" font="1">Study IV 1996, SANDS </text>
<text top="296" left="356" width="124" height="20" font="1">2008, Lewis 1999 and </text>
<text top="314" left="356" width="103" height="20" font="1">the Steno-2 study.<b> </b></text>
<text top="107" left="501" width="66" height="20" font="1">intensive or </text>
<text top="124" left="501" width="111" height="20" font="1">standard BP control </text>
<text top="141" left="501" width="38" height="20" font="1">group. </text>
<text top="107" left="630" width="237" height="20" font="4"><b>Results</b>: Only 1 trial (ACCORD) compared </text>
<text top="124" left="630" width="241" height="20" font="1">outcomes associated with 'lower' (&lt;120 mm </text>
<text top="141" left="630" width="245" height="20" font="1">Hg) or 'standard' (&lt;140 mm Hg) SBP targets </text>
<text top="159" left="630" width="245" height="20" font="1">in 4734 pts. Despite achieving a significantly </text>
<text top="176" left="630" width="242" height="20" font="1">lower BP (119.3/64.4 mm Hg vs. 133.5/70.5 </text>
<text top="193" left="630" width="197" height="20" font="1">mm Hg, p&lt;0.0001), and using more </text>
<text top="210" left="630" width="212" height="20" font="1">antihypertensive medications, the only </text>
<text top="228" left="630" width="233" height="20" font="1">significant benefit in the group assigned to </text>
<text top="245" left="630" width="244" height="20" font="1">'lower' SBP was a reduction in the incidence </text>
<text top="262" left="630" width="222" height="20" font="1">of stroke: RR: 0.58; (95% CI: 0.39–0.88; </text>
<text top="279" left="630" width="242" height="20" font="1">p=0.009), absolute risk reduction 1.1%. The </text>
<text top="296" left="630" width="208" height="20" font="1">effect of SBP targets on mortality was </text>
<text top="314" left="630" width="204" height="20" font="1">compatible with both a reduction and </text>
<text top="331" left="630" width="223" height="20" font="1">increase in risk: RR: 1.05 (95% CI: 0.84, </text>
<text top="348" left="630" width="249" height="20" font="1">1.30), low quality evidence. Trying to achieve </text>
<text top="365" left="630" width="244" height="20" font="1">the 'lower' SBP target was associated with a </text>
<text top="383" left="630" width="232" height="20" font="1">significant increase in the number of other </text>
<text top="400" left="630" width="240" height="20" font="1">serious adverse events: RR: 2.58, (95% CI: </text>
<text top="417" left="630" width="249" height="20" font="1">1.70–3.91; p&lt;0.00001, absolute risk increase </text>
<text top="434" left="630" width="247" height="20" font="1">2.0%. 4 trials (ABCD-H, ABCD-N, ABCD-2V, </text>
<text top="451" left="630" width="241" height="20" font="1">and a subgroup of HTN Optimal Treatment) </text>
<text top="469" left="630" width="218" height="20" font="1">specifically compared clinical outcomes </text>
<text top="486" left="630" width="241" height="20" font="1">associated with 'lower' vs. 'standard' targets </text>
<text top="503" left="630" width="241" height="20" font="1">for DBP in pts with DM. The total number of </text>
<text top="520" left="630" width="239" height="20" font="1">pts included in the DBP target analysis was </text>
<text top="537" left="630" width="222" height="20" font="1">2580. Pts assigned to 'lower' DBP had a </text>
<text top="555" left="630" width="241" height="20" font="1">significantly lower achieved BP: 128/76 mm </text>
<text top="572" left="630" width="245" height="20" font="1">Hg vs. 135/83 mm Hg; p&lt;0.0001. There was </text>
<text top="589" left="630" width="245" height="20" font="1">a trend towards reduction in total mortality in </text>
<text top="606" left="630" width="247" height="20" font="1">the group assigned to the 'lower' DBP target: </text>
<text top="623" left="630" width="245" height="20" font="1">RR: 0.73 (95% CI: 0.53–1.01), mainly due to </text>
<text top="641" left="630" width="247" height="20" font="1">a trend to lower non-CV mortality. There was </text>
<text top="658" left="630" width="234" height="20" font="1">no difference in stroke: RR: 0.67, (95% CI: </text>
<text top="675" left="630" width="233" height="20" font="1">0.42–1.05), in MI: RR: 0.95 (95% CI: 0.64–</text>
<text top="692" left="630" width="225" height="20" font="1">1.40) or in CHF: RR: 1.06 (95% CI: 0.58–</text>
<text top="710" left="630" width="243" height="20" font="1">1.92), low-quality evidence. End-stage renal </text>
<text top="727" left="630" width="248" height="20" font="1">failure and total serious adverse events were </text>
<text top="744" left="630" width="241" height="20" font="1">not reported in any of the trials. A sensitivity </text>
<text top="761" left="630" width="246" height="20" font="1">analysis of trials comparing DBP targets &lt;80 </text>
<text top="778" left="630" width="240" height="20" font="1">mm Hg (as suggested in clinical guidelines) </text>
<text top="107" left="893" width="178" height="20" font="1">than standard targets in pts with </text>
<text top="124" left="893" width="79" height="20" font="1">HTN and DM. </text>
</page>
<page number="182" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">182 </text>
<text top="107" left="630" width="250" height="20" font="1">vs. &lt;90 mm Hg showed similar results. There </text>
<text top="124" left="630" width="228" height="20" font="1">was a high risk of selection bias for every </text>
<text top="141" left="630" width="219" height="20" font="1">outcome analyzed in favor of the 'lower' </text>
<text top="159" left="630" width="247" height="20" font="1">target in the trials included for the analysis of </text>
<text top="176" left="630" width="73" height="20" font="1">DBP targets.<b> </b></text>
<text top="194" left="98" width="100" height="20" font="1">Palmer SC, et al., </text>
<text top="211" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(245)</a> </text>
<text top="228" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26009228?dopt=Citation">26009228</a></text>
<text top="228" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26009228?dopt=Citation"> </a></text>
<text top="194" left="225" width="111" height="20" font="4"><b>Aim: </b>To investigate </text>
<text top="211" left="225" width="91" height="20" font="1">the benefits and </text>
<text top="228" left="225" width="72" height="20" font="1">harms of BP-</text>
<text top="246" left="225" width="96" height="20" font="1">lowering drugs in </text>
<text top="263" left="225" width="84" height="20" font="1">adults with DM </text>
<text top="280" left="225" width="3" height="20" font="4"><b> </b></text>
<text top="297" left="225" width="118" height="20" font="4"><b>Study type</b>: Network </text>
<text top="314" left="225" width="93" height="20" font="1">meta-analysis of </text>
<text top="332" left="225" width="38" height="20" font="1">RCTs. </text>
<text top="349" left="225" width="3" height="20" font="1"> </text>
<text top="366" left="225" width="111" height="20" font="4"><b>Size</b>: 157 studies in </text>
<text top="383" left="225" width="100" height="20" font="1">43,256 pts mostly </text>
<text top="400" left="225" width="105" height="20" font="1">with DM and CKD. </text>
<text top="418" left="225" width="3" height="20" font="4"><b> </b></text>
<text top="435" left="225" width="117" height="20" font="4"><b>Mean follow-up</b>: 4.5 </text>
<text top="452" left="225" width="10" height="20" font="1">y<b> </b></text>
<text top="194" left="356" width="126" height="20" font="4"><b>Inclusion criteria</b>: Pts </text>
<text top="211" left="356" width="107" height="20" font="1">≥18 y with DM and </text>
<text top="228" left="356" width="125" height="20" font="1">CKD and were treated </text>
<text top="246" left="356" width="107" height="20" font="1">in clinical trials that </text>
<text top="263" left="356" width="114" height="20" font="1">compared any orally </text>
<text top="280" left="356" width="74" height="20" font="1">administered </text>
<text top="297" left="356" width="127" height="20" font="1">antihypertensive agent </text>
<text top="314" left="356" width="131" height="20" font="1">alone or in combination </text>
<text top="332" left="356" width="59" height="20" font="1">with a 2nd </text>
<text top="349" left="356" width="127" height="20" font="1">antihypertensive agent </text>
<text top="366" left="356" width="87" height="20" font="1">or combination, </text>
<text top="383" left="356" width="108" height="20" font="1">placebo, or control. </text>
<text top="400" left="356" width="3" height="20" font="4"><b> </b></text>
<text top="418" left="356" width="131" height="20" font="4"><b>Exclusion criteria</b>: Pts </text>
<text top="435" left="356" width="126" height="20" font="1">who underwent kidney </text>
<text top="452" left="356" width="98" height="20" font="1">transplantation or </text>
<text top="469" left="356" width="47" height="20" font="1">dialysis.<b> </b></text>
<text top="194" left="501" width="24" height="20" font="1">N/A </text>
<text top="195" left="630" width="246" height="20" font="4"><b>1</b>°<b> outcomes</b>: All-cause mortality and ESKD </text>
<text top="212" left="630" width="202" height="20" font="1">(need for dialysis or transplantation). </text>
<text top="229" left="630" width="3" height="20" font="1"> </text>
<text top="247" left="630" width="203" height="20" font="4"><b>Results</b>: No drug regimen was more </text>
<text top="264" left="630" width="244" height="20" font="1">effective than placebo for reducing all-cause </text>
<text top="281" left="630" width="242" height="20" font="1">mortality. However, compared with placebo, </text>
<text top="298" left="630" width="241" height="20" font="1">ESRD was significantly less likely after dual </text>
<text top="316" left="630" width="228" height="20" font="1">treatment with an ARB and an ACEI: OR: </text>
<text top="333" left="630" width="221" height="20" font="1">0.62 (95% CI: 0.43–0.90) and after ARB </text>
<text top="350" left="630" width="248" height="20" font="1">monotherapy: OR: 0.77 (95% CI: 0.65–0.92). </text>
<text top="367" left="630" width="191" height="20" font="1">No regimen significantly increased </text>
<text top="384" left="630" width="250" height="20" font="1">hyperkalemia or acute kidney injury, although </text>
<text top="402" left="630" width="241" height="20" font="1">combined ACEI and ARB treatment had the </text>
<text top="419" left="630" width="245" height="20" font="1">lowest rank among all interventions because </text>
<text top="436" left="630" width="240" height="20" font="1">of borderline increases in estimated risks of </text>
<text top="453" left="630" width="241" height="20" font="1">these harms; OR: 2.69 (95% CI: 0.97–7.47) </text>
<text top="470" left="630" width="232" height="20" font="1">for hyperkalemia; OR: 2.69 (95% CI: 0.98–</text>
<text top="488" left="630" width="158" height="20" font="1">7.38) for acute kidney injury.<b> </b></text>
<text top="194" left="893" width="203" height="20" font="4"><b>Limitations: </b>Effects of BP treatment </text>
<text top="211" left="893" width="192" height="20" font="1">on CV events and related mortality </text>
<text top="228" left="893" width="155" height="20" font="1">were uncertain. Data for the </text>
<text top="246" left="893" width="185" height="20" font="1">outcome of ESKD were restricted </text>
<text top="263" left="893" width="203" height="20" font="1">largely to pts with macroalbuminuria. </text>
<text top="280" left="893" width="169" height="20" font="1">Acute kidney injury was poorly </text>
<text top="297" left="893" width="200" height="20" font="1">defined with low quality of evidence.<b> </b></text>
<text top="314" left="893" width="3" height="20" font="4"><b> </b></text>
<text top="332" left="893" width="170" height="20" font="4"><b>Conclusions:</b> No BP-lowering </text>
<text top="349" left="893" width="200" height="20" font="1">strategy prolonged survival in adults </text>
<text top="366" left="893" width="167" height="20" font="1">with DM and CKD. ACEIs and </text>
<text top="383" left="893" width="203" height="20" font="1">ARBs, alone or in combination, were </text>
<text top="400" left="893" width="200" height="20" font="1">the most effective strategies against </text>
<text top="418" left="893" width="182" height="20" font="1">ESKD. Any benefits of combined </text>
<text top="435" left="893" width="202" height="20" font="1">ACEI and ARB treatment need to be </text>
<text top="452" left="893" width="198" height="20" font="1">balanced against potential harms of </text>
<text top="469" left="893" width="173" height="20" font="1">hyperkalemia and acute kidney </text>
<text top="487" left="893" width="36" height="20" font="1">injury. </text>
<text top="506" left="98" width="99" height="20" font="1">Turnbull F, et al.,  </text>
<text top="523" left="98" width="63" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(246)</a> </text>
<text top="540" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15983291?dopt=Citation">15983291</a></text>
<text top="540" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15983291?dopt=Citation"> </a></text>
<text top="506" left="225" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="523" left="225" width="67" height="20" font="1">the benefits </text>
<text top="540" left="225" width="87" height="20" font="1">associated with </text>
<text top="557" left="225" width="103" height="20" font="1">different treatment </text>
<text top="574" left="225" width="112" height="20" font="1">regimens in pts with </text>
<text top="592" left="225" width="113" height="20" font="1">and without DM and </text>
<text top="609" left="225" width="100" height="20" font="1">whether there are </text>
<text top="626" left="225" width="118" height="20" font="1">important differences </text>
<text top="643" left="225" width="87" height="20" font="1">in the effects of </text>
<text top="660" left="225" width="117" height="20" font="1">different BP-lowering </text>
<text top="678" left="225" width="111" height="20" font="1">regimens in these 2 </text>
<text top="695" left="225" width="58" height="20" font="1">pt groups. </text>
<text top="712" left="225" width="3" height="20" font="4"><b> </b></text>
<text top="729" left="225" width="101" height="20" font="4"><b>Study type</b>: Meta-</text>
<text top="747" left="225" width="100" height="20" font="1">analysis of RCTs. </text>
<text top="764" left="225" width="3" height="20" font="1"> </text>
<text top="506" left="356" width="105" height="20" font="4"><b>Inclusion criteria</b>:<b> </b></text>
<text top="523" left="356" width="119" height="20" font="1">Randomization of pts </text>
<text top="540" left="356" width="130" height="20" font="1">between a BP-lowering </text>
<text top="557" left="356" width="109" height="20" font="1">agent and a control </text>
<text top="574" left="356" width="90" height="20" font="1">(placebo or less </text>
<text top="592" left="356" width="121" height="20" font="1">intensive BP-lowering </text>
<text top="609" left="356" width="66" height="20" font="1">regimen) or </text>
<text top="626" left="356" width="114" height="20" font="1">randomization of pts </text>
<text top="643" left="356" width="104" height="20" font="1">between regimens </text>
<text top="660" left="356" width="102" height="20" font="1">based on different </text>
<text top="678" left="356" width="128" height="20" font="1">classes of BP-lowering </text>
<text top="695" left="356" width="38" height="20" font="1">drugs. </text>
<text top="712" left="356" width="3" height="20" font="1"> </text>
<text top="729" left="356" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="747" left="356" width="132" height="20" font="1">Studies not meeting the </text>
<text top="764" left="356" width="81" height="20" font="1">above criteria.<b> </b></text>
<text top="506" left="501" width="24" height="20" font="1">N/A </text>
<text top="507" left="630" width="245" height="20" font="4"><b>1</b>°<b> outcomes: </b>Nonfatal stroke or death from </text>
<text top="524" left="630" width="219" height="20" font="1">cerebrovascular disease; nonfatal MI or </text>
<text top="541" left="630" width="209" height="20" font="1">death from CAD; HF causing death or </text>
<text top="558" left="630" width="226" height="20" font="1">requiring hospitalization; total CV events; </text>
<text top="576" left="630" width="195" height="20" font="1">total CV deaths; and total mortality. </text>
<text top="593" left="630" width="3" height="20" font="1"> </text>
<text top="610" left="630" width="206" height="20" font="4"><b>Results</b>: Total major CV events were </text>
<text top="627" left="630" width="250" height="20" font="1">reduced to a comparable extent in individuals </text>
<text top="644" left="630" width="239" height="20" font="1">with and without DM by regimens based on </text>
<text top="662" left="630" width="215" height="20" font="1">ACEIs, calcium antagonists, ARBs and </text>
<text top="679" left="630" width="226" height="20" font="1">diuretics/ BBs (p&lt;0.19 for all). There was </text>
<text top="696" left="630" width="201" height="20" font="1">limited evidence that lower BP goals </text>
<text top="713" left="630" width="244" height="20" font="1">produced larger reductions in total major CV </text>
<text top="730" left="630" width="235" height="20" font="1">events in pts with vs. without DM (p&lt;0.03). </text>
<text top="506" left="893" width="185" height="20" font="4"><b>Limitations: </b>No analysis of renal </text>
<text top="523" left="893" width="159" height="20" font="1">outcomes, risk of new DM or </text>
<text top="540" left="893" width="152" height="20" font="1">progression of existing DM; </text>
<text top="557" left="893" width="185" height="20" font="1">combined comparison of persons </text>
<text top="574" left="893" width="176" height="20" font="1">taking diuretics and BB s; some </text>
<text top="592" left="893" width="195" height="20" font="1">studies selected pts on the basis of </text>
<text top="609" left="893" width="182" height="20" font="1">the presence or absence of DM.  </text>
<text top="626" left="893" width="3" height="20" font="4"><b> </b></text>
<text top="643" left="893" width="188" height="20" font="4"><b>Summary:</b> Effects of BP-lowering </text>
<text top="660" left="893" width="182" height="20" font="1">agents on major CV events were </text>
<text top="678" left="893" width="198" height="20" font="1">broadly comparable for pts with and </text>
<text top="695" left="893" width="68" height="20" font="1">without DM.<b> </b></text>
</page>
<page number="183" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">183 </text>
<text top="107" left="225" width="83" height="20" font="4"><b>Size</b>: 27 RCTs </text>
<text top="124" left="225" width="100" height="20" font="1">including 158,709 </text>
<text top="141" left="225" width="113" height="20" font="1">pts (33,395 with DM </text>
<text top="159" left="225" width="114" height="20" font="1">and 125,314 without </text>
<text top="176" left="225" width="30" height="20" font="1">DM). </text>
<text top="193" left="225" width="3" height="20" font="1"> </text>
<text top="210" left="225" width="118" height="20" font="4"><b>Follow-up</b>: Minimum </text>
<text top="227" left="225" width="58" height="20" font="1">1,000 pt-y<b> </b></text>
<text top="245" left="98" width="53" height="20" font="4"><b>ALLHAT </b></text>
<text top="263" left="98" width="105" height="20" font="1">Whelton PK, et al., </text>
<text top="280" left="98" width="63" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(247)</a> </text>
<text top="297" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15983290?dopt=Citation">15983290</a></text>
<text top="297" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15983290?dopt=Citation"> </a></text>
<text top="245" left="225" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="263" left="225" width="113" height="20" font="1">the optimal first step </text>
<text top="280" left="225" width="93" height="20" font="1">antihypertensive </text>
<text top="297" left="225" width="109" height="20" font="1">drug therapy in DM-</text>
<text top="314" left="225" width="115" height="20" font="1">2 or impaired fasting </text>
<text top="332" left="225" width="114" height="20" font="1">blood glucose levels </text>
<text top="349" left="225" width="87" height="20" font="1">and specifically </text>
<text top="366" left="225" width="103" height="20" font="1">whether treatment </text>
<text top="383" left="225" width="111" height="20" font="1">with a CCB or ACEI </text>
<text top="401" left="225" width="100" height="20" font="1">decreases clinical </text>
<text top="418" left="225" width="78" height="20" font="1">complications </text>
<text top="435" left="225" width="72" height="20" font="1">compared to </text>
<text top="452" left="225" width="91" height="20" font="1">treatment with a </text>
<text top="469" left="225" width="72" height="20" font="1">thiazide type </text>
<text top="487" left="225" width="46" height="20" font="1">diuretic. </text>
<text top="504" left="225" width="3" height="20" font="4"><b> </b></text>
<text top="521" left="225" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="538" left="225" width="3" height="20" font="1"> </text>
<text top="555" left="225" width="92" height="20" font="4"><b>Size</b>: 31,512 pts </text>
<text top="573" left="225" width="110" height="20" font="1">stratified into type 2 </text>
<text top="590" left="225" width="99" height="20" font="1">DM (13,101), IFG </text>
<text top="607" left="225" width="66" height="20" font="1">(1,399) and </text>
<text top="624" left="225" width="87" height="20" font="1">normoglycemia </text>
<text top="641" left="225" width="49" height="20" font="1">(17,012) </text>
<text top="245" left="356" width="126" height="20" font="4"><b>Inclusion criteria</b>:<b> </b>Pts </text>
<text top="263" left="356" width="126" height="20" font="1">≥55 y with HTN and at </text>
<text top="280" left="356" width="128" height="20" font="1">least 1 other risk factor </text>
<text top="297" left="356" width="51" height="20" font="1">for CHD. </text>
<text top="314" left="356" width="3" height="20" font="1"> </text>
<text top="332" left="356" width="128" height="20" font="4"><b>Exclusion criteria</b>: No </text>
<text top="349" left="356" width="107" height="20" font="1">history of DM or no </text>
<text top="366" left="356" width="85" height="20" font="1">fasting glucose </text>
<text top="383" left="356" width="93" height="20" font="1">measurement or </text>
<text top="400" left="356" width="106" height="20" font="1">nonfasting glucose </text>
<text top="418" left="356" width="105" height="20" font="1">level ≥110 mg/dL. <b> </b></text>
<text top="247" left="501" width="7" height="18" font="1">•</text>
<text top="247" left="508" width="55" height="20" font="1"> Pts were </text>
<text top="264" left="501" width="107" height="20" font="1">randomly assigned </text>
<text top="281" left="501" width="108" height="20" font="1">to double-blind first-</text>
<text top="298" left="501" width="107" height="20" font="1">step treatment with </text>
<text top="316" left="501" width="80" height="20" font="1">chlorthalidone </text>
<text top="333" left="501" width="75" height="20" font="1">12.525 mg/d, </text>
<text top="350" left="501" width="104" height="20" font="1">amlodipine 2.5–10 </text>
<text top="367" left="501" width="97" height="20" font="1">mg/d or Lisinopril </text>
<text top="384" left="501" width="72" height="20" font="1">10–40 mg/d. </text>
<text top="247" left="630" width="231" height="20" font="4"><b>1</b>°<b> outcomes: </b>Fatal CHD and nonfatal MI </text>
<text top="264" left="630" width="3" height="20" font="1"> </text>
<text top="281" left="630" width="51" height="20" font="4"><b>Results</b>: </text>
<text top="281" left="681" width="194" height="20" font="15">There was no significant difference </text>
<text top="298" left="630" width="13" height="20" font="15">in </text>
<text top="298" left="643" width="18" height="20" font="1">RR</text>
<text top="298" left="660" width="71" height="20" font="15"> (RR) for the </text>
<text top="298" left="731" width="13" height="20" font="1">1°</text>
<text top="298" left="744" width="126" height="20" font="15"> outcome in DM or NG </text>
<text top="316" left="630" width="230" height="20" font="15">pts assigned to amlodipine or lisinopril vs. </text>
<text top="333" left="630" width="217" height="20" font="15">chlorthalidone or in IFG pts assigned to </text>
<text top="350" left="630" width="250" height="20" font="15">lisinopril vs. chlorthalidone RR: 1.73 (95% CI: </text>
<text top="367" left="630" width="24" height="20" font="15">1.10</text>
<text top="367" left="654" width="7" height="20" font="1">, </text>
<text top="367" left="660" width="197" height="20" font="15">2.72). A significantly higher RR was </text>
<text top="384" left="630" width="73" height="20" font="15">noted for the </text>
<text top="384" left="702" width="13" height="20" font="1">1°</text>
<text top="384" left="715" width="163" height="20" font="15"> outcome in IFG pts assigned </text>
<text top="402" left="630" width="243" height="20" font="15">to amlodipine vs. chlorthalidone. Stroke was </text>
<text top="419" left="630" width="203" height="20" font="15">more common in NG pts assigned to </text>
<text top="436" left="630" width="250" height="20" font="15">lisinopril vs. chlorthalidone RR: 1.31 (95% CI: </text>
<text top="453" left="630" width="228" height="20" font="15">1.10, 1.57). HF was more common in DM </text>
<text top="470" left="630" width="247" height="20" font="15">and NG pts assigned to amlodipine RR: 1.39 </text>
<text top="488" left="630" width="75" height="20" font="15">(95% CI: 1.22</text>
<text top="488" left="705" width="7" height="20" font="1">, </text>
<text top="488" left="712" width="158" height="20" font="15">1.59) and 1.30 (95% CI: 1.12</text>
<text top="488" left="869" width="7" height="20" font="1">, </text>
<text top="505" left="630" width="247" height="20" font="15">1.51), respectively or lisinopril: 1.15 (95% CI: </text>
<text top="522" left="630" width="24" height="20" font="15">1.00</text>
<text top="522" left="654" width="7" height="20" font="1">–</text>
<text top="522" left="660" width="158" height="20" font="15">1.32) and 1.19 (95% CI: 1.02</text>
<text top="522" left="818" width="7" height="20" font="1">, </text>
<text top="522" left="825" width="35" height="20" font="15">1.39), </text>
<text top="539" left="630" width="171" height="20" font="15">respectively vs. chlorthalidone. </text>
<text top="245" left="893" width="195" height="20" font="4"><b>Limitations: </b>Microalbuminuria was </text>
<text top="263" left="893" width="82" height="20" font="1">not measured. </text>
<text top="280" left="893" width="3" height="20" font="4"><b> </b></text>
<text top="297" left="893" width="64" height="20" font="4"><b>Summary:</b> </text>
<text top="297" left="956" width="125" height="20" font="15">Our results provide no </text>
<text top="314" left="893" width="200" height="20" font="15">evidence of superiority for treatment </text>
<text top="332" left="893" width="72" height="20" font="15">with CCBs or</text>
<text top="332" left="964" width="38" height="20" font="1"> ACEIs</text>
<text top="332" left="1003" width="87" height="20" font="15"> compared with </text>
<text top="349" left="893" width="188" height="20" font="15">a thiazide-type diuretic during first-</text>
<text top="366" left="893" width="203" height="20" font="15">step antihypertensive therapy in DM, </text>
<text top="383" left="893" width="67" height="20" font="15">IFG, or NG. </text>
<text top="661" left="108" width="3" height="19" font="1"> </text>
<text top="695" left="81" width="737" height="24" font="3"><b>Data Supplement 47. Nonrandomized Trials, Observational Studies, and/or Registries in DM (Section 9.6) </b></text>
<text top="735" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="752" left="128" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="769" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="735" left="245" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="752" left="261" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="735" left="429" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="735" left="618" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="752" left="596" width="224" height="20" font="4"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="735" left="911" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="752" left="939" width="75" height="20" font="4"><b>Comment(s) </b></text>
</page>
<page number="184" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">184 </text>
<text top="107" left="98" width="64" height="20" font="4"><b>ADVANCE </b></text>
<text top="124" left="98" width="79" height="20" font="1">Hata J, et al.,  </text>
<text top="141" left="98" width="66" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(248)</a>  </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23926207?dopt=Citation">23926207</a></text>
<text top="159" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23926207?dopt=Citation"> </a></text>
<text top="107" left="219" width="163" height="20" font="4"><b>Aim</b>: To assess the effects of </text>
<text top="124" left="219" width="147" height="20" font="1">visit-to-visit SBP variability </text>
<text top="141" left="219" width="146" height="20" font="1">and maximum SBP on the </text>
<text top="159" left="219" width="140" height="20" font="1">risks of macrovascular or </text>
<text top="176" left="219" width="152" height="20" font="1">microvascular outcomes by </text>
<text top="193" left="219" width="109" height="20" font="1">using data from the </text>
<text top="210" left="219" width="89" height="20" font="1">ADVANCE trial. </text>
<text top="227" left="219" width="3" height="20" font="1"> </text>
<text top="245" left="219" width="150" height="20" font="4"><b>Study type:</b> Observational </text>
<text top="262" left="219" width="48" height="20" font="1">analysis </text>
<text top="279" left="219" width="3" height="20" font="1"> </text>
<text top="296" left="219" width="90" height="20" font="4"><b>Size:</b> 8,811 pts  </text>
<text top="107" left="402" width="150" height="20" font="4"><b>Inclusion criteria</b>: Pts had </text>
<text top="124" left="402" width="125" height="20" font="1">not experienced major </text>
<text top="141" left="402" width="135" height="20" font="1">macro- or microvascular </text>
<text top="159" left="402" width="154" height="20" font="1">events during first 2 y of the </text>
<text top="176" left="402" width="86" height="20" font="1">ADVANCE trial </text>
<text top="193" left="402" width="3" height="20" font="1"> </text>
<text top="210" left="402" width="142" height="20" font="4"><b>Exclusion criteria</b>: None </text>
<text top="108" left="580" width="210" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite of CV death, </text>
<text top="125" left="580" width="255" height="20" font="1">nonfatal MI, nonfatal stroke, new or worsening </text>
<text top="143" left="580" width="157" height="20" font="1">nephropathy, or retinopathy. </text>
<text top="160" left="580" width="3" height="20" font="1"> </text>
<text top="177" left="580" width="235" height="20" font="4"><b>Results:</b> Major macro- and micro-vascular </text>
<text top="194" left="580" width="240" height="20" font="1">events were associated with SBP variability </text>
<text top="211" left="580" width="226" height="20" font="1">even after adjustment for mean SBP and </text>
<text top="229" left="580" width="231" height="20" font="1">other confounding factors. For the highest </text>
<text top="246" left="580" width="252" height="20" font="1">10% variability, HR: 1.54 (95% CI: 0.99, 2.39) </text>
<text top="263" left="580" width="241" height="20" font="1">for macrovascular events; for microvascular </text>
<text top="280" left="580" width="215" height="20" font="1">events, HR: 1.84 (95% CI: 1.19, 2.84).  </text>
<text top="107" left="848" width="236" height="20" font="4"><b>Summary:</b> Visit-to-visit SBP variability and </text>
<text top="124" left="848" width="240" height="20" font="1">maximum SBP are independent risk factors </text>
<text top="141" left="848" width="210" height="20" font="1">for macro- and micro-vascular events. </text>
<text top="314" left="98" width="87" height="20" font="4"><b>ADVANCE-ON </b></text>
<text top="332" left="98" width="100" height="20" font="1">Zoungas S, et al., </text>
<text top="349" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(249)</a> </text>
<text top="366" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25234206?dopt=Citation">25234206</a></text>
<text top="366" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25234206?dopt=Citation"> </a></text>
<text top="314" left="219" width="153" height="20" font="4"><b>Aim</b>: To determine whether </text>
<text top="332" left="219" width="159" height="20" font="1">the mortality benefit that had </text>
<text top="349" left="219" width="146" height="20" font="1">been observed among pts </text>
<text top="366" left="219" width="139" height="20" font="1">originally assigned to BP-</text>
<text top="383" left="219" width="145" height="20" font="1">lowering therapy were still </text>
<text top="400" left="219" width="135" height="20" font="1">evident at the end of 6-y </text>
<text top="418" left="219" width="53" height="20" font="1">follow-up </text>
<text top="435" left="219" width="3" height="20" font="4"><b> </b></text>
<text top="452" left="219" width="150" height="20" font="4"><b>Study type:</b> Observational </text>
<text top="469" left="219" width="48" height="20" font="1">analysis </text>
<text top="487" left="219" width="3" height="20" font="1"> </text>
<text top="504" left="219" width="90" height="20" font="4"><b>Size:</b> 8,494 pts  </text>
<text top="314" left="402" width="152" height="20" font="4"><b>Inclusion criteria: </b>Pts with </text>
<text top="332" left="402" width="156" height="20" font="1">DM who participated in post-</text>
<text top="349" left="402" width="114" height="20" font="1">trial follow-up for 6 y </text>
<text top="366" left="402" width="3" height="20" font="1"> </text>
<text top="383" left="402" width="135" height="20" font="4"><b>Exclusion criteria:</b> See </text>
<text top="400" left="402" width="37" height="20" font="1">above </text>
<text top="316" left="580" width="223" height="20" font="4"><b>1</b>°<b> endpoint:</b> Death from any cause and </text>
<text top="333" left="580" width="210" height="20" font="1">major macrovascular complications (a </text>
<text top="350" left="580" width="243" height="20" font="1">composite of nonfatal MI, nonfatal stroke, or </text>
<text top="367" left="580" width="146" height="20" font="1">death from any CV cause. </text>
<text top="384" left="580" width="3" height="20" font="1"> </text>
<text top="402" left="580" width="241" height="20" font="4"><b>Results:</b> The reductions in the risk of death </text>
<text top="419" left="580" width="250" height="20" font="1">from any cause and of death from CV causes </text>
<text top="436" left="580" width="254" height="20" font="1">that had been observed in the group receiving </text>
<text top="453" left="580" width="219" height="20" font="1">active BP-lowering treatment during the </text>
<text top="470" left="580" width="198" height="20" font="1">ADVANCE trial were attenuated but </text>
<text top="488" left="580" width="236" height="20" font="1">significant at the end of the post-trial follow-</text>
<text top="505" left="580" width="218" height="20" font="1">up. HRs were 0.95 (95% CI: 0.84–0.99; </text>
<text top="522" left="580" width="210" height="20" font="1">p=0.03) and 0.88 (95% CI: 0.77–0.99; </text>
<text top="539" left="580" width="121" height="20" font="1">p=0.04), respectively. </text>
<text top="314" left="848" width="245" height="20" font="4"><b>Summary: </b>Benefits were attenuated but still </text>
<text top="332" left="848" width="139" height="20" font="1">present at the end of 6 y.<b> </b></text>
<text top="557" left="98" width="67" height="20" font="4"><b>ROADMAP </b></text>
<text top="574" left="98" width="84" height="20" font="1">Mene J, et al.,  </text>
<text top="592" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(250)</a> </text>
<text top="609" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24772521?dopt=Citation">24772521</a></text>
<text top="609" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24772521?dopt=Citation"> </a></text>
<text top="557" left="219" width="154" height="20" font="4"><b>Aim:</b> To determine whether </text>
<text top="574" left="219" width="150" height="20" font="1">the ROADMAP olmesartan </text>
<text top="592" left="219" width="165" height="20" font="1">medoxomil treatment resulted </text>
<text top="609" left="219" width="166" height="20" font="1">in a potential long-term micro- </text>
<text top="626" left="219" width="155" height="20" font="1">and macro-vascular benefit. </text>
<text top="643" left="219" width="3" height="20" font="1"> </text>
<text top="660" left="219" width="149" height="20" font="4"><b>Study type</b>: Observational </text>
<text top="678" left="219" width="48" height="20" font="1">analysis </text>
<text top="695" left="219" width="3" height="20" font="1"> </text>
<text top="712" left="219" width="154" height="20" font="4"><b>Size</b>: 1,758 pts; 3.3 y follow-</text>
<text top="729" left="219" width="17" height="20" font="1">up </text>
<text top="557" left="402" width="131" height="20" font="4"><b>Inclusion criteria: </b>See </text>
<text top="574" left="402" width="37" height="20" font="1">above<b> </b></text>
<text top="592" left="402" width="3" height="20" font="4"><b> </b></text>
<text top="609" left="402" width="135" height="20" font="4"><b>Exclusion criteria: </b>See </text>
<text top="626" left="402" width="37" height="20" font="1">above<b> </b></text>
<text top="558" left="580" width="138" height="20" font="4"><b>1</b>°<b> endpoint: </b>See above<b> </b></text>
<text top="576" left="580" width="3" height="20" font="4"><b> </b></text>
<text top="593" left="580" width="218" height="20" font="4"><b>Results: </b>The original ROADMAP study </text>
<text top="610" left="580" width="248" height="20" font="1">showed a 23% reduction in microalbuminuria </text>
<text top="627" left="580" width="239" height="20" font="1">despite good and comparable BP control in </text>
<text top="644" left="580" width="179" height="20" font="1">both groups. Pts who developed </text>
<text top="662" left="580" width="238" height="20" font="1">microalbuminuria had a higher incidence of </text>
<text top="679" left="580" width="251" height="20" font="1">cardio- and cerebrovascular events: OR: 1.77 </text>
<text top="696" left="580" width="237" height="20" font="1">(95% CI: 1.03–3.03; p=0.039) compared to </text>
<text top="713" left="580" width="227" height="20" font="1">those in whom this was not the case. DM </text>
<text top="730" left="580" width="241" height="20" font="1">retinopathy and HF requiring hospitalization </text>
<text top="748" left="580" width="107" height="20" font="1">also were reduced.<b> </b></text>
<text top="557" left="848" width="230" height="20" font="4"><b>Summary:</b> renal artery stenosis blockade </text>
<text top="574" left="848" width="241" height="20" font="1">might cause a sustained reduction in micro- </text>
<text top="592" left="848" width="155" height="20" font="1">and macro-vascular events.<b> </b></text>
<text top="766" left="98" width="91" height="20" font="1">Edmin C, et al.,  </text>
<text top="783" left="98" width="66" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(251)</a>  </text>
<text top="766" left="219" width="162" height="20" font="4"><b>Aim:</b> Determine associations </text>
<text top="783" left="219" width="119" height="20" font="1">between BP-lowering </text>
<text top="766" left="402" width="157" height="20" font="4"><b>Inclusion criteria</b>: All RCTs </text>
<text top="783" left="402" width="152" height="20" font="1">of BP-lowering treatment in </text>
<text top="767" left="580" width="7" height="18" font="1">•</text>
<text top="767" left="587" width="222" height="20" font="1"> BP-lowering drug vs. placebo: 26 RCTs </text>
<text top="766" left="848" width="244" height="20" font="4"><b>Limitations</b>: Reliability of this meta-analysis </text>
<text top="783" left="848" width="232" height="20" font="1">is limited by the scarcity of large trials with </text>
</page>
<page number="185" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">185 </text>
<text top="107" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25668264?dopt=Citation">25668264</a></text>
<text top="107" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25668264?dopt=Citation"> </a></text>
<text top="107" left="219" width="147" height="20" font="1">treatment and presence of </text>
<text top="124" left="219" width="141" height="20" font="1">vascular disease in DM-2 </text>
<text top="141" left="219" width="3" height="20" font="1"> </text>
<text top="159" left="219" width="137" height="20" font="4"><b>Study type:</b> Large meta-</text>
<text top="176" left="219" width="62" height="20" font="1">analysis of </text>
<text top="193" left="219" width="166" height="20" font="1">40 high quality RCTs (1/1966–</text>
<text top="210" left="219" width="150" height="20" font="1">10/2014) judged low risk of </text>
<text top="228" left="219" width="26" height="20" font="1">bias </text>
<text top="245" left="219" width="3" height="20" font="1"> </text>
<text top="262" left="219" width="167" height="20" font="4"><b>Size:</b> 100,354 pts with DM; all </text>
<text top="279" left="219" width="161" height="20" font="1">trials &gt;1,000 pt-y of follow-up </text>
<text top="296" left="219" width="167" height="20" font="1">BP-lowering drug vs. placebo: </text>
<text top="314" left="219" width="52" height="20" font="1">26 RCTs </text>
<text top="331" left="219" width="3" height="20" font="1"> </text>
<text top="350" left="219" width="7" height="18" font="1">•</text>
<text top="349" left="226" width="131" height="20" font="1"> More intensive vs. less </text>
<text top="366" left="219" width="170" height="20" font="1">intensive BP lowering: 7 RCTs </text>
<text top="386" left="219" width="7" height="18" font="1">•</text>
<text top="385" left="226" width="137" height="20" font="1"> BP-lowering vs. another </text>
<text top="402" left="219" width="83" height="20" font="1">drug: 17 RCTs </text>
<text top="107" left="402" width="152" height="20" font="1">which entire trial population </text>
<text top="124" left="402" width="140" height="20" font="1">had DM-2 or in which the </text>
<text top="141" left="402" width="141" height="20" font="1">results of a DM subgroup </text>
<text top="159" left="402" width="159" height="20" font="1">were obtained. Studies were </text>
<text top="176" left="402" width="144" height="20" font="1">included regardless of the </text>
<text top="193" left="402" width="132" height="20" font="1">presence or absence of </text>
<text top="210" left="402" width="76" height="20" font="1">defined HTN. </text>
<text top="227" left="402" width="3" height="20" font="1"> </text>
<text top="245" left="402" width="143" height="20" font="4"><b>Exclusion criteria</b>: Trials </text>
<text top="262" left="402" width="154" height="20" font="1">conducted predominantly in </text>
<text top="279" left="402" width="135" height="20" font="1">pts with type 1 DM were </text>
<text top="296" left="402" width="56" height="20" font="1">excluded. </text>
<text top="109" left="580" width="7" height="18" font="1">•</text>
<text top="108" left="587" width="203" height="20" font="1"> More intensive vs. less intensive BP </text>
<text top="125" left="580" width="98" height="20" font="1">lowering: 7 RCTs </text>
<text top="144" left="580" width="7" height="18" font="1">•</text>
<text top="144" left="587" width="221" height="20" font="1"> BP-lowering vs. another drug: 17 RCTs </text>
<text top="161" left="580" width="3" height="20" font="1"> </text>
<text top="178" left="580" width="225" height="20" font="4"><b>Results</b>: Baseline BP: A 10-mm Hg SBP </text>
<text top="195" left="580" width="244" height="20" font="1">reduction was associated with a significantly </text>
<text top="213" left="580" width="224" height="20" font="1">lower risk of all-cause mortality RR: 0.87 </text>
<text top="230" left="580" width="238" height="20" font="1">(95% CI: 0.78–0.96), CVD events RR: 0.89 </text>
<text top="247" left="580" width="242" height="20" font="1">(95% CI: 0.80–0.98), and stroke events RR: </text>
<text top="264" left="580" width="240" height="20" font="1">0.73 (95% CI: 0.64–0.83). The associations </text>
<text top="282" left="580" width="241" height="20" font="1">for HF and renal failure were not significant. </text>
<text top="299" left="580" width="250" height="20" font="1">For microvascular events, a 10-mm reduction </text>
<text top="316" left="580" width="233" height="20" font="1">in SBP was associated with a lower risk of </text>
<text top="333" left="580" width="254" height="20" font="1">retinopathy RR: 0.87 (95% CI: 0.76–0.99) and </text>
<text top="350" left="580" width="236" height="20" font="1">albuminuria RR: 0.83 (95% CI: 0.79–0.87). </text>
<text top="368" left="580" width="3" height="20" font="1"> </text>
<text top="385" left="580" width="142" height="20" font="4"><b>Stratified by initial SBP</b>: </text>
<text top="402" left="580" width="247" height="20" font="1">Trials stratified by SBP &gt;140 to &lt;140 mm Hg </text>
<text top="419" left="580" width="241" height="20" font="1">showed significant interactions for all-cause </text>
<text top="436" left="580" width="235" height="20" font="1">mortality RR: 0.73 (95% CI: 0.64–0.84) vs. </text>
<text top="454" left="580" width="226" height="20" font="1">1.07 (95% CI: 0.92–1.26), CVD RR: 0.74 </text>
<text top="471" left="580" width="236" height="20" font="1">(95% CI: 0.65–0.85) vs. RR: 0.96 (95% CI: </text>
<text top="488" left="580" width="230" height="20" font="1">0.88–1.05), CHD RR: 0.73 (95% CI: 0.61–</text>
<text top="505" left="580" width="239" height="20" font="1">0.87) vs. RR: 0.97 (95% CI: 0.86–1.10), HF </text>
<text top="523" left="580" width="237" height="20" font="1">RR: 0.75 (95% CI: 0.59–0.94) vs. RR: 0.97 </text>
<text top="540" left="580" width="229" height="20" font="1">(95% CI: 0.79–1.19) and albuminuria RR: </text>
<text top="557" left="580" width="244" height="20" font="1">0.71 (95% CI: 0.63–0.79) vs. RR: 0.86 (95% </text>
<text top="574" left="580" width="85" height="20" font="1">CI: 0.81–0.99). </text>
<text top="591" left="580" width="3" height="20" font="4"><b> </b></text>
<text top="609" left="580" width="163" height="20" font="4"><b>Stratified by achieved SBP</b>: </text>
<text top="626" left="580" width="214" height="20" font="1">Trials stratified by SBP achieved in the </text>
<text top="644" left="580" width="235" height="20" font="1">treatment group ≥130 or &lt;130 mm Hg and </text>
<text top="661" left="580" width="204" height="20" font="1">the associations of a 10-mm Hg SBP </text>
<text top="679" left="580" width="217" height="20" font="1">reduction compared between the strata </text>
<text top="696" left="580" width="241" height="20" font="1">showed significant interactions for all-cause </text>
<text top="713" left="580" width="235" height="20" font="1">mortality RR: 0.75 (95% CI: 0.65–0.86) vs. </text>
<text top="730" left="580" width="230" height="20" font="1">RR: 1.06 (95% CI: 0.90–1.265), CVD RR: </text>
<text top="747" left="580" width="244" height="20" font="1">0.74 (95% CI: 0.64–0.85) vs. RR: 0.96 (95% </text>
<text top="765" left="580" width="249" height="20" font="1">CI: 0.88–1.05), CHD RR: 0.70 (95% CI: 0.58–</text>
<text top="782" left="580" width="239" height="20" font="1">0.83) vs. RR: 0.97 (95% CI: 0.85–1.10), HF </text>
<text top="107" left="848" width="243" height="20" font="1">achieved SBP levels in the 120–130 mm Hg </text>
<text top="124" left="848" width="212" height="20" font="1">range. The relatively short follow-up of </text>
<text top="141" left="848" width="194" height="20" font="1">included trails may have prevented </text>
<text top="159" left="848" width="235" height="20" font="1">associations of BP-lowering treatment with </text>
<text top="176" left="848" width="225" height="20" font="1">vascular outcomes from being observed, </text>
<text top="193" left="848" width="227" height="20" font="1">particularly for outcomes such as HF and </text>
<text top="210" left="848" width="245" height="20" font="1">renal failure, which are often a consequence </text>
<text top="228" left="848" width="187" height="20" font="1">of MI or albuminuria, respectively. </text>
<text top="245" left="848" width="3" height="20" font="1"> </text>
<text top="262" left="848" width="63" height="20" font="4"><b>Summary</b>: </text>
<text top="281" left="848" width="7" height="18" font="1">•</text>
<text top="280" left="855" width="206" height="20" font="1"> This large meta-analysis of 40 RCTs </text>
<text top="298" left="848" width="208" height="20" font="1">provides evidence that BP lowering is </text>
<text top="315" left="848" width="252" height="20" font="1">associated with lower risks of outcomes in pts </text>
<text top="333" left="848" width="252" height="20" font="1">with initial mean SBP ≥140 mm Hg compared </text>
<text top="350" left="848" width="248" height="20" font="1">with those &lt;140 mm Hg with the exception of </text>
<text top="368" left="848" width="234" height="20" font="1">stroke, albuminuria and retinopathy. When </text>
<text top="385" left="848" width="206" height="20" font="1">trials were stratified by achieved SBP </text>
<text top="402" left="848" width="256" height="20" font="1">treatment was associated with lower risks only </text>
<text top="419" left="848" width="231" height="20" font="1">in the &lt;130 mm Hg stratum for stroke and </text>
<text top="437" left="848" width="70" height="20" font="1">albuminuria. </text>
<text top="456" left="848" width="7" height="18" font="1">•</text>
<text top="455" left="855" width="242" height="20" font="1"> This meta-analysis shows that although BP </text>
<text top="472" left="848" width="248" height="20" font="1">lowering was not associated with a lower risk </text>
<text top="489" left="848" width="228" height="20" font="1">of CVD or CHD events at a baseline SBP </text>
<text top="506" left="848" width="240" height="20" font="1">&lt;140 mm Hg, it does observe lower risks of </text>
<text top="524" left="848" width="210" height="20" font="1">stroke, retinopathy and progression of </text>
<text top="541" left="848" width="70" height="20" font="1">albuminuria. </text>
<text top="560" left="848" width="7" height="18" font="1">•</text>
<text top="559" left="855" width="207" height="20" font="1"> This study provides evidence that for </text>
<text top="576" left="848" width="232" height="20" font="1">individuals at high risk for these outcomes </text>
<text top="594" left="848" width="235" height="20" font="1">(history of cerebrovascular disease or mild </text>
<text top="611" left="848" width="250" height="20" font="1">nonproliferative retinopathy), commencement </text>
<text top="628" left="848" width="251" height="20" font="1">of therapy below an initial SBP of 140 mm Hg </text>
<text top="645" left="848" width="252" height="20" font="1">and treatment to SBP &lt;130 may be indicated. </text>
</page>
<page number="186" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">186 </text>
<text top="107" left="580" width="237" height="20" font="1">RR: 0.75 (95% CI: 0.59–0.95) vs. RR: 1.00 </text>
<text top="124" left="580" width="229" height="20" font="1">(95% CI: 0.81–1.23) and albuminuria RR: </text>
<text top="141" left="580" width="244" height="20" font="1">0.71 (95% CI: 0.64–0.79) vs. RR: 0.86 (95% </text>
<text top="160" left="580" width="233" height="20" font="1">CI: 0.81–0.90) with higher risk in the ≥130 </text>
<text top="177" left="580" width="81" height="20" font="1">mm Hg group. </text>
<text top="194" left="580" width="3" height="20" font="1"> </text>
<text top="211" left="580" width="229" height="20" font="4"><b>Stratified by class of medications</b>: Few </text>
<text top="229" left="580" width="246" height="20" font="1">differences were observed in the association </text>
<text top="246" left="580" width="199" height="20" font="1">between BP-lowering treatment and </text>
<text top="263" left="580" width="230" height="20" font="1">outcomes for regimens based on different </text>
<text top="280" left="580" width="241" height="20" font="1">classes of medications, except HF, in which </text>
<text top="298" left="580" width="251" height="20" font="1">diuretics were associated with lower RR: 0.83 </text>
<text top="315" left="580" width="236" height="20" font="1">(95% CI: 0.72–0.95) than all other classes. </text>
<text top="332" left="580" width="219" height="20" font="1">This was driven largely by the results of </text>
<text top="349" left="580" width="53" height="20" font="1">ALLHAT.<b> </b></text>
<text top="367" left="98" width="90" height="20" font="1">Cheng J, et al.,  </text>
<text top="384" left="98" width="66" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(252)</a>  </text>
<text top="402" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24687000?dopt=Citation">24687000</a></text>
<text top="402" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24687000?dopt=Citation"> </a></text>
<text top="367" left="219" width="158" height="20" font="4"><b>Aim</b>: To separately evaluate </text>
<text top="384" left="219" width="136" height="20" font="1">the effects of ACEIs and </text>
<text top="402" left="219" width="158" height="20" font="1">ARBs on all-cause mortality, </text>
<text top="419" left="219" width="143" height="20" font="1">CV deaths, and major CV </text>
<text top="436" left="219" width="120" height="20" font="1">events in pts with DM </text>
<text top="453" left="219" width="3" height="20" font="1"> </text>
<text top="470" left="219" width="163" height="20" font="4"><b>Study type</b>: Meta-analysis of </text>
<text top="488" left="219" width="156" height="20" font="1">35 high quality RCTs (1966–</text>
<text top="505" left="219" width="35" height="20" font="1">2012) </text>
<text top="522" left="219" width="3" height="20" font="1"> </text>
<text top="539" left="219" width="160" height="20" font="4"><b>Size:</b> 56,444 pts with DM; all </text>
<text top="557" left="219" width="163" height="20" font="1">trials had follow-up of at least </text>
<text top="574" left="219" width="38" height="20" font="1">12 mo </text>
<text top="367" left="402" width="140" height="20" font="4"><b>Inclusion criteria</b>: RCTs </text>
<text top="384" left="402" width="154" height="20" font="1">including post hoc analyses </text>
<text top="402" left="402" width="150" height="20" font="1">and subgroups for DM with </text>
<text top="419" left="402" width="153" height="20" font="1">median follow-up of at least </text>
<text top="436" left="402" width="142" height="20" font="1">12 mo. Comparisons with </text>
<text top="453" left="402" width="137" height="20" font="1">placebo, no treatment or </text>
<text top="470" left="402" width="162" height="20" font="1">other antihypertensive drugs, </text>
<text top="488" left="402" width="152" height="20" font="1">including ACEIs and ARBs. </text>
<text top="505" left="402" width="3" height="20" font="1"> </text>
<text top="522" left="402" width="145" height="20" font="4"><b>Exclusion criteria</b>: Cross-</text>
<text top="539" left="402" width="57" height="20" font="1">over trials<b> </b></text>
<text top="369" left="580" width="7" height="18" font="1">•</text>
<text top="368" left="587" width="230" height="20" font="1"> ACEIs significantly reduced the risk of all-</text>
<text top="386" left="580" width="237" height="20" font="1">cause mortality by 13% (RR: 0.87; 95% CI: </text>
<text top="403" left="580" width="230" height="20" font="1">0.78–0.98), CV deaths by 17% (RR: 0.83; </text>
<text top="420" left="580" width="247" height="20" font="1">95% CI: 0.70–0.99), and major CV events by </text>
<text top="437" left="580" width="252" height="20" font="1">14% (RR: 0.86; 95% CI: 0.77–0.95), including </text>
<text top="454" left="580" width="254" height="20" font="1">MI by 21% (RR: 0.79; 95% CI: 0.65–0.95) and </text>
<text top="472" left="580" width="237" height="20" font="1">HF by 19% (RR: 0.81; 95% CI: 0.71–0.93). </text>
<text top="489" left="580" width="227" height="20" font="1">Treatment with ARBs did not significantly </text>
<text top="506" left="580" width="243" height="20" font="1">affect all-cause mortality (RR: 0.94 (95% CI: </text>
<text top="523" left="580" width="252" height="20" font="1">0.82–1.08), CV death rate (RR: 1.21 (95% CI: </text>
<text top="540" left="580" width="240" height="20" font="1">0.81–1.80) and major CV events (RR: 0.94; </text>
<text top="558" left="580" width="245" height="20" font="1">95% CI: 0.85–1.01) with the exception of HF </text>
<text top="575" left="580" width="172" height="20" font="1">(RR: 0.70; 95% CI: 0.59–0.82).<b> </b></text>
<text top="367" left="848" width="66" height="20" font="4"><b>Summary</b>:  </text>
<text top="386" left="848" width="7" height="18" font="1">•</text>
<text top="386" left="855" width="189" height="20" font="1"> RCTs comparing ACEs vs. active </text>
<text top="403" left="848" width="230" height="20" font="1">drugs/placebo/no treatment: 26 RCTs (12 </text>
<text top="420" left="848" width="141" height="20" font="1">active drugs, 11 placebo) </text>
<text top="439" left="848" width="7" height="18" font="1">•</text>
<text top="438" left="855" width="189" height="20" font="1"> RCTs comparing ARBs vs. active </text>
<text top="456" left="848" width="223" height="20" font="1">drugs/placebo/no treatment: 13 RCTs (3 </text>
<text top="473" left="848" width="141" height="20" font="1">active drugs, 10 placebo) </text>
<text top="492" left="848" width="7" height="18" font="1">•</text>
<text top="491" left="855" width="236" height="20" font="1"> This meta-analysis provides evidence that </text>
<text top="508" left="848" width="206" height="20" font="1">ACEIs reduce all-cause mortality, CV </text>
<text top="526" left="848" width="256" height="20" font="1">mortality, and major CV events in pts with DM, </text>
<text top="543" left="848" width="223" height="20" font="1">whereas ARBs had no benefits on these </text>
<text top="560" left="848" width="60" height="20" font="1">outcomes. </text>
<text top="593" left="98" width="91" height="20" font="1">Arguedas JA, et </text>
<text top="610" left="98" width="83" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(244)</a> </text>
<text top="627" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24170669?dopt=Citation">24170669</a></text>
<text top="627" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24170669?dopt=Citation"> </a></text>
<text top="593" left="219" width="157" height="20" font="4"><b>Aim: </b>To determine if “lower” </text>
<text top="610" left="219" width="123" height="20" font="1">BP targets (any target </text>
<text top="627" left="219" width="117" height="20" font="1">&lt;130/85 mm Hg) are </text>
<text top="644" left="219" width="154" height="20" font="1">associated with reduction in </text>
<text top="662" left="219" width="127" height="20" font="1">mortality and morbidity </text>
<text top="679" left="219" width="151" height="20" font="1">compared to “standard” BP </text>
<text top="696" left="219" width="148" height="20" font="1">targets (&lt;140–160/90–100 </text>
<text top="713" left="219" width="131" height="20" font="1">mm Hg) in pts with DM. </text>
<text top="730" left="219" width="3" height="20" font="4"><b> </b></text>
<text top="748" left="219" width="163" height="20" font="4"><b>Study type</b>: Meta-analysis of </text>
<text top="765" left="219" width="38" height="20" font="1">RCTs. </text>
<text top="782" left="219" width="3" height="20" font="1"> </text>
<text top="593" left="402" width="153" height="20" font="4"><b>Inclusion criteria</b>: RCTs in </text>
<text top="610" left="402" width="126" height="20" font="1">which individuals were </text>
<text top="627" left="402" width="132" height="20" font="1">randomized to a “lower” </text>
<text top="644" left="402" width="153" height="20" font="1">compared with a “standard” </text>
<text top="662" left="402" width="62" height="20" font="1">BP target.  </text>
<text top="679" left="402" width="3" height="20" font="4"><b> </b></text>
<text top="696" left="402" width="154" height="20" font="4"><b>Exclusion criteria</b>: Studies </text>
<text top="713" left="402" width="116" height="20" font="1">that did not meet the </text>
<text top="730" left="402" width="149" height="20" font="1">inclusion criteria. Excluded </text>
<text top="748" left="402" width="152" height="20" font="1">studies were UKPDS 1998, </text>
<text top="765" left="402" width="143" height="20" font="1">HTN in Diabetes Study IV </text>
<text top="594" left="580" width="235" height="20" font="4"><b>1</b>°<b> outcomes</b>: Total mortality, total serious </text>
<text top="611" left="580" width="248" height="20" font="1">adverse events, MI, stroke, CHF, and ESRD. </text>
<text top="628" left="580" width="3" height="20" font="1"> </text>
<text top="646" left="580" width="237" height="20" font="4"><b>Results</b>: Only 1 trial (ACCORD) compared </text>
<text top="663" left="580" width="241" height="20" font="1">outcomes associated with 'lower' (&lt;120 mm </text>
<text top="680" left="580" width="245" height="20" font="1">Hg) or 'standard' (&lt;140 mm Hg) SBP targets </text>
<text top="697" left="580" width="245" height="20" font="1">in 4734 pts. Despite achieving a significantly </text>
<text top="714" left="580" width="242" height="20" font="1">lower BP (119.3/64.4 mm Hg vs. 133.5/70.5 </text>
<text top="732" left="580" width="197" height="20" font="1">mm Hg, p&lt;0.0001), and using more </text>
<text top="749" left="580" width="212" height="20" font="1">antihypertensive medications, the only </text>
<text top="766" left="580" width="233" height="20" font="1">significant benefit in the group assigned to </text>
<text top="783" left="580" width="244" height="20" font="1">'lower' SBP was a reduction in the incidence </text>
<text top="593" left="848" width="249" height="20" font="4"><b>Conclusions: </b>Evidence from RCTs does not </text>
<text top="610" left="848" width="217" height="20" font="1">support BP targets lower than standard </text>
<text top="627" left="848" width="178" height="20" font="1">targets in pts with HTN and DM. </text>
</page>
<page number="187" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">187 </text>
<text top="107" left="219" width="167" height="20" font="4"><b>Size</b>: 5 RCTs recruiting a total </text>
<text top="124" left="219" width="68" height="20" font="1">of 7,314 ps. </text>
<text top="141" left="219" width="3" height="20" font="4"><b> </b></text>
<text top="159" left="219" width="127" height="20" font="4"><b>Mean follow-up</b>: 4.5 y </text>
<text top="107" left="402" width="149" height="20" font="1">1996, SANDS 2008, Lewis </text>
<text top="124" left="402" width="158" height="20" font="1">1999 and the Steno-2 study. </text>
<text top="107" left="580" width="219" height="20" font="1">of stroke: RR: 0.58 (95% CI: 0.39–0.88; </text>
<text top="124" left="580" width="242" height="20" font="1">p=0.009), absolute risk reduction 1.1%. The </text>
<text top="141" left="580" width="208" height="20" font="1">effect of SBP targets on mortality was </text>
<text top="159" left="580" width="254" height="20" font="1">compatible with both a reduction and increase </text>
<text top="176" left="580" width="230" height="20" font="1">in risk: RR: 1.05 (95% CI: 0.84–1.30), low-</text>
<text top="193" left="580" width="250" height="20" font="1">quality evidence. Trying to achieve the 'lower' </text>
<text top="210" left="580" width="244" height="20" font="1">SBP target was associated with a significant </text>
<text top="228" left="580" width="217" height="20" font="1">increase in the number of other serious </text>
<text top="245" left="580" width="255" height="20" font="1">adverse events: RR: 2.58 (95% CI: 1.70–3.91; </text>
<text top="262" left="580" width="237" height="20" font="1">p&lt;0.00001), absolute risk increase 2.0%. 4 </text>
<text top="279" left="580" width="236" height="20" font="1">trials (ABCD-H, ABCD-N, ABCD-2V, and a </text>
<text top="296" left="580" width="223" height="20" font="1">subgroup of HOT) specifically compared </text>
<text top="314" left="580" width="241" height="20" font="1">clinical outcomes associated with 'lower' vs. </text>
<text top="331" left="580" width="252" height="20" font="1">'standard' targets for DBP in pts with DM. The </text>
<text top="348" left="580" width="251" height="20" font="1">total number of pts included in the DBP target </text>
<text top="365" left="580" width="232" height="20" font="1">analysis was 2580. Pts assigned to 'lower' </text>
<text top="383" left="580" width="238" height="20" font="1">DBP had a significantly lower achieved BP: </text>
<text top="400" left="580" width="191" height="20" font="1">128/76 mm Hg vs. 135/83 mm Hg, </text>
<text top="417" left="580" width="208" height="20" font="1">p&lt;0.0001. There was a trend towards </text>
<text top="434" left="580" width="212" height="20" font="1">reduction in total mortality in the group </text>
<text top="451" left="580" width="243" height="20" font="1">assigned to the 'lower' DBP target: RR: 0.73 </text>
<text top="469" left="580" width="249" height="20" font="1">(95% CI: 0.53–1.01), mainly due to a trend to </text>
<text top="486" left="580" width="213" height="20" font="1">lower non- CV mortality. There was no </text>
<text top="503" left="580" width="245" height="20" font="1">difference in stroke: RR: 0.67 (95% CI: 0.42–</text>
<text top="520" left="580" width="248" height="20" font="1">1.05), in MI: RR: 0.95 (95% CI: 0.64–1.40) or </text>
<text top="537" left="580" width="236" height="20" font="1">in CHF: RR: 1.06 (95% CI: 0.58–1.92), low </text>
<text top="555" left="580" width="246" height="20" font="1">quality evidence. End-stage renal failure and </text>
<text top="572" left="580" width="207" height="20" font="1">total serious adverse events were not </text>
<text top="589" left="580" width="221" height="20" font="1">reported in any of the trials. A sensitivity </text>
<text top="606" left="580" width="246" height="20" font="1">analysis of trials comparing DBP targets &lt;80 </text>
<text top="623" left="580" width="240" height="20" font="1">mm Hg (as suggested in clinical guidelines) </text>
<text top="641" left="580" width="250" height="20" font="1">vs. &lt;90 mm Hg showed similar results. There </text>
<text top="658" left="580" width="228" height="20" font="1">was a high risk of selection bias for every </text>
<text top="675" left="580" width="254" height="20" font="1">outcome analyzed in favor of the 'lower' target </text>
<text top="692" left="580" width="240" height="20" font="1">in the trials included for the analysis of DBP </text>
<text top="710" left="580" width="44" height="20" font="1">targets. </text>
<text top="727" left="98" width="97" height="20" font="1">Cushman WC, et </text>
<text top="745" left="98" width="83" height="20" font="1">al., 2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#276">(234)</a> </text>
<text top="762" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20228401?dopt=Citation">20228401</a></text>
<text top="762" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20228401?dopt=Citation"> </a></text>
<text top="727" left="219" width="137" height="20" font="4"><b>Aim</b>: To assess whether </text>
<text top="745" left="219" width="165" height="20" font="1">therapy targeting normal SBP </text>
<text top="762" left="219" width="164" height="20" font="1">(&lt;120 mm Hg) reduces major </text>
<text top="727" left="402" width="146" height="20" font="4"><b>Inclusion criteria</b>: Type 2 </text>
<text top="746" left="402" width="163" height="20" font="1">DM with HgbA1c ≥7.5%; ≥40 </text>
<text top="764" left="402" width="139" height="20" font="1">y with CVD or ≥55 y with </text>
<text top="781" left="402" width="129" height="20" font="1">anatomical evidence of </text>
<text top="727" left="580" width="224" height="20" font="1">Pts were randomly assigned to intensive </text>
<text top="745" left="580" width="253" height="20" font="1">therapy SBP&lt;120 mm Hg or standard therapy </text>
<text top="762" left="580" width="102" height="20" font="1">SBP&lt;140 mm Hg. </text>
<text top="779" left="580" width="3" height="20" font="1"> </text>
<text top="727" left="848" width="224" height="20" font="4"><b>Limitations</b>: This trial had an open label </text>
<text top="745" left="848" width="226" height="20" font="1">design. The rate of adverse events in the </text>
<text top="762" left="848" width="209" height="20" font="1">standard therapy group was less than </text>
</page>
<page number="188" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">188 </text>
<text top="107" left="219" width="146" height="20" font="1">CV events in type 2 DM at </text>
<text top="124" left="219" width="131" height="20" font="1">high risk for CV events. </text>
<text top="141" left="219" width="3" height="20" font="1"> </text>
<text top="159" left="219" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="176" left="219" width="3" height="20" font="1"> </text>
<text top="193" left="219" width="154" height="20" font="4"><b>Size</b>: 4,733 pts, 4.7 y follow-</text>
<text top="210" left="219" width="17" height="20" font="1">up </text>
<text top="107" left="402" width="160" height="20" font="1">atherosclerosis, albuminuria, </text>
<text top="124" left="402" width="154" height="20" font="1">LVH, or at least 2 additional </text>
<text top="141" left="402" width="113" height="20" font="1">risk factors for CVD. </text>
<text top="159" left="402" width="3" height="20" font="1"> </text>
<text top="177" left="402" width="163" height="20" font="4"><b>Exclusion criteria</b>: BMI ≥45, </text>
<text top="194" left="402" width="149" height="20" font="1">serum creatinine &gt;1.5, and </text>
<text top="211" left="402" width="116" height="20" font="1">other serious illness. </text>
<text top="108" left="580" width="253" height="20" font="4"><b>1</b>°<b> outcomes</b>: Nonfatal MI, nonfatal stroke, or </text>
<text top="125" left="580" width="58" height="20" font="1">CV death. </text>
<text top="143" left="580" width="3" height="20" font="1"> </text>
<text top="160" left="580" width="243" height="20" font="4"><b>Results</b>: Mean SBP in the intensive therapy </text>
<text top="177" left="580" width="246" height="20" font="1">group was 119.3 mm Hg and in the standard </text>
<text top="194" left="580" width="250" height="20" font="1">therapy group was 133.5 mm Hg. The annual </text>
<text top="211" left="580" width="235" height="20" font="1">1° outcome 1.87% in the intensive therapy </text>
<text top="229" left="580" width="226" height="20" font="1">group and 2.09% in the standard therapy </text>
<text top="246" left="580" width="206" height="20" font="1">group HR: 0.88 (95% CI: 0.073–1.06; </text>
<text top="263" left="580" width="244" height="20" font="1">p=0.20). The annual rates of death from any </text>
<text top="280" left="580" width="255" height="20" font="1">cause were 1.28% and 1.19% in the 2 groups, </text>
<text top="298" left="580" width="237" height="20" font="1">respectively (HR: 0.59; 95% CI: 0.39–0.89; </text>
<text top="315" left="580" width="249" height="20" font="1">p=0.01). Serious adverse events attributed to </text>
<text top="332" left="580" width="244" height="20" font="1">antihypertensive treatment occurred in 3.3% </text>
<text top="349" left="580" width="255" height="20" font="1">of the intensive therapy group and 1.3% of the </text>
<text top="366" left="580" width="190" height="20" font="1">standard therapy group (p&lt;0.001). </text>
<text top="107" left="848" width="252" height="20" font="1">expected. Pts younger than 40 y or older than </text>
<text top="124" left="848" width="130" height="20" font="1">79 y were not included. </text>
<text top="141" left="848" width="3" height="20" font="1"> </text>
<text top="159" left="848" width="254" height="20" font="4"><b>Summary</b>: In pts with type 2 DM and high risk </text>
<text top="176" left="848" width="222" height="20" font="1">for CV events, targeting SBP of &lt;120 as </text>
<text top="193" left="848" width="239" height="20" font="1">compared with &lt;140 mm Hg did not reduce </text>
<text top="210" left="848" width="233" height="20" font="1">the rate of composite outcome of fatal and </text>
<text top="228" left="848" width="253" height="20" font="1">nonfatal major CV events and was associated </text>
<text top="245" left="848" width="198" height="20" font="1">with greater risk for adverse events. </text>
<text top="384" left="98" width="89" height="20" font="1">Hartley L, et al., </text>
<text top="402" left="98" width="66" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(253)</a>  </text>
<text top="419" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25436436?dopt=Citation">25436436</a></text>
<text top="419" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25436436?dopt=Citation"> </a></text>
<text top="384" left="219" width="127" height="20" font="4"><b>Aim</b>: To determine the </text>
<text top="402" left="219" width="89" height="20" font="1">effectiveness of </text>
<text top="419" left="219" width="162" height="20" font="1">transcendental meditation for </text>
<text top="436" left="219" width="141" height="20" font="1">the 1° prevention of CVD </text>
<text top="453" left="219" width="3" height="20" font="1"> </text>
<text top="470" left="219" width="164" height="20" font="4"><b>Study type</b>: Literature review </text>
<text top="488" left="219" width="49" height="20" font="1">of RCTs </text>
<text top="505" left="219" width="3" height="20" font="1"> </text>
<text top="522" left="219" width="147" height="20" font="4"><b>Size</b>: 4 trials with a total of </text>
<text top="539" left="219" width="44" height="20" font="1">430 pts </text>
<text top="384" left="402" width="144" height="20" font="4"><b>Inclusion criteria</b>: ≥3 mo </text>
<text top="402" left="402" width="145" height="20" font="1">duration, healthy adults or </text>
<text top="419" left="402" width="145" height="20" font="1">adults at high risk of CVD, </text>
<text top="436" left="402" width="158" height="20" font="1">comparison of no or minimal </text>
<text top="453" left="402" width="70" height="20" font="1">intervention. </text>
<text top="470" left="402" width="3" height="20" font="1"> </text>
<text top="488" left="402" width="139" height="20" font="4"><b>Exclusion criteria</b>: Multi-</text>
<text top="505" left="402" width="105" height="20" font="1">factorial interviews </text>
<text top="386" left="580" width="251" height="20" font="4"><b>1</b>°<b> outcomes</b>: Clinical CVD events and major </text>
<text top="403" left="580" width="92" height="20" font="1">CVD risk factors </text>
<text top="420" left="580" width="3" height="20" font="1"> </text>
<text top="437" left="580" width="247" height="20" font="4"><b>Results</b>: No conclusions of the effectiveness </text>
<text top="454" left="580" width="212" height="20" font="1">of transcendental meditation for the 1° </text>
<text top="472" left="580" width="104" height="20" font="1">prevention of CVD </text>
<text top="384" left="848" width="168" height="20" font="4"><b>Limitations</b>: Limited evidence </text>
<text top="402" left="848" width="3" height="20" font="1"> </text>
<text top="419" left="848" width="200" height="20" font="4"><b>Summary</b>: No conclusions as to the </text>
<text top="436" left="848" width="251" height="20" font="1">effectiveness of transcendental meditation for </text>
<text top="453" left="848" width="205" height="20" font="1">the 1° prevention of CVD. There was </text>
<text top="470" left="848" width="254" height="20" font="1">considerable heterogeneity between trials and </text>
<text top="488" left="848" width="241" height="20" font="1">the included studies were small, short-term, </text>
<text top="505" left="848" width="186" height="20" font="1">and at overall serious risk of bias. </text>
<text top="557" left="98" width="100" height="20" font="1">Schmieder RE, et </text>
<text top="574" left="98" width="83" height="20" font="1">al., 2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(254)</a> </text>
<text top="592" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17416265?dopt=Citation">17416265</a></text>
<text top="592" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17416265?dopt=Citation"> </a></text>
<text top="557" left="219" width="142" height="20" font="4"><b>Study type</b>: Topic review </text>
<text top="557" left="402" width="129" height="20" font="4"><b>Inclusion criteria</b>: N/A </text>
<text top="574" left="402" width="3" height="20" font="1"> </text>
<text top="592" left="402" width="133" height="20" font="4"><b>Exclusion criteria</b>: N/A </text>
<text top="558" left="580" width="105" height="20" font="4"><b>1</b>°<b> outcomes</b>: N/A </text>
<text top="576" left="580" width="3" height="20" font="1"> </text>
<text top="593" left="580" width="75" height="20" font="4"><b>Results</b>: N/A </text>
<text top="557" left="848" width="96" height="20" font="4"><b>Limitations</b>: N/A </text>
<text top="574" left="848" width="3" height="20" font="1"> </text>
<text top="592" left="848" width="87" height="20" font="4"><b>Summary</b>: N/A </text>
<text top="609" left="98" width="57" height="20" font="1">Lv, et al.,  </text>
<text top="624" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#270">(127)</a> </text>
<text top="642" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459?dopt=Citation">23798459</a></text>
<text top="642" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459?dopt=Citation"> </a></text>
<text top="609" left="219" width="165" height="20" font="4"><b>Aim:</b> To assess the renal and </text>
<text top="625" left="219" width="145" height="20" font="1">CV effects of intensive BP </text>
<text top="640" left="219" width="157" height="20" font="1">lowering in people with CKD </text>
<text top="655" left="219" width="3" height="20" font="1"> </text>
<text top="671" left="219" width="134" height="20" font="4"><b>Study type: </b>Systematic </text>
<text top="686" left="219" width="39" height="20" font="1">review </text>
<text top="701" left="219" width="3" height="20" font="1"> </text>
<text top="717" left="219" width="165" height="20" font="4"><b>Size:</b> 9,287 pts with CKD and </text>
<text top="732" left="219" width="153" height="20" font="1">1,264 kidney failure events  </text>
<text top="609" left="402" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="625" left="402" width="7" height="18" font="1">•</text>
<text top="624" left="409" width="139" height="20" font="1"> Randomized trials of pts </text>
<text top="640" left="402" width="121" height="20" font="1">with CKD assigned to </text>
<text top="655" left="402" width="126" height="20" font="1">different target BP that </text>
<text top="670" left="402" width="149" height="20" font="1">reported kidney failure and </text>
<text top="686" left="402" width="64" height="20" font="1">CV events.<b> </b></text>
<text top="702" left="402" width="7" height="18" font="1">•</text>
<text top="702" left="409" width="146" height="20" font="1"> 11 trials on 9,287 pts with </text>
<text top="717" left="402" width="163" height="20" font="1">CKD and 1,264 kidney failure </text>
<text top="732" left="402" width="145" height="20" font="1">events (doubling of serum </text>
<text top="747" left="402" width="143" height="20" font="1">creatinine, 50% decline in </text>
<text top="762" left="402" width="85" height="20" font="1">GFR or ESKD) </text>
<text top="781" left="402" width="7" height="18" font="1">•</text>
<text top="780" left="409" width="140" height="20" font="1"> Included AASK, REIN-2, </text>
<text top="611" left="580" width="247" height="20" font="4"><b>Results: </b>Compared with standard regimens, </text>
<text top="629" left="580" width="237" height="20" font="1">more intensive BP lowering reduced risk of </text>
<text top="646" left="580" width="244" height="20" font="1">composite endpoint HR: 0.82 (95% CI: 0.68–</text>
<text top="663" left="580" width="226" height="20" font="1">0.98) and ESKD HR: 0.79 (95% CI: 0.67–</text>
<text top="680" left="580" width="223" height="20" font="1">0.93). Effect was modified by proteinuria </text>
<text top="698" left="580" width="207" height="20" font="1">(p=0.006) and markers of trial quality. </text>
<text top="715" left="580" width="226" height="20" font="1">Intensive BP lowering reduced the risk of </text>
<text top="732" left="580" width="241" height="20" font="1">kidney failure HR: 0.73 (95% CI: 0.62–0.86) </text>
<text top="749" left="580" width="241" height="20" font="1">but not in pts without proteinuria at baseline </text>
<text top="766" left="580" width="218" height="20" font="1">HR: 1.12 (95% CI: 0.67–1.87). No clear </text>
<text top="784" left="580" width="163" height="20" font="1">effect on CV events or death.<b> </b></text>
<text top="610" left="848" width="256" height="20" font="4"><b>Limitations</b>: All trials used open label, in 2 pts </text>
<text top="625" left="848" width="246" height="20" font="1">were blinded, substantial variability in design </text>
<text top="641" left="848" width="253" height="20" font="1">quality. There was substantial variability in BP </text>
<text top="656" left="848" width="244" height="20" font="1">targets by MAP, SBP and DBP or only DBP. </text>
<text top="672" left="848" width="233" height="20" font="1">Most trials did not include pts with diabetic </text>
<text top="687" left="848" width="85" height="20" font="1">kidney disease </text>
<text top="705" left="848" width="3" height="20" font="1"> </text>
<text top="724" left="848" width="67" height="20" font="4"><b>Summary:  </b></text>
<text top="744" left="848" width="7" height="18" font="1">•</text>
<text top="743" left="855" width="246" height="20" font="1"> Renal outcomes: 7 trials (N=5308) recorded </text>
<text top="760" left="848" width="240" height="20" font="1">a total of 1,264 kidney failure events. A -7.7 </text>
<text top="777" left="848" width="243" height="20" font="1">mm Hg difference in SBP and a -4.9 mm Hg </text>
</page>
<page number="189" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">189 </text>
<text top="107" left="402" width="165" height="20" font="1">MDRD, Wuhl (children), Toto, </text>
<text top="124" left="402" width="163" height="20" font="1">Schrier plus 5 trials with CKD </text>
<text top="141" left="402" width="160" height="20" font="1">subgroups, also included the </text>
<text top="159" left="402" width="164" height="20" font="1">late nonrandomized follow-up </text>
<text top="176" left="402" width="161" height="20" font="1">studies for AASK and MDRD </text>
<text top="196" left="402" width="7" height="18" font="1">•</text>
<text top="195" left="409" width="101" height="20" font="1"> BP targets varied </text>
<text top="212" left="402" width="164" height="20" font="1">substantially between trials. 2 </text>
<text top="229" left="402" width="156" height="20" font="1">trials targeted mean BP &lt;92 </text>
<text top="247" left="402" width="133" height="20" font="1">mm Hg for the intensive </text>
<text top="264" left="402" width="155" height="20" font="1">treatment arm, and 107 mm </text>
<text top="281" left="402" width="159" height="20" font="1">Hg in the standard treatment </text>
<text top="298" left="402" width="136" height="20" font="1">arm. 1 trial aimed for BP </text>
<text top="315" left="402" width="163" height="20" font="1">&lt;130/80 mm Hg vs. a DBP of </text>
<text top="333" left="402" width="155" height="20" font="1">90 mm Hg, 1 study targeted </text>
<text top="350" left="402" width="138" height="20" font="1">&lt;120/80 mm Hg vs. 135–</text>
<text top="367" left="402" width="142" height="20" font="1">140/85–90 mm Hg, and 4 </text>
<text top="384" left="402" width="164" height="20" font="1">studies had DBP &lt;75–80 mm </text>
<text top="402" left="402" width="162" height="20" font="1">Hg vs. from 80–90 mm Hg. A </text>
<text top="419" left="402" width="144" height="20" font="1">trial involving pediatric pts </text>
<text top="436" left="402" width="141" height="20" font="1">targeted a 24-h mean BP </text>
<text top="453" left="402" width="115" height="20" font="1">&lt;the 50th percentile, </text>
<text top="470" left="402" width="145" height="20" font="1">compared with the 50th to </text>
<text top="488" left="402" width="164" height="20" font="1">95th percentiles in the control </text>
<text top="505" left="402" width="133" height="20" font="1">group. 2 trials had more </text>
<text top="522" left="402" width="147" height="20" font="1">liberal targets for intensive </text>
<text top="539" left="402" width="161" height="20" font="1">treatment (&lt;140–150 mm Hg </text>
<text top="556" left="402" width="124" height="20" font="1">SBP, 85 mm Hg DBP) </text>
<text top="108" left="580" width="3" height="20" font="1"> </text>
<text top="107" left="848" width="235" height="20" font="1">difference in DBP seen between treatment </text>
<text top="124" left="848" width="222" height="20" font="1">arms. Overall, a more intensive regimen </text>
<text top="141" left="848" width="219" height="20" font="1">reduced risk of composite kidney failure </text>
<text top="159" left="848" width="256" height="20" font="1">events by 17% (HR: 0.82; 95% CI: 0.68, 0.98), </text>
<text top="176" left="848" width="219" height="20" font="1">reduced the risk of ESKD alone by 18% </text>
<text top="193" left="848" width="234" height="20" font="1">(pooled HR for composite outcomes: 0.79; </text>
<text top="210" left="848" width="113" height="20" font="1">95% CI: 0.67, 0.93).<b> </b></text>
<text top="231" left="848" width="7" height="18" font="1">•</text>
<text top="230" left="855" width="217" height="20" font="1"> Intensive BP lowering had no effect on </text>
<text top="247" left="848" width="205" height="20" font="1">kidney failure in pts who did not have </text>
<text top="264" left="848" width="239" height="20" font="1">proteinuria (3 trials involving 1,218 pts (HR: </text>
<text top="282" left="848" width="255" height="20" font="1">1.12; 95% CI: 0.67–1.87), but it did reduce the </text>
<text top="299" left="848" width="238" height="20" font="1">risk of progressive kidney failure by 27% (5 </text>
<text top="316" left="848" width="241" height="20" font="1">trials involving 1,703 pts (HR: 0.73; 95% CI: </text>
<text top="333" left="848" width="246" height="20" font="1">0.62–0.86) in pts who did have proteinuria at </text>
<text top="350" left="848" width="56" height="20" font="1">baseline.  </text>
<text top="370" left="848" width="7" height="18" font="1">•</text>
<text top="370" left="855" width="241" height="20" font="1"> CV outcomes: major CV events reported in </text>
<text top="387" left="848" width="257" height="20" font="1">5 trials (472 CV events in 5,308 pts with CKD). </text>
<text top="404" left="848" width="239" height="20" font="1">Intensive BP lowering did not reduce risk of </text>
<text top="421" left="848" width="214" height="20" font="1">CV events in pts with CKD, but the CIs </text>
<text top="439" left="848" width="225" height="20" font="1">remained wide (RR: 1.09 (95% CI: 0.83,  </text>
<text top="457" left="848" width="246" height="20" font="1">1.42). 6 trials reported stroke outcomes (197 </text>
<text top="474" left="848" width="248" height="20" font="1">events in 5,411 pts), 5 trials reported MI (138 </text>
<text top="491" left="848" width="247" height="20" font="1">events in 4,317 pts), and 5 trials reported HF </text>
<text top="509" left="848" width="245" height="20" font="1">(118 events in 5,308 pts). They saw no clear </text>
<text top="526" left="848" width="242" height="20" font="1">effect of intensive treatment on any of these </text>
<text top="543" left="848" width="113" height="20" font="1">vascular outcomes.  </text>
<text top="563" left="848" width="7" height="18" font="1">•</text>
<text top="562" left="855" width="244" height="20" font="1"> Death: 10 trials involving 6,788 pts reported </text>
<text top="580" left="848" width="223" height="20" font="1">846 deaths. There was no clear effect of </text>
<text top="597" left="848" width="227" height="20" font="1">intensive BP lowering on risk of all-cause </text>
<text top="614" left="848" width="239" height="20" font="1">death (RR: 0.94 (95% CI: 0.84, 1.05) or CV </text>
<text top="631" left="848" width="207" height="20" font="1">death (RR: 1.20 (95% CI: 0.82, 1.75). </text>
<text top="651" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="190" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">190 </text>
<text top="106" left="81" width="362" height="24" font="3"><b>Data Supplement 48. Atrial Fibrillation (Section 9.8) </b></text>
<text top="146" left="116" width="38" height="20" font="4"><b>Study </b></text>
<text top="163" left="104" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="180" left="110" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="212" left="119" width="30" height="20" font="4"><b>Year </b></text>
<text top="230" left="103" width="62" height="20" font="4"><b>Published </b></text>
<text top="146" left="188" width="79" height="20" font="4"><b>Aim of Study </b></text>
<text top="146" left="291" width="445" height="20" font="4"><b>Study Type  Study Size (N)  Patient Population  Study Intervention (# </b></text>
<text top="163" left="624" width="99" height="20" font="4"><b>patients) / Study </b></text>
<text top="195" left="629" width="87" height="20" font="4"><b>Comparator (# </b></text>
<text top="213" left="646" width="55" height="20" font="4"><b>patients) </b></text>
<text top="146" left="766" width="64" height="20" font="4"><b>Endpoints </b></text>
<text top="146" left="861" width="117" height="20" font="4"><b>P Value; OR, HR, or </b></text>
<text top="163" left="879" width="81" height="20" font="4"><b>RR; &amp; 95% CI </b></text>
<text top="146" left="1025" width="38" height="20" font="4"><b>Study </b></text>
<text top="163" left="1003" width="82" height="20" font="4"><b>Limitations &amp; </b></text>
<text top="180" left="995" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="263" left="98" width="72" height="20" font="1">Jibrini, et al., </text>
<text top="282" left="98" width="34" height="20" font="1">2008  </text>
<text top="317" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(255)</a> </text>
<text top="352" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18223352?dopt=Citation">18223352</a></text>
<text top="352" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18223352?dopt=Citation"> </a></text>
<text top="263" left="184" width="48" height="20" font="4"><b>Aim</b>: To </text>
<text top="280" left="184" width="62" height="20" font="1">assess the </text>
<text top="297" left="184" width="75" height="20" font="1">effectiveness </text>
<text top="314" left="184" width="76" height="20" font="1">of ACEIs and </text>
<text top="332" left="184" width="68" height="20" font="1">ARBs in the </text>
<text top="349" left="184" width="75" height="20" font="1">prevention of </text>
<text top="366" left="184" width="60" height="20" font="1">AF, and to </text>
<text top="383" left="184" width="76" height="20" font="1">identify those </text>
<text top="400" left="184" width="83" height="20" font="1">clinical entities </text>
<text top="418" left="184" width="85" height="20" font="1">in which RAAS </text>
<text top="435" left="184" width="87" height="20" font="1">inhibition would </text>
<text top="452" left="184" width="61" height="20" font="1">most likely </text>
<text top="469" left="184" width="84" height="20" font="1">benefit the pts. </text>
<text top="263" left="285" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="280" left="285" width="83" height="20" font="1">Meta-analysis  </text>
<text top="264" left="380" width="7" height="18" font="1">•</text>
<text top="264" left="386" width="76" height="20" font="1"> 11 published </text>
<text top="281" left="380" width="66" height="20" font="1">studies; 55, </text>
<text top="298" left="380" width="44" height="20" font="1">989 pts </text>
<text top="315" left="380" width="78" height="20" font="1">(26,973 pts in </text>
<text top="333" left="380" width="70" height="20" font="1">intervention, </text>
<text top="350" left="380" width="70" height="20" font="1">29,016pts in </text>
<text top="367" left="380" width="70" height="20" font="1">comparator) </text>
<text top="263" left="481" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="280" left="481" width="95" height="20" font="1">Studies of RAAS </text>
<text top="297" left="481" width="98" height="20" font="1">blockade in CHF, </text>
<text top="314" left="481" width="72" height="20" font="1">MI, electrical </text>
<text top="332" left="481" width="104" height="20" font="1">cardioversion, and </text>
<text top="349" left="481" width="113" height="20" font="1">HTN) with incidence </text>
<text top="366" left="481" width="105" height="20" font="1">of AF noted during </text>
<text top="383" left="481" width="56" height="20" font="1">follow-up. </text>
<text top="400" left="481" width="3" height="20" font="1"> </text>
<text top="418" left="481" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="435" left="481" width="107" height="20" font="1">Studies without the </text>
<text top="452" left="481" width="111" height="20" font="1">measurement of AF </text>
<text top="469" left="481" width="88" height="20" font="1">or use of RAAS </text>
<text top="486" left="481" width="56" height="20" font="1">blockade. </text>
<text top="263" left="609" width="115" height="20" font="4"><b>Intervention: </b>RAAS </text>
<text top="280" left="609" width="53" height="20" font="1">blockade </text>
<text top="297" left="609" width="3" height="20" font="1"> </text>
<text top="314" left="609" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="332" left="609" width="117" height="20" font="1">Placebo, amlodipine, </text>
<text top="349" left="609" width="123" height="20" font="1">BB or thiazide diuretic </text>
<text top="263" left="751" width="72" height="20" font="4"><b>1° endpoint </b></text>
<text top="280" left="751" width="83" height="20" font="4"><b>(efficacy) and </b></text>
<text top="297" left="751" width="67" height="20" font="4"><b>results:</b> AF </text>
<text top="314" left="751" width="79" height="20" font="1">occurrence or </text>
<text top="332" left="751" width="79" height="20" font="1">reoccurrence. </text>
<text top="263" left="859" width="121" height="20" font="1">Treatment with RAAS </text>
<text top="280" left="859" width="118" height="20" font="1">blockers reduced RR </text>
<text top="297" left="859" width="120" height="20" font="1">of AF in pts with HTN </text>
<text top="314" left="859" width="121" height="20" font="1">by 23% (p&lt;0.001), by </text>
<text top="332" left="859" width="106" height="20" font="1">11% in pts after MI </text>
<text top="349" left="859" width="97" height="20" font="1">(p&lt;0.05), by 51% </text>
<text top="366" left="859" width="80" height="20" font="1">after electrical </text>
<text top="383" left="859" width="77" height="20" font="1">cardioversion </text>
<text top="400" left="859" width="117" height="20" font="1">(p&lt;0.001), by 32% in </text>
<text top="418" left="859" width="121" height="20" font="1">pts with HF (p&lt;0.001) </text>
<text top="435" left="859" width="108" height="20" font="1">and by 19% overall </text>
<text top="452" left="859" width="60" height="20" font="1">(p&lt;0.001). </text>
<text top="264" left="994" width="7" height="18" font="1">•</text>
<text top="264" left="1000" width="36" height="20" font="1"> Not a </text>
<text top="281" left="994" width="87" height="20" font="1">comprehensive </text>
<text top="298" left="994" width="77" height="20" font="1">analysis of all </text>
<text top="315" left="994" width="96" height="20" font="1">antihypertensive. </text>
<text top="333" left="994" width="88" height="20" font="1">Adverse events </text>
<text top="350" left="994" width="97" height="20" font="1">not catalogued in </text>
<text top="367" left="994" width="83" height="20" font="1">meta-analysis. </text>
<text top="504" left="98" width="65" height="20" font="1">Zhao et al., </text>
<text top="524" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(256)</a> </text>
<text top="559" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26668582">26668582</a></text>
<text top="559" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26668582"> </a></text>
<text top="504" left="184" width="49" height="20" font="4"><b>Aim:</b> To </text>
<text top="522" left="184" width="83" height="20" font="1">investigate the </text>
<text top="539" left="184" width="75" height="20" font="1">effectiveness </text>
<text top="556" left="184" width="74" height="20" font="1">and safety of </text>
<text top="573" left="184" width="42" height="20" font="1">ACEIs  </text>
<text top="590" left="184" width="81" height="20" font="1">or angiotensin </text>
<text top="608" left="184" width="59" height="20" font="1">II receptor </text>
<text top="625" left="184" width="49" height="20" font="1">blockers </text>
<text top="642" left="184" width="60" height="20" font="1">(ARBs) on </text>
<text top="659" left="184" width="80" height="20" font="1">preventing AF </text>
<text top="676" left="184" width="65" height="20" font="1">in essential </text>
<text top="694" left="184" width="73" height="20" font="1">hypertensive </text>
<text top="711" left="184" width="23" height="20" font="1">pts. </text>
<text top="728" left="184" width="3" height="20" font="1"> </text>
<text top="745" left="184" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="762" left="184" width="79" height="20" font="1">Meta-analysis </text>
<text top="780" left="184" width="3" height="20" font="1"> </text>
<text top="504" left="285" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="522" left="285" width="37" height="20" font="1">RAAS </text>
<text top="539" left="285" width="60" height="20" font="1">blockade,  </text>
<text top="556" left="285" width="58" height="20" font="1">n=20,491  </text>
<text top="573" left="285" width="3" height="20" font="1"> </text>
<text top="590" left="285" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="608" left="285" width="65" height="20" font="1">BB/calcium </text>
<text top="625" left="285" width="67" height="20" font="1">antagonist,  </text>
<text top="642" left="285" width="55" height="20" font="1">n=22,401 </text>
<text top="504" left="380" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="522" left="380" width="83" height="20" font="4"><b>criteria:</b> RCTs </text>
<text top="539" left="380" width="77" height="20" font="1">on the effects </text>
<text top="556" left="380" width="49" height="20" font="1">of ACEI/ </text>
<text top="573" left="380" width="52" height="20" font="1">ARBs on </text>
<text top="590" left="380" width="52" height="20" font="1">essential </text>
<text top="608" left="380" width="73" height="20" font="1">hypertensive </text>
<text top="625" left="380" width="23" height="20" font="1">pts. </text>
<text top="642" left="380" width="3" height="20" font="1"> </text>
<text top="659" left="380" width="62" height="20" font="4"><b>Exclusion </b></text>
<text top="676" left="380" width="75" height="20" font="4"><b>criteria:</b> Non-</text>
<text top="694" left="380" width="87" height="20" font="1">RCTs, subjects </text>
<text top="711" left="380" width="76" height="20" font="1">who were not </text>
<text top="728" left="380" width="67" height="20" font="1">treated with </text>
<text top="745" left="380" width="79" height="20" font="1">ACEI or ARB, </text>
<text top="762" left="380" width="74" height="20" font="1">and trials not </text>
<text top="505" left="481" width="95" height="20" font="4"><b>1</b>°<b> endpoint:</b> AF </text>
<text top="523" left="481" width="79" height="20" font="1">occurrence or </text>
<text top="540" left="481" width="82" height="20" font="1">reoccurrence.  </text>
<text top="506" left="609" width="7" height="18" font="1">•</text>
<text top="505" left="616" width="118" height="20" font="1"> ACEI/ARBs reduced </text>
<text top="523" left="609" width="109" height="20" font="1">the incidence of AF </text>
<text top="540" left="609" width="120" height="20" font="1">recurrence compared </text>
<text top="557" left="609" width="125" height="20" font="1">to calcium antagonists </text>
<text top="574" left="609" width="107" height="20" font="1">(RR: 0.48; 95% CI: </text>
<text top="591" left="609" width="128" height="20" font="1">0.40–0.58; p&lt;0.00001) </text>
<text top="609" left="609" width="103" height="20" font="1">or b-blockers (RR: </text>
<text top="626" left="609" width="109" height="20" font="1">0.39; 95% CI: 0.20–</text>
<text top="643" left="609" width="87" height="20" font="1">0.74; p=0.005). </text>
<text top="660" left="609" width="93" height="20" font="1">ACEI/ARBs may </text>
<text top="678" left="609" width="117" height="20" font="1">reduce the incidence </text>
<text top="695" left="609" width="119" height="20" font="1">of AF recurrence and </text>
<text top="712" left="609" width="91" height="20" font="1">CHF, with fewer </text>
<text top="729" left="609" width="90" height="20" font="1">serious adverse </text>
<text top="747" left="609" width="104" height="20" font="1">effects, but did not </text>
<text top="764" left="609" width="118" height="20" font="1">prevent new onset of </text>
<text top="781" left="609" width="22" height="20" font="1">AF.<b> </b></text>
<text top="504" left="751" width="24" height="20" font="1">N/A </text>
<text top="506" left="859" width="7" height="18" font="1">•</text>
<text top="505" left="865" width="90" height="20" font="1"> Doxazosin was </text>
<text top="523" left="859" width="98" height="20" font="1">associated with a </text>
<text top="540" left="859" width="93" height="20" font="1">higher incidence </text>
<text top="557" left="859" width="116" height="20" font="1">(2%) of AF/AFL prior </text>
<text top="574" left="859" width="102" height="20" font="1">to having the drug </text>
<text top="591" left="859" width="109" height="20" font="1">discontinued by the </text>
<text top="609" left="859" width="83" height="20" font="1">trial. Excluding </text>
<text top="626" left="859" width="119" height="20" font="1">doxazosin, there was </text>
<text top="643" left="859" width="83" height="20" font="1">no relationship </text>
<text top="660" left="859" width="105" height="20" font="1">between treatment </text>
<text top="678" left="859" width="97" height="20" font="1">drug and AF/AFL </text>
<text top="695" left="859" width="59" height="20" font="1">incidence. </text>
<text top="506" left="994" width="7" height="18" font="1">•</text>
<text top="505" left="1000" width="81" height="20" font="1"> 2° analysis of </text>
<text top="526" left="994" width="32" height="20" font="1">RCT. </text>
</page>
<page number="191" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">191 </text>
<text top="107" left="184" width="49" height="20" font="4"><b>Size:</b> 10 </text>
<text top="124" left="184" width="46" height="20" font="1">studies, </text>
<text top="141" left="184" width="55" height="20" font="1">n=42,892 </text>
<text top="107" left="380" width="77" height="20" font="1">mentioning of </text>
<text top="124" left="380" width="83" height="20" font="1">AF prevention. </text>
<text top="159" left="108" width="3" height="20" font="1"> </text>
<text top="194" left="81" width="404" height="24" font="3"><b>Data Supplement 49. Valvular Heart Disease (Section 9.9) </b></text>
<text top="234" left="125" width="38" height="20" font="4"><b>Study </b></text>
<text top="251" left="114" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="268" left="120" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="285" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="234" left="222" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="251" left="227" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="268" left="221" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="234" left="371" width="38" height="20" font="4"><b>Study </b></text>
<text top="251" left="345" width="88" height="20" font="4"><b>Intervention (# </b></text>
<text top="268" left="340" width="99" height="20" font="4"><b>patients) / Study </b></text>
<text top="285" left="346" width="87" height="20" font="4"><b>Comparator (# </b></text>
<text top="303" left="362" width="55" height="20" font="4"><b>patients) </b></text>
<text top="234" left="477" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="234" left="657" width="64" height="20" font="4"><b>Endpoints </b></text>
<text top="234" left="770" width="155" height="20" font="4"><b>P Value; OR, HR, or RR; &amp; </b></text>
<text top="251" left="826" width="44" height="20" font="4"><b>95% CI </b></text>
<text top="234" left="947" width="119" height="20" font="4"><b>Study Limitations &amp; </b></text>
<text top="251" left="959" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="321" left="98" width="75" height="20" font="1">Healey et al., </text>
<text top="340" left="98" width="63" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(257)</a> </text>
<text top="375" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15936615">15936615</a></text>
<text top="375" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15936615"> </a></text>
<text top="321" left="204" width="94" height="20" font="4"><b>Aim:</b> Systematic </text>
<text top="338" left="204" width="97" height="20" font="1">review of all RCT </text>
<text top="355" left="204" width="80" height="20" font="1">evaluating the </text>
<text top="372" left="204" width="97" height="20" font="1">benefit of trials of </text>
<text top="389" left="204" width="104" height="20" font="1">ACEI and ARBs in </text>
<text top="407" left="204" width="94" height="20" font="1">prevention of AF </text>
<text top="424" left="204" width="3" height="20" font="1"> </text>
<text top="441" left="204" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="458" left="204" width="48" height="20" font="1">analysis </text>
<text top="475" left="204" width="3" height="20" font="1"> </text>
<text top="493" left="204" width="91" height="20" font="4"><b>Size:</b> 11 studies </text>
<text top="510" left="204" width="115" height="20" font="1">included with 56,308 </text>
<text top="527" left="204" width="20" height="20" font="1">pts </text>
<text top="321" left="336" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="338" left="336" width="92" height="20" font="1">n=27,089 RAAS </text>
<text top="355" left="336" width="53" height="20" font="1">blockade </text>
<text top="372" left="336" width="3" height="20" font="1"> </text>
<text top="389" left="336" width="84" height="20" font="4"><b>Comparators: </b></text>
<text top="407" left="336" width="102" height="20" font="1">n=29,220 placebo </text>
<text top="424" left="336" width="90" height="20" font="1">or active control </text>
<text top="441" left="336" width="96" height="20" font="1">antihypertensive  </text>
<text top="321" left="456" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="338" left="456" width="148" height="20" font="1">Studies of RAAS blockade </text>
<text top="355" left="456" width="117" height="20" font="1">in CHF, MI, electrical </text>
<text top="372" left="456" width="137" height="20" font="1">cardioversion, and HTN) </text>
<text top="389" left="456" width="148" height="20" font="1">with incidence of AF noted </text>
<text top="407" left="456" width="94" height="20" font="1">during follow-up  </text>
<text top="424" left="456" width="3" height="20" font="1"> </text>
<text top="441" left="456" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="458" left="456" width="107" height="20" font="1">Studies without the </text>
<text top="475" left="456" width="149" height="20" font="1">measurement of AF or use </text>
<text top="493" left="456" width="107" height="20" font="1">of RAAS blockade. </text>
<text top="322" left="622" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="339" left="622" width="98" height="20" font="1">AF occurrence or </text>
<text top="356" left="622" width="79" height="20" font="1">reoccurrence  </text>
<text top="322" left="768" width="7" height="18" font="1">•</text>
<text top="322" left="775" width="148" height="20" font="1"> ACEIs and ARBs reduced </text>
<text top="339" left="768" width="98" height="20" font="1">RR of AF by 28% </text>
<text top="356" left="768" width="147" height="20" font="1">(p=0.0002), greatest in pts </text>
<text top="373" left="768" width="158" height="20" font="1">with HF [RR reduction: 44%; </text>
<text top="391" left="768" width="133" height="20" font="1">p=0.007). No significant </text>
<text top="408" left="768" width="144" height="20" font="1">reduction in AF in pts with </text>
<text top="425" left="768" width="143" height="20" font="1">HTN (RR reduction: 12%; </text>
<text top="442" left="768" width="141" height="20" font="1">p=0.4), but 1 trial found a </text>
<text top="459" left="768" width="153" height="20" font="1">significant 29% reduction in </text>
<text top="477" left="768" width="131" height="20" font="1">pts with LVH. Following </text>
<text top="494" left="768" width="143" height="20" font="1">cardioversion there was a </text>
<text top="511" left="768" width="117" height="20" font="1">large effect (48% RR </text>
<text top="528" left="768" width="136" height="20" font="1">reduction; 95% CI: 21%–</text>
<text top="545" left="768" width="36" height="20" font="1">65%). </text>
<text top="322" left="940" width="7" height="18" font="1">•</text>
<text top="322" left="947" width="101" height="20" font="1"> ACEIs and ARBs </text>
<text top="339" left="940" width="122" height="20" font="1">appear to be effective </text>
<text top="356" left="940" width="107" height="20" font="1">in prevention of AF </text>
<text top="373" left="940" width="123" height="20" font="1">probably limited to pts </text>
<text top="391" left="940" width="87" height="20" font="1">with systolic LV </text>
<text top="408" left="940" width="109" height="20" font="1">dysfunction or HTN </text>
<text top="425" left="940" width="27" height="20" font="1">LVH </text>
<text top="564" left="98" width="73" height="20" font="1">Jibrini et al.,  </text>
<text top="598" left="98" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(255)</a> </text>
<text top="633" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18223352">18223352</a></text>
<text top="633" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18223352"> </a></text>
<text top="563" left="204" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="581" left="204" width="89" height="20" font="1">effectiveness of </text>
<text top="598" left="204" width="110" height="20" font="1">ACEIs and ARBs in </text>
<text top="615" left="204" width="118" height="20" font="1">the prevention of AF, </text>
<text top="632" left="204" width="113" height="20" font="1">and to identify those </text>
<text top="649" left="204" width="96" height="20" font="1">clinical entities in </text>
<text top="667" left="204" width="72" height="20" font="1">which RAAS </text>
<text top="684" left="204" width="117" height="20" font="1">inhibition would most </text>
<text top="701" left="204" width="115" height="20" font="1">likely benefit the pts. </text>
<text top="718" left="204" width="3" height="20" font="1"> </text>
<text top="735" left="204" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="753" left="204" width="51" height="20" font="1">analysis  </text>
<text top="770" left="204" width="3" height="20" font="1"> </text>
<text top="563" left="336" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="581" left="336" width="92" height="20" font="1">n=26,973 RAAS </text>
<text top="598" left="336" width="53" height="20" font="1">blockade </text>
<text top="615" left="336" width="3" height="20" font="1"> </text>
<text top="632" left="336" width="84" height="20" font="4"><b>Comparators:</b> </text>
<text top="649" left="336" width="105" height="20" font="1">n=29,016 placebo, </text>
<text top="667" left="336" width="100" height="20" font="1">amlodipine, BB or </text>
<text top="684" left="336" width="89" height="20" font="1">thiazide diuretic </text>
<text top="563" left="456" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="581" left="456" width="148" height="20" font="1">Studies of RAAS blockade </text>
<text top="598" left="456" width="117" height="20" font="1">in CHF, MI, electrical </text>
<text top="615" left="456" width="137" height="20" font="1">cardioversion, and HTN) </text>
<text top="632" left="456" width="148" height="20" font="1">with incidence of AF noted </text>
<text top="649" left="456" width="94" height="20" font="1">during follow-up  </text>
<text top="667" left="456" width="3" height="20" font="1"> </text>
<text top="684" left="456" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="701" left="456" width="107" height="20" font="1">Studies without the </text>
<text top="718" left="456" width="149" height="20" font="1">measurement of AF or use </text>
<text top="735" left="456" width="107" height="20" font="1">of RAAS blockade. </text>
<text top="565" left="622" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="582" left="622" width="98" height="20" font="1">AF occurrence or </text>
<text top="599" left="622" width="82" height="20" font="1">reoccurrence.  </text>
<text top="565" left="768" width="7" height="18" font="1">•</text>
<text top="565" left="775" width="125" height="20" font="1"> Treatment with RAAS </text>
<text top="582" left="768" width="151" height="20" font="1">blockers reduced RR of AF </text>
<text top="599" left="768" width="131" height="20" font="1">in pts with HTN by 23% </text>
<text top="616" left="768" width="137" height="20" font="1">(p&lt;0.001), by 11% in pts </text>
<text top="633" left="768" width="142" height="20" font="1">after MI (p&lt;0.05), by 51% </text>
<text top="651" left="768" width="156" height="20" font="1">after electrical cardioversion </text>
<text top="668" left="768" width="137" height="20" font="1">(p&lt;0.001), by 32% in pts </text>
<text top="685" left="768" width="142" height="20" font="1">with HF (p&lt;0.001) and by </text>
<text top="702" left="768" width="128" height="20" font="1">19% overall (p&lt;0.001). </text>
<text top="563" left="940" width="24" height="20" font="1">N/A </text>
</page>
<page number="192" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">192 </text>
<text top="107" left="204" width="95" height="20" font="4"><b>Size:</b> 11 studies, </text>
<text top="124" left="204" width="61" height="20" font="1">55,989 pts </text>
<text top="142" left="98" width="65" height="20" font="1">Zhao et al., </text>
<text top="162" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(256)</a> </text>
<text top="197" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26668582">26668582</a></text>
<text top="197" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26668582"> </a></text>
<text top="142" left="204" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="159" left="204" width="120" height="20" font="1">the effectiveness and </text>
<text top="177" left="204" width="92" height="20" font="1">safety of ACEIs  </text>
<text top="194" left="204" width="91" height="20" font="1">or angiotensin II </text>
<text top="211" left="204" width="98" height="20" font="1">receptor blockers </text>
<text top="228" left="204" width="60" height="20" font="1">(ARBs) on </text>
<text top="246" left="204" width="93" height="20" font="1">preventing AF in </text>
<text top="263" left="204" width="52" height="20" font="1">essential </text>
<text top="280" left="204" width="96" height="20" font="1">hypertensive pts. </text>
<text top="297" left="204" width="3" height="20" font="1"> </text>
<text top="314" left="204" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="332" left="204" width="48" height="20" font="1">analysis </text>
<text top="349" left="204" width="3" height="20" font="1"> </text>
<text top="366" left="204" width="95" height="20" font="4"><b>Size:</b> 10 studies, </text>
<text top="383" left="204" width="55" height="20" font="1">n=42,892 </text>
<text top="142" left="336" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="159" left="336" width="96" height="20" font="1">RAAS blockade,  </text>
<text top="177" left="336" width="58" height="20" font="1">n=20,491  </text>
<text top="194" left="336" width="3" height="20" font="1"> </text>
<text top="211" left="336" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="228" left="336" width="65" height="20" font="1">BB/calcium </text>
<text top="245" left="336" width="67" height="20" font="1">antagonist,  </text>
<text top="263" left="336" width="55" height="20" font="1">n=22,401 </text>
<text top="142" left="456" width="141" height="20" font="4"><b>Inclusion criteria:</b> RCTs </text>
<text top="159" left="456" width="127" height="20" font="1">on the effects of ACEI/ </text>
<text top="177" left="456" width="104" height="20" font="1">ARBs on essential </text>
<text top="194" left="456" width="96" height="20" font="1">hypertensive pts. </text>
<text top="211" left="456" width="3" height="20" font="1"> </text>
<text top="228" left="456" width="137" height="20" font="4"><b>Exclusion criteria:</b> Non-</text>
<text top="245" left="456" width="143" height="20" font="1">RCTs, subjects who were </text>
<text top="263" left="456" width="134" height="20" font="1">not treated with ACEI or </text>
<text top="280" left="456" width="106" height="20" font="1">ARB, and trials not </text>
<text top="297" left="456" width="96" height="20" font="1">mentioning of AF </text>
<text top="314" left="456" width="64" height="20" font="1">prevention. </text>
<text top="332" left="456" width="3" height="20" font="1"> </text>
<text top="143" left="622" width="95" height="20" font="4"><b>1</b>°<b> endpoint:</b> AF </text>
<text top="161" left="622" width="79" height="20" font="1">occurrence or </text>
<text top="178" left="622" width="79" height="20" font="1">reoccurrence. </text>
<text top="144" left="768" width="7" height="18" font="1">•</text>
<text top="143" left="775" width="139" height="20" font="1"> ACEI/ARBs reduced the </text>
<text top="161" left="768" width="150" height="20" font="1">incidence of AF recurrence </text>
<text top="178" left="768" width="117" height="20" font="1">compared to calcium </text>
<text top="195" left="768" width="154" height="20" font="1">antagonists (RR: 0.48; 95% </text>
<text top="212" left="768" width="147" height="20" font="1">CI: 0.40–0.58; p&lt;0.00001) </text>
<text top="229" left="768" width="134" height="20" font="1">or b-blockers (RR: 0.39; </text>
<text top="247" left="768" width="109" height="20" font="1">95% CI: 0.20–0.74; </text>
<text top="264" left="768" width="149" height="20" font="1">p=0.005). ACEI/ARBs may </text>
<text top="281" left="768" width="150" height="20" font="1">reduce the incidence of AF </text>
<text top="298" left="768" width="143" height="20" font="1">recurrence and CHF, with </text>
<text top="316" left="768" width="124" height="20" font="1">fewer serious adverse </text>
<text top="333" left="768" width="148" height="20" font="1">effects, but did not prevent </text>
<text top="350" left="768" width="96" height="20" font="1">new onset of AF. </text>
<text top="142" left="940" width="24" height="20" font="1">N/A </text>
<text top="401" left="98" width="85" height="20" font="1">Hansson et al., </text>
<text top="421" left="98" width="63" height="20" font="1">1999 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(258)</a> </text>
<text top="456" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10030325">10030325</a></text>
<text top="456" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10030325"> </a></text>
<text top="401" left="204" width="95" height="20" font="4"><b>Aim: </b>CAPP Trial </text>
<text top="418" left="204" width="92" height="20" font="1">was designed to </text>
<text top="436" left="204" width="111" height="20" font="1">compare the effects </text>
<text top="453" left="204" width="118" height="20" font="1">of ACE inhibition and </text>
<text top="470" left="204" width="117" height="20" font="1">conventional therapy </text>
<text top="487" left="204" width="115" height="20" font="1">on CV morbidity and </text>
<text top="504" left="204" width="108" height="20" font="1">mortality in pts with </text>
<text top="522" left="204" width="32" height="20" font="1">HTN. </text>
<text top="539" left="204" width="3" height="20" font="1"> </text>
<text top="556" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="573" left="204" width="3" height="20" font="1"> </text>
<text top="591" left="204" width="73" height="20" font="4"><b>Size:</b> 10,985 </text>
<text top="401" left="336" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="418" left="336" width="104" height="20" font="1">Captopril, n=5,592 </text>
<text top="436" left="336" width="3" height="20" font="1"> </text>
<text top="453" left="336" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="470" left="336" width="84" height="20" font="1">5,493 pts were </text>
<text top="487" left="336" width="66" height="20" font="1">allocated to </text>
<text top="504" left="336" width="90" height="20" font="1">diuretics or BBs </text>
<text top="401" left="456" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="418" left="456" width="135" height="20" font="1">Pts aged 25–66 y with a </text>
<text top="436" left="456" width="132" height="20" font="1">measured DBP of ≥100 </text>
<text top="453" left="456" width="128" height="20" font="1">mm Hg on 2 occasions </text>
<text top="470" left="456" width="83" height="20" font="1">were included. </text>
<text top="487" left="456" width="3" height="20" font="4"><b> </b></text>
<text top="504" left="456" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="522" left="456" width="141" height="20" font="1">2º HTN, serum creatinine </text>
<text top="539" left="456" width="150" height="20" font="1">concentration of more than </text>
<text top="556" left="456" width="115" height="20" font="1">150 micromol/L, and </text>
<text top="573" left="456" width="127" height="20" font="1">disorders that required </text>
<text top="591" left="456" width="104" height="20" font="1">treatment with BB. </text>
<text top="402" left="622" width="130" height="20" font="4"><b>1</b>°<b> endpoint:</b> Fatal and </text>
<text top="420" left="622" width="129" height="20" font="1">nonfatal MI and stroke, </text>
<text top="437" left="622" width="120" height="20" font="1">and other CV deaths. </text>
<text top="454" left="622" width="3" height="20" font="1"> </text>
<text top="471" left="622" width="3" height="20" font="1"> </text>
<text top="490" left="622" width="79" height="20" font="4"><b>2</b>°<b> endpoint:</b>  </text>
<text top="507" left="622" width="111" height="20" font="1">New or deteriorated </text>
<text top="524" left="622" width="129" height="20" font="1">IHD and CHF, AF, DM, </text>
<text top="541" left="622" width="122" height="20" font="1">TIA s, and death from </text>
<text top="558" left="622" width="62" height="20" font="1">all causes. </text>
<text top="403" left="768" width="7" height="18" font="1">•</text>
<text top="402" left="775" width="152" height="20" font="1"> Captopril and conventional </text>
<text top="420" left="768" width="139" height="20" font="1">treatment did not differ in </text>
<text top="437" left="768" width="152" height="20" font="1">rates of all cardiac events—</text>
<text top="454" left="768" width="150" height="20" font="1">fatal and nonfatal MI, other </text>
<text top="471" left="768" width="128" height="20" font="1">CV deaths and sudden </text>
<text top="488" left="768" width="137" height="20" font="1">deaths, IHD, CHF, or AF </text>
<text top="506" left="768" width="85" height="20" font="1">(0·94; p=0·30). </text>
<text top="401" left="940" width="24" height="20" font="1">N/A </text>
<text top="609" left="98" width="85" height="20" font="1">Hansson et al., </text>
<text top="628" left="98" width="63" height="20" font="1">1999 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(259)</a> </text>
<text top="663" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10577635">10577635</a></text>
<text top="663" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/10577635"> </a></text>
<text top="608" left="204" width="87" height="20" font="4"><b>Aim:</b> STOPH-2 </text>
<text top="626" left="204" width="102" height="20" font="1">aimed to compare </text>
<text top="643" left="204" width="74" height="20" font="1">the effects of </text>
<text top="660" left="204" width="96" height="20" font="1">conventional and </text>
<text top="677" left="204" width="37" height="20" font="1">newer </text>
<text top="694" left="204" width="93" height="20" font="1">antihypertensive </text>
<text top="712" left="204" width="72" height="20" font="1">drugs on CV </text>
<text top="729" left="204" width="74" height="20" font="1">mortality and </text>
<text top="746" left="204" width="106" height="20" font="1">morbidity in elderly </text>
<text top="763" left="204" width="23" height="20" font="1">pts. </text>
<text top="781" left="204" width="3" height="20" font="1"> </text>
<text top="608" left="336" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="626" left="336" width="106" height="20" font="1">n=2205 pts treated </text>
<text top="643" left="336" width="61" height="20" font="1">with ACEI  </text>
<text top="660" left="336" width="10" height="20" font="1">   </text>
<text top="677" left="336" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="694" left="336" width="68" height="20" font="1">n=2,213 pts </text>
<text top="712" left="336" width="101" height="20" font="1">treated with BB or </text>
<text top="729" left="336" width="43" height="20" font="1">diuretic </text>
<text top="746" left="336" width="84" height="20" font="1">combination or </text>
<text top="763" left="336" width="68" height="20" font="1">n=2,196 pts </text>
<text top="781" left="336" width="96" height="20" font="1">treated with CCB </text>
<text top="608" left="456" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="626" left="456" width="109" height="20" font="1">HTN with BP ≥ 180 </text>
<text top="643" left="456" width="142" height="21" font="1">mm Hg systolic, aged 70–</text>
<text top="660" left="456" width="27" height="20" font="1">84 y </text>
<text top="677" left="456" width="3" height="20" font="1"> </text>
<text top="695" left="456" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="712" left="456" width="139" height="20" font="1">Outside of the age range </text>
<text top="729" left="456" width="39" height="20" font="1">(n=14) </text>
<text top="610" left="622" width="130" height="20" font="4"><b>1</b>°<b> endpoint:</b> CV death </text>
<text top="627" left="622" width="3" height="20" font="1"> </text>
<text top="644" left="622" width="3" height="20" font="1"> </text>
<text top="662" left="622" width="79" height="20" font="4"><b>2</b>°<b> endpoint:</b>  </text>
<text top="680" left="622" width="129" height="20" font="1">CV events, DM and AF </text>
<text top="610" left="768" width="7" height="18" font="1">•</text>
<text top="610" left="775" width="76" height="20" font="1"> Old and new </text>
<text top="627" left="768" width="157" height="20" font="1">antihypertensive drugs were </text>
<text top="644" left="768" width="147" height="20" font="1">similar in prevention of CV </text>
<text top="661" left="768" width="141" height="20" font="1">mortality or major events. </text>
<text top="678" left="768" width="128" height="20" font="1">Decrease in BP was of </text>
<text top="696" left="768" width="137" height="20" font="1">major importance for the </text>
<text top="713" left="768" width="157" height="20" font="1">prevention of CV events. No </text>
<text top="730" left="768" width="147" height="20" font="1">difference in AF frequency </text>
<text top="747" left="768" width="156" height="20" font="1">was found (5.3% with ACEI, </text>
<text top="764" left="768" width="141" height="20" font="1">4.1% with CCB and 5.2% </text>
<text top="782" left="768" width="98" height="20" font="1">with older drugs). </text>
<text top="608" left="940" width="24" height="20" font="1">N/A </text>
</page>
<page number="193" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">193 </text>
<text top="107" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="124" left="204" width="3" height="20" font="1"> </text>
<text top="141" left="204" width="66" height="20" font="4"><b>Size:</b> 6,614 </text>
<text top="159" left="98" width="84" height="20" font="1">Wachtell et al., </text>
<text top="179" left="98" width="63" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#277">(260)</a> </text>
<text top="214" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15734615">15734615</a></text>
<text top="214" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15734615"> </a></text>
<text top="159" left="204" width="83" height="20" font="4"><b>Aim:</b> LIFE trial </text>
<text top="177" left="204" width="109" height="20" font="1">aimed to determine </text>
<text top="194" left="204" width="113" height="20" font="1">whether angiotensin </text>
<text top="211" left="204" width="111" height="20" font="1">II receptor blockade </text>
<text top="228" left="204" width="103" height="20" font="1">is better than beta-</text>
<text top="246" left="204" width="66" height="20" font="1">blockade in </text>
<text top="263" left="204" width="87" height="20" font="1">preventing new-</text>
<text top="280" left="204" width="56" height="20" font="1">onset AF. </text>
<text top="297" left="204" width="3" height="20" font="1"> </text>
<text top="314" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="332" left="204" width="3" height="20" font="1"> </text>
<text top="349" left="204" width="66" height="20" font="4"><b>Size:</b> 9,193 </text>
<text top="159" left="336" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="177" left="336" width="90" height="20" font="1">n=4,298 treated </text>
<text top="194" left="336" width="73" height="20" font="1">with losartan </text>
<text top="211" left="336" width="3" height="20" font="1"> </text>
<text top="228" left="336" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="245" left="336" width="90" height="20" font="1">n=4,182 treated </text>
<text top="263" left="336" width="72" height="20" font="1">with atenolol </text>
<text top="159" left="456" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="177" left="456" width="147" height="20" font="1">Hypertensive pts with LVH </text>
<text top="194" left="456" width="46" height="20" font="1">by echo </text>
<text top="211" left="456" width="3" height="20" font="1"> </text>
<text top="228" left="456" width="139" height="20" font="4"><b>Exclusion criteria:</b> Prior </text>
<text top="245" left="456" width="116" height="20" font="1">AF history in 342 pts </text>
<text top="161" left="622" width="102" height="20" font="4"><b>1</b>°<b> endpoint:</b> new </text>
<text top="178" left="622" width="66" height="20" font="1">onset of AF </text>
<text top="195" left="622" width="3" height="20" font="1"> </text>
<text top="212" left="622" width="3" height="20" font="1"> </text>
<text top="231" left="622" width="109" height="20" font="4"><b>2</b>°<b> endpoint:</b> None </text>
<text top="161" left="768" width="7" height="18" font="1">•</text>
<text top="161" left="775" width="149" height="20" font="1"> New-onset AF occurred in </text>
<text top="178" left="768" width="125" height="20" font="1">150 pts randomized to </text>
<text top="195" left="768" width="150" height="20" font="1">losartan vs. 221 to atenolol </text>
<text top="212" left="768" width="123" height="20" font="1">(6.8 vs.10.1 per 1,000 </text>
<text top="229" left="768" width="157" height="20" font="1">person-y; RR: 0.67; 95% CI: </text>
<text top="247" left="768" width="157" height="20" font="1">0.55–0.83; p&lt;0.001) despite </text>
<text top="264" left="768" width="137" height="20" font="1">similar BP reduction. Pts </text>
<text top="281" left="768" width="154" height="20" font="1">receiving losartan tended to </text>
<text top="298" left="768" width="150" height="20" font="1">stay in sinus rhythm longer </text>
<text top="316" left="768" width="117" height="20" font="1">(p=0.057) than those </text>
<text top="333" left="768" width="103" height="20" font="1">receiving atenolol. </text>
<text top="159" left="940" width="24" height="20" font="1">N/A </text>
<text top="367" left="98" width="88" height="20" font="1">Haywood et al., </text>
<text top="387" left="98" width="63" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(261)</a> </text>
<text top="421" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19926008">19926008</a></text>
<text top="421" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19926008"> </a></text>
<text top="367" left="204" width="111" height="20" font="4"><b>Aim:</b> To investigate </text>
<text top="384" left="204" width="69" height="20" font="1">incidence of </text>
<text top="401" left="204" width="87" height="20" font="1">development of </text>
<text top="418" left="204" width="78" height="20" font="1">AF/AFL in pts </text>
<text top="436" left="204" width="83" height="20" font="1">enrolled in this </text>
<text top="453" left="204" width="107" height="20" font="1">comparative trial of </text>
<text top="470" left="204" width="99" height="20" font="1">antihypertensives </text>
<text top="487" left="204" width="62" height="20" font="1">(ALLHAT). </text>
<text top="504" left="204" width="3" height="20" font="1"> </text>
<text top="522" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="539" left="204" width="3" height="20" font="1"> </text>
<text top="556" left="204" width="73" height="20" font="4"><b>Size:</b> 81,474 </text>
<text top="367" left="336" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="384" left="336" width="72" height="20" font="1">n=42,418 on </text>
<text top="401" left="336" width="49" height="20" font="1">diuretics </text>
<text top="418" left="336" width="3" height="20" font="1"> </text>
<text top="436" left="336" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="453" left="336" width="55" height="20" font="1">n=39,056 </text>
<text top="367" left="456" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="384" left="456" width="127" height="20" font="1">Essential HTN with BP </text>
<text top="401" left="456" width="91" height="20" font="1">&gt;140/90 without </text>
<text top="418" left="456" width="147" height="20" font="1">medications, &gt;180 systolic </text>
<text top="436" left="456" width="96" height="20" font="1">if on medications </text>
<text top="453" left="456" width="3" height="20" font="1"> </text>
<text top="470" left="456" width="132" height="20" font="4"><b>Exclusion criteria:</b> Not </text>
<text top="487" left="456" width="139" height="20" font="1">meeting inclusion criteria </text>
<text top="368" left="622" width="106" height="20" font="4"><b>1</b>°<b> endpoint:</b> ECG </text>
<text top="385" left="622" width="129" height="20" font="1">evidence of AF/AFL on </text>
<text top="402" left="622" width="119" height="20" font="1">follow-up of HTN and </text>
<text top="420" left="622" width="71" height="20" font="1">dyslipidemia </text>
<text top="369" left="768" width="7" height="18" font="1">•</text>
<text top="368" left="775" width="137" height="20" font="1"> AF/AFL occurred in 641 </text>
<text top="385" left="768" width="149" height="20" font="1">pts on follow-up. Incidence </text>
<text top="402" left="768" width="132" height="20" font="1">did not differ by class of </text>
<text top="420" left="768" width="155" height="20" font="1">antihypertensive, other than </text>
<text top="437" left="768" width="148" height="20" font="1">increased frequency in the </text>
<text top="454" left="768" width="157" height="20" font="1">doxazosin group by 33% vs. </text>
<text top="471" left="768" width="115" height="20" font="1">chlorthalidone group </text>
<text top="488" left="768" width="96" height="20" font="1">(p=0.05 after risk </text>
<text top="506" left="768" width="71" height="20" font="1">adjustment). </text>
<text top="369" left="940" width="7" height="18" font="1">•</text>
<text top="368" left="947" width="124" height="20" font="1"> Doxazosin group was </text>
<text top="385" left="940" width="93" height="20" font="1">limited by higher </text>
<text top="402" left="940" width="131" height="20" font="1">cardiac event rates and </text>
<text top="420" left="940" width="130" height="20" font="1">early termination of this </text>
<text top="437" left="940" width="102" height="20" font="1">portion of the trial. </text>
<text top="574" left="98" width="68" height="20" font="1">Julius et al., </text>
<text top="594" left="98" width="69" height="20" font="1">2004 Julius, </text>
<text top="614" left="98" width="59" height="20" font="1">2004 610} </text>
<text top="649" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15207952">15207952</a></text>
<text top="649" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15207952"> </a></text>
<text top="574" left="204" width="111" height="20" font="4"><b>Aim:</b> The Valsartan </text>
<text top="591" left="204" width="94" height="20" font="1">Antihypertensive </text>
<text top="608" left="204" width="85" height="20" font="1">Long-term Use </text>
<text top="626" left="204" width="113" height="20" font="1">Evaluation (VALUE) </text>
<text top="643" left="204" width="110" height="20" font="1">trial: does valsartan </text>
<text top="660" left="204" width="84" height="20" font="1">reduce cardiac </text>
<text top="677" left="204" width="77" height="20" font="1">morbidity and </text>
<text top="694" left="204" width="109" height="20" font="1">mortality more than </text>
<text top="712" left="204" width="101" height="20" font="1">amlodipine for the </text>
<text top="729" left="204" width="109" height="20" font="1">same degree of BP </text>
<text top="746" left="204" width="80" height="20" font="1">reduction in in </text>
<text top="763" left="204" width="107" height="20" font="1">hypertensive pts at </text>
<text top="781" left="204" width="73" height="20" font="1">high CV risk. </text>
<text top="574" left="336" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="591" left="336" width="65" height="20" font="1">n=7,649 on </text>
<text top="608" left="336" width="53" height="20" font="1">valsartan </text>
<text top="626" left="336" width="3" height="20" font="1"> </text>
<text top="643" left="336" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="660" left="336" width="65" height="20" font="1">n=7,596 on </text>
<text top="677" left="336" width="63" height="20" font="1">amlodipine </text>
<text top="574" left="456" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="591" left="456" width="133" height="20" font="1">Hypertensive pts, ≥50 y </text>
<text top="608" left="456" width="93" height="20" font="1">with DM, current </text>
<text top="626" left="456" width="106" height="20" font="1">smoking, high total </text>
<text top="643" left="456" width="144" height="20" font="1">cholesterol, LVH by ECG, </text>
<text top="660" left="456" width="123" height="20" font="1">proteinuria on dipstick </text>
<text top="677" left="456" width="144" height="20" font="1">and CKD (not end-stage)  </text>
<text top="694" left="456" width="3" height="20" font="1"> </text>
<text top="712" left="456" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="729" left="456" width="107" height="20" font="1">ESRD, renal artery </text>
<text top="746" left="456" width="145" height="20" font="1">stenosis, pregnancy, AMI, </text>
<text top="763" left="456" width="144" height="20" font="1">PTCA or CABG within the </text>
<text top="781" left="456" width="110" height="20" font="1">past 3 mo, clinically </text>
<text top="575" left="622" width="122" height="20" font="4"><b>1</b>°<b> endpoint:</b> Cardiac </text>
<text top="592" left="622" width="133" height="20" font="1">mortality, morbidity, HF, </text>
<text top="610" left="622" width="130" height="20" font="1">stroke, all-cause death, </text>
<text top="627" left="622" width="82" height="20" font="1">new onset DM </text>
<text top="644" left="622" width="3" height="20" font="1"> </text>
<text top="661" left="622" width="100" height="20" font="4"><b>Safety endpoint:</b> </text>
<text top="678" left="622" width="124" height="20" font="1">Hypotension, syncope </text>
<text top="696" left="622" width="3" height="20" font="1"> </text>
<text top="714" left="622" width="95" height="20" font="4"><b>2</b>°<b> endpoint: </b>AF </text>
<text top="576" left="768" width="7" height="18" font="1">•</text>
<text top="575" left="775" width="143" height="20" font="1"> AF occurred in 2.4% with </text>
<text top="592" left="768" width="134" height="20" font="1">valsartan and 2.0% with </text>
<text top="610" left="768" width="128" height="20" font="1">amlodipine; p=0.1197.  </text>
<text top="574" left="940" width="24" height="20" font="1">N/A </text>
</page>
<page number="194" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">194 </text>
<text top="107" left="204" width="3" height="20" font="1"> </text>
<text top="124" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="141" left="204" width="3" height="20" font="1"> </text>
<text top="159" left="204" width="73" height="20" font="4"><b>Size:</b> 15,245 </text>
<text top="107" left="456" width="142" height="20" font="1">relevant valvular disease, </text>
<text top="124" left="456" width="140" height="20" font="1">cerebrovascular accident </text>
<text top="141" left="456" width="135" height="20" font="1">in the past 3 mo, severe </text>
<text top="159" left="456" width="132" height="20" font="1">hepatic disease, severe </text>
<text top="176" left="456" width="143" height="20" font="1">chronic renal failure, CHF </text>
<text top="193" left="456" width="152" height="20" font="1">requiring ACEI therapy and </text>
<text top="210" left="456" width="137" height="20" font="1">pts on monotherapy with </text>
<text top="228" left="456" width="148" height="20" font="1">blockers for both CAD and </text>
<text top="245" left="456" width="32" height="20" font="1">HTN. </text>
<text top="264" left="108" width="3" height="19" font="1"> </text>
<text top="298" left="81" width="660" height="24" font="3"><b>Data Supplement 50. RCTs and Meta-analysis Comparing Valvular Heart Disease (Section 9.9) </b></text>
<text top="338" left="125" width="38" height="20" font="4"><b>Study </b></text>
<text top="355" left="114" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="373" left="120" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="390" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="338" left="225" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="355" left="230" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="373" left="224" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="338" left="377" width="38" height="20" font="4"><b>Study </b></text>
<text top="355" left="352" width="88" height="20" font="4"><b>Intervention (# </b></text>
<text top="373" left="350" width="92" height="20" font="4"><b>patients)/Study </b></text>
<text top="390" left="353" width="87" height="20" font="4"><b>Comparator (# </b></text>
<text top="407" left="369" width="55" height="20" font="4"><b>patients) </b></text>
<text top="338" left="480" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="338" left="663" width="64" height="20" font="4"><b>Endpoints </b></text>
<text top="338" left="792" width="117" height="20" font="4"><b>P Value; OR, HR, or </b></text>
<text top="355" left="810" width="81" height="20" font="4"><b>RR; &amp; 95% CI </b></text>
<text top="338" left="937" width="119" height="20" font="4"><b>Study Limitations &amp; </b></text>
<text top="355" left="949" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="425" left="98" width="68" height="20" font="4"><b>SCOPE-AS </b></text>
<text top="442" left="98" width="81" height="20" font="1">Chockalingam </text>
<text top="460" left="98" width="79" height="20" font="1">A, et al., 2004 </text>
<text top="477" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(262)</a> </text>
<text top="494" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15077102?dopt=Citation">15077102</a></text>
<text top="494" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15077102?dopt=Citation"> </a></text>
<text top="425" left="204" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="442" left="204" width="115" height="20" font="1">the clinical tolerance </text>
<text top="460" left="204" width="103" height="20" font="1">and efficacy of the </text>
<text top="477" left="204" width="115" height="20" font="1">ACEI enalapril in the </text>
<text top="494" left="204" width="126" height="20" font="1">setting of symptomatic </text>
<text top="511" left="204" width="64" height="20" font="1">severe AS. </text>
<text top="528" left="204" width="3" height="20" font="1"> </text>
<text top="546" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="563" left="204" width="3" height="20" font="1"> </text>
<text top="580" left="204" width="69" height="20" font="4"><b>Size:</b> 56 pts </text>
<text top="425" left="343" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="442" left="343" width="92" height="20" font="1">Enalapril 2.5 mg </text>
<text top="460" left="343" width="97" height="20" font="1">BID increasing to </text>
<text top="477" left="343" width="83" height="20" font="1">10 mg BID (37 </text>
<text top="494" left="343" width="24" height="20" font="1">pts) </text>
<text top="511" left="343" width="3" height="20" font="1"> </text>
<text top="528" left="343" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="546" left="343" width="93" height="20" font="1">Placebo (19 pts) </text>
<text top="425" left="462" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="442" left="462" width="124" height="20" font="1">Severe aortic stenosis </text>
<text top="460" left="462" width="132" height="20" font="1">(aortic valve area &lt;0.75 </text>
<text top="477" left="462" width="16" height="20" font="1">cm</text>
<text top="478" left="479" width="4" height="13" font="6">2</text>
<text top="477" left="483" width="122" height="20" font="1">, mean aortic gradient </text>
<text top="494" left="462" width="119" height="20" font="1">&gt;50 mm Hg, or aortic </text>
<text top="511" left="462" width="123" height="20" font="1">valve Doppler jet &gt;4.5 </text>
<text top="528" left="462" width="124" height="20" font="1">m/s) and symptomatic </text>
<text top="546" left="462" width="112" height="20" font="1">NYHA class III or IV </text>
<text top="563" left="462" width="105" height="20" font="1">dyspnea or angina </text>
<text top="580" left="462" width="3" height="20" font="1"> </text>
<text top="597" left="462" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="614" left="462" width="128" height="20" font="1">Persistent hypotension </text>
<text top="632" left="462" width="125" height="20" font="1">(SBP &lt;90 or mean BP </text>
<text top="649" left="462" width="106" height="20" font="1">&lt;60), severe mitral </text>
<text top="666" left="462" width="118" height="20" font="1">stenosis (mitral valve </text>
<text top="683" left="462" width="80" height="20" font="1">orifice &lt;1.0 cm</text>
<text top="685" left="543" width="4" height="13" font="6">2</text>
<text top="683" left="547" width="50" height="20" font="1">), known </text>
<text top="701" left="462" width="141" height="20" font="1">intolerance for ACEI, and </text>
<text top="718" left="462" width="138" height="20" font="1">renal dysfunction (serum </text>
<text top="735" left="462" width="130" height="20" font="1">creatinine &gt;2.5 mg/dL). </text>
<text top="426" left="622" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="443" left="622" width="124" height="20" font="1">Improvements in Borg </text>
<text top="461" left="622" width="141" height="20" font="1">dyspnea index and 6-min </text>
<text top="478" left="622" width="122" height="20" font="1">walk distance at 1 mo </text>
<text top="495" left="622" width="3" height="20" font="1"> </text>
<text top="512" left="622" width="100" height="20" font="4"><b>Safety endpoint:</b> </text>
<text top="530" left="622" width="89" height="20" font="1">Development of </text>
<text top="547" left="622" width="70" height="20" font="1">hypotension </text>
<text top="564" left="622" width="3" height="20" font="1"> </text>
<text top="582" left="622" width="142" height="20" font="4"><b>2</b>°<b> endpoint:</b> Minor ACEI </text>
<text top="600" left="622" width="107" height="20" font="1">intolerance, cough, </text>
<text top="617" left="622" width="145" height="20" font="1">presyncope, improvement </text>
<text top="634" left="622" width="139" height="20" font="1">in NYHA class, and echo </text>
<text top="651" left="622" width="66" height="20" font="1">parameters </text>
<text top="427" left="781" width="7" height="18" font="1">•</text>
<text top="426" left="788" width="102" height="20" font="1"> Pts who tolerated </text>
<text top="443" left="781" width="113" height="20" font="1">enalapril (n=34) had </text>
<text top="461" left="781" width="132" height="20" font="1">significant improvement </text>
<text top="478" left="781" width="115" height="20" font="1">in NYHA class, Borg </text>
<text top="495" left="781" width="129" height="20" font="1">index (5.4 ± 1.2 vs. 5.6 </text>
<text top="512" left="781" width="119" height="20" font="1">± 1.7; p=0.03), and 6-</text>
<text top="530" left="781" width="128" height="20" font="1">min walk distance (402 </text>
<text top="547" left="781" width="118" height="20" font="1">± 150 vs. 376 ± 174; </text>
<text top="564" left="781" width="136" height="20" font="1">p=0.003) compared with </text>
<text top="581" left="781" width="64" height="20" font="1">control pts. </text>
<text top="427" left="933" width="7" height="18" font="1">•</text>
<text top="426" left="940" width="88" height="20" font="1"> Treatment with </text>
<text top="443" left="933" width="110" height="20" font="1">enalapril resulted in </text>
<text top="461" left="933" width="117" height="20" font="1">hypotension in 3 of 5 </text>
<text top="478" left="933" width="63" height="20" font="1">pts with LV </text>
<text top="495" left="933" width="89" height="20" font="1">dysfunction and </text>
<text top="512" left="933" width="106" height="20" font="1">congestive HF had </text>
<text top="530" left="933" width="73" height="20" font="1">hypotension. </text>
</page>
<page number="195" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">195 </text>
<text top="107" left="98" width="37" height="20" font="4"><b>SEAS </b></text>
<text top="124" left="98" width="54" height="20" font="1">Rieck ÅE </text>
<text top="141" left="98" width="79" height="20" font="1">Hypertension, </text>
<text top="159" left="98" width="63" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(263)</a> </text>
<text top="176" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22647889">22647889</a></text>
<text top="176" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22647889"> </a></text>
<text top="107" left="204" width="107" height="20" font="4"><b>Aim:</b> To determine </text>
<text top="124" left="204" width="120" height="20" font="1">the impact of HTN on </text>
<text top="141" left="204" width="94" height="20" font="1">LV structure and </text>
<text top="159" left="204" width="88" height="20" font="1">outcome during </text>
<text top="176" left="204" width="115" height="20" font="1">progression of aortic </text>
<text top="193" left="204" width="81" height="20" font="1">valve stenosis </text>
<text top="210" left="204" width="3" height="20" font="1"> </text>
<text top="227" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="245" left="204" width="76" height="20" font="1">observational </text>
<text top="262" left="204" width="126" height="20" font="1">substudy of SEAS trial </text>
<text top="279" left="204" width="3" height="20" font="1"> </text>
<text top="296" left="204" width="83" height="20" font="4"><b>Size:</b> 1616 pts </text>
<text top="107" left="343" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="124" left="343" width="79" height="20" font="1">1,340 pts with </text>
<text top="141" left="343" width="29" height="20" font="1">HTN </text>
<text top="159" left="343" width="3" height="20" font="1"> </text>
<text top="176" left="343" width="101" height="20" font="4"><b>Comparator:</b> 276 </text>
<text top="193" left="343" width="91" height="20" font="1">pts without HTN </text>
<text top="107" left="462" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="124" left="462" width="98" height="20" font="1">45- 85 y who had </text>
<text top="141" left="462" width="124" height="20" font="1">asymptomatic, mild-to-</text>
<text top="159" left="462" width="121" height="20" font="1">moderate aortic valve </text>
<text top="176" left="462" width="141" height="20" font="1">stenosis, as assessed on </text>
<text top="193" left="462" width="133" height="20" font="1">echo, with a peak aortic-</text>
<text top="210" left="462" width="143" height="20" font="1">jet velocity of 2.5–4 m per </text>
<text top="228" left="462" width="136" height="20" font="1">second, were eligible for </text>
<text top="245" left="462" width="57" height="20" font="1">the study. </text>
<text top="108" left="622" width="126" height="20" font="4"><b>1</b>°<b> endpoint:</b> Echo LV </text>
<text top="125" left="622" width="132" height="20" font="1">mass; MACE; mortality  </text>
<text top="109" left="781" width="7" height="18" font="1">•</text>
<text top="108" left="788" width="114" height="20" font="1"> HTN predicted 51% </text>
<text top="125" left="781" width="107" height="20" font="1">higher incidence of </text>
<text top="143" left="781" width="128" height="20" font="1">abnormal LV geometry </text>
<text top="160" left="781" width="97" height="20" font="1">at final study visit </text>
<text top="177" left="781" width="116" height="20" font="1">independent of other </text>
<text top="194" left="781" width="128" height="20" font="1">confounders (p&lt;0.01).  </text>
<text top="213" left="781" width="7" height="18" font="1">•</text>
<text top="213" left="788" width="120" height="20" font="1"> HTN was associated </text>
<text top="230" left="781" width="140" height="20" font="1">with a 56% higher rate of </text>
<text top="247" left="781" width="135" height="20" font="1">ischemic CV events and </text>
<text top="264" left="781" width="101" height="20" font="1">a 2-fold increased </text>
<text top="282" left="781" width="130" height="20" font="1">mortality (both p&lt;0.01). </text>
<text top="109" left="933" width="7" height="18" font="1">•</text>
<text top="108" left="940" width="67" height="20" font="1"> No specific </text>
<text top="125" left="933" width="68" height="20" font="1">randomized </text>
<text top="143" left="933" width="117" height="20" font="1">intervention for HTN. </text>
<text top="314" left="98" width="89" height="20" font="1">Eleid MF, et al., </text>
<text top="334" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(264)</a> </text>
<text top="354" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23956211">23956211</a></text>
<text top="354" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23956211"> </a></text>
<text top="314" left="204" width="119" height="20" font="4"><b>Aim:</b> To evaluate the </text>
<text top="332" left="204" width="120" height="20" font="1">hemodynamic effects </text>
<text top="349" left="204" width="121" height="20" font="1">of vasodilator therapy </text>
<text top="366" left="204" width="103" height="20" font="1">in pts with LGSAS </text>
<text top="383" left="204" width="3" height="20" font="1"> </text>
<text top="400" left="204" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="418" left="204" width="122" height="20" font="1">Nitroprusside infusion </text>
<text top="435" left="204" width="3" height="20" font="1"> </text>
<text top="452" left="204" width="49" height="20" font="4"><b>Size:</b> 24 </text>
<text top="314" left="343" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="332" left="343" width="75" height="20" font="1">Infusion of IV </text>
<text top="349" left="343" width="43" height="20" font="1">sodium </text>
<text top="366" left="343" width="87" height="20" font="1">nitroprusside to </text>
<text top="383" left="343" width="85" height="20" font="1">reduce BP and </text>
<text top="400" left="343" width="92" height="20" font="1">arterial afterload </text>
<text top="418" left="343" width="66" height="20" font="1">(18 pts with </text>
<text top="435" left="343" width="73" height="20" font="1">hypertensive </text>
<text top="452" left="343" width="49" height="20" font="1">LGSAS) </text>
<text top="469" left="343" width="3" height="20" font="1"> </text>
<text top="487" left="343" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="504" left="343" width="50" height="20" font="1">Baseline </text>
<text top="521" left="343" width="100" height="20" font="1">hemodynamics (6 </text>
<text top="538" left="343" width="86" height="20" font="1">pts with low EF </text>
<text top="555" left="343" width="49" height="20" font="1">LGSAS) </text>
<text top="314" left="462" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="332" left="462" width="120" height="20" font="1">Symptomatic pts with </text>
<text top="349" left="462" width="125" height="20" font="1">HTN (aortic SBP &gt;140 </text>
<text top="366" left="462" width="141" height="20" font="1">mm Hg) and low-gradient </text>
<text top="383" left="462" width="134" height="20" font="1">(mean gradient &lt;40 mm </text>
<text top="400" left="462" width="145" height="20" font="1">Hg) severe aortic stenosis </text>
<text top="418" left="462" width="135" height="20" font="1">(aortic valve area &lt;1 cm </text>
<text top="435" left="462" width="125" height="20" font="1">(2)) with preserved EF </text>
<text top="452" left="462" width="66" height="20" font="1">(EF &gt;50%). </text>
<text top="469" left="462" width="3" height="20" font="1"> </text>
<text top="487" left="462" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="504" left="462" width="110" height="20" font="1">Moderate or severe </text>
<text top="521" left="462" width="115" height="20" font="1">concomitant valvular </text>
<text top="538" left="462" width="146" height="20" font="1">heart disease (e.g., aortic, </text>
<text top="555" left="462" width="97" height="20" font="1">mitral or tricuspid </text>
<text top="573" left="462" width="127" height="20" font="1">regurgitation), reduced </text>
<text top="590" left="462" width="146" height="20" font="1">left ventricular EF (&gt;50%), </text>
<text top="607" left="462" width="134" height="20" font="1">age &lt;18 y, and complex </text>
<text top="624" left="462" width="33" height="20" font="1">CHD. </text>
<text top="316" left="622" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="333" left="622" width="124" height="20" font="1">Nitroprusside reduced </text>
<text top="350" left="622" width="105" height="20" font="1">mean PA pressure </text>
<text top="367" left="622" width="133" height="20" font="1">(25±10 mm Hg) and LV </text>
<text top="384" left="622" width="136" height="20" font="1">end-DBP (11±5 mm Hg; </text>
<text top="402" left="622" width="93" height="20" font="1">p&lt;0.001 for both </text>
<text top="419" left="622" width="140" height="20" font="1">compared with baseline). </text>
<text top="436" left="622" width="3" height="20" font="1"> </text>
<text top="454" left="622" width="143" height="20" font="4"><b>2</b>°<b> endpoint:</b> Aortic valve </text>
<text top="472" left="622" width="105" height="20" font="1">area (0.86±0.11 to </text>
<text top="489" left="622" width="101" height="20" font="1">1.02±0.16 cm (2); </text>
<text top="506" left="622" width="111" height="20" font="1">p=0.001) and mean </text>
<text top="523" left="622" width="130" height="20" font="1">gradient (27±5 to 29±6 </text>
<text top="540" left="622" width="92" height="20" font="1">mm Hg; p=0.02) </text>
<text top="558" left="622" width="82" height="20" font="1">increased with </text>
<text top="575" left="622" width="77" height="20" font="1">nitroprusside. </text>
<text top="316" left="781" width="7" height="18" font="1">•</text>
<text top="316" left="788" width="131" height="20" font="1"> Treatment of HTN with </text>
<text top="333" left="781" width="107" height="20" font="1">vasodilator therapy </text>
<text top="350" left="781" width="126" height="20" font="1">results in a lowering of </text>
<text top="367" left="781" width="120" height="20" font="1">the total LV afterload, </text>
<text top="384" left="781" width="121" height="20" font="1">with a decrease in LV </text>
<text top="402" left="781" width="132" height="20" font="1">filling pressures and PA </text>
<text top="419" left="781" width="61" height="20" font="1">pressures. </text>
<text top="316" left="933" width="7" height="18" font="1">•</text>
<text top="316" left="940" width="96" height="20" font="1"> No translation to </text>
<text top="333" left="933" width="119" height="20" font="1">clinical or ambulatory </text>
<text top="350" left="933" width="90" height="20" font="1">vasodilator use. </text>
<text top="642" left="98" width="66" height="20" font="4"><b>RIAS Trial  </b></text>
<text top="662" left="98" width="72" height="20" font="1">Bull S, et al., </text>
<text top="682" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(265)</a> </text>
<text top="702" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=25796267">25796267</a></text>
<text top="702" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=25796267"> </a></text>
<text top="642" left="204" width="116" height="20" font="4"><b>Aim:</b> To determine if </text>
<text top="659" left="204" width="85" height="20" font="1">ACEIs improve </text>
<text top="677" left="204" width="93" height="20" font="1">outcomes in AS. </text>
<text top="694" left="204" width="3" height="20" font="1"> </text>
<text top="711" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="728" left="204" width="3" height="20" font="1"> </text>
<text top="745" left="204" width="56" height="20" font="4"><b>Size:</b> 100 </text>
<text top="642" left="343" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="659" left="343" width="94" height="20" font="1">Ramipril ramped </text>
<text top="677" left="343" width="103" height="20" font="1">up from 2.5 to 5 to </text>
<text top="694" left="343" width="96" height="20" font="1">10 mg for 1 y (50 </text>
<text top="711" left="343" width="24" height="20" font="1">pts) </text>
<text top="728" left="343" width="3" height="20" font="1"> </text>
<text top="745" left="343" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="763" left="343" width="93" height="20" font="1">Placebo (50 pts) </text>
<text top="642" left="462" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="659" left="462" width="129" height="20" font="1">&gt;18 y with moderate or </text>
<text top="677" left="462" width="122" height="20" font="1">severe aortic stenosis </text>
<text top="694" left="462" width="108" height="20" font="1">(valve area &lt;1.5 cm</text>
<text top="695" left="571" width="4" height="13" font="6">2</text>
<text top="694" left="575" width="21" height="20" font="1">, or </text>
<text top="711" left="462" width="125" height="20" font="1">peak velocity &gt;3.0 m/s </text>
<text top="728" left="462" width="138" height="20" font="1">[peak valve gradient &gt;36 </text>
<text top="745" left="462" width="120" height="20" font="1">mm Hg]), 2 who were </text>
<text top="763" left="462" width="136" height="20" font="1">asymptomatic as judged </text>
<text top="780" left="462" width="143" height="20" font="1">by pt-reported symptoms, </text>
<text top="643" left="622" width="124" height="20" font="4"><b>1</b>°<b> endpoint:</b> Adverse </text>
<text top="660" left="622" width="101" height="20" font="1">events; laboratory </text>
<text top="678" left="622" width="137" height="20" font="1">abnormalities; change in </text>
<text top="695" left="622" width="137" height="20" font="1">LVM from baseline to 12 </text>
<text top="712" left="622" width="133" height="20" font="1">mo measured by CMR.  </text>
<text top="729" left="622" width="3" height="20" font="1"> </text>
<text top="748" left="622" width="135" height="20" font="4"><b>2</b>°<b> endpoint:</b> Change in </text>
<text top="765" left="622" width="124" height="20" font="1">LV EF and function by </text>
<text top="782" left="622" width="145" height="20" font="1">CMR and echo, change in </text>
<text top="644" left="781" width="7" height="18" font="1">•</text>
<text top="643" left="788" width="117" height="20" font="1"> Reduction in LVM in </text>
<text top="660" left="781" width="118" height="20" font="1">the ramipril group vs. </text>
<text top="678" left="781" width="120" height="20" font="1">placebo group (mean </text>
<text top="695" left="781" width="129" height="20" font="1">change -3.9 vs. +4.5 g, </text>
<text top="712" left="781" width="134" height="20" font="1">respectively; p=0.0057); </text>
<text top="729" left="781" width="94" height="20" font="1">preserved tissue </text>
<text top="747" left="781" width="134" height="20" font="1">Doppler systolic velocity </text>
<text top="764" left="781" width="130" height="20" font="1">compared with placebo </text>
<text top="781" left="781" width="108" height="20" font="1">(+0.0 vs. -0.5 cm/s; </text>
<text top="644" left="933" width="7" height="18" font="1">•</text>
<text top="643" left="940" width="90" height="20" font="1"> A larger clinical </text>
<text top="660" left="933" width="87" height="20" font="1">outcome trial to </text>
<text top="678" left="933" width="123" height="20" font="1">confirm these findings </text>
<text top="695" left="933" width="95" height="20" font="1">and explore their </text>
<text top="712" left="933" width="109" height="20" font="1">clinical relevance is </text>
<text top="729" left="933" width="52" height="20" font="1">required. </text>
</page>
<page number="196" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">196 </text>
<text top="107" left="462" width="120" height="20" font="1">and who did not have </text>
<text top="124" left="462" width="111" height="20" font="1">indications for valve </text>
<text top="141" left="462" width="119" height="20" font="1">replacement surgery. </text>
<text top="159" left="462" width="3" height="20" font="1"> </text>
<text top="176" left="462" width="135" height="20" font="4"><b>Exclusion criteria:</b> Any </text>
<text top="193" left="462" width="131" height="20" font="1">other significant (&gt;mild) </text>
<text top="210" left="462" width="123" height="20" font="1">VHD, excess hypo- or </text>
<text top="228" left="462" width="115" height="20" font="1">HTN (BP &lt;100/40 or </text>
<text top="245" left="462" width="106" height="20" font="1">&gt;200/110 mm Hg). </text>
<text top="262" left="462" width="130" height="20" font="1">Intolerance of ACEIs or </text>
<text top="279" left="462" width="143" height="20" font="1">ARBs or their prescription </text>
<text top="296" left="462" width="129" height="20" font="1">over the previous 3 mo </text>
<text top="107" left="622" width="117" height="20" font="1">BNP); and change in </text>
<text top="124" left="622" width="108" height="20" font="1">distance walked on </text>
<text top="141" left="622" width="146" height="20" font="1">exercise tolerance testing. </text>
<text top="107" left="781" width="119" height="20" font="1">p=0.04); trend to less </text>
<text top="124" left="781" width="135" height="20" font="1">progression of the aortic </text>
<text top="141" left="781" width="133" height="20" font="1">stenosis (valve area 0.0 </text>
<text top="159" left="781" width="16" height="20" font="1">cm</text>
<text top="160" left="797" width="4" height="13" font="6">2</text>
<text top="159" left="802" width="63" height="20" font="1"> vs. -0.2 cm</text>
<text top="160" left="865" width="4" height="13" font="6">2</text>
<text top="159" left="870" width="37" height="20" font="1"> in the </text>
<text top="176" left="781" width="130" height="20" font="1">placebo arm; p=0.067). </text>
<text top="314" left="98" width="93" height="20" font="1">Scognamiglio R, </text>
<text top="334" left="98" width="37" height="20" font="1">et al.,  </text>
<text top="354" left="98" width="63" height="20" font="1">1994 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(266)</a> </text>
<text top="374" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8058074">8058074</a></text>
<text top="374" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=8058074"> </a></text>
<text top="314" left="204" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="332" left="204" width="110" height="20" font="1">whether vasodilator </text>
<text top="349" left="204" width="106" height="20" font="1">therapy reduces or </text>
<text top="366" left="204" width="108" height="20" font="1">delays the need for </text>
<text top="383" left="204" width="103" height="20" font="1">valve replacement </text>
<text top="400" left="204" width="3" height="20" font="1"> </text>
<text top="418" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="435" left="204" width="3" height="20" font="1"> </text>
<text top="452" left="204" width="56" height="20" font="4"><b>Size:</b> 143 </text>
<text top="314" left="343" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="332" left="343" width="96" height="20" font="1">Nifedipine 20 mg </text>
<text top="349" left="343" width="84" height="20" font="1">Q12 H (69 pts) </text>
<text top="366" left="343" width="3" height="20" font="1"> </text>
<text top="383" left="343" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="400" left="343" width="92" height="20" font="1">Digoxin 0.25 mg </text>
<text top="418" left="343" width="74" height="20" font="1">daily (74 pts) </text>
<text top="314" left="462" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="332" left="462" width="126" height="20" font="1">Asymptomatic pts with </text>
<text top="349" left="462" width="136" height="20" font="1">isolated, chronic, severe </text>
<text top="366" left="462" width="129" height="20" font="1">aortic regurgitation and </text>
<text top="383" left="462" width="103" height="20" font="1">normal LV systolic </text>
<text top="400" left="462" width="46" height="20" font="1">function </text>
<text top="418" left="462" width="3" height="20" font="1"> </text>
<text top="435" left="462" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="452" left="462" width="96" height="20" font="1">Worsening aortic </text>
<text top="469" left="462" width="141" height="20" font="1">regurgitation within 6 mo, </text>
<text top="487" left="462" width="129" height="20" font="1">DBP above 90 mm Hg, </text>
<text top="504" left="462" width="146" height="20" font="1">CAD, aortic valve gradient </text>
<text top="521" left="462" width="107" height="20" font="1">≥ 20 mm Hg, other </text>
<text top="538" left="462" width="121" height="20" font="1">valvular or CHD, poor </text>
<text top="555" left="462" width="138" height="20" font="1">quality echo or an LV EF </text>
<text top="573" left="462" width="39" height="20" font="1">&lt;50%. </text>
<text top="316" left="622" width="137" height="20" font="4"><b>1</b>°<b> endpoint:</b> Frequency </text>
<text top="333" left="622" width="117" height="20" font="1">of valve replacement </text>
<text top="316" left="781" width="7" height="18" font="1">•</text>
<text top="316" left="788" width="114" height="20" font="1"> At 6 y, a 34% of the </text>
<text top="333" left="781" width="101" height="20" font="1">digoxin group had </text>
<text top="350" left="781" width="94" height="20" font="1">undergone valve </text>
<text top="367" left="781" width="121" height="20" font="1">replacement, but only </text>
<text top="384" left="781" width="118" height="20" font="1">15% of the nifedipine </text>
<text top="402" left="781" width="91" height="20" font="1">group (p&lt;0.001) </text>
<text top="316" left="933" width="7" height="18" font="1">•</text>
<text top="316" left="940" width="107" height="20" font="1"> No placebo group, </text>
<text top="333" left="933" width="117" height="20" font="1">and digoxin is a poor </text>
<text top="350" left="933" width="103" height="20" font="1">comparator due to </text>
<text top="367" left="933" width="114" height="20" font="1">toxicity which is now </text>
<text top="384" left="933" width="67" height="20" font="1">recognized. </text>
<text top="591" left="98" width="82" height="20" font="1">Evangelista A, </text>
<text top="610" left="98" width="64" height="20" font="1">et al., 2005 </text>
<text top="630" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(267)</a> </text>
<text top="650" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16192479">16192479</a></text>
<text top="650" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16192479"> </a></text>
<text top="591" left="204" width="111" height="20" font="4"><b>Aim:</b> To identify the </text>
<text top="608" left="204" width="104" height="20" font="1">possible beneficial </text>
<text top="625" left="204" width="116" height="20" font="1">effects of vasodilator </text>
<text top="642" left="204" width="126" height="20" font="1">therapy on LV function </text>
<text top="659" left="204" width="93" height="20" font="1">and the need for </text>
<text top="677" left="204" width="66" height="20" font="1">aortic-valve </text>
<text top="694" left="204" width="75" height="20" font="1">replacement. </text>
<text top="711" left="204" width="3" height="20" font="1"> </text>
<text top="728" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="745" left="204" width="3" height="20" font="1"> </text>
<text top="763" left="204" width="69" height="20" font="4"><b>Size:</b> 95 pts </text>
<text top="591" left="343" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="608" left="343" width="96" height="20" font="1">Nifedipine 20 mg </text>
<text top="625" left="343" width="96" height="20" font="1">Q12 H or enalpril </text>
<text top="642" left="343" width="87" height="20" font="1">20 mg daily (32 </text>
<text top="659" left="343" width="96" height="20" font="1">pts nifedipine, 32 </text>
<text top="677" left="343" width="74" height="20" font="1">pts enalapril) </text>
<text top="694" left="343" width="3" height="20" font="1"> </text>
<text top="711" left="343" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="728" left="343" width="93" height="20" font="1">Placebo (31 pts) </text>
<text top="591" left="462" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="608" left="462" width="116" height="20" font="1">Consecutive pts with </text>
<text top="625" left="462" width="129" height="20" font="1">asymptomatic, chronic, </text>
<text top="642" left="462" width="146" height="20" font="1">severe aortic regurgitation </text>
<text top="659" left="462" width="130" height="20" font="1">and normal LV function </text>
<text top="677" left="462" width="3" height="20" font="1"> </text>
<text top="694" left="462" width="144" height="20" font="4"><b>Exclusion criteria:</b> LVEF </text>
<text top="711" left="462" width="136" height="20" font="1">&lt;50%, AF, CAD or other </text>
<text top="728" left="462" width="83" height="20" font="1">nonaortic VHD </text>
<text top="592" left="622" width="137" height="20" font="4"><b>1</b>°<b> endpoint:</b> Frequency </text>
<text top="609" left="622" width="117" height="20" font="1">of valve replacement </text>
<text top="592" left="781" width="7" height="18" font="1">•</text>
<text top="592" left="788" width="113" height="20" font="1"> Rate of aortic-valve </text>
<text top="609" left="781" width="135" height="20" font="1">replacement was similar </text>
<text top="626" left="781" width="134" height="20" font="1">among the groups: 39% </text>
<text top="643" left="781" width="112" height="20" font="1">in the control group, </text>
<text top="660" left="781" width="111" height="20" font="1">50% in the enalapril </text>
<text top="678" left="781" width="38" height="20" font="1">group, </text>
<text top="695" left="781" width="85" height="20" font="1">and 41% in the </text>
<text top="712" left="781" width="91" height="20" font="1">nifedipine group </text>
<text top="729" left="781" width="53" height="20" font="1">(p=0.62). </text>
<text top="591" left="933" width="24" height="20" font="1">N/A </text>
</page>
<page number="197" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">197 </text>
<text top="107" left="98" width="93" height="20" font="1">Scognamiglio R, </text>
<text top="127" left="98" width="64" height="20" font="1">et al., 1994 </text>
<text top="147" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(266)</a> </text>
<text top="166" left="98" width="48" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8058074">8058074</a></text>
<text top="166" left="145" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8058074"> </a></text>
<text top="107" left="204" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="124" left="204" width="110" height="20" font="1">whether vasodilator </text>
<text top="141" left="204" width="114" height="20" font="1">therapy delays need </text>
<text top="159" left="204" width="121" height="20" font="1">for valve replacement </text>
<text top="176" left="204" width="58" height="20" font="1">in pts with </text>
<text top="193" left="204" width="120" height="20" font="1">asymptomatic severe </text>
<text top="210" left="204" width="24" height="20" font="1">AR. </text>
<text top="227" left="204" width="3" height="20" font="1"> </text>
<text top="245" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="262" left="204" width="3" height="20" font="1"> </text>
<text top="279" left="204" width="76" height="20" font="4"><b>Size:</b> 143 pts<b> </b></text>
<text top="107" left="343" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="124" left="343" width="87" height="20" font="1">69 pts received </text>
<text top="141" left="343" width="56" height="20" font="1">nifedipine </text>
<text top="159" left="343" width="3" height="20" font="1"> </text>
<text top="176" left="343" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="193" left="343" width="87" height="20" font="1">74 pts received </text>
<text top="210" left="343" width="42" height="20" font="1">digoxin<b> </b></text>
<text top="107" left="462" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="124" left="462" width="76" height="20" font="1">Severe aortic </text>
<text top="141" left="462" width="114" height="20" font="1">regurgitation without </text>
<text top="159" left="462" width="59" height="20" font="1">symptoms </text>
<text top="176" left="462" width="3" height="20" font="1"> </text>
<text top="193" left="462" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="210" left="462" width="94" height="20" font="1">DBP &gt;90, recent </text>
<text top="227" left="462" width="107" height="20" font="1">worsening of aortic </text>
<text top="245" left="462" width="145" height="20" font="1">regurgitation, mixed aortic </text>
<text top="262" left="462" width="89" height="20" font="1">stenosis / aortic </text>
<text top="279" left="462" width="109" height="20" font="1">regurgitation or any </text>
<text top="296" left="462" width="137" height="20" font="1">additional valve disease, </text>
<text top="314" left="462" width="62" height="20" font="1">LVEF &lt;50.<b> </b></text>
<text top="108" left="622" width="138" height="20" font="4"><b>1</b>°<b> endpoint:</b> Worsening </text>
<text top="125" left="622" width="139" height="20" font="1">symptoms, LVEF decline </text>
<text top="143" left="622" width="145" height="20" font="1">to &lt;50% or both, requiring </text>
<text top="160" left="622" width="103" height="20" font="1">valve replacement </text>
<text top="177" left="622" width="48" height="20" font="1">surgery <b> </b></text>
<text top="109" left="781" width="7" height="18" font="1">•</text>
<text top="108" left="788" width="113" height="20" font="1"> 15% met criteria for </text>
<text top="125" left="781" width="128" height="20" font="1">valve replacement with </text>
<text top="143" left="781" width="128" height="20" font="1">nifedipine, but 34% did </text>
<text top="160" left="781" width="124" height="20" font="1">with digoxin (p&lt;0.001) </text>
<text top="109" left="933" width="7" height="18" font="1">•</text>
<text top="108" left="940" width="113" height="20" font="1"> No placebo control. </text>
<text top="332" left="98" width="82" height="20" font="1">Evangelista A, </text>
<text top="351" left="98" width="90" height="20" font="1">et al., 2005 (14) </text>
<text top="371" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16192479">16192479</a></text>
<text top="371" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16192479"> </a></text>
<text top="332" left="204" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="349" left="204" width="110" height="20" font="1">whether vasodilator </text>
<text top="366" left="204" width="114" height="20" font="1">therapy delays need </text>
<text top="383" left="204" width="121" height="20" font="1">for valve replacement </text>
<text top="400" left="204" width="58" height="20" font="1">in pts with </text>
<text top="418" left="204" width="120" height="20" font="1">asymptomatic severe </text>
<text top="435" left="204" width="24" height="20" font="1">AR. </text>
<text top="452" left="204" width="3" height="20" font="1"> </text>
<text top="469" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="487" left="204" width="3" height="20" font="1"> </text>
<text top="504" left="204" width="69" height="20" font="4"><b>Size:</b> 95 pts </text>
<text top="332" left="343" width="94" height="20" font="4"><b>Intervention</b>: 32 </text>
<text top="349" left="343" width="70" height="20" font="1">pts received </text>
<text top="366" left="343" width="90" height="20" font="1">enalapril; 32 pts </text>
<text top="383" left="343" width="106" height="20" font="1">received nifedipine </text>
<text top="400" left="343" width="3" height="20" font="1"> </text>
<text top="418" left="343" width="84" height="20" font="4"><b>Comparators: </b></text>
<text top="435" left="343" width="87" height="20" font="1">31 pts received </text>
<text top="452" left="343" width="46" height="20" font="1">placebo<b> </b></text>
<text top="332" left="462" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="349" left="462" width="76" height="20" font="1">Severe aortic </text>
<text top="366" left="462" width="114" height="20" font="1">regurgitation without </text>
<text top="383" left="462" width="59" height="20" font="1">symptoms </text>
<text top="400" left="462" width="3" height="20" font="1"> </text>
<text top="418" left="462" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="435" left="462" width="58" height="20" font="1">Not listed.<b> </b></text>
<text top="333" left="622" width="138" height="20" font="4"><b>1</b>°<b> endpoint:</b> Worsening </text>
<text top="350" left="622" width="139" height="20" font="1">symptoms, LVEF decline </text>
<text top="367" left="622" width="145" height="20" font="1">to &lt;50% or both, requiring </text>
<text top="384" left="622" width="103" height="20" font="1">valve replacement </text>
<text top="402" left="622" width="48" height="20" font="1">surgery <b> </b></text>
<text top="333" left="781" width="7" height="18" font="1">•</text>
<text top="333" left="788" width="113" height="20" font="1"> 41% met criteria for </text>
<text top="350" left="781" width="128" height="20" font="1">valve replacement with </text>
<text top="367" left="781" width="132" height="20" font="1">nifedipine, 50% did with </text>
<text top="384" left="781" width="139" height="20" font="1">enalapril, and 39% in the </text>
<text top="402" left="781" width="125" height="20" font="1">control group (p=0.62) </text>
<text top="333" left="933" width="7" height="18" font="1">•</text>
<text top="333" left="940" width="78" height="20" font="1"> BP of 145/75 </text>
<text top="350" left="933" width="118" height="20" font="1">average between the </text>
<text top="367" left="933" width="126" height="20" font="1">3 groups, indicate lack </text>
<text top="384" left="933" width="110" height="20" font="1">of severity. Post-Rx </text>
<text top="402" left="933" width="105" height="20" font="1">BP is not reported. </text>
<text top="523" left="108" width="3" height="19" font="1"> </text>
<text top="557" left="81" width="480" height="24" font="3"><b>Data Supplement 51. RCTs Comparing Race/Ethnicity (Section 10.1) </b></text>
<text top="597" left="125" width="38" height="20" font="4"><b>Study </b></text>
<text top="614" left="113" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="632" left="119" width="48" height="20" font="4"><b>Author; </b></text>
<text top="649" left="97" width="92" height="20" font="4"><b>Year Published</b> </text>
<text top="597" left="226" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="614" left="231" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="632" left="225" width="86" height="20" font="4"><b>Study Size (N)</b> </text>
<text top="597" left="362" width="111" height="20" font="4"><b>Patient Population</b> </text>
<text top="597" left="535" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="614" left="553" width="76" height="20" font="4"><b>(# patients) / </b></text>
<text top="632" left="535" width="111" height="20" font="4"><b>Study Comparator </b></text>
<text top="649" left="556" width="69" height="20" font="4"><b>(# patients)</b> </text>
<text top="597" left="736" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="614" left="720" width="137" height="20" font="4"><b>(Absolute Event Rates, </b></text>
<text top="632" left="726" width="126" height="20" font="4"><b>P value; OR or RR; &amp; </b></text>
<text top="649" left="765" width="48" height="20" font="4"><b>95% CI)</b> </text>
<text top="598" left="899" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="616" left="932" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="633" left="937" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="650" left="957" width="59" height="20" font="4"><b>Summary</b> </text>
<text top="668" left="96" width="92" height="20" font="1">Leenen F, et al., </text>
<text top="685" left="96" width="63" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(268)</a> </text>
<text top="702" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16864749">16864749</a></text>
<text top="702" left="150" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16864749"> </a></text>
<text top="668" left="204" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="685" left="204" width="98" height="20" font="1">comparison of an </text>
<text top="702" left="204" width="115" height="20" font="1">alpha blocker, ACEI, </text>
<text top="720" left="204" width="77" height="20" font="1">or CCB, each </text>
<text top="737" left="204" width="82" height="20" font="1">compared to a </text>
<text top="754" left="204" width="119" height="20" font="1">thiazide-type diuretic. </text>
<text top="771" left="204" width="89" height="20" font="1">This is post hoc </text>
<text top="788" left="204" width="117" height="20" font="1">comparison between </text>
<text top="670" left="346" width="7" height="18" font="1">•</text>
<text top="669" left="352" width="37" height="20" font="1"> &gt;50 y </text>
<text top="688" left="346" width="7" height="18" font="1">•</text>
<text top="687" left="352" width="115" height="20" font="1"> Lisinopril (n=9,054); </text>
<text top="705" left="346" width="107" height="20" font="1">Amlodipine (9,048) </text>
<text top="724" left="346" width="7" height="18" font="1">•</text>
<text top="723" left="352" width="101" height="20" font="1"> African American </text>
<text top="740" left="346" width="87" height="20" font="1">15,085 (35.5%) </text>
<text top="759" left="346" width="7" height="18" font="1">•</text>
<text top="759" left="352" width="126" height="20" font="1"> White 11,580 (47.0%) </text>
<text top="670" left="503" width="7" height="18" font="1">•</text>
<text top="669" left="510" width="139" height="20" font="1"> Amlodipine vs. Lisinopril </text>
<text top="670" left="691" width="7" height="18" font="1">•</text>
<text top="669" left="698" width="167" height="20" font="1"> No significant difference in 1° </text>
<text top="686" left="691" width="170" height="20" font="1">outcome (nonfatal MI and fatal </text>
<text top="704" left="691" width="150" height="20" font="1">CHD) or other prespecified </text>
<text top="721" left="691" width="60" height="20" font="1">outcomes: </text>
<text top="740" left="691" width="7" height="18" font="1">•</text>
<text top="739" left="698" width="130" height="20" font="1"> CHD, 1° outcome plus </text>
<text top="756" left="691" width="188" height="20" font="1">revascularization and hospitalized </text>
<text top="670" left="899" width="7" height="18" font="1">•</text>
<text top="669" left="906" width="124" height="20" font="1"> In African Americans, </text>
<text top="686" left="899" width="154" height="20" font="1">Lisinopril less effective than </text>
<text top="704" left="899" width="154" height="20" font="1">amlodipine for BP reduction </text>
<text top="721" left="899" width="175" height="20" font="1">(mean follow-up BP 2.7/1.6 mm </text>
<text top="738" left="899" width="175" height="20" font="1">Hg higher with Lisinopril) and in </text>
<text top="755" left="899" width="150" height="20" font="1">reducing strokes (RR:1.51; </text>
<text top="772" left="899" width="133" height="20" font="1">95% CI: 1.22–1.86) and </text>
</page>
<page number="198" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">198 </text>
<text top="107" left="204" width="115" height="20" font="1">CCB vs. ACEI incl in </text>
<text top="124" left="204" width="89" height="20" font="1">race subgroup.  </text>
<text top="141" left="204" width="3" height="20" font="1"> </text>
<text top="159" left="204" width="73" height="20" font="4"><b>Size</b>: 42,418 </text>
<text top="107" left="691" width="159" height="20" font="1">angina, composite CVD, HF, </text>
<text top="124" left="691" width="124" height="20" font="1">ESRD, except strokes </text>
<text top="107" left="899" width="174" height="20" font="1">combined CVD (RR: 1.13; 95% </text>
<text top="124" left="899" width="130" height="20" font="1">CI:1.02–1.24; p=0.025) </text>
<text top="177" left="96" width="86" height="20" font="1">Wright JT et al. </text>
<text top="194" left="96" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(269)</a> </text>
<text top="211" left="96" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18227370?dopt=Citation">18227370 </a></text>
<text top="177" left="204" width="102" height="20" font="4"><b>Study type</b>: Race </text>
<text top="194" left="204" width="122" height="20" font="1">subgroup comparison </text>
<text top="211" left="204" width="123" height="20" font="1">of RCT comparison of </text>
<text top="228" left="204" width="93" height="20" font="1">an ACEI or CCB </text>
<text top="246" left="204" width="82" height="20" font="1">compared to a </text>
<text top="263" left="204" width="116" height="20" font="1">thiazide-type diuretic </text>
<text top="280" left="204" width="105" height="20" font="1">on nonfatal or fatal </text>
<text top="297" left="204" width="88" height="20" font="1">CHD in pts with </text>
<text top="314" left="204" width="114" height="20" font="1">metabolic syndrome </text>
<text top="178" left="346" width="7" height="18" font="1">•</text>
<text top="178" left="352" width="37" height="20" font="1"> &gt;50 y </text>
<text top="197" left="346" width="7" height="18" font="1">•</text>
<text top="196" left="352" width="101" height="20" font="1"> African American </text>
<text top="213" left="346" width="55" height="20" font="1">n=12,818 </text>
<text top="232" left="346" width="7" height="18" font="1">•</text>
<text top="232" left="352" width="127" height="20" font="1"> Non-African American </text>
<text top="249" left="346" width="55" height="20" font="1">n=24,473 </text>
<text top="178" left="503" width="7" height="18" font="1">•</text>
<text top="178" left="510" width="105" height="20" font="1"> Chlorthalidone vs. </text>
<text top="195" left="503" width="134" height="20" font="1">Amlodipine, or Lisinopril </text>
<text top="178" left="691" width="7" height="18" font="1">•</text>
<text top="178" left="698" width="160" height="20" font="1"> No difference in 1° outcome </text>
<text top="195" left="691" width="191" height="20" font="1">(nonfatal MI and fatal CHD). Other </text>
<text top="212" left="691" width="130" height="20" font="1">prespecified outcomes: </text>
<text top="231" left="691" width="7" height="18" font="1">•</text>
<text top="231" left="698" width="130" height="20" font="1"> CHD, 1° outcome plus </text>
<text top="248" left="691" width="188" height="20" font="1">revascularization and hospitalized </text>
<text top="265" left="691" width="176" height="20" font="1">angina, composite CVD, stroke, </text>
<text top="282" left="691" width="61" height="20" font="1">HF, ESRD </text>
<text top="178" left="899" width="7" height="18" font="1">•</text>
<text top="178" left="906" width="145" height="20" font="1"> In African Americans with </text>
<text top="195" left="899" width="145" height="20" font="1">metabolic/cardiometabolic </text>
<text top="212" left="899" width="164" height="20" font="1">syndrome: Amlodipine similar </text>
<text top="229" left="899" width="131" height="20" font="1">for chlorthalidone for all </text>
<text top="247" left="899" width="156" height="20" font="1">outcomes but inferior for HF </text>
<text top="264" left="899" width="169" height="20" font="1">(HR: 1.50; 95% CI: 1.18–1.90) </text>
<text top="281" left="899" width="169" height="20" font="1">and combined CVD (HR: 1.14; </text>
<text top="298" left="899" width="165" height="20" font="1">95% CI: 1.00–1.29). Lisinopril </text>
<text top="316" left="899" width="174" height="20" font="1">less effective for SBP reduction </text>
<text top="333" left="899" width="160" height="20" font="1">by 4 mm Hg; combined CHD </text>
<text top="350" left="899" width="173" height="20" font="1">(HR: 1.19 (95% CI: 1.01, 1.40); </text>
<text top="367" left="899" width="174" height="20" font="1">combined CVD (HR: 1.24; 95% </text>
<text top="384" left="899" width="150" height="20" font="1">CI: 1.09–1.40); stroke (HR: </text>
<text top="402" left="899" width="163" height="20" font="1">1.37; 95% CI: 1.07–1.76); HF </text>
<text top="419" left="899" width="172" height="20" font="1">(HR: 1.49; 95% CI: 1.17–1.90); </text>
<text top="436" left="899" width="168" height="20" font="1">and ESRD (HR: 1.70; 95% CI: </text>
<text top="453" left="899" width="62" height="20" font="1">1.13–2.55) </text>
<text top="471" left="96" width="93" height="20" font="1">Wright JT, et al., </text>
<text top="488" left="96" width="63" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(270)</a> </text>
<text top="506" left="96" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19433694?dopt=Citation">19433694</a></text>
<text top="506" left="150" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19433694?dopt=Citation"> </a></text>
<text top="471" left="204" width="102" height="20" font="4"><b>Study type</b>: Race </text>
<text top="488" left="204" width="122" height="20" font="1">subgroup comparison </text>
<text top="506" left="204" width="123" height="20" font="1">of RCT comparison of </text>
<text top="523" left="204" width="123" height="20" font="1">an alpha blocker vs. a </text>
<text top="540" left="204" width="116" height="20" font="1">thiazide-type diuretic </text>
<text top="557" left="204" width="3" height="20" font="1"> </text>
<text top="574" left="204" width="66" height="20" font="4"><b>Size</b>: 9,061 </text>
<text top="473" left="346" width="7" height="18" font="1">•</text>
<text top="472" left="352" width="37" height="20" font="1"> &gt;50 y </text>
<text top="491" left="346" width="7" height="18" font="1">•</text>
<text top="491" left="352" width="87" height="20" font="1"> (35.5% African </text>
<text top="508" left="346" width="59" height="20" font="1">American) </text>
<text top="473" left="503" width="7" height="18" font="1">•</text>
<text top="472" left="510" width="348" height="20" font="1"> Chlorthalidone vs. Doxazosin  • No difference in 1° outcome </text>
<text top="490" left="691" width="191" height="20" font="1">(nonfatal MI and fatal CHD). Other </text>
<text top="507" left="691" width="130" height="20" font="1">prespecified outcomes: </text>
<text top="525" left="691" width="126" height="20" font="1">CHD, 1° outcome plus </text>
<text top="542" left="691" width="188" height="20" font="1">revascularization and hospitalized </text>
<text top="560" left="691" width="176" height="20" font="1">angina, composite CVD, stroke, </text>
<text top="577" left="691" width="61" height="20" font="1">HF, ESRD </text>
<text top="473" left="899" width="7" height="18" font="1">•</text>
<text top="472" left="906" width="124" height="20" font="1"> In African Americans: </text>
<text top="490" left="899" width="174" height="20" font="1">combined CVD (HR: 1.28; 95% </text>
<text top="507" left="899" width="164" height="20" font="1">CI: 1.16–1.42); HF (HR: 1.84; </text>
<text top="524" left="899" width="171" height="20" font="1">95% CI: 1.51–2.24); stroke HR </text>
<text top="541" left="899" width="90" height="20" font="1">(CI): 1.10–1.73) </text>
<text top="595" left="96" width="49" height="20" font="4"><b>SPRINT </b></text>
<text top="612" left="96" width="87" height="20" font="1">Wright JT Jr, et </text>
<text top="629" left="96" width="83" height="20" font="1">al., 2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#269">(114)</a> </text>
<text top="646" left="96" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=Citation">26551272</a></text>
<text top="646" left="150" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=Citation"> </a></text>
<text top="595" left="204" width="92" height="20" font="4"><b>Aim:</b> To test the </text>
<text top="612" left="204" width="126" height="20" font="1">effectiveness of a goal </text>
<text top="629" left="204" width="128" height="20" font="1">SBP&lt;120 mm Hg vs. a </text>
<text top="646" left="204" width="125" height="20" font="1">goal SBP&lt;140 mm Hg </text>
<text top="664" left="204" width="113" height="20" font="1">for the prevention of </text>
<text top="681" left="204" width="87" height="20" font="1">CVD in pts with </text>
<text top="698" left="204" width="113" height="20" font="1">SBP≥130 mm Hg at </text>
<text top="715" left="204" width="53" height="20" font="1">baseline. </text>
<text top="732" left="204" width="3" height="20" font="1"> </text>
<text top="750" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="767" left="204" width="3" height="20" font="1"> </text>
<text top="595" left="346" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="612" left="346" width="128" height="20" font="1">SBP≥130 mm Hg, with </text>
<text top="629" left="346" width="120" height="20" font="1">upper limit varying as </text>
<text top="646" left="346" width="124" height="20" font="1">number of pre-trial BP-</text>
<text top="664" left="346" width="143" height="20" font="1">lowering meds increased. </text>
<text top="681" left="346" width="62" height="20" font="1">age ≥50 y<b>  </b></text>
<text top="698" left="346" width="136" height="20" font="1">Presence of at least 1 of </text>
<text top="715" left="346" width="75" height="20" font="1">the following: </text>
<text top="734" left="346" width="7" height="18" font="1">•</text>
<text top="733" left="352" width="121" height="20" font="1"> Clinical or subclinical </text>
<text top="751" left="346" width="29" height="20" font="1">CVD </text>
<text top="770" left="346" width="7" height="18" font="1">•</text>
<text top="769" left="352" width="133" height="20" font="1"> CKD stage 3 or greater </text>
<text top="788" left="346" width="7" height="18" font="1">•</text>
<text top="787" left="352" width="60" height="20" font="1"> Age≥75 y </text>
<text top="595" left="503" width="151" height="20" font="4"><b>Intervention:</b> Intensive BP-</text>
<text top="612" left="503" width="145" height="20" font="1">lowering treatment to goal </text>
<text top="629" left="503" width="99" height="20" font="1">SBP&lt;120 mm Hg </text>
<text top="646" left="503" width="3" height="20" font="1"> </text>
<text top="664" left="503" width="83" height="20" font="4"><b>Comparison:  </b></text>
<text top="683" left="503" width="7" height="18" font="1">•</text>
<text top="682" left="510" width="126" height="20" font="1"> Standard BP-lowering </text>
<text top="699" left="503" width="175" height="20" font="1">treatment to goal SBP&lt;140 mm </text>
<text top="716" left="503" width="19" height="20" font="1">Hg </text>
<text top="735" left="503" width="7" height="18" font="1">•</text>
<text top="735" left="510" width="156" height="20" font="1"> Net treatment difference ~3 </text>
<text top="752" left="503" width="157" height="20" font="1">drugs (2.8) on average vs. 2 </text>
<text top="769" left="503" width="128" height="20" font="1">drugs (1.8) on average </text>
<text top="595" left="691" width="162" height="20" font="1">1°<b> endpoint: </b>CVD (MI, ACS, </text>
<text top="612" left="691" width="135" height="20" font="1">stroke, HF, CVD death)  </text>
<text top="629" left="691" width="118" height="20" font="1">HR: 0.75 (0.64–0.89) </text>
<text top="646" left="691" width="3" height="20" font="1"> </text>
<text top="664" left="691" width="103" height="20" font="4"><b>Other endpoints:</b> </text>
<text top="683" left="691" width="7" height="18" font="1">•</text>
<text top="682" left="698" width="172" height="20" font="1"> Total deaths: 0.73 (0.60–0.90) </text>
<text top="701" left="691" width="7" height="18" font="1">•</text>
<text top="700" left="698" width="165" height="20" font="1"> 1° or death: 0.78 (0.67–0.90) </text>
<text top="719" left="691" width="7" height="18" font="1">•</text>
<text top="719" left="698" width="166" height="20" font="1"> Components of 1° composite </text>
<text top="736" left="691" width="192" height="20" font="1">mostly consistent in direction other </text>
<text top="753" left="691" width="144" height="20" font="1">than ACS – no difference. </text>
<text top="770" left="691" width="3" height="20" font="1"> </text>
<text top="787" left="691" width="96" height="20" font="4"><b>CKD outcomes: </b></text>
<text top="595" left="899" width="67" height="20" font="4"><b>Summary:</b>  </text>
<text top="614" left="899" width="7" height="18" font="1">•</text>
<text top="613" left="906" width="164" height="20" font="1"> More intensive SBP lowering </text>
<text top="630" left="899" width="164" height="20" font="1">to a goal of &lt;120 mm Hg with </text>
<text top="647" left="899" width="175" height="20" font="1">achieved mean of ~121 mm Hg </text>
<text top="665" left="899" width="172" height="20" font="1">resulted in less CVD and lower </text>
<text top="682" left="899" width="154" height="20" font="1">total mortality over 3.26 y in </text>
<text top="699" left="899" width="129" height="20" font="1">comparison with a goal </text>
<text top="716" left="899" width="175" height="20" font="1">SBP&lt;140 mm Hg and achieved </text>
<text top="734" left="899" width="119" height="20" font="1">SBP of ~135 mm Hg. </text>
<text top="753" left="899" width="7" height="18" font="1">•</text>
<text top="752" left="906" width="157" height="20" font="1"> There were small increases </text>
<text top="769" left="899" width="137" height="20" font="1">in some expected SAEs. </text>
<text top="786" left="899" width="172" height="20" font="1">Perhaps unexpected, a sizable </text>
</page>
<page number="199" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">199 </text>
<text top="107" left="204" width="63" height="20" font="4"><b>Size: </b>9361 </text>
<text top="124" left="204" width="115" height="20" font="1">participants followed </text>
<text top="141" left="204" width="98" height="20" font="1">median of 3.26 y<b> </b> </text>
<text top="109" left="346" width="7" height="18" font="1">•</text>
<text top="108" left="352" width="123" height="20" font="1"> Framingham General </text>
<text top="125" left="346" width="128" height="20" font="1">CVD risk≥15% in 10 y  </text>
<text top="143" left="346" width="3" height="20" font="1"> </text>
<text top="160" left="346" width="144" height="20" font="4"><b>Exclusion criteria: </b>Major </text>
<text top="177" left="346" width="105" height="20" font="1">ones included DM, </text>
<text top="194" left="346" width="131" height="20" font="1">history of stroke, ESRD </text>
<text top="211" left="346" width="69" height="20" font="1">(eGFR &lt;20) </text>
<text top="109" left="503" width="7" height="18" font="1">•</text>
<text top="108" left="510" width="152" height="20" font="1"> During the trial, mean SBP </text>
<text top="125" left="503" width="116" height="20" font="1">was 121.5 vs. 134.6. </text>
<text top="109" left="691" width="7" height="18" font="1">•</text>
<text top="108" left="698" width="182" height="20" font="1"> 1° in CKD pts: reduction in GFR </text>
<text top="125" left="691" width="164" height="20" font="1">of ≥50% or ESRD 0.89 (0.42–</text>
<text top="143" left="691" width="31" height="20" font="1">1.87) </text>
<text top="162" left="691" width="7" height="18" font="1">•</text>
<text top="161" left="698" width="183" height="20" font="1"> Incident albuminuria: 0.72 (0.48–</text>
<text top="178" left="691" width="31" height="20" font="1">1.07) </text>
<text top="197" left="691" width="7" height="18" font="1">•</text>
<text top="197" left="698" width="179" height="20" font="1"> In pts without CKD: reduction in </text>
<text top="214" left="691" width="128" height="20" font="1">GFR ≥30% and to &lt;60 </text>
<text top="233" left="691" width="7" height="18" font="1">•</text>
<text top="232" left="698" width="97" height="20" font="1"> 3.49 (2.44–5.10) </text>
<text top="251" left="691" width="7" height="18" font="1">•</text>
<text top="251" left="698" width="183" height="20" font="1"> Incident albuminuria: 0.81 (0.63–</text>
<text top="268" left="691" width="31" height="20" font="1">1.04) </text>
<text top="285" left="691" width="3" height="20" font="1"> </text>
<text top="302" left="691" width="98" height="20" font="4"><b>Adverse events:</b> </text>
<text top="321" left="691" width="7" height="18" font="1">•</text>
<text top="321" left="698" width="113" height="20" font="1"> SAEs: 1.04; p=0.25 </text>
<text top="340" left="691" width="7" height="18" font="1">•</text>
<text top="339" left="698" width="170" height="20" font="1"> Significant absolute increases </text>
<text top="356" left="691" width="148" height="20" font="1">seen in intensive group for </text>
<text top="373" left="691" width="152" height="20" font="1">hypotension (1%), syncope </text>
<text top="391" left="691" width="169" height="20" font="1">(0.6%), electrolyte abnormality </text>
<text top="408" left="691" width="182" height="20" font="1">(0.8%), acute kidney injury/acute </text>
<text top="425" left="691" width="188" height="20" font="1">renal failure (1.6%) over the study </text>
<text top="442" left="691" width="41" height="20" font="1">period. </text>
<text top="461" left="691" width="7" height="18" font="1">•</text>
<text top="461" left="698" width="172" height="20" font="1"> 1.7% fewer pts had orthostatic </text>
<text top="478" left="691" width="173" height="20" font="1">hypotension in intensive group; </text>
<text top="495" left="691" width="48" height="20" font="1">p=0.01.  </text>
<text top="107" left="899" width="160" height="20" font="1">increase in reduced eGFR in </text>
<text top="124" left="899" width="133" height="20" font="1">the non-CKD group and </text>
<text top="141" left="899" width="170" height="20" font="1">AKI/ARF overall was observed </text>
<text top="159" left="899" width="172" height="20" font="1">in the intensive group. While of </text>
<text top="176" left="899" width="124" height="20" font="1">uncertain etiology and </text>
<text top="193" left="899" width="115" height="20" font="1">significance, there is </text>
<text top="210" left="899" width="155" height="20" font="1">speculation this could be an </text>
<text top="228" left="899" width="150" height="20" font="1">acute hemodynamic effect, </text>
<text top="245" left="899" width="156" height="20" font="1">especially given the findings </text>
<text top="262" left="899" width="126" height="20" font="1">regarding albuminuria. </text>
<text top="279" left="899" width="3" height="20" font="1"> </text>
<text top="296" left="899" width="166" height="20" font="4"><b>Limitations:</b> Few participants </text>
<text top="314" left="899" width="148" height="20" font="1">were untreated at baseline </text>
<text top="331" left="899" width="172" height="20" font="1">~9%, so SPRINT provides little </text>
<text top="348" left="899" width="130" height="20" font="1">if any insight at present </text>
<text top="365" left="899" width="125" height="20" font="1">regarding BP-lowering </text>
<text top="382" left="899" width="129" height="20" font="1">medication initiation for </text>
<text top="400" left="899" width="149" height="20" font="1">untreated people with SBP </text>
<text top="417" left="899" width="55" height="20" font="1">130–139. </text>
<text top="513" left="96" width="59" height="20" font="4"><b>VA Coop</b>  </text>
<text top="530" left="96" width="63" height="20" font="1">1967 (262) </text>
<text top="547" left="96" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4862069">4862069</a></text>
<text top="547" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4862069"> </a></text>
<text top="513" left="204" width="113" height="20" font="4"><b>Study type: </b>RCT to </text>
<text top="530" left="204" width="97" height="20" font="1">examine effect of </text>
<text top="547" left="204" width="109" height="20" font="1">treatment of severe </text>
<text top="565" left="204" width="29" height="20" font="1">HTN </text>
<text top="582" left="204" width="3" height="20" font="1"> </text>
<text top="599" left="204" width="55" height="20" font="4"><b>Size</b>: 143 </text>
<text top="515" left="346" width="7" height="18" font="1">•</text>
<text top="514" left="352" width="128" height="20" font="1"> 54% African American </text>
<text top="533" left="346" width="7" height="18" font="1">•</text>
<text top="532" left="352" width="127" height="20" font="1"> DBP 115–129 mm Hg </text>
<text top="515" left="503" width="7" height="18" font="1">•</text>
<text top="514" left="510" width="106" height="20" font="1"> HCTZ, Reserpine, </text>
<text top="531" left="503" width="134" height="20" font="1">Hydralazine vs. placebo </text>
<text top="515" left="691" width="7" height="18" font="1">•</text>
<text top="514" left="698" width="175" height="20" font="1"> CVD or stroke events, Grade 3 </text>
<text top="531" left="691" width="156" height="20" font="1">or 4 retinopathy, doubling of </text>
<text top="549" left="691" width="139" height="20" font="1">creatinine or BUN. Study </text>
<text top="566" left="691" width="185" height="20" font="1">terminated early for 27 events vs. </text>
<text top="583" left="691" width="159" height="20" font="1">2 events (placebo vs. active) </text>
<text top="513" left="899" width="24" height="20" font="1">N/A </text>
<text top="617" left="96" width="59" height="20" font="4"><b>VA Coop</b>  </text>
<text top="634" left="96" width="63" height="20" font="1">1970 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(271)</a> </text>
<text top="651" left="96" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4914579">4914579</a></text>
<text top="651" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4914579"> </a></text>
<text top="617" left="204" width="113" height="20" font="4"><b>Study type: </b>RCT to </text>
<text top="634" left="204" width="97" height="20" font="1">examine effect of </text>
<text top="651" left="204" width="109" height="20" font="1">treatment of mild to </text>
<text top="669" left="204" width="105" height="20" font="1">moderately severe </text>
<text top="686" left="204" width="29" height="20" font="1">HTN </text>
<text top="703" left="204" width="3" height="20" font="1"> </text>
<text top="720" left="204" width="55" height="20" font="4"><b>Size</b>: 380 </text>
<text top="619" left="346" width="7" height="18" font="1">•</text>
<text top="618" left="352" width="128" height="20" font="1"> 42% African American </text>
<text top="637" left="346" width="7" height="18" font="1">•</text>
<text top="636" left="352" width="120" height="20" font="1"> DBP 90–115 mm Hg </text>
<text top="619" left="503" width="7" height="18" font="1">•</text>
<text top="618" left="510" width="106" height="20" font="1"> HCTZ, Reserpine, </text>
<text top="635" left="503" width="134" height="20" font="1">Hydralazine vs. placebo </text>
<text top="619" left="691" width="7" height="18" font="1">•</text>
<text top="618" left="698" width="175" height="20" font="1"> CVD or stroke events, Grade 3 </text>
<text top="635" left="691" width="156" height="20" font="1">or 4 retinopathy, doubling of </text>
<text top="653" left="691" width="100" height="20" font="1">creatinine or BUN </text>
<text top="617" left="899" width="3" height="20" font="1"> </text>
</page>
<page number="200" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">200 </text>
<text top="107" left="96" width="84" height="20" font="1">HTN Detection </text>
<text top="124" left="96" width="81" height="20" font="1">and Follow-up </text>
<text top="141" left="96" width="51" height="20" font="1">Program </text>
<text top="159" left="96" width="45" height="20" font="1">(<b>HDFP)</b> </text>
<text top="176" left="96" width="31" height="20" font="1">1979 </text>
<text top="193" left="96" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6480895">6480895</a></text>
<text top="193" left="144" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6480895"> </a></text>
<text top="210" left="96" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(272)</a> </text>
<text top="107" left="204" width="103" height="20" font="4"><b>Study type: </b>RCT; </text>
<text top="124" left="204" width="128" height="20" font="1">comparison of stepped </text>
<text top="141" left="204" width="97" height="20" font="1">care at academic </text>
<text top="159" left="204" width="123" height="20" font="1">centers vs. usual care </text>
<text top="176" left="204" width="67" height="20" font="1">provided by </text>
<text top="193" left="204" width="63" height="20" font="1">community </text>
<text top="210" left="204" width="3" height="20" font="1"> </text>
<text top="227" left="204" width="92" height="20" font="4"><b>Size</b>: 10,950 pts </text>
<text top="109" left="346" width="7" height="18" font="1">•</text>
<text top="108" left="352" width="128" height="20" font="1"> 44% African American </text>
<text top="127" left="346" width="7" height="18" font="1">•</text>
<text top="127" left="352" width="51" height="20" font="1"> 30–69 y </text>
<text top="109" left="503" width="7" height="18" font="1">•</text>
<text top="108" left="510" width="152" height="20" font="1"> Chlorthalidone, Reserpine, </text>
<text top="125" left="503" width="167" height="20" font="1">Hydralazine, Guanethidine vs. </text>
<text top="143" left="503" width="146" height="20" font="1">referral to community care </text>
<text top="109" left="691" width="7" height="18" font="1">•</text>
<text top="108" left="698" width="161" height="20" font="1"> 23% decrease in mortality in </text>
<text top="125" left="691" width="169" height="20" font="1">African Americans on Stepped </text>
<text top="143" left="691" width="30" height="20" font="1">Care </text>
<text top="107" left="899" width="24" height="20" font="1">N/A </text>
<text top="245" left="96" width="30" height="20" font="4"><b>LIFE </b></text>
<text top="263" left="96" width="84" height="20" font="1">Dahlof B, et al. </text>
<text top="280" left="96" width="34" height="20" font="1">2002  </text>
<text top="297" left="96" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11937178?dopt=Citation">11937178 </a></text>
<text top="314" left="96" width="25" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#264">(14)</a> </text>
<text top="245" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="263" left="204" width="126" height="20" font="1">comparison of an ARB </text>
<text top="280" left="204" width="119" height="20" font="1">compared to a BB on </text>
<text top="297" left="204" width="29" height="20" font="1">CVD </text>
<text top="247" left="346" width="7" height="18" font="1">•</text>
<text top="247" left="352" width="130" height="20" font="1"> 55–80 y (mean 66.9 y) </text>
<text top="266" left="346" width="7" height="18" font="1">•</text>
<text top="265" left="352" width="124" height="20" font="1"> African American 533 </text>
<text top="282" left="346" width="19" height="20" font="1">(6) </text>
<text top="301" left="346" width="7" height="18" font="1">•</text>
<text top="301" left="352" width="98" height="20" font="1"> White 8,503 (92) </text>
<text top="320" left="346" width="7" height="18" font="1">•</text>
<text top="319" left="352" width="84" height="20" font="1"> Asian 43 (0.5) </text>
<text top="338" left="346" width="7" height="18" font="1">•</text>
<text top="337" left="352" width="96" height="20" font="1"> Hispanic 100 (1) </text>
<text top="356" left="346" width="7" height="18" font="1">•</text>
<text top="356" left="352" width="84" height="20" font="1"> Other 14 (0.2) </text>
<text top="247" left="503" width="7" height="18" font="1">•</text>
<text top="247" left="510" width="122" height="20" font="1"> Losartan vs. Atenolol </text>
<text top="247" left="691" width="7" height="18" font="1">•</text>
<text top="247" left="698" width="185" height="20" font="1"> Interaction of race and treatment </text>
<text top="264" left="691" width="143" height="20" font="1">on CVD events (p=0.005) </text>
<text top="281" left="691" width="169" height="20" font="1">CVD increased 55% in African </text>
<text top="298" left="691" width="181" height="20" font="1">Americans in the Losartan group<b> </b></text>
<text top="245" left="899" width="24" height="20" font="1">N/A </text>
<text top="374" left="96" width="45" height="20" font="4"><b>VALUE </b></text>
<text top="391" left="96" width="80" height="20" font="1">Julius S, et al. </text>
<text top="408" left="96" width="63" height="20" font="1">2006 (265) </text>
<text top="425" left="96" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16864741?dopt=Citation">16864741</a></text>
<text top="425" left="150" width="7" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16864741?dopt=Citation">  </a></text>
<text top="443" left="96" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(273)</a> </text>
<text top="374" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="391" left="204" width="126" height="20" font="1">comparison of an ARB </text>
<text top="408" left="204" width="105" height="20" font="1">vs. a CCB on CVD </text>
<text top="376" left="346" width="7" height="18" font="1">•</text>
<text top="375" left="352" width="117" height="20" font="1"> &gt;50 y (mean 67.3 y) </text>
<text top="394" left="346" width="7" height="18" font="1">•</text>
<text top="393" left="352" width="124" height="20" font="1"> African American 658 </text>
<text top="410" left="346" width="29" height="20" font="1">(4.3) </text>
<text top="429" left="346" width="7" height="18" font="1">•</text>
<text top="429" left="352" width="115" height="20" font="1"> White 13,643 (89.1) </text>
<text top="448" left="346" width="7" height="18" font="1">•</text>
<text top="447" left="352" width="90" height="20" font="1"> Asian 535 (3.5) </text>
<text top="466" left="346" width="7" height="18" font="1">•</text>
<text top="466" left="352" width="90" height="20" font="1"> Other 474 (3.1) </text>
<text top="376" left="503" width="7" height="18" font="1">•</text>
<text top="375" left="510" width="142" height="20" font="1"> Valsartan vs. Amlodipine<b> </b></text>
<text top="376" left="691" width="7" height="18" font="1">•</text>
<text top="375" left="698" width="166" height="20" font="1"> CVD increased ~20% (NS) in </text>
<text top="392" left="691" width="172" height="20" font="1">African Americans in Valsartan </text>
<text top="409" left="691" width="35" height="20" font="1">group </text>
<text top="374" left="899" width="24" height="20" font="1">N/A </text>
<text top="484" left="96" width="38" height="20" font="4"><b>AASK </b></text>
<text top="501" left="96" width="81" height="20" font="1">Norris K, et al. </text>
<text top="518" left="96" width="34" height="20" font="1">2006  </text>
<text top="535" left="96" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17059993?dopt=Citation">17059993 </a></text>
<text top="552" left="96" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#273">(174)</a> </text>
<text top="484" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="501" left="204" width="111" height="20" font="1">comparison of 2 BP </text>
<text top="518" left="204" width="103" height="20" font="1">targets and 3 drug </text>
<text top="535" left="204" width="102" height="20" font="1">regimens on renal </text>
<text top="552" left="204" width="57" height="20" font="1">outcomes </text>
<text top="570" left="204" width="3" height="20" font="1"> </text>
<text top="587" left="204" width="85" height="20" font="4"><b>Size</b>: 1,094 pts </text>
<text top="485" left="346" width="7" height="18" font="1">•</text>
<text top="485" left="352" width="96" height="20" font="1"> 18–70 y; African </text>
<text top="502" left="346" width="65" height="20" font="1">Americans; </text>
<text top="521" left="346" width="7" height="18" font="1">•</text>
<text top="520" left="352" width="81" height="20" font="1"> eGFR: 25–65 </text>
<text top="537" left="346" width="81" height="20" font="1">mL/min/1.73 m</text>
<text top="539" left="427" width="4" height="13" font="6">2</text>
<text top="537" left="431" width="3" height="20" font="1"> </text>
<text top="485" left="503" width="7" height="18" font="1">•</text>
<text top="485" left="510" width="114" height="20" font="1"> MAP of &lt;92 mm Hg </text>
<text top="502" left="503" width="153" height="20" font="1">compared to MAP 102–107 </text>
<text top="519" left="503" width="160" height="20" font="1">mm Hg and an ACEI or CCB </text>
<text top="536" left="503" width="132" height="20" font="1">each compared to a BB </text>
<text top="486" left="691" width="7" height="18" font="1">•</text>
<text top="485" left="698" width="150" height="20" font="1"> No difference between BP </text>
<text top="502" left="691" width="147" height="20" font="1">targets. ACEI &gt; BB &gt; CCB </text>
<text top="484" left="899" width="24" height="20" font="1">N/A </text>
<text top="605" left="96" width="53" height="20" font="4"><b>ALLHAT </b></text>
<text top="622" left="96" width="63" height="20" font="1">2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(274)</a> </text>
<text top="639" left="96" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12479763?dopt=Citation">12479763</a></text>
<text top="639" left="150" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12479763?dopt=Citation"> </a></text>
<text top="605" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="622" left="204" width="98" height="20" font="1">comparison of an </text>
<text top="639" left="204" width="115" height="20" font="1">alpha blocker, ACEI, </text>
<text top="656" left="204" width="77" height="20" font="1">or CCB, each </text>
<text top="674" left="204" width="82" height="20" font="1">compared to a </text>
<text top="691" left="204" width="120" height="20" font="1">thiazide-type diuretic  </text>
<text top="708" left="204" width="3" height="20" font="1"> </text>
<text top="725" left="204" width="73" height="20" font="4"><b>Size</b>: 42,418 </text>
<text top="607" left="346" width="7" height="18" font="1">•</text>
<text top="606" left="352" width="37" height="20" font="1"> &gt;50 y </text>
<text top="625" left="346" width="7" height="18" font="1">•</text>
<text top="624" left="352" width="101" height="20" font="1"> African American </text>
<text top="641" left="346" width="77" height="20" font="1">15,085 (35.5) </text>
<text top="661" left="346" width="7" height="18" font="1">•</text>
<text top="660" left="352" width="115" height="20" font="1"> White 19,977 (47.0) </text>
<text top="679" left="346" width="7" height="18" font="1">•</text>
<text top="678" left="352" width="130" height="20" font="1"> Hispanics 5,299 (12.5) </text>
<text top="607" left="503" width="7" height="18" font="1">•</text>
<text top="606" left="510" width="105" height="20" font="1"> Chlorthalidone vs. </text>
<text top="623" left="503" width="146" height="20" font="1">Doxazosin, Amlodipine, or </text>
<text top="640" left="503" width="52" height="20" font="1">Lisinopril<b> </b></text>
<text top="607" left="691" width="7" height="18" font="1">•</text>
<text top="606" left="698" width="160" height="20" font="1"> No difference in 1° outcome </text>
<text top="623" left="691" width="153" height="20" font="1">(nonfatal MI and fatal CHD) </text>
<text top="607" left="899" width="7" height="18" font="1">•</text>
<text top="606" left="906" width="114" height="20" font="1"> Chlorthalidone (and </text>
<text top="623" left="899" width="149" height="20" font="1">amlodipine was superior in </text>
<text top="640" left="899" width="174" height="20" font="1">reducing BP by 4/1 mm Hg and </text>
<text top="658" left="899" width="167" height="20" font="1">CVD events (stroke and CVD) </text>
<text top="675" left="899" width="122" height="20" font="1">vs. lisinopril in African </text>
<text top="692" left="899" width="62" height="20" font="1">Americans </text>
<text top="743" left="96" width="48" height="20" font="4"><b>INVEST </b></text>
<text top="760" left="96" width="77" height="20" font="1">Pepine CJ, et </text>
<text top="778" left="96" width="83" height="20" font="1">al., 2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(275)</a> </text>
<text top="743" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="760" left="204" width="110" height="20" font="1">comparison of CCB </text>
<text top="778" left="204" width="75" height="20" font="1">plus an ACEI </text>
<text top="745" left="346" width="7" height="18" font="1">•</text>
<text top="744" left="352" width="120" height="20" font="1"> ≥ 50 y with HTN and </text>
<text top="762" left="346" width="30" height="20" font="1">CHD </text>
<text top="781" left="346" width="7" height="18" font="1">•</text>
<text top="780" left="352" width="82" height="20" font="1"> 36% Hispanic </text>
<text top="745" left="503" width="7" height="18" font="1">•</text>
<text top="744" left="510" width="146" height="20" font="1"> Verapamil/trandolapril vs. </text>
<text top="762" left="503" width="87" height="20" font="1">Atenolol/ HCTZ </text>
<text top="745" left="691" width="7" height="18" font="1">•</text>
<text top="744" left="698" width="156" height="20" font="1">No difference in 1° outcome </text>
<text top="762" left="691" width="176" height="20" font="1">(nonfatal MI, nonfatal stroke, all-</text>
<text top="779" left="691" width="156" height="20" font="1">cause mortality). Mean SBP </text>
<text top="743" left="899" width="24" height="20" font="1">N/A </text>
</page>
<page number="201" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">201 </text>
<text top="107" left="96" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14657064?dopt=Citation">14657064</a></text>
<text top="107" left="150" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14657064?dopt=Citation"> </a></text>
<text top="107" left="204" width="128" height="20" font="1">compared to a BB plus </text>
<text top="124" left="204" width="99" height="20" font="1">a thiazide diuretic </text>
<text top="141" left="204" width="3" height="20" font="1"> </text>
<text top="159" left="204" width="73" height="20" font="4"><b>Size</b>: 22,576 </text>
<text top="109" left="346" width="7" height="18" font="1">•</text>
<text top="108" left="352" width="129" height="20" font="1"> 13% African American </text>
<text top="127" left="346" width="7" height="18" font="1">•</text>
<text top="127" left="352" width="66" height="20" font="1"> 49% White </text>
<text top="107" left="691" width="154" height="20" font="1">reduction Hispanics vs. non-</text>
<text top="124" left="691" width="180" height="20" font="1">Hispanic pts (-21.3 vs. -17.4 mm </text>
<text top="141" left="691" width="78" height="20" font="1">Hg; p&lt;0.001)  </text>
<text top="177" left="96" width="93" height="20" font="1">Wright JT, et al., </text>
<text top="194" left="96" width="63" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(276)</a> </text>
<text top="211" left="96" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15811979?dopt=Citation">15811979 </a></text>
<text top="177" left="204" width="103" height="20" font="4"><b>Study type: </b>Race </text>
<text top="194" left="204" width="122" height="20" font="1">subgroup comparison </text>
<text top="211" left="204" width="123" height="20" font="1">of RCT comparison of </text>
<text top="228" left="204" width="97" height="20" font="1">an alpha blocker, </text>
<text top="246" left="204" width="79" height="20" font="1">ACEI, or CCB </text>
<text top="263" left="204" width="82" height="20" font="1">compared to a </text>
<text top="280" left="204" width="116" height="20" font="1">thiazide-type diuretic </text>
<text top="178" left="346" width="7" height="18" font="1">•</text>
<text top="178" left="352" width="37" height="20" font="1"> &gt;50 y </text>
<text top="197" left="346" width="7" height="18" font="1">•</text>
<text top="196" left="352" width="104" height="20" font="1"> African American, </text>
<text top="213" left="346" width="55" height="20" font="1">n=11,792 </text>
<text top="232" left="346" width="7" height="18" font="1">•</text>
<text top="232" left="352" width="130" height="20" font="1"> Non-African American, </text>
<text top="249" left="346" width="55" height="20" font="1">n=21,565 </text>
<text top="178" left="503" width="7" height="18" font="1">•</text>
<text top="178" left="510" width="105" height="20" font="1"> Chlorthalidone vs. </text>
<text top="195" left="503" width="134" height="20" font="1">Amlodipine, or Lisinopril </text>
<text top="178" left="691" width="7" height="18" font="1">•</text>
<text top="178" left="698" width="160" height="20" font="1"> No difference in 1° outcome </text>
<text top="195" left="691" width="191" height="20" font="1">(nonfatal MI and fatal CHD). Other </text>
<text top="212" left="691" width="130" height="20" font="1">prespecified outcomes: </text>
<text top="231" left="691" width="126" height="20" font="1">CHD, 1° outcome plus </text>
<text top="248" left="691" width="188" height="20" font="1">revascularization and hospitalized </text>
<text top="265" left="691" width="176" height="20" font="1">angina, composite CVD, stroke, </text>
<text top="282" left="691" width="61" height="20" font="1">HF, ESRD </text>
<text top="178" left="899" width="7" height="18" font="1">•</text>
<text top="178" left="906" width="124" height="20" font="1"> In African Americans: </text>
<text top="195" left="899" width="117" height="20" font="1">Amlodipine similar to </text>
<text top="212" left="899" width="170" height="20" font="1">chlorthalidone for all outcomes </text>
<text top="229" left="899" width="159" height="20" font="1">but inferior for HF (HR: 1.37; </text>
<text top="247" left="899" width="165" height="20" font="1">95% CI: 1.24–1.51). Lisinopril </text>
<text top="264" left="899" width="174" height="20" font="1">less effective for SBP reduction </text>
<text top="281" left="899" width="169" height="20" font="1">by 4 mm Hg, stroke (HR: 1.40; </text>
<text top="298" left="899" width="169" height="20" font="1">95% CI: 1.17–1.68), combined </text>
<text top="316" left="899" width="167" height="20" font="1">CVD (HR: 1.19; 95% CI: 1.09–</text>
<text top="333" left="899" width="161" height="20" font="1">1.30), HF (HR: 1.30; 95% CI: </text>
<text top="350" left="899" width="66" height="20" font="1">1.10–1.54). </text>
<text top="369" left="108" width="3" height="19" font="1"> </text>
<text top="404" left="81" width="578" height="24" font="3"><b>Data Supplement 52. RCTs Comparing Women With Hypertension (Section 10.2.1) </b></text>
<text top="443" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="461" left="128" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="478" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="443" left="242" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="461" left="247" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="478" left="241" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="443" left="380" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="443" left="524" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="461" left="539" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="478" left="524" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="495" left="545" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="443" left="699" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="461" left="683" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="478" left="689" width="129" height="20" font="4"><b>P value; OR or RR; &amp;  </b></text>
<text top="495" left="727" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="445" left="893" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="462" left="926" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="479" left="931" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="496" left="951" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="514" left="98" width="96" height="20" font="1">Turnbull F, et al., </text>
<text top="531" left="98" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(277)</a> </text>
<text top="549" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18852183?dopt=Citation">18852183</a></text>
<text top="549" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18852183?dopt=Citation"> </a></text>
<text top="514" left="220" width="96" height="20" font="4"><b>Aim:</b> Assess sex </text>
<text top="531" left="220" width="76" height="20" font="1">differences in </text>
<text top="549" left="220" width="87" height="20" font="1">response to BP </text>
<text top="566" left="220" width="59" height="20" font="1">treatment  </text>
<text top="583" left="220" width="3" height="20" font="1"> </text>
<text top="600" left="220" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="618" left="220" width="114" height="20" font="1">analysis of 31 RCTs </text>
<text top="635" left="220" width="3" height="20" font="1"> </text>
<text top="652" left="220" width="111" height="20" font="4"><b>Size: </b>103,268 men, </text>
<text top="669" left="220" width="84" height="20" font="1">87,349 women </text>
<text top="514" left="361" width="70" height="20" font="4"><b>Mean ages: </b></text>
<text top="533" left="361" width="7" height="18" font="1">•</text>
<text top="533" left="368" width="90" height="20" font="1"> Women: 63.0 y </text>
<text top="552" left="361" width="7" height="18" font="1">•</text>
<text top="551" left="368" width="71" height="20" font="1"> Men: 61.7 y </text>
<text top="514" left="523" width="102" height="20" font="4"><b>Intervention:</b> N/A </text>
<text top="531" left="523" width="3" height="20" font="1"> </text>
<text top="549" left="523" width="101" height="20" font="4"><b>Comparator:</b> N/A </text>
<text top="515" left="649" width="176" height="20" font="4"><b>1</b>°<b> endpoint:</b> Nonfatal stroke or </text>
<text top="533" left="649" width="199" height="20" font="1">death from cerebrovascular disease </text>
<text top="550" left="649" width="183" height="20" font="1">(ICD 430–438); (ii) nonfatal MI or </text>
<text top="567" left="649" width="187" height="20" font="1">deaths from CHD, excluding SCD </text>
<text top="584" left="649" width="173" height="20" font="1">(ICD 410–414); (iii) HF causing </text>
<text top="601" left="649" width="181" height="20" font="1">death or requiring hospitalization </text>
<text top="619" left="649" width="202" height="20" font="1">(ICD 428); (iv) total major CV events </text>
<text top="636" left="649" width="193" height="20" font="1">(stroke, CHD events, HF, other CV </text>
<text top="653" left="649" width="176" height="20" font="1">death); (v) total CV deaths (ICD </text>
<text top="670" left="649" width="180" height="20" font="1">396–459); and (vi) total mortality </text>
<text top="688" left="730" width="3" height="20" font="4"><b> </b></text>
<text top="705" left="649" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A  </text>
<text top="514" left="867" width="227" height="20" font="4"><b>Summary</b>: Achieved BP reductions were </text>
<text top="531" left="867" width="226" height="20" font="1">comparable for men and women in every </text>
<text top="550" left="867" width="228" height="20" font="1">comparison made. For the 1° outcome of </text>
<text top="567" left="867" width="195" height="20" font="1">total major CV events there was no </text>
<text top="584" left="867" width="222" height="20" font="1">evidence that men and women obtained </text>
<text top="601" left="867" width="202" height="20" font="1">different levels of protection from BP-</text>
<text top="619" left="867" width="196" height="20" font="1">lowering or that regimens based on </text>
<text top="636" left="867" width="209" height="20" font="1">ACEIs, calcium antagonists, ARBs, or </text>
<text top="653" left="867" width="206" height="20" font="1">diuretics/BBs were more effective in1 </text>
<text top="670" left="867" width="206" height="20" font="1">sex than the other (all p-homogeneity </text>
<text top="688" left="867" width="42" height="20" font="1">&gt;0.08). </text>
<text top="723" left="98" width="79" height="20" font="1">Wing L, et al., </text>
<text top="740" left="98" width="63" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#278">(278)</a> </text>
<text top="757" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12584366?dopt=Citation">12584366</a></text>
<text top="757" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12584366?dopt=Citation"> </a></text>
<text top="723" left="220" width="114" height="20" font="4"><b>Aim: </b>Comparison of </text>
<text top="740" left="220" width="110" height="20" font="1">ACE vs. Diuretic on </text>
<text top="757" left="220" width="75" height="20" font="1">incident CVD </text>
<text top="774" left="220" width="7" height="20" font="1">  </text>
<text top="723" left="361" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="740" left="361" width="47" height="20" font="1">65–84 y </text>
<text top="757" left="361" width="3" height="20" font="1"> </text>
<text top="723" left="523" width="106" height="20" font="4"><b>Intervention:</b> ACE </text>
<text top="740" left="523" width="3" height="20" font="1"> </text>
<text top="757" left="523" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="774" left="523" width="45" height="20" font="1">Diuretic </text>
<text top="723" left="649" width="61" height="20" font="4"><b>Endpoint:</b> </text>
<text top="723" left="709" width="126" height="20" font="21">All CV events or death </text>
<text top="740" left="649" width="84" height="20" font="21">from any cause</text>
<text top="740" left="733" width="3" height="20" font="4"><b> </b></text>
<text top="757" left="649" width="3" height="20" font="4"><b> </b></text>
<text top="774" left="649" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A  </text>
<text top="723" left="867" width="63" height="20" font="4"><b>Summary</b>: </text>
<text top="723" left="930" width="149" height="20" font="21">Among male subjects, HR: </text>
<text top="740" left="867" width="102" height="20" font="21">0.83 (95% CI: 0.71</text>
<text top="740" left="969" width="7" height="20" font="1">–</text>
<text top="740" left="976" width="80" height="20" font="21">0.97; p=0.02); </text>
<text top="757" left="867" width="218" height="20" font="21">among female subjects, HR: 1.00 (95% </text>
<text top="774" left="867" width="43" height="20" font="21">CI: 0.83</text>
<text top="774" left="910" width="7" height="20" font="1">–</text>
<text top="774" left="917" width="161" height="20" font="21">1.21; p=0.98); the p value for </text>
</page>
<page number="202" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">202 </text>
<text top="107" left="220" width="119" height="20" font="4"><b>Study type:</b> Practice-</text>
<text top="124" left="220" width="126" height="20" font="1">based RCT open label </text>
<text top="141" left="220" width="102" height="20" font="1">treatment, blinded </text>
<text top="159" left="220" width="37" height="20" font="1">event  </text>
<text top="176" left="220" width="3" height="20" font="1"> </text>
<text top="193" left="220" width="86" height="20" font="4"><b>Size: </b>6,083 pts </text>
<text top="107" left="361" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="107" left="471" width="24" height="20" font="21">Life-</text>
<text top="124" left="361" width="106" height="20" font="21">threatening illness, </text>
<text top="141" left="361" width="117" height="20" font="21">contraindication to an</text>
<text top="141" left="478" width="3" height="20" font="1"> </text>
<text top="159" left="361" width="28" height="20" font="1">ACEI</text>
<text top="159" left="389" width="118" height="20" font="21"> or diuretic, a plasma </text>
<text top="176" left="361" width="148" height="20" font="21">creatinine concentration of </text>
<text top="193" left="361" width="121" height="20" font="21">more than 2.5 mg per </text>
<text top="210" left="361" width="148" height="20" font="21">deciliter (221 micromol per </text>
<text top="228" left="361" width="87" height="20" font="21">liter), malignant </text>
<text top="245" left="361" width="142" height="20" font="21">hypertension, or dementia</text>
<text top="245" left="503" width="3" height="20" font="1"> </text>
<text top="107" left="523" width="3" height="20" font="1"> </text>
<text top="124" left="523" width="89" height="20" font="1">Note: Clinicians </text>
<text top="141" left="523" width="100" height="20" font="1">chose which ACE </text>
<text top="159" left="523" width="57" height="20" font="1">or diuretic </text>
<text top="107" left="867" width="177" height="20" font="21">the interaction between sex and </text>
<text top="124" left="867" width="210" height="20" font="21">treatment-group assignment was 0.15.</text>
<text top="124" left="1077" width="3" height="20" font="1"> </text>
<text top="263" left="98" width="96" height="20" font="1">Fletcher A, et al., </text>
<text top="280" left="98" width="66" height="20" font="1">1988 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(279)</a>  </text>
<text top="297" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2907053?dopt=Citation">2907053</a></text>
<text top="297" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2907053?dopt=Citation"> </a></text>
<text top="263" left="220" width="125" height="20" font="4"><b>Aim: </b>Monitoring event </text>
<text top="280" left="220" width="116" height="20" font="1">rates in pts assigned </text>
<text top="297" left="220" width="85" height="20" font="1">to treatment by </text>
<text top="314" left="220" width="53" height="20" font="1">clinicians<b> </b></text>
<text top="332" left="220" width="3" height="20" font="1"> </text>
<text top="349" left="220" width="70" height="20" font="4"><b>Study type:</b> </text>
<text top="366" left="220" width="79" height="20" font="1">Observational </text>
<text top="383" left="220" width="3" height="20" font="1"> </text>
<text top="400" left="220" width="66" height="20" font="4"><b>Size: </b>2,607 </text>
<text top="263" left="361" width="131" height="20" font="4"><b>Inclusion criteria:</b> Age </text>
<text top="280" left="361" width="34" height="20" font="1">&gt;18 y </text>
<text top="297" left="361" width="3" height="20" font="1"> </text>
<text top="314" left="361" width="137" height="20" font="4"><b>Exclusion criteria: </b>N/A  </text>
<text top="263" left="523" width="102" height="20" font="4"><b>Intervention:</b> N/A </text>
<text top="264" left="649" width="156" height="20" font="4"><b>1</b>°<b> endpoint:</b> Total mortality </text>
<text top="281" left="649" width="79" height="20" font="1">incident “IHD” </text>
<text top="298" left="649" width="3" height="20" font="4"><b> </b></text>
<text top="316" left="649" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A  </text>
<text top="263" left="867" width="227" height="20" font="4"><b>Summary</b>: BBs reduced mortality in men </text>
<text top="280" left="867" width="134" height="20" font="1">but not women (p&lt;0.01) </text>
<text top="418" left="98" width="90" height="20" font="1">Forette F, et al., </text>
<text top="436" left="98" width="63" height="20" font="1">2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(280)</a> </text>
<text top="453" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12374512?dopt=Citation">12374512</a></text>
<text top="453" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12374512?dopt=Citation"> </a></text>
<text top="418" left="220" width="126" height="20" font="4"><b>Aim: </b>Legacy follow-up </text>
<text top="436" left="220" width="72" height="20" font="1">for dementia </text>
<text top="453" left="220" width="61" height="20" font="1">prevention </text>
<text top="470" left="220" width="3" height="20" font="1"> </text>
<text top="487" left="220" width="124" height="20" font="4"><b>Study type:</b> RCT with </text>
<text top="504" left="220" width="92" height="20" font="1">legacy follow-up </text>
<text top="522" left="220" width="3" height="20" font="1"> </text>
<text top="539" left="220" width="100" height="20" font="4"><b>Size:</b> 2,902 in the </text>
<text top="556" left="220" width="92" height="20" font="1">legacy follow-up </text>
<text top="418" left="361" width="131" height="20" font="4"><b>Inclusion criteria: </b>Age<b> </b></text>
<text top="436" left="361" width="35" height="20" font="1">≥60 y<b> </b></text>
<text top="453" left="361" width="3" height="20" font="1"> </text>
<text top="470" left="361" width="138" height="20" font="4"><b>Exclusion criteria: </b>HTN </text>
<text top="487" left="361" width="112" height="20" font="1">2° to a disorder that </text>
<text top="504" left="361" width="149" height="20" font="1">needed specific medical or </text>
<text top="522" left="361" width="105" height="20" font="1">surgical treatment; </text>
<text top="539" left="361" width="143" height="20" font="1">congestive HF; dissecting </text>
<text top="556" left="361" width="132" height="20" font="1">aortic aneurysm; serum </text>
<text top="573" left="361" width="148" height="20" font="1">creatinine concentration at </text>
<text top="591" left="361" width="109" height="20" font="1">presentation of 180 </text>
<text top="608" left="361" width="146" height="20" font="1">micromol/l or more; stroke </text>
<text top="625" left="361" width="133" height="20" font="1">or MI in the y before the </text>
<text top="642" left="361" width="94" height="20" font="1">study; dementia; </text>
<text top="659" left="361" width="123" height="20" font="1">substance abuse; any </text>
<text top="677" left="361" width="118" height="20" font="1">disorder prohibiting a </text>
<text top="694" left="361" width="149" height="20" font="1">sitting or standing position; </text>
<text top="711" left="361" width="148" height="20" font="1">any severe concomitant or </text>
<text top="728" left="361" width="54" height="20" font="1">non-CVD<b> </b></text>
<text top="418" left="523" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="436" left="523" width="80" height="20" font="1">Nitrendipine + </text>
<text top="453" left="523" width="36" height="20" font="1">HCTZ </text>
<text top="470" left="523" width="3" height="20" font="1"> </text>
<text top="487" left="523" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="504" left="523" width="48" height="20" font="1">Placebo </text>
<text top="420" left="649" width="203" height="20" font="4"><b>1</b>°<b> endpoint:</b> Incidence of dementia  </text>
<text top="437" left="649" width="3" height="20" font="1"> </text>
<text top="455" left="649" width="173" height="20" font="4"><b>2</b>°<b> endpoint:</b> Cognitive decline </text>
<text top="472" left="649" width="115" height="20" font="1">measured by MMSE </text>
<text top="490" left="649" width="3" height="20" font="1"> </text>
<text top="507" left="649" width="123" height="20" font="4"><b>Safety endpoint:</b> N/A </text>
<text top="526" left="649" width="7" height="18" font="1">•</text>
<text top="525" left="655" width="99" height="20" font="1"> Cases Active: 21 </text>
<text top="544" left="649" width="7" height="18" font="1">•</text>
<text top="543" left="655" width="110" height="20" font="1"> Cases Placebo; 43 </text>
<text top="563" left="649" width="7" height="18" font="1">•</text>
<text top="562" left="655" width="186" height="20" font="1"> Rate 3.3 vs. 7.4 cases/1,000 pt y </text>
<text top="579" left="649" width="102" height="20" font="1">0.38 (95% CI: 0.23</text>
<text top="579" left="751" width="7" height="20" font="21">–</text>
<text top="579" left="758" width="83" height="20" font="1">0.64; p&lt;0.001) </text>
<text top="598" left="649" width="7" height="18" font="1">•</text>
<text top="597" left="655" width="106" height="20" font="1"> MMSE: No impact<b> </b></text>
<text top="420" left="867" width="7" height="18" font="1">•</text>
<text top="420" left="874" width="188" height="20" font="1"> Study discontinued early for CVD </text>
<text top="437" left="867" width="211" height="20" font="1">benefit so a legacy follow-up with both </text>
<text top="454" left="867" width="219" height="20" font="1">groups (off protocol) yielded a follow-up </text>
<text top="471" left="867" width="177" height="20" font="1">of 3.7 y SBP was 149 mm Hg in </text>
<text top="488" left="867" width="223" height="20" font="1">treatment vs. 156 mm Hg in control arm  </text>
<text top="506" left="867" width="3" height="20" font="1"> </text>
<text top="523" left="867" width="124" height="20" font="4"><b>Summary dementia:</b>  </text>
<text top="542" left="867" width="7" height="18" font="1">•</text>
<text top="541" left="874" width="215" height="20" font="1"> Compared with the controls, long-term </text>
<text top="558" left="867" width="206" height="20" font="1">antihypertensive therapy reduced the </text>
<text top="576" left="867" width="211" height="20" font="1">risk of dementia by 55%, from 7.4–3.3 </text>
<text top="593" left="867" width="211" height="20" font="1">cases per 1,000 pt-y (43 vs. 21 cases; </text>
<text top="610" left="867" width="220" height="20" font="1">p&lt;0.001). After adjustment for sex, age, </text>
<text top="627" left="867" width="223" height="20" font="1">education, and entry BP, the relative HR </text>
<text top="644" left="867" width="212" height="20" font="1">associated with the use of nitrendipine </text>
<text top="662" left="867" width="225" height="20" font="1">was 0.38 (95% CI: 0.23, 0.64), p&lt;0.001.  </text>
<text top="681" left="867" width="7" height="18" font="1">•</text>
<text top="680" left="874" width="164" height="20" font="1"> Lack of impact on MMSE not </text>
<text top="697" left="867" width="226" height="20" font="1">surprising given low sensitivity to change </text>
<text top="714" left="867" width="123" height="20" font="1">and large sample size </text>
<text top="748" left="108" width="3" height="19" font="13"> </text>
</page>
<page number="203" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="26" size="12" family="Times" color="#131313"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">203 </text>
<text top="106" left="81" width="466" height="24" font="3"><b>Data Supplement 53. RCTs Comparing Pregnancy (Section 10.2.2) </b></text>
<text top="146" left="105" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="163" left="110" width="86" height="20" font="4"><b>(if applicable)  </b></text>
<text top="180" left="115" width="77" height="20" font="4"><b>Author Year  </b></text>
<text top="146" left="233" width="123" height="20" font="4"><b>Study Type/Design*; </b></text>
<text top="163" left="251" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="401" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="146" left="594" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="163" left="571" width="224" height="20" font="4"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="146" left="904" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="163" left="932" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="198" left="98" width="84" height="20" font="1">Pucci M, et al., </text>
<text top="218" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(281)</a> </text>
<text top="253" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25612630?dopt=Citation">25612630 </a></text>
<text top="198" left="219" width="128" height="20" font="4"><b>Study type:</b> Review of </text>
<text top="215" left="219" width="111" height="20" font="1">published reports of </text>
<text top="233" left="219" width="133" height="20" font="1">fetotoxicity of ACE/ARB </text>
<text top="250" left="219" width="132" height="20" font="1">antihypertensives in the </text>
<text top="267" left="219" width="88" height="20" font="1">first trimester of </text>
<text top="284" left="219" width="64" height="20" font="1">pregnancy. </text>
<text top="301" left="219" width="113" height="20" font="1">Usually case/control </text>
<text top="319" left="219" width="43" height="20" font="1">design. </text>
<text top="336" left="219" width="3" height="20" font="1"> </text>
<text top="353" left="219" width="56" height="20" font="4"><b>Size:</b> N/A </text>
<text top="198" left="383" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="215" left="383" width="149" height="20" font="1">Pregnant women receiving </text>
<text top="233" left="383" width="98" height="20" font="1">ACE/ARB in the 1</text>
<text top="234" left="480" width="6" height="13" font="6">st</text>
<text top="233" left="486" width="3" height="20" font="1"> </text>
<text top="250" left="382" width="126" height="20" font="1">trimester of pregnancy </text>
<text top="267" left="382" width="118" height="20" font="1">only and comparable </text>
<text top="284" left="382" width="46" height="20" font="1">controls </text>
<text top="301" left="383" width="3" height="20" font="1"> </text>
<text top="319" left="383" width="149" height="20" font="4"><b>Exclusion criteria:</b> Use of </text>
<text top="336" left="383" width="98" height="20" font="1">ACE/ARB later in </text>
<text top="353" left="383" width="61" height="20" font="1">pregnancy </text>
<text top="199" left="545" width="256" height="20" font="4"><b>1</b>°<b> endpoint:</b> Adverse outcomes of pregnancy </text>
<text top="217" left="545" width="3" height="20" font="1"> </text>
<text top="234" left="545" width="212" height="20" font="4"><b>Results:</b> Adverse events are higher in </text>
<text top="251" left="545" width="266" height="20" font="1">pregnancies of women who receive ACE/ARB in </text>
<text top="268" left="545" width="271" height="20" font="1">the first trimester of pregnancy but results are not </text>
<text top="285" left="545" width="198" height="20" font="1">independent of known confounders  </text>
<text top="200" left="835" width="7" height="18" font="1">•</text>
<text top="199" left="842" width="252" height="20" font="1"> Fetotoxicity in the first trimester of pregnancy </text>
<text top="217" left="835" width="235" height="20" font="1">cannot be definitely attributed to ACE/ARB </text>
<text top="234" left="835" width="181" height="20" font="1">treatment; data are inconclusive. </text>
<text top="253" left="835" width="7" height="18" font="1">•</text>
<text top="252" left="842" width="235" height="20" font="1">Other known causes of fetotoxicity may be </text>
<text top="269" left="835" width="220" height="20" font="1">responsible for increased risk in the first </text>
<text top="287" left="835" width="265" height="20" font="1">trimester (HTN, obesity, undiagnosed DM, other </text>
<text top="304" left="835" width="107" height="20" font="1">anti-hypertensives) </text>
<text top="371" left="98" width="100" height="20" font="1">Moretti ME, et al., </text>
<text top="391" left="98" width="31" height="20" font="1">2012<b> </b></text>
<text top="426" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22203847?dopt=Citation">22203847 </a></text>
<text top="460" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(282)</a> </text>
<text top="371" left="219" width="143" height="20" font="4"><b>Study type:</b> Case control </text>
<text top="388" left="219" width="144" height="20" font="1">comparing pts exposed to </text>
<text top="406" left="219" width="114" height="20" font="1">ACE/ARB in the first </text>
<text top="423" left="219" width="108" height="20" font="1">trimester to healthy </text>
<text top="440" left="219" width="121" height="20" font="1">controls and those on </text>
<text top="457" left="219" width="135" height="20" font="1">other anti-hypertensives </text>
<text top="474" left="219" width="3" height="20" font="1"> </text>
<text top="492" left="219" width="149" height="20" font="4"><b>Size:</b> 388 total pts (equally </text>
<text top="509" left="219" width="46" height="20" font="1">divided) </text>
<text top="371" left="383" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="388" left="383" width="130" height="20" font="1">Mothers calling into the </text>
<text top="406" left="383" width="137" height="20" font="1">Mother Risk Program re: </text>
<text top="423" left="383" width="141" height="20" font="1">medication toxicity during </text>
<text top="440" left="383" width="64" height="20" font="1">pregnancy  </text>
<text top="457" left="383" width="3" height="20" font="1"> </text>
<text top="474" left="383" width="137" height="20" font="4"><b>Exclusion criteria:</b> Non-</text>
<text top="492" left="383" width="96" height="20" font="1">English speaking </text>
<text top="372" left="545" width="254" height="20" font="4"><b>1</b>°<b> endpoint:</b> Malformations and adverse fetal </text>
<text top="389" left="545" width="57" height="20" font="1">outcomes </text>
<text top="407" left="545" width="3" height="20" font="1"> </text>
<text top="424" left="545" width="264" height="20" font="4"><b>Results: </b>No difference among groups but study </text>
<text top="441" left="545" width="86" height="20" font="1">under-powered </text>
<text top="373" left="835" width="7" height="18" font="1">•</text>
<text top="372" left="842" width="155" height="20" font="1"> Supportive of above review </text>
<text top="527" left="98" width="96" height="20" font="1">Ferrer RL, et al.,  </text>
<text top="562" left="98" width="63" height="20" font="1">2000 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(283)</a> </text>
<text top="596" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11094241">11094241</a></text>
<text top="596" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11094241"> </a></text>
<text top="527" left="219" width="150" height="20" font="4"><b>Study type:</b> Meta-analysis </text>
<text top="544" left="219" width="3" height="20" font="1"> </text>
<text top="561" left="219" width="126" height="20" font="4"><b>Size: </b>46 observational </text>
<text top="578" left="219" width="134" height="20" font="1">studies and randomized </text>
<text top="596" left="219" width="73" height="20" font="1">control trials  </text>
<text top="527" left="383" width="129" height="20" font="4"><b>Inclusion criteria:</b> Pre-</text>
<text top="544" left="383" width="142" height="20" font="1">specified quality entrance </text>
<text top="561" left="383" width="40" height="20" font="1">criteria </text>
<text top="578" left="383" width="3" height="20" font="1"> </text>
<text top="596" left="383" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="528" left="545" width="242" height="20" font="4"><b>1</b>°<b> endpoint:</b> Adverse pregnancy outcomes </text>
<text top="545" left="545" width="3" height="20" font="1"> </text>
<text top="562" left="545" width="55" height="20" font="4"><b>Results:</b>  </text>
<text top="581" left="545" width="7" height="18" font="1">•</text>
<text top="581" left="551" width="245" height="20" font="1"> Maternal HTN increases risk for 1) perinatal </text>
<text top="598" left="545" width="260" height="20" font="1">mortality (OR: 3.4:1) and 2) placental abruption </text>
<text top="615" left="545" width="39" height="20" font="1">(2.1:1) </text>
<text top="634" left="545" width="7" height="18" font="1">•</text>
<text top="633" left="551" width="266" height="20" font="1"> ACEIs are associated with fetopathy (fetal renal </text>
<text top="651" left="545" width="41" height="20" font="1">failure) </text>
<text top="529" left="835" width="7" height="18" font="1">•</text>
<text top="528" left="842" width="224" height="20" font="1"> HTN by itself is associated with adverse </text>
<text top="545" left="835" width="107" height="20" font="1">perinatal outcomes </text>
<text top="564" left="835" width="7" height="18" font="1">•</text>
<text top="563" left="842" width="260" height="20" font="1"> ACEIs independently are responsible for some </text>
<text top="581" left="835" width="57" height="20" font="1">outcomes </text>
<text top="670" left="128" width="716" height="19" font="26">*Quality assessment analysis may need to be applied on a case-by-case basis for controversial studies (by ERC chairs).</text>
<text top="670" left="844" width="3" height="19" font="4"><b> </b></text>
<text top="706" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="204" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">204 </text>
<text top="106" left="81" width="425" height="24" font="3"><b>Data Supplement 54. RCT for Older Persons (Section 10.3.1) </b></text>
<text top="146" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="163" left="129" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="180" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="146" left="250" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="163" left="255" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="180" left="249" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="146" left="404" width="44" height="20" font="4"><b>Patient </b></text>
<text top="163" left="393" width="67" height="20" font="4"><b>Population </b></text>
<text top="146" left="509" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="163" left="525" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="180" left="510" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="197" left="530" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="146" left="702" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="163" left="685" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="180" left="691" width="129" height="20" font="4"><b>P value; OR or RR; &amp;  </b></text>
<text top="197" left="730" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="147" left="883" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="164" left="915" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="181" left="921" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="199" left="941" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="217" left="98" width="87" height="20" font="1">SPRINT Senior </text>
<text top="234" left="98" width="98" height="20" font="1">Williamson JD, et </text>
<text top="251" left="98" width="51" height="20" font="1">al., 2016 </text>
<text top="268" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(190)</a> </text>
<text top="285" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27195814">27195814</a></text>
<text top="285" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27195814"> </a></text>
<text top="217" left="221" width="138" height="20" font="4"><b>Aim: </b>Intensive SBP goal </text>
<text top="234" left="221" width="97" height="20" font="1">&lt;120 mm Hg) vs. </text>
<text top="251" left="220" width="110" height="20" font="1">standard (SBP goal </text>
<text top="268" left="220" width="35" height="20" font="1">&lt;140) </text>
<text top="285" left="221" width="3" height="20" font="1"> </text>
<text top="303" left="221" width="102" height="20" font="4"><b>Study type:</b> RCT  </text>
<text top="320" left="221" width="3" height="20" font="1"> </text>
<text top="337" left="221" width="121" height="20" font="4"><b>Size:</b> 2,636; 30% met </text>
<text top="354" left="221" width="92" height="20" font="1">criteria for being </text>
<text top="371" left="221" width="134" height="20" font="1">classified as ambulatory </text>
<text top="389" left="221" width="23" height="20" font="1">frail </text>
<text top="406" left="221" width="3" height="20" font="1"> </text>
<text top="423" left="221" width="121" height="20" font="4"><b>Mean follo</b>w-up:3.1 y </text>
<text top="217" left="376" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="234" left="376" width="100" height="20" font="4"><b>criteria:</b> Men and </text>
<text top="251" left="376" width="95" height="20" font="1">women age 75+; </text>
<text top="268" left="376" width="98" height="20" font="1">mean age 79.8 y; </text>
<text top="285" left="376" width="74" height="20" font="1">38% women; </text>
<text top="303" left="376" width="91" height="20" font="1">17% black, 74% </text>
<text top="320" left="376" width="62" height="20" font="1">Caucasian </text>
<text top="337" left="376" width="3" height="20" font="1"> </text>
<text top="354" left="376" width="62" height="20" font="4"><b>Exclusion</b> </text>
<text top="371" left="376" width="93" height="20" font="4"><b>criteria</b>: Nursing </text>
<text top="389" left="376" width="91" height="20" font="1">home residents; </text>
<text top="406" left="376" width="80" height="20" font="1">prevalent DM, </text>
<text top="423" left="376" width="74" height="20" font="1">stroke, Class </text>
<text top="440" left="376" width="52" height="20" font="1">III/IV HF, </text>
<text top="458" left="376" width="54" height="20" font="1">dementia </text>
<text top="217" left="491" width="147" height="20" font="4"><b>Intervention:</b> Medications </text>
<text top="234" left="491" width="117" height="20" font="1">and dietary advice to </text>
<text top="251" left="491" width="142" height="20" font="1">achieve SBP of &lt;120 mm </text>
<text top="268" left="491" width="19" height="20" font="1">Hg </text>
<text top="285" left="491" width="3" height="20" font="1"> </text>
<text top="303" left="491" width="146" height="20" font="4"><b>Comparator:</b> Medications </text>
<text top="320" left="491" width="117" height="20" font="1">and dietary advice to </text>
<text top="337" left="491" width="142" height="20" font="1">achieve SBP of &lt;140 mm </text>
<text top="354" left="491" width="19" height="20" font="1">Hg </text>
<text top="371" left="491" width="3" height="20" font="1"> </text>
<text top="391" left="491" width="7" height="18" font="1">•</text>
<text top="390" left="497" width="90" height="20" font="1"> Achieved SBP<b>: </b></text>
<text top="407" left="491" width="134" height="20" font="1">Intensive=123.4 mm Hg </text>
<text top="424" left="491" width="134" height="20" font="1">Standard=134.8 mm Hg </text>
<text top="218" left="653" width="167" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite CVD </text>
<text top="235" left="653" width="198" height="20" font="1">outcome (AMI, non-MI ACS, stroke, </text>
<text top="252" left="653" width="90" height="20" font="1">HF, CVD death. </text>
<text top="269" left="653" width="3" height="20" font="1"> </text>
<text top="287" left="653" width="55" height="20" font="4"><b>Results</b>:  </text>
<text top="306" left="653" width="7" height="18" font="1">•</text>
<text top="305" left="659" width="3" height="20" font="1"> </text>
<text top="305" left="663" width="149" height="20" font="10">102 events in the intensive </text>
<text top="322" left="653" width="186" height="20" font="10">treatment group vs. 148 events in </text>
<text top="339" left="653" width="190" height="20" font="10">the standard treatment group; HR: </text>
<text top="357" left="653" width="176" height="20" font="10">0.66; 95% CI: 0.51–0.85 and all-</text>
<text top="374" left="653" width="191" height="20" font="10">cause mortality (73 deaths vs. 107 </text>
<text top="391" left="653" width="199" height="20" font="10">deaths, respectively; HR: 0.67; 95% </text>
<text top="408" left="653" width="199" height="20" font="10">CI: 0.49–0.91. No difference in falls, </text>
<text top="426" left="653" width="187" height="20" font="10">orthostatic hypotension, or overall </text>
<text top="443" left="653" width="38" height="20" font="10">SAEs. </text>
<text top="462" left="653" width="7" height="18" font="1">•</text>
<text top="461" left="659" width="3" height="20" font="1"> </text>
<text top="461" left="663" width="46" height="20" font="10">NNT for </text>
<text top="461" left="709" width="13" height="20" font="1">1°</text>
<text top="461" left="722" width="128" height="20" font="10"> outcome=27 and NNT </text>
<text top="478" left="653" width="138" height="20" font="10">for all-cause mortality=41</text>
<text top="478" left="790" width="3" height="20" font="1"> </text>
<text top="217" left="869" width="172" height="20" font="4"><b>Limitations</b>: Does not apply to </text>
<text top="234" left="869" width="171" height="20" font="1">nursing home pts or those with </text>
<text top="251" left="869" width="118" height="20" font="1">dementia or advance </text>
<text top="268" left="869" width="3" height="20" font="1"> </text>
<text top="285" left="869" width="201" height="20" font="4"><b>Conclusions: </b>Intensive SBP is safe </text>
<text top="303" left="869" width="169" height="20" font="1">and effective for lowering CVD </text>
<text top="320" left="869" width="189" height="20" font="1">events and total mortality in adults </text>
<text top="337" left="869" width="38" height="20" font="1">≥75 y <b> </b></text>
<text top="498" left="108" width="3" height="19" font="1"> </text>
<text top="532" left="81" width="650" height="24" font="3"><b>Data Supplement 55.  RCTs Comparing Hypertensive Crises and Emergencies (Section 11.2) </b></text>
<text top="572" left="126" width="38" height="20" font="4"><b>Study </b></text>
<text top="589" left="114" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="606" left="121" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="623" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="572" left="221" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="589" left="226" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="606" left="220" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="572" left="339" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="572" left="485" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="589" left="501" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="606" left="485" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="623" left="506" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="572" left="655" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="589" left="638" width="137" height="20" font="4"><b>(Absolute Event Rates, </b></text>
<text top="606" left="628" width="157" height="20" font="4"><b> P value; OR or RR; &amp; 95% </b></text>
<text top="623" left="697" width="20" height="20" font="4"><b>CI) </b></text>
<text top="573" left="850" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="590" left="883" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="607" left="888" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="625" left="908" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="643" left="98" width="37" height="20" font="4"><b>CLUE </b></text>
<text top="660" left="98" width="90" height="20" font="1">Peacock WF, et </text>
<text top="677" left="98" width="83" height="20" font="1">al., 2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(284)</a> </text>
<text top="694" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21707983?dopt=Citation">21707983</a></text>
<text top="694" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21707983?dopt=Citation"> </a></text>
<text top="643" left="204" width="85" height="20" font="4"><b>Aim: </b>Compare </text>
<text top="660" left="204" width="105" height="20" font="1">safety and efficacy </text>
<text top="677" left="204" width="111" height="20" font="1">of IV nicardipine vs. </text>
<text top="694" left="204" width="83" height="20" font="1">labetalol in the </text>
<text top="711" left="204" width="89" height="20" font="1">management of </text>
<text top="729" left="204" width="66" height="20" font="1">acute HTN. </text>
<text top="746" left="204" width="3" height="20" font="1"> </text>
<text top="763" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="780" left="204" width="3" height="20" font="1"> </text>
<text top="643" left="334" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="661" left="334" width="120" height="20" font="1">SBP ≥180 mm Hg on </text>
<text top="678" left="334" width="78" height="20" font="1">2 consecutive </text>
<text top="695" left="334" width="98" height="20" font="1">occasions 10 min </text>
<text top="713" left="334" width="89" height="20" font="1">apart in the ED. </text>
<text top="643" left="469" width="138" height="20" font="1">● 110 pts randomized to </text>
<text top="660" left="469" width="104" height="20" font="1">nicardipine; 116 to </text>
<text top="677" left="469" width="113" height="20" font="1">labetalol. End-organ </text>
<text top="694" left="469" width="103" height="20" font="1">damage preceded </text>
<text top="711" left="469" width="132" height="20" font="1">randomization in 63%% </text>
<text top="729" left="469" width="100" height="20" font="1">with no difference </text>
<text top="746" left="469" width="140" height="20" font="1">between the groups. The </text>
<text top="763" left="469" width="130" height="20" font="1">target BP range (TR; at </text>
<text top="780" left="469" width="111" height="20" font="1">the discretion of the </text>
<text top="643" left="626" width="132" height="20" font="4"><b>Results</b>: Within 39 min, </text>
<text top="660" left="626" width="150" height="20" font="1">nicardipine pts reached TR </text>
<text top="677" left="626" width="147" height="20" font="1">than labetalol pts (91.7 vs. </text>
<text top="695" left="626" width="145" height="20" font="1">82.5%; p=0.039). Of 6 BP </text>
<text top="713" left="626" width="152" height="20" font="1">measurements taken 5 min </text>
<text top="730" left="626" width="152" height="20" font="1">apart, nicardipine pts had a </text>
<text top="747" left="626" width="148" height="20" font="1">higher rate of 5 and 6 SBP </text>
<text top="764" left="626" width="138" height="20" font="1">measures in the TR than </text>
<text top="781" left="626" width="161" height="20" font="1">labetalol pts (47.3 vs. 32.8%; </text>
<text top="643" left="801" width="258" height="20" font="4"><b>Limitations: </b>Study unblinded;<b> </b>large number of </text>
<text top="660" left="801" width="250" height="20" font="1">pts without end-organ damage (which usually </text>
<text top="677" left="801" width="259" height="20" font="1">defines a hypertensive emergency); physicians </text>
<text top="694" left="801" width="250" height="20" font="1">ordered fewer dose titrations of labetalol than </text>
<text top="711" left="801" width="261" height="20" font="1">nicardipine; thus, lack of BP decline might have </text>
<text top="729" left="801" width="247" height="20" font="1">been due to insufficient dosing by physicians </text>
<text top="746" left="801" width="252" height="20" font="1">hesitant to administer successively increasing </text>
<text top="763" left="801" width="266" height="20" font="1">doses of labetalol as recommended by the FDA. </text>
<text top="780" left="801" width="3" height="20" font="4"><b> </b></text>
</page>
<page number="205" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">205 </text>
<text top="107" left="204" width="76" height="20" font="4"><b>Size: </b>226 pts </text>
<text top="107" left="469" width="128" height="20" font="1">treating physician) was </text>
<text top="125" left="469" width="141" height="20" font="1">defined as SBP ± 20 mm </text>
<text top="143" left="469" width="26" height="20" font="1">Hg.  </text>
<text top="160" left="469" width="134" height="20" font="1">● Dosing titrations were </text>
<text top="177" left="469" width="132" height="20" font="1">those recommended by </text>
<text top="194" left="469" width="52" height="20" font="1">the FDA. </text>
<text top="108" left="626" width="102" height="20" font="1">p=0.026). Rescue </text>
<text top="125" left="626" width="140" height="20" font="1">medications did not differ </text>
<text top="143" left="626" width="157" height="20" font="1">between the nicardipine and </text>
<text top="160" left="626" width="158" height="20" font="1">labetalol groups. Nicardipine </text>
<text top="177" left="626" width="145" height="20" font="1">pts were more likely in the </text>
<text top="194" left="626" width="145" height="20" font="1">TR than labetalol pts (OR: </text>
<text top="212" left="626" width="126" height="20" font="1">2.73; 95% CI: 1.1–6.7; </text>
<text top="230" left="626" width="57" height="20" font="1">p=0.028). </text>
<text top="107" left="801" width="253" height="20" font="4"><b>Conclusions</b>: Pts treated with nicardipine are </text>
<text top="124" left="801" width="258" height="20" font="1">more likely to reach the physician-specified TR </text>
<text top="141" left="801" width="249" height="20" font="1">than those treated with labetalol. In this study </text>
<text top="159" left="801" width="243" height="20" font="1">(2014), initial SBP was not a predictor of the </text>
<text top="176" left="801" width="265" height="20" font="1">ability to achieve the pre-specified TR in 30 min. </text>
<text top="193" left="801" width="243" height="20" font="1">Subgroup analysis demonstrated the similar </text>
<text top="210" left="801" width="233" height="20" font="1">results for sub-populations with end-organ </text>
<text top="227" left="801" width="264" height="20" font="1">damage (n=141) and renal dysfunction (n=104).<b> </b></text>
<text top="248" left="98" width="83" height="20" font="1">Liu-DeRyke X, </text>
<text top="265" left="98" width="64" height="20" font="1">et al., 2013 </text>
<text top="282" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(285)</a> </text>
<text top="299" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23760911?dopt=Citation">23760911</a></text>
<text top="299" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23760911?dopt=Citation"> </a></text>
<text top="248" left="204" width="85" height="20" font="4"><b>Aim: </b>Compare </text>
<text top="265" left="204" width="63" height="20" font="1">ability of IV </text>
<text top="282" left="204" width="87" height="20" font="1">nicardipine and </text>
<text top="300" left="204" width="115" height="20" font="1">labetalol to lower BP </text>
<text top="317" left="204" width="46" height="20" font="1">in acute </text>
<text top="334" left="204" width="86" height="20" font="1">hemorrhagic or </text>
<text top="351" left="204" width="92" height="20" font="1">ischemic stroke. </text>
<text top="368" left="204" width="3" height="20" font="1"> </text>
<text top="386" left="204" width="99" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="403" left="204" width="49" height="20" font="1">(pseudo-</text>
<text top="420" left="204" width="85" height="20" font="1">randomization) </text>
<text top="437" left="204" width="3" height="20" font="1"> </text>
<text top="454" left="204" width="69" height="20" font="4"><b>Size: </b>54 pts </text>
<text top="248" left="334" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="265" left="334" width="80" height="20" font="1">Pts with acute </text>
<text top="282" left="334" width="86" height="20" font="1">hemorrhagic or </text>
<text top="300" left="334" width="114" height="20" font="1">ischemic stroke who </text>
<text top="317" left="334" width="115" height="20" font="1">were at or exceeded </text>
<text top="334" left="334" width="107" height="20" font="1">AHA guidelines BP </text>
<text top="351" left="334" width="105" height="20" font="1">recommendations. </text>
<text top="368" left="334" width="3" height="20" font="1"> </text>
<text top="386" left="334" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="403" left="334" width="89" height="20" font="1">Traumatic brain </text>
<text top="420" left="334" width="100" height="20" font="1">injury; intracranial </text>
<text top="437" left="334" width="110" height="20" font="1">neoplasm, received </text>
<text top="454" left="334" width="93" height="20" font="1">antihypertensive </text>
<text top="472" left="334" width="98" height="20" font="1">medication within </text>
<text top="489" left="334" width="111" height="20" font="1">previous 24 h, brain </text>
<text top="506" left="334" width="91" height="20" font="1">stem herniation, </text>
<text top="523" left="334" width="91" height="20" font="1">immediate brain </text>
<text top="540" left="334" width="106" height="20" font="1">death, acute MI, or </text>
<text top="559" left="334" width="93" height="20" font="1">bradycardia &lt;50 </text>
<text top="576" left="334" width="31" height="20" font="1">bpm. </text>
<text top="250" left="469" width="7" height="18" font="1">•</text>
<text top="249" left="475" width="122" height="20" font="1"> 28 pts randomized to </text>
<text top="266" left="469" width="104" height="20" font="1">labetalol and 26 to </text>
<text top="283" left="469" width="115" height="20" font="1">nicardipine. Goal BP </text>
<text top="301" left="469" width="130" height="20" font="1">defined using the latest </text>
<text top="318" left="469" width="62" height="20" font="1">consensus </text>
<text top="335" left="469" width="105" height="20" font="1">recommendations. </text>
<text top="248" left="626" width="141" height="20" font="4"><b>Results</b>: All pts receiving </text>
<text top="265" left="626" width="135" height="20" font="1">nicardipine achieved BP </text>
<text top="282" left="626" width="154" height="20" font="1">goal Compared with 61% in </text>
<text top="300" left="626" width="105" height="20" font="1">the labetalol group </text>
<text top="317" left="626" width="122" height="20" font="1">(p&lt;0.001). 89% of the </text>
<text top="334" left="626" width="150" height="20" font="1">nicardipine group achieved </text>
<text top="351" left="626" width="149" height="20" font="1">goal within 60 min vs. 25% </text>
<text top="368" left="626" width="118" height="20" font="1">in the labetalol group </text>
<text top="386" left="626" width="147" height="20" font="1">(p&lt;0.001). The nicardipine </text>
<text top="403" left="626" width="94" height="20" font="1">group had better </text>
<text top="420" left="626" width="153" height="20" font="1">maintenance of BP, greater </text>
<text top="437" left="626" width="153" height="20" font="1">percent of time spent within </text>
<text top="454" left="626" width="150" height="20" font="1">goal and less BP variability </text>
<text top="472" left="626" width="153" height="20" font="1">compared with the labetalol </text>
<text top="489" left="626" width="124" height="20" font="1">group (p&lt;0.001). Less </text>
<text top="506" left="626" width="158" height="20" font="1">rescue medication had to be </text>
<text top="523" left="626" width="157" height="20" font="1">given to the nicardipine than </text>
<text top="540" left="626" width="105" height="20" font="1">the labetalol group </text>
<text top="558" left="626" width="60" height="20" font="1">(p&lt;0.001). </text>
<text top="575" left="626" width="3" height="20" font="1"> </text>
<text top="248" left="801" width="266" height="20" font="4"><b>Limitations:</b> Very small; pseudo-randomization. </text>
<text top="265" left="801" width="3" height="20" font="1"> </text>
<text top="282" left="801" width="270" height="20" font="4"><b>Conclusions</b>: In acutely hypertensive stroke pts, </text>
<text top="299" left="801" width="260" height="20" font="1">a superior BP-lowering response was achieved </text>
<text top="317" left="801" width="271" height="20" font="1">with nicardipine over labetalol. Despite this, there </text>
<text top="334" left="801" width="271" height="20" font="1">was no significant difference in clinical outcomes. </text>
<text top="594" left="98" width="40" height="20" font="4"><b>CATIS </b></text>
<text top="611" left="98" width="69" height="20" font="1">He J, et al.,  </text>
<text top="628" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(202)</a> </text>
<text top="646" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24240777?dopt=Citation">24240777</a></text>
<text top="646" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24240777?dopt=Citation"><b> </b></a></text>
<text top="594" left="204" width="82" height="20" font="4"><b>Aim: </b>Evaluate </text>
<text top="611" left="204" width="107" height="20" font="1">whether immediate </text>
<text top="628" left="204" width="107" height="20" font="1">BP reduction in pts </text>
<text top="646" left="204" width="110" height="20" font="1">with acute ischemic </text>
<text top="663" left="204" width="113" height="20" font="1">stroke would reduce </text>
<text top="680" left="204" width="92" height="20" font="1">death and major </text>
<text top="697" left="204" width="105" height="20" font="1">disability in 14 d or </text>
<text top="714" left="204" width="106" height="20" font="1">hospital discharge. </text>
<text top="732" left="204" width="3" height="20" font="1"> </text>
<text top="749" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="766" left="204" width="3" height="20" font="1"> </text>
<text top="783" left="204" width="86" height="20" font="4"><b>Size:</b> 4,071 pts </text>
<text top="594" left="334" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="611" left="334" width="45" height="20" font="1">Pts had </text>
<text top="628" left="334" width="98" height="20" font="1">nonthrombolysed </text>
<text top="646" left="334" width="88" height="20" font="1">ischemic stroke </text>
<text top="663" left="334" width="109" height="20" font="1">within 48 h of onset </text>
<text top="680" left="334" width="105" height="20" font="1">and elevated SBP. </text>
<text top="697" left="334" width="104" height="20" font="1">Baseline SBP was </text>
<text top="714" left="334" width="111" height="20" font="1">166.7 mm Hg in the </text>
<text top="732" left="334" width="93" height="20" font="1">antihypertensive </text>
<text top="749" left="334" width="114" height="20" font="1">treatment group and </text>
<text top="766" left="334" width="111" height="20" font="1">165.6 mm Hg in the </text>
<text top="783" left="334" width="79" height="20" font="1">control group. </text>
<text top="596" left="469" width="7" height="18" font="1">•</text>
<text top="595" left="475" width="114" height="20" font="1"> This was a Chinese </text>
<text top="612" left="469" width="103" height="20" font="1">multicenter, single-</text>
<text top="630" left="469" width="89" height="20" font="1">blinded, blinded </text>
<text top="647" left="469" width="85" height="20" font="1">endpoints RCT </text>
<text top="664" left="469" width="142" height="20" font="1">conducted in 26 hospitals </text>
<text top="681" left="469" width="136" height="20" font="1">in China. 2,038 pts were </text>
<text top="698" left="469" width="124" height="20" font="1">randomized to receive </text>
<text top="716" left="469" width="93" height="20" font="1">antihypertensive </text>
<text top="733" left="469" width="144" height="20" font="1">treatment and 2,033 were </text>
<text top="750" left="469" width="142" height="20" font="1">randomized to the control </text>
<text top="767" left="469" width="111" height="20" font="1">group. The trial was </text>
<text top="784" left="469" width="120" height="20" font="1">designed to test a BP </text>
<text top="594" left="626" width="85" height="20" font="4"><b>Results</b>: In the </text>
<text top="611" left="626" width="148" height="20" font="1">antihypertensive treatment </text>
<text top="628" left="626" width="139" height="20" font="1">group, SBP was reduced </text>
<text top="646" left="626" width="153" height="20" font="1">from 166.7 to 144.7 mm Hg </text>
<text top="663" left="626" width="150" height="20" font="1">(-12.7%) within 24 h and in </text>
<text top="680" left="626" width="158" height="20" font="1">the control group from 165.6 </text>
<text top="697" left="626" width="135" height="20" font="1">to 152.9 mm Hg (-7.2%) </text>
<text top="714" left="626" width="160" height="20" font="1">(absolute difference -9.1 mm </text>
<text top="732" left="626" width="136" height="20" font="1">Hg; 95% CI: -10.2– -8.1; </text>
<text top="749" left="626" width="143" height="20" font="1">p&lt;0.001). Mean SBP was </text>
<text top="766" left="626" width="111" height="20" font="1">137.3 mm Hg in the </text>
<text top="783" left="626" width="148" height="20" font="1">antihypertensive treatment </text>
<text top="594" left="801" width="226" height="20" font="4"><b>Limitations:</b> Study excluded pts with BP </text>
<text top="611" left="801" width="263" height="20" font="1">≥220/120 mm Hg, so the results do not apply to </text>
<text top="628" left="801" width="253" height="20" font="1">such pts. Pts treated acutely with thrombolytic </text>
<text top="646" left="801" width="217" height="20" font="1">therapy were excluded. Trial performed </text>
<text top="663" left="801" width="148" height="20" font="1">exclusively in Chinese pts. </text>
<text top="680" left="801" width="3" height="20" font="4"><b> </b></text>
<text top="697" left="801" width="253" height="20" font="4"><b>Conclusions</b>: Among pts with acute ischemic </text>
<text top="714" left="801" width="232" height="20" font="1">stroke, BP reduction with antihypertensive </text>
<text top="732" left="801" width="208" height="20" font="1">medications, compared to absence of </text>
<text top="749" left="801" width="268" height="20" font="1">antihypertensive medications, did not reduce the </text>
<text top="766" left="801" width="267" height="20" font="1">likelihood of death and major disability at 14 d or </text>
<text top="783" left="801" width="106" height="20" font="1">hospital discharge.<b> </b></text>
</page>
<page number="206" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">206 </text>
<text top="107" left="469" width="137" height="20" font="1">reduction strategy rather </text>
<text top="124" left="469" width="107" height="20" font="1">than the efficacy of </text>
<text top="141" left="469" width="137" height="20" font="1">specific antihypertensive </text>
<text top="159" left="469" width="132" height="20" font="1">drugs. Pts in the control </text>
<text top="176" left="469" width="135" height="20" font="1">group discontinued their </text>
<text top="193" left="469" width="127" height="20" font="1">home BP medications. </text>
<text top="210" left="469" width="3" height="20" font="1"> </text>
<text top="227" left="469" width="74" height="20" font="4"><b>1° outcome</b>: </text>
<text top="245" left="469" width="144" height="20" font="1">Combination of death and </text>
<text top="262" left="469" width="140" height="20" font="1">major disability at 14 d or </text>
<text top="279" left="469" width="106" height="20" font="1">hospital discharge. </text>
<text top="107" left="626" width="149" height="20" font="1">group and 146.5 mm Hg in </text>
<text top="124" left="626" width="137" height="20" font="1">the control group at the 7</text>
<text top="126" left="763" width="7" height="13" font="6">th</text>
<text top="124" left="770" width="14" height="20" font="1"> d </text>
<text top="141" left="626" width="148" height="20" font="1">of randomization (absolute </text>
<text top="159" left="626" width="157" height="20" font="1">difference -9.3 mm Hg; 95% </text>
<text top="176" left="626" width="141" height="20" font="1">CI: -10.1– -8.4; p&lt;0.001). </text>
<text top="193" left="626" width="132" height="20" font="1">The 1° outcome did not </text>
<text top="210" left="626" width="136" height="20" font="1">differ between treatment </text>
<text top="228" left="626" width="148" height="20" font="1">groups (OR: 1.00; 95% CI: </text>
<text top="245" left="626" width="118" height="20" font="1">0.88–1.14) at 14 d or </text>
<text top="262" left="626" width="145" height="20" font="1">hospital discharge. The 2º </text>
<text top="279" left="626" width="157" height="20" font="1">outcome of death and major </text>
<text top="296" left="626" width="122" height="20" font="1">disability at 3 mo post-</text>
<text top="314" left="626" width="148" height="20" font="1">treatment follow-up did not </text>
<text top="331" left="626" width="146" height="20" font="1">differ between the groups. </text>
<text top="349" left="98" width="69" height="20" font="4"><b>INTERAC-2 </b></text>
<text top="366" left="98" width="93" height="20" font="1">Anderson CS, et </text>
<text top="383" left="98" width="83" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#274">(191)</a> </text>
<text top="400" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23713578?dopt=Citation">23713578</a></text>
<text top="400" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23713578?dopt=Citation"><b> </b></a></text>
<text top="349" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="366" left="204" width="3" height="20" font="1"> </text>
<text top="383" left="204" width="86" height="20" font="4"><b>Size:</b> 2,839 pts </text>
<text top="351" left="334" width="7" height="18" font="1">•</text>
<text top="350" left="341" width="90" height="20" font="1">To compare the </text>
<text top="367" left="334" width="75" height="20" font="1">management </text>
<text top="384" left="334" width="112" height="20" font="1">strategy of targeting </text>
<text top="402" left="334" width="99" height="20" font="1">SBP&lt;140 mm Hg </text>
<text top="419" left="334" width="101" height="20" font="1">within 1 h with the </text>
<text top="436" left="334" width="94" height="20" font="1">current guideline </text>
<text top="453" left="334" width="112" height="20" font="1">strategy of targeting </text>
<text top="470" left="334" width="116" height="20" font="1">SBP to &lt;180 mm Hg </text>
<text top="488" left="334" width="83" height="20" font="1">with the use of </text>
<text top="505" left="334" width="75" height="20" font="1">agents of the </text>
<text top="522" left="334" width="120" height="20" font="1">physicians’ choosing. </text>
<text top="351" left="469" width="7" height="18" font="1">•</text>
<text top="350" left="475" width="72" height="20" font="1"> This was an </text>
<text top="367" left="469" width="141" height="20" font="1">international, multicenter, </text>
<text top="384" left="469" width="134" height="20" font="1">prospective randomized </text>
<text top="402" left="469" width="133" height="20" font="1">open-treatment, blinded </text>
<text top="419" left="469" width="122" height="20" font="1">endpoint trial. The pts </text>
<text top="436" left="469" width="71" height="20" font="1">had onset of </text>
<text top="453" left="469" width="143" height="20" font="1">spontaneous ICH within 6 </text>
<text top="470" left="469" width="88" height="20" font="1">h of enrollment. </text>
<text top="488" left="469" width="3" height="20" font="1"> </text>
<text top="506" left="469" width="125" height="20" font="4"><b>1</b>°<b> outcome</b>: Death or </text>
<text top="523" left="469" width="132" height="20" font="1">major disability, defined </text>
<text top="540" left="469" width="133" height="20" font="1">as a score of 3-6 on the </text>
<text top="558" left="469" width="141" height="20" font="1">modified Rankin scale, at </text>
<text top="575" left="469" width="31" height="20" font="1">90 d. </text>
<text top="349" left="626" width="143" height="20" font="4"><b>Results</b>: 719 of 1,382 pts </text>
<text top="366" left="626" width="160" height="20" font="1">receiving intensive treatment </text>
<text top="383" left="626" width="160" height="20" font="1">as compared to 785 of 1,412 </text>
<text top="400" left="626" width="126" height="20" font="1">pts receiving guideline-</text>
<text top="418" left="626" width="161" height="20" font="1">recommended treatment had </text>
<text top="435" left="626" width="161" height="20" font="1">a 1° outcome event [OR with </text>
<text top="452" left="626" width="141" height="20" font="1">intensive treatment: 0.87; </text>
<text top="469" left="626" width="157" height="20" font="1">95% CI: 0.75–1.01; p=0.06). </text>
<text top="487" left="626" width="137" height="20" font="1">Ordinal analysis showed </text>
<text top="504" left="626" width="150" height="20" font="1">significantly lower modified </text>
<text top="521" left="626" width="158" height="20" font="1">Rankin scores with intensive </text>
<text top="538" left="626" width="142" height="20" font="1">treatment (OR for greater </text>
<text top="555" left="626" width="132" height="20" font="1">disability: 0.87; 95% CI: </text>
<text top="573" left="626" width="160" height="20" font="1">0.77–1.00; p=0.04). Mortality </text>
<text top="590" left="626" width="132" height="20" font="1">was 11.9% in the group </text>
<text top="607" left="626" width="160" height="20" font="1">receiving intensive treatment </text>
<text top="624" left="626" width="131" height="20" font="1">and 12.0% in the group </text>
<text top="641" left="626" width="106" height="20" font="1">receiving guideline-</text>
<text top="659" left="626" width="141" height="20" font="1">recommended treatment. </text>
<text top="676" left="626" width="132" height="20" font="1">Nonfatal serious events </text>
<text top="693" left="626" width="117" height="20" font="1">were not significantly </text>
<text top="710" left="626" width="118" height="20" font="1">different between the </text>
<text top="727" left="626" width="44" height="20" font="1">groups. </text>
<text top="349" left="801" width="191" height="20" font="4"><b>Limitations: </b>No major limitations.  </text>
<text top="366" left="801" width="3" height="20" font="4"><b> </b></text>
<text top="383" left="801" width="269" height="20" font="4"><b>Conclusions</b>: In pts with ICH, intensive lowering </text>
<text top="400" left="801" width="220" height="20" font="1">of BP resulted in a borderline significant </text>
<text top="418" left="801" width="265" height="20" font="1">reduction in the rate of death or severe disability </text>
<text top="435" left="801" width="256" height="20" font="1">at 90 d. An ordinal analysis of modified Rankin </text>
<text top="452" left="801" width="259" height="20" font="1">scores indicated improved functional outcomes </text>
<text top="469" left="801" width="236" height="20" font="1">with intensive lowering of BP. Intensive BP </text>
<text top="487" left="801" width="260" height="20" font="1">reduction was shown to be safe and to result in </text>
<text top="504" left="801" width="256" height="20" font="1">significantly better health-related quality of life.<b> </b></text>
</page>
<page number="207" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">207 </text>
<text top="107" left="98" width="56" height="20" font="4"><b>PRONTO </b></text>
<text top="124" left="98" width="90" height="20" font="1">Peacock WF, et </text>
<text top="141" left="98" width="83" height="20" font="1">al., 2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(286)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24655702?dopt=Citation">24655702</a></text>
<text top="159" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24655702?dopt=Citation"><b> </b></a></text>
<text top="107" left="204" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="124" left="204" width="3" height="20" font="1"> </text>
<text top="141" left="204" width="76" height="20" font="4"><b>Size:</b> 104 pts </text>
<text top="109" left="334" width="7" height="18" font="1">•</text>
<text top="108" left="341" width="100" height="20" font="1"> To determine the </text>
<text top="125" left="334" width="119" height="20" font="1">efficacy and safety of </text>
<text top="143" left="334" width="80" height="20" font="1">clevidipine vs. </text>
<text top="160" left="334" width="94" height="20" font="1">standard-of-care </text>
<text top="177" left="334" width="50" height="20" font="1">(SOC) iv </text>
<text top="194" left="334" width="93" height="20" font="1">antihypertensive </text>
<text top="212" left="334" width="57" height="20" font="1">therapy in </text>
<text top="229" left="334" width="107" height="20" font="1">hypertensive acute </text>
<text top="246" left="334" width="23" height="20" font="1">HF. </text>
<text top="109" left="469" width="7" height="18" font="1">•</text>
<text top="108" left="475" width="137" height="20" font="1"> This was a randomized, </text>
<text top="125" left="469" width="140" height="20" font="1">open-label, active control </text>
<text top="143" left="469" width="126" height="20" font="1">study of clevidipine vs. </text>
<text top="160" left="469" width="127" height="20" font="1">standard-of-care in ED </text>
<text top="177" left="469" width="124" height="20" font="1">pts with acute HF with </text>
<text top="194" left="469" width="107" height="20" font="1">SBP ≥160 mm Hg. </text>
<text top="211" left="469" width="3" height="20" font="1"> </text>
<text top="230" left="469" width="111" height="20" font="4"><b>1</b>°<b> outcome</b>: Co-1° </text>
<text top="247" left="469" width="131" height="20" font="1">endpoints were median </text>
<text top="264" left="469" width="139" height="20" font="1">time to and % attaining a </text>
<text top="282" left="469" width="143" height="20" font="1">SBP within a prespecified </text>
<text top="299" left="469" width="77" height="20" font="1">TR at 30 min. </text>
<text top="107" left="626" width="144" height="20" font="4"><b>Results: </b>More clevidipine </text>
<text top="124" left="626" width="122" height="20" font="1">pts reached target BP </text>
<text top="141" left="626" width="137" height="20" font="1">reduction (71%) than did </text>
<text top="159" left="626" width="152" height="20" font="1">those receiving standard-of-</text>
<text top="176" left="626" width="148" height="20" font="1">care (37%) and clevidipine </text>
<text top="193" left="626" width="108" height="20" font="1">was faster to target </text>
<text top="210" left="626" width="159" height="20" font="1">(p=0.0006). Serious adverse </text>
<text top="228" left="626" width="158" height="20" font="1">events were similar between </text>
<text top="245" left="626" width="151" height="20" font="1">clevidipine and standard-of-</text>
<text top="262" left="626" width="31" height="20" font="1">care. </text>
<text top="107" left="801" width="248" height="20" font="4"><b>Limitations: </b>Small study, open-label design.<b> </b></text>
<text top="124" left="801" width="3" height="20" font="4"><b> </b></text>
<text top="141" left="801" width="224" height="20" font="4"><b>Conclusions</b>: In hypertensive acute HF, </text>
<text top="159" left="801" width="251" height="20" font="1">clevidipine safely and rapidly reduced BP and </text>
<text top="176" left="801" width="269" height="20" font="1">improved dyspnea more effectively that standard-</text>
<text top="193" left="801" width="45" height="20" font="1">of-care.<b> </b></text>
<text top="317" left="98" width="86" height="20" font="1">Farias S, et al., </text>
<text top="334" left="98" width="31" height="20" font="1">2014 </text>
<text top="351" left="98" width="58" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13849948?dopt=Citation">13849948 </a></text>
<text top="368" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(287)</a> </text>
<text top="317" left="204" width="116" height="20" font="4"><b>Aim: </b>To determine if </text>
<text top="334" left="204" width="87" height="20" font="1">achievement of </text>
<text top="351" left="204" width="92" height="20" font="1">target BP is less </text>
<text top="368" left="204" width="89" height="20" font="1">likely in pts with </text>
<text top="386" left="204" width="89" height="20" font="1">higher initial BP </text>
<text top="403" left="204" width="93" height="20" font="1">using a post hoc </text>
<text top="420" left="204" width="85" height="20" font="1">analysis in a pt </text>
<text top="437" left="204" width="104" height="20" font="1">subset from CLUE </text>
<text top="454" left="204" width="3" height="20" font="4"><b> </b></text>
<text top="472" left="204" width="98" height="20" font="4"><b>Study type</b>: RCT </text>
<text top="489" left="204" width="101" height="20" font="1">Post-hoc Analysis </text>
<text top="506" left="204" width="3" height="20" font="1"> </text>
<text top="523" left="204" width="75" height="20" font="4"><b>Size</b>: 223 pts </text>
<text top="317" left="334" width="105" height="20" font="4"><b>Inclusion criteria</b>: </text>
<text top="335" left="334" width="120" height="20" font="1">SBP ≥180 mm Hg on </text>
<text top="352" left="334" width="78" height="20" font="1">2 consecutive </text>
<text top="370" left="334" width="98" height="20" font="1">occasions 10 min </text>
<text top="387" left="334" width="89" height="20" font="1">apart in the ED. </text>
<text top="404" left="334" width="3" height="20" font="1"> </text>
<text top="421" left="334" width="109" height="20" font="4"><b>Exclusion criteria</b>: </text>
<text top="438" left="334" width="106" height="20" font="1">Contraindication to </text>
<text top="456" left="334" width="114" height="20" font="1">giving either a BB or </text>
<text top="473" left="334" width="84" height="20" font="1">CCB or clinical </text>
<text top="490" left="334" width="114" height="20" font="1">scenarios in which a </text>
<text top="507" left="334" width="96" height="20" font="1">compelling agent </text>
<text top="524" left="334" width="81" height="20" font="1">was indicated. </text>
<text top="319" left="469" width="7" height="18" font="1">•</text>
<text top="318" left="475" width="115" height="20" font="1"> This was a post hoc </text>
<text top="335" left="469" width="118" height="20" font="1">analysis of CLUE, an </text>
<text top="352" left="469" width="130" height="20" font="1">RCT, in which pts were </text>
<text top="370" left="469" width="129" height="20" font="1">dichotomized using the </text>
<text top="387" left="469" width="133" height="20" font="1">median presenting SBP </text>
<text top="404" left="469" width="118" height="20" font="1">as the partition point. </text>
<text top="421" left="469" width="122" height="20" font="1">Individuals above and </text>
<text top="438" left="469" width="130" height="20" font="1">below the median were </text>
<text top="456" left="469" width="107" height="20" font="1">evaluated as to the </text>
<text top="473" left="469" width="135" height="20" font="1">proportion achieving the </text>
<text top="490" left="469" width="70" height="20" font="1">1° outcome. </text>
<text top="507" left="469" width="3" height="20" font="1"> </text>
<text top="524" left="469" width="74" height="20" font="4"><b>1° outcome</b>: </text>
<text top="542" left="469" width="123" height="20" font="1">Achievement of target </text>
<text top="559" left="469" width="141" height="20" font="1">SBP range within 30 min. </text>
<text top="317" left="626" width="156" height="20" font="4"><b>Results</b>: Early achievement </text>
<text top="334" left="626" width="102" height="20" font="1">of target SBP was </text>
<text top="351" left="626" width="146" height="20" font="1">independent of presenting </text>
<text top="368" left="626" width="31" height="20" font="1">SBP. </text>
<text top="317" left="801" width="259" height="20" font="4"><b>Limitations: </b>2º analysis of the 1° CLUE study; </text>
<text top="334" left="801" width="253" height="20" font="1">SBP control only evaluated for the first 30 min </text>
<text top="351" left="801" width="246" height="20" font="1">posttreatment; no inclusion of critically ill pts; </text>
<text top="368" left="801" width="269" height="20" font="1">80% of enrolled subjects were African-American.<b> </b></text>
<text top="386" left="801" width="3" height="20" font="4"><b> </b></text>
<text top="403" left="801" width="263" height="20" font="4"><b>Conclusions</b>: Presenting SBP does not appear </text>
<text top="420" left="801" width="261" height="20" font="1">to affect the ultimate ability to reduce BP for pts </text>
<text top="437" left="801" width="264" height="20" font="1">with marked, acute HTN in the ED when treated </text>
<text top="454" left="801" width="219" height="20" font="1">with either IV nicardipine or IV labetalol. </text>
<text top="578" left="108" width="3" height="19" font="1"> </text>
<text top="613" left="81" width="765" height="24" font="3"><b>Data Supplement 56. RCTs Assessing Impact of Hypertension Therapy on Dementia Incidence (Section 11.3) </b></text>
<text top="652" left="106" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="670" left="132" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="687" left="109" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="652" left="242" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="670" left="247" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="687" left="241" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="652" left="385" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="652" left="541" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="670" left="557" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="687" left="542" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="704" left="562" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="652" left="714" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="670" left="697" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="687" left="679" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="653" left="902" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="671" left="934" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="688" left="939" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="705" left="960" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="723" left="98" width="37" height="20" font="4"><b>SHEP</b> </text>
<text top="740" left="98" width="116" height="20" font="1">Applegate WB, et al., </text>
<text top="757" left="98" width="66" height="20" font="1">1994 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(288)</a>  </text>
<text top="775" left="98" width="47" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7944835?dopt=Citation">7944835</a></text>
<text top="775" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7944835?dopt=Citation"> </a></text>
<text top="723" left="226" width="110" height="20" font="4"><b>Aim: </b>Compare loss </text>
<text top="740" left="226" width="84" height="20" font="1">of instrumental </text>
<text top="757" left="226" width="93" height="20" font="1">activities of daily </text>
<text top="775" left="226" width="76" height="20" font="1">living by SBP </text>
<text top="723" left="354" width="152" height="20" font="4"><b>Inclusion criteria</b>: 60–80 y </text>
<text top="740" left="354" width="79" height="20" font="1">(mean 71.6 y) </text>
<text top="757" left="354" width="3" height="20" font="1"> </text>
<text top="723" left="540" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="740" left="540" width="93" height="20" font="1">Chlorthalidone + </text>
<text top="757" left="540" width="62" height="20" font="1">Atenolol or </text>
<text top="775" left="540" width="55" height="20" font="1">reserpine </text>
<text top="724" left="666" width="173" height="20" font="4"><b>1</b>°<b> endpoint:</b> Loss of dementia-</text>
<text top="741" left="666" width="168" height="20" font="1">related functions (instrumental </text>
<text top="759" left="666" width="128" height="20" font="1">activities of daily living) </text>
<text top="776" left="666" width="7" height="20" font="1">  </text>
<text top="723" left="879" width="202" height="20" font="4"><b>Relevant  2° endpoint: </b>Incidence of </text>
<text top="740" left="879" width="175" height="20" font="1">surrogate markers for dementia<b> </b></text>
<text top="757" left="879" width="3" height="20" font="1"> </text>
</page>
<page number="208" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">208 </text>
<text top="107" left="226" width="75" height="20" font="1">treatment vs. </text>
<text top="124" left="226" width="46" height="20" font="1">placebo </text>
<text top="141" left="226" width="3" height="20" font="1"> </text>
<text top="159" left="226" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="176" left="226" width="3" height="20" font="1"> </text>
<text top="193" left="226" width="66" height="20" font="4"><b>Size:</b> 4,736 </text>
<text top="210" left="226" width="3" height="20" font="1"> </text>
<text top="227" left="226" width="78" height="20" font="4"><b>Duration: </b>5 y </text>
<text top="107" left="354" width="151" height="20" font="4"><b>Exclusion criteria:</b> History </text>
<text top="124" left="354" width="154" height="20" font="1">and/or signs of major CVDs </text>
<text top="141" left="354" width="153" height="20" font="1">(e.g., previous MI, coronary </text>
<text top="159" left="354" width="117" height="20" font="1">artery surgery, major </text>
<text top="176" left="354" width="134" height="20" font="1">arrhythmias, conduction </text>
<text top="193" left="354" width="159" height="20" font="1">defect, recent stroke, carotid </text>
<text top="210" left="354" width="155" height="20" font="1">artery disease, ≥2 TIAs and </text>
<text top="228" left="354" width="165" height="20" font="1">signs or symptoms in a single </text>
<text top="245" left="354" width="172" height="20" font="1">neurological distribution); other </text>
<text top="262" left="354" width="161" height="20" font="1">major diseases (e.g., cancer, </text>
<text top="279" left="354" width="126" height="20" font="1">alcoholic liver disease, </text>
<text top="296" left="354" width="166" height="20" font="1">established renal dysfunction) </text>
<text top="314" left="354" width="166" height="20" font="1">with competing risk factors for </text>
<text top="332" left="354" width="131" height="20" font="1">the 1° endpoint; stroke; </text>
<text top="349" left="354" width="113" height="20" font="1">presence of medical </text>
<text top="367" left="354" width="161" height="20" font="1">management problems (e.g., </text>
<text top="384" left="354" width="165" height="20" font="1">insulin dependent DM, history </text>
<text top="401" left="354" width="137" height="20" font="1">of dementia, evidence of </text>
<text top="418" left="354" width="158" height="20" font="1">alcohol abuse); bradycardia; </text>
<text top="435" left="354" width="150" height="20" font="1">people maintained on BBs, </text>
<text top="453" left="354" width="84" height="20" font="1">diuretics, other </text>
<text top="470" left="354" width="130" height="20" font="1">antihypertensive drugs, </text>
<text top="487" left="354" width="86" height="20" font="1">anticoagulants. </text>
<text top="107" left="540" width="3" height="20" font="1"> </text>
<text top="124" left="540" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="141" left="540" width="48" height="20" font="1">Placebo </text>
<text top="159" left="540" width="3" height="20" font="4"><b> </b></text>
<text top="176" left="540" width="28" height="20" font="4"><b>SBP </b></text>
<text top="193" left="540" width="114" height="20" font="4"><b>Treatment/Placebo </b></text>
<text top="210" left="540" width="69" height="20" font="4"><b>difference</b>:  </text>
<text top="227" left="540" width="64" height="20" font="1">-12 mm Hg </text>
<text top="245" left="540" width="88" height="20" font="1">Achieved mean </text>
<text top="262" left="540" width="111" height="20" font="1">SPB: 143 mm Hg in </text>
<text top="279" left="540" width="109" height="20" font="1">treatment group vs. </text>
<text top="296" left="540" width="80" height="20" font="1">155 mm Hg in </text>
<text top="314" left="540" width="81" height="20" font="1">placebo group </text>
<text top="107" left="666" width="40" height="20" font="4"><b>Cases </b></text>
<text top="126" left="666" width="7" height="18" font="1">•</text>
<text top="125" left="673" width="64" height="20" font="1"> Active: 37  </text>
<text top="144" left="666" width="7" height="18" font="1">•</text>
<text top="144" left="673" width="72" height="20" font="1"> Placebo: 44 </text>
<text top="163" left="666" width="7" height="18" font="1">•</text>
<text top="162" left="673" width="108" height="20" font="1"> p=0.84 (0.54,1.31) </text>
<text top="181" left="666" width="7" height="18" font="1">•</text>
<text top="181" left="673" width="182" height="20" font="1"> No cognitive function instrument </text>
<text top="198" left="666" width="85" height="20" font="1">included in trial<b> </b></text>
<text top="107" left="879" width="205" height="20" font="4"><b>Summary:</b> Nonsignificant 16% lower </text>
<text top="124" left="879" width="185" height="20" font="1">incidence of incident instrumental </text>
<text top="141" left="879" width="169" height="20" font="1">activity of daily living disability. </text>
<text top="159" left="879" width="203" height="20" font="1">However, assignment to the placebo </text>
<text top="176" left="879" width="207" height="20" font="1">group and the resulting occurrence of </text>
<text top="193" left="879" width="194" height="20" font="1">CV events independently predicted </text>
<text top="210" left="879" width="209" height="20" font="1">missed assessments. However, when </text>
<text top="228" left="879" width="177" height="20" font="1">20%–30% and 40%–80% of the </text>
<text top="245" left="879" width="206" height="20" font="1">subjects who missed the assessment </text>
<text top="262" left="879" width="114" height="20" font="1">were assumed to be </text>
<text top="279" left="879" width="180" height="20" font="1">cognitively/functionally impaired, </text>
<text top="296" left="879" width="219" height="20" font="1">assignment to active treatment reduced </text>
<text top="314" left="879" width="218" height="20" font="1">the risk of these outcomes. Thus, in the </text>
<text top="331" left="879" width="169" height="20" font="1">SHEP study, the cognitive and </text>
<text top="348" left="879" width="192" height="20" font="1">functional evaluations were biased </text>
<text top="365" left="879" width="193" height="20" font="1">toward the null effect by differential </text>
<text top="383" left="879" width="213" height="20" font="1">dropout. This might have obscured the </text>
<text top="400" left="879" width="181" height="20" font="1">appraisal of a protective effect of </text>
<text top="417" left="879" width="169" height="20" font="1">treatment on the cognitive and </text>
<text top="434" left="879" width="216" height="20" font="1">functional decline of older hypertensive </text>
<text top="451" left="879" width="36" height="20" font="1">adults </text>
<text top="505" left="98" width="57" height="20" font="4"><b>Syst-Eur </b> </text>
<text top="522" left="98" width="89" height="20" font="1">Forette F, et al., </text>
<text top="539" left="98" width="62" height="20" font="1">1998 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(289)</a> </text>
<text top="557" left="98" width="48" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9802273?dopt=Citation">9802273</a></text>
<text top="557" left="145" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9802273?dopt=Citation"> </a></text>
<text top="505" left="226" width="76" height="20" font="4"><b>Aim: </b>Incident </text>
<text top="522" left="226" width="53" height="20" font="1">dementia </text>
<text top="539" left="226" width="3" height="20" font="1"> </text>
<text top="557" left="226" width="98" height="20" font="4"><b>Study type: </b>RCT </text>
<text top="574" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="591" left="226" width="85" height="20" font="4"><b>Size: </b>2,418 pts<b> </b></text>
<text top="608" left="226" width="3" height="20" font="1"> </text>
<text top="625" left="226" width="77" height="20" font="4"><b>Duration:</b> 2 y </text>
<text top="505" left="354" width="141" height="20" font="4"><b>Inclusion criteria: </b>≥60 y<b> </b></text>
<text top="522" left="354" width="3" height="20" font="4"><b> </b></text>
<text top="539" left="354" width="168" height="20" font="4"><b>Exclusion criteria: </b>HTN 2° to </text>
<text top="557" left="354" width="171" height="20" font="1">a disorder that needed specific </text>
<text top="574" left="354" width="165" height="20" font="1">medical or surgical treatment; </text>
<text top="591" left="354" width="143" height="20" font="1">congestive HF; dissecting </text>
<text top="608" left="354" width="132" height="20" font="1">aortic aneurysm; serum </text>
<text top="625" left="354" width="148" height="20" font="1">creatinine concentration at </text>
<text top="643" left="354" width="109" height="20" font="1">presentation of 180 </text>
<text top="660" left="354" width="173" height="20" font="1">micromoles/l or more; stroke or </text>
<text top="677" left="354" width="155" height="20" font="1">MI in the y before the study; </text>
<text top="694" left="354" width="157" height="20" font="1">dementia; substance abuse; </text>
<text top="711" left="354" width="141" height="20" font="1">any disorder prohibiting a </text>
<text top="729" left="354" width="172" height="20" font="1">sitting or standing position; any </text>
<text top="746" left="354" width="149" height="20" font="1">severe concomitant or non-</text>
<text top="763" left="354" width="33" height="20" font="1">CVD<b>  </b></text>
<text top="505" left="540" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="522" left="540" width="81" height="20" font="1">Nitrendipine ± </text>
<text top="539" left="540" width="98" height="20" font="1">enalapril ± HCTZ </text>
<text top="557" left="540" width="3" height="20" font="1"> </text>
<text top="574" left="540" width="80" height="20" font="4"><b>Comparator:</b>  </text>
<text top="591" left="540" width="48" height="20" font="1">Placebo </text>
<text top="608" left="540" width="3" height="20" font="1"> </text>
<text top="625" left="540" width="28" height="20" font="4"><b>SBP </b></text>
<text top="643" left="540" width="110" height="20" font="4"><b>treatment/placebo </b></text>
<text top="660" left="540" width="66" height="20" font="4"><b>difference: </b></text>
<text top="677" left="540" width="68" height="20" font="1">-8.3 mm Hg </text>
<text top="694" left="540" width="95" height="20" font="1">Achieved SBP in </text>
<text top="711" left="540" width="67" height="20" font="1">152 mm Hg </text>
<text top="729" left="540" width="107" height="20" font="1">treatment arm; 160 </text>
<text top="746" left="540" width="89" height="20" font="1">mm Hg placebo </text>
<text top="763" left="540" width="25" height="20" font="1">arm </text>
<text top="505" left="666" width="181" height="20" font="4"><b>Endpoint:</b> Dementia (defined by </text>
<text top="522" left="666" width="44" height="20" font="1">MMSE) </text>
<text top="539" left="666" width="3" height="20" font="1"> </text>
<text top="557" left="666" width="44" height="20" font="4"><b>Cases: </b></text>
<text top="576" left="666" width="7" height="18" font="1">•</text>
<text top="575" left="673" width="64" height="20" font="1"> Active: 11  </text>
<text top="594" left="666" width="7" height="18" font="1">•</text>
<text top="593" left="673" width="75" height="20" font="1"> Placebo: 21  </text>
<text top="612" left="666" width="7" height="18" font="1">•</text>
<text top="612" left="673" width="151" height="20" font="1"> (3.8 vs. 7.7 per 1,000 pt-y) </text>
<text top="631" left="666" width="7" height="18" font="1">•</text>
<text top="630" left="673" width="45" height="20" font="1"> p=0.05 </text>
<text top="505" left="879" width="185" height="20" font="4"><b>Summary</b>: Trial stopped early for </text>
<text top="522" left="879" width="185" height="20" font="1">positive effect on CVD outcomes. </text>
</page>
<page number="209" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">209 </text>
<text top="107" left="98" width="100" height="20" font="4"><b>Syst-Eur (legacy </b></text>
<text top="124" left="98" width="66" height="20" font="4"><b>follow-up)  </b></text>
<text top="141" left="98" width="94" height="20" font="1">Forette F, et al.,  </text>
<text top="159" left="98" width="63" height="20" font="1">2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(280)</a> </text>
<text top="176" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12374512?dopt=Citation">12374512</a></text>
<text top="176" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12374512?dopt=Citation"> </a></text>
<text top="107" left="226" width="109" height="20" font="4"><b>Aim: </b>Legacy follow-</text>
<text top="124" left="226" width="89" height="20" font="1">up for dementia </text>
<text top="141" left="226" width="61" height="20" font="1">prevention </text>
<text top="159" left="226" width="3" height="20" font="1"> </text>
<text top="176" left="226" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="193" left="226" width="100" height="20" font="1">with legacy follow-</text>
<text top="210" left="226" width="17" height="20" font="1">up </text>
<text top="227" left="226" width="3" height="20" font="1"> </text>
<text top="245" left="226" width="86" height="20" font="4"><b>Size:</b> 2,902 pts </text>
<text top="262" left="226" width="3" height="20" font="1"> </text>
<text top="279" left="226" width="88" height="20" font="4"><b>Duration: </b>3.7 y<b> </b></text>
<text top="107" left="354" width="141" height="20" font="4"><b>Inclusion criteria:</b> ≥60 y<b> </b></text>
<text top="124" left="354" width="3" height="20" font="1"> </text>
<text top="141" left="354" width="172" height="20" font="4"><b>Exclusion criteria: </b>HTN 2°ary </text>
<text top="159" left="354" width="140" height="20" font="1">to a disorder that needed </text>
<text top="176" left="354" width="150" height="20" font="1">specific medical or surgical </text>
<text top="193" left="354" width="144" height="20" font="1">treatment; congestive HF; </text>
<text top="210" left="354" width="152" height="20" font="1">dissecting aortic aneurysm; </text>
<text top="228" left="354" width="172" height="20" font="1">serum creatinine concentration </text>
<text top="245" left="354" width="122" height="20" font="1">at presentation of 180 </text>
<text top="262" left="354" width="173" height="20" font="1">micromoles/l or more; stroke or </text>
<text top="279" left="354" width="155" height="20" font="1">MI in the y before the study; </text>
<text top="296" left="354" width="157" height="20" font="1">dementia; substance abuse; </text>
<text top="314" left="354" width="141" height="20" font="1">any disorder prohibiting a </text>
<text top="331" left="354" width="172" height="20" font="1">sitting or standing position; any </text>
<text top="348" left="354" width="149" height="20" font="1">severe concomitant or non-</text>
<text top="365" left="354" width="29" height="20" font="1">CVD<b> </b></text>
<text top="107" left="540" width="111" height="20" font="4"><b>Intervention:</b> Open </text>
<text top="124" left="540" width="96" height="20" font="1">label follow-up of </text>
<text top="141" left="540" width="70" height="20" font="1">Syst-Eur pts </text>
<text top="159" left="540" width="104" height="20" font="1">originally assigned </text>
<text top="176" left="540" width="94" height="20" font="1">to Nitrendipine ± </text>
<text top="193" left="540" width="98" height="20" font="1">enalapril ± HCTZ </text>
<text top="210" left="540" width="66" height="20" font="1">vs. placebo </text>
<text top="227" left="540" width="3" height="20" font="1"> </text>
<text top="245" left="540" width="28" height="20" font="4"><b>SBP </b></text>
<text top="262" left="540" width="114" height="20" font="4"><b>Treatment/Placebo </b></text>
<text top="279" left="540" width="90" height="20" font="4"><b>difference</b>: -7.0 </text>
<text top="296" left="540" width="46" height="20" font="1">mm Hg  </text>
<text top="314" left="540" width="95" height="20" font="1">Achieved SBP in </text>
<text top="331" left="540" width="67" height="20" font="1">149 mm Hg </text>
<text top="348" left="540" width="104" height="20" font="1">treatment arm 156 </text>
<text top="365" left="540" width="89" height="20" font="1">mm Hg placebo </text>
<text top="382" left="540" width="25" height="20" font="1">arm </text>
<text top="108" left="666" width="145" height="20" font="4"><b>1</b>°<b> endpoint:</b> Incidence of </text>
<text top="125" left="666" width="57" height="20" font="1">dementia  </text>
<text top="143" left="666" width="3" height="20" font="1"> </text>
<text top="160" left="666" width="168" height="20" font="4"><b>Endpoint 2:</b> Cognitive decline </text>
<text top="177" left="666" width="115" height="20" font="1">measured by MMSE </text>
<text top="194" left="666" width="3" height="20" font="1"> </text>
<text top="211" left="666" width="123" height="20" font="4"><b>Safety endpoint:</b> N/A </text>
<text top="231" left="666" width="7" height="18" font="1">•</text>
<text top="230" left="673" width="101" height="20" font="1"> Cases active: 21  </text>
<text top="249" left="666" width="7" height="18" font="1">•</text>
<text top="248" left="673" width="109" height="20" font="1"> Cases placebo; 43 </text>
<text top="267" left="666" width="7" height="18" font="1">•</text>
<text top="267" left="673" width="187" height="20" font="1"> Rate 3.3 vs. 7.4 cases/1,000 pt-y </text>
<text top="286" left="666" width="7" height="18" font="1">•</text>
<text top="285" left="673" width="143" height="20" font="1"> 0.38 (95% CI: 0.23–0.64; </text>
<text top="302" left="666" width="52" height="20" font="1">p&lt;0.001)<b> </b></text>
<text top="109" left="879" width="7" height="18" font="1">•</text>
<text top="108" left="885" width="174" height="20" font="1"> This legacy follow-up with both </text>
<text top="125" left="879" width="219" height="20" font="1">groups (off protocol) yielded a follow-up </text>
<text top="143" left="879" width="177" height="20" font="1">of 3.7 y SBP was 149 mm Hg in </text>
<text top="160" left="879" width="223" height="20" font="1">treatment vs. 156 mm Hg in control arm  </text>
<text top="177" left="879" width="3" height="20" font="1"> </text>
<text top="194" left="879" width="124" height="20" font="4"><b>Summary dementia:</b>  </text>
<text top="213" left="879" width="7" height="18" font="1">•</text>
<text top="213" left="885" width="187" height="20" font="1"> Compared with the controls, long-</text>
<text top="230" left="879" width="213" height="20" font="1">term antihypertensive therapy reduced </text>
<text top="247" left="879" width="211" height="20" font="1">the risk of dementia by 55%, from 7.4–</text>
<text top="264" left="879" width="193" height="20" font="1">3.3 cases per 1,000 pt-y (43 vs. 21 </text>
<text top="282" left="879" width="206" height="20" font="1">cases; p&lt;0.001). After adjustment for </text>
<text top="299" left="879" width="212" height="20" font="1">sex, age, education, and entry BP, the </text>
<text top="316" left="879" width="191" height="20" font="1">RH rate associated with the use of </text>
<text top="333" left="879" width="201" height="20" font="1">nitrendipine was 0.38; 95% CI: 0.23–</text>
<text top="350" left="879" width="86" height="20" font="1">0.64; p&lt;0.001.  </text>
<text top="369" left="879" width="7" height="18" font="1">•</text>
<text top="369" left="885" width="164" height="20" font="1"> Lack of impact on MMSE not </text>
<text top="386" left="879" width="182" height="20" font="1">surprising given low sensitivity to </text>
<text top="403" left="879" width="167" height="20" font="1">change and large sample size </text>
<text top="421" left="98" width="46" height="20" font="4"><b>SCOPE</b> </text>
<text top="438" left="98" width="87" height="20" font="1">Lithell H, et al.,  </text>
<text top="456" left="98" width="66" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(290)</a>  </text>
<text top="473" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12714861?dopt=Citation">12714861</a></text>
<text top="473" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12714861?dopt=Citation"> </a></text>
<text top="421" left="226" width="77" height="20" font="4"><b>Aim: </b>Incident </text>
<text top="438" left="226" width="110" height="20" font="1">dementia (cognitive </text>
<text top="456" left="226" width="73" height="20" font="1">decline as 2º </text>
<text top="473" left="226" width="55" height="20" font="1">outcome)<b> </b></text>
<text top="490" left="226" width="3" height="20" font="1"> </text>
<text top="507" left="226" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="524" left="226" width="3" height="20" font="1"> </text>
<text top="542" left="226" width="66" height="20" font="4"><b>Size: </b>4,964 </text>
<text top="559" left="226" width="3" height="20" font="1"> </text>
<text top="576" left="226" width="88" height="20" font="4"><b>Duration:</b> 3.7 y </text>
<text top="421" left="354" width="153" height="20" font="4"><b>Inclusion criteria:</b> 70–89 y </text>
<text top="438" left="354" width="69" height="20" font="1">(mean 76 y) </text>
<text top="456" left="354" width="3" height="20" font="1"> </text>
<text top="473" left="354" width="165" height="20" font="4"><b>Exclusion criteria: </b>Prevalent </text>
<text top="490" left="354" width="163" height="20" font="1">dementia; 2º HTN, SBP &gt;180 </text>
<text top="507" left="354" width="107" height="20" font="1">mm Hg, orthostatic </text>
<text top="524" left="354" width="122" height="20" font="1">hypotension, need for </text>
<text top="542" left="354" width="148" height="20" font="1">antihypertensive treatment </text>
<text top="559" left="354" width="169" height="20" font="1">other than hydrochlorothiazide </text>
<text top="576" left="354" width="144" height="20" font="1">during run-in; stroke or MI </text>
<text top="593" left="354" width="160" height="20" font="1">within 6 mo; decompensated </text>
<text top="610" left="354" width="145" height="20" font="1">HF; serum creatinine&gt;180 </text>
<text top="628" left="354" width="144" height="20" font="1">micromole/l (men) or&gt;140 </text>
<text top="645" left="354" width="124" height="20" font="1">micromole/l (women);  </text>
<text top="421" left="540" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="438" left="540" width="85" height="20" font="1">Candesartan ± </text>
<text top="456" left="540" width="36" height="20" font="1">HCTZ </text>
<text top="473" left="540" width="3" height="20" font="1"> </text>
<text top="490" left="540" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="507" left="540" width="96" height="20" font="1">Placebo ± Rx for </text>
<text top="524" left="540" width="100" height="20" font="1">community based </text>
<text top="542" left="540" width="79" height="20" font="1">SPB standard </text>
<text top="559" left="540" width="3" height="20" font="1"> </text>
<text top="576" left="540" width="28" height="20" font="4"><b>SBP </b></text>
<text top="593" left="540" width="114" height="20" font="4"><b>Treatment/Placebo </b></text>
<text top="610" left="540" width="69" height="20" font="4"><b>difference</b>:  </text>
<text top="628" left="540" width="68" height="20" font="1">-3.2 mm Hg </text>
<text top="421" left="666" width="64" height="20" font="4"><b>Endpoint:</b>  </text>
<text top="440" left="666" width="7" height="18" font="1">•</text>
<text top="440" left="673" width="104" height="20" font="1"> Incident dementia </text>
<text top="459" left="666" width="7" height="18" font="1">•</text>
<text top="458" left="673" width="130" height="20" font="1"> Also decline in MMSE  </text>
<text top="475" left="666" width="3" height="20" font="4"><b> </b></text>
<text top="492" left="666" width="106" height="20" font="4"><b>Dementia Cases: </b> </text>
<text top="511" left="666" width="7" height="18" font="1">•</text>
<text top="511" left="673" width="61" height="20" font="1"> Active: 62 </text>
<text top="530" left="666" width="7" height="18" font="1">•</text>
<text top="529" left="673" width="72" height="20" font="1"> Placebo: 57 </text>
<text top="548" left="666" width="7" height="18" font="1">•</text>
<text top="547" left="673" width="111" height="20" font="1"> p=1.08 (0.75–1.56) </text>
<text top="566" left="666" width="7" height="18" font="1">•</text>
<text top="566" left="673" width="152" height="20" font="1"> Cognitive decline slower in </text>
<text top="583" left="666" width="94" height="20" font="1">treatment group  </text>
<text top="421" left="879" width="66" height="20" font="4"><b>Summary</b>:  </text>
<text top="440" left="879" width="7" height="18" font="1">•</text>
<text top="440" left="885" width="183" height="20" font="1"> Mean follow-up 3.7 y. Treatment </text>
<text top="457" left="879" width="204" height="20" font="1">group SBP=144 mm Hg and placebo </text>
<text top="474" left="879" width="198" height="20" font="1">147 mm Hg; thus, relatively minimal </text>
<text top="491" left="879" width="207" height="20" font="1">differences in achieved SBP between </text>
<text top="508" left="879" width="31" height="20" font="1">arms </text>
<text top="527" left="879" width="7" height="18" font="1">•</text>
<text top="527" left="885" width="208" height="20" font="1"> There were no significant differences </text>
<text top="544" left="879" width="214" height="20" font="1">between the treatment groups in either </text>
<text top="561" left="879" width="170" height="20" font="1">dementia or cognitive decline.  </text>
<text top="663" left="98" width="73" height="20" font="4"><b>PROGRESS </b></text>
<text top="680" left="98" width="97" height="20" font="1">Tzourio C, et al.,  </text>
<text top="697" left="98" width="63" height="20" font="1">2003 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(291)</a> </text>
<text top="714" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12742805?dopt=Citation">12742805</a></text>
<text top="714" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12742805?dopt=Citation"><b> </b></a></text>
<text top="663" left="226" width="110" height="20" font="4"><b>AIM: </b>Dementia with </text>
<text top="680" left="226" width="108" height="20" font="1">or without recurrent </text>
<text top="697" left="226" width="37" height="20" font="1">stroke<b> </b></text>
<text top="714" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="732" left="226" width="98" height="20" font="4"><b>Study type: </b>RCT<b> </b></text>
<text top="749" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="766" left="226" width="85" height="20" font="4"><b>Size: </b>6,105 pts<b> </b></text>
<text top="783" left="226" width="3" height="20" font="4"><b> </b></text>
<text top="663" left="354" width="172" height="20" font="4"><b>Inclusion criteria: </b>Prior stroke </text>
<text top="680" left="354" width="118" height="20" font="1">or TIA, any adult age<b> </b></text>
<text top="697" left="354" width="3" height="20" font="1"> </text>
<text top="714" left="354" width="3" height="20" font="1"> </text>
<text top="663" left="540" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="680" left="540" width="74" height="20" font="1">Perindopril ± </text>
<text top="697" left="540" width="67" height="20" font="1">indapamide </text>
<text top="714" left="540" width="3" height="20" font="4"><b> </b></text>
<text top="732" left="540" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="749" left="540" width="48" height="20" font="1">Placebo </text>
<text top="766" left="595" width="3" height="20" font="1"> </text>
<text top="663" left="666" width="190" height="20" font="4"><b>Endpoint:</b> Dementia alone or with </text>
<text top="680" left="666" width="90" height="20" font="1">recurrent stroke </text>
<text top="697" left="666" width="3" height="20" font="4"><b> </b></text>
<text top="714" left="666" width="167" height="20" font="4"><b>Dementia cases: </b>Only stroke-</text>
<text top="732" left="666" width="191" height="20" font="1">related dementia reduction of 34% </text>
<text top="749" left="666" width="134" height="20" font="1">(95% CI: 3–55), p=0.03. </text>
<text top="663" left="879" width="199" height="20" font="4"><b>Summary: </b>Dementia alone was not </text>
<text top="680" left="879" width="192" height="20" font="1">affected in this trial. Only dementia </text>
<text top="697" left="879" width="133" height="20" font="1">associated with incident </text>
<text top="714" left="879" width="140" height="20" font="1">cerebrovascular accident<b> </b></text>
</page>
<page number="210" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">210 </text>
<text top="107" left="226" width="88" height="20" font="4"><b>Duration: </b>3.9 y<b> </b></text>
<text top="107" left="540" width="28" height="20" font="4"><b>SBP </b></text>
<text top="124" left="540" width="114" height="20" font="4"><b>Treatment/Placebo </b></text>
<text top="141" left="540" width="69" height="20" font="4"><b>difference</b>:  </text>
<text top="159" left="540" width="68" height="20" font="1">-9.4 mm Hg </text>
<text top="178" left="540" width="7" height="18" font="1">•</text>
<text top="177" left="547" width="98" height="20" font="1"> Achieved SBP in </text>
<text top="194" left="540" width="67" height="20" font="1">138 mm Hg </text>
<text top="211" left="540" width="104" height="20" font="1">treatment arm 147 </text>
<text top="229" left="540" width="89" height="20" font="1">mm Hg placebo </text>
<text top="246" left="540" width="25" height="20" font="1">arm </text>
<text top="264" left="98" width="109" height="20" font="1">Hypertension in the </text>
<text top="281" left="98" width="97" height="20" font="1">Very Elderly Trial </text>
<text top="298" left="98" width="98" height="20" font="1">cognitive function </text>
<text top="316" left="98" width="69" height="20" font="1">assessment<b> </b></text>
<text top="333" left="98" width="83" height="20" font="4"><b>(HYVET-Cog)</b>  </text>
<text top="350" left="98" width="92" height="20" font="1">Peters R, et al.,  </text>
<text top="367" left="98" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(292)</a> </text>
<text top="384" left="98" width="54" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18614402?dopt=Citation">18614402</a></text>
<text top="384" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18614402?dopt=Citation"> </a></text>
<text top="264" left="226" width="77" height="20" font="4"><b>Aim:</b> Incident </text>
<text top="281" left="226" width="92" height="20" font="1">dementia 2º aim </text>
<text top="298" left="226" width="3" height="20" font="1"> </text>
<text top="316" left="226" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="333" left="226" width="3" height="20" font="1"> </text>
<text top="350" left="226" width="69" height="20" font="4"><b>Size</b>: 3,336  </text>
<text top="367" left="226" width="3" height="20" font="1"> </text>
<text top="384" left="226" width="88" height="20" font="4"><b>Duration:</b> 2.2 y<b> </b></text>
<text top="264" left="354" width="141" height="20" font="4"><b>Inclusion criteria:</b> ≥80 y </text>
<text top="281" left="354" width="3" height="20" font="1"> </text>
<text top="298" left="354" width="165" height="20" font="4"><b>Exclusion criteria: </b>Prevalent </text>
<text top="316" left="354" width="57" height="20" font="1">dementia  </text>
<text top="264" left="540" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="281" left="540" width="79" height="20" font="1">Indapamide ± </text>
<text top="298" left="540" width="62" height="20" font="1">Perindopril </text>
<text top="316" left="540" width="3" height="20" font="1"> </text>
<text top="333" left="540" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="350" left="540" width="48" height="20" font="1">Placebo </text>
<text top="367" left="540" width="3" height="20" font="1"> </text>
<text top="384" left="540" width="28" height="20" font="4"><b>SBP </b></text>
<text top="402" left="540" width="110" height="20" font="4"><b>treatment/placebo </b></text>
<text top="419" left="540" width="69" height="20" font="4"><b>difference</b>:  </text>
<text top="436" left="540" width="68" height="20" font="1">- 15 mm Hg<b> </b></text>
<text top="455" left="540" width="7" height="18" font="1">•</text>
<text top="454" left="547" width="94" height="20" font="1"> Target SBP 150 </text>
<text top="472" left="540" width="46" height="20" font="1">mm Hg  </text>
<text top="491" left="540" width="7" height="18" font="1">•</text>
<text top="490" left="547" width="98" height="20" font="1"> Achieved SPB in </text>
<text top="507" left="540" width="108" height="20" font="1">treatment arm=146 </text>
<text top="524" left="540" width="43" height="20" font="1">mm Hg </text>
<text top="265" left="666" width="176" height="20" font="4"><b>1</b>° <b>endpoint:</b> Incident dementia </text>
<text top="282" left="666" width="3" height="20" font="1"> </text>
<text top="299" left="666" width="51" height="20" font="4"><b>Events:</b>  </text>
<text top="319" left="666" width="7" height="18" font="1">•</text>
<text top="318" left="673" width="91" height="20" font="1"> Treatment=126 </text>
<text top="337" left="666" width="7" height="18" font="1">•</text>
<text top="336" left="673" width="79" height="20" font="1"> Placebo=137 </text>
<text top="355" left="666" width="7" height="18" font="1">•</text>
<text top="355" left="673" width="164" height="20" font="1"> 14% reduction not significant </text>
<text top="372" left="666" width="169" height="20" font="1"> HR: 0.86 (95% CI: 0.67–1.09) </text>
<text top="389" left="666" width="3" height="20" font="4"><b> </b></text>
<text top="264" left="879" width="221" height="20" font="4"><b>Summary:</b> Stopped early due to benefit </text>
<text top="282" left="879" width="83" height="20" font="1">in 1° outcome. </text>
<text top="544" left="108" width="3" height="19" font="1"> </text>
<text top="578" left="81" width="612" height="24" font="3"><b>Data Supplement 57. RCTs for Patients Undergoing Surgical Procedures (Section 11.5) </b></text>
<text top="618" left="99" width="150" height="20" font="4"><b>Study Acronym; Author;  </b></text>
<text top="635" left="126" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="618" left="286" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="635" left="291" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="652" left="284" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="618" left="433" width="44" height="20" font="4"><b>Patient </b></text>
<text top="635" left="422" width="67" height="20" font="4"><b>Population </b></text>
<text top="618" left="535" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="635" left="551" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="652" left="535" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="670" left="556" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="618" left="741" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="635" left="724" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="652" left="706" width="174" height="20" font="4"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="619" left="928" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="636" left="960" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="654" left="966" width="100" height="20" font="4"><b>Adverse Events; </b></text>
<text top="671" left="986" width="63" height="20" font="4"><b>Summary  </b></text>
<text top="689" left="98" width="130" height="20" font="4"><b>POISE</b> Study Group, et </text>
<text top="706" left="98" width="83" height="20" font="1">al., 2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(293)</a> </text>
<text top="723" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16875901">16875901</a></text>
<text top="723" left="152" width="7" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16875901">  </a></text>
<text top="689" left="260" width="93" height="20" font="4"><b>Aim: </b>Definitively </text>
<text top="706" left="260" width="126" height="20" font="1">establish the effects of </text>
<text top="723" left="260" width="97" height="20" font="1">BB therapy in pts </text>
<text top="740" left="260" width="129" height="20" font="1">undergoing noncardiac </text>
<text top="757" left="260" width="44" height="20" font="1">surgery </text>
<text top="775" left="260" width="3" height="20" font="1"> </text>
<text top="689" left="408" width="58" height="20" font="4"><b>Inclusion </b></text>
<text top="706" left="408" width="69" height="20" font="4"><b>criteria:</b> Pts </text>
<text top="723" left="408" width="65" height="20" font="1">undergoing </text>
<text top="740" left="408" width="64" height="20" font="1">noncardiac </text>
<text top="757" left="408" width="87" height="20" font="1">surgery with, or </text>
<text top="775" left="408" width="91" height="20" font="1">at risk for ASVD </text>
<text top="689" left="516" width="132" height="20" font="4"><b>Intervention:</b> extended </text>
<text top="706" left="516" width="105" height="20" font="1">release metoprolol </text>
<text top="723" left="516" width="55" height="20" font="1">succinate </text>
<text top="740" left="516" width="3" height="20" font="1"> </text>
<text top="757" left="516" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="690" left="678" width="230" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite of CV death, NF </text>
<text top="707" left="678" width="118" height="20" font="1">MI, NF cardiac arrest </text>
<text top="724" left="678" width="3" height="20" font="1"> </text>
<text top="741" left="678" width="206" height="20" font="4"><b>Results</b>: Fewer pts taking metoprolol </text>
<text top="759" left="678" width="213" height="20" font="1">than placebo reached the 1° endpoint, </text>
<text top="776" left="678" width="219" height="20" font="1">HR: 0.84; 95% CI 0.70–0.99; p=0.0399. </text>
<text top="689" left="921" width="181" height="20" font="4"><b>Limitations</b>: No data for pts &lt;45 </text>
<text top="706" left="921" width="160" height="20" font="1">y, no data for pts undergoing </text>
<text top="723" left="921" width="87" height="20" font="1">cardiac surgery </text>
<text top="740" left="921" width="3" height="20" font="1"> </text>
<text top="757" left="921" width="140" height="20" font="4"><b>Conclusions</b>: This study </text>
<text top="775" left="921" width="183" height="20" font="1">highlights combined benefits and </text>
</page>
<page number="211" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">211 </text>
<text top="107" left="260" width="102" height="20" font="4"><b>Study type:</b> RCT  </text>
<text top="124" left="260" width="3" height="20" font="1"> </text>
<text top="141" left="260" width="66" height="20" font="4"><b>Size:</b> 8,351 </text>
<text top="107" left="678" width="216" height="20" font="1">However more in metoprolol group had </text>
<text top="124" left="678" width="230" height="20" font="1">death HR: 1.33; 1.03–1.74; p=0.0317 and </text>
<text top="141" left="678" width="209" height="20" font="1">more had stroke HR: 2.17; 1.26–3.74; </text>
<text top="159" left="678" width="58" height="20" font="1">p=0.0053. </text>
<text top="107" left="921" width="180" height="20" font="1">risk of BB regimen in noncardiac </text>
<text top="124" left="921" width="160" height="20" font="1">surgery and importance of pt </text>
<text top="141" left="921" width="178" height="20" font="1">physician discussion in deciding </text>
<text top="159" left="921" width="73" height="20" font="1">upon its use.<b> </b></text>
<text top="178" left="108" width="3" height="19" font="1"> </text>
<text top="212" left="81" width="875" height="24" font="3"><b>Data Supplement 58. Observational and Nonrandomized Studies for Patients Undergoing Surgical Procedures (Section 11.5) </b></text>
<text top="252" left="118" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="269" left="143" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="287" left="121" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="252" left="267" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="269" left="283" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="252" left="419" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="252" left="577" width="183" height="20" font="4"><b>Primary Endpoint and Results  </b></text>
<text top="269" left="578" width="178" height="20" font="4"><b>(P value; OR or RR; &amp; 95% CI) </b></text>
<text top="252" left="875" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="269" left="902" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="305" left="96" width="126" height="20" font="1">Howell SJ, et al., 2004 </text>
<text top="322" left="96" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(294)</a> </text>
<text top="339" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15013960">15013960</a></text>
<text top="339" left="150" width="7" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15013960"> <b> </b></a></text>
<text top="305" left="251" width="143" height="20" font="4"><b>Study type:</b> A systematic </text>
<text top="322" left="251" width="142" height="20" font="1">review and meta-analysis </text>
<text top="339" left="251" width="3" height="20" font="1"> </text>
<text top="356" left="251" width="126" height="20" font="4"><b>Size:</b> 30 observational </text>
<text top="373" left="251" width="42" height="20" font="1">studies </text>
<text top="305" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="322" left="413" width="109" height="20" font="1">Available crude OR </text>
<text top="339" left="413" width="83" height="20" font="1">for association </text>
<text top="356" left="413" width="102" height="20" font="1">between HTN and </text>
<text top="373" left="413" width="58" height="20" font="1">periop CV </text>
<text top="391" left="413" width="111" height="20" font="1">complications along </text>
<text top="408" left="413" width="75" height="20" font="1">with variance </text>
<text top="425" left="413" width="3" height="20" font="1"> </text>
<text top="442" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="460" left="413" width="118" height="20" font="1">N/A. Studies defining </text>
<text top="477" left="413" width="80" height="20" font="1">HTN solely on </text>
<text top="494" left="413" width="79" height="20" font="1">admission BP </text>
<text top="306" left="548" width="213" height="20" font="4"><b>1</b>°<b> endpoint:</b> Periop CV complications </text>
<text top="323" left="548" width="3" height="20" font="1"> </text>
<text top="340" left="548" width="232" height="20" font="4"><b>Results:</b> Pts with SBP &gt;180 or DBP &gt;110 </text>
<text top="357" left="548" width="216" height="20" font="1">mm Hg more prone to periop ischemia, </text>
<text top="375" left="548" width="206" height="20" font="1">arrhythmias, and CV lability OR: 1.35 </text>
<text top="392" left="548" width="70" height="20" font="1">(1.17–1.56). </text>
<text top="306" left="798" width="7" height="18" font="1">•</text>
<text top="306" left="805" width="258" height="20" font="1"> Pts with SBP &gt;180 or DBP &gt;110 mm Hg more </text>
<text top="323" left="798" width="257" height="20" font="1">prone to periop ischemia, arrhythmias, and CV </text>
<text top="340" left="798" width="256" height="20" font="1">lability OR: 1.35 (1.17–1.56). But there was no </text>
<text top="357" left="798" width="282" height="20" font="1">evidence that deferring surgery in such pts reduces </text>
<text top="375" left="798" width="64" height="20" font="1">periop risk  </text>
<text top="394" left="798" width="7" height="18" font="1">•</text>
<text top="393" left="805" width="252" height="20" font="1"> Conclude that planned surgery should not be </text>
<text top="410" left="798" width="271" height="20" font="1">deferred on basis of single admission BP. History </text>
<text top="427" left="798" width="280" height="20" font="1">of target organ damage more important than preop </text>
<text top="445" left="798" width="168" height="20" font="1">BP in predicting complications </text>
<text top="512" left="96" width="128" height="20" font="1">Hart GR and Anderson </text>
<text top="529" left="96" width="85" height="20" font="1">RJ, 1981 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(295)</a> </text>
<text top="546" left="96" width="48" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6114720">6114720</a></text>
<text top="546" left="144" width="7" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/6114720"> </a><b> </b></text>
<text top="512" left="251" width="126" height="20" font="4"><b>Study type:</b> Literature </text>
<text top="529" left="251" width="39" height="20" font="1">review </text>
<text top="546" left="251" width="3" height="20" font="1"> </text>
<text top="564" left="251" width="145" height="20" font="4"><b>Size:</b> 72 pts BB s, 148 pts </text>
<text top="581" left="251" width="55" height="20" font="1">Clonidine </text>
<text top="512" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="529" left="413" width="78" height="20" font="1">Symptoms on </text>
<text top="546" left="413" width="109" height="20" font="1">cessation of BBs or </text>
<text top="564" left="413" width="52" height="20" font="1">clonidine </text>
<text top="581" left="413" width="3" height="20" font="1"> </text>
<text top="598" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="615" left="413" width="108" height="20" font="1">CP Bypass, carotid </text>
<text top="632" left="413" width="89" height="20" font="1">endarterectomy </text>
<text top="513" left="548" width="210" height="20" font="4"><b>1</b>°<b> endpoint:</b> CV symptoms or events </text>
<text top="530" left="548" width="228" height="20" font="1">after abrupt cessation of BBs or clonidine </text>
<text top="548" left="548" width="3" height="20" font="1"> </text>
<text top="565" left="548" width="232" height="20" font="4"><b>Results:</b> Symptoms of anxiety, chest pain </text>
<text top="582" left="548" width="190" height="20" font="1">with tachycardia, HTN, myocardial </text>
<text top="599" left="548" width="232" height="20" font="1">ischemia; less frequently MI may occur on </text>
<text top="616" left="548" width="202" height="20" font="1">abrupt withdrawal of BB or Clonidine </text>
<text top="514" left="798" width="7" height="18" font="1">•</text>
<text top="513" left="805" width="254" height="20" font="1"> Summary of case reports. CV events such as </text>
<text top="530" left="798" width="275" height="20" font="1">tachycardia, HTN, angina, myocardial ischemia or </text>
<text top="548" left="798" width="271" height="20" font="1">infarction can occur after abrupt withdrawal of BB </text>
<text top="565" left="798" width="235" height="20" font="1">or Clonidine. No information on incidence.  </text>
<text top="650" left="96" width="120" height="20" font="1">Shammash JB, et al., </text>
<text top="668" left="96" width="63" height="20" font="1">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(296)</a> </text>
<text top="685" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11136500">11136500</a></text>
<text top="685" left="150" width="7" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11136500"> <b> </b></a></text>
<text top="650" left="251" width="138" height="20" font="4"><b>Study type:</b> Prospective </text>
<text top="668" left="251" width="109" height="20" font="1">observational study </text>
<text top="685" left="251" width="3" height="20" font="1"> </text>
<text top="702" left="251" width="76" height="20" font="4"><b>Size:</b> 140 pts </text>
<text top="650" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="668" left="413" width="101" height="20" font="1">Review of 140 pts </text>
<text top="685" left="413" width="114" height="20" font="1">undergoing vascular </text>
<text top="702" left="413" width="113" height="20" font="1">surgery at university </text>
<text top="719" left="413" width="52" height="20" font="1">hospitals </text>
<text top="736" left="413" width="3" height="20" font="1"> </text>
<text top="754" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="771" left="413" width="24" height="20" font="1">N/A </text>
<text top="651" left="548" width="186" height="20" font="4"><b>1</b>°<b> endpoint:</b> In-hospital mortality </text>
<text top="669" left="548" width="3" height="20" font="1"> </text>
<text top="686" left="548" width="218" height="20" font="4"><b>Results:</b> 50% mortality in 8 pts with BB </text>
<text top="703" left="548" width="231" height="20" font="1">discontinued vs. 1.5% mortality in pts with </text>
<text top="720" left="548" width="184" height="20" font="1">BB continued. OR: 65.0; p=0.001 </text>
<text top="652" left="798" width="7" height="18" font="1">•</text>
<text top="651" left="805" width="247" height="20" font="1"> Discontinuing BB immediately after vascular </text>
<text top="669" left="798" width="275" height="20" font="1">surgery may increase the risk of postoperative CV </text>
<text top="686" left="798" width="127" height="20" font="1">morbidity and mortality </text>
</page>
<page number="212" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">212 </text>
<text top="107" left="96" width="121" height="20" font="1">Lindenauer PK, et al., </text>
<text top="124" left="96" width="63" height="20" font="1">2005 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(297)</a> </text>
<text top="141" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16049209">16049209</a></text>
<text top="141" left="150" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16049209"><b> </b></a></text>
<text top="107" left="251" width="149" height="20" font="4"><b>Study type:</b> Retrospective </text>
<text top="124" left="251" width="38" height="20" font="1">cohort </text>
<text top="141" left="251" width="3" height="20" font="1"> </text>
<text top="159" left="251" width="100" height="20" font="4"><b>Size:</b> 122,338 pts </text>
<text top="107" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="124" left="413" width="97" height="20" font="1">Age &gt;18 y, major </text>
<text top="141" left="413" width="108" height="20" font="1">noncardiac surgery </text>
<text top="159" left="413" width="3" height="20" font="1"> </text>
<text top="176" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="193" left="413" width="103" height="20" font="1">contraindication to </text>
<text top="210" left="413" width="64" height="20" font="1">BB therapy </text>
<text top="108" left="548" width="186" height="20" font="4"><b>1</b>°<b> endpoint:</b> In-hospital mortality </text>
<text top="125" left="548" width="3" height="20" font="1"> </text>
<text top="143" left="548" width="224" height="20" font="4"><b>Results:</b> On BB therapy, mortality in low </text>
<text top="160" left="548" width="214" height="20" font="1">risk (RCRI =0) OR: 1.43 (1.29–1.58) to </text>
<text top="177" left="548" width="224" height="20" font="1">high risk (RCRI) OR 4 or higher OR 0.57 </text>
<text top="194" left="548" width="66" height="20" font="1">(0.42–0.76) </text>
<text top="109" left="798" width="7" height="18" font="1">•</text>
<text top="108" left="805" width="265" height="20" font="1"> Periop BB therapy is associated with a reduced </text>
<text top="125" left="798" width="265" height="20" font="1">risk of in-hospital death among high-risk, but not </text>
<text top="143" left="798" width="276" height="20" font="1">low-risk pts undergoing major noncardiac surgery. </text>
<text top="228" left="96" width="107" height="20" font="1">Wallace AW, et al., </text>
<text top="245" left="96" width="63" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#279">(298)</a> </text>
<text top="263" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20864832">20864832</a></text>
<text top="263" left="150" width="7" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20864832"> <b> </b></a></text>
<text top="228" left="251" width="149" height="20" font="4"><b>Study type:</b> Retrospective </text>
<text top="245" left="251" width="33" height="20" font="1">study </text>
<text top="263" left="251" width="3" height="20" font="1"> </text>
<text top="280" left="251" width="134" height="20" font="4"><b>Size:</b> 38,779 operations </text>
<text top="228" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="245" left="413" width="115" height="20" font="1">All surgical pts at SF </text>
<text top="263" left="413" width="39" height="20" font="1">VAMC </text>
<text top="280" left="413" width="3" height="20" font="1"> </text>
<text top="297" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="314" left="413" width="24" height="20" font="1">N/A </text>
<text top="229" left="548" width="198" height="20" font="4"><b>1</b>°<b> endpoint:</b> 30-d and 1-y mortality </text>
<text top="247" left="548" width="3" height="20" font="1"> </text>
<text top="264" left="548" width="178" height="20" font="4"><b>Results:</b> Addition of BB therapy </text>
<text top="281" left="548" width="235" height="20" font="1">associated with reduction in 30-d OR: 0.52 </text>
<text top="298" left="548" width="205" height="20" font="1">(0.33–83; p=0.006) and 1-y OR: 0.64 </text>
<text top="316" left="548" width="175" height="20" font="1">(0.51–0.79; p&lt;0.0001) mortality </text>
<text top="230" left="798" width="7" height="18" font="1">•</text>
<text top="229" left="805" width="258" height="20" font="1"> Periop BB therapy based upon periop Cardiac </text>
<text top="247" left="798" width="243" height="20" font="1">Risk Reduction protocol is associated with a </text>
<text top="264" left="798" width="232" height="20" font="1">reduction in 30-d and 1-y mortality. Periop </text>
<text top="281" left="798" width="252" height="20" font="1">withdrawal of BB is associated with increased </text>
<text top="298" left="798" width="50" height="20" font="1">mortality </text>
<text top="334" left="96" width="105" height="20" font="1">Andersson C, et al </text>
<text top="351" left="96" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(299)</a> </text>
<text top="368" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24247428">24247428</a></text>
<text top="368" left="150" width="7" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24247428"> <b> </b></a></text>
<text top="334" left="251" width="149" height="20" font="4"><b>Study type:</b> Retrospective </text>
<text top="351" left="251" width="70" height="20" font="1">cohort study </text>
<text top="368" left="251" width="3" height="20" font="1"> </text>
<text top="385" left="251" width="93" height="20" font="4"><b>Size:</b> 28,263 pts </text>
<text top="334" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="351" left="413" width="71" height="20" font="1">Pts with IHD </text>
<text top="368" left="413" width="65" height="20" font="1">undergoing </text>
<text top="385" left="413" width="108" height="20" font="1">noncardiac surgery </text>
<text top="402" left="413" width="3" height="20" font="1"> </text>
<text top="420" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="437" left="413" width="24" height="20" font="1">N/A </text>
<text top="335" left="548" width="219" height="20" font="4"><b>1</b>°<b> endpoint:</b> 30-d risk of MACE and all-</text>
<text top="352" left="548" width="86" height="20" font="1">cause mortality </text>
<text top="369" left="548" width="3" height="20" font="1"> </text>
<text top="386" left="548" width="222" height="20" font="4"><b>Results:</b> Among pts with HF BB Rx HR: </text>
<text top="404" left="548" width="217" height="20" font="1">0.78 (0.67–90) for MACE and all-cause </text>
<text top="421" left="548" width="193" height="20" font="1">mortality 0.80 (0.70-0.92) all-cause </text>
<text top="438" left="548" width="227" height="20" font="1">mortality; and with recent Hx MI HR: 0.60 </text>
<text top="455" left="548" width="219" height="20" font="1">(0.42–0.86) MACE, 0.80 (0.53–1.21) all-</text>
<text top="472" left="548" width="86" height="20" font="1">cause mortality </text>
<text top="335" left="798" width="7" height="18" font="1">•</text>
<text top="335" left="805" width="244" height="20" font="1"> Among pts with IHD undergoing noncardiac </text>
<text top="352" left="798" width="278" height="20" font="1">surgery, use of BB associated with lower risk of 30 </text>
<text top="369" left="798" width="283" height="20" font="1">d MACE and mortality only among those with HF or </text>
<text top="386" left="798" width="55" height="20" font="1">recent MI </text>
<text top="490" left="96" width="95" height="20" font="1">Hoeks SE, et al., </text>
<text top="508" left="96" width="63" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(300)</a> </text>
<text top="525" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16935011">16935011</a></text>
<text top="525" left="150" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16935011"><b> </b></a></text>
<text top="490" left="251" width="138" height="20" font="4"><b>Study type:</b> Prospective </text>
<text top="508" left="251" width="40" height="20" font="1">survey </text>
<text top="525" left="251" width="3" height="20" font="1"> </text>
<text top="542" left="251" width="76" height="20" font="4"><b>Size:</b> 771 pts </text>
<text top="490" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="508" left="413" width="102" height="20" font="1">Pts 18 y and older </text>
<text top="525" left="413" width="65" height="20" font="1">undergoing </text>
<text top="542" left="413" width="107" height="20" font="1">peripheral vascular </text>
<text top="559" left="413" width="44" height="20" font="1">surgery </text>
<text top="576" left="413" width="3" height="20" font="1"> </text>
<text top="594" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="611" left="413" width="24" height="20" font="1">N/A </text>
<text top="491" left="548" width="146" height="20" font="4"><b>1</b>°<b> endpoint:</b> 1-y mortality </text>
<text top="509" left="548" width="3" height="20" font="1"> </text>
<text top="526" left="548" width="221" height="20" font="4"><b>Results:</b> 1 y BB use had lower mortality </text>
<text top="543" left="548" width="224" height="20" font="1">c/w non-BB users (HR: 0.4; 95% CI: 0.2–</text>
<text top="560" left="548" width="190" height="20" font="1">0.7); BB withdrawal had increased </text>
<text top="577" left="548" width="225" height="20" font="1">mortality c/w nonusers (HR: 2.7; 95% CI: </text>
<text top="595" left="548" width="49" height="20" font="1">1.2–5.9) </text>
<text top="492" left="798" width="7" height="18" font="1">•</text>
<text top="491" left="805" width="253" height="20" font="1"> Periop BB use was independently associated </text>
<text top="509" left="798" width="234" height="20" font="1">with lower risk of 1-y mortality while periop </text>
<text top="526" left="798" width="268" height="20" font="1">withdrawal was associated with higher risk of 1 y </text>
<text top="543" left="798" width="50" height="20" font="1">mortality </text>
<text top="629" left="96" width="93" height="20" font="1">Barrett TW, et al </text>
<text top="646" left="96" width="63" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(301)</a> </text>
<text top="663" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17702038">17702038</a></text>
<text top="663" left="150" width="7" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17702038"> <b> </b></a></text>
<text top="629" left="251" width="149" height="20" font="4"><b>Study type:</b> Retrospective </text>
<text top="646" left="251" width="70" height="20" font="1">cohort study </text>
<text top="663" left="251" width="3" height="20" font="1"> </text>
<text top="680" left="251" width="86" height="20" font="4"><b>Size:</b> 3,062 pts </text>
<text top="629" left="413" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="646" left="413" width="86" height="20" font="1">Pts undergoing </text>
<text top="663" left="413" width="94" height="20" font="1">vascular surgery </text>
<text top="680" left="413" width="3" height="20" font="1"> </text>
<text top="698" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="715" left="413" width="24" height="20" font="1">N/A </text>
<text top="630" left="548" width="232" height="20" font="4"><b>1</b>°<b> endpoint:</b> Long-term mortality, median </text>
<text top="647" left="548" width="83" height="20" font="1">follow-up 2.7 y </text>
<text top="664" left="548" width="3" height="20" font="1"> </text>
<text top="681" left="548" width="230" height="20" font="4"><b>Results:</b> Use of BB over study period c/w </text>
<text top="699" left="548" width="222" height="20" font="1">no BB reduced mortality (HR: 0.84; 95% </text>
<text top="716" left="548" width="140" height="20" font="1">CI: 0.73–0.96; p=0.0106) </text>
<text top="630" left="798" width="7" height="18" font="1">•</text>
<text top="630" left="805" width="241" height="20" font="1"> The use of propensity-adjusted BB c/w use </text>
<text top="647" left="798" width="198" height="20" font="1">reduced long-term mortality by 16% </text>
<text top="734" left="96" width="98" height="20" font="1">London MJ, et al. </text>
<text top="751" left="96" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(302)</a> </text>
<text top="768" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23613075">23613075</a></text>
<text top="768" left="150" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23613075"><b> </b></a></text>
<text top="734" left="251" width="149" height="20" font="4"><b>Study type:</b> Retrospective </text>
<text top="751" left="251" width="85" height="20" font="1">cohort analysis </text>
<text top="768" left="251" width="3" height="20" font="1"> </text>
<text top="785" left="251" width="100" height="20" font="4"><b>Size:</b> 136,745 pts </text>
<text top="734" left="413" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="751" left="413" width="120" height="20" font="1">Pts undergoing major </text>
<text top="768" left="413" width="108" height="20" font="1">noncardiac surgery </text>
<text top="785" left="413" width="3" height="20" font="1"> </text>
<text top="735" left="548" width="231" height="20" font="4"><b>1</b>°<b> endpoint:</b> All-cause 30-d mortality and </text>
<text top="752" left="548" width="234" height="20" font="1">cardiac morbidity (cardiac arrest, or non-Q </text>
<text top="769" left="548" width="49" height="20" font="1">wave MI </text>
<text top="787" left="548" width="3" height="20" font="1"> </text>
<text top="736" left="798" width="7" height="18" font="1">•</text>
<text top="735" left="805" width="258" height="20" font="1"> BB therapy was associated with lower rates of </text>
<text top="752" left="798" width="255" height="20" font="1">30-d all-cause mortality in pts with ≥2 Revised </text>
<text top="769" left="798" width="124" height="20" font="1">Cardiac Index Factors </text>
</page>
<page number="213" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">213 </text>
<text top="107" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="124" left="413" width="24" height="20" font="1">N/A </text>
<text top="107" left="548" width="237" height="20" font="4"><b>Results:</b> BB exposure lower 30-d mortality </text>
<text top="124" left="548" width="234" height="20" font="1">in pts with 2 or more RCIF (RR: 0.63; 95% </text>
<text top="141" left="548" width="130" height="20" font="1">CI: 0.50–0.80; p&lt;.001)  </text>
<text top="159" left="96" width="81" height="20" font="1">Turan A, et al. </text>
<text top="177" left="96" width="63" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(303)</a> </text>
<text top="194" left="96" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22253266?dopt=Citation">22253266</a></text>
<text top="194" left="150" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22253266?dopt=Citation"><b> </b></a></text>
<text top="159" left="251" width="121" height="20" font="4"><b>Study type:</b> Matched </text>
<text top="177" left="251" width="109" height="20" font="1">observational study </text>
<text top="194" left="251" width="3" height="20" font="1"> </text>
<text top="211" left="251" width="93" height="20" font="4"><b>Size:</b> 79,228 pts </text>
<text top="159" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="177" left="413" width="110" height="20" font="1">Pts with noncardiac </text>
<text top="194" left="413" width="44" height="20" font="1">surgery </text>
<text top="211" left="413" width="3" height="20" font="1"> </text>
<text top="228" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="245" left="413" width="24" height="20" font="1">N/A </text>
<text top="161" left="548" width="206" height="20" font="4"><b>1</b>°<b> endpoint:</b> Intraoperative and post-</text>
<text top="178" left="548" width="223" height="20" font="1">operative upper airway complications, in-</text>
<text top="195" left="548" width="229" height="20" font="1">hospital complications, and 30-d mortality </text>
<text top="212" left="548" width="3" height="20" font="1"> </text>
<text top="229" left="548" width="229" height="20" font="4"><b>Results:</b> ACEI usage was not associated </text>
<text top="247" left="548" width="226" height="20" font="1">with either 30-d mortality (OR: 0.93; 95% </text>
<text top="264" left="548" width="122" height="20" font="1">CI: 0.73–1.19; p=0.22 </text>
<text top="161" left="798" width="7" height="18" font="1">•</text>
<text top="161" left="805" width="271" height="20" font="1"> No association found between use of ACEIs and </text>
<text top="178" left="798" width="243" height="20" font="1">intraoperative or postoperative upper airway </text>
<text top="195" left="798" width="265" height="20" font="1">complications, in-hospital complications, or 30-d </text>
<text top="212" left="798" width="50" height="20" font="1">mortality </text>
<text top="282" left="96" width="111" height="20" font="1">Rosenman DJ, et al </text>
<text top="299" left="96" width="63" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(304)</a> </text>
<text top="316" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18698608">18698608</a></text>
<text top="316" left="150" width="7" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18698608"> <b> </b></a></text>
<text top="282" left="251" width="128" height="20" font="4"><b>Study type:</b> Review of </text>
<text top="299" left="251" width="100" height="20" font="1">observational and </text>
<text top="316" left="251" width="110" height="20" font="1">randomized studies </text>
<text top="334" left="251" width="3" height="20" font="1"> </text>
<text top="351" left="251" width="76" height="20" font="4"><b>Size:</b> 434 pts </text>
<text top="282" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="299" left="413" width="122" height="20" font="1">Adult pts, most &gt;18 y, </text>
<text top="316" left="413" width="76" height="20" font="1">nonemergent </text>
<text top="334" left="413" width="113" height="20" font="1">surgery, using ACEI </text>
<text top="351" left="413" width="105" height="20" font="1">or ARA chronically </text>
<text top="368" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="385" left="413" width="24" height="20" font="1">N/A </text>
<text top="283" left="548" width="199" height="20" font="4"><b>1</b>°<b> endpoint:</b> Hypotension requiring </text>
<text top="300" left="548" width="225" height="20" font="1">vasopressors at or shortly after induction </text>
<text top="317" left="548" width="77" height="20" font="1">of anesthesia </text>
<text top="335" left="548" width="3" height="20" font="1"> </text>
<text top="352" left="548" width="230" height="20" font="4"><b>Results:</b> Pts receiving preoperative ACEI </text>
<text top="369" left="548" width="235" height="20" font="1">or ARA more likely to develop hypotension </text>
<text top="386" left="548" width="234" height="20" font="1">requiring vasopressors. RR: 1.51; 95% CI: </text>
<text top="404" left="548" width="58" height="20" font="1">1.14–2.01 </text>
<text top="284" left="798" width="7" height="18" font="1">•</text>
<text top="283" left="805" width="256" height="20" font="1"> Pts receiving immediate preoperative ACEI or </text>
<text top="300" left="798" width="251" height="20" font="1">ARA were more likely to develop hypotension </text>
<text top="317" left="798" width="276" height="20" font="1">requiring vasopressors at or shortly after induction </text>
<text top="335" left="798" width="270" height="20" font="1">of anesthesia. Sufficient data were not present to </text>
<text top="352" left="798" width="133" height="20" font="1">assess other outcomes. </text>
<text top="421" left="96" width="119" height="20" font="1">Roshanov P.S., et al. </text>
<text top="439" left="96" width="63" height="20" font="1">2017 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(305)</a> </text>
<text top="456" left="96" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27775997">27775997</a></text>
<text top="456" left="150" width="3" height="20" font="4"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27775997"><b> </b></a></text>
<text top="421" left="251" width="142" height="20" font="4"><b>Study type:</b> International </text>
<text top="439" left="251" width="104" height="20" font="1">prospective cohort </text>
<text top="456" left="251" width="3" height="20" font="1"> </text>
<text top="473" left="251" width="93" height="20" font="4"><b>Size:</b> 14,687 pts </text>
<text top="421" left="413" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="439" left="413" width="91" height="20" font="1">Pts at least 44 y </text>
<text top="456" left="413" width="65" height="20" font="1">undergoing </text>
<text top="473" left="413" width="108" height="20" font="1">noncardiac surgery </text>
<text top="490" left="413" width="105" height="20" font="1">requiring overnight </text>
<text top="508" left="413" width="105" height="20" font="1">hospital admission </text>
<text top="525" left="413" width="3" height="20" font="1"> </text>
<text top="542" left="413" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="559" left="413" width="24" height="20" font="1">N/A </text>
<text top="423" left="548" width="234" height="20" font="4"><b>1</b>°<b> endpoint:</b> 30-d all-cause death, stroke, </text>
<text top="440" left="548" width="110" height="20" font="1">or myocardial injury </text>
<text top="457" left="548" width="3" height="20" font="1"> </text>
<text top="474" left="548" width="221" height="20" font="4"><b>Results:</b> ACEI/ARB users who withheld </text>
<text top="491" left="548" width="237" height="20" font="1">ACEI/ARB in the 24 H before surgery were </text>
<text top="509" left="548" width="210" height="20" font="1">less likely to suffer death, MI or stroke </text>
<text top="526" left="548" width="181" height="20" font="1">0.82; 95% CI: 0.70–0.96; p=0.01 </text>
<text top="423" left="798" width="7" height="18" font="1">•</text>
<text top="423" left="805" width="268" height="20" font="1"> Withholding ACEI/ARB before major noncardiac </text>
<text top="440" left="798" width="271" height="20" font="1">surgery was associated with a lower risk of death </text>
<text top="457" left="798" width="193" height="20" font="1">and postoperative vascular events. </text>
<text top="579" left="108" width="3" height="19" font="1"> </text>
<text top="613" left="81" width="815" height="24" font="3"><b>Data Supplement 59. RCTs of Adherence and Compliance with Fixed Dose Combinations Regimens (Section 12.1.1) </b></text>
<text top="653" left="102" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="670" left="127" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="687" left="105" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="653" left="251" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="670" left="256" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="687" left="250" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="653" left="398" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="653" left="555" width="111" height="20" font="4"><b>Study Intervention </b></text>
<text top="670" left="571" width="83" height="20" font="4"><b> (# patients) /  </b></text>
<text top="687" left="556" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="704" left="576" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="653" left="724" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="670" left="707" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="687" left="699" width="154" height="20" font="4"><b>P value; OR or RR; &amp; 95% </b></text>
<text top="704" left="766" width="20" height="20" font="4"><b>CI) </b></text>
<text top="654" left="893" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="671" left="925" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="688" left="933" width="96" height="20" font="4"><b>Adverse Events </b></text>
</page>
<page number="214" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="27" size="12" family="Times" color="#434343"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">214 </text>
<text top="107" left="98" width="66" height="20" font="4"><b>COMFORT </b></text>
<text top="124" left="98" width="94" height="20" font="1">Matsumura K, et </text>
<text top="141" left="98" width="83" height="20" font="1">al., 2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(306)</a> </text>
<text top="159" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22447014">22447014</a></text>
<text top="159" left="152" width="3" height="20" font="27"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22447014"> </a></text>
<text top="159" left="156" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22447014"> </a></text>
<text top="107" left="218" width="139" height="20" font="4"><b>Aim:</b> Evaluate whether a </text>
<text top="124" left="218" width="102" height="20" font="1">combination pill of </text>
<text top="141" left="218" width="127" height="20" font="1">antihypertensive drugs </text>
<text top="159" left="218" width="116" height="20" font="1">improves medication </text>
<text top="176" left="218" width="148" height="20" font="1">adherence in hypertensive </text>
<text top="193" left="218" width="111" height="20" font="1">pts vs. use of single </text>
<text top="210" left="218" width="44" height="20" font="1">agents. </text>
<text top="228" left="218" width="3" height="20" font="1"> </text>
<text top="245" left="218" width="137" height="20" font="4"><b>Study type:</b> Multicenter, </text>
<text top="262" left="218" width="135" height="20" font="1">open, RCT at 29 sites in </text>
<text top="279" left="218" width="103" height="20" font="1">Japan. Adherence </text>
<text top="296" left="218" width="127" height="20" font="1">assessed by pill count. </text>
<text top="314" left="218" width="3" height="20" font="1"> </text>
<text top="331" left="218" width="76" height="20" font="4"><b>Size:</b> 207 pts </text>
<text top="107" left="381" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="126" left="381" width="7" height="18" font="1">•</text>
<text top="125" left="388" width="127" height="20" font="1"> ≥20 y agent with HTN </text>
<text top="144" left="381" width="7" height="18" font="1">•</text>
<text top="144" left="388" width="123" height="20" font="1"> Could be treated with </text>
<text top="161" left="381" width="113" height="20" font="1">an ARB and diuretic </text>
<text top="178" left="381" width="3" height="20" font="1"> </text>
<text top="195" left="381" width="117" height="20" font="4"><b>Exclusion criteria:</b>   </text>
<text top="214" left="381" width="7" height="18" font="1">•</text>
<text top="214" left="388" width="108" height="20" font="1"> Extremely high BP </text>
<text top="231" left="381" width="121" height="20" font="1">(≥200 mm Hg SBP or </text>
<text top="248" left="381" width="108" height="20" font="1">≥120 mm Hg DBP) </text>
<text top="267" left="381" width="7" height="18" font="1">•</text>
<text top="267" left="388" width="120" height="20" font="1"> Serious renal or liver </text>
<text top="284" left="381" width="66" height="20" font="1">dysfunction </text>
<text top="303" left="381" width="7" height="18" font="1">•</text>
<text top="302" left="388" width="104" height="20" font="1"> Taking &gt;4 tablets, </text>
<text top="319" left="381" width="122" height="20" font="1">excluding study drugs </text>
<text top="107" left="539" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="124" left="539" width="119" height="20" font="1">Combination tablet of </text>
<text top="141" left="539" width="129" height="20" font="1">(Losartan 50 mg/HCTZ </text>
<text top="159" left="539" width="97" height="20" font="1">12.5 mg; n=103)  </text>
<text top="176" left="539" width="7" height="20" font="1">  </text>
<text top="193" left="539" width="140" height="20" font="4"><b>Comparator:</b> ARB and a </text>
<text top="210" left="539" width="105" height="20" font="1">thiazide diuretic as </text>
<text top="227" left="539" width="138" height="20" font="1">separate agents (n=104) </text>
<text top="108" left="696" width="139" height="20" font="4"><b>1</b>°<b> endpoint:</b> Adherence </text>
<text top="125" left="696" width="137" height="20" font="1">rates as assessed by pill </text>
<text top="143" left="696" width="143" height="20" font="1">count 98% in both groups </text>
<text top="160" left="696" width="144" height="20" font="1">(p=0.89) over entire study </text>
<text top="177" left="696" width="97" height="20" font="1">period (0–6 mo).  </text>
<text top="194" left="696" width="3" height="20" font="1"> </text>
<text top="211" left="696" width="119" height="20" font="4"><b>Safety endpoint:</b> No </text>
<text top="229" left="696" width="120" height="20" font="1">differences in serious </text>
<text top="246" left="696" width="156" height="20" font="1">adverse events (1% vs. 1%; </text>
<text top="263" left="696" width="133" height="20" font="1">p=0.99) or mild adverse </text>
<text top="280" left="696" width="158" height="20" font="1">events (6% vs. 10%; p-0.31)<b> </b></text>
<text top="108" left="869" width="223" height="20" font="4"><b>2</b>°<b> endpoint:</b> No significant difference in </text>
<text top="125" left="869" width="208" height="20" font="1">mean SBP and DBP (0.3 and 0.1 mm </text>
<text top="143" left="869" width="167" height="20" font="1">Hg respectively; p=0.84/0.96). </text>
<text top="160" left="869" width="3" height="20" font="1"> </text>
<text top="177" left="869" width="110" height="20" font="4"><b>Study limitations:  </b></text>
<text top="196" left="869" width="7" height="18" font="1">•</text>
<text top="195" left="876" width="190" height="20" font="1"> Adherence rate very high for both </text>
<text top="213" left="869" width="202" height="20" font="1">groups and likely does not represent </text>
<text top="230" left="869" width="92" height="20" font="1">real-world rates. </text>
<text top="249" left="869" width="7" height="18" font="1">•</text>
<text top="248" left="876" width="204" height="20" font="1"> Short duration (6 mo) and thus does </text>
<text top="265" left="869" width="179" height="20" font="1">not provide much information on </text>
<text top="283" left="869" width="217" height="20" font="1">medication persistence (continuation of </text>
<text top="300" left="869" width="132" height="20" font="1">drug therapy long-term) </text>
<text top="319" left="869" width="7" height="18" font="1">•</text>
<text top="318" left="876" width="202" height="20" font="1"> Possible selection bias with 2 run-in </text>
<text top="336" left="869" width="43" height="20" font="1">phases </text>
<text top="355" left="869" width="7" height="18" font="1">•</text>
<text top="354" left="876" width="202" height="20" font="1"> Different healthcare system (Japan) </text>
<text top="371" left="869" width="190" height="20" font="1">with medications provided through </text>
<text top="388" left="869" width="141" height="20" font="1">public medical insurance  </text>
<text top="408" left="108" width="3" height="19" font="1"> </text>
<text top="442" left="81" width="980" height="24" font="3"><b>Data Supplement 60. Nonrandomized Trials, Observational Studies, and/or Registries of Antihypertensive Medication Adherence Strategies </b></text>
<text top="466" left="81" width="112" height="24" font="3"><b>(Section 12.1.1) </b></text>
<text top="506" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="523" left="129" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="540" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="506" left="245" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="523" left="261" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="506" left="444" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="506" left="654" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="523" left="662" width="167" height="20" font="4"><b>(include P value; OR or RR;  </b></text>
<text top="540" left="714" width="60" height="20" font="4"><b>&amp; 95% CI) </b></text>
<text top="506" left="928" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="523" left="955" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="558" left="98" width="109" height="20" font="1">Schroeder K, et al., </text>
<text top="575" left="98" width="63" height="20" font="1">2004 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(307)</a> </text>
<text top="592" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15078641">15078641</a></text>
<text top="592" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=15078641"> </a></text>
<text top="558" left="221" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="575" left="221" width="94" height="20" font="1">review of RCTs.  </text>
<text top="592" left="221" width="3" height="20" font="1"> </text>
<text top="610" left="221" width="148" height="20" font="4"><b>Size:</b> 38 studies testing 58 </text>
<text top="627" left="221" width="121" height="20" font="1">different interventions </text>
<text top="644" left="221" width="145" height="20" font="1">containing data on 15,519 </text>
<text top="661" left="221" width="131" height="20" font="1">pts; 9 studies assessed </text>
<text top="678" left="221" width="127" height="20" font="1">simplification of dosing </text>
<text top="696" left="221" width="48" height="20" font="1">regimen<b> </b></text>
<text top="558" left="401" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="577" left="401" width="7" height="18" font="1">•</text>
<text top="576" left="408" width="187" height="20" font="1"> Database search for all RCTs, all </text>
<text top="593" left="401" width="193" height="20" font="1">languages, in Cochrane Controlled </text>
<text top="611" left="401" width="147" height="20" font="1">Trials Register, MEDLINE, </text>
<text top="628" left="401" width="160" height="20" font="1">EMBASE, and CINAHL (all y </text>
<text top="645" left="401" width="80" height="20" font="1">through 2002) </text>
<text top="664" left="401" width="7" height="18" font="1">•</text>
<text top="663" left="408" width="172" height="20" font="1"> Population of interest were pts </text>
<text top="681" left="401" width="194" height="20" font="1">with essential HTN in primary care, </text>
<text top="698" left="401" width="178" height="20" font="1">outpatient, or community setting </text>
<text top="717" left="401" width="7" height="18" font="1">•</text>
<text top="716" left="408" width="178" height="20" font="1"> Interventions aimed to increase </text>
<text top="734" left="401" width="145" height="20" font="1">adherence to BP-lowering </text>
<text top="751" left="401" width="63" height="20" font="1">medication </text>
<text top="770" left="401" width="7" height="18" font="1">•</text>
<text top="769" left="408" width="133" height="20" font="1"> Reported outcome was </text>
<text top="786" left="401" width="62" height="20" font="1">adherence </text>
<text top="559" left="612" width="252" height="20" font="4"><b>1</b>° <b>endpoints: </b>Adherence as assessed by pill </text>
<text top="576" left="612" width="237" height="20" font="1">counts, self-report, or electronic monitoring </text>
<text top="593" left="612" width="42" height="20" font="1">system<b> </b></text>
<text top="611" left="612" width="3" height="20" font="4"><b> </b></text>
<text top="628" left="612" width="52" height="20" font="4"><b>Results: </b></text>
<text top="647" left="612" width="7" height="18" font="1">•</text>
<text top="646" left="619" width="239" height="20" font="1"> 9 studies assessed simplification of dosing </text>
<text top="663" left="612" width="230" height="20" font="1">regimen, 7 of which compared adherence </text>
<text top="681" left="612" width="239" height="20" font="1">associated with frequency of administration </text>
<text top="698" left="612" width="259" height="20" font="1">(twice daily vs. once daily [n=6] or 3 times daily </text>
<text top="715" left="612" width="118" height="20" font="1">vs. twice daily [n=1]).<b> </b></text>
<text top="734" left="612" width="7" height="18" font="1">•</text>
<text top="733" left="619" width="209" height="20" font="1"> All studies examining effect of dosing </text>
<text top="751" left="612" width="252" height="20" font="1">frequency demonstrated improved adherence </text>
<text top="768" left="612" width="242" height="20" font="1">(range: 8%, 19.6% improvement; p&lt;0.01 for </text>
<text top="785" left="612" width="23" height="20" font="1">all).<b> </b></text>
<text top="560" left="889" width="7" height="18" font="1">•</text>
<text top="559" left="896" width="173" height="20" font="1"> Adherence to antihypertensive </text>
<text top="576" left="889" width="155" height="20" font="1">medication was significantly </text>
<text top="593" left="889" width="203" height="20" font="1">improved with once daily vs. multiple </text>
<text top="611" left="889" width="198" height="20" font="1">daily dosing regimens. Most studies </text>
<text top="628" left="889" width="164" height="20" font="1">used an electronic monitoring </text>
<text top="645" left="889" width="203" height="20" font="1">system. Limitations in the systematic </text>
<text top="662" left="889" width="195" height="20" font="1">review include heterogeneity in pts, </text>
<text top="680" left="889" width="205" height="20" font="1">interventions, and outcomes, and the </text>
<text top="697" left="889" width="168" height="20" font="1">majority of studies were of low </text>
<text top="714" left="889" width="154" height="20" font="1">quality. In addition, different </text>
<text top="731" left="889" width="202" height="20" font="1">definitions of adherence in the RCTs </text>
<text top="748" left="889" width="169" height="20" font="1">make it difficult to examine the </text>
<text top="766" left="889" width="198" height="20" font="1">precise relationship of adherence to </text>
<text top="783" left="889" width="64" height="20" font="1">BP control. </text>
</page>
<page number="215" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">215 </text>
<text top="109" left="401" width="7" height="18" font="1">•</text>
<text top="108" left="408" width="190" height="20" font="1"> RCT where pt care in intervention </text>
<text top="125" left="401" width="172" height="20" font="1">group(s) compared to either no </text>
<text top="143" left="401" width="142" height="20" font="1">intervention or usual care </text>
<text top="160" left="401" width="3" height="20" font="4"><b> </b></text>
<text top="109" left="612" width="7" height="18" font="1">•</text>
<text top="108" left="619" width="208" height="20" font="1"> Only 1 of the 7 studies demonstrated </text>
<text top="125" left="612" width="260" height="20" font="1">improved BP control (change in SBP 6 mm Hg; </text>
<text top="143" left="612" width="251" height="20" font="1">p&lt;0.01). However, different medications used </text>
<text top="160" left="612" width="260" height="20" font="1">for comparison (once daily amlodipine 5 mg vs. </text>
<text top="177" left="612" width="181" height="20" font="1">diltiazem SR 60 mg twice daily). <b> </b></text>
<text top="195" left="98" width="102" height="20" font="22">Iskedjian M, et al., </text>
<text top="212" left="98" width="63" height="20" font="22">2002 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(308)</a> </text>
<text top="229" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11911560">11911560</a></text>
<text top="229" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11911560"> </a></text>
<text top="195" left="221" width="153" height="20" font="4"><b>Study type:</b> Meta-analysis  </text>
<text top="212" left="221" width="3" height="20" font="1"> </text>
<text top="229" left="221" width="146" height="20" font="4"><b>Size:</b> 8 studies involving a </text>
<text top="247" left="221" width="154" height="20" font="1">total of 11,485 observations </text>
<text top="264" left="221" width="158" height="20" font="1">(1,830 for once daily dosing, </text>
<text top="281" left="221" width="155" height="20" font="1">4,405 for twice daily dosing, </text>
<text top="298" left="221" width="162" height="20" font="1">4,147 for &gt;twice daily dosing, </text>
<text top="316" left="221" width="137" height="20" font="1">9,655 for maximum daily </text>
<text top="333" left="221" width="38" height="20" font="1">dose).<b> </b></text>
<text top="195" left="401" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="214" left="401" width="7" height="18" font="1">•</text>
<text top="213" left="408" width="175" height="20" font="1"> Database search of MEDLINE, </text>
<text top="231" left="401" width="153" height="20" font="1">EMBASE, and International </text>
<text top="248" left="401" width="181" height="20" font="1">Pharmaceutical Abstracts (1980–</text>
<text top="265" left="401" width="35" height="20" font="1">1998)<b> </b></text>
<text top="284" left="401" width="7" height="18" font="1">•</text>
<text top="283" left="408" width="144" height="20" font="1"> 1° studies that compared </text>
<text top="301" left="401" width="190" height="20" font="1">adherence rates between different </text>
<text top="318" left="401" width="94" height="20" font="1">dosing regimens<b> </b></text>
<text top="337" left="401" width="7" height="18" font="1">•</text>
<text top="336" left="408" width="170" height="20" font="1"> Prospective trials (e.g., RCTs, </text>
<text top="354" left="401" width="161" height="20" font="1">cohort studies), retrospective </text>
<text top="371" left="401" width="152" height="20" font="1">studies, database analyses<b> </b></text>
<text top="390" left="401" width="7" height="18" font="1">•</text>
<text top="389" left="408" width="167" height="20" font="1"> Any published study using an </text>
<text top="406" left="401" width="191" height="20" font="1">instrument to measure adherence, </text>
<text top="423" left="401" width="144" height="20" font="1">but must have used some </text>
<text top="441" left="401" width="145" height="20" font="1">measurement tool in each </text>
<text top="458" left="401" width="105" height="20" font="1">comparison group.<b> </b></text>
<text top="477" left="401" width="7" height="18" font="1">•</text>
<text top="476" left="408" width="167" height="20" font="1"> Adherence rates to solid, oral </text>
<text top="493" left="401" width="187" height="20" font="1">dosage form for treatment of HTN </text>
<text top="511" left="401" width="140" height="20" font="1">of at least 10 wk duration<b> </b></text>
<text top="196" left="612" width="238" height="20" font="4"><b>1</b>°<b> endpoints: </b>Medication adherence rates </text>
<text top="213" left="612" width="247" height="20" font="1">compared between once daily and maximum </text>
<text top="231" left="612" width="240" height="20" font="1">daily dose, once daily and twice daily, twice </text>
<text top="248" left="612" width="120" height="20" font="1">daily and &gt;twice daily<b> </b></text>
<text top="265" left="612" width="3" height="20" font="4"><b> </b></text>
<text top="282" left="612" width="52" height="20" font="4"><b>Results: </b></text>
<text top="301" left="612" width="7" height="18" font="1">•</text>
<text top="301" left="619" width="229" height="20" font="1"> Average adherence rates with once daily </text>
<text top="318" left="612" width="241" height="20" font="1">dosing were greater compared to maximum </text>
<text top="335" left="612" width="237" height="20" font="1">daily dose regimens (91.4% [SD=2.2%] vs. </text>
<text top="352" left="612" width="204" height="20" font="1">83.2% [SD=3.5%]; z=4.46; p&lt;0001.) <b> </b></text>
<text top="371" left="612" width="7" height="18" font="1">•</text>
<text top="371" left="619" width="229" height="20" font="1"> Average adherence rates with once daily </text>
<text top="388" left="612" width="244" height="20" font="1">dosing were greater compared to twice daily </text>
<text top="405" left="612" width="256" height="20" font="1">dosing regimens (92.7% [SD=2.3%] vs. 87.1% </text>
<text top="422" left="612" width="166" height="20" font="1">[SD=2.9%]; z=2.22; p=0.026.)<b> </b></text>
<text top="441" left="612" width="7" height="18" font="1">•</text>
<text top="441" left="619" width="244" height="20" font="1"> There was no difference in adherence rates </text>
<text top="458" left="612" width="258" height="20" font="1">between regimens dosed twice daily or greater </text>
<text top="475" left="612" width="250" height="20" font="1">than twice daily (90.8% [SD=4.7%] vs. 86.3% </text>
<text top="492" left="612" width="166" height="20" font="1">[SD=6.7%]; z=1.82; p=0.069).<b> </b></text>
<text top="197" left="889" width="7" height="18" font="1">•</text>
<text top="196" left="896" width="189" height="20" font="1"> Antihypertensive regimens dosed </text>
<text top="213" left="889" width="176" height="20" font="1">once daily were associated with </text>
<text top="231" left="889" width="182" height="20" font="1">significantly improved adherence </text>
<text top="248" left="889" width="203" height="20" font="1">compared to twice daily or maximum </text>
<text top="265" left="889" width="116" height="20" font="1">daily dose regimens. </text>
<text top="529" left="98" width="100" height="20" font="22">Claxton AJ, et al., </text>
<text top="546" left="98" width="63" height="20" font="22">2001 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(309)</a> </text>
<text top="563" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11558866">11558866</a></text>
<text top="563" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=11558866"> </a></text>
<text top="529" left="221" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="546" left="221" width="42" height="20" font="1">review  </text>
<text top="563" left="221" width="3" height="20" font="1"> </text>
<text top="580" left="221" width="92" height="20" font="4"><b>Size:</b> 76 studies<b> </b></text>
<text top="529" left="401" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="548" left="401" width="7" height="18" font="1">•</text>
<text top="547" left="408" width="175" height="20" font="1"> Database search of MEDLINE, </text>
<text top="564" left="401" width="176" height="20" font="1">Psychinfo, HealthStar, Health &amp; </text>
<text top="581" left="401" width="174" height="20" font="1">Psychological Instruments, and </text>
<text top="599" left="401" width="159" height="20" font="1">Cochrane library 1986–2000<b> </b></text>
<text top="618" left="401" width="7" height="18" font="1">•</text>
<text top="617" left="408" width="191" height="20" font="1"> Compliance rates assessed using </text>
<text top="634" left="401" width="156" height="20" font="1">electronic monitoring device<b> </b></text>
<text top="653" left="401" width="7" height="18" font="1">•</text>
<text top="653" left="408" width="173" height="20" font="1"> Data pooled to calculate mean </text>
<text top="670" left="401" width="185" height="20" font="1">compliance with once daily, twice </text>
<text top="687" left="401" width="174" height="20" font="1">daily, 3 times daily, and 4 times </text>
<text top="704" left="401" width="122" height="20" font="1">daily dosing regimens<b> </b></text>
<text top="530" left="612" width="230" height="20" font="4"><b>1</b>° <b>endpoints: </b>Mean compliance rates by </text>
<text top="547" left="612" width="139" height="20" font="1">prescribed dose regimen<b> </b></text>
<text top="564" left="612" width="3" height="20" font="4"><b> </b></text>
<text top="581" left="612" width="52" height="20" font="4"><b>Results: </b></text>
<text top="600" left="612" width="7" height="18" font="1">•</text>
<text top="600" left="619" width="228" height="20" font="1"> 26 studies evaluated CVD; 17 HTN only. </text>
<text top="619" left="612" width="7" height="18" font="1">•</text>
<text top="618" left="619" width="254" height="20" font="1"> For all studies, mean dose-taking compliance </text>
<text top="635" left="612" width="254" height="20" font="1">defined as number of appropriate doses taken </text>
<text top="653" left="612" width="257" height="20" font="1">during each d was 79% for once daily, 69% for </text>
<text top="670" left="612" width="261" height="20" font="1">twice daily, 65% for 3 times daily and 51% for 4 </text>
<text top="687" left="612" width="260" height="20" font="1">times daily dosing (p≤0.001 for once daily vs. 3 </text>
<text top="704" left="612" width="242" height="20" font="1">times daily, once daily vs. 4 times daily, and </text>
<text top="721" left="612" width="234" height="20" font="1">twice daily vs. 4 times daily; no statistically </text>
<text top="739" left="612" width="260" height="20" font="1">significant between once daily vs. twice daily or </text>
<text top="756" left="612" width="198" height="20" font="1">twice daily vs. 3 times daily dosing).<b> </b></text>
<text top="530" left="889" width="7" height="18" font="1">•</text>
<text top="530" left="896" width="148" height="20" font="1"> Medication compliance as </text>
<text top="547" left="889" width="191" height="20" font="1">measured by electronic monitoring </text>
<text top="564" left="889" width="180" height="20" font="1">devices were improved with less </text>
<text top="581" left="889" width="193" height="20" font="1">frequent dosing. Once-daily dosing </text>
<text top="599" left="889" width="206" height="20" font="1">was associated with the greatest rate </text>
<text top="616" left="889" width="181" height="20" font="1">of compliance. Limitations of this </text>
<text top="633" left="889" width="182" height="20" font="1">analysis include heterogeneity of </text>
<text top="650" left="889" width="195" height="20" font="1">studies and disease states studied. </text>
</page>
<page number="216" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">216 </text>
<text top="109" left="612" width="7" height="18" font="1">•</text>
<text top="108" left="619" width="239" height="20" font="1"> For 14 studies that assessed ability to take </text>
<text top="125" left="612" width="256" height="20" font="1">doses within prescribed time frame, once daily </text>
<text top="143" left="612" width="264" height="20" font="1">regimens were associated with better dose-time </text>
<text top="160" left="612" width="245" height="20" font="1">compliance (74% ± 31%) compared to twice </text>
<text top="177" left="612" width="263" height="20" font="1">daily (58% ± 23%) or 3 times daily (46% ± 8%); </text>
<text top="194" left="612" width="258" height="20" font="1">formal statistical analysis not conducted due to </text>
<text top="211" left="612" width="89" height="20" font="1">too few studies.<b> </b></text>
<text top="229" left="98" width="90" height="20" font="1">Sherrill B, et al., </text>
<text top="247" left="98" width="63" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(310)</a> </text>
<text top="264" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22142349">22142349</a></text>
<text top="264" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22142349"> </a></text>
<text top="229" left="221" width="163" height="20" font="4"><b>Study type:</b> Meta-analysis to </text>
<text top="247" left="221" width="163" height="20" font="1">compare health resource use </text>
<text top="264" left="221" width="118" height="20" font="1">cost, adherence, and </text>
<text top="281" left="221" width="157" height="20" font="1">persistence between groups </text>
<text top="298" left="221" width="70" height="20" font="1">of pts taking </text>
<text top="316" left="221" width="150" height="20" font="1">antihypertensives as SPCs </text>
<text top="333" left="221" width="104" height="20" font="1">vs. free-equivalent </text>
<text top="350" left="221" width="77" height="20" font="1">components.  </text>
<text top="367" left="221" width="3" height="20" font="1"> </text>
<text top="384" left="221" width="123" height="20" font="4"><b>Size:</b> 15 retrospective </text>
<text top="402" left="221" width="138" height="20" font="1">database studies in HTN<b> </b></text>
<text top="229" left="401" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="249" left="401" width="7" height="18" font="1">•</text>
<text top="248" left="408" width="166" height="20" font="1"> Database search of PubMed, </text>
<text top="265" left="401" width="184" height="20" font="1">EMBASE, The Cochrane Library, </text>
<text top="282" left="401" width="194" height="20" font="1">and EconLit (no limit on publication </text>
<text top="300" left="401" width="38" height="20" font="1">dates) </text>
<text top="319" left="401" width="7" height="18" font="1">•</text>
<text top="318" left="408" width="174" height="20" font="1"> English-language publications  </text>
<text top="337" left="401" width="7" height="18" font="1">•</text>
<text top="336" left="408" width="161" height="20" font="1"> Clinical trial or observational </text>
<text top="354" left="401" width="181" height="20" font="1">study (e.g., database or registry) </text>
<text top="371" left="401" width="161" height="20" font="1">that compared SPC with free-</text>
<text top="388" left="401" width="130" height="20" font="1">equivalent components </text>
<text top="407" left="401" width="7" height="18" font="1">•</text>
<text top="406" left="408" width="184" height="20" font="1"> Data on compliance, adherence, </text>
<text top="423" left="401" width="172" height="20" font="1">persistence, and/or health care </text>
<text top="441" left="401" width="145" height="20" font="1">costs and/or resource use </text>
<text top="458" left="401" width="150" height="20" font="1">(unadjusted cost analyses)<b> </b></text>
<text top="231" left="612" width="249" height="20" font="4"><b>1</b>° <b>endpoints: </b>Health care costs, adherence, </text>
<text top="248" left="612" width="66" height="20" font="1">persistence<b> </b></text>
<text top="265" left="612" width="3" height="20" font="4"><b> </b></text>
<text top="282" left="612" width="52" height="20" font="4"><b>Results: </b></text>
<text top="301" left="612" width="7" height="18" font="1">•</text>
<text top="301" left="619" width="234" height="20" font="1"> All-cause total costs were estimated to be </text>
<text top="318" left="612" width="261" height="20" font="1">lower with SPC vs. free-equivalent components </text>
<text top="335" left="612" width="264" height="20" font="1">free-equivalent components by $2,039 (95% CI: </text>
<text top="352" left="612" width="240" height="20" font="1">$1030, $3047) in 2009 dollars and HTN/CV-</text>
<text top="370" left="612" width="234" height="20" font="1">related costs were lower by $709 (95% CI: </text>
<text top="387" left="612" width="157" height="20" font="1">$117, $1,032), 2009 dollars. </text>
<text top="406" left="612" width="7" height="18" font="1">•</text>
<text top="405" left="619" width="256" height="20" font="1"> Adherence as measured by MPR was greater </text>
<text top="422" left="612" width="252" height="20" font="1">for SPC vs. free-equivalent components (total </text>
<text top="440" left="612" width="250" height="20" font="1">inverse variance 13.31; 95% CI: 8.26–18.35). </text>
<text top="459" left="612" width="7" height="18" font="1">•</text>
<text top="458" left="619" width="251" height="20" font="1"> Persistence to therapy was greater with SPC </text>
<text top="475" left="612" width="240" height="20" font="1">than free-equivalent components (risk ratio: </text>
<text top="492" left="612" width="140" height="20" font="1">2.13; 95% CI: 1.11–4.09) </text>
<text top="231" left="889" width="7" height="18" font="1">•</text>
<text top="231" left="896" width="152" height="20" font="1"> Medication adherence and </text>
<text top="248" left="889" width="201" height="20" font="1">persistence was significantly greater </text>
<text top="265" left="889" width="166" height="20" font="1">with SPC than free-equivalent </text>
<text top="282" left="889" width="165" height="20" font="1">components. Costs were also </text>
<text top="300" left="889" width="206" height="20" font="1">significantly lower with SPC than with </text>
<text top="317" left="889" width="159" height="20" font="1">free-equivalent components. </text>
<text top="334" left="889" width="165" height="20" font="1">However, cost data should be </text>
<text top="351" left="889" width="197" height="20" font="1">interpreted with caution considering </text>
<text top="368" left="889" width="192" height="20" font="1">unadjusted costs were used in this </text>
<text top="386" left="889" width="146" height="20" font="1">meta-analysis. In addition, </text>
<text top="403" left="889" width="161" height="20" font="1">heterogeneity was present in </text>
<text top="420" left="889" width="176" height="20" font="1">analyses of each outcome. This </text>
<text top="437" left="889" width="182" height="20" font="1">meta-analysis did not include the </text>
<text top="454" left="889" width="205" height="20" font="1">observational study by Yang et al. as </text>
<text top="472" left="889" width="202" height="20" font="1">that study used an adjusted analysis </text>
<text top="489" left="889" width="77" height="20" font="1">methodology. </text>
<text top="510" left="98" width="87" height="20" font="1">Yang W, et al.,  </text>
<text top="527" left="98" width="63" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(311)</a> </text>
<text top="545" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20629600">20629600</a></text>
<text top="545" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20629600"> </a></text>
<text top="510" left="221" width="150" height="20" font="4"><b>Study type:</b> Observational </text>
<text top="527" left="221" width="147" height="20" font="1">analysis using multivariate </text>
<text top="545" left="221" width="159" height="20" font="1">regression-adjusted analysis </text>
<text top="562" left="221" width="65" height="20" font="1">to compare </text>
<text top="579" left="221" width="135" height="20" font="1">compliance/persistence, </text>
<text top="596" left="221" width="149" height="20" font="1">health care resources, and </text>
<text top="614" left="221" width="156" height="20" font="1">cost associated with SPC or </text>
<text top="631" left="221" width="156" height="20" font="1">FC antihypertensives over 6 </text>
<text top="648" left="221" width="118" height="20" font="1">mo study period both </text>
<text top="665" left="221" width="143" height="20" font="1">nationally and at the state </text>
<text top="682" left="221" width="32" height="20" font="1">level. </text>
<text top="700" left="221" width="3" height="20" font="4"><b> </b></text>
<text top="717" left="221" width="152" height="20" font="4"><b>Size:</b> 579,581 pts (382,476 </text>
<text top="734" left="221" width="124" height="20" font="1">SPC and 197,375 FC) </text>
<text top="751" left="221" width="134" height="20" font="1">identified in MarketScan </text>
<text top="768" left="221" width="129" height="20" font="1">Database (2006–2008) </text>
<text top="510" left="401" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="529" left="401" width="7" height="18" font="1">•</text>
<text top="529" left="408" width="163" height="20" font="1"> Pts in MarketScan Database<b> </b></text>
<text top="548" left="401" width="7" height="18" font="1">•</text>
<text top="547" left="408" width="182" height="20" font="1"> Diagnosis of HTN based on ICD-</text>
<text top="564" left="401" width="150" height="20" font="1">9 codes 401.xx and 405.xx<b> </b></text>
<text top="583" left="401" width="7" height="18" font="1">•</text>
<text top="583" left="408" width="145" height="20" font="1"> Pts initiated on any of the </text>
<text top="600" left="401" width="176" height="20" font="1">following SPC treatments or the </text>
<text top="617" left="401" width="168" height="20" font="1">same FC: ARB + CCB, ARB + </text>
<text top="634" left="401" width="119" height="20" font="1">HCTZ, ACEI + HCTZ<b> </b></text>
<text top="653" left="401" width="7" height="18" font="1">•</text>
<text top="653" left="408" width="148" height="20" font="1"> For SPC cohort, at least 1 </text>
<text top="670" left="401" width="185" height="20" font="1">prescription filled in observational </text>
<text top="687" left="401" width="44" height="20" font="1">window<b> </b></text>
<text top="706" left="401" width="7" height="18" font="1">•</text>
<text top="705" left="408" width="189" height="20" font="1"> For FC cohort, pts filled individual </text>
<text top="723" left="401" width="193" height="20" font="1">components separately within 15 d </text>
<text top="740" left="401" width="196" height="20" font="1">of each other and with 15 d overlap </text>
<text top="757" left="401" width="56" height="20" font="1">of supply <b> </b></text>
<text top="776" left="401" width="7" height="18" font="1">•</text>
<text top="775" left="408" width="38" height="20" font="1"> ≥18 y<b> </b></text>
<text top="510" left="612" width="68" height="20" font="4"><b>Endpoints: </b></text>
<text top="529" left="612" width="7" height="18" font="1">•</text>
<text top="529" left="619" width="232" height="20" font="1"> 1° outcome: Compliance and persistence </text>
<text top="546" left="612" width="252" height="20" font="1">with the index therapy (SPC or FC) measured </text>
<text top="563" left="612" width="187" height="20" font="1">by MPR within 6 mo of index date<b> </b></text>
<text top="582" left="612" width="7" height="18" font="1">•</text>
<text top="581" left="619" width="249" height="20" font="1"> 2° outcomes: Healthcare resource utilization </text>
<text top="599" left="612" width="252" height="20" font="1">(number of all-cause hospitalizations, number </text>
<text top="616" left="612" width="256" height="20" font="1">ER visits, number CV hospitalizations, and CV-</text>
<text top="633" left="612" width="237" height="20" font="1">related ER visits) and health care costs (all </text>
<text top="650" left="612" width="229" height="20" font="1">cause medical costs, all-prescription drug </text>
<text top="667" left="612" width="245" height="20" font="1">costs, CV-related medical service costs, and </text>
<text top="685" left="612" width="202" height="20" font="1">HTN prescription-related drug costs)<b> </b></text>
<text top="702" left="612" width="3" height="20" font="4"><b> </b></text>
<text top="719" left="612" width="52" height="20" font="4"><b>Results: </b></text>
<text top="738" left="612" width="7" height="18" font="1">•</text>
<text top="737" left="619" width="246" height="20" font="1"> Compliance nationally as assessed by MPR </text>
<text top="755" left="612" width="216" height="20" font="1">was improved in pts taking SPC vs. FC </text>
<text top="772" left="612" width="253" height="20" font="1">antihypertensives (difference=11.6%; 95% CI: </text>
<text top="789" left="612" width="91" height="20" font="1">11.4%–11.7%). <b> </b></text>
<text top="512" left="889" width="7" height="18" font="1">•</text>
<text top="511" left="896" width="170" height="20" font="1"> This large observational study </text>
<text top="529" left="889" width="121" height="20" font="1">found that medication </text>
<text top="546" left="889" width="145" height="20" font="1">compliance/persistence to </text>
<text top="563" left="889" width="204" height="20" font="1">antihypertensives was improved with </text>
<text top="580" left="889" width="170" height="20" font="1">SPC compared to FC using an </text>
<text top="597" left="889" width="177" height="20" font="1">adjusted multivariate regression </text>
<text top="615" left="889" width="202" height="20" font="1">model. All-cause medical costs were </text>
<text top="632" left="889" width="205" height="20" font="1">also decreased with the used of SPC </text>
<text top="649" left="889" width="153" height="20" font="1">antihypertensives, although </text>
<text top="666" left="889" width="175" height="20" font="1">prescription costs were greater. </text>
</page>
<page number="217" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">217 </text>
<text top="109" left="401" width="7" height="18" font="1">•</text>
<text top="108" left="408" width="186" height="20" font="1"> Continuous eligibility in database </text>
<text top="125" left="401" width="137" height="20" font="1">for 6 mo after index date<b> </b></text>
<text top="144" left="401" width="7" height="18" font="1">•</text>
<text top="144" left="408" width="187" height="20" font="1"> Valid 3-digit zip code in database<b> </b></text>
<text top="109" left="612" width="7" height="18" font="1">•</text>
<text top="108" left="619" width="242" height="20" font="1"> Treatment discontinuation rates were lower </text>
<text top="125" left="612" width="253" height="20" font="1">with SPC vs. FC antihypertensives (40.7% vs. </text>
<text top="143" left="612" width="158" height="20" font="1">59.3%; 95% CI: 0.46–0.48).  </text>
<text top="162" left="612" width="7" height="18" font="1">•</text>
<text top="161" left="619" width="243" height="20" font="1"> There were fewer all-cause hospitalizations </text>
<text top="178" left="612" width="263" height="20" font="1">and ER visits in SPC vs. FC pts IRR: 0.77 (95% </text>
<text top="195" left="612" width="243" height="20" font="1">CI: 0.75–0.79) and IRR: 0.87 (95% CI: 0.86, </text>
<text top="213" left="612" width="110" height="20" font="1">0.89), respectively. <b> </b></text>
<text top="232" left="612" width="7" height="18" font="1">•</text>
<text top="231" left="619" width="239" height="20" font="1"> All-cause medical costs were reduced with </text>
<text top="248" left="612" width="262" height="20" font="1">SPC vs. FC (-$208; 95% CI: -$302– -$114), but </text>
<text top="265" left="612" width="222" height="20" font="1">antihypertensive prescription costs were </text>
<text top="283" left="612" width="180" height="20" font="1">greater ($53; 95% CI: $51–$55).<b> </b></text>
<text top="301" left="98" width="77" height="20" font="1">Gupta, et al.,  </text>
<text top="318" left="98" width="63" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(312)</a> </text>
<text top="335" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19805653">20026768</a></text>
<text top="335" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19805653"> </a></text>
<text top="301" left="221" width="163" height="20" font="4"><b>Study type:</b> Meta-analysis to </text>
<text top="318" left="221" width="111" height="20" font="1">assess compliance, </text>
<text top="335" left="221" width="154" height="20" font="1">adherence, persistence, BP </text>
<text top="352" left="221" width="158" height="20" font="1">control, and safety with FDC </text>
<text top="370" left="221" width="157" height="20" font="1">antihypertensives compared </text>
<text top="387" left="221" width="136" height="20" font="1">to their free components </text>
<text top="404" left="221" width="3" height="20" font="1"> </text>
<text top="421" left="221" width="155" height="20" font="4"><b>Size:</b> 15 studies (n=32,331) </text>
<text top="438" left="221" width="165" height="20" font="1">with ≥1 evaluated outcome; 3 </text>
<text top="456" left="221" width="157" height="20" font="1">cohort studies and 2 trials of </text>
<text top="473" left="221" width="143" height="20" font="1">compliance (n=17,999); 3 </text>
<text top="490" left="221" width="163" height="20" font="1">cohort studies on persistence </text>
<text top="507" left="221" width="167" height="20" font="1">(n=12,653); 5 trials of adverse </text>
<text top="524" left="221" width="116" height="20" font="1">drug effects of FDCs </text>
<text top="542" left="221" width="133" height="20" font="1">(n=1,775); 9 trials of BP </text>
<text top="559" left="221" width="100" height="20" font="1">change (n=1,671) </text>
<text top="301" left="401" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="320" left="401" width="7" height="18" font="1">•</text>
<text top="319" left="408" width="163" height="20" font="1"> Database search of PubMed </text>
<text top="336" left="401" width="172" height="20" font="1">(1966–February 2008), Web of </text>
<text top="354" left="401" width="186" height="20" font="1">Science (1970 to April 2008), and </text>
<text top="371" left="401" width="164" height="20" font="1">the Cochrane Controlled Trial </text>
<text top="388" left="401" width="105" height="20" font="1">(1800–April 2008). </text>
<text top="407" left="401" width="7" height="18" font="1">•</text>
<text top="406" left="408" width="170" height="20" font="1"> Clinical trials or cohort studies </text>
<text top="423" left="401" width="196" height="20" font="1">included if published in English and </text>
<text top="441" left="401" width="191" height="20" font="1">compared an FDC of hypertensive </text>
<text top="458" left="401" width="189" height="20" font="1">agents with free-drug combination </text>
<text top="475" left="401" width="103" height="20" font="1">of its components. </text>
<text top="494" left="401" width="7" height="18" font="1">•</text>
<text top="493" left="408" width="145" height="20" font="1"> Extractable data reported </text>
<text top="511" left="401" width="136" height="20" font="1">including compliance (or </text>
<text top="528" left="401" width="159" height="20" font="1">adherence), persistence, BP-</text>
<text top="545" left="401" width="179" height="20" font="1">lowering effects, adverse effects </text>
<text top="302" left="612" width="76" height="20" font="4"><b>1</b>°<b> endpoint: </b></text>
<text top="321" left="612" width="7" height="18" font="1">•</text>
<text top="320" left="619" width="246" height="20" font="1"> Compliance (or adherence) and persistence </text>
<text top="337" left="612" width="58" height="20" font="1">to therapy<b> </b></text>
<text top="356" left="612" width="7" height="18" font="1">•</text>
<text top="356" left="619" width="118" height="20" font="1"> BP-lowering efficacy<b> </b></text>
<text top="375" left="612" width="7" height="18" font="1">•</text>
<text top="374" left="619" width="92" height="20" font="1"> Adverse effects<b> </b></text>
<text top="391" left="612" width="3" height="20" font="1"> </text>
<text top="409" left="612" width="52" height="20" font="4"><b>Results:</b> </text>
<text top="428" left="612" width="7" height="18" font="1">•</text>
<text top="427" left="619" width="239" height="20" font="1"> Use of FDC therapy was associated with a </text>
<text top="444" left="612" width="259" height="20" font="1">21% increase in compliance, both in the cohort </text>
<text top="461" left="612" width="257" height="20" font="1">studies (n=5) and clinical trials (OR: 1.21; 95% </text>
<text top="479" left="612" width="243" height="20" font="1">CI: 1.00–1.47) and (OR: 1.21; 95% CI: 1.03–</text>
<text top="496" left="612" width="263" height="20" font="1">1.43). There was a 50% increase in persistence </text>
<text top="513" left="612" width="225" height="20" font="1">with therapy, but this was not statistically </text>
<text top="530" left="612" width="231" height="20" font="1">significant (OR: 1.54: 95% CI: 0.95–2.49). </text>
<text top="547" left="612" width="243" height="20" font="1">Analysis of all 6 retrospective cohort studies </text>
<text top="565" left="612" width="262" height="20" font="1">indicated that FDC therapy was associated with </text>
<text top="582" left="612" width="257" height="20" font="1">a 29% increase in compliance and persistence </text>
<text top="599" left="612" width="250" height="20" font="1">to therapy (OR: 1.29; 95% CI: 1.11–1.50). No </text>
<text top="616" left="612" width="223" height="20" font="1">sign of heterogeneity of publication bias. </text>
<text top="635" left="612" width="7" height="18" font="1">•</text>
<text top="635" left="619" width="200" height="20" font="1"> FDC therapy was associated with a </text>
<text top="652" left="612" width="249" height="20" font="1">nonsignificant reduction in SBP (-4.1 mm Hg; </text>
<text top="669" left="612" width="248" height="20" font="1">95% CI: -9.8–1.5 mm Hg; p=0.15) and DBP (-</text>
<text top="686" left="612" width="255" height="20" font="1">3.1 mm Hg; 95% CI: -7.1–0.9 mm Hg; p=0.13) </text>
<text top="704" left="612" width="244" height="20" font="1">compared to free-drug combinations. Strong </text>
<text top="721" left="612" width="248" height="20" font="1">evidence of heterogeneity but no evidence of </text>
<text top="738" left="612" width="92" height="20" font="1">publication bias.<b> </b></text>
<text top="757" left="612" width="7" height="18" font="1">•</text>
<text top="756" left="619" width="228" height="20" font="1"> FDC therapy was associated with a 20% </text>
<text top="773" left="612" width="262" height="20" font="1">nonsignificant decrease in adverse effects (OR: </text>
<text top="303" left="889" width="7" height="18" font="1">•</text>
<text top="302" left="896" width="190" height="20" font="1"> Use of FDC therapy is associated </text>
<text top="319" left="889" width="177" height="20" font="1">with significant improvements in </text>
<text top="336" left="889" width="169" height="20" font="1">compliance and persistence to </text>
<text top="354" left="889" width="161" height="20" font="1">antihypertensive therapy and </text>
<text top="371" left="889" width="196" height="20" font="1">possible improvement in BP control </text>
<text top="388" left="889" width="168" height="20" font="1">and decreased risk of adverse </text>
<text top="405" left="889" width="43" height="20" font="1">effects. </text>
</page>
<page number="218" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">218 </text>
<text top="107" left="612" width="237" height="20" font="1">0.80; 95% CI: 0.58, 1.11) compared to free-</text>
<text top="124" left="612" width="107" height="20" font="1">drug combinations.<b> </b></text>
<text top="142" left="98" width="108" height="20" font="1">Bangalore S, et al., </text>
<text top="159" left="98" width="63" height="20" font="1">2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(313)</a> </text>
<text top="177" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17679131">17679131</a></text>
<text top="177" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17679131"> </a></text>
<text top="142" left="221" width="163" height="20" font="4"><b>Study type:</b> Meta-analysis to </text>
<text top="159" left="221" width="129" height="20" font="1">assess if compliance is </text>
<text top="177" left="221" width="152" height="20" font="1">improved with FDC therapy </text>
<text top="194" left="221" width="125" height="20" font="1">compared to free-drug </text>
<text top="211" left="221" width="162" height="20" font="1">regimens in chronic diseases </text>
<text top="228" left="221" width="111" height="20" font="1">including HTN, HIV, </text>
<text top="246" left="221" width="119" height="20" font="1">tuberculosis, and DM </text>
<text top="263" left="221" width="3" height="20" font="1"> </text>
<text top="280" left="221" width="111" height="20" font="4"><b>Size:</b> 9 studies total </text>
<text top="297" left="221" width="156" height="20" font="1">(n=20,242), 4 of which were </text>
<text top="314" left="221" width="152" height="20" font="1">in hypertensive populations </text>
<text top="332" left="221" width="63" height="20" font="1">(n=17,175)<b> </b></text>
<text top="142" left="401" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="161" left="401" width="7" height="18" font="1">•</text>
<text top="161" left="408" width="172" height="20" font="1"> Database search of MEDLINE </text>
<text top="178" left="401" width="73" height="20" font="1">(1966–2005) </text>
<text top="197" left="401" width="7" height="18" font="1">•</text>
<text top="196" left="408" width="176" height="20" font="1"> Studies included if published in </text>
<text top="213" left="401" width="197" height="20" font="1">English and compared an FDC with </text>
<text top="231" left="401" width="152" height="20" font="1">free-drug combination of its </text>
<text top="248" left="401" width="144" height="20" font="1">components and reported </text>
<text top="265" left="401" width="198" height="20" font="1">medication compliance (adherence) </text>
<text top="282" left="401" width="81" height="20" font="1">or persistence<b> </b></text>
<text top="143" left="612" width="262" height="20" font="4"><b>1</b>°<b> endpoint: </b>Compliance, considered as either </text>
<text top="161" left="612" width="263" height="20" font="1">adherence or persistence to medication therapy<b> </b></text>
<text top="178" left="612" width="3" height="20" font="1"> </text>
<text top="195" left="612" width="52" height="20" font="4"><b>Results:</b> </text>
<text top="214" left="612" width="7" height="18" font="1">•</text>
<text top="213" left="619" width="239" height="20" font="1"> Use of FDC therapy was associated with a </text>
<text top="231" left="612" width="256" height="20" font="1">26% decreased risk of noncompliance vs. free-</text>
<text top="248" left="612" width="251" height="20" font="1">drug combinations (pooled RR: 0.74 (95% CI: </text>
<text top="265" left="612" width="245" height="20" font="1">0.69, 0.80), p&lt;0.0001) in all diseases states. </text>
<text top="282" left="612" width="226" height="20" font="1">There was no evidence of heterogeneity. </text>
<text top="301" left="612" width="7" height="18" font="1">•</text>
<text top="301" left="619" width="255" height="20" font="1"> In hypertensive pts, FDC was associated with </text>
<text top="318" left="612" width="256" height="20" font="1">24% decreased risk of noncompliance (pooled </text>
<text top="335" left="612" width="228" height="20" font="1">RR: 0.76 (95% CI: 0.71, 0.81), p&lt;0.0001) </text>
<text top="352" left="612" width="254" height="20" font="1">compared to free-drug regimen. There was no </text>
<text top="370" left="612" width="158" height="20" font="1">evidence of publication bias. </text>
<text top="389" left="612" width="7" height="18" font="1">•</text>
<text top="388" left="619" width="256" height="20" font="1"> Marked heterogeneity in how compliance was </text>
<text top="405" left="612" width="141" height="20" font="1">measured among studies </text>
<text top="144" left="889" width="7" height="18" font="1">•</text>
<text top="143" left="896" width="198" height="20" font="1"> Use of FDC combination therapy in </text>
<text top="161" left="889" width="206" height="20" font="1">hypertensive pts was associated with </text>
<text top="178" left="889" width="135" height="20" font="1">a 24% decreased risk of </text>
<text top="195" left="889" width="195" height="20" font="1">noncompliance compared to use of </text>
<text top="212" left="889" width="111" height="20" font="1">free-drug regimens. </text>
<text top="423" left="98" width="101" height="20" font="1">Kumagai N, et al., </text>
<text top="440" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(314)</a> </text>
<text top="457" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23072348">23072348</a></text>
<text top="457" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23072348"> </a></text>
<text top="423" left="221" width="141" height="20" font="4"><b>Study type:</b> Prospective, </text>
<text top="440" left="221" width="143" height="20" font="1">multicenter, observational </text>
<text top="457" left="221" width="152" height="20" font="1">study of pts converted from </text>
<text top="475" left="221" width="160" height="20" font="1">free-drug combinations of an </text>
<text top="492" left="221" width="150" height="20" font="1">ARB and amlodipine to the </text>
<text top="509" left="221" width="140" height="20" font="1">same product as a FDC.  </text>
<text top="526" left="221" width="3" height="20" font="1"> </text>
<text top="544" left="221" width="76" height="20" font="4"><b>Size:</b> 196 pts<b> </b></text>
<text top="423" left="401" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="442" left="401" width="7" height="18" font="1">•</text>
<text top="441" left="408" width="176" height="20" font="1"> Outpatients with essential HTN </text>
<text top="460" left="401" width="7" height="18" font="1">•</text>
<text top="460" left="408" width="141" height="20" font="1"> Self-measured home BP </text>
<text top="479" left="401" width="7" height="18" font="1">•</text>
<text top="478" left="408" width="189" height="20" font="1"> Prescribed FDC of an ARB (8 mg </text>
<text top="495" left="401" width="183" height="20" font="1">candesartan, 80 mg valsartan, or </text>
<text top="513" left="401" width="198" height="20" font="1">40 mg telmisartan) and 5 mg) and 5 </text>
<text top="530" left="401" width="83" height="20" font="1">mg amlodipine </text>
<text top="549" left="401" width="7" height="18" font="1">•</text>
<text top="548" left="408" width="183" height="20" font="1"> Pts divided into 2 groups: Group </text>
<text top="565" left="401" width="193" height="20" font="1">1 received an ARB and amlodipine </text>
<text top="583" left="401" width="150" height="20" font="1">in the morning as free drug </text>
<text top="600" left="401" width="174" height="20" font="1">combinations and Group 2 took </text>
<text top="617" left="401" width="197" height="20" font="1">ARB in the morning and amlodipine </text>
<text top="634" left="401" width="174" height="20" font="1">in the evening. After 1 mo, both </text>
<text top="651" left="401" width="171" height="20" font="1">groups converted to once daily </text>
<text top="669" left="401" width="76" height="20" font="1">FDC product. </text>
<text top="686" left="401" width="3" height="20" font="1"> </text>
<text top="703" left="401" width="114" height="20" font="4"><b>Exclusion criteria:  </b></text>
<text top="722" left="401" width="7" height="18" font="1">•</text>
<text top="721" left="408" width="182" height="20" font="1"> Severe renal of liver dysfunction </text>
<text top="740" left="401" width="7" height="18" font="1">•</text>
<text top="740" left="408" width="66" height="20" font="1"> Severe HF </text>
<text top="759" left="401" width="7" height="18" font="1">•</text>
<text top="758" left="408" width="157" height="20" font="1"> Prescription of time-specific </text>
<text top="775" left="401" width="36" height="20" font="1">packs </text>
<text top="423" left="612" width="68" height="20" font="4"><b>Endpoints: </b></text>
<text top="442" left="612" width="7" height="18" font="1">•</text>
<text top="441" left="619" width="234" height="20" font="1"> Adherence to antihypertensive therapy as </text>
<text top="459" left="612" width="150" height="20" font="1">measured by self-reporting<b> </b></text>
<text top="478" left="612" width="7" height="18" font="1">•</text>
<text top="477" left="619" width="256" height="20" font="1"> Self-monitored BP measurements and clinical </text>
<text top="494" left="612" width="246" height="20" font="1">BP measurements before and after switch to </text>
<text top="511" left="612" width="170" height="20" font="1">FDC antihypertensive therapy.<b> </b></text>
<text top="530" left="612" width="7" height="18" font="1">•</text>
<text top="530" left="619" width="66" height="20" font="1"> Drug costs<b> </b></text>
<text top="547" left="612" width="3" height="20" font="1"> </text>
<text top="564" left="612" width="52" height="20" font="4"><b>Results:</b> </text>
<text top="583" left="612" width="7" height="18" font="1">•</text>
<text top="583" left="619" width="228" height="20" font="1"> Self-monitoring BP measurements taken </text>
<text top="600" left="612" width="228" height="20" font="1">during early morning was lower with FDC </text>
<text top="617" left="612" width="263" height="20" font="1">compared to free-drug combinations (-5 mm Hg </text>
<text top="634" left="612" width="212" height="20" font="1">SBP, -2 mm Hg DBP; p&lt;0.01 for both) </text>
<text top="653" left="612" width="7" height="18" font="1">•</text>
<text top="653" left="619" width="215" height="20" font="1"> Average clinic BP was lower with FDC </text>
<text top="670" left="612" width="256" height="20" font="1">compared to free-drug combination (-5 mm Hg </text>
<text top="687" left="612" width="173" height="20" font="1">SBP, -2 mm Hg SBP; p&lt;-0.01). </text>
<text top="706" left="612" width="7" height="18" font="1">•</text>
<text top="705" left="619" width="244" height="20" font="1"> Self-reported adherence was improved with </text>
<text top="723" left="612" width="242" height="20" font="1">FDC vs. free-combination agents (~99% vs. </text>
<text top="740" left="612" width="264" height="20" font="1">95% p&lt;0.01). SBP was significantly lower in the </text>
<text top="757" left="612" width="255" height="20" font="1">group with improved adherence (~7.5 mm Hg) </text>
<text top="425" left="889" width="7" height="18" font="1">•</text>
<text top="424" left="896" width="166" height="20" font="1"> Use of FDC with an ARB and </text>
<text top="441" left="889" width="176" height="20" font="1">amlodipine was associated with </text>
<text top="459" left="889" width="199" height="20" font="1">improved adherence, lower BP, and </text>
<text top="476" left="889" width="157" height="20" font="1">decreased health care costs </text>
<text top="493" left="889" width="195" height="20" font="1">compared to free-drug combination </text>
<text top="510" left="889" width="179" height="20" font="1">therapy. Limitations to this study </text>
<text top="527" left="889" width="205" height="20" font="1">include the observational design, low </text>
<text top="545" left="889" width="198" height="20" font="1">numbers of pts, use of self-reported </text>
<text top="562" left="889" width="189" height="20" font="1">adherence, short follow-up period, </text>
<text top="579" left="889" width="179" height="20" font="1">non-U.S. country with a different </text>
<text top="596" left="889" width="206" height="20" font="1">health care system (Japan), and very </text>
<text top="614" left="889" width="176" height="20" font="1">high baseline rate of adherence </text>
<text top="631" left="889" width="192" height="20" font="1">(~95%) as well post-switch to FDC </text>
<text top="648" left="889" width="199" height="20" font="1">(~99%), which is not what is seen in </text>
<text top="665" left="889" width="83" height="20" font="1">usual practice. </text>
</page>
<page number="219" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">219 </text>
<text top="107" left="612" width="252" height="20" font="1">compared to the group without improved drug </text>
<text top="124" left="612" width="179" height="20" font="1">adherence (~4 mm Hg; p&lt;0.05). </text>
<text top="143" left="612" width="7" height="18" font="1">•</text>
<text top="143" left="619" width="255" height="20" font="1"> Healthcare costs were decreased by 31% per </text>
<text top="160" left="612" width="158" height="20" font="1">pt from 17,075 yen ($216.93 </text>
<text top="160" left="770" width="89" height="20" font="22">USD; Aug. 2012</text>
<text top="160" left="859" width="7" height="20" font="1">) </text>
<text top="177" left="612" width="89" height="20" font="1">to 11,815 yen ($</text>
<text top="177" left="701" width="138" height="20" font="22">150.10 USD; Aug. 2012) </text>
<text top="177" left="838" width="27" height="20" font="1">over </text>
<text top="194" left="612" width="92" height="20" font="1">the 3 mo period. </text>
<text top="212" left="98" width="109" height="20" font="1">Mazzaglia G, et al., </text>
<text top="229" left="98" width="66" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(315)</a>  </text>
<text top="247" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19805653">19805653</a></text>
<text top="247" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19805653"> </a></text>
<text top="212" left="221" width="149" height="20" font="4"><b>Study type: </b>Retrospective </text>
<text top="229" left="221" width="41" height="20" font="1">cohort  </text>
<text top="247" left="221" width="3" height="20" font="1"> </text>
<text top="264" left="221" width="93" height="20" font="4"><b>Size: </b>18,046 pts </text>
<text top="212" left="401" width="143" height="20" font="4"><b>Inclusion criteria: </b>Newly </text>
<text top="229" left="401" width="126" height="20" font="1">diagnosed and treated </text>
<text top="247" left="401" width="193" height="20" font="1">hypertensive pts ≥35 y initially free </text>
<text top="264" left="401" width="160" height="20" font="1">of CVD identified from Italian </text>
<text top="281" left="401" width="105" height="20" font="1">general pt registry.<b> </b></text>
<text top="298" left="401" width="3" height="20" font="1"> </text>
<text top="316" left="401" width="143" height="20" font="4"><b>Exclusion criteria: </b>CHD, </text>
<text top="333" left="401" width="148" height="20" font="1">cerebrovascular disorders, </text>
<text top="350" left="401" width="163" height="20" font="1">congestive HF who had been </text>
<text top="367" left="401" width="190" height="20" font="1">hospitalized for CABG or coronary </text>
<text top="384" left="401" width="184" height="20" font="1">angioplasty, those recovered in a </text>
<text top="402" left="401" width="161" height="20" font="1">cardiology ward before index </text>
<text top="419" left="401" width="192" height="20" font="1">diagnosis, incident CV event in the </text>
<text top="436" left="401" width="174" height="20" font="1">180 d after index diagnosis, pts </text>
<text top="453" left="401" width="96" height="20" font="1">receiving nitrates </text>
<text top="213" left="612" width="203" height="20" font="4"><b>1</b>°<b> endpoint: </b>Describe adherence to </text>
<text top="231" left="612" width="258" height="20" font="1">antihypertensive therapy and its associate with </text>
<text top="248" left="612" width="262" height="20" font="1">concurrent drug use, comorbidities, and CV risk </text>
<text top="265" left="612" width="205" height="20" font="1">factors. Adherence was estimated by </text>
<text top="282" left="612" width="256" height="20" font="1">calculating the proportion of days which pt had </text>
<text top="300" left="612" width="191" height="20" font="1">pills available during the follow-up. </text>
<text top="317" left="612" width="3" height="20" font="1"> </text>
<text top="334" left="612" width="212" height="20" font="4"><b>Results:</b> At baseline (6 mo after index </text>
<text top="351" left="612" width="252" height="20" font="1">diagnosis), adherence rates were high (≥80% </text>
<text top="368" left="612" width="234" height="20" font="1">proportion of days covered) in 8.1% of pts, </text>
<text top="386" left="612" width="255" height="20" font="1">intermediate (40-79% proportion of d covered) </text>
<text top="403" left="612" width="217" height="20" font="1">in 4.5%, and low (≤40% proportion of d </text>
<text top="420" left="612" width="260" height="20" font="1">covered) in 51%. Multiple drug treatment (1.62; </text>
<text top="437" left="612" width="247" height="20" font="1">95% CI: 1.43–1.83), dyslipidemia (1.52; 95% </text>
<text top="454" left="612" width="255" height="20" font="1">CI: 1.24–1.87), DM (1.40; 95% CI: 1.15–1.71), </text>
<text top="472" left="612" width="211" height="20" font="1">obesity (1.50; 95% CI: 1.26–1.78) and </text>
<text top="489" left="612" width="242" height="20" font="1">antihypertensive combination therapy (1.29; </text>
<text top="506" left="612" width="254" height="20" font="1">95% CI: 1.15–1.45) were associated with high </text>
<text top="523" left="612" width="190" height="20" font="1">adherence to treatment (p&lt;0.001). </text>
<text top="214" left="889" width="7" height="18" font="1">•</text>
<text top="213" left="896" width="181" height="20" font="1"> High adherence was associated </text>
<text top="231" left="889" width="181" height="20" font="1">with a 38% decreased risk of CV </text>
<text top="248" left="889" width="145" height="20" font="1">events compared with low </text>
<text top="265" left="889" width="182" height="20" font="1">adherence. Combination therapy </text>
<text top="282" left="889" width="169" height="20" font="1">associated with 29% improved </text>
<text top="300" left="889" width="133" height="20" font="1">adherence compared to </text>
<text top="317" left="889" width="82" height="20" font="1">monotherapy.  </text>
<text top="541" left="98" width="106" height="20" font="1">Jackson KC, et al., </text>
<text top="558" left="98" width="66" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#280">(316)</a>  </text>
<text top="576" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18803997">18803997</a></text>
<text top="576" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=18803997"> </a></text>
<text top="541" left="221" width="149" height="20" font="4"><b>Study type: </b>Retrospective </text>
<text top="558" left="221" width="70" height="20" font="1">cohort study </text>
<text top="576" left="221" width="3" height="20" font="1"> </text>
<text top="593" left="221" width="76" height="20" font="4"><b>Size: </b>908 pts<b> </b></text>
<text top="541" left="401" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="560" left="401" width="7" height="18" font="1">•</text>
<text top="560" left="408" width="160" height="20" font="1"> ≥18 y and diagnosis of HTN </text>
<text top="579" left="401" width="7" height="18" font="1">•</text>
<text top="578" left="408" width="163" height="20" font="1"> Benefit-eligible for pharmacy </text>
<text top="595" left="401" width="38" height="20" font="1">claims </text>
<text top="614" left="401" width="7" height="18" font="1">•</text>
<text top="613" left="408" width="152" height="20" font="1"> Antihypertensive naive (no </text>
<text top="631" left="401" width="193" height="20" font="1">prescription fill for antihypertensive </text>
<text top="648" left="401" width="176" height="20" font="1">drug ≥110 d prior to index date) </text>
<text top="667" left="401" width="7" height="18" font="1">•</text>
<text top="666" left="408" width="178" height="20" font="1"> Received 1 of 3 regimens: 1.) 2 </text>
<text top="683" left="401" width="156" height="20" font="1">pill regimen with valsartan + </text>
<text top="701" left="401" width="187" height="20" font="1">amlodipine, 2.) 2-pill regimen with </text>
<text top="718" left="401" width="142" height="20" font="1">valsartan/HCTZ in FDC + </text>
<text top="735" left="401" width="187" height="20" font="1">amlodipine, 3.) 3-pill regimen with </text>
<text top="752" left="401" width="190" height="20" font="1">valsartan + HCTZ + amlodipine as </text>
<text top="770" left="401" width="124" height="20" font="1">free-drug components </text>
<text top="787" left="401" width="3" height="20" font="1"> </text>
<text top="542" left="612" width="260" height="20" font="4"><b>1</b>°<b> endpoint:</b> Adherence as measured by MPR </text>
<text top="560" left="612" width="3" height="20" font="1"> </text>
<text top="577" left="612" width="210" height="20" font="4"><b>Results:</b> 224 pts received valsartan + </text>
<text top="594" left="612" width="240" height="20" font="1">amlodipine, 619 received valsartan/HCTZ + </text>
<text top="611" left="612" width="257" height="20" font="1">amlodipine, and 65 received valsartan + HCTZ </text>
<text top="628" left="612" width="235" height="20" font="1">+ amlodipine. MPR ratios were 75.4% with </text>
<text top="646" left="612" width="194" height="20" font="1">valsartan + amlodipine, 73.1% with </text>
<text top="663" left="612" width="254" height="20" font="1">valsartan/HCTZ + amlodipine, and 60.5% with </text>
<text top="680" left="612" width="234" height="20" font="1">valsartan + HCTZ + amlodipine (p=0.005). </text>
<text top="697" left="612" width="255" height="20" font="1">Older age was associated with improved MPR </text>
<text top="714" left="612" width="262" height="20" font="1">(75.2% for those ≥64 y. vs. 69.6% for 18 to &lt;36 </text>
<text top="732" left="612" width="69" height="20" font="1">y; p=0.023).<b> </b></text>
<text top="543" left="889" width="7" height="18" font="1">•</text>
<text top="542" left="896" width="174" height="20" font="1"> An inverse relationship existed </text>
<text top="560" left="889" width="178" height="20" font="1">between the number of pills and </text>
<text top="577" left="889" width="204" height="20" font="1">adjusted MPR, with lower adherence </text>
<text top="594" left="889" width="179" height="20" font="1">noted in 3-pill regimens vs. 2-pill </text>
<text top="611" left="889" width="57" height="20" font="1">regimens. </text>
</page>
<page number="220" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">220 </text>
<text top="107" left="401" width="157" height="20" font="4"><b>Exclusion criteria:</b> Pts who </text>
<text top="124" left="401" width="179" height="20" font="1">received &lt;2 prescription fills, did </text>
<text top="141" left="401" width="195" height="20" font="1">not continuously have prescriptions </text>
<text top="159" left="401" width="168" height="20" font="1">refilled for each medication, or </text>
<text top="176" left="401" width="163" height="20" font="1">switched from1 medication to </text>
<text top="193" left="401" width="168" height="20" font="1">another without a time overlap </text>
<text top="211" left="98" width="98" height="20" font="1">Dickson M, et al., </text>
<text top="228" left="98" width="66" height="20" font="1">2008 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(317)</a>  </text>
<text top="245" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18303937">18303937</a></text>
<text top="245" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18303937"> </a></text>
<text top="211" left="221" width="149" height="20" font="4"><b>Study type: </b>Retrospective </text>
<text top="228" left="221" width="70" height="20" font="1">cohort study </text>
<text top="245" left="221" width="3" height="20" font="1"> </text>
<text top="263" left="221" width="86" height="20" font="4"><b>Size: </b>5,704 pts </text>
<text top="211" left="401" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="230" left="401" width="7" height="18" font="1">•</text>
<text top="229" left="408" width="135" height="20" font="1"> 65–100 y on index date </text>
<text top="249" left="401" width="7" height="18" font="1">•</text>
<text top="248" left="408" width="185" height="20" font="1"> Received at least 2 prescriptions </text>
<text top="265" left="401" width="85" height="20" font="1">for study drugs </text>
<text top="282" left="401" width="156" height="20" font="1">(amlodipine/benazepril FDC </text>
<text top="300" left="401" width="194" height="20" font="1">n=2336] or DHP-CCB and ACEI as </text>
<text top="317" left="401" width="193" height="20" font="1">separate agents [n=3368] between </text>
<text top="334" left="401" width="65" height="20" font="1">1997–2001 </text>
<text top="353" left="401" width="7" height="18" font="1">•</text>
<text top="352" left="408" width="190" height="20" font="1"> Continuously eligible for Medicaid </text>
<text top="370" left="401" width="170" height="20" font="1">for 12 mo following index date  </text>
<text top="387" left="401" width="3" height="20" font="4"><b> </b></text>
<text top="404" left="401" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="423" left="401" width="7" height="18" font="1">•</text>
<text top="422" left="408" width="140" height="20" font="1"> &gt;180 d of hospitalization </text>
<text top="441" left="401" width="7" height="18" font="1">•</text>
<text top="441" left="408" width="152" height="20" font="1"> &lt;30 d of study drug supply </text>
<text top="460" left="401" width="7" height="18" font="1">•</text>
<text top="459" left="408" width="182" height="20" font="1"> Any nursing home claims during </text>
<text top="476" left="401" width="145" height="20" font="1">the12 mo follow-up period </text>
<text top="212" left="612" width="246" height="20" font="4"><b>1</b>°<b> endpoint:</b> Determine rates of compliance </text>
<text top="229" left="612" width="254" height="20" font="1">(MPR) and total costs of care (defined as sum </text>
<text top="247" left="612" width="261" height="20" font="1">of payments for Medicaid claims for ambulatory </text>
<text top="264" left="612" width="255" height="20" font="1">care, hospital claims, prescription drug claims, </text>
<text top="281" left="612" width="247" height="20" font="1">and Medicare ross claims) in pts treated with </text>
<text top="298" left="612" width="241" height="20" font="1">FDC amlodipine/benazepril vs. a DHP-CCB </text>
<text top="316" left="612" width="228" height="20" font="1">and ACEI prescribed as free-combination </text>
<text top="333" left="612" width="44" height="20" font="1">agents. </text>
<text top="350" left="612" width="3" height="20" font="1"> </text>
<text top="367" left="612" width="250" height="20" font="4"><b>Results:</b> MPR was significantly higher for pts </text>
<text top="384" left="612" width="260" height="20" font="1">receiving FDC compared with free-combination </text>
<text top="402" left="612" width="262" height="20" font="1">therapy (63.5% vs. 49%; p&lt;0.05). Average total </text>
<text top="419" left="612" width="259" height="20" font="1">cost of care (2002 value) was $3,179 with FDC </text>
<text top="436" left="612" width="233" height="20" font="1">compared to $5,236 with free-combination </text>
<text top="453" left="612" width="234" height="20" font="1">agents (p&lt;0.0001). Multivariate regression </text>
<text top="470" left="612" width="260" height="20" font="1">analysis indicated an increase of 0.5% for each </text>
<text top="488" left="612" width="203" height="20" font="1">1-unit increase in MPR, and for each </text>
<text top="505" left="612" width="256" height="20" font="1">comorbidity there was a 10.4% increase. Total </text>
<text top="522" left="612" width="245" height="20" font="1">cost of care for FDC group was 12.5% lower </text>
<text top="539" left="612" width="214" height="20" font="1">than free-combination group (p&lt;0.003) </text>
<text top="213" left="889" width="7" height="18" font="1">•</text>
<text top="212" left="896" width="172" height="20" font="1"> FDC combination therapy with </text>
<text top="229" left="889" width="148" height="20" font="1">amlodipine/benazepril was </text>
<text top="247" left="889" width="188" height="20" font="1">associated with better compliance </text>
<text top="264" left="889" width="195" height="20" font="1">than a DHP-CCB and ACEI as free-</text>
<text top="281" left="889" width="194" height="20" font="1">combination agents. FDC was also </text>
<text top="298" left="889" width="193" height="20" font="1">associated with lower total costs of </text>
<text top="316" left="889" width="31" height="20" font="1">care. </text>
<text top="559" left="108" width="3" height="19" font="1"> </text>
<text top="593" left="81" width="770" height="24" font="3"><b>Data Supplement 61. RCTs and Meta-analysis on Strategies to Promote Lifestyle Modification (Section 12.1.2) </b></text>
<text top="633" left="126" width="38" height="20" font="4"><b>Study </b></text>
<text top="650" left="114" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="667" left="121" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="684" left="98" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="633" left="223" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="650" left="228" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="667" left="222" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="633" left="366" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="633" left="557" width="191" height="20" font="4"><b>Study Intervention (# patients) /  </b></text>
<text top="650" left="560" width="180" height="20" font="4"><b>Study Comparator (# patients) </b></text>
<text top="633" left="810" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="650" left="814" width="97" height="20" font="4"><b>(Absolute Event </b></text>
<text top="667" left="798" width="128" height="20" font="4"><b>Rates, P value; OR or </b></text>
<text top="684" left="820" width="85" height="20" font="4"><b>RR; &amp; 95% CI) </b></text>
<text top="634" left="942" width="132" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint; </b></text>
<text top="651" left="953" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="668" left="960" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="686" left="978" width="59" height="20" font="4"><b>Summary </b></text>
<text top="704" left="98" width="82" height="20" font="1">Artinian NT, et </text>
<text top="721" left="98" width="83" height="20" font="1">al., 2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(318)</a> </text>
<text top="738" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20625115?dopt=Citation">20625115</a></text>
<text top="738" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20625115?dopt=Citation"> </a></text>
<text top="704" left="204" width="92" height="20" font="4"><b>Aim:</b> To provide </text>
<text top="721" left="204" width="90" height="20" font="1">evidence-based </text>
<text top="738" left="204" width="118" height="20" font="1">recommendations on </text>
<text top="755" left="204" width="120" height="20" font="1">implementing PA and </text>
<text top="772" left="204" width="113" height="20" font="1">dietary interventions </text>
<text top="790" left="204" width="81" height="20" font="1">among adults, </text>
<text top="704" left="339" width="156" height="20" font="4"><b>Inclusion criteria:</b> Included </text>
<text top="721" left="339" width="155" height="20" font="1">studies were limited to adult </text>
<text top="738" left="339" width="159" height="20" font="1">pts ≥18 y; English language; </text>
<text top="755" left="339" width="139" height="20" font="1">randomized controlled or </text>
<text top="772" left="339" width="153" height="20" font="1">quasi-experimental designs </text>
<text top="704" left="518" width="248" height="20" font="1">Cognitive-behavioral strategies for promoting </text>
<text top="721" left="518" width="246" height="20" font="1">behavior change including Goal Setting, Self-</text>
<text top="738" left="518" width="250" height="20" font="1">Monitoring, Frequent and Prolonged Contact, </text>
<text top="755" left="518" width="240" height="20" font="1">Feedback and Reinforcement, Self-Efficacy </text>
<text top="772" left="518" width="251" height="20" font="1">Enhancement, Incentives, Modeling, Problem </text>
<text top="790" left="518" width="230" height="20" font="1">Solving, Relapse Prevention, Motivational </text>
<text top="705" left="796" width="7" height="18" font="1">•</text>
<text top="705" left="803" width="76" height="20" font="1"> Variable, too </text>
<text top="722" left="796" width="72" height="20" font="1">numerous to </text>
<text top="739" left="796" width="98" height="20" font="1">summarize here. <b> </b></text>
<text top="705" left="942" width="7" height="18" font="1">•</text>
<text top="705" left="948" width="76" height="20" font="1"> Variable, too </text>
<text top="722" left="942" width="72" height="20" font="1">numerous to </text>
<text top="739" left="942" width="95" height="20" font="1">summarize here. </text>
</page>
<page number="221" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">221 </text>
<text top="107" left="204" width="102" height="20" font="1">including adults of </text>
<text top="124" left="204" width="115" height="20" font="1">racial/ethnic minority </text>
<text top="141" left="204" width="38" height="20" font="1">and/or </text>
<text top="159" left="204" width="103" height="20" font="1">socioeconomically </text>
<text top="176" left="204" width="83" height="20" font="1">disadvantaged </text>
<text top="193" left="204" width="70" height="20" font="1">populations. </text>
<text top="210" left="204" width="3" height="20" font="1"> </text>
<text top="227" left="204" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="245" left="204" width="98" height="20" font="1">Literature review, </text>
<text top="262" left="204" width="107" height="20" font="1">evidence synthesis </text>
<text top="279" left="204" width="24" height="20" font="1">and </text>
<text top="296" left="204" width="101" height="20" font="1">recommendations </text>
<text top="314" left="204" width="91" height="20" font="1">using ACC/AHA </text>
<text top="331" left="204" width="104" height="20" font="1">evidence grading.  </text>
<text top="348" left="204" width="3" height="20" font="1"> </text>
<text top="365" left="204" width="95" height="20" font="4"><b>Size:</b> 70 studies, </text>
<text top="382" left="204" width="104" height="20" font="1">including 65 RCTs </text>
<text top="400" left="204" width="84" height="20" font="1">published from </text>
<text top="417" left="204" width="72" height="20" font="1">1997–2007.  </text>
<text top="107" left="339" width="165" height="20" font="1">or meta-analyses; focused on </text>
<text top="124" left="339" width="131" height="20" font="1">the effects of diet or PA </text>
<text top="141" left="339" width="156" height="20" font="1">interventions on weight, BP, </text>
<text top="159" left="339" width="120" height="20" font="1">PA level, aerobic and </text>
<text top="176" left="339" width="154" height="20" font="1">resistance exercise, fitness, </text>
<text top="193" left="339" width="150" height="20" font="1">or consumption of calories, </text>
<text top="210" left="339" width="157" height="20" font="1">fruits, vegetables, fiber, total </text>
<text top="228" left="339" width="159" height="20" font="1">fat, saturated fat, cholesterol </text>
<text top="245" left="339" width="37" height="20" font="1">or salt </text>
<text top="262" left="339" width="3" height="20" font="1"> </text>
<text top="279" left="339" width="158" height="20" font="4"><b>Exclusion criteria:</b> Feeding </text>
<text top="296" left="339" width="165" height="20" font="1">trials, observational studies of </text>
<text top="314" left="339" width="122" height="20" font="1">specific nutrients, and </text>
<text top="331" left="339" width="132" height="20" font="1">observational studies of </text>
<text top="348" left="339" width="122" height="20" font="1">aerobic capacity were </text>
<text top="365" left="339" width="155" height="20" font="1">excluded. Given the varying </text>
<text top="383" left="339" width="148" height="20" font="1">goals and outcomes of the </text>
<text top="400" left="339" width="100" height="20" font="1">different identified </text>
<text top="417" left="339" width="145" height="20" font="1">intervention studies, when </text>
<text top="434" left="339" width="158" height="20" font="1">possible we used a common </text>
<text top="451" left="339" width="137" height="20" font="1">measure of effect size to </text>
<text top="469" left="339" width="142" height="20" font="1">quantify and compare the </text>
<text top="486" left="339" width="162" height="20" font="1">success of each intervention. </text>
<text top="107" left="518" width="241" height="20" font="1">Interviewing; also Intervention Processes or </text>
<text top="124" left="518" width="255" height="20" font="1">Delivery Strategies, including Targeting Single </text>
<text top="141" left="518" width="254" height="20" font="1">Behaviors Versus Multiple Behaviors, Print- or </text>
<text top="159" left="518" width="218" height="20" font="1">Media-Only Delivery Strategies, Group, </text>
<text top="176" left="518" width="244" height="20" font="1">Individual, Technology, and Multicomponent-</text>
<text top="193" left="518" width="225" height="20" font="1">Based Delivery Strategies, Group-Based </text>
<text top="210" left="518" width="261" height="20" font="1">Interventions, Individual-Focused Interventions, </text>
<text top="228" left="518" width="265" height="20" font="1">Computer/Technology-Based Interventions, and </text>
<text top="245" left="517" width="206" height="20" font="1">Multicomponent Intervention Delivery </text>
<text top="262" left="517" width="239" height="20" font="1">Strategies; also, Special Considerations for </text>
<text top="279" left="518" width="172" height="20" font="1">Interventions With Minority and </text>
<text top="296" left="518" width="262" height="20" font="1">Socioeconomically Disadvantaged Populations, </text>
<text top="314" left="518" width="220" height="20" font="1">including Setting in Which Healthcare Is </text>
<text top="331" left="518" width="257" height="20" font="1">Delivered, Peer/Lay Led Versus Professionally </text>
<text top="348" left="518" width="215" height="20" font="1">Led, Cultural Sensitivity, Literacy Level </text>
<text top="365" left="518" width="248" height="20" font="1">Sensitivity, Barriers to Behavior Change, and </text>
<text top="383" left="518" width="245" height="20" font="1">Acculturation. In addition, Fostering Initiation </text>
<text top="400" left="518" width="217" height="20" font="1">and Maintenance of Behavior Change.  </text>
<text top="417" left="518" width="3" height="20" font="4"><b> </b></text>
<text top="434" left="518" width="252" height="20" font="4"><b>Comparator:</b> Usual care or other comparison </text>
<text top="451" left="518" width="35" height="20" font="1">group<b> </b></text>
<text top="504" left="98" width="91" height="20" font="1">Eckel RH, et al., </text>
<text top="521" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(319)</a> </text>
<text top="538" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24239922?dopt=Citation">24239922</a></text>
<text top="538" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24239922?dopt=Citation"> </a></text>
<text top="504" left="204" width="68" height="20" font="4"><b>Document:</b> </text>
<text top="521" left="204" width="59" height="20" font="1">Guideline  </text>
<text top="504" left="339" width="130" height="20" font="4"><b>Inclusion criteria:</b> N/A </text>
<text top="521" left="339" width="3" height="20" font="1"> </text>
<text top="538" left="339" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="504" left="518" width="252" height="20" font="4"><b>Comparator:</b> Usual care or other comparison </text>
<text top="521" left="518" width="35" height="20" font="1">group </text>
<text top="504" left="796" width="24" height="20" font="1">N/A </text>
<text top="504" left="942" width="24" height="20" font="1">N/A </text>
<text top="591" left="108" width="3" height="19" font="1"> </text>
<text top="625" left="81" width="923" height="24" font="3"><b>Data Supplement 62. RCTs, Meta-analyses, and Systematic Reviews on the Effect of Structured, Team-based Care Interventions for </b></text>
<text top="649" left="81" width="255" height="24" font="3"><b>Hypertension Control (Section 12.2) </b></text>
<text top="689" left="98" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="706" left="124" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="723" left="102" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="689" left="238" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="706" left="242" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="723" left="236" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="689" left="368" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="689" left="516" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="706" left="548" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="723" left="516" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="740" left="551" width="55" height="20" font="4"><b>patients) </b></text>
<text top="689" left="701" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="706" left="679" width="149" height="20" font="4"><b>(Absolute Event Rates, P </b></text>
<text top="723" left="672" width="162" height="20" font="4"><b>value; OR or RR; &amp; 95% CI) </b></text>
<text top="690" left="874" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="707" left="906" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="724" left="914" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="742" left="932" width="59" height="20" font="4"><b>Summary </b></text>
</page>
<page number="222" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">222 </text>
<text top="107" left="98" width="100" height="20" font="1">Brownstein JN, et </text>
<text top="124" left="98" width="83" height="20" font="1">al., 2007 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(320)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17478270?dopt=Citation">17478270</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17478270?dopt=Citation"> </a></text>
<text top="107" left="211" width="102" height="20" font="4"><b>Aim:</b> Examine the </text>
<text top="124" left="211" width="89" height="20" font="1">effectiveness of </text>
<text top="141" left="211" width="100" height="20" font="1">community health </text>
<text top="159" left="211" width="120" height="20" font="1">workers in supporting </text>
<text top="176" left="211" width="135" height="20" font="1">the care of pts with HTN </text>
<text top="193" left="211" width="3" height="20" font="1"> </text>
<text top="210" left="211" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="227" left="211" width="42" height="20" font="1">review  </text>
<text top="245" left="211" width="3" height="20" font="1"> </text>
<text top="262" left="211" width="95" height="20" font="4"><b>Size:</b> 14 studies, </text>
<text top="279" left="211" width="97" height="20" font="1">including 8 RCTs </text>
<text top="107" left="361" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="124" left="361" width="124" height="20" font="1">Studies examining the </text>
<text top="141" left="361" width="70" height="20" font="1">effects of an </text>
<text top="159" left="361" width="118" height="20" font="1">intervention involving </text>
<text top="176" left="361" width="100" height="20" font="1">community health </text>
<text top="193" left="361" width="111" height="20" font="1">workers on the care </text>
<text top="210" left="361" width="87" height="20" font="1">of pts with HTN </text>
<text top="227" left="361" width="3" height="20" font="1"> </text>
<text top="245" left="361" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="262" left="361" width="115" height="20" font="1">Studies that focused </text>
<text top="279" left="361" width="80" height="20" font="1">exclusively on </text>
<text top="296" left="361" width="98" height="20" font="1">outcomes among </text>
<text top="314" left="361" width="100" height="20" font="1">community health </text>
<text top="331" left="361" width="104" height="20" font="1">workers and those </text>
<text top="348" left="361" width="111" height="20" font="1">involving peers who </text>
<text top="365" left="361" width="105" height="20" font="1">merely led support </text>
<text top="382" left="361" width="41" height="20" font="1">groups </text>
<text top="107" left="499" width="144" height="20" font="4"><b>Intervention:</b> Community </text>
<text top="124" left="499" width="156" height="20" font="1">health workers as HTN care </text>
<text top="141" left="499" width="154" height="20" font="1">team members. Community </text>
<text top="159" left="499" width="157" height="20" font="1">health workers were broadly </text>
<text top="176" left="499" width="143" height="20" font="1">defined as health workers </text>
<text top="193" left="499" width="152" height="20" font="1">who were trained as part of </text>
<text top="210" left="499" width="129" height="20" font="1">an intervention, had no </text>
<text top="228" left="499" width="132" height="20" font="1">formal paraprofessional </text>
<text top="245" left="499" width="118" height="20" font="1">designation, and had </text>
<text top="262" left="499" width="112" height="20" font="1">relationship with the </text>
<text top="279" left="499" width="140" height="20" font="1">community being served. </text>
<text top="296" left="499" width="124" height="20" font="1">The community health </text>
<text top="314" left="499" width="130" height="20" font="1">workers, predominantly </text>
<text top="331" left="499" width="156" height="20" font="1">women, were recruited from </text>
<text top="348" left="499" width="111" height="20" font="1">the community, and </text>
<text top="365" left="499" width="114" height="20" font="1">resembled the pts in </text>
<text top="383" left="499" width="100" height="20" font="1">race/ethnicity and </text>
<text top="400" left="499" width="156" height="20" font="1">socioeconomic background. </text>
<text top="417" left="499" width="159" height="20" font="1">Roles included: (1) providing </text>
<text top="434" left="499" width="118" height="20" font="1">health education and </text>
<text top="451" left="499" width="122" height="20" font="1">information to pts and </text>
<text top="469" left="499" width="141" height="20" font="1">families; (2) ensuring that </text>
<text top="486" left="499" width="118" height="20" font="1">pts received services </text>
<text top="503" left="499" width="159" height="20" font="1">necessary for BP control; (3) </text>
<text top="520" left="499" width="139" height="20" font="1">providing direct services, </text>
<text top="537" left="499" width="137" height="20" font="1">including measuring and </text>
<text top="555" left="499" width="156" height="20" font="1">monitoring BP; (4) providing </text>
<text top="572" left="499" width="157" height="20" font="1">social support to the pts and </text>
<text top="589" left="499" width="145" height="20" font="1">their family members; and </text>
<text top="606" left="499" width="135" height="20" font="1">(5) serving as mediators </text>
<text top="623" left="499" width="114" height="20" font="1">between pts and the </text>
<text top="641" left="499" width="120" height="20" font="1">healthcare and social </text>
<text top="658" left="499" width="98" height="20" font="1">service systems.  </text>
<text top="675" left="499" width="3" height="20" font="1"> </text>
<text top="692" left="499" width="154" height="20" font="4"><b>Comparator:</b> Usual care or </text>
<text top="710" left="499" width="140" height="20" font="1">other comparison group<b>   </b></text>
<text top="108" left="671" width="145" height="20" font="4"><b>1</b>°<b> endpoint:</b>  Differences </text>
<text top="125" left="671" width="164" height="20" font="1">between groups in BP control </text>
<text top="143" left="671" width="148" height="20" font="1">groups favored community </text>
<text top="160" left="671" width="146" height="20" font="1">health worker groups over </text>
<text top="177" left="671" width="158" height="20" font="1">control and ranged from 4%–</text>
<text top="194" left="671" width="160" height="20" font="1">46% over 6–24 mo, across 7 </text>
<text top="212" left="671" width="164" height="20" font="1">RCTs; though 1 RCT showed </text>
<text top="229" left="671" width="124" height="20" font="1">no difference between </text>
<text top="246" left="671" width="44" height="20" font="1">groups. </text>
<text top="263" left="671" width="3" height="20" font="1"> </text>
<text top="280" left="671" width="127" height="20" font="4"><b>Safety endpoint:</b>  N/A<b> </b></text>
<text top="108" left="848" width="86" height="20" font="4"><b>2</b>°<b> endpoints: </b> </text>
<text top="127" left="848" width="7" height="18" font="1">•</text>
<text top="127" left="855" width="184" height="20" font="1"> Appointment keeping: significant </text>
<text top="144" left="848" width="213" height="20" font="1">improvements ranging from 19%–39% </text>
<text top="161" left="848" width="200" height="20" font="1">(relative changes) over 12–24 mo in </text>
<text top="178" left="848" width="207" height="20" font="1">community health worker intervention </text>
<text top="197" left="848" width="7" height="18" font="1">•</text>
<text top="197" left="855" width="206" height="20" font="1"> Adherence to medications: Range of </text>
<text top="214" left="848" width="153" height="20" font="1">findings included significant </text>
<text top="231" left="848" width="187" height="20" font="1">improvement in community health </text>
<text top="248" left="848" width="226" height="20" font="1">worker intervention group compared with </text>
<text top="266" left="848" width="193" height="20" font="1">control, between-group differences </text>
<text top="283" left="848" width="196" height="20" font="1">ranged from 8%–14%; 26% greater </text>
<text top="300" left="848" width="222" height="20" font="1">compliance among pts receiving intense </text>
<text top="317" left="848" width="217" height="20" font="1">community health worker interventions; </text>
<text top="334" left="848" width="198" height="20" font="1">and 17% significant improvement in </text>
<text top="352" left="848" width="226" height="20" font="1">adherence to medication with counseling </text>
<text top="369" left="848" width="166" height="20" font="1">by community health workers. </text>
<text top="386" left="848" width="3" height="20" font="1"> </text>
<text top="403" left="848" width="221" height="20" font="4"><b>Limitations</b>: High level of heterogeneity </text>
<text top="420" left="848" width="153" height="20" font="1">of the populations, settings, </text>
<text top="438" left="848" width="157" height="20" font="1">interventions, and outcomes </text>
<text top="455" left="848" width="3" height="20" font="1"> </text>
<text top="472" left="848" width="215" height="20" font="4"><b>Summary</b>: Including community health </text>
<text top="489" left="848" width="209" height="20" font="1">workers as part of the HTN care team </text>
<text top="506" left="848" width="218" height="20" font="1">resulted in significant improvements BP </text>
<text top="524" left="848" width="189" height="20" font="1">control, appointment keeping, and </text>
<text top="541" left="848" width="168" height="20" font="1">adherence to antihypertensive </text>
<text top="558" left="848" width="185" height="20" font="1">medications, primarily among low </text>
<text top="575" left="848" width="192" height="20" font="1">income, urban African Americans.  </text>
</page>
<page number="223" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">223 </text>
<text top="107" left="98" width="93" height="20" font="1">Carter BL, et al., </text>
<text top="124" left="98" width="63" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(321)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19858431?dopt=Citation">19858431</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19858431?dopt=Citation"> </a></text>
<text top="107" left="211" width="91" height="20" font="4"><b>Aim:</b> Determine </text>
<text top="124" left="211" width="133" height="20" font="1">potency of interventions </text>
<text top="141" left="211" width="129" height="20" font="1">for BP involving nurses </text>
<text top="159" left="211" width="94" height="20" font="1">and pharmacists </text>
<text top="176" left="211" width="3" height="20" font="1"> </text>
<text top="193" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="210" left="211" width="48" height="20" font="1">analysis </text>
<text top="227" left="211" width="3" height="20" font="1"> </text>
<text top="245" left="211" width="129" height="20" font="4"><b>Size:</b> 37 RCTs of team-</text>
<text top="262" left="211" width="93" height="20" font="1">based HTN care </text>
<text top="279" left="211" width="100" height="20" font="1">involving nurse or </text>
<text top="296" left="211" width="131" height="20" font="1">pharmacist intervention </text>
<text top="107" left="361" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="124" left="361" width="111" height="20" font="1">RCT of team-based </text>
<text top="141" left="361" width="107" height="20" font="1">HTN care involving </text>
<text top="159" left="361" width="112" height="20" font="1">nurse or pharmacist </text>
<text top="176" left="361" width="67" height="20" font="1">intervention </text>
<text top="193" left="361" width="3" height="20" font="1"> </text>
<text top="210" left="361" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="227" left="361" width="102" height="20" font="1">Absence of above </text>
<text top="107" left="499" width="150" height="20" font="4"><b>Intervention:</b> Team-based </text>
<text top="124" left="499" width="156" height="20" font="1">HTN care involving nurse or </text>
<text top="141" left="499" width="131" height="20" font="1">pharmacist intervention </text>
<text top="141" left="629" width="13" height="20" font="9">in </text>
<text top="159" left="499" width="143" height="20" font="9">nearly all studies involving</text>
<text top="159" left="641" width="3" height="20" font="1"> </text>
<text top="176" left="499" width="137" height="20" font="9">nurses or pharmacists in </text>
<text top="193" left="499" width="123" height="20" font="9">clinics, consistent and </text>
<text top="210" left="499" width="86" height="20" font="9">dedicated case </text>
<text top="228" left="499" width="156" height="20" font="9">management activities were </text>
<text top="245" left="499" width="146" height="20" font="9">provided that were distinct </text>
<text top="262" left="499" width="143" height="20" font="9">from traditional nursing or </text>
<text top="279" left="499" width="158" height="20" font="9">pharmacist duties. However, </text>
<text top="296" left="499" width="145" height="20" font="9">pharmacists in community </text>
<text top="314" left="499" width="146" height="20" font="9">pharmacies usually had to </text>
<text top="331" left="499" width="152" height="20" font="9">incorporate the intervention </text>
<text top="348" left="499" width="145" height="20" font="9">with traditional medication </text>
<text top="365" left="499" width="115" height="20" font="9">dispensing functions.</text>
<text top="365" left="613" width="3" height="20" font="1"> </text>
<text top="382" left="499" width="3" height="20" font="1"> </text>
<text top="400" left="499" width="146" height="20" font="4"><b>Comparator:</b> Usual care<b>   </b></text>
<text top="108" left="671" width="76" height="20" font="4"><b>1</b>°<b> endpoint:</b> </text>
<text top="108" left="747" width="73" height="20" font="9">OR (95% CI) </text>
<text top="125" left="671" width="124" height="20" font="9">for controlled BP were </text>
<text top="143" left="671" width="99" height="20" font="9">nurses: 1.69 (1.48</text>
<text top="143" left="770" width="7" height="20" font="1">, </text>
<text top="143" left="777" width="35" height="20" font="9">1.93); </text>
<text top="160" left="671" width="149" height="20" font="9">pharmacists within primary </text>
<text top="177" left="671" width="123" height="20" font="9">care clinics: 2.17 (1.75</text>
<text top="177" left="794" width="7" height="20" font="1">, </text>
<text top="194" left="671" width="122" height="20" font="9">2.68); and community </text>
<text top="212" left="671" width="129" height="20" font="9">pharmacists: 2.89 (1.83</text>
<text top="212" left="800" width="7" height="20" font="1">, </text>
<text top="229" left="671" width="158" height="20" font="9">4.55). Mean (SD) reductions </text>
<text top="246" left="671" width="109" height="20" font="9">in SBP were: nurse </text>
<text top="263" left="671" width="157" height="20" font="9">intervention, 5.84 (8.05) mm </text>
<text top="280" left="671" width="145" height="20" font="9">Hg; pharmacists in clinics, </text>
<text top="298" left="671" width="133" height="20" font="9">7.76 (7.81) mm Hg; and </text>
<text top="315" left="671" width="163" height="20" font="9">community pharmacists, 9.31 </text>
<text top="332" left="671" width="85" height="20" font="9">(5.00) mm Hg.  </text>
<text top="349" left="671" width="141" height="20" font="9">There were no significant </text>
<text top="366" left="671" width="148" height="20" font="9">differences between nurse </text>
<text top="384" left="671" width="127" height="20" font="9">and pharmacist effects </text>
<text top="401" left="671" width="54" height="20" font="9">(p≥0.19). </text>
<text top="418" left="671" width="3" height="20" font="1"> </text>
<text top="436" left="671" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A </text>
<text top="109" left="848" width="7" height="18" font="1">•</text>
<text top="108" left="855" width="3" height="20" font="1"> </text>
<text top="108" left="859" width="183" height="20" font="9">Stepwise regression was used to </text>
<text top="125" left="848" width="210" height="20" font="9">compare studies that included a given </text>
<text top="143" left="848" width="226" height="20" font="9">intervention strategy with studies that did </text>
<text top="160" left="848" width="208" height="20" font="9">not. Several individual components of </text>
<text top="177" left="848" width="211" height="20" font="9">the interventions were associated with </text>
<text top="194" left="848" width="162" height="20" font="9">significant reductions in mean</text>
<text top="194" left="1010" width="3" height="20" font="1"> </text>
<text top="194" left="1014" width="28" height="20" font="9">SBP </text>
<text top="212" left="848" width="194" height="20" font="9">including pharmacist recommended</text>
<text top="212" left="1043" width="3" height="20" font="1"> </text>
<text top="229" left="848" width="220" height="20" font="9">medication to physician (-27.21 mm Hg; </text>
<text top="246" left="848" width="197" height="20" font="9">p=0.002), counseling about lifestyle </text>
<text top="263" left="848" width="207" height="20" font="9">modification (-12.63 mm Hg; p=0.03), </text>
<text top="280" left="848" width="219" height="20" font="9">pharmacist performed the intervention (-</text>
<text top="298" left="848" width="177" height="20" font="9">11.70 mm Hg; p=0.03), use of a </text>
<text top="315" left="848" width="191" height="20" font="9">treatment algorithm (-8.46 mm Hg; </text>
<text top="332" left="848" width="208" height="20" font="9">p&lt;0.001), completion of a drug profile </text>
<text top="349" left="848" width="223" height="20" font="9">and/or medication history (-8.28 mm Hg; </text>
<text top="367" left="848" width="203" height="20" font="9">p=0.001),and the overall intervention </text>
<text top="384" left="848" width="203" height="20" font="9">potency score assigned by the study </text>
<text top="401" left="848" width="181" height="20" font="9">reviewers (p&lt;0.001). The factors </text>
<text top="418" left="848" width="194" height="20" font="9">associated with a reduction in DBP </text>
<text top="435" left="848" width="221" height="20" font="9">were: referral was made to a specialist (-</text>
<text top="453" left="848" width="197" height="20" font="9">19.61 mm Hg; p=0.04), providing pt </text>
<text top="470" left="848" width="219" height="20" font="9">education about BP medications (-17.60</text>
<text top="470" left="1067" width="3" height="20" font="1"> </text>
<text top="487" left="848" width="217" height="20" font="9">mm Hg; p=0.003), completion of a drug </text>
<text top="504" left="848" width="213" height="20" font="9">profile and/or medication history (-7.27 </text>
<text top="521" left="848" width="225" height="20" font="9">mm Hg; p=0.006), pharmacist performed </text>
<text top="539" left="848" width="218" height="20" font="9">the intervention (-4.03 mm Hg; p=0.04), </text>
<text top="556" left="848" width="204" height="20" font="9">or nurse performed the intervention (-</text>
<text top="573" left="848" width="123" height="20" font="9">3.94 mm Hg; p=0.04). </text>
<text top="590" left="848" width="3" height="20" font="1"> </text>
<text top="607" left="848" width="63" height="20" font="4"><b>Summary</b>: </text>
<text top="607" left="911" width="125" height="20" font="9">Interventions involving </text>
<text top="625" left="848" width="217" height="20" font="9">pharmacists or nurses were associated </text>
<text top="642" left="848" width="206" height="20" font="9">with significantly improved BP control.</text>
<text top="642" left="1055" width="3" height="20" font="1"> </text>
<text top="660" left="98" width="89" height="20" font="1">Clark CE, et al., </text>
<text top="677" left="98" width="63" height="20" font="1">2010 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(322)</a> </text>
<text top="694" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20732968?dopt=Citation">20732968</a></text>
<text top="694" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20732968?dopt=Citation"><b> </b></a></text>
<text top="660" left="211" width="117" height="20" font="4"><b>Aim:</b> Review trials of </text>
<text top="677" left="211" width="127" height="20" font="1">nurse led interventions </text>
<text top="694" left="211" width="131" height="20" font="1">for HTN in primary care </text>
<text top="711" left="211" width="122" height="20" font="1">to clarify the evidence </text>
<text top="729" left="211" width="132" height="20" font="1">base, establish whether </text>
<text top="746" left="211" width="127" height="20" font="1">nurse prescribing is an </text>
<text top="763" left="211" width="122" height="20" font="1">important intervention </text>
<text top="780" left="211" width="3" height="20" font="1"> </text>
<text top="660" left="361" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="677" left="361" width="86" height="20" font="1">RCT of nursing </text>
<text top="694" left="361" width="117" height="20" font="1">intervention for HTN  </text>
<text top="711" left="361" width="3" height="20" font="1"> </text>
<text top="729" left="361" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="746" left="361" width="102" height="20" font="1">Absence of above </text>
<text top="660" left="499" width="152" height="20" font="4"><b>Intervention:</b> Interventions </text>
<text top="677" left="499" width="148" height="20" font="1">were categorized as nurse </text>
<text top="694" left="499" width="148" height="20" font="1">support delivered by either </text>
<text top="711" left="499" width="124" height="20" font="1">telephone, community </text>
<text top="729" left="499" width="129" height="20" font="1">monitoring or nurse led </text>
<text top="746" left="499" width="148" height="20" font="1">clinics. These were held in </text>
<text top="763" left="499" width="135" height="20" font="1">either primary care or 2º </text>
<text top="780" left="499" width="155" height="20" font="1">care. 1 study used alternate </text>
<text top="661" left="671" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="680" left="671" width="7" height="18" font="1">•</text>
<text top="679" left="678" width="157" height="20" font="1"> Compared with usual care,  </text>
<text top="697" left="671" width="157" height="20" font="1">Interventions that included a </text>
<text top="714" left="671" width="157" height="20" font="1">stepped treatment algorithm </text>
<text top="731" left="671" width="161" height="20" font="1">showed greater reductions in </text>
<text top="748" left="671" width="156" height="20" font="1">SBP (weighted MD -8.2 mm </text>
<text top="767" left="671" width="98" height="20" font="1">Hg (95% CI: -11.5</text>
<text top="767" left="770" width="8" height="21" font="0">–</text>
<text top="767" left="778" width="39" height="20" font="1"> -4.9);  </text>
<text top="660" left="848" width="216" height="20" font="4"><b>Summary</b>: Nurse led interventions that </text>
<text top="677" left="848" width="216" height="20" font="1">included a stepped treatment algorithm </text>
<text top="694" left="848" width="178" height="20" font="1">or nurse led prescribing showed </text>
<text top="711" left="848" width="211" height="20" font="1">significantly greater reductions of SBP </text>
<text top="729" left="848" width="205" height="20" font="1">and DBP than usual care. Telephone </text>
<text top="746" left="848" width="211" height="20" font="1">monitoring was associated with higher </text>
<text top="763" left="848" width="202" height="20" font="1">achievement of study targets for BP. </text>
<text top="780" left="848" width="205" height="20" font="1">Community monitoring showed lower </text>
</page>
<page number="224" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">224 </text>
<text top="107" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="124" left="211" width="51" height="20" font="1">analysis  </text>
<text top="141" left="211" width="3" height="20" font="1"> </text>
<text top="159" left="211" width="98" height="20" font="4"><b>Size:</b> 32 RCTs of </text>
<text top="176" left="211" width="129" height="20" font="1">nursing intervention for </text>
<text top="193" left="211" width="29" height="20" font="1">HTN </text>
<text top="107" left="499" width="130" height="20" font="1">sessions with nurses at </text>
<text top="124" left="499" width="116" height="20" font="1">home and in general </text>
<text top="141" left="499" width="158" height="20" font="1">practice. 14 studies included </text>
<text top="159" left="499" width="113" height="20" font="1">a stepped treatment </text>
<text top="176" left="499" width="137" height="20" font="1">algorithm and 9 included </text>
<text top="193" left="499" width="131" height="20" font="1">nurse prescribing in the </text>
<text top="210" left="499" width="51" height="20" font="1">protocol. </text>
<text top="227" left="499" width="3" height="20" font="1"> </text>
<text top="245" left="499" width="139" height="20" font="4"><b>Comparator:</b> Usual care<b> </b></text>
<text top="109" left="671" width="11" height="22" font="0">• </text>
<text top="110" left="683" width="145" height="20" font="1">Nurse prescribing showed </text>
<text top="127" left="671" width="162" height="20" font="1">greater reductions SBP, −8.9 </text>
<text top="146" left="671" width="129" height="20" font="1">mm Hg, (95% CI: −12.5</text>
<text top="146" left="800" width="8" height="21" font="0">–</text>
<text top="146" left="808" width="7" height="20" font="1"> -</text>
<text top="165" left="671" width="158" height="20" font="1">5.3), and DBP, −4.0 mm Hg, </text>
<text top="184" left="671" width="75" height="20" font="1">(95% CI: −5.3</text>
<text top="183" left="747" width="8" height="21" font="0">–</text>
<text top="184" left="755" width="36" height="20" font="1"> -2.7); </text>
<text top="204" left="671" width="11" height="22" font="0">• </text>
<text top="205" left="683" width="122" height="20" font="1">Telephone monitoring </text>
<text top="222" left="671" width="156" height="20" font="1">showed higher achievement </text>
<text top="239" left="671" width="162" height="20" font="1">of BP targets (RR: 1.24; 95% </text>
<text top="258" left="671" width="43" height="20" font="1">CI: 1.08</text>
<text top="258" left="714" width="8" height="21" font="0">–</text>
<text top="258" left="723" width="35" height="20" font="1">1.43); </text>
<text top="278" left="671" width="11" height="22" font="0">• </text>
<text top="279" left="683" width="126" height="20" font="1">Community monitoring </text>
<text top="297" left="671" width="161" height="20" font="1">showed greater reductions in </text>
<text top="314" left="671" width="142" height="20" font="1">(weighted MD) SBP, −4.8 </text>
<text top="333" left="671" width="119" height="20" font="1">mm Hg, (95% CI: -7.0</text>
<text top="333" left="790" width="8" height="21" font="0">–</text>
<text top="333" left="798" width="36" height="20" font="1"> -2.7), </text>
<text top="352" left="671" width="162" height="20" font="1">and DBP, −3.5 mm Hg, (95% </text>
<text top="369" left="671" width="86" height="20" font="1">CI: −4.5– -2.5). </text>
<text top="386" left="683" width="3" height="20" font="1"> </text>
<text top="403" left="671" width="124" height="20" font="4"><b>Safety endpoint:</b> N/A </text>
<text top="107" left="848" width="226" height="20" font="1">outcome SBP, greater reductions in SBP </text>
<text top="124" left="848" width="218" height="20" font="1">and DBP, and, although pooling of data </text>
<text top="141" left="848" width="213" height="20" font="1">was not possible, greater achievement </text>
<text top="159" left="848" width="114" height="20" font="1">of study BP targets.  </text>
<text top="421" left="98" width="89" height="20" font="1">Proia KK, et al., </text>
<text top="438" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(323)</a> </text>
<text top="456" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24933494?dopt=Citation">24933494</a></text>
<text top="456" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24933494?dopt=Citation"> </a></text>
<text top="421" left="211" width="124" height="20" font="4"><b>Aim:</b> Examine current </text>
<text top="438" left="211" width="90" height="20" font="1">evidence on the </text>
<text top="456" left="211" width="120" height="20" font="1">effectiveness of team-</text>
<text top="473" left="211" width="134" height="20" font="1">based care in improving </text>
<text top="490" left="211" width="135" height="20" font="1">BP outcomes (update of </text>
<text top="507" left="211" width="133" height="20" font="1">prior systematic review) </text>
<text top="524" left="211" width="3" height="20" font="1"> </text>
<text top="542" left="211" width="134" height="20" font="4"><b>Study type:</b> Systematic </text>
<text top="559" left="211" width="42" height="20" font="1">review  </text>
<text top="576" left="211" width="3" height="20" font="1"> </text>
<text top="593" left="211" width="105" height="20" font="4"><b>Size:</b> 52 studies of </text>
<text top="611" left="211" width="113" height="20" font="1">team-based primary </text>
<text top="628" left="211" width="135" height="20" font="1">care for pts with 1° HTN </text>
<text top="421" left="361" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="438" left="361" width="117" height="20" font="1">Study of team-based </text>
<text top="456" left="361" width="114" height="20" font="1">care; conducted in a </text>
<text top="473" left="361" width="70" height="20" font="1">high-income </text>
<text top="490" left="361" width="120" height="20" font="1">economy; reported at </text>
<text top="507" left="361" width="124" height="20" font="1">least 1 BP outcome of </text>
<text top="524" left="361" width="107" height="20" font="1">interest; included a </text>
<text top="542" left="361" width="116" height="20" font="1">comparison group or </text>
<text top="559" left="361" width="103" height="20" font="1">had an interrupted </text>
<text top="576" left="361" width="103" height="20" font="1">time-series design </text>
<text top="593" left="361" width="78" height="20" font="1">with at least 2 </text>
<text top="611" left="361" width="123" height="20" font="1">measurements before </text>
<text top="628" left="361" width="73" height="20" font="1">and after the </text>
<text top="645" left="361" width="119" height="20" font="1">intervention; targeted </text>
<text top="662" left="361" width="108" height="20" font="1">populations with 1° </text>
<text top="679" left="361" width="109" height="20" font="1">HTN or populations </text>
<text top="697" left="361" width="79" height="20" font="1">with comorbid </text>
<text top="714" left="361" width="104" height="20" font="1">conditions such as </text>
<text top="731" left="361" width="119" height="20" font="1">DM as long as the 1° </text>
<text top="748" left="361" width="67" height="20" font="1">focus of the </text>
<text top="765" left="361" width="112" height="20" font="1">intervention was BP </text>
<text top="783" left="361" width="111" height="20" font="1">control; and did not  </text>
<text top="421" left="499" width="150" height="20" font="4"><b>Intervention:</b> Team-based </text>
<text top="438" left="499" width="153" height="20" font="1">care was defined as adding </text>
<text top="456" left="499" width="141" height="20" font="1">new staff or changing the </text>
<text top="473" left="499" width="158" height="20" font="1">roles of existing staff to work </text>
<text top="490" left="499" width="141" height="20" font="1">with a PCP for HTN care. </text>
<text top="507" left="499" width="116" height="20" font="1">Team members who </text>
<text top="524" left="499" width="139" height="20" font="1">collaborated with pts and </text>
<text top="542" left="499" width="145" height="20" font="1">PCPs were predominantly </text>
<text top="559" left="499" width="111" height="20" font="1">nurses (28 studies); </text>
<text top="576" left="499" width="141" height="20" font="1">pharmacists (15 studies); </text>
<text top="593" left="499" width="92" height="20" font="1">both nurses and </text>
<text top="611" left="499" width="148" height="20" font="1">pharmacists (5 studies); or </text>
<text top="628" left="499" width="150" height="20" font="1">community health workers, </text>
<text top="645" left="499" width="147" height="20" font="1">integrated care managers, </text>
<text top="662" left="499" width="75" height="20" font="1">or behavioral </text>
<text top="679" left="499" width="150" height="20" font="1">interventionists (4 studies). </text>
<text top="697" left="499" width="132" height="20" font="1">Key roles included HTN </text>
<text top="714" left="499" width="141" height="20" font="1">medication management, </text>
<text top="731" left="499" width="129" height="20" font="1">active pt follow-up, and </text>
<text top="748" left="499" width="109" height="20" font="1">adherence and self-</text>
<text top="765" left="499" width="123" height="20" font="1">management support. </text>
<text top="783" left="499" width="145" height="20" font="1">Interventions were usually </text>
<text top="422" left="671" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="441" left="671" width="7" height="18" font="1">•</text>
<text top="441" left="678" width="145" height="20" font="1"> Proportion with controlled </text>
<text top="458" left="671" width="139" height="20" font="1">BP: Absolute percentage </text>
<text top="475" left="671" width="148" height="20" font="1">point (pct pt) change in pts </text>
<text top="492" left="671" width="147" height="20" font="1">with controlled BP from 33 </text>
<text top="510" left="671" width="135" height="20" font="1">studies comparing team-</text>
<text top="527" left="671" width="141" height="20" font="1">based care to usual care: </text>
<text top="544" left="671" width="152" height="20" font="1">median effect estimate was </text>
<text top="561" left="671" width="156" height="20" font="1">12 pct pts (IQI=3.2–20.8 pct </text>
<text top="578" left="671" width="145" height="20" font="1">pts). Most individual effect </text>
<text top="596" left="671" width="143" height="20" font="1">estimates in the favorable </text>
<text top="613" left="671" width="138" height="20" font="1">direction were significant </text>
<text top="630" left="671" width="53" height="20" font="1">(p&lt;0.05). </text>
<text top="649" left="671" width="7" height="18" font="1">•</text>
<text top="648" left="678" width="124" height="20" font="1"> Reduction in SBP (44 </text>
<text top="666" left="671" width="118" height="20" font="1">studies): The median </text>
<text top="683" left="671" width="141" height="20" font="1">reduction in SBP was 5.4 </text>
<text top="700" left="671" width="139" height="20" font="1">mm Hg (IQI=2.0–7.2 mm </text>
<text top="717" left="671" width="145" height="20" font="1">Hg). Most individual effect </text>
<text top="734" left="671" width="144" height="20" font="1">estimates were significant </text>
<text top="752" left="671" width="53" height="20" font="1">(p&lt;0.05). </text>
<text top="771" left="671" width="7" height="18" font="1">•</text>
<text top="770" left="678" width="132" height="20" font="1"> Reduction in DBP: The </text>
<text top="787" left="671" width="150" height="20" font="1">overall median reduction in </text>
<text top="422" left="848" width="202" height="20" font="4"><b>2</b>°<b> endpoints: </b>Compared with pts in </text>
<text top="440" left="848" width="176" height="20" font="1">usual care, the proportion of pts </text>
<text top="457" left="848" width="208" height="20" font="1">receiving team-based care with “high” </text>
<text top="474" left="848" width="225" height="20" font="1">medication adherence (defined as taking </text>
<text top="491" left="848" width="216" height="20" font="1">medications as prescribed &gt;80% of the </text>
<text top="508" left="848" width="219" height="20" font="1">time) increased by a median of 16.3 pct </text>
<text top="526" left="848" width="84" height="20" font="1">pts (9 studies). </text>
<text top="543" left="848" width="3" height="20" font="4"><b> </b></text>
<text top="560" left="848" width="217" height="20" font="4"><b>Stratified analyses for BP outcomes</b>: </text>
<text top="579" left="848" width="7" height="18" font="1">•</text>
<text top="578" left="855" width="187" height="20" font="1"> Team member role in medication </text>
<text top="596" left="848" width="211" height="20" font="1">management: Larger improvements in </text>
<text top="613" left="848" width="200" height="20" font="1">BP outcomes than overall estimates </text>
<text top="630" left="848" width="172" height="20" font="1">were demonstrated when team </text>
<text top="647" left="848" width="185" height="20" font="1">members could make changes to </text>
<text top="664" left="848" width="217" height="20" font="1">medications independent of the PCP or </text>
<text top="682" left="848" width="225" height="20" font="1">team members could provide medication </text>
<text top="699" left="848" width="209" height="20" font="1">recommendations and make changes </text>
<text top="716" left="848" width="222" height="20" font="1">with the PCP’s approval as compared to </text>
<text top="733" left="848" width="226" height="20" font="1">team members providing only adherence </text>
<text top="750" left="848" width="213" height="20" font="1">support and information on medication </text>
<text top="768" left="848" width="56" height="20" font="1">and HTN. </text>
</page>
<page number="225" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">225 </text>
<text top="107" left="361" width="3" height="20" font="1"> </text>
<text top="124" left="361" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="141" left="361" width="66" height="20" font="1">Inclusion of </text>
<text top="159" left="361" width="106" height="20" font="1">populations with 2º </text>
<text top="176" left="361" width="60" height="20" font="1">HTN (e.g., </text>
<text top="193" left="361" width="115" height="20" font="1">pregnancy) or with a </text>
<text top="210" left="361" width="114" height="20" font="1">history of CVD (e.g., </text>
<text top="228" left="361" width="21" height="20" font="1">MI) </text>
<text top="107" left="499" width="159" height="20" font="1">implemented across multiple </text>
<text top="124" left="499" width="140" height="20" font="1">settings in the healthcare </text>
<text top="141" left="499" width="100" height="20" font="1">system and in the </text>
<text top="159" left="499" width="130" height="20" font="1">community, where they </text>
<text top="176" left="499" width="117" height="20" font="1">were implemented in </text>
<text top="193" left="499" width="136" height="20" font="1">pharmacies and through </text>
<text top="210" left="499" width="120" height="20" font="1">home outreach visits. </text>
<text top="227" left="499" width="3" height="20" font="1"> </text>
<text top="245" left="499" width="139" height="20" font="4"><b>Comparator:</b> Usual care<b> </b></text>
<text top="107" left="671" width="117" height="20" font="1">DBP was 1.8 mm Hg </text>
<text top="124" left="671" width="147" height="20" font="1">(IQI=0.7–3.2 mm Hg) from </text>
<text top="141" left="671" width="63" height="20" font="1">38 studies. </text>
<text top="159" left="671" width="3" height="20" font="1"> </text>
<text top="176" left="671" width="164" height="20" font="4"><b>Safety endpoint:</b> No harm to </text>
<text top="193" left="671" width="157" height="20" font="1">pts was identified from team-</text>
<text top="210" left="671" width="150" height="20" font="1">based care interventions in </text>
<text top="228" left="671" width="147" height="20" font="1">the included studies or the </text>
<text top="245" left="671" width="100" height="20" font="1">broader literature. </text>
<text top="109" left="848" width="7" height="18" font="1">•</text>
<text top="108" left="855" width="187" height="20" font="1">Number of team members added: </text>
<text top="125" left="848" width="193" height="20" font="1">Adding ≥2 members demonstrated </text>
<text top="143" left="848" width="222" height="20" font="1">larger improvements in the proportion of </text>
<text top="160" left="848" width="213" height="20" font="1">pts with controlled BP and reduction in </text>
<text top="177" left="848" width="224" height="20" font="1">DBP compared to adding only 1; median </text>
<text top="194" left="848" width="170" height="20" font="1">reductions in SBP were similar </text>
<text top="212" left="848" width="134" height="20" font="1">regardless of team size. </text>
<text top="231" left="848" width="7" height="18" font="1">•</text>
<text top="230" left="855" width="205" height="20" font="1"> Improvement in the proportion of pts </text>
<text top="247" left="848" width="226" height="20" font="1">with controlled BP was similar for studies </text>
<text top="264" left="848" width="203" height="20" font="1">from both healthcare and community </text>
<text top="282" left="848" width="49" height="20" font="1">settings. </text>
<text top="299" left="848" width="3" height="20" font="1"> </text>
<text top="316" left="848" width="73" height="20" font="4"><b>Limitations</b>: </text>
<text top="333" left="848" width="200" height="20" font="1">Included studies reported significant </text>
<text top="350" left="848" width="221" height="20" font="1">differences in pt demographics between </text>
<text top="368" left="848" width="213" height="20" font="1">intervention and comparison groups at </text>
<text top="385" left="848" width="216" height="20" font="1">baseline, possible contamination within </text>
<text top="402" left="848" width="226" height="20" font="1">intervention and comparison groups, and </text>
<text top="419" left="848" width="220" height="20" font="1">issues related to inadequate description </text>
<text top="437" left="848" width="178" height="20" font="1">of populations and implemented </text>
<text top="454" left="848" width="77" height="20" font="1">interventions. </text>
<text top="471" left="848" width="3" height="20" font="1"> </text>
<text top="488" left="848" width="63" height="20" font="4"><b>Summary</b>: </text>
<text top="505" left="848" width="193" height="20" font="1">There is strong evidence that team-</text>
<text top="523" left="848" width="215" height="20" font="1">based care is effective in improving BP </text>
<text top="540" left="848" width="220" height="20" font="1">outcomes, especially when pharmacists </text>
<text top="557" left="848" width="179" height="20" font="1">and nurses are part of the team. </text>
<text top="575" left="98" width="99" height="20" font="1">Santschi V, et al., </text>
<text top="592" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(324)</a> </text>
<text top="609" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24721801?dopt=Citation">24721801</a></text>
<text top="609" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24721801?dopt=Citation"> </a></text>
<text top="575" left="211" width="121" height="20" font="4"><b>Aim:</b> Assess effect of </text>
<text top="592" left="211" width="70" height="20" font="1">pharmacists </text>
<text top="609" left="211" width="134" height="20" font="1">interventions on BP and </text>
<text top="627" left="211" width="108" height="20" font="1">determine potential </text>
<text top="644" left="211" width="88" height="20" font="1">determinants of </text>
<text top="661" left="211" width="78" height="20" font="1">heterogeneity </text>
<text top="678" left="211" width="3" height="20" font="1"> </text>
<text top="695" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="713" left="211" width="48" height="20" font="1">analysis </text>
<text top="730" left="211" width="3" height="20" font="1"> </text>
<text top="747" left="211" width="114" height="20" font="4"><b>Size:</b> 39 RCTs were </text>
<text top="764" left="211" width="135" height="20" font="1">included with 14,224 pts </text>
<text top="575" left="361" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="592" left="361" width="106" height="20" font="1">RCT of pharmacist </text>
<text top="609" left="361" width="120" height="20" font="1">intervention delivered </text>
<text top="627" left="361" width="124" height="20" font="1">by a pharmacist alone </text>
<text top="644" left="361" width="100" height="20" font="1">or in collaboration </text>
<text top="661" left="361" width="118" height="20" font="1">with other healthcare </text>
<text top="678" left="361" width="76" height="20" font="1">professionals </text>
<text top="695" left="361" width="3" height="20" font="1"> </text>
<text top="713" left="361" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="730" left="361" width="102" height="20" font="1">Absence of above </text>
<text top="575" left="499" width="143" height="20" font="4"><b>Intervention:</b> Pharmacist </text>
<text top="592" left="499" width="147" height="20" font="1">intervention delivered by a </text>
<text top="609" left="499" width="124" height="20" font="1">pharmacist alone or in </text>
<text top="627" left="499" width="130" height="20" font="1">collaboration with other </text>
<text top="644" left="499" width="140" height="20" font="1">healthcare professionals. </text>
<text top="661" left="499" width="138" height="20" font="1">Pharmacist interventions </text>
<text top="678" left="499" width="102" height="20" font="1">mainly included pt </text>
<text top="695" left="499" width="127" height="20" font="1">education, feedback to </text>
<text top="713" left="499" width="145" height="20" font="1">physician, and medication </text>
<text top="730" left="499" width="79" height="20" font="1">management. </text>
<text top="747" left="499" width="7" height="20" font="1">  </text>
<text top="764" left="499" width="143" height="20" font="4"><b>Comparator:</b> Usual care<b>  </b></text>
<text top="576" left="671" width="141" height="20" font="4"><b>1</b>°<b> endpoint:</b> Pharmacist </text>
<text top="593" left="671" width="103" height="20" font="1">interventions were </text>
<text top="610" left="671" width="128" height="20" font="1">associated with a large </text>
<text top="628" left="671" width="163" height="20" font="1">reduction in systolic and DBP </text>
<text top="645" left="671" width="161" height="20" font="1">of -7.6 mm Hg (95% CI: -9.0–</text>
<text top="662" left="671" width="163" height="20" font="1">-6.3 mm Hg) and -3.9 mm Hg </text>
<text top="679" left="671" width="148" height="20" font="1">(95% CI: -5– -2.8 mm Hg), </text>
<text top="697" left="671" width="68" height="20" font="1">respectively </text>
<text top="714" left="671" width="3" height="20" font="4"><b> </b></text>
<text top="731" left="671" width="124" height="20" font="4"><b>Safety endpoint:</b> N/A </text>
<text top="575" left="848" width="204" height="20" font="4"><b>Summary</b>: Pharmacist interventions, </text>
<text top="592" left="848" width="191" height="20" font="1">alone or in collaboration with other </text>
<text top="609" left="848" width="214" height="20" font="1">healthcare professionals, improved BP </text>
<text top="627" left="848" width="75" height="20" font="1">management </text>
</page>
<page number="226" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">226 </text>
<text top="107" left="98" width="89" height="20" font="1">Shaw RJ, et al., </text>
<text top="124" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(325)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25023250?dopt=Citation">25023250</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25023250?dopt=Citation"> </a></text>
<text top="107" left="211" width="91" height="20" font="4"><b>Aim:</b> Determine </text>
<text top="124" left="211" width="137" height="20" font="1">whether nurse-managed </text>
<text top="141" left="211" width="124" height="20" font="1">protocols are effective </text>
<text top="159" left="211" width="75" height="20" font="1">for outpatient </text>
<text top="176" left="211" width="134" height="20" font="1">management of pts with </text>
<text top="193" left="211" width="82" height="20" font="1">DM, HTN, and </text>
<text top="210" left="211" width="115" height="20" font="1">hyperlipidemia (HTN </text>
<text top="228" left="211" width="111" height="20" font="1">RCT outcomes only </text>
<text top="245" left="211" width="81" height="20" font="1">included here) </text>
<text top="262" left="211" width="3" height="20" font="1"> </text>
<text top="279" left="211" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="296" left="211" width="48" height="20" font="1">analysis </text>
<text top="314" left="211" width="3" height="20" font="1"> </text>
<text top="331" left="211" width="113" height="20" font="4"><b>Size:</b> 12 RCTs, with </text>
<text top="348" left="211" width="113" height="20" font="1">10,362 pts, of nurse-</text>
<text top="365" left="211" width="126" height="20" font="1">managed protocols for </text>
<text top="382" left="211" width="133" height="20" font="1">outpatient management </text>
<text top="400" left="211" width="42" height="20" font="1">of HTN </text>
<text top="107" left="361" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="124" left="361" width="77" height="20" font="1">RCT of nurse-</text>
<text top="141" left="361" width="108" height="20" font="1">managed protocols </text>
<text top="159" left="361" width="75" height="20" font="1">for outpatient </text>
<text top="176" left="361" width="118" height="20" font="1">management of HTN </text>
<text top="193" left="361" width="3" height="20" font="1"> </text>
<text top="210" left="361" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="227" left="361" width="102" height="20" font="1">Absence of above </text>
<text top="107" left="499" width="148" height="20" font="4"><b>Intervention:</b> Involvement </text>
<text top="124" left="499" width="141" height="20" font="1">of a registered nurse or a </text>
<text top="141" left="499" width="132" height="20" font="1">licensed practical nurse </text>
<text top="159" left="499" width="127" height="20" font="1">functioning beyond the </text>
<text top="176" left="499" width="132" height="20" font="1">usual scope of practice, </text>
<text top="193" left="499" width="98" height="20" font="1">such as adjusting </text>
<text top="210" left="499" width="156" height="20" font="1">medications and conducting </text>
<text top="228" left="499" width="137" height="20" font="1">interventions based on a </text>
<text top="245" left="499" width="150" height="20" font="1">written protocol. All studies </text>
<text top="262" left="499" width="141" height="20" font="1">used a nurse who titrated </text>
<text top="279" left="499" width="147" height="20" font="1">medications by following a </text>
<text top="296" left="499" width="51" height="20" font="1">protocol. </text>
<text top="314" left="499" width="7" height="20" font="1">  </text>
<text top="331" left="499" width="139" height="20" font="4"><b>Comparator:</b> Usual care<b> </b></text>
<text top="108" left="671" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="127" left="671" width="7" height="18" font="1">•</text>
<text top="127" left="678" width="145" height="20" font="1"> SBP and DBP decreased </text>
<text top="144" left="671" width="138" height="20" font="1">by 3.68 mm Hg (95% CI: </text>
<text top="161" left="671" width="157" height="20" font="1">1.05–6.31 mm Hg) and 1.56 </text>
<text top="178" left="671" width="152" height="20" font="1">mm Hg (95% CI: 0.36–2.76 </text>
<text top="195" left="671" width="147" height="20" font="1">mm Hg), respectively, with </text>
<text top="213" left="671" width="89" height="20" font="1">high variability (I</text>
<text top="214" left="760" width="4" height="13" font="6">2</text>
<text top="213" left="764" width="39" height="20" font="1">&gt;70%) </text>
<text top="232" left="671" width="7" height="18" font="1">•</text>
<text top="231" left="678" width="148" height="20" font="1"> Nurse-managed protocols </text>
<text top="248" left="671" width="152" height="20" font="1">were more likely to achieve </text>
<text top="265" left="671" width="122" height="20" font="1">target BP than control </text>
<text top="283" left="671" width="161" height="20" font="1">protocols (OR: 1.41; 95% CI: </text>
<text top="300" left="671" width="164" height="20" font="1">0.98–2.02), though difference </text>
<text top="317" left="671" width="128" height="20" font="1">was not significant and </text>
<text top="334" left="671" width="161" height="20" font="1">treatment effects were highly </text>
<text top="352" left="671" width="105" height="20" font="1">variable (Q 35.20; I</text>
<text top="353" left="776" width="4" height="13" font="6">2</text>
<text top="352" left="780" width="43" height="20" font="1">=74%). </text>
<text top="369" left="671" width="3" height="20" font="1"> </text>
<text top="386" left="671" width="124" height="20" font="4"><b>Safety endpoint:</b> N/A<b> </b></text>
<text top="109" left="848" width="7" height="18" font="1">•</text>
<text top="108" left="855" width="217" height="20" font="1"> Included studies of low/good quality as </text>
<text top="125" left="848" width="213" height="20" font="1">well as moderate/fair, and high quality  </text>
<text top="144" left="848" width="7" height="18" font="1">•</text>
<text top="144" left="855" width="185" height="20" font="1"> Descriptions of interventions and </text>
<text top="161" left="848" width="122" height="20" font="1">protocols were limited </text>
<text top="178" left="848" width="3" height="20" font="1"> </text>
<text top="195" left="848" width="226" height="20" font="4"><b>Summary</b>: Nurse-managed protocols for </text>
<text top="213" left="848" width="218" height="20" font="1">HTN care were associated with a mean </text>
<text top="230" left="848" width="189" height="20" font="1">decrease in SBP and DBP but not </text>
<text top="247" left="848" width="135" height="20" font="1">increase in HTN control. </text>
<text top="418" left="98" width="93" height="20" font="1">Carter BL, et al., </text>
<text top="435" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(326)</a> </text>
<text top="452" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25805647?dopt=Citation">25805647</a></text>
<text top="452" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25805647?dopt=Citation"> </a></text>
<text top="418" left="211" width="102" height="20" font="4"><b>Aim:</b> Evaluate if a </text>
<text top="435" left="211" width="118" height="20" font="1">physician/pharmacist </text>
<text top="452" left="211" width="109" height="20" font="1">collaborative model </text>
<text top="469" left="211" width="127" height="20" font="1">would be implemented </text>
<text top="487" left="211" width="98" height="20" font="1">as determined by </text>
<text top="504" left="211" width="114" height="20" font="1">improved BP control </text>
<text top="521" left="211" width="126" height="20" font="1">and whether long-term </text>
<text top="538" left="211" width="110" height="20" font="1">BP control could be </text>
<text top="555" left="211" width="56" height="20" font="1">sustained </text>
<text top="573" left="211" width="3" height="20" font="1"> </text>
<text top="590" left="211" width="113" height="20" font="4"><b>Study type:</b> Cluster </text>
<text top="607" left="211" width="29" height="20" font="1">RCT </text>
<text top="624" left="211" width="3" height="20" font="1"> </text>
<text top="641" left="211" width="121" height="20" font="4"><b>Size:</b> 32 primary care </text>
<text top="659" left="211" width="120" height="20" font="1">offices from 15 states </text>
<text top="676" left="211" width="116" height="20" font="1">enrolled 625 pts with </text>
<text top="693" left="211" width="131" height="20" font="1">uncontrolled HTN; 54% </text>
<text top="710" left="211" width="97" height="20" font="1">from racial/ethnic </text>
<text top="727" left="211" width="111" height="20" font="1">minority groups and </text>
<text top="745" left="211" width="120" height="20" font="1">50% with DM or CKD </text>
<text top="418" left="361" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="435" left="361" width="120" height="20" font="1">Offices were required </text>
<text top="452" left="361" width="97" height="20" font="1">to have an onsite </text>
<text top="469" left="361" width="104" height="20" font="1">clinical pharmacist </text>
<text top="487" left="361" width="113" height="20" font="1">must have practiced </text>
<text top="504" left="361" width="121" height="20" font="1">in the office. Pts were </text>
<text top="521" left="361" width="108" height="20" font="1">eligible if they were </text>
<text top="538" left="361" width="106" height="20" font="1">English or Spanish </text>
<text top="555" left="361" width="81" height="20" font="1">speaking, ≥18 </text>
<text top="573" left="361" width="105" height="20" font="1">y with uncontrolled </text>
<text top="590" left="361" width="111" height="20" font="1">BP as measured by </text>
<text top="607" left="361" width="78" height="20" font="1">the SC on the </text>
<text top="624" left="361" width="77" height="20" font="1">baseline visit. </text>
<text top="641" left="361" width="3" height="20" font="1"> </text>
<text top="659" left="361" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="676" left="361" width="102" height="20" font="1">Absence of above </text>
<text top="418" left="499" width="81" height="20" font="4"><b>Intervention:</b>  </text>
<text top="435" left="499" width="125" height="20" font="1">Pharmacist conducted </text>
<text top="452" left="499" width="157" height="20" font="1">medical record review and a </text>
<text top="469" left="499" width="156" height="20" font="1">structured interview with the </text>
<text top="487" left="499" width="112" height="20" font="1">subject, including 1) </text>
<text top="504" left="499" width="148" height="20" font="1">a medication history; 2) an </text>
<text top="521" left="499" width="158" height="20" font="1">assessment of knowledge of </text>
<text top="538" left="499" width="92" height="20" font="1">BP medications, </text>
<text top="555" left="499" width="137" height="20" font="1">dosages and timing, and </text>
<text top="573" left="499" width="157" height="20" font="1">potential side effects; and 3) </text>
<text top="590" left="499" width="150" height="20" font="1">other barriers to BP control </text>
<text top="607" left="499" width="121" height="20" font="1">(e.g., side effects and </text>
<text top="624" left="499" width="151" height="20" font="1">nonadherence). The model </text>
<text top="641" left="499" width="150" height="20" font="1">recommended a telephone </text>
<text top="659" left="499" width="153" height="20" font="1">call at 2 wk, structured face-</text>
<text top="676" left="499" width="152" height="20" font="1">to-face visits at baseline, 1, </text>
<text top="693" left="499" width="120" height="20" font="1">2, 4, 6, and 8 mo and </text>
<text top="710" left="499" width="116" height="20" font="1">additional visits if BP </text>
<text top="727" left="499" width="153" height="20" font="1">remained uncontrolled. The </text>
<text top="745" left="499" width="146" height="20" font="1">pharmacist created a care </text>
<text top="762" left="499" width="153" height="20" font="1">plan with recommendations </text>
<text top="779" left="499" width="143" height="20" font="1">for the physician to adjust </text>
<text top="419" left="671" width="160" height="20" font="4"><b>1</b>°<b> endpoint:</b> BP control at 9 </text>
<text top="436" left="671" width="154" height="20" font="1">mo was 43% in intervention </text>
<text top="453" left="671" width="163" height="20" font="1">offices compared with 34% in </text>
<text top="470" left="671" width="154" height="20" font="1">control group (adjusted OR: </text>
<text top="488" left="671" width="144" height="20" font="1">1.57 (95% CI: 0.99, 2.50), </text>
<text top="505" left="671" width="59" height="20" font="1">p=0.059).  </text>
<text top="522" left="671" width="3" height="20" font="4"><b> </b></text>
<text top="539" left="671" width="124" height="20" font="4"><b>Safety endpoint:</b> N/A </text>
<text top="419" left="848" width="86" height="20" font="4"><b>2</b>°<b> endpoints:</b>  </text>
<text top="438" left="848" width="7" height="18" font="1">•</text>
<text top="437" left="855" width="183" height="20" font="1"> The adjusted difference in mean </text>
<text top="454" left="848" width="218" height="20" font="1">SBP/DBP between the intervention and </text>
<text top="472" left="848" width="204" height="20" font="1">control groups for all pts at 9 mo was </text>
<text top="489" left="848" width="209" height="20" font="1">−6.1/−2.9 mm Hg (p=0.002 / p=0.005, </text>
<text top="506" left="848" width="214" height="20" font="1">respectively), and it was −6.4/−2.9 mm </text>
<text top="523" left="848" width="215" height="20" font="1">Hg (p=0.009 / p=0.044, respectively) in </text>
<text top="540" left="848" width="194" height="20" font="1">pts from racial or ethnic minorities.  </text>
<text top="559" left="848" width="7" height="18" font="1">•</text>
<text top="559" left="855" width="172" height="20" font="1"> BP control and mean BP were </text>
<text top="576" left="848" width="215" height="20" font="1">significantly improved in pts from racial </text>
<text top="593" left="848" width="206" height="20" font="1">minorities in intervention offices at 18 </text>
<text top="610" left="848" width="190" height="20" font="1">and 24 mo (p=0.048 and p&lt;0.001) </text>
<text top="628" left="848" width="183" height="20" font="1">compared with the control group. </text>
<text top="645" left="848" width="3" height="20" font="1"> </text>
<text top="662" left="848" width="226" height="20" font="4"><b>Summary</b>: Although the results of the 1° </text>
<text top="679" left="848" width="223" height="20" font="1">outcome (BP control) were negative, the </text>
<text top="697" left="848" width="175" height="20" font="1">key 2º endpoint (mean BP) was </text>
<text top="714" left="848" width="222" height="20" font="1">significantly improved in the intervention </text>
<text top="731" left="848" width="171" height="20" font="1">group. Thus, the findings for 2º </text>
<text top="748" left="848" width="223" height="20" font="1">endpoints suggest that team-based care </text>
<text top="765" left="848" width="210" height="20" font="1">using clinical pharmacists significantly </text>
</page>
<page number="227" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">227 </text>
<text top="107" left="499" width="147" height="20" font="1">therapy based on the JNC-</text>
<text top="124" left="499" width="141" height="20" font="1">7, and the BP goals were </text>
<text top="141" left="499" width="109" height="20" font="1">&lt;140/90 mm Hg for </text>
<text top="159" left="499" width="126" height="20" font="1">uncomplicated HTN or </text>
<text top="176" left="499" width="154" height="20" font="1">&lt;130/80 mm Hg for pts with </text>
<text top="193" left="499" width="94" height="20" font="1">DM or CKD. The </text>
<text top="210" left="499" width="145" height="20" font="1">pharmacists did not follow </text>
<text top="228" left="499" width="159" height="20" font="1">algorithms or protocols other </text>
<text top="245" left="499" width="131" height="20" font="1">than JNC-7. Physicians </text>
<text top="262" left="499" width="136" height="20" font="1">were free to accept or to </text>
<text top="279" left="499" width="152" height="20" font="1">reject any recommendation </text>
<text top="296" left="499" width="118" height="20" font="1">or to modify the plan. </text>
<text top="314" left="499" width="106" height="20" font="1">Recommendations </text>
<text top="331" left="499" width="97" height="20" font="1">to pts focused on </text>
<text top="348" left="499" width="123" height="20" font="1">medication education, </text>
<text top="365" left="499" width="146" height="20" font="1">improving adherence, and </text>
<text top="382" left="499" width="130" height="20" font="1">strategies to implement </text>
<text top="400" left="499" width="123" height="20" font="1">lifestyle modifications. </text>
<text top="417" left="499" width="7" height="20" font="1">  </text>
<text top="434" left="499" width="148" height="20" font="4"><b>Comparator:</b> Pharmacists </text>
<text top="451" left="499" width="122" height="20" font="1">in control offices were </text>
<text top="469" left="499" width="103" height="20" font="1">instructed to avoid </text>
<text top="486" left="499" width="137" height="20" font="1">intervention for study pts </text>
<text top="503" left="499" width="137" height="20" font="1">with HTN, but they could </text>
<text top="520" left="499" width="154" height="20" font="1">provide usual care curbside </text>
<text top="537" left="499" width="145" height="20" font="1">consultations if physicians </text>
<text top="555" left="499" width="159" height="20" font="1">specifically asked questions. </text>
<text top="107" left="848" width="190" height="20" font="1">reduced BP in subjects from racial </text>
<text top="124" left="848" width="91" height="20" font="1">minority groups. </text>
<text top="574" left="108" width="3" height="19" font="1"> </text>
<text top="608" left="81" width="609" height="24" font="3"><b>Data Supplement 63. Electronic Health Records and Patient Registries (Section 12.3.1) </b></text>
<text top="648" left="115" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="665" left="141" width="44" height="20" font="4"><b>Author </b></text>
<text top="683" left="116" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="648" left="261" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="665" left="266" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="683" left="260" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="648" left="395" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="648" left="540" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="665" left="572" width="62" height="20" font="4"><b>patients) / </b></text>
<text top="683" left="540" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="700" left="575" width="55" height="20" font="4"><b>patients) </b></text>
<text top="648" left="710" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="665" left="688" width="149" height="20" font="4"><b>(Absolute Event Rates, P </b></text>
<text top="683" left="691" width="142" height="20" font="4"><b>value; OR or RR; &amp; 95% </b></text>
<text top="700" left="752" width="20" height="20" font="4"><b>CI) </b></text>
<text top="649" left="877" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="667" left="861" width="206" height="20" font="4"><b>Study Limitations; Adverse Events </b></text>
<text top="684" left="935" width="59" height="20" font="4"><b>Summary </b></text>
<text top="718" left="98" width="107" height="20" font="1">Bardach NS, et al., </text>
<text top="735" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(327)</a> </text>
<text top="752" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24026600?dopt=Citation">24026600</a></text>
<text top="752" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24026600?dopt=Citation"> </a></text>
<text top="718" left="240" width="111" height="20" font="4"><b>Aim: </b>To assess the </text>
<text top="735" left="240" width="74" height="20" font="1">effect of P4P </text>
<text top="752" left="240" width="114" height="20" font="1">incentives on quality </text>
<text top="769" left="240" width="122" height="20" font="1">in EHR-enabled small </text>
<text top="787" left="240" width="86" height="20" font="1">practices in the </text>
<text top="720" left="378" width="7" height="18" font="1">•</text>
<text top="719" left="385" width="112" height="20" font="1"> Participating clinics </text>
<text top="736" left="378" width="122" height="20" font="1">(n=42 for each group) </text>
<text top="753" left="378" width="112" height="20" font="1">had similar baseline </text>
<text top="771" left="378" width="111" height="20" font="1">characteristics, with </text>
<text top="720" left="536" width="7" height="18" font="1">•</text>
<text top="719" left="543" width="86" height="20" font="1"> A city program </text>
<text top="736" left="536" width="66" height="20" font="1">provided all </text>
<text top="753" left="536" width="132" height="20" font="1">participating clinics with </text>
<text top="771" left="536" width="133" height="20" font="1">the same EHR software </text>
<text top="788" left="536" width="118" height="20" font="1">with decision support </text>
<text top="720" left="683" width="7" height="18" font="1">•</text>
<text top="719" left="689" width="132" height="20" font="1"> Intervention clinics had </text>
<text top="736" left="683" width="142" height="20" font="1">greater adjusted absolute </text>
<text top="753" left="683" width="132" height="20" font="1">improvement in rates of </text>
<text top="771" left="683" width="146" height="20" font="1">appropriate antithrombotic </text>
<text top="788" left="683" width="128" height="20" font="1">prescription (12.0% vs. </text>
<text top="720" left="855" width="7" height="18" font="1">•</text>
<text top="719" left="861" width="211" height="20" font="1"> Although the effect of the intervention </text>
<text top="736" left="855" width="209" height="20" font="1">was lower than the 10% improvement </text>
<text top="753" left="855" width="215" height="20" font="1">that we estimated a priori, the absolute </text>
<text top="771" left="855" width="215" height="20" font="1">risk reduction for BP control among pts </text>
<text top="788" left="855" width="192" height="20" font="1">with DM was 7.8% (NNT, 13). This </text>
</page>
<page number="228" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">228 </text>
<text top="107" left="240" width="74" height="20" font="1">context of an </text>
<text top="124" left="240" width="82" height="20" font="1">established QI </text>
<text top="141" left="240" width="51" height="20" font="1">initiative. </text>
<text top="159" left="240" width="3" height="20" font="1"> </text>
<text top="176" left="240" width="123" height="20" font="4"><b>Study type and size: </b></text>
<text top="193" left="240" width="119" height="20" font="1">A cluster-randomized </text>
<text top="210" left="240" width="97" height="20" font="1">trial of small (&lt;10 </text>
<text top="228" left="240" width="102" height="20" font="1">clinicians) primary </text>
<text top="245" left="240" width="105" height="20" font="1">care clinics in New </text>
<text top="262" left="240" width="109" height="20" font="1">York City from April </text>
<text top="279" left="240" width="114" height="20" font="1">2009 through March </text>
<text top="296" left="240" width="38" height="20" font="1">2010. <b> </b></text>
<text top="107" left="378" width="144" height="20" font="1">a mean of 4,592 (median, </text>
<text top="124" left="378" width="92" height="20" font="1">2,500) pts at the </text>
<text top="141" left="378" width="139" height="20" font="1">intervention group clinics </text>
<text top="159" left="378" width="109" height="20" font="1">and 3,042 (median, </text>
<text top="176" left="378" width="113" height="20" font="1">2,000) at the control </text>
<text top="193" left="378" width="75" height="20" font="1">group clinics.<b> </b></text>
<text top="107" left="536" width="81" height="20" font="1">and pt registry </text>
<text top="124" left="536" width="118" height="20" font="1">functionalities and QI </text>
<text top="141" left="536" width="104" height="20" font="1">specialists offering </text>
<text top="159" left="536" width="117" height="20" font="1">technical assistance. </text>
<text top="178" left="536" width="7" height="18" font="1">•</text>
<text top="177" left="543" width="109" height="20" font="1"> Incentivized clinics </text>
<text top="194" left="536" width="118" height="20" font="1">were paid for each pt </text>
<text top="211" left="536" width="111" height="20" font="1">whose care met the </text>
<text top="229" left="536" width="116" height="20" font="1">performance criteria, </text>
<text top="246" left="536" width="97" height="20" font="1">but they received </text>
<text top="263" left="536" width="132" height="20" font="1">higher payments for pts </text>
<text top="280" left="536" width="130" height="20" font="1">with comorbidities, who </text>
<text top="298" left="536" width="76" height="20" font="1">had Medicaid </text>
<text top="315" left="536" width="130" height="20" font="1">insurance, or who were </text>
<text top="332" left="536" width="118" height="20" font="1">uninsured (maximum </text>
<text top="349" left="536" width="108" height="20" font="1">payments: $200/pt; </text>
<text top="367" left="536" width="93" height="20" font="1">$100,000/clinic). </text>
<text top="384" left="536" width="113" height="20" font="1">Quality reports were </text>
<text top="401" left="536" width="125" height="20" font="1">given quarterly to both </text>
<text top="418" left="536" width="111" height="20" font="1">the intervention and </text>
<text top="435" left="536" width="85" height="20" font="1">control groups.<b> </b></text>
<text top="107" left="683" width="127" height="20" font="1">6.1%, difference: 6.0% </text>
<text top="124" left="683" width="125" height="20" font="1">(95% CI: 2.2%, 9.7%), </text>
<text top="141" left="683" width="126" height="20" font="1">p=0.001 for interaction </text>
<text top="159" left="683" width="117" height="20" font="1">term), BP control (no </text>
<text top="176" left="683" width="130" height="20" font="1">comorbidities: 9.7% vs. </text>
<text top="193" left="683" width="127" height="20" font="1">4.3%, difference: 5.5% </text>
<text top="210" left="683" width="125" height="20" font="1">(95% CI: 1.6%, 9.3%), </text>
<text top="228" left="683" width="151" height="20" font="1">p=0.01 for interaction term; </text>
<text top="245" left="683" width="137" height="20" font="1">with DM: 9.0% vs. 1.2%, </text>
<text top="262" left="683" width="143" height="20" font="1">difference: 7.8% (95% CI: </text>
<text top="279" left="683" width="147" height="20" font="1">3.2%, 12.4%), p=0.007 for </text>
<text top="296" left="683" width="154" height="20" font="1">interaction term; with DM or </text>
<text top="314" left="683" width="150" height="20" font="1">ischemic vascular disease: </text>
<text top="331" left="683" width="146" height="20" font="1">9.5% vs. 1.7%, difference: </text>
<text top="348" left="683" width="117" height="20" font="1">7.8% (95% CI: 3.0%, </text>
<text top="365" left="683" width="105" height="20" font="1">12.6%), p=0.01 for </text>
<text top="383" left="683" width="133" height="20" font="1">interaction term), and in </text>
<text top="400" left="683" width="104" height="20" font="1">smoking cessation </text>
<text top="417" left="683" width="134" height="20" font="1">interventions (12.4% vs. </text>
<text top="434" left="683" width="127" height="20" font="1">7.7%, difference: 4.7% </text>
<text top="451" left="683" width="129" height="20" font="1">(95% CI: -0.3%, 9.6%), </text>
<text top="469" left="683" width="155" height="20" font="1">p=0.02 for interaction term). </text>
<text top="486" left="683" width="104" height="20" font="1">Intervention clinics </text>
<text top="503" left="683" width="127" height="20" font="1">performed better on all </text>
<text top="520" left="683" width="152" height="20" font="1">measures for Medicaid and </text>
<text top="537" left="683" width="117" height="20" font="1">uninsured pts except </text>
<text top="555" left="683" width="144" height="20" font="1">cholesterol control, but no </text>
<text top="572" left="683" width="156" height="20" font="1">differences were statistically </text>
<text top="589" left="683" width="62" height="20" font="1">significant. </text>
<text top="107" left="855" width="208" height="20" font="1">suggests that, for every 13 pts seeing </text>
<text top="124" left="855" width="215" height="20" font="1">incentivized clinicians, 1 more pt would </text>
<text top="141" left="855" width="215" height="20" font="1">achieve BP control. The 7.8% absolute </text>
<text top="159" left="855" width="202" height="20" font="1">change in BP control for pts with DM </text>
<text top="176" left="855" width="206" height="20" font="1">represents a 46% relative increase in </text>
<text top="193" left="855" width="188" height="20" font="1">BP control among intervention pts </text>
<text top="210" left="855" width="208" height="20" font="1">compared with the baseline of 16.8%. </text>
<text top="228" left="855" width="165" height="20" font="1">Further research is needed to </text>
<text top="245" left="855" width="196" height="20" font="1">determine whether this effect of the </text>
<text top="262" left="855" width="171" height="20" font="1">P4P intervention on BP control </text>
<text top="279" left="855" width="188" height="20" font="1">increases or decreases over time. </text>
<text top="296" left="855" width="186" height="20" font="1">However, this NNT to achieve BP </text>
<text top="314" left="855" width="180" height="20" font="1">control through incentives, taken </text>
<text top="331" left="855" width="218" height="20" font="1">together with the large relative increase </text>
<text top="348" left="855" width="197" height="20" font="1">in percentage of pts with BP control </text>
<text top="365" left="855" width="219" height="20" font="1">and the potential effect of BP control on </text>
<text top="383" left="855" width="180" height="20" font="1">risk of ischemic vascular events, </text>
<text top="400" left="855" width="205" height="20" font="1">suggests a reasonable opportunity to </text>
<text top="417" left="855" width="213" height="20" font="1">reduce morbidity and mortality through </text>
<text top="434" left="855" width="173" height="20" font="1">P4P as structured in this study. </text>
<text top="451" left="855" width="3" height="20" font="1"> </text>
<text top="469" left="855" width="202" height="20" font="4"><b>Limitations: </b>Some clinics exited the </text>
<text top="486" left="855" width="218" height="20" font="1">program after randomization, with more </text>
<text top="503" left="855" width="214" height="20" font="1">control clinics leaving than intervention </text>
<text top="520" left="855" width="200" height="20" font="1">clinics. Additionally, this intervention </text>
<text top="537" left="855" width="218" height="20" font="1">occurred in the setting of a voluntary QI </text>
<text top="555" left="855" width="208" height="20" font="1">program. This may reflect a high level </text>
<text top="572" left="855" width="220" height="20" font="1">of intrinsic motivation to improve among </text>
<text top="589" left="855" width="217" height="20" font="1">practices in the study, as demonstrated </text>
<text top="606" left="855" width="211" height="20" font="1">by engagement with the QI specialists<b> </b></text>
<text top="624" left="98" width="102" height="20" font="1">Banerjee D, et al., </text>
<text top="641" left="98" width="63" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(328)</a> </text>
<text top="659" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22031453?dopt=Citation">22031453</a></text>
<text top="659" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22031453?dopt=Citation"> </a></text>
<text top="624" left="240" width="94" height="20" font="4"><b>Study type</b>: 3-y, </text>
<text top="641" left="240" width="85" height="20" font="1">cross-sectional </text>
<text top="659" left="240" width="89" height="20" font="1">sample using pt </text>
<text top="676" left="240" width="39" height="20" font="1">EHRs. </text>
<text top="626" left="378" width="7" height="18" font="1">•</text>
<text top="625" left="385" width="109" height="20" font="1"> 251,590 pts ≥18 y. </text>
<text top="643" left="378" width="116" height="20" font="1">Underlying HTN was </text>
<text top="660" left="378" width="116" height="20" font="1">defined as 2 or more </text>
<text top="677" left="378" width="125" height="20" font="1">abnormal BP readings </text>
<text top="694" left="378" width="131" height="20" font="1">≥140/90 mm Hg and/or </text>
<text top="711" left="378" width="87" height="20" font="1">pharmaceutical </text>
<text top="729" left="378" width="126" height="20" font="1">treatment. Appropriate </text>
<text top="746" left="378" width="109" height="20" font="1">HTN diagnosis was </text>
<text top="763" left="378" width="133" height="20" font="1">defined by the reporting </text>
<text top="780" left="378" width="127" height="20" font="1">of ICD-9 codes (401.0–</text>
<text top="626" left="536" width="7" height="18" font="1">•</text>
<text top="625" left="543" width="118" height="20" font="1"> To identify prevalent </text>
<text top="643" left="536" width="98" height="20" font="1">and incident HTN </text>
<text top="660" left="536" width="89" height="20" font="1">cases in a large </text>
<text top="677" left="536" width="118" height="20" font="1">outpatient healthcare </text>
<text top="694" left="536" width="116" height="20" font="1">system, examine the </text>
<text top="711" left="536" width="100" height="20" font="1">diagnosis rates of </text>
<text top="729" left="536" width="124" height="20" font="1">prevalent and incident </text>
<text top="746" left="536" width="98" height="20" font="1">HTN, and identify </text>
<text top="763" left="536" width="64" height="20" font="1">clinical and </text>
<text top="780" left="536" width="115" height="20" font="1">demographic factors </text>
<text top="626" left="683" width="7" height="18" font="1">•</text>
<text top="625" left="689" width="134" height="20" font="1"> The prevalence of HTN </text>
<text top="643" left="683" width="111" height="20" font="1">was 28.7%, and the </text>
<text top="660" left="683" width="147" height="20" font="1">diagnosis rate was 62.9%. </text>
<text top="677" left="683" width="147" height="20" font="1">The incidence of HTN was </text>
<text top="694" left="683" width="157" height="20" font="1">13.3%, with a diagnosis rate </text>
<text top="711" left="683" width="128" height="20" font="1">of 19.9%. Predictors of </text>
<text top="729" left="683" width="156" height="20" font="1">diagnosis for prevalent HTN </text>
<text top="746" left="683" width="145" height="20" font="1">included older age, Asian, </text>
<text top="763" left="683" width="138" height="20" font="1">African American, higher </text>
<text top="780" left="683" width="154" height="20" font="1">BMI, and increased number </text>
<text top="626" left="855" width="7" height="18" font="1">•</text>
<text top="625" left="861" width="201" height="20" font="1"> Outpatient EHR diagnosis rates are </text>
<text top="643" left="855" width="213" height="20" font="1">suboptimal, yet EHR diagnosis of HTN </text>
<text top="660" left="855" width="205" height="20" font="1">is strongly associated with treatment. </text>
<text top="677" left="855" width="206" height="20" font="1">Targeted efforts to improve diagnosis </text>
<text top="694" left="855" width="111" height="20" font="1">should be a priority. </text>
</page>
<page number="229" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="28" size="12" family="Times" color="#1c1c1c"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">229 </text>
<text top="107" left="378" width="86" height="20" font="1">401.9). Factors </text>
<text top="124" left="378" width="116" height="20" font="1">associated with HTN </text>
<text top="141" left="378" width="141" height="20" font="1">diagnosis were assessed </text>
<text top="159" left="378" width="111" height="20" font="1">through multivariate </text>
<text top="176" left="378" width="144" height="20" font="1">analyses of pt clinical and </text>
<text top="193" left="378" width="74" height="20" font="1">demographic </text>
<text top="210" left="378" width="89" height="20" font="1">characteristics.  </text>
<text top="107" left="536" width="87" height="20" font="1">associated with </text>
<text top="124" left="536" width="94" height="20" font="1">appropriate HTN </text>
<text top="141" left="536" width="59" height="20" font="1">diagnosis. </text>
<text top="159" left="536" width="3" height="20" font="1"> </text>
<text top="107" left="683" width="154" height="20" font="1">of ABP readings. Predictors </text>
<text top="124" left="683" width="147" height="20" font="1">for incident HTN diagnosis </text>
<text top="141" left="683" width="156" height="20" font="1">were similar. In pts with 2 or </text>
<text top="159" left="683" width="106" height="20" font="1">more abnormal BP </text>
<text top="176" left="683" width="138" height="20" font="1">readings, HTN diagnosis </text>
<text top="193" left="683" width="113" height="20" font="1">was associated with </text>
<text top="210" left="683" width="105" height="20" font="1">significantly higher </text>
<text top="228" left="683" width="149" height="20" font="1">medication treatment rates </text>
<text top="245" left="683" width="103" height="20" font="1">(92.6% vs. 15.8%; </text>
<text top="262" left="683" width="63" height="20" font="1">p&lt;0.0001). </text>
<text top="280" left="98" width="121" height="20" font="1">Jaffe MG, et al., 2013 </text>
<text top="297" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(329)</a> </text>
<text top="314" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23989679?dopt=Citation">23989679</a></text>
<text top="314" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23989679?dopt=Citation"> </a></text>
<text top="280" left="240" width="120" height="20" font="4"><b>Aim: </b>Study the effect </text>
<text top="297" left="240" width="102" height="20" font="1">of a multipronged, </text>
<text top="314" left="240" width="100" height="20" font="1">system-based, QI </text>
<text top="332" left="240" width="100" height="20" font="1">approach on HTN </text>
<text top="349" left="240" width="44" height="20" font="1">control.<b> </b></text>
<text top="366" left="240" width="3" height="20" font="1"> </text>
<text top="383" left="240" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="400" left="240" width="79" height="20" font="1">Observational </text>
<text top="418" left="240" width="3" height="20" font="4"><b> </b></text>
<text top="435" left="240" width="123" height="20" font="4"><b>Size: </b>All pts with HTN </text>
<text top="452" left="240" width="113" height="20" font="1">in the KPNC system </text>
<text top="469" left="240" width="79" height="20" font="1">were included </text>
<text top="280" left="378" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="297" left="378" width="139" height="20" font="1">350,000 pts in the KPNC </text>
<text top="314" left="378" width="143" height="20" font="1">system with HTN in 2001, </text>
<text top="332" left="378" width="134" height="20" font="1">increasing to 650,000 in </text>
<text top="349" left="378" width="31" height="20" font="1">2009<b> </b></text>
<text top="366" left="378" width="3" height="20" font="1"> </text>
<text top="383" left="378" width="66" height="20" font="4"><b>Eligibility:  </b></text>
<text top="402" left="378" width="7" height="18" font="1">•</text>
<text top="402" left="385" width="110" height="20" font="1"> ≥2 HTN diagnoses </text>
<text top="419" left="378" width="122" height="20" font="1">coded in primary care </text>
<text top="436" left="378" width="112" height="20" font="1">visits in the prior 2 y </text>
<text top="455" left="378" width="7" height="18" font="1">•</text>
<text top="454" left="385" width="122" height="20" font="1"> ≥1 primary care HTN </text>
<text top="472" left="378" width="140" height="20" font="1">diagnoses and 1 or more </text>
<text top="489" left="378" width="139" height="20" font="1">hospitalizations with a 1° </text>
<text top="506" left="378" width="127" height="20" font="1">or 2° HTN diagnosis in </text>
<text top="523" left="378" width="68" height="20" font="1">the prior 2 y </text>
<text top="542" left="378" width="7" height="18" font="1">•</text>
<text top="542" left="385" width="122" height="20" font="1"> ≥1 primary care HTN </text>
<text top="559" left="378" width="140" height="20" font="1">diagnoses and 1 or more </text>
<text top="576" left="378" width="120" height="20" font="1">filled prescriptions for </text>
<text top="593" left="378" width="126" height="20" font="1">HTN medication within </text>
<text top="610" left="378" width="100" height="20" font="1">the prior 6 mo, or  </text>
<text top="629" left="378" width="7" height="18" font="1">•</text>
<text top="629" left="385" width="122" height="20" font="1"> ≥1 primary care HTN </text>
<text top="646" left="378" width="140" height="20" font="1">diagnoses and 1 or more </text>
<text top="663" left="378" width="79" height="20" font="1">stroke-related </text>
<text top="680" left="378" width="112" height="20" font="1">hospitalizations or a </text>
<text top="698" left="378" width="105" height="20" font="1">history of coronary </text>
<text top="715" left="378" width="109" height="20" font="1">disease, HF, or DM </text>
<text top="280" left="536" width="115" height="20" font="4"><b>Intervention:</b> KPNC </text>
<text top="297" left="536" width="131" height="20" font="1">HTN Program includes: </text>
<text top="314" left="536" width="104" height="20" font="1">HTN registry, HTN </text>
<text top="332" left="536" width="125" height="20" font="1">control monitoring and </text>
<text top="349" left="536" width="99" height="20" font="1">feedback system, </text>
<text top="366" left="536" width="90" height="20" font="1">evidence-based </text>
<text top="383" left="536" width="109" height="20" font="1">practice guidelines, </text>
<text top="401" left="536" width="117" height="20" font="1">medical assistant BP </text>
<text top="418" left="536" width="123" height="20" font="1">recheck program, and </text>
<text top="435" left="536" width="107" height="20" font="1">promotion of single </text>
<text top="452" left="536" width="105" height="20" font="1">polypill formulation </text>
<text top="469" left="536" width="53" height="20" font="1">(lisinopril-</text>
<text top="487" left="536" width="107" height="20" font="28">hydrochlorothiazide</text>
<text top="487" left="642" width="8" height="20" font="1">) </text>
<text top="504" left="536" width="7" height="20" font="1">  </text>
<text top="521" left="536" width="122" height="20" font="4"><b>Comparator:</b> Insured </text>
<text top="538" left="536" width="116" height="20" font="1">pts in California from </text>
<text top="555" left="536" width="121" height="20" font="1">2006–2009 who were </text>
<text top="573" left="536" width="124" height="20" font="1">included in the HEDIS </text>
<text top="590" left="536" width="66" height="20" font="1">commercial </text>
<text top="607" left="536" width="95" height="20" font="1">measurement by </text>
<text top="624" left="536" width="92" height="20" font="1">California health </text>
<text top="641" left="536" width="89" height="20" font="1">insurance plans </text>
<text top="659" left="536" width="103" height="20" font="1">participating in the </text>
<text top="676" left="536" width="129" height="20" font="1">NCQA quality measure </text>
<text top="693" left="536" width="128" height="20" font="1">reporting process. A 2º </text>
<text top="710" left="536" width="127" height="20" font="1">comparison group was </text>
<text top="727" left="536" width="120" height="20" font="1">included to obtain the </text>
<text top="745" left="536" width="130" height="20" font="1">reported national mean </text>
<text top="762" left="536" width="80" height="20" font="1">NCQA HEDIS </text>
<text top="779" left="536" width="111" height="20" font="1">commercial rates of </text>
<text top="281" left="683" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="300" left="683" width="7" height="18" font="1">•</text>
<text top="299" left="689" width="116" height="20" font="1"> HTN control rates in </text>
<text top="317" left="683" width="111" height="20" font="1">KPNC pts with HTN </text>
<text top="334" left="683" width="152" height="20" font="1">improved from 43.6% (95% </text>
<text top="351" left="683" width="147" height="20" font="1">CI: 39.4%, 48.6%) in 2001 </text>
<text top="368" left="683" width="145" height="20" font="1">to 80.4% (95% CI: 75.6%, </text>
<text top="386" left="683" width="137" height="20" font="1">84.4%) by the end of the </text>
<text top="403" left="683" width="141" height="20" font="1">study period (p&lt;0.001 for </text>
<text top="420" left="683" width="39" height="20" font="1">trend). </text>
<text top="439" left="683" width="7" height="18" font="1">•</text>
<text top="438" left="689" width="138" height="20" font="1"> By comparison, national </text>
<text top="456" left="683" width="114" height="20" font="1">mean NCQA HEDIS </text>
<text top="473" left="683" width="145" height="20" font="1">commercial measurement </text>
<text top="490" left="683" width="154" height="20" font="1">HTN control increased from </text>
<text top="507" left="683" width="87" height="20" font="1">55.4%–64.1%.  </text>
<text top="526" left="683" width="7" height="18" font="1">•</text>
<text top="526" left="689" width="132" height="20" font="1"> California mean NCQA </text>
<text top="543" left="683" width="152" height="20" font="1">HEDIS commercial rates of </text>
<text top="560" left="683" width="152" height="20" font="1">HTN control were similar to </text>
<text top="577" left="683" width="138" height="20" font="1">those reported nationally </text>
<text top="594" left="683" width="139" height="20" font="1">from 2006–2009 (63.4%–</text>
<text top="612" left="683" width="46" height="20" font="1">69.4%).<b> </b></text>
<text top="629" left="683" width="3" height="20" font="4"><b> </b></text>
<text top="647" left="683" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A </text>
<text top="282" left="855" width="7" height="18" font="1">•</text>
<text top="281" left="861" width="192" height="20" font="1"> A system-based approach to HTN </text>
<text top="298" left="855" width="185" height="20" font="1">control that includes performance </text>
<text top="316" left="855" width="220" height="20" font="1">measurement and QI strategies led to a </text>
<text top="333" left="855" width="215" height="20" font="1">significant improvement in HTN control </text>
<text top="350" left="855" width="185" height="20" font="1">(80%, compared to 44% baseline </text>
<text top="367" left="855" width="215" height="20" font="1">control) in a large population of pts in a </text>
<text top="384" left="855" width="149" height="20" font="1">managed care health plan. </text>
</page>
<page number="230" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">230 </text>
<text top="107" left="536" width="97" height="20" font="1">HTN control from </text>
<text top="124" left="536" width="130" height="20" font="1">2001–2009 from health </text>
<text top="141" left="536" width="124" height="20" font="1">plans that participated </text>
<text top="159" left="536" width="113" height="20" font="1">in the NCQA HEDIS </text>
<text top="176" left="536" width="90" height="20" font="1">quality measure </text>
<text top="193" left="536" width="102" height="20" font="1">reporting process. </text>
<text top="211" left="98" width="104" height="20" font="1">Rakotz MK, et al.,  </text>
<text top="228" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(330)</a> </text>
<text top="245" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25024244?dopt=Citation">25024244</a></text>
<text top="245" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25024244?dopt=Citation"> </a></text>
<text top="211" left="240" width="118" height="20" font="4"><b>Aim</b>: The goal of this </text>
<text top="228" left="240" width="118" height="20" font="1">study was to develop </text>
<text top="245" left="240" width="111" height="20" font="1">a technology-based </text>
<text top="263" left="240" width="123" height="20" font="1">strategy to identify pts </text>
<text top="280" left="240" width="99" height="20" font="1">with undiagnosed </text>
<text top="297" left="240" width="103" height="20" font="1">HTN in 23 primary </text>
<text top="314" left="240" width="104" height="20" font="1">care practices and </text>
<text top="332" left="240" width="74" height="20" font="1">integrate this </text>
<text top="349" left="240" width="93" height="20" font="1">innovation into a </text>
<text top="366" left="240" width="79" height="20" font="1">continuous QI </text>
<text top="383" left="240" width="105" height="20" font="1">initiative in a large, </text>
<text top="401" left="240" width="95" height="20" font="1">integrated health </text>
<text top="418" left="240" width="46" height="20" font="1">system. </text>
<text top="213" left="378" width="7" height="18" font="1">•</text>
<text top="212" left="385" width="124" height="20" font="1"> Of the 139,666 active </text>
<text top="229" left="378" width="135" height="20" font="1">adult primary care pts in </text>
<text top="247" left="378" width="107" height="20" font="1">these 23 practices, </text>
<text top="264" left="378" width="119" height="20" font="1">47,822 already had a </text>
<text top="281" left="378" width="134" height="20" font="1">diagnosis of HTN, white-</text>
<text top="298" left="378" width="127" height="20" font="1">coat HTN, pre-HTN, or </text>
<text top="316" left="378" width="108" height="20" font="1">elevated BP. The 3 </text>
<text top="333" left="378" width="135" height="20" font="1">screening algorithms for </text>
<text top="350" left="378" width="132" height="20" font="1">undiagnosed HTN were </text>
<text top="367" left="378" width="135" height="20" font="1">applied to the remaining </text>
<text top="384" left="378" width="127" height="20" font="1">pts’ EHRs. There were </text>
<text top="402" left="378" width="124" height="20" font="1">1,586 pts who met the </text>
<text top="419" left="378" width="144" height="20" font="1">criteria of 1 or more of the </text>
<text top="436" left="378" width="114" height="20" font="1">algorithms and were </text>
<text top="453" left="378" width="130" height="20" font="1">therefore considered at </text>
<text top="470" left="378" width="114" height="20" font="1">risk for undiagnosed </text>
<text top="488" left="378" width="32" height="20" font="1">HTN. </text>
<text top="213" left="536" width="7" height="18" font="1">•</text>
<text top="212" left="543" width="87" height="20" font="1"> In phase 1, we </text>
<text top="229" left="536" width="121" height="20" font="1">reviewed EHRs using </text>
<text top="247" left="536" width="127" height="20" font="1">algorithms designed to </text>
<text top="264" left="536" width="116" height="20" font="1">identify pts at risk for </text>
<text top="281" left="536" width="128" height="20" font="1">undiagnosed HTN. We </text>
<text top="298" left="536" width="133" height="20" font="1">then invited each at-risk </text>
<text top="316" left="536" width="98" height="20" font="1">pt to complete an </text>
<text top="333" left="536" width="114" height="20" font="1">automated office BP </text>
<text top="350" left="536" width="115" height="20" font="1">protocol. In phase 2, </text>
<text top="367" left="536" width="98" height="20" font="1">we instituted a QI </text>
<text top="384" left="536" width="120" height="20" font="1">process that included </text>
<text top="402" left="536" width="96" height="20" font="1">regular physician </text>
<text top="419" left="536" width="111" height="20" font="1">feedback and office-</text>
<text top="436" left="536" width="125" height="20" font="1">based computer alerts </text>
<text top="453" left="536" width="120" height="20" font="1">to evaluate at-risk pts </text>
<text top="470" left="536" width="124" height="20" font="1">not screened in phase </text>
<text top="488" left="536" width="98" height="20" font="1">1. Study pts were </text>
<text top="505" left="536" width="89" height="20" font="1">observed for 24 </text>
<text top="522" left="536" width="90" height="20" font="1">additional mo to </text>
<text top="539" left="536" width="103" height="20" font="1">determine rates of </text>
<text top="557" left="536" width="119" height="20" font="1">diagnostic resolution. </text>
<text top="574" left="536" width="99" height="20" font="1">After phase 1, we </text>
<text top="591" left="536" width="76" height="20" font="1">established a </text>
<text top="608" left="536" width="127" height="20" font="1">continuous QI initiative </text>
<text top="625" left="536" width="122" height="20" font="1">to further evaluate pts </text>
<text top="643" left="536" width="117" height="20" font="1">who remained at risk </text>
<text top="660" left="536" width="124" height="20" font="1">for undiagnosed HTN. </text>
<text top="677" left="536" width="127" height="20" font="1">In this 24-mo follow-up </text>
<text top="694" left="536" width="111" height="20" font="1">phase (phase 2), all </text>
<text top="711" left="536" width="132" height="20" font="1">primary care physicians </text>
<text top="729" left="536" width="121" height="20" font="1">received monthly lists </text>
<text top="746" left="536" width="87" height="20" font="1">of their pts who </text>
<text top="763" left="536" width="124" height="20" font="1">continued to be at risk </text>
<text top="780" left="536" width="124" height="20" font="1">for undiagnosed HTN. </text>
<text top="213" left="683" width="7" height="18" font="1">•</text>
<text top="212" left="689" width="131" height="20" font="1"> Of the 1,033 at-risk pts </text>
<text top="229" left="683" width="154" height="20" font="1">who remained active during </text>
<text top="247" left="683" width="141" height="20" font="1">phase 2, 740 (72%) were </text>
<text top="264" left="683" width="149" height="20" font="1">classified by the end of the </text>
<text top="281" left="683" width="141" height="20" font="1">follow-up period: 361 had </text>
<text top="298" left="683" width="140" height="20" font="1">HTN diagnosed, 290 had </text>
<text top="316" left="683" width="147" height="20" font="1">either white coat HTN, pre-</text>
<text top="333" left="683" width="116" height="20" font="1">HTN, or elevated BP </text>
<text top="350" left="683" width="129" height="20" font="1">diagnosed, and 89 had </text>
<text top="367" left="683" width="140" height="20" font="1">normal BP. By the end of </text>
<text top="384" left="683" width="158" height="20" font="1">the follow-up period, 293 pts </text>
<text top="402" left="683" width="111" height="20" font="1">(28%) had not been </text>
<text top="419" left="683" width="146" height="20" font="1">classified and remained at </text>
<text top="436" left="683" width="146" height="20" font="1">risk for undiagnosed HTN. </text>
<text top="213" left="855" width="7" height="18" font="1">•</text>
<text top="212" left="861" width="211" height="20" font="1"> Although we used multiple algorithms </text>
<text top="229" left="855" width="171" height="20" font="1">to identify pts with elevated BP </text>
<text top="247" left="855" width="216" height="20" font="1">readings, it is unlikely that we identified </text>
<text top="264" left="855" width="167" height="20" font="1">all pts with undiagnosed HTN. </text>
</page>
<page number="231" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">231 </text>
<text top="107" left="536" width="87" height="20" font="1">These pts were </text>
<text top="124" left="536" width="119" height="20" font="1">contacted by staff via </text>
<text top="141" left="536" width="116" height="20" font="1">telephone or letter to </text>
<text top="159" left="536" width="109" height="20" font="1">arrange a follow-up </text>
<text top="176" left="536" width="132" height="20" font="1">appointment. These pts </text>
<text top="193" left="536" width="92" height="20" font="1">remained on the </text>
<text top="210" left="536" width="131" height="20" font="1">physicians’ lists until an </text>
<text top="228" left="536" width="114" height="20" font="1">automated office BP </text>
<text top="245" left="536" width="85" height="20" font="1">evaluation was </text>
<text top="262" left="536" width="127" height="20" font="1">completed or an ICD-9 </text>
<text top="279" left="536" width="126" height="20" font="1">diagnosis was entered </text>
<text top="296" left="536" width="98" height="20" font="1">into the chart that </text>
<text top="314" left="536" width="132" height="20" font="1">indicated the pt’s at-risk </text>
<text top="331" left="536" width="91" height="20" font="1">status had been </text>
<text top="348" left="536" width="117" height="20" font="1">resolved. In addition, </text>
<text top="365" left="536" width="100" height="20" font="1">when an at-risk pt </text>
<text top="383" left="536" width="133" height="20" font="1">arrived for an office visit </text>
<text top="400" left="536" width="122" height="20" font="1">for any reason, a best </text>
<text top="417" left="536" width="121" height="20" font="1">practice advisory was </text>
<text top="434" left="536" width="122" height="20" font="1">prominently displayed </text>
<text top="451" left="536" width="133" height="20" font="1">on that pt’s EHR screen </text>
<text top="469" left="536" width="113" height="20" font="1">to notify the medical </text>
<text top="486" left="536" width="130" height="20" font="1">assistant and physician </text>
<text top="503" left="536" width="103" height="20" font="1">that an automated </text>
<text top="520" left="536" width="131" height="20" font="1">office BP measurement </text>
<text top="537" left="536" width="73" height="20" font="1">was needed. </text>
<text top="555" left="98" width="107" height="20" font="1">Borden WB, et al.,  </text>
<text top="573" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(331)</a> </text>
<text top="590" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25447261?dopt=Citation">25447261</a></text>
<text top="590" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25447261?dopt=Citation"> </a></text>
<text top="555" left="240" width="116" height="20" font="4"><b>Aim</b>: The purpose of </text>
<text top="573" left="240" width="94" height="20" font="1">this study was to </text>
<text top="590" left="240" width="118" height="20" font="1">examine the effect of </text>
<text top="607" left="240" width="122" height="20" font="1">the 2014 expert panel </text>
<text top="624" left="240" width="95" height="20" font="1">BP management </text>
<text top="641" left="240" width="118" height="20" font="1">recommendations on </text>
<text top="659" left="240" width="115" height="20" font="1">pts managed in U.S. </text>
<text top="676" left="240" width="85" height="20" font="1">ambulatory CV </text>
<text top="693" left="240" width="63" height="20" font="1">practices.   </text>
<text top="557" left="378" width="7" height="18" font="1">•</text>
<text top="556" left="385" width="128" height="20" font="1"> Using the National CV </text>
<text top="574" left="378" width="143" height="20" font="1">Data Registry PINNACLE </text>
<text top="591" left="378" width="126" height="20" font="1">Registry, we assessed </text>
<text top="608" left="378" width="93" height="20" font="1">the proportion of </text>
<text top="625" left="378" width="128" height="20" font="1">1,185,253 pts who met </text>
<text top="643" left="378" width="140" height="20" font="1">the 2003 and 2014 panel </text>
<text top="660" left="378" width="105" height="20" font="1">recommendations, </text>
<text top="677" left="378" width="86" height="20" font="1">highlighting the </text>
<text top="694" left="378" width="118" height="20" font="1">populations of pts for </text>
<text top="711" left="378" width="109" height="20" font="1">whom the BP goals </text>
<text top="729" left="378" width="54" height="20" font="1">changed. </text>
<text top="555" left="536" width="24" height="20" font="1">N/A </text>
<text top="557" left="683" width="7" height="18" font="1">•</text>
<text top="556" left="689" width="131" height="20" font="1"> Of 1,185,253 pts in the </text>
<text top="574" left="683" width="122" height="20" font="1">study cohort, 706,859 </text>
<text top="591" left="683" width="150" height="20" font="1">(59.6%) achieved the 2003 </text>
<text top="608" left="683" width="130" height="20" font="1">JNC-7 goals. Using the </text>
<text top="625" left="683" width="135" height="20" font="1">2014 recommendations, </text>
<text top="643" left="683" width="158" height="20" font="1">880,378 (74.3%) pts were at </text>
<text top="660" left="683" width="141" height="20" font="1">goal. Among the 173,519 </text>
<text top="677" left="683" width="127" height="20" font="1">(14.6%) for whom goal </text>
<text top="694" left="683" width="127" height="20" font="1">achievement changed, </text>
<text top="711" left="683" width="150" height="20" font="1">40,323 (23.2%) had a prior </text>
<text top="729" left="683" width="149" height="20" font="1">stroke or TIA, and 112,174 </text>
<text top="746" left="683" width="117" height="20" font="1">(64.6%) had CAD. In </text>
<text top="763" left="683" width="118" height="20" font="1">addition, the average </text>
<text top="780" left="683" width="141" height="20" font="1">Framingham risk score in </text>
<text top="557" left="855" width="7" height="18" font="1">•</text>
<text top="556" left="861" width="197" height="20" font="1"> Among U.S. ambulatory cardiology </text>
<text top="574" left="855" width="214" height="20" font="1">pts with HTN, nearly 1 in 7 who did not </text>
<text top="591" left="855" width="206" height="20" font="1">meet JNC-7 recommendations would </text>
<text top="608" left="855" width="200" height="20" font="1">now meet the 2014 treatment goals. </text>
</page>
<page number="232" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">232 </text>
<text top="107" left="683" width="150" height="20" font="1">this group was 8.5 ± 3.2%, </text>
<text top="124" left="683" width="155" height="20" font="1">and the 10-y atherosclerotic </text>
<text top="141" left="683" width="150" height="20" font="1">CVD risk score was 28.0 ± </text>
<text top="159" left="683" width="42" height="20" font="1">19.5%. </text>
<text top="178" left="108" width="3" height="19" font="1"> </text>
<text top="212" left="81" width="1001" height="24" font="3"><b>Data Supplement 64. RCTs, Meta-analyses, and Systematic Reviews on the Effect of Telehealth Interventions to Improve Hypertension Control </b></text>
<text top="236" left="81" width="112" height="24" font="3"><b>(Section 12.3.2) </b></text>
<text top="276" left="102" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="293" left="127" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="310" left="105" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="276" left="242" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="293" left="247" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="310" left="241" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="276" left="382" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="276" left="532" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="293" left="564" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="310" left="532" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="328" left="568" width="55" height="20" font="4"><b>patients) </b></text>
<text top="276" left="710" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="293" left="688" width="149" height="20" font="4"><b>(Absolute Event Rates, P </b></text>
<text top="310" left="681" width="162" height="20" font="4"><b>value; OR or RR; &amp; 95% CI) </b></text>
<text top="277" left="878" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="294" left="911" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="312" left="918" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="329" left="936" width="59" height="20" font="4"><b>Summary </b></text>
<text top="347" left="98" width="91" height="20" font="1">Burke LE, et al., </text>
<text top="364" left="98" width="63" height="20" font="1">2015 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(332)</a> </text>
<text top="381" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26271892">26271892</a></text>
<text top="381" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26271892"> </a></text>
<text top="347" left="218" width="109" height="20" font="4"><b>Aim:</b> Review of the </text>
<text top="364" left="218" width="125" height="20" font="1">Scientific Literature on </text>
<text top="381" left="218" width="128" height="20" font="1">mHealth Tools Related </text>
<text top="398" left="218" width="105" height="20" font="1">to CVD Prevention </text>
<text top="416" left="218" width="3" height="20" font="1"> </text>
<text top="433" left="218" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="450" left="218" width="103" height="20" font="1">Systematic review </text>
<text top="467" left="218" width="3" height="20" font="1"> </text>
<text top="484" left="218" width="126" height="20" font="4"><b>Size:</b> 69 studies of the </text>
<text top="502" left="218" width="76" height="20" font="1">use of mobile </text>
<text top="519" left="218" width="127" height="20" font="1">technologies to reduce </text>
<text top="536" left="218" width="109" height="20" font="1">CVD risk behaviors<b> </b></text>
<text top="347" left="363" width="102" height="20" font="4"><b>Inclusion criteria</b> </text>
<text top="364" left="363" width="138" height="20" font="1">Studies of electronic and </text>
<text top="381" left="363" width="145" height="20" font="1">mobile technology tools in </text>
<text top="398" left="363" width="141" height="20" font="1">CV prevention; published </text>
<text top="416" left="363" width="106" height="20" font="1">from 2004–2014 in </text>
<text top="433" left="363" width="101" height="20" font="1">English language; </text>
<text top="450" left="363" width="143" height="20" font="1">enrolling adults except for </text>
<text top="467" left="363" width="126" height="20" font="1">smoking cessation, for </text>
<text top="484" left="363" width="134" height="20" font="1">which adolescents were </text>
<text top="502" left="363" width="139" height="20" font="1">also included; conducted </text>
<text top="519" left="363" width="98" height="20" font="1">in the U.S. and in </text>
<text top="536" left="363" width="117" height="20" font="1">developed countries. </text>
<text top="553" left="363" width="3" height="20" font="4"><b> </b></text>
<text top="570" left="363" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="588" left="363" width="105" height="20" font="1">Absence of above.<b> </b></text>
<text top="347" left="525" width="118" height="20" font="4"><b>Intervention:</b> Mobile </text>
<text top="364" left="525" width="127" height="20" font="1">technologies to reduce </text>
<text top="381" left="525" width="112" height="20" font="1">CVD risk behaviors–</text>
<text top="398" left="525" width="119" height="20" font="1">varied across studies </text>
<text top="416" left="525" width="3" height="20" font="1"> </text>
<text top="433" left="525" width="116" height="20" font="4"><b>Comparator:</b> Varied </text>
<text top="450" left="525" width="85" height="20" font="1">across studies.<b> </b></text>
<text top="348" left="678" width="154" height="20" font="4"><b>1</b>°<b> endpoint:</b> Varied across </text>
<text top="365" left="678" width="46" height="20" font="1">studies. </text>
<text top="382" left="678" width="3" height="20" font="1"> </text>
<text top="401" left="678" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A<b> </b></text>
<text top="347" left="859" width="166" height="20" font="4"><b>Summary</b>: mHealth or mobile </text>
<text top="364" left="859" width="187" height="20" font="1">technologies have the potential to </text>
<text top="381" left="859" width="173" height="20" font="1">transform the delivery of health-</text>
<text top="398" left="859" width="172" height="20" font="1">related messages and ongoing </text>
<text top="416" left="859" width="175" height="20" font="1">interventions targeting behavior </text>
<text top="433" left="859" width="163" height="20" font="1">change. Moreover, the use of </text>
<text top="450" left="859" width="193" height="20" font="1">monitoring devices (e.g., Bluetooth-</text>
<text top="467" left="859" width="175" height="20" font="1">enabled BP monitors and blood </text>
<text top="484" left="859" width="209" height="20" font="1">glucose monitors) permits the sharing </text>
<text top="502" left="859" width="181" height="20" font="1">of important pt self-management </text>
<text top="519" left="859" width="206" height="20" font="1">parameters with healthcare providers </text>
<text top="536" left="859" width="167" height="20" font="1">in real time and the delivery of </text>
<text top="553" left="859" width="197" height="20" font="1">feedback and guidance to pts when </text>
<text top="570" left="859" width="178" height="20" font="1">they need it. Furthermore, using </text>
<text top="588" left="859" width="207" height="20" font="1">mHealth tools for monitoring provides </text>
<text top="605" left="859" width="209" height="20" font="1">the clinician data that far exceed what </text>
<text top="622" left="859" width="200" height="20" font="1">can be measured in the brief clinical </text>
<text top="639" left="859" width="190" height="20" font="1">encounter and reflect the status of </text>
<text top="657" left="859" width="206" height="20" font="1">physiological or behavioral measures </text>
<text top="674" left="859" width="168" height="20" font="1">in the person’s natural setting. </text>
<text top="692" left="98" width="72" height="20" font="1">Liu S, et al.,  </text>
<text top="709" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(333)</a> </text>
<text top="726" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23618507?dopt=Citation">23618507</a></text>
<text top="726" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23618507?dopt=Citation"> </a></text>
<text top="692" left="218" width="94" height="20" font="4"><b>Aim:</b> Assess the </text>
<text top="709" left="218" width="70" height="20" font="1">efficacy of e-</text>
<text top="726" left="218" width="128" height="20" font="1">counselling in reducing </text>
<text top="743" left="218" width="20" height="20" font="1">BP </text>
<text top="760" left="218" width="3" height="20" font="1"> </text>
<text top="692" left="363" width="120" height="20" font="4"><b>Inclusion criteria:</b> 1) </text>
<text top="709" left="363" width="147" height="20" font="1">Trials that investigated the </text>
<text top="726" left="363" width="130" height="20" font="1">effect of Internet-based </text>
<text top="743" left="363" width="134" height="20" font="1">lifestyle interventions on </text>
<text top="760" left="363" width="128" height="20" font="1">SBP and DBP, 2) trials </text>
<text top="778" left="363" width="73" height="20" font="1">that included </text>
<text top="692" left="525" width="124" height="20" font="4"><b>Intervention:</b> Internet-</text>
<text top="709" left="525" width="120" height="20" font="1">based intervention as </text>
<text top="726" left="525" width="136" height="20" font="1">preventive e-counselling </text>
<text top="743" left="525" width="115" height="20" font="1">or advice using Web </text>
<text top="760" left="525" width="139" height="20" font="1">sites or e-mails to modify </text>
<text top="778" left="525" width="113" height="20" font="1">exercise or diet as a </text>
<text top="693" left="678" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="710" left="678" width="159" height="20" font="1">MD in BP reduction (Internet-</text>
<text top="727" left="678" width="115" height="20" font="1">based – usual care): </text>
<text top="744" left="678" width="154" height="20" font="1">SBP: -3.8 mm Hg (95% CI: -</text>
<text top="762" left="678" width="77" height="20" font="1">5.63– -2.06), I</text>
<text top="763" left="755" width="4" height="13" font="6">2</text>
<text top="762" left="759" width="24" height="20" font="1">=61 </text>
<text top="693" left="859" width="7" height="18" font="1">•</text>
<text top="693" left="866" width="186" height="20" font="1"> Behavior change techniques that </text>
<text top="710" left="859" width="194" height="20" font="1">were used in more than 50% of the </text>
<text top="727" left="859" width="143" height="20" font="1">successful internet-based </text>
<text top="744" left="859" width="198" height="20" font="1">interventions included the following: </text>
<text top="762" left="859" width="135" height="20" font="1">providing information on </text>
<text top="779" left="859" width="204" height="20" font="1">consequences of behavior in general </text>
</page>
<page number="233" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">233 </text>
<text top="107" left="218" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="124" left="218" width="106" height="20" font="1">Systematic review, </text>
<text top="141" left="218" width="79" height="20" font="1">meta-analysis </text>
<text top="159" left="218" width="3" height="20" font="1"> </text>
<text top="176" left="218" width="128" height="20" font="4"><b>Size:</b> 13 RCTs or case-</text>
<text top="193" left="218" width="83" height="20" font="1">control studies<b> </b></text>
<text top="107" left="363" width="147" height="20" font="1">supplemental components </text>
<text top="124" left="363" width="109" height="20" font="1">such as mobile text </text>
<text top="141" left="363" width="138" height="20" font="1">messages, telephone, or </text>
<text top="159" left="363" width="117" height="20" font="1">in-person support, 3) </text>
<text top="176" left="363" width="142" height="20" font="1">intervention duration of at </text>
<text top="193" left="363" width="128" height="20" font="1">least 8 wk, and 4) SBP </text>
<text top="210" left="363" width="149" height="20" font="1">and DBP reported as 1° or </text>
<text top="228" left="363" width="142" height="20" font="1">2° outcome, measured at </text>
<text top="245" left="363" width="92" height="20" font="1">a clinic or office. </text>
<text top="262" left="363" width="3" height="20" font="1"> </text>
<text top="279" left="363" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="296" left="363" width="105" height="20" font="1">Absence of above.<b> </b></text>
<text top="107" left="525" width="130" height="20" font="1">means of improving BP </text>
<text top="124" left="525" width="127" height="20" font="1">control. These Internet-</text>
<text top="141" left="525" width="140" height="20" font="1">based interventions were </text>
<text top="159" left="525" width="117" height="20" font="1">primarily self-guided, </text>
<text top="176" left="525" width="131" height="20" font="1">and access was gained </text>
<text top="193" left="525" width="124" height="20" font="1">via desktop computer, </text>
<text top="210" left="525" width="126" height="20" font="1">laptop, tablet, or smart </text>
<text top="228" left="525" width="127" height="20" font="1">phone. The duration of </text>
<text top="245" left="525" width="135" height="20" font="1">each intervention had to </text>
<text top="262" left="525" width="134" height="20" font="1">be at least 8 wk in order </text>
<text top="279" left="525" width="109" height="20" font="1">to achieve clinically </text>
<text top="296" left="525" width="124" height="20" font="1">meaningful outcomes, </text>
<text top="314" left="525" width="130" height="20" font="1">including the pt’s ability </text>
<text top="331" left="525" width="124" height="20" font="1">to learn and adhere to </text>
<text top="348" left="525" width="135" height="20" font="1">complex new behaviors, </text>
<text top="365" left="525" width="139" height="20" font="1">and to allow for sufficient </text>
<text top="383" left="525" width="122" height="20" font="1">time to demonstrate a </text>
<text top="400" left="525" width="126" height="20" font="1">stable reduction in BP. </text>
<text top="417" left="525" width="120" height="20" font="1">The majority (9/13) of </text>
<text top="434" left="525" width="97" height="20" font="1">interventions had </text>
<text top="451" left="525" width="76" height="20" font="1">supplemental </text>
<text top="469" left="525" width="124" height="20" font="1">components that were </text>
<text top="486" left="525" width="135" height="20" font="1">not internet-based, such </text>
<text top="503" left="525" width="116" height="20" font="1">as text messages, in-</text>
<text top="520" left="525" width="121" height="20" font="1">person visits, and live </text>
<text top="537" left="525" width="103" height="20" font="1">support and 10/13 </text>
<text top="555" left="525" width="125" height="20" font="1">targeted both exercise </text>
<text top="572" left="525" width="107" height="20" font="1">and diet behaviors. </text>
<text top="589" left="525" width="7" height="20" font="1">  </text>
<text top="606" left="525" width="139" height="20" font="4"><b>Comparator:</b> Usual care </text>
<text top="623" left="525" width="124" height="20" font="1">with no internet-based </text>
<text top="641" left="525" width="51" height="20" font="1">strategy.<b> </b></text>
<text top="107" left="678" width="155" height="20" font="1">DBP: -2.1 mm Hg (95% CI: -</text>
<text top="124" left="678" width="77" height="20" font="1">3.51– -0.65), I</text>
<text top="126" left="755" width="4" height="13" font="6">2</text>
<text top="124" left="759" width="24" height="20" font="1">=57 </text>
<text top="141" left="678" width="3" height="20" font="1"> </text>
<text top="159" left="678" width="146" height="20" font="4"><b>Influence of intervention </b></text>
<text top="176" left="678" width="64" height="20" font="4"><b>attributes: </b></text>
<text top="193" left="678" width="119" height="20" font="1">Intervention duration: </text>
<text top="210" left="678" width="107" height="20" font="1">Long-term (≥6 mo) </text>
<text top="227" left="678" width="166" height="20" font="1">intervention: SBP -5.8 mm Hg </text>
<text top="245" left="678" width="111" height="20" font="1">(95% CI: -4.3– -4.1) </text>
<text top="262" left="678" width="108" height="20" font="1">Short-term (&lt;6 mo) </text>
<text top="279" left="678" width="154" height="20" font="1">intervention: SBP -3.47 mm </text>
<text top="296" left="678" width="131" height="20" font="1">Hg (95% CI: -5.2– -1.7) </text>
<text top="314" left="678" width="160" height="20" font="1">DBP mean reduction: results </text>
<text top="331" left="678" width="156" height="20" font="1">not reported, not statistically </text>
<text top="348" left="678" width="62" height="20" font="1">significant. </text>
<text top="365" left="678" width="118" height="20" font="1"># of behavior change </text>
<text top="382" left="678" width="66" height="20" font="1">techniques: </text>
<text top="400" left="678" width="113" height="20" font="1">≥5 behavior change </text>
<text top="417" left="678" width="150" height="20" font="1">techniques: SBP -5.92 mm </text>
<text top="434" left="678" width="151" height="20" font="1">Hg (95% CI: -7.43– -4.42) / </text>
<text top="451" left="678" width="158" height="20" font="1">DBP -2.45 mm Hg (95% CI: -</text>
<text top="469" left="678" width="70" height="20" font="1">3.50– -1.41) </text>
<text top="486" left="678" width="112" height="20" font="1">&lt;5 behavior change </text>
<text top="503" left="678" width="150" height="20" font="1">techniques: SBP -2.69 mm </text>
<text top="520" left="678" width="151" height="20" font="1">Hg (95% CI: -4.61– -0.78) / </text>
<text top="537" left="678" width="158" height="20" font="1">DBP -0.02 mm Hg (95% CI: -</text>
<text top="555" left="678" width="66" height="20" font="1">1.20–1.17)  </text>
<text top="572" left="678" width="3" height="20" font="1"> </text>
<text top="590" left="678" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A<b> </b></text>
<text top="107" left="859" width="185" height="20" font="1">(86%), incorporating feedback on </text>
<text top="124" left="859" width="193" height="20" font="1">performance (86%), prompting self-</text>
<text top="141" left="859" width="195" height="20" font="1">monitoring of behaviors (71%), and </text>
<text top="159" left="859" width="204" height="20" font="1">giving instructions on how to perform </text>
<text top="176" left="859" width="203" height="20" font="1">the targeted behavior change (71%). </text>
<text top="193" left="859" width="3" height="20" font="1"> </text>
<text top="210" left="859" width="146" height="20" font="4"><b>Summary</b>: Internet-based </text>
<text top="227" left="859" width="202" height="20" font="1">interventions reduced SBP and DBP </text>
<text top="245" left="859" width="203" height="20" font="1">significantly compared to usual care. </text>
<text top="262" left="859" width="180" height="20" font="1">Internet-based interventions had </text>
<text top="279" left="859" width="198" height="20" font="1">greater effect on BP lowering if they </text>
<text top="296" left="859" width="164" height="20" font="1">were 1) long-term (≥ 6 mo) in </text>
<text top="314" left="859" width="188" height="20" font="1">duration, and 2) used &gt;5 behavior </text>
<text top="331" left="859" width="110" height="20" font="1">change techniques.<b> </b></text>
<text top="659" left="98" width="95" height="20" font="1">Omboni S, et al., </text>
<text top="676" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(334)</a> </text>
<text top="693" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23299557?dopt=Citation">23299557</a></text>
<text top="693" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23299557?dopt=Citation"> </a></text>
<text top="659" left="218" width="130" height="20" font="4"><b>Aim: </b>Review data from </text>
<text top="676" left="218" width="72" height="20" font="1">RCTs on the </text>
<text top="693" left="218" width="125" height="20" font="1">effectiveness of HBPT </text>
<text top="710" left="218" width="104" height="20" font="1">vs. usual care with </text>
<text top="727" left="218" width="132" height="20" font="1">respect to improvement </text>
<text top="745" left="218" width="77" height="20" font="1">of BP control, </text>
<text top="762" left="218" width="118" height="20" font="1">healthcare resources </text>
<text top="779" left="218" width="114" height="20" font="1">utilization and costs, </text>
<text top="659" left="363" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="678" left="363" width="7" height="18" font="1">•</text>
<text top="677" left="370" width="102" height="20" font="1"> English<b> l</b>anguage </text>
<text top="696" left="363" width="7" height="18" font="1">•</text>
<text top="695" left="370" width="120" height="20" font="1"> Published up to Feb. </text>
<text top="713" left="363" width="31" height="20" font="1">2012 </text>
<text top="732" left="363" width="7" height="18" font="1">•</text>
<text top="731" left="370" width="127" height="20" font="1"> RCT testing HBPT vs. </text>
<text top="748" left="363" width="67" height="20" font="1">usual care.  </text>
<text top="765" left="363" width="3" height="20" font="1"> </text>
<text top="659" left="525" width="138" height="20" font="4"><b>Intervention: </b>HBPT had </text>
<text top="676" left="525" width="129" height="20" font="1">to be based on the use </text>
<text top="693" left="525" width="87" height="20" font="1">of an electronic </text>
<text top="710" left="525" width="126" height="20" font="1">automated BP monitor </text>
<text top="727" left="525" width="130" height="20" font="1">storing values obtained </text>
<text top="745" left="525" width="115" height="20" font="1">at the pt’s home and </text>
<text top="762" left="525" width="120" height="20" font="1">transferring them to a </text>
<text top="779" left="525" width="96" height="20" font="1">remote computer </text>
<text top="660" left="678" width="150" height="20" font="4"><b>1</b>°<b> endpoint: </b>Compared to </text>
<text top="677" left="678" width="161" height="20" font="1">usual care, HBPT improved:  </text>
<text top="696" left="678" width="7" height="18" font="1">•</text>
<text top="695" left="685" width="154" height="20" font="4"><b> </b>Office SBP by 4.71 mm Hg </text>
<text top="713" left="678" width="113" height="20" font="1">(95% CI: 6.18–3.24; </text>
<text top="730" left="678" width="59" height="20" font="1">p&lt;0.001); I</text>
<text top="731" left="737" width="4" height="13" font="6">2</text>
<text top="730" left="742" width="97" height="20" font="1">=52.2%; p=0.003 </text>
<text top="749" left="678" width="7" height="18" font="1">•</text>
<text top="748" left="685" width="154" height="20" font="4"><b> </b>Office DBP by 2.45 mm Hg </text>
<text top="765" left="678" width="113" height="20" font="1">(95% CI: 3.33–1.57; </text>
<text top="783" left="678" width="59" height="20" font="1">p&lt;0.001); I</text>
<text top="784" left="737" width="4" height="13" font="6">2</text>
<text top="783" left="742" width="97" height="20" font="1">=40.4%; p=0.048 </text>
<text top="659" left="859" width="73" height="20" font="4"><b>Limitations: </b></text>
<text top="678" left="859" width="7" height="18" font="1">•</text>
<text top="677" left="866" width="154" height="20" font="4"><b> </b>HBPT intervention features </text>
<text top="694" left="859" width="180" height="20" font="1">(telemonitoring systems and self-</text>
<text top="711" left="859" width="178" height="20" font="1">monitoring programs) as well as </text>
<text top="729" left="859" width="190" height="20" font="1">inclusion criteria and demographic </text>
<text top="746" left="859" width="180" height="20" font="1">and clinical characteristics of the </text>
<text top="763" left="859" width="188" height="20" font="1">comparative groups varied across </text>
</page>
<page number="234" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">234 </text>
<text top="107" left="218" width="118" height="20" font="1">pt’s quality of life and </text>
<text top="124" left="218" width="90" height="20" font="1">adverse events. </text>
<text top="141" left="218" width="3" height="20" font="4"><b> </b></text>
<text top="159" left="218" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="176" left="218" width="48" height="20" font="1">analysis<b> </b></text>
<text top="193" left="218" width="3" height="20" font="4"><b> </b></text>
<text top="210" left="218" width="124" height="20" font="4"><b>Size: </b>23 unique RCTs </text>
<text top="227" left="218" width="121" height="20" font="1">with 7037 pts (though </text>
<text top="245" left="218" width="128" height="20" font="1">not all studies reported </text>
<text top="262" left="218" width="103" height="20" font="1">on all outcomes of </text>
<text top="279" left="218" width="48" height="20" font="1">interest)<b> </b></text>
<text top="107" left="363" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="124" left="363" width="105" height="20" font="1">Absence of above<b>  </b></text>
<text top="107" left="525" width="135" height="20" font="1">through a telephone line </text>
<text top="124" left="525" width="117" height="20" font="1">(wired or wireless), a </text>
<text top="141" left="525" width="121" height="20" font="1">modem or an Internet </text>
<text top="159" left="525" width="121" height="20" font="1">connection. At least 1 </text>
<text top="176" left="525" width="121" height="20" font="1">self BP measurement </text>
<text top="193" left="525" width="124" height="20" font="1">had to be available for </text>
<text top="210" left="525" width="77" height="20" font="1">each pt in the </text>
<text top="228" left="525" width="105" height="20" font="1">intervention group. </text>
<text top="245" left="525" width="3" height="20" font="4"><b> </b></text>
<text top="262" left="525" width="139" height="20" font="4"><b>Comparator: </b>Usual care<b> </b></text>
<text top="109" left="678" width="7" height="18" font="1">•</text>
<text top="108" left="685" width="154" height="20" font="4"><b> </b>Office BP Control (&lt;140/90 </text>
<text top="125" left="678" width="153" height="20" font="1">mm Hg nondiabetic pts and<b> </b></text>
<text top="143" left="678" width="164" height="20" font="1">&lt;130/80 mm Hg diabetic pts): </text>
<text top="160" left="678" width="165" height="20" font="1">RR: 1.16 (95% CI: 1.04–1.29; </text>
<text top="177" left="678" width="59" height="20" font="1">p&lt;0.001); I</text>
<text top="179" left="737" width="4" height="13" font="6">2</text>
<text top="177" left="742" width="90" height="20" font="1">=69%; p&lt;0.001<i>  </i></text>
<text top="194" left="678" width="3" height="20" font="4"><b> </b></text>
<text top="213" left="678" width="150" height="20" font="4"><b>2</b>°<b> endpoint: </b>Compared to </text>
<text top="230" left="678" width="161" height="20" font="1">usual care, HBPT improved:  </text>
<text top="249" left="678" width="7" height="18" font="1">•</text>
<text top="248" left="685" width="129" height="20" font="4"><b> </b>Greater prescription of </text>
<text top="265" left="678" width="165" height="20" font="1">antihypertensive medications: </text>
<text top="283" left="678" width="154" height="20" font="1">weighted MD 0.40 (95% CI: </text>
<text top="300" left="678" width="117" height="20" font="1">0.17–0.62; p&lt;0.001); </text>
<text top="317" left="678" width="3" height="20" font="1">I</text>
<text top="319" left="681" width="4" height="13" font="6">2</text>
<text top="317" left="686" width="97" height="20" font="1">=84.2%; p&lt;0.001 </text>
<text top="336" left="678" width="7" height="18" font="1">•</text>
<text top="335" left="685" width="132" height="20" font="4"><b> </b>Lower number of office </text>
<text top="353" left="678" width="141" height="20" font="1">visits: weighted MD -0.18 </text>
<text top="370" left="678" width="121" height="20" font="1">(95% CI: -0.37–0.00); </text>
<text top="387" left="678" width="3" height="20" font="1">I</text>
<text top="389" left="681" width="4" height="13" font="6">2</text>
<text top="387" left="686" width="100" height="20" font="1">=32.7%; p=0.146  </text>
<text top="406" left="678" width="7" height="18" font="1">•</text>
<text top="406" left="685" width="125" height="20" font="4"><b> </b>Quality of life physical </text>
<text top="423" left="678" width="166" height="20" font="1">component of SF-12 or SF-36 </text>
<text top="440" left="678" width="156" height="20" font="1">questionnaire: weighted MD </text>
<text top="457" left="678" width="144" height="20" font="1">2.78 (95% CI: 1.15–4.41); </text>
<text top="474" left="678" width="3" height="20" font="1">I</text>
<text top="476" left="681" width="4" height="13" font="6">2</text>
<text top="474" left="686" width="90" height="20" font="1">=0.0%; p=0.853 </text>
<text top="493" left="678" width="7" height="18" font="1">•</text>
<text top="493" left="685" width="139" height="20" font="4"><b> </b>There was no difference </text>
<text top="510" left="678" width="143" height="20" font="1">between HBPT and usual </text>
<text top="527" left="678" width="47" height="20" font="1">care in:  </text>
<text top="546" left="678" width="7" height="18" font="1">•</text>
<text top="546" left="685" width="133" height="20" font="4"><b> </b>Therapeutic adherence </text>
<text top="563" left="678" width="148" height="20" font="1">[92% HBPT vs. 90% usual </text>
<text top="580" left="678" width="116" height="20" font="1">care; between-group </text>
<text top="597" left="678" width="158" height="20" font="1">difference +1.30% (95% CI: -</text>
<text top="614" left="678" width="117" height="20" font="1">2.31–4.90; p=0.481), </text>
<text top="632" left="678" width="3" height="20" font="1">I</text>
<text top="633" left="681" width="4" height="13" font="6">2</text>
<text top="632" left="686" width="101" height="20" font="1">=0.00%; p=0.888) </text>
<text top="651" left="678" width="7" height="18" font="1">•</text>
<text top="650" left="685" width="118" height="20" font="4"><b> </b>Quality of life mental </text>
<text top="667" left="678" width="166" height="20" font="1">component of SF-12 or SF-36 </text>
<text top="684" left="678" width="160" height="20" font="1">questionnaire: weighted MD -</text>
<text top="702" left="678" width="148" height="20" font="1">0.11 (95% CI: -1.65–1.43); </text>
<text top="719" left="678" width="3" height="20" font="1">I</text>
<text top="720" left="681" width="4" height="13" font="6">2</text>
<text top="719" left="686" width="90" height="20" font="1">=0.0%; p=0.984<b> </b></text>
<text top="736" left="678" width="3" height="20" font="1"> </text>
<text top="753" left="678" width="32" height="20" font="1">Cost: </text>
<text top="772" left="678" width="7" height="18" font="1">•</text>
<text top="772" left="685" width="128" height="20" font="4"><b> </b>Healthcare costs were </text>
<text top="789" left="678" width="138" height="20" font="1">significantly higher in the </text>
<text top="107" left="859" width="191" height="20" font="1">studies and contributed to the high </text>
<text top="124" left="859" width="155" height="20" font="1">heterogeneity of the studies<b> </b></text>
<text top="143" left="859" width="7" height="18" font="1">•</text>
<text top="143" left="866" width="193" height="20" font="4"><b> </b>Most studies were powered to test </text>
<text top="160" left="859" width="184" height="20" font="1">differences in BP lowering, not 2º </text>
<text top="177" left="859" width="57" height="20" font="1">outcomes </text>
<text top="194" left="859" width="3" height="20" font="4"><b> </b></text>
<text top="211" left="859" width="212" height="20" font="4"><b>Summary</b>: HBPT yielded greater SBP </text>
<text top="229" left="859" width="182" height="20" font="1">and DBP reductions and a larger </text>
<text top="246" left="859" width="208" height="20" font="1">proportion of pts achieving BP control </text>
<text top="263" left="859" width="206" height="20" font="1">than usual care. HBPT vs. usual care </text>
<text top="280" left="859" width="183" height="20" font="1">resulted in greater prescription of </text>
<text top="298" left="859" width="186" height="20" font="1">antihypertensive medications and </text>
<text top="315" left="859" width="205" height="20" font="1">fewer office visits but no difference in </text>
<text top="332" left="859" width="192" height="20" font="1">therapeutic adherence. Healthcare </text>
<text top="349" left="859" width="189" height="20" font="1">costs were higher with HBPT than </text>
<text top="366" left="859" width="195" height="20" font="1">usual care, but when HBPT-related </text>
<text top="384" left="859" width="196" height="20" font="1">costs were excluded, medical costs </text>
<text top="401" left="859" width="202" height="20" font="1">were similar between groups. Use of </text>
<text top="418" left="859" width="208" height="20" font="1">HBPT vs. usual care improved quality </text>
<text top="435" left="859" width="186" height="20" font="1">of life physical component but not </text>
<text top="453" left="859" width="206" height="20" font="1">mental. Authors note that the amount </text>
<text top="470" left="859" width="198" height="20" font="1">of office BP reduction attributable to </text>
<text top="487" left="859" width="213" height="20" font="1">HBPT was in line with that observed in </text>
<text top="504" left="859" width="176" height="20" font="1">RCTs of antihypertensive drugs </text>
<text top="521" left="859" width="208" height="20" font="1">compared with placebo. The estimate </text>
<text top="539" left="859" width="179" height="20" font="1">was also larger than that usually </text>
<text top="556" left="859" width="206" height="20" font="1">related to HBP self-monitoring, which </text>
<text top="573" left="859" width="196" height="20" font="1">speaks in favor of a possible added </text>
<text top="590" left="859" width="159" height="20" font="1">value of the teletransmission </text>
<text top="607" left="859" width="58" height="20" font="1">approach.<b> </b></text>
</page>
<page number="235" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">235 </text>
<text top="107" left="678" width="154" height="20" font="1">HBPT group vs. usual care: </text>
<text top="124" left="678" width="167" height="20" font="1">weighted MD 662.92 (95% CI: </text>
<text top="141" left="678" width="162" height="20" font="1">540.81–785.04) euros per pt; </text>
<text top="159" left="678" width="3" height="20" font="1">I</text>
<text top="160" left="681" width="4" height="13" font="6">2</text>
<text top="159" left="686" width="153" height="20" font="1">=99.6%; p&lt;0.001, but costs </text>
<text top="176" left="678" width="128" height="20" font="1">were similar when only </text>
<text top="193" left="678" width="137" height="20" font="1">medical costs (excluding </text>
<text top="210" left="678" width="144" height="20" font="1">HBPT-related costs) were </text>
<text top="228" left="678" width="154" height="20" font="1">considered (-12.4; 95% CI: -</text>
<text top="245" left="678" width="127" height="20" font="1">930.52–906.23) euros; </text>
<text top="262" left="678" width="55" height="20" font="1">p=0.767.  </text>
<text top="279" left="678" width="3" height="20" font="1"> </text>
<text top="296" left="678" width="119" height="20" font="4"><b>Safety endpoint: </b>No </text>
<text top="314" left="678" width="150" height="20" font="1">difference was observed in </text>
<text top="331" left="678" width="143" height="20" font="1">the risk of adverse events </text>
<text top="348" left="678" width="141" height="20" font="1">(RR: 1.22; 95% CI: 0.86– </text>
<text top="365" left="678" width="83" height="20" font="1">1.71; p=0.111)<b> </b></text>
<text top="383" left="98" width="98" height="20" font="1">Verberk W, et al., </text>
<text top="400" left="98" width="63" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(335)</a> </text>
<text top="418" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21527847?dopt=Citation">21527847</a></text>
<text top="418" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21527847?dopt=Citation"> </a></text>
<text top="383" left="218" width="102" height="20" font="4"><b>Aim: </b>Examine the </text>
<text top="400" left="218" width="123" height="20" font="1">usefulness of telecare </text>
<text top="418" left="218" width="122" height="20" font="1">for HTN management<b> </b></text>
<text top="435" left="218" width="3" height="20" font="4"><b> </b></text>
<text top="452" left="218" width="102" height="20" font="4"><b>Study type: </b>Meta-</text>
<text top="469" left="218" width="48" height="20" font="1">analysis<b> </b></text>
<text top="487" left="218" width="3" height="20" font="4"><b> </b></text>
<text top="504" left="218" width="102" height="20" font="4"><b>Size: </b>9 RCTs with </text>
<text top="521" left="218" width="57" height="20" font="1">2,501 pts  </text>
<text top="383" left="363" width="120" height="20" font="4"><b>Inclusion criteria: </b>1) </text>
<text top="400" left="363" width="135" height="20" font="1">Published in the English </text>
<text top="418" left="363" width="122" height="20" font="1">language, 2) pts were </text>
<text top="435" left="363" width="76" height="20" font="1">diagnosed as </text>
<text top="452" left="363" width="97" height="20" font="1">hypertensive and </text>
<text top="469" left="363" width="102" height="20" font="1">performed BP self-</text>
<text top="487" left="363" width="144" height="20" font="1">measurement at home, 3) </text>
<text top="504" left="363" width="117" height="20" font="1">RCTs that compared </text>
<text top="521" left="363" width="139" height="20" font="1">telecare of BP with usual </text>
<text top="538" left="363" width="103" height="20" font="1">care, 4) data were </text>
<text top="555" left="363" width="139" height="20" font="1">transmitted to healthcare </text>
<text top="573" left="363" width="70" height="20" font="1">providers by </text>
<text top="590" left="363" width="109" height="20" font="1">telephone, modem, </text>
<text top="607" left="363" width="131" height="20" font="1">Internet, or mail, and 5) </text>
<text top="624" left="363" width="146" height="20" font="1">either change in BP or the </text>
<text top="641" left="363" width="103" height="20" font="1">number of pts that </text>
<text top="659" left="363" width="130" height="20" font="1">reached their target BP </text>
<text top="676" left="363" width="142" height="20" font="1">was an outcome and was </text>
<text top="693" left="363" width="120" height="20" font="1">provided in the study. </text>
<text top="710" left="363" width="113" height="20" font="1">Date restrictions not </text>
<text top="727" left="363" width="53" height="20" font="1">reported. </text>
<text top="745" left="363" width="3" height="20" font="4"><b> </b></text>
<text top="762" left="363" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="779" left="363" width="102" height="20" font="1">Absence of above </text>
<text top="383" left="525" width="129" height="20" font="4"><b>Intervention: </b>Telecare </text>
<text top="400" left="525" width="122" height="20" font="1">for HTN management </text>
<text top="418" left="525" width="98" height="20" font="1">(treatment and/or </text>
<text top="435" left="525" width="111" height="20" font="1">coaching). Telecare </text>
<text top="452" left="525" width="86" height="20" font="1">involved a data </text>
<text top="469" left="525" width="132" height="20" font="1">transmission process to </text>
<text top="487" left="525" width="115" height="20" font="1">collect data on a pt’s </text>
<text top="504" left="525" width="118" height="20" font="1">health status to allow </text>
<text top="521" left="525" width="70" height="20" font="1">remote HTN </text>
<text top="538" left="525" width="79" height="20" font="1">management. </text>
<text top="555" left="525" width="116" height="20" font="1">Procedures varied in </text>
<text top="573" left="525" width="132" height="20" font="1">length and frequency of </text>
<text top="590" left="525" width="125" height="20" font="1">contact and method of </text>
<text top="607" left="525" width="104" height="20" font="1">delivery (i.e., often </text>
<text top="624" left="525" width="131" height="20" font="1">telephone or cell phone </text>
<text top="641" left="525" width="82" height="20" font="1">with or without </text>
<text top="659" left="525" width="128" height="20" font="1">internet/computer; with </text>
<text top="676" left="525" width="117" height="20" font="1">or without behavioral </text>
<text top="693" left="525" width="127" height="20" font="1">counseling by nurse or </text>
<text top="710" left="525" width="135" height="20" font="1">pharmacist), often as an </text>
<text top="727" left="525" width="125" height="20" font="1">adjunct to “usual care” </text>
<text top="745" left="525" width="78" height="20" font="1">clinical visits. <b> </b></text>
<text top="762" left="525" width="3" height="20" font="1"> </text>
<text top="779" left="525" width="139" height="20" font="4"><b>Comparator: </b>Usual care </text>
<text top="384" left="678" width="168" height="20" font="4"><b>1</b>°<b> endpoint: </b>Difference in BP </text>
<text top="402" left="678" width="150" height="20" font="1">Reduction (Telecare-Usual </text>
<text top="419" left="678" width="35" height="20" font="1">care):<b> </b></text>
<text top="438" left="678" width="7" height="18" font="1">•</text>
<text top="437" left="685" width="159" height="20" font="4"><b> </b>SBP 5.2 ± 1.5 mm Hg (95% </text>
<text top="454" left="678" width="81" height="20" font="1">CI: 2.31–8.07)<b> </b></text>
<text top="473" left="678" width="7" height="18" font="1">•</text>
<text top="473" left="685" width="160" height="20" font="4"><b> </b>DBP 2.1 ± 0.8 mm Hg (95% </text>
<text top="490" left="678" width="81" height="20" font="1">CI: 0.52–3.69)<b> </b></text>
<text top="507" left="678" width="3" height="20" font="4"><b> </b></text>
<text top="524" left="678" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="383" left="859" width="191" height="20" font="4"><b>Limitations</b>: Telecare intervention </text>
<text top="400" left="859" width="210" height="20" font="1">methods varied greatly across studies </text>
<text top="418" left="859" width="3" height="20" font="4"><b> </b></text>
<text top="435" left="859" width="200" height="20" font="4"><b>Summary</b>: Telecare led to a greater </text>
<text top="452" left="859" width="206" height="20" font="1">decrease in SBP and DBP compared </text>
<text top="469" left="859" width="190" height="20" font="1">with usual care. Telecare seems a </text>
<text top="487" left="859" width="159" height="20" font="1">valuable tool to support HTN </text>
<text top="504" left="859" width="82" height="20" font="1">management.  </text>
</page>
<page number="236" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">236 </text>
<text top="107" left="98" width="97" height="20" font="1">Agarwal R, et al., </text>
<text top="124" left="98" width="56" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(27)</a> </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21115879?dopt=Citation">21115879</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21115879?dopt=Citation"> </a></text>
<text top="107" left="218" width="128" height="20" font="4"><b>Aim: </b>Quantify both the </text>
<text top="124" left="218" width="85" height="20" font="1">magnitude and </text>
<text top="141" left="218" width="126" height="20" font="1">mechanisms of benefit </text>
<text top="159" left="218" width="107" height="20" font="1">(including effect on </text>
<text top="176" left="218" width="119" height="20" font="1">therapeutic inertia) of </text>
<text top="193" left="218" width="132" height="20" font="1">home BP monitoring on </text>
<text top="210" left="218" width="77" height="20" font="1">BP reduction. </text>
<text top="228" left="218" width="131" height="20" font="1">Therapeutic inertia was </text>
<text top="245" left="218" width="121" height="20" font="1">defined as no change </text>
<text top="262" left="218" width="82" height="20" font="1">in medications </text>
<text top="279" left="218" width="82" height="20" font="1">combined with </text>
<text top="296" left="218" width="94" height="20" font="1">uncontrolled BP.<b> </b></text>
<text top="314" left="218" width="3" height="20" font="4"><b> </b></text>
<text top="331" left="218" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="348" left="218" width="126" height="20" font="1">Systematic review and </text>
<text top="365" left="218" width="79" height="20" font="1">meta-analysis<b> </b></text>
<text top="382" left="218" width="3" height="20" font="4"><b> </b></text>
<text top="400" left="218" width="109" height="20" font="4"><b>Size: </b>37 RCTs with </text>
<text top="417" left="218" width="130" height="20" font="1">9,446 pts. Trial settings </text>
<text top="434" left="218" width="112" height="20" font="1">included community </text>
<text top="451" left="218" width="103" height="20" font="1">(n=5), dialysis unit </text>
<text top="469" left="218" width="80" height="20" font="1">(n=2), general </text>
<text top="486" left="218" width="95" height="20" font="1">practices (n=18), </text>
<text top="503" left="218" width="120" height="20" font="1">hospitals and general </text>
<text top="520" left="218" width="106" height="20" font="1">practice (n=1), and </text>
<text top="537" left="218" width="83" height="20" font="1">hospital-based </text>
<text top="555" left="218" width="130" height="20" font="1">outpatient units (n=11). </text>
<text top="107" left="363" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="124" left="363" width="136" height="20" font="1">Studies that randomized </text>
<text top="141" left="363" width="142" height="20" font="1">pts to control or home BP </text>
<text top="159" left="363" width="96" height="20" font="1">monitoring group </text>
<text top="176" left="363" width="3" height="20" font="1"> </text>
<text top="193" left="363" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="210" left="363" width="105" height="20" font="1">Absence of above<b>  </b></text>
<text top="107" left="525" width="134" height="20" font="4"><b>Intervention: </b>Home BP </text>
<text top="124" left="525" width="137" height="20" font="1">monitoring as an adjunct </text>
<text top="141" left="525" width="120" height="20" font="1">to usual care for HTN<b> </b></text>
<text top="159" left="525" width="3" height="20" font="4"><b> </b></text>
<text top="176" left="525" width="139" height="20" font="4"><b>Comparator: </b>Usual care </text>
<text top="193" left="525" width="119" height="20" font="1">with BP monitoring in </text>
<text top="210" left="525" width="31" height="20" font="1">clinic </text>
<text top="108" left="678" width="162" height="20" font="4"><b>1</b>°<b> endpoint: </b>Compared with </text>
<text top="125" left="678" width="132" height="20" font="1">usual care alone, home-</text>
<text top="143" left="678" width="121" height="20" font="1">based BP monitoring: </text>
<text top="162" left="678" width="7" height="18" font="1">•</text>
<text top="161" left="685" width="158" height="20" font="1">Reduced SBP: -2.63 mm Hg </text>
<text top="178" left="678" width="152" height="20" font="1">(95% CI: -4.24 – -1.02) and </text>
<text top="197" left="678" width="7" height="18" font="1">•</text>
<text top="197" left="685" width="143" height="20" font="1"> Reduced DBP: -1.68 mm </text>
<text top="214" left="678" width="144" height="20" font="1">Hg (95% CI: -2.58– -0.79) </text>
<text top="233" left="678" width="7" height="18" font="1">•</text>
<text top="232" left="685" width="160" height="20" font="4"><b> </b>Greater reduction in SBP by </text>
<text top="249" left="678" width="168" height="20" font="1">HBPM interventions was seen </text>
<text top="267" left="678" width="143" height="20" font="1">with added telemonitoring </text>
<text top="284" left="678" width="149" height="20" font="1">(effect size -3.20; 95% CI: -</text>
<text top="301" left="678" width="143" height="20" font="1">4.66– -1.73) vs. home BP </text>
<text top="318" left="678" width="159" height="20" font="1">monitoring (effect size -1.26; </text>
<text top="336" left="678" width="120" height="20" font="1">95% CI: -2.20– -0.31; </text>
<text top="353" left="678" width="134" height="20" font="1">p=0.029). This finding is </text>
<text top="370" left="678" width="142" height="20" font="1">relevant to telemonitoring<b> </b></text>
<text top="108" left="859" width="89" height="20" font="4"><b>2</b>°<b> endpoints:   </b></text>
<text top="127" left="859" width="7" height="18" font="1">•</text>
<text top="127" left="866" width="157" height="20" font="1"> More frequent reductions in </text>
<text top="144" left="859" width="156" height="20" font="1">antihypertensive medication </text>
<text top="161" left="859" width="194" height="20" font="1">(presumably due to identification of </text>
<text top="178" left="859" width="198" height="20" font="1">white coat HTN): RR: 2.02 (95% CI: </text>
<text top="195" left="859" width="66" height="20" font="1">1.32–3.11)  </text>
<text top="214" left="859" width="7" height="18" font="1">•</text>
<text top="214" left="866" width="183" height="20" font="4"><b> </b>Lowered therapeutic inertia (i.e., </text>
<text top="231" left="859" width="170" height="20" font="1">unchanged medication despite </text>
<text top="248" left="859" width="176" height="20" font="1">elevated BP: RR for unchanged </text>
<text top="265" left="859" width="204" height="20" font="1">medication 0.82 (95% CI: 0.68–0.99)<b> </b></text>
<text top="283" left="859" width="3" height="20" font="4"><b> </b></text>
<text top="300" left="859" width="198" height="20" font="4"><b>Limitations: </b>Different inclusion and </text>
<text top="317" left="859" width="166" height="20" font="1">exclusion criteria, different BP </text>
<text top="334" left="859" width="173" height="20" font="1">measurement techniques, drug </text>
<text top="352" left="859" width="208" height="20" font="1">titration protocols, pt populations, and </text>
<text top="369" left="859" width="196" height="20" font="1">duration of follow-up across studies </text>
<text top="386" left="859" width="150" height="20" font="1">likely introduced significant </text>
<text top="403" left="859" width="153" height="20" font="1">heterogeneity in effect size. </text>
<text top="420" left="859" width="3" height="20" font="4"><b> </b></text>
<text top="438" left="859" width="213" height="20" font="4"><b>Summary</b>: Home BP monitoring leads </text>
<text top="455" left="859" width="202" height="20" font="1">to a small but significant reduction in </text>
<text top="472" left="859" width="196" height="20" font="1">SBP and DBP. Greater reduction in </text>
<text top="489" left="859" width="154" height="20" font="1">SBP is seen when HBPM is </text>
<text top="506" left="859" width="206" height="20" font="1">accompanied by specific programs to </text>
<text top="524" left="859" width="204" height="20" font="1">titrate antihypertensive drugs. 1 such </text>
<text top="541" left="859" width="211" height="20" font="1">strategy is telemonitoring, in which BP </text>
<text top="558" left="859" width="170" height="20" font="1">readings obtained at home are </text>
<text top="575" left="859" width="203" height="20" font="1">relayed to the provider who can then </text>
<text top="593" left="859" width="209" height="20" font="1">take appropriate action, thus reducing </text>
<text top="610" left="859" width="105" height="20" font="1">therapeutic inertia. </text>
<text top="629" left="108" width="3" height="19" font="1"> </text>
<text top="663" left="81" width="951" height="24" font="3"><b>Data Supplement 65. RCTs and Observational Studies that Report on the Effect of Performance Measures and on Hypertension Control </b></text>
<text top="687" left="81" width="112" height="24" font="3"><b>(Section 12.4.1) </b></text>
<text top="727" left="101" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="744" left="126" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="761" left="104" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="727" left="246" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="744" left="251" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="761" left="245" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="727" left="392" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="727" left="535" width="180" height="20" font="4"><b>Study Intervention (# patients) </b></text>
<text top="744" left="622" width="10" height="20" font="4"><b>/  </b></text>
<text top="761" left="536" width="180" height="20" font="4"><b>Study Comparator (# patients) </b></text>
<text top="727" left="752" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="744" left="730" width="149" height="20" font="4"><b>(Absolute Event Rates, P </b></text>
<text top="761" left="733" width="142" height="20" font="4"><b>value; OR or RR; &amp; 95% </b></text>
<text top="779" left="794" width="20" height="20" font="4"><b>CI) </b></text>
<text top="728" left="919" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="745" left="951" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="762" left="959" width="96" height="20" font="4"><b>Adverse Events </b></text>
</page>
<page number="237" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">237 </text>
<text top="107" left="98" width="102" height="20" font="1">Svetkey LP, et al., </text>
<text top="124" left="98" width="66" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(336)</a>  </text>
<text top="141" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19920081?dopt=Citation">19920081</a></text>
<text top="141" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19920081?dopt=Citation"> </a></text>
<text top="107" left="215" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="124" left="215" width="121" height="20" font="1">physician intervention </text>
<text top="141" left="215" width="138" height="20" font="1">and/or pt intervention vs. </text>
<text top="159" left="215" width="139" height="20" font="1">usual care, to assess the </text>
<text top="176" left="215" width="113" height="20" font="1">impact of education, </text>
<text top="193" left="215" width="141" height="20" font="1">monitoring, and feedback </text>
<text top="210" left="215" width="135" height="20" font="1">protocol to help improve </text>
<text top="228" left="215" width="69" height="20" font="1">HTN control<b> </b></text>
<text top="245" left="215" width="3" height="20" font="1"> </text>
<text top="262" left="215" width="137" height="20" font="4"><b>Study type:</b> Nested 2×2 </text>
<text top="279" left="215" width="29" height="20" font="1">RCT </text>
<text top="296" left="215" width="3" height="20" font="4"><b> </b></text>
<text top="314" left="215" width="114" height="20" font="4"><b>Size: </b>8 primary care </text>
<text top="331" left="215" width="137" height="20" font="1">practices, 32 physicians, </text>
<text top="348" left="215" width="44" height="20" font="1">574 pts<b> </b></text>
<text top="107" left="374" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="124" left="374" width="138" height="20" font="1">Practices: matched pairs </text>
<text top="141" left="374" width="123" height="20" font="1">(intervention vs. usual </text>
<text top="159" left="374" width="147" height="20" font="1">care) by specialty (internal </text>
<text top="176" left="374" width="107" height="20" font="1">medicine vs. family </text>
<text top="193" left="374" width="113" height="20" font="1">physician) and by pt </text>
<text top="210" left="374" width="128" height="20" font="1">socioeconomic mix. All </text>
<text top="228" left="374" width="143" height="20" font="1">physicians were invited to </text>
<text top="245" left="374" width="67" height="20" font="1">participate. <b> </b></text>
<text top="262" left="374" width="3" height="20" font="1"> </text>
<text top="279" left="374" width="115" height="20" font="4"><b>Pt eligibility:</b> ≥25 y, </text>
<text top="296" left="374" width="124" height="20" font="1">hypertensive by billing </text>
<text top="314" left="374" width="33" height="20" font="1">code.<b> </b></text>
<text top="331" left="374" width="3" height="20" font="1"> </text>
<text top="348" left="374" width="105" height="20" font="4"><b>Pt exclusion: </b>Self-</text>
<text top="365" left="374" width="145" height="20" font="1">reported CKD, CVD event </text>
<text top="382" left="374" width="96" height="20" font="1">within past 6 mo, </text>
<text top="400" left="374" width="137" height="20" font="1">pregnant, breastfeeding, </text>
<text top="417" left="374" width="139" height="20" font="1">or planning a pregnancy. </text>
<text top="107" left="534" width="177" height="20" font="4"><b>Physician Intervention:</b> 18 mo </text>
<text top="124" left="534" width="120" height="20" font="1">of online training, self-</text>
<text top="141" left="534" width="169" height="20" font="1">monitoring, quarterly feedback </text>
<text top="159" left="534" width="45" height="20" font="1">reports. </text>
<text top="176" left="534" width="3" height="20" font="1"> </text>
<text top="193" left="534" width="152" height="20" font="4"><b>Pt Intervention: </b>20 weekly </text>
<text top="210" left="534" width="138" height="20" font="1">group sessions for 6 mo, </text>
<text top="227" left="534" width="128" height="20" font="1">followed by 12 monthly </text>
<text top="245" left="534" width="172" height="20" font="1">telephone counseling contacts, </text>
<text top="262" left="534" width="169" height="20" font="1">focused on weight loss, DASH </text>
<text top="279" left="534" width="155" height="20" font="1">dietary patter, exercise, and </text>
<text top="296" left="534" width="127" height="20" font="1">reduce sodium intake.  </text>
<text top="314" left="534" width="7" height="20" font="1">  </text>
<text top="331" left="534" width="139" height="20" font="4"><b>Comparator:</b> Usual care </text>
<text top="108" left="730" width="91" height="20" font="4"><b>1</b>°<b> endpoint:</b> Pt </text>
<text top="125" left="730" width="132" height="20" font="1">intervention + physician </text>
<text top="143" left="730" width="126" height="20" font="1">intervention group had </text>
<text top="160" left="730" width="141" height="20" font="1">greatest BP lowering at 6 </text>
<text top="177" left="730" width="139" height="20" font="1">mo (-9.7 mm Hg ± 12.7), </text>
<text top="194" left="730" width="146" height="20" font="1">but at 18 mo there was no </text>
<text top="212" left="730" width="115" height="20" font="1">significant difference </text>
<text top="229" left="730" width="94" height="20" font="1">between groups. </text>
<text top="246" left="730" width="3" height="20" font="4"><b> </b></text>
<text top="264" left="730" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A<b> </b></text>
<text top="109" left="892" width="7" height="18" font="1">•</text>
<text top="108" left="898" width="172" height="20" font="1"> This trial suggests that pt level </text>
<text top="125" left="892" width="224" height="20" font="1">monitoring and feedback, in combination </text>
<text top="143" left="892" width="194" height="20" font="1">with physician level monitoring and </text>
<text top="160" left="892" width="213" height="20" font="1">feedback, provides additional 6 mo BP </text>
<text top="177" left="892" width="209" height="20" font="1">control above and beyond usual care. </text>
<text top="194" left="892" width="228" height="20" font="1">The impact of the intervention diminished </text>
<text top="212" left="892" width="227" height="20" font="1">after the weekly pt group sessions ended </text>
<text top="229" left="892" width="194" height="20" font="1">and monthly telephone calls began </text>
<text top="246" left="892" width="46" height="20" font="1">instead. </text>
<text top="435" left="98" width="90" height="20" font="1">Jaffe MG, et al., </text>
<text top="452" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(329)</a> </text>
<text top="469" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23989679?dopt=Citation">23989679</a></text>
<text top="469" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23989679?dopt=Citation"> </a></text>
<text top="435" left="215" width="143" height="20" font="4"><b>Aim: </b>Study the effect of a </text>
<text top="452" left="215" width="121" height="20" font="1">multipronged, system-</text>
<text top="469" left="215" width="129" height="20" font="1">based, QI approach on </text>
<text top="487" left="215" width="73" height="20" font="1">HTN control.<b> </b></text>
<text top="504" left="215" width="3" height="20" font="1"> </text>
<text top="521" left="215" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="538" left="215" width="79" height="20" font="1">Observational </text>
<text top="555" left="215" width="3" height="20" font="4"><b> </b></text>
<text top="573" left="215" width="136" height="20" font="4"><b>Size: </b>All pts with HTN in </text>
<text top="590" left="215" width="130" height="20" font="1">the KPNC system were </text>
<text top="607" left="215" width="49" height="20" font="1">included<b> </b></text>
<text top="435" left="374" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="452" left="374" width="139" height="20" font="1">350,000 pts in the KPNC </text>
<text top="469" left="374" width="143" height="20" font="1">system with HTN in 2001, </text>
<text top="487" left="374" width="134" height="20" font="1">increasing to 650,000 in </text>
<text top="504" left="374" width="31" height="20" font="1">2009<b> </b></text>
<text top="521" left="374" width="3" height="20" font="1"> </text>
<text top="538" left="374" width="66" height="20" font="4"><b>Eligibility:  </b></text>
<text top="557" left="374" width="7" height="18" font="1">•</text>
<text top="556" left="381" width="110" height="20" font="1"> ≥2 HTN diagnoses </text>
<text top="574" left="374" width="122" height="20" font="1">coded in primary care </text>
<text top="591" left="374" width="112" height="20" font="1">visits in the prior 2 y </text>
<text top="610" left="374" width="7" height="18" font="1">•</text>
<text top="609" left="381" width="122" height="20" font="1"> ≥1 primary care HTN </text>
<text top="627" left="374" width="140" height="20" font="1">diagnoses and 1 or more </text>
<text top="644" left="374" width="139" height="20" font="1">hospitalizations with a 1° </text>
<text top="661" left="374" width="127" height="20" font="1">or 2° HTN diagnosis in </text>
<text top="678" left="374" width="68" height="20" font="1">the prior 2 y </text>
<text top="697" left="374" width="7" height="18" font="1">•</text>
<text top="696" left="381" width="122" height="20" font="1"> ≥1 primary care HTN </text>
<text top="714" left="374" width="140" height="20" font="1">diagnoses and 1 or more </text>
<text top="731" left="374" width="120" height="20" font="1">filled prescriptions for </text>
<text top="748" left="374" width="147" height="20" font="1">HTN medication within the </text>
<text top="765" left="374" width="80" height="20" font="1">prior 6 mo, or  </text>
<text top="435" left="534" width="144" height="20" font="4"><b>Intervention:</b> KPNC HTN </text>
<text top="452" left="534" width="178" height="20" font="1">Program includes: HTN registry, </text>
<text top="469" left="534" width="154" height="20" font="1">HTN control monitoring and </text>
<text top="487" left="534" width="152" height="20" font="1">feedback system, evidence-</text>
<text top="504" left="534" width="145" height="20" font="1">based practice guidelines, </text>
<text top="521" left="534" width="164" height="20" font="1">medical assistant BP recheck </text>
<text top="538" left="534" width="149" height="20" font="1">program, and promotion of </text>
<text top="555" left="534" width="141" height="20" font="1">single polypill formulation </text>
<text top="573" left="534" width="53" height="20" font="1">(lisinopril-</text>
<text top="573" left="587" width="107" height="20" font="28">hydrochlorothiazide</text>
<text top="573" left="693" width="8" height="20" font="1">) </text>
<text top="590" left="534" width="7" height="20" font="1">  </text>
<text top="607" left="534" width="154" height="20" font="4"><b>Comparator:</b> Insured pts in </text>
<text top="624" left="534" width="174" height="20" font="1">California from 2006–2009 who </text>
<text top="641" left="534" width="154" height="20" font="1">were included in the HEDIS </text>
<text top="659" left="534" width="161" height="20" font="1">commercial measurement by </text>
<text top="676" left="534" width="182" height="20" font="1">California health insurance plans </text>
<text top="693" left="534" width="181" height="20" font="1">participating in the NCQA quality </text>
<text top="710" left="534" width="179" height="20" font="1">measure reporting process. A 2º </text>
<text top="727" left="534" width="176" height="20" font="1">comparison group was included </text>
<text top="745" left="534" width="167" height="20" font="1">to obtain the reported national </text>
<text top="762" left="534" width="180" height="20" font="1">mean NCQA HEDIS commercial </text>
<text top="779" left="534" width="176" height="20" font="1">rates of HTN control from 2001–</text>
<text top="436" left="730" width="79" height="20" font="4"><b>1</b>°<b> endpoint:</b>  </text>
<text top="455" left="730" width="7" height="18" font="1">•</text>
<text top="454" left="736" width="116" height="20" font="1"> HTN control rates in </text>
<text top="472" left="730" width="111" height="20" font="1">KPNC pts with HTN </text>
<text top="489" left="730" width="120" height="20" font="1">improved from 43.6% </text>
<text top="506" left="730" width="148" height="20" font="1">(95% CI: 39.4%–48.6%) in </text>
<text top="523" left="730" width="134" height="20" font="1">2001 to 80.4% (95% CI: </text>
<text top="540" left="730" width="145" height="20" font="1">75.6%–84.4%) by the end </text>
<text top="558" left="730" width="105" height="20" font="1">of the study period </text>
<text top="575" left="730" width="109" height="20" font="1">(p&lt;0.001 for trend). </text>
<text top="594" left="730" width="7" height="18" font="1">•</text>
<text top="593" left="736" width="138" height="20" font="1"> By comparison, national </text>
<text top="610" left="730" width="114" height="20" font="1">mean NCQA HEDIS </text>
<text top="628" left="730" width="145" height="20" font="1">commercial measurement </text>
<text top="645" left="730" width="126" height="20" font="1">HTN control increased </text>
<text top="662" left="730" width="115" height="20" font="1">from 55.4%–64.1%.  </text>
<text top="681" left="730" width="7" height="18" font="1">•</text>
<text top="680" left="736" width="132" height="20" font="1"> California mean NCQA </text>
<text top="698" left="730" width="138" height="20" font="1">HEDIS commercial rates </text>
<text top="715" left="730" width="113" height="20" font="1">of HTN control were </text>
<text top="732" left="730" width="135" height="20" font="1">similar to those reported </text>
<text top="749" left="730" width="148" height="20" font="1">nationally from 2006–2009 </text>
<text top="766" left="730" width="92" height="20" font="1">(63.4%–69.4%).<b> </b></text>
<text top="784" left="730" width="3" height="20" font="4"><b> </b></text>
<text top="437" left="892" width="7" height="18" font="1">•</text>
<text top="436" left="898" width="192" height="20" font="1"> A system-based approach to HTN </text>
<text top="453" left="892" width="185" height="20" font="1">control that includes performance </text>
<text top="470" left="892" width="220" height="20" font="1">measurement and QI strategies led to a </text>
<text top="488" left="892" width="215" height="20" font="1">significant improvement in HTN control </text>
<text top="505" left="892" width="229" height="20" font="1">(80%, compared to 44% baseline control) </text>
<text top="522" left="892" width="226" height="20" font="1">in a large population of pts in a managed </text>
<text top="539" left="892" width="94" height="20" font="1">care health plan. </text>
</page>
<page number="238" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">238 </text>
<text top="109" left="374" width="7" height="18" font="1">•</text>
<text top="108" left="381" width="122" height="20" font="1"> ≥1 primary care HTN </text>
<text top="125" left="374" width="140" height="20" font="1">diagnoses and 1 or more </text>
<text top="143" left="374" width="79" height="20" font="1">stroke-related </text>
<text top="160" left="374" width="112" height="20" font="1">hospitalizations or a </text>
<text top="177" left="374" width="105" height="20" font="1">history of coronary </text>
<text top="194" left="374" width="109" height="20" font="1">disease, HF, or DM </text>
<text top="107" left="534" width="152" height="20" font="1">2009 from health plans that </text>
<text top="124" left="534" width="180" height="20" font="1">participated in the NCQA HEDIS </text>
<text top="141" left="534" width="142" height="20" font="1">quality measure reporting </text>
<text top="159" left="534" width="50" height="20" font="1">process. </text>
<text top="108" left="730" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> N/A<b> </b></text>
<text top="212" left="98" width="89" height="20" font="1">Lusignan Sd, et </text>
<text top="229" left="98" width="83" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(337)</a> </text>
<text top="247" left="98" width="55" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23536132">23536132</a></text>
<text top="247" left="152" width="3" height="20" font="1"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23536132"> </a></text>
<text top="212" left="215" width="133" height="20" font="4"><b>Aim: </b>Study the effect of </text>
<text top="229" left="215" width="141" height="20" font="1">an audit-based education </text>
<text top="247" left="215" width="81" height="20" font="1">intervention to </text>
<text top="264" left="215" width="129" height="20" font="1">guidelines/prompts, vs. </text>
<text top="281" left="215" width="104" height="20" font="1">usual care, to help </text>
<text top="298" left="215" width="140" height="20" font="1">improve BP control in pts </text>
<text top="316" left="215" width="55" height="20" font="1">with CKD<b> </b></text>
<text top="333" left="215" width="3" height="20" font="1"> </text>
<text top="350" left="215" width="141" height="20" font="4"><b>Study type:</b> Cluster RCT </text>
<text top="367" left="215" width="3" height="20" font="4"><b> </b></text>
<text top="384" left="215" width="94" height="20" font="4"><b>Size: </b>93 general </text>
<text top="402" left="215" width="141" height="20" font="1">practices (30 audit-based </text>
<text top="419" left="215" width="144" height="20" font="1">education intervention, 32 </text>
<text top="436" left="215" width="137" height="20" font="1">Guidelines/prompts, and </text>
<text top="453" left="215" width="81" height="20" font="1">31 usual care)<b> </b></text>
<text top="212" left="374" width="143" height="20" font="4"><b>Inclusion criteria: </b>All pts </text>
<text top="229" left="374" width="88" height="20" font="1">with CKD in the </text>
<text top="247" left="374" width="122" height="20" font="1">participating practices </text>
<text top="212" left="534" width="147" height="20" font="4"><b>Intervention:</b> Audit-based </text>
<text top="229" left="534" width="76" height="20" font="1">education vs. </text>
<text top="247" left="534" width="107" height="20" font="1">guidelines/prompts </text>
<text top="264" left="534" width="3" height="20" font="1"> </text>
<text top="281" left="534" width="139" height="20" font="4"><b>Comparator:</b> Usual care </text>
<text top="213" left="730" width="129" height="20" font="4"><b>1</b>°<b> endpoint:</b> SBP was </text>
<text top="231" left="730" width="133" height="20" font="1">significantly lower in the </text>
<text top="248" left="730" width="124" height="20" font="1">audit-based education </text>
<text top="265" left="730" width="145" height="20" font="1">group (-2.41 mm Hg; 95% </text>
<text top="282" left="730" width="146" height="20" font="1">CI: 0.59–4.29). There was </text>
<text top="300" left="730" width="132" height="20" font="1">no significant change in </text>
<text top="317" left="730" width="139" height="20" font="1">BP in the other 2 groups. </text>
<text top="334" left="730" width="3" height="20" font="4"><b> </b></text>
<text top="352" left="730" width="135" height="20" font="4"><b>1</b>°<b> Safety endpoint:</b> No </text>
<text top="370" left="730" width="90" height="20" font="1">reports of harm.<b> </b></text>
<text top="214" left="892" width="7" height="18" font="1">•</text>
<text top="213" left="898" width="214" height="20" font="1"> This trial suggests that an intervention </text>
<text top="231" left="892" width="213" height="20" font="1">that includes specific performance and </text>
<text top="248" left="892" width="222" height="20" font="1">feedback reports improves BP control in </text>
<text top="265" left="892" width="213" height="20" font="1">pts with CKD, compared to usual care. </text>
<text top="282" left="892" width="193" height="20" font="1">To the contrary, the use of practice </text>
<text top="300" left="892" width="218" height="20" font="1">guidelines and prompts did not improve </text>
<text top="317" left="892" width="196" height="20" font="1">BP control compared to usual care. </text>
<text top="473" left="108" width="3" height="19" font="1"> </text>
<text top="507" left="81" width="1002" height="24" font="3"><b>Data Supplement 66. RCTs, Meta-analyses, and Systematic Reviews on Quality Improvement Strategies on Hypertension Treatment Outcomes </b></text>
<text top="531" left="81" width="112" height="24" font="3"><b>(Section 12.4.2) </b></text>
<text top="570" left="102" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="588" left="127" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="605" left="105" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="570" left="241" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="588" left="246" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="605" left="240" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="570" left="379" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="570" left="530" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="588" left="562" width="65" height="20" font="4"><b>patients) /  </b></text>
<text top="605" left="530" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="622" left="565" width="55" height="20" font="4"><b>patients) </b></text>
<text top="570" left="709" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="588" left="687" width="149" height="20" font="4"><b>(Absolute Event Rates, P </b></text>
<text top="605" left="680" width="162" height="20" font="4"><b>value; OR or RR; &amp; 95% CI) </b></text>
<text top="572" left="878" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="589" left="911" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="606" left="889" width="155" height="20" font="4"><b>Adverse Events Summary </b></text>
<text top="640" left="98" width="94" height="20" font="1">Walsh JM, et al., </text>
<text top="657" left="98" width="63" height="20" font="1">2006 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(338)</a> </text>
<text top="674" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16799359?dopt=Citation">16799359</a></text>
<text top="674" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16799359?dopt=Citation"> </a></text>
<text top="640" left="217" width="94" height="20" font="4"><b>Aim: </b>Assess the </text>
<text top="657" left="217" width="105" height="20" font="1">effectiveness of QI </text>
<text top="674" left="217" width="119" height="20" font="1">strategies in lowering </text>
<text top="692" left="217" width="20" height="20" font="1">BP </text>
<text top="709" left="217" width="3" height="20" font="4"><b> </b></text>
<text top="726" left="217" width="71" height="20" font="4"><b>Study type: </b></text>
<text top="743" left="217" width="106" height="20" font="1">Systematic review<b>  </b></text>
<text top="760" left="217" width="3" height="20" font="4"><b> </b></text>
<text top="640" left="361" width="143" height="20" font="4"><b>Inclusion criteria: </b>Trials, </text>
<text top="657" left="361" width="127" height="20" font="1">controlled before–after </text>
<text top="674" left="361" width="132" height="20" font="1">studies, and interrupted </text>
<text top="692" left="361" width="139" height="20" font="1">time series evaluating QI </text>
<text top="709" left="361" width="124" height="20" font="1">interventions targeting </text>
<text top="726" left="361" width="145" height="20" font="1">HTN control and reporting </text>
<text top="743" left="361" width="80" height="20" font="1">BP outcomes. </text>
<text top="760" left="361" width="3" height="20" font="1"> </text>
<text top="640" left="523" width="94" height="20" font="4"><b>Intervention: </b>QI </text>
<text top="657" left="523" width="124" height="20" font="1">interventions targeting </text>
<text top="674" left="523" width="111" height="20" font="1">some component of </text>
<text top="692" left="523" width="113" height="20" font="1">provider behavior or </text>
<text top="709" left="523" width="137" height="20" font="1">organizational change to </text>
<text top="726" left="523" width="116" height="20" font="1">improve HTN control </text>
<text top="743" left="523" width="7" height="20" font="4"><b>  </b></text>
<text top="760" left="523" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="778" left="523" width="105" height="20" font="1">Contemporaneous </text>
<text top="642" left="676" width="7" height="18" font="1">•</text>
<text top="641" left="683" width="130" height="20" font="1"> The majority of articles </text>
<text top="658" left="676" width="130" height="20" font="1">described interventions </text>
<text top="676" left="676" width="141" height="20" font="1">consisting of more than 1 </text>
<text top="693" left="676" width="137" height="20" font="1">strategy with the median </text>
<text top="710" left="676" width="153" height="20" font="1">number of QI strategies per </text>
<text top="727" left="676" width="153" height="20" font="1">comparison =3. Results are </text>
<text top="744" left="676" width="166" height="20" font="1">organized below by type of QI </text>
<text top="762" left="676" width="51" height="20" font="1">strategy. </text>
<text top="781" left="676" width="7" height="18" font="1">•</text>
<text top="780" left="683" width="146" height="20" font="1"> Variety of strategies used </text>
<text top="640" left="860" width="171" height="20" font="4"><b>Limitations:</b> Studies varied by </text>
<text top="657" left="860" width="178" height="20" font="1">design, population, sample size, </text>
<text top="674" left="860" width="196" height="20" font="1">setting, and methodological quality. </text>
<text top="692" left="860" width="199" height="20" font="1">Definition of each QI strategy varied </text>
<text top="709" left="860" width="210" height="20" font="1">across studies. Few studies assessed </text>
<text top="726" left="860" width="193" height="20" font="1">a single QI strategy; because most </text>
<text top="743" left="860" width="177" height="20" font="1">studies included more than 1 QI </text>
<text top="761" left="860" width="187" height="20" font="1">strategy, it could not be discerned </text>
<text top="778" left="860" width="207" height="20" font="1">which individual QI strategies had the </text>
</page>
<page number="239" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">239 </text>
<text top="107" left="217" width="91" height="20" font="4"><b>Size: </b>44 articles </text>
<text top="124" left="217" width="69" height="20" font="1">reporting 57 </text>
<text top="141" left="217" width="73" height="20" font="1">comparisons<b> </b></text>
<text top="107" left="361" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="124" left="361" width="136" height="20" font="1">Articles focusing only on </text>
<text top="141" left="361" width="122" height="20" font="1">2º HTN or specialized </text>
<text top="159" left="361" width="146" height="20" font="1">subpopulations (e.g., HTN </text>
<text top="176" left="361" width="124" height="20" font="1">in pts with alcoholism)<b> </b></text>
<text top="107" left="523" width="124" height="20" font="1">observation of<b> </b>cohorts </text>
<text top="124" left="523" width="122" height="20" font="1">differing primarily with </text>
<text top="141" left="523" width="125" height="20" font="1">respect to exposure to </text>
<text top="159" left="523" width="104" height="20" font="1">the QI intervention<b> </b></text>
<text top="107" left="676" width="161" height="20" font="1">SBP/DBP, median reduction: </text>
<text top="124" left="676" width="155" height="20" font="1">4.5 mm Hg (IQR: 1.5–11.0)/ </text>
<text top="141" left="676" width="149" height="20" font="1">2.1 mm Hg (IQR: -0.2–5.0) </text>
<text top="159" left="676" width="161" height="20" font="1">SBP/DBP control: 16% (IQR: </text>
<text top="176" left="676" width="143" height="20" font="1">10.3–32.2)/ 6% (IQR: 1.5–</text>
<text top="193" left="676" width="31" height="20" font="1">17.5) </text>
<text top="212" left="676" width="7" height="18" font="1">•</text>
<text top="211" left="683" width="111" height="20" font="1"> Provider reminders </text>
<text top="229" left="676" width="161" height="20" font="1">SBP/DBP, median reduction: </text>
<text top="246" left="676" width="169" height="20" font="1">1.2 mm Hg (IQR: 1.0–1.9)/ 0.3 </text>
<text top="263" left="676" width="129" height="20" font="1">mm Hg (IQR: -0.2–1.7) </text>
<text top="280" left="676" width="150" height="20" font="1">DBP control: 5% (IQR: 2.0–</text>
<text top="298" left="676" width="25" height="20" font="1">7.0) </text>
<text top="317" left="676" width="7" height="18" font="1">•</text>
<text top="316" left="683" width="147" height="20" font="1"> Facilitated relay of clinical </text>
<text top="333" left="676" width="27" height="20" font="1">data </text>
<text top="350" left="676" width="161" height="20" font="1">SBP/DBP, median reduction: </text>
<text top="368" left="676" width="155" height="20" font="1">8.0 mm Hg (IQR: 2.5–12.3)/ </text>
<text top="385" left="676" width="149" height="20" font="1">1.8 mm Hg (IQR: -0.1–4.5) </text>
<text top="402" left="676" width="161" height="20" font="1">SBP/DBP control: 25% (IQR: </text>
<text top="419" left="676" width="168" height="20" font="1">17.0–34.2)/ 2% (IQR: 1.6–5.0) </text>
<text top="438" left="676" width="7" height="18" font="1">•</text>
<text top="438" left="683" width="116" height="20" font="1"> Audit and feedback  </text>
<text top="455" left="676" width="161" height="20" font="1">SBP/DBP, median reduction: </text>
<text top="472" left="676" width="169" height="20" font="1">1.5 mm Hg (IQR: 1.2–1.7)/ 0.6 </text>
<text top="489" left="676" width="124" height="20" font="1">mm Hg (IQR: 0.4–1.0) </text>
<text top="506" left="676" width="169" height="20" font="1">SBP/DBP control: -3.5% (IQR: </text>
<text top="524" left="676" width="169" height="20" font="1">-5.7–1.4)/ 2.0% (IQR: 1.7–4.3) </text>
<text top="543" left="676" width="7" height="18" font="1">•</text>
<text top="542" left="683" width="113" height="20" font="1"> Provider education  </text>
<text top="559" left="676" width="161" height="20" font="1">SBP/DBP, median reduction: </text>
<text top="576" left="676" width="169" height="20" font="1">3.3 mm Hg (IQR: 1.2–5.4)/ 0.6 </text>
<text top="594" left="676" width="128" height="20" font="1">mm Hg (IQR: -0.7v3.4) </text>
<text top="611" left="676" width="161" height="20" font="1">SBP/DBP control: 11% (IQR: </text>
<text top="628" left="676" width="168" height="20" font="1">1.4–13.1)/ 4% (IQR: 1.7–11.3) </text>
<text top="647" left="676" width="7" height="18" font="1">•</text>
<text top="646" left="683" width="79" height="20" font="1"> Pt education  </text>
<text top="664" left="676" width="161" height="20" font="1">SBP/DBP, median reduction: </text>
<text top="681" left="676" width="155" height="20" font="1">8.1 mm Hg (IQR: 3.3–11.8)/ </text>
<text top="698" left="676" width="148" height="20" font="1">3.8 mm Hg (IQR: 0.6–6.7)  </text>
<text top="715" left="676" width="161" height="20" font="1">SBP/DBP control: 19% (IQR: </text>
<text top="733" left="676" width="157" height="20" font="1">11.4–33.2)/ 17% (IQR: 11.4–</text>
<text top="750" left="676" width="31" height="20" font="1">24.5) </text>
<text top="769" left="676" width="7" height="18" font="1">•</text>
<text top="768" left="683" width="102" height="20" font="1"> Promotion of self–</text>
<text top="785" left="676" width="75" height="20" font="1">management </text>
<text top="107" left="860" width="189" height="20" font="1">greatest effects or whether certain </text>
<text top="124" left="860" width="161" height="20" font="1">combinations of individual QI </text>
<text top="141" left="860" width="192" height="20" font="1">strategies were more “potent” than </text>
<text top="159" left="860" width="41" height="20" font="1">others. </text>
<text top="176" left="860" width="3" height="20" font="4"><b> </b></text>
<text top="193" left="860" width="157" height="20" font="4"><b>Summary</b>: QI strategies are </text>
<text top="210" left="860" width="170" height="20" font="1">associated with improved HTN </text>
<text top="227" left="860" width="199" height="20" font="1">control. QI strategies improved SBP </text>
<text top="245" left="860" width="192" height="20" font="1">and the proportion of pts achieving </text>
<text top="262" left="860" width="202" height="20" font="1">SBP control and had a more modest </text>
<text top="279" left="860" width="196" height="20" font="1">effect on DBP and the proportion of </text>
<text top="296" left="860" width="183" height="20" font="1">pts achieving DBP control. Team </text>
<text top="314" left="860" width="176" height="20" font="1">change (i.e., a focus on HTN by </text>
<text top="331" left="860" width="170" height="20" font="1">someone in addition to the pt’s </text>
<text top="348" left="860" width="194" height="20" font="1">physician) had the largest effect on </text>
<text top="365" left="860" width="163" height="20" font="1">both SBP and DBP. All of the </text>
<text top="383" left="860" width="211" height="20" font="1">strategies assessed may be beneficial </text>
<text top="400" left="860" width="174" height="20" font="1">in terms of clinically meaningful </text>
<text top="417" left="860" width="161" height="20" font="1">reductions in BP under some </text>
<text top="434" left="860" width="162" height="20" font="1">circumstances and in varying </text>
<text top="451" left="860" width="79" height="20" font="1">combinations.<b> </b></text>
</page>
<page number="240" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">240 </text>
<text top="107" left="676" width="161" height="20" font="1">SBP/DBP, median reduction: </text>
<text top="124" left="676" width="155" height="20" font="1">3.3 mm Hg (IQR: 2.6–10.1)/ </text>
<text top="141" left="676" width="145" height="20" font="1">2.8 mm Hg (IQR: 0.4–6.7) </text>
<text top="159" left="676" width="153" height="20" font="1">SBP/DBP control: 13%/ 9% </text>
<text top="176" left="676" width="88" height="20" font="1">(IQR: 5.3–11.4) </text>
<text top="195" left="676" width="7" height="18" font="1">•</text>
<text top="194" left="683" width="80" height="20" font="1"> Pt reminders  </text>
<text top="211" left="676" width="161" height="20" font="1">SBP/DBP, median reduction: </text>
<text top="229" left="676" width="169" height="20" font="1">3.3 mm Hg (IQR: 2.3–4.5)/ 0.4 </text>
<text top="246" left="676" width="129" height="20" font="1">mm Hg (IQR: -2.4–5.0) </text>
<text top="263" left="676" width="150" height="20" font="1">DBP control: 2% (IQR: 1.1–</text>
<text top="280" left="676" width="25" height="20" font="1">9.4) </text>
<text top="299" left="676" width="7" height="18" font="1">•</text>
<text top="299" left="683" width="85" height="20" font="1"> Team change  </text>
<text top="316" left="676" width="161" height="20" font="1">SBP/DBP, median reduction: </text>
<text top="333" left="676" width="152" height="20" font="1">9.7 mm Hg (IQR: 4.2–14.0) </text>
<text top="350" left="676" width="149" height="20" font="1">(p&lt;0.05)/ 4.2 mm Hg (IQR: </text>
<text top="368" left="676" width="98" height="20" font="1">0.2–6.8) (p&lt;0.05) </text>
<text top="385" left="676" width="161" height="20" font="1">SBP/DBP control: 22% (IQR: </text>
<text top="402" left="676" width="143" height="20" font="1">9.0–33.8)/ 17% (IQR: 5.7–</text>
<text top="419" left="676" width="31" height="20" font="1">24.5) </text>
<text top="438" left="676" width="7" height="18" font="1">•</text>
<text top="438" left="683" width="114" height="20" font="1"> Financial incentives </text>
<text top="455" left="676" width="165" height="20" font="1">SBP/DBP, median reduction: -</text>
<text top="472" left="676" width="170" height="20" font="1">13.3 mm Hg/ 0.0 mm Hg (IQR: </text>
<text top="489" left="676" width="53" height="20" font="1">-2.0–2.5) </text>
<text top="506" left="676" width="154" height="20" font="1">DBP control: 4% (IQR: -1.1–</text>
<text top="524" left="676" width="25" height="20" font="1">9.4) </text>
<text top="541" left="676" width="3" height="20" font="1"> </text>
<text top="558" left="676" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="576" left="98" width="93" height="20" font="1">Carter BL, et al., </text>
<text top="593" left="98" width="63" height="20" font="1">2009 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(321)</a> </text>
<text top="610" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19858431?dopt=Citation">19858431</a></text>
<text top="610" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19858431?dopt=Citation"> </a></text>
<text top="576" left="217" width="91" height="20" font="4"><b>Aim:</b> Determine </text>
<text top="593" left="217" width="60" height="20" font="1">potency of </text>
<text top="610" left="217" width="111" height="20" font="1">interventions for BP </text>
<text top="628" left="217" width="115" height="20" font="1">involving nurses and </text>
<text top="645" left="217" width="70" height="20" font="1">pharmacists </text>
<text top="662" left="217" width="3" height="20" font="1"> </text>
<text top="679" left="217" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="697" left="217" width="48" height="20" font="1">analysis </text>
<text top="714" left="217" width="3" height="20" font="1"> </text>
<text top="731" left="217" width="98" height="20" font="4"><b>Size:</b> 37 RCTs of </text>
<text top="748" left="217" width="124" height="20" font="1">team-based HTN care </text>
<text top="765" left="217" width="100" height="20" font="1">involving nurse or </text>
<text top="576" left="361" width="148" height="20" font="4"><b>Inclusion criteria:</b> RCT of </text>
<text top="593" left="361" width="124" height="20" font="1">team-based HTN care </text>
<text top="610" left="361" width="100" height="20" font="1">involving nurse or </text>
<text top="628" left="361" width="131" height="20" font="1">pharmacist intervention </text>
<text top="645" left="361" width="3" height="20" font="1"> </text>
<text top="662" left="361" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="679" left="361" width="105" height="20" font="1">Absence of above  </text>
<text top="576" left="523" width="114" height="20" font="4"><b>Intervention:</b> Team-</text>
<text top="593" left="523" width="93" height="20" font="1">based HTN care </text>
<text top="610" left="523" width="100" height="20" font="1">involving nurse or </text>
<text top="628" left="523" width="131" height="20" font="1">pharmacist intervention </text>
<text top="645" left="523" width="109" height="20" font="9">In nearly all studies </text>
<text top="662" left="523" width="106" height="20" font="9">involving nurses or </text>
<text top="679" left="523" width="123" height="20" font="9">pharmacists in clinics, </text>
<text top="697" left="523" width="139" height="20" font="9">consistent and dedicated </text>
<text top="714" left="523" width="105" height="20" font="9">case management </text>
<text top="731" left="523" width="131" height="20" font="9">activities were provided </text>
<text top="748" left="523" width="124" height="20" font="9">that were distinct from </text>
<text top="765" left="523" width="115" height="20" font="9">traditional nursing or </text>
<text top="577" left="676" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="596" left="676" width="7" height="18" font="1">•</text>
<text top="596" left="683" width="3" height="20" font="1"> </text>
<text top="596" left="686" width="148" height="20" font="9">OR (95% CI) for controlled </text>
<text top="613" left="676" width="152" height="20" font="9">BP were: nurses: 1.69 (1.48</text>
<text top="613" left="828" width="7" height="20" font="1">, </text>
<text top="630" left="676" width="139" height="20" font="9">1.93); pharmacists within </text>
<text top="647" left="676" width="139" height="20" font="9">primary care clinics: 2.17 </text>
<text top="664" left="676" width="28" height="20" font="9">(1.75</text>
<text top="664" left="704" width="7" height="20" font="1">, </text>
<text top="664" left="711" width="122" height="20" font="9">2.68); and community </text>
<text top="682" left="676" width="129" height="20" font="9">pharmacists: 2.89 (1.83</text>
<text top="682" left="804" width="7" height="20" font="1">, </text>
<text top="682" left="811" width="38" height="20" font="9">4.55).  </text>
<text top="701" left="676" width="7" height="18" font="1">•</text>
<text top="700" left="683" width="3" height="20" font="1"> </text>
<text top="700" left="686" width="136" height="20" font="9">Mean (SD) reductions in </text>
<text top="717" left="676" width="166" height="20" font="9">SBP were: nurse intervention: </text>
<text top="734" left="676" width="113" height="20" font="9">5.84 (8.05) mm Hg;  </text>
<text top="752" left="676" width="123" height="20" font="9">pharmacists in clinics: </text>
<text top="769" left="676" width="130" height="20" font="9">7.76(7.81) mm Hg; and </text>
<text top="578" left="860" width="7" height="18" font="1">•</text>
<text top="577" left="866" width="3" height="20" font="1"> </text>
<text top="577" left="870" width="183" height="20" font="9">Stepwise regression was used to </text>
<text top="594" left="860" width="210" height="20" font="9">compare studies that included a given </text>
<text top="612" left="860" width="206" height="20" font="9">intervention strategy with studies that </text>
<text top="629" left="860" width="143" height="20" font="9">did not. Several individual </text>
<text top="646" left="860" width="208" height="20" font="9">components of the interventions were </text>
<text top="663" left="860" width="206" height="20" font="9">associated with significant reductions </text>
<text top="680" left="860" width="191" height="20" font="9">in mean SBP including pharmacist </text>
<text top="698" left="860" width="213" height="20" font="9">recommended medication to physician </text>
<text top="715" left="860" width="207" height="20" font="9">(-27.21 mm Hg; p=0.002), counseling </text>
<text top="732" left="859" width="190" height="20" font="9">about lifestyle modification (-12.63 </text>
<text top="749" left="859" width="159" height="20" font="9">mm Hg; p=0.03), pharmacist </text>
<text top="766" left="859" width="213" height="20" font="9">performed the intervention (-11.70 mm </text>
<text top="784" left="860" width="174" height="20" font="9">Hg; p=0.03), use of a treatment </text>
</page>
<page number="241" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">241 </text>
<text top="107" left="217" width="64" height="20" font="1">pharmacist </text>
<text top="124" left="217" width="67" height="20" font="1">intervention </text>
<text top="107" left="523" width="103" height="20" font="9">pharmacist duties. </text>
<text top="124" left="523" width="125" height="20" font="9">However, pharmacists </text>
<text top="141" left="523" width="76" height="20" font="9">in community </text>
<text top="159" left="523" width="132" height="20" font="9">pharmacies usually had </text>
<text top="176" left="523" width="99" height="20" font="9">to incorporate the </text>
<text top="193" left="523" width="92" height="20" font="9">intervention with </text>
<text top="210" left="523" width="120" height="20" font="9">traditional medication </text>
<text top="228" left="523" width="118" height="20" font="9">dispensing functions. </text>
<text top="245" left="523" width="3" height="20" font="1"> </text>
<text top="262" left="523" width="139" height="20" font="4"><b>Comparator:</b> Usual care<b> </b></text>
<text top="107" left="676" width="163" height="20" font="9">community pharmacists: 9.31 </text>
<text top="124" left="676" width="86" height="20" font="9">(5.00) mm Hg.  </text>
<text top="143" left="676" width="7" height="18" font="1">•</text>
<text top="143" left="683" width="3" height="20" font="1"> </text>
<text top="143" left="686" width="141" height="20" font="9">There were no significant </text>
<text top="160" left="676" width="148" height="20" font="9">differences between nurse </text>
<text top="177" left="676" width="127" height="20" font="9">and pharmacist effects </text>
<text top="194" left="676" width="54" height="20" font="9">(p≥0.19). </text>
<text top="211" left="676" width="3" height="20" font="1"> </text>
<text top="229" left="676" width="124" height="20" font="4"><b>Safety endpoint:</b> N/A </text>
<text top="107" left="860" width="192" height="20" font="9">algorithm (-8.46 mm Hg; p&lt;0.001), </text>
<text top="124" left="860" width="190" height="20" font="9">completion of a drug profile and/or </text>
<text top="141" left="860" width="185" height="20" font="9">medication history (-8.28 mm Hg; </text>
<text top="159" left="860" width="207" height="20" font="9">p=0.001), and the overall intervention </text>
<text top="176" left="860" width="203" height="20" font="9">potency score assigned by the study </text>
<text top="193" left="860" width="181" height="20" font="9">reviewers (p&lt;0.001). The factors </text>
<text top="210" left="860" width="194" height="20" font="9">associated with a reduction in DBP </text>
<text top="228" left="860" width="213" height="20" font="9">were: referral was made to a specialist </text>
<text top="245" left="860" width="208" height="20" font="9">(−19.61 mm Hg; p=0.04), providing pt </text>
<text top="262" left="860" width="188" height="20" font="9">education about BP medications (-</text>
<text top="279" left="860" width="213" height="20" font="9">17.60 mm Hg; p=0.003), completion of </text>
<text top="296" left="860" width="176" height="20" font="9">a drug profile and/or medication </text>
<text top="314" left="860" width="177" height="20" font="9">history (-7.27 mm Hg; p=0.006), </text>
<text top="331" left="860" width="211" height="20" font="9">pharmacist performed the intervention </text>
<text top="348" left="860" width="180" height="20" font="9">(-4.03 mm Hg; p=0.04), or nurse </text>
<text top="365" left="860" width="206" height="20" font="9">performed the intervention (-3.94 mm </text>
<text top="383" left="860" width="71" height="20" font="9">Hg; p=0.04). </text>
<text top="400" left="860" width="3" height="20" font="1"> </text>
<text top="417" left="860" width="63" height="20" font="4"><b>Summary</b>: </text>
<text top="417" left="922" width="125" height="20" font="9">Interventions involving </text>
<text top="434" left="860" width="154" height="20" font="9">pharmacists or nurses were </text>
<text top="451" left="860" width="208" height="20" font="9">associated with significantly improved </text>
<text top="469" left="860" width="60" height="20" font="9">BP control.</text>
<text top="469" left="920" width="3" height="20" font="1"> </text>
<text top="487" left="98" width="97" height="20" font="1">Agarwal R, et al., </text>
<text top="504" left="98" width="56" height="20" font="1">2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#265">(27)</a> </text>
<text top="521" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21115879?dopt=Citation">21115879</a></text>
<text top="521" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21115879?dopt=Citation"> </a></text>
<text top="487" left="217" width="128" height="20" font="4"><b>Aim: </b>Quantify both the </text>
<text top="504" left="217" width="85" height="20" font="1">magnitude and </text>
<text top="521" left="217" width="126" height="20" font="1">mechanisms of benefit </text>
<text top="538" left="217" width="107" height="20" font="1">(including effect on </text>
<text top="555" left="217" width="119" height="20" font="1">therapeutic inertia) of </text>
<text top="573" left="217" width="115" height="20" font="1">home BP monitoring </text>
<text top="590" left="217" width="94" height="20" font="1">on BP reduction. </text>
<text top="607" left="217" width="105" height="20" font="1">Therapeutic inertia </text>
<text top="624" left="217" width="102" height="20" font="1">was defined as no </text>
<text top="641" left="217" width="126" height="20" font="1">change in medications </text>
<text top="659" left="217" width="82" height="20" font="1">combined with </text>
<text top="676" left="217" width="94" height="20" font="1">uncontrolled BP.<b> </b></text>
<text top="693" left="217" width="3" height="20" font="4"><b> </b></text>
<text top="710" left="217" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="727" left="217" width="107" height="20" font="1">Systematic Review </text>
<text top="745" left="217" width="103" height="20" font="1">and Meta-analysis<b> </b></text>
<text top="762" left="217" width="3" height="20" font="4"><b> </b></text>
<text top="487" left="361" width="106" height="20" font="4"><b>Inclusion criteria: </b></text>
<text top="504" left="361" width="136" height="20" font="1">Studies that randomized </text>
<text top="521" left="361" width="142" height="20" font="1">pts to control or home BP </text>
<text top="538" left="361" width="96" height="20" font="1">monitoring group </text>
<text top="555" left="361" width="3" height="20" font="1"> </text>
<text top="573" left="361" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="590" left="361" width="105" height="20" font="1">Absence of above<b>  </b></text>
<text top="487" left="523" width="134" height="20" font="4"><b>Intervention: </b>Home BP </text>
<text top="504" left="523" width="137" height="20" font="1">monitoring as an adjunct </text>
<text top="521" left="523" width="120" height="20" font="1">to usual care for HTN </text>
<text top="538" left="523" width="3" height="20" font="4"><b> </b></text>
<text top="555" left="523" width="139" height="20" font="4"><b>Comparator: </b>Usual care </text>
<text top="573" left="523" width="119" height="20" font="1">with BP monitoring in </text>
<text top="590" left="523" width="31" height="20" font="1">clinic </text>
<text top="488" left="676" width="162" height="20" font="4"><b>1</b>°<b> endpoint: </b>Compared with </text>
<text top="505" left="676" width="169" height="20" font="1">usual care alone, home-based </text>
<text top="522" left="676" width="84" height="20" font="1">BP monitoring: </text>
<text top="541" left="676" width="7" height="18" font="1">•</text>
<text top="540" left="683" width="162" height="20" font="4"><b> </b>Reduced SBP: -2.63 mm Hg </text>
<text top="558" left="676" width="149" height="20" font="1">(95%<b> </b>CI: -4.24– -1.02) and<b> </b></text>
<text top="577" left="676" width="7" height="18" font="1">•</text>
<text top="576" left="683" width="162" height="20" font="1"> Reduced DBP: -1.68 mm Hg </text>
<text top="593" left="676" width="125" height="20" font="1">(95% CI: -2.58– -0.79)<b> </b></text>
<text top="612" left="676" width="7" height="18" font="1">•</text>
<text top="612" left="683" width="160" height="20" font="4"><b> </b>Greater reduction in SBP by </text>
<text top="629" left="676" width="115" height="20" font="1">home BP monitoring </text>
<text top="646" left="676" width="154" height="20" font="1">interventions was seen with </text>
<text top="663" left="676" width="152" height="20" font="1">added telemonitoring effect </text>
<text top="680" left="676" width="154" height="20" font="1">size: -3.20 (95% CI: -4.66– -</text>
<text top="698" left="676" width="165" height="20" font="1">1.73) vs. home BP monitoring </text>
<text top="715" left="676" width="148" height="20" font="1">effect size: -1.26; 95% CI: -</text>
<text top="732" left="676" width="124" height="20" font="1">2.20– -0.31; p=0.029.  </text>
<text top="749" left="676" width="3" height="20" font="4"><b> </b></text>
<text top="766" left="676" width="127" height="20" font="4"><b>Safety endpoint: </b>N/A<b>  </b></text>
<text top="488" left="860" width="89" height="20" font="4"><b>2</b>°<b> endpoints:   </b></text>
<text top="507" left="860" width="7" height="18" font="1">•</text>
<text top="506" left="867" width="157" height="20" font="1"> More frequent reductions in </text>
<text top="523" left="859" width="156" height="20" font="1">antihypertensive medication </text>
<text top="540" left="859" width="194" height="20" font="1">(presumably due to identification of </text>
<text top="558" left="859" width="197" height="20" font="1">white coat HTN): RR: 2.02; 95% CI: </text>
<text top="575" left="859" width="62" height="20" font="1">1.32–3.11  </text>
<text top="594" left="860" width="7" height="18" font="1">•</text>
<text top="593" left="867" width="183" height="20" font="4"><b> </b>Lowered therapeutic inertia (i.e., </text>
<text top="610" left="859" width="170" height="20" font="1">unchanged medication despite </text>
<text top="628" left="859" width="176" height="20" font="1">elevated BP: RR for unchanged </text>
<text top="645" left="859" width="204" height="20" font="1">medication 0.82 (95% CI: 0.68–0.99)<b> </b></text>
<text top="662" left="860" width="3" height="20" font="4"><b> </b></text>
<text top="679" left="860" width="198" height="20" font="4"><b>Limitations: </b>Different inclusion and </text>
<text top="697" left="860" width="166" height="20" font="1">exclusion criteria, different BP </text>
<text top="714" left="860" width="173" height="20" font="1">measurement techniques, drug </text>
<text top="731" left="860" width="208" height="20" font="1">titration protocols, pt populations, and </text>
<text top="748" left="860" width="196" height="20" font="1">duration of follow-up across studies </text>
<text top="765" left="860" width="150" height="20" font="1">likely introduced significant </text>
<text top="783" left="860" width="153" height="20" font="1">heterogeneity in effect size. </text>
</page>
<page number="242" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">242 </text>
<text top="107" left="217" width="109" height="20" font="4"><b>Size: </b>37 RCTs with </text>
<text top="124" left="217" width="127" height="20" font="1">9446 pts. Trial settings </text>
<text top="141" left="217" width="112" height="20" font="1">included community </text>
<text top="159" left="217" width="103" height="20" font="1">(n=5), dialysis unit </text>
<text top="176" left="217" width="80" height="20" font="1">(n=2), general </text>
<text top="193" left="217" width="95" height="20" font="1">practices (n=18), </text>
<text top="210" left="217" width="120" height="20" font="1">hospitals and general </text>
<text top="228" left="217" width="106" height="20" font="1">practice (n=1), and </text>
<text top="245" left="217" width="83" height="20" font="1">hospital-based </text>
<text top="262" left="217" width="130" height="20" font="1">outpatient units (n=11). </text>
<text top="107" left="860" width="3" height="20" font="4"><b> </b></text>
<text top="124" left="860" width="66" height="20" font="4"><b>Summary</b>:  </text>
<text top="143" left="860" width="7" height="18" font="1">•</text>
<text top="143" left="867" width="199" height="20" font="4"><b> </b>Home BP monitoring leads to small </text>
<text top="160" left="859" width="198" height="20" font="1">but significant reduction in SBP and </text>
<text top="177" left="859" width="185" height="20" font="1">DBP. Greater reduction in SBP is </text>
<text top="194" left="859" width="167" height="20" font="1">seen accompanied by specific </text>
<text top="211" left="859" width="196" height="20" font="1">programs to titrate antihypertensive<b> </b></text>
<text top="229" left="859" width="153" height="20" font="1">drugs. One such strategy is </text>
<text top="246" left="859" width="202" height="20" font="1">telemonitoring, in which BP<b> </b>readings </text>
<text top="263" left="859" width="198" height="20" font="1">obtained at home are relayed to the </text>
<text top="280" left="859" width="151" height="20" font="1">provider who can then take </text>
<text top="298" left="860" width="105" height="20" font="1">appropriate action. </text>
<text top="316" left="98" width="97" height="20" font="1">Anchala R, et al., </text>
<text top="333" left="98" width="63" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(339)</a> </text>
<text top="350" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23071713?dopt=Citation">23071713</a></text>
<text top="350" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23071713?dopt=Citation"> </a></text>
<text top="316" left="217" width="126" height="20" font="4"><b>Aim: </b>Evaluate the role </text>
<text top="333" left="217" width="107" height="20" font="1">of decision support </text>
<text top="350" left="217" width="122" height="20" font="1">systems in prevention </text>
<text top="367" left="217" width="104" height="20" font="1">of CVD among pts </text>
<text top="384" left="217" width="3" height="20" font="4"><b> </b></text>
<text top="402" left="217" width="71" height="20" font="4"><b>Study type: </b></text>
<text top="419" left="217" width="126" height="20" font="1">Systematic review and </text>
<text top="436" left="217" width="79" height="20" font="1">meta-analysis </text>
<text top="453" left="217" width="3" height="20" font="4"><b> </b></text>
<text top="470" left="217" width="127" height="20" font="4"><b>Size: </b>10 studies with 5 </text>
<text top="488" left="217" width="128" height="20" font="1">studies reporting effect </text>
<text top="505" left="217" width="126" height="20" font="1">on BP (BP results only </text>
<text top="522" left="217" width="81" height="20" font="1">reported here) </text>
<text top="316" left="361" width="120" height="20" font="4"><b>Inclusion criteria: </b>1) </text>
<text top="333" left="361" width="121" height="20" font="1">Cross-sectional, case </text>
<text top="350" left="361" width="147" height="20" font="1">control, cohort, and RCTs, </text>
<text top="367" left="361" width="119" height="20" font="1">2) Studies conducted </text>
<text top="384" left="361" width="134" height="20" font="1">among adult pts ≥18, 3) </text>
<text top="402" left="361" width="134" height="20" font="1">studies on prevention of </text>
<text top="419" left="361" width="139" height="20" font="1">CV disorders (MI, stroke, </text>
<text top="436" left="361" width="141" height="20" font="1">CHD, peripheral vascular </text>
<text top="453" left="361" width="126" height="20" font="1">disorders and HF) and </text>
<text top="470" left="361" width="135" height="20" font="1">management of HTN, 4) </text>
<text top="488" left="361" width="132" height="20" font="1">studies on interventions </text>
<text top="505" left="361" width="148" height="20" font="1">including: decision support </text>
<text top="522" left="361" width="141" height="20" font="1">systems, clinical decision </text>
<text top="539" left="361" width="102" height="20" font="1">supports systems, </text>
<text top="557" left="361" width="126" height="20" font="1">computerized decision </text>
<text top="574" left="361" width="137" height="20" font="1">support systems, clinical </text>
<text top="591" left="361" width="145" height="20" font="1">decision making tools and </text>
<text top="608" left="361" width="138" height="20" font="1">medical decision making </text>
<text top="625" left="361" width="3" height="20" font="4"><b> </b></text>
<text top="643" left="361" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="660" left="361" width="102" height="20" font="1">Absence of above<b> </b></text>
<text top="316" left="523" width="128" height="20" font="4"><b>Intervention: </b>Decision </text>
<text top="333" left="523" width="137" height="20" font="1">support systems, clinical </text>
<text top="350" left="523" width="99" height="20" font="1">decision supports </text>
<text top="367" left="523" width="129" height="20" font="1">systems, computerized </text>
<text top="384" left="523" width="49" height="20" font="1">decision<b> </b></text>
<text top="402" left="523" width="137" height="20" font="1">support systems, clinical </text>
<text top="419" left="523" width="121" height="20" font="1">decision making tools </text>
<text top="436" left="523" width="118" height="20" font="1">and medical decision </text>
<text top="453" left="523" width="76" height="20" font="1">making in the </text>
<text top="470" left="523" width="118" height="20" font="1">management of HTN </text>
<text top="488" left="523" width="3" height="20" font="4"><b> </b></text>
<text top="505" left="523" width="139" height="20" font="4"><b>Comparator: </b>Usual care </text>
<text top="317" left="676" width="79" height="20" font="4"><b>1</b>°<b> endpoint:  </b></text>
<text top="336" left="676" width="7" height="18" font="1">•</text>
<text top="335" left="683" width="117" height="20" font="4"><b> </b>Reduction in SBP (5 </text>
<text top="352" left="676" width="152" height="20" font="1">studies): 2.32 mm Hg (95% </text>
<text top="370" left="676" width="93" height="20" font="1">CI: -3.96– -0.69) </text>
<text top="389" left="676" width="7" height="18" font="1">•</text>
<text top="388" left="683" width="118" height="20" font="4"><b> </b>Reduction in DBP (2 </text>
<text top="405" left="676" width="152" height="20" font="1">studies): 0.42 mm Hg (95% </text>
<text top="422" left="676" width="85" height="20" font="1">CI: -2.30–1.47) </text>
<text top="440" left="676" width="3" height="20" font="4"><b> </b></text>
<text top="457" left="676" width="124" height="20" font="4"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="316" left="860" width="73" height="20" font="4"><b>Limitations: </b></text>
<text top="335" left="860" width="7" height="18" font="1">•</text>
<text top="334" left="867" width="189" height="20" font="1"> Small number of studies of varied </text>
<text top="351" left="859" width="42" height="20" font="1">quality.<b> </b></text>
<text top="370" left="860" width="7" height="18" font="1">•</text>
<text top="370" left="867" width="199" height="20" font="4"><b> </b>Interventions varied across studies.<b> </b></text>
<text top="387" left="860" width="3" height="20" font="4"><b> </b></text>
<text top="404" left="860" width="199" height="20" font="4"><b>Summary</b>: Clinical decision support </text>
<text top="421" left="860" width="199" height="20" font="1">resulted in modest reduction of SBP </text>
<text top="438" left="860" width="199" height="20" font="1">and no significant reduction of DBP.<b> </b></text>
<text top="678" left="98" width="89" height="20" font="1">Proia KK, et al., </text>
<text top="695" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(323)</a> </text>
<text top="712" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24933494?dopt=Citation">24933494</a></text>
<text top="712" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24933494?dopt=Citation"> </a></text>
<text top="678" left="217" width="124" height="20" font="4"><b>Aim:</b> Examine current </text>
<text top="695" left="217" width="90" height="20" font="1">evidence on the </text>
<text top="712" left="217" width="120" height="20" font="1">effectiveness of team-</text>
<text top="729" left="217" width="77" height="20" font="1">based care in </text>
<text top="747" left="217" width="76" height="20" font="1">improving BP </text>
<text top="764" left="217" width="116" height="20" font="1">outcomes (update of </text>
<text top="678" left="361" width="141" height="20" font="4"><b>Inclusion criteria:</b> Study </text>
<text top="695" left="361" width="113" height="20" font="1">of team-based care; </text>
<text top="712" left="361" width="111" height="20" font="1">conducted in a high-</text>
<text top="729" left="361" width="149" height="20" font="1">income economy; reported </text>
<text top="747" left="361" width="137" height="20" font="1">at least 1 BP outcome of </text>
<text top="764" left="361" width="107" height="20" font="1">interest; included a </text>
<text top="781" left="361" width="140" height="20" font="1">comparison group or had </text>
<text top="678" left="523" width="114" height="20" font="4"><b>Intervention:</b> Team-</text>
<text top="695" left="523" width="133" height="20" font="1">based care was defined </text>
<text top="712" left="523" width="124" height="20" font="1">as adding new staff or </text>
<text top="729" left="523" width="118" height="20" font="1">changing the roles of </text>
<text top="747" left="523" width="140" height="20" font="1">existing staff to work with </text>
<text top="764" left="523" width="116" height="20" font="1">a PCP for HTN care. </text>
<text top="781" left="523" width="116" height="20" font="1">Team members who </text>
<text top="679" left="676" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="698" left="676" width="7" height="18" font="1">•</text>
<text top="697" left="683" width="145" height="20" font="1"> Proportion with controlled </text>
<text top="714" left="676" width="169" height="20" font="1">BP: Absolute percentage point </text>
<text top="732" left="676" width="143" height="20" font="1">(pct pt) change in pts with </text>
<text top="749" left="676" width="164" height="20" font="1">controlled BP from 33 studies </text>
<text top="766" left="676" width="170" height="20" font="1">comparing team-based care to </text>
<text top="783" left="676" width="141" height="20" font="1">usual care: median effect </text>
<text top="679" left="860" width="201" height="20" font="4"><b>2</b>°<b> endpoints: </b>Compared with pts in </text>
<text top="696" left="860" width="176" height="20" font="1">usual care, the proportion of pts </text>
<text top="713" left="860" width="208" height="20" font="1">receiving team-based care with “high” </text>
<text top="730" left="859" width="189" height="20" font="1">medication adherence (defined as </text>
<text top="748" left="859" width="182" height="20" font="1">taking medications as prescribed </text>
<text top="765" left="859" width="183" height="20" font="1">&gt;80% of the time) increased by a </text>
<text top="782" left="860" width="189" height="20" font="1">median of 16.3 pct pts (9 studies). </text>
</page>
<page number="243" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">243 </text>
<text top="107" left="217" width="89" height="20" font="1">prior systematic </text>
<text top="124" left="217" width="43" height="20" font="1">review) </text>
<text top="141" left="217" width="3" height="20" font="1"> </text>
<text top="159" left="217" width="71" height="20" font="4"><b>Study type: </b></text>
<text top="176" left="217" width="103" height="20" font="1">Systematic review </text>
<text top="193" left="217" width="3" height="20" font="1"> </text>
<text top="210" left="217" width="105" height="20" font="4"><b>Size:</b> 52 studies of </text>
<text top="227" left="217" width="113" height="20" font="1">team-based primary </text>
<text top="245" left="217" width="106" height="20" font="1">care for pts with 1° </text>
<text top="262" left="217" width="29" height="20" font="1">HTN </text>
<text top="107" left="361" width="143" height="20" font="1">an interrupted time-series </text>
<text top="124" left="361" width="118" height="20" font="1">design with at least 2 </text>
<text top="141" left="361" width="147" height="20" font="1">measurements before and </text>
<text top="159" left="361" width="119" height="20" font="1">after the intervention; </text>
<text top="176" left="361" width="140" height="20" font="1">targeted populations with </text>
<text top="193" left="361" width="125" height="20" font="1">1° HTN or populations </text>
<text top="210" left="361" width="138" height="20" font="1">with comorbid conditions </text>
<text top="228" left="361" width="148" height="20" font="1">such as DM as long as the </text>
<text top="245" left="361" width="111" height="20" font="1">primary focus of the </text>
<text top="262" left="361" width="112" height="20" font="1">intervention was BP </text>
<text top="279" left="361" width="111" height="20" font="1">control; and did not  </text>
<text top="296" left="361" width="3" height="20" font="1"> </text>
<text top="314" left="361" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="331" left="361" width="132" height="20" font="1">Inclusion of populations </text>
<text top="348" left="361" width="100" height="20" font="1">with 2º HTN (e.g., </text>
<text top="365" left="361" width="115" height="20" font="1">pregnancy) or with a </text>
<text top="382" left="361" width="135" height="20" font="1">history of CVD (e.g., MI) </text>
<text top="107" left="523" width="139" height="20" font="1">collaborated with pts and </text>
<text top="124" left="523" width="65" height="20" font="1">PCPs were </text>
<text top="141" left="523" width="121" height="20" font="1">predominantly nurses </text>
<text top="159" left="523" width="71" height="20" font="1">(28 studies); </text>
<text top="176" left="523" width="91" height="20" font="1">pharmacists (15 </text>
<text top="193" left="523" width="118" height="20" font="1">studies); both nurses </text>
<text top="210" left="523" width="108" height="20" font="1">and pharmacists (5 </text>
<text top="228" left="523" width="127" height="20" font="1">studies); or community </text>
<text top="245" left="523" width="87" height="20" font="1">health workers, </text>
<text top="262" left="523" width="85" height="20" font="1">integrated care </text>
<text top="279" left="523" width="136" height="20" font="1">managers, or behavioral </text>
<text top="296" left="523" width="100" height="20" font="1">interventionists (4 </text>
<text top="314" left="523" width="104" height="20" font="1">studies). Key roles </text>
<text top="331" left="523" width="78" height="20" font="1">included HTN </text>
<text top="348" left="523" width="63" height="20" font="1">medication </text>
<text top="365" left="523" width="128" height="20" font="1">management, active pt </text>
<text top="383" left="523" width="80" height="20" font="1">follow-up, and </text>
<text top="400" left="523" width="109" height="20" font="1">adherence and self-</text>
<text top="417" left="523" width="123" height="20" font="1">management support. </text>
<text top="434" left="523" width="104" height="20" font="1">Interventions were </text>
<text top="451" left="523" width="115" height="20" font="1">usually implemented </text>
<text top="469" left="523" width="131" height="20" font="1">across multiple settings </text>
<text top="486" left="523" width="137" height="20" font="1">in the healthcare system </text>
<text top="503" left="523" width="124" height="20" font="1">and in the community, </text>
<text top="520" left="523" width="94" height="20" font="1">where they were </text>
<text top="537" left="523" width="87" height="20" font="1">implemented in </text>
<text top="555" left="523" width="136" height="20" font="1">pharmacies and through </text>
<text top="572" left="523" width="120" height="20" font="1">home outreach visits. </text>
<text top="589" left="523" width="3" height="20" font="1"> </text>
<text top="606" left="523" width="139" height="20" font="4"><b>Comparator:</b> Usual care<b> </b></text>
<text top="107" left="676" width="132" height="20" font="1">estimate was 12 pct pts </text>
<text top="124" left="676" width="156" height="20" font="1">(IQI=3.2–20.8 pct pts). Most </text>
<text top="141" left="676" width="157" height="20" font="1">individual effect estimates in </text>
<text top="159" left="676" width="154" height="20" font="1">the favorable direction were </text>
<text top="176" left="676" width="111" height="20" font="1">significant (p&lt;0.05). </text>
<text top="195" left="676" width="7" height="18" font="1">•</text>
<text top="194" left="683" width="124" height="20" font="1"> Reduction in SBP (44 </text>
<text top="211" left="676" width="118" height="20" font="1">studies): The median </text>
<text top="229" left="676" width="165" height="20" font="1">reduction in SBP was 5.4 mm </text>
<text top="246" left="676" width="142" height="20" font="1">Hg (IQI=2.0–7.2 mm Hg). </text>
<text top="263" left="676" width="118" height="20" font="1">Most individual effect </text>
<text top="280" left="676" width="144" height="20" font="1">estimates were significant </text>
<text top="298" left="676" width="53" height="20" font="1">(p&lt;0.05). </text>
<text top="317" left="676" width="7" height="18" font="1">•</text>
<text top="316" left="683" width="132" height="20" font="1"> Reduction in DBP: The </text>
<text top="333" left="676" width="150" height="20" font="1">overall median reduction in </text>
<text top="350" left="676" width="117" height="20" font="1">DBP was 1.8 mm Hg </text>
<text top="368" left="676" width="165" height="20" font="1">(IQI=0.7–3.2 mm Hg) from 38 </text>
<text top="385" left="676" width="46" height="20" font="1">studies. </text>
<text top="402" left="676" width="3" height="20" font="1"> </text>
<text top="419" left="676" width="164" height="20" font="4"><b>Safety endpoint:</b> No harm to </text>
<text top="436" left="676" width="157" height="20" font="1">pts was identified from team-</text>
<text top="454" left="676" width="171" height="20" font="1">based care interventions in the </text>
<text top="471" left="676" width="126" height="20" font="1">included studies or the </text>
<text top="488" left="676" width="100" height="20" font="1">broader literature. </text>
<text top="107" left="860" width="3" height="20" font="4"><b> </b></text>
<text top="124" left="860" width="152" height="20" font="4"><b>Stratified analyses for BP </b></text>
<text top="141" left="860" width="65" height="20" font="4"><b>outcomes</b>: </text>
<text top="160" left="860" width="7" height="18" font="1">•</text>
<text top="160" left="866" width="187" height="20" font="1"> Team member role in medication </text>
<text top="177" left="860" width="211" height="20" font="1">management: Larger improvements in </text>
<text top="194" left="860" width="200" height="20" font="1">BP outcomes than overall estimates </text>
<text top="211" left="860" width="172" height="20" font="1">were demonstrated when team </text>
<text top="229" left="860" width="185" height="20" font="1">members could make changes to </text>
<text top="246" left="860" width="203" height="20" font="1">medications independent of the PCP </text>
<text top="263" left="860" width="176" height="20" font="1">or team members could provide </text>
<text top="280" left="860" width="188" height="20" font="1">medication recommendations and </text>
<text top="298" left="860" width="167" height="20" font="1">make changes with the PCP’s </text>
<text top="315" left="860" width="170" height="20" font="1">approval as compared to team </text>
<text top="332" left="860" width="195" height="20" font="1">members providing only adherence </text>
<text top="349" left="860" width="213" height="20" font="1">support and information on medication </text>
<text top="367" left="860" width="56" height="20" font="1">and HTN. </text>
<text top="386" left="860" width="7" height="18" font="1">•</text>
<text top="385" left="866" width="191" height="20" font="1"> Number of team members added: </text>
<text top="402" left="860" width="194" height="20" font="1">Adding ≥2 members demonstrated </text>
<text top="419" left="860" width="208" height="20" font="1">larger improvements in the proportion </text>
<text top="437" left="860" width="213" height="20" font="1">of pts with controlled BP and reduction </text>
<text top="454" left="860" width="194" height="20" font="1">in DBP compared to adding only 1; </text>
<text top="471" left="860" width="175" height="20" font="1">median reductions in SBP were </text>
<text top="488" left="860" width="173" height="20" font="1">similar regardless of team size. </text>
<text top="507" left="860" width="7" height="18" font="1">•</text>
<text top="506" left="866" width="205" height="20" font="1"> Improvement in the proportion of pts </text>
<text top="524" left="860" width="184" height="20" font="1">with controlled BP was similar for </text>
<text top="541" left="860" width="183" height="20" font="1">studies from both healthcare and </text>
<text top="558" left="860" width="112" height="20" font="1">community settings. </text>
<text top="575" left="860" width="3" height="20" font="1"> </text>
<text top="593" left="860" width="165" height="20" font="4"><b>Limitations</b>: Included studies </text>
<text top="610" left="860" width="198" height="20" font="1">reported significant differences in pt </text>
<text top="627" left="860" width="198" height="20" font="1">demographics between intervention </text>
<text top="644" left="860" width="198" height="20" font="1">and comparison groups at baseline, </text>
<text top="661" left="860" width="163" height="20" font="1">possible contamination within </text>
<text top="679" left="860" width="202" height="20" font="1">intervention and comparison groups, </text>
<text top="696" left="860" width="181" height="20" font="1">and issues related to inadequate </text>
<text top="713" left="860" width="167" height="20" font="1">description of populations and </text>
<text top="730" left="860" width="150" height="20" font="1">implemented interventions. </text>
<text top="747" left="860" width="3" height="20" font="1"> </text>
<text top="765" left="860" width="201" height="20" font="4"><b>Summary</b>: There is strong evidence </text>
<text top="782" left="860" width="194" height="20" font="1">that team-based care is effective in </text>
</page>
<page number="244" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">244 </text>
<text top="107" left="860" width="194" height="20" font="1">improving BP outcomes, especially </text>
<text top="124" left="860" width="213" height="20" font="1">when pharmacists and nurses are part </text>
<text top="141" left="860" width="68" height="20" font="1">of the team. </text>
<text top="159" left="108" width="3" height="20" font="1"> </text>
<text top="194" left="81" width="931" height="24" font="3"><b>Data Supplement 67. Nonrandomized Trials, Observational Studies, and/or Registries of Effect of Quality Improvement Strategies on </b></text>
<text top="218" left="81" width="362" height="24" font="3"><b>Hypertension Treatment Outcomes (Section 12.4.2) </b></text>
<text top="258" left="113" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="275" left="138" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="292" left="116" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="258" left="265" width="118" height="20" font="4"><b>Study Type/Design; </b></text>
<text top="275" left="281" width="86" height="20" font="4"><b>Study Size (N)</b> </text>
<text top="258" left="433" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="258" left="631" width="179" height="20" font="4"><b>Primary Endpoint and Results </b></text>
<text top="275" left="638" width="167" height="20" font="4"><b>(include P value; OR or RR;  </b></text>
<text top="292" left="690" width="60" height="20" font="4"><b>&amp; 95% CI) </b></text>
<text top="258" left="914" width="130" height="20" font="4"><b>Summary/Conclusion </b></text>
<text top="275" left="942" width="75" height="20" font="4"><b>Comment(s) </b></text>
<text top="310" left="98" width="103" height="20" font="1">Thomas KL, et al., </text>
<text top="327" left="98" width="63" height="20" font="1">2014 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(340)</a> </text>
<text top="344" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25351480?dopt=Citation">25351480</a></text>
<text top="344" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25351480?dopt=Citation"> </a></text>
<text top="310" left="240" width="137" height="20" font="4"><b>Study type:</b> Community-</text>
<text top="327" left="240" width="131" height="20" font="1">based HTN QI program </text>
<text top="344" left="240" width="133" height="20" font="1">[multifaceted BP control </text>
<text top="361" left="240" width="156" height="20" font="1">program using a web-based </text>
<text top="379" left="240" width="137" height="20" font="1">health portal (Heart360), </text>
<text top="396" left="240" width="152" height="20" font="1">community health coaches, </text>
<text top="413" left="240" width="161" height="20" font="1">and PA guidance] to improve </text>
<text top="430" left="240" width="135" height="20" font="1">HTN control in a diverse </text>
<text top="448" left="240" width="103" height="20" font="1">community setting </text>
<text top="465" left="240" width="3" height="20" font="4"><b> </b></text>
<text top="482" left="240" width="130" height="20" font="4"><b>Design</b>: Pre-post study </text>
<text top="499" left="240" width="155" height="20" font="1">without a concurrent control </text>
<text top="516" left="240" width="3" height="20" font="4"><b> </b></text>
<text top="534" left="240" width="165" height="20" font="4"><b>Size:</b> 1756 pts with HTN from </text>
<text top="551" left="240" width="51" height="20" font="1">8 clinics: </text>
<text top="570" left="240" width="7" height="18" font="1">•</text>
<text top="569" left="247" width="101" height="20" font="1"> Median age, 60 y </text>
<text top="588" left="240" width="7" height="18" font="1">•</text>
<text top="587" left="247" width="90" height="20" font="1"> Female, 65.6% </text>
<text top="607" left="240" width="7" height="18" font="1">•</text>
<text top="606" left="247" width="142" height="20" font="1"> African American, 76.1% </text>
<text top="310" left="422" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="327" left="422" width="132" height="20" font="1">Individuals from pt sites </text>
<text top="344" left="422" width="119" height="20" font="1">&gt;18 y with a previous </text>
<text top="361" left="422" width="133" height="20" font="1">billing diagnosis of HTN </text>
<text top="379" left="422" width="124" height="20" font="1">(ICD-9 code 401.X) or </text>
<text top="396" left="422" width="100" height="20" font="1">a previous clinical </text>
<text top="413" left="422" width="131" height="20" font="1">diagnosis of HTN in the </text>
<text top="430" left="422" width="87" height="20" font="1">medical record. </text>
<text top="448" left="422" width="3" height="20" font="1"> </text>
<text top="465" left="422" width="132" height="20" font="4"><b>Exclusion criteria:</b> Did </text>
<text top="482" left="422" width="118" height="20" font="1">not reside in Durham </text>
<text top="499" left="422" width="91" height="20" font="1">County or had a </text>
<text top="516" left="422" width="131" height="20" font="1">neurocognitive disorder </text>
<text top="534" left="422" width="82" height="20" font="1">that prevented </text>
<text top="551" left="422" width="61" height="20" font="1">enrollment </text>
<text top="311" left="568" width="271" height="20" font="4"><b>1</b>°<b> endpoint:</b> 1) Difference in SBP and DBP from </text>
<text top="328" left="568" width="292" height="20" font="1">enrollment (BP obtained in the clinic at enrollment) to </text>
<text top="345" left="568" width="275" height="20" font="1">the last BP as measured in clinic within 6 mo after </text>
<text top="363" left="568" width="267" height="20" font="1">enrollment, 2) proportion of pts that achieved BP </text>
<text top="380" left="568" width="293" height="20" font="1">&lt;140/90 mm Hg by last clinic visit within 6 mo, and 3) </text>
<text top="397" left="568" width="284" height="20" font="1">proportion of pts with BP &lt;140/90 mm Hg or drop in </text>
<text top="414" left="568" width="244" height="20" font="1">SBP ≥10 mm Hg by last visit relative to their </text>
<text top="431" left="568" width="84" height="20" font="1">enrollment BP. </text>
<text top="449" left="568" width="3" height="20" font="4"><b> </b></text>
<text top="466" left="568" width="59" height="20" font="4"><b>Results:</b>   </text>
<text top="485" left="568" width="7" height="18" font="1">•</text>
<text top="484" left="575" width="285" height="20" font="1"> Mean change in BP: -4.7 mm Hg (SD ± 21.4) / -2.8 </text>
<text top="501" left="568" width="170" height="20" font="1">mm Hg (SD ± 11.8) after 6 mo </text>
<text top="520" left="568" width="7" height="18" font="1">•</text>
<text top="520" left="575" width="277" height="20" font="1"> BP control (&lt;140/90 mm Hg) rate: Increased from </text>
<text top="537" left="568" width="177" height="20" font="1">51% at baseline to 63% at 6 mo </text>
<text top="556" left="568" width="7" height="18" font="1">•</text>
<text top="555" left="575" width="290" height="20" font="1"> Proportion with BP&lt;140/90 or ≥10 mm Hg decrease </text>
<text top="573" left="568" width="139" height="20" font="1">in SBP at 6 mo was 69% </text>
<text top="592" left="568" width="7" height="18" font="1">•</text>
<text top="591" left="575" width="257" height="20" font="1"> Among those who were in tiers 1 (BP=140/90–</text>
<text top="608" left="568" width="253" height="20" font="1">159/99 mm Hg) and 2 (BP≥159/99 mm Hg) at </text>
<text top="625" left="568" width="303" height="20" font="1">enrollment (n=889), BP change was -8.8 mm Hg (SD ± </text>
<text top="643" left="568" width="297" height="20" font="1">15.8) / -5.0 mm Hg (SD ± 10.0) and -23.7 mm Hg (SD </text>
<text top="660" left="568" width="267" height="20" font="1">± 26.5) / -10.1 mm Hg (SD ± 14.1), respectively. </text>
<text top="310" left="886" width="166" height="20" font="4"><b>Summary: </b>A multicomponent-</text>
<text top="327" left="886" width="185" height="20" font="1">tiered HTN program that included </text>
<text top="344" left="886" width="171" height="20" font="1">team-based care with PAs and </text>
<text top="361" left="886" width="174" height="20" font="1">community health coaches was </text>
<text top="379" left="886" width="161" height="20" font="1">associated with improved BP </text>
<text top="396" left="886" width="170" height="20" font="1">control in a diverse community-</text>
<text top="413" left="886" width="166" height="20" font="1">based population. Though the </text>
<text top="430" left="886" width="176" height="20" font="1">web-based approach presented </text>
<text top="448" left="886" width="165" height="20" font="1">technical challenges for some </text>
<text top="465" left="886" width="124" height="20" font="1">pts, there was a direct </text>
<text top="482" left="886" width="176" height="20" font="1">association between higher use </text>
<text top="499" left="886" width="179" height="20" font="1">of Heart360 and larger recorded </text>
<text top="516" left="886" width="153" height="20" font="1">BP declines as entered into </text>
<text top="534" left="886" width="167" height="20" font="1">Heart360. This provides some </text>
<text top="551" left="886" width="173" height="20" font="1">indirect evidence that those pts </text>
<text top="568" left="886" width="164" height="20" font="1">who were more engaged with </text>
<text top="585" left="886" width="184" height="20" font="1">their BP self-monitoring achieved </text>
<text top="603" left="886" width="102" height="20" font="1">better BP control.  </text>
<text top="678" left="98" width="121" height="20" font="1">Jaffe MG, et al., 2013 </text>
<text top="695" left="98" width="32" height="20" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(329)</a> </text>
<text top="712" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23989679?dopt=Citation">23989679</a></text>
<text top="712" left="152" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23989679?dopt=Citation"><b> </b></a></text>
<text top="678" left="240" width="107" height="20" font="4"><b>Study type:</b> Quasi-</text>
<text top="695" left="240" width="147" height="20" font="1">experimental evaluation of </text>
<text top="712" left="240" width="163" height="20" font="1">multi-faceted QI program that </text>
<text top="730" left="240" width="145" height="20" font="1">included 1) Health system-</text>
<text top="747" left="240" width="147" height="20" font="1">wide HTN registry, 2) HTN </text>
<text top="764" left="240" width="148" height="20" font="1">control rates (with provider </text>
<text top="781" left="240" width="129" height="20" font="1">audit and feedback), 3) </text>
<text top="678" left="422" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="695" left="422" width="106" height="20" font="1">identified with HTN </text>
<text top="712" left="422" width="110" height="20" font="1">within an integrated </text>
<text top="730" left="422" width="110" height="20" font="1">health care delivery </text>
<text top="747" left="422" width="116" height="20" font="1">system (KPNC) from </text>
<text top="764" left="422" width="65" height="20" font="1">2001–2009 </text>
<text top="781" left="422" width="3" height="20" font="1"> </text>
<text top="679" left="568" width="249" height="20" font="4"><b>1</b>°<b> endpoint:</b> BP control using NCQA HEDIS </text>
<text top="696" left="568" width="57" height="20" font="1">measures </text>
<text top="713" left="568" width="3" height="20" font="4"><b> </b></text>
<text top="731" left="568" width="284" height="20" font="4"><b>Results:</b> BP control increased from 44%–80% from </text>
<text top="748" left="568" width="286" height="20" font="1">2001–2009 with the KPNC QI program compared to </text>
<text top="765" left="568" width="285" height="20" font="1">55.4% to 64.1% for the national mean and 63.4% to </text>
<text top="678" left="886" width="175" height="20" font="4"><b>Summary:</b> Implementation of a </text>
<text top="695" left="886" width="167" height="20" font="1">large-scale HTN program was </text>
<text top="712" left="886" width="156" height="20" font="1">associated with a significant </text>
<text top="730" left="886" width="132" height="20" font="1">increase in HTN control </text>
<text top="747" left="886" width="184" height="20" font="1">compared with state and national </text>
<text top="764" left="886" width="75" height="20" font="1">control rates. </text>
</page>
<page number="245" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">245 </text>
<text top="107" left="240" width="165" height="20" font="1">evidence-based practice HTN </text>
<text top="124" left="240" width="168" height="20" font="1">guideline, 4) medical assistant </text>
<text top="141" left="240" width="101" height="20" font="1">visits for follow-up </text>
<text top="159" left="240" width="141" height="20" font="1">measurements with no pt </text>
<text top="176" left="240" width="167" height="20" font="1">copayment for these follow-up </text>
<text top="193" left="240" width="144" height="20" font="1">visits, and 5) promotion of </text>
<text top="210" left="240" width="124" height="20" font="1">single-pill combination </text>
<text top="228" left="240" width="48" height="20" font="1">therapy. </text>
<text top="245" left="240" width="3" height="20" font="1"> </text>
<text top="262" left="240" width="152" height="20" font="4"><b>Design</b>: Contemporaneous </text>
<text top="279" left="240" width="136" height="20" font="1">control group external to </text>
<text top="296" left="240" width="103" height="20" font="1">healthcare system </text>
<text top="314" left="240" width="3" height="20" font="4"><b> </b></text>
<text top="331" left="240" width="143" height="20" font="4"><b>Size:</b> Kaiser HTN registry </text>
<text top="348" left="240" width="165" height="20" font="1">increased from 349,937 pts in </text>
<text top="365" left="240" width="139" height="20" font="1">2001 to 652,763 in 2009. </text>
<text top="107" left="422" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="124" left="422" width="73" height="20" font="1">None stated  </text>
<text top="107" left="568" width="272" height="20" font="1">69.4% for the Ca mean from 2006 to 2009 NCQA </text>
<text top="124" left="568" width="301" height="20" font="1">HEDIS commercial measurement comparison groups.  </text>
<text top="383" left="128" width="3" height="20" font="13"> </text>
<text top="418" left="81" width="522" height="24" font="3"><b>Data Supplement 68.  RCTs Comparing Financial Incentives (Section 12.5) </b></text>
<text top="458" left="103" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="475" left="128" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="492" left="106" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="458" left="243" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="475" left="248" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="492" left="242" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="458" left="381" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="458" left="528" width="126" height="20" font="4"><b>Study Intervention (# </b></text>
<text top="475" left="560" width="62" height="20" font="4"><b>patients) / </b></text>
<text top="492" left="528" width="125" height="20" font="4"><b>Study Comparator (# </b></text>
<text top="509" left="564" width="55" height="20" font="4"><b>patients) </b></text>
<text top="458" left="681" width="165" height="20" font="4"><b>Endpoint Results (Absolute </b></text>
<text top="475" left="681" width="165" height="20" font="4"><b>Event Rates, P value; OR or </b></text>
<text top="492" left="721" width="85" height="20" font="4"><b>RR; &amp; 95% CI) </b></text>
<text top="459" left="882" width="175" height="20" font="4"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="476" left="889" width="163" height="20" font="4"><b>Study Limitations; Adverse </b></text>
<text top="493" left="918" width="103" height="20" font="4"><b>Events Summary </b></text>
<text top="527" left="98" width="108" height="20" font="1">Peterson LA, et al., </text>
<text top="544" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(341)</a> </text>
<text top="562" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24026599?dopt=Citation">24026599</a></text>
<text top="562" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24026599?dopt=Citation"> </a></text>
<text top="579" left="98" width="3" height="20" font="1"> </text>
<text top="596" left="98" width="103" height="20" font="1">Hysong, SJ, et al., </text>
<text top="613" left="98" width="63" height="20" font="1">2012 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(342)</a> </text>
<text top="630" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23145846">23145846</a></text>
<text top="630" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23145846"> </a></text>
<text top="527" left="219" width="126" height="20" font="4"><b>Aim:</b> To test the effect </text>
<text top="544" left="219" width="103" height="20" font="1">of explicit financial </text>
<text top="562" left="219" width="113" height="20" font="1">incentives to reward </text>
<text top="579" left="219" width="53" height="20" font="1">guideline </text>
<text top="596" left="219" width="111" height="20" font="1">recommended HTN </text>
<text top="613" left="219" width="31" height="20" font="1">care.<b> </b></text>
<text top="630" left="219" width="3" height="20" font="1"> </text>
<text top="648" left="219" width="113" height="20" font="4"><b>Study type:</b> Cluster </text>
<text top="665" left="219" width="122" height="20" font="1">randomized trial of 12 </text>
<text top="682" left="219" width="117" height="20" font="1">VA Outpatient clinics </text>
<text top="699" left="219" width="108" height="20" font="1">with 5 performance </text>
<text top="716" left="219" width="116" height="20" font="1">periods and a 12-mo </text>
<text top="734" left="219" width="49" height="20" font="1">washout </text>
<text top="751" left="219" width="3" height="20" font="1"> </text>
<text top="768" left="219" width="125" height="20" font="4"><b>Size:</b> 83 PCPs and 42 </text>
<text top="785" left="219" width="75" height="20" font="1">nonphysician </text>
<text top="529" left="363" width="7" height="18" font="1">•</text>
<text top="528" left="370" width="124" height="20" font="1"> Study population was </text>
<text top="545" left="363" width="111" height="20" font="1">providers, not pts: a </text>
<text top="563" left="363" width="120" height="20" font="1">minimum of 5 fulltime </text>
<text top="580" left="363" width="126" height="20" font="1">PCPs from 12 hospital-</text>
<text top="597" left="363" width="145" height="20" font="1">based primary care clinics </text>
<text top="614" left="363" width="128" height="20" font="1">in 5 A Networks. Then, </text>
<text top="632" left="363" width="87" height="20" font="1">the clinics were </text>
<text top="649" left="363" width="116" height="20" font="1">randomized to 1 of 4 </text>
<text top="666" left="363" width="146" height="20" font="1">study groups, 1) physician </text>
<text top="683" left="363" width="91" height="20" font="1">level (individual) </text>
<text top="700" left="363" width="123" height="20" font="1">incentives, 2) practice-</text>
<text top="718" left="363" width="105" height="20" font="1">level incentives, 3) </text>
<text top="735" left="363" width="110" height="20" font="1">physician-level plus </text>
<text top="752" left="363" width="141" height="20" font="1">practice-level (combined) </text>
<text top="769" left="363" width="117" height="20" font="1">incentives, and 4) no </text>
<text top="786" left="363" width="114" height="20" font="1">incentives (control).  </text>
<text top="527" left="522" width="85" height="20" font="4"><b>Interventions: </b></text>
<text top="544" left="522" width="114" height="20" font="1">Education, Financial </text>
<text top="562" left="522" width="118" height="20" font="1">Incentives, Audit and </text>
<text top="579" left="522" width="128" height="20" font="1">Feedback; Intervention </text>
<text top="596" left="522" width="135" height="20" font="1">group pts received up to </text>
<text top="613" left="522" width="132" height="20" font="1">5 incentive payments in </text>
<text top="630" left="522" width="129" height="20" font="1">their paychecks ~every </text>
<text top="648" left="522" width="128" height="20" font="1">4 mo and were notified </text>
<text top="665" left="522" width="118" height="20" font="1">each time a payment </text>
<text top="682" left="522" width="69" height="20" font="1">was posted. </text>
<text top="699" left="522" width="7" height="20" font="1">  </text>
<text top="716" left="522" width="135" height="20" font="4"><b>Comparator:</b> 4 different </text>
<text top="734" left="522" width="136" height="20" font="1">groups,1 paid incentives </text>
<text top="751" left="522" width="120" height="20" font="1">at the practice level,1 </text>
<text top="768" left="522" width="119" height="20" font="1">paid incentives at the </text>
<text top="785" left="522" width="124" height="20" font="1">physician level, 1 paid </text>
<text top="528" left="673" width="153" height="20" font="4"><b>1</b>°<b> endpoint:</b> In unadjusted </text>
<text top="545" left="673" width="174" height="20" font="1">analyses, the percentage of pts </text>
<text top="563" left="673" width="159" height="20" font="1">either with controlled HTN or </text>
<text top="580" left="673" width="135" height="20" font="1">receiving an appropriate </text>
<text top="597" left="673" width="159" height="20" font="1">response increased for each </text>
<text top="614" left="673" width="137" height="20" font="1">incentive group between </text>
<text top="632" left="673" width="172" height="20" font="1">baseline and final performance </text>
<text top="649" left="673" width="144" height="20" font="1">period, 75% to 84% in the </text>
<text top="666" left="673" width="176" height="20" font="1">individual group, 80% to 85% in </text>
<text top="683" left="673" width="157" height="20" font="1">the practice group, and 79% </text>
<text top="700" left="673" width="167" height="20" font="1">to88% in the combined group. </text>
<text top="718" left="673" width="171" height="20" font="1">Performance did not change in </text>
<text top="735" left="673" width="135" height="20" font="1">control group, 86%. The </text>
<text top="752" left="673" width="161" height="20" font="1">adjusted estimated ab-solute </text>
<text top="769" left="673" width="178" height="20" font="1">change over the study of the pts </text>
<text top="786" left="673" width="159" height="20" font="1">meeting the combined BP or </text>
<text top="527" left="867" width="66" height="20" font="4"><b>Summary</b>:  </text>
<text top="546" left="867" width="7" height="18" font="1">•</text>
<text top="545" left="874" width="38" height="20" font="1"> Mean </text>
<text top="545" left="912" width="25" height="20" font="9">(SD)</text>
<text top="545" left="937" width="135" height="20" font="1"> total payments over the </text>
<text top="563" left="867" width="184" height="20" font="1">study were $4,270 ($459), $2672 </text>
<text top="580" left="867" width="185" height="20" font="1">($153), and $1,648 ($248) for the </text>
<text top="597" left="867" width="190" height="20" font="1">combined, individual, and practice-</text>
<text top="614" left="867" width="177" height="20" font="1">level interventions, respectively. </text>
<text top="632" left="867" width="200" height="20" font="1">Change in BP control or appropriate </text>
<text top="649" left="867" width="158" height="20" font="1">response to uncontrolled BP </text>
<text top="666" left="867" width="204" height="20" font="1">compared with the control group was </text>
<text top="683" left="867" width="169" height="20" font="1">significantly greater only in the </text>
<text top="700" left="867" width="198" height="20" font="1">individual incentives group. Change </text>
<text top="718" left="867" width="148" height="20" font="1">in guideline-recommended </text>
<text top="735" left="867" width="190" height="20" font="1">medication use was not significant </text>
<text top="752" left="867" width="183" height="20" font="1">compared with the control group. </text>
<text top="769" left="867" width="190" height="20" font="1">The effect of the incentive was not </text>
<text top="786" left="867" width="147" height="20" font="1">sustained after a washout. </text>
</page>
<page number="246" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">246 </text>
<text top="107" left="219" width="89" height="20" font="1">personnel (e.g., </text>
<text top="124" left="219" width="121" height="20" font="1">nurses, pharmacists). </text>
<text top="141" left="219" width="3" height="20" font="1"> </text>
<text top="159" left="219" width="120" height="20" font="4"><b>Main Outcomes and </b></text>
<text top="176" left="219" width="117" height="20" font="4"><b>Measures:</b> Among a </text>
<text top="193" left="219" width="92" height="20" font="1">random sample, </text>
<text top="210" left="219" width="79" height="20" font="1">number of pts </text>
<text top="228" left="219" width="108" height="20" font="1">achieving guideline-</text>
<text top="245" left="219" width="102" height="20" font="1">recommended BP </text>
<text top="262" left="219" width="127" height="20" font="1">thresholds or receiving </text>
<text top="279" left="219" width="83" height="20" font="1">an appropriate </text>
<text top="296" left="219" width="68" height="20" font="1">response to </text>
<text top="314" left="219" width="94" height="20" font="1">uncontrolled BP, </text>
<text top="331" left="219" width="79" height="20" font="1">number of pts </text>
<text top="348" left="219" width="114" height="20" font="1">prescribed guideline-</text>
<text top="365" left="219" width="82" height="20" font="1">recommended </text>
<text top="383" left="219" width="96" height="20" font="1">medications, and </text>
<text top="400" left="219" width="131" height="20" font="1">number who developed </text>
<text top="417" left="219" width="73" height="20" font="1">hypotension. </text>
<text top="107" left="522" width="124" height="20" font="1">for both levels and the </text>
<text top="124" left="522" width="7" height="20" font="1">4</text>
<text top="126" left="529" width="7" height="13" font="6">th</text>
<text top="124" left="536" width="109" height="20" font="1"> paid no incentives. </text>
<text top="141" left="522" width="115" height="20" font="1">(19–20 physicians in </text>
<text top="159" left="522" width="69" height="20" font="1">each group)<b> </b></text>
<text top="107" left="673" width="171" height="20" font="1">appropriate response measure </text>
<text top="124" left="673" width="156" height="20" font="1">was 8.84% (95% CI: 4.20%–</text>
<text top="141" left="673" width="180" height="20" font="1">11.80%) for the individual group, </text>
<text top="159" left="673" width="173" height="20" font="1">3.70% (95% CI: 0.24%, 7.68%) </text>
<text top="176" left="673" width="161" height="20" font="1">for the practice group, 5.54% </text>
<text top="193" left="673" width="174" height="20" font="1">(95% CI: 1.92%–9.52%) for the </text>
<text top="210" left="673" width="157" height="20" font="1">combined group, and 0.47% </text>
<text top="228" left="673" width="181" height="20" font="1">(95% CI: −3.12%–4.04%) for the </text>
<text top="245" left="673" width="153" height="20" font="1">control group. The adjusted </text>
<text top="262" left="673" width="164" height="20" font="1">estimated absolute difference </text>
<text top="279" left="673" width="158" height="20" font="1">over the study in the change </text>
<text top="296" left="673" width="163" height="20" font="1">between the proportion of the </text>
<text top="314" left="673" width="158" height="20" font="1">physician’s pts achieving BP </text>
<text top="331" left="673" width="124" height="20" font="1">control or receiving an </text>
<text top="348" left="673" width="158" height="20" font="1">appropriate response for the </text>
<text top="365" left="673" width="165" height="20" font="1">individual incentive group and </text>
<text top="383" left="673" width="163" height="20" font="1">the controls was 8.36% (95% </text>
<text top="400" left="673" width="165" height="20" font="1">CI: 2.40%–13.00%; p=0.005). </text>
<text top="417" left="673" width="3" height="20" font="1"> </text>
<text top="435" left="673" width="140" height="20" font="4"><b>1</b>°<b> Safety endpoint: </b>N/A </text>
<text top="109" left="867" width="7" height="18" font="1">•</text>
<text top="108" left="874" width="197" height="20" font="1"> Financial incentives may constitute </text>
<text top="125" left="867" width="206" height="20" font="1">an insufficiently strong intervention to </text>
<text top="143" left="867" width="182" height="20" font="1">influence goal commitment when </text>
<text top="160" left="867" width="188" height="20" font="1">providers attribute performance to </text>
<text top="177" left="867" width="199" height="20" font="1">external forces beyond their control. </text>
<text top="453" left="98" width="100" height="20" font="1">Karunaratne K, et </text>
<text top="470" left="98" width="83" height="20" font="1">al., 2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(343)</a> </text>
<text top="488" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23658247?dopt=Citation">23658247</a></text>
<text top="488" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23658247?dopt=Citation"> </a></text>
<text top="453" left="219" width="115" height="20" font="4"><b>Aim:</b> The aim of this </text>
<text top="470" left="219" width="121" height="20" font="1">study was to evaluate </text>
<text top="488" left="219" width="109" height="20" font="1">the effectiveness of </text>
<text top="505" left="219" width="87" height="20" font="1">renal indicators </text>
<text top="522" left="219" width="124" height="20" font="1">outlined in P4P on the </text>
<text top="539" left="219" width="130" height="20" font="1">management of HTN in </text>
<text top="557" left="219" width="93" height="20" font="1">primary care. To </text>
<text top="574" left="219" width="96" height="20" font="1">estimate the cost </text>
<text top="591" left="219" width="102" height="20" font="1">implications of the </text>
<text top="608" left="219" width="113" height="20" font="1">resulting changes in </text>
<text top="625" left="219" width="125" height="20" font="1">prescribing patterns of </text>
<text top="643" left="219" width="93" height="20" font="1">antihypertensive </text>
<text top="660" left="219" width="114" height="20" font="1">medication following </text>
<text top="677" left="219" width="110" height="20" font="1">introduction of such </text>
<text top="694" left="219" width="60" height="20" font="1">indicators. </text>
<text top="711" left="219" width="3" height="20" font="1"> </text>
<text top="729" left="219" width="71" height="20" font="4"><b>Study type:</b> </text>
<text top="746" left="219" width="105" height="20" font="1">Prospective cohort </text>
<text top="763" left="219" width="107" height="20" font="1">study using a large </text>
<text top="780" left="219" width="129" height="20" font="1">primary care database. </text>
<text top="453" left="363" width="144" height="20" font="4"><b>Inclusion criteria:</b> A total </text>
<text top="470" left="363" width="98" height="20" font="1">of 10,040 pts had </text>
<text top="488" left="363" width="144" height="20" font="1">confirmed stage 3–5 CKD </text>
<text top="505" left="363" width="129" height="20" font="1">in the 2 y pre-QOF and </text>
<text top="522" left="363" width="136" height="20" font="1">formed the study cohort. </text>
<text top="539" left="363" width="3" height="20" font="1"> </text>
<text top="557" left="363" width="146" height="20" font="4"><b>Exclusion criteria:</b> None  </text>
<text top="453" left="522" width="103" height="20" font="4"><b>Intervention:</b> The </text>
<text top="470" left="522" width="100" height="20" font="1">implementation of </text>
<text top="488" left="522" width="132" height="20" font="1">national estimated GFR </text>
<text top="505" left="522" width="96" height="20" font="1">reporting and the </text>
<text top="522" left="522" width="96" height="20" font="1">inclusion of renal-</text>
<text top="539" left="522" width="124" height="20" font="1">specific indicators in a </text>
<text top="557" left="522" width="98" height="20" font="1">primary care P4P </text>
<text top="574" left="522" width="133" height="20" font="1">system since April 2006 </text>
<text top="591" left="522" width="79" height="20" font="1">has promoted </text>
<text top="608" left="522" width="130" height="20" font="1">identification and better </text>
<text top="625" left="522" width="111" height="20" font="1">management of risk </text>
<text top="643" left="522" width="128" height="20" font="1">factors related to CKD. </text>
<text top="660" left="522" width="105" height="20" font="1">In the UK, the P4P </text>
<text top="677" left="522" width="128" height="20" font="1">framework is known as </text>
<text top="694" left="522" width="54" height="20" font="1">the QOF. </text>
<text top="711" left="522" width="7" height="20" font="1">  </text>
<text top="729" left="522" width="101" height="20" font="4"><b>Comparator:</b> N/A<b> </b></text>
<text top="455" left="673" width="7" height="18" font="1">•</text>
<text top="454" left="680" width="168" height="20" font="1"> Mean age of the cohort at the </text>
<text top="472" left="673" width="157" height="20" font="1">start of the study period was </text>
<text top="489" left="673" width="156" height="20" font="1">64.8 y, 55% were female. In </text>
<text top="506" left="673" width="165" height="20" font="1">those pts with stage 3–5 CKD </text>
<text top="523" left="673" width="145" height="20" font="1">83.9% were hypertensive, </text>
<text top="540" left="673" width="152" height="20" font="1">defined by a pre-P4P BP of </text>
<text top="558" left="673" width="149" height="20" font="1">&gt;140/85 or currently taking </text>
<text top="575" left="673" width="159" height="20" font="1">antihypertensive medication. </text>
<text top="592" left="673" width="171" height="20" font="1">The proportion of pts with CKD </text>
<text top="609" left="673" width="163" height="20" font="1">3–5 attaining the BP target of </text>
<text top="627" left="673" width="177" height="20" font="1">145/80 increased from 41.5% in </text>
<text top="644" left="673" width="175" height="20" font="1">the pre-QOF period to 50.0% in </text>
<text top="661" left="673" width="146" height="20" font="1">the post-QOF period. This </text>
<text top="678" left="673" width="181" height="20" font="1">increase was even more marked </text>
<text top="695" left="673" width="161" height="20" font="1">for those with HTN in the pre-</text>
<text top="713" left="673" width="173" height="20" font="1">QOF period (28.8%–45.1%). In </text>
<text top="730" left="673" width="171" height="20" font="1">the hypertensive pts, mean BP </text>
<text top="747" left="673" width="145" height="20" font="1">fell from 146/79 mm Hg to </text>
<text top="764" left="673" width="172" height="20" font="1">140/76 in the first 2 y post-P4P </text>
<text top="781" left="673" width="166" height="20" font="1">[p&lt;0.01, analysis of variance]. </text>
<text top="453" left="867" width="185" height="20" font="4"><b>Summary</b>: Population BP control </text>
<text top="470" left="867" width="197" height="20" font="1">has improved since the introduction </text>
<text top="488" left="867" width="177" height="20" font="1">of P4P renal indicators, and this </text>
<text top="505" left="867" width="188" height="20" font="1">improvement has been sustained. </text>
<text top="522" left="867" width="150" height="20" font="1">This was associated with a </text>
<text top="539" left="867" width="178" height="20" font="1">significant increase in the use of </text>
<text top="557" left="867" width="159" height="20" font="1">antihypertensive medication, </text>
<text top="574" left="867" width="187" height="20" font="1">resulting in increased prescription </text>
<text top="591" left="867" width="173" height="20" font="1">cost. Longer-term follow-up will </text>
<text top="608" left="867" width="156" height="20" font="1">establish whether or not this </text>
<text top="625" left="867" width="194" height="20" font="1">translates to improved outcomes in </text>
<text top="643" left="867" width="191" height="20" font="1">terms of progression of CKD, CVD </text>
<text top="660" left="867" width="91" height="20" font="1">and pt mortality. </text>
<text top="677" left="867" width="3" height="20" font="1"> </text>
</page>
<page number="247" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">247 </text>
<text top="107" left="219" width="123" height="20" font="1">This cohort was taken </text>
<text top="124" left="219" width="92" height="20" font="1">from a database </text>
<text top="141" left="219" width="111" height="20" font="1">collated as part of a </text>
<text top="159" left="219" width="89" height="20" font="1">clinical decision </text>
<text top="176" left="219" width="130" height="20" font="1">support system used to </text>
<text top="193" left="219" width="131" height="20" font="1">assist the management </text>
<text top="210" left="219" width="131" height="20" font="1">of CKD in primary care. </text>
<text top="227" left="219" width="3" height="20" font="1"> </text>
<text top="245" left="219" width="110" height="20" font="4"><b>Size:</b> 90,250 pts on </text>
<text top="262" left="219" width="109" height="20" font="1">general practitioner </text>
<text top="279" left="219" width="115" height="20" font="1">registers with a valid </text>
<text top="296" left="219" width="94" height="20" font="1">serum creatinine </text>
<text top="314" left="219" width="113" height="20" font="1">estimation in the 6-y </text>
<text top="331" left="219" width="126" height="20" font="1">study period. A total of </text>
<text top="348" left="219" width="85" height="20" font="1">10 040 pts had </text>
<text top="365" left="219" width="115" height="20" font="1">confirmed stage 3–5 </text>
<text top="383" left="219" width="105" height="20" font="1">CKD in the 2 y pre-</text>
<text top="400" left="219" width="116" height="20" font="1">QOF and formed the </text>
<text top="417" left="219" width="74" height="20" font="1">study cohort. </text>
<text top="107" left="673" width="168" height="20" font="1">BP reduction was sustained in </text>
<text top="124" left="673" width="174" height="20" font="1">the last 2 y of the study, 139/75 </text>
<text top="141" left="673" width="168" height="20" font="1">(p&lt;0.01, analysis of variance). </text>
<text top="159" left="673" width="170" height="20" font="1">The proportion of hypertensive </text>
<text top="176" left="673" width="175" height="20" font="1">pts taking ACEIs or angiotensin </text>
<text top="193" left="673" width="157" height="20" font="1">blockers increased, this was </text>
<text top="210" left="673" width="169" height="20" font="1">also sustained in the third time </text>
<text top="228" left="673" width="143" height="20" font="1">period. An increase in the </text>
<text top="245" left="673" width="165" height="20" font="1">prescribing of diuretics, CCBs </text>
<text top="262" left="673" width="158" height="20" font="1">and BBs was also observed. </text>
<text top="279" left="673" width="177" height="20" font="1">The additional cost of increased </text>
<text top="296" left="673" width="178" height="20" font="1">prescribing was calculated to be </text>
<text top="314" left="673" width="170" height="20" font="1">euro 25.00 per hypertensive pt </text>
<text top="331" left="673" width="173" height="20" font="1">based on GP prescription data.<b> </b></text>
<text top="435" left="98" width="89" height="20" font="1">Serumaga B, et </text>
<text top="452" left="98" width="83" height="20" font="1">al., 2011 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(344)</a> </text>
<text top="469" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21266440?dopt=Citation">21266440</a></text>
<text top="469" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21266440?dopt=Citation"> </a></text>
<text top="435" left="219" width="115" height="20" font="4"><b>Aim:</b> The aim of this </text>
<text top="452" left="219" width="121" height="20" font="1">study was to evaluate </text>
<text top="469" left="219" width="109" height="20" font="1">the effectiveness of </text>
<text top="487" left="219" width="87" height="20" font="1">renal indicators </text>
<text top="504" left="219" width="124" height="20" font="1">outlined in P4P on the </text>
<text top="521" left="219" width="130" height="20" font="1">management of HTN in </text>
<text top="538" left="219" width="93" height="20" font="1">primary care. To </text>
<text top="555" left="219" width="96" height="20" font="1">estimate the cost </text>
<text top="573" left="219" width="102" height="20" font="1">implications of the </text>
<text top="590" left="219" width="113" height="20" font="1">resulting changes in </text>
<text top="607" left="219" width="125" height="20" font="1">prescribing patterns of </text>
<text top="624" left="219" width="93" height="20" font="1">antihypertensive </text>
<text top="641" left="219" width="114" height="20" font="1">medication following </text>
<text top="659" left="219" width="110" height="20" font="1">introduction of such </text>
<text top="676" left="219" width="60" height="20" font="1">indicators. </text>
<text top="693" left="219" width="3" height="20" font="1"> </text>
<text top="710" left="219" width="71" height="20" font="4"><b>Study type: </b></text>
<text top="727" left="219" width="126" height="20" font="1">Interrupted time series </text>
<text top="745" left="219" width="36" height="20" font="1">study  </text>
<text top="762" left="219" width="3" height="20" font="1"> </text>
<text top="435" left="363" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="452" left="363" width="114" height="20" font="1">with HTN diagnosed </text>
<text top="469" left="363" width="139" height="20" font="1">between Jan. 2000–Aug. </text>
<text top="487" left="363" width="34" height="20" font="1">2007. </text>
<text top="504" left="363" width="3" height="20" font="1"> </text>
<text top="521" left="363" width="146" height="20" font="4"><b>Exclusion criteria:</b> None <b> </b></text>
<text top="435" left="522" width="123" height="20" font="4"><b>Intervention:</b> The UK </text>
<text top="452" left="522" width="103" height="20" font="1">P4P incentive (the </text>
<text top="469" left="522" width="125" height="20" font="1">Quality and Outcomes </text>
<text top="487" left="522" width="132" height="20" font="1">Framework), which was </text>
<text top="504" left="522" width="115" height="20" font="1">implemented in April </text>
<text top="521" left="522" width="104" height="20" font="1">2004 and included </text>
<text top="538" left="522" width="103" height="20" font="1">specific targets for </text>
<text top="555" left="522" width="129" height="20" font="1">general practitioners to </text>
<text top="573" left="522" width="125" height="20" font="1">show high quality care </text>
<text top="590" left="522" width="120" height="20" font="1">for pts with HTN (and </text>
<text top="607" left="522" width="91" height="20" font="1">other diseases). </text>
<text top="624" left="522" width="7" height="20" font="1">  </text>
<text top="641" left="522" width="113" height="20" font="4"><b>Comparator: </b>None<b>  </b></text>
<text top="437" left="673" width="7" height="18" font="1">•</text>
<text top="436" left="680" width="157" height="20" font="1"> After accounting for secular </text>
<text top="453" left="673" width="141" height="20" font="1">trends, no changes in BP </text>
<text top="470" left="673" width="167" height="20" font="1">monitoring: level change: 0.85 </text>
<text top="488" left="673" width="172" height="20" font="1">(95% CI: −3.04–4.74), p=0.669 </text>
<text top="505" left="673" width="173" height="20" font="1">and trend change: −0.01, (95% </text>
<text top="522" left="673" width="144" height="20" font="1">CI: −0.24–0.21), p=0.615, </text>
<text top="539" left="673" width="164" height="20" font="1">control: −1.19 (95% CI: -2.06–</text>
<text top="557" left="673" width="174" height="20" font="1">1.09), p=0.109 and −0.01 (95% </text>
<text top="574" left="673" width="158" height="20" font="1">CI: −0.06–0.03), p=0.569, or </text>
<text top="591" left="673" width="170" height="20" font="1">treatment intensity; 0.67: (95% </text>
<text top="608" left="673" width="164" height="20" font="1">CI: −1.27–2.81), p=0.412 and </text>
<text top="625" left="673" width="147" height="20" font="1">0.02 (95% CI: −0.23–0.19, </text>
<text top="643" left="673" width="156" height="20" font="1">p=0.706 were attributable to </text>
<text top="660" left="673" width="169" height="20" font="1">P4P. P4P had no effect on the </text>
<text top="677" left="673" width="172" height="20" font="1">cumulative incidence of stroke, </text>
<text top="694" left="673" width="146" height="20" font="1">MI, renal failure, HF, or all-</text>
<text top="711" left="673" width="126" height="20" font="1">cause mortality in both </text>
<text top="729" left="673" width="156" height="20" font="1">treatments experienced and </text>
<text top="746" left="673" width="141" height="20" font="1">newly treated subgroups. </text>
<text top="435" left="867" width="194" height="20" font="4"><b>Summary</b>: Good quality of care for </text>
<text top="452" left="867" width="200" height="20" font="1">HTN was stable or improving before </text>
<text top="469" left="867" width="184" height="20" font="1">P4P was introduced. P4P had no </text>
<text top="487" left="867" width="192" height="20" font="1">discernible effects on processes of </text>
<text top="504" left="867" width="169" height="20" font="1">care or on HTN related clinical </text>
<text top="521" left="867" width="166" height="20" font="1">outcomes. Generous financial </text>
<text top="538" left="867" width="185" height="20" font="1">incentives, as designed in the UK </text>
<text top="555" left="867" width="195" height="20" font="1">P4P policy, may not be sufficient to </text>
<text top="573" left="867" width="151" height="20" font="1">improve quality of care and </text>
<text top="590" left="867" width="159" height="20" font="1">outcomes for HTN and other </text>
<text top="607" left="867" width="156" height="20" font="1">common chronic conditions. </text>
</page>
<page number="248" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">248 </text>
<text top="107" left="219" width="125" height="20" font="4"><b>Size:</b> 470,725 pts with </text>
<text top="124" left="219" width="89" height="20" font="1">HTN diagnosed </text>
<text top="141" left="219" width="107" height="20" font="1">between Jan 2000–</text>
<text top="159" left="219" width="60" height="20" font="1">Aug 2007.<b> </b></text>
<text top="177" left="98" width="107" height="20" font="1">Bardach NS, et al., </text>
<text top="194" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(327)</a> </text>
<text top="211" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24026600?dopt=Citation">24026600</a></text>
<text top="211" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24026600?dopt=Citation"> </a></text>
<text top="177" left="219" width="111" height="20" font="4"><b>Aim: </b>To assess the </text>
<text top="194" left="219" width="74" height="20" font="1">effect of P4P </text>
<text top="211" left="219" width="127" height="20" font="1">incentives on quality in </text>
<text top="228" left="219" width="109" height="20" font="1">EHR-enabled small </text>
<text top="246" left="219" width="129" height="20" font="1">practices in the context </text>
<text top="263" left="219" width="113" height="20" font="1">of an established QI </text>
<text top="280" left="219" width="51" height="20" font="1">initiative. </text>
<text top="297" left="219" width="3" height="20" font="1"> </text>
<text top="314" left="219" width="126" height="20" font="4"><b>Study Type &amp; Size: </b>A </text>
<text top="332" left="219" width="131" height="20" font="1">cluster-randomized trial </text>
<text top="349" left="219" width="74" height="20" font="1">of small (&lt;10 </text>
<text top="366" left="219" width="129" height="20" font="1">clinicians) primary care </text>
<text top="383" left="219" width="131" height="20" font="1">clinics in New York City </text>
<text top="400" left="219" width="128" height="20" font="1">from April 2009–March </text>
<text top="418" left="219" width="38" height="20" font="1">2010. <b> </b></text>
<text top="178" left="363" width="7" height="18" font="1">•</text>
<text top="178" left="370" width="112" height="20" font="1"> Participating clinics </text>
<text top="195" left="363" width="146" height="20" font="1">(n=42 for each group) had </text>
<text top="212" left="363" width="88" height="20" font="1">similar baseline </text>
<text top="229" left="363" width="121" height="20" font="1">characteristics, with a </text>
<text top="247" left="363" width="133" height="20" font="1">mean of 4,592 (median, </text>
<text top="264" left="363" width="92" height="20" font="1">2,500) pts at the </text>
<text top="281" left="363" width="139" height="20" font="1">intervention group clinics </text>
<text top="298" left="363" width="109" height="20" font="1">and 3,042 (median, </text>
<text top="316" left="363" width="113" height="20" font="1">2,000) at the control </text>
<text top="333" left="363" width="75" height="20" font="1">group clinics.<b> </b></text>
<text top="178" left="522" width="7" height="18" font="1">•</text>
<text top="178" left="529" width="86" height="20" font="1"> A city program </text>
<text top="195" left="522" width="136" height="20" font="1">provided all participating </text>
<text top="212" left="522" width="116" height="20" font="1">clinics with the same </text>
<text top="229" left="522" width="104" height="20" font="1">EHR software with </text>
<text top="247" left="522" width="131" height="20" font="1">decision support and pt </text>
<text top="264" left="522" width="121" height="20" font="1">registry functionalities </text>
<text top="281" left="522" width="100" height="20" font="1">and QI specialists </text>
<text top="298" left="522" width="96" height="20" font="1">offering technical </text>
<text top="316" left="522" width="65" height="20" font="1">assistance. </text>
<text top="335" left="522" width="7" height="18" font="1">•</text>
<text top="334" left="529" width="109" height="20" font="1"> Incentivized clinics </text>
<text top="351" left="522" width="118" height="20" font="1">were paid for each pt </text>
<text top="368" left="522" width="111" height="20" font="1">whose care met the </text>
<text top="386" left="522" width="137" height="20" font="1">performance criteria, but </text>
<text top="403" left="522" width="114" height="20" font="1">they received higher </text>
<text top="420" left="522" width="120" height="20" font="1">payments for pts with </text>
<text top="437" left="522" width="129" height="20" font="1">comorbidities, who had </text>
<text top="454" left="522" width="127" height="20" font="1">Medicaid insurance, or </text>
<text top="472" left="522" width="113" height="20" font="1">who were uninsured </text>
<text top="489" left="522" width="121" height="20" font="1">(maximum payments: </text>
<text top="506" left="522" width="134" height="20" font="1">$200/pt; 100,000/clinic). </text>
<text top="523" left="522" width="113" height="20" font="1">Quality reports were </text>
<text top="540" left="522" width="125" height="20" font="1">given quarterly to both </text>
<text top="558" left="522" width="111" height="20" font="1">the intervention and </text>
<text top="575" left="522" width="85" height="20" font="1">control groups.<b> </b></text>
<text top="178" left="673" width="7" height="18" font="1">•</text>
<text top="178" left="680" width="174" height="20" font="1"> Intervention clinics had greater </text>
<text top="195" left="673" width="174" height="20" font="1">adjusted absolute improvement </text>
<text top="212" left="673" width="123" height="20" font="1">in rates of appropriate </text>
<text top="229" left="673" width="148" height="20" font="1">antithrombotic prescription </text>
<text top="247" left="673" width="153" height="20" font="1">12.0% vs. 6.1%, difference: </text>
<text top="264" left="673" width="152" height="20" font="1">6.0% (95% CI: 2.2%–9.7%; </text>
<text top="281" left="673" width="181" height="20" font="1">p=0.001 for interaction term), BP </text>
<text top="298" left="673" width="176" height="20" font="1">control (no comorbidities): 9.7% </text>
<text top="316" left="673" width="178" height="20" font="1">vs. 4.3%, difference: 5.5% (95% </text>
<text top="333" left="673" width="148" height="20" font="1">CI: 1.6%–9.3%; p=0.01 for </text>
<text top="350" left="673" width="178" height="20" font="1">interaction term); with DM: 9.0% </text>
<text top="367" left="673" width="178" height="20" font="1">vs. 1.2%, difference: 7.8% (95% </text>
<text top="384" left="673" width="162" height="20" font="1">CI: 3.2%–12.4%; p=0.007 for </text>
<text top="402" left="673" width="158" height="20" font="1">interaction term); with DM or </text>
<text top="419" left="673" width="181" height="20" font="1">ischemic vascular disease: 9.5% </text>
<text top="436" left="673" width="178" height="20" font="1">vs. 1.7%, difference: 7.8% (95% </text>
<text top="453" left="673" width="148" height="20" font="1">CI: 3.0%–2.6%; p=0.01 for </text>
<text top="470" left="673" width="133" height="20" font="1">interaction term), and in </text>
<text top="488" left="673" width="178" height="20" font="1">smoking cessation interventions </text>
<text top="505" left="673" width="161" height="20" font="1">(12.4% vs. 7.7%), difference: </text>
<text top="522" left="673" width="159" height="20" font="1">4.7% (95% CI: −0.3%–9.6%; </text>
<text top="539" left="673" width="155" height="20" font="1">p=0.02 for interaction term). </text>
<text top="557" left="673" width="164" height="20" font="1">Intervention clinics performed </text>
<text top="574" left="673" width="143" height="20" font="1">better on all measures for </text>
<text top="591" left="673" width="154" height="20" font="1">Medicaid and uninsured pts </text>
<text top="608" left="673" width="167" height="20" font="1">except cholesterol control, but </text>
<text top="625" left="673" width="174" height="20" font="1">no differences were statistically </text>
<text top="643" left="673" width="62" height="20" font="1">significant. </text>
<text top="177" left="867" width="205" height="20" font="4"><b>Summary</b>: In our study, although the </text>
<text top="194" left="867" width="193" height="20" font="1">effect of the intervention was lower </text>
<text top="211" left="867" width="194" height="20" font="1">than the 10% improvement that we </text>
<text top="228" left="867" width="194" height="20" font="1">estimated a priori, the absolute risk </text>
<text top="246" left="867" width="193" height="20" font="1">reduction for BP control among pts </text>
<text top="263" left="867" width="192" height="20" font="1">with DM was 7.8% (NNT, 13). This </text>
<text top="280" left="867" width="168" height="20" font="1">suggests that, for every 13 pts </text>
<text top="297" left="867" width="206" height="20" font="1">seeing incentivized clinicians, 1 more </text>
<text top="314" left="867" width="183" height="20" font="1">pt would achieve BP control. The </text>
<text top="332" left="867" width="198" height="20" font="1">7.8% absolute change in BP control </text>
<text top="349" left="867" width="185" height="20" font="1">for pts with DM represents a 46% </text>
<text top="366" left="867" width="166" height="20" font="1">relative increase in BP control </text>
<text top="383" left="867" width="186" height="20" font="1">among intervention pts compared </text>
<text top="401" left="867" width="194" height="20" font="1">with the baseline of 16.8%. Further </text>
<text top="418" left="867" width="180" height="20" font="1">research is needed to determine </text>
<text top="435" left="867" width="164" height="20" font="1">whether this effect of the P4P </text>
<text top="452" left="867" width="200" height="20" font="1">intervention on BP control increases </text>
<text top="469" left="867" width="187" height="20" font="1">or decreases over time. However, </text>
<text top="487" left="867" width="171" height="20" font="1">this NNT to achieve BP control </text>
<text top="504" left="867" width="189" height="20" font="1">through incentives, taken together </text>
<text top="521" left="867" width="182" height="20" font="1">with the large relative increase in </text>
<text top="538" left="867" width="184" height="20" font="1">percentage of pts with BP control </text>
<text top="555" left="867" width="202" height="20" font="1">and the potential effect of BP control </text>
<text top="573" left="867" width="197" height="20" font="1">on risk of ischemic vascular events, </text>
<text top="590" left="867" width="205" height="20" font="1">suggests a reasonable opportunity to </text>
<text top="607" left="867" width="168" height="20" font="1">reduce morbidity and mortality </text>
<text top="624" left="867" width="182" height="20" font="1">through P4P as structured in this </text>
<text top="641" left="867" width="36" height="20" font="1">study. </text>
<text top="659" left="867" width="3" height="20" font="1"> </text>
<text top="676" left="867" width="202" height="20" font="4"><b>Limitations: </b>Some clinics exited the </text>
<text top="693" left="867" width="187" height="20" font="1">program after randomization, with </text>
<text top="710" left="867" width="178" height="20" font="1">more control clinics leaving than </text>
<text top="727" left="867" width="200" height="20" font="1">intervention clinics. Additionally, this </text>
<text top="745" left="867" width="205" height="20" font="1">intervention occurred in the setting of </text>
<text top="762" left="867" width="186" height="20" font="1">a voluntary QI program. This may </text>
<text top="779" left="867" width="161" height="20" font="1">reflect a high level of intrinsic </text>
</page>
<page number="249" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">249 </text>
<text top="107" left="867" width="161" height="20" font="1">motivation to improve among </text>
<text top="124" left="867" width="139" height="20" font="1">practices in the study, as </text>
<text top="141" left="867" width="192" height="20" font="1">demonstrated by engagement with </text>
<text top="159" left="867" width="97" height="20" font="1">the QI specialists<b> </b></text>
<text top="177" left="98" width="105" height="20" font="1">Maimaris W, et al., </text>
<text top="194" left="98" width="63" height="20" font="1">2013 <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(345)</a> </text>
<text top="211" left="98" width="55" height="20" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23935461?dopt=Citation">23935461</a></text>
<text top="211" left="152" width="3" height="20" font="1"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23935461?dopt=Citation"> </a></text>
<text top="177" left="219" width="90" height="20" font="4"><b>Aim:</b> To assess </text>
<text top="194" left="219" width="75" height="20" font="1">strategies for </text>
<text top="211" left="219" width="118" height="20" font="1">influencing HTN care </text>
<text top="228" left="219" width="124" height="20" font="1">including procurement </text>
<text top="246" left="219" width="66" height="20" font="1">of essential </text>
<text top="263" left="219" width="93" height="20" font="1">medications, the </text>
<text top="280" left="219" width="108" height="20" font="1">existence of simple </text>
<text top="297" left="219" width="123" height="20" font="1">national guidelines for </text>
<text top="314" left="219" width="107" height="20" font="1">HTN management, </text>
<text top="332" left="219" width="129" height="20" font="1">introduction of financial </text>
<text top="349" left="219" width="113" height="20" font="1">incentives for health </text>
<text top="366" left="219" width="111" height="20" font="1">care practitioners to </text>
<text top="383" left="219" width="128" height="20" font="1">diagnose or treat HTN, </text>
<text top="401" left="219" width="118" height="20" font="1">and enhanced health </text>
<text top="418" left="219" width="114" height="20" font="1">insurance coverage. </text>
<text top="435" left="219" width="3" height="20" font="1"> </text>
<text top="452" left="219" width="70" height="20" font="4"><b>Study type</b>: </text>
<text top="469" left="219" width="102" height="20" font="1">Systematic review </text>
<text top="487" left="219" width="127" height="20" font="1">examining the effect of </text>
<text top="504" left="219" width="108" height="20" font="1">national or regional </text>
<text top="521" left="219" width="79" height="20" font="1">health system </text>
<text top="538" left="219" width="125" height="20" font="1">arrangements on HTN </text>
<text top="555" left="219" width="92" height="20" font="1">care and control </text>
<text top="177" left="363" width="139" height="20" font="4"><b>Study selection criteria </b></text>
<text top="194" left="363" width="105" height="20" font="4"><b>based on:</b> 1) HTN </text>
<text top="211" left="363" width="128" height="20" font="1">awareness. Defined as </text>
<text top="228" left="363" width="94" height="20" font="1">pts with clinically </text>
<text top="246" left="363" width="137" height="20" font="1">measured hypertensives </text>
<text top="263" left="363" width="87" height="20" font="1">who have been </text>
<text top="280" left="363" width="124" height="20" font="1">diagnosed by a health </text>
<text top="297" left="363" width="113" height="20" font="1">care professional as </text>
<text top="314" left="363" width="120" height="20" font="1">hypertensive. 2) HTN </text>
<text top="332" left="363" width="141" height="20" font="1">treatment. Defined as the </text>
<text top="349" left="363" width="90" height="20" font="1">use of at least 1 </text>
<text top="366" left="363" width="93" height="20" font="1">antihypertensive </text>
<text top="383" left="363" width="125" height="20" font="1">medication in a pt with </text>
<text top="401" left="363" width="85" height="20" font="1">known HTN. 3) </text>
<text top="418" left="363" width="94" height="20" font="1">Antihypertensive </text>
<text top="435" left="363" width="128" height="20" font="1">medication adherence. </text>
<text top="452" left="363" width="130" height="20" font="1">Defined as consistently </text>
<text top="469" left="363" width="57" height="20" font="1">taking the </text>
<text top="487" left="363" width="93" height="20" font="1">antihypertensive </text>
<text top="504" left="363" width="127" height="20" font="1">medication regimen as </text>
<text top="521" left="363" width="135" height="20" font="1">prescribed by the health </text>
<text top="538" left="363" width="122" height="20" font="1">care provider. 4) HTN </text>
<text top="555" left="363" width="124" height="20" font="1">control: defined as the </text>
<text top="573" left="363" width="87" height="20" font="1">achievement of </text>
<text top="590" left="363" width="126" height="20" font="1">BP&lt;140/90 mm Hg (or </text>
<text top="607" left="363" width="125" height="20" font="1">other explicitly defined </text>
<text top="624" left="363" width="132" height="20" font="1">threshold) in individuals </text>
<text top="641" left="363" width="143" height="20" font="1">being treated for HTN, or, </text>
<text top="659" left="363" width="131" height="20" font="1">alternatively, measured </text>
<text top="676" left="363" width="141" height="20" font="1">by the mean BP amongst </text>
<text top="693" left="363" width="118" height="20" font="1">individuals with HTN. </text>
<text top="178" left="522" width="7" height="18" font="1">•</text>
<text top="178" left="529" width="85" height="20" font="1"> The screening </text>
<text top="195" left="522" width="115" height="20" font="1">process is described </text>
<text top="212" left="522" width="98" height="20" font="1">using an adapted </text>
<text top="229" left="522" width="107" height="20" font="1">PRISMA flowchart. </text>
<text top="247" left="522" width="107" height="20" font="1">5,514 articles were </text>
<text top="264" left="522" width="117" height="20" font="1">screened by title and </text>
<text top="281" left="522" width="120" height="20" font="1">abstract for inclusion. </text>
<text top="298" left="522" width="118" height="20" font="1">The full text of 122 of </text>
<text top="316" left="522" width="122" height="20" font="1">the 5,514 articles was </text>
<text top="333" left="522" width="130" height="20" font="1">obtained and assessed </text>
<text top="350" left="522" width="130" height="20" font="1">for eligibility. 53 studies </text>
<text top="367" left="522" width="132" height="20" font="1">met eligibility criteria for </text>
<text top="384" left="522" width="116" height="20" font="1">this review. 51 of the </text>
<text top="402" left="522" width="121" height="20" font="1">included studies were </text>
<text top="419" left="522" width="131" height="20" font="1">quantitative and 2 were </text>
<text top="436" left="522" width="116" height="20" font="1">qualitative. Of the 51 </text>
<text top="453" left="522" width="122" height="20" font="1">quantitative studies, 1 </text>
<text top="470" left="522" width="121" height="20" font="1">was an RCT; 12 were </text>
<text top="488" left="522" width="107" height="20" font="1">cohort studies, 2 of </text>
<text top="505" left="522" width="65" height="20" font="1">which were </text>
<text top="522" left="522" width="118" height="20" font="1">retrospective; 3 were </text>
<text top="539" left="522" width="133" height="20" font="1">case-control studies; 32 </text>
<text top="557" left="522" width="115" height="20" font="1">were cross-sectional </text>
<text top="574" left="522" width="110" height="20" font="1">studies; and 3 were </text>
<text top="591" left="522" width="135" height="20" font="1">ecological studies. 42 of </text>
<text top="608" left="522" width="116" height="20" font="1">the 53 studies (79%) </text>
<text top="625" left="522" width="105" height="20" font="1">were carried out in </text>
<text top="643" left="522" width="124" height="20" font="1">countries classified by </text>
<text top="660" left="522" width="131" height="20" font="1">the World Bank as high-</text>
<text top="677" left="522" width="131" height="20" font="1">income countries, 36 of </text>
<text top="694" left="522" width="136" height="20" font="1">which were in the U.S. 6 </text>
<text top="712" left="522" width="134" height="20" font="1">studies were carried out </text>
<text top="729" left="522" width="131" height="20" font="1">in upper middle-income </text>
<text top="746" left="522" width="113" height="20" font="1">countries, 3 in lower </text>
<text top="763" left="522" width="83" height="20" font="1">middle-income </text>
<text top="178" left="673" width="7" height="18" font="1">•</text>
<text top="178" left="680" width="156" height="20" font="1"> Health insurance status: 15 </text>
<text top="195" left="673" width="177" height="20" font="1">cross-sectional studies reported </text>
<text top="212" left="673" width="172" height="20" font="1">comparisons of HTN outcomes </text>
<text top="229" left="673" width="172" height="20" font="1">in insured and uninsured pts. 8 </text>
<text top="247" left="673" width="180" height="20" font="1">of these 15 studies reported that </text>
<text top="264" left="673" width="169" height="20" font="1">insurance was associated with </text>
<text top="281" left="673" width="141" height="20" font="1">improved HTN treatment, </text>
<text top="298" left="673" width="118" height="20" font="1">control or medication </text>
<text top="316" left="673" width="165" height="20" font="1">adherence. The 7 other cross-</text>
<text top="333" left="673" width="176" height="20" font="1">sectional studies that compared </text>
<text top="350" left="673" width="162" height="20" font="1">HTN outcomes in insured pts </text>
<text top="367" left="673" width="171" height="20" font="1">and uninsured pts, reported no </text>
<text top="384" left="673" width="167" height="20" font="1">significant negative or positive </text>
<text top="402" left="673" width="178" height="20" font="1">associations between insurance </text>
<text top="419" left="673" width="146" height="20" font="1">status and HTN outcome.  </text>
<text top="438" left="673" width="7" height="18" font="1">•</text>
<text top="437" left="680" width="113" height="20" font="1"> Medication costs or </text>
<text top="454" left="673" width="181" height="20" font="1">medication co-payments: All 6 of </text>
<text top="472" left="673" width="125" height="20" font="1">these studies reported </text>
<text top="489" left="673" width="179" height="20" font="1">significant associations between </text>
<text top="506" left="673" width="168" height="20" font="1">reduced co-payments or costs </text>
<text top="523" left="673" width="161" height="20" font="1">and improved HTN control or </text>
<text top="540" left="673" width="128" height="20" font="1">medication adherence. </text>
<text top="559" left="673" width="7" height="18" font="1">•</text>
<text top="559" left="680" width="174" height="20" font="1"> Co-payments for medical care: </text>
<text top="576" left="673" width="126" height="20" font="1">14 quantitative studies </text>
<text top="593" left="673" width="157" height="20" font="1">measured the association of </text>
<text top="610" left="673" width="151" height="20" font="1">medication co-payments or </text>
<text top="628" left="673" width="141" height="20" font="1">costs with HTN control or </text>
<text top="645" left="673" width="179" height="20" font="1">treatment adherence, 9 of which </text>
<text top="662" left="673" width="161" height="20" font="1">were set in the U.S., and 1 in </text>
<text top="679" left="673" width="147" height="20" font="1">each of Cameroon, China, </text>
<text top="697" left="673" width="169" height="20" font="1">Finland, Israel, and Brazil. 2 of </text>
<text top="714" left="673" width="172" height="20" font="1">the 14 studies had a low risk of </text>
<text top="731" left="673" width="163" height="20" font="1">bias. 7 of the 14 studies were </text>
<text top="748" left="673" width="159" height="20" font="1">cohort studies, 1 was a case-</text>
<text top="765" left="673" width="174" height="20" font="1">control study, and 6 were cross-</text>
<text top="783" left="673" width="163" height="20" font="1">sectional studies. All 7 cohort </text>
<text top="178" left="867" width="7" height="18" font="1">•</text>
<text top="178" left="874" width="163" height="20" font="1"> Although lacking longitudinal </text>
<text top="195" left="867" width="185" height="20" font="1">studies, we found a large positive </text>
<text top="212" left="867" width="206" height="20" font="1">association between having a routine </text>
<text top="229" left="867" width="189" height="20" font="1">physician or place of care for HTN </text>
<text top="247" left="867" width="158" height="20" font="1">management and treatment, </text>
<text top="264" left="867" width="196" height="20" font="1">awareness, control, and adherence </text>
<text top="281" left="867" width="199" height="20" font="1">to antihypertensive treatment, again </text>
<text top="298" left="867" width="199" height="20" font="1">in the U.S. publication and reporting </text>
<text top="316" left="867" width="128" height="20" font="1">bias noted by authors.  </text>
</page>
<page number="250" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">250 </text>
<text top="107" left="522" width="114" height="20" font="1">countries, and 1 in a </text>
<text top="124" left="522" width="113" height="20" font="1">low-income country. </text>
<text top="107" left="673" width="163" height="20" font="1">studies reported associations </text>
<text top="124" left="673" width="169" height="20" font="1">between increased medication </text>
<text top="141" left="673" width="144" height="20" font="1">costs or co-payments and </text>
<text top="159" left="673" width="156" height="20" font="1">reductions in HTN control or </text>
<text top="176" left="673" width="123" height="20" font="1">reduced adherence to </text>
<text top="193" left="673" width="159" height="20" font="1">antihypertensive medication, </text>
<text top="210" left="673" width="174" height="20" font="1">although for 1 of these 7 cohort </text>
<text top="228" left="673" width="181" height="20" font="1">studies, the association between </text>
<text top="245" left="673" width="150" height="20" font="1">increased copayments and </text>
<text top="262" left="673" width="172" height="20" font="1">reduced medication adherence </text>
<text top="279" left="673" width="125" height="20" font="1">was only found for low </text>
<text top="296" left="673" width="178" height="20" font="1">medication co-payments, and at </text>
<text top="314" left="673" width="129" height="20" font="1">high co-payment levels </text>
<text top="331" left="673" width="150" height="20" font="1">medication adherence was </text>
<text top="348" left="673" width="169" height="20" font="1">actually found to increase (OR </text>
<text top="365" left="673" width="161" height="20" font="1">for medication adherence vs. </text>
<text top="383" left="673" width="125" height="20" font="1">baseline of 1 for $0 co-</text>
<text top="400" left="673" width="165" height="20" font="1">payments was 0.72 for $1–$9 </text>
<text top="417" left="673" width="172" height="20" font="1">co-payments (p=0.05), 1.02 for </text>
<text top="434" left="673" width="178" height="20" font="1">$10–$29 co-payments (p=0.05), </text>
<text top="451" left="673" width="174" height="20" font="1">and 1.32 for co-payments . $30 </text>
<text top="469" left="673" width="49" height="20" font="1">(p=0.05) </text>
<text top="488" left="673" width="7" height="18" font="1">•</text>
<text top="487" left="680" width="135" height="20" font="1"> Physician remuneration </text>
<text top="504" left="673" width="176" height="20" font="1">models: 2 studies evaluated the </text>
<text top="521" left="673" width="133" height="20" font="1">association of physician </text>
<text top="539" left="673" width="173" height="20" font="1">remuneration models with HTN </text>
<text top="556" left="673" width="175" height="20" font="1">control or treatment adherence, </text>
<text top="573" left="673" width="151" height="20" font="1">1 an ecological study set in </text>
<text top="590" left="673" width="155" height="20" font="1">Canada, and 1 a U.S. cross-</text>
<text top="607" left="673" width="164" height="20" font="1">sectional study. Neither study </text>
<text top="625" left="673" width="174" height="20" font="1">had a low risk of bias. The U.S. </text>
<text top="642" left="673" width="181" height="20" font="1">study reported improved rates of </text>
<text top="659" left="673" width="181" height="20" font="1">HTN control amongst pts treated </text>
<text top="676" left="673" width="138" height="20" font="1">under a capitation model </text>
<text top="693" left="673" width="173" height="20" font="1">compared to fee-for service pts </text>
<text top="711" left="673" width="166" height="20" font="1">(adjusted OR for HTN control: </text>
<text top="728" left="673" width="159" height="20" font="1">1.82 (95% CI: 1.02–3.27) for </text>
<text top="745" left="673" width="157" height="20" font="1">capitation vs. fee-for-service </text>
<text top="762" left="673" width="141" height="20" font="1">pts). The Canadian study </text>
<text top="780" left="673" width="165" height="20" font="1">reported highest rates of HTN </text>
</page>
<page number="251" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="828" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="828" left="1059" width="24" height="20" font="1">251 </text>
<text top="107" left="673" width="161" height="20" font="1">treatment and control among </text>
<text top="124" left="673" width="152" height="20" font="1">practices using a capitation </text>
<text top="141" left="673" width="152" height="20" font="1">model, compared to fee-for-</text>
<text top="159" left="673" width="171" height="20" font="1">service and salary model. HTN </text>
<text top="176" left="673" width="171" height="20" font="1">awareness levels were highest </text>
<text top="193" left="673" width="167" height="20" font="1">in practices with a fixed salary </text>
<text top="210" left="673" width="116" height="20" font="1">remuneration model. </text>
</page>
<page number="252" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">252 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="106" left="81" width="340" height="24" font="3"><b>Additional Data Supplement Tables and Figures </b></text>
<text top="149" left="81" width="417" height="23" font="3"><b>Data Supplement A. Treatment of HF<i>r</i></b><b>EF Stages C and D </b></text>
<text top="703" left="810" width="3" height="19" font="1"> </text>
<text top="735" left="108" width="686" height="19" font="1">Colors correspond to COR in Table 1. For all medical therapies dosing should be optimized and serial assessment </text>
<text top="756" left="108" width="68" height="19" font="1">exercised.  </text>
<text top="792" left="108" width="279" height="19" font="1">*See text for important treatment directions. </text>
<text top="829" left="108" width="687" height="19" font="1">†Hydral-Nitrates Green Box- The combination of ISDN/HYD with ARNI has not been robustly tested. BP response </text>
<text top="849" left="108" width="183" height="19" font="1">should be carefully followed.  </text>
<text top="885" left="108" width="153" height="19" font="1">‡See 2013 HF guideline.  </text>
<text top="921" left="108" width="577" height="19" font="1">§Participation in investigational studies is also appropriate for stage C, NYHA class II and III HF. </text>
<text top="958" left="108" width="670" height="19" font="1">ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin </text>
<text top="979" left="108" width="671" height="19" font="1">receptor-neprilysin inhibitor; BP, blood pressure; bpm, beats per minute; C/I, contraindication; CRT-D, cardiac </text>
<text top="1000" left="108" width="653" height="19" font="1">resynchronization therapy-device; COR, class of recommendation; Dx, diagnosis; GDMT, guideline-directed </text>
<text top="1021" left="108" width="663" height="19" font="1">management and therapy; HF<i>r</i>EF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-</text>
<text top="1042" left="108" width="691" height="19" font="1">defibrillator; ISDN/HYD, isosorbide dinitrate hydral-nitrates; LBBB, left bundle-branch block; LVEF, left ventricular </text>
</page>
<page number="253" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="29" size="12" family="Times" color="#243f60"/>
	<fontspec id="30" size="12" family="Times" color="#243f60"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">253 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="657" height="19" font="1">ejection fraction; LVAD, left ventricular assist device; NSR, normal sinus rhythm; and NYHA, New York Heart </text>
<text top="129" left="108" width="77" height="19" font="1">Association. </text>
<text top="168" left="81" width="470" height="23" font="3"><b>Data Supplement B. Medication Adherence Assessment Scales </b></text>
<text top="203" left="104" width="207" height="19" font="4"><b>Hill-Bone Compliance Scale</b> <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(346)</a> </text>
<text top="224" left="118" width="117" height="19" font="1">How often do you: </text>
<text top="250" left="131" width="15" height="13" font="1">1. </text>
<text top="246" left="158" width="239" height="19" font="1">Forget to take your high BP medicine?  </text>
<text top="268" left="131" width="15" height="13" font="1">2. </text>
<text top="264" left="158" width="268" height="19" font="1">Decide NOT to take your high BP medicine? </text>
<text top="286" left="131" width="15" height="13" font="1">3. </text>
<text top="282" left="158" width="92" height="19" font="1">Eat salty foods </text>
<text top="305" left="131" width="15" height="13" font="1">4. </text>
<text top="301" left="158" width="258" height="19" font="1">Shake salt on your food before you eat it? </text>
<text top="323" left="131" width="15" height="13" font="1">5. </text>
<text top="319" left="158" width="88" height="19" font="1">Eat fast food? </text>
<text top="342" left="131" width="15" height="13" font="1">6. </text>
<text top="337" left="158" width="357" height="19" font="1">Make the next appointment before you leave the doctor’s </text>
<text top="356" left="158" width="45" height="19" font="1">office? </text>
<text top="378" left="131" width="15" height="13" font="1">7. </text>
<text top="374" left="158" width="193" height="19" font="1">Miss scheduled appointments? </text>
<text top="396" left="131" width="15" height="13" font="1">8. </text>
<text top="392" left="158" width="206" height="19" font="1">Forget to get prescriptions filled? </text>
<text top="415" left="131" width="15" height="13" font="1">9. </text>
<text top="411" left="158" width="151" height="19" font="1">Run out of high BP pills? </text>
<text top="433" left="131" width="23" height="13" font="1">10. </text>
<text top="429" left="158" width="347" height="19" font="1">Skip your high BP medicine before you go to the doctor? </text>
<text top="451" left="131" width="23" height="13" font="1">11. </text>
<text top="447" left="158" width="321" height="19" font="1">Miss taking your high BP pills when you feel better?  </text>
<text top="470" left="131" width="23" height="13" font="1">12. </text>
<text top="465" left="158" width="302" height="19" font="1">Miss taking your high BP pills when you feel sick? </text>
<text top="488" left="131" width="23" height="13" font="1">13. </text>
<text top="484" left="158" width="213" height="19" font="1">Take someone else’s high BP pills? </text>
<text top="506" left="131" width="23" height="13" font="1">14. </text>
<text top="502" left="158" width="326" height="19" font="1">Miss taking your high BP pills when you are careless? </text>
<text top="205" left="571" width="3" height="19" font="29"><i> </i></text>
<text top="227" left="572" width="66" height="19" font="30">Response:<i> </i></text>
<text top="249" left="579" width="107" height="19" font="1">1. All of the Time </text>
<text top="267" left="579" width="126" height="19" font="1">2. Most of the Time  </text>
<text top="285" left="579" width="126" height="19" font="1">3. Some of the Time </text>
<text top="304" left="579" width="124" height="19" font="1">4. None of the Time </text>
<text top="325" left="579" width="3" height="19" font="1"> </text>
<text top="346" left="571" width="237" height="19" font="1">Medication taking subscale: Items 1,2, </text>
<text top="365" left="585" width="121" height="19" font="1">8,9,10,11,12,13,14. </text>
<text top="383" left="571" width="208" height="19" font="1">Reducing sodium intake subscale: </text>
<text top="401" left="585" width="78" height="19" font="1">Items 3,4,5.  </text>
<text top="420" left="571" width="232" height="19" font="1">Appointment keeping subscale: Items </text>
<text top="438" left="585" width="29" height="19" font="1">6,7.  </text>
<text top="524" left="95" width="176" height="19" font="1">BP indicates blood pressure. </text>
<text top="569" left="81" width="654" height="23" font="3"><b>Data Supplement C. Categories Defining Normal BP, Elevated BP, and Stages 1, 2, and 3 </b></text>
<text top="595" left="81" width="105" height="23" font="3"><b>Hypertension </b></text>
<text top="1018" left="747" width="3" height="19" font="1"> </text>
</page>
<page number="254" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">254 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="323" height="19" font="1">Stages 1, 2, and 3 refer to the stage of hypertension. </text>
<text top="144" left="108" width="564" height="19" font="1">BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure. </text>
<text top="180" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="255" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="31" size="10" family="Times" color="#000000"/>
	<fontspec id="32" size="11" family="Times" color="#000000"/>
	<fontspec id="33" size="11" family="Times" color="#000000"/>
	<fontspec id="34" size="11" family="Times" color="#000000"/>
	<fontspec id="35" size="11" family="Times" color="#0000ff"/>
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">255 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="521" height="23" font="3"><b>Data Supplement D. Fixed-Dose Combination Antihypertensive Drugs </b></text>
<text top="150" left="173" width="28" height="15" font="31"><b>Class </b></text>
<text top="150" left="406" width="27" height="15" font="31"><b>Drug </b></text>
<text top="150" left="588" width="136" height="15" font="31"><b>Dosage Strengths (mg/mg) </b></text>
<text top="143" left="788" width="28" height="15" font="31"><b>Daily </b></text>
<text top="157" left="772" width="61" height="15" font="31"><b>Frequency* </b></text>
<text top="173" left="89" width="119" height="17" font="32"><b>2-drug combinations </b></text>
<text top="190" left="89" width="77" height="17" font="33">ACE Inhibitors</text>
<text top="191" left="166" width="2" height="11" font="6"> </text>
<text top="190" left="168" width="58" height="17" font="33">+ Thiazide </text>
<text top="190" left="298" width="178" height="17" font="33">Benazepril/Hydrochlorothiazide </text>
<text top="190" left="555" width="134" height="17" font="33">10/12.5, 20/12.5, 20/25 </text>
<text top="190" left="771" width="10" height="17" font="33">1 </text>
<text top="207" left="298" width="170" height="17" font="33">Captopril/Hydrochlorothiazide </text>
<text top="207" left="555" width="153" height="17" font="33">25/15, 50/15, 25/25, 50/25 </text>
<text top="207" left="771" width="10" height="17" font="33">2 </text>
<text top="225" left="298" width="168" height="17" font="33">Enalapril/Hydrochlorothiazide </text>
<text top="225" left="555" width="78" height="17" font="33">5/12.5, 10/25 </text>
<text top="225" left="771" width="35" height="17" font="33">1 or 2 </text>
<text top="242" left="298" width="174" height="17" font="33">Fosinopril/Hydrochlorothiazide </text>
<text top="242" left="555" width="95" height="17" font="33">10/12.5, 20/12.5 </text>
<text top="242" left="771" width="10" height="17" font="33">1 </text>
<text top="259" left="298" width="169" height="17" font="33">Lisinopril/Hydrochlorothiazide </text>
<text top="259" left="555" width="134" height="17" font="33">10/12.5, 20/12.5, 20/25 </text>
<text top="259" left="771" width="10" height="17" font="33">1 </text>
<text top="276" left="298" width="175" height="17" font="33">Moexipril/Hydrochlorothiazide  </text>
<text top="276" left="555" width="138" height="17" font="33">7.5/12.5, 15/12.5, 15/25 </text>
<text top="276" left="771" width="35" height="17" font="33">1 or 2 </text>
<text top="294" left="298" width="171" height="17" font="33">Quinapril/Hydrochlorothiazide </text>
<text top="294" left="555" width="134" height="17" font="33">10/12.5, 20/12.5, 20/25 </text>
<text top="294" left="771" width="35" height="17" font="33">1 or 2 </text>
<text top="311" left="89" width="92" height="17" font="33">ARBs + Thiazide  </text>
<text top="311" left="298" width="144" height="17" font="33">Azilsartan/Chlorthalidone </text>
<text top="311" left="555" width="85" height="17" font="33">40/12.5, 40/25 </text>
<text top="311" left="771" width="10" height="17" font="33">1 </text>
<text top="328" left="298" width="189" height="17" font="33">Candesartan/Hydrochlorothiazide </text>
<text top="328" left="555" width="134" height="17" font="33">16/12.5, 32/12.5, 32/25 </text>
<text top="328" left="771" width="13" height="17" font="33">1  </text>
<text top="345" left="298" width="180" height="17" font="33">Eprosartan/Hydrochlorothiazide </text>
<text top="345" left="555" width="99" height="17" font="33">600/12.5, 600/25 </text>
<text top="345" left="771" width="10" height="17" font="33">1 </text>
<text top="362" left="298" width="176" height="17" font="33">Irbesartan/Hydrochlorothiazide </text>
<text top="362" left="555" width="155" height="17" font="33">150/12.5, 300/12.5, 300/25 </text>
<text top="362" left="771" width="10" height="17" font="33">1 </text>
<text top="380" left="298" width="167" height="17" font="33">Losartan/Hydrochlorothiazide </text>
<text top="380" left="555" width="148" height="17" font="33">50/12.5, 100/12.5, 100/25 </text>
<text top="380" left="771" width="35" height="17" font="33">1 or 2 </text>
<text top="397" left="298" width="184" height="17" font="33">Olmesartan/Hydrochlorothiazide </text>
<text top="397" left="555" width="134" height="17" font="33">20/12.5, 40/12.5, 40/25 </text>
<text top="397" left="771" width="10" height="17" font="33">1 </text>
<text top="414" left="298" width="185" height="17" font="33">Telmisartan/Hydrochlorothiazide </text>
<text top="414" left="555" width="134" height="17" font="33">40/12.5, 80/12.5, 80/25 </text>
<text top="414" left="771" width="10" height="17" font="33">1 </text>
<text top="431" left="298" width="172" height="17" font="33">Valsartan/Hydrochlorothiazide </text>
<text top="431" left="555" width="162" height="17" font="33">80/12.5, 160/12.5, 320/12.5, </text>
<text top="448" left="555" width="88" height="17" font="33">160/25, 320/25 </text>
<text top="431" left="771" width="10" height="17" font="33">1 </text>
<text top="465" left="89" width="168" height="17" font="33">CCB – dihydropyridine + ACEIs </text>
<text top="465" left="298" width="129" height="17" font="33">Amlodipine/Benazepril </text>
<text top="465" left="555" width="178" height="17" font="33">2.5/10, 5/10, 5/20, 10/20, 5/40, </text>
<text top="482" left="555" width="36" height="17" font="33">10/40 </text>
<text top="465" left="771" width="10" height="17" font="33">1 </text>
<text top="499" left="298" width="113" height="17" font="33">Enalapril/Felodipine </text>
<text top="499" left="555" width="22" height="17" font="33">5/5 </text>
<text top="499" left="771" width="10" height="17" font="33">1 </text>
<text top="516" left="298" width="132" height="17" font="33">Perindopril/Amlodipine </text>
<text top="516" left="555" width="107" height="17" font="33">3.5/2.5, 7/5, 14/10 </text>
<text top="516" left="771" width="10" height="17" font="33">1 </text>
<text top="533" left="89" width="160" height="17" font="33">CCB – dihydropyridine + ARB </text>
<text top="533" left="298" width="135" height="17" font="33">Amlodipine/Olmesartan </text>
<text top="533" left="555" width="100" height="17" font="33">5/20, 10/20, 4/40 </text>
<text top="533" left="771" width="10" height="17" font="33">1 </text>
<text top="551" left="298" width="123" height="17" font="33">Amlodipine/Valsartan </text>
<text top="551" left="555" width="166" height="17" font="33">5/160, 10/160, 5/320, 10/320 </text>
<text top="551" left="771" width="10" height="17" font="33">1 </text>
<text top="568" left="298" width="136" height="17" font="33">Telmisartan/Amlodipine </text>
<text top="568" left="555" width="139" height="17" font="33">40/5, 80/5, 40/10, 80/10 </text>
<text top="568" left="771" width="10" height="17" font="33">1 </text>
<text top="585" left="89" width="189" height="17" font="33">CCB – nondihydropyridine + ACEIs </text>
<text top="585" left="298" width="131" height="17" font="33">Trandolapril/Verapamil </text>
<text top="585" left="555" width="153" height="17" font="33">2/180, 1/250, 2/240, 4/240 </text>
<text top="585" left="771" width="10" height="17" font="33">1 </text>
<text top="602" left="89" width="130" height="17" font="33">Beta blocker + Thiazide </text>
<text top="602" left="298" width="136" height="17" font="33">Atenolol/Chlorthalidone </text>
<text top="602" left="555" width="82" height="17" font="33">50/25, 100/25 </text>
<text top="602" left="771" width="10" height="17" font="33">1 </text>
<text top="619" left="298" width="175" height="17" font="33">Bisoprolol/Hydrochlorothiazide </text>
<text top="619" left="555" width="141" height="17" font="33">2.5/6.25, 5/6.25, 10/6.25 </text>
<text top="619" left="771" width="10" height="17" font="33">1 </text>
<text top="637" left="298" width="237" height="17" font="33">Metoprolol succinate/Hydrochlorothiazide </text>
<text top="637" left="555" width="151" height="17" font="33">25/12.5, 50/12.5, 100/12.5 </text>
<text top="637" left="771" width="10" height="17" font="33">1 </text>
<text top="654" left="298" width="231" height="17" font="33">Metoprolol tartrate/ Hydrochlorothiazide </text>
<text top="654" left="555" width="127" height="17" font="33">50/25, 100/25, 100/50 </text>
<text top="654" left="771" width="35" height="17" font="33">1 or 2 </text>
<text top="671" left="298" width="166" height="17" font="33">Nadolol/Bendroflumethiazide </text>
<text top="671" left="555" width="61" height="17" font="33">40/5, 80/5 </text>
<text top="671" left="771" width="10" height="17" font="33">1 </text>
<text top="688" left="298" width="184" height="17" font="33">Propranolol/Hydrochlorothiazide </text>
<text top="688" left="555" width="75" height="17" font="33">40/25, 80/25 </text>
<text top="688" left="771" width="35" height="17" font="33">1 or 2 </text>
<text top="706" left="89" width="162" height="17" font="33">Direct renin inhibitor + CCB – </text>
<text top="722" left="89" width="90" height="17" font="33">dihydropyridine<i> </i></text>
<text top="706" left="298" width="117" height="17" font="33">Aliskiren/amlodipine </text>
<text top="706" left="555" width="166" height="17" font="33">150/5, 150/10, 300/5, 300/10 </text>
<text top="706" left="771" width="10" height="17" font="33">1 </text>
<text top="739" left="89" width="176" height="17" font="33">Direct renin inhibitor + Thiazide<i> </i></text>
<text top="739" left="298" width="170" height="17" font="33">Aliskiren/ Hydrochlorothiazide </text>
<text top="739" left="555" width="226" height="17" font="33">150/12.5, 150/25, 300/12.5, 300/25  1 </text>
<text top="756" left="89" width="162" height="17" font="33">Direct renin inhibitor + CCB – </text>
<text top="773" left="89" width="90" height="17" font="33">dihydropyridine </text>
<text top="756" left="298" width="118" height="17" font="33">Aliskiren/Amlodipine </text>
<text top="756" left="555" width="166" height="17" font="33">150/5, 150/10, 300/5, 300/10 </text>
<text top="756" left="771" width="10" height="17" font="33">1 </text>
<text top="790" left="89" width="176" height="17" font="33">Direct renin inhibitor + Thiazide </text>
<text top="790" left="298" width="167" height="17" font="33">Aliskiren/Hydrochlorothiazide </text>
<text top="790" left="555" width="226" height="17" font="33">150/12.5, 150/25, 300/12.5, 300/25  1 </text>
<text top="807" left="89" width="172" height="17" font="33">Central acting agent + Thiazide </text>
<text top="824" left="89" width="3" height="17" font="33"> </text>
<text top="807" left="298" width="141" height="17" font="33">Clonidine/Chlorthalidone </text>
<text top="807" left="555" width="124" height="17" font="33">0.1/15, 0.2/15, 0.3/15 </text>
<text top="807" left="771" width="35" height="17" font="33">1 or 2 </text>
<text top="825" left="298" width="187" height="17" font="33">Methyldopa/Hydrochlorothiazide </text>
<text top="825" left="555" width="88" height="17" font="33">250/15, 250/25 </text>
<text top="825" left="771" width="10" height="17" font="33">2 </text>
<text top="842" left="89" width="163" height="17" font="33">Diuretic- potassium sparing + </text>
<text top="858" left="89" width="49" height="17" font="33">Thiazide </text>
<text top="842" left="298" width="174" height="17" font="33">Amiloride/Hydrochlorothiazide </text>
<text top="842" left="555" width="29" height="17" font="33">5/50 </text>
<text top="842" left="771" width="10" height="17" font="33">1 </text>
<text top="859" left="298" width="188" height="17" font="33">Triamterene/Hydrochlorothiazide </text>
<text top="859" left="555" width="85" height="17" font="33">37.5/25, 75/50 </text>
<text top="859" left="771" width="10" height="17" font="33">1 </text>
<text top="876" left="89" width="190" height="17" font="33">Diuretic- aldosterone antagonist + </text>
<text top="893" left="89" width="49" height="17" font="33">Thiazide </text>
<text top="876" left="298" width="206" height="17" font="33">Spironolactone/ Hydrochlorothiazide </text>
<text top="876" left="555" width="36" height="17" font="33">25/25 </text>
<text top="876" left="771" width="35" height="17" font="33">1 or 2 </text>
<text top="910" left="89" width="119" height="17" font="32"><b>3-drug combinations </b></text>
<text top="927" left="89" width="170" height="17" font="33">ARB + CCB – dihydropyridine + </text>
<text top="944" left="89" width="49" height="17" font="33">Thiazide </text>
<text top="927" left="298" width="458" height="17" font="33">Amlodipine/Valsartan/ Hydrochlorothiazide  5/160/12.5, 10/160/12.5, 5/160/25, </text>
<text top="944" left="555" width="129" height="17" font="33">10/160/25, 10/320/25  </text>
<text top="927" left="771" width="10" height="17" font="33">1 </text>
<text top="961" left="298" width="141" height="17" font="33">Olmesartan/Amlodipine/ </text>
<text top="978" left="298" width="115" height="17" font="33">Hydrochlorothiazide </text>
<text top="961" left="555" width="174" height="17" font="33">20/5/12.5, 40/5/12.5, 40/5/25, </text>
<text top="978" left="555" width="123" height="17" font="33">40/10/12.5, 40/10/25 </text>
<text top="961" left="771" width="10" height="17" font="33">1 </text>
<text top="995" left="89" width="162" height="17" font="33">Direct renin inhibitor + CCB – </text>
<text top="1011" left="89" width="149" height="17" font="33">dihydropyridine + Thiazide </text>
<text top="995" left="298" width="235" height="17" font="33">Aliskiren/Amlodipine/Hydrochlorothiazide </text>
<text top="995" left="555" width="194" height="17" font="33">150/5/12.5, 300/5/12.5, 300/5/25, </text>
<text top="1011" left="555" width="136" height="17" font="33">300/10/12.5, 300/10/25 </text>
<text top="995" left="771" width="10" height="17" font="33">1 </text>
<text top="1028" left="88" width="366" height="17" font="33">*Dosages may vary from those listed in the FDA approved labelin<a href="http://dailymed.nlm.nih.gov/dailymed/index.cfm">g </a></text>
<text top="1028" left="454" width="270" height="17" font="35"><a href="http://dailymed.nlm.nih.gov/dailymed/index.cfm">http://dailymed.nlm.nih.gov/dailymed/index.cfm</a></text>
<text top="1028" left="724" width="14" height="17" font="33"><a href="http://dailymed.nlm.nih.gov/dailymed/index.cfm">)</a>.  </text>
</page>
<page number="256" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">256 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="88" width="641" height="17" font="33">ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; and CCB, calcium channel blocker. </text>
<text top="142" left="108" width="192" height="17" font="33">From Chobanian et al. JNC 7. <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(347)</a> </text>
<text top="179" left="81" width="595" height="23" font="3"><b>Data Supplement E. Examples of Hypertension Quality Improvement Strategies </b></text>
<text top="214" left="134" width="193" height="19" font="4"><b>Quality Improvement Strategy </b></text>
<text top="214" left="574" width="62" height="19" font="4"><b>Examples </b></text>
<text top="280" left="98" width="223" height="19" font="1">Audit and feedback on performance </text>
<text top="233" left="381" width="317" height="20" font="1">•  Feedback of performance to individual providers </text>
<text top="252" left="381" width="441" height="20" font="1">•  Benchmarking – provision of outcomes data from top performers for </text>
<text top="271" left="401" width="231" height="19" font="1">comparison with provider’s own  data </text>
<text top="290" left="381" width="348" height="20" font="1">•  Performance measures, quality indicators and reports </text>
<text top="309" left="381" width="418" height="20" font="1">•  Use of registries to track BP control status at system and provider </text>
<text top="328" left="401" width="37" height="19" font="1">levels </text>
<text top="375" left="98" width="119" height="19" font="1">Provider education </text>
<text top="347" left="381" width="448" height="20" font="1">•  In person, online, or other education to improve BP measurement and </text>
<text top="366" left="401" width="116" height="19" font="1">management skills </text>
<text top="384" left="381" width="440" height="20" font="1">•  Training to improve communication, cultural competency, and ability </text>
<text top="403" left="401" width="270" height="19" font="1">to inspire and support lifestyle modification  </text>
<text top="441" left="98" width="112" height="19" font="1">Patient education </text>
<text top="423" left="381" width="382" height="20" font="1">•  Intensive education strategies promoting hypertension self-</text>
<text top="441" left="401" width="84" height="19" font="1">management </text>
<text top="460" left="381" width="432" height="20" font="1">•  Cultural and linguistic tailoring of materials to increase acceptability </text>
<text top="489" left="98" width="195" height="19" font="1">Promotion of self-management </text>
<text top="480" left="381" width="451" height="20" font="1">•  Reduce barriers for patients to receive and adhere to medications and </text>
<text top="499" left="401" width="218" height="19" font="1">to implement lifestyle modification </text>
<text top="518" left="98" width="159" height="19" font="1">Patient reminder systems </text>
<text top="536" left="98" width="247" height="19" font="1">(for follow-up appointments, BP checks, </text>
<text top="554" left="98" width="141" height="19" font="1">and self-management) </text>
<text top="518" left="381" width="286" height="20" font="1">•  Postcards, calls, texts, or emails to patients </text>
<text top="537" left="381" width="216" height="20" font="1">•  Telehealth-delivered reminders </text>
<text top="668" left="98" width="95" height="19" font="1">System change </text>
<text top="574" left="381" width="433" height="20" font="1">•  Standardization of BP measurement using an automated device and </text>
<text top="593" left="401" width="136" height="19" font="1">standardized protocol </text>
<text top="611" left="381" width="455" height="20" font="1">•  Screening to identify all patients eligible for hypertension management  </text>
<text top="630" left="381" width="450" height="20" font="1">•  Systematic follow-up of patients for the initiation and intensification of </text>
<text top="649" left="401" width="155" height="19" font="1">antihypertensive therapy </text>
<text top="668" left="381" width="414" height="20" font="1">•  Decision support to providers to guide protocol-based treatment </text>
<text top="687" left="401" width="62" height="19" font="1">decisions  </text>
<text top="705" left="381" width="438" height="20" font="1">•  Physician or other clinical champion designated to lead hypertension </text>
<text top="724" left="401" width="176" height="19" font="1">care improvement initiatives </text>
<text top="742" left="381" width="288" height="20" font="1">•  Hypertension specialist available for consult </text>
<text top="762" left="381" width="402" height="20" font="1">•  Partner with community resources to support BP management </text>
<text top="781" left="81" width="179" height="19" font="1">BP indicates blood pressure.  </text>
<text top="817" left="81" width="306" height="19" font="1">Adapted with permission from Walsh et al. <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(348)</a>.  </text>
</page>
<page number="257" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">257 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="672" height="23" font="3"><b>Data Supplement F. Barriers and Improvement Strategies in Antihypertensive Medication </b></text>
<text top="133" left="108" width="161" height="23" font="3"><b>Adherence <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(349-353)</a></b><b> </b></text>
<text top="168" left="197" width="52" height="19" font="4"><b>Barriers </b></text>
<text top="168" left="524" width="154" height="19" font="4"><b>Improvement Strategies </b></text>
<text top="187" left="98" width="84" height="19" font="4"><b>Patient Level </b></text>
<text top="207" left="98" width="204" height="20" font="1">•  Multiple comorbid conditions </text>
<text top="226" left="118" width="186" height="19" font="1">requiring complex medication </text>
<text top="244" left="118" width="60" height="19" font="1">regimens </text>
<text top="262" left="98" width="225" height="20" font="1">•  Convenience factors (e.g., dosing </text>
<text top="281" left="118" width="73" height="19" font="1">frequency)  </text>
<text top="300" left="98" width="108" height="20" font="1">•  Health beliefs </text>
<text top="319" left="98" width="137" height="20" font="1">•  Behavioral factors  </text>
<text top="338" left="98" width="250" height="20" font="1">•  Lack of involvement in the treatment </text>
<text top="357" left="118" width="155" height="19" font="1">decision–making process </text>
<text top="375" left="98" width="172" height="20" font="1">•  Issues with treatment of </text>
<text top="394" left="118" width="178" height="19" font="1">asymptomatic diseases (e.g., </text>
<text top="413" left="118" width="146" height="19" font="1">treatment side effects)  </text>
<text top="431" left="98" width="154" height="20" font="1">•  Resource constraints  </text>
<text top="450" left="98" width="184" height="20" font="1">•  Suboptimal health literacy </text>
<text top="207" left="361" width="476" height="20" font="1">•  Educate patients about hypertension, consequences of hypertension, and </text>
<text top="226" left="384" width="243" height="19" font="1">possible adverse effects of medications </text>
<text top="244" left="361" width="452" height="20" font="1">•  Collaborate with patient to establish goals of therapy and plan of care </text>
<text top="263" left="361" width="466" height="20" font="1">•  Maintain contact with patients; consider telehealth approaches (Section </text>
<text top="282" left="384" width="50" height="19" font="1">12.3.2). </text>
<text top="301" left="361" width="426" height="20" font="1">•  Integrate pill-taking into daily routine activities of daily living with </text>
<text top="319" left="384" width="452" height="19" font="1">adherence support tools such as reminders, pillboxes, packaging, or other </text>
<text top="338" left="384" width="28" height="19" font="1">aids </text>
<text top="356" left="361" width="438" height="20" font="1">•  Use motivation interventions to support medication adherence and </text>
<text top="375" left="384" width="175" height="19" font="1">lifestyle modification efforts </text>
<text top="394" left="361" width="480" height="20" font="1">•  Use medication adherence scales to facilitate identification of barriers and </text>
<text top="413" left="384" width="401" height="19" font="1">facilitators to and behaviors associated with adequate adherence </text>
<text top="431" left="361" width="166" height="20" font="1">•  Address health literacy </text>
<text top="455" left="378" width="9" height="12" font="1">o</text>
<text top="454" left="387" width="4" height="14" font="1"> </text>
<text top="450" left="398" width="124" height="19" font="1">Teach-back method </text>
<text top="473" left="378" width="9" height="12" font="1">o</text>
<text top="472" left="387" width="4" height="14" font="1"> </text>
<text top="468" left="398" width="217" height="19" font="1">Empower patients to ask questions </text>
<text top="492" left="378" width="9" height="12" font="1">o</text>
<text top="490" left="387" width="4" height="14" font="1"> </text>
<text top="487" left="398" width="205" height="19" font="1">Use visual, interactive education  </text>
<text top="510" left="378" width="9" height="12" font="1">o</text>
<text top="509" left="387" width="4" height="14" font="1"> </text>
<text top="505" left="398" width="276" height="19" font="1">Health literacy universal precautions tool kit  </text>
<text top="528" left="378" width="9" height="12" font="1">o</text>
<text top="527" left="387" width="4" height="14" font="1"> </text>
<text top="523" left="398" width="328" height="19" font="1">Provide medication list/pictorial medication schedule </text>
<text top="542" left="98" width="218" height="19" font="4"><b>Provider and Health System Levels </b></text>
<text top="562" left="98" width="199" height="20" font="1">•  Prescription of complex drug </text>
<text top="580" left="118" width="60" height="19" font="1">regimens </text>
<text top="599" left="98" width="222" height="20" font="1">•  Inadequate communication with </text>
<text top="618" left="118" width="195" height="19" font="1">patient about regimen, adverse </text>
<text top="636" left="118" width="149" height="19" font="1">effects, treatment goals </text>
<text top="655" left="98" width="237" height="20" font="1">•  Inadequate communication among </text>
<text top="674" left="118" width="118" height="19" font="1">multiple providers  </text>
<text top="692" left="98" width="187" height="20" font="1">•  Office visit time limitations </text>
<text top="711" left="98" width="239" height="20" font="1">•  Limited access to care, pharmacies, </text>
<text top="730" left="118" width="114" height="19" font="1">prescription refills </text>
<text top="562" left="361" width="462" height="20" font="1">•  Assess for nonadherence and explore barriers to medication adherence </text>
<text top="581" left="361" width="348" height="20" font="1">•  Use a multifactorial approach to optimize adherence </text>
<text top="600" left="361" width="441" height="20" font="1">•  Participate in training to enhance communication skills and increase </text>
<text top="619" left="384" width="129" height="19" font="1">cultural competence </text>
<text top="637" left="361" width="348" height="20" font="1">•  Use a multifactorial approach to optimize adherence </text>
<text top="656" left="361" width="284" height="20" font="1">•  Reduce complexity of medication regimen </text>
<text top="675" left="361" width="476" height="20" font="1">•  Utilize agents that are dosed once daily over those which require multiple </text>
<text top="694" left="384" width="71" height="19" font="1">daily doses </text>
<text top="713" left="361" width="459" height="20" font="1">•  Utilize fixed-dose combination agents when available and simplify drug </text>
<text top="732" left="384" width="60" height="19" font="1">regimens </text>
<text top="750" left="361" width="468" height="20" font="1">•  Consider overall side effect profile and preferentially use agents that are </text>
<text top="769" left="384" width="89" height="19" font="1">well tolerated </text>
<text top="788" left="361" width="476" height="20" font="1">•  Use low-cost and generic antihypertensives from drug classes where RCTs </text>
<text top="807" left="384" width="383" height="19" font="1">have demonstrated a reduction in cardiovascular events when </text>
<text top="825" left="384" width="111" height="19" font="1">appropriate <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#282">(354)</a> </text>
<text top="843" left="361" width="317" height="20" font="1">•  Use team-based care approaches (Section 12.2) </text>
<text top="862" left="361" width="441" height="20" font="1">•  Use health information technology-based approaches (Section 12.3) </text>
<text top="882" left="81" width="264" height="19" font="1">RCTs indicate randomized controlled trials. </text>
<text top="918" left="108" width="3" height="19" font="1"> </text>
</page>
<page number="258" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">258 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="81" width="706" height="23" font="3"><b>Data Supplement G. Examples of Strategies to Promote Lifestyle Modification Interventions in </b></text>
<text top="133" left="81" width="359" height="23" font="3"><b>Patients With Hypertension <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#281">(318, 319, </a></b><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#283"><b>355-361)</b></a><b> </b></text>
<text top="168" left="161" width="3" height="19" font="1"> </text>
<text top="168" left="360" width="220" height="19" font="4"><b>Lifestyle Modification Intervention </b></text>
<text top="168" left="722" width="72" height="19" font="4"><b>References </b></text>
<text top="187" left="98" width="122" height="19" font="4"><b>Tobacco Cessation  </b></text>
<text top="187" left="245" width="219" height="20" font="1">•  Ask all adults about tobacco use </text>
<text top="207" left="245" width="233" height="20" font="1">•  Advise them to stop using tobacco </text>
<text top="226" left="245" width="223" height="20" font="1">•  Provide behavioral interventions </text>
<text top="245" left="245" width="323" height="20" font="1">•  Consider pharmacotherapy for tobacco cessation </text>
<text top="187" left="713" width="65" height="19" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#283">(361, 362)</a> </text>
<text top="264" left="98" width="82" height="19" font="4"><b>Weight Loss  </b></text>
<text top="265" left="245" width="414" height="20" font="1">•  Offer or refer obese adults to intensive cognitive and behavioral </text>
<text top="284" left="265" width="431" height="19" font="1">interventions aimed at to improve weight status and other risk factors </text>
<text top="302" left="265" width="196" height="19" font="1">for important health outcomes. </text>
<text top="264" left="713" width="65" height="19" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#283">(355, 356)</a> </text>
<text top="321" left="98" width="117" height="19" font="4"><b>Sodium Reduction </b></text>
<text top="321" left="245" width="429" height="20" font="1">•  Offer or refer to behavioral counselling aimed at reduced intake of </text>
<text top="340" left="265" width="95" height="19" font="1">dietary sodium </text>
<text top="358" left="245" width="406" height="20" font="1">•  Encourage use of food labels to choose lower sodium products </text>
<text top="321" left="713" width="3" height="19" font="1"> </text>
<text top="378" left="98" width="54" height="19" font="4"><b>Alcohol  </b></text>
<text top="378" left="245" width="425" height="20" font="1">•  Screen adults ≥18 y of age for alcohol misuse and provide persons </text>
<text top="397" left="265" width="404" height="19" font="1">engaged in risky or hazardous drinking with behavioral counseling </text>
<text top="416" left="265" width="244" height="19" font="1">interventions to reduce alcohol misuse. </text>
<text top="378" left="713" width="65" height="19" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#283">(357, 358)</a> </text>
<text top="435" left="98" width="104" height="19" font="4"><b>Physical Activity </b></text>
<text top="453" left="98" width="60" height="19" font="4"><b>and Diet  </b></text>
<text top="435" left="245" width="446" height="20" font="1">•  Use medium- to high-intensity behavioral counseling interventions to </text>
<text top="454" left="265" width="418" height="19" font="1">improve intermediate health outcomes; addressing barriers, such as </text>
<text top="472" left="265" width="411" height="19" font="1">lack of access to affordable healthier foods, transportation barriers </text>
<text top="490" left="265" width="138" height="19" font="1">and poor local safety.  </text>
<text top="435" left="713" width="65" height="19" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#283">(359, 360)</a> </text>
<text top="508" left="108" width="3" height="20" font="1"> </text>
<text top="543" left="108" width="3" height="20" font="1"> </text>
<text top="577" left="108" width="3" height="20" font="1"> </text>
<text top="612" left="108" width="3" height="20" font="1"> </text>
<text top="647" left="108" width="3" height="20" font="1"> </text>
<text top="682" left="108" width="3" height="20" font="1"> </text>
<text top="717" left="108" width="3" height="20" font="1"> </text>
<text top="751" left="108" width="3" height="20" font="1"> </text>
<text top="786" left="108" width="3" height="20" font="1"> </text>
<text top="821" left="108" width="3" height="20" font="1"> </text>
<text top="856" left="108" width="3" height="20" font="1"> </text>
</page>
<page number="259" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">259 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="551" height="23" font="3"><b>Data Supplement H. Responsibilities and Roles of the Hypertension Team </b></text>
<text top="143" left="98" width="226" height="19" font="4"><b>Hypertension Team Responsibilities </b></text>
<text top="162" left="118" width="667" height="20" font="1">•  Communication and care coordination among various team members, the patient and family members or </text>
<text top="181" left="138" width="147" height="19" font="1">other support persons.  </text>
<text top="200" left="118" width="452" height="20" font="1">•  Effective use of evidence-based diagnosis and management guidelines </text>
<text top="219" left="118" width="596" height="20" font="1">•  Regular, structured follow-up mechanisms and reminder systems to monitor patient progress  </text>
<text top="238" left="118" width="365" height="20" font="1">•  Engage patients in their care by shared decision making  </text>
<text top="257" left="118" width="574" height="20" font="1">•  Medication adherence support and appropriate education about hypertension medication </text>
<text top="276" left="118" width="496" height="20" font="1">•  Medication addition and titration using evidence-based treatment algorithms </text>
<text top="295" left="118" width="636" height="20" font="1">•  Use of evidence-based tools and resources designed to maximize self-management (including health </text>
<text top="314" left="138" width="274" height="19" font="1">behavior change, lifestyle modification, etc.) </text>
<text top="333" left="118" width="552" height="20" font="1">•  Follow a single, personalized plan of care based upon patient characteristics and needs<b> </b></text>
<text top="352" left="98" width="254" height="19" font="4"><b>Individual Hypertension Team Members </b></text>
<text top="352" left="529" width="109" height="19" font="4"><b>Roles (examples) </b></text>
<text top="371" left="98" width="206" height="19" font="1">Primary Care Physician, Physician </text>
<text top="390" left="98" width="217" height="19" font="1">Assistant, Advanced Practice Nurse </text>
<text top="371" left="366" width="394" height="19" font="1">Routine and complex hypertension care, managing primary care </text>
<text top="390" left="366" width="44" height="19" font="1">issues. </text>
<text top="409" left="98" width="76" height="19" font="1">Cardiologist </text>
<text top="409" left="366" width="412" height="19" font="1">Routine and complex hypertension care, especially for patient with </text>
<text top="427" left="366" width="366" height="19" font="1">cardiac disease or high risk for major cardiovascular events. </text>
<text top="446" left="98" width="188" height="19" font="1">Nephrologist, Endocrinologist, </text>
<text top="464" left="98" width="146" height="19" font="1">Hypertension Specialist </text>
<text top="446" left="366" width="379" height="19" font="1">Management of complex hypertension care, especially due to </text>
<text top="464" left="366" width="303" height="19" font="1">secondary causes, and/or resistant hypertension. </text>
<text top="483" left="98" width="232" height="19" font="1">Nurse (including in-office, home care, </text>
<text top="502" left="98" width="243" height="19" font="1">internal and external population health </text>
<text top="520" left="98" width="69" height="19" font="1">personnel) </text>
<text top="483" left="366" width="380" height="19" font="1">Accurate assessment of BP, medication reconciliation, patient </text>
<text top="502" left="366" width="412" height="19" font="1">education, self-management, lifestyle modification and adherence. </text>
<text top="539" left="98" width="121" height="19" font="1">Clinical Pharmacist  </text>
<text top="539" left="366" width="436" height="19" font="1">Comprehensive medication management, which involves identification </text>
<text top="557" left="366" width="386" height="19" font="1">and documentation of medication-related problems, initiating, </text>
<text top="576" left="366" width="381" height="19" font="1">modifying, and discontinuing medication to address identified </text>
<text top="594" left="366" width="393" height="19" font="1">problems, and educating patients on their medication regimen.  </text>
<text top="613" left="98" width="60" height="19" font="1">Dietician  </text>
<text top="613" left="366" width="401" height="19" font="1">Ongoing patient-centered counseling to assess dietary habits and </text>
<text top="631" left="366" width="337" height="19" font="1">preferences, set and monitor goals for healthy lifestyle </text>
<text top="651" left="98" width="88" height="19" font="1">Social Worker </text>
<text top="651" left="366" width="420" height="19" font="1">Assess for psychosocial, cultural and financial barriers, find solutions </text>
<text top="669" left="366" width="173" height="19" font="1">to overcome these barriers. </text>
<text top="688" left="98" width="182" height="19" font="1">Community Health Providers  </text>
<text top="688" left="366" width="410" height="19" font="1">Assess for psychosocial, cultural and financial barriers, identify and </text>
<text top="706" left="366" width="420" height="19" font="1">promote acceptable community-based resources to overcome these </text>
<text top="724" left="366" width="55" height="19" font="1">barriers. </text>
<text top="743" left="88" width="176" height="19" font="1">BP indicates blood pressure. </text>
<text top="782" left="81" width="4" height="23" font="3"><b> </b></text>
<text top="825" left="81" width="4" height="23" font="3"><b> </b></text>
<text top="869" left="81" width="4" height="23" font="3"><b> </b></text>
<text top="912" left="81" width="4" height="23" font="3"><b> </b></text>
<text top="955" left="81" width="4" height="23" font="3"><b> </b></text>
<text top="999" left="81" width="4" height="23" font="3"><b> </b></text>
<text top="1042" left="81" width="4" height="23" font="3"><b> </b></text>
</page>
<page number="260" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">260 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="81" width="697" height="23" font="3"><b>Data Supplement I. Examples of Telehealth Strategies and Technologies to Promote Effective </b></text>
<text top="133" left="81" width="209" height="23" font="3"><b>Hypertension Management </b></text>
<text top="168" left="98" width="137" height="19" font="4"><b>Telehealth strategies  </b></text>
<text top="187" left="98" width="517" height="20" font="1">•  Automated BP data capture and transmission of the patient’s self-measured BP  </text>
<text top="207" left="98" width="689" height="20" font="1">•  Self-management support including education, reminders, and feedback that is automated or delivered by a </text>
<text top="226" left="125" width="146" height="19" font="1">healthcare professional </text>
<text top="244" left="98" width="439" height="20" font="1">•  Medication titration and follow-up monitoring protocols/algorithm </text>
<text top="263" left="98" width="201" height="20" font="1">•  Prescription refill reminders </text>
<text top="282" left="98" width="251" height="20" font="1">•  Medication adherence assessments  </text>
<text top="301" left="98" width="255" height="20" font="1">•  Self-monitoring of lifestyle behaviors </text>
<text top="320" left="98" width="509" height="20" font="1">•  Integration of behavior change techniques, including in person or e-counseling </text>
<text top="340" left="98" width="290" height="20" font="1">•  Case/care/population health management </text>
<text top="359" left="98" width="257" height="19" font="4"><b>Commonly used telehealth technologies  </b></text>
<text top="378" left="98" width="202" height="20" font="1">•  Wired “land line” telephone </text>
<text top="398" left="98" width="240" height="20" font="1">•  Wireless smart phone applications </text>
<text top="417" left="98" width="398" height="20" font="1">•  Internet-based website via computers and handheld devices </text>
<text top="436" left="98" width="127" height="20" font="1">•  Text messaging  </text>
<text top="455" left="98" width="135" height="20" font="1">•  E-mail messaging </text>
<text top="474" left="98" width="384" height="20" font="1">•  Social networking and social media websites/applications  </text>
<text top="493" left="98" width="239" height="20" font="1">•  Wireless BP measurement devices </text>
<text top="512" left="98" width="240" height="20" font="1">•  Electronic pill dispensers/counters </text>
<text top="532" left="108" width="176" height="19" font="1">BP indicates blood pressure. </text>
<text top="568" left="108" width="3" height="19" font="1"> </text>
<text top="607" left="68" width="4" height="23" font="3"><b> </b></text>
<text top="650" left="68" width="4" height="23" font="3"><b> </b></text>
<text top="693" left="68" width="4" height="23" font="3"><b> </b></text>
<text top="737" left="68" width="4" height="23" font="3"><b> </b></text>
<text top="780" left="68" width="4" height="23" font="3"><b> </b></text>
<text top="823" left="68" width="4" height="23" font="3"><b> </b></text>
<text top="866" left="68" width="4" height="23" font="3"><b> </b></text>
<text top="910" left="68" width="4" height="23" font="3"><b> </b></text>
<text top="953" left="68" width="4" height="23" font="3"><b> </b></text>
<text top="986" left="108" width="3" height="20" font="1"> </text>
</page>
<page number="261" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">261 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="68" width="720" height="23" font="3"><b>Data Supplement J. Publicly Available Performance Measures Used to Assess Hypertension Care </b></text>
<text top="133" left="68" width="199" height="23" font="3"><b>Quality Services <a href="2017_HBP_FT_DATA_SUPPLEMENT.html#283">(363-367)</a></b><b> </b></text>
<text top="173" left="119" width="107" height="19" font="4"><b>Quality Measure </b></text>
<text top="173" left="281" width="46" height="19" font="4"><b>Source </b></text>
<text top="173" left="418" width="75" height="19" font="4"><b>Description </b></text>
<text top="173" left="659" width="146" height="19" font="4"><b>Additional information </b></text>
<text top="197" left="77" width="121" height="19" font="1">Controlling High BP </text>
<text top="215" left="77" width="161" height="19" font="1">PQRS Measure #236; NQF </text>
<text top="233" left="77" width="41" height="19" font="1">#0018 </text>
<text top="197" left="280" width="40" height="19" font="1">NCQA </text>
<text top="197" left="341" width="209" height="19" font="1">Percentage of patients 18–85 y of </text>
<text top="215" left="341" width="168" height="19" font="1">age who had a diagnosis of </text>
<text top="233" left="341" width="200" height="19" font="1">hypertension and whose BP was </text>
<text top="251" left="341" width="224" height="19" font="1">adequately controlled (&lt;140/90 mm </text>
<text top="270" left="341" width="223" height="19" font="1">Hg during the measurement period) </text>
<text top="197" left="584" width="250" height="19" font="1">Used in the CMS, PQRS, MSSP, Medicare </text>
<text top="215" left="584" width="253" height="19" font="1">Advantage “Stars” ratings; component of </text>
<text top="233" left="584" width="291" height="19" font="1">Commercial Health Plan HEDIS quality measure </text>
<text top="251" left="584" width="22" height="19" font="1">set </text>
<text top="289" left="77" width="155" height="19" font="1">Comprehensive Diabetes </text>
<text top="307" left="77" width="162" height="19" font="1">Care: BP Control (&lt;140/90 </text>
<text top="325" left="77" width="52" height="19" font="1">mm Hg) </text>
<text top="344" left="77" width="71" height="19" font="1">NQF #0061 </text>
<text top="289" left="280" width="280" height="19" font="1">NCQA   The percentage of patients 18–75 y </text>
<text top="307" left="341" width="215" height="19" font="1">of age with DM (type 1 and type 2) </text>
<text top="325" left="341" width="209" height="19" font="1">whose most recent BP level taken </text>
<text top="344" left="341" width="178" height="19" font="1">during the measurement y is </text>
<text top="362" left="341" width="102" height="19" font="1">&lt;140/90 mm Hg </text>
<text top="289" left="584" width="59" height="19" font="1">Used for: </text>
<text top="307" left="584" width="108" height="20" font="1">•  Accreditation  </text>
<text top="326" left="584" width="291" height="20" font="1">•  Decision-making by businesses about health </text>
<text top="345" left="602" width="103" height="19" font="1">plan purchasing  </text>
<text top="364" left="584" width="292" height="20" font="1">•  Decision-making by consumers about health </text>
<text top="383" left="602" width="134" height="19" font="1">plan/provider choice  </text>
<text top="401" left="584" width="198" height="20" font="1">•  External oversight/Medicaid  </text>
<text top="420" left="584" width="199" height="20" font="1">•  External oversight/Medicare  </text>
<text top="439" left="584" width="248" height="20" font="1">•  External oversight/State government </text>
<text top="458" left="602" width="59" height="19" font="1">program  </text>
<text top="477" left="584" width="205" height="20" font="1">•  Internal quality improvement  </text>
<text top="496" left="584" width="119" height="20" font="1">•  Public reporting </text>
<text top="516" left="77" width="154" height="19" font="1">Adult Kidney Disease: BP </text>
<text top="534" left="77" width="85" height="19" font="1">Management </text>
<text top="552" left="77" width="70" height="19" font="1">PQRS #122 </text>
<text top="516" left="280" width="34" height="19" font="1">PCPI, </text>
<text top="534" left="280" width="28" height="19" font="1">RPA </text>
<text top="516" left="341" width="228" height="19" font="1">Percentage of patient visits for those </text>
<text top="534" left="341" width="171" height="19" font="1">patients ≥18 y of age with a </text>
<text top="552" left="341" width="230" height="19" font="1">diagnosis of CKD (stage 3, 4, or 5, not </text>
<text top="571" left="341" width="229" height="19" font="1">receiving renal replacement therapy) </text>
<text top="589" left="341" width="180" height="19" font="1">with a BP&lt;140/90 mm Hg OR </text>
<text top="607" left="341" width="224" height="19" font="1">≥140/90 mm Hg with a documented </text>
<text top="626" left="341" width="75" height="19" font="1">plan of care </text>
<text top="516" left="584" width="85" height="19" font="1">Used in PQRS </text>
<text top="645" left="77" width="177" height="19" font="1">Percentage of patients ≥18 y </text>
<text top="663" left="77" width="187" height="19" font="1">of age with BP documented in </text>
<text top="681" left="77" width="181" height="19" font="1">the medical record (every 2 y </text>
<text top="700" left="77" width="176" height="19" font="1">if &lt;120/80 mm Hg, every y if </text>
<text top="718" left="77" width="152" height="19" font="1">120–139/80–89 mm Hg) </text>
<text top="645" left="280" width="26" height="19" font="1">ICSI </text>
<text top="645" left="341" width="211" height="19" font="1">This measure is used to assess the </text>
<text top="663" left="341" width="211" height="19" font="1">percentage of patients age 18 y of </text>
<text top="681" left="341" width="218" height="19" font="1">age and older with BP documented </text>
<text top="700" left="341" width="207" height="19" font="1">in the medical record (every 2 y if </text>
<text top="718" left="341" width="194" height="19" font="1">&lt;120/80 mm Hg, every y if 120–</text>
<text top="736" left="341" width="122" height="19" font="1">139/80–89 mm Hg) </text>
<text top="645" left="584" width="238" height="19" font="1">Used for internal quality improvement </text>
<text top="755" left="77" width="188" height="19" font="1">Controlling High BP for People </text>
<text top="774" left="77" width="170" height="19" font="1">with Serious Mental Illness  </text>
<text top="792" left="77" width="71" height="19" font="1">NQF #2602 </text>
<text top="755" left="280" width="280" height="19" font="1">NCQA   The percentage of patients 18–85 y </text>
<text top="774" left="341" width="206" height="19" font="1">of age with serious mental illness </text>
<text top="792" left="341" width="226" height="19" font="1">who had a diagnosis of hypertension </text>
<text top="810" left="341" width="188" height="19" font="1">and whose BP was adequately </text>
<text top="829" left="341" width="225" height="19" font="1">controlled during the measurement  </text>
<text top="755" left="584" width="84" height="19" font="1">Current Use:  </text>
<text top="774" left="584" width="108" height="20" font="1">•  Accreditation  </text>
<text top="793" left="584" width="291" height="20" font="1">•  Decision-making by businesses about health </text>
<text top="812" left="602" width="103" height="19" font="1">plan purchasing  </text>
<text top="830" left="584" width="292" height="20" font="1">•  Decision-making by consumers about health </text>
<text top="849" left="602" width="134" height="19" font="1">plan/provider choice  </text>
<text top="868" left="584" width="198" height="20" font="1">•  External oversight/Medicaid  </text>
<text top="887" left="584" width="247" height="20" font="1">•  External oversight/state government </text>
<text top="906" left="602" width="244" height="19" font="1">program \internal quality improvement </text>
<text top="925" left="77" width="185" height="19" font="1">Diabetes Care for People with </text>
<text top="943" left="77" width="160" height="19" font="1">Serious Mental Illness: BP </text>
<text top="961" left="77" width="160" height="19" font="1">Control (&lt;140/90 mm Hg) </text>
<text top="980" left="77" width="71" height="19" font="1">NQF #2606 </text>
<text top="925" left="280" width="280" height="19" font="1">NCQA   The percentage of patients 18–75 y </text>
<text top="943" left="341" width="216" height="19" font="1">of age with a serious mental illness </text>
<text top="961" left="341" width="213" height="19" font="1">and DM (type 1 and type 2) whose </text>
<text top="980" left="341" width="212" height="19" font="1">most recent BP reading during the </text>
<text top="998" left="341" width="214" height="19" font="1">measurement year is &lt;140/90 mm </text>
<text top="1016" left="341" width="20" height="19" font="1">Hg </text>
<text top="925" left="584" width="80" height="19" font="1">Current Use: </text>
<text top="943" left="584" width="108" height="20" font="1">•  Accreditation  </text>
<text top="962" left="584" width="291" height="20" font="1">•  Decision-making by businesses about health </text>
<text top="981" left="602" width="103" height="19" font="1">plan purchasing  </text>
<text top="1000" left="584" width="292" height="20" font="1">•  Decision-making by consumers about health </text>
<text top="1019" left="602" width="134" height="19" font="1">plan/provider choice  </text>
<text top="1037" left="584" width="198" height="20" font="1">•  External oversight/Medicaid  </text>
</page>
<page number="262" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">262 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="113" left="119" width="107" height="19" font="4"><b>Quality Measure </b></text>
<text top="113" left="281" width="46" height="19" font="4"><b>Source </b></text>
<text top="113" left="418" width="75" height="19" font="4"><b>Description </b></text>
<text top="113" left="659" width="146" height="19" font="4"><b>Additional information </b></text>
<text top="137" left="584" width="247" height="20" font="1">•  External oversight/state government </text>
<text top="156" left="602" width="59" height="19" font="1">program  </text>
<text top="175" left="584" width="202" height="20" font="1">•  Internal quality improvement </text>
<text top="194" left="77" width="172" height="19" font="1">Hypertension diagnosis and </text>
<text top="213" left="77" width="158" height="19" font="1">treatment: percentage of </text>
<text top="231" left="77" width="165" height="19" font="1">adult patients ≥18 y of age </text>
<text top="249" left="77" width="180" height="19" font="1">diagnosed with hypertension </text>
<text top="268" left="77" width="143" height="19" font="1">who are not at goal for </text>
<text top="286" left="77" width="143" height="19" font="1">hypertension and have </text>
<text top="304" left="77" width="170" height="19" font="1">received counseling on diet </text>
<text top="323" left="77" width="164" height="19" font="1">and physical activity in the </text>
<text top="341" left="77" width="71" height="19" font="1">past 12 mo </text>
<text top="194" left="280" width="26" height="19" font="1">ICSI </text>
<text top="194" left="341" width="223" height="19" font="1">Used to assess the percentage adult </text>
<text top="213" left="341" width="200" height="19" font="1">patients ≥ 18 y of age diagnosed </text>
<text top="231" left="341" width="208" height="19" font="1">with hypertension who are not at </text>
<text top="249" left="341" width="193" height="19" font="1">goal for hypertension and have </text>
<text top="268" left="341" width="197" height="19" font="1">received counseling on diet and </text>
<text top="286" left="341" width="209" height="19" font="1">physical activity in the past 12 mo </text>
<text top="194" left="584" width="244" height="19" font="1">Used for Internal Quality Improvement  </text>
<text top="360" left="77" width="162" height="19" font="1">Ambulatory care sensitive </text>
<text top="378" left="77" width="179" height="19" font="1">conditions: age-standardized </text>
<text top="397" left="77" width="188" height="19" font="1">acute care hospitalization rate </text>
<text top="415" left="77" width="130" height="19" font="1">for conditions where </text>
<text top="433" left="77" width="179" height="19" font="1">appropriate ambulatory care </text>
<text top="451" left="77" width="183" height="19" font="1">prevents or reduces the need </text>
<text top="470" left="77" width="178" height="19" font="1">for admission to the hospital </text>
<text top="488" left="77" width="183" height="19" font="1">per 100,000 population &lt;75 y </text>
<text top="506" left="77" width="41" height="19" font="1">of age </text>
<text top="360" left="280" width="32" height="19" font="1"> CIHI </text>
<text top="360" left="341" width="224" height="19" font="1">Used to assess the age-standardized </text>
<text top="378" left="341" width="209" height="19" font="1">acute care hospitalization rate for </text>
<text top="397" left="341" width="185" height="19" font="1">conditions where appropriate </text>
<text top="415" left="341" width="228" height="19" font="1">ambulatory care prevents or reduces </text>
<text top="433" left="341" width="184" height="19" font="1">the need for admission to the </text>
<text top="451" left="341" width="225" height="19" font="1">hospital per 100,000 population &lt;75 </text>
<text top="470" left="341" width="51" height="19" font="1">y of age </text>
<text top="360" left="584" width="59" height="19" font="1">Used for: </text>
<text top="378" left="582" width="183" height="20" font="1">•  Monitoring health state(s) </text>
<text top="397" left="582" width="201" height="20" font="1">•  National health policymaking </text>
<text top="417" left="582" width="136" height="20" font="1">•  National reporting </text>
<text top="436" left="582" width="246" height="20" font="1">•  State/Provincial health policymaking </text>
<text top="525" left="77" width="163" height="19" font="1">Hypertension: the relative </text>
<text top="544" left="77" width="161" height="19" font="1">resource use by members </text>
<text top="562" left="77" width="181" height="19" font="1">with hypertension during the </text>
<text top="580" left="77" width="99" height="19" font="1">measurement y </text>
<text top="525" left="280" width="283" height="19" font="1">NCQA   Used to assess the relative resource </text>
<text top="544" left="341" width="218" height="19" font="1">use by members with hypertension </text>
<text top="562" left="341" width="223" height="19" font="1">by reporting total standard cost and </text>
<text top="580" left="341" width="222" height="19" font="1">service frequency for all services for </text>
<text top="599" left="341" width="214" height="19" font="1">which the organization has paid or </text>
<text top="617" left="341" width="158" height="19" font="1">expects to pay during the </text>
<text top="635" left="341" width="99" height="19" font="1">measurement y </text>
<text top="525" left="584" width="59" height="19" font="1">Used for: </text>
<text top="544" left="582" width="105" height="20" font="1">•  Accreditation </text>
<text top="563" left="582" width="196" height="20" font="1">•  External oversight/Medicaid </text>
<text top="582" left="582" width="201" height="20" font="1">•  External oversight/Medicare  </text>
<text top="601" left="582" width="249" height="20" font="1">•  External oversight/State government </text>
<text top="620" left="602" width="56" height="19" font="1">program </text>
<text top="639" left="582" width="175" height="20" font="1">•  Monitoring and planning </text>
<text top="658" left="582" width="121" height="20" font="1">•  Public reporting </text>
<text top="678" left="68" width="751" height="19" font="1">BP indicates blood pressure; CIHI, Canadian Institute for Health Information; CKD, chronic kidney disease; CMS, Centers for </text>
<text top="699" left="68" width="786" height="19" font="1">Medicare and Medicaid Services; DM, diabetes mellitus; HEDIS, healthcare Effectiveness Data and Information Set; ICSI, Institute </text>
<text top="720" left="68" width="777" height="19" font="1">for Clinical Systems Improvement; MSSP, Medicare Shared Savings Program; NCQA, National Committee for Quality Assurance; </text>
<text top="741" left="68" width="767" height="19" font="1">NQF, National Quality Forum; OR, odds ratio; PCPI, Physician Consortium for Performance Improvement; and PQRS, Physician </text>
<text top="762" left="68" width="400" height="19" font="1">Quality Reporting System; and RPA, Renal Physicians Association. </text>
<text top="798" left="108" width="3" height="19" font="1"> </text>
<text top="834" left="108" width="3" height="19" font="1"> </text>
<text top="834" left="324" width="3" height="19" font="1"> </text>
</page>
<page number="263" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">263 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="81" width="672" height="23" font="3"><b>Data Supplement K. Online Quality Improvement Resources for Treatment and Control of </b></text>
<text top="133" left="81" width="105" height="23" font="3"><b>Hypertension </b></text>
<text top="167" left="95" width="704" height="19" font="4"><b>American College of Cardiology/American Heart Association/Centers for Disease Control</b> Science Advisory for the </text>
<text top="188" left="95" width="306" height="19" font="1">Effective Approach to High Blood Pressure Control</text>
<text top="188" left="402" width="2" height="12" font="6"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#283">i</a></text>
<text top="188" left="404" width="3" height="19" font="1"><a href="2017_HBP_FT_DATA_SUPPLEMENT.html#283"> </a></text>
<text top="224" left="94" width="370" height="19" font="7"><a href="http://content.onlinejacc.org/article.aspx?articleid=1778408">http://content.onlinejacc.org/article.aspx?articleid=1778408</a></text>
<text top="224" left="465" width="3" height="19" font="1"><a href="http://content.onlinejacc.org/article.aspx?articleid=1778408"> </a></text>
<text top="260" left="95" width="3" height="19" font="4"><b> </b></text>
<text top="297" left="95" width="672" height="19" font="4"><b>American Medical Association</b> Measure, Act and Partner (M.A.P.) to help patients control blood pressure and </text>
<text top="318" left="95" width="201" height="19" font="1">ultimately prevent heart disease </text>
<text top="354" left="95" width="676" height="19" font="7"><a href="http://www.ama-assn.org/ama/pub/about-ama/strategic-focus/improving-health-outcomes/improving-blood-pressure-control.page">http://www.ama-assn.org/ama/pub/about-ama/strategic-focus/improving-health-outcomes/improving-blood-</a></text>
<text top="375" left="95" width="135" height="19" font="7"><a href="http://www.ama-assn.org/ama/pub/about-ama/strategic-focus/improving-health-outcomes/improving-blood-pressure-control.page">pressure-control.page</a></text>
<text top="375" left="229" width="3" height="19" font="1"><a href="http://www.ama-assn.org/ama/pub/about-ama/strategic-focus/improving-health-outcomes/improving-blood-pressure-control.page"> </a></text>
<text top="411" left="95" width="3" height="19" font="4"><b> </b></text>
<text top="447" left="95" width="668" height="19" font="4"><b>United States Health and Human Services (HHS)/Centers for Disease Control (CDC)</b> Million Hearts Campaign </text>
<text top="468" left="95" width="458" height="19" font="1">Evidence-based Treatment Protocols for Improving Blood Pressure Control </text>
<text top="504" left="95" width="333" height="19" font="7"><a href="http://millionhearts.hhs.gov/resources/protocols.html">http://millionhearts.hhs.gov/resources/protocols.html</a></text>
<text top="504" left="428" width="3" height="19" font="1"><a href="http://millionhearts.hhs.gov/resources/protocols.html"> </a></text>
<text top="540" left="95" width="3" height="19" font="4"><b> </b></text>
<text top="576" left="95" width="264" height="19" font="4"><b>Department of Defense/Veterans’ Affairs  </b></text>
<text top="612" left="95" width="324" height="19" font="7"><a href="http://www.healthquality.va.gov/guidelines/CD/htn/">http://www.healthquality.va.gov/guidelines/CD/htn/</a></text>
<text top="612" left="419" width="3" height="19" font="1"><a href="http://www.healthquality.va.gov/guidelines/CD/htn/"> </a></text>
<text top="648" left="95" width="3" height="19" font="4"><b> </b></text>
<text top="684" left="95" width="567" height="19" font="4"><b>Kaiser Permanente</b> Hypertension Management programs to improve blood pressure control </text>
<text top="720" left="95" width="333" height="19" font="7"><a href="http://kpcmi.org/how-we-work/hypertension-control/">http://kpcmi.org/how-we-work/hypertension-control/</a></text>
<text top="720" left="427" width="3" height="19" font="1"><a href="http://kpcmi.org/how-we-work/hypertension-control/"> </a></text>
<text top="756" left="95" width="3" height="19" font="4"><b> </b></text>
<text top="792" left="95" width="613" height="19" font="4"><b>Institute for Clinical Systems Improvement (ICSI) </b>Hypertension Diagnosis and Treatment Guidelines </text>
<text top="829" left="95" width="710" height="19" font="7"><a href="https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_cardiovascular_guidelines/hypertension/">https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_cardiovascular_g</a></text>
<text top="850" left="95" width="147" height="19" font="7"><a href="https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_cardiovascular_guidelines/hypertension/">uidelines/hypertension/</a></text>
<text top="850" left="242" width="3" height="19" font="1"><a href="https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_cardiovascular_guidelines/hypertension/"> </a></text>
<text top="885" left="95" width="3" height="19" font="4"><b> </b></text>
<text top="921" left="95" width="575" height="19" font="4"><b>New York Health and Hospitals Corporation (HHC) </b>Hypertension Collaborative Care Pathway  </text>
<text top="958" left="95" width="445" height="19" font="7"><a href="http://millionhearts.hhs.gov/Docs/NYC_HHC_Hypertension_Protocol.pdf">http://millionhearts.hhs.gov/Docs/NYC_HHC_Hypertension_Protocol.pdf</a></text>
<text top="958" left="540" width="3" height="19" font="1"><a href="http://millionhearts.hhs.gov/Docs/NYC_HHC_Hypertension_Protocol.pdf"> </a></text>
<text top="994" left="95" width="3" height="19" font="1"> </text>
</page>
<page number="264" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">264 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="106" left="81" width="84" height="24" font="3"><b>References </b></text>
<text top="145" left="81" width="4" height="24" font="3"><b> </b></text>
<text top="186" left="108" width="15" height="19" font="1">1. </text>
<text top="186" left="149" width="665" height="19" font="1">Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch. </text>
<text top="207" left="149" width="194" height="19" font="1">Intern. Med. 1999; 159:1104-9. </text>
<text top="228" left="108" width="15" height="19" font="1">2. </text>
<text top="228" left="149" width="665" height="19" font="1">Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. The New England journal of medicine. </text>
<text top="249" left="149" width="107" height="19" font="1">2012; 366:321-9. </text>
<text top="270" left="108" width="15" height="19" font="1">3. </text>
<text top="270" left="149" width="665" height="19" font="1">Franklin SS, Thijs L, Hansen TW, et al. Significance of white-coat hypertension in older persons with isolated </text>
<text top="291" left="149" width="668" height="19" font="1">systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure </text>
<text top="312" left="149" width="585" height="19" font="1">Monitoring in Relation to Cardiovascular Outcomes population. Hypertension. 2012; 59:564-71. </text>
<text top="333" left="108" width="15" height="19" font="1">4. </text>
<text top="333" left="149" width="669" height="19" font="1">Guo X, Zhang X, Guo L, et al. Association between pre-hypertension and cardiovascular outcomes: a </text>
<text top="354" left="149" width="609" height="19" font="1">systematic review and meta-analysis of prospective studies. Curr. Hypertens. Rep. 2013; 15:703-16. </text>
<text top="375" left="108" width="15" height="19" font="1">5. </text>
<text top="375" left="149" width="665" height="19" font="1">Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC </text>
<text top="396" left="148" width="122" height="19" font="1">Med. 2013; 11:177. </text>
<text top="417" left="108" width="15" height="19" font="1">6. </text>
<text top="417" left="148" width="665" height="19" font="1">Huang Y, Cai X, Zhang J, et al. Prehypertension and Incidence of ESRD: a systematic review and meta-analysis. </text>
<text top="438" left="148" width="660" height="19" font="1">American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014; 63:76-83. </text>
<text top="459" left="108" width="15" height="19" font="1">7. </text>
<text top="459" left="148" width="661" height="19" font="1">Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a meta-analysis. Neurology. 2014; 82:1153-</text>
<text top="480" left="148" width="22" height="19" font="1">61. </text>
<text top="501" left="108" width="15" height="19" font="1">8. </text>
<text top="501" left="148" width="662" height="19" font="1">Huang Y, Su L, Cai X, et al. Association of all-cause and cardiovascular mortality with prehypertension: a meta-</text>
<text top="522" left="148" width="239" height="19" font="1">analysis. Am. Heart J. 2014; 167:160-8. </text>
<text top="544" left="108" width="15" height="19" font="1">9. </text>
<text top="544" left="148" width="666" height="19" font="1">Huang Y, Cai X, Liu C, et al. Prehypertension and the risk of coronary heart disease in Asian and Western </text>
<text top="565" left="148" width="497" height="19" font="1">populations: a meta-analysis. Journal of the American Heart Association. 2015; 4. </text>
<text top="586" left="108" width="702" height="19" font="1">10.  Lee M, Saver JL, Chang B, et al. Presence of baseline prehypertension and risk of incident stroke: a meta-</text>
<text top="607" left="148" width="232" height="19" font="1">analysis. Neurology. 2011; 77:1330-7. </text>
<text top="628" left="108" width="705" height="19" font="1">11.  Shen L, Ma H, Xiang MX, et al. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary </text>
<text top="649" left="149" width="423" height="19" font="1">heart disease. The American journal of cardiology. 2013; 112:266-71. </text>
<text top="670" left="108" width="705" height="19" font="1">12.  Wang S, Wu H, Zhang Q, et al. Impact of baseline prehypertension on cardiovascular events and all-cause </text>
<text top="691" left="149" width="668" height="19" font="1">mortality in the general population: a meta-analysis of prospective cohort studies. Int. J. Cardiol. 2013; </text>
<text top="712" left="149" width="84" height="19" font="1">168:4857-60. </text>
<text top="733" left="108" width="707" height="19" font="1">13.  Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North </text>
<text top="754" left="149" width="665" height="19" font="1">American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). </text>
<text top="775" left="149" width="301" height="19" font="1">J. Clin. Hypertens. (Greenwich). 2002; 4:393-404. </text>
<text top="796" left="108" width="705" height="19" font="1">14.  Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention </text>
<text top="817" left="149" width="668" height="19" font="1">For Endpoint reduction in hypertension study (LIFE): a randomised  trial against atenolol. Lancet. 2002; </text>
<text top="838" left="149" width="92" height="19" font="1">359:995-1003. </text>
<text top="859" left="108" width="702" height="19" font="1">15.  Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-</text>
<text top="881" left="149" width="615" height="19" font="1">analysis on 11,000 participants from 42 trials. The American journal of medicine. 2009; 122:290-300. </text>
<text top="902" left="108" width="705" height="19" font="1">16.  Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: </text>
<text top="923" left="148" width="665" height="19" font="1">a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360:1903-13. </text>
<text top="944" left="108" width="707" height="19" font="1">17.  Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and </text>
<text top="965" left="148" width="446" height="19" font="1">death: a systematic review and meta-analysis. Lancet. 2016; 387:957-67. </text>
<text top="986" left="108" width="705" height="19" font="1">18.  Law MR, Morris JK and Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular </text>
<text top="1007" left="148" width="672" height="19" font="1">disease: meta-analysis of 147 randomised trials in the context of expectations from prospective </text>
<text top="1028" left="148" width="428" height="19" font="1">epidemiological studies. BMJ (Clinical research ed.). 2009; 338:b1665. </text>
</page>
<page number="265" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">265 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="705" height="19" font="1">19.  Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic </text>
<text top="129" left="149" width="388" height="19" font="1">review and meta-analysis. Ann. Intern. Med. 2015; 162:184-91. </text>
<text top="150" left="108" width="708" height="19" font="1">20.  Thomopoulos C, Parati G and Zanchetti A. Effects of blood pressure lowering on outcome incidence in </text>
<text top="171" left="149" width="665" height="19" font="1">hypertension: 2. Effects at different baseline and achieved blood pressure levels--overview and meta-analyses </text>
<text top="192" left="149" width="333" height="19" font="1">of randomized trials. J. Hypertens. 2014; 32:2296-304. </text>
<text top="213" left="108" width="705" height="19" font="1">21.  Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: </text>
<text top="234" left="149" width="370" height="19" font="1">updated systematic review and meta-analysis. Lancet. 2015. </text>
<text top="255" left="108" width="694" height="19" font="1">22.  Pickering TG, James GD, Boddie C, et al. How common is white coat hypertension? JAMA. 1988; 259:225-8. </text>
<text top="277" left="108" width="709" height="19" font="1">23.  Uhlig K, Balk EM, Patel K, et al. Self-measured blood pressure monitoring: comparative effectiveness. </text>
<text top="298" left="148" width="666" height="19" font="1">Comparative Effectiveness Review No. 45. Rockville, MD: Agency for Healthcare Research and Quality, U.S. </text>
<text top="319" left="148" width="306" height="19" font="1">Department of Health and Human Services, 2012. </text>
<text top="340" left="108" width="705" height="19" font="1">24.  McManus RJ, Mant J, Haque MS, et al. Effect of self-monitoring and medication self-titration on systolic blood </text>
<text top="361" left="148" width="666" height="19" font="1">pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical </text>
<text top="382" left="148" width="196" height="19" font="1">trial. JAMA. 2014; 312:799-808. </text>
<text top="403" left="108" width="708" height="19" font="1">25.  Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist </text>
<text top="424" left="148" width="606" height="19" font="1">management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013; 310:46-56. </text>
<text top="445" left="108" width="705" height="19" font="1">26.  Yi SS, Tabaei BP, Angell SY, et al. Self-blood pressure monitoring in an urban, ethnically diverse population: a </text>
<text top="466" left="148" width="670" height="19" font="1">randomized clinical trial utilizing the electronic health record. Circulation.Cardiovascular quality and </text>
<text top="487" left="148" width="167" height="19" font="1">outcomes. 2015; 8:138-45. </text>
<text top="508" left="108" width="705" height="19" font="1">27.  Agarwal R, Bills JE, Hecht TJ, et al. Role of home blood pressure monitoring in overcoming therapeutic inertia </text>
<text top="529" left="148" width="656" height="19" font="1">and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011; 57:29-38. </text>
<text top="550" left="108" width="708" height="19" font="1">28.  Fagard RH and Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained </text>
<text top="571" left="148" width="540" height="19" font="1">hypertension versus true normotension: a meta-analysis. J. Hypertens. 2007; 25:2193-8. </text>
<text top="593" left="108" width="705" height="19" font="1">29.  Viera AJ, Hinderliter AL, Kshirsagar AV, et al. Reproducibility of masked hypertension in adults with untreated </text>
<text top="614" left="148" width="666" height="19" font="1">borderline office blood pressure: comparison of ambulatory and home monitoring. Am. J. Hypertens. 2010; </text>
<text top="635" left="148" width="69" height="19" font="1">23:1190-7. </text>
<text top="656" left="108" width="705" height="19" font="1">30.  Viera AJ, Lin FC, Tuttle LA, et al. Reproducibility of masked hypertension among adults 30 years or older. Blood </text>
<text top="677" left="148" width="190" height="19" font="1">Press. Monit. 2014; 19:208-15. </text>
<text top="698" left="108" width="705" height="19" font="1">31.  Bayo J, Cos FX, Roca C, et al. Home blood pressure self-monitoring: diagnostic performance in white-coat </text>
<text top="719" left="148" width="309" height="19" font="1">hypertension. Blood Press. Monit. 2006; 11:47-52. </text>
<text top="740" left="108" width="706" height="19" font="1">32.  Asayama K, Thijs L, Li Y, et al. Setting thresholds to varying blood pressure monitoring intervals differentially </text>
<text top="761" left="148" width="665" height="19" font="1">affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension </text>
<text top="782" left="148" width="107" height="19" font="1">2014; 64:935-42. </text>
<text top="803" left="108" width="705" height="19" font="1">33.  Conen D, Aeschbacher S, Thijs L, et al. Age-specific differences between conventional and ambulatory daytime </text>
<text top="824" left="148" width="337" height="19" font="1">blood pressure values. Hypertension. 2014; 64:1073-9. </text>
<text top="845" left="108" width="706" height="19" font="1">34.  Nasothimiou EG, Tzamouranis D, Rarra V, et al. Diagnostic accuracy of home vs. ambulatory blood pressure </text>
<text top="866" left="148" width="666" height="19" font="1">monitoring in untreated and treated hypertension. Hypertension research : official journal of the Japanese </text>
<text top="887" left="148" width="252" height="19" font="1">Society of Hypertension. 2012; 35:750-5. </text>
<text top="908" left="108" width="705" height="19" font="1">35.  Coll de TG, Llibre JB, Poncelas AR, et al. Isolated clinical hypertension diagnosis: self-home BP, ambulatory BP </text>
<text top="929" left="148" width="440" height="19" font="1">monitoring, or both simultaneously? Blood Press. Monit. 2011; 16:11-5. </text>
<text top="950" left="108" width="705" height="19" font="1">36.  Stergiou GS, Salgami EV, Tzamouranis DG, et al. Masked hypertension assessed by ambulatory blood pressure </text>
<text top="971" left="148" width="637" height="19" font="1">versus home blood pressure monitoring: is it the same phenomenon? Am. J. Hypertens. 2005; 18:772-8. </text>
<text top="993" left="108" width="709" height="19" font="1">37.  Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, </text>
<text top="1014" left="148" width="665" height="19" font="1">ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro </text>
<text top="1035" left="148" width="383" height="19" font="1">Associazioni [PAMELA] Study). Circulation. 2001; 104:1385-92. </text>
</page>
<page number="266" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">266 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="707" height="19" font="1">38.  Vinyoles E, Felip A, Pujol E, et al. Clinical characteristics of isolated clinic hypertension. J. Hypertens. 2008; </text>
<text top="129" left="149" width="69" height="19" font="1">26:438-45. </text>
<text top="150" left="108" width="705" height="19" font="1">39.  Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screening methods </text>
<text top="171" left="149" width="666" height="19" font="1">with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. </text>
<text top="192" left="149" width="233" height="19" font="1">Ann. Intern. Med. 2015; 162:192-204. </text>
<text top="213" left="108" width="705" height="19" font="1">40.  Alwan H, Pruijm M, Ponte B, et al. Epidemiology of masked and white-coat hypertension: the family-based </text>
<text top="234" left="149" width="266" height="19" font="1">SKIPOGH study. PLoS One. 2014; 9:e92522. </text>
<text top="255" left="108" width="708" height="19" font="1">41.  Stergiou GS, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: International </text>
<text top="277" left="149" width="648" height="19" font="1">Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension. 2014; 63:675-82. </text>
<text top="298" left="108" width="707" height="19" font="1">42.  Pierdomenico SD and Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by </text>
<text top="319" left="149" width="665" height="19" font="1">ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am. J. Hypertens.  2011; </text>
<text top="340" left="148" width="54" height="19" font="1">24:52-8. </text>
<text top="361" left="108" width="706" height="19" font="1">43.  Hansen TW, Kikuya M, Thijs L, et al. Prognostic superiority of daytime ambulatory over conventional blood </text>
<text top="382" left="148" width="600" height="19" font="1">pressure in four populations: a meta-analysis of 7,030 individuals. J. Hypertens. 2007; 25:1554-64. </text>
<text top="403" left="108" width="709" height="19" font="1">44.  National Instutite for Health and Clinical Excellence. Hypertension: the clinical management of primary </text>
<text top="424" left="148" width="560" height="19" font="1">hypertnesion in adults: clincial guidelines: methods, evidence and recommendations. 2011. </text>
<text top="445" left="108" width="705" height="19" font="1">45.  Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. </text>
<text top="466" left="148" width="189" height="19" font="1">Hypertension. 2005; 45:203-8. </text>
<text top="487" left="108" width="706" height="19" font="1">46.  Mancia G, Bombelli M, Brambilla G, et al. Long-term prognostic value of white coat hypertension: an insight </text>
<text top="508" left="148" width="668" height="19" font="1">from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013; </text>
<text top="529" left="148" width="69" height="19" font="1">62:168-74. </text>
<text top="550" left="108" width="705" height="19" font="1">47.  Tomiyama M, Horio T, Yoshii M, et al. Masked hypertension and target organ damage in treated hypertensive </text>
<text top="571" left="148" width="266" height="19" font="1">patients. Am. J. Hypertens. 2006; 19:880-6. </text>
<text top="593" left="108" width="707" height="19" font="1">48.  Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of &#34;masked&#34; hypertension and &#34;white-coat&#34; hypertension </text>
<text top="614" left="148" width="665" height="19" font="1">detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J. Am. </text>
<text top="635" left="148" width="187" height="19" font="1">Coll. Cardiol. 2005; 46:508-15. </text>
<text top="656" left="108" width="706" height="19" font="1">49.  Tientcheu D, Ayers C, Das SR, et al. Target Organ Complications and Cardiovascular Events Associated With </text>
<text top="677" left="148" width="668" height="19" font="1">Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study. J. Am. Coll. </text>
<text top="698" left="148" width="165" height="19" font="1">Cardiol. 2015; 66:2159-69. </text>
<text top="719" left="108" width="705" height="19" font="1">50.  Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. </text>
<text top="740" left="148" width="189" height="19" font="1">J. Hypertens. 2003; 21:707-16. </text>
<text top="761" left="108" width="705" height="19" font="1">51.  Riaz IB, Husnain M, Riaz H, et al. Meta-analysis of revascularization versus medical therapy for atherosclerotic </text>
<text top="782" left="148" width="474" height="19" font="1">renal artery stenosis. The American journal of cardiology. 2014; 114:1116-23. </text>
<text top="803" left="108" width="705" height="19" font="1">52.  Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. </text>
<text top="824" left="148" width="342" height="19" font="1">The New England journal of medicine. 2014; 370:13-22. </text>
<text top="845" left="108" width="708" height="19" font="1">53.  Brunstr”m M and Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in </text>
<text top="866" left="148" width="668" height="19" font="1">patients  with diabetes mellitus: systematic review and meta-analyses. BMJ (Clinical research ed.). 2016; </text>
<text top="887" left="148" width="60" height="19" font="1">352:i717. </text>
<text top="908" left="108" width="708" height="19" font="1">54.  Thomopoulos C, Parati G and Zanchetti A. Effects of blood pressure lowering on outcome incidence in </text>
<text top="929" left="148" width="667" height="19" font="1">hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood </text>
<text top="950" left="148" width="652" height="19" font="1">pressure levels - updated overview and meta-analyses of randomized trials. J. Hypertens. 2016; 34:613-22. </text>
<text top="971" left="108" width="705" height="19" font="1">55.  Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor </text>
<text top="993" left="148" width="409" height="19" font="1">blocker. The New England journal of medicine. 2006; 354:1685-97. </text>
<text top="1014" left="108" width="706" height="19" font="1">56.  Ference BA, Julius S, Mahajan N, et al. Clinical effect of naturally random allocation to lower systolic blood </text>
<text top="1035" left="148" width="572" height="19" font="1">pressure beginning before the development of hypertension. Hypertension. 2014; 63:1182-8. </text>
</page>
<page number="267" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">267 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="709" height="19" font="1">57.  Barbe F, Duran-Cantolla J, Capote F, et al. Long-term effect of continuous positive airway pressure in </text>
<text top="129" left="149" width="541" height="19" font="1">hypertensive patients with sleep apnea. Am. J. Respir. Crit. Care Med. 2010; 181:718-26. </text>
<text top="150" left="108" width="706" height="19" font="1">58.  Martinez-Garcia MA, Capote F, Campos-Rodriguez F, et al. Effect of CPAP on blood pressure in patients with </text>
<text top="171" left="149" width="667" height="19" font="1">obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013; </text>
<text top="192" left="149" width="84" height="19" font="1">310:2407-15. </text>
<text top="213" left="108" width="706" height="19" font="1">59.  Lozano L, Tovar JL, Sampol G, et al. Continuous positive airway pressure treatment in sleep apnea patients </text>
<text top="234" left="149" width="552" height="19" font="1">with resistant hypertension: a randomized, controlled trial. J. Hypertens. 2010; 28:2161-8. </text>
<text top="255" left="108" width="705" height="19" font="1">60.  Muxfeldt ES, Margallo V, Costa LM, et al. Effects of continuous positive airway pressure treatment on clinic </text>
<text top="277" left="149" width="668" height="19" font="1">and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a </text>
<text top="298" left="149" width="370" height="19" font="1">randomized controlled trial. Hypertension. 2015; 65:736-42. </text>
<text top="319" left="108" width="709" height="19" font="1">61.  Pedrosa RP, Drager LF, de Paula LK, et al. Effects of OSA treatment on BP in patients  with resistant </text>
<text top="340" left="149" width="370" height="19" font="1">hypertension: a randomized trial. Chest. 2013; 144:1487-94. </text>
<text top="361" left="108" width="706" height="19" font="1">62.  Whelton SP, Hyre AD, Pedersen B, et al. Effect of dietary fiber intake on blood pressure: a meta-analysis of </text>
<text top="382" left="149" width="417" height="19" font="1">randomized, controlled clinical trials. J. Hypertens. 2005; 23:475-81. </text>
<text top="403" left="108" width="708" height="19" font="1">63.  Streppel MT, Arends LR, van tV, et al. Dietary fiber and blood pressure: a meta-analysis of randomized </text>
<text top="424" left="149" width="378" height="19" font="1">placebo-controlled trials. Arch. Intern. Med. 2005; 165:150-6. </text>
<text top="445" left="108" width="706" height="19" font="1">64.  Evans CE, Greenwood DC, Threapleton DE, et al. Effects of dietary fibre type on blood pressure: a systematic </text>
<text top="466" left="149" width="662" height="19" font="1">review and meta-analysis of randomized controlled trials of healthy individuals. J. Hypertens. 2015; 33:897-</text>
<text top="487" left="149" width="30" height="19" font="1">911. </text>
<text top="508" left="108" width="705" height="19" font="1">65.  Campbell F, Dickinson HO, Critchley JA, et al. A systematic review of fish-oil supplements for the prevention </text>
<text top="529" left="149" width="566" height="19" font="1">and treatment of hypertension. European journal of preventive cardiology. 2013; 20:107-20. </text>
<text top="550" left="108" width="710" height="19" font="1">66.  Rodriguez-Leyva D, Weighell W, Edel AL, et al. Potent antihypertensive action of dietary flaxseed in </text>
<text top="571" left="149" width="336" height="19" font="1">hypertensive patients. Hypertension. 2013; 62:1081-9. </text>
<text top="593" left="108" width="706" height="19" font="1">67.  Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized </text>
<text top="614" left="149" width="312" height="19" font="1">controlled clinical trials. JAMA. 1997; 277:1624-32. </text>
<text top="635" left="108" width="705" height="19" font="1">68.  Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk factors and </text>
<text top="656" left="149" width="561" height="19" font="1">disease: systematic review and meta-analyses. BMJ (Clinical research ed.). 2013; 346:f1378. </text>
<text top="677" left="108" width="705" height="19" font="1">69.  Geleijnse JM, Kok FJ and Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a </text>
<text top="698" left="149" width="504" height="19" font="1">metaregression analysis of randomised trials. J. Hum. Hypertens. 2003; 17:471-80. </text>
<text top="719" left="108" width="707" height="19" font="1">70.  Rebholz CM, Friedman EE, Powers LJ, et al. Dietary protein intake and blood pressure: a meta-analysis of </text>
<text top="740" left="148" width="456" height="19" font="1">randomized controlled trials. Am. J. Epidemiol. 2012; 176 Suppl 7:S27-S43. </text>
<text top="761" left="108" width="706" height="19" font="1">71.  Tielemans SM, Altorf-van der Kuil W, Engberink MF, et al. Intake of total protein, plant protein and animal </text>
<text top="782" left="148" width="667" height="19" font="1">protein in relation to blood pressure: a meta-analysis of observational and intervention studies. J. Hum. </text>
<text top="803" left="148" width="177" height="19" font="1">Hypertens. 2013; 27:564-71. </text>
<text top="824" left="108" width="705" height="19" font="1">72.  Dong JY, Zhang ZL, Wang PY, et al. Effects of high-protein diets on body weight, glycaemic control, blood lipids </text>
<text top="845" left="148" width="666" height="19" font="1">and blood pressure in type 2 diabetes: meta-analysis of randomised controlled trials. The British journal of </text>
<text top="866" left="148" width="168" height="19" font="1">nutrition. 2013; 110:781-9. </text>
<text top="887" left="108" width="706" height="19" font="1">73.  Dong JY, Szeto IM, Makinen K, et al. Effect of probiotic fermented milk on blood pressure: a meta-analysis of </text>
<text top="908" left="148" width="369" height="19" font="1">randomised controlled trials. Br. J. Nutr. 2013; 110:1188-94. </text>
<text top="929" left="108" width="706" height="19" font="1">74.  Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption and death from cardiovascular causes. </text>
<text top="950" left="148" width="349" height="19" font="1">The New England journal of medicine. 2014; 371:624-34. </text>
<text top="971" left="108" width="705" height="19" font="1">75.  He FJ, Fan S, MacGregor GA, et al. Plasma sodium and blood pressure in individuals on haemodialysis. J. Hum. </text>
<text top="993" left="149" width="162" height="19" font="1">Hypertens. 2013; 27:85-9. </text>
</page>
<page number="268" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">268 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="708" height="19" font="1">76.  Graudal NA, Hubeck-Graudal T and Jurgens G. Effects of low-sodium diet vs. high-sodium diet on blood </text>
<text top="129" left="149" width="670" height="19" font="1">pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am. J. </text>
<text top="150" left="149" width="162" height="19" font="1">Hypertens. 2012; 25:1-15. </text>
<text top="171" left="108" width="705" height="19" font="1">77.  Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary </text>
<text top="192" left="149" width="664" height="19" font="1">Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. The New England </text>
<text top="213" left="149" width="225" height="19" font="1">journal of medicine. 2001; 344:3-10. </text>
<text top="234" left="108" width="705" height="19" font="1">78.  Kumanyika SK, Cook NR, Cutler JA, et al. Sodium reduction for hypertension prevention in overweight adults: </text>
<text top="255" left="149" width="627" height="19" font="1">further results from the Trials of Hypertension Prevention Phase II. J. Hum. Hypertens. 2005; 19:33-45. </text>
<text top="277" left="108" width="705" height="19" font="1">79.  The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results </text>
<text top="298" left="149" width="466" height="19" font="1">of the Trials of Hypertension Prevention, Phase I. JAMA. 1992; 267:1213-20. </text>
<text top="319" left="108" width="707" height="19" font="1">80.  Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular </text>
<text top="340" left="149" width="667" height="19" font="1">disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ (Clinical </text>
<text top="361" left="149" width="194" height="19" font="1">research ed.). 2007; 334:885-8. </text>
<text top="382" left="108" width="705" height="19" font="1">81.  Canter PH and Ernst E. Insufficient evidence to conclude whether or not Transcendental Meditation decreases </text>
<text top="403" left="149" width="653" height="19" font="1">blood pressure: results of a systematic review of randomized clinical trials. J. Hypertens. 2004; 22:2049-54. </text>
<text top="424" left="108" width="707" height="19" font="1">82.  Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. </text>
<text top="445" left="149" width="583" height="19" font="1">DASH Collaborative Research Group. The New England journal of medicine. 1997; 336:1117-24. </text>
<text top="466" left="108" width="705" height="19" font="1">83.  Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure </text>
<text top="487" left="149" width="468" height="19" font="1">control: main results of the PREMIER clinical trial. JAMA. 2003; 289:2083-93. </text>
<text top="508" left="108" width="705" height="19" font="1">84.  Appel LJ, Sacks FM, Carey VJ, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood </text>
<text top="529" left="149" width="590" height="19" font="1">pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005; 294:2455-64. </text>
<text top="550" left="108" width="706" height="19" font="1">85.  Bazzano LA, Hu T, Reynolds K, et al. Effects of low-carbohydrate and low-fat diets: a randomized trial. Ann. </text>
<text top="571" left="149" width="194" height="19" font="1">Intern. Med. 2014; 161:309-18. </text>
<text top="593" left="108" width="707" height="19" font="1">86.  Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and </text>
<text top="614" left="149" width="661" height="19" font="1">cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 2006; 166:285-</text>
<text top="635" left="149" width="22" height="19" font="1">93. </text>
<text top="656" left="108" width="705" height="19" font="1">87.  Nordmann AJ, Suter-Zimmermann K, Bucher HC, et al. Meta-analysis comparing Mediterranean to low-fat </text>
<text top="677" left="148" width="643" height="19" font="1">diets for modification of cardiovascular risk factors. The American journal of medicine. 2011; 124:841-51. </text>
<text top="698" left="108" width="707" height="19" font="1">88.  Yokoyama Y, Nishimura K, Barnard ND, et al. Vegetarian diets and blood pressure: a meta-analysis. JAMA </text>
<text top="719" left="148" width="229" height="19" font="1">internal medicine. 2014; 174:577-87. </text>
<text top="740" left="108" width="706" height="19" font="1">89.  Toledo E, Hu FB, Estruch R, et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: </text>
<text top="761" left="148" width="416" height="19" font="1">results from a randomized controlled trial. BMC Med. 2013; 11:207. </text>
<text top="782" left="108" width="706" height="19" font="1">90.  Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized </text>
<text top="803" left="148" width="299" height="19" font="1">controlled trials. Hypertension. 2001; 38:1112-7. </text>
<text top="824" left="108" width="705" height="19" font="1">91.  Stewart SH, Latham PK, Miller PM, et al. Blood pressure reduction during treatment for alcohol dependence: </text>
<text top="845" left="148" width="668" height="19" font="1">results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. </text>
<text top="866" left="148" width="180" height="19" font="1">Addiction. 2008; 103:1622-8. </text>
<text top="887" left="108" width="708" height="19" font="1">92.  Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a </text>
<text top="908" left="148" width="497" height="19" font="1">systematic review of randomized controlled trials. J. Hypertens. 2006; 24:215-33. </text>
<text top="929" left="108" width="705" height="19" font="1">93.  Wallace P, Cutler S and Haines A. Randomised controlled trial of general practitioner intervention in patients </text>
<text top="950" left="148" width="366" height="19" font="1">with excessive alcohol consumption. BMJ. 1988; 297:663-8. </text>
<text top="971" left="108" width="709" height="19" font="1">94.  Lang T, Nicaud V, Darne B, et al. Improving hypertension control among excessive alcohol drinkers: a </text>
<text top="993" left="148" width="653" height="19" font="1">randomised controlled trial in France. The WALPA Group. J. Epidemiol. Community Health. 1995; 49:610-6. </text>
<text top="1014" left="108" width="702" height="19" font="1">95.  van Mierlo LA, Arends LR, Streppel MT, et al. Blood pressure response to calcium supplementation: a meta-</text>
<text top="1035" left="148" width="472" height="19" font="1">analysis of randomized controlled trials. J. Hum. Hypertens. 2006; 20:571-80. </text>
</page>
<page number="269" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">269 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="705" height="19" font="1">96.  Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, </text>
<text top="129" left="149" width="337" height="19" font="1">controlled trials. Ann. Intern. Med. 2002; 136:493-503. </text>
<text top="150" left="108" width="705" height="19" font="1">97.  Cornelissen VA and Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. </text>
<text top="171" left="149" width="373" height="19" font="1">Journal of the American Heart Association. 2013; 2:e004473. </text>
<text top="192" left="108" width="709" height="19" font="1">98.  Rossi AM, Moullec G, Lavoie KL, et al. The evolution of a Canadian Hypertension Education Program </text>
<text top="213" left="149" width="666" height="19" font="1">recommendation: the impact of resistance training on resting blood pressure in adults as an example. The </text>
<text top="234" left="149" width="292" height="19" font="1">Canadian journal of cardiology. 2013; 29:622-7. </text>
<text top="255" left="108" width="708" height="19" font="1">99.  Garcia-Hermoso A, Saavedra JM and Escalante Y. Effects of exercise on resting blood pressure in obese </text>
<text top="277" left="148" width="669" height="19" font="1">children: a meta-analysis of randomized controlled trials. Obesity reviews : an official journal of the </text>
<text top="298" left="148" width="415" height="19" font="1">International Association for the Study of Obesity. 2013; 14:919-28. </text>
<text top="319" left="108" width="705" height="19" font="1">100.  Carlson DJ, Dieberg G, Hess NC, et al. Isometric exercise training for blood pressure management: a systematic </text>
<text top="340" left="148" width="371" height="19" font="1">review and meta-analysis. Mayo Clin. Proc. 2014; 89:327-34. </text>
<text top="361" left="108" width="706" height="19" font="1">101.  Cornelissen VA, Fagard RH, Coeckelberghs E, et al. Impact of resistance training on blood pressure and other </text>
<text top="382" left="148" width="651" height="19" font="1">cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension. 2011; 58:950-8. </text>
<text top="403" left="108" width="705" height="19" font="1">102.  Kass L, Weekes J and Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. </text>
<text top="424" left="148" width="204" height="19" font="1">Eur. J. Clin. Nutr. 2012; 66:411-8. </text>
<text top="445" left="108" width="709" height="19" font="1">103.  Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of </text>
<text top="466" left="148" width="376" height="19" font="1">randomized controlled trials. Hypertension. 2003; 42:878-84. </text>
<text top="487" left="108" width="705" height="19" font="1">104.  Ho M, Garnett SP, Baur L, et al. Effectiveness of lifestyle interventions in child obesity: systematic review with </text>
<text top="508" left="148" width="295" height="19" font="1">meta-analysis. Pediatrics. 2012; 130:e1647-e71. </text>
<text top="529" left="108" width="705" height="19" font="1">105.  Cai L, Wu Y, Wilson RF, et al. Effect of childhood obesity prevention programs on blood pressure: a systematic </text>
<text top="550" left="148" width="349" height="19" font="1">review and meta-analysis. Circulation. 2014; 129:1832-9. </text>
<text top="571" left="108" width="707" height="19" font="1">106.  Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in </text>
<text top="593" left="148" width="667" height="19" font="1">overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The </text>
<text top="614" left="148" width="626" height="19" font="1">Trials of Hypertension Prevention Collaborative Research Group. Arch. Intern. Med. 1997; 157:657-67. </text>
<text top="635" left="108" width="705" height="19" font="1">107.  Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension </text>
<text top="656" left="148" width="664" height="19" font="1">in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE </text>
<text top="677" left="148" width="345" height="19" font="1">Collaborative Research Group. JAMA. 1998; 279:839-46. </text>
<text top="698" left="108" width="708" height="19" font="1">108.  Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during </text>
<text top="719" left="148" width="326" height="19" font="1">treatment of hypertension. JAMA. 2004; 292:2350-6. </text>
<text top="740" left="108" width="705" height="19" font="1">109.  Armstrong AC, Jacobs DR, Jr., Gidding SS, et al. Framingham score and LV mass predict events in young adults: </text>
<text top="761" left="148" width="283" height="19" font="1">CARDIA study. Int. J. Cardiol. 2014; 172:350-5. </text>
<text top="782" left="108" width="705" height="19" font="1">110.  Okwuosa TM, Soliman EZ, Lopez F, et al. Left ventricular hypertrophy and cardiovascular disease risk </text>
<text top="803" left="148" width="665" height="19" font="1">prediction and reclassification in blacks and whites: the Atherosclerosis Risk in Communities Study. Am. Heart </text>
<text top="824" left="148" width="126" height="19" font="1">J. 2015; 169:155-61. </text>
<text top="845" left="108" width="707" height="19" font="1">111.  Zalawadiya SK, Gunasekaran PC, Bavishi CP, et al. Left ventricular hypertrophy and risk reclassification for </text>
<text top="866" left="148" width="602" height="19" font="1">coronary events in multi-ethnic adults. European journal of preventive cardiology. 2015; 22:673-9. </text>
<text top="887" left="108" width="706" height="19" font="1">112.  Sundstrom J, Arima H, Woodward M, et al. Blood pressure-lowering treatment based on cardiovascular risk: </text>
<text top="908" left="148" width="412" height="19" font="1">a meta-analysis of individual patient data. Lancet. 2014; 384:591-8. </text>
<text top="929" left="108" width="709" height="19" font="1">113.  Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of </text>
<text top="950" left="148" width="661" height="19" font="1">cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011; 305:913-</text>
<text top="971" left="148" width="22" height="19" font="1">22. </text>
<text top="993" left="108" width="702" height="19" font="1">114.  Wright JT, Jr., Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-</text>
<text top="1014" left="148" width="466" height="19" font="1">Pressure Control. The New England journal of medicine. 2015; 373:2103-16. </text>
</page>
<page number="270" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">270 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="705" height="19" font="1">115.  Lawes CM, Bennett DA, Lewington S, et al. Blood pressure and coronary heart disease: a review of the </text>
<text top="129" left="149" width="276" height="19" font="1">evidence. Semin. Vasc. Med. 2002; 2:355-68. </text>
<text top="150" left="108" width="707" height="19" font="1">116.  Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-Pressure Lowering in Intermediate-Risk Persons without </text>
<text top="171" left="149" width="419" height="19" font="1">Cardiovascular Disease. The New England journal of medicine. 2016. </text>
<text top="192" left="108" width="705" height="19" font="1">117.  Neaton JD, Grimm RH, Jr., Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of </text>
<text top="213" left="149" width="416" height="19" font="1">Mild Hypertension Study Research Group. JAMA. 1993; 270:713-24. </text>
<text top="234" left="108" width="708" height="19" font="1">118.  van DS, Kengne AP, Chalmers J, et al. Effects of blood pressure lowering on cardiovascular outcomes in </text>
<text top="255" left="149" width="665" height="19" font="1">different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res. Clin. Pract. 2012; </text>
<text top="277" left="149" width="61" height="19" font="1">98:83-90. </text>
<text top="298" left="108" width="705" height="19" font="1">119.  Montgomery AA, Fahey T, Ben-Shlomo Y, et al. The influence of absolute cardiovascular risk, patient utilities, </text>
<text top="319" left="149" width="653" height="19" font="1">and costs on the decision to treat hypertension: a Markov decision analysis. J. Hypertens. 2003; 21:1753-9. </text>
<text top="340" left="108" width="705" height="19" font="1">120.  Kassai B, Boissel JP, Cucherat M, et al. Treatment of high blood pressure and gain in event-free life expectancy. </text>
<text top="361" left="149" width="328" height="19" font="1">Vascular health and risk management. 2005; 1:163-9. </text>
<text top="382" left="108" width="706" height="19" font="1">121.  Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood </text>
<text top="403" left="149" width="661" height="19" font="1">pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-</text>
<text top="424" left="149" width="354" height="19" font="1">analysis of randomized trials. J. Hypertens. 2011; 29:4-16. </text>
<text top="445" left="108" width="706" height="19" font="1">122.  Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two </text>
<text top="466" left="149" width="665" height="19" font="1">strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin. </text>
<text top="487" left="149" width="146" height="19" font="1">Trials. 2014; 11:532-46. </text>
<text top="508" left="108" width="705" height="19" font="1">123.  Cushman WC, Grimm RH, Jr., Cutler JA, et al. Rationale and design for the blood pressure intervention of the </text>
<text top="529" left="149" width="666" height="19" font="1">Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. The American journal of cardiology. 2007; </text>
<text top="550" left="149" width="68" height="19" font="1">99:44i-55i. </text>
<text top="571" left="108" width="709" height="19" font="1">124.  Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic </text>
<text top="593" left="149" width="451" height="19" font="1">nephropathy. The New England journal of medicine. 2013; 369:1892-903. </text>
<text top="614" left="108" width="706" height="19" font="1">125.  Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. </text>
<text top="635" left="148" width="357" height="19" font="1">The New England journal of medicine. 2012; 367:2204-13. </text>
<text top="656" left="108" width="706" height="19" font="1">126.  Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. The </text>
<text top="677" left="149" width="331" height="19" font="1">New England journal of medicine. 2008; 358:1547-59. </text>
<text top="698" left="108" width="705" height="19" font="1">127.  Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic </text>
<text top="719" left="148" width="665" height="19" font="1">kidney disease: a systematic review and meta-analysis. CMAJ : Canadian Medical Association journal = journal </text>
<text top="740" left="148" width="349" height="19" font="1">de l'Association medicale canadienne. 2013; 185:949-57. </text>
<text top="761" left="108" width="706" height="19" font="1">128.  Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pressure target, time to intensification, and time </text>
<text top="782" left="148" width="668" height="19" font="1">to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ (Clinical </text>
<text top="803" left="148" width="189" height="19" font="1">research ed.). 2015; 350:h158. </text>
<text top="824" left="108" width="706" height="19" font="1">129.  Birtwhistle RV, Godwin MS, Delva MD, et al. Randomised equivalence trial comparing three month and six </text>
<text top="845" left="148" width="667" height="19" font="1">month follow up of patients with hypertension by family practitioners. BMJ (Clinical research ed.). 2004; </text>
<text top="866" left="148" width="57" height="19" font="1">328:204. </text>
<text top="887" left="108" width="705" height="19" font="1">130.  Brennan T, Spettell C, Villagra V, et al. Disease management to promote blood pressure control among African </text>
<text top="908" left="148" width="371" height="19" font="1">Americans. Population health management. 2010; 13:65-72. </text>
<text top="929" left="108" width="705" height="19" font="1">131.  Bosworth HB, Olsen MK, Grubber JM, et al. Two self-management interventions to improve hypertension </text>
<text top="950" left="148" width="395" height="19" font="1">control: a randomized trial. Ann. Intern. Med. 2009; 151:687-95. </text>
<text top="971" left="108" width="706" height="19" font="1">132.  Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pressure management and improved blood pressure </text>
<text top="993" left="148" width="550" height="19" font="1">control: results from a randomized controlled trial. Arch. Intern. Med. 2011; 171:1173-80. </text>
<text top="1014" left="108" width="705" height="19" font="1">133.  Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, </text>
<text top="1035" left="148" width="630" height="19" font="1">and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008; 299:2857-67. </text>
</page>
<page number="271" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">271 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="707" height="19" font="1">134.  Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood pressure control through a clinical pharmacist </text>
<text top="129" left="149" width="665" height="19" font="1">outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and </text>
<text top="150" left="149" width="665" height="19" font="1">intensification of medications cluster randomized, controlled pragmatic trial. Circulation. 2012; 125:2863-72. </text>
<text top="171" left="108" width="705" height="19" font="1">135.  Bangalore S, Gong Y, Cooper-DeHoff RM, et al. 2014 Eighth Joint National Committee panel recommendation </text>
<text top="192" left="149" width="637" height="19" font="1">for blood pressure targets revisited: results from the INVEST study. J. Am. Coll. Cardiol. 2014; 64:784-93. </text>
<text top="213" left="108" width="710" height="19" font="1">136.  Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on </text>
<text top="234" left="148" width="666" height="19" font="1">cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. </text>
<text top="255" left="148" width="349" height="19" font="1">The New England journal of medicine. 2000; 342:145-53. </text>
<text top="277" left="108" width="706" height="19" font="1">137.  Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left </text>
<text top="298" left="149" width="665" height="19" font="1">ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. </text>
<text top="319" left="149" width="496" height="19" font="1">The SAVE Investigators. The New England journal of medicine. 1992; 327:669-77. </text>
<text top="340" left="108" width="707" height="19" font="1">138.  Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary </text>
<text top="361" left="149" width="666" height="19" font="1">artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. </text>
<text top="382" left="148" width="107" height="19" font="1">2003; 362:782-8. </text>
<text top="403" left="108" width="705" height="19" font="1">139.  Goldstein S and Hjalmarson A. The mortality effect of metoprolol CR/XL in patients with heart failure: results </text>
<text top="424" left="148" width="374" height="19" font="1">of the MERIT-HF Trial. Clin. Cardiol. 1999; 22 Suppl 5:V30-V5. </text>
<text top="445" left="108" width="706" height="19" font="1">140.  Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. The New </text>
<text top="466" left="148" width="292" height="19" font="1">England journal of medicine. 2001; 344:1651-8. </text>
<text top="487" left="108" width="705" height="19" font="1">141.  Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular </text>
<text top="508" left="148" width="455" height="19" font="1">dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357:1385-90. </text>
<text top="529" left="108" width="705" height="19" font="1">142.  Herlitz J, Wikstrand J, Denny M, et al. Effects of metoprolol CR/XL on mortality and hospitalizations in patients </text>
<text top="550" left="148" width="444" height="19" font="1">with heart failure and history of hypertension. J. Card. Fail. 2002; 8:8-14. </text>
<text top="571" left="108" width="632" height="19" font="1">143.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353:9-13. </text>
<text top="593" left="108" width="706" height="19" font="1">144.  Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the </text>
<text top="614" left="148" width="664" height="19" font="1">efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the </text>
<text top="635" left="148" width="468" height="19" font="1">treatment of chronic congestive heart failure. Circulation. 1990; 82:1954-61. </text>
<text top="656" left="108" width="705" height="19" font="1">145.  The Multicenter Diltiazem Postinfarction Trial Research G. The effect of diltiazem on mortality and reinfarction </text>
<text top="677" left="148" width="519" height="19" font="1">after myocardial infarction. The New England journal of medicine. 1988; 319:385-92. </text>
<text top="698" left="108" width="710" height="19" font="1">146.  Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in </text>
<text top="719" left="148" width="665" height="19" font="1">postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the </text>
<text top="740" left="148" width="501" height="19" font="1">Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991; 83:52-60. </text>
<text top="761" left="108" width="705" height="19" font="1">147.  Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta </text>
<text top="782" left="148" width="403" height="19" font="1">regression analysis. BMJ (Clinical research ed.). 1999; 318:1730-7. </text>
<text top="803" left="108" width="705" height="19" font="1">148.  de Peuter OR, Lussana F, Peters RJ, et al. A systematic review of selective and non-selective beta blockers for </text>
<text top="824" left="148" width="666" height="19" font="1">prevention of vascular events in patients with acute coronary syndrome or heart failure. The Netherlands </text>
<text top="845" left="148" width="232" height="19" font="1">journal of medicine. 2009; 67:284-94. </text>
<text top="866" left="108" width="706" height="19" font="1">149.  Leon MB, Rosing DR, Bonow RO, et al. Clinical efficacy of verapamil alone and combined with propranolol in </text>
<text top="887" left="148" width="644" height="19" font="1">treating patients with chronic stable angina pectoris. The American journal of cardiology. 1981; 48:131-9. </text>
<text top="908" left="108" width="705" height="19" font="1">150.  Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for </text>
<text top="929" left="148" width="669" height="19" font="1">older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial </text>
<text top="950" left="148" width="248" height="19" font="1">Investigators. Lancet. 1997; 350:757-64. </text>
<text top="971" left="108" width="708" height="19" font="1">151.  Bangalore S, Qin J, Sloan S, et al. What is the optimal blood pressure in patients after acute coronary </text>
<text top="993" left="148" width="665" height="19" font="1">syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin </text>
<text top="1014" left="148" width="665" height="19" font="1">Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. </text>
<text top="1035" left="148" width="122" height="19" font="1">2010; 122:2142-51. </text>
</page>
<page number="272" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">272 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="707" height="19" font="1">152.  Cohn JN and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart </text>
<text top="129" left="149" width="403" height="19" font="1">failure. The New England journal of medicine. 2001; 345:1667-75. </text>
<text top="150" left="108" width="705" height="19" font="1">153.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart </text>
<text top="171" left="149" width="559" height="19" font="1">failure. The SOLVD Investigators. The New England journal of medicine. 1991; 325:293-302. </text>
<text top="192" left="108" width="705" height="19" font="1">154.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence </text>
<text top="213" left="148" width="648" height="19" font="1">of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342:821-8. </text>
<text top="234" left="108" width="706" height="19" font="1">155.  Garg R and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality </text>
<text top="255" left="148" width="668" height="19" font="1">and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995; </text>
<text top="277" left="148" width="77" height="19" font="1">273:1450-6. </text>
<text top="298" left="108" width="705" height="19" font="1">156.  Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated </text>
<text top="319" left="149" width="661" height="19" font="1">by heart failure, left ventricular dysfunction, or both. The New England journal of medicine. 2003; 349:1893-</text>
<text top="340" left="149" width="30" height="19" font="1">906. </text>
<text top="361" left="108" width="705" height="19" font="1">157.  Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart </text>
<text top="382" left="149" width="620" height="19" font="1">failure not receiving angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. 2002; 40:1414-21. </text>
<text top="403" left="108" width="705" height="19" font="1">158.  Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and </text>
<text top="424" left="149" width="661" height="19" font="1">reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-</text>
<text top="445" left="149" width="257" height="19" font="1">Alternative trial. Lancet. 2003; 362:772-6. </text>
<text top="466" left="108" width="705" height="19" font="1">159.  Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular </text>
<text top="487" left="149" width="602" height="19" font="1">dysfunction after myocardial infarction. The New England journal of medicine. 2003; 348:1309-21. </text>
<text top="508" left="108" width="706" height="19" font="1">160.  Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart </text>
<text top="529" left="149" width="403" height="19" font="1">failure. The New England journal of medicine. 2004; 351:2049-57. </text>
<text top="550" left="108" width="706" height="19" font="1">161.  Pfeffer MA, Claggett B, Assmann SF, et al. Regional Variation in Patients and Outcomes in the Treatment of </text>
<text top="571" left="149" width="665" height="19" font="1">Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation. 2015; </text>
<text top="593" left="149" width="69" height="19" font="1">131:34-42. </text>
<text top="614" left="108" width="705" height="19" font="1">162.  Aronow WS, Ahn C and Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal </text>
<text top="635" left="149" width="667" height="19" font="1">myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left </text>
<text top="656" left="149" width="665" height="19" font="1">ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. </text>
<text top="677" left="149" width="320" height="19" font="1">The American journal of cardiology. 1997; 80:207-9. </text>
<text top="698" left="108" width="705" height="19" font="1">163.  Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older </text>
<text top="719" left="148" width="635" height="19" font="1">persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997; 278:212-6. </text>
<text top="740" left="108" width="706" height="19" font="1">164.  Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. The </text>
<text top="761" left="148" width="331" height="19" font="1">New England journal of medicine. 2008; 358:1887-98. </text>
<text top="782" left="108" width="705" height="19" font="1">165.  van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients </text>
<text top="803" left="148" width="668" height="19" font="1">with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of </text>
<text top="824" left="148" width="665" height="19" font="1">Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J. Am. Coll. Cardiol. </text>
<text top="845" left="148" width="107" height="19" font="1">2009; 53:2150-8. </text>
<text top="866" left="108" width="707" height="19" font="1">166.  Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and </text>
<text top="887" left="148" width="602" height="19" font="1">preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362:777-81. </text>
<text top="908" left="108" width="706" height="19" font="1">167.  Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection </text>
<text top="929" left="148" width="412" height="19" font="1">fraction. The New England journal of medicine. 2008; 359:2456-67. </text>
<text top="950" left="108" width="709" height="19" font="1">168.  Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of participants with heart failure in the </text>
<text top="971" left="148" width="668" height="19" font="1">antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011; </text>
<text top="993" left="148" width="77" height="19" font="1">124:1811-8. </text>
</page>
<page number="273" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">273 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="706" height="19" font="1">169.  Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the </text>
<text top="129" left="149" width="666" height="19" font="1">progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. The New England </text>
<text top="150" left="149" width="240" height="19" font="1">journal of medicine. 1994; 330:877-84. </text>
<text top="171" left="108" width="707" height="19" font="1">170.  Peterson JC, Adler S, Burkart JM, et  al. Blood pressure control, proteinuria, and the progression of renal </text>
<text top="192" left="149" width="574" height="19" font="1">disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med. 1995; 123:754-62. </text>
<text top="213" left="108" width="705" height="19" font="1">171.  Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic </text>
<text top="234" left="149" width="603" height="19" font="1">chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005; 365:939-46. </text>
<text top="255" left="108" width="706" height="19" font="1">172.  Wright JT, Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on </text>
<text top="277" left="149" width="602" height="19" font="1">progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288:2421-31. </text>
<text top="298" left="108" width="710" height="19" font="1">173.  Contreras G, Greene T, Agodoa LY, et al. Blood pressure control, drug therapy, and kidney disease. </text>
<text top="319" left="149" width="189" height="19" font="1">Hypertension. 2005; 46:44-50. </text>
<text top="340" left="108" width="706" height="19" font="1">174.  Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of Kidney </text>
<text top="361" left="149" width="668" height="19" font="1">Disease and Hypertension (AASK) Trial. American journal of kidney diseases : the official journal of the </text>
<text top="382" left="149" width="284" height="19" font="1">National Kidney Foundation. 2006; 48:739-51. </text>
<text top="403" left="108" width="705" height="19" font="1">175.  Esnault VL, Brown EA, Apetrei E, et al. The effects of amlodipine and enalapril on renal function in adults with </text>
<text top="424" left="149" width="662" height="19" font="1">hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-</text>
<text top="445" left="149" width="278" height="19" font="1">controlled study. Clin. Ther. 2008; 30:482-98. </text>
<text top="466" left="108" width="705" height="19" font="1">176.  Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with </text>
<text top="487" left="149" width="327" height="19" font="1">primary renal disease. J. Hypertens. 2001; 19:1871-6. </text>
<text top="508" left="108" width="705" height="19" font="1">177.  Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in </text>
<text top="529" left="149" width="666" height="19" font="1">patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary </text>
<text top="550" left="149" width="420" height="19" font="1">analysis of a randomised controlled trial. Lancet. 2010; 375:1173-81. </text>
<text top="571" left="108" width="706" height="19" font="1">178.  Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. </text>
<text top="593" left="149" width="357" height="19" font="1">The New England journal of medicine. 2008; 358:2433-46. </text>
<text top="614" left="108" width="706" height="19" font="1">179.  Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease </text>
<text top="635" left="149" width="449" height="19" font="1">and proteinuria as an effect modifier. Ann. Intern. Med. 2011; 154:541-8. </text>
<text top="656" left="108" width="705" height="19" font="1">180.  Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, </text>
<text top="677" left="149" width="666" height="19" font="1">proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. </text>
<text top="698" left="149" width="114" height="19" font="1">2003; 139:244-52. </text>
<text top="719" left="108" width="708" height="19" font="1">181.  Giatras I, Lau J and Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of </text>
<text top="740" left="149" width="666" height="19" font="1">nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition </text>
<text top="761" left="148" width="496" height="19" font="1">and Progressive Renal Disease Study Group. Ann. Intern. Med. 1997; 127:337-45. </text>
<text top="782" left="108" width="705" height="19" font="1">182.  White HD, Aylward PE, Huang Z, et al. Mortality and morbidity remain high despite captopril and/or Valsartan </text>
<text top="803" left="148" width="669" height="19" font="1">therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute </text>
<text top="824" left="148" width="665" height="19" font="1">myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation. </text>
<text top="845" left="148" width="114" height="19" font="1">2005; 112:3391-9. </text>
<text top="866" left="108" width="707" height="19" font="1">183.  Midtvedt K, Ihlen H, Hartmann A, et al. Reduction of left ventricular mass by lisinopril and nifedipine in </text>
<text top="887" left="148" width="668" height="19" font="1">hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation. </text>
<text top="908" left="148" width="107" height="19" font="1">2001; 72:107-11. </text>
<text top="929" left="108" width="708" height="19" font="1">184.  Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in </text>
<text top="950" left="148" width="666" height="19" font="1">hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation. </text>
<text top="971" left="148" width="114" height="19" font="1">2001; 72:1787-92. </text>
<text top="993" left="108" width="705" height="19" font="1">185.  Suwelack B, Gerhardt U, Hausberg M, et al. Comparison of quinapril versus atenolol: effects on blood pressure </text>
<text top="1014" left="148" width="627" height="19" font="1">and cardiac mass after renal transplantation. The American journal of cardiology. 2000; 86:583-5, A10. </text>
</page>
<page number="274" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">274 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="706" height="19" font="1">186.  Paoletti E, Cassottana P, Amidone M, et al. ACE inhibitors and persistent left ventricular hypertrophy after </text>
<text top="129" left="149" width="665" height="19" font="1">renal transplantation: a randomized clinical trial. American journal of kidney diseases : the official journal of </text>
<text top="150" left="149" width="307" height="19" font="1">the National Kidney Foundation. 2007; 50:133-42. </text>
<text top="171" left="108" width="707" height="19" font="1">187.  Cross NB, Webster AC, Masson P, et al. Antihypertensive treatment for kidney transplant recipients. The </text>
<text top="192" left="149" width="363" height="19" font="1">Cochrane database of systematic reviews. 2009:CD003598. </text>
<text top="213" left="108" width="707" height="19" font="1">188.  Jennings DL and Taber DJ. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to </text>
<text top="234" left="149" width="564" height="19" font="1">twelve weeks after renal transplantation. The Annals of pharmacotherapy. 2008; 42:116-20. </text>
<text top="255" left="108" width="706" height="19" font="1">189.  Ninomiya T, Perkovic V, Turnbull F, et al. Blood pressure lowering and major cardiovascular events in people </text>
<text top="277" left="149" width="664" height="19" font="1">with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ (Clinical research </text>
<text top="298" left="148" width="138" height="19" font="1">ed.). 2013; 347:f5680. </text>
<text top="319" left="108" width="710" height="19" font="1">190.  Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard  Blood Pressure Control and </text>
<text top="340" left="148" width="667" height="19" font="1">Cardiovascular Disease Outcomes in Adults Aged &gt;/=75 Years: A Randomized Clinical Trial. JAMA. 2016; </text>
<text top="361" left="148" width="84" height="19" font="1">315:2673-82. </text>
<text top="382" left="108" width="707" height="19" font="1">191.  Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral </text>
<text top="403" left="149" width="439" height="19" font="1">hemorrhage. The New England journal of medicine. 2013; 368:2355-65. </text>
<text top="424" left="108" width="606" height="19" font="1">192.  Antihypertensive treatment of acute cerebral hemorrhage. Crit. Care Med. 2010; 38:637-48. </text>
<text top="445" left="108" width="705" height="19" font="1">193.  Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial </text>
<text top="466" left="149" width="458" height="19" font="1">(INTERACT): a randomised pilot trial. The Lancet.Neurology. 2008; 7:391-9. </text>
<text top="487" left="108" width="709" height="19" font="1">194.  Tsivgoulis G, Katsanos AH, Butcher KS, et al. Intensive blood pressure reduction in acute intracerebral </text>
<text top="508" left="148" width="362" height="19" font="1">hemorrhage: a meta-analysis. Neurology. 2014; 83:1523-9. </text>
<text top="529" left="108" width="705" height="19" font="1">195.  Wang H, Tang Y, Rong X, et al. Effects of early blood pressure lowering on early and long-term outcomes after </text>
<text top="550" left="148" width="414" height="19" font="1">acute stroke: an updated meta-analysis. PLoS One. 2014; 9:e97917. </text>
<text top="571" left="108" width="706" height="19" font="1">196.  Zhao R, Liu FD, Wang S, et al. Blood Pressure Reduction in the Acute Phase of an Ischemic Stroke Does Not </text>
<text top="593" left="148" width="667" height="19" font="1">Improve Short-  or Long-Term Dependency or Mortality: A Meta-Analysis of Current Literature. Medicine. </text>
<text top="614" left="148" width="94" height="19" font="1">2015; 94:e896. </text>
<text top="635" left="108" width="705" height="19" font="1">197.  Ahmed N, Nasman P and Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome </text>
<text top="656" left="148" width="467" height="19" font="1">after acute stroke. Stroke; a journal of cerebral circulation. 2000; 31:1250-5. </text>
<text top="677" left="108" width="705" height="19" font="1">198.  Bath PM and Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. The Cochrane </text>
<text top="698" left="148" width="324" height="19" font="1">database of systematic reviews. 2014; 10:CD000039. </text>
<text top="719" left="108" width="708" height="19" font="1">199.  Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and </text>
<text top="740" left="148" width="670" height="19" font="1">outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe </text>
<text top="761" left="148" width="666" height="19" font="1">Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke; a </text>
<text top="782" left="148" width="294" height="19" font="1">journal of cerebral circulation. 2009; 40:2442-9. </text>
<text top="803" left="108" width="704" height="19" font="1">200.  Schrader J, Luders S, Kulschewski A, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy </text>
<text top="824" left="148" width="487" height="19" font="1">in Stroke Survivors. Stroke; a journal of cerebral circulation. 2003; 34:1699-703. </text>
<text top="845" left="108" width="706" height="19" font="1">201.  Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute </text>
<text top="866" left="148" width="583" height="19" font="1">stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011; 377:741-50. </text>
<text top="887" left="108" width="707" height="19" font="1">202.  He J, Zhang Y, Xu T, et al. Effects of immediate blood pressure reduction on death and major disability in </text>
<text top="908" left="148" width="594" height="19" font="1">patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014; 311:479-89. </text>
<text top="929" left="108" width="705" height="19" font="1">203.  Robinson TG, Potter JF, Ford GA, et al. Effects of antihypertensive treatment after acute stroke in the Continue </text>
<text top="950" left="148" width="668" height="19" font="1">or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, </text>
<text top="971" left="148" width="381" height="19" font="1">blinded-endpoint trial. The Lancet.Neurology. 2010; 9:767-75. </text>
<text top="993" left="108" width="705" height="19" font="1">204.  Potter JF, Robinson TG, Ford GA, et al. Controlling hypertension and hypotension immediately post-stroke </text>
<text top="1014" left="148" width="650" height="19" font="1">(CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. The Lancet.Neurology. 2009; 8:48-56. </text>
</page>
<page number="275" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">275 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="706" height="19" font="1">205.  Bath PM, Woodhouse L, Scutt P, et al. Efficacy of nitric oxide, with or without continuing antihypertensive </text>
<text top="129" left="149" width="666" height="19" font="1">treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised </text>
<text top="150" left="149" width="259" height="19" font="1">controlled trial. Lancet. 2015; 385:617-28. </text>
<text top="171" left="108" width="706" height="19" font="1">206.  Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. </text>
<text top="192" left="149" width="357" height="19" font="1">The New England journal of medicine. 2008; 359:1317-29. </text>
<text top="213" left="108" width="706" height="19" font="1">207.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and </text>
<text top="234" left="149" width="553" height="19" font="1">Stroke rt-PA Stroke Study Group. The New England journal of medicine. 1995; 333:1581-7. </text>
<text top="255" left="108" width="642" height="19" font="1">208.  Post-stroke antihypertensive treatment study. A preliminary result. Chin. Med. J. 1995; 108:710-7. </text>
<text top="277" left="108" width="708" height="19" font="1">209.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with </text>
<text top="298" left="149" width="450" height="19" font="1">previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-41. </text>
<text top="319" left="108" width="706" height="19" font="1">210.  Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with </text>
<text top="340" left="149" width="669" height="19" font="1">Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study </text>
<text top="361" left="149" width="419" height="19" font="1">(MOSES). Stroke; a journal of cerebral circulation. 2005; 36:1218-26. </text>
<text top="382" left="108" width="706" height="19" font="1">211.  Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. The </text>
<text top="403" left="149" width="331" height="19" font="1">New England journal of medicine. 2008; 359:1225-37. </text>
<text top="424" left="108" width="706" height="19" font="1">212.  Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the </text>
<text top="445" left="148" width="302" height="19" font="1">SPS3 randomised trial. Lancet. 2013; 382:507-15. </text>
<text top="466" left="108" width="705" height="19" font="1">213.  Rashid P, Leonardi-Bee J and Bath P. Blood pressure reduction and secondary prevention of stroke and other </text>
<text top="487" left="148" width="580" height="19" font="1">vascular events: a systematic review. Stroke; a journal of cerebral circulation. 2003; 34:2741-8. </text>
<text top="508" left="108" width="706" height="19" font="1">214.  Lakhan SE and Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence: a systematic </text>
<text top="529" left="148" width="328" height="19" font="1">review and meta-analysis. Int. Arch. Med. 2009; 2:30. </text>
<text top="550" left="108" width="706" height="19" font="1">215.  Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial </text>
<text top="571" left="148" width="666" height="19" font="1">and a systematic review of the literature. Hypertension research : official journal of the Japanese Society of </text>
<text top="593" left="148" width="204" height="19" font="1">Hypertension. 2009; 32:1032-40. </text>
<text top="614" left="108" width="705" height="19" font="1">216.  Lee M, Saver JL, Hong KS, et al. Does achieving an intensive versus usual blood pressure level prevent stroke? </text>
<text top="635" left="148" width="187" height="19" font="1">Ann. Neurol. 2012; 71:133-40. </text>
<text top="656" left="108" width="705" height="19" font="1">217.  Lee M, Saver JL, Hong KS, et al. Renin-Angiotensin system modulators modestly reduce vascular risk in persons </text>
<text top="677" left="148" width="453" height="19" font="1">with prior stroke. Stroke; a journal of cerebral circulation. 2012; 43:113-9. </text>
<text top="698" left="108" width="708" height="19" font="1">218.  Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the </text>
<text top="719" left="148" width="505" height="19" font="1">prevention of recurrent stroke: the PROGRESS trial. J. Hypertens. 2006; 24:1201-8. </text>
<text top="740" left="108" width="705" height="19" font="1">219.  White CL, Szychowski JM, Pergola PE, et al. Can blood pressure be lowered safely in older adults with lacunar </text>
<text top="761" left="148" width="666" height="19" font="1">stroke? The Secondary Prevention of Small Subcortical Strokes study experience. J. Am. Geriatr. Soc. 2015; </text>
<text top="782" left="148" width="61" height="19" font="1">63:722-9. </text>
<text top="803" left="108" width="706" height="19" font="1">220.  Ovbiagele B, Diener HC, Yusuf S, et al. Level of systolic blood pressure within the normal range and risk of </text>
<text top="824" left="148" width="271" height="19" font="1">recurrent stroke. JAMA. 2011; 306:2137-44. </text>
<text top="845" left="108" width="711" height="19" font="1">221.  Ovbiagele B. Low-normal systolic blood pressure and secondary stroke risk. Journal of stroke and </text>
<text top="866" left="148" width="567" height="19" font="1">cerebrovascular diseases : the official journal of National Stroke Association. 2013; 22:633-8. </text>
<text top="887" left="108" width="706" height="19" font="1">222.  Lin MP, Ovbiagele B, Markovic D, et al. Systolic blood pressure and mortality after stroke: too low, no go? </text>
<text top="908" left="148" width="359" height="19" font="1">Stroke; a journal of cerebral circulation. 2015; 46:1307-13. </text>
<text top="929" left="108" width="705" height="19" font="1">223.  Kim J, Gall SL, Nelson MR, et al. Lower systolic blood pressure is associated with poorer survival in long-term </text>
<text top="950" left="148" width="309" height="19" font="1">survivors of stroke. J. Hypertens. 2014; 32:904-11. </text>
<text top="971" left="108" width="706" height="19" font="1">224.  Wang WT, You LK, Chiang CE, et al. Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients </text>
<text top="993" left="148" width="667" height="19" font="1">who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized </text>
<text top="1014" left="148" width="278" height="19" font="1">Trials. Medicine (Baltimore). 2016; 95:e3302. </text>
</page>
<page number="276" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">276 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="707" height="19" font="1">225.  Katsanos AH, Filippatou A, Manios E, et al. Blood Pressure Reduction and Secondary Stroke Prevention: A </text>
<text top="129" left="149" width="665" height="19" font="1">Systematic Review and Metaregression Analysis of Randomized Clinical Trials. Hypertension. 2017; 69:171-9. </text>
<text top="150" left="108" width="706" height="19" font="1">226.  Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical </text>
<text top="171" left="149" width="343" height="19" font="1">peripheral arterial disease. Eur. Heart J. 2004; 25:17-24. </text>
<text top="192" left="108" width="708" height="19" font="1">227.  Overlack A, Adamczak M, Bachmann W, et al. ACE-inhibition with perindopril in essential hypertensive </text>
<text top="213" left="149" width="666" height="19" font="1">patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group. The </text>
<text top="234" left="149" width="294" height="19" font="1">American journal of medicine. 1994; 97:126-34. </text>
<text top="255" left="108" width="705" height="19" font="1">228.  Schweizer J, Kirch W, Koch R, et al. Effect of high dose verapamil on restenosis after peripheral angioplasty. J. </text>
<text top="277" left="149" width="230" height="19" font="1">Am. Coll. Cardiol. 1998; 31:1299-305. </text>
<text top="298" left="108" width="706" height="19" font="1">229.  Espinola-Klein C, Weisser G, Jagodzinski A, et al. beta-Blockers in patients with intermittent claudication and </text>
<text top="319" left="149" width="664" height="19" font="1">arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. </text>
<text top="340" left="149" width="107" height="19" font="1">2011; 58:148-54. </text>
<text top="361" left="108" width="706" height="19" font="1">230.  Bavry AA, Anderson RD, Gong Y, et al. Outcomes Among hypertensive patients with concomitant peripheral </text>
<text top="382" left="149" width="665" height="19" font="1">and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension </text>
<text top="403" left="149" width="99" height="19" font="1">2010; 55:48-53. </text>
<text top="424" left="108" width="705" height="19" font="1">231.  Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens </text>
<text top="445" left="149" width="661" height="19" font="1">based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J. Hypertens. 2006; 24:2163-</text>
<text top="466" left="149" width="15" height="19" font="1">8. </text>
<text top="487" left="108" width="705" height="19" font="1">232.  Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and long-term follow-up of participants with peripheral </text>
<text top="508" left="149" width="431" height="19" font="1">arterial disease during ALLHAT. J. Gen. Intern. Med. 2014; 29:1475-83. </text>
<text top="529" left="108" width="587" height="19" font="1">233.  Kaplan NM. Vascular outcome in type 2 diabetes: an ADVANCE? Lancet. 2007; 370:804-5. </text>
<text top="550" left="108" width="707" height="19" font="1">234.  Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes </text>
<text top="571" left="149" width="413" height="19" font="1">mellitus. The New England journal of medicine. 2010; 362:1575-85. </text>
<text top="593" left="108" width="705" height="19" font="1">235.  Margolis KL, O'Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management </text>
<text top="614" left="149" width="565" height="19" font="1">strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014; 37:1721-8. </text>
<text top="635" left="108" width="707" height="19" font="1">236.  Soliman EZ, Byington RP, Bigger JT, et al. Effect of Intensive Blood Pressure Lowering on Left Ventricular </text>
<text top="656" left="149" width="667" height="19" font="1">Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood </text>
<text top="677" left="149" width="286" height="19" font="1">Pressure Trial. Hypertension. 2015; 66:1123-9. </text>
<text top="698" left="108" width="707" height="19" font="1">237.  Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in </text>
<text top="719" left="149" width="362" height="19" font="1">patients with diabetes. J. Am. Coll. Cardiol. 2010; 56:77-85. </text>
<text top="740" left="108" width="702" height="19" font="1">238.  Ostergren J, Poulter NR, Sever PS, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-</text>
<text top="761" left="148" width="531" height="19" font="1">lowering limb: effects in patients with type II diabetes. J. Hypertens. 2008; 26:2103-11. </text>
<text top="782" left="108" width="706" height="19" font="1">239.  Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes </text>
<text top="803" left="148" width="664" height="19" font="1">in subjects with isolated systolic hypertension with and without diabetes. The American journal of cardiology. </text>
<text top="824" left="148" width="99" height="19" font="1">2005; 95:29-35. </text>
<text top="845" left="108" width="708" height="19" font="1">240.  Menne J, Izzo JL, Jr., Ito S, et al. Prevention of  microalbuminuria in patients with type 2 diabetes and </text>
<text top="866" left="148" width="269" height="19" font="1">hypertension. J. Hypertens. 2012; 30:811-8. </text>
<text top="887" left="108" width="705" height="19" font="1">241.  Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular </text>
<text top="908" left="148" width="666" height="19" font="1">outcomes in patients with non-insulin-dependent diabetes and hypertension. The New England journal of </text>
<text top="929" left="148" width="177" height="19" font="1">medicine. 1998; 338:645-52. </text>
<text top="950" left="108" width="705" height="19" font="1">242.  Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin </text>
<text top="971" left="148" width="666" height="19" font="1">in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised </text>
<text top="993" left="148" width="314" height="19" font="1">trial. HOT Study Group. Lancet. 1998; 351:1755-62. </text>
<text top="1014" left="108" width="706" height="19" font="1">243.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: </text>
<text top="1035" left="148" width="584" height="19" font="1">UKPDS 38. UK Prospective Diabetes Study Group. BMJ (Clinical research ed.). 1998; 317:703-13. </text>
</page>
<page number="277" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">277 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="705" height="19" font="1">244.  Arguedas JA, Leiva V and Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. </text>
<text top="129" left="149" width="412" height="19" font="1">The Cochrane database of systematic reviews. 2013; 10:CD008277. </text>
<text top="150" left="108" width="706" height="19" font="1">245.  Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents </text>
<text top="171" left="149" width="590" height="19" font="1">in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015; 385:2047-56. </text>
<text top="192" left="108" width="710" height="19" font="1">246.  Turnbull F, Neal B, Algert C, et al. Effects of different blood  pressure-lowering regimens on major </text>
<text top="213" left="149" width="667" height="19" font="1">cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed </text>
<text top="234" left="149" width="424" height="19" font="1">overviews of randomized trials. Arch. Intern. Med. 2005; 165:1410-9. </text>
<text top="255" left="108" width="705" height="19" font="1">247.  Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, </text>
<text top="277" left="149" width="665" height="19" font="1">impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment </text>
<text top="298" left="149" width="463" height="19" font="1">to Prevent Heart Attack Trial (ALLHAT). Arch.Intern.Med. 2005; 165:1401-9. </text>
<text top="319" left="108" width="710" height="19" font="1">248.  Hata J, Arima H, Rothwell PM, et al. Effects of visit-to-visit variability in systolic blood pressure on </text>
<text top="340" left="149" width="665" height="19" font="1">macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. </text>
<text top="361" left="149" width="195" height="19" font="1">Circulation. 2013; 128:1325-34. </text>
<text top="382" left="108" width="707" height="19" font="1">249.  Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 </text>
<text top="403" left="149" width="424" height="19" font="1">diabetes. The New England journal of medicine. 2014; 371:1392-406. </text>
<text top="424" left="108" width="706" height="19" font="1">250.  Menne J, Ritz E, Ruilope LM, et al. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention </text>
<text top="445" left="149" width="664" height="19" font="1">(ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained </text>
<text top="466" left="149" width="545" height="19" font="1">after study discontinuation. Journal of the American Heart Association. 2014; 3:e000810. </text>
<text top="487" left="108" width="702" height="19" font="1">251.  Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-</text>
<text top="508" left="149" width="211" height="19" font="1">analysis. JAMA. 2015; 313:603-15. </text>
<text top="529" left="108" width="708" height="19" font="1">252.  Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II </text>
<text top="550" left="149" width="666" height="19" font="1">receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with </text>
<text top="571" left="149" width="480" height="19" font="1">diabetes mellitus: a meta-analysis. JAMA internal medicine. 2014; 174:773-85. </text>
<text top="593" left="108" width="710" height="19" font="1">253.  Hartley L, Mavrodaris A, Flowers N, et al. Transcendental meditation for the primary prevention of </text>
<text top="614" left="149" width="555" height="19" font="1">cardiovascular disease. The Cochrane database of systematic reviews. 2014; 12:CD010359. </text>
<text top="635" left="108" width="706" height="19" font="1">254.  Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007; </text>
<text top="656" left="148" width="84" height="19" font="1">369:1208-19. </text>
<text top="677" left="108" width="702" height="19" font="1">255.  Jibrini MB, Molnar J and Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-</text>
<text top="698" left="149" width="540" height="19" font="1">angiotensin system: a systematic review and meta-analysis. Am. J. Ther. 2008; 15:36-43. </text>
<text top="719" left="108" width="706" height="19" font="1">256.  Zhao D, Wang ZM and Wang LS. Prevention of atrial fibrillation with renin-angiotensin system inhibitors on </text>
<text top="740" left="149" width="669" height="19" font="1">essential hypertensive patients: a meta-analysis of randomized controlled trials. Journal of biomedical </text>
<text top="761" left="149" width="167" height="19" font="1">research. 2015; 29:475-85. </text>
<text top="782" left="108" width="706" height="19" font="1">257.  Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme </text>
<text top="803" left="148" width="605" height="19" font="1">inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 2005; 45:1832-9. </text>
<text top="824" left="108" width="705" height="19" font="1">258.  Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with </text>
<text top="845" left="148" width="666" height="19" font="1">conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention </text>
<text top="866" left="148" width="361" height="19" font="1">Project (CAPPP) randomised trial. Lancet. 1999; 353:611-6. </text>
<text top="887" left="108" width="706" height="19" font="1">259.  Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly </text>
<text top="908" left="148" width="665" height="19" font="1">patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. </text>
<text top="929" left="148" width="162" height="19" font="1">Lancet. 1999; 354:1751-6. </text>
<text top="950" left="108" width="705" height="19" font="1">260.  Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and </text>
<text top="971" left="148" width="665" height="19" font="1">subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension </text>
<text top="993" left="148" width="297" height="19" font="1">(LIFE) study. J. Am. Coll. Cardiol. 2005; 45:712-9. </text>
</page>
<page number="278" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">278 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="710" height="19" font="1">261.  Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT </text>
<text top="129" left="149" width="667" height="19" font="1">(Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J. Am. Coll. Cardiol. 2009; </text>
<text top="150" left="149" width="77" height="19" font="1">54:2023-31. </text>
<text top="171" left="108" width="706" height="19" font="1">262.  Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy of angiotensin-converting enzyme </text>
<text top="192" left="149" width="665" height="19" font="1">inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in </text>
<text top="213" left="149" width="342" height="19" font="1">Aortic Stenosis (SCOPE-AS). Am. Heart J. 2004; 147:E19. </text>
<text top="234" left="108" width="705" height="19" font="1">263.  Rieck E, Cramariuc D, Boman K, et al. Hypertension in aortic stenosis: implications for left ventricular structure </text>
<text top="255" left="149" width="346" height="19" font="1">and cardiovascular events. Hypertension. 2012; 60:90-7. </text>
<text top="277" left="108" width="707" height="19" font="1">264.  Eleid MF, Nishimura RA, Sorajja P, et al. Systemic hypertension in low-gradient severe aortic stenosis with </text>
<text top="298" left="149" width="367" height="19" font="1">preserved ejection fraction. Circulation. 2013; 128:1349-53. </text>
<text top="319" left="108" width="702" height="19" font="1">265.  Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-</text>
<text top="340" left="149" width="666" height="19" font="1">converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur. Heart J. Cardiovasc. Imaging. 2015; </text>
<text top="361" left="149" width="69" height="19" font="1">16:834-41. </text>
<text top="382" left="108" width="709" height="19" font="1">266.  Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptomatic patients with severe aortic </text>
<text top="403" left="149" width="657" height="19" font="1">regurgitation and normal left ventricular function. The New England journal of medicine. 1994; 331:689-94. </text>
<text top="424" left="108" width="705" height="19" font="1">267.  Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator therapy in patients with severe  aortic </text>
<text top="445" left="149" width="436" height="19" font="1">regurgitation. The New England journal of medicine. 2005; 353:1342-9. </text>
<text top="466" left="108" width="705" height="19" font="1">268.  Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned </text>
<text top="487" left="149" width="661" height="19" font="1">to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-</text>
<text top="508" left="149" width="491" height="19" font="1">lowering treatment to prevent heart attack trial. Hypertension 2006; 48:374-84. </text>
<text top="529" left="108" width="706" height="19" font="1">269.  Wright JT, Jr., Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and </text>
<text top="550" left="149" width="666" height="19" font="1">without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack </text>
<text top="571" left="149" width="316" height="19" font="1">Trial (ALLHAT). Arch.Intern.Med. 2008; 168:207-17. </text>
<text top="593" left="108" width="707" height="19" font="1">270.  Wright JT, Jr., Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent </text>
<text top="614" left="149" width="477" height="19" font="1">analyses, other trials, and meta-analyses. Arch.Intern.Med. 2009; 169:832-42. </text>
<text top="635" left="108" width="709" height="19" font="1">271.  Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure </text>
<text top="656" left="149" width="375" height="19" font="1">averaging 90 through 114 mm Hg. JAMA. 1970; 213:1143-52. </text>
<text top="677" left="108" width="707" height="19" font="1">272.  Five-year findings of the Hypertension Detection and Follow-up Program: mortality by race-sex and blood </text>
<text top="698" left="149" width="667" height="19" font="1">pressure level. A further analysis. Hypertension Detection and Follow-up Program Cooperative Group. J. </text>
<text top="719" left="149" width="221" height="19" font="1">Community Health. 1984; 9:314-27. </text>
<text top="740" left="108" width="707" height="19" font="1">273.  Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) </text>
<text top="761" left="149" width="508" height="19" font="1">trial: outcomes in patients receiving monotherapy. Hypertension. 2006; 48:385-91. </text>
<text top="782" left="108" width="707" height="19" font="1">274.  The AO and Coordinators for the ACG. Major outcomes in high-risk hypertensive patients randomized to </text>
<text top="803" left="149" width="666" height="19" font="1">angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and </text>
<text top="824" left="149" width="565" height="19" font="1">Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. </text>
<text top="845" left="108" width="709" height="19" font="1">275.  Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist </text>
<text top="866" left="149" width="661" height="19" font="1">hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-</text>
<text top="887" left="149" width="524" height="19" font="1">Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290:2805-16. </text>
<text top="908" left="108" width="706" height="19" font="1">276.  Wright JT, Jr., Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with </text>
<text top="929" left="149" width="429" height="19" font="1">chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-608. </text>
<text top="950" left="108" width="705" height="19" font="1">277.  Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering </text>
<text top="971" left="149" width="665" height="19" font="1">treatment? Results of prospectively designed overviews of randomized trials. Eur. Heart J. 2008; 29:2669-80. </text>
<text top="993" left="108" width="706" height="19" font="1">278.  Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors </text>
<text top="1014" left="149" width="624" height="19" font="1">and diuretics for hypertension in the elderly. The New England journal of medicine. 2003; 348:583-92. </text>
</page>
<page number="279" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">279 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="706" height="19" font="1">279.  Fletcher A, Beevers DG, Bulpitt C, et al. Beta adrenoceptor blockade is associated with increased survival in </text>
<text top="129" left="149" width="666" height="19" font="1">male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project </text>
<text top="150" left="149" width="276" height="19" font="1">(DHCCP). J. Hum. Hypertens. 1988; 2:219-27. </text>
<text top="171" left="108" width="707" height="19" font="1">280.  Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new </text>
<text top="192" left="149" width="651" height="19" font="1">evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 2002; 162:2046-52. </text>
<text top="213" left="108" width="708" height="19" font="1">281.  Pucci M, Sarween N, Knox E, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor </text>
<text top="234" left="149" width="645" height="19" font="1">blockers in women of childbearing age: risks versus benefits. Expert Rev. Clin. Pharmacol. 2015; 8:221-31. </text>
<text top="255" left="108" width="707" height="19" font="1">282.  Moretti ME, Caprara D, Drehuta I, et al. The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and </text>
<text top="277" left="149" width="458" height="19" font="1">Angiotensin II Receptor Blockers. Obstet. Gynecol. Int. 2012; 2012:658310. </text>
<text top="298" left="108" width="705" height="19" font="1">283.  Ferrer RL, Sibai BM, Mulrow CD, et al. Management of mild chronic hypertension during pregnancy: a review. </text>
<text top="319" left="149" width="212" height="19" font="1">Obstet. Gynecol. 2000; 96:849-60. </text>
<text top="340" left="108" width="705" height="19" font="1">284.  Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine </text>
<text top="361" left="149" width="472" height="19" font="1">versus labetalol use in the emergency department. Crit. Care. 2011; 15:R157. </text>
<text top="382" left="108" width="706" height="19" font="1">285.  Liu-DeRyke X, Levy PD, Parker D, Jr., et al. A prospective evaluation of labetalol versus nicardipine for blood </text>
<text top="403" left="149" width="514" height="19" font="1">pressure management in patients with acute stroke. Neurocrit. Care. 2013; 19:41-7. </text>
<text top="424" left="108" width="707" height="19" font="1">286.  Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: Results of the A Study of Blood </text>
<text top="445" left="149" width="584" height="19" font="1">Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). Am. Heart J. 2014; 167:529-36. </text>
<text top="466" left="108" width="707" height="19" font="1">287.  Farias S, Peacock WF, Gonzalez M, et al. Impact of initial blood pressure on antihypertensive response in </text>
<text top="487" left="149" width="592" height="19" font="1">patients with acute hypertension. The American journal of emergency medicine. 2014; 32:833-6. </text>
<text top="508" left="108" width="709" height="19" font="1">288.  Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on </text>
<text top="529" left="149" width="665" height="19" font="1">behavioral variables. Results from the systolic hypertension in the elderly program. Arch. Intern. Med. 1994; </text>
<text top="550" left="149" width="84" height="19" font="1">154:2154-60. </text>
<text top="571" left="108" width="705" height="19" font="1">289.  Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled </text>
<text top="593" left="149" width="459" height="19" font="1">Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998; 352:1347-51. </text>
<text top="614" left="108" width="707" height="19" font="1">290.  Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal </text>
<text top="635" left="149" width="527" height="19" font="1">results of a randomized double-blind intervention trial. J. Hypertens. 2003; 21:875-86. </text>
<text top="656" left="108" width="705" height="19" font="1">291.  Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide </text>
<text top="677" left="149" width="665" height="19" font="1">therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 2003; </text>
<text top="698" left="149" width="84" height="19" font="1">163:1069-75. </text>
<text top="719" left="108" width="706" height="19" font="1">292.  Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in </text>
<text top="740" left="149" width="666" height="19" font="1">the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. </text>
<text top="761" left="149" width="232" height="19" font="1">The Lancet.Neurology. 2008; 7:683-9. </text>
<text top="782" left="108" width="707" height="19" font="1">293.  Devereaux PJ, Yang H, Guyatt GH, et al. Rationale, design, and organization of the PeriOperative ISchemic </text>
<text top="803" left="149" width="666" height="19" font="1">Evaluation (POISE) trial: a randomised controlled trial of metoprolol versus placebo in patients undergoing </text>
<text top="824" left="149" width="315" height="19" font="1">noncardiac surgery. Am. Heart J. 2006; 152:223-30. </text>
<text top="845" left="108" width="705" height="19" font="1">294.  Howell SJ, Sear JW and Foex P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br. J. </text>
<text top="866" left="149" width="164" height="19" font="1">Anaesth. 2004; 92:570-83. </text>
<text top="887" left="108" width="705" height="19" font="1">295.  Hart GR and Anderson RJ. Withdrawal syndromes and the cessation of antihypertensive therapy. Arch. Intern. </text>
<text top="908" left="149" width="150" height="19" font="1">Med. 1981; 141:1125-7. </text>
<text top="929" left="108" width="705" height="19" font="1">296.  Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical </text>
<text top="950" left="149" width="249" height="19" font="1">patients. Am. Heart J. 2001; 141:148-53. </text>
<text top="971" left="108" width="709" height="19" font="1">297.  Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major </text>
<text top="993" left="148" width="473" height="19" font="1">noncardiac surgery. The New England journal of medicine. 2005; 353:349-61. </text>
<text top="1014" left="108" width="708" height="19" font="1">298.  Wallace AW, Au S and Cason BA. Association of the pattern of use of perioperative beta-blockade and </text>
<text top="1035" left="148" width="374" height="19" font="1">postoperative mortality. Anesthesiology. 2010; 113:794-805. </text>
</page>
<page number="280" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">280 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="705" height="19" font="1">299.  Andersson C, M‚rie C, Jorgensen M, et al. Association of ƒ-blocker therapy with risks of adverse cardiovascular </text>
<text top="129" left="149" width="669" height="19" font="1">events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish </text>
<text top="150" left="149" width="423" height="19" font="1">nationwide cohort study. JAMA internal medicine. 2014; 174:336-44. </text>
<text top="171" left="108" width="705" height="19" font="1">300.  Hoeks SE, Scholte Op Reimer WJM, van UH, et al. Increase of 1-year mortality after perioperative beta-blocker </text>
<text top="192" left="149" width="666" height="19" font="1">withdrawal in endovascular and vascular surgery patients. European journal of vascular and endovascular </text>
<text top="213" left="149" width="542" height="19" font="1">surgery : the official journal of the European Society for Vascular Surgery. 2007; 33:13-9. </text>
<text top="234" left="108" width="705" height="19" font="1">301.  Barrett TW, Mori M and De Boer D. Association of ambulatory use of statins and beta-blockers with long-term </text>
<text top="255" left="149" width="665" height="19" font="1">mortality after vascular surgery. Journal of hospital medicine : an official publication of the Society of Hospital </text>
<text top="277" left="149" width="163" height="19" font="1">Medicine. 2007; 2:241-52. </text>
<text top="298" left="108" width="711" height="19" font="1">302.  London MJ, Hur K, Schwartz GG, et al. Association of perioperative ƒ-blockade with mortality and </text>
<text top="319" left="149" width="541" height="19" font="1">cardiovascular morbidity following major noncardiac surgery. JAMA. 2013; 309:1704-13. </text>
<text top="340" left="108" width="706" height="19" font="1">303.  Turan A, You J, Shiba A, et al. Angiotensin converting enzyme inhibitors are not associated with respiratory </text>
<text top="361" left="149" width="526" height="19" font="1">complications or mortality after noncardiac surgery. Anesth. Analg. 2012; 114:552-60. </text>
<text top="382" left="108" width="702" height="19" font="1">304.  Rosenman DJ, McDonald FS, Ebbert JO, et al. Clinical consequences of withholding versus administering renin-</text>
<text top="403" left="149" width="667" height="19" font="1">angiotensin-aldosterone system antagonists in the preoperative period. Journal of hospital medicine : an </text>
<text top="424" left="149" width="435" height="19" font="1">official publication of the Society of Hospital Medicine. 2008; 3:319-25. </text>
<text top="445" left="108" width="708" height="19" font="1">305.  Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus Continuing Angiotensin-converting Enzyme </text>
<text top="466" left="149" width="665" height="19" font="1">Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events </text>
<text top="487" left="149" width="566" height="19" font="1">In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology. 2016. </text>
<text top="508" left="108" width="708" height="19" font="1">306.  Matsumura K, Arima H, Tominaga M, et al. Does a combination pill of antihypertensive drugs improve </text>
<text top="529" left="149" width="665" height="19" font="1">medication adherence in Japanese? A randomized controlled trial. Circulation journal : official journal of the </text>
<text top="550" left="149" width="294" height="19" font="1">Japanese Circulation Society. 2012; 76:1415-22. </text>
<text top="571" left="108" width="705" height="19" font="1">307.  Schroeder K, Fahey T and Ebrahim S. How can we improve adherence to blood pressure-lowering medication </text>
<text top="593" left="148" width="664" height="19" font="1">in ambulatory care? Systematic review of randomized controlled trials. Arch. Intern. Med. 2004; 164:722-32. </text>
<text top="614" left="108" width="706" height="19" font="1">308.  Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to </text>
<text top="635" left="148" width="587" height="19" font="1">antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin. Ther. 2002; 24:302-16. </text>
<text top="656" left="108" width="708" height="19" font="1">309.  Claxton AJ, Cramer J and Pierce C. A systematic review  of the associations between dose regimens and </text>
<text top="677" left="148" width="336" height="19" font="1">medication compliance. Clin. Ther. 2001; 23:1296-310. </text>
<text top="698" left="108" width="706" height="19" font="1">310.  Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a </text>
<text top="719" left="148" width="616" height="19" font="1">meta-analysis of health care costs and adherence. J. Clin. Hypertens. (Greenwich). 2011; 13:898-909. </text>
<text top="740" left="108" width="705" height="19" font="1">311.  Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with </text>
<text top="761" left="148" width="552" height="19" font="1">single pill vs. free combination antihypertensives. Curr. Med. Res. Opin. 2010; 26:2065-76. </text>
<text top="782" left="108" width="707" height="19" font="1">312.  Gupta AK, Arshad S and Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of </text>
<text top="803" left="148" width="459" height="19" font="1">antihypertensive agents: a meta-analysis. Hypertension. 2010; 55:399-407. </text>
<text top="824" left="108" width="706" height="19" font="1">313.  Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a </text>
<text top="845" left="148" width="411" height="19" font="1">meta-analysis. The American journal of medicine. 2007; 120:713-9. </text>
<text top="866" left="108" width="706" height="19" font="1">314.  Kumagai N, Onishi K, Hoshino K, et al. Improving drug adherence using fixed combinations caused beneficial </text>
<text top="887" left="148" width="664" height="19" font="1">treatment outcomes and decreased health-care costs in patients with hypertension. Clinical and experimental </text>
<text top="908" left="148" width="335" height="19" font="1">hypertension (New York, N.Y.: 1993). 2013; 35:355-60. </text>
<text top="929" left="108" width="706" height="19" font="1">315.  Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular </text>
<text top="950" left="148" width="556" height="19" font="1">morbidity among newly diagnosed hypertensive patients. Circulation. 2009; 120:1598-605. </text>
<text top="971" left="108" width="714" height="19" font="1">316.  Jackson KC, Sheng X, Nelson RE, et al. Adherence with multiple-combination antihypertensive </text>
<text top="993" left="148" width="500" height="19" font="1">pharmacotherapies in a US managed care database. Clin. Ther. 2008; 30:1558-63. </text>
</page>
<page number="281" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">281 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="707" height="19" font="1">317.  Dickson M and Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of </text>
<text top="129" left="149" width="674" height="19" font="1">fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. </text>
<text top="150" left="149" width="597" height="19" font="1">American journal of cardiovascular drugs : drugs, devices, and other interventions. 2008; 8:45-50. </text>
<text top="171" left="108" width="706" height="19" font="1">318.  Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle </text>
<text top="192" left="149" width="667" height="19" font="1">changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart </text>
<text top="213" left="149" width="264" height="19" font="1">Association. Circulation. 2010; 122:406-41. </text>
<text top="234" left="108" width="705" height="19" font="1">319.  Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular </text>
<text top="255" left="149" width="667" height="19" font="1">risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="277" left="149" width="676" height="19" font="1">Guidelines. J. Am. Coll. Cardiol. 2013; published online before print November 7, 2013. </text>
<text top="298" left="149" width="196" height="19" font="1">doi:10.1016/j.jacc.2013.11.003. </text>
<text top="319" left="108" width="707" height="19" font="1">320.  Brownstein JN, Chowdhury FM, Norris SL, et al. Effectiveness of community health workers in the care of </text>
<text top="340" left="149" width="380" height="19" font="1">people with hypertension. Am. J. Prev. Med. 2007; 32:435-47. </text>
<text top="361" left="108" width="702" height="19" font="1">321.  Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-</text>
<text top="382" left="149" width="292" height="19" font="1">analysis. Arch. Intern. Med. 2009; 169:1748-55. </text>
<text top="403" left="108" width="706" height="19" font="1">322.  Clark CE, Smith LF, Taylor RS, et al. Nurse led interventions to improve control of blood pressure in people </text>
<text top="424" left="149" width="625" height="19" font="1">with hypertension: systematic review and meta-analysis. BMJ (Clinical research ed.). 2010; 341:c3995. </text>
<text top="445" left="108" width="705" height="19" font="1">323.  Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide </text>
<text top="466" left="148" width="325" height="19" font="1">systematic review. Am. J. Prev. Med. 2014; 47:86-99. </text>
<text top="487" left="108" width="705" height="19" font="1">324.  Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: </text>
<text top="508" left="148" width="665" height="19" font="1">a meta-analysis of randomized controlled trials. Journal of the American Heart Association. 2014; 3:e000718. </text>
<text top="529" left="108" width="706" height="19" font="1">325.  Shaw RJ, McDuffie JR, Hendrix CC, et al. Effects of nurse-managed protocols in the outpatient management </text>
<text top="550" left="148" width="661" height="19" font="1">of adults with chronic conditions: a systematic review and meta-analysis. Ann. Intern. Med. 2014; 161:113-</text>
<text top="571" left="148" width="22" height="19" font="1">21. </text>
<text top="593" left="108" width="706" height="19" font="1">326.  Carter BL, Coffey CS, Ardery G, et al. Cluster-randomized trial of a physician/pharmacist collaborative model </text>
<text top="614" left="148" width="617" height="19" font="1">to improve blood pressure control. Circulation.Cardiovascular quality and outcomes. 2015; 8:235-43. </text>
<text top="635" left="108" width="706" height="19" font="1">327.  Bardach NS, Wang JJ, De Leon SF, et al. Effect of pay-for-performance incentives on quality of care in small </text>
<text top="656" left="148" width="523" height="19" font="1">practices with electronic health records: a randomized trial. JAMA. 2013; 310:1051-9. </text>
<text top="677" left="108" width="706" height="19" font="1">328.  Banerjee D, Chung S, Wong EC, et al. Underdiagnosis of hypertension using electronic health records. Am. J. </text>
<text top="698" left="148" width="177" height="19" font="1">Hypertens. 2012; 25:97-102. </text>
<text top="719" left="108" width="705" height="19" font="1">329.  Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure control associated with a large-scale hypertension </text>
<text top="740" left="148" width="224" height="19" font="1">program. JAMA. 2013; 310:699-705. </text>
<text top="761" left="108" width="708" height="19" font="1">330.  Rakotz MK, Ewigman BG, Sarav M, et al. A technology-based quality innovation to identify undiagnosed </text>
<text top="782" left="148" width="506" height="19" font="1">hypertension among active primary care patients. Ann. Fam. Med. 2014; 12:352-8. </text>
<text top="803" left="108" width="706" height="19" font="1">331.  Borden WB, Maddox TM, Tang F, et al. Impact of the 2014 expert panel recommendations for management </text>
<text top="824" left="148" width="665" height="19" font="1">of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. </text>
<text top="845" left="148" width="242" height="19" font="1">J. Am. Coll. Cardiol. 2014; 64:2196-203. </text>
<text top="866" left="108" width="705" height="19" font="1">332.  Burke LE, Ma J, Azar KM, et al. Current Science on Consumer Use of Mobile Health for Cardiovascular Disease </text>
<text top="887" left="148" width="650" height="19" font="1">Prevention: A Scientific Statement From the American Heart Association. Circulation. 2015; 132:1157-213. </text>
<text top="908" left="108" width="702" height="19" font="1">333.  Liu S, Dunford SD, Leung YW, et al. Reducing blood pressure with Internet-based interventions: a meta-</text>
<text top="929" left="148" width="380" height="19" font="1">analysis. The Canadian journal of cardiology. 2013; 29:613-21. </text>
<text top="950" left="108" width="707" height="19" font="1">334.  Omboni S, Gazzola T, Carabelli G, et al. Clinical usefulness and cost effectiveness of home blood pressure </text>
<text top="971" left="148" width="584" height="19" font="1">telemonitoring: meta-analysis of randomized controlled studies. J. Hypertens. 2013; 31:455-67. </text>
<text top="993" left="108" width="706" height="19" font="1">335.  Verberk WJ, Kessels AG and Thien T. Telecare is a valuable tool for hypertension management, a systematic </text>
<text top="1014" left="148" width="391" height="19" font="1">review and meta-analysis. Blood Press. Monit. 2011; 16:149-55. </text>
</page>
<page number="282" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">282 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="707" height="19" font="1">336.  Svetkey LP, Pollak KI, Yancy WS, Jr., et al. Hypertension improvement project: randomized trial of quality </text>
<text top="129" left="149" width="613" height="19" font="1">improvement for physicians and lifestyle modification for patients. Hypertension. 2009; 54:1226-33. </text>
<text top="150" left="108" width="705" height="19" font="1">337.  Lusignan S, Gallagher H, Jones S, et al. Audit-based education lowers systolic blood pressure in chronic kidney </text>
<text top="171" left="149" width="556" height="19" font="1">disease: the Quality Improvement in CKD (QICKD) trial results. Kidney Int. 2013; 84:609-20. </text>
<text top="192" left="108" width="706" height="19" font="1">338.  Walsh JM, McDonald KM, Shojania KG, et al. Quality improvement strategies for hypertension management: </text>
<text top="213" left="149" width="305" height="19" font="1">a systematic review. Med. Care. 2006; 44:646-57. </text>
<text top="234" left="108" width="705" height="19" font="1">339.  Anchala R, Pinto MP, Shroufi A, et al. The role of Decision Support System (DSS) in prevention of cardiovascular </text>
<text top="255" left="149" width="460" height="19" font="1">disease: a systematic review and meta-analysis. PLoS One. 2012; 7:e47064. </text>
<text top="277" left="108" width="705" height="19" font="1">340.  Thomas KL, Shah BR, Elliot-Bynum S, et al. Check it, change it: a community-based, multifaceted intervention </text>
<text top="298" left="149" width="617" height="19" font="1">to improve blood pressure control. Circulation.Cardiovascular quality and outcomes. 2014; 7:828-34. </text>
<text top="319" left="108" width="709" height="19" font="1">341.  Petersen LA, Simpson K, Pietz K, et al. Effects of individual physician-level and practice-level financial </text>
<text top="340" left="149" width="484" height="19" font="1">incentives on hypertension care: a randomized trial. JAMA. 2013; 310:1042-50. </text>
<text top="361" left="108" width="702" height="19" font="1">342.  Hysong SJ, Simpson K, Pietz K, et al. Financial incentives and physician commitment to guideline-</text>
<text top="382" left="149" width="630" height="19" font="1">recommended hypertension management. The American journal of managed care. 2012; 18:e378-e91. </text>
<text top="403" left="108" width="706" height="19" font="1">343.  Karunaratne K, Stevens P, Irving J, et al. The impact of pay for performance on the control of blood pressure </text>
<text top="424" left="149" width="665" height="19" font="1">in people with chronic kidney disease stage 3-5. Nephrology, dialysis, transplantation : official publication of </text>
<text top="445" left="149" width="601" height="19" font="1">the European Dialysis and Transplant Association - European Renal Association. 2013; 28:2107-16. </text>
<text top="466" left="108" width="705" height="19" font="1">344.  Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the management and outcomes </text>
<text top="487" left="149" width="667" height="19" font="1">of hypertension in the United Kingdom: interrupted time series study. BMJ (Clinical research ed.). 2011; </text>
<text top="508" left="149" width="65" height="19" font="1">342:d108. </text>
<text top="529" left="108" width="705" height="19" font="1">345.  Maimaris W, Paty J, Perel P, et al. The influence of health systems on hypertension awareness, treatment, and </text>
<text top="550" left="149" width="432" height="19" font="1">control: a systematic literature review. PLoS Med. 2013; 10:e1001490. </text>
<text top="571" left="108" width="705" height="19" font="1">346.  Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone Compliance to High Blood Pressure </text>
<text top="593" left="149" width="327" height="19" font="1">Therapy Scale. Prog. Cardiovasc. Nurs. 2000; 15:90-6. </text>
<text top="614" left="108" width="707" height="19" font="1">347.  Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, </text>
<text top="635" left="149" width="582" height="19" font="1">Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42:1206-52. </text>
<text top="656" left="108" width="706" height="19" font="1">348.  Walsh J, McDonald KM, Shojania KG, et al. Closing the quality gap: a critical analysis of quality improvement </text>
<text top="677" left="149" width="340" height="19" font="1">strategies. Technical Review 9. ed. Rockville, MD: 2005. </text>
<text top="698" left="108" width="708" height="19" font="1">349.  Gwadry-Sridhar FH, Manias E, Lal L, et al. Impact of interventions on medication adherence and blood </text>
<text top="719" left="149" width="668" height="19" font="1">pressure control in patients with essential hypertension: a systematic review by the ISPOR medication </text>
<text top="740" left="149" width="665" height="19" font="1">adherence and persistence special interest group. Value in health : the journal of the International Society for </text>
<text top="761" left="149" width="392" height="19" font="1">Pharmacoeconomics and Outcomes Research. 2013; 16:863-71. </text>
<text top="782" left="108" width="632" height="19" font="1">350.  Brown MT and Bussell JK. Medication adherence: WHO cares? Mayo Clin. Proc. 2011; 86:304-14. </text>
<text top="803" left="108" width="705" height="19" font="1">351.  Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. The Cochrane </text>
<text top="824" left="149" width="324" height="19" font="1">database of systematic reviews. 2014; 11:CD000011. </text>
<text top="845" left="108" width="708" height="19" font="1">352.  Viswanathan M, olin CE, ones CD, et al. Medication adherence interventions: comparative effectiveness. </text>
<text top="866" left="149" width="665" height="19" font="1">Closing the quality gap: revisiting the state of the science. Evidence Report No.208. Rockville, MD: Agency for </text>
<text top="887" left="149" width="244" height="19" font="1">Healthcare Research and Quality, 2012. </text>
<text top="908" left="108" width="708" height="19" font="1">353.  Krousel-Wood MA, Muntner P, Islam T, et al. Barriers to and determinants of medication adherence in </text>
<text top="929" left="149" width="666" height="19" font="1">hypertension management: perspective of the cohort study of medication adherence among older adults. </text>
<text top="950" left="149" width="337" height="19" font="1">The Medical clinics of North America. 2009; 93:753-69. </text>
<text top="971" left="108" width="707" height="19" font="1">354.  Choudhry NK, Denberg TD and Qaseem A. Improving Adherence to Therapy and Clinical Outcomes While </text>
<text top="993" left="149" width="665" height="19" font="1">Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the </text>
<text top="1014" left="149" width="631" height="19" font="1">Clinical Guidelines Committee of the American College of Physicians. Ann. Intern. Med. 2016; 164:41-9. </text>
</page>
<page number="283" position="absolute" top="0" left="0" height="1188" width="918">
<text top="54" left="108" width="326" height="21" font="0">2017 Hypertension Guideline Data Supplements </text>
<text top="1063" left="789" width="24" height="20" font="1">283 </text>
<text top="1098" left="108" width="490" height="20" font="1">© 2017 American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="108" left="108" width="706" height="19" font="1">355.  Leblanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary care-relevant treatments for obesity in </text>
<text top="129" left="149" width="667" height="19" font="1">adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2011; </text>
<text top="150" left="149" width="77" height="19" font="1">155:434-47. </text>
<text top="171" left="108" width="569" height="19" font="1">356.  Final recommendation statement obesity in adults: screening and management. 2012. </text>
<text top="192" left="108" width="705" height="19" font="1">357.  Jonas DE, Garbutt JC, Amick HR, et al. Behavioral counseling after screening for alcohol misuse in primary care: </text>
<text top="213" left="149" width="666" height="19" font="1">a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2012; </text>
<text top="234" left="149" width="77" height="19" font="1">157:645-54. </text>
<text top="255" left="108" width="586" height="19" font="1">358.  Alcohol misuse: screening and behavioral counseling interventions in primary care. 2013. </text>
<text top="277" left="108" width="706" height="19" font="1">359.  Lin JS, O'Connor E, Whitlock EP, et al. Behavioral counseling to promote physical activity and a healthful diet </text>
<text top="298" left="149" width="666" height="19" font="1">to prevent cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force. </text>
<text top="319" left="149" width="226" height="19" font="1">Ann. Intern. Med. 2010; 153:736-50. </text>
<text top="340" left="108" width="707" height="19" font="1">360.  Healthful diet and physical activity for cardiovascular disease prevention in adults: behavioral counseling. </text>
<text top="361" left="149" width="38" height="19" font="1">2012. </text>
<text top="382" left="108" width="711" height="19" font="1">361.  Tobacco smoking cessation in adults, including pregnant women: behavioral and pharmacotherapy </text>
<text top="403" left="149" width="126" height="19" font="1">interventions. 2015. </text>
<text top="424" left="108" width="707" height="19" font="1">362.  Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant </text>
<text top="445" left="149" width="667" height="19" font="1">women: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann. Intern. Med. </text>
<text top="466" left="149" width="107" height="19" font="1">2009; 150:551-5. </text>
<text top="487" left="108" width="354" height="19" font="1">363.  Centers for Medicare and Medicaid Services. 2016. </text>
<text top="508" left="108" width="597" height="19" font="1">364.  American Medical Association, Physician Consortium for Performance Improvement. 2016. </text>
<text top="529" left="108" width="341" height="19" font="1">365.  National committee for Quality Assurance. 2016. </text>
<text top="550" left="108" width="227" height="19" font="1">366.  National Quality Forum. 2016. </text>
<text top="571" left="108" width="609" height="19" font="1">367.  Agency for Healthcare Research and Quality Natioanl Quality Measures Clearinghouse. 2016. </text>
<text top="605" left="108" width="4" height="24" font="3"><b> </b></text>
<text top="679" left="108" width="3" height="20" font="1"> </text>
<text top="715" left="108" width="3" height="19" font="1"> </text>
<text top="644" left="108" width="219" height="20" font="1">                                                                 </text>
</page>
<outline>
<item page="7">Data Supplement 1. Coexistence of Hypertension and Related Chronic Conditions (Section 2.4)</item>
<item page="8">Data Supplement 2. Definition of High BP (Section 3.1)</item>
<item page="18">Data Supplement 3. Out-of-Office and Self-Monitoring of BP (Section 4.2)</item>
<item page="21">Data Supplement 4. White Coat Hypertension (Section 4.4)</item>
<item page="23">Data Supplement 5. White Coat Hypertension (Prevalence) (Section 4.4)</item>
<item page="25">Data Supplement 6. White Coat Hypertension (Correlation with Clinical Outcomes) (Section 4.4)</item>
<item page="27">Data Supplement 7. Renal Artery Stenosis (Section 5.4.3)</item>
<item page="29">Data Supplement 8. RCTs Comparing Obstructive Sleep Apnea (Section 5.4.4)</item>
<item page="31">Data Supplement 9. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Fiber Intake) (Section 6.2)</item>
<item page="33">Data Supplement 10. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Fish Oil) (Section 6.2)</item>
<item page="34">Data Supplement 11. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Potassium Supplementation to Placebo or Usual Diet) (Section 6.2)</item>
<item page="36">Data Supplement 12. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Protein Intake on BP) (Section 6.2)</item>
<item page="38">Data Supplement 13. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Sodium Reduction to Placebo or Usual Diet) (Section 6.2)</item>
<item page="43">Data Supplement 14. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Stress Reduction) (Section 6.2)</item>
<item page="44">Data Supplement 15. RCTs and Meta-analyses Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Patterns) (Section 6.2)</item>
<item page="51">Data Supplement 16. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Alcohol Reduction) (Section 6.2)</item>
<item page="55">Data Supplement 17. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Calcium Supplementation) (Section 6.2)</item>
<item page="56">Data Supplement 18. RCTs and Meta-analyses RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Physical Activity) (Section 6.2)</item>
<item page="59">Data Supplement 19. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Magnesium Supplementation) (Section 6.2)</item>
<item page="61">Data Supplement 20. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Weight Loss) (Section 6.2)</item>
<item page="64">Data Supplement 21. RCTs and Systematic Reviews for RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Section 6.2)</item>
<item page="66">Data Supplement 22. Observational Studies of CV Target Organ Damage Including LVH (Section 7.2)</item>
<item page="67">Data Supplement 23. RCTs on Use of Risk Estimation to Guide Treatment of Hypertension (Section 8.1.2)</item>
<item page="81">Data Supplement 24. Follow-Up After Initial BP Evaluation (Section 8.1.3)</item>
<item page="83">Data Supplement 25. RCTs for General Principles of Drug Therapy (Combination Therapies that Inhibit the RAAS) (Section 8.1.4)</item>
<item page="85">Data Supplement 26. BP Goal for Patients with Hypertension (Section 8.1.5)</item>
<item page="92">Data Supplement 27. Choice of Initial Medication (Section 8.1.6)</item>
<item page="95">Data Supplement 28. Follow-Up After Initiating Antihypertensive Drug Therapy (Section 8.3.1)</item>
<item page="97">Data Supplement 29. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP (Section 8.3.2)</item>
<item page="100">Data Supplement 30. RCTs Comparing Stable Ischemic Heart Disease (Section 9.1)</item>
<item page="110">Data Supplement 31. Meta-analyses of ischemic heart disease (Section 9.1)</item>
<item page="111">Data Supplement 32. Nonrandomized Trials, Observational Studies, and/or Registries of Ischemic Heart Disease (Section 9.1)</item>
<item page="112">Data Supplement 33. RCTs Comparing Heart Failure (Section 9.2)</item>
<item page="113">Data Supplement 34. RCTs Comparing HFrEF (Section 9.2.1)</item>
<item page="119">Data Supplement 35. RCTs Comparing HFpEF (Section 9.2.2)</item>
<item page="122">Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries of HFpEF (Section 9.2.2)</item>
<item page="123">Data Supplement 37. RCTs Comparing CKD (Section 9.3)</item>
<item page="133">Data Supplement 38. Nonrandomized Trials, Observational Studies, and/or Registries of CKD (Section 9.3)</item>
<item page="137">Data Supplement 39. RCTs Comparing Hypertension after Renal Transplantation (Section 9.3.1)</item>
<item page="140">Data Supplement 40. Nonrandomized Trials, Observational Studies, and/or Registries for Hypertension after Renal Transplantation (Section 9.3.1)</item>
<item page="143">Data Supplement 41. RCTs Comparing Acute Intracerebral Hemorrhage Outcomes (Section 9.4.1)</item>
<item page="147">Data Supplement 42. RCTs Comparing Acute Ischemic Stroke Outcomes (Section 9.4.2)</item>
<item page="158">Data Supplement 43. RCTs Comparing Secondary Stroke Prevention (Section 9.4.3)</item>
<item page="161">Data Supplement 44. Nonrandomized Trials, Observational Studies, and/or Registries of Secondary Stroke Prevention (Section 9.4.3)</item>
<item page="168">Data Supplement 45. RCTs and Meta-analysis Comparing PAD (Section 9.5)</item>
<item page="174">Data Supplement 46. RCTs and Meta-analyses Comparing BP Targets in DM (Section 9.6)</item>
<item page="183">Data Supplement 47. Nonrandomized Trials, Observational Studies, and/or Registries in DM (Section 9.6)</item>
<item page="190">Data Supplement 48. Atrial Fibrillation (Section 9.8)</item>
<item page="191">Data Supplement 49. Valvular Heart Disease (Section 9.9)</item>
<item page="194">Data Supplement 50. RCTs and Meta-analysis Comparing Valvular Heart Disease (Section 9.9)</item>
<item page="197">Data Supplement 51. RCTs Comparing Race/Ethnicity (Section 10.1)</item>
<item page="201">Data Supplement 52. RCTs Comparing Women With Hypertension (Section 10.2.1)</item>
<item page="203">Data Supplement 53. RCTs Comparing Pregnancy (Section 10.2.2)</item>
<item page="204">Data Supplement 54. RCT for Older Persons (Section 10.3.1)</item>
<item page="204">Data Supplement 55. RCTs Comparing Hypertensive Crises and Emergencies (Section 11.2)</item>
<item page="207">Data Supplement 56. RCTs Assessing Impact of Hypertension Therapy on Dementia Incidence (Section 11.3)</item>
<item page="210">Data Supplement 57. RCTs for Patients Undergoing Surgical Procedures (Section 11.5)</item>
<item page="211">Data Supplement 58. Observational and Nonrandomized Studies for Patients Undergoing Surgical Procedures (Section 11.5)</item>
<item page="213">Data Supplement 59. RCTs of Adherence and Compliance with Fixed Dose Combinations Regimens (Section 12.1.1)</item>
<item page="214">Data Supplement 60. Nonrandomized Trials, Observational Studies, and/or Registries of Antihypertensive Medication Adherence Strategies (Section 12.1.1)</item>
<item page="220">Data Supplement 61. RCTs and Meta-analysis on Strategies to Promote Lifestyle Modification (Section 12.1.2)</item>
<item page="221">Data Supplement 62. RCTs, Meta-analyses, and Systematic Reviews on the Effect of Structured, Team-based Care Interventions for Hypertension Control (Section 12.2)</item>
<item page="227">Data Supplement 63. Electronic Health Records and Patient Registries (Section 12.3.1)</item>
<item page="232">Data Supplement 64. RCTs, Meta-analyses, and Systematic Reviews on the Effect of Telehealth Interventions to Improve Hypertension Control (Section 12.3.2)</item>
<item page="236">Data Supplement 65. RCTs and Observational Studies that Report on the Effect of Performance Measures and on Hypertension Control (Section 12.4.1)</item>
<item page="238">Data Supplement 66. RCTs, Meta-analyses, and Systematic Reviews on Quality Improvement Strategies on Hypertension Treatment Outcomes (Section 12.4.2)</item>
<item page="244">Data Supplement 67. Nonrandomized Trials, Observational Studies, and/or Registries of Effect of Quality Improvement Strategies on Hypertension Treatment Outcomes (Section 12.4.2)</item>
<item page="245">Data Supplement 68. RCTs Comparing Financial Incentives (Section 12.5)</item>
<item page="252">Additional Data Supplement Tables and Figures</item>
<outline>
<item page="252">Data Supplement A. Treatment of HFrEF Stages C and D</item>
<item page="253">Data Supplement B. Medication Adherence Assessment Scales</item>
<item page="253">Data Supplement C. Categories Defining Normal BP, Elevated BP, and Stages 1, 2, and 3 Hypertension</item>
<item page="255">Data Supplement D. Fixed-Dose Combination Antihypertensive Drugs</item>
<item page="256">Data Supplement E. Examples of Hypertension Quality Improvement Strategies</item>
<item page="257">Data Supplement F. Barriers and Improvement Strategies in Antihypertensive Medication Adherence (349-353)</item>
<item page="258">Data Supplement G. Examples of Strategies to Promote Lifestyle Modification Interventions in Patients With Hypertension (318, 319, 355-361)</item>
<item page="259">Data Supplement H. Responsibilities and Roles of the Hypertension Team</item>
<item page="260">Data Supplement I. Examples of Telehealth Strategies and Technologies to Promote Effective Hypertension Management</item>
<item page="261">Data Supplement J. Publicly Available Performance Measures Used to Assess Hypertension Care Quality Services (363-367)</item>
<item page="263">Data Supplement K. Online Quality Improvement Resources for Treatment and Control of Hypertension</item>
</outline>
<item page="253">Response:</item>
<item page="264">References</item>
</outline>
</pdf2xml>
